{"drugs": {"DB05107": {"dbids": ["DB05107"], "name": "HE2000", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05106": {"dbids": ["DB05106"], "name": "IR208", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05105": {"dbids": ["DB05105", "DB08716"], "name": "Pleconaril", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05104": {"dbids": ["DB05104"], "name": "Asimadoline", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05103": {"dbids": ["DB05103"], "name": "Pivaloyloxymethyl butyrate", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05102": {"dbids": ["DB05102"], "name": "AG7088", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05101": {"dbids": ["DB05101"], "name": "Matuzumab", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05100": {"dbids": ["DB05100"], "name": "AG3340", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB09300": {"dbids": ["DB09300"], "name": "Scopolamine butylbromide", "groups": ["APPROVED"], "targets": []}, "DB05109": {"dbids": ["DB05109"], "name": "Trabectedin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB05108": {"dbids": ["DB05108"], "name": "EHT899", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB09303": {"dbids": ["DB09303"], "name": "Evolocumab", "groups": ["APPROVED"], "targets": []}, "DB01958": {"dbids": ["DB01958", "EXPT03101"], "name": "5-[4-Tert-Butylphenylsulfanyl]-2,4-Quinazolinediamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01959": {"dbids": ["DB01959", "EXPT00309"], "name": "3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01488": {"dbids": ["DB01488"], "name": "Dimethyltryptamine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01489": {"dbids": ["DB01489"], "name": "Camazepam", "groups": ["APPROVED", "ILLICIT"], "targets": []}, "DB01486": {"dbids": ["DB01486"], "name": "Cathine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01487": {"dbids": ["DB01487"], "name": "Embutramide", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01484": {"dbids": ["DB01484"], "name": "4-Bromo-2,5-dimethoxyamphetamine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01485": {"dbids": ["DB01485"], "name": "4-Hydroxytestosterone", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01482": {"dbids": ["DB01482"], "name": "Fenethylline", "groups": ["APPROVED"], "targets": []}, "DB01483": {"dbids": ["DB01483"], "name": "Barbital", "groups": ["ILLICIT"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01483"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01483"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01483"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB01483"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01483"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01483"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB01483"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB01483"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB01483"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB01483"}]}, "DB01480": {"dbids": ["DB01480"], "name": "Cyprenorphine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01481": {"dbids": ["DB01481"], "name": "Delta1-dihydrotestosterone", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P10275", "drug": "DB01481"}]}, "DB00964": {"dbids": ["APRD00012", "DB00964"], "name": "Apraclonidine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P08913", "drug": "DB00964"}, {"action": "AGONIST", "target": "P35348", "drug": "DB00964"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00964"}]}, "DB08768": {"dbids": ["DB08768"], "name": "N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08764": {"dbids": ["DB08764"], "name": "4-BROMO-2-FLUORO-N-[(4E)-6-METHOXY-7-[(1-METHYLPIPERIDIN-4-YL)METHOXY]QUINAZOLIN-4(1H)-YLIDENE]ANILINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08765": {"dbids": ["DB08765"], "name": "6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08766": {"dbids": ["DB08766"], "name": "L-PROLINE, 1-[(2S)-3-MERCAPTO-2-METHYL-1-OXOPROPYL]-4-(PHENYLTHIO)-, 4S", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08767": {"dbids": ["DB08767"], "name": "2-(4-METHOXYPHENYL)ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08760": {"dbids": ["DB08760"], "name": "(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08761": {"dbids": ["DB08761"], "name": "(3S,6S)-3,6-bis(4-hydroxybenzyl)piperazine-2,5-dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08762": {"dbids": ["DB08762"], "name": "O-(((1R)-((N-PHENYLMETHOXYCARBONYL-L-ALANYL)AMINO)ETHYL)HYDROXYPHOSPHONO)-L-BENZYLACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08763": {"dbids": ["DB08763"], "name": "[N-(BENZYLOXYCARBONYL)AMINO](4-AMIDINOPHENYL)METHANE-PHOSPHONATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00579": {"dbids": ["APRD01085", "DB00579"], "name": "Mazindol", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23975", "drug": "DB00579"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00579"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00579"}]}, "DB00578": {"dbids": ["APRD00846", "DB00578"], "name": "Carbenicillin", "groups": ["APPROVED"], "targets": []}, "DB06908": {"dbids": ["DB06908"], "name": "(2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06909": {"dbids": ["DB06909"], "name": "1-ethyl-N-(phenylmethyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00571": {"dbids": ["APRD00194", "DB00571"], "name": "Propranolol", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB00571"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00571"}, {"action": "ANTAGONIST", "target": "P13945", "drug": "DB00571"}, {"action": "OTHER/UNKNOWN", "target": "P08908", "drug": "DB00571"}, {"action": "OTHER/UNKNOWN", "target": "P28222", "drug": "DB00571"}]}, "DB00570": {"dbids": ["APRD00708", "DB00570"], "name": "Vinblastine", "groups": ["APPROVED"], "targets": [{"action": "ADDUCT", "target": "Q71U36", "drug": "DB00570"}, {"action": "ADDUCT", "target": "P07437", "drug": "DB00570"}, {"action": "ADDUCT", "target": "Q9UJT1", "drug": "DB00570"}, {"action": "ADDUCT", "target": "P23258", "drug": "DB00570"}, {"action": "ADDUCT", "target": "Q9UJT0", "drug": "DB00570"}, {"action": "OTHER/UNKNOWN", "target": "P05412", "drug": "DB00570"}]}, "DB00573": {"dbids": ["APRD00970", "DB00573"], "name": "Fenoprofen", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00573"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00573"}]}, "DB00572": {"dbids": ["APRD00807", "DB00572", "EXPT02427"], "name": "Atropine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00572"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00572"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00572"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00572"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00572"}]}, "DB00575": {"dbids": ["APRD00174", "DB00575", "DB07566"], "name": "Clonidine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P08913", "drug": "DB00575"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00575"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00575"}, {"action": "AGONIST", "target": "P35348", "drug": "DB00575"}, {"action": "AGONIST", "target": "P35368", "drug": "DB00575"}, {"action": "AGONIST", "target": "P25100", "drug": "DB00575"}]}, "DB00574": {"dbids": ["APRD00319", "DB00574"], "name": "Fenfluramine", "groups": ["ILLICIT", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P31645", "drug": "DB00574"}, {"action": "AGONIST", "target": "P41595", "drug": "DB00574"}, {"action": "AGONIST", "target": "P28335", "drug": "DB00574"}]}, "DB00577": {"dbids": ["APRD00697", "DB00577"], "name": "Valaciclovir", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P04293", "drug": "DB00577"}, {"action": "INDUCER", "target": "Q9QNF7", "drug": "DB00577"}]}, "DB00576": {"dbids": ["APRD00684", "DB00576"], "name": "Sulfamethizole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0AC13", "drug": "DB00576"}]}, "DB03888": {"dbids": ["DB03888", "EXPT02737"], "name": "Allyl-{6-[3-(4-Bromo-Phenyl)-1-Methyl-1h-Indazol-6-Yl]Oxy}Hexyl)-N-Methylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03889": {"dbids": ["DB03889", "EXPT01552"], "name": "S-(N-Hydroxy-N-Bromophenylcarbamoyl)Glutathione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03880": {"dbids": ["DB03880", "EXPT00627"], "name": "Batimastat", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03881": {"dbids": ["DB03881", "EXPT02245"], "name": "MT-Immucillin-H", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03882": {"dbids": ["DB01507", "DB03882", "EXPT00530"], "name": "5-Alpha-Androstane-3-Beta,17beta-Diol", "groups": ["EXPERIMENTAL"], "targets": [{"action": "AGONIST", "target": "Q92731", "drug": "DB03882"}]}, "DB03883": {"dbids": ["DB03883", "EXPT01023"], "name": "Carboxyethyllumazine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03884": {"dbids": ["DB03884", "EXPT02649"], "name": "3-Phenylpyruvic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03885": {"dbids": ["DB03885", "EXPT01588"], "name": "1-Menaphthyl Glutathione Conjugate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03886": {"dbids": ["DB03886", "EXPT00708"], "name": "Biopterin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03887": {"dbids": ["DB03887", "EXPT00383"], "name": "Alpha-Adenosine Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04218": {"dbids": ["DB04218", "EXPT00071"], "name": "1-Deaza-Adenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04219": {"dbids": ["DB04219", "EXPT03215"], "name": "Trivanadate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04210": {"dbids": ["DB04210", "EXPT00779"], "name": "BV1", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04211": {"dbids": ["DB04211", "EXPT01499"], "name": "3-Fluorosialic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04212": {"dbids": ["DB04212", "EXPT02290"], "name": "2-Iminiopropanoate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04213": {"dbids": ["DB04213", "EXPT01006"], "name": "N-Cyclohexyl-N'-(Propyl)Phenyl Urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04214": {"dbids": ["DB04214", "EXPT00223"], "name": "4-Nitrophenyl Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04215": {"dbids": ["DB04215", "EXPT00340"], "name": "CRA_9076", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04216": {"dbids": ["DB04216", "EXPT02732"], "name": "Quercetin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04217": {"dbids": ["DB04217", "EXPT02057"], "name": "L-2-amino-3-butynoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00683": {"dbids": ["APRD00680", "DB00683"], "name": "Midazolam", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "Q9UN88", "drug": "DB00683"}]}, "DB00682": {"dbids": ["APRD00341", "DB00682"], "name": "Warfarin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9BQB6", "drug": "DB00682"}]}, "DB00681": {"dbids": ["APRD00797", "DB00681"], "name": "Amphotericin B", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB00680": {"dbids": ["APRD01124", "DB00680"], "name": "Moricizine", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB00680"}]}, "DB00687": {"dbids": ["APRD00756", "DB00687", "DB02478"], "name": "Fludrocortisone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P08235", "drug": "DB00687"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00687"}, {"action": "AGONIST", "target": "P10275", "drug": "DB00687"}]}, "DB00686": {"dbids": ["APRD01175", "DB00686"], "name": "Pentosan Polysulfate", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P09038", "drug": "DB00686"}, {"action": "ANTAGONIST", "target": "P05230", "drug": "DB00686"}, {"action": "INHIBITOR", "target": "P08620", "drug": "DB00686"}]}, "DB00685": {"dbids": ["APRD01281", "DB00685"], "name": "Trovafloxacin", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P43700", "drug": "DB00685"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB00685"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00685"}]}, "DB00684": {"dbids": ["APRD00582", "DB00684"], "name": "Tobramycin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P0A7S3", "drug": "DB00684"}]}, "DB00689": {"dbids": ["APRD00858", "DB00689"], "name": "Cephaloglycin", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q65HB5", "drug": "DB00689"}]}, "DB00688": {"dbids": ["APRD01602", "DB00688"], "name": "Mycophenolate mofetil", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P20839", "drug": "DB00688"}, {"action": "INHIBITOR", "target": "P12268", "drug": "DB00688"}]}, "DB08427": {"dbids": ["DB08427"], "name": "PREPHENIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08426": {"dbids": ["DB08426"], "name": "THIENO[3,2-B]PYRIDINE-2-SULFONIC ACID [2-OXO-1-(1H-PYRROLO[2,3-C]PYRIDIN-2-YLMETHYL)-PYRROLIDIN-3-YL]-AMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08425": {"dbids": ["DB08425"], "name": "3(S)-AMINO-4-PHENYL-BUTAN-2(R)-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08424": {"dbids": ["DB08424"], "name": "[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08423": {"dbids": ["DB08423"], "name": "[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08422": {"dbids": ["DB08422"], "name": "[PHENYLALANINYL-PROLINYL]-[2-(PYRIDIN-4-YLAMINO)-ETHYL]-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08892": {"dbids": ["DB08892"], "name": "Arbaclofen Placarbil", "groups": ["INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "Q9UBS5", "drug": "DB08892"}, {"action": "AGONIST", "target": "O75899", "drug": "DB08892"}]}, "DB08421": {"dbids": ["DB08421"], "name": "PIPERIDINE-2-CARBOXYLIC ACID TERT-BUTYLAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08420": {"dbids": ["DB08420"], "name": "1-{[1-(2-AMINO-3-PHENYL-PROPIONYL)-PYRROLIDINE-2-CARBONYL]-AMINO}-2-(3-CYANO-PHENYL)-ETHANEBORONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08891": {"dbids": ["DB08891"], "name": "Arbaclofen", "groups": ["INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "Q9UBS5", "drug": "DB08891"}, {"action": "AGONIST", "target": "O75899", "drug": "DB08891"}]}, "DB07353": {"dbids": ["DB07353"], "name": "4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08955": {"dbids": ["DB08955"], "name": "Ibuproxam", "groups": ["WITHDRAWN"], "targets": []}, "DB09309": {"dbids": ["DB09309"], "name": "Kitasamycin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02133": {"dbids": ["DB02133", "EXPT00935"], "name": "Chlorophyll A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02132": {"dbids": ["DB02132", "EXPT03287"], "name": "[3-(4-Bromo-2-Fluoro-Benzyl)-7-Chloro-2,4-Dioxo-3,4-Dihydro-2h-Quinazolin-1-Yl]-Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02131": {"dbids": ["DB02131", "EXPT01516"], "name": "N-1-Methylheptylformamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02130": {"dbids": ["DB02130", "EXPT03229"], "name": "4-Hydroxy-3-Methoxybenzoate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02137": {"dbids": ["DB02137", "EXPT02517"], "name": "Molybdenum Cofactor", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02136": {"dbids": ["DB02136", "EXPT00887"], "name": "Cephalosporin Analog", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02135": {"dbids": ["DB02135", "EXPT03118"], "name": "4-{2,6,8-Trioxo-9-[(2r,3s,4r)-2,3,4,5-Tetrahydroxypentyl]-1,2,3,6,8,9-Hexahydro-7h-Purin-7-Yl}Butyl Dihydrogen Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02134": {"dbids": ["DB02134", "EXPT03251"], "name": "Xanthine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02139": {"dbids": ["DB02139", "EXPT02738"], "name": "(2e)-N-Allyl-4-{[3-(4-Bromophenyl)-5-Fluoro-1-Methyl-1h-Indazol-6-Yl]Oxy}-N-Methyl-2-Buten-1-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02138": {"dbids": ["DB02138", "EXPT01324"], "name": "Diethyl 4-Methylbenzylphosphonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07747": {"dbids": ["DB07747"], "name": "(3R)-N-(4-CHLOROPHENYL)-3-(HYDROXYMETHYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07746": {"dbids": ["DB07746"], "name": "3-ETHYL-6-{[(4-FLUOROPHENYL)SULFONYL]AMINO}-2-METHYLBENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07745": {"dbids": ["DB07745"], "name": "2-{[4-(TRIFLUOROMETHOXY)BENZOYL]AMINO}ETHYL DIHYDROGEN PHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07744": {"dbids": ["DB07744"], "name": "3-[2-(2-BENZYLOXYCARBONYLAMINO-3-METHYL-BUTYRYLAMINO)-PROPIONYLAMINO]-4-OXO-PENTANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07743": {"dbids": ["DB07743"], "name": "S-[5-(TRIFLUOROMETHYL)-4H-1,2,4-TRIAZOL-3-YL] 5-(PHENYLETHYNYL)FURAN-2-CARBOTHIOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07742": {"dbids": ["DB07742"], "name": "N-(2,3-DIFLUORO-BENZYL)-4-SULFAMOYL-BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07741": {"dbids": ["DB07741"], "name": "4-(1R,3AS,4R,8AS,8BR)-[1-DIFLUOROMETHYL-2-(4-FLUOROBENZYL)-3-OXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZAMIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07740": {"dbids": ["DB07740"], "name": "(3R,5S,7R,12S,13R)-13-FORMYL-12,14-DIHYDROXY-3,5,7-TRIMETHYLTETRADECANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08428": {"dbids": ["DB08428"], "name": "3(S)-AMINO-4-PHENYL-BUTAN-2(S)-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07749": {"dbids": ["DB07749"], "name": "2-ACETYLAMINO-4-METHYL-PENTANOIC ACID (1-FORMYL-2-PHENYL-ETHYL)-AMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07748": {"dbids": ["DB07748"], "name": "2-({[4-(TRIFLUOROMETHOXY)PHENYL]SULFONYL}AMINO)ETHYL DIHYDROGEN PHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03080": {"dbids": ["DB03080", "EXPT01979"], "name": "17-Dmag", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03081": {"dbids": ["DB03081", "EXPT00864"], "name": "Crc200 (Chiron-Behring)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03082": {"dbids": ["DB03082", "EXPT03178"], "name": "6-[(Z)-Amino(Imino)Methyl]-N-[4-(Aminomethyl)Phenyl]-4-(Pyrimidin-2-Ylamino)-2-Naphthamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03083": {"dbids": ["DB03083", "EXPT01830"], "name": "IC261", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03084": {"dbids": ["DB03084", "EXPT00348"], "name": "Cyclopropyl-{4-[5-(3,4-Dichlorophenyl)-2-[(1-Methyl)-Piperidin]-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03085": {"dbids": ["DB03085", "EXPT01629"], "name": "Hydroxyacetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03086": {"dbids": ["DB03086", "EXPT00527"], "name": "N'-(2s,3r)-3-Amino-4-Cyclohexyl-2-Hydroxy-Butano-N-(4-Methylphenyl)Hydrazide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03087": {"dbids": ["DB03087", "EXPT03152"], "name": "2-(Sec-Butyl)Thiazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03088": {"dbids": ["DB03088", "EXPT00247"], "name": "Pyroglutamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03089": {"dbids": ["DB03089", "EXPT00571"], "name": "L-Iso-Aspartate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02861": {"dbids": ["DB02861", "EXPT01904"], "name": "4-(Aminosulfonyl)-N-[(3,4,5-Trifluorophenyl)Methyl]-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02860": {"dbids": ["DB02860", "EXPT01080"], "name": "Calyculin A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02863": {"dbids": ["DB02863", "EXPT00932"], "name": "Alpha Chlorophyll A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02862": {"dbids": ["DB02862", "EXPT01838"], "name": "Gluco-Phenylimidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02689": {"dbids": ["DB02689", "EXPT02875"], "name": "S-{2-[Amino(Dihydroxy)-Lambda~4~-Sulfanyl]Ethyl}-D-Cysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02688": {"dbids": ["DB02688", "EXPT01186"], "name": "2,3-Didehydroalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02867": {"dbids": ["DB02867", "EXPT02084"], "name": "D-Mannose 1-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02866": {"dbids": ["DB02866", "EXPT02203"], "name": "Dansylamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02685": {"dbids": ["DB02685", "EXPT00540"], "name": "3-Methylphenylalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02684": {"dbids": ["DB02684", "EXPT00241"], "name": "5'-O-(N-(L-Cysteinyl)-Sulfamoyl)Adenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02686": {"dbids": ["DB02686", "EXPT03188"], "name": "Undecyl-Beta-D-Maltopyranoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02681": {"dbids": ["DB02681", "EXPT03214"], "name": "Meta Vanadate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02680": {"dbids": ["DB02680", "EXPT02350"], "name": "Dinitrophenylene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02683": {"dbids": ["DB02683", "EXPT00666"], "name": "Inhibitor Bea428", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02682": {"dbids": ["DB02682", "EXPT02944"], "name": "2-Deamino-6-Deoxy-6thiophosphite-5'-Phosphate Guanosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06268": {"dbids": ["DB06268"], "name": "Sitaxentan", "groups": ["APPROVED", "INVESTIGATIONAL", "WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P25101", "drug": "DB06268"}, {"action": "ANTAGONIST", "target": "P24530", "drug": "DB06268"}]}, "DB05482": {"dbids": ["DB05482"], "name": "LE-SN38", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05483": {"dbids": ["DB05483"], "name": "PCL-016", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05480": {"dbids": ["DB05480"], "name": "PBI-1402", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05481": {"dbids": ["DB05481"], "name": "Recombinant alpha 1-antitrypsin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05486": {"dbids": ["DB05486"], "name": "MLN-1202", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05487": {"dbids": ["DB05487"], "name": "CC-8490", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05484": {"dbids": ["DB05484"], "name": "MDX-018", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05485": {"dbids": ["DB05485"], "name": "ADH-1", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05488": {"dbids": ["DB05488"], "name": "99mTc-ciprofloxacin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05489": {"dbids": ["DB05489"], "name": "ACA 125", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03624": {"dbids": ["DB03624", "EXPT01273"], "name": "7-(Carboxyamino)-8-Amino-Nonanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03625": {"dbids": ["DB03625", "EXPT01143"], "name": "5,10-Dideazatetrahydrofolic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03626": {"dbids": ["DB03626", "EXPT00154"], "name": "5-Methoxy-1,2-Dimethyl-3-(Phenoxymethyl)Indole-4,7-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03627": {"dbids": ["DB03627", "EXPT00433"], "name": "Adamantane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03621": {"dbids": ["DB03621", "EXPT00237"], "name": "L-709,587", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03622": {"dbids": ["DB03622", "EXPT00635"], "name": "2-Hydroxy-5-[4-(2-Hydroxy-Ethyl)-Piperidin-1-Yl]-5-Phenyl-1h-Pyrimidine-4,6-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03623": {"dbids": ["DB03623", "EXPT00358"], "name": "9-(4-Hydroxyphenyl)-2,7-Phenanthroline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03628": {"dbids": ["DB03628", "EXPT01930"], "name": "ISO24", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03629": {"dbids": ["DB03629", "EXPT02377"], "name": "Pyridoxal-5'-Phosphate-N-Oxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06262": {"dbids": ["DB06262"], "name": "Droxidopa", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P35348", "drug": "DB06262"}, {"action": "AGONIST", "target": "P35368", "drug": "DB06262"}, {"action": "AGONIST", "target": "P25100", "drug": "DB06262"}, {"action": "AGONIST", "target": "P08913", "drug": "DB06262"}, {"action": "AGONIST", "target": "P18089", "drug": "DB06262"}, {"action": "AGONIST", "target": "P18825", "drug": "DB06262"}, {"action": "AGONIST", "target": "P08588", "drug": "DB06262"}, {"action": "AGONIST", "target": "P07550", "drug": "DB06262"}, {"action": "AGONIST", "target": "P13945", "drug": "DB06262"}, {"action": "INHIBITOR", "target": "P00439", "drug": "DB06262"}]}, "DB06261": {"dbids": ["DB06261"], "name": "Hexaminolevulinate", "groups": ["APPROVED"], "targets": []}, "DB07385": {"dbids": ["DB07385"], "name": "3-(HYDROXYMETHYL)-1-METHYL-5-(2-METHYLAZIRIDIN-1-YL)-2-PHENYL-1H-INDOLE-4,7-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05665": {"dbids": ["DB05665"], "name": "SCH-503034", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05662": {"dbids": ["DB05662"], "name": "NP-50301", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07384": {"dbids": ["DB07384"], "name": "1-ACETYL-2-CARBOXYPIPERIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04478": {"dbids": ["DB04478", "EXPT00235"], "name": "Cp-166572, 2-Hydroxymethyl-4-(4-N,N-Dimethylaminosulfonyl-1-Piperazino)-Pyrimidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04479": {"dbids": ["DB04479", "EXPT02349"], "name": "4-Nitro-Inden-1-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01954": {"dbids": ["DB01954", "EXPT02804"], "name": "4-[3-(Cyclopentyloxy)-4-Methoxyphenyl]-2-Pyrrolidinone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01955": {"dbids": ["DB01955", "EXPT00771"], "name": "1,4-Butanediol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01956": {"dbids": ["DB01956", "EXPT03010"], "name": "2-Aminoethanesulfonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01957": {"dbids": ["DB01957", "EXPT00165"], "name": "3-Chlorophenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01950": {"dbids": ["DB01950", "EXPT03075"], "name": "N-(4-Methoxybenzyl)-N'-(5-Nitro-1,3-Thiazol-2-Yl)Urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01951": {"dbids": ["DB01951", "EXPT01638"], "name": "Gpi-1046", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01952": {"dbids": ["DB01952", "EXPT01319"], "name": "1,N6-Ethenoadenine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04473": {"dbids": ["DB04473", "EXPT00452"], "name": "Alpha-L-Fucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07572": {"dbids": ["DB07572"], "name": "3-{[(4-methylphenyl)sulfonyl]amino}propyl pyridin-4-ylcarbamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02740": {"dbids": ["DB02740", "EXPT00173"], "name": "3-Indolebutyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08569": {"dbids": ["DB08569"], "name": "3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02741": {"dbids": ["DB02741", "EXPT00233"], "name": "CD564", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02742": {"dbids": ["DB02742", "EXPT01973"], "name": "Kifunensine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02743": {"dbids": ["DB02743", "EXPT00610"], "name": "Beta-1,4-Galactobioside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02744": {"dbids": ["DB02744", "EXPT02653"], "name": "RPR131247", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02745": {"dbids": ["DB02745", "EXPT03205"], "name": "Uridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01550": {"dbids": ["DB01550"], "name": "Fenproporex", "groups": ["APPROVED", "ILLICIT", "WITHDRAWN"], "targets": []}, "DB02746": {"dbids": ["DB02746", "EXPT02595"], "name": "Phthalic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04071": {"dbids": ["DB04071", "EXPT02487"], "name": "Cpad", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02747": {"dbids": ["DB02747", "EXPT01886"], "name": "N-(R-Carboxy-Ethyl)-Alpha-(S)-(2-Phenylethyl)Glycyl-L-Arginine-N-Phenylamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01552": {"dbids": ["DB01552"], "name": "Betameprodine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01553": {"dbids": ["DB01553"], "name": "Cloxazolam", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB01569": {"dbids": ["DB01569"], "name": "Formebolone", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01568": {"dbids": ["DB01568"], "name": "Codeine-N-oxide", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB04045": {"dbids": ["DB04045", "EXPT02132"], "name": "Methylmalonyl-Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01554": {"dbids": ["DB01554"], "name": "19-Nor-4-androstenediol", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01567": {"dbids": ["DB01567"], "name": "Fludiazepam", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB01567"}]}, "DB01566": {"dbids": ["DB01566"], "name": "3,4-Methylenedioxy-N-ethylamphetamine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01561": {"dbids": ["DB01561", "DB03620"], "name": "Androstanedione", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01560": {"dbids": ["DB01560"], "name": "Cathinone", "groups": ["ILLICIT"], "targets": []}, "DB01563": {"dbids": ["DB01563"], "name": "Chloral hydrate", "groups": ["APPROVED", "ILLICIT"], "targets": []}, "DB01555": {"dbids": ["DB01555"], "name": "Alphacetylmethadol", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB00968": {"dbids": ["APRD01106", "DB00968"], "name": "Methyldopa", "groups": ["APPROVED"], "targets": []}, "DB00969": {"dbids": ["APRD00580", "DB00969"], "name": "Alosetron", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P46098", "drug": "DB00969"}]}, "DB00218": {"dbids": ["APRD00281", "DB00218"], "name": "Moxifloxacin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P43702", "drug": "DB00218"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB00218"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00218"}]}, "DB00219": {"dbids": ["APRD00189", "DB00219"], "name": "Oxyphenonium", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00219"}]}, "DB00748": {"dbids": ["APRD00765", "DB00748"], "name": "Carbinoxamine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00748"}]}, "DB00749": {"dbids": ["APRD00067", "DB00749"], "name": "Etodolac", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00749"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00749"}, {"action": "OTHER", "target": "P19793", "drug": "DB00749"}]}, "DB00214": {"dbids": ["APRD00217", "APRD00295", "DB00214"], "name": "Torasemide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q13621", "drug": "DB00214"}]}, "DB00215": {"dbids": ["APRD00147", "DB00215"], "name": "Citalopram", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P31645", "drug": "DB00215"}, {"action": "BINDER", "target": "P35367", "drug": "DB00215"}, {"action": "BINDER", "target": "P35348", "drug": "DB00215"}, {"action": "BINDER", "target": "P11229", "drug": "DB00215"}]}, "DB00216": {"dbids": ["APRD00945", "DB00216"], "name": "Eletriptan", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P28221", "drug": "DB00216"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00216"}, {"action": "AGONIST", "target": "P30939", "drug": "DB00216"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00216"}, {"action": "AGONIST", "target": "P28566", "drug": "DB00216"}, {"action": "AGONIST", "target": "P41595", "drug": "DB00216"}, {"action": "AGONIST", "target": "P34969", "drug": "DB00216"}]}, "DB00217": {"dbids": ["APRD00825", "DB00217"], "name": "Bethanidine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P08913", "drug": "DB00217"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00217"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00217"}, {"action": "INHIBITOR", "target": "P48048", "drug": "DB00217"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB00217"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00217"}, {"action": "ANTAGONIST", "target": "P13945", "drug": "DB00217"}]}, "DB00966": {"dbids": ["APRD01247", "DB00966"], "name": "Telmisartan", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P30556", "drug": "DB00966"}, {"action": "PARTIAL AGONIST", "target": "P37231", "drug": "DB00966"}]}, "DB00967": {"dbids": ["APRD00324", "DB00967"], "name": "Desloratadine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00967"}]}, "DB00740": {"dbids": ["APRD00145", "DB00740"], "name": "Riluzole", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB00740"}, {"action": "INDUCER", "target": "Q9UPY5", "drug": "DB00740"}]}, "DB00965": {"dbids": ["APRD00960", "DB00965"], "name": "Ethiodized oil", "groups": ["APPROVED"], "targets": []}, "DB06906": {"dbids": ["DB06906"], "name": "2-AMINO-4-HYDROXYPYRIMIDINE-5-CARBOXYLIC ACID ETHYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04079": {"dbids": ["DB04079", "EXPT01791"], "name": "Heptane-1,2,3-Triol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06904": {"dbids": ["DB06904"], "name": "(5S,6S)-6-[(R)ACETOXYETH-2-YL]-PENEM-3-CARBOXYLATEPROPANE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06905": {"dbids": ["DB06905"], "name": "(2S,3S,4E,6E,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06902": {"dbids": ["DB06902"], "name": "4-(1-methyl-1-phenylethyl)phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08401": {"dbids": ["DB08401"], "name": "(2E)-2-({(2S)-2-CARBOXY-2-[(PHENOXYACETYL)AMINO]ETHOXY}IMINO)PENTANEDIOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06903": {"dbids": ["DB06903"], "name": "(1S,3aS,5aR,8aS)-1,7,7-trimethyl-1,2,3,3a,5a,6,7,8-octahydrocyclopenta[c]pentalene-4-carboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06900": {"dbids": ["DB06900"], "name": "1-[4-(hydroxymethyl)phenyl]guanidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06901": {"dbids": ["DB06901"], "name": "2-(2-HYDROXY-CYCLOPENTYL)-PENT-4-ENAL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03163": {"dbids": ["DB03163", "EXPT01980"], "name": "(2-[2-Ketopropylthio]Ethanesulfonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03162": {"dbids": ["DB03162", "EXPT01550"], "name": "4-Hydroxy-1,2,5-Thiadiazole-3-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00979": {"dbids": ["APRD00893", "DB00979"], "name": "Cyclopentolate", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00979"}]}, "DB03693": {"dbids": ["DB03693", "EXPT00931"], "name": "N-(2-Aminoethyl)-5-Chloroisoquinoline-8-Sulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00978": {"dbids": ["APRD01076", "DB00978"], "name": "Lomefloxacin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P43702", "drug": "DB00978"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB00978"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00978"}]}, "DB03692": {"dbids": ["DB03692", "EXPT02830"], "name": "1-Hexadecanosulfonyl-O-L-Serine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00757": {"dbids": ["APRD00518", "DB00757"], "name": "Dolasetron", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P46098", "drug": "DB00757"}]}, "DB08403": {"dbids": ["DB08403"], "name": "METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03167": {"dbids": ["DB03167", "EXPT02511"], "name": "Pentabromophenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00756": {"dbids": ["APRD00722", "DB00756"], "name": "Hexachlorophene", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P06149", "drug": "DB00756"}, {"action": "INHIBITOR", "target": "O14521", "drug": "DB00756"}, {"action": "INHIBITOR", "target": "P00367", "drug": "DB00756"}]}, "DB03166": {"dbids": ["DB03166", "DB04184", "EXPT00423"], "name": "Acetic acid", "groups": ["APPROVED"], "targets": []}, "DB00759": {"dbids": ["APRD00572", "DB00759"], "name": "Tetracycline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P02359", "drug": "DB00759"}, {"action": "INHIBITOR", "target": "P0AG59", "drug": "DB00759"}, {"action": "INHIBITOR", "target": "P0A7V3", "drug": "DB00759"}, {"action": "INHIBITOR", "target": "P0A7W7", "drug": "DB00759"}, {"action": "INHIBITOR", "target": "P0A7U3", "drug": "DB00759"}, {"action": "INHIBITOR", "target": "P04156", "drug": "DB00759"}]}, "DB03165": {"dbids": ["DB03165", "EXPT01154"], "name": "2-Dimethylamino-Ethyl-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00758": {"dbids": ["APRD00444", "DB00758"], "name": "Clopidogrel", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "ANTAGONIST", "target": "Q9H244", "drug": "DB00758"}]}, "DB03696": {"dbids": ["DB03696", "EXPT02002"], "name": "Lanosterol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00977": {"dbids": ["APRD00691", "DB00977"], "name": "Ethinyl Estradiol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P03372", "drug": "DB00977"}, {"action": "AGONIST", "target": "O75469", "drug": "DB00977"}]}, "DB00976": {"dbids": ["APRD00483", "DB00976"], "name": "Telithromycin", "groups": ["APPROVED"], "targets": []}, "DB00971": {"dbids": ["APRD01323", "DB00971"], "name": "Selenium Sulfide", "groups": ["APPROVED"], "targets": []}, "DB00970": {"dbids": ["APRD00124", "DB00970"], "name": "Dactinomycin", "groups": ["APPROVED"], "targets": []}, "DB03439": {"dbids": ["DB03439", "EXPT00456"], "name": "4,6-Dideoxy-4-Amino-Alpha-D-Glucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03438": {"dbids": ["DB03438", "EXPT02571"], "name": "Lysophosphatidylglycerol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00973": {"dbids": ["APRD00619", "DB00973"], "name": "Ezetimibe", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35610", "drug": "DB00973"}, {"action": "INHIBITOR", "target": "Q9UHC9", "drug": "DB00973"}, {"action": "OTHER", "target": "P15144", "drug": "DB00973"}]}, "DB03430": {"dbids": ["DB03430", "EXPT01197"], "name": "(2s)-Hydroxy(4-Hydroxyphenyl)Ethanenitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03433": {"dbids": ["DB03433", "EXPT00153"], "name": "{3-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Amino]-2-Methyl-Propyl}-Phosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00972": {"dbids": ["APRD00813", "DB00972"], "name": "Azelastine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00972"}]}, "DB03435": {"dbids": ["DB03435", "EXPT03172"], "name": "Uridine-5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03434": {"dbids": ["DB03434", "EXPT02224"], "name": "3[N-Morpholino]Propane Sulfonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03437": {"dbids": ["DB03437", "EXPT02521"], "name": "2-{1-[2-(2-Amino-Thiazol-4-Yl)-2-Methoxyimino-Acetylamino]-2-Oxo-Ethyl}-5,5-Dimethyl-Thiazolidine-4-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03436": {"dbids": ["DB03436", "EXPT01562"], "name": "Gallichrome", "groups": ["EXPERIMENTAL"], "targets": [{"action": "ANTAGONIST", "target": "P07822", "drug": "DB03436"}]}, "DB08249": {"dbids": ["DB08249"], "name": "3,6,9,12,15-PENTAOXATRICOSAN-1-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08248": {"dbids": ["DB08248"], "name": "3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08242": {"dbids": ["DB08242"], "name": "N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08241": {"dbids": ["DB08241"], "name": "4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08240": {"dbids": ["DB08240"], "name": "N-(4-CHLOROPHENYL)-3-(PHOSPHONOOXY)NAPHTHALENE-2-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08247": {"dbids": ["DB08247"], "name": "6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08246": {"dbids": ["DB08246"], "name": "(2S)-4-(2,5-DIFLUOROPHENYL)-N,N-DIMETHYL-2-PHENYL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08245": {"dbids": ["DB08245"], "name": "1-(2-DEOXY-5-O-PHOSPHONO-BETA-D-ERYTHRO-PENTOFURANOSYL)-5-NITRO-1H-INDOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08244": {"dbids": ["DB08244"], "name": "(1S)-1-CYCLOPROPYL-2-[(2S)-4-(2,5-DIFLUOROPHENYL)-2-PHENYL-2,5-DIHYDRO-1H-PYRROL-1-YL]-2-OXOETHANAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06372": {"dbids": ["DB06372"], "name": "Rilonacept", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "P01584", "drug": "DB06372"}, {"action": "BINDER", "target": "P01583", "drug": "DB06372"}, {"action": "BINDER", "target": "P18510", "drug": "DB06372"}]}, "DB09138": {"dbids": ["DB09138"], "name": "Technetium Tc-99m Medronate", "groups": ["APPROVED"], "targets": []}, "DB05873": {"dbids": ["DB05873"], "name": "AVI-4020", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05872": {"dbids": ["DB05872"], "name": "PA mAb", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05871": {"dbids": ["DB05871"], "name": "UC-781", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05870": {"dbids": ["DB05870"], "name": "anti-alpha5Beta1-integrin antibody", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05877": {"dbids": ["DB05877"], "name": "PYY3-36", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05876": {"dbids": ["DB05876"], "name": "PDE4", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05875": {"dbids": ["DB05875"], "name": "substance P", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05874": {"dbids": ["DB05874"], "name": "AEOL 10150", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05879": {"dbids": ["DB05879"], "name": "AME-527", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB02472": {"dbids": ["DB02472", "EXPT01774"], "name": "6-Hydroxy-7,8-Dihydro Purine Nucleoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02473": {"dbids": ["DB02473", "EXPT00041"], "name": "6-[N-(1-Isopropyl-3,4-Dihydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02470": {"dbids": ["DB02470", "EXPT02091"], "name": "D-Glycero-D-Mannopyranose-7-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02471": {"dbids": ["DB02471", "EXPT02395"], "name": "Nojirimycine Tetrazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02477": {"dbids": ["DB02477", "EXPT02176"], "name": "[Cyclohexylethyl]-[[[[4-[2-Methyl-1-Imidazolyl-Butyl]Phenyl]Acetyl]-Seryl]-Lysinyl]-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02474": {"dbids": ["DB02474", "EXPT00089"], "name": "Bmsc-0013", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02475": {"dbids": ["DB02475", "EXPT02527"], "name": "Deoxyguanidinoproclavaminic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09358": {"dbids": ["DB09358"], "name": "Riboflavin 5'-phosphate sodium", "groups": ["APPROVED"], "targets": []}, "DB02479": {"dbids": ["DB02479", "EXPT02859"], "name": "(R)-N-(3-Indol-1-Yl-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09524": {"dbids": ["DB09524"], "name": "Sodium phosphate, dibasic anhydrous", "groups": ["APPROVED"], "targets": []}, "DB05297": {"dbids": ["DB05297"], "name": "DHA-paclitaxel", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05296": {"dbids": ["DB05296"], "name": "motexafin lutetium", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05295": {"dbids": ["DB05295"], "name": "ED-71", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05294": {"dbids": ["DB05294"], "name": "Vandetanib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P15692", "drug": "DB05294"}, {"action": "INHIBITOR", "target": "P00533", "drug": "DB05294"}, {"action": "INHIBITOR", "target": "Q13882", "drug": "DB05294"}, {"action": "INHIBITOR", "target": "Q02763", "drug": "DB05294"}]}, "DB05293": {"dbids": ["DB05293"], "name": "IDM-2", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05292": {"dbids": ["DB05292"], "name": "IDM-1", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05291": {"dbids": ["DB05291"], "name": "lidocaine patch", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05290": {"dbids": ["DB05290"], "name": "SPP 301", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05299": {"dbids": ["DB05299"], "name": "keyhole limpet hemocyanin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05298": {"dbids": ["DB05298"], "name": "OPC-6535", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05121": {"dbids": ["DB05121"], "name": "1D09C3", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05120": {"dbids": ["DB05120"], "name": "AT1391", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05123": {"dbids": ["DB05123"], "name": "Gemcabene", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05122": {"dbids": ["DB05122"], "name": "R1295", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05125": {"dbids": ["DB05125"], "name": "SC12267", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05124": {"dbids": ["DB05124"], "name": "ARC183", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05127": {"dbids": ["DB05127"], "name": "ANA971", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05126": {"dbids": ["DB05126"], "name": "PYM50018", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05129": {"dbids": ["DB05129"], "name": "Elsamitrucin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05128": {"dbids": ["DB05128"], "name": "Aminocandin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04456": {"dbids": ["DB04456", "EXPT03008"], "name": "Trihydroxyarsenite(Iii)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04457": {"dbids": ["DB04457", "EXPT01182"], "name": "2'-Deoxyguanosine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01974": {"dbids": ["DB01974", "EXPT00029"], "name": "2-Amino-3-[5-(Amino-Carboxy-Methyl)-2,3-Dihydro-Isoxazol-3-Ylsulfanyl]-Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01975": {"dbids": ["DB01975", "EXPT00439"], "name": "AMPCPR", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01972": {"dbids": ["DB01972", "EXPT00246"], "name": "Guanosine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01973": {"dbids": ["DB01973", "EXPT02878"], "name": "O-Benzylsulfonyl-Serine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01970": {"dbids": ["DB01970", "EXPT01736"], "name": "Hg9a-9, Nonanoyl-N-Hydroxyethylglucamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04451": {"dbids": ["DB04451", "EXPT02419"], "name": "4-Methylpiperazin-1-Yl Carbonyl Group", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01978": {"dbids": ["DB01978", "EXPT02320"], "name": "7,9-Dimethylguanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01979": {"dbids": ["DB01979", "DB02284", "EXPT02195"], "name": "Methyl alpha-D-mannoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04188": {"dbids": ["DB04188", "EXPT02139"], "name": "MDL72527", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04189": {"dbids": ["DB04189", "EXPT00953"], "name": "N2-(Carboxyethyl)-L-Arginine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08744": {"dbids": ["DB08744"], "name": "6-methoxy-9-methyl[1,3]dioxolo[4,5-h]quinolin-8(9H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08745": {"dbids": ["DB08745"], "name": "4-[[(1E)-2-(4-CHLOROPHENYL)ETHENYL]SULFONYL]-1-[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]PIPERAZINONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08742": {"dbids": ["DB08742"], "name": "1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08743": {"dbids": ["DB08743"], "name": "2-({8-[(3R)-3-AMINOPIPERIDIN-1-YL]-1,3-DIMETHYL-2,6-DIOXO-1,2,3,6-TETRAHYDRO-7H-PURIN-7-YL}METHYL)BENZONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08740": {"dbids": ["DB08740"], "name": "CYCLOHEXYLMETHYL-2,3-DIHYDROXY-5-METHYL-HEXYLAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08741": {"dbids": ["DB08741"], "name": "5-[[(2R)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl]methyl]pyrimidine-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04180": {"dbids": ["DB04180", "EXPT01896"], "name": "4-(Aminosulfonyl)-N-[(2,4-Difluorophenyl)Methyl]-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04181": {"dbids": ["DB04181", "EXPT00885"], "name": "Cefotaxime Group", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04182": {"dbids": ["DB04182", "EXPT01982"], "name": "(S)-2-Amino-4-[(2s,3r)-2,3,5-Trihydroxy-4-Oxo-Pentyl]Mercapto-Butyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04183": {"dbids": ["DB04183", "EXPT01309"], "name": "Methylmalonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04185": {"dbids": ["DB04185", "EXPT02397"], "name": "Norvaline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04186": {"dbids": ["DB04186", "EXPT00083"], "name": "N'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04187": {"dbids": ["DB04187", "EXPT01642"], "name": "(9s,10s)-9-(S-Glutathionyl)-10-Hydroxy-9,10-Dihydrophenanthrene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00513": {"dbids": ["APRD00791", "DB00513", "DB04134", "EXPT00408", "EXPT00461"], "name": "Aminocaproic Acid", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P00747", "drug": "DB00513"}, {"action": "ANTAGONIST", "target": "P00750", "drug": "DB00513"}, {"action": "OTHER", "target": "P08519", "drug": "DB00513"}]}, "DB00512": {"dbids": ["APRD01287", "DB00512", "EXPT03217"], "name": "Vancomycin", "groups": ["APPROVED"], "targets": [{"action": "OTHER", "target": "P96558", "drug": "DB00512"}]}, "DB00511": {"dbids": ["APRD01334", "DB00511"], "name": "Acetyldigitoxin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P05023", "drug": "DB00511"}]}, "DB00517": {"dbids": ["APRD00800", "DB00517"], "name": "Anisotropine Methylbromide", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00517"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00517"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00517"}]}, "DB00516": {"dbids": ["APRD00819", "DB00516"], "name": "Bentoquatam", "groups": ["APPROVED"], "targets": []}, "DB00515": {"dbids": ["APRD00359", "DB00515"], "name": "Cisplatin", "groups": ["APPROVED"], "targets": []}, "DB00514": {"dbids": ["APRD00655", "DB00514"], "name": "Dextromethorphan", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "Q99720", "drug": "DB00514"}, {"action": "AGONIST", "target": "Q5T1J1", "drug": "DB00514"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00514"}, {"action": "ANTAGONIST", "target": "Q15822", "drug": "DB00514"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00514"}, {"action": "BINDER", "target": "O00264", "drug": "DB00514"}, {"action": "ANTAGONIST", "target": "P32297", "drug": "DB00514"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00514"}, {"action": "ANTAGONIST", "target": "P30926", "drug": "DB00514"}, {"action": "ANTAGONIST", "target": "P17787", "drug": "DB00514"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00514"}, {"action": "AGONIST", "target": "P35372", "drug": "DB00514"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00514"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00514"}, {"action": "INHIBITOR", "target": "P04839", "drug": "DB00514"}, {"action": "INHIBITOR", "target": "P13498", "drug": "DB00514"}, {"action": "INHIBITOR", "target": "P14598", "drug": "DB00514"}, {"action": "INHIBITOR", "target": "P19878", "drug": "DB00514"}, {"action": "INHIBITOR", "target": "Q15080", "drug": "DB00514"}, {"action": "INHIBITOR", "target": "P63000", "drug": "DB00514"}, {"action": "INHIBITOR", "target": "P15153", "drug": "DB00514"}]}, "DB00519": {"dbids": ["APRD01269", "DB00519"], "name": "Trandolapril", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P12821", "drug": "DB00519"}]}, "DB00518": {"dbids": ["APRD00782", "DB00518"], "name": "Albendazole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "F1L7U3", "drug": "DB00518"}, {"action": "INHIBITOR", "target": "Q71U36", "drug": "DB00518"}, {"action": "INHIBITOR", "target": "P68371", "drug": "DB00518"}, {"action": "INHIBITOR", "target": "P83223", "drug": "DB00518"}]}, "DB06968": {"dbids": ["DB06968"], "name": "1,1'-HEXANE-1,6-DIYLBIS(1H-IMIDAZOLE)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06969": {"dbids": ["DB06969"], "name": "2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06960": {"dbids": ["DB06960"], "name": "N-[(1R,2R,3E)-2-hydroxy-1-(hydroxymethyl)heptadec-3-en-1-yl]acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06961": {"dbids": ["DB06961"], "name": "5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06962": {"dbids": ["DB06962"], "name": "(5-(aminomethyl)-2H-spiro[benzofuran-3,4'-piperidine]-1'-yl)(5-(phenylethynyl)furan-2-yl)methanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06963": {"dbids": ["DB06963"], "name": "3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06964": {"dbids": ["DB06964"], "name": "5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06965": {"dbids": ["DB06965"], "name": "HEXYLPHOSPHONIC ACID (R)-2-METHYL-3-PHENYLPROPYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06966": {"dbids": ["DB06966"], "name": "HEXYLPHOSPHONIC ACID (S)-2-METHYL-3-PHENYLPROPYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06967": {"dbids": ["DB06967"], "name": "6-ETHYL-5-[9-(3-METHOXYPROPYL)-9H-CARBAZOL-2-YL]PYRIMIDINE-2,4-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01604": {"dbids": ["DB01604"], "name": "Pivampicillin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01604"}]}, "DB04981": {"dbids": ["DB04981"], "name": "CG7870", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04230": {"dbids": ["DB04230", "EXPT02369"], "name": "Nitromethyldethia Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04983": {"dbids": ["DB04983"], "name": "Denufosol", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01600": {"dbids": ["DB01600"], "name": "Tiaprofenic acid", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB01600"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB01600"}]}, "DB04237": {"dbids": ["DB04237", "EXPT03004"], "name": "Tris(Hydroxyethyl)Aminomethane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04986": {"dbids": ["DB04986"], "name": "ZYC300", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01603": {"dbids": ["DB01603"], "name": "Meticillin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q53707", "drug": "DB01603"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB01603"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB01603"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB01603"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB01603"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB01603"}]}, "DB04988": {"dbids": ["DB04988"], "name": "IGN311", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04989": {"dbids": ["DB04989"], "name": "Ty800", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04238": {"dbids": ["DB04238", "EXPT01409"], "name": "N-Alpha-(2-Naphthylsulfonyl)-N-(3-Amidino-L-Phenylalaninyl)-D-Pipecolinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04239": {"dbids": ["DB04239", "EXPT01975"], "name": "2-Amino-6-Aminomethyl-8-Phenylsulfanylmethyl-3h-Quinazolin-4-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01608": {"dbids": ["DB01608"], "name": "Propericiazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P21728", "drug": "DB01608"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01608"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01608"}]}, "DB01609": {"dbids": ["DB01609"], "name": "Deferasirox", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB06089": {"dbids": ["DB06089"], "name": "ICA-105665", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB09249": {"dbids": ["DB09249"], "name": "Octamoxin", "groups": ["WITHDRAWN"], "targets": []}, "DB06080": {"dbids": ["DB06080"], "name": "ABT-869", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07185": {"dbids": ["DB07185"], "name": "2-{[(4-CHLOROPHENOXY)ACETYL]AMINO}BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07184": {"dbids": ["DB07184"], "name": "6-(cyclohexylsulfanyl)-1-(ethoxymethyl)-5-(1-methylethyl)pyrimidine-2,4(1H,3H)-dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07187": {"dbids": ["DB07187"], "name": "6-[(5-CHLORO-3-METHYL-1-BENZOFURAN-2-YL)SULFONYL]PYRIDAZIN-3(2H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07186": {"dbids": ["DB07186"], "name": "4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07181": {"dbids": ["DB07181"], "name": "4'-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]biphenyl-3-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07180": {"dbids": ["DB07180"], "name": "5-[(Z)-(5-CHLORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]-N-(DIETHYLAMINO)ETHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07183": {"dbids": ["DB07183"], "name": "N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07182": {"dbids": ["DB07182"], "name": "(2S)-2-(3-{[AMINO(IMINO)METHYL]AMINO}PHENYL)-3-[(S)-HYDROXY(3-PHENYLPROPYL)PHOSPHORYL]PROPANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07189": {"dbids": ["DB07189"], "name": "(1S,3R,6S)-4-oxo-6-{4-[(2-phenylquinolin-4-yl)methoxy]phenyl}-5-azaspiro[2.4]heptane-1-carboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07188": {"dbids": ["DB07188"], "name": "(3S)-1-CYCLOHEXYL-N-(3,5-DICHLOROPHENYL)-5-OXOPYRROLIDINE-3-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07577": {"dbids": ["DB07577"], "name": "6-ETHYL-5-PHENYLPYRIMIDINE-2,4-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09322": {"dbids": ["DB09322"], "name": "Zinc sulfate", "groups": ["APPROVED"], "targets": []}, "DB02119": {"dbids": ["DB02119", "EXPT01746"], "name": "6-Hydroxymethyl-7,8-Dihydropterin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02118": {"dbids": ["DB02118", "EXPT00996"], "name": "CP-271485", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02115": {"dbids": ["DB02115", "EXPT01311"], "name": "Daidzin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02114": {"dbids": ["DB02114", "EXPT01936"], "name": "Para-Isopropylaniline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02116": {"dbids": ["DB02116", "EXPT02433"], "name": "Olomoucine", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P24941", "drug": "DB02116"}, {"action": "INHIBITOR", "target": "Q00535", "drug": "DB02116"}, {"action": "BINDER", "target": "P06493", "drug": "DB02116"}]}, "DB02111": {"dbids": ["DB02111", "EXPT01545"], "name": "3-Hydroxyisoxazole-4-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02110": {"dbids": ["DB02110", "EXPT00984"], "name": "Protoporphyrin Ix Containing Co", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02113": {"dbids": ["DB02113", "EXPT00287"], "name": "6-Methylpurine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02112": {"dbids": ["DB02112", "EXPT00320"], "name": "Zk-806450", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07761": {"dbids": ["DB07761"], "name": "(2R)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07760": {"dbids": ["DB07760"], "name": "3-[(1E,7E)-8-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-3,6-dioxa-2,7-diazaocta-1,7-dien-1-yl]benzoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07763": {"dbids": ["DB07763"], "name": "(5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07762": {"dbids": ["DB07762"], "name": "4-(N-ACETYLAMINO)-3-[N-(2-ETHYLBUTANOYLAMINO)]BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07765": {"dbids": ["DB07765"], "name": "METHYL 1-(4-{[(2,4-DIAMINOPTERIDIN-6-YL)METHYL](METHYL)AMINO}BENZOYL)PIPERIDINE-4-CARBOXYLATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07764": {"dbids": ["DB07764"], "name": "FLUORESCIN", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07767": {"dbids": ["DB07767"], "name": "3-(4-HYDROXY-3-METHOXYPHENYL)-2-PROPENOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07766": {"dbids": ["DB07766"], "name": "(2Z,3E)-2,3'-BIINDOLE-2',3(1H,1'H)-DIONE 3-{O-[(3R)-3,4-DIHYDROXYBUTYL]OXIME}", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07769": {"dbids": ["DB07769"], "name": "S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07768": {"dbids": ["DB07768"], "name": "(10ALPHA,13ALPHA,14BETA,17ALPHA)-17-HYDROXYANDROST-4-EN-3-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08801": {"dbids": ["DB08801"], "name": "Dimetindene", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB08801"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB08801"}]}, "DB02227": {"dbids": ["DB02227", "EXPT01564"], "name": "4,5-Dihydroxy-Tetrahydro-Pyran-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06589": {"dbids": ["DB06589"], "name": "Pazopanib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P17948", "drug": "DB06589"}, {"action": "INHIBITOR", "target": "P35968", "drug": "DB06589"}, {"action": "INHIBITOR", "target": "P16234", "drug": "DB06589"}, {"action": "INHIBITOR", "target": "P09619", "drug": "DB06589"}, {"action": "INHIBITOR", "target": "P10721", "drug": "DB06589"}, {"action": "INHIBITOR", "target": "P22607", "drug": "DB06589"}, {"action": "INHIBITOR", "target": "Q08881", "drug": "DB06589"}, {"action": "INHIBITOR", "target": "P05230", "drug": "DB06589"}, {"action": "INHIBITOR", "target": "Q9UQQ2", "drug": "DB06589"}]}, "DB06581": {"dbids": ["DB06581"], "name": "Bevirimat", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB02809": {"dbids": ["DB02809", "EXPT00651"], "name": "Brodimoprim-4,6-Dicarboxylate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02808": {"dbids": ["DB02808", "EXPT01427"], "name": "Trifluorofurnesyl Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02803": {"dbids": ["DB02803", "EXPT02644"], "name": "3-Phenyl-1,2-Propandiol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02802": {"dbids": ["DB02802", "EXPT01462"], "name": "5-Aminocarbonyl-3-Nitrophenyl-Alpha-D-Galactopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02801": {"dbids": ["DB02801", "EXPT01385"], "name": "2,3 -Anhydro-Quinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02800": {"dbids": ["DB02800", "EXPT03049"], "name": "5-Hydroxymethylene-6-Hydrofolic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02807": {"dbids": ["DB02807", "EXPT02819"], "name": "D-2-Keto-3-Deoxygalactonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02806": {"dbids": ["DB02806", "EXPT02260"], "name": "2-Methoxyethanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02805": {"dbids": ["DB02805", "EXPT03163"], "name": "1-(3-O-Phosphono-Beta-L-Arabinofuranosyl)Pyrimidine-2,4(1h,3h)-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02804": {"dbids": ["DB02804", "EXPT00377"], "name": "A-98881", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05468": {"dbids": ["DB05468"], "name": "R411", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05469": {"dbids": ["DB05469"], "name": "R450", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05464": {"dbids": ["DB05464"], "name": "NOX-700", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05465": {"dbids": ["DB05465"], "name": "MLN-518", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05466": {"dbids": ["DB05466"], "name": "R673", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05467": {"dbids": ["DB05467"], "name": "R667", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05460": {"dbids": ["DB05460"], "name": "TLK-199", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05461": {"dbids": ["DB05461"], "name": "OPC-28326", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05462": {"dbids": ["DB05462"], "name": "131-I-TM-601", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05463": {"dbids": ["DB05463"], "name": "ISS-1018", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03608": {"dbids": ["DB03608", "EXPT00754"], "name": "Diminazene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03609": {"dbids": ["DB03609", "EXPT00167"], "name": "3-Deoxyguanosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03606": {"dbids": ["DB03606", "EXPT00229"], "name": "(S)-Rolipram", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "Q07343", "drug": "DB03606"}]}, "DB03607": {"dbids": ["DB03607", "EXPT00936"], "name": "D-Para-Chlorophenyl-1-Acetamidoboronic Acid Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03604": {"dbids": ["DB03604", "EXPT00217"], "name": "[4-(4-Hydroxy-3-Iodo-Phenoxy)-3,5-Diiodo-Phenyl]-Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03605": {"dbids": ["DB03605", "EXPT00039"], "name": "(2s)-2-[(2,4-Dichloro-Benzoyl)-(3-Trifluoromethyl-Benzyl)-Amino]-3-Phenyl-Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03602": {"dbids": ["DB03602", "EXPT01647"], "name": "S-Benzyl-Glutathione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03603": {"dbids": ["DB03603", "EXPT01594"], "name": "Glucarate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03600": {"dbids": ["DB03600", "DB03838", "EXPT01213"], "name": "Decanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03601": {"dbids": ["DB03601", "EXPT01172"], "name": "5-deoxyflavanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09208": {"dbids": ["DB09208"], "name": "Pegloticase", "groups": ["APPROVED"], "targets": []}, "DB09209": {"dbids": ["DB09209"], "name": "Pholcodine", "groups": ["APPROVED", "ILLICIT"], "targets": []}, "DB09200": {"dbids": ["DB09200"], "name": "Rivoglitazone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09201": {"dbids": ["DB09201"], "name": "Ciglitazone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09202": {"dbids": ["DB09202"], "name": "Cirazoline", "groups": ["EXPERIMENTAL"], "targets": [{"action": "AGONIST", "target": "P35348", "drug": "DB09202"}, {"action": "PARTIAL AGONIST", "target": "P35368", "drug": "DB09202"}, {"action": "PARTIAL AGONIST", "target": "P25100", "drug": "DB09202"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB09202"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB09202"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB09202"}]}, "DB06129": {"dbids": ["DB06129"], "name": "SVV-001", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB09203": {"dbids": ["DB09203"], "name": "Synephrine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09205": {"dbids": ["DB09205"], "name": "Moxisylyte", "groups": ["APPROVED"], "targets": []}, "DB06696": {"dbids": ["DB06696"], "name": "Arbekacin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A7S3", "drug": "DB06696"}]}, "DB09206": {"dbids": ["DB09206"], "name": "Trimazosin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06697": {"dbids": ["DB06697"], "name": "Artemether", "groups": ["APPROVED"], "targets": []}, "DB09207": {"dbids": ["DB09207"], "name": "AS-8112", "groups": ["EXPERIMENTAL"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB09207"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB09207"}, {"action": "ANTAGONIST", "target": "Q9UE69", "drug": "DB09207"}]}, "DB06694": {"dbids": ["DB06694"], "name": "Xylometazoline", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35348", "drug": "DB06694"}, {"action": "AGONIST", "target": "P08913", "drug": "DB06694"}, {"action": "AGONIST", "target": "P18089", "drug": "DB06694"}, {"action": "AGONIST", "target": "P35368", "drug": "DB06694"}, {"action": "AGONIST", "target": "P25100", "drug": "DB06694"}, {"action": "AGONIST", "target": "P18825", "drug": "DB06694"}]}, "DB06127": {"dbids": ["DB06127"], "name": "KRP-104", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06692": {"dbids": ["DB06692"], "name": "Aprotinin", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB09328": {"dbids": ["DB09328"], "name": "Vayarin", "groups": ["APPROVED"], "targets": []}, "DB06693": {"dbids": ["DB06693"], "name": "Mevastatin", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P04035", "drug": "DB06693"}]}, "DB06690": {"dbids": ["DB06690"], "name": "Nitrous oxide", "groups": ["APPROVED"], "targets": []}, "DB06691": {"dbids": ["DB06691"], "name": "Mepyramine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB06691"}]}, "DB07974": {"dbids": ["DB07974"], "name": "1-{2-[(4-CHLOROPHENYL)AMINO]-2-OXOETHYL}-N-(1-ISOPROPYLPIPERIDIN-4-YL)-1H-INDOLE-2-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07975": {"dbids": ["DB07975"], "name": "2-({[3,5-DIFLUORO-3'-(TRIFLUOROMETHOXY)BIPHENYL-4-YL]AMINO}CARBONYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07976": {"dbids": ["DB07976"], "name": "3-{[(3-FLUORO-3'-METHOXYBIPHENYL-4-YL)AMINO]CARBONYL}THIOPHENE-2-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07977": {"dbids": ["DB07977"], "name": "3-({[3,5-DIFLUORO-3'-(TRIFLUOROMETHOXY)BIPHENYL-4-YL]AMINO}CARBONYL)THIOPHENE-2-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07970": {"dbids": ["DB07970"], "name": "5-[(2-methyl-5-{[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)amino]pyridine-3-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07971": {"dbids": ["DB07971"], "name": "5-AMINO-2-{4-[(4-AMINOPHENYL)SULFANYL]PHENYL}-1H-ISOINDOLE-1,3(2H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07972": {"dbids": ["DB07972"], "name": "1-(3-METHYLPHENYL)-1H-BENZIMIDAZOL-5-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07973": {"dbids": ["DB07973"], "name": "N-(1-ISOPROPYLPIPERIDIN-4-YL)-1-(3-METHOXYBENZYL)-1H-INDOLE-2-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07978": {"dbids": ["DB07978"], "name": "2-({[2,3,5,6-TETRAFLUORO-3'-(TRIFLUOROMETHOXY)BIPHENYL-4-YL]AMINO}CARBONYL)CYCLOPENTA-1,3-DIENE-1-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07979": {"dbids": ["DB07979"], "name": "(2E)-3-(3,4-DIHYDROXYPHENYL)-2-IMINOPROPANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08541": {"dbids": ["DB08541"], "name": "[(3S)-9-hydroxy-1-methyl-10-oxo-4,10-dihydro-3H-benzo[g]isochromen-3-yl]acetic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01953": {"dbids": ["DB01953", "EXPT01988"], "name": "Inhibitor of P38 Kinase", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00728": {"dbids": ["APRD01221", "DB00728"], "name": "Rocuronium", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q15822", "drug": "DB00728"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00728"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00728"}]}, "DB00729": {"dbids": ["APRD00928", "DB00729"], "name": "Diphemanil Methylsulfate", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P20309", "drug": "DB00729"}]}, "DB08668": {"dbids": ["DB08668"], "name": "3-(5-amino-3-imino-3H-pyrazol-4-ylazo)-benzoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00720": {"dbids": ["APRD00639", "DB00720"], "name": "Clodronate", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P12235", "drug": "DB00720"}, {"action": "INHIBITOR", "target": "P05141", "drug": "DB00720"}, {"action": "INHIBITOR", "target": "P12236", "drug": "DB00720"}]}, "DB00721": {"dbids": ["APRD00650", "DB00721"], "name": "Procaine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00721"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00721"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00721"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00721"}, {"action": "ANTAGONIST", "target": "Q15822", "drug": "DB00721"}, {"action": "BINDER", "target": "Q12791", "drug": "DB00721"}, {"action": "BINDER", "target": "Q16558", "drug": "DB00721"}, {"action": "BINDER", "target": "Q9Y691", "drug": "DB00721"}, {"action": "BINDER", "target": "Q9NPA1", "drug": "DB00721"}, {"action": "BINDER", "target": "Q86W47", "drug": "DB00721"}, {"action": "BINDER", "target": "O15554", "drug": "DB00721"}, {"action": "BINDER", "target": "Q92952", "drug": "DB00721"}, {"action": "BINDER", "target": "Q9H2S1", "drug": "DB00721"}, {"action": "BINDER", "target": "Q9UGI6", "drug": "DB00721"}]}, "DB00722": {"dbids": ["APRD00560", "DB00722"], "name": "Lisinopril", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P12821", "drug": "DB00722"}, {"action": "INHIBITOR", "target": "Q9BYF1", "drug": "DB00722"}]}, "DB00723": {"dbids": ["APRD00062", "DB00723"], "name": "Methoxamine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35348", "drug": "DB00723"}, {"action": "AGONIST", "target": "P35368", "drug": "DB00723"}, {"action": "BINDER", "target": "P25100", "drug": "DB00723"}]}, "DB00724": {"dbids": ["APRD01030", "DB00724"], "name": "Imiquimod", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "Q9NYK1", "drug": "DB00724"}, {"action": "AGONIST", "target": "Q9NR97", "drug": "DB00724"}]}, "DB00725": {"dbids": ["APRD01017", "DB00725"], "name": "Homatropine Methylbromide", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08172", "drug": "DB00725"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00725"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00725"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00725"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00725"}]}, "DB00726": {"dbids": ["APRD00498", "DB00726"], "name": "Trimipramine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P31645", "drug": "DB00726"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00726"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00726"}, {"action": "AGONIST", "target": "P28223", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00726"}, {"action": "OTHER/UNKNOWN", "target": "P14416", "drug": "DB00726"}, {"action": "OTHER/UNKNOWN", "target": "P18089", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00726"}, {"action": "BINDER", "target": "P46098", "drug": "DB00726"}, {"action": "BINDER", "target": "P28221", "drug": "DB00726"}, {"action": "DESENSITIZE THE TARGET", "target": "P08913", "drug": "DB00726"}, {"action": "BINDER", "target": "P21728", "drug": "DB00726"}, {"action": "BINDER", "target": "P21918", "drug": "DB00726"}, {"action": "BINDER", "target": "P08588", "drug": "DB00726"}, {"action": "BINDER", "target": "P07550", "drug": "DB00726"}, {"action": "BINDER", "target": "P13945", "drug": "DB00726"}, {"action": "BINDER", "target": "P11229", "drug": "DB00726"}, {"action": "BINDER", "target": "P08172", "drug": "DB00726"}, {"action": "BINDER", "target": "P20309", "drug": "DB00726"}, {"action": "BINDER", "target": "P08173", "drug": "DB00726"}, {"action": "BINDER", "target": "P08912", "drug": "DB00726"}, {"action": "BINDER", "target": "P08909", "drug": "DB00726"}]}, "DB00727": {"dbids": ["APRD00153", "DB00727"], "name": "Nitroglycerin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P16066", "drug": "DB00727"}]}, "DB08230": {"dbids": ["DB08230"], "name": "5,7-DIHYDROXY-2-(3,4,5-TRIHYDROXYPHENYL)-4H-CHROMEN-4-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08953": {"dbids": ["DB08953"], "name": "Indalpine", "groups": ["INVESTIGATIONAL", "WITHDRAWN"], "targets": []}, "DB08667": {"dbids": ["DB08667"], "name": "4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08952": {"dbids": ["DB08952"], "name": "Indenolol", "groups": ["WITHDRAWN"], "targets": []}, "DB02865": {"dbids": ["DB02865", "EXPT01634"], "name": "Glucosamine 4-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08666": {"dbids": ["DB08666"], "name": "5-imino-4-(3-trifluoromethyl-phenylazo)-5H-pyrazol-3-ylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02864": {"dbids": ["DB02864", "EXPT00720"], "name": "Biliverdin Ix Gamma Chromophore", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08950": {"dbids": ["DB08950"], "name": "Indoramin", "groups": ["WITHDRAWN"], "targets": []}, "DB08957": {"dbids": ["DB08957"], "name": "Hexoprenaline", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB08956": {"dbids": ["DB08956"], "name": "Hydroxydione", "groups": ["INVESTIGATIONAL", "WITHDRAWN"], "targets": []}, "DB00236": {"dbids": ["APRD00693", "DB00236"], "name": "Pipobroman", "groups": ["APPROVED"], "targets": []}, "DB02869": {"dbids": ["DB02869", "EXPT02332"], "name": "3-amino-5-phenylpentane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00234": {"dbids": ["APRD00198", "DB00234"], "name": "Reboxetine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P23975", "drug": "DB00234"}]}, "DB00235": {"dbids": ["APRD00010", "DB00235"], "name": "Milrinone", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14432", "drug": "DB00235"}]}, "DB00232": {"dbids": ["APRD01104", "DB00232"], "name": "Methyclothiazide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q13621", "drug": "DB00232"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00232"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00232"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00232"}]}, "DB00233": {"dbids": ["APRD00749", "DB00233", "EXPT00693"], "name": "Aminosalicylic Acid", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00233"}, {"action": "INHIBITOR", "target": "O15111", "drug": "DB00233"}, {"action": "INHIBITOR", "target": "P09917", "drug": "DB00233"}, {"action": "UNKNOWN", "target": "Q9NZK7", "drug": "DB00233"}, {"action": "UNKNOWN", "target": "P64143", "drug": "DB00233"}]}, "DB00230": {"dbids": ["APRD01198", "DB00230"], "name": "Pregabalin", "groups": ["APPROVED", "ILLICIT", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "O00555", "drug": "DB00230"}]}, "DB02868": {"dbids": ["DB02868", "EXPT01963"], "name": "3''-(Beta-Chloroethyl)-2'',4''-Dioxo-3, 5''-Spiro-Oxazolidino-4-Deacetoxy-Vinblastine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08954": {"dbids": ["DB08954"], "name": "Ifenprodil", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "Q05586", "drug": "DB08954"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB08954"}]}, "DB00238": {"dbids": ["APRD00705", "DB00238", "DB08311"], "name": "Nevirapine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q72547", "drug": "DB00238"}]}, "DB00239": {"dbids": ["APRD01154", "DB00239"], "name": "Oxiconazole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P10613", "drug": "DB00239"}, {"action": "INHIBITOR", "target": "Q04782", "drug": "DB00239"}]}, "DB03453": {"dbids": ["DB03453", "EXPT01490"], "name": "(R)\u2014N[2-[1-(aminoiminomethyl)-3-piperidinyl]-1-oxoethyl]-4-(phenylethynyl)-l-phenylalanine methylester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03452": {"dbids": ["DB03452", "EXPT02910"], "name": "3-Trimethylsilylsuccinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03451": {"dbids": ["DB03451", "EXPT01970"], "name": "1-alpha, 25-dihydroxyl-20-epi-22-oxa-24, 26 ,27-trihomovitamin D3", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03450": {"dbids": ["DB03450", "EXPT00891"], "name": "Cephalothin Group", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03456": {"dbids": ["DB03456", "EXPT02301"], "name": "N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03455": {"dbids": ["DB03455", "EXPT02219"], "name": "(1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03454": {"dbids": ["DB03454", "EXPT02120"], "name": "3-methyl-benzene-1,2-diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03459": {"dbids": ["DB03459", "EXPT02494"], "name": "N-(phosphonacetyl)-L-aspartic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03458": {"dbids": ["DB03458", "EXPT02836"], "name": "N(4)-adenosyl-N(4)-methyl-2,4-diaminobutanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06267": {"dbids": ["DB06267"], "name": "Udenafil", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "O76074", "drug": "DB06267"}]}, "DB08264": {"dbids": ["DB08264"], "name": "(1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08267": {"dbids": ["DB08267"], "name": "6-amino-4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04396": {"dbids": ["DB04396", "EXPT03030"], "name": "Thiodigalactoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08261": {"dbids": ["DB08261"], "name": "2-hydroxy-7-methoxy-5-methyl-naphthalene-1-carboxylic acid meso-2,5-dihydroxy-cyclopent-3-enyl ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08260": {"dbids": ["DB08260"], "name": "(1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08263": {"dbids": ["DB08263"], "name": "N-(carboxycarbonyl)-D-phenylalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08262": {"dbids": ["DB08262"], "name": "2,6-dicarboxynaphthalene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08268": {"dbids": ["DB08268"], "name": "6-AMINO-4-[2-(4-METHYLPHENYL)ETHYL]-1,7-DIHYDRO-8H-IMIDAZO[4,5-G]QUINAZOLIN-8-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07378": {"dbids": ["DB07378"], "name": "4-AMINO-2-OCTYLOXY-6-HYDROXYMETHYL-TETRAHYDRO-PYRAN-3,5-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07379": {"dbids": ["DB07379"], "name": "(2S)-2-({6-[(3-AMINO-5-CHLOROPHENYL)AMINO]-9-ISOPROPYL-9H-PURIN-2-YL}AMINO)-3-METHYLBUTAN-1-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04570": {"dbids": ["DB04570"], "name": "Latamoxef", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P42971", "drug": "DB04570"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB04570"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB04570"}, {"action": "INHIBITOR", "target": "P24228", "drug": "DB04570"}]}, "DB00892": {"dbids": ["APRD00817", "DB00892"], "name": "Oxybuprocaine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00892"}]}, "DB00893": {"dbids": ["APRD01053", "DB00893"], "name": "Iron Dextran", "groups": ["APPROVED"], "targets": [{"action": "ACTIVATOR", "target": "P68871", "drug": "DB00893"}, {"action": "ACTIVATOR", "target": "P69905", "drug": "DB00893"}, {"action": "OTHER", "target": "P02794", "drug": "DB00893"}, {"action": "OTHER", "target": "P02792", "drug": "DB00893"}]}, "DB00890": {"dbids": ["APRD00917", "DB00890"], "name": "Dienestrol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P03372", "drug": "DB00890"}]}, "DB00891": {"dbids": ["APRD00491", "DB00891"], "name": "Sulfapyridine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q49184", "drug": "DB00891"}]}, "DB00672": {"dbids": ["APRD00029", "DB00672"], "name": "Chlorpropamide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q09428", "drug": "DB00672"}]}, "DB00673": {"dbids": ["APRD00100", "DB00673"], "name": "Aprepitant", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P25103", "drug": "DB00673"}]}, "DB00670": {"dbids": ["APRD00515", "DB00670"], "name": "Pirenzepine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00670"}]}, "DB00895": {"dbids": ["APRD00822", "DB00895"], "name": "Benzylpenicilloyl Polylysine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P30273", "drug": "DB00895"}, {"action": "AGONIST", "target": "P12319", "drug": "DB00895"}]}, "DB05859": {"dbids": ["DB05859"], "name": "PI-166", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05858": {"dbids": ["DB05858"], "name": "BI-K0376", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05855": {"dbids": ["DB05855"], "name": "Rivanicline", "groups": ["INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P10145", "drug": "DB05855"}]}, "DB05854": {"dbids": ["DB05854"], "name": "CLX-0921", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05857": {"dbids": ["DB05857"], "name": "Q-Derp1", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05856": {"dbids": ["DB05856"], "name": "CPD 923", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05851": {"dbids": ["DB05851"], "name": "Biomed 101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05852": {"dbids": ["DB05852"], "name": "cryopreserved human liver cells", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB02498": {"dbids": ["DB02498", "EXPT00963"], "name": "Carba-Nicotinamide-Adenine-Dinucleotide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02499": {"dbids": ["DB02499", "EXPT01209"], "name": "Dinor-N(Omega)-Hydroxy-L-Arginine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02494": {"dbids": ["DB02494", "EXPT01733"], "name": "Alpha-Hydroxy-Beta-Phenyl-Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02495": {"dbids": ["DB02495", "EXPT00745"], "name": "9-(4-hydroxybutyl)-N2-phenylguanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02496": {"dbids": ["DB02496", "EXPT01308"], "name": "1-Deoxy-D-xylulose 5-phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02497": {"dbids": ["DB02497", "EXPT01649"], "name": "L-Alpha-Glycerophosphorylserine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02490": {"dbids": ["DB02490", "EXPT01907"], "name": "(Diaminomethyl-Methyl-Amino)-Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02491": {"dbids": ["DB02491", "EXPT00378"], "name": "4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02492": {"dbids": ["DB02492", "EXPT01590"], "name": "Ghavamiol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02493": {"dbids": ["DB02150", "DB02493", "EXPT01683"], "name": "Hydantocidin-5'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05149": {"dbids": ["DB05149"], "name": "XL844", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05148": {"dbids": ["DB05148"], "name": "CG0070", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05143": {"dbids": ["DB05143"], "name": "OXI4503", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05142": {"dbids": ["DB05142"], "name": "ND7001", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05141": {"dbids": ["DB05141"], "name": "LY2181308", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05140": {"dbids": ["DB05140"], "name": "RAV12", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05147": {"dbids": ["DB05147"], "name": "CYT997", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05146": {"dbids": ["DB05146"], "name": "XL820", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05145": {"dbids": ["DB05145"], "name": "TH0318", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05144": {"dbids": ["DB05144"], "name": "PEV3A", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01910": {"dbids": ["DB01910", "EXPT02890"], "name": "Adenosyl-Ornithine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01911": {"dbids": ["DB01911", "EXPT02198"], "name": "N-Methylmesoporphyrin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01912": {"dbids": ["DB01912", "EXPT03097"], "name": "2,2':6',2''-Terpyridine Platinum(Ii)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04433": {"dbids": ["DB04433", "EXPT00499"], "name": "N''-{3-[(3s,8ar)-1,4-Dioxooctahydropyrrolo[1,2-a]Pyrazin-3-Yl]Propyl}Guanidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01914": {"dbids": ["DB01914", "EXPT01609"], "name": "D-Glucose in Linear Form", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01915": {"dbids": ["DB01915", "DB03398", "EXPT01035"], "name": "S-Hydroxycysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04436": {"dbids": ["DB04436", "EXPT03275"], "name": "3-Fluorotyrosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01917": {"dbids": ["DB01917", "EXPT02702"], "name": "Putrescine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01918": {"dbids": ["DB01918", "EXPT02242"], "name": "[Methyltelluro]Acetate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01919": {"dbids": ["DB01919", "EXPT02684"], "name": "Pentanal", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08555": {"dbids": ["DB08555"], "name": "1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08720": {"dbids": ["DB08720"], "name": "5-(5-(4-(4,5-dihydro-2-oxazoly)phenoxy)pentyl)-3-methyl osoxazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08721": {"dbids": ["DB08721"], "name": "5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-(hydroxyethyl oxymethyleneoxymethyl) isoxazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08722": {"dbids": ["DB08722"], "name": "5-(7-(6-chloro-4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08554": {"dbids": ["DB08554"], "name": "N-(3-carboxypropanoyl)-L-norvaline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08724": {"dbids": ["DB08724"], "name": "5-(5-(4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)pentyl)-3-methyl isoxazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08725": {"dbids": ["DB08725"], "name": "5-(7-(5-hydro-4-ethyl-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08726": {"dbids": ["DB08726"], "name": "5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08727": {"dbids": ["DB08727"], "name": "5-(7-(5-hydro-4-methyl-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08728": {"dbids": ["DB08728"], "name": "5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08553": {"dbids": ["DB08553"], "name": "(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08552": {"dbids": ["DB08552"], "name": "(1R)-1-(2-thienylacetylamino)-1-phenylmethylboronic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06942": {"dbids": ["DB06942"], "name": "N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-L-prolinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06943": {"dbids": ["DB06943"], "name": "(3S)-1-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}pyrrolidine-3-thiol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06940": {"dbids": ["DB06940"], "name": "N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06941": {"dbids": ["DB06941"], "name": "(Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00539": {"dbids": ["APRD00391", "DB00539"], "name": "Toremifene", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "MODULATOR", "target": "P03372", "drug": "DB00539"}]}, "DB00538": {"dbids": ["APRD00993", "DB00538"], "name": "Gadoversetamide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB06944": {"dbids": ["DB06944"], "name": "N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06945": {"dbids": ["DB06945"], "name": "N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00535": {"dbids": ["APRD00644", "DB00535"], "name": "Cefdinir", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P08149", "drug": "DB00535"}, {"action": "INHIBITOR", "target": "Q60FT7", "drug": "DB00535"}, {"action": "INHIBITOR", "target": "P05164", "drug": "DB00535"}]}, "DB00534": {"dbids": ["APRD00864", "DB00534"], "name": "Chlormerodrin", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INDUCER", "target": "Q13621", "drug": "DB00534"}, {"action": "INHIBITOR", "target": "P51649", "drug": "DB00534"}]}, "DB00537": {"dbids": ["APRD00424", "DB00537", "EXPT00999"], "name": "Ciprofloxacin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P43702", "drug": "DB00537"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB00537"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00537"}]}, "DB00536": {"dbids": ["APRD01008", "DB00536", "EXPT01546"], "name": "Guanidine", "groups": ["APPROVED"], "targets": []}, "DB00531": {"dbids": ["APRD00408", "DB00531"], "name": "Cyclophosphamide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB00530": {"dbids": ["APRD00951", "DB00530"], "name": "Erlotinib", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P00533", "drug": "DB00530"}, {"action": "AGONIST", "target": "O75469", "drug": "DB00530"}]}, "DB00533": {"dbids": ["APRD00151", "DB00533"], "name": "Rofecoxib", "groups": ["INVESTIGATIONAL", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00533"}, {"action": "OTHER/UNKNOWN", "target": "P15502", "drug": "DB00533"}]}, "DB00532": {"dbids": ["APRD00512", "DB00532"], "name": "Mephenytoin", "groups": ["INVESTIGATIONAL", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB00532"}]}, "DB01628": {"dbids": ["DB01628", "DB07166"], "name": "Etoricoxib", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB01628"}]}, "DB01629": {"dbids": ["DB01629", "EXPT00263"], "name": "5-Fluorouridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01626": {"dbids": ["DB01626"], "name": "Pargyline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P27338", "drug": "DB01626"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB01626"}]}, "DB01627": {"dbids": ["DB01627"], "name": "Lincomycin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A7J6", "drug": "DB01627"}]}, "DB01624": {"dbids": ["DB01624", "DB08919", "DB08920"], "name": "Zuclopenthixol", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P21728", "drug": "DB01624"}, {"action": "ANTAGONIST", "target": "P21918", "drug": "DB01624"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01624"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01624"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01624"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01624"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01624"}]}, "DB01625": {"dbids": ["DB01625"], "name": "Isopropamide", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P20309", "drug": "DB01625"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01625"}]}, "DB01622": {"dbids": ["DB01622"], "name": "Thioproperazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB01622"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01622"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01622"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01622"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01622"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01622"}]}, "DB01623": {"dbids": ["DB01623"], "name": "Thiothixene", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB01623"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01623"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01623"}]}, "DB01620": {"dbids": ["DB01620"], "name": "Pheniramine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB01620"}]}, "DB01621": {"dbids": ["DB01621"], "name": "Pipotiazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB01621"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01621"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01621"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01621"}]}, "DB08098": {"dbids": ["DB08098"], "name": "[5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-yl]thio}acetic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08099": {"dbids": ["DB08099"], "name": "6-ethyl-5-[(2S)-1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08559": {"dbids": ["DB08559"], "name": "N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08092": {"dbids": ["DB08092"], "name": "3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08093": {"dbids": ["DB08093"], "name": "3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08090": {"dbids": ["DB08090"], "name": "(3Z,5S,6R,7S,8R,8aR)-3-(octylimino)hexahydro[1,3]oxazolo[3,4-a]pyridine-5,6,7,8-tetrol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08091": {"dbids": ["DB08091"], "name": "3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08096": {"dbids": ["DB08096"], "name": "8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08097": {"dbids": ["DB08097"], "name": "2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08094": {"dbids": ["DB08094"], "name": "(4-AMINO-2-{[1-(METHYLSULFONYL)PIPERIDIN-4-YL]AMINO}PYRIMIDIN-5-YL)(2,3-DIFLUORO-6-METHOXYPHENYL)METHANONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08095": {"dbids": ["DB08095"], "name": "3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00391": {"dbids": ["APRD00032", "DB00391"], "name": "Sulpiride", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB00391"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB00391"}]}, "DB00390": {"dbids": ["APRD00098", "DB00390"], "name": "Digoxin", "groups": ["APPROVED"], "targets": []}, "DB00393": {"dbids": ["APRD00612", "DB00393"], "name": "Nimodipine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q13936", "drug": "DB00393"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB00393"}, {"action": "INHIBITOR", "target": "O60840", "drug": "DB00393"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB00393"}, {"action": "INHIBITOR", "target": "Q02641", "drug": "DB00393"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB00393"}, {"action": "INHIBITOR", "target": "P54284", "drug": "DB00393"}, {"action": "INHIBITOR", "target": "O00305", "drug": "DB00393"}, {"action": "ANTAGONIST", "target": "P08235", "drug": "DB00393"}, {"action": "AGONIST", "target": "P35869", "drug": "DB00393"}]}, "DB00392": {"dbids": ["APRD00729", "DB00392"], "name": "Ethopropazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00392"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00392"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00392"}]}, "DB00395": {"dbids": ["APRD00417", "DB00395"], "name": "Carisoprodol", "groups": ["APPROVED"], "targets": []}, "DB00394": {"dbids": ["APRD00564", "DB00394"], "name": "Beclomethasone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00394"}]}, "DB00397": {"dbids": ["APRD00457", "DB00397"], "name": "Phenylpropanolamine", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "AGONIST", "target": "P35348", "drug": "DB00397"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00397"}, {"action": "PARTIAL AGONIST", "target": "P21728", "drug": "DB00397"}, {"action": "AGONIST", "target": "P08588", "drug": "DB00397"}, {"action": "AGONIST", "target": "P07550", "drug": "DB00397"}]}, "DB00396": {"dbids": ["APRD00700", "DB00396"], "name": "Progesterone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P06401", "drug": "DB00396"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00396"}, {"action": "ANTAGONIST", "target": "P08235", "drug": "DB00396"}, {"action": "INHIBITOR", "target": "P05093", "drug": "DB00396"}, {"action": "ACTIVATOR", "target": "P41145", "drug": "DB00396"}]}, "DB00399": {"dbids": ["APRD01294", "DB00399", "DB06286"], "name": "Zoledronate", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P14324", "drug": "DB00399"}, {"action": "INHIBITOR", "target": "O95749", "drug": "DB00399"}]}, "DB00398": {"dbids": ["APRD01304", "DB00398", "DB07438"], "name": "Sorafenib", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P15056", "drug": "DB00398"}, {"action": "INHIBITOR", "target": "P04049", "drug": "DB00398"}, {"action": "ANTAGONIST", "target": "P35916", "drug": "DB00398"}, {"action": "ANTAGONIST", "target": "P35968", "drug": "DB00398"}, {"action": "ANTAGONIST", "target": "P36888", "drug": "DB00398"}, {"action": "ANTAGONIST", "target": "P09619", "drug": "DB00398"}, {"action": "ANTAGONIST", "target": "P10721", "drug": "DB00398"}, {"action": "INHIBITOR", "target": "P11362", "drug": "DB00398"}, {"action": "INHIBITOR", "target": "P07949", "drug": "DB00398"}, {"action": "INHIBITOR", "target": "P17948", "drug": "DB00398"}]}, "DB07165": {"dbids": ["DB07165"], "name": "N-(5-CHLORO-BENZO[B]THIOPHEN-3-YLMETHYL)-2-[6-CHLORO-OXO-3-(2-PYRIDIN-2-YL-ETHYLAMINO)-2H-PYRAZIN-1-YL]-ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07164": {"dbids": ["DB07164"], "name": "N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07163": {"dbids": ["DB07163"], "name": "5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07162": {"dbids": ["DB07162"], "name": "4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07161": {"dbids": ["DB07161"], "name": "5-phenyl-1H-indazol-3-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07160": {"dbids": ["DB07160"], "name": "N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09413": {"dbids": ["DB09413"], "name": "Potassium phosphate, monobasic", "groups": ["APPROVED"], "targets": []}, "DB09412": {"dbids": ["DB09412"], "name": "Gallium citrate Ga-67", "groups": ["APPROVED"], "targets": []}, "DB03848": {"dbids": ["DB03848", "EXPT00732"], "name": "Benzenesulfonyl", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03849": {"dbids": ["DB03849", "EXPT00920"], "name": "Cis-4-Cyano-4-[3-(Cyclopentyloxy)-4-Methoxyphenyl]Cyclohexanecarboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03844": {"dbids": ["DB03844", "EXPT01382"], "name": "N-(2,6-Diflouro-Benzyl)-4-Sulfamoyl-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03845": {"dbids": ["DB03845", "EXPT03281"], "name": "P1-(5'-Adenosyl)P5-(5'-(3'azido-3'-Deoxythymidyl))Pentaphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03846": {"dbids": ["DB03846", "EXPT00248"], "name": "5-Hydroxymethyluridine-2'-Deoxy-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03847": {"dbids": ["DB03847", "EXPT00902"], "name": "Gamma-Carboxy-Glutamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03840": {"dbids": ["DB03840", "EXPT01866"], "name": "Tetra(Imidazole)Diaquacopper (Ii)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03841": {"dbids": ["DB03841", "EXPT03278"], "name": "Y-700", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03842": {"dbids": ["DB03842", "EXPT00109"], "name": "2-Chloro-6-Methyl-Aniline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03843": {"dbids": ["DB03843", "EXPT01444"], "name": "Formaldehyde", "groups": ["APPROVED"], "targets": []}, "DB07708": {"dbids": ["DB07708"], "name": "3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07703": {"dbids": ["DB07703"], "name": "(3R,4S,5S,7R,9E,11R,12R)-12-ETHYL-4-HYDROXY-3,5,7,11-TETRAMETHYLOXACYCLODODEC-9-ENE-2,8-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07702": {"dbids": ["DB07702"], "name": "(16ALPHA,17ALPHA)-ESTRA-1,3,5(10)-TRIENE-3,16,17-TRIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07701": {"dbids": ["DB07701"], "name": "1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON-2-YL)METHYL]PIPERIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07700": {"dbids": ["DB07700"], "name": "3-CARBOXAMIDO-1,3,5(10)-ESTRATRIEN-17(R)-SPIRO-2'(5',5'-DIMETHYL-6'OXO)TETRAHYDROPYRAN", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07707": {"dbids": ["DB07707"], "name": "(9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07706": {"dbids": ["DB07706"], "name": "2,3,17BETA-TRIHYDROXY-1,3,5(10)-ESTRATRIENE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07705": {"dbids": ["DB07705"], "name": "1-[(2S)-2-[(4-CHLOROBENZYL)OXY]-2-(2,4-DICHLOROPHENYL)ETHYL]-1H-IMIDAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07704": {"dbids": ["DB07704"], "name": "6-AMINO-4-[2-(4-METHOXYPHENYL)ETHYL]-1,7-DIHYDRO-8H-IMIDAZO[4,5-G]QUINAZOLIN-8-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05807": {"dbids": ["DB05807"], "name": "HGTV-43", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05801": {"dbids": ["DB05801"], "name": "GTI 2040", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05446": {"dbids": ["DB05446"], "name": "LJP 1082", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05447": {"dbids": ["DB05447"], "name": "AVI-4557", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05444": {"dbids": ["DB05444"], "name": "BRX-235", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05445": {"dbids": ["DB05445"], "name": "TA-NIC", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05442": {"dbids": ["DB05442"], "name": "BNP-166", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05443": {"dbids": ["DB05443"], "name": "ADL 10-0101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05440": {"dbids": ["DB05440"], "name": "SRP 299", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05441": {"dbids": ["DB05441"], "name": "AVAC", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05448": {"dbids": ["DB05448"], "name": "PX-12", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05449": {"dbids": ["DB05449"], "name": "FM-VP4", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03668": {"dbids": ["DB03668", "EXPT00725"], "name": "1-(5'-Phospho-Beta-D-Ribofuranosyl)Barbituric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03669": {"dbids": ["DB03669", "EXPT00212"], "name": "4-Fluorophenethyl Alcohol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03660": {"dbids": ["DB03660", "EXPT02587"], "name": "Iodo-Phenylalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03661": {"dbids": ["DB03661", "EXPT02415"], "name": "Cysteinesulfonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03662": {"dbids": ["DB03662", "EXPT02714"], "name": "Vitamin B6 Complexed with 2-Amino-Pentanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03663": {"dbids": ["DB03663", "EXPT02125"], "name": "1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03664": {"dbids": ["DB03664", "EXPT03194"], "name": "P1-(Adenosine-5'-P5-(Uridine-5')Pentaphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03666": {"dbids": ["DB03666", "EXPT00583"], "name": "3'-Azido-3'-Deoxythymidine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03667": {"dbids": ["DB03667", "EXPT02867"], "name": "Acetic Acid Salicyloyl-Amino-Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02825": {"dbids": ["DB02825", "EXPT03237"], "name": "Methylphosphonic Acid Ester Group", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02824": {"dbids": ["DB02824", "EXPT02606"], "name": "N-Pyridoxyl-Glycine-5-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02827": {"dbids": ["DB02827", "EXPT01119"], "name": "7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02390": {"dbids": ["DB02390", "EXPT01117"], "name": "5-Bromo-N[2-(Dimethylamino)Ethyl]-9-Aminoacridine-4-Carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02821": {"dbids": ["DB02821", "EXPT00828"], "name": "Canaline", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P04181", "drug": "DB02821"}]}, "DB02820": {"dbids": ["DB02820", "EXPT03033"], "name": "1-Azepan-1-Yl-2-Phenyl-2-(4-Thioxo-1,4-Dihydro-Pyrazolo[3,4-D]Pyrimidin-5-Yl)Ethanone Adduct", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02823": {"dbids": ["DB02823", "EXPT02488"], "name": "Phosphonoacetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02822": {"dbids": ["DB02822", "EXPT00748"], "name": "Para-Bromobenzyl Alcohol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02399": {"dbids": ["DB02399", "EXPT02796"], "name": "L-Rhamnitol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02398": {"dbids": ["DB02398", "EXPT00091"], "name": "6-[N-(4-(Aminomethyl)Phenyl)Carbamyl]-2-Naphthalenecarboxamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02829": {"dbids": ["DB02829", "EXPT02963"], "name": "4-(Acetylamino)-3-[(Aminoacetyl)Amino]Benzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02828": {"dbids": ["DB02828", "EXPT01997"], "name": "5-Fluorolevulinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09345": {"dbids": ["DB09345"], "name": "Pramocaine", "groups": ["APPROVED"], "targets": []}, "DB09344": {"dbids": ["DB09344"], "name": "Invert sugar", "groups": ["APPROVED"], "targets": []}, "DB09347": {"dbids": ["DB09347"], "name": "Acetrizoic acid", "groups": ["APPROVED"], "targets": []}, "DB09323": {"dbids": ["DB09323"], "name": "Benzathine benzylpenicillin", "groups": ["APPROVED"], "targets": []}, "DB09346": {"dbids": ["DB09346"], "name": "Metrizoic acid", "groups": ["APPROVED"], "targets": []}, "DB09341": {"dbids": ["DB09341"], "name": "Glucose", "groups": ["APPROVED"], "targets": []}, "DB09340": {"dbids": ["DB09340"], "name": "Tyropanoic acid", "groups": ["APPROVED"], "targets": []}, "DB09343": {"dbids": ["DB09343"], "name": "Tipiracil", "groups": ["APPROVED"], "targets": []}, "DB09342": {"dbids": ["DB09342"], "name": "Propoxycaine", "groups": ["APPROVED"], "targets": []}, "DB02537": {"dbids": ["DB02537", "EXPT02126"], "name": "2-Hydroxy-5-({1-[(4-Methylphenoxy)Methyl]-3-Oxoprop-1-Enyl}Amino)-L-Tyrosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02536": {"dbids": ["DB02536", "EXPT00170"], "name": "(2r)-2,3-Dihydroxypropanal", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02535": {"dbids": ["DB02535", "EXPT01328"], "name": "Aminodi(Ethyloxy)Ethylaminocarbonylbenzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02534": {"dbids": ["DB02534", "EXPT00127"], "name": "2-Allylphenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02533": {"dbids": ["DB02533", "EXPT00459"], "name": "Aminoguanidine", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P35228", "drug": "DB02533"}]}, "DB02532": {"dbids": ["DB02532", "EXPT03006"], "name": "2,4,6-Triaminoquinazoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02531": {"dbids": ["DB02531", "DB04305", "EXPT01932"], "name": "Isobutyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02530": {"dbids": ["DB02530", "EXPT00402"], "name": "Gamma(Amino)-Butyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09349": {"dbids": ["DB09349"], "name": "Gastric intrinsic factor", "groups": ["APPROVED"], "targets": []}, "DB01462": {"dbids": ["DB01462"], "name": "Etonitazene", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB02539": {"dbids": ["DB02539", "EXPT02886"], "name": "S-Ethylisothiourea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02538": {"dbids": ["DB02538", "EXPT01718"], "name": "N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01463": {"dbids": ["DB01463"], "name": "Fencamfamine", "groups": ["APPROVED", "ILLICIT", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "Q01959", "drug": "DB01463"}]}, "DB01464": {"dbids": ["DB01464"], "name": "Furethidine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01465": {"dbids": ["DB01465"], "name": "2,5-Dimethoxyamphetamine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01466": {"dbids": ["DB01466"], "name": "Ethylmorphine", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB01466"}]}, "DB01467": {"dbids": ["DB01467"], "name": "2,5-Dimethoxy-4-ethylamphetamine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01036": {"dbids": ["APRD00146", "DB01036"], "name": "Tolterodine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P20309", "drug": "DB01036"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01036"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB01036"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01036"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01036"}]}, "DB01468": {"dbids": ["DB01468"], "name": "Ethylmethylthiambutene", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01469": {"dbids": ["DB01469"], "name": "Acetorphine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB07007": {"dbids": ["DB07007"], "name": "(3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07958": {"dbids": ["DB07958"], "name": "(2-CARBAMOYLMETHYL-5-PROPYL-OCTAHYDRO-INDOL-7-YL)ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07959": {"dbids": ["DB07959"], "name": "3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07956": {"dbids": ["DB07956"], "name": "[1-(3-CHLORO-2-FORMYL-PHENYLCARBAMOYL)-2-METHYL-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07957": {"dbids": ["DB07957"], "name": "METHYL(2-ACETOXY-2-(2-CARBOXY-4-AMINO-PHENYL))ACETATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07954": {"dbids": ["DB07954"], "name": "3-ISOBUTYL-1-METHYLXANTHINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07955": {"dbids": ["DB07955"], "name": "(2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07952": {"dbids": ["DB07952"], "name": "N-[1H-INDOL-3-YL-ACETYL]GLYCINE ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07953": {"dbids": ["DB07953"], "name": "N-[1H-INDOL-3-YL-ACETYL]VALINE ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07950": {"dbids": ["DB07950"], "name": "1H-INDOL-3-YLACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07951": {"dbids": ["DB07951"], "name": "N-[1H-INDOL-3-YL-ACETYL]ASPARTIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07109": {"dbids": ["DB07109"], "name": "(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07108": {"dbids": ["DB07108"], "name": "4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00487": {"dbids": ["APRD00108", "DB00487"], "name": "Pefloxacin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P43702", "drug": "DB00487"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB00487"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00487"}]}, "DB00486": {"dbids": ["APRD01127", "DB00486"], "name": "Nabilone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "PARTIAL AGONIST", "target": "P34972", "drug": "DB00486"}, {"action": "PARTIAL AGONIST", "target": "P21554", "drug": "DB00486"}]}, "DB00489": {"dbids": ["APRD01230", "DB00489"], "name": "Sotalol", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q12809", "drug": "DB00489"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB00489"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00489"}]}, "DB00488": {"dbids": ["APRD00652", "DB00488"], "name": "Altretamine", "groups": ["APPROVED"], "targets": []}, "DB07107": {"dbids": ["DB07107"], "name": "(1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07106": {"dbids": ["DB07106"], "name": "4-(DIMETHYLAMINO)BUTYL IMIDOTHIOCARBAMATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07101": {"dbids": ["DB07101"], "name": "N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07100": {"dbids": ["DB07100"], "name": "4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07103": {"dbids": ["DB07103"], "name": "2-(4-METHYLPHENOXY)ETHYLPHOSPHINATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07102": {"dbids": ["DB07102"], "name": "(2S)-2-amino-5-oxo-5-[(4-phenylmethoxyphenyl)amino]pentanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08126": {"dbids": ["DB08126"], "name": "3-{[4-([AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08127": {"dbids": ["DB08127"], "name": "1,3,3-trimethyl-2-[(1E,3E)-3-methylpenta-1,3-dien-1-yl]cyclohexene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08123": {"dbids": ["DB08123"], "name": "N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04377": {"dbids": ["DB04377", "EXPT02109"], "name": "3-Hydroxy-3-Methyl-Glutaric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04376": {"dbids": ["DB04376", "EXPT02656"], "name": "13-Acetylphorbol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04375": {"dbids": ["DB04375", "EXPT00804"], "name": "5-Methyl-5,6,7,8-Tetrahydrofolic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04374": {"dbids": ["DB04374", "EXPT01787"], "name": "4-Carboxy-5-(1-Pentyl)Hexylsulfanyl-1,2,3-Triazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04373": {"dbids": ["DB04373", "EXPT02745"], "name": "4-Amino-N-{4-[2-(2,6-Dimethyl-Phenoxy)-Acetylamino]-3-Hydroxy-1-Isobutyl-5-Phenyl-Pentyl}-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04372": {"dbids": ["DB04372", "EXPT01218"], "name": "Di-Linoleoyl-3-Sn-Phosphatidylcholine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04371": {"dbids": ["DB04371", "EXPT00490"], "name": "AL6528", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04370": {"dbids": ["DB04370", "EXPT01039"], "name": "S-sulphocysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04379": {"dbids": ["DB04379", "EXPT02581"], "name": "N-Methyl-N-(Methylbenzyl)Formamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04378": {"dbids": ["DB04378", "EXPT02746"], "name": "3-Amino-N-{4-[2-(2,6-Dimethyl-Phenoxy)-Acetylamino]-3-Hydroxy-1-Isobutyl-5-Phenyl-Pentyl}-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07509": {"dbids": ["DB07509"], "name": "difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00250": {"dbids": ["APRD00345", "DB00250"], "name": "Dapsone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P0C0X2", "drug": "DB00250"}, {"action": "INHIBITOR", "target": "P0C0X1", "drug": "DB00250"}]}, "DB00251": {"dbids": ["APRD00659", "DB00251"], "name": "Terconazole", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P10613", "drug": "DB00251"}]}, "DB00252": {"dbids": ["APRD00241", "DB00252"], "name": "Phenytoin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB00252"}, {"action": "INHIBITOR", "target": "P35498", "drug": "DB00252"}]}, "DB00253": {"dbids": ["APRD01091", "DB00253"], "name": "Medrysone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00253"}]}, "DB00254": {"dbids": ["APRD00597", "DB00254"], "name": "Doxycycline", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P0A7X3", "drug": "DB00254"}, {"action": "INHIBITOR", "target": "P0A7V8", "drug": "DB00254"}]}, "DB00255": {"dbids": ["APRD00920", "DB00255", "EXPT01164"], "name": "Diethylstilbestrol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P03372", "drug": "DB00255"}, {"action": "AGONIST", "target": "P62508", "drug": "DB00255"}, {"action": "AGONIST", "target": "Q92731", "drug": "DB00255"}]}, "DB00256": {"dbids": ["APRD00565", "DB00256", "EXPT01049"], "name": "Lymecycline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A7X3", "drug": "DB00256"}, {"action": "INHIBITOR", "target": "P0A7V8", "drug": "DB00256"}]}, "DB00257": {"dbids": ["APRD00244", "DB00257"], "name": "Clotrimazole", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P10613", "drug": "DB00257"}, {"action": "INHIBITOR", "target": "P10613", "drug": "DB00257"}, {"action": "INHIBITOR", "target": "O15554", "drug": "DB00257"}]}, "DB00258": {"dbids": ["APRD00839", "DB00258"], "name": "Calcium Acetate", "groups": ["APPROVED"], "targets": []}, "DB00259": {"dbids": ["APRD00438", "DB00259"], "name": "Sulfanilamide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0AC13", "drug": "DB00259"}]}, "DB00708": {"dbids": ["APRD00671", "DB00708"], "name": "Sufentanil", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB00708"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00708"}, {"action": "OTHER", "target": "P41145", "drug": "DB00708"}]}, "DB00709": {"dbids": ["APRD00681", "DB00709"], "name": "Lamivudine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q72547", "drug": "DB00709"}, {"action": "INHIBITOR", "target": "Q05486", "drug": "DB00709"}]}, "DB03479": {"dbids": ["DB03479", "EXPT01600"], "name": "8,9,10-Trihydroxy-7-Hydroxymethyl-3-Methyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03478": {"dbids": ["DB03478", "EXPT02408"], "name": "2'-O-Acetyl Adenosine-5-Diphosphoribose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03475": {"dbids": ["DB03475", "EXPT02752"], "name": "1-[4-Carboxy-2-(3-Pentylamino)Phenyl]-5,5'-Di(Hydroxymethyl)Pyrrolidin-2-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03474": {"dbids": ["DB03474", "EXPT02815"], "name": "Reactive Red 1 Dye", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03477": {"dbids": ["DB03477", "EXPT02833"], "name": "1-Phenylsulfonamide-3-Trifluoromethyl-5-Parabromophenylpyrazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03476": {"dbids": ["DB03476", "EXPT00296"], "name": "Trans-6-(2-Phenylcyclopropyl)-Naphthalene-2-Carboxamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03471": {"dbids": ["DB03471", "EXPT00747"], "name": "6-Phenyl-4(R)-(7-Phenyl-Heptanoylamino)-Hexanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03470": {"dbids": ["DB03470", "EXPT01557"], "name": "Trypanothione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03473": {"dbids": ["DB03473", "EXPT02152"], "name": "N5-Methylglutamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03472": {"dbids": ["DB03472", "EXPT02102"], "name": "Cyclohexyl-Hexyl-Beta-D-Maltoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08289": {"dbids": ["DB08289"], "name": "N-(PARA-GLUTARAMIDOPHENYL-ETHYL)-PIPERIDINIUM-N-OXIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08288": {"dbids": ["DB08288"], "name": "CYCLOHEXYL-NORSTATINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08287": {"dbids": ["DB08287"], "name": "(1R,2R)-N-(2-AMINOETHYL)-2-{[(4-METHOXYPHENYL)SULFONYL]METHYL}CYCLOHEXANECARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08286": {"dbids": ["DB08286"], "name": "NAPHTHYLOXYACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08285": {"dbids": ["DB08285"], "name": "(2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08284": {"dbids": ["DB08284"], "name": "O-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl] (4-iodophenyl)thiocarbamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08283": {"dbids": ["DB08283"], "name": "(2R,3R,4R,5S)-2-(HYDROXYMETHYL)-1-NONYLPIPERIDINE-3,4,5-TRIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08282": {"dbids": ["DB08282"], "name": "O-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl] (4-chlorophenyl)thiocarbamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08281": {"dbids": ["DB08281"], "name": "O-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl] (4-bromophenyl)thiocarbamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08280": {"dbids": ["DB08280"], "name": "(1S,3R,4S,5S,7S)-4-{[2-(4-METHOXYPHENOXY)-2-METHYLPROPANOYL]AMINO}ADAMANTANE-1-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09002": {"dbids": ["DB09002"], "name": "Cloperastine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB08172": {"dbids": ["DB08172"], "name": "(2Z)-N-(3-chloro-2'-methoxybiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00874": {"dbids": ["APRD01005", "DB00874"], "name": "Guaifenesin", "groups": ["APPROVED"], "targets": []}, "DB00875": {"dbids": ["APRD00388", "DB00875"], "name": "Flupentixol", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB00875"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00875"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00875"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00875"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00875"}]}, "DB00876": {"dbids": ["APRD00950", "DB00876"], "name": "Eprosartan", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P30556", "drug": "DB00876"}]}, "DB00877": {"dbids": ["APRD00178", "DB00877", "DB02439"], "name": "Sirolimus", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P42345", "drug": "DB00877"}, {"action": "OTHER", "target": "P62942", "drug": "DB00877"}, {"action": "OTHER/UNKNOWN", "target": "P09038", "drug": "DB00877"}]}, "DB00870": {"dbids": ["APRD00230", "DB00870"], "name": "Suprofen", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P23219", "drug": "DB00870"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00870"}]}, "DB00871": {"dbids": ["APRD00589", "DB00871"], "name": "Terbutaline", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P07550", "drug": "DB00871"}]}, "DB00872": {"dbids": ["APRD01302", "DB00872"], "name": "Conivaptan", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P37288", "drug": "DB00872"}, {"action": "ANTAGONIST", "target": "P30518", "drug": "DB00872"}]}, "DB00873": {"dbids": ["APRD01078", "DB00873"], "name": "Loteprednol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00873"}]}, "DB00878": {"dbids": ["APRD00545", "DB00878"], "name": "Chlorhexidine", "groups": ["APPROVED"], "targets": []}, "DB00879": {"dbids": ["APRD00226", "DB00879"], "name": "Emtricitabine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q72547", "drug": "DB00879"}]}, "DB04120": {"dbids": ["DB04120", "EXPT02138"], "name": "4-Methyl-1,2-Benzenediol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08912": {"dbids": ["DB08912"], "name": "Dabrafenib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P15056", "drug": "DB08912"}, {"action": "INHIBITOR", "target": "P04049", "drug": "DB08912"}, {"action": "INHIBITOR", "target": "P57059", "drug": "DB08912"}, {"action": "INHIBITOR", "target": "Q8NG66", "drug": "DB08912"}, {"action": "INHIBITOR", "target": "P53667", "drug": "DB08912"}]}, "DB02709": {"dbids": ["DB02709", "EXPT02968"], "name": "Resveratrol", "groups": ["EXPERIMENTAL", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P23219", "drug": "DB02709"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB02709"}]}, "DB02704": {"dbids": ["DB02704", "EXPT00717"], "name": "(2r,3r,4r,5r)-3,4-Dihydroxy-N,N'-Bis[(1s,2r)-2-Hydroxy-2,3-Dihydro-1h-Inden-1-Yl]-2,5-Bis(2-Phenylethyl)Hexanediamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02705": {"dbids": ["DB02705", "EXPT00148"], "name": "6-[N-(1-Isopropyl-1,2,3,4-Tetrahydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02706": {"dbids": ["DB02706", "EXPT02134"], "name": "Mercaptocarboxylate Inhibitor", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02707": {"dbids": ["DB02707", "EXPT02472"], "name": "Pentyl Trihydrogen Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02700": {"dbids": ["DB02700", "EXPT01559"], "name": "3-Deoxy-D-Glucosamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02701": {"dbids": ["DB02701", "EXPT02307"], "name": "Nicotinamide", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "P09874", "drug": "DB02701"}]}, "DB02702": {"dbids": ["DB02702", "EXPT00267"], "name": "XV638", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02703": {"dbids": ["DB02703", "EXPT01507"], "name": "Fusidic Acid", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P13551", "drug": "DB02703"}, {"action": "INHIBITOR", "target": "P62580", "drug": "DB02703"}, {"action": "INHIBITOR", "target": "P00484", "drug": "DB02703"}]}, "DB09396": {"dbids": ["DB09396"], "name": "Propoxyphene napsylate", "groups": ["APPROVED"], "targets": []}, "DB09397": {"dbids": ["DB09397"], "name": "Technetium tc 99m sulfur colloid", "groups": ["APPROVED"], "targets": []}, "DB09394": {"dbids": ["DB09394"], "name": "Phosphoric acid", "groups": ["APPROVED"], "targets": []}, "DB09395": {"dbids": ["DB09395"], "name": "Sodium acetate", "groups": ["APPROVED"], "targets": []}, "DB09391": {"dbids": ["DB09391"], "name": "Sorbitol", "groups": ["APPROVED"], "targets": []}, "DB09398": {"dbids": ["DB09398"], "name": "Sodium fluoride F-18", "groups": ["APPROVED"], "targets": []}, "DB07501": {"dbids": ["DB07501"], "name": "(2S)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07500": {"dbids": ["DB07500"], "name": "(2E)-1-[2-hydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04125": {"dbids": ["DB04125", "EXPT01411"], "name": "N-Alpha-(2-Naphthylsulfonyl)-N(3-Amidino-L-Phenylalaninyl)-4-Acetyl-Piperazine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03494": {"dbids": ["DB03494", "EXPT00343"], "name": "CRA_10950", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07503": {"dbids": ["DB07503"], "name": "(5E)-5-[(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)METHYLENE]-1,3-THIAZOLIDINE-2,4-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07502": {"dbids": ["DB07502"], "name": "4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05165": {"dbids": ["DB05165"], "name": "LY2275796", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05164": {"dbids": ["DB05164"], "name": "CMLVAX100", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05167": {"dbids": ["DB05167"], "name": "PDPSC18", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05166": {"dbids": ["DB05166"], "name": "APD668", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05161": {"dbids": ["DB05161"], "name": "Elafin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05160": {"dbids": ["DB05160"], "name": "PRX302", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05163": {"dbids": ["DB05163"], "name": "PV903", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05162": {"dbids": ["DB05162"], "name": "GSK716155", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03498": {"dbids": ["DB03498", "EXPT02199"], "name": "Mercaptomethyl Phosphonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05169": {"dbids": ["DB05169"], "name": "AT9283", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05168": {"dbids": ["DB05168"], "name": "EC145", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08918": {"dbids": ["DB08918"], "name": "Levomilnacipran", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P31645", "drug": "DB08918"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB08918"}]}, "DB07504": {"dbids": ["DB07504"], "name": "(2R)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01938": {"dbids": ["DB01938", "EXPT01699"], "name": "L-Histidine Beta Naphthylamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01939": {"dbids": ["DB01939", "EXPT00397"], "name": "5-Amidino-Benzimidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01428": {"dbids": ["DB01428"], "name": "Oxybenzone", "groups": ["APPROVED"], "targets": []}, "DB04149": {"dbids": ["DB04149", "EXPT00228"], "name": "(R)-Rolipram", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "Q07343", "drug": "DB04149"}]}, "DB01398": {"dbids": ["DB01398"], "name": "Salicylate-sodium", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB01398"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB01398"}]}, "DB01399": {"dbids": ["DB01399"], "name": "Salsalate", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB01399"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB01399"}]}, "DB01424": {"dbids": ["DB01424"], "name": "Aminophenazone", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB01425": {"dbids": ["DB01425"], "name": "Alizapride", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB01425"}]}, "DB04146": {"dbids": ["DB04146", "EXPT01086"], "name": "I-Coeleneterazine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01395": {"dbids": ["DB01395"], "name": "Drospirenone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P06401", "drug": "DB01395"}, {"action": "ANTAGONIST", "target": "P08235", "drug": "DB01395"}, {"action": "ANTAGONIST", "target": "P10275", "drug": "DB01395"}]}, "DB01392": {"dbids": ["DB01392"], "name": "Yohimbine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08913", "drug": "DB01392"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB01392"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB01392"}, {"action": "PARTIAL AGONIST", "target": "P08908", "drug": "DB01392"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB01392"}, {"action": "ANTAGONIST", "target": "P28221", "drug": "DB01392"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01392"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB01392"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01392"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01392"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB01392"}]}, "DB04141": {"dbids": ["DB04141", "EXPT00697"], "name": "2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04142": {"dbids": ["DB04142", "EXPT00631"], "name": "3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01423": {"dbids": ["DB01423"], "name": "Stepronin", "groups": ["APPROVED"], "targets": []}, "DB07507": {"dbids": ["DB07507"], "name": "2-(4-hydroxybiphenyl-3-yl)-4-methyl-1H-isoindole-1,3(2H)-dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08709": {"dbids": ["DB08709"], "name": "2,3-diphenyl-1H-indole-7-carboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08702": {"dbids": ["DB08702"], "name": "2,5-DIPHENYLFURAN-3,4-DICARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08703": {"dbids": ["DB08703"], "name": "12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08700": {"dbids": ["DB08700"], "name": "3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01415": {"dbids": ["DB01415"], "name": "Ceftibuten", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0AD68", "drug": "DB01415"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB01415"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB01415"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB01415"}]}, "DB08706": {"dbids": ["DB08706"], "name": "(2S)-({(5Z)-5-[(5-ETHYL-2-FURYL)METHYLENE]-4-OXO-4,5-DIHYDRO-1,3-THIAZOL-2-YL}AMINO)(4-FLUOROPHENYL)ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08707": {"dbids": ["DB08707"], "name": "4-[3-(4-chlorophenyl)-2,1-benzisoxazol-5-yl]pyrimidin-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08704": {"dbids": ["DB08704"], "name": "[[(3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(pentanoylamino)oxan-2-ylidene]amino] N-phenylcarbamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08705": {"dbids": ["DB08705"], "name": "6-(5-BROMO-2-HYDROXYPHENYL)-2-OXO-4-PHENYL-1,2-DIHYDROPYRIDINE-3-CARBONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04144": {"dbids": ["DB04144", "EXPT01877"], "name": "Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03511": {"dbids": ["DB03334", "DB03511", "EXPT01661"], "name": "Galacturonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07506": {"dbids": ["DB07506"], "name": "L-BENZYLSUCCINIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01648": {"dbids": ["DB01648", "EXPT01657"], "name": "O1-Methyl-4-Deoxy-4-Thio-Beta-D-Glucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01649": {"dbids": ["DB01649", "EXPT01652"], "name": "7-Methyl-Gpppa", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04145": {"dbids": ["DB04145", "EXPT02720"], "name": "Pyridin-3-Ylmethanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01894": {"dbids": ["DB01894", "EXPT02292"], "name": "5-N-Acetyl-Alpha-D-Neuraminic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01640": {"dbids": ["DB01640", "EXPT00272"], "name": "(5r)-6-(4-{[2-(3-Iodobenzyl)-3-Oxocyclohex-1-En-1-Yl]Amino}Phenyl)-5-Methyl-4,5-Dihydropyridazin-3(2h)-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01641": {"dbids": ["DB01641", "EXPT00264"], "name": "(5z)-2-[(1s,2r)-1-Amino-2-Hydroxypropyl]-5-[(4-Amino-1h-Indol-3-Yl)Methylene]-3-(2-Hydroxyethyl)-3,5-Dihydro-4h-Imidazol-4-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01642": {"dbids": ["DB01642", "EXPT02166"], "name": "O1-Methyl-Glucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01643": {"dbids": ["DB01643", "EXPT02988", "EXPT03073"], "name": "Thymidine-5'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03516": {"dbids": ["DB03516", "EXPT03299"], "name": "Eniluracil", "groups": ["INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P47989", "drug": "DB03516"}]}, "DB01645": {"dbids": ["DB01645", "EXPT01582"], "name": "Genistein", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01646": {"dbids": ["DB01646", "EXPT00506"], "name": "N-Acetylmethionine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01647": {"dbids": ["DB01647", "EXPT00259"], "name": "(R)-Mesopram", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08434": {"dbids": ["DB08434"], "name": "2-METHYLCARBAMOYL-3-(4-PHOSPHONOOXY-PHENYL)-CYCLOPROPANECARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08435": {"dbids": ["DB08435"], "name": "(5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03514": {"dbids": ["DB03514", "EXPT01375"], "name": "2-Methoxy-4-Vinyl-Phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08436": {"dbids": ["DB08436"], "name": "8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07149": {"dbids": ["DB07149"], "name": "(7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07148": {"dbids": ["DB07148"], "name": "(6S)-1-chloro-3-[(4-fluorobenzyl)oxy]-6-(pyrrolidin-1-ylcarbonyl)pyrrolo[1,2-a]pyrazin-4(6H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07499": {"dbids": ["DB07499"], "name": "N-(4-{[amino(imino)methyl]amino}butyl)-2,4'-bi-1,3-thiazole-4-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07498": {"dbids": ["DB07498"], "name": "4-[3-(3-NITROPHENYL)-1,2,4-OXADIAZOL-5-YL]BUTANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07141": {"dbids": ["DB07141"], "name": "5-[(3R)-3-(5-methoxy-4'-methylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07140": {"dbids": ["DB07140"], "name": "5-[(3R)-3-(5-methoxybiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07143": {"dbids": ["DB07143"], "name": "D-phenylalanyl-N-benzyl-L-prolinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07142": {"dbids": ["DB07142"], "name": "5-[(3R)-3-(5-methoxy-3',5'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07145": {"dbids": ["DB07145"], "name": "(2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07144": {"dbids": ["DB07144"], "name": "5-[(3R)-3-(5-methoxy-2',6'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07147": {"dbids": ["DB07147"], "name": "methyl (1R,2S)-2-(hydroxycarbamoyl)-1-{4-[(2-methylquinolin-4-yl)methoxy]benzyl}cyclopropanecarboxylate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07146": {"dbids": ["DB07146"], "name": "2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03866": {"dbids": ["DB03866", "EXPT02577"], "name": "Prostaglandin G2", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03867": {"dbids": ["DB03867", "EXPT02352"], "name": "Meta-Nitro-Tyrosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03864": {"dbids": ["DB03864", "EXPT02897"], "name": "Monothioglycerol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03865": {"dbids": ["DB03865", "EXPT00023"], "name": "6-Chloro-2-(2-Hydroxy-Biphenyl-3-Yl)-1h-Indole-5-Carboxamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03862": {"dbids": ["DB03862", "EXPT02466"], "name": "Tetrahydrooxazine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03863": {"dbids": ["DB03863", "EXPT02262"], "name": "2-O-Methyl Fucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03515": {"dbids": ["DB03515", "EXPT01356"], "name": "Equilenin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03861": {"dbids": ["DB03861", "EXPT01846"], "name": "(2r,3r,4s,5r)-2-Acetamido-3,4-Dihydroxy-5-Hydroxymethyl-Piperidinium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08433": {"dbids": ["DB08433"], "name": "phenyl ethenesulfonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03868": {"dbids": ["DB03868", "EXPT01264"], "name": "3-Dehydroquinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03869": {"dbids": ["DB03869", "EXPT02955"], "name": "5'-O-(N-(L-Seryl)-Sulfamoyl)Adenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09479": {"dbids": ["DB09479"], "name": "Rubidium chloride Rb-82", "groups": ["APPROVED"], "targets": []}, "DB09473": {"dbids": ["DB09473"], "name": "Indium In-111 oxyquinoline", "groups": ["APPROVED"], "targets": []}, "DB09472": {"dbids": ["DB09472"], "name": "Sodium sulfate anhydrous", "groups": ["APPROVED"], "targets": []}, "DB09470": {"dbids": ["DB09470"], "name": "Sodium acetate anhydrous", "groups": ["APPROVED"], "targets": []}, "DB09477": {"dbids": ["DB09477"], "name": "Enalaprilat", "groups": ["APPROVED"], "targets": []}, "DB09476": {"dbids": ["DB09476"], "name": "Sodium sulfate", "groups": ["APPROVED"], "targets": []}, "DB00117": {"dbids": ["DB00117", "NUTR00030"], "name": "L-Histidine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00116": {"dbids": ["DB00116", "NUTR00056"], "name": "Tetrahydrofolic acid", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "COFACTOR", "target": "P11586", "drug": "DB00116"}, {"action": "COFACTOR", "target": "P13995", "drug": "DB00116"}, {"action": "COFACTOR", "target": "P48728", "drug": "DB00116"}, {"action": "COFACTOR", "target": "O75891", "drug": "DB00116"}, {"action": "COFACTOR", "target": "Q99707", "drug": "DB00116"}, {"action": "COFACTOR", "target": "O95954", "drug": "DB00116"}, {"action": "COFACTOR", "target": "P31939", "drug": "DB00116"}, {"action": "COFACTOR", "target": "P34896", "drug": "DB00116"}, {"action": "COFACTOR", "target": "P34897", "drug": "DB00116"}, {"action": "COFACTOR", "target": "P42898", "drug": "DB00116"}, {"action": "COFACTOR", "target": "Q53ET4", "drug": "DB00116"}, {"action": "COFACTOR", "target": "P34896", "drug": "DB00116"}, {"action": "COFACTOR", "target": "P34896", "drug": "DB00116"}, {"action": "COFACTOR", "target": "P42898", "drug": "DB00116"}, {"action": "COFACTOR", "target": "P34897", "drug": "DB00116"}, {"action": "COFACTOR", "target": "Q96DP5", "drug": "DB00116"}]}, "DB00115": {"dbids": ["APRD00326", "DB00115", "EXPT00965", "NUTR00004"], "name": "Cyanocobalamin", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "COFACTOR", "target": "Q99707", "drug": "DB00115"}, {"action": "COFACTOR", "target": "P22033", "drug": "DB00115"}, {"action": "COFACTOR", "target": "Q9UBK8", "drug": "DB00115"}, {"action": "COFACTOR", "target": "Q8IVH4", "drug": "DB00115"}, {"action": "COFACTOR", "target": "Q9Y4U1", "drug": "DB00115"}, {"action": "COFACTOR", "target": "P42898", "drug": "DB00115"}]}, "DB00114": {"dbids": ["DB00114", "NUTR00045"], "name": "Pyridoxal Phosphate", "groups": ["NUTRACEUTICAL"], "targets": [{"action": "COFACTOR", "target": "Q9BYV1", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q99259", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P35520", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q16719", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P34896", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q9Y697", "drug": "DB00114"}, {"action": "ACTIVATOR", "target": "P17174", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P04181", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P11926", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q8N5Z0", "drug": "DB00114"}, {"action": "INHIBITOR", "target": "P80404", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q9NVS9", "drug": "DB00114"}, {"action": "COFACTOR", "target": "O95470", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P17735", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q16773", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q8IYQ7", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P06737", "drug": "DB00114"}, {"action": "COFACTOR", "target": "O15270", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q9Y600", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P19113", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q96A70", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P20132", "drug": "DB00114"}, {"action": "COFACTOR", "target": "O75600", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P23378", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P24298", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q9Y617", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P13196", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P21549", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q96GD0", "drug": "DB00114"}, {"action": "COFACTOR", "target": "O15269", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P32929", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P54687", "drug": "DB00114"}, {"action": "COFACTOR", "target": "O15382", "drug": "DB00114"}, {"action": "COFACTOR", "target": "O94903", "drug": "DB00114"}, {"action": "COFACTOR", "target": "O95954", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P00505", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P11216", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P11217", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P20711", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P34897", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q2TU84", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q49AK1", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q53ET4", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q59FK2", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q59GM9", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q59HE2", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P34896", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P34896", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q5JAM2", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q5VZ30", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q6IBS8", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q6P996", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q6YP21", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q6ZQY3", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q96I15", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q6WRI0", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q8IUZ5", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q8IVA8", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P34897", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q8TD30", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q96EN8", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q96GA7", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q96JQ3", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q9BXA1", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q9GZT4", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q9HD40", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q9NUV7", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q9UGI5", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q9UJX1", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q9Y600", "drug": "DB00114"}]}, "DB00113": {"dbids": ["BIOD00107", "BTD00107", "DB00113"], "name": "Arcitumomab", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "OTHER/UNKNOWN", "target": "P13688", "drug": "DB00113"}]}, "DB00112": {"dbids": ["BIOD00087", "BTD00087", "DB00112"], "name": "Bevacizumab", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB00111": {"dbids": ["BIOD00007", "BTD00007", "DB00111"], "name": "Daclizumab", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTIBODY", "target": "P01589", "drug": "DB00111"}, {"action": "ANTIBODY", "target": "P14784", "drug": "DB00111"}]}, "DB00110": {"dbids": ["BIOD00097", "BTD00097", "DB00110"], "name": "Palivizumab", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB08438": {"dbids": ["DB08438"], "name": "(2E,4R,5S)-2,3,4,5-TETRAHYDROXY-6-(PALMITOYLOXY)HEX-2-ENOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08868": {"dbids": ["DB08868"], "name": "Fingolimod", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "MODULATOR", "target": "Q9H228", "drug": "DB08868"}]}, "DB07729": {"dbids": ["DB07729"], "name": "3-fluoro-N-[3-(1H-tetrazol-5-yl)phenyl]benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07728": {"dbids": ["DB07728"], "name": "2-[2-(2-FLUOROPHENYL)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00119": {"dbids": ["DB00119", "NUTR00050"], "name": "Pyruvic acid", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "INHIBITOR", "target": "P80404", "drug": "DB00119"}]}, "DB00118": {"dbids": ["DB00118", "NUTR00052"], "name": "S-Adenosylmethionine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "COFACTOR", "target": "Q14749", "drug": "DB00118"}, {"action": "COFACTOR", "target": "P17707", "drug": "DB00118"}, {"action": "COFACTOR", "target": "P31153", "drug": "DB00118"}, {"action": "ACTIVATOR", "target": "P35520", "drug": "DB00118"}, {"action": "COFACTOR", "target": "Q00266", "drug": "DB00118"}, {"action": "COFACTOR", "target": "P21964", "drug": "DB00118"}]}, "DB08867": {"dbids": ["DB08867"], "name": "Ulipristal", "groups": ["APPROVED"], "targets": [{"action": "MODULATOR", "target": "P06401", "drug": "DB08867"}, {"action": "ANTAGONIST", "target": "P04150", "drug": "DB08867"}]}, "DB08866": {"dbids": ["DB08866"], "name": "Estradiol valerate/Dienogest", "groups": ["APPROVED"], "targets": []}, "DB08611": {"dbids": ["DB08611"], "name": "2-[(2',3',4'-TRIFLUOROBIPHENYL-2-YL)OXY]ETHANOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07428": {"dbids": ["DB07428"], "name": "4-[(5-methoxy-2-methylphenoxy)methyl]pyridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07429": {"dbids": ["DB07429"], "name": "2-({[4-bromo-3-(diethylsulfamoyl)phenyl]carbonyl}amino)benzoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03399": {"dbids": ["DB03399", "EXPT01344"], "name": "Ethyl Isocyanide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07676": {"dbids": ["DB07676"], "name": "3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03390": {"dbids": ["DB03390", "EXPT02679"], "name": "N-Propyl-Tartramic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03391": {"dbids": ["DB03391", "EXPT00904"], "name": "Chromophore (Met-Tyr-Gly)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03392": {"dbids": ["DB03392", "EXPT01599"], "name": "(3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yl)-Phosphoramidic Acid Dimethyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03393": {"dbids": ["DB03393", "EXPT02889"], "name": "(3s,6s,9r,10r,11s,12s,13e,15e,18s,21s)-18-{(1e,3e,7s,8s)-9-[(2s,3r,4s,5s,6r,9s,11s)-9-Ethyl-4-Hydroxy-3,5,11-Trimethyl-8-Oxo-1-Oxa-7-Azaspiro[5.5]Undec-2-Yl]-8-Hydroxy-1,7-Dimethylnona-1,3-Dienyl}-10,12-Dihydroxy-3-(3-Hydroxybenzyl)-6-Isopropyl-11-Methyl-", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03395": {"dbids": ["DB03395", "EXPT03298"], "name": "Enalkiren", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P00797", "drug": "DB03395"}]}, "DB03396": {"dbids": ["DB03396", "EXPT03029"], "name": "(E)-(2r,3r,4s,5r)-3,4,5-Trihydroxy-2-Methoxy-8,8-Dimethyl-Non-6-Enoic Acid ((3s,6r)-6-Hydroxy-2-Oxo-Azepan-3-Yl)-Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03397": {"dbids": ["DB03397", "EXPT03168"], "name": "Uridine-Diphosphate-N-Acetylglucosamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07674": {"dbids": ["DB07674"], "name": "O,O-DIETHYL HYDROGEN THIOPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07673": {"dbids": ["DB07673"], "name": "DEAMINO-METHYL-PHENYLALANINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00800": {"dbids": ["APRD00969", "DB00800"], "name": "Fenoldopam", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P21918", "drug": "DB00800"}, {"action": "AGONIST", "target": "P21728", "drug": "DB00800"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00800"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB00800"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00800"}]}, "DB05420": {"dbids": ["DB05420"], "name": "gallium maltolate", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05421": {"dbids": ["DB05421"], "name": "CP-122721", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05422": {"dbids": ["DB05422"], "name": "OPC-14523", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05423": {"dbids": ["DB05423"], "name": "ORG-34517", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05424": {"dbids": ["DB05424"], "name": "CI-1033", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07671": {"dbids": ["DB07671"], "name": "2-[1-METHYLHEXYL]-4,6-DINITROPHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05426": {"dbids": ["DB05426"], "name": "talactoferrin alpha", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05427": {"dbids": ["DB05427"], "name": "IDD-3", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05428": {"dbids": ["DB05428"], "name": "motexafin gadolinium", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05429": {"dbids": ["DB05429"], "name": "CAT-213", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07670": {"dbids": ["DB07670"], "name": "4-METHYL-N-METHYL-N-(2-PHENYL-2H-PYRAZOL-3-YL)BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03134": {"dbids": ["DB03134", "EXPT02383"], "name": "2-Aminopimelic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03135": {"dbids": ["DB03135", "EXPT00020"], "name": "[2(Formyl-Hydroxy-Amino)-Ethyl]-Phosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03640": {"dbids": ["DB02157", "DB03640", "EXPT00696"], "name": "Beta-Hydroxyaspartic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03641": {"dbids": ["DB03641", "EXPT01298"], "name": "2'-deoxyuridine 5'-alpha,beta-imido-diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03130": {"dbids": ["DB03130", "EXPT01625"], "name": "S-P-Nitrobenzyloxycarbonylglutathione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03647": {"dbids": ["DB03647", "EXPT01914"], "name": "3-[Isopropyl(4-Methylbenzoyl)Amino]-5-Phenylthiophene-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03132": {"dbids": ["DB03132", "EXPT00770"], "name": "3-(2-Benzothiazolylthio)-1-Propanesulfonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03133": {"dbids": ["DB03133", "EXPT01871"], "name": "2-(Beta-D-Glucopyranosyl)-5-Methyl-1,2,3-Benzimidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03648": {"dbids": ["DB03648", "EXPT00713"], "name": "2-{N'-[2-(5-Amino-1-Phenylcarbamoyl-Pentylcarbamoyl)-Hexyl]-Hydrazinomethyl}-Hexanoic Acid(5-Amino-1-Phenylcarbamoyl-Pentyl)-Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03649": {"dbids": ["DB03649", "EXPT00850"], "name": "[{(5-Chloro-2-Pyridinyl)Amino} Methylene]-1,1-Bisphosphonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03138": {"dbids": ["DB03138", "EXPT02010"], "name": "Perchlorate Ion", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03139": {"dbids": ["DB03139", "EXPT00692"], "name": "6-[5-(2-Oxo-Hexahydro-Thieno[3,4-D]Imidazol-4-Yl)-Pentanoylamino]-Hexanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03656": {"dbids": ["DB03656", "EXPT00085"], "name": "Tribenuron Methyl", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06271": {"dbids": ["DB06271"], "name": "Sulodexide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P05546", "drug": "DB06271"}, {"action": "POTENTIATOR", "target": "P01008", "drug": "DB06271"}]}, "DB06273": {"dbids": ["DB06273"], "name": "Tocilizumab", "groups": ["APPROVED"], "targets": [{"action": "ANTIBODY", "target": "P08887", "drug": "DB06273"}]}, "DB05398": {"dbids": ["DB05398"], "name": "C31G", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05399": {"dbids": ["DB05399"], "name": "AGI-1067", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05392": {"dbids": ["DB05392"], "name": "AI-700", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05393": {"dbids": ["DB05393"], "name": "NOV-002", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05390": {"dbids": ["DB05390"], "name": "INS 316", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05391": {"dbids": ["DB05391"], "name": "liposomal prostaglandin E1", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05396": {"dbids": ["DB05396"], "name": "albumin-interferon alpha", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05397": {"dbids": ["DB05397"], "name": "personalized immunotherapy", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05394": {"dbids": ["DB05394"], "name": "corticotropin-releasing factor", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05395": {"dbids": ["DB05395"], "name": "SR 58611", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07422": {"dbids": ["DB07422"], "name": "(2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04449": {"dbids": ["DB04449", "EXPT01734"], "name": "5-(3,3-Dihydroxypropeny)-3-Methoxy-Benzene-1,2-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04302": {"dbids": ["DB04302", "EXPT03065"], "name": "4-Hydroxy-3,5-Dimethyl-5-(2-Methyl-Buta-1,3-Dienyl)-5h-Thiophen-2-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04448": {"dbids": ["DB04448", "EXPT00093"], "name": "2,4-Difluorobenzyl Alcohol 2,4-Difluoro-1-(Hydroxymethyl)Benzene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07423": {"dbids": ["DB07423"], "name": "(2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07420": {"dbids": ["DB07420"], "name": "(1R)-4-(3-phenoxyphenyl)-1-phosphonobutane-1-sulfonic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04441": {"dbids": ["DB04441", "EXPT00114"], "name": "2-Fluoroadenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04440": {"dbids": ["DB04440", "EXPT02701"], "name": "Purine Riboside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04191": {"dbids": ["DB04191", "EXPT01606"], "name": "Skf 107457", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03652": {"dbids": ["DB03652", "EXPT02024"], "name": "L-Glucuronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02511": {"dbids": ["DB02511", "EXPT02304"], "name": "2-Hydroxy-5-({1-[(2-Naphthyloxy)Methyl]-3-Oxoprop-1-Enyl}Amino)Tyrosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02510": {"dbids": ["DB02510", "EXPT02481"], "name": "'5'-O-(N-(L-Prolyl)-Sulfamoyl)Adenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02513": {"dbids": ["DB02513", "EXPT01913"], "name": "Thymol", "groups": ["APPROVED"], "targets": []}, "DB01962": {"dbids": ["DB01962", "EXPT02687"], "name": "Phosphonotyrosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02515": {"dbids": ["DB02515", "EXPT01531"], "name": "3-Phosphoglycerol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02514": {"dbids": ["DB02514", "EXPT00995"], "name": "(2z)-3-{[Oxido(Oxo)Phosphino]Oxy}-2-Phenylacrylate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02517": {"dbids": ["DB02517", "EXPT01180"], "name": "D-Glutamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02516": {"dbids": ["DB02516", "EXPT00863"], "name": "O5'-(4-(3-{2-[2-((R)-3-Hydroxy-4-(Trimethylammonio)-1-Oxo-Butyl)Sulfanyl-Ethylcarbamoyl]-Ethylcarbamoyl}-(R)-3-Hydroxy-2,2-Dimethyl-Propyl)-1-Hydroxy-3-Oxido-1,3-Dioxo-2,4-Dioxa-1,3-Diphosphabut-1-Yl) 3'-Phospho-Adenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02519": {"dbids": ["DB02519", "EXPT01891"], "name": "Indirubin-5-Sulphonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04445": {"dbids": ["DB04445", "EXPT01740"], "name": "Mercury Diiodide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07421": {"dbids": ["DB07421"], "name": "4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04444": {"dbids": ["DB04444", "EXPT00497"], "name": "Tetrafluoroaluminate Ion", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04447": {"dbids": ["DB04447", "EXPT01291"], "name": "1,4-Dithiothreitol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04446": {"dbids": ["DB04446", "EXPT01365"], "name": "Benzo[B]Thiophene-2-Carboxamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08759": {"dbids": ["DB08759"], "name": "[(3R,4S,5S,7R)-4,8-DIHYDROXY-3,5,7-TRIMETHYL-2-OXOOCTYL]PHOSPHONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08758": {"dbids": ["DB08758"], "name": "IMIDAZO[2,1-A]ISOQUINOLINE-2-CARBOHYDRAZIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07426": {"dbids": ["DB07426"], "name": "[1-HYDROXY-2-(1,1':3',1''-TERPHENYL-3-YLOXY)ETHANE-1,1-DIYL]BIS(PHOSPHONIC ACID)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07427": {"dbids": ["DB07427"], "name": "2-[(2-methoxy-5-methylphenoxy)methyl]pyridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07938": {"dbids": ["DB07938"], "name": "5-[[(2R)-2-cyclopropyl-7,8-dimethoxy-chroman-5-yl]methyl]pyrimidine-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07939": {"dbids": ["DB07939"], "name": "N-(3-MERCAPTOPROPANOYL)-D-ALANINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07930": {"dbids": ["DB07930"], "name": "(3R)-3-HYDROXYDODECANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07931": {"dbids": ["DB07931"], "name": "4-[(1R,2S)-1-ethyl-2-(4-hydroxyphenyl)butyl]phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04307": {"dbids": ["DB04307", "EXPT02781"], "name": "5-Hydroxy-N-Propargyl-1(R)-Aminoindan", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07933": {"dbids": ["DB07933"], "name": "(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07934": {"dbids": ["DB07934"], "name": "[[CYCLOHEXANESULFONYL-GLYCYL]-3[PYRIDIN-4-YL-AMINOMETHYL]ALANYL]PIPERIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07935": {"dbids": ["DB07935"], "name": "5-[(5-fluoro-3-methyl-1H-indazol-4-yl)oxy]benzene-1,3-dicarbonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07936": {"dbids": ["DB07936"], "name": "N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07937": {"dbids": ["DB07937"], "name": "2-butoxy-9-(2,6-difluorobenzyl)-N-(2-morpholin-4-ylethyl)-9H-purin-6-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07424": {"dbids": ["DB07424"], "name": "tripotassium (1R)-4-biphenyl-4-yl-1-phosphonatobutane-1-sulfonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08757": {"dbids": ["DB08757"], "name": "5-(2-chlorophenyl)furan-2-carbohydrazide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02779": {"dbids": ["DB02779", "EXPT00833"], "name": "Dodecane-Trimethylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08756": {"dbids": ["DB08756"], "name": "(R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05761": {"dbids": ["DB05761"], "name": "ASF-1096", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB02778": {"dbids": ["DB02778", "EXPT00466"], "name": "2,5-Anhydroglucitol-1,6-Biphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05760": {"dbids": ["DB05760"], "name": "MK-0974", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01099": {"dbids": ["APRD00299", "DB01099"], "name": "Flucytosine", "groups": ["APPROVED"], "targets": [{"action": "OTHER", "target": "P26358", "drug": "DB01099"}, {"action": "INHIBITOR", "target": "P12461", "drug": "DB01099"}]}, "DB01098": {"dbids": ["APRD00546", "DB01098"], "name": "Rosuvastatin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P04035", "drug": "DB01098"}]}, "DB01095": {"dbids": ["APRD00346", "DB01095"], "name": "Fluvastatin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P04035", "drug": "DB01095"}]}, "DB05095": {"dbids": ["DB05095"], "name": "Cimicoxib", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01097": {"dbids": ["APRD00205", "DB01097"], "name": "Leflunomide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q02127", "drug": "DB01097"}, {"action": "AGONIST", "target": "P35869", "drug": "DB01097"}, {"action": "ANTAGONIST", "target": "Q14289", "drug": "DB01097"}]}, "DB01096": {"dbids": ["APRD01150", "DB01096"], "name": "Oxamniquine", "groups": ["APPROVED"], "targets": []}, "DB01091": {"dbids": ["APRD00833", "DB01091"], "name": "Butenafine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14534", "drug": "DB01091"}]}, "DB01090": {"dbids": ["APRD00038", "DB01090"], "name": "Pentolinium", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q9GZZ6", "drug": "DB01090"}, {"action": "ANTAGONIST", "target": "P32297", "drug": "DB01090"}, {"action": "ANTAGONIST", "target": "P30926", "drug": "DB01090"}]}, "DB01093": {"dbids": ["APRD00925", "DB01093", "EXPT01231"], "name": "Dimethyl sulfoxide", "groups": ["APPROVED"], "targets": []}, "DB05094": {"dbids": ["DB05094"], "name": "MDV3100", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05097": {"dbids": ["DB05097"], "name": "Labetuzumab", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB02774": {"dbids": ["DB02774", "EXPT02534"], "name": "1,3-Propandiol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04049": {"dbids": ["DB04049", "EXPT00888"], "name": "Coelenteramide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05096": {"dbids": ["DB05096"], "name": "LY2140023", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04048": {"dbids": ["DB04048", "EXPT02308"], "name": "N-Carbamoyl-Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07448": {"dbids": ["DB07448"], "name": "(2S)-3-[(R)-[(1S)-1-amino-3-phenylpropyl](hydroxy)phosphoryl]-2-benzylpropanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01895": {"dbids": ["DB01895", "EXPT00511"], "name": "Aspartyl-Adenosine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01565": {"dbids": ["DB01565"], "name": "Dihydromorphine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB01565"}, {"action": "AGONIST", "target": "P41143", "drug": "DB01565"}, {"action": "AGONIST", "target": "P41145", "drug": "DB01565"}, {"action": "AGONIST", "target": "O60858", "drug": "DB01565"}, {"action": "AGONIST", "target": "P01189", "drug": "DB01565"}]}, "DB01897": {"dbids": ["DB01897", "EXPT02404"], "name": "2-(2f-Benzothiazolyl)-5-Styryl-3-(4f-Phthalhydrazidyl)Tetrazolium Chloride", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01896": {"dbids": ["DB01896", "EXPT00538"], "name": "M-Aminophenylboronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01891": {"dbids": ["DB01891", "EXPT01893"], "name": "Tl-3-093", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01890": {"dbids": ["DB01890", "EXPT01003"], "name": "Deoxy-Bigchap", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01893": {"dbids": ["DB01893", "EXPT02305"], "name": "N6-Benzyl Adenosine-5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01892": {"dbids": ["DB01892", "EXPT01804"], "name": "Hyperforin", "groups": ["NUTRACEUTICAL"], "targets": [{"action": "INHIBITOR", "target": "P23219", "drug": "DB01892"}, {"action": "INHIBITOR", "target": "P09917", "drug": "DB01892"}]}, "DB01899": {"dbids": ["DB01899", "EXPT01752"], "name": "Nd1-Phosphonohistidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04047": {"dbids": ["DB04047", "EXPT01742"], "name": "[Pterin-6-Yl Methanyl]-Phosphonophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04046": {"dbids": ["DB03324", "DB04046", "EXPT02122"], "name": "Methyl beta-galactoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06419": {"dbids": ["DB06419"], "name": "Cethromycin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04041": {"dbids": ["DB04041", "EXPT02306"], "name": "Nitrocefin Acyl-Serine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04040": {"dbids": ["DB04040", "EXPT00072"], "name": "N-(2-Morpholin-4-Yl-1-Morpholin-4-Ylmethyl-Ethyl)-3-Nitro-5-(3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yloxy)-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04043": {"dbids": ["DB04043", "EXPT00952"], "name": "Carboxymycobactin T", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04042": {"dbids": ["DB04042", "EXPT00465"], "name": "2-[4-(Hydroxy-Methoxy-Methyl)-Benzyl]-7-(4-Hydroxymethyl-Benzyl)-1,1-Dioxo-3,6-Bis-Phenoxymethyl-1lambda6-[1,2,7]Thiadiazepane-4,5-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04224": {"dbids": ["DB04224", "EXPT02430"], "name": "Oleic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04991": {"dbids": ["DB04991"], "name": "XL784", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04351": {"dbids": ["DB04351", "EXPT03104"], "name": "Aconitate Ion", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04350": {"dbids": ["DB04350", "EXPT02785"], "name": "Argadin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04353": {"dbids": ["DB04353", "EXPT02729"], "name": "{(1s)-1-Benzyl-4-[3-Carbamoyl-1-(1-Carbamoyl-2-Phenyl-Ethylcarbamoyl)-(S)-Propylcarbamoyl]-2-Oxo-5-Phenyl-Pentyl}-Carbamic Acid Tert-Butyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04352": {"dbids": ["DB04352", "EXPT02809"], "name": "[(2r,3s,4s,5r)-3,4,5-Trihydroxytetrahydrofuran-2-Yl]Methyl Dihydrogen Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04355": {"dbids": ["DB04355", "EXPT03198"], "name": "Uridine-5'-Monophosphate Glucopyranosyl-Monophosphateester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04609": {"dbids": ["DB04609"], "name": "INHIBITOR Q8467 OF DUPONT MERCK", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04608": {"dbids": ["DB04608"], "name": "9-HYDROXY-4-PHENYL-6H-PYRROLO[3,4-C]CARBAZOLE-1,3-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04607": {"dbids": ["DB04607"], "name": "PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04606": {"dbids": ["DB04606"], "name": "2-[2-ETHANESULFONYLAMINO-3-(5-PROPOXY-1H-INDOL-3-YL)-PROPIONYLAMINO]-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIMIDOYL-BENZYLAMIDE)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04605": {"dbids": ["DB04605"], "name": "5-Aminoisoquinoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04604": {"dbids": ["DB04604"], "name": "5-iodotubercidin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04603": {"dbids": ["DB04603"], "name": "2'-DEOXY-5-FORMYLCYTIDINE-5'-MONOPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04602": {"dbids": ["DB04602"], "name": "PUROMYCIN AMINONUCLEOSIDE-5'-MONOPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04601": {"dbids": ["DB04601"], "name": "4-[(4-O-SULFAMOYLBENZYL)(4-CYANOPHENYL)AMINO]-4H-[1,2,4]-TRIAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04600": {"dbids": ["DB04600"], "name": "4-[(3-BROMO-4-O-SULFAMOYLBENZYL)(4-CYANOPHENYL)AMINO]-4H-[1,2,4]-TRIAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06413": {"dbids": ["DB06413"], "name": "Armodafinil", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "Q01959", "drug": "DB06413"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB06413"}]}, "DB04223": {"dbids": ["DB04223", "EXPT02387"], "name": "Nitroarginine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08119": {"dbids": ["DB08119"], "name": "1,1,1-TRIFLUORO-3-((N-ACETYL)-L-LEUCYLAMIDO)-4-PHENYL-BUTAN-2-ONE(N-ACETYL-L-LEUCYL-L-PHENYLALANYL TRIFLUOROMETHYL KETONE)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08118": {"dbids": ["DB08118"], "name": "2-(methylamino)-N-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06414": {"dbids": ["DB06414"], "name": "Etravirine", "groups": ["APPROVED"], "targets": []}, "DB08115": {"dbids": ["DB08115"], "name": "2-aminoethyl naphthalen-1-ylacetate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04222": {"dbids": ["DB04222", "EXPT02949"], "name": "Sparsomycin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08113": {"dbids": ["DB08113"], "name": "3-pyridin-4-yl-1H-indazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08112": {"dbids": ["DB08112"], "name": "N-({6-[(4-CYANO-2-FLUOROBENZYL)OXY]NAPHTHALEN-2-YL}SULFONYL)-D-GLUTAMIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08111": {"dbids": ["DB08111"], "name": "4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06415": {"dbids": ["DB06415"], "name": "Calfactant", "groups": ["APPROVED"], "targets": []}, "DB00962": {"dbids": ["APRD00411", "DB00962"], "name": "Zaleplon", "groups": ["APPROVED", "ILLICIT", "INVESTIGATIONAL"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00962"}, {"action": "OTHER", "target": "P30536", "drug": "DB00962"}]}, "DB00278": {"dbids": ["APRD00105", "DB00278"], "name": "Argatroban", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P00734", "drug": "DB00278"}]}, "DB00279": {"dbids": ["APRD01074", "DB00279"], "name": "Liothyronine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P10827", "drug": "DB00279"}, {"action": "AGONIST", "target": "P10828", "drug": "DB00279"}]}, "DB00963": {"dbids": ["APRD00831", "DB00963"], "name": "Bromfenac", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00963"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00963"}]}, "DB00272": {"dbids": ["APRD00714", "DB00272"], "name": "Betazole", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P25021", "drug": "DB00272"}]}, "DB00273": {"dbids": ["APRD00237", "DB00273"], "name": "Topiramate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P14867", "drug": "DB00273"}, {"action": "INHIBITOR", "target": "P35498", "drug": "DB00273"}, {"action": "ANTAGONIST", "target": "P39086", "drug": "DB00273"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00273"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00273"}]}, "DB00270": {"dbids": ["APRD00298", "DB00270"], "name": "Isradipine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q13936", "drug": "DB00270"}, {"action": "INHIBITOR", "target": "P54289", "drug": "DB00270"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB00270"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB00270"}, {"action": "INHIBITOR", "target": "Q9NY47", "drug": "DB00270"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB00270"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB00270"}]}, "DB00271": {"dbids": ["APRD00913", "DB00271"], "name": "Diatrizoate", "groups": ["APPROVED"], "targets": []}, "DB00276": {"dbids": ["APRD00064", "DB00276"], "name": "Amsacrine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P11388", "drug": "DB00276"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00276"}]}, "DB00277": {"dbids": ["APRD00082", "DB00277", "DB09359"], "name": "Theophylline", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P30542", "drug": "DB00277"}, {"action": "ANTAGONIST", "target": "P29274", "drug": "DB00277"}, {"action": "ANTAGONIST", "target": "P29275", "drug": "DB00277"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB00277"}, {"action": "INHIBITOR", "target": "O76074", "drug": "DB00277"}, {"action": "INHIBITOR", "target": "P27815", "drug": "DB00277"}, {"action": "INHIBITOR", "target": "Q14432", "drug": "DB00277"}, {"action": "ACTIVATOR", "target": "Q92769", "drug": "DB00277"}]}, "DB00274": {"dbids": ["APRD00852", "DB00274"], "name": "Cefmetazole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "C1KC03", "drug": "DB00274"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB00274"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB00274"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB00274"}, {"action": "INHIBITOR", "target": "P0AEB2", "drug": "DB00274"}, {"action": "INHIBITOR", "target": "P08506", "drug": "DB00274"}]}, "DB00275": {"dbids": ["APRD00223", "DB00275"], "name": "Olmesartan", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P30556", "drug": "DB00275"}]}, "DB07444": {"dbids": ["DB07444"], "name": "6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00961": {"dbids": ["APRD01094", "DB00961"], "name": "Mepivacaine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00961"}]}, "DB00210": {"dbids": ["APRD00780", "DB00210"], "name": "Adapalene", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P13631", "drug": "DB00210"}, {"action": "AGONIST", "target": "P10826", "drug": "DB00210"}, {"action": "AGONIST", "target": "P48443", "drug": "DB00210"}, {"action": "AGONIST", "target": "P28702", "drug": "DB00210"}, {"action": "AGONIST", "target": "P10276", "drug": "DB00210"}, {"action": "OTHER/UNKNOWN", "target": "P19793", "drug": "DB00210"}]}, "DB06603": {"dbids": ["DB06603"], "name": "Panobinostat", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q9UBN7", "drug": "DB06603"}, {"action": "INHIBITOR", "target": "P56524", "drug": "DB06603"}, {"action": "INHIBITOR", "target": "O15379", "drug": "DB06603"}, {"action": "INHIBITOR", "target": "Q13547", "drug": "DB06603"}, {"action": "INHIBITOR", "target": "Q92769", "drug": "DB06603"}, {"action": "INHIBITOR", "target": "Q9BY41", "drug": "DB06603"}, {"action": "INHIBITOR", "target": "Q9UQL6", "drug": "DB06603"}, {"action": "INHIBITOR", "target": "Q8WUI4", "drug": "DB06603"}, {"action": "INHIBITOR", "target": "Q9UKV0", "drug": "DB06603"}, {"action": "INHIBITOR", "target": "Q969S8", "drug": "DB06603"}]}, "DB06605": {"dbids": ["DB06605", "DB07828"], "name": "Apixaban", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00742", "drug": "DB06605"}]}, "DB00211": {"dbids": ["APRD01116", "DB00211"], "name": "Midodrine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35348", "drug": "DB00211"}, {"action": "AGONIST", "target": "P35368", "drug": "DB00211"}, {"action": "AGONIST", "target": "P25100", "drug": "DB00211"}]}, "DB00212": {"dbids": ["APRD00163", "DB00212"], "name": "Remikiren", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00797", "drug": "DB00212"}]}, "DB04227": {"dbids": ["DB04227", "EXPT00352"], "name": "9-Amino-2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00213": {"dbids": ["APRD00073", "DB00213"], "name": "Pantoprazole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P20648", "drug": "DB00213"}]}, "DB07445": {"dbids": ["DB07445"], "name": "N'-[(1E)-(3,5-DIBROMO-2,4-DIHYDROXYPHENYL)METHYLENE]NICOTINOHYDRAZIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07546": {"dbids": ["DB07546"], "name": "[1-(6-{6-[(1-methylethyl)amino]-1H-indazol-1-yl}pyrazin-2-yl)-1H-pyrrol-3-yl]acetic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07446": {"dbids": ["DB07446"], "name": "N-(biphenyl-4-ylsulfonyl)-D-leucine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04221": {"dbids": ["DB04221", "EXPT00009"], "name": "Didecyl-Dimethyl-Ammonium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07447": {"dbids": ["DB07447"], "name": "5-beta-DIHYDROTESTOSTERONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07540": {"dbids": ["DB07540"], "name": "4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00858": {"dbids": ["APRD00938", "DB00858"], "name": "Drostanolone", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P10275", "drug": "DB00858"}]}, "DB00859": {"dbids": ["APRD01171", "DB00859"], "name": "Penicillamine", "groups": ["APPROVED"], "targets": []}, "DB00856": {"dbids": ["APRD00867", "DB00856"], "name": "Chlorphenesin", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB00857": {"dbids": ["APRD00508", "DB00857"], "name": "Terbinafine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q14534", "drug": "DB00857"}]}, "DB00854": {"dbids": ["APRD00764", "DB00854"], "name": "Levorphanol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB00854"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00854"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00854"}]}, "DB00855": {"dbids": ["APRD00793", "DB00855", "DB05277"], "name": "Aminolevulinic acid", "groups": ["APPROVED"], "targets": [{"action": "INDUCER", "target": "P13716", "drug": "DB00855"}]}, "DB00852": {"dbids": ["APRD00634", "DB00852"], "name": "Pseudoephedrine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23975", "drug": "DB00852"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00852"}, {"action": "AGONIST", "target": "P35348", "drug": "DB00852"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00852"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00852"}, {"action": "PARTIAL AGONIST", "target": "P07550", "drug": "DB00852"}, {"action": "AGONIST", "target": "P08588", "drug": "DB00852"}, {"action": "PARTIAL AGONIST", "target": "P08588", "drug": "DB00852"}]}, "DB00853": {"dbids": ["APRD00557", "DB00853"], "name": "Temozolomide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB00850": {"dbids": ["APRD00429", "DB00850"], "name": "Perphenazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB00850"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00850"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB00850"}]}, "DB00851": {"dbids": ["APRD00331", "DB00851"], "name": "Dacarbazine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "OTHER/UNKNOWN", "target": "Q14181", "drug": "DB00851"}, {"action": "INHIBITOR", "target": "P52209", "drug": "DB00851"}]}, "DB04220": {"dbids": ["DB04220", "EXPT02784"], "name": "Rifamycin Cgp 4832", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07440": {"dbids": ["DB07440"], "name": "4-TERT-BUTYLBENZENESULFONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02726": {"dbids": ["DB02389", "DB02726", "EXPT02567"], "name": "2-Phosphoglycolic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02727": {"dbids": ["DB02727", "EXPT00698"], "name": "N-Butyl-N'-Hydroxyguanidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02724": {"dbids": ["DB02724", "EXPT00495"], "name": "Delta-2-Albomycin A1", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02725": {"dbids": ["DB02725", "EXPT00424"], "name": "2-Amino-4-(4-Amino-Cyclohexa-2,5-Dienyl)-Butyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02722": {"dbids": ["DB02722", "EXPT01567"], "name": "4-O-Methyl-Beta-D-Glucuronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02723": {"dbids": ["DB02723", "EXPT00716"], "name": "4-Oxo-2-Phenylmethanesulfonyl-Octahydro-Pyrrolo[1,2-a]Pyrazine-6-Carboxylic Acid [1-(N-Hydroxycarbamimidoyl)-Piperidin-4-Ylmethyl]-Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02720": {"dbids": ["DB02720", "EXPT01605"], "name": "Alpha-D-Glucopyranosyl-2-Carboxylic Acid Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02721": {"dbids": ["DB02721", "EXPT02726"], "name": "4-Iodopyrazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02728": {"dbids": ["DB02728", "EXPT03279"], "name": "7-Hydroxy-2-Oxo-Chromene-3-Carboxylic Acid Ethyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02729": {"dbids": ["DB02729", "EXPT00032"], "name": "SD146", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07441": {"dbids": ["DB07441"], "name": "3-{[(9-CYANO-9,10-DIHYDRO-10-METHYLACRIDIN-9-YL)CARBONYL]AMINO}PROPANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04150": {"dbids": ["DB04150", "EXPT01952"], "name": "Threonine Derivative", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07443": {"dbids": ["DB07443"], "name": "(2Z)-N-biphenyl-4-yl-2-cyano-3-hydroxybut-2-enamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07529": {"dbids": ["DB07529"], "name": "2-IMINO-5-(1-PYRIDIN-2-YL-METH-(E)-YLIDENE)-1,3-THIAZOLIDIN-4-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07528": {"dbids": ["DB07528"], "name": "3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04060": {"dbids": ["DB04060", "EXPT02250"], "name": "(5-Methyl-6-Oxo-1,6-Dihydro-Pyridin-3-Yl)-1,2-Dideoxy-Ribofuranose-5-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07527": {"dbids": ["DB07527"], "name": "N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]-4-METHOXY-2,3,6-TRIMETHYLBENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08931": {"dbids": ["DB08931"], "name": "Riociguat", "groups": ["APPROVED"], "targets": []}, "DB08930": {"dbids": ["DB08930"], "name": "Dolutegravir", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q7ZJM1", "drug": "DB08930"}]}, "DB08933": {"dbids": ["DB08933"], "name": "Luliconazole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P10613", "drug": "DB08933"}]}, "DB08932": {"dbids": ["DB08932"], "name": "MACITENTAN", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P25101", "drug": "DB08932"}, {"action": "ANTAGONIST", "target": "P24530", "drug": "DB08932"}]}, "DB08935": {"dbids": ["DB08935"], "name": "Obinutuzumab", "groups": ["APPROVED"], "targets": [{"action": "ANTIBODY", "target": "P11836", "drug": "DB08935"}]}, "DB08934": {"dbids": ["DB08934"], "name": "Sofosbuvir", "groups": ["APPROVED"], "targets": []}, "DB05189": {"dbids": ["DB05189"], "name": "EPC2407", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05188": {"dbids": ["DB05188"], "name": "KD3010", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05187": {"dbids": ["DB05187"], "name": "GFT505", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05186": {"dbids": ["DB05186"], "name": "SQ109", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05185": {"dbids": ["DB05185"], "name": "TRO19622", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05184": {"dbids": ["DB05184"], "name": "XL228", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05183": {"dbids": ["DB05183"], "name": "MLN0415", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05182": {"dbids": ["DB05182"], "name": "AS1409", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05181": {"dbids": ["DB05181"], "name": "BTA798", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05180": {"dbids": ["DB05180"], "name": "LX6171", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07525": {"dbids": ["DB07525"], "name": "3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06094": {"dbids": ["DB06094"], "name": "OGX-427", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07602": {"dbids": ["DB07602"], "name": "S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06096": {"dbids": ["DB06096"], "name": "NXN-188", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06986": {"dbids": ["DB06986"], "name": "2-CHLORO-N-[(1R,2R)-1-HYDROXY-2,3-DIHYDRO-1H-INDEN-2-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06987": {"dbids": ["DB06987"], "name": "2-(4-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)PHENYL)ETHANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06984": {"dbids": ["DB06984"], "name": "(1R,2R,3R,4S,5R)-4-(BENZYLAMINO)-5-(METHYLTHIO)CYCLOPENTANE-1,2,3-TRIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06097": {"dbids": ["DB06097"], "name": "GSK-923295", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06982": {"dbids": ["DB06982"], "name": "(2S)-8-[(tert-butoxycarbonyl)amino]-2-(1H-indol-3-yl)octanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06983": {"dbids": ["DB06983"], "name": "(5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06980": {"dbids": ["DB06980"], "name": "(2S)-2-(1H-indol-3-yl)hexanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06981": {"dbids": ["DB06981"], "name": "(2S)-2-(1H-indol-3-yl)pentanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06090": {"dbids": ["DB06090"], "name": "TC-5619", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06988": {"dbids": ["DB06988"], "name": "2-HYDROXY-5-{[(1E)-2-PHENYLETHYLIDENE]AMINO}-L-TYROSINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06989": {"dbids": ["DB06989"], "name": "{4-[2-BENZYL-3-METHOXY-2-(METHOXYCARBONYL)-3-OXOPROPYL]PHENYL}SULFAMIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07603": {"dbids": ["DB07603"], "name": "N-hexanoyl-L-homocysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06093": {"dbids": ["DB06093"], "name": "ABT-560", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08902": {"dbids": ["DB08902"], "name": "Raxibacumab", "groups": ["APPROVED"], "targets": [{"action": "ANTIBODY", "target": "P13423", "drug": "DB08902"}]}, "DB06098": {"dbids": ["DB06098"], "name": "PRLX 93936", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07522": {"dbids": ["DB07522"], "name": "N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]NAPHTHALENE-2-SULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07601": {"dbids": ["DB07601"], "name": "4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07521": {"dbids": ["DB07521"], "name": "6-CHLORO-1-(2-{[(5-CHLORO-1-BENZOTHIEN-3-YL)METHYL]AMINO}ETHYL)-3-[(2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04166": {"dbids": ["DB04166", "EXPT00656"], "name": "2-Aminobenzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04167": {"dbids": ["DB04167", "EXPT02358"], "name": "N-Acetyl-L-Glutamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01404": {"dbids": ["DB01404"], "name": "Ginseng", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "ANTAGONIST", "target": "P05231", "drug": "DB01404"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB01404"}, {"action": "AGONIST", "target": "P35869", "drug": "DB01404"}]}, "DB04165": {"dbids": ["DB04165", "EXPT03231"], "name": "Valpromide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04162": {"dbids": ["DB04162", "EXPT01887"], "name": "5-Nitro-6-Ribityl-Amino-2,4(1h,3h)-Pyrimidinedione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01403": {"dbids": ["DB01403"], "name": "Methotrimeprazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P21918", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB01403"}]}, "DB01400": {"dbids": ["DB01400"], "name": "Neostigmine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P22303", "drug": "DB01400"}]}, "DB04161": {"dbids": ["DB04161", "EXPT02807"], "name": "Propionamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09183": {"dbids": ["DB09183"], "name": "Dasabuvir", "groups": ["APPROVED"], "targets": []}, "DB09182": {"dbids": ["DB09182"], "name": "Benzylfentanyl", "groups": ["ILLICIT"], "targets": []}, "DB07606": {"dbids": ["DB07606"], "name": "6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09180": {"dbids": ["DB09180"], "name": "Thienylfentanyl", "groups": ["ILLICIT"], "targets": []}, "DB09187": {"dbids": ["DB09187"], "name": "Lortalamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09186": {"dbids": ["DB09186"], "name": "Nisoxetine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01408": {"dbids": ["DB01408"], "name": "Bambuterol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P07550", "drug": "DB01408"}]}, "DB01409": {"dbids": ["DB01409"], "name": "Tiotropium", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P20309", "drug": "DB01409"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01409"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01409"}]}, "DB07123": {"dbids": ["DB07123"], "name": "N-(4-METHYLBENZOYL)-4-BENZYLPIPERIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07122": {"dbids": ["DB07122"], "name": "1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07121": {"dbids": ["DB07121"], "name": "4-({4-[(4-AMINOBUT-2-YNYL)OXY]PHENYL}SULFONYL)-N-HYDROXY-2,2-DIMETHYLTHIOMORPHOLINE-3-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07120": {"dbids": ["DB07120"], "name": "N4-(N,N-DIPHENYLCARBAMOYL)-AMINOGUANIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07127": {"dbids": ["DB07127"], "name": "{4-[2,2-BIS(5-METHYL-1,2,4-OXADIAZOL-3-YL)-3-PHENYLPROPYL]PHENYL}SULFAMIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07126": {"dbids": ["DB07126"], "name": "O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07125": {"dbids": ["DB07125"], "name": "4-(6-{[(1R)-1-(hydroxymethyl)propyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07124": {"dbids": ["DB07124"], "name": "(2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07129": {"dbids": ["DB07129"], "name": "(2R)-1-(2,6-dimethylphenoxy)propan-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07128": {"dbids": ["DB07128"], "name": "N7-BUTYL-N2-(5-CHLORO-2-METHYLPHENYL)-5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE-2,7-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07520": {"dbids": ["DB07520"], "name": "N-[1-(AMINOMETHYL)CYCLOPROPYL]-3-(MORPHOLIN-4-YLSULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)ETHYL]-L-ALANINAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07607": {"dbids": ["DB07607"], "name": "4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03800": {"dbids": ["DB03800", "EXPT03187"], "name": "2'-deoxyuridylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03801": {"dbids": ["DB03801", "EXPT01965"], "name": "Lysine Nz-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03802": {"dbids": ["DB03802", "EXPT00446"], "name": "1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03803": {"dbids": ["DB03803", "EXPT02235"], "name": "Inhibitor Msa367", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03804": {"dbids": ["DB03804", "EXPT00766"], "name": "5-Bromothienyldeoxyuridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03805": {"dbids": ["DB03805", "EXPT00364"], "name": "Antiproliferative Agent A771726", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03807": {"dbids": ["DB03807", "EXPT00284"], "name": "1-(2-Chlorophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03808": {"dbids": ["DB03808", "EXPT01203"], "name": "4,4'[1,6-Hexanediylbis(Oxy)]Bisbenzenecarboximidamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03809": {"dbids": ["DB03809", "EXPT02696"], "name": "9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09459": {"dbids": ["DB09459"], "name": "Tartaric acid", "groups": ["APPROVED"], "targets": []}, "DB04290": {"dbids": ["DB04290", "EXPT00867"], "name": "[2-Cytidylate-O'-Phosphonyloxyl]-Ethyl-Trimethyl-Ammonium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04291": {"dbids": ["DB04291", "EXPT01097"], "name": "(2s)-Amino(4-Hydroxyphenyl)Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04292": {"dbids": ["DB04292", "EXPT01821"], "name": "4-[(Isopropylamino)Methyl]Phenylalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04293": {"dbids": ["DB04293", "EXPT02052"], "name": "7-(2-Amino-2-Phenyl-Acetylamino)-3-Chloro-8-Oxo-1-Aza-Bicyclo[4.2.0]Oct-2-Ene-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04294": {"dbids": ["DB04294", "EXPT02637"], "name": "5-Phosphoribosyl-1-(Beta-Methylene) Pyrophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01667": {"dbids": ["DB01667", "EXPT00603"], "name": "8-azaguanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04296": {"dbids": ["DB04296", "EXPT02438"], "name": "5-Oxo-L-Norleucine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04297": {"dbids": ["DB04297", "EXPT03123"], "name": "7-[4-(Dimethylamino)Phenyl]-N-Hydroxy-4,6-Dimethyl-7-Oxo-2,4-Heptadienamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04298": {"dbids": ["DB04298", "EXPT02340"], "name": "3-(4-Amino-2-Tert-Butyl-5-Methyl-Phenylsulfanyl)-6-Cyclopentyl-4-Hydroxy-6-[2-(4-Hydroxy-Phenyl)-Ethyl]-5,6-Dihydro-Pyran-2-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04299": {"dbids": ["DB04299", "EXPT02106"], "name": "Maleic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01668": {"dbids": ["DB01668", "EXPT02375"], "name": "Nanaomycin D", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01669": {"dbids": ["DB01669", "EXPT03225"], "name": "Virginiamycin M1", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00131": {"dbids": ["DB00131", "EXPT00512", "NUTR00011"], "name": "Adenosine monophosphate", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "ACTIVATOR", "target": "P16220", "drug": "DB00131"}, {"action": "PRODUCT OF", "target": "P11309", "drug": "DB00131"}, {"action": "PRODUCT OF", "target": "Q07343", "drug": "DB00131"}, {"action": "ACTIVATOR", "target": "P06737", "drug": "DB00131"}, {"action": "ACTIVATOR", "target": "Q9Y478", "drug": "DB00131"}, {"action": "PRODUCT OF", "target": "P49773", "drug": "DB00131"}, {"action": "PRODUCT OF", "target": "Q08499", "drug": "DB00131"}, {"action": "PRODUCT OF", "target": "Q9NUB1", "drug": "DB00131"}, {"action": "PRODUCT OF", "target": "Q9NR19", "drug": "DB00131"}, {"action": "ACTIVATOR", "target": "Q13131", "drug": "DB00131"}, {"action": "ACTIVATOR", "target": "O43741", "drug": "DB00131"}, {"action": "PRODUCT OF", "target": "Q08828", "drug": "DB00131"}, {"action": "PRODUCT OF", "target": "P33121", "drug": "DB00131"}, {"action": "ANTAGONIST", "target": "P09467", "drug": "DB00131"}, {"action": "INHIBITORY ALLOSTERIC MODULATOR", "target": "P09467", "drug": "DB00131"}, {"action": "PRODUCT OF", "target": "P55263", "drug": "DB00131"}]}, "DB00130": {"dbids": ["DB00130", "NUTR00026"], "name": "L-Glutamine", "groups": ["APPROVED", "INVESTIGATIONAL", "NUTRACEUTICAL"], "targets": [{"action": "ANTAGONIST", "target": "P17812", "drug": "DB00130"}, {"action": "PRODUCT OF", "target": "Q06203", "drug": "DB00130"}, {"action": "PRODUCT OF", "target": "P15104", "drug": "DB00130"}]}, "DB00133": {"dbids": ["DB00133", "DB03375", "NUTR00053"], "name": "L-Serine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00132": {"dbids": ["DB00132", "NUTR00034"], "name": "Alpha-Linolenic Acid", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "LIGAND", "target": "O60427", "drug": "DB00132"}, {"action": "LIGAND", "target": "O95864", "drug": "DB00132"}]}, "DB00135": {"dbids": ["DB00135", "NUTR00059"], "name": "L-Tyrosine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "BINDER", "target": "P07101", "drug": "DB00135"}]}, "DB00134": {"dbids": ["DB00134", "NUTR00038"], "name": "L-Methionine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "PRODUCT OF", "target": "Q9UBK8", "drug": "DB00134"}, {"action": "PRODUCT OF", "target": "Q99707", "drug": "DB00134"}, {"action": "PRODUCT OF", "target": "P50579", "drug": "DB00134"}, {"action": "PRODUCT OF", "target": "Q93088", "drug": "DB00134"}, {"action": "PRODUCT OF", "target": "Q9H2M3", "drug": "DB00134"}]}, "DB00137": {"dbids": ["DB00137", "NUTR00036"], "name": "Xanthophyll", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00136": {"dbids": ["APRD00246", "DB00136", "NUTR00003"], "name": "Calcitriol", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "ANTAGONIST", "target": "P11473", "drug": "DB00136"}]}, "DB00139": {"dbids": ["DB00139", "NUTR00054"], "name": "Succinic acid", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "INHIBITOR", "target": "P51649", "drug": "DB00139"}]}, "DB00138": {"dbids": ["DB00138", "NUTR00023"], "name": "L-Cystine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB07605": {"dbids": ["DB07605"], "name": "2-({4-[(5-CHLORO-1H-INDOL-2-YL)SULFONYL]PIPERAZIN-1-YL}CARBONYL)THIENO[3,2-B]PYRIDINE 4-OXIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06292": {"dbids": ["DB06292"], "name": "Dapagliflozin", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P31639", "drug": "DB06292"}, {"action": "INHIBITOR, COMPETITIVE", "target": "P31639", "drug": "DB06292"}]}, "DB06290": {"dbids": ["DB06290"], "name": "Simeprevir", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q91RS4", "drug": "DB06290"}]}, "DB07479": {"dbids": ["DB07479"], "name": "(1S)-1,2,3,4-TETRAHYDRO-BENZO[C]PHENANTHRENE-2,3,4-TRIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04834": {"dbids": ["DB04834"], "name": "Rapacuronium", "groups": ["WITHDRAWN"], "targets": []}, "DB04835": {"dbids": ["DB04835"], "name": "Maraviroc", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P51681", "drug": "DB04835"}]}, "DB04836": {"dbids": ["DB04836"], "name": "Amineptine", "groups": ["ILLICIT", "WITHDRAWN"], "targets": []}, "DB04837": {"dbids": ["DB04837"], "name": "Clofedanol", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB04837"}]}, "DB04830": {"dbids": ["DB04830"], "name": "Buformin", "groups": ["WITHDRAWN"], "targets": []}, "DB04831": {"dbids": ["DB04831"], "name": "Ticrynafen", "groups": ["WITHDRAWN"], "targets": []}, "DB04832": {"dbids": ["DB04832"], "name": "Zimelidine", "groups": ["WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P27338", "drug": "DB04832"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB04832"}]}, "DB04833": {"dbids": ["DB04833"], "name": "Methaqualone", "groups": ["ILLICIT", "WITHDRAWN"], "targets": []}, "DB04838": {"dbids": ["DB04838"], "name": "Cyclandelate", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P54289", "drug": "DB04838"}]}, "DB02225": {"dbids": ["DB02225", "EXPT02514"], "name": "1,2-Di-N-Pentanoyl-Sn-Glycero-3-Dithiophosphocholine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08324": {"dbids": ["DB08324"], "name": "N-3-OXO-DODECANOYL-L-HOMOSERINE LACTONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08325": {"dbids": ["DB08325"], "name": "2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9-ISOPROPYLPURINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08326": {"dbids": ["DB08326"], "name": "2-(6-HYDROXY-1,3-BENZOTHIAZOL-2-YL)-1,3-THIAZOL-4(5H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02224": {"dbids": ["DB02224", "EXPT01185"], "name": "(2s,3s)-Trans-Dihydroquercetin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08320": {"dbids": ["DB08320"], "name": "DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08321": {"dbids": ["DB08321"], "name": "(1S,2S,3R,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08322": {"dbids": ["DB08322"], "name": "2-DEOXY-3,4-BIS-O-[3-(4-HYDROXYPHENYL)PROPANOYL]-L-THREO-PENTARIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08323": {"dbids": ["DB08323"], "name": "3-OXO-N-[(3S)-2-OXOPYRROLIDIN-3-YL]DODECANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02223": {"dbids": ["DB02223", "EXPT02076"], "name": "Ly231514 Tetra Glu", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08328": {"dbids": ["DB08328"], "name": "PANTOTHENYL-AMINOETHANOL-11-PIVALIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08329": {"dbids": ["DB08329"], "name": "SULTHIAME", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02222": {"dbids": ["DB02222", "EXPT00361"], "name": "2,6-Diamino-(S)-9-[2-(Phosphonomethoxy)Propyl]Purine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05408": {"dbids": ["DB05408"], "name": "IDN-6556", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05409": {"dbids": ["DB05409"], "name": "NCX 701", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB02221": {"dbids": ["DB02221", "EXPT01903"], "name": "4-(Aminosulfonyl)-N-[(2,4,6-Trifluorophenyl)Methyl]-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05402": {"dbids": ["DB05402"], "name": "ME-609", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05403": {"dbids": ["DB05403"], "name": "CEP-1347", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05400": {"dbids": ["DB05400"], "name": "QS-21", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB02220": {"dbids": ["DB02220", "EXPT00492"], "name": "Al7089a", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05406": {"dbids": ["DB05406"], "name": "GTI-2501", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05407": {"dbids": ["DB05407"], "name": "TBC-3711", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05404": {"dbids": ["DB05404"], "name": "AZD 3355", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05405": {"dbids": ["DB05405"], "name": "XTL-001", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03118": {"dbids": ["DB03118", "EXPT00006"], "name": "1-(5-Chloroindol-3-Yl)-3-Hydroxy-3-(2h-Tetrazol-5-Yl)-Propenone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07403": {"dbids": ["DB07403"], "name": "4-[(3-CHLORO-4-{[(2R)-3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPANOYL]AMINO}PHENYL)SULFONYL]-N,N-DIMETHYLBENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03116": {"dbids": ["DB03116", "EXPT02914"], "name": "5-(1-Carboxy-1-Phosphonooxy-Ethoxyl)-Shikimate-3-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03117": {"dbids": ["DB03117", "EXPT00110"], "name": "2-Carboxypropyl-Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03114": {"dbids": ["DB03114", "EXPT00088"], "name": "PAS219", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03115": {"dbids": ["DB03115", "EXPT00634"], "name": "5-Bromo-N-(2,3-Dihydroxypropoxy)-3,4-Difluoro-2-[(2-Fluoro-4-Iodophenyl)Amino]Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03112": {"dbids": ["DB03112", "EXPT02904"], "name": "6-(2-Oxo-Hexahydro-Thieno[3,4-D]Imidazol-4-Yl)-Hexanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03113": {"dbids": ["DB03113", "EXPT01475"], "name": "3-Fluoro-2-(Phosphonooxy)Propanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03110": {"dbids": ["DB03110", "EXPT00108"], "name": "2-Chlorophenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03111": {"dbids": ["DB03111", "EXPT01631"], "name": "Glucosamine 1-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06744": {"dbids": ["DB06744"], "name": "ginkgolide-B", "groups": ["NUTRACEUTICAL"], "targets": []}, "DB09239": {"dbids": ["DB09239"], "name": "Niguldipine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09238": {"dbids": ["DB09238"], "name": "Manidipine", "groups": ["APPROVED"], "targets": []}, "DB07404": {"dbids": ["DB07404"], "name": "(1-HYDROXY-1-PHOSPHONO-2-[1,1';3',1'']TERPHENYL-3-YL-ETHYL)-PHOSPHONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06745": {"dbids": ["DB06745"], "name": "ginkgolide-C", "groups": ["NUTRACEUTICAL"], "targets": []}, "DB07405": {"dbids": ["DB07405"], "name": "1-(6-CYANO-3-PYRIDYLCARBONYL)-5',8'-DIFLUOROSPIRO[PIPERIDINE-4,2'(1'H)-QUINAZOLINE]-4'-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07726": {"dbids": ["DB07726"], "name": "2-tert-butylbenzene-1,4-diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06746": {"dbids": ["DB06746"], "name": "ginkgolide-J", "groups": ["NUTRACEUTICAL"], "targets": []}, "DB07721": {"dbids": ["DB07721"], "name": "DIETHYL 4-METHOXYPHENYL PHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06747": {"dbids": ["DB06747"], "name": "ginkgolide-M", "groups": ["NUTRACEUTICAL"], "targets": []}, "DB07407": {"dbids": ["DB07407"], "name": "5-(2-METHOXYPHENYL)-2-FUROIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07720": {"dbids": ["DB07720"], "name": "EPIBATIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02579": {"dbids": ["DB02579", "EXPT00484"], "name": "Acrylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03432": {"dbids": ["DB03432", "EXPT00706"], "name": "Beta-Amino Isobutyrate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02573": {"dbids": ["DB02573", "EXPT00997"], "name": "2'-Deoxycytidine-2'-Deoxyadenosine-3',5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02572": {"dbids": ["DB02572", "EXPT00782"], "name": "BV4", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02571": {"dbids": ["DB02571", "EXPT01240"], "name": "2-Amino-6-Oxo-Hexanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02570": {"dbids": ["DB02570", "EXPT01931"], "name": "PD150606", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02577": {"dbids": ["DB02577", "EXPT02172"], "name": "Mesoheme", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02576": {"dbids": ["DB02576", "EXPT01471"], "name": "F-Loop of Vitamin B12", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09215": {"dbids": ["DB09215"], "name": "Droxicam", "groups": ["APPROVED"], "targets": []}, "DB02574": {"dbids": ["DB02574", "EXPT00780"], "name": "BV2", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06741": {"dbids": ["DB06741"], "name": "Gavestinel", "groups": ["INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "Q05586", "drug": "DB06741"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB06741"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB06741"}, {"action": "ANTAGONIST", "target": "Q14957", "drug": "DB06741"}, {"action": "ANTAGONIST", "target": "O15399", "drug": "DB06741"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB06741"}, {"action": "ANTAGONIST", "target": "O60391", "drug": "DB06741"}]}, "DB07512": {"dbids": ["DB07512"], "name": "7-[(3-CHLOROBENZYL)OXY]-2-OXO-2H-CHROMENE-4-CARBALDEHYDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB11280": {"dbids": ["DB11280"], "name": "Anhydrous dextrose", "groups": ["APPROVED"], "targets": []}, "DB07912": {"dbids": ["DB07912"], "name": "2-OXOHEPTYLPHOSPHONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07913": {"dbids": ["DB07913"], "name": "HOMOPHENYLALANINYLMETHANE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07910": {"dbids": ["DB07910"], "name": "PHENYLALANINDIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07911": {"dbids": ["DB07911"], "name": "(3E)-2,6-DIOXO-6-PHENYLHEX-3-ENOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07916": {"dbids": ["DB07916"], "name": "3-{6-[(8-HYDROXY-QUINOLINE-2-CARBONYL)-AMINO]-2-THIOPHEN-2-YL-HEXANOYLAMINO}-4-OXO-BUTYRI ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07917": {"dbids": ["DB07917"], "name": "4-(BENZHYDRYLOXY)-1-[3-(1H-TETRAAZOL-5-YL)PROPYL]PIPERIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07914": {"dbids": ["DB07914"], "name": "(2Z,4E)-2-HYDROXY-6-OXO-6-PHENYLHEXA-2,4-DIENOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07915": {"dbids": ["DB07915"], "name": "(2E,4E)-2-HYDROXY-6-OXO-6-PHENYLHEXA-2,4-DIENOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07918": {"dbids": ["DB07918"], "name": "2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07919": {"dbids": ["DB07919"], "name": "7-METHOXY-1-METHYL-9H-BETA-CARBOLINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06743": {"dbids": ["DB06743"], "name": "ginkgolide-A", "groups": ["NUTRACEUTICAL"], "targets": []}, "DB07563": {"dbids": ["DB07563"], "name": "1-{7-cyclohexyl-6-[4-(4-methylpiperazin-1-yl)benzyl]-7H-pyrrolo[2,3-d]pyrimidin-2-yl}methanamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07562": {"dbids": ["DB07562"], "name": "N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07561": {"dbids": ["DB07561"], "name": "(2Z)-2-cyano-N-(3'-ethoxybiphenyl-4-yl)-3-hydroxybut-2-enamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07560": {"dbids": ["DB07560"], "name": "N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01879": {"dbids": ["DB01879", "EXPT03011"], "name": "(S)-2-{Methyl-[2-(Naphthalene-2-Sulfonylamino)-5-(Naphthalene-2-Sulfonyloxy)-Benzoyl]-Amino}-Succinicacid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01878": {"dbids": ["DB01878", "EXPT00794"], "name": "Benzophenone", "groups": ["APPROVED"], "targets": []}, "DB01877": {"dbids": ["DB01877", "EXPT02941"], "name": "N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01876": {"dbids": ["DB01876", "EXPT00626"], "name": "Bis(5-Amidino-2-Benzimidazolyl)Methanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01875": {"dbids": ["DB01875", "EXPT00599"], "name": "8-Azaxanthine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01874": {"dbids": ["DB01874", "EXPT03077"], "name": "Tropinone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01873": {"dbids": ["DB01873", "EXPT01350"], "name": "Epothilone D", "groups": ["EXPERIMENTAL", "INVESTIGATIONAL"], "targets": []}, "DB01872": {"dbids": ["DB01872", "EXPT02337"], "name": "Acetylgalactosamine-4-Sulfate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01871": {"dbids": ["DB01871", "EXPT02989"], "name": "[1-(1-Benzyl-3-Hydroxy-2-Oxo-Propylcarbamoyl)-2-Phenyl-Ethyl]-Carbamic Acid Benzyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01870": {"dbids": ["DB01870", "EXPT02092"], "name": "1,4-Dithio-Alpha-D-Mannose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00464": {"dbids": ["APRD00575", "DB00464"], "name": "Sodium Tetradecyl Sulfate", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P04070", "drug": "DB00464"}, {"action": "INHIBITOR", "target": "P07225", "drug": "DB00464"}]}, "DB07567": {"dbids": ["DB07567"], "name": "(2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04629": {"dbids": ["DB04629"], "name": "Aplyronine A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04628": {"dbids": ["DB04628"], "name": "Allosamidin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04339": {"dbids": ["DB02476", "DB04339", "EXPT00835"], "name": "Carbocisteine", "groups": ["APPROVED"], "targets": []}, "DB04338": {"dbids": ["DB04338", "EXPT02849"], "name": "SB220025", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04333": {"dbids": ["DB04333", "EXPT01201"], "name": "Octamethylenediamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04620": {"dbids": ["DB04620"], "name": "Cycloleucine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04331": {"dbids": ["DB04331", "EXPT02296"], "name": "Monastrol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04330": {"dbids": ["DB04330", "EXPT00194"], "name": "Bilh 434", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04337": {"dbids": ["DB04337", "EXPT02202"], "name": "Methyl Isocyanide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04336": {"dbids": ["DB04336", "EXPT01635"], "name": "1-(4-Amidinophenyl)-3-(4-Chlorophenyl)Urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04627": {"dbids": ["DB04627"], "name": "Cyclouridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04626": {"dbids": ["DB04626"], "name": "Apramycin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08139": {"dbids": ["DB08139"], "name": "5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08138": {"dbids": ["DB08138"], "name": "{[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08131": {"dbids": ["DB08131"], "name": "2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-3-METHYL-BUTYRIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07565": {"dbids": ["DB07565"], "name": "CHLORAMPHENICOL SUCCINATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08133": {"dbids": ["DB08133"], "name": "N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08132": {"dbids": ["DB08132"], "name": "5-hydroxynaphthalene-1-sulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08135": {"dbids": ["DB08135"], "name": "N-phenyl-1H-pyrazole-3-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08134": {"dbids": ["DB08134"], "name": "4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08137": {"dbids": ["DB08137"], "name": "(4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08136": {"dbids": ["DB08136"], "name": "4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02876": {"dbids": ["DB02876", "EXPT01303"], "name": "3-(4-Carbamoyl-1-Carboxy-2-Methylsulfonyl-Buta-1,3-Dienylamino)-Indolizine-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02877": {"dbids": ["DB02877", "EXPT03128"], "name": "TTNPB", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02875": {"dbids": ["DB02875", "EXPT00318"], "name": "CRA_1802", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07564": {"dbids": ["DB07564"], "name": "6-amino-2-[(2-morpholin-4-ylethyl)amino]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02872": {"dbids": ["DB02872", "EXPT01878"], "name": "Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02873": {"dbids": ["DB02873", "EXPT01266"], "name": "1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06623": {"dbids": ["DB06623"], "name": "Flupirtine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB02870": {"dbids": ["DB02870", "EXPT02400"], "name": "N-Allyl-Aniline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02871": {"dbids": ["DB02871", "EXPT02956"], "name": "3-Butylthiolane 1-Oxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08394": {"dbids": ["DB08394"], "name": "PARA-NITROPHENYLPHOSPHONOBUTANOYL-GLYCINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00838": {"dbids": ["APRD00877", "DB00838"], "name": "Clocortolone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00838"}]}, "DB00839": {"dbids": ["APRD01267", "DB00839"], "name": "Tolazamide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P48048", "drug": "DB00839"}]}, "DB00830": {"dbids": ["APRD00262", "DB00830"], "name": "Phenmetrazine", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "INHIBITOR", "target": "P23975", "drug": "DB00830"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00830"}]}, "DB00831": {"dbids": ["APRD00173", "DB00831", "DB08616"], "name": "Trifluoperazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB00831"}, {"action": "ANTAGONIST", "target": "Q9NYX4", "drug": "DB00831"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00831"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB00831"}, {"action": "INHIBITOR", "target": "P26447", "drug": "DB00831"}]}, "DB00832": {"dbids": ["APRD00496", "DB00832"], "name": "Phensuximide", "groups": ["APPROVED"], "targets": []}, "DB00833": {"dbids": ["APRD00243", "DB00833"], "name": "Cefaclor", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00833"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB00833"}]}, "DB00834": {"dbids": ["APRD00432", "DB00834"], "name": "Mifepristone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P06401", "drug": "DB00834"}, {"action": "ANTAGONIST", "target": "P04150", "drug": "DB00834"}]}, "DB00835": {"dbids": ["APRD00832", "DB00835"], "name": "Brompheniramine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00835"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00835"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00835"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00835"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00835"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00835"}]}, "DB00836": {"dbids": ["APRD00275", "DB00836"], "name": "Loperamide", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB00836"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00836"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00836"}, {"action": "INHIBITOR", "target": "O00555", "drug": "DB00836"}, {"action": "MODULATOR", "target": "P01189", "drug": "DB00836"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB00836"}]}, "DB00837": {"dbids": ["APRD00072", "DB00837"], "name": "Progabide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "Q9UBS5", "drug": "DB00837"}, {"action": "AGONIST", "target": "P14867", "drug": "DB00837"}]}, "DB06663": {"dbids": ["DB06663"], "name": "Pasireotide", "groups": ["APPROVED"], "targets": []}, "DB02964": {"dbids": ["DB02964", "EXPT01597"], "name": "8,9,10-Trihydroxy-7-Hydroxymethyl-2-Thioxo-6-Oxa-1,3-Diaza-Spiro[4.5]Decan-4-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02965": {"dbids": ["DB02965", "EXPT02674"], "name": "Ndelta-(N'-Sulphodiaminophosphinyl)-L-Ornithine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02966": {"dbids": ["DB02966", "EXPT01513"], "name": "Fluoro-Willardiine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02967": {"dbids": ["DB02967", "EXPT02327"], "name": "N-Ethylmaleimide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02960": {"dbids": ["DB02960", "EXPT02200"], "name": "1-Carboxyethylaminomethyl-4-Aminomethylbenzene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02961": {"dbids": ["DB01869", "DB02961", "EXPT02795"], "name": "L-Rhamnose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02962": {"dbids": ["DB02962", "EXPT00791"], "name": "Benzimidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02963": {"dbids": ["DB02963", "EXPT01045"], "name": "(5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02749": {"dbids": ["DB02749", "EXPT02613"], "name": "Pyromellitic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02968": {"dbids": ["DB02968", "EXPT02561"], "name": "Penicillin G Acyl-Serine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02969": {"dbids": ["DB02969", "EXPT03151"], "name": "4-Methyl-5-Hydroxyethylthiazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04160": {"dbids": ["DB04160", "EXPT01258"], "name": "Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03567": {"dbids": ["DB03567", "EXPT00365"], "name": "N-Acetyl-2-Deoxy-2-Amino-Galactose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03566": {"dbids": ["DB03566", "EXPT02942"], "name": "Spermidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03565": {"dbids": ["DB03565", "EXPT01580"], "name": "1-O-Octyl-2-Heptylphosphonyl-Sn-Glycero-3-Phosphoethanolamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03564": {"dbids": ["DB03564", "EXPT02231"], "name": "(4r)-2-Methylpentane-2,4-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03562": {"dbids": ["DB03562", "EXPT03059"], "name": "Tetrahydrodeoxyuridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03560": {"dbids": ["DB03560", "EXPT01694"], "name": "P-Hydroxybenzaldehyde", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03569": {"dbids": ["DB03569", "EXPT01844"], "name": "4,5-Dehydro-L-Iduronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03568": {"dbids": ["DB03568", "EXPT00774"], "name": "Butanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05219": {"dbids": ["DB05219"], "name": "AN2728", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05218": {"dbids": ["DB05218"], "name": "PN0621", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05217": {"dbids": ["DB05217"], "name": "GMX1777", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05216": {"dbids": ["DB05216"], "name": "MP470", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05215": {"dbids": ["DB05215"], "name": "RHIIP", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05214": {"dbids": ["DB05214"], "name": "KD7040", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05213": {"dbids": ["DB05213"], "name": "AC220", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05212": {"dbids": ["DB05212"], "name": "HE3286", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05211": {"dbids": ["DB05211"], "name": "PS386113", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05210": {"dbids": ["DB05210"], "name": "SF1126", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08489": {"dbids": ["DB08489"], "name": "N4-HYDROXY-2-ISOBUTYL-N1-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.013,18]NONADECA-12(19),13,15,17-TETRAEN-10-YL)-SUCCINAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08488": {"dbids": ["DB08488"], "name": "4-{[(E)-2-(5-CHLOROTHIEN-2-YL)VINYL]SULFONYL}-1-(1H-PYRROLO[3,2-C]PYRIDIN-2-YLMETHYL)PIPERAZIN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08959": {"dbids": ["DB08959"], "name": "Hexestrol", "groups": ["WITHDRAWN"], "targets": []}, "DB08958": {"dbids": ["DB08958"], "name": "Hexetidine", "groups": ["APPROVED"], "targets": []}, "DB08481": {"dbids": ["DB08481"], "name": "4-METHYL-N-{(5E)-5-[(5-METHYL-2-FURYL)METHYLENE]-4-OXO-4,5-DIHYDRO-1,3-THIAZOL-2-YL}BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08480": {"dbids": ["DB08480"], "name": "4-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08951": {"dbids": ["DB08951"], "name": "Indoprofen", "groups": ["WITHDRAWN"], "targets": []}, "DB08482": {"dbids": ["DB08482"], "name": "[[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08485": {"dbids": ["DB08485"], "name": "(1S,4S,5S)-1,4,5-TRIHYDROXY-3-[3-(PHENYLTHIO)PHENYL]CYCLOHEX-2-ENE-1-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08484": {"dbids": ["DB08484"], "name": "4-AMINO-N-[(2-SULFANYLETHYL)CARBAMOYL]BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08487": {"dbids": ["DB08487"], "name": "3-({4-[(6-CHLORO-1-BENZOTHIEN-2-YL)SULFONYL]-2-OXOPIPERAZIN-1-YL}METHYL)BENZENECARBOXIMIDAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08486": {"dbids": ["DB08486"], "name": "2-{4-[(3,5-DIMETHYLANILINO)-CARBONYL-METHYL]-PHENOXY}-2-METHYLPROPIONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08544": {"dbids": ["DB08544"], "name": "(3S)-N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08545": {"dbids": ["DB08545"], "name": "(1R)-1-PHENYLETHYL 4-(ACETYLAMINO)BENZYLPHOSPHONATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08546": {"dbids": ["DB08546"], "name": "4-[(3AS,4R,7R,8AS,8BR)-2-(1,3-BENZODIOXOL-5-YLMETHYL)-7-HYDROXY-1,3-DIOXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZENECARBOXIMIDAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08547": {"dbids": ["DB08547"], "name": "PROGESTERONE-11-ALPHA-OL-HEMISUCCINATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08540": {"dbids": ["DB08540"], "name": "2-[4-(2H-1,4-BENZOTHIAZINE-3-YL)-PIPERAZINE-1-LY]-1,3-THIAZOLE-4-CARBOXYLIC ACID ETHYLESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05021": {"dbids": ["DB05021"], "name": "EMZ702", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08542": {"dbids": ["DB08542"], "name": "3,4-dihydroxy-9,10-secoandrosta-1(10),2,4-triene-9,17-dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08543": {"dbids": ["DB08543"], "name": "1-[2-HYDROXY-3-(4-CYCLOHEXYL-PHENOXY)-PROPYL]-4-(2-PYRIDYL)-PIPERAZINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08548": {"dbids": ["DB08548"], "name": "[(4S)-2,2-DIMETHYL-1,3-DIOXOLAN-4-YL]METHYL HYDROGEN HEX-5-ENYLPHOSPHONATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08549": {"dbids": ["DB08549"], "name": "(3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04100": {"dbids": ["DB04100", "EXPT02771"], "name": "(1,10 Phenanthroline)-(Tri-Carbon Monoxide) Rhenium (I)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04101": {"dbids": ["DB04101", "EXPT00926"], "name": "N-[4-(2,4-Dimethyl-1,3-Thiazol-5-Yl)Pyrimidin-2-Yl]-N'-Hydroxyimidoformamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04102": {"dbids": ["DB04102", "EXPT00101"], "name": "2-Amino-Adenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04103": {"dbids": ["DB04103", "EXPT00178"], "name": "3-Methylcytosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04104": {"dbids": ["DB04104", "EXPT00431"], "name": "3-Methyladenine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04105": {"dbids": ["DB04105", "EXPT01771"], "name": "N-Heptylformamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04106": {"dbids": ["DB04106", "EXPT03300"], "name": "Fotemustine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04107": {"dbids": ["DB04107", "EXPT02999"], "name": "[(1-{2[(4-Carbamimidoyl-Phenylamino)-Methyl]-1-Methyl-1h-Benzoimidazol-5-Yl}-Cyclopropyl)-Pyridin-2-Yl-Methyleneaminooxy]-Acetic Acid Ethyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04108": {"dbids": ["DB04108", "EXPT00526"], "name": "(2s,3r)-3-Amino-2-Hydroxy-5-(Ethylsulfanyl)Pentanoyl-((S)-(-)-(1-Naphthyl)Ethyl)Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04109": {"dbids": ["DB04109", "EXPT02862"], "name": "[4-(1,3,2-Dioxaborolan-2-Yloxy)Methyl]Benzamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00481": {"dbids": ["APRD00400", "DB00481"], "name": "Raloxifene", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P03372", "drug": "DB00481"}, {"action": "AGONIST", "target": "Q92731", "drug": "DB00481"}]}, "DB00480": {"dbids": ["APRD01303", "DB00480"], "name": "Lenalidomide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q96SW2", "drug": "DB00480"}, {"action": "INHIBITOR", "target": "O14788", "drug": "DB00480"}, {"action": "ANTAGONIST", "target": "P33151", "drug": "DB00480"}, {"action": "NEGATIVE MODULATOR", "target": "P35354", "drug": "DB00480"}]}, "DB00483": {"dbids": ["APRD00712", "DB00483"], "name": "Gallamine Triethiodide", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08172", "drug": "DB00483"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB00483"}, {"action": "ANTAGONIST", "target": "Q15822", "drug": "DB00483"}]}, "DB00482": {"dbids": ["APRD00373", "DB00482"], "name": "Celecoxib", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00482"}, {"action": "INHIBITOR", "target": "O15530", "drug": "DB00482"}]}, "DB00485": {"dbids": ["APRD00916", "DB00485"], "name": "Dicloxacillin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "B8DCL9", "drug": "DB00485"}, {"action": "INHIBITOR", "target": "B8DD61", "drug": "DB00485"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB00485"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB00485"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00485"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB00485"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB00485"}]}, "DB00484": {"dbids": ["APRD00034", "DB00484"], "name": "Brimonidine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P08913", "drug": "DB00484"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00484"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00484"}]}, "DB00339": {"dbids": ["APRD01206", "DB00339"], "name": "Pyrazinamide", "groups": ["APPROVED"], "targets": []}, "DB00338": {"dbids": ["APRD00446", "DB00338"], "name": "Omeprazole", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P20648", "drug": "DB00338"}]}, "DB00337": {"dbids": ["APRD01182", "DB00337"], "name": "Pimecrolimus", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "POTENTIATOR", "target": "P42345", "drug": "DB00337"}, {"action": "POTENTIATOR", "target": "P62942", "drug": "DB00337"}]}, "DB00336": {"dbids": ["APRD00050", "DB00336"], "name": "Nitrofural", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P07003", "drug": "DB00336"}, {"action": "INHIBITOR", "target": "P06715", "drug": "DB00336"}, {"action": "INHIBITOR", "target": "P61889", "drug": "DB00336"}, {"action": "INHIBITOR", "target": "P77390", "drug": "DB00336"}]}, "DB00335": {"dbids": ["APRD00172", "DB00335"], "name": "Atenolol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB00335"}]}, "DB00334": {"dbids": ["APRD00138", "DB00334"], "name": "Olanzapine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P28223", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00334"}, {"action": "AGONIST", "target": "P14416", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P21918", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P28221", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P28566", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P47898", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P21918", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P25021", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "Q9H3N8", "drug": "DB00334"}]}, "DB00333": {"dbids": ["APRD00485", "DB00333"], "name": "Methadone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB00333"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00333"}, {"action": "ANTAGONIST", "target": "Q9GZZ6", "drug": "DB00333"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00333"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00333"}]}, "DB00332": {"dbids": ["APRD00537", "DB00332"], "name": "Ipratropium bromide", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00332"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00332"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00332"}]}, "DB00331": {"dbids": ["APRD01099", "DB00331"], "name": "Metformin", "groups": ["APPROVED"], "targets": [{"action": "INDUCER", "target": "Q9Y478", "drug": "DB00331"}]}, "DB00330": {"dbids": ["APRD00957", "DB00330"], "name": "Ethambutol", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P72059", "drug": "DB00330"}, {"action": "INHIBITOR", "target": "P72030", "drug": "DB00330"}, {"action": "INHIBITOR", "target": "P0A560", "drug": "DB00330"}]}, "DB03828": {"dbids": ["DB03828", "EXPT00099"], "name": "RU78299", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03829": {"dbids": ["DB03829", "EXPT02677"], "name": "Pseudouridine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03822": {"dbids": ["DB03822", "EXPT01327"], "name": "Ethyl Dihydrogen Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03823": {"dbids": ["DB03823", "EXPT01331"], "name": "Epigallocatechin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03820": {"dbids": ["DB03820", "EXPT01725"], "name": "(2s,5r,6r)-6-{[(6r)-6-(Glycylamino)-7-Oxido-7-Oxoheptanoyl]Amino}-3,3-Dimethyl-7-Oxo-4-Thia-1-Azabicyclo[3.2.0]Heptane-2-Carboxylate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03821": {"dbids": ["DB03821", "EXPT01431"], "name": "2-Amino-3-Hydroxy-3-Phosphonooxy-Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03826": {"dbids": ["DB03826", "EXPT03206"], "name": "5,6-Diaminouracil", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03827": {"dbids": ["DB03827", "EXPT00186"], "name": "(3s)-3,4-Di-N-Hexanoyloxybutyl-1-Phosphocholine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03824": {"dbids": ["DB03824", "EXPT01840"], "name": "7-Iodo-1,2,3,4-Tetrahydro-Isoquinoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03825": {"dbids": ["DB03825", "EXPT02782"], "name": "Rhodamine 6g", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01688": {"dbids": ["DB01688", "EXPT02525"], "name": "P-Cresol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01689": {"dbids": ["DB01689", "EXPT01819"], "name": "Inhibitor Idd 384", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01684": {"dbids": ["DB01684", "EXPT02896"], "name": "1-Hydroxy-1-Thio-Glycerol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01685": {"dbids": ["DB01685", "EXPT01517"], "name": "4-[5-Pyridin-4-Yl-1h-[1,2,4]Triazol-3-Yl]-Pyridine-2-Carbonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01686": {"dbids": ["DB01686", "EXPT01101"], "name": "N,N-dimethylarginine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01687": {"dbids": ["DB01687", "EXPT02103"], "name": "Mannobiose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01681": {"dbids": ["DB01681", "EXPT00695"], "name": "Benzene Hexacarboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01682": {"dbids": ["DB01682", "EXPT02089"], "name": "6'-Methyl-Thiamin Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01683": {"dbids": ["DB01683", "EXPT00915"], "name": "Chymostatin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00159": {"dbids": ["DB00159", "NUTR00024"], "name": "Icosapent", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00159"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00159"}, {"action": "AGONIST", "target": "P37231", "drug": "DB00159"}, {"action": "AGONIST", "target": "Q03181", "drug": "DB00159"}, {"action": "AGONIST", "target": "O60427", "drug": "DB00159"}, {"action": "INDUCER", "target": "O60488", "drug": "DB00159"}, {"action": "INDUCER", "target": "O95573", "drug": "DB00159"}, {"action": "AGONIST", "target": "O14842", "drug": "DB00159"}, {"action": "INHIBITOR", "target": "P32418", "drug": "DB00159"}, {"action": "INDUCER", "target": "Q8NER1", "drug": "DB00159"}]}, "DB00158": {"dbids": ["DB00158", "NUTR00025"], "name": "Folic Acid", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "BINDER", "target": "P14207", "drug": "DB00158"}, {"action": "BINDER", "target": "P41439", "drug": "DB00158"}]}, "DB00153": {"dbids": ["APRD00426", "DB00153", "NUTR00005"], "name": "Ergocalciferol", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "AGONIST", "target": "P11473", "drug": "DB00153"}]}, "DB00152": {"dbids": ["APRD00552", "DB00152", "EXPT03222", "NUTR00009"], "name": "Thiamine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "LIGAND", "target": "Q9H3S4", "drug": "DB00152"}, {"action": "BINDER", "target": "O60779", "drug": "DB00152"}]}, "DB00151": {"dbids": ["DB00151", "DB04443", "NUTR00018"], "name": "L-Cysteine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00150": {"dbids": ["DB00150", "EXPT02064", "NUTR00058"], "name": "L-Tryptophan", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "INHIBITOR", "target": "Q9UGM6", "drug": "DB00150"}, {"action": "INHIBITOR", "target": "P00953", "drug": "DB00150"}, {"action": "INHIBITOR", "target": "P23381", "drug": "DB00150"}]}, "DB00157": {"dbids": ["DB00157", "DB01907", "DB03527", "EXPT02287", "NUTR00041"], "name": "NADH", "groups": ["NUTRACEUTICAL"], "targets": [{"action": "BINDER", "target": "P03891", "drug": "DB00157"}, {"action": "BINDER", "target": "P03897", "drug": "DB00157"}, {"action": "BINDER", "target": "P03886", "drug": "DB00157"}]}, "DB00156": {"dbids": ["DB00156", "NUTR00057"], "name": "L-Threonine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00155": {"dbids": ["DB00155", "NUTR00021"], "name": "L-Citrulline", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00154": {"dbids": ["DB00154", "NUTR00032"], "name": "Dihomo-gamma-linolenic acid", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "INHIBITOR", "target": "P23219", "drug": "DB00154"}]}, "DB03358": {"dbids": ["DB03358", "EXPT02169"], "name": "7n-Methyl-8-Hydroguanosine-5'-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03359": {"dbids": ["DB03359", "EXPT02285"], "name": "M-(N,N,N-Trimethylammonio)-2,2,2-Trifluoro-1,1-Dihydroxyethylbenzene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03354": {"dbids": ["DB03354", "EXPT02455"], "name": "2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Oxadiazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03355": {"dbids": ["DB03355", "EXPT03121"], "name": "5'-O-(N-(L-Threonyl)-Sulfamoyl)Adenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03357": {"dbids": ["DB03357", "EXPT02923"], "name": "(S)-Mandelic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03350": {"dbids": ["DB03350", "EXPT02313"], "name": "Cobalt Hexammine Ion", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03351": {"dbids": ["DB03351", "EXPT02031"], "name": "Sri-9439", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03352": {"dbids": ["DB03352", "EXPT01037"], "name": "S-Arsonocysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03353": {"dbids": ["DB03353", "EXPT01870"], "name": "2-Iminobiotin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04818": {"dbids": ["DB04818"], "name": "Iproniazid", "groups": ["WITHDRAWN"], "targets": []}, "DB04819": {"dbids": ["DB04819"], "name": "Methapyrilene", "groups": ["WITHDRAWN"], "targets": []}, "DB04816": {"dbids": ["DB04816"], "name": "Dantron", "groups": ["INVESTIGATIONAL", "WITHDRAWN"], "targets": []}, "DB04817": {"dbids": ["DB04817"], "name": "Metamizole", "groups": ["WITHDRAWN"], "targets": []}, "DB04814": {"dbids": ["DB04814"], "name": "Bunamiodyl", "groups": ["WITHDRAWN"], "targets": []}, "DB04815": {"dbids": ["DB04815"], "name": "Clioquinol", "groups": ["WITHDRAWN"], "targets": []}, "DB04812": {"dbids": ["DB04812"], "name": "Benoxaprofen", "groups": ["WITHDRAWN"], "targets": []}, "DB04813": {"dbids": ["DB04813"], "name": "Bithionol", "groups": ["WITHDRAWN"], "targets": []}, "DB04810": {"dbids": ["DB04810"], "name": "Salophen-10-carboxylate iron chelate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04811": {"dbids": ["DB04811"], "name": "Salophen iron chelate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08308": {"dbids": ["DB08308"], "name": "SUCCINIC ACID MONO-(13-METHYL-3-OXO-2,3,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-17-YL) ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08309": {"dbids": ["DB08309"], "name": "3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08306": {"dbids": ["DB08306"], "name": "3-{[(3-NITROANILINE]SULFONYL}THIOPHENE-2-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08307": {"dbids": ["DB08307"], "name": "2-{HYDROXY[2-NITRO-4-(TRIFLUOROMETHYL)PHENYL]METHYLENE}CYCLOHEXANE-1,3-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08304": {"dbids": ["DB08304"], "name": "(3R)-3-cyclopentyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2-benzothiazine 1,1-dioxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08305": {"dbids": ["DB08305"], "name": "(3R)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2-benzothiazine 1,1-dioxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08302": {"dbids": ["DB08302"], "name": "3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08303": {"dbids": ["DB08303"], "name": "(3S)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08300": {"dbids": ["DB08300"], "name": "1-methyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08301": {"dbids": ["DB08301"], "name": "N-({[4-(AMINOSULFONYL)PHENYL]AMINO}CARBONYL)-4-METHYLBENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03686": {"dbids": ["DB03686", "EXPT01653"], "name": "S-(P-Nitrobenzyl)Glutathione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03687": {"dbids": ["DB03687", "EXPT00873"], "name": "4-Diphosphocytidyl-2-C-Methyl-D-Erythritol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03685": {"dbids": ["DB03685", "EXPT03155"], "name": "Uridine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03682": {"dbids": ["DB03682", "EXPT01120"], "name": "Dibenzofuran-4,6-Dicarboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03683": {"dbids": ["DB03683", "EXPT02969"], "name": "2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03680": {"dbids": ["DB03680", "EXPT03129"], "name": "Tartronate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03681": {"dbids": ["DB03681", "EXPT00895"], "name": "Chloro Diiron-Oxo Moiety", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03688": {"dbids": ["DB03688", "EXPT00183"], "name": "3-Hydroxy-Propanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03178": {"dbids": ["DB03178", "EXPT02899"], "name": "Guanosine-2',3'-Cyclophosphorothioate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03179": {"dbids": ["DB03179", "EXPT02943"], "name": "Sinapoyl Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03170": {"dbids": ["DB03170", "EXPT00980"], "name": "Dephospho Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03171": {"dbids": ["DB03171", "EXPT01918"], "name": "Indole-3-Propanol Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03172": {"dbids": ["DB03172", "EXPT03017"], "name": "Tubercidin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03173": {"dbids": ["DB03173", "EXPT01012"], "name": "CRA_10433", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03174": {"dbids": ["DB03174", "EXPT02628"], "name": "Phosphonoacetaldehyde", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03175": {"dbids": ["DB03175", "EXPT02630"], "name": "1-Proponol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03176": {"dbids": ["DB03176", "EXPT01852"], "name": "3,5-Dichloro-4-[(4-Hydroxy-3-Isopropylphenoxy)Phenylacetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03177": {"dbids": ["DB03177", "EXPT00250"], "name": "5-methylbenzimidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02883": {"dbids": ["DB02883", "EXPT01242"], "name": "2',3'-Dideoxycytidine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02882": {"dbids": ["DB02882", "EXPT02227"], "name": "Cyanocinnoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02881": {"dbids": ["DB02881", "EXPT00056"], "name": "4-(4-Hydroxy-3-Isopropylphenylthio)-2-Isopropylphenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02880": {"dbids": ["DB02880", "EXPT00680"], "name": "N-[1-(4-Bromophenyl)Ethyl]-5-Fluoro Salicylamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02887": {"dbids": ["DB02887", "EXPT01098"], "name": "2',3'-Dehydro-2',3'-Deoxy-Thymidine 5'-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02885": {"dbids": ["DB02885", "EXPT01848"], "name": "4-Imino-5-Methidyl-2-Trifluoromethylpyrimidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02884": {"dbids": ["DB02884", "EXPT01686"], "name": "Beta-Cyclohexyl-Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02889": {"dbids": ["DB02889", "EXPT00191"], "name": "4-O-(4,6-Dideoxy-4-{[4,5,6-Trihydroxy-3-(Hydroxymethyl)Cyclohex-2-En-1-Yl]Amino}-Beta-D-Lyxo-Hexopyranosyl)-Alpha-D-Erythro-Hexopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02888": {"dbids": ["DB02888", "EXPT00001"], "name": "FKB-001", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04674": {"dbids": ["DB04674"], "name": "2-HYDROXY-3,5-DIIODOBENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09502": {"dbids": ["DB09502"], "name": "Fludeoxyglucose F-18", "groups": ["APPROVED"], "targets": []}, "DB07464": {"dbids": ["DB07464"], "name": "1(R)-1-ACETAMIDO-2-(3-CARBOXY-2-HYDROXYPHENYL)ETHYL BORONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09352": {"dbids": ["DB09352"], "name": "Hydroxyamphetamine hydrobromide", "groups": ["APPROVED"], "targets": []}, "DB02089": {"dbids": ["DB02089", "EXPT00994"], "name": "CP-526423", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02088": {"dbids": ["DB02088", "EXPT02357"], "name": "Norleucine Phosphonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09353": {"dbids": ["DB09353"], "name": "Sulfur", "groups": ["APPROVED"], "targets": []}, "DB02083": {"dbids": ["DB02083", "EXPT01225"], "name": "Dimethylglycine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02082": {"dbids": ["DB02082", "EXPT01658"], "name": "Phosphoaminophosphonic Acid Guanylate Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02081": {"dbids": ["DB02081", "EXPT00632"], "name": "Bis-Benzamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02080": {"dbids": ["DB02080", "EXPT03116"], "name": "1-{2-[2-(2-Methoxyethoxy)Ethoxy]Ethoxy}-4-(1,1,3,3-Tetramethylbutyl)Benzene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02087": {"dbids": ["DB02087", "EXPT01398"], "name": "3,5-Difluorobenzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02086": {"dbids": ["DB02086", "EXPT03130"], "name": "(3,4-Dihydroxy-Phenyl)-Triphenyl-Arsonium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02085": {"dbids": ["DB02085", "EXPT00065"], "name": "1-Aminocyclopropanecarboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02084": {"dbids": ["DB02084", "EXPT00149"], "name": "CRA_17312", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09351": {"dbids": ["DB09351"], "name": "Levobetaxolol", "groups": ["APPROVED"], "targets": []}, "DB09357": {"dbids": ["DB09357"], "name": "Dexpanthenol", "groups": ["APPROVED"], "targets": []}, "DB02555": {"dbids": ["DB02555", "EXPT01492"], "name": "SP4160", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02554": {"dbids": ["DB02554", "EXPT03209"], "name": "Sulfoquinovose-Uridine-C1,5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02557": {"dbids": ["DB02557", "EXPT02764"], "name": "Phosphoramidon", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P08473", "drug": "DB02557"}]}, "DB02556": {"dbids": ["DB02556", "EXPT01257"], "name": "D-Phenylalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02551": {"dbids": ["DB02551", "EXPT00201"], "name": "6-[N-(4-Ethyl-1,2,3,4-Tetrahydro-6-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02550": {"dbids": ["DB02550", "EXPT02692"], "name": "8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02553": {"dbids": ["DB02553", "EXPT03119"], "name": "Glutathionylspermidine Disulfide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02552": {"dbids": ["DB02552", "EXPT01640"], "name": "Geranyl Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02559": {"dbids": ["DB02559", "EXPT03103"], "name": "6-(Octahydro-1h-Indol-1-Ylmethyl)Decahydroquinazoline-2,4-Diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02558": {"dbids": ["DB02558", "EXPT02428"], "name": "N-(3-Phenyl-2-Sulfanylpropanoyl)Phenylalanylalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02229": {"dbids": ["DB02229", "EXPT02239"], "name": "5'-O-[(L-Methionyl)-Sulphamoyl]Adenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02228": {"dbids": ["DB02228", "EXPT00116"], "name": "2-Fluoro-2-Deoxy-Beta-D-Galactopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05685": {"dbids": ["DB05685"], "name": "FX06", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05687": {"dbids": ["DB05687"], "name": "BL-1020", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05688": {"dbids": ["DB05688"], "name": "CRx-119", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01459": {"dbids": ["DB01459"], "name": "Bezitramide", "groups": ["EXPERIMENTAL", "ILLICIT", "WITHDRAWN"], "targets": []}, "DB01458": {"dbids": ["DB01458"], "name": "2,5-Dimethoxy-4-(n)-propylthiophenethylamine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01327": {"dbids": ["DB01327"], "name": "Cefazolin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P02918", "drug": "DB01327"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB01327"}, {"action": "INHIBITOR", "target": "P76577", "drug": "DB01327"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB01327"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB01327"}, {"action": "INHIBITOR", "target": "P27169", "drug": "DB01327"}]}, "DB01326": {"dbids": ["DB01326"], "name": "Cefamandole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q70KI2", "drug": "DB01326"}]}, "DB01325": {"dbids": ["DB01325"], "name": "Quinethazone", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00915", "drug": "DB01325"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB01325"}, {"action": "INHIBITOR", "target": "Q13621", "drug": "DB01325"}, {"action": "INHIBITOR", "target": "P55011", "drug": "DB01325"}, {"action": "INHIBITOR", "target": "P55017", "drug": "DB01325"}]}, "DB01456": {"dbids": ["DB01456"], "name": "5-androstenedione", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB07030": {"dbids": ["DB07030"], "name": "(5-CHLORO-2-{[(3-NITROBENZYL)AMINO]CARBONYL}PHENOXY)ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01451": {"dbids": ["DB01451"], "name": "1-Androstenedione", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01450": {"dbids": ["DB01450"], "name": "Dihydroetorphine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01453": {"dbids": ["DB01453"], "name": "Beta-hydroxyfentanyl", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01452": {"dbids": ["DB01452"], "name": "Heroin", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB01452"}, {"action": "AGONIST", "target": "P41145", "drug": "DB01452"}, {"action": "AGONIST", "target": "P41143", "drug": "DB01452"}]}, "DB01147": {"dbids": ["APRD00882", "DB01147", "EXPT01068"], "name": "Cloxacillin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01147"}, {"action": "INDUCER", "target": "P00811", "drug": "DB01147"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB01147"}, {"action": "INHIBITOR", "target": "P0A3M5", "drug": "DB01147"}, {"action": "INHIBITOR", "target": "Q51504", "drug": "DB01147"}, {"action": "INHIBITOR", "target": "P0AEB3", "drug": "DB01147"}]}, "DB04314": {"dbids": ["DB04314", "EXPT00076"], "name": "1-Methylcytosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07036": {"dbids": ["DB07036"], "name": "(3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01145": {"dbids": ["APRD00704", "DB01145"], "name": "Sulfoxone", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q27738", "drug": "DB01145"}]}, "DB04316": {"dbids": ["DB04316", "EXPT01884"], "name": "D-[(N-Hydroxyamino)Carbonyl]Phenylalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04647": {"dbids": ["DB04647"], "name": "BOC-GAMMA-D-GLU-L-LYS(CBZ)-D-BOROALA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01142": {"dbids": ["APRD00398", "DB01142"], "name": "Doxepin", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P25021", "drug": "DB01142"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB01142"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01142"}, {"action": "BINDER", "target": "P50406", "drug": "DB01142"}, {"action": "BINDER", "target": "Q9H3N8", "drug": "DB01142"}]}, "DB05024": {"dbids": ["DB05024"], "name": "CTA018", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05025": {"dbids": ["DB05025"], "name": "Arimoclomol", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05026": {"dbids": ["DB05026"], "name": "APD125", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05027": {"dbids": ["DB05027"], "name": "DG041", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05020": {"dbids": ["DB05020"], "name": "ANA380", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04313": {"dbids": ["DB04313", "EXPT00104"], "name": "3-Methyl-Aspartic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05022": {"dbids": ["DB05022"], "name": "Amonafide", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05023": {"dbids": ["DB05023"], "name": "ATL1101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01140": {"dbids": ["APRD00196", "DB01140"], "name": "Cefadroxil", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB01140"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB01140"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB01140"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB01140"}]}, "DB05028": {"dbids": ["DB05028"], "name": "Microplasmin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05029": {"dbids": ["DB05029"], "name": "Duramycin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07508": {"dbids": ["DB07508"], "name": "4-(5-BENZENESULFONYLAMINO-1-METHYL-1H-BENZOIMIDAZOL-2-YLMETHYL)-BENZAMIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00496": {"dbids": ["APRD00903", "DB00496"], "name": "Darifenacin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P20309", "drug": "DB00496"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00496"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00496"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00496"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00496"}]}, "DB00497": {"dbids": ["APRD00387", "DB00497"], "name": "Oxycodone", "groups": ["APPROVED", "ILLICIT", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB00497"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00497"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00497"}, {"action": "BINDER", "target": "P02763", "drug": "DB00497"}, {"action": "BINDER", "target": "P19652", "drug": "DB00497"}]}, "DB00494": {"dbids": ["APRD00416", "DB00494"], "name": "Entacapone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P21964", "drug": "DB00494"}]}, "DB00495": {"dbids": ["APRD00449", "DB00495"], "name": "Zidovudine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q72547", "drug": "DB00495"}, {"action": "INHIBITOR", "target": "O14746", "drug": "DB00495"}]}, "DB00492": {"dbids": ["APRD00526", "DB00492"], "name": "Fosinopril", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P12821", "drug": "DB00492"}]}, "DB08551": {"dbids": ["DB08551"], "name": "(1R)-1-(2-THIENYLACETYLAMINO)-1-(3-CARBOXYPHENYL)METHYLBORONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04419": {"dbids": ["DB04419", "EXPT02355"], "name": "Norleucine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00493": {"dbids": ["APRD00854", "DB00493"], "name": "Cefotaxime", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB00493"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB00493"}, {"action": "INHIBITOR", "target": "P42971", "drug": "DB00493"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB00493"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB00493"}]}, "DB01859": {"dbids": ["DB01859", "EXPT02978"], "name": "4-Diphosphocytidyl-2-C-Methyl-D-Erythritol 2-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01858": {"dbids": ["DB01858", "EXPT01501"], "name": "[1-(4-Fluorobenzyl)Cyclobutyl]Methyl (1s)-1-[Oxo(1h-Pyrazol-5-Ylamino)Acetyl]Pentylcarbamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00490": {"dbids": ["APRD00222", "DB00490"], "name": "Buspirone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "PARTIAL AGONIST", "target": "P08908", "drug": "DB00490"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00490"}]}, "DB01851": {"dbids": ["DB01851", "EXPT03013"], "name": "Tetrabutylammonium Ion", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01850": {"dbids": ["DB01850", "EXPT02162"], "name": "(2s,3s,8s,9s)-3-Amino-9-Methoxy-2,6,8-Trimethyl-10-Phenyldeca-4,6-Dienoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01853": {"dbids": ["DB01853", "EXPT00640"], "name": "Bacteriochlorophyll A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01852": {"dbids": ["DB01852", "EXPT01976"], "name": "Kaempherol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01855": {"dbids": ["DB01855", "EXPT00682"], "name": "5-(Hydroxy-Methyl-Amino)-3-Methyl-Pyrrolidine-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01854": {"dbids": ["DB01854", "EXPT00757"], "name": "5-Bromonicotinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01857": {"dbids": ["DB01857", "DB03713", "DB04247", "EXPT00574"], "name": "Phosphoaspartate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01856": {"dbids": ["DB01856", "EXPT02618"], "name": "Pimelic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04315": {"dbids": ["DB04315", "EXPT01573"], "name": "Guanosine-5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04642": {"dbids": ["DB04642"], "name": "7-{2,6-DICHLORO-4-[3-(2-CHLORO-BENZOYL)-UREIDO]-PHENOXY}-HEPTANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04317": {"dbids": ["DB04317", "EXPT01136"], "name": "3,3-Dichloro-2-Phosphonomethyl-Acrylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04640": {"dbids": ["DB04640"], "name": "Naphthalene-2,6-disulfonic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04311": {"dbids": ["DB04311", "EXPT02510"], "name": "4-Phenylbutylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04310": {"dbids": ["DB04310", "EXPT00630"], "name": "2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01141": {"dbids": ["APRD01114", "DB01141"], "name": "Micafungin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "A2QLK4", "drug": "DB01141"}]}, "DB04312": {"dbids": ["DB04312", "EXPT01168"], "name": "2,3-Difluorobenzyl Alcohol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04649": {"dbids": ["DB04649"], "name": "TETRAHEDRAL INTERMEDIATE OF BLASTICIDIN S", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04648": {"dbids": ["DB04648"], "name": "S-propylamine-L-cysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04319": {"dbids": ["DB04319", "EXPT01615"], "name": "6-Deoxyglucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04318": {"dbids": ["DB04318", "EXPT02827"], "name": "1-Benzyloxycarbonylamino-2-Phenyl-Ethyl)-{2-[1-Carbamoyl-2-(1h-Indol-3-Yl)-Ethylcarbamoyl]-5-Phenyl-Pentyl}-Phosphinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01149": {"dbids": ["APRD00402", "DB01149"], "name": "Nefazodone", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P28223", "drug": "DB01149"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01149"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB01149"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01149"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB01149"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB01149"}, {"action": "OTHER/UNKNOWN", "target": "P35368", "drug": "DB01149"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01149"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01149"}]}, "DB01148": {"dbids": ["APRD00972", "DB01148"], "name": "Flavoxate", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08172", "drug": "DB01148"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01148"}]}, "DB08153": {"dbids": ["DB08153"], "name": "(5E)-14-CHLORO-15,17-DIHYDROXY-4,7,8,9,10,11-HEXAHYDRO-2-BENZOXACYCLOPENTADECINE-1,12(3H,13H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08152": {"dbids": ["DB08152"], "name": "{(2S)-1-[N-(tert-butoxycarbonyl)glycyl]pyrrolidin-2-yl}methyl (3-chlorophenyl)acetate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08151": {"dbids": ["DB08151"], "name": "(5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08150": {"dbids": ["DB08150"], "name": "4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08157": {"dbids": ["DB08157"], "name": "ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08156": {"dbids": ["DB08156"], "name": "3-[4-(AMINOSULFONYL)PHENYL]PROPANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08155": {"dbids": ["DB08155"], "name": "N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08154": {"dbids": ["DB08154"], "name": "3-chloro-5-[2-chloro-5-(1H-indazol-3-ylmethoxy)phenoxy]benzonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08159": {"dbids": ["DB08159"], "name": "4-(5,11-DIOXO-5H-INDENO[1,2-C]ISOQUINOLIN-6(11H)-YL)BUTANOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08158": {"dbids": ["DB08158"], "name": "2,4-DINITROPHENYL 2-DEOXY-2-FLUORO-BETA-D-MANNOPYRANOSIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08550": {"dbids": ["DB08550"], "name": "7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00812": {"dbids": ["APRD00409", "DB00812", "DB08343"], "name": "Phenylbutazone", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00812"}, {"action": "INHIBITOR", "target": "Q16647", "drug": "DB00812"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00812"}]}, "DB00813": {"dbids": ["APRD00347", "DB00813", "DB05853"], "name": "Fentanyl", "groups": ["APPROVED", "ILLICIT", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB00813"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00813"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00813"}]}, "DB00810": {"dbids": ["APRD00725", "DB00810"], "name": "Biperiden", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00810"}, {"action": "ANTAGONIST", "target": "Q15822", "drug": "DB00810"}]}, "DB00811": {"dbids": ["APRD00081", "DB00811"], "name": "Ribavirin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P20839", "drug": "DB00811"}, {"action": "ACTIVATOR", "target": "P55263", "drug": "DB00811"}, {"action": "ANTAGONIST", "target": "P26676", "drug": "DB00811"}, {"action": "INHIBITOR", "target": "P16502", "drug": "DB00811"}, {"action": "INDUCER", "target": "P49902", "drug": "DB00811"}, {"action": "INHIBITOR", "target": "P22413", "drug": "DB00811"}]}, "DB00816": {"dbids": ["APRD00210", "DB00816"], "name": "Orciprenaline", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P07550", "drug": "DB00816"}]}, "DB00817": {"dbids": ["APRD00369", "DB00817"], "name": "Rosoxacin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0AES6", "drug": "DB00817"}, {"action": "INHIBITOR", "target": "P0AFI2", "drug": "DB00817"}]}, "DB00814": {"dbids": ["APRD00529", "DB00814"], "name": "Meloxicam", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00814"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00814"}]}, "DB00815": {"dbids": ["APRD01606", "DB00815"], "name": "Sodium lauryl sulfate", "groups": ["APPROVED"], "targets": []}, "DB00818": {"dbids": ["APRD01201", "DB00818", "DB05893", "EXPT02558"], "name": "Propofol", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "POTENTIATOR", "target": "P47870", "drug": "DB00818"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB00818"}, {"action": "INHIBITOR", "target": "P35499", "drug": "DB00818"}, {"action": "INHIBITOR", "target": "Q99250", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00818"}]}, "DB00819": {"dbids": ["APRD00119", "DB00819", "EXPT00604"], "name": "Acetazolamide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00915", "drug": "DB00819"}, {"action": "INHIBITOR", "target": "Q9ULX7", "drug": "DB00819"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00819"}, {"action": "INHIBITOR", "target": "P07451", "drug": "DB00819"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00819"}, {"action": "INHIBITOR", "target": "P43166", "drug": "DB00819"}, {"action": "INHIBITOR", "target": "P29972", "drug": "DB00819"}]}, "DB07668": {"dbids": ["DB07668"], "name": "3-(4-DIETHYLAMINO-2-HYDROXY-PHENYL)-2-METHYL-PROPIONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07669": {"dbids": ["DB07669"], "name": "2,3-DIMETHYL-1,4-NAPHTHOQUINONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04410": {"dbids": ["DB04410", "EXPT02655"], "name": "3-Phenylpropylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01160": {"dbids": ["APRD00926", "DB01160"], "name": "Dinoprost Tromethamine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P43088", "drug": "DB01160"}, {"action": "ANTAGONIST", "target": "P43119", "drug": "DB01160"}]}, "DB04411": {"dbids": ["DB04411", "EXPT00940"], "name": "Alpha-N-Dichloroacetyl-P-Aminophenylserinol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02768": {"dbids": ["DB02768", "EXPT00736"], "name": "Tert-Butyloxycarbonyl Group", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02948": {"dbids": ["DB02948", "EXPT01469"], "name": "Fosmidomycin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02949": {"dbids": ["DB02949", "EXPT01709"], "name": "2-Acetyl-Protoporphyrin Ix", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02762": {"dbids": ["DB02762", "EXPT00300"], "name": "RU79072", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02763": {"dbids": ["DB02763", "EXPT02201"], "name": "5-Mercapto-2-Nitro-Benzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02760": {"dbids": ["DB02760", "EXPT01379"], "name": "1,6-Di-O-Phosphono-D-Allitol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02945": {"dbids": ["DB02945", "EXPT01842"], "name": "L-Iduronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02766": {"dbids": ["DB02766", "EXPT03288"], "name": "(3r)-3-{[(Benzyloxy)Carbonyl]Amino}-2-Oxo-4-Phenylbutane-1-Diazonium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02767": {"dbids": ["DB02767", "EXPT01506"], "name": "3-Hydroxy-Myristic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02940": {"dbids": ["DB02940", "EXPT03149"], "name": "(4s)-2-[(1e)-1-Aminoprop-1-Enyl]-4,5-Dihydro-1,3-Thiazole-4-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02765": {"dbids": ["DB02765", "EXPT00559"], "name": "9-Hydroxypropyladenine, R-Isomer", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04416": {"dbids": ["DB04416", "EXPT02128"], "name": "R-2-{[4'-Methoxy-(1,1'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07373": {"dbids": ["DB07373"], "name": "ANDROSTA-1,4-DIENE-3,17-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04417": {"dbids": ["DB04417", "EXPT02385"], "name": "P-Nitrophenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07370": {"dbids": ["DB07370"], "name": "(3Z,5S,6R,7S,8R,8aS)-3-(octylimino)hexahydro[1,3]thiazolo[3,4-a]pyridine-5,6,7,8-tetrol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04414": {"dbids": ["DB04414", "EXPT02207"], "name": "Heptamolybdate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03541": {"dbids": ["DB03541", "EXPT00839"], "name": "10-Propargyl-5,8-Dideazafolic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03540": {"dbids": ["DB03540", "EXPT02311"], "name": "Norcamphor", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03543": {"dbids": ["DB03543", "EXPT00024"], "name": "1-(O-Carboxy-Phenylamino)-1-Deoxy-D-Ribulose-5-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03542": {"dbids": ["DB03542", "EXPT02036"], "name": "L-Myo-Inositol-1-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03544": {"dbids": ["DB03544", "EXPT01036"], "name": "S-Phosphocysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03546": {"dbids": ["DB03546", "EXPT01969"], "name": "10-CF3C(OH)2-DDACTHF", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03549": {"dbids": ["DB03549", "EXPT00731"], "name": "Biotinyl P-Nitroaniline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03548": {"dbids": ["DB03548", "EXPT01967"], "name": "3-Deoxy-D-Manno-Oct-2-Ulosonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07371": {"dbids": ["DB07371"], "name": "3-(10-METHYL-ANTHRACEN-9-YL)-PROPIONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04415": {"dbids": ["DB04415", "EXPT02589"], "name": "3-Amino-1-Chloro-4-Phenyl-Butanol-2-Yl", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07376": {"dbids": ["DB07376"], "name": "5-(DIMETHYLAMINO)-1-NAPHTHALENESULFONIC ACID(DANSYL ACID)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05239": {"dbids": ["DB05239"], "name": "Cobimetinib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q02750", "drug": "DB05239"}]}, "DB05238": {"dbids": ["DB05238"], "name": "PLX4032", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05230": {"dbids": ["DB05230"], "name": "AC3056", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05233": {"dbids": ["DB05233"], "name": "AP1081", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05232": {"dbids": ["DB05232"], "name": "Tetrodotoxin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05235": {"dbids": ["DB05235"], "name": "NRP409", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05234": {"dbids": ["DB05234"], "name": "LGD2941", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05237": {"dbids": ["DB05237"], "name": "rhMBL", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05236": {"dbids": ["DB05236"], "name": "ReN001", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07377": {"dbids": ["DB07377"], "name": "N'-((2S,3R)-3-AMINO-2-HYDROXY-5-(ISOPROPYLSULFANYL)PENTANOYL)-N-3-CHLOROBENZOYL HYDRAZIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08975": {"dbids": ["DB08975"], "name": "Florantyrone", "groups": ["WITHDRAWN"], "targets": []}, "DB08974": {"dbids": ["DB08974"], "name": "Flubendazole", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB08977": {"dbids": ["DB08977"], "name": "Fibrinolysin", "groups": ["APPROVED"], "targets": []}, "DB08976": {"dbids": ["DB08976"], "name": "Floctafenine", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB08971": {"dbids": ["DB08971"], "name": "Fluocortolone", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB08970": {"dbids": ["DB08970"], "name": "Fluprednidene Acetate", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB08973": {"dbids": ["DB08973"], "name": "Fluclorolone acetonide", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB08972": {"dbids": ["DB08972"], "name": "Flumequine", "groups": ["WITHDRAWN"], "targets": []}, "DB07374": {"dbids": ["DB07374"], "name": "ANISOMYCIN", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08979": {"dbids": ["DB08979"], "name": "Fenspiride", "groups": ["APPROVED"], "targets": []}, "DB08978": {"dbids": ["DB08978"], "name": "Fentonium", "groups": ["WITHDRAWN"], "targets": []}, "DB07375": {"dbids": ["DB07375"], "name": "5-BETA-ANDROSTANE-3,17-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04754": {"dbids": ["DB04754"], "name": "GUANOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07897": {"dbids": ["DB07897"], "name": "1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07896": {"dbids": ["DB07896"], "name": "(2S)-hydroxy(4-hydroxyphenyl)ethanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07895": {"dbids": ["DB07895"], "name": "ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07894": {"dbids": ["DB07894"], "name": "4-(2-HYDROXY-4-FLUOROPHENYLTHIO)-BUTYLPHOSPHONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07893": {"dbids": ["DB07893"], "name": "PHENYL[1-(N-SUCCINYLAMINO)PENTYL]PHOSPHONATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07892": {"dbids": ["DB07892"], "name": "1-(2-HYDROXYETHYLOXYMETHYL)-6-PHENYL THIOTHYMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07891": {"dbids": ["DB07891"], "name": "4-{[(14beta,17alpha)-3-hydroxyestra-1,3,5(10)-trien-17-yl]oxy}-4-oxobutanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07890": {"dbids": ["DB07890"], "name": "4-(2-HYDROXYPHENYLTHIO)-1-BUTENYLPHOSPHONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07899": {"dbids": ["DB07899"], "name": "(2S) N-ACETYL-L-ALANYL-ALPHAL-PHENYLALANYL-CHLOROETHYLKETONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07898": {"dbids": ["DB07898"], "name": "2-(BUTYRYLOXY)-1-{[(TETRAHYDROXYPHOSPHORANYL)OXY]METHYL}ETHYL BUTYRATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04751": {"dbids": ["DB04751"], "name": "Purvalanol A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09149": {"dbids": ["DB09149"], "name": "Florbetapir (18F)", "groups": ["APPROVED"], "targets": []}, "DB09148": {"dbids": ["DB09148"], "name": "Florbetaben (18F)", "groups": ["APPROVED"], "targets": []}, "DB09147": {"dbids": ["DB09147"], "name": "Ferric pyrophosphate", "groups": ["APPROVED"], "targets": []}, "DB09146": {"dbids": ["DB09146"], "name": "Sucroferric Oxyhydroxide", "groups": ["APPROVED"], "targets": []}, "DB09145": {"dbids": ["DB09145"], "name": "Water", "groups": ["APPROVED"], "targets": []}, "DB09144": {"dbids": ["DB05425", "DB09144"], "name": "Uridine triacetate", "groups": ["APPROVED"], "targets": []}, "DB09143": {"dbids": ["DB09143"], "name": "Sonidegib", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "Q99835", "drug": "DB09143"}]}, "DB09142": {"dbids": ["DB09142"], "name": "Sincalide", "groups": ["APPROVED"], "targets": []}, "DB09141": {"dbids": ["DB09141"], "name": "Protamine sulfate", "groups": ["APPROVED"], "targets": []}, "DB09140": {"dbids": ["DB09140"], "name": "Oxygen", "groups": ["APPROVED"], "targets": []}, "DB04128": {"dbids": ["DB04128", "EXPT02045"], "name": "5-Nitroso-6-Ribityl-Amino-2,4(1h,3h)-Pyrimidinedione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04129": {"dbids": ["DB04129", "EXPT01797"], "name": "Willardiine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01338": {"dbids": ["DB01338"], "name": "Pipecuronium", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q15822", "drug": "DB01338"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01338"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01338"}]}, "DB01339": {"dbids": ["DB01339"], "name": "Vecuronium", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q15822", "drug": "DB01339"}]}, "DB04122": {"dbids": ["DB04122", "EXPT00684"], "name": "Beta-D-Glucose-6-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01443": {"dbids": ["DB01443"], "name": "19-Nor-5-androstenedione", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01440": {"dbids": ["DB01440"], "name": "Gamma Hydroxybutyric Acid", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "Q9HAB3", "drug": "DB01440"}, {"action": "AGONIST", "target": "P18505", "drug": "DB01440"}]}, "DB01441": {"dbids": ["DB01441"], "name": "5-Methoxy-N,N-diisopropyltryptamine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01446": {"dbids": ["DB01446"], "name": "Alpha-methyltryptamine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01447": {"dbids": ["DB01447"], "name": "4-Methylaminorex", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01444": {"dbids": ["DB01444"], "name": "Dimethylthiambutene", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB01444"}, {"action": "AGONIST", "target": "P41143", "drug": "DB01444"}]}, "DB01333": {"dbids": ["DB01333"], "name": "Cefradine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P02918", "drug": "DB01333"}]}, "DB00319": {"dbids": ["APRD00325", "DB00319"], "name": "Piperacillin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00319"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB00319"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB00319"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB00319"}]}, "DB00318": {"dbids": ["APRD00120", "DB00318", "DB09471"], "name": "Codeine", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "PARTIAL AGONIST", "target": "P35372", "drug": "DB00318"}, {"action": "PARTIAL AGONIST", "target": "P41145", "drug": "DB00318"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00318"}]}, "DB08400": {"dbids": ["DB08400"], "name": "4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzyl)piperidine-1-carboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00311": {"dbids": ["APRD00732", "DB00311", "DB07727"], "name": "Ethoxzolamide", "groups": ["WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P00915", "drug": "DB00311"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00311"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00311"}, {"action": "INHIBITOR", "target": "P43166", "drug": "DB00311"}]}, "DB00310": {"dbids": ["APRD00127", "DB00310"], "name": "Chlorthalidone", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q13621", "drug": "DB00310"}]}, "DB00313": {"dbids": ["APRD00066", "APRD00256", "DB00313", "DB00510"], "name": "Valproic Acid", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q9UKV0", "drug": "DB00313"}, {"action": "INHIBITOR", "target": "P80404", "drug": "DB00313"}, {"action": "INHIBITOR", "target": "P45954", "drug": "DB00313"}, {"action": "INHIBITOR", "target": "Q02218", "drug": "DB00313"}, {"action": "INHIBITOR", "target": "P51649", "drug": "DB00313"}]}, "DB00312": {"dbids": ["APRD01174", "DB00312"], "name": "Pentobarbital", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00312"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00312"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00312"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00312"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00312"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "Q05586", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "Q14957", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "O15399", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "O60391", "drug": "DB00312"}]}, "DB00315": {"dbids": ["APRD00376", "DB00315"], "name": "Zolmitriptan", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P28222", "drug": "DB00315"}, {"action": "AGONIST", "target": "P28221", "drug": "DB00315"}, {"action": "AGONIST", "target": "P30939", "drug": "DB00315"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00315"}]}, "DB00314": {"dbids": ["APRD00844", "DB00314"], "name": "Capreomycin", "groups": ["APPROVED"], "targets": []}, "DB00317": {"dbids": ["APRD00997", "DB00317", "DB07998"], "name": "Gefitinib", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P00533", "drug": "DB00317"}]}, "DB00316": {"dbids": ["APRD00252", "DB00316"], "name": "Acetaminophen", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00316"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00316"}]}, "DB04753": {"dbids": ["DB04753"], "name": "9-DEAZAINOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08402": {"dbids": ["DB08402"], "name": "2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08405": {"dbids": ["DB08405"], "name": "S-(2-{[N-(2-HYDROXY-4-{[HYDROXY(OXIDO)PHOSPHINO]OXY}-3,3-DIMETHYLBUTANOYL)-BETA-ALANYL]AMINO}ETHYL) HEPTANETHIOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04654": {"dbids": ["DB04654"], "name": "4-PIPERIDIN-4-YLBUTANAL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08404": {"dbids": ["DB08404"], "name": "S-(2-{[N-(2-HYDROXY-4-{[HYDROXY(OXIDO)PHOSPHINO]OXY}-3,3-DIMETHYLBUTANOYL)-BETA-ALANYL]AMINO}ETHYL) HEXANETHIOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09499": {"dbids": ["DB09499"], "name": "Sodium thiosulfate", "groups": ["APPROVED"], "targets": []}, "DB09498": {"dbids": ["DB09498"], "name": "Strontium chloride Sr-89", "groups": ["APPROVED"], "targets": []}, "DB08407": {"dbids": ["DB08407"], "name": "PLATENSIMYCIN", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02604": {"dbids": ["DB02604", "EXPT01099"], "name": "2-Deoxy-Glucose-6-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09490": {"dbids": ["DB09490"], "name": "Indium In-111 chloride", "groups": ["APPROVED"], "targets": []}, "DB08406": {"dbids": ["DB08406"], "name": "[N-(2,4-DIAMINOPTERIDIN-6-YL)-METHYL]-DIBENZ[B,F]AZEPINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09495": {"dbids": ["DB09495"], "name": "Avobenzone", "groups": ["APPROVED"], "targets": []}, "DB02607": {"dbids": ["DB02607", "EXPT02938"], "name": "Adenosine Phosphonoacetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04752": {"dbids": ["DB04752"], "name": "Phosphatidyl ethanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09496": {"dbids": ["DB09496"], "name": "Octinoxate", "groups": ["APPROVED"], "targets": []}, "DB08409": {"dbids": ["DB08409"], "name": "4-NITRO-BENZYLPHOSPHONOBUTANOYL-GLYCINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02606": {"dbids": ["DB02606", "EXPT02861"], "name": "2-Butanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08408": {"dbids": ["DB08408"], "name": "(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-({3-oxo-3-[(2-sulfanylethyl)amino]propyl}amino)butyl 2,2-dimethylpropanoate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02601": {"dbids": ["DB02601", "EXPT01591"], "name": "4-Hydroxyphenylglycine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02600": {"dbids": ["DB02600", "EXPT01528"], "name": "5-N-Acetyl-3-(1-Ethylpropyl)-1-Cyclohexene-1-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02603": {"dbids": ["DB02603", "EXPT00086"], "name": "1-Amino-6-Cyclohex-3-Enylmethyloxypurine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02602": {"dbids": ["DB02602", "EXPT00486"], "name": "AL7182", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08874": {"dbids": ["DB08874"], "name": "Fidaxomicin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q18BX5", "drug": "DB08874"}]}, "DB08875": {"dbids": ["DB08875"], "name": "Cabozantinib", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08581", "drug": "DB08875"}, {"action": "ANTAGONIST", "target": "P35968", "drug": "DB08875"}, {"action": "ANTAGONIST", "target": "P07949", "drug": "DB08875"}]}, "DB08876": {"dbids": ["DB08876"], "name": "Taliglucerase Alfa", "groups": ["APPROVED"], "targets": []}, "DB05885": {"dbids": ["DB05885"], "name": "UCB 44212", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04788": {"dbids": ["DB04788"], "name": "Tagetitoxin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04789": {"dbids": ["DB04789"], "name": "5-methyltetrahydrofolate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04786": {"dbids": ["DB04786"], "name": "Suramin", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P41231", "drug": "DB04786"}, {"action": "INHIBITOR", "target": "Q9NXA8", "drug": "DB04786"}, {"action": "ANTAGONIST", "target": "P23945", "drug": "DB04786"}, {"action": "AGONIST", "target": "P21817", "drug": "DB04786"}, {"action": "INHIBITOR", "target": "P00734", "drug": "DB04786"}, {"action": "INHIBITOR", "target": "P14555", "drug": "DB04786"}]}, "DB04787": {"dbids": ["DB04787"], "name": "Tanaproget", "groups": ["INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P06401", "drug": "DB04787"}]}, "DB04784": {"dbids": ["DB04784"], "name": "Methylphenyl carbinol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04785": {"dbids": ["DB04785"], "name": "Streptolydigin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04782": {"dbids": ["DB04782"], "name": "(S)-4-Nitrostyrene oxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04783": {"dbids": ["DB04783"], "name": "Sphinxolide B", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04780": {"dbids": ["DB04780"], "name": "Sulfatide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04781": {"dbids": ["DB04781"], "name": "5-hydroxyvaleric acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08872": {"dbids": ["DB08872"], "name": "gabapentin enacarbil", "groups": ["APPROVED"], "targets": []}, "DB08873": {"dbids": ["DB08873"], "name": "Boceprevir", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "B0B3C9", "drug": "DB08873"}]}, "DB03376": {"dbids": ["DB03376", "EXPT00374"], "name": "'5'-O-(N-(L-Alanyl)-Sulfamoyl)Adenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03374": {"dbids": ["DB03374", "EXPT03137"], "name": "3,5-Diiodotyrosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06255": {"dbids": ["DB06255"], "name": "Incadronate", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB03372": {"dbids": ["DB03372", "EXPT02171"], "name": "3-Mercapto-1-(1,3,4,9-Tetrahydro-B-Carbolin-2-Yl)-Propan-1-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03373": {"dbids": ["DB03373", "EXPT00295"], "name": "ZK-806711", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03370": {"dbids": ["DB03370", "EXPT01486"], "name": "FR239087", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03371": {"dbids": ["DB03371", "EXPT00553"], "name": "Modified Ribosylated Glutamyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03378": {"dbids": ["DB03378", "EXPT02039"], "name": "4-Amino-1-[(1s,3r,4r,7s)-7-Hydroxy-1-(Hydroxymethyl)-2,5-Dioxabicyclo[2.2.1]Hept-3-Yl]-5-Methylpyrimidin-2(1h)-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03379": {"dbids": ["DB03379", "EXPT00189"], "name": "2-Carboxyethylphosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06788": {"dbids": ["DB06788"], "name": "Histrelin", "groups": ["APPROVED"], "targets": []}, "DB06789": {"dbids": ["DB06789"], "name": "Hydroxyprogesterone caproate", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB06781": {"dbids": ["DB06781"], "name": "Difluprednate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB06781"}]}, "DB06782": {"dbids": ["DB06782"], "name": "Dimercaprol", "groups": ["APPROVED"], "targets": []}, "DB06783": {"dbids": ["DB06783"], "name": "Prussian blue", "groups": ["APPROVED"], "targets": []}, "DB06785": {"dbids": ["DB06785"], "name": "Ganirelix", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P30968", "drug": "DB06785"}]}, "DB06786": {"dbids": ["DB06786"], "name": "Halcinonide", "groups": ["APPROVED"], "targets": []}, "DB06787": {"dbids": ["DB06787"], "name": "Hexocyclium", "groups": ["APPROVED"], "targets": []}, "DB04878": {"dbids": ["DB04878"], "name": "Voglibose", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "O43451", "drug": "DB04878"}]}, "DB04879": {"dbids": ["DB04879"], "name": "Vatalanib", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07665": {"dbids": ["DB07665"], "name": "N-[2-(carbamimidamidooxy)ethyl]-2-{6-cyano-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-fluorophenyl}acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04870": {"dbids": ["DB04870"], "name": "Oleoyl estrone", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04871": {"dbids": ["DB04871"], "name": "Lorcaserin", "groups": ["APPROVED"], "targets": []}, "DB04872": {"dbids": ["DB04872"], "name": "Osanetant", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04873": {"dbids": ["DB04873"], "name": "Piboserod", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04874": {"dbids": ["DB04874"], "name": "Picoplatin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04875": {"dbids": ["DB04875"], "name": "Pralnacasan", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04876": {"dbids": ["DB04876"], "name": "Vildagliptin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P27487", "drug": "DB04876"}]}, "DB04877": {"dbids": ["DB04877"], "name": "Voacamine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR, COMPETITIVE", "target": "P08183", "drug": "DB04877"}]}, "DB00175": {"dbids": ["APRD00328", "DB00175"], "name": "Pravastatin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P04035", "drug": "DB00175"}]}, "DB00174": {"dbids": ["DB00174", "NUTR00015"], "name": "L-Asparagine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00177": {"dbids": ["APRD00133", "DB00177"], "name": "Valsartan", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P30556", "drug": "DB00177"}]}, "DB00176": {"dbids": ["APRD00425", "DB00176"], "name": "Fluvoxamine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P31645", "drug": "DB00176"}]}, "DB00171": {"dbids": ["DB00171", "EXPT00007", "NUTR00017"], "name": "Adenosine triphosphate", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "INHIBITOR", "target": "P42684", "drug": "DB00171"}, {"action": "INHIBITOR", "target": "P00519", "drug": "DB00171"}]}, "DB00170": {"dbids": ["DB00170", "NUTR00062"], "name": "Menadione", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "COFACTOR", "target": "P38435", "drug": "DB00170"}, {"action": "COFACTOR", "target": "Q9BQB6", "drug": "DB00170"}, {"action": "COFACTOR", "target": "Q8N0U8", "drug": "DB00170"}, {"action": "ACTIVATOR", "target": "P00734", "drug": "DB00170"}, {"action": "ACTIVATOR", "target": "P08709", "drug": "DB00170"}, {"action": "ACTIVATOR", "target": "P00740", "drug": "DB00170"}, {"action": "ACTIVATOR", "target": "P00742", "drug": "DB00170"}, {"action": "ACTIVATOR", "target": "P04070", "drug": "DB00170"}, {"action": "ACTIVATOR", "target": "P07225", "drug": "DB00170"}, {"action": "ACTIVATOR", "target": "P22891", "drug": "DB00170"}, {"action": "AGONIST", "target": "P02818", "drug": "DB00170"}]}, "DB00173": {"dbids": ["DB00173", "EXPT00520", "NUTR00012"], "name": "Adenine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00172": {"dbids": ["DB00172", "NUTR00047"], "name": "L-Proline", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "BINDER", "target": "P23284", "drug": "DB00172"}, {"action": "BINDER", "target": "P62937", "drug": "DB00172"}]}, "DB08360": {"dbids": ["DB08360"], "name": "2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07660": {"dbids": ["DB07660"], "name": "AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07789": {"dbids": ["DB07789"], "name": "1-[5-methyl-2-(trifluoromethyl)furan-3-yl]-3-[(2Z)-5-(2-{[6-(1H-1,2,4-triazol-3-ylamino)pyrimidin-4-yl]amino}ethyl)-1,3-thiazol-2(3H)-ylidene]urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07788": {"dbids": ["DB07788"], "name": "(3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00179": {"dbids": ["APRD01084", "DB00179"], "name": "Masoprocol", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P09917", "drug": "DB00179"}]}, "DB00178": {"dbids": ["APRD00009", "DB00178"], "name": "Ramipril", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P12821", "drug": "DB00178"}]}, "DB08366": {"dbids": ["DB08366"], "name": "3-({3-[(1S,4aS,6S,7S,9S,9aR)-1,6-dimethyl-2-oxodecahydro-6,9-epoxy-4a,7-methanobenzo[7]annulen-1-yl]propanoyl}amino)-2,4-dihydroxybenzoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07661": {"dbids": ["DB07661"], "name": "1,6-DIHYDROXY NAPHTHALENE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03152": {"dbids": ["DB03152", "EXPT00687"], "name": "B-2-Octylglucoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03153": {"dbids": ["DB03153", "EXPT02643"], "name": "3h-Pyrazolo[4,3-D]Pyrimidin-7-Ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03150": {"dbids": ["DB03150", "EXPT00113"], "name": "2',3'-Dideoxythymidine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03151": {"dbids": ["DB03151", "EXPT01060"], "name": "(Mu-4-Sulfido)-Tetra-Nuclear Copper Ion", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03156": {"dbids": ["DB03156", "EXPT01175"], "name": "D-Glucuronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03157": {"dbids": ["DB03157", "EXPT01150"], "name": "N,O-Didansyl-L-Tyrosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03154": {"dbids": ["DB03154", "EXPT01463"], "name": "{[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03155": {"dbids": ["DB03155", "EXPT03185"], "name": "1-(2-Deoxy-2-Fluoro-3-O-Phosphono-Beta-L-Ribofuranosyl)Pyrimidine-2,4(1h,3h)-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03158": {"dbids": ["DB03158", "EXPT00125"], "name": "D-Myo-Inositol-1,4-Bisphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03159": {"dbids": ["DB03159", "EXPT00282"], "name": "CRA_8696", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04454": {"dbids": ["DB04454", "EXPT00390"], "name": "Alpha-Aminobutyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06793": {"dbids": ["DB06793"], "name": "Levopropoxyphene", "groups": ["APPROVED"], "targets": []}, "DB04455": {"dbids": ["DB04455", "EXPT00674"], "name": "Trimethyl Glycine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06792": {"dbids": ["DB06792"], "name": "Lanthanum carbonate", "groups": ["APPROVED"], "targets": []}, "DB04452": {"dbids": ["DB04452", "EXPT02388"], "name": "N,N'-Bis(4-Amino-2-Methylquinolin-6-Yl)Urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06243": {"dbids": ["DB06243"], "name": "Eflornithine", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P11926", "drug": "DB06243"}, {"action": "BLOCKER", "target": "P11926", "drug": "DB06243"}]}, "DB04453": {"dbids": ["DB04453", "EXPT00557"], "name": "4-O-(4,6-Dideoxy-4-{[4-[(4-O-Hexopyranosylhexopyranosyl)Oxy]-5,6-Dihydroxy-3-(Hydroxymethyl)Cyclohex-2-En-1-Yl]Amino}Hexopyranosyl)Hexopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06790": {"dbids": ["DB06790"], "name": "Iron sucrose", "groups": ["APPROVED"], "targets": []}, "DB04450": {"dbids": ["DB04450", "EXPT01788"], "name": "Heptyl 1-Thiohexopyranoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01971": {"dbids": ["DB01971", "EXPT03207"], "name": "trans-urocanic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01046": {"dbids": ["APRD01298", "DB01046"], "name": "Lubiprostone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INDUCER", "target": "P51788", "drug": "DB01046"}]}, "DB06796": {"dbids": ["DB06796"], "name": "Mangafodipir", "groups": ["APPROVED"], "targets": []}, "DB06795": {"dbids": ["DB06795"], "name": "Mafenide", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P23280", "drug": "DB06795"}]}, "DB04992": {"dbids": ["DB04992"], "name": "AP5346", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07112": {"dbids": ["DB07112"], "name": "N-[(4-HYDROXY-8-IODOISOQUINOLIN-3-YL)CARBONYL]GLYCINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01047": {"dbids": ["APRD00978", "DB01047"], "name": "Fluocinonide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB01047"}, {"action": "AGONIST", "target": "Q99835", "drug": "DB01047"}]}, "DB04458": {"dbids": ["DB04458", "EXPT02234"], "name": "2,2-Dichloro-1-Methanesulfinyl-3-Methyl-Cyclopropanecarboxylic Acid [1-(4-Bromo-Phenyl)-Ethyl]-Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04459": {"dbids": ["DB04459", "EXPT01202"], "name": "3,4-Dichloroisocoumarin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07113": {"dbids": ["DB07113"], "name": "(2S)-6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2-(3,5-DIFLUOROPHENYL)-4-(3-METHOXYPROPYL)-2H-1,4-BENZOXAZIN-3(4H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08746": {"dbids": ["DB08746"], "name": "1-[[(1E)-2-(4-CHLOROPHENYL)ETHENYL]SULFONYL]-4-[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]PIPERAZINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08747": {"dbids": ["DB08747"], "name": "(11R)-10-acetyl-11-(2,4-dichlorophenyl)-6-hydroxy-3,3-dimethyl-2,3,4,5,10,11-hexahydro-1H-dibenzo[b,e][1,4]diazepin-1-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01044": {"dbids": ["APRD00996", "DB01044"], "name": "Gatifloxacin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P72524", "drug": "DB01044"}, {"action": "INHIBITOR", "target": "P0A4L9", "drug": "DB01044"}, {"action": "INHIBITOR", "target": "P72525", "drug": "DB01044"}, {"action": "INHIBITOR", "target": "Q59961", "drug": "DB01044"}]}, "DB01660": {"dbids": ["DB01660", "EXPT02847"], "name": "Adenosine-5'-Diphosphate Monothiophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04135": {"dbids": ["DB04135", "EXPT01480"], "name": "5-Fluoro-4-(S)-Hydroxy-3,4-Dihydropyrimidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07110": {"dbids": ["DB07110"], "name": "4-(4-FLUOROBENZYL)PIPERIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01045": {"dbids": ["APRD00207", "DB01045", "EXPT02777"], "name": "Rifampicin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A8V2", "drug": "DB01045"}, {"action": "INHIBITOR", "target": "P0A8T7", "drug": "DB01045"}, {"action": "AGONIST", "target": "O75469", "drug": "DB01045"}]}, "DB08110": {"dbids": ["DB08110"], "name": "(1R,4S,7AS)-1-(1-FORMYLPROP-1-EN-1-YL)-4-METHOXY-2,4,5,6,7,7A-HEXAHYDRO-1H-ISOINDOLE-3-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02201": {"dbids": ["DB02201", "EXPT02183"], "name": "Malonate Ion", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02200": {"dbids": ["DB02200", "EXPT03232"], "name": "3-[N-[Benzyloxycarbonyl]-Phenylalaninyl-Amino]-5-Phenyl-Pentane-1-Sulfonylmethylbenzene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02203": {"dbids": ["DB02203", "EXPT00968"], "name": "Acetone Cyanohydrin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02202": {"dbids": ["DB02202", "EXPT00772"], "name": "1,3-Butanediol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04997": {"dbids": ["DB04997"], "name": "ATL1102", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04865": {"dbids": ["DB04865"], "name": "Homoharringtonine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P20276", "drug": "DB04865"}, {"action": "ANTAGONIST", "target": "P39023", "drug": "DB04865"}]}, "DB02207": {"dbids": ["DB02207", "EXPT00314"], "name": "7-Nitroindazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01661": {"dbids": ["DB01661", "EXPT02665"], "name": "Phosphoribosyl Atp", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02209": {"dbids": ["DB02209", "EXPT02710"], "name": "Pyridoxine-5'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07111": {"dbids": ["DB07111"], "name": "(4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01042": {"dbids": ["APRD00118", "DB01042"], "name": "Melphalan", "groups": ["APPROVED"], "targets": []}, "DB04996": {"dbids": ["DB04996"], "name": "Satraplatin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08378": {"dbids": ["DB08378"], "name": "4-[4-(2,5-DIOXO-PYRROLIDIN-1-YL)-PHENYLAMINO]-4-HYDROXY-BUTYRIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08748": {"dbids": ["DB08748"], "name": "4-(DIMETHYLAMINO)BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07116": {"dbids": ["DB07116"], "name": "1-(2-DEOXY-5-O-PHOSPHONO-BETA-D-ERYTHRO-PENTOFURANOSYL)-4-METHYL-1H-INDOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08749": {"dbids": ["DB08749"], "name": "3-(2-AMINO-6-BENZOYLQUINAZOLIN-3(4H)-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01043": {"dbids": ["APRD00221", "DB01043"], "name": "Memantine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB01043"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB01043"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB01043"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB01043"}, {"action": "ANTAGONIST", "target": "Q693P7", "drug": "DB01043"}, {"action": "AGONIST", "target": "P14416", "drug": "DB01043"}, {"action": "BINDER", "target": "Q05586", "drug": "DB01043"}]}, "DB04995": {"dbids": ["DB04995"], "name": "AT1022", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08372": {"dbids": ["DB08372"], "name": "1-[2-(4-ETHOXY-3-FLUOROPYRIDIN-2-YL)ETHYL]-3-(5-METHYLPYRIDIN-2-YL)THIOUREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07117": {"dbids": ["DB07117"], "name": "5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01040": {"dbids": ["APRD01024", "DB01040"], "name": "Hydroxystilbamidine Isethionate", "groups": ["APPROVED"], "targets": []}, "DB06643": {"dbids": ["DB06643"], "name": "Denosumab", "groups": ["APPROVED"], "targets": [{"action": "ANTIBODY", "target": "O14788", "drug": "DB06643"}]}, "DB07114": {"dbids": ["DB07114"], "name": "4-[(METHYLSULFONYL)AMINO]BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08374": {"dbids": ["DB08374"], "name": "PHENYLALANYLMETHYLCHLORIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01041": {"dbids": ["APRD01251", "DB01041"], "name": "Thalidomide", "groups": ["APPROVED", "INVESTIGATIONAL", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "Q96SW2", "drug": "DB01041"}, {"action": "INHIBITOR", "target": "P01375", "drug": "DB01041"}, {"action": "ANTAGONIST", "target": "P19838", "drug": "DB01041"}, {"action": "ANTAGONIST", "target": "P21802", "drug": "DB01041"}, {"action": "ANTAGONIST", "target": "P35354", "drug": "DB01041"}, {"action": "BINDER", "target": "P02763", "drug": "DB01041"}, {"action": "BINDER", "target": "P19652", "drug": "DB01041"}]}, "DB03145": {"dbids": ["DB03145", "EXPT03154"], "name": "4-Methyl-5-Hydroxyethylthiazole Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07259": {"dbids": ["DB07259"], "name": "1-(4-thiophen-2-ylphenyl)methanamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07115": {"dbids": ["DB07115"], "name": "N-(4-chlorobenzyl)-N-methylbenzene-1,4-disulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07258": {"dbids": ["DB07258"], "name": "(R)-pyridin-4-yl[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05008": {"dbids": ["DB05008"], "name": "NB001", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05009": {"dbids": ["DB05009"], "name": "BMS068645", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05006": {"dbids": ["DB05006"], "name": "MT201", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05007": {"dbids": ["DB05007"], "name": "XL647", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05004": {"dbids": ["DB05004"], "name": "AC162352", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05005": {"dbids": ["DB05005"], "name": "CCX282", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08562": {"dbids": ["DB08562"], "name": "4-(4-STYRYL-PHENYLCARBAMOYL)-BUTYRIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04058": {"dbids": ["DB04058", "EXPT01885"], "name": "D-[(Amino)Carbonyl]Phenylalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05000": {"dbids": ["DB05000"], "name": "AeroLEF", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05001": {"dbids": ["DB05001"], "name": "PSN9301", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB02946": {"dbids": ["DB02946", "EXPT01898"], "name": "Carpropamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04059": {"dbids": ["DB04059", "EXPT03179"], "name": "8-(Pyrimidin-2-Ylamino)Naphthalene-2-Carboximidamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02947": {"dbids": ["DB02947", "EXPT00115"], "name": "2-Fluoro-2'-Deoxyadenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01833": {"dbids": ["DB01833", "EXPT01587"], "name": "L-2-Amino-4-(Guanidinooxy)Butyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01832": {"dbids": ["DB01832", "EXPT01703"], "name": "4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01831": {"dbids": ["DB01831", "EXPT03138"], "name": "Tryptophanyl-5'amp", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01830": {"dbids": ["DB01830", "EXPT00856"], "name": "{4-[2-Acetylamino-2-(3-Carbamoyl-2-Cyclohexylmethoxy-6,7,8,9-Tetrahydro-5h-Benzocyclohepten-5ylcarbamoyl)-Ethyl]-2-Phosphono-Phenyl}-Phosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01837": {"dbids": ["DB01837", "EXPT02411"], "name": "O-Acetylserine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01836": {"dbids": ["DB01836", "EXPT03286"], "name": "[4-(6-Chloro-Naphthalene-2-Sulfonyl)-Piperazin-1-Yl]-(3,4,5,6-Tetrahydro-2h-[1,4']Bipyridinyl-4-Yl)-Methanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01835": {"dbids": ["DB01835", "EXPT01816"], "name": "4r-Fluoro-N6-Ethanimidoyl-L-Lysine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01834": {"dbids": ["DB01834", "EXPT01641"], "name": "(9r,10r)-9-(S-Glutathionyl)-10-Hydroxy-9,10-Dihydrophenanthrene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02942": {"dbids": ["DB02942", "EXPT01941"], "name": "Inositol 1,3-Bisphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01839": {"dbids": ["DB01839", "EXPT02572"], "name": "1,2-Propanediol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01838": {"dbids": ["DB01838", "EXPT01439"], "name": "6,4'-Dihydroxy-3-Methyl-3',5'-Dibromoflavone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01789": {"dbids": ["DB01789", "EXPT00430"], "name": "1-Amino-2,3-Dihydroxy-5-Hydroxymethyl Cyclohex-5-Ene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01788": {"dbids": ["DB01788", "EXPT01833"], "name": "4-Imino-5-Methidyl-2-Methylpyrimidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02943": {"dbids": ["DB02943", "EXPT00404"], "name": "N-(4-Aminobutanoyl)-S-(4-Methoxybenzyl)-L-Cysteinylglycine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04052": {"dbids": ["DB04052", "EXPT00131"], "name": "3,4-Dimethylphenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04053": {"dbids": ["DB04053", "EXPT02627"], "name": "Hypophosphite", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04750": {"dbids": ["DB04750"], "name": "OREGON GREEN 488 CARBOXYLATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07808": {"dbids": ["DB07808"], "name": "(1S,2R)-2-[(2,5-difluorophenyl)carbamoyl]cyclopropanecarboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02941": {"dbids": ["DB02941", "EXPT01858"], "name": "3-(1-Aminoethyl)Nonanedioic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04050": {"dbids": ["DB04050", "EXPT02384"], "name": "N-Propyl Isocyanide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04051": {"dbids": ["DB04051", "EXPT00258"], "name": "5-Phenylvaleric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04056": {"dbids": ["DB04056", "EXPT00283"], "name": "6-Aminobenzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04057": {"dbids": ["DB04057", "EXPT02233"], "name": "Beta-Dadf, Msa, Multisubstrate Adduct Inhibitor", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04054": {"dbids": ["DB04054", "EXPT02691"], "name": "9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08357": {"dbids": ["DB08357"], "name": "1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07255": {"dbids": ["DB07255"], "name": "N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3-MORPHOLIN-4-YLPHENYL)PYRIMIDINE-2,4-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04055": {"dbids": ["DB04055", "EXPT00707"], "name": "2,3-Dicarboxy-4-(2-Chloro-Phenyl)-1-Ethyl-5-Isopropoxycarbonyl-6-Methyl-Pyridinium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01161": {"dbids": ["APRD00404", "DB01161"], "name": "Chloroprocaine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB01161"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB01161"}, {"action": "ANTAGONIST", "target": "Q9GZZ6", "drug": "DB01161"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB01161"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB01161"}]}, "DB04232": {"dbids": ["DB04232", "EXPT02946"], "name": "N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01163": {"dbids": ["APRD00789", "DB01163"], "name": "Amdinocillin", "groups": ["WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB01163"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB01163"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB01163"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB01163"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB01163"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB01163"}]}, "DB01162": {"dbids": ["APRD00667", "DB01162"], "name": "Terazosin", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35348", "drug": "DB01162"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01162"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB01162"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB01162"}, {"action": "INHIBITOR", "target": "Q9H252", "drug": "DB01162"}, {"action": "INHIBITOR", "target": "Q9NS40", "drug": "DB01162"}]}, "DB04669": {"dbids": ["DB04669"], "name": "TRIAZOLOPYRIMIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04668": {"dbids": ["DB04668"], "name": "CHROMOPHORE (GLU-TYR-GLY)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01167": {"dbids": ["APRD00040", "DB01167"], "name": "Itraconazole", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q16850", "drug": "DB01167"}, {"action": "INHIBITOR", "target": "P50859", "drug": "DB01167"}]}, "DB01605": {"dbids": ["DB01605"], "name": "Pivmecillinam", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01605"}]}, "DB04665": {"dbids": ["DB04665"], "name": "2H-1-BENZOPYRAN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04664": {"dbids": ["DB04664"], "name": "Cyclohexyl-pentyl-maltoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04667": {"dbids": ["DB04667"], "name": "CHROMOPHORE (HIS-TYR-GLY)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04666": {"dbids": ["DB04666"], "name": "CHROMOPHORE (LYS-TYR-GLY)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04661": {"dbids": ["DB04661"], "name": "Cis-tetracosenoyl sulfatide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04982": {"dbids": ["DB04982"], "name": "Talampanel", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04663": {"dbids": ["DB04663"], "name": "2-KETO-6-PHOSPHATE-D-GLUCONIC ACID, ALPHA-FURANOSE FORM", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04662": {"dbids": ["DB04662"], "name": "OLOMOUCINE II", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01607": {"dbids": ["DB01607"], "name": "Ticarcillin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "C1KC03", "drug": "DB01607"}]}, "DB08179": {"dbids": ["DB08179"], "name": "methyl 4-(2,3-dihydroxy-5-methylphenoxy)-2-hydroxy-6-methylbenzoate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08178": {"dbids": ["DB08178"], "name": "4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07254": {"dbids": ["DB07254"], "name": "N-[3-[[4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL]AMINO]PHENYL]METHANESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04236": {"dbids": ["DB04236", "EXPT03091"], "name": "2-Amino-3-(1h-Indol-3-Yl)-Propan-1-Ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08177": {"dbids": ["DB08177"], "name": "(E)-3-(5((5-(4-CHLOROPHENYL)FURAN-2-YL)METHYLENE)-4-OXO-2-THIOXOTHIAZOLIDIN-3-YL)PROPANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08176": {"dbids": ["DB08176"], "name": "(1Z)-4-(4-FLUOROPHENYL)-2-METHYLIDENEBUTAN-1-IMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08171": {"dbids": ["DB08171"], "name": "11-MERCAPTOUNDECANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08170": {"dbids": ["DB08170"], "name": "(1R)-N,6-DIHYDROXY-7-METHOXY-2-[(4-METHOXYPHENYL)SULFONYL]-1,2,3,4-TETRAHYDROISOQUINOLINE-1-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08173": {"dbids": ["DB08173"], "name": "5-CHLORO-N-(2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)ETHYL)THIOPHENE-2-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01601": {"dbids": ["DB01601", "EXPT00388"], "name": "Lopinavir", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q72874", "drug": "DB01601"}]}, "DB00788": {"dbids": ["APRD01135", "DB00788"], "name": "Naproxen", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00788"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00788"}]}, "DB00789": {"dbids": ["APRD00991", "DB00789"], "name": "Gadopentetate dimeglumine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P52209", "drug": "DB00789"}]}, "DB01602": {"dbids": ["DB01602"], "name": "Bacampicillin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01602"}]}, "DB00782": {"dbids": ["APRD00177", "DB00782"], "name": "Propantheline", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00782"}]}, "DB00783": {"dbids": ["APRD00311", "DB00783"], "name": "Estradiol", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P03372", "drug": "DB00783"}, {"action": "AGONIST", "target": "Q92731", "drug": "DB00783"}]}, "DB00780": {"dbids": ["APRD00099", "DB00780"], "name": "Phenelzine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P21397", "drug": "DB00780"}, {"action": "ANTAGONIST", "target": "P27338", "drug": "DB00780"}, {"action": "INHIBITOR", "target": "Q16853", "drug": "DB00780"}, {"action": "INHIBITOR", "target": "P80404", "drug": "DB00780"}, {"action": "INHIBITOR", "target": "P24298", "drug": "DB00780"}, {"action": "INHIBITOR", "target": "Q8TD30", "drug": "DB00780"}, {"action": "INHIBITOR", "target": "Q9UGI5", "drug": "DB00780"}]}, "DB04987": {"dbids": ["DB04987"], "name": "P113D", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB00786": {"dbids": ["APRD00559", "DB00786"], "name": "Marimastat", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P03956", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "P08253", "drug": "DB00786"}, {"action": "ANTAGONIST", "target": "P08254", "drug": "DB00786"}, {"action": "ANTAGONIST", "target": "P09237", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "P22894", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "P14780", "drug": "DB00786"}, {"action": "ANTAGONIST", "target": "P09238", "drug": "DB00786"}, {"action": "ANTAGONIST", "target": "P24347", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "P39900", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "P45452", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "P50281", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "P51511", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "P51512", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "Q9ULZ9", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "Q99542", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "O60882", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "Q8N119", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "O75900", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "Q9Y5R2", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "Q9NPA2", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "Q9NRE1", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "Q9H306", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "Q9H239", "drug": "DB00786"}]}, "DB00787": {"dbids": ["APRD00567", "DB00787", "DB05347", "EXPT00406"], "name": "Aciclovir", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P03176", "drug": "DB00787"}, {"action": "INHIBITOR", "target": "P04293", "drug": "DB00787"}, {"action": "INHIBITOR", "target": "P09252", "drug": "DB00787"}]}, "DB00784": {"dbids": ["APRD00730", "DB00784"], "name": "Mefenamic acid", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00784"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00784"}]}, "DB00785": {"dbids": ["APRD00890", "DB00785"], "name": "Cryptenamine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08172", "drug": "DB00785"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00785"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00785"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00785"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00785"}]}, "DB00733": {"dbids": ["APRD01193", "DB00733"], "name": "Pralidoxime", "groups": ["APPROVED"], "targets": [{"action": "ACTIVATOR", "target": "P22303", "drug": "DB00733"}, {"action": "ACTIVATOR", "target": "P06276", "drug": "DB00733"}]}, "DB07257": {"dbids": ["DB07257"], "name": "4-(2-chlorophenyl)-8-(2-hydroxyethyl)-6-methylpyrrolo[3,4-e]indole-1,3(2H,6H)-dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00732": {"dbids": ["APRD00806", "DB00732"], "name": "Atracurium besylate", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q15822", "drug": "DB00732"}]}, "DB00731": {"dbids": ["APRD00593", "DB00731"], "name": "Nateglinide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q09428", "drug": "DB00731"}, {"action": "AGONIST", "target": "P37231", "drug": "DB00731"}]}, "DB06401": {"dbids": ["DB06401"], "name": "Bazedoxifene", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P03372", "drug": "DB06401"}, {"action": "AGONIST", "target": "P03372", "drug": "DB06401"}]}, "DB00730": {"dbids": ["APRD01252", "DB00730", "DB08630"], "name": "Thiabendazole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00363", "drug": "DB00730"}]}, "DB02891": {"dbids": ["DB02891", "EXPT00658"], "name": "Tricyclazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04434": {"dbids": ["DB04434", "EXPT00199"], "name": "Naphthyridine Inhibitor", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00737": {"dbids": ["APRD00354", "DB00737"], "name": "Meclizine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00737"}]}, "DB00736": {"dbids": ["APRD00363", "DB00736"], "name": "Esomeprazole", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P20648", "drug": "DB00736"}]}, "DB07256": {"dbids": ["DB07256"], "name": "3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00735": {"dbids": ["APRD01131", "DB00735"], "name": "Naftifine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14534", "drug": "DB00735"}]}, "DB00734": {"dbids": ["APRD00187", "DB00734"], "name": "Risperidone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P28223", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P28221", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00734"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00734"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00734"}]}, "DB01606": {"dbids": ["DB01606", "EXPT03012"], "name": "Tazobactam", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0AD63", "drug": "DB01606"}, {"action": "INHIBITOR", "target": "P62594", "drug": "DB01606"}]}, "DB02897": {"dbids": ["DB02897", "EXPT03212"], "name": "Acetylphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07251": {"dbids": ["DB07251"], "name": "N'-(3-CHLORO-4-METHOXY-PHENYL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07250": {"dbids": ["DB07250"], "name": "N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3,4,5- TRIMETHOXYPHENYL)PYRIMIDINE-2,4-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08558": {"dbids": ["DB08558"], "name": "2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07318": {"dbids": ["DB07318"], "name": "N-[2-(4-AMINO-5,8-DIFLUORO-1,2-DIHYDROQUINAZOLIN-2-YL)ETHYL]-3-FURAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07319": {"dbids": ["DB07319"], "name": "6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07648": {"dbids": ["DB07648"], "name": "(2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07649": {"dbids": ["DB07649"], "name": "(3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(benzylsulfanyl)methyl]pyrrolidin-3-ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07314": {"dbids": ["DB07314"], "name": "1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07315": {"dbids": ["DB07315"], "name": "5-chloro-N-{4-[(1R)-1,2-dihydroxyethyl]phenyl}-1H-indole-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07316": {"dbids": ["DB07316"], "name": "N-{1-[(1-carbamoylcyclopropyl)methyl]piperidin-4-yl}-N-cyclopropyl-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07317": {"dbids": ["DB07317"], "name": "(3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07310": {"dbids": ["DB07310"], "name": "(5S)-2-{[(1S)-1-(2-fluorophenyl)ethyl]amino}-5-methyl-5-(trifluoromethyl)-1,3-thiazol-4(5H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07311": {"dbids": ["DB07311"], "name": "18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07312": {"dbids": ["DB07312"], "name": "2,5-DICHLORO-N-(5-CHLORO-1,3-BENZOXAZOL-2-YL)BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07313": {"dbids": ["DB07313"], "name": "5-METHYL-2-[(PHENYLSULFONYL)AMINO]BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07253": {"dbids": ["DB07253"], "name": "N'-(5-chloro-1,3-benzodioxol-4-yl)-N-(3-methylsulfonylphenyl)pyrimidine-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06441": {"dbids": ["DB06441"], "name": "Cangrelor", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9H244", "drug": "DB06441"}]}, "DB07354": {"dbids": ["DB07354"], "name": "2,3-DIMETHOXY-12H-[1,3]DIOXOLO[5,6]INDENO[1,2-C]ISOQUINOLIN-6-IUM", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02928": {"dbids": ["DB02928", "EXPT03140"], "name": "3-Amino-6-Hydroxy-Tyrosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02929": {"dbids": ["DB02929", "EXPT01958"], "name": "K201", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02920": {"dbids": ["DB02920", "EXPT03285"], "name": "Zn(Ii)-(20-Oxo-Protoporphyrin Ix)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02921": {"dbids": ["DB02921", "EXPT02872"], "name": "(South)-Methanocarba-Thymidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02922": {"dbids": ["DB02922", "EXPT01390"], "name": "Hexafluoroacetone Hydrate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02923": {"dbids": ["DB02923", "EXPT00746"], "name": "Biphenyl-2,3-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02924": {"dbids": ["DB02924", "EXPT02019"], "name": "D-Limonene 1,2-Epoxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02925": {"dbids": ["DB02925", "EXPT03308"], "name": "Piretanide", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "Q13621", "drug": "DB02925"}]}, "DB02927": {"dbids": ["DB02927", "EXPT01262"], "name": "Mixed Carbamic Phosphoric Acid Anhydride of 7,8-Diaminononanic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06404": {"dbids": ["DB06404"], "name": "C1 Esterase Inhibitor (Human)", "groups": ["APPROVED"], "targets": []}, "DB07356": {"dbids": ["DB07356"], "name": "(1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-ETHYNYLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07644": {"dbids": ["DB07644"], "name": "5-[(1S)-1-(3-chlorophenyl)ethoxy]quinazoline-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03528": {"dbids": ["DB03528", "EXPT03264"], "name": "9-Beta-D-Xylofuranosyl-Adenine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07645": {"dbids": ["DB07645"], "name": "SEBACIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03523": {"dbids": ["DB03523", "EXPT00752"], "name": "6-Fluoro-2-(2'-Fluoro-1,1'-Biphenyl-4-Yl)-3-Methylquinoline-4-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03522": {"dbids": ["DB03522", "EXPT00567"], "name": "Aspartic Acid-4-Carboxymethyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03520": {"dbids": ["DB03520", "EXPT00896"], "name": "6-Chloro-2-Fluoropurine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03526": {"dbids": ["DB03526", "EXPT00493"], "name": "AL5927", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03525": {"dbids": ["DB03525", "EXPT00304"], "name": "RU79073", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03524": {"dbids": ["DB03524", "EXPT01953"], "name": "N-{3-[4-(3-Amino-Propyl)-Piperazin-1-Yl]-Propyl}-3-(2-Thiophen-2-Yl-Acetylamino)-5-(3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yloxy)-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01324": {"dbids": ["DB01324"], "name": "Polythiazide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P55017", "drug": "DB01324"}]}, "DB05253": {"dbids": ["DB05253"], "name": "Proellex", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05252": {"dbids": ["DB05252"], "name": "ACCLAIM", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05251": {"dbids": ["DB05251"], "name": "VRX496", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05250": {"dbids": ["DB05250"], "name": "681323", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05257": {"dbids": ["DB05257"], "name": "Neocartilage", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05256": {"dbids": ["DB05256"], "name": "659032", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05255": {"dbids": ["DB05255"], "name": "751689", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05254": {"dbids": ["DB05254"], "name": "Plasmin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05259": {"dbids": ["APRD00999", "DB05259"], "name": "Glatiramer Acetate", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "BINDER", "target": "P04229", "drug": "DB05259"}]}, "DB05258": {"dbids": ["DB05258"], "name": "Natural alpha interferon", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB01323": {"dbids": ["DB01323"], "name": "St. John's Wort", "groups": ["NUTRACEUTICAL"], "targets": []}, "DB07643": {"dbids": ["DB07643"], "name": "5-{[1-(2,3-dichlorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04770": {"dbids": ["DB04770"], "name": "O6-(R)-ROSCOVITINE, R-2-(6-BENZYLOXY-9-ISOPROPYL-9H-PURIN-2-YLAMINO)-BUTAN-1-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01322": {"dbids": ["DB01322"], "name": "Kava", "groups": ["NUTRACEUTICAL"], "targets": []}, "DB04777": {"dbids": ["DB04777"], "name": "(R)-4-Nitrostyrene oxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08999": {"dbids": ["DB08999"], "name": "Cyclopentamine", "groups": ["WITHDRAWN"], "targets": []}, "DB08998": {"dbids": ["DB08998"], "name": "Demexiptiline", "groups": ["APPROVED"], "targets": []}, "DB08997": {"dbids": ["DB08997"], "name": "Dexetimide", "groups": ["WITHDRAWN"], "targets": []}, "DB08996": {"dbids": ["DB08996"], "name": "Dimetacrine", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P22303", "drug": "DB08996"}]}, "DB08995": {"dbids": ["DB08995"], "name": "Diosmin", "groups": ["APPROVED"], "targets": []}, "DB08994": {"dbids": ["DB08994"], "name": "Ditazole", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB00746": {"dbids": ["APRD00904", "DB00746"], "name": "Deferoxamine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB08992": {"dbids": ["DB08992"], "name": "Eperisone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB08991": {"dbids": ["DB08991"], "name": "Epirizole", "groups": ["APPROVED"], "targets": []}, "DB08990": {"dbids": ["DB08990"], "name": "Eprazinone", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB01321": {"dbids": ["DB01321"], "name": "Josamycin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P44345", "drug": "DB01321"}]}, "DB04776": {"dbids": ["DB04776"], "name": "N6-METHYL-(R)-ROSCOVITINE, R-2-[6-(BENZYL-METHYL-AMINO)-9-ISOPROPYL-9H-PURIN-2-YLAMINO]-BUTAN-1-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06212": {"dbids": ["DB06212"], "name": "Tolvaptan", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P30518", "drug": "DB06212"}, {"action": "ANTAGONIST", "target": "P37288", "drug": "DB06212"}]}, "DB00747": {"dbids": ["APRD00616", "DB00747"], "name": "Scopolamine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00747"}, {"action": "INHIBITOR", "target": "P14410", "drug": "DB00747"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00747"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00747"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00747"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00747"}]}, "DB01320": {"dbids": ["DB01320"], "name": "Fosphenytoin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB01320"}]}, "DB06213": {"dbids": ["DB06213"], "name": "Regadenoson", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P29274", "drug": "DB06213"}]}, "DB00744": {"dbids": ["APRD00265", "DB00744"], "name": "Zileuton", "groups": ["APPROVED", "INVESTIGATIONAL", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P09917", "drug": "DB00744"}]}, "DB06210": {"dbids": ["DB06210"], "name": "Eltrombopag", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P40238", "drug": "DB06210"}]}, "DB00745": {"dbids": ["APRD00534", "DB00745"], "name": "Modafinil", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q01959", "drug": "DB00745"}, {"action": "PARTIAL AGONIST", "target": "P35368", "drug": "DB00745"}]}, "DB06211": {"dbids": ["DB06211"], "name": "Doripenem", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P02918", "drug": "DB06211"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB06211"}, {"action": "ANTAGONIST", "target": "P02919", "drug": "DB06211"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB06211"}, {"action": "ANTAGONIST", "target": "P0AD65", "drug": "DB06211"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB06211"}, {"action": "ANTAGONIST", "target": "Q51504", "drug": "DB06211"}, {"action": "INHIBITOR", "target": "Q51504", "drug": "DB06211"}, {"action": "ANTAGONIST", "target": "P72355", "drug": "DB06211"}, {"action": "INHIBITOR", "target": "P72355", "drug": "DB06211"}]}, "DB00742": {"dbids": ["APRD01083", "DB00742", "EXPT02246"], "name": "Mannitol", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB06216": {"dbids": ["DB06216"], "name": "Asenapine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P47898", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P25021", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB06216"}]}, "DB09169": {"dbids": ["DB09169"], "name": "3-Allylfentanyl", "groups": ["ILLICIT"], "targets": []}, "DB09168": {"dbids": ["DB09168"], "name": "4-Phenylfentanyl", "groups": ["ILLICIT"], "targets": []}, "DB00743": {"dbids": ["APRD00989", "DB00743"], "name": "Gadobenate Dimeglumine", "groups": ["APPROVED"], "targets": []}, "DB09161": {"dbids": ["DB09161"], "name": "Technetium Tc-99m sestamibi", "groups": ["APPROVED"], "targets": []}, "DB09160": {"dbids": ["DB09160"], "name": "Technetium Tc-99m tetrofosmin", "groups": ["APPROVED"], "targets": []}, "DB09163": {"dbids": ["DB09163"], "name": "Technetium Tc-99m exametazime", "groups": ["APPROVED"], "targets": []}, "DB09162": {"dbids": ["DB09162"], "name": "Ferric Citrate", "groups": ["APPROVED"], "targets": []}, "DB09165": {"dbids": ["DB09165"], "name": "Technetium Tc-99m pyrophosphate", "groups": ["APPROVED"], "targets": []}, "DB09164": {"dbids": ["DB09164"], "name": "Technetium Tc-99m disofenin", "groups": ["APPROVED"], "targets": []}, "DB09167": {"dbids": ["DB09167"], "name": "Dosulepin", "groups": ["APPROVED"], "targets": []}, "DB01319": {"dbids": ["DB01319"], "name": "Fosamprenavir", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q72874", "drug": "DB01319"}]}, "DB00741": {"dbids": ["APRD01019", "DB00741", "DB07886"], "name": "Hydrocortisone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00741"}, {"action": "AGONIST", "target": "P04083", "drug": "DB00741"}]}, "DB07599": {"dbids": ["DB07599"], "name": "[(2-AMINO-ALPHA-METHOXYIMINO-4-THIAZOLYLACETYL)AMINO]METHYLBORONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00373": {"dbids": ["APRD00229", "DB00373", "DB08625"], "name": "Timolol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB00373"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00373"}]}, "DB00372": {"dbids": ["APRD00323", "DB00372"], "name": "Thiethylperazine", "groups": ["WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB00372"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00372"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB00372"}]}, "DB00371": {"dbids": ["APRD01095", "DB00371"], "name": "Meprobamate", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P14867", "drug": "DB00371"}, {"action": "AGONIST", "target": "P47869", "drug": "DB00371"}, {"action": "AGONIST", "target": "P34903", "drug": "DB00371"}, {"action": "AGONIST", "target": "P48169", "drug": "DB00371"}, {"action": "AGONIST", "target": "P31644", "drug": "DB00371"}, {"action": "AGONIST", "target": "Q16445", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00371"}]}, "DB00370": {"dbids": ["APRD00685", "DB00370"], "name": "Mirtazapine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P28223", "drug": "DB00370"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00370"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00370"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00370"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00370"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00370"}, {"action": "BINDER", "target": "P18825", "drug": "DB00370"}, {"action": "BINDING", "target": "P34969", "drug": "DB00370"}, {"action": "BINDER", "target": "P35348", "drug": "DB00370"}, {"action": "BINDER", "target": "P35368", "drug": "DB00370"}, {"action": "BINDER", "target": "P25100", "drug": "DB00370"}, {"action": "BINDER", "target": "P14416", "drug": "DB00370"}, {"action": "BINDER", "target": "P23975", "drug": "DB00370"}, {"action": "BINDER", "target": "P31645", "drug": "DB00370"}, {"action": "BINDER", "target": "Q01959", "drug": "DB00370"}, {"action": "BINDER", "target": "P41595", "drug": "DB00370"}, {"action": "BINDER", "target": "P21728", "drug": "DB00370"}, {"action": "BINDER", "target": "P21918", "drug": "DB00370"}, {"action": "ANTAGONIST", "target": "Q9Y5N1", "drug": "DB00370"}, {"action": "BINDER", "target": "P35348", "drug": "DB00370"}, {"action": "BINDER", "target": "P08588", "drug": "DB00370"}, {"action": "BINDER", "target": "P07550", "drug": "DB00370"}]}, "DB00377": {"dbids": ["APRD00351", "DB00377"], "name": "Palonosetron", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P46098", "drug": "DB00377"}]}, "DB00376": {"dbids": ["APRD00070", "DB00376"], "name": "Trihexyphenidyl", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00376"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00376"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00376"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00376"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00376"}]}, "DB00375": {"dbids": ["APRD00884", "DB00375"], "name": "Colestipol", "groups": ["APPROVED"], "targets": []}, "DB00374": {"dbids": ["APRD01272", "DB00374"], "name": "Treprostinil", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P43119", "drug": "DB00374"}, {"action": "AGONIST", "target": "Q03181", "drug": "DB00374"}, {"action": "AGONIST", "target": "Q9H244", "drug": "DB00374"}]}, "DB08690": {"dbids": ["DB08690"], "name": "UBIQUINONE-2", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08691": {"dbids": ["DB08691"], "name": "ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00379": {"dbids": ["APRD00242", "DB00379"], "name": "Mexiletine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB00379"}, {"action": "AGONIST", "target": "P35869", "drug": "DB00379"}]}, "DB00378": {"dbids": ["APRD00941", "DB00378"], "name": "Dydrogesterone", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "AGONIST", "target": "P06401", "drug": "DB00378"}]}, "DB08694": {"dbids": ["DB08694"], "name": "9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidin-4-ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08695": {"dbids": ["DB08695"], "name": "3-(4-nitrophenyl)-1H-pyrazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08696": {"dbids": ["DB08696"], "name": "5-{2-[1-(1-METHYL-PROPYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-2-METHYLENE-CYCLOHEXANE-1,3-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08697": {"dbids": ["DB08697"], "name": "4-(2-aminoethoxy)-N-(3-chloro-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03310": {"dbids": ["DB03310", "EXPT01575"], "name": "Oxidized Glutathione Disulfide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03311": {"dbids": ["DB03311", "EXPT01493"], "name": "3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03312": {"dbids": ["DB03312", "EXPT00783"], "name": "5-Bromovinyldeoxyuridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03313": {"dbids": ["DB03313", "EXPT01031"], "name": "Cephalosporin C", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB03313"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB03313"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB03313"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB03313"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB03313"}]}, "DB03314": {"dbids": ["DB03314", "EXPT01505"], "name": "Fluorotryptophane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03315": {"dbids": ["DB03315", "EXPT00169"], "name": "Guanosine-3'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03316": {"dbids": ["DB03316", "EXPT01208"], "name": "1,4-Diethylene Dioxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03317": {"dbids": ["DB03317", "EXPT01722"], "name": "Heme C", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03318": {"dbids": ["DB03318", "EXPT00075"], "name": "6-Hydro-1-Methyladenosine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03319": {"dbids": ["DB03319", "EXPT00882"], "name": "(S)-ATPA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04504": {"dbids": ["DB04504", "EXPT03253"], "name": "(3s)-2,3,4,5-Tetrahydropyridin-3-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04505": {"dbids": ["DB04505", "EXPT02699"], "name": "8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04506": {"dbids": ["DB04506", "EXPT00908"], "name": "Chlorophyll B", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04851": {"dbids": ["DB04851"], "name": "Biricodar dicitrate", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04500": {"dbids": ["DB04500", "EXPT03145"], "name": "4-acetamidobenzoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04501": {"dbids": ["DB04501", "EXPT00824"], "name": "Camphane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04502": {"dbids": ["DB04502", "EXPT03235"], "name": "WRR-204", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04503": {"dbids": ["DB04503", "EXPT03086"], "name": "Sp-722", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04858": {"dbids": ["DB04858"], "name": "Tirapazamine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04859": {"dbids": ["DB04859"], "name": "Zanapezil", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04508": {"dbids": ["DB04508", "EXPT03243"], "name": "Methyl(6s)-1-Thio-L-Manno-Hexodialdo-6,2-Pyranoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04509": {"dbids": ["DB04509", "EXPT02359"], "name": "N-Methylnaloxonium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08342": {"dbids": ["DB08342"], "name": "S-PALMITOYL-L-CYSTEINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02234": {"dbids": ["DB02234", "EXPT01944"], "name": "Ethylisothiourea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08340": {"dbids": ["DB08340"], "name": "N,N'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08341": {"dbids": ["DB08341"], "name": "4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08346": {"dbids": ["DB08346"], "name": "(5Z)-13-CHLORO-14,16-DIHYDROXY-3,4,7,8,9,10-HEXAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,11(12H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08347": {"dbids": ["DB08347"], "name": "4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08344": {"dbids": ["DB08344"], "name": "4-chloro-N-(3-methoxypropyl)-N-[(3S)-1-(2-phenylethyl)piperidin-3-yl]benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02235": {"dbids": ["DB02235", "EXPT02921"], "name": "Methionine Sulfoxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08348": {"dbids": ["DB08348"], "name": "N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08349": {"dbids": ["DB08349"], "name": "N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02236": {"dbids": ["DB02236", "EXPT01547"], "name": "Glycinamide Ribonucleotide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02237": {"dbids": ["DB02237", "EXPT02252"], "name": "Maltotetraose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00199": {"dbids": ["APRD00953", "DB00199"], "name": "Erythromycin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P61177", "drug": "DB00199"}, {"action": "INHIBITOR", "target": "P60725", "drug": "DB00199"}]}, "DB00198": {"dbids": ["APRD01148", "DB00198"], "name": "Oseltamivir", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P11485", "drug": "DB00198"}, {"action": "OTHER", "target": "P23141", "drug": "DB00198"}, {"action": "INHIBITOR", "target": "Q99519", "drug": "DB00198"}, {"action": "INHIBITOR", "target": "Q9Y3R4", "drug": "DB00198"}]}, "DB00197": {"dbids": ["APRD00488", "DB00197"], "name": "Troglitazone", "groups": ["WITHDRAWN"], "targets": [{"action": "AGONIST", "target": "P37231", "drug": "DB00197"}, {"action": "INHIBITOR", "target": "O60488", "drug": "DB00197"}, {"action": "ANTAGONIST", "target": "P05121", "drug": "DB00197"}, {"action": "INHIBITOR", "target": "Q99808", "drug": "DB00197"}, {"action": "INVERSE AGONIST", "target": "P62508", "drug": "DB00197"}, {"action": "INVERSE AGONIST", "target": "P11474", "drug": "DB00197"}]}, "DB00196": {"dbids": ["APRD00327", "DB00196"], "name": "Fluconazole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P10613", "drug": "DB00196"}]}, "DB00195": {"dbids": ["APRD00245", "DB00195"], "name": "Betaxolol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB00195"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00195"}]}, "DB00194": {"dbids": ["APRD00333", "DB00194", "EXPT02753"], "name": "Vidarabine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P03198", "drug": "DB00194"}, {"action": "INDUCER", "target": "P09250", "drug": "DB00194"}, {"action": "INDUCER", "target": "Q9QNF7", "drug": "DB00194"}]}, "DB00193": {"dbids": ["APRD00028", "DB00193"], "name": "Tramadol", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB00193"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00193"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00193"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00193"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00193"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00193"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00193"}, {"action": "ANTAGONIST", "target": "Q693P7", "drug": "DB00193"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00193"}]}, "DB00192": {"dbids": ["APRD01032", "DB00192"], "name": "Indecainide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB00192"}]}, "DB00191": {"dbids": ["APRD00093", "DB00191"], "name": "Phentermine", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "INHIBITOR", "target": "P23975", "drug": "DB00191"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00191"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00191"}, {"action": "ANTAGONIST", "target": "P21397", "drug": "DB00191"}, {"action": "ANTAGONIST", "target": "P27338", "drug": "DB00191"}]}, "DB00190": {"dbids": ["APRD00160", "DB00190"], "name": "Carbidopa", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P20711", "drug": "DB00190"}]}, "DB02232": {"dbids": ["DB02232", "EXPT00830"], "name": "1,2-Dihydroxybenzene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02233": {"dbids": ["DB02233", "EXPT01147"], "name": "6-Hydroxy-D-Norleucine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09228": {"dbids": ["DB09228"], "name": "Conestat alfa", "groups": ["APPROVED"], "targets": []}, "DB06103": {"dbids": ["DB06103"], "name": "VX-148", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB00997": {"dbids": ["APRD00185", "DB00997"], "name": "Doxorubicin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P11388", "drug": "DB00997"}]}, "DB00996": {"dbids": ["APRD00015", "DB00996"], "name": "Gabapentin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P54289", "drug": "DB00996"}, {"action": "INHIBITOR", "target": "Q9NY47", "drug": "DB00996"}, {"action": "INHIBITOR", "target": "Q00975", "drug": "DB00996"}, {"action": "AGONIST", "target": "P30542", "drug": "DB00996"}]}, "DB00995": {"dbids": ["APRD00808", "DB00995"], "name": "Auranofin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P30044", "drug": "DB00995"}, {"action": "INHIBITOR", "target": "O14920", "drug": "DB00995"}]}, "DB00994": {"dbids": ["APRD00013", "DB00994"], "name": "Neomycin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A7S3", "drug": "DB00994"}]}, "DB00993": {"dbids": ["APRD00811", "DB00993"], "name": "Azathioprine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00492", "drug": "DB00993"}]}, "DB00992": {"dbids": ["APRD01105", "DB00992"], "name": "Methyl aminolevulinate", "groups": ["APPROVED"], "targets": [{"action": "ANTIBODY", "target": "P12314", "drug": "DB00992"}]}, "DB00991": {"dbids": ["APRD00030", "DB00991"], "name": "Oxaprozin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23219", "drug": "DB00991"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00991"}]}, "DB00990": {"dbids": ["APRD00144", "DB00990"], "name": "Exemestane", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P11511", "drug": "DB00990"}]}, "DB06101": {"dbids": ["DB06101"], "name": "IMC-1C11", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB00999": {"dbids": ["APRD00092", "DB00999"], "name": "Hydrochlorothiazide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P55017", "drug": "DB00999"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00999"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00999"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00999"}, {"action": "INHIBITOR", "target": "Q16790", "drug": "DB00999"}, {"action": "INHIBITOR", "target": "O43570", "drug": "DB00999"}, {"action": "OTHER/UNKNOWN", "target": "Q12791", "drug": "DB00999"}]}, "DB00998": {"dbids": ["APRD00270", "DB00998"], "name": "Frovatriptan", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P28221", "drug": "DB00998"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00998"}]}, "DB01257": {"dbids": ["DB01257"], "name": "Eculizumab", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTIBODY", "target": "P01031", "drug": "DB01257"}]}, "DB02049": {"dbids": ["DB02049", "EXPT00849"], "name": "2-{4-[4-(4-Chloro-Phenoxy)-Benzenesulfonyl]-Tetrahydro-Pyran-4-Yl}-N-Hydroxy-Acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02048": {"dbids": ["DB02048", "EXPT03150"], "name": "1,2,4-Triazole-Carboxamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02047": {"dbids": ["DB02047", "EXPT00679"], "name": "2-(1,1'-Biphenyl-4-Yl)Propanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02046": {"dbids": ["DB02046", "EXPT01449"], "name": "N-[(Furan-2-Yl)Carbonyl]-(S)-Leucyl-(R)-[1-Amino-2(1h-Indol-3-Yl)Ethyl]-Phosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02045": {"dbids": ["DB02045", "EXPT00510"], "name": "Amylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02044": {"dbids": ["DB02044", "EXPT00036"], "name": "N-(3-(Aminomethyl)Benzyl)Acetamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02043": {"dbids": ["DB02043", "EXPT02025"], "name": "1,2-Dipalmitoyl-Phosphatidyl-Glycerole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02042": {"dbids": ["DB02042", "EXPT00082"], "name": "2-(2-{2-[2-(2-Methoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02041": {"dbids": ["DB02041", "EXPT00549"], "name": "4-Aminophthalhydrazide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01254": {"dbids": ["DB01254"], "name": "Dasatinib", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "MULTITARGET", "target": "P00519", "drug": "DB01254"}, {"action": "MULTITARGET", "target": "P12931", "drug": "DB01254"}, {"action": "ANTAGONIST", "target": "P29317", "drug": "DB01254"}, {"action": "MULTITARGET", "target": "P06239", "drug": "DB01254"}, {"action": "INHIBITOR", "target": "P07947", "drug": "DB01254"}, {"action": "ANTAGONIST", "target": "P10721", "drug": "DB01254"}, {"action": "ANTAGONIST", "target": "P09619", "drug": "DB01254"}, {"action": "INHIBITOR", "target": "P51692", "drug": "DB01254"}, {"action": "MULTITARGET", "target": "P42684", "drug": "DB01254"}, {"action": "MULTITARGET", "target": "P06241", "drug": "DB01254"}]}, "DB01253": {"dbids": ["DB01253"], "name": "Ergonovine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35348", "drug": "DB01253"}]}, "DB01252": {"dbids": ["DB01252"], "name": "Mitiglinide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q09428", "drug": "DB01252"}, {"action": "AGONIST", "target": "P37231", "drug": "DB01252"}]}, "DB01251": {"dbids": ["DB01251"], "name": "Gliquidone", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q09428", "drug": "DB01251"}, {"action": "INHIBITOR", "target": "Q15842", "drug": "DB01251"}]}, "DB01250": {"dbids": ["DB01250"], "name": "Olsalazine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P51580", "drug": "DB01250"}]}, "DB01077": {"dbids": ["APRD00964", "DB01077"], "name": "Etidronic acid", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q13332", "drug": "DB01077"}, {"action": "INHIBITOR", "target": "P38606", "drug": "DB01077"}]}, "DB04772": {"dbids": ["DB04772"], "name": "1-GUANIDINO-4-(N-PHENYLMETHANESULFONYL-L-LEUCYL-L-PROLYLAMINO)BUTANE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01075": {"dbids": ["APRD00587", "DB01075", "DB06975"], "name": "Diphenhydramine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB01075"}]}, "DB02599": {"dbids": ["DB02599", "EXPT00543"], "name": "2,6-Diamino-8-Propylsulfanylmethyl-3h-Quinazoline-4-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02598": {"dbids": ["DB02598", "EXPT01950"], "name": "N-Alpha-Acetyl-3,5-Diiodotyrosylglycine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02269": {"dbids": ["DB02269", "EXPT01864"], "name": "[4-({[5-Benzyloxy-1-(3-Carbamimidoyl-Benzyl)-1h-Indole-2-Carbonyl]-Amino}-Methyl)-Phenyl]-Trimethyl-Ammonium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02268": {"dbids": ["DB02268", "EXPT02960"], "name": "4-(Acetylamino)-3-Amino Benzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02263": {"dbids": ["DB02263", "EXPT01530"], "name": "Glyceraldehyde-3-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02262": {"dbids": ["DB02262", "EXPT02447"], "name": "Orotic Acid", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P05020", "drug": "DB02262"}]}, "DB02261": {"dbids": ["DB02261", "EXPT02559"], "name": "Platelet Activating Factor", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02260": {"dbids": ["DB02260", "EXPT00224"], "name": "4-Oxosebacic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02267": {"dbids": ["DB02267", "EXPT00565"], "name": "Argininosuccinate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02266": {"dbids": ["DB02266", "EXPT01442"], "name": "Flufenamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02265": {"dbids": ["DB02265", "EXPT00892"], "name": "Ethyl-Trimethyl-Silane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02264": {"dbids": ["DB02264", "EXPT01843"], "name": "O2-Sulfo-Glucuronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04775": {"dbids": ["DB04775"], "name": "Reidispongiolide C", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01070": {"dbids": ["APRD00143", "DB01070"], "name": "Dihydrotachysterol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P11473", "drug": "DB01070"}]}, "DB00426": {"dbids": ["APRD00600", "DB00426"], "name": "Famciclovir", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P04293", "drug": "DB00426"}, {"action": "INHIBITOR", "target": "P09252", "drug": "DB00426"}]}, "DB07273": {"dbids": ["DB07273"], "name": "1-[(2-AMINO-4-CHLORO-5-METHYLPHENYL)SULFONYL]-L-PROLINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08596": {"dbids": ["DB08596"], "name": "5'-deoxy-5'-piperidin-1-ylthymidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01146": {"dbids": ["APRD00719", "DB01146"], "name": "Diphenylpyraline", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB01146"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB01146"}]}, "DB00425": {"dbids": ["APRD00095", "DB00425"], "name": "Zolpidem", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00425"}, {"action": "AGONIST", "target": "P47869", "drug": "DB00425"}, {"action": "AGONIST", "target": "P34903", "drug": "DB00425"}]}, "DB07272": {"dbids": ["DB07272"], "name": "N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05068": {"dbids": ["DB05068"], "name": "ATG002", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05069": {"dbids": ["DB05069"], "name": "ATG003", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07271": {"dbids": ["DB07271"], "name": "(3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-(2,2,2-TRIFLUOROETHYL)-1,4-DIAZEPAN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05060": {"dbids": ["DB05060"], "name": "R1626", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05061": {"dbids": ["DB05061"], "name": "GFT14", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05062": {"dbids": ["DB05062"], "name": "INCB9471", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05063": {"dbids": ["DB05063"], "name": "Mitoquinone", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05064": {"dbids": ["DB05064"], "name": "INCB13739", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05065": {"dbids": ["DB05065"], "name": "PHX1149", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05066": {"dbids": ["DB05066"], "name": "AV411", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08507": {"dbids": ["DB08507"], "name": "N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07587": {"dbids": ["DB07587"], "name": "N-(1-CYANOCYCLOPROPYL)-3-({[(2S)-5-OXOPYRROLIDIN-2-YL]METHYL}SULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)ETHYL]-L-ALANINAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07270": {"dbids": ["DB07270"], "name": "N-[7-(3-AMINOPHENYL)-5-METHOXY-1,3-BENZOXAZOL-2-YL]-2,5-DICHLOROBENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06865": {"dbids": ["DB06865"], "name": "6-CARBAMIMIDOYL-2-[2-HYDROXY-6-(4-HYDROXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01819": {"dbids": ["DB01819", "EXPT02550"], "name": "Phosphoenolpyruvate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01818": {"dbids": ["DB01818", "EXPT02894"], "name": "O3-Sulfonylgalactose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01769": {"dbids": ["DB01769", "EXPT01040"], "name": "Double Oxidized Cysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01768": {"dbids": ["DB01768", "EXPT02257"], "name": "Methylumbelliferyl Sialic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01767": {"dbids": ["DB01767", "EXPT00622"], "name": "Hemi-Babim", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01766": {"dbids": ["DB01766", "EXPT02291"], "name": "Beta-(2-Naphthyl)-Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01765": {"dbids": ["DB01765", "EXPT01927"], "name": "(5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01764": {"dbids": ["DB01764", "EXPT01246"], "name": "Dalfopristin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P50870", "drug": "DB01764"}]}, "DB01763": {"dbids": ["DB01763", "EXPT03005"], "name": "Tatp", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01762": {"dbids": ["DB01762", "DB04025", "EXPT00381"], "name": "Acetoacetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01761": {"dbids": ["DB01761", "EXPT00004"], "name": "4-[5-[2-(1-Phenyl-Ethylamino)-Pyrimidin-4-Yl]-1-Methyl-4-(3-Trifluoromethylphenyl)-1h-Imidazol-2-Yl]-Piperidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01760": {"dbids": ["DB01760", "EXPT01926"], "name": "2-Methoxy-3-Isopropylpyrazine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07586": {"dbids": ["DB07586"], "name": "5-(4-METHYL-BENZOYLAMINO)-BIPHENYL-3,4'-DICARBOXYLIC ACID 3-DIMETHYLAMIDE-4'-HYDROXYAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06866": {"dbids": ["DB06866"], "name": "6-CARBAMIMIDOYL-2-[2-HYDROXY-5-(3-METHOXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06861": {"dbids": ["DB06861"], "name": "6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07277": {"dbids": ["DB07277"], "name": "2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHANESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06860": {"dbids": ["DB06860"], "name": "2-(2-chloropyridin-4-yl)-4-methyl-1H-isoindole-1,3(2H)-dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06862": {"dbids": ["DB06862"], "name": "2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07589": {"dbids": ["DB07589"], "name": "N-[1-(AMINOMETHYL)CYCLOPROPYL]-3-(BENZYLSULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-HYDROXYPHENYL)ETHYL]-L-ALANINAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07276": {"dbids": ["DB07276"], "name": "5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01109": {"dbids": ["APRD00056", "DB01109"], "name": "Heparin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "POTENTIATOR", "target": "P01008", "drug": "DB01109"}, {"action": "INHIBITOR", "target": "P00742", "drug": "DB01109"}, {"action": "INHIBITOR", "target": "P16109", "drug": "DB01109"}]}, "DB01108": {"dbids": ["APRD01276", "DB01108"], "name": "Trilostane", "groups": ["APPROVED", "INVESTIGATIONAL", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P14060", "drug": "DB01108"}, {"action": "INHIBITOR", "target": "P26439", "drug": "DB01108"}, {"action": "ALLOSTERIC MODULATOR", "target": "P03372", "drug": "DB01108"}, {"action": "ALLOSTERIC MODULATOR", "target": "Q92731", "drug": "DB01108"}]}, "DB01103": {"dbids": ["APRD00317", "DB01103"], "name": "Quinacrine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "O60733", "drug": "DB01103"}, {"action": "INHIBITOR", "target": "P47712", "drug": "DB01103"}, {"action": "INHIBITOR", "target": "Q15111", "drug": "DB01103"}]}, "DB01102": {"dbids": ["APRD00802", "DB01102"], "name": "Arbutamine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P08588", "drug": "DB01102"}, {"action": "AGONIST", "target": "P07550", "drug": "DB01102"}, {"action": "AGONIST", "target": "P13945", "drug": "DB01102"}]}, "DB01101": {"dbids": ["APRD00203", "DB01101"], "name": "Capecitabine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P04818", "drug": "DB01101"}]}, "DB01100": {"dbids": ["APRD00218", "DB01100"], "name": "Pimozide", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB01100"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB01100"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB01100"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB01100"}]}, "DB01107": {"dbids": ["APRD00734", "DB01107"], "name": "Methyprylon", "groups": ["APPROVED", "ILLICIT", "WITHDRAWN"], "targets": [{"action": "AGONIST", "target": "P14867", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01107"}]}, "DB01106": {"dbids": ["APRD01069", "DB01106"], "name": "Levocabastine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB01106"}, {"action": "PARTIAL ANTAGONIST", "target": "O95665", "drug": "DB01106"}]}, "DB01105": {"dbids": ["APRD00456", "DB01105"], "name": "Sibutramine", "groups": ["APPROVED", "ILLICIT", "INVESTIGATIONAL", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P23975", "drug": "DB01105"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB01105"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB01105"}]}, "DB01104": {"dbids": ["APRD00175", "DB01104"], "name": "Sertraline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P31645", "drug": "DB01104"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB01104"}]}, "DB07275": {"dbids": ["DB07275"], "name": "3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1-(3-methylbutyl)quinolin-2(1H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07664": {"dbids": ["DB07664"], "name": "5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07274": {"dbids": ["DB07274"], "name": "N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09198": {"dbids": ["DB09198"], "name": "Lobeglitazone", "groups": ["APPROVED"], "targets": []}, "DB04044": {"dbids": ["DB04044", "EXPT00061"], "name": "4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09199": {"dbids": ["DB09199"], "name": "Netoglitazone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07666": {"dbids": ["DB07666"], "name": "(3R,4S)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07336": {"dbids": ["DB07336"], "name": "4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07337": {"dbids": ["DB07337"], "name": "4-[4-AMINO-6-(5-CHLORO-1H-INDOL-4-YLMETHYL)-[1,3,5]TRIAZIN-2-YLAMINO]-BENZONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07334": {"dbids": ["DB07334"], "name": "N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07335": {"dbids": ["DB07335"], "name": "3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07332": {"dbids": ["DB07332"], "name": "ALPHA-(2,6-DICHLOROPHENYL)-ALPHA-(2-ACETYL-5-METHYLANILINO)ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07333": {"dbids": ["DB07333"], "name": "N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07330": {"dbids": ["DB07330"], "name": "trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07331": {"dbids": ["DB07331"], "name": "2-(4-NITROPHENYL)ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07338": {"dbids": ["DB07338"], "name": "5-[2-CHLORO-4-(TRIFLUOROMETHYL)PHENOXY]-2-NITROBENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07339": {"dbids": ["DB07339"], "name": "(3S)-3-hydroxy-1-methyl-2,3-dihydro-1H-indole-5,6-dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07628": {"dbids": ["DB07628"], "name": "6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07629": {"dbids": ["DB07629"], "name": "N-((1R,2S)-2-(5-CHLORO-1H-INDOLE-2-CARBOXAMIDO)CYCLOHEXYL)-5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07620": {"dbids": ["DB07620"], "name": "2-[(2,4-DICHLORO-5-METHYLPHENYL)SULFONYL]-1,3-DINITRO-5-(TRIFLUOROMETHYL)BENZENE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07621": {"dbids": ["DB07621"], "name": "(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07622": {"dbids": ["DB07622"], "name": "1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07623": {"dbids": ["DB07623"], "name": "4,4'-DIPYRIDYL DISULFIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07624": {"dbids": ["DB07624"], "name": "1-{[(3R)-3-methyl-4-({4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]phenyl}sulfonyl)piperazin-1-yl]methyl}cyclopropanecarboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07625": {"dbids": ["DB07625"], "name": "4-(2-aminoethoxy)-N-(2,5-diethoxyphenyl)-3,5-dimethylbenzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07626": {"dbids": ["DB07626"], "name": "4-(2-aminoethoxy)-N-(3-chloro-2-ethoxy-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07627": {"dbids": ["DB07627"], "name": "(2S)-4-METHYL-2-(3-PHENYLTHIOUREIDO)-N-((3S)-TETRAHYDRO-2-HYDROXY-3-FURANYL)PENTANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07278": {"dbids": ["DB07278"], "name": "2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08429": {"dbids": ["DB08429"], "name": "N-({(2S)-1-[(3R)-3-amino-4-(3-chlorophenyl)butanoyl]pyrrolidin-2-yl}methyl)-3-(methylsulfonyl)benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07662": {"dbids": ["DB07662"], "name": "N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07663": {"dbids": ["DB07663"], "name": "2-[(1R)-1-CARBOXY-2-(4-HYDROXYPHENYL)ETHYL]-1,3-DIOXOISOINDOLINE-5-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03057": {"dbids": ["DB03057", "EXPT02141"], "name": "Malonaldehyde", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03056": {"dbids": ["DB03056", "EXPT00227"], "name": "4-Piperidino-Piperidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03507": {"dbids": ["DB03507", "EXPT00294"], "name": "6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03054": {"dbids": ["DB03054", "EXPT02127"], "name": "Tribromomethane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03053": {"dbids": ["DB03053", "EXPT02186"], "name": "1-Aminocyclopropylphosphonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03500": {"dbids": ["DB03500", "EXPT01377"], "name": "Tricosanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03051": {"dbids": ["DB03051", "EXPT03042"], "name": "Tetrahydrofuran-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03502": {"dbids": ["DB03502", "EXPT01789"], "name": "(4s)-4-{[(2s)-2-Amino-3-Oxopropyl]Sulfanyl}-L-Homoserinate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03509": {"dbids": ["DB03509", "EXPT00973"], "name": "2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03508": {"dbids": ["DB03508", "EXPT02148"], "name": "1-Ethoxy-2-(2-Methoxyethoxy)Ethane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03059": {"dbids": ["DB03059", "EXPT00820"], "name": "Acetoacetyl-Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03058": {"dbids": ["DB03058", "EXPT02934"], "name": "Isatoic Anhydride", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02902": {"dbids": ["DB02902", "EXPT02647"], "name": "3'-Phosphate-Adenosine-5'-Phosphate Sulfate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02903": {"dbids": ["DB02903", "EXPT00781"], "name": "BV3", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02900": {"dbids": ["DB02900", "EXPT02088"], "name": "Alpha-D-Mannose-6-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02901": {"dbids": ["DB02901", "EXPT01199"], "name": "Dihydrotestosterone", "groups": ["ILLICIT"], "targets": []}, "DB02906": {"dbids": ["DB02906", "EXPT00834"], "name": "(2s,4s)-Alpha-Campholinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02907": {"dbids": ["DB02907", "EXPT01321"], "name": "2-Amino-Vinyl-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02904": {"dbids": ["DB02904", "EXPT00762"], "name": "Beta-3-Serine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02905": {"dbids": ["DB02905", "EXPT02475"], "name": "Phosphoric Acid Mono-[3,4-Dihydroxy-5-(5-Hydroxy-Benzoimidazol-1-Yl)Tetrahydro-Furan-2-Ylmethyl] Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02908": {"dbids": ["DB02908", "EXPT00303"], "name": "RU78783", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02909": {"dbids": ["DB02909", "EXPT01402"], "name": "5-(2-Chlorophenyl)Furan-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09469": {"dbids": ["DB09469"], "name": "Sodium phosphate, monobasic, anhydrous", "groups": ["APPROVED"], "targets": []}, "DB05278": {"dbids": ["DB05278"], "name": "inhaled insulin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB05909": {"dbids": ["DB05909"], "name": "cat hair allergenic extracts", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05907": {"dbids": ["DB05907"], "name": "AL-108", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05906": {"dbids": ["DB05906"], "name": "CCR5 mAb", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05905": {"dbids": ["DB05905"], "name": "TD-2749", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05904": {"dbids": ["DB05904"], "name": "BLX-883", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05271": {"dbids": ["DB05271"], "name": "Rotigotine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35462", "drug": "DB05271"}, {"action": "AGONIST", "target": "P21917", "drug": "DB05271"}, {"action": "AGONIST", "target": "P14416", "drug": "DB05271"}, {"action": "AGONIST", "target": "P21918", "drug": "DB05271"}, {"action": "AGONIST", "target": "P21728", "drug": "DB05271"}, {"action": "AGONIST", "target": "P08908", "drug": "DB05271"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB05271"}]}, "DB05902": {"dbids": ["DB05902"], "name": "dust mite allergen extracts", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05901": {"dbids": ["DB05901"], "name": "ABR-215757", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05900": {"dbids": ["DB05900"], "name": "INSM-18", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06913": {"dbids": ["DB06913"], "name": "(2R,3R)-3-{[3,5-BIS(TRIFLUOROMETHYL)PHENYL]AMINO}-2-CYANO-3-THIOXOPROPANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06912": {"dbids": ["DB06912"], "name": "UNDECA-3,7-DIENE-1,3,7,11-TETRACARBALDEHYDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09192": {"dbids": ["DB09192"], "name": "Tandamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06915": {"dbids": ["DB06915"], "name": "naphthalene-1,2,4,5,7-pentol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09193": {"dbids": ["DB09193"], "name": "CP-39,332", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09535": {"dbids": ["DB09535"], "name": "Octocrylene", "groups": ["APPROVED"], "targets": []}, "DB02674": {"dbids": ["DB02674", "EXPT02932"], "name": "4-(2-Oxo-Hexahydro-Thieno[3,4-D]Imidazol-4-Yl)-Butyricacid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02675": {"dbids": ["DB02675", "EXPT02905"], "name": "(4-Hydroxymaltosephenyl)Glycine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02676": {"dbids": ["DB02676", "EXPT00612"], "name": "2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02677": {"dbids": ["DB02677", "EXPT02852"], "name": "D-Naphthyl-1-Acetamido Boronic Acid Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02670": {"dbids": ["DB02670", "EXPT01533"], "name": "4-Deoxy-Alpha-D-Glucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02671": {"dbids": ["DB02671", "EXPT00077"], "name": "1-Methylimidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02673": {"dbids": ["DB02673", "EXPT01601"], "name": "(4ar,6s,8ar)-11-[8-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Octyl]-6-Hydroxy-3-Methoxy-5,6,9,10-Tetrahydro-4ah-[1]Benzofuro[3a,3,2-Ef][2]Benzazepin-11-Ium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02678": {"dbids": ["DB02678", "EXPT00074"], "name": "2-Deoxy-2-Aminogalactose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02679": {"dbids": ["DB02679", "EXPT00971"], "name": "Cyanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08571": {"dbids": ["DB08571"], "name": "4-(ACETYLAMINO)-5-AMINO-3-HYDROXYBENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08570": {"dbids": ["DB08570"], "name": "4-(ACETYLAMINO)-3-HYDROXY-5-NITROBENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08573": {"dbids": ["DB08573"], "name": "3-[(4-CHLOROANILINO)SULFONYL]THIOPHENE-2-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08572": {"dbids": ["DB08572"], "name": "4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB11320": {"dbids": ["DB11320"], "name": "Histamine", "groups": ["APPROVED"], "targets": []}, "DB08575": {"dbids": ["DB08575"], "name": "2-[(1S)-1-BENZYL-2-SULFANYLETHYL]-1H-IMIDAZO[4,5-C]PYRIDIN-5-IUM", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08574": {"dbids": ["DB08574"], "name": "(5R)-2-SULFANYL-5-[4-(TRIFLUOROMETHYL)BENZYL]-1,3-THIAZOL-4-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08577": {"dbids": ["DB08577"], "name": "3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08576": {"dbids": ["DB08576"], "name": "1-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)-2-(METHYLAMINO)ETHANONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08579": {"dbids": ["DB08579"], "name": "4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}aniline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08578": {"dbids": ["DB08578"], "name": "4-[(5-bromopyridin-2-yl)amino]-4-oxobutanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06919": {"dbids": ["DB06919"], "name": "D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09103": {"dbids": ["DB09103"], "name": "Ancestim", "groups": ["APPROVED"], "targets": []}, "DB09102": {"dbids": ["DB09102"], "name": "Daclatasvir", "groups": ["APPROVED"], "targets": []}, "DB09101": {"dbids": ["DB09101"], "name": "Elvitegravir", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q7ZJM1", "drug": "DB09101"}]}, "DB09100": {"dbids": ["DB09100"], "name": "Thyroid extract", "groups": ["APPROVED"], "targets": []}, "DB09107": {"dbids": ["DB09107"], "name": "Methoxy polyethylene glycol-epoetin beta", "groups": ["APPROVED"], "targets": []}, "DB09106": {"dbids": ["DB09106"], "name": "Hydroxyethyl starch", "groups": ["APPROVED"], "targets": []}, "DB09105": {"dbids": ["DB09105"], "name": "Asfotase Alfa", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB09104": {"dbids": ["DB09104"], "name": "Magnesium hydroxide", "groups": ["APPROVED"], "targets": []}, "DB09109": {"dbids": ["DB09109"], "name": "Turoctocog alfa", "groups": ["APPROVED"], "targets": []}, "DB09108": {"dbids": ["DB09108"], "name": "Simoctocog Alfa", "groups": ["APPROVED"], "targets": []}, "DB01370": {"dbids": ["DB01370"], "name": "Aluminium", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "P05023", "drug": "DB01370"}]}, "DB01373": {"dbids": ["DB01373"], "name": "Calcium", "groups": ["NUTRACEUTICAL"], "targets": [{"action": "LIGAND", "target": "Q13936", "drug": "DB01373"}, {"action": "AGONIST", "target": "P98194", "drug": "DB01373"}, {"action": "AGONIST", "target": "P02585", "drug": "DB01373"}, {"action": "AGONIST", "target": "P63316", "drug": "DB01373"}, {"action": "AGONIST", "target": "Q01082", "drug": "DB01373"}]}, "DB01375": {"dbids": ["DB01375"], "name": "Dihydroxyaluminium", "groups": ["APPROVED"], "targets": [{"action": "STIMULATOR", "target": "P63316", "drug": "DB01375"}, {"action": "INHIBITOR", "target": "P21796", "drug": "DB01375"}, {"action": "INHIBITOR", "target": "P45880", "drug": "DB01375"}, {"action": "INHIBITOR", "target": "Q9Y277", "drug": "DB01375"}]}, "DB01377": {"dbids": ["DB01377"], "name": "Magnesium oxide", "groups": ["APPROVED"], "targets": []}, "DB01378": {"dbids": ["DB01378"], "name": "Magnesium", "groups": ["NUTRACEUTICAL"], "targets": []}, "DB08035": {"dbids": ["DB08035"], "name": "1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08819": {"dbids": ["DB08819"], "name": "Tafluprost", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P43088", "drug": "DB08819"}]}, "DB01501": {"dbids": ["DB01501"], "name": "Difenoxin", "groups": ["APPROVED", "ILLICIT"], "targets": []}, "DB01594": {"dbids": ["DB01594"], "name": "Cinolazepam", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB01594"}]}, "DB01595": {"dbids": ["DB01595"], "name": "Nitrazepam", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01595"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01595"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01595"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB01595"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01595"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01595"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB01595"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB01595"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB01595"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB01595"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB01595"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB01595"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB01595"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB01595"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB01595"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB01595"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB01595"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB01595"}, {"action": "POTENTIATOR", "target": "Q9UN88", "drug": "DB01595"}, {"action": "OTHER/UNKNOWN", "target": "P35498", "drug": "DB01595"}]}, "DB01597": {"dbids": ["DB01597", "EXPT00918"], "name": "Cilastatin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P16444", "drug": "DB01597"}]}, "DB01590": {"dbids": ["DB01590"], "name": "Everolimus", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P42345", "drug": "DB01590"}]}, "DB01591": {"dbids": ["APRD00168", "DB01591"], "name": "Solifenacin", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P20309", "drug": "DB01591"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01591"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01591"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01591"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB01591"}]}, "DB01592": {"dbids": ["DB01592"], "name": "Iron", "groups": ["APPROVED"], "targets": []}, "DB01593": {"dbids": ["DB01593"], "name": "Zinc", "groups": ["APPROVED"], "targets": []}, "DB01598": {"dbids": ["DB01598"], "name": "Imipenem", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0AD65", "drug": "DB01598"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB01598"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB01598"}, {"action": "INHIBITOR", "target": "P42971", "drug": "DB01598"}, {"action": "OTHER/UNKNOWN", "target": "P00807", "drug": "DB01598"}]}, "DB01599": {"dbids": ["DB01599"], "name": "Probucol", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "O95477", "drug": "DB01599"}]}, "DB06816": {"dbids": ["DB06816"], "name": "Pyrvinium", "groups": ["APPROVED"], "targets": []}, "DB06817": {"dbids": ["DB05355", "DB06817"], "name": "Raltegravir", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q7ZJM1", "drug": "DB06817"}]}, "DB00359": {"dbids": ["APRD00190", "DB00359"], "name": "Sulfadiazine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q27738", "drug": "DB00359"}]}, "DB00358": {"dbids": ["APRD00300", "DB00358"], "name": "Mefloquine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P69905", "drug": "DB00358"}, {"action": "ANTAGONIST", "target": "P29274", "drug": "DB00358"}]}, "DB00429": {"dbids": ["APRD00847", "DB00429"], "name": "Carboprost Tromethamine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P34995", "drug": "DB00429"}]}, "DB00428": {"dbids": ["APRD00209", "DB00428"], "name": "Streptozocin", "groups": ["APPROVED"], "targets": [{"action": "LIGAND", "target": "P11168", "drug": "DB00428"}, {"action": "ANTAGONIST", "target": "Q89ZI2", "drug": "DB00428"}]}, "DB00355": {"dbids": ["APRD00815", "DB00355", "EXPT00605"], "name": "Aztreonam", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P42971", "drug": "DB00355"}, {"action": "POTENTIATOR", "target": "P05193", "drug": "DB00355"}]}, "DB00354": {"dbids": ["APRD00723", "DB00354"], "name": "Buclizine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00354"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00354"}]}, "DB00357": {"dbids": ["APRD00592", "DB00357"], "name": "Aminoglutethimide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P11511", "drug": "DB00357"}, {"action": "INHIBITOR", "target": "P05108", "drug": "DB00357"}]}, "DB00356": {"dbids": ["APRD00308", "DB00356"], "name": "Chlorzoxazone", "groups": ["APPROVED"], "targets": []}, "DB00351": {"dbids": ["APRD01092", "DB00351"], "name": "Megestrol acetate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P06401", "drug": "DB00351"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00351"}]}, "DB00350": {"dbids": ["APRD00086", "DB00350", "DB08225"], "name": "Minoxidil", "groups": ["APPROVED"], "targets": [{"action": "INDUCER", "target": "P48048", "drug": "DB00350"}, {"action": "INDUCER", "target": "P23219", "drug": "DB00350"}]}, "DB00353": {"dbids": ["APRD00739", "DB00353"], "name": "Methylergometrine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P21728", "drug": "DB00353"}]}, "DB00420": {"dbids": ["APRD00358", "DB00420"], "name": "Promazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00420"}]}, "DB03338": {"dbids": ["DB03338", "EXPT00614"], "name": "Heptyl-Beta-D-Glucopyranoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03339": {"dbids": ["DB03339", "EXPT01901"], "name": "3-Iodo-Benzyl Alcohol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06748": {"dbids": ["DB06748"], "name": "ginsenoside C", "groups": ["NUTRACEUTICAL"], "targets": []}, "DB06749": {"dbids": ["DB06749"], "name": "ginsenoside Rb1", "groups": ["NUTRACEUTICAL"], "targets": []}, "DB03998": {"dbids": ["DB03998", "EXPT01011"], "name": "[2-(Methyleneamine)-4-(4-Hydroxy-Benzylidine)-5-Oxo-4,5-Dihydro-Imidazol-1-Yl]-Acetaldehyde", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03999": {"dbids": ["DB03999", "EXPT00862"], "name": "Butylphosphonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03332": {"dbids": ["DB03332", "EXPT00534"], "name": "5,6-Cyclic-Tetrahydropteridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03997": {"dbids": ["DB03997", "EXPT01781"], "name": "Phosphoric Acid Mono-[2-Amino-3-(3h-Imidazol-4-Yl)-Propyl]Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03330": {"dbids": ["DB03330", "EXPT01593"], "name": "S-(N-Hydroxy-N-Iodophenylcarbamoyl)Glutathione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03995": {"dbids": ["DB03995", "EXPT00638"], "name": "Cyclo-Hepta-Amylose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03336": {"dbids": ["DB03336", "EXPT00705"], "name": "BIA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03337": {"dbids": ["DB03337", "EXPT01636"], "name": "1-(2-Amidinophenyl)-3-(Phenoxyphenyl)Urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03990": {"dbids": ["DB03990", "EXPT02001"], "name": "4'-Nitrophenyl-3i-Thiolaminaritrioside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03991": {"dbids": ["DB03991", "EXPT01111"], "name": "2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04528": {"dbids": ["DB04528", "EXPT01235"], "name": "2,4-Dinitrophenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04529": {"dbids": ["DB04529", "EXPT01304"], "name": "Desvancosaminyl Vancomycin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04526": {"dbids": ["DB04526", "EXPT01620"], "name": "L-Glycero-D-Manno-Heptopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04527": {"dbids": ["DB04527", "EXPT00462"], "name": "Beta-Hydroxyasparagine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04524": {"dbids": ["DB04524", "EXPT02180"], "name": "Malonyl-Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04525": {"dbids": ["DB04525", "EXPT01897"], "name": "2-(Carboxymethoxy)-5-[(2s)-2-({(2s)-2-[(3-Carboxypropanoyl)Amino] -3-Phenylpropanoyl}Amino)-3-Oxo-3-(Pentylamino)Propyl]Benzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04522": {"dbids": ["DB04522", "EXPT02883"], "name": "Phosphonoserine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04523": {"dbids": ["DB04523", "EXPT03026"], "name": "Tert-Butyl(1s)-1-Cyclohexyl-2-Oxoethylcarbamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04520": {"dbids": ["DB04520", "EXPT03139"], "name": "(3s,8ar)-3-(4-Hydroxybenzyl)Hexahydropyrrolo[1,2-a]Pyrazine-1,4-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04521": {"dbids": ["DB04521", "EXPT01689"], "name": "GSHNA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01500": {"dbids": ["DB01500"], "name": "4-Hydroxy-19-nortestosterone", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB07291": {"dbids": ["DB07291"], "name": "5-amino-1-(4-chlorophenyl)-1H-pyrazole-4-carbonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07290": {"dbids": ["DB07290"], "name": "(2R)-2-{[(4-FLUORO-3-METHYLPHENYL)SULFONYL]AMINO}-N-HYDROXY-2-TETRAHYDRO-2H-PYRAN-4-YLACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07293": {"dbids": ["DB07293"], "name": "benzyl (2-oxopropyl)carbamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07292": {"dbids": ["DB07292"], "name": "4-(2-amino-1,3-thiazol-4-yl)phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07295": {"dbids": ["DB07295"], "name": "2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07294": {"dbids": ["DB07294"], "name": "3-FLUORO-4-[2-HYDROXY-2-(5,5,8,8-TETRAMETHYL-5,6,7,8,-TETRAHYDRO-NAPHTALEN-2-YL)-ACETYLAMINO]-BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07297": {"dbids": ["DB07297"], "name": "5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07296": {"dbids": ["DB07296"], "name": "(5Z)-3-(4-CHLOROPHENYL)-4-HYDROXY-5-(1-NAPHTHYLMETHYLENE)FURAN-2(5H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07299": {"dbids": ["DB07299"], "name": "4-METHYL-PENTANOIC ACID {1-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYLCARBAMOYL]-2-METHYL-PROPYL}-AMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07298": {"dbids": ["DB07298"], "name": "3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08698": {"dbids": ["DB08698"], "name": "1-[(3S)-5-PHENYL-3-THIOPHEN-2-YL-3H-1,4-BENZODIAZEPIN-2-YL]AZETIDIN-3-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09297": {"dbids": ["DB09297"], "name": "Paritaprevir", "groups": ["APPROVED"], "targets": []}, "DB09511": {"dbids": ["DB09511"], "name": "Talc", "groups": ["APPROVED"], "targets": []}, "DB09512": {"dbids": ["DB09512"], "name": "Simethicone", "groups": ["APPROVED"], "targets": []}, "DB08699": {"dbids": ["DB08699"], "name": "1-tert-butyl-3-(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09513": {"dbids": ["DB09513"], "name": "Urea, C-14", "groups": ["APPROVED"], "targets": []}, "DB09296": {"dbids": ["DB09296"], "name": "Ombitasvir", "groups": ["APPROVED"], "targets": []}, "DB02069": {"dbids": ["DB02069", "EXPT01497"], "name": "N-(2-Flouro-Benzyl)-4-Sulfamoyl-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02068": {"dbids": ["DB02068", "EXPT01116"], "name": "Delta-Amino Valeric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06734": {"dbids": ["DB06734"], "name": "Bafilomycin B1", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P38606", "drug": "DB06734"}]}, "DB02061": {"dbids": ["DB02061", "EXPT00844"], "name": "Cellobiose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02060": {"dbids": ["DB02060", "EXPT01075"], "name": "Cyclohexanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02063": {"dbids": ["DB02063", "EXPT00325"], "name": "CRA_16847", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02062": {"dbids": ["DB02062", "EXPT00710"], "name": "N-[3-[(1-Aminoethyl)(Hydroxy)Phosphoryl]-2-(1,1'-Biphenyl-4-Ylmethyl)Propanoyl]Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02065": {"dbids": ["DB02065", "EXPT01157"], "name": "4-Deoxylactose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02067": {"dbids": ["DB02067", "EXPT03045"], "name": "Triglu-5-Formyl-Tetrahydrofolate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02066": {"dbids": ["DB02066", "EXPT01450"], "name": "N7-Methyl-Formycin A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06731": {"dbids": ["DB06731"], "name": "Seproxetine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03196": {"dbids": ["DB03196", "EXPT01972"], "name": "4-Nitrophenyl-Ara", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03197": {"dbids": ["DB03197", "EXPT01747"], "name": "6-Hydroxymethylpterin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03194": {"dbids": ["DB03194", "EXPT02161"], "name": "Beta-L-Methyl-Fucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03195": {"dbids": ["DB03195", "EXPT01414"], "name": "Phosphoric Acid Mono-[3-Fluoro-5-(5-Methyl-2,4-Dioxo-3,4-Dihydro-2h-Pyrimidin-1-Yl)-Tetrahyro-Furan-2-Ylmethyl] Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03192": {"dbids": ["DB03192", "EXPT01712"], "name": "3r-Hydroxydecanoyl-Coa", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03193": {"dbids": ["DB03193", "EXPT02965"], "name": "Stearic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03190": {"dbids": ["DB03190", "EXPT02451"], "name": "N-Octanoyl-B-D-Fructofuranosyl-a-D-Glucopyranoside,Sucrose Monocaproylate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03191": {"dbids": ["DB03191", "EXPT02037"], "name": "3-Oxiran-2ylalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06732": {"dbids": ["DB06732"], "name": "beta-Naphthoflavone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03198": {"dbids": ["DB03198", "EXPT03068"], "name": "Thio-Maltohexaose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03199": {"dbids": ["DB03199", "EXPT01358"], "name": "4-Methoxy-E-Rhodomycin T", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02245": {"dbids": ["DB02245", "EXPT00310"], "name": "7-Deazaguanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09292": {"dbids": ["DB09292"], "name": "Sacubitril", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08473", "drug": "DB09292"}, {"action": "INHIBITOR", "target": "P08473", "drug": "DB09292"}]}, "DB02247": {"dbids": ["DB02247", "EXPT00890", "EXPT01964"], "name": "Hydrolyzed Cephalothin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09290": {"dbids": ["DB09290"], "name": "Ramosetron", "groups": ["APPROVED"], "targets": []}, "DB02241": {"dbids": ["DB02241", "EXPT01085"], "name": "8-Benzyl-2-Hydroperoxy-2-(4-Hydroxy-Benzyl)-6-(4-Hydroxy-Phenyl)-2h-Imidazo[1,2-a]Pyrazin-3-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02240": {"dbids": ["DB02240", "EXPT02733"], "name": "N-{(1s)-4-[Bis(2-Chloroethyl)Amino]-1-Methylbutyl}-N-(6-Chloro-2-Methoxy-9-Acridinyl)Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02243": {"dbids": ["DB02243", "EXPT02269"], "name": "4-Morpholin-4-Yl-Piperidine-1-Carboxylic Acid [1-(3-Benzenesulfonyl-1-Propyl-Allylcarbamoyl)-2-Phenylethyl]-Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02242": {"dbids": ["DB02242", "EXPT01069"], "name": "Cyclohexane Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09299": {"dbids": ["DB09299"], "name": "Tenofovir alafenamide", "groups": ["APPROVED"], "targets": []}, "DB09298": {"dbids": ["DB09298"], "name": "Silibinin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02249": {"dbids": ["DB02249", "EXPT01374"], "name": "2-Ethoxyethanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02248": {"dbids": ["DB02248", "EXPT00681"], "name": "3-Methyl-5-Sulfo-Pyrrolidine-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB11092": {"dbids": ["DB11092"], "name": "Stannous fluoride", "groups": ["APPROVED"], "targets": []}, "DB01448": {"dbids": ["DB01448"], "name": "19-Nor-4-androstenedione", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB07646": {"dbids": ["DB07646"], "name": "UNDECYLAMINE-N,N-DIMETHYL-N-OXIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01442": {"dbids": ["DB01442"], "name": "MMDA", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P28223", "drug": "DB01442"}, {"action": "NEGATIVE MODULATOR", "target": "Q01959", "drug": "DB01442"}, {"action": "NEGATIVE MODULATOR", "target": "P31645", "drug": "DB01442"}, {"action": "NEGATIVE MODULATOR", "target": "P23975", "drug": "DB01442"}, {"action": "INHIBITOR", "target": "Q05940", "drug": "DB01442"}, {"action": "INHIBITOR", "target": "P54219", "drug": "DB01442"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB01442"}, {"action": "INHIBITOR", "target": "P27338", "drug": "DB01442"}]}, "DB07999": {"dbids": ["DB07999"], "name": "{4-[(CARBOXYMETHOXY)CARBONYL]-3,3-DIOXIDO-1-OXONAPHTHO[1,2-D]ISOTHIAZOL-2(1H)-YL}ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06819": {"dbids": ["DB06819"], "name": "Sodium phenylbutyrate", "groups": ["APPROVED"], "targets": []}, "DB04123": {"dbids": ["DB04123", "EXPT01921"], "name": "(P-Iodophenylacetylamino)Methylphosphinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07992": {"dbids": ["DB07992"], "name": "3-SULFOOXY-1H-INDOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07993": {"dbids": ["DB07993"], "name": "N~3~-[3-(1H-INDOL-6-YL)BENZYL]PYRIDINE-2,3-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07990": {"dbids": ["DB07990"], "name": "(RP,SP)-O-(2R)-(1-PHENOXYBUT-2-YL)-METHYLPHOSPHONIC ACID CHLORIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07991": {"dbids": ["DB07991"], "name": "N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07996": {"dbids": ["DB07996"], "name": "1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01336": {"dbids": ["DB01336"], "name": "Metocurine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q15822", "drug": "DB01336"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01336"}]}, "DB07994": {"dbids": ["DB07994"], "name": "N~3~-[5-(1H-INDOL-6-YL)-2-(PYRIDIN-2-YLMETHOXY)BENZYL]PYRIDINE-2,3-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07995": {"dbids": ["DB07995"], "name": "N-[2-(4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE SULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04121": {"dbids": ["DB04121", "EXPT01529"], "name": "Guanosine-3'-Monophosphate-5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04126": {"dbids": ["DB04126", "EXPT01318"], "name": "N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-2-Methyl-Butane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05595": {"dbids": ["DB05595"], "name": "Farletuzumab", "groups": ["INVESTIGATIONAL"], "targets": [{"action": "ANTIBODY", "target": "P15328", "drug": "DB05595"}]}, "DB04127": {"dbids": ["DB04127", "EXPT00395"], "name": "Beta-D-Arabinofuranose-5'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04124": {"dbids": ["DB04124", "EXPT02115"], "name": "Aurodox", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01445": {"dbids": ["DB01445"], "name": "Bufotenine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01154": {"dbids": ["APRD00154", "DB01154"], "name": "Thiamylal", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P14867", "drug": "DB01154"}, {"action": "INHIBITOR", "target": "Q15842", "drug": "DB01154"}, {"action": "INHIBITOR", "target": "Q14654", "drug": "DB01154"}]}, "DB01419": {"dbids": ["DB01419"], "name": "Antrafenine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23219", "drug": "DB01419"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB01419"}]}, "DB04303": {"dbids": ["DB04303", "EXPT01566"], "name": "4-O-Methyl-Alpha-D-Glucuronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07029": {"dbids": ["DB07029"], "name": "4-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]-6-METHYLPYRIMIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04652": {"dbids": ["DB04652"], "name": "(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05042": {"dbids": ["DB05042"], "name": "SGS518", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05043": {"dbids": ["DB05043"], "name": "GSK159797", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05040": {"dbids": ["DB05040"], "name": "MVA3000", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04301": {"dbids": ["DB04301", "EXPT00621"], "name": "Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone Hydrate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05046": {"dbids": ["DB05046"], "name": "V1003", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05047": {"dbids": ["DB05047"], "name": "CX717", "groups": ["ILLICIT", "INVESTIGATIONAL"], "targets": []}, "DB05044": {"dbids": ["DB05044"], "name": "PSN357", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05045": {"dbids": ["DB05045"], "name": "TM30338", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01150": {"dbids": ["APRD00461", "DB01150"], "name": "Cefprozil", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q04707", "drug": "DB01150"}, {"action": "INHIBITOR", "target": "P14677", "drug": "DB01150"}, {"action": "INHIBITOR", "target": "P0A3M5", "drug": "DB01150"}]}, "DB05048": {"dbids": ["DB05048"], "name": "Cannabinor", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05049": {"dbids": ["DB05049"], "name": "DDP733", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05738": {"dbids": ["DB05738"], "name": "vapitadine dihydrochloride", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05739": {"dbids": ["DB05739"], "name": "CYT006-AngQb", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04655": {"dbids": ["DB04655"], "name": "METOPRINE, METHODICHLOROPHEN", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01418": {"dbids": ["DB01418"], "name": "Acenocoumarol", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9BQB6", "drug": "DB01418"}]}, "DB04304": {"dbids": ["DB04304", "EXPT01560"], "name": "Gluconic Acid", "groups": ["APPROVED"], "targets": []}, "DB01153": {"dbids": ["APRD00305", "DB01153"], "name": "Sertaconazole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P10613", "drug": "DB01153"}]}, "DB07471": {"dbids": ["DB07471"], "name": "5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07470": {"dbids": ["DB07470"], "name": "(3aS)-3a-hydroxy-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07473": {"dbids": ["DB07473"], "name": "(R)-(+) 5(9BH)-OXO-9B-PHENYL-2,3-DIHYDROTHIAZOLO[2,3-A]ISOINDOL-3-CARBOXYLIC ACID METHYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01749": {"dbids": ["DB01749", "EXPT01306"], "name": "1,2-Dimethoxyethane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01748": {"dbids": ["DB01748", "EXPT00761"], "name": "N-Benzyl-4-Sulfamoyl-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01299": {"dbids": ["DB01299"], "name": "Sulfadoxine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P13922", "drug": "DB01299"}]}, "DB01298": {"dbids": ["DB01298"], "name": "Sulfacytine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0AC13", "drug": "DB01298"}]}, "DB01741": {"dbids": ["DB01741", "EXPT00281"], "name": "CRA_17693", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01740": {"dbids": ["DB01740", "EXPT02885"], "name": "2-Amino-4-Butyl-5-Propylselenazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01291": {"dbids": ["DB01291"], "name": "Pirbuterol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P07550", "drug": "DB01291"}, {"action": "AGONIST", "target": "P08588", "drug": "DB01291"}]}, "DB01742": {"dbids": ["DB01742", "EXPT00079"], "name": "(3r)-1-Acetyl-3-Methylpiperidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01297": {"dbids": ["DB01297"], "name": "Practolol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB01297"}]}, "DB01296": {"dbids": ["DB01296", "EXPT01563"], "name": "Glucosamine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14780", "drug": "DB01296"}, {"action": "ANTAGONIST", "target": "Q00653", "drug": "DB01296"}]}, "DB01295": {"dbids": ["DB01295"], "name": "Bevantolol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB01295"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB01295"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01295"}]}, "DB01294": {"dbids": ["DB01294", "DB01402"], "name": "Bismuth Subsalicylate", "groups": ["APPROVED"], "targets": []}, "DB07477": {"dbids": ["DB07477"], "name": "BIPHENYL-4-YL-ACETALDEHYDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08692": {"dbids": ["DB08692"], "name": "D-1-(4-CHLOROPHENYL)-2-(ACETAMIDO)ETHANE BORONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07476": {"dbids": ["DB07476"], "name": "N-[4-(AMINOSULFONYL)PHENYL]-2-MERCAPTOBENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08142": {"dbids": ["DB08142"], "name": "4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08693": {"dbids": ["DB08693"], "name": "L-1-(4-CHLOROPHENYL)-2-(ACETAMIDO)ETHANE BORONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09414": {"dbids": ["DB09414"], "name": "Potassium phosphate, dibasic", "groups": ["APPROVED"], "targets": []}, "DB01125": {"dbids": ["APRD00799", "DB01125"], "name": "Anisindione", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P38435", "drug": "DB01125"}]}, "DB01124": {"dbids": ["APRD00267", "DB01124"], "name": "Tolbutamide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q09428", "drug": "DB01124"}, {"action": "INHIBITOR", "target": "P48048", "drug": "DB01124"}]}, "DB01127": {"dbids": ["APRD00943", "DB01127"], "name": "Econazole", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P10613", "drug": "DB01127"}]}, "DB01126": {"dbids": ["APRD00385", "DB01126"], "name": "Dutasteride", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P31213", "drug": "DB01126"}, {"action": "INHIBITOR", "target": "P18405", "drug": "DB01126"}]}, "DB01121": {"dbids": ["APRD00089", "DB01121"], "name": "Phenacemide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35498", "drug": "DB01121"}]}, "DB01120": {"dbids": ["APRD00460", "DB01120"], "name": "Gliclazide", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "Q09428", "drug": "DB01120"}, {"action": "OTHER/UNKNOWN", "target": "P15692", "drug": "DB01120"}]}, "DB01123": {"dbids": ["APRD00535", "DB01123"], "name": "Proflavine", "groups": ["APPROVED"], "targets": [{"action": "OTHER/UNKNOWN", "target": "P00734", "drug": "DB01123"}]}, "DB01122": {"dbids": ["APRD00771", "DB01122"], "name": "Ambenonium", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P22303", "drug": "DB01122"}]}, "DB01129": {"dbids": ["APRD01212", "DB01129"], "name": "Rabeprazole", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P20648", "drug": "DB01129"}]}, "DB01128": {"dbids": ["APRD00042", "DB01128", "DB06284"], "name": "Bicalutamide", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P10275", "drug": "DB01128"}]}, "DB00654": {"dbids": ["APRD01065", "DB00654"], "name": "Latanoprost", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P43088", "drug": "DB00654"}]}, "DB00655": {"dbids": ["APRD00588", "DB00655"], "name": "Estrone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P03372", "drug": "DB00655"}]}, "DB00656": {"dbids": ["APRD00533", "DB00656"], "name": "Trazodone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P28223", "drug": "DB00656"}, {"action": "AGONIST", "target": "P28335", "drug": "DB00656"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00656"}, {"action": "PARTIAL AGONIST", "target": "P08908", "drug": "DB00656"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00656"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00656"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00656"}]}, "DB00657": {"dbids": ["APRD00458", "DB00657"], "name": "Mecamylamine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q15822", "drug": "DB00657"}]}, "DB00650": {"dbids": ["APRD00698", "DB00650"], "name": "Leucovorin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P04818", "drug": "DB00650"}]}, "DB00651": {"dbids": ["APRD00769", "DB00651"], "name": "Dyphylline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q07343", "drug": "DB00651"}, {"action": "INHIBITOR", "target": "P27815", "drug": "DB00651"}, {"action": "INHIBITOR", "target": "Q08493", "drug": "DB00651"}, {"action": "INHIBITOR", "target": "Q08499", "drug": "DB00651"}, {"action": "ANTAGONIST", "target": "P30542", "drug": "DB00651"}, {"action": "ANTAGONIST", "target": "P29274", "drug": "DB00651"}, {"action": "INHIBITOR", "target": "Q13946", "drug": "DB00651"}, {"action": "INHIBITOR", "target": "Q9NP56", "drug": "DB00651"}]}, "DB00652": {"dbids": ["APRD01173", "DB00652"], "name": "Pentazocine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35372", "drug": "DB00652"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00652"}, {"action": "AGONIST", "target": "Q99720", "drug": "DB00652"}]}, "DB00653": {"dbids": ["APRD01080", "DB00653"], "name": "Magnesium Sulfate", "groups": ["APPROVED"], "targets": []}, "DB07358": {"dbids": ["DB07358"], "name": "2-amino-N-(4-methyl-1,3-thiazol-2-yl)-5-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07359": {"dbids": ["DB07359"], "name": "3-[(4-fluorophenyl)sulfanyl]-N-(4-methyl-1,3-thiazol-2-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridine-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07608": {"dbids": ["DB07608"], "name": "N-(5-{[(2S)-4-amino-2-(3-chlorophenyl)butanoyl]amino}-1H-indazol-3-yl)benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07609": {"dbids": ["DB07609"], "name": "N,N-DIMETHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00658": {"dbids": ["APRD01226", "DB00658"], "name": "Sevelamer", "groups": ["APPROVED"], "targets": []}, "DB00659": {"dbids": ["APRD00661", "DB00659"], "name": "Acamprosate", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "POSITIVE MODULATOR", "target": "P14867", "drug": "DB00659"}, {"action": "POSITIVE MODULATOR", "target": "P47869", "drug": "DB00659"}, {"action": "POSITIVE MODULATOR", "target": "P34903", "drug": "DB00659"}, {"action": "POSITIVE MODULATOR", "target": "P48169", "drug": "DB00659"}, {"action": "POSITIVE MODULATOR", "target": "P31644", "drug": "DB00659"}, {"action": "POSITIVE MODULATOR", "target": "Q16445", "drug": "DB00659"}, {"action": "POSITIVE MODULATOR", "target": "P18505", "drug": "DB00659"}, {"action": "POSITIVE MODULATOR", "target": "P47870", "drug": "DB00659"}, {"action": "POSITIVE MODULATOR", "target": "P28472", "drug": "DB00659"}, {"action": "POSITIVE MODULATOR", "target": "O14764", "drug": "DB00659"}, {"action": "POSITIVE MODULATOR", "target": "P78334", "drug": "DB00659"}, {"action": "POSITIVE MODULATOR", "target": "Q8N1C3", "drug": "DB00659"}, {"action": "POSITIVE MODULATOR", "target": "P18507", "drug": "DB00659"}, {"action": "POSITIVE MODULATOR", "target": "Q99928", "drug": "DB00659"}, {"action": "POSITIVE MODULATOR", "target": "O00591", "drug": "DB00659"}, {"action": "POSITIVE MODULATOR", "target": "Q9UN88", "drug": "DB00659"}, {"action": "ANTAGONIST", "target": "Q05586", "drug": "DB00659"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB00659"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB00659"}, {"action": "ANTAGONIST", "target": "Q14957", "drug": "DB00659"}, {"action": "ANTAGONIST", "target": "O15399", "drug": "DB00659"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00659"}, {"action": "ANTAGONIST", "target": "O60391", "drug": "DB00659"}, {"action": "ANTAGONIST", "target": "P41594", "drug": "DB00659"}]}, "DB04619": {"dbids": ["DB04619"], "name": "ACETOPHENONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09312": {"dbids": ["DB09312"], "name": "Anti-thymocyte Globulin (Equine)", "groups": ["APPROVED"], "targets": []}, "DB03295": {"dbids": ["DB03295", "EXPT03120"], "name": "Glutathionylspermidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03294": {"dbids": ["DB03294", "EXPT02893"], "name": "1-Methyl-3-Oxo-1,3-Dihydro-Benzo[C]Isothiazole-5-Sulfonic Acid Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03297": {"dbids": ["DB03297", "EXPT02622"], "name": "Benzylsulfinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03296": {"dbids": ["DB03296", "EXPT02917"], "name": "Lactose Sialic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03291": {"dbids": ["DB03291", "EXPT01568"], "name": "4-Deoxy-4-Amino-Beta-D-Glucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03290": {"dbids": ["DB03290", "EXPT02856"], "name": "L-Naphthyl-1-Acetamido Boronic Acid Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03293": {"dbids": ["DB03293", "EXPT02255"], "name": "9-Methyl Uric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03292": {"dbids": ["DB03292", "EXPT00542"], "name": "D-2-Amino-3-Phosphono-Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03299": {"dbids": ["DB03299", "EXPT02381"], "name": "N-Succinyl Phenylglycine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03298": {"dbids": ["DB03298", "EXPT01775"], "name": "Phenylphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04957": {"dbids": ["DB04957"], "name": "Azimilide", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04956": {"dbids": ["DB04956"], "name": "Afelimomab", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04955": {"dbids": ["DB04955"], "name": "Pumactant", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04954": {"dbids": ["DB04954"], "name": "Tecadenoson", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04953": {"dbids": ["DB04953"], "name": "Ezogabine", "groups": ["APPROVED"], "targets": []}, "DB04952": {"dbids": ["DB04952"], "name": "Ramoplanin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04951": {"dbids": ["DB04951"], "name": "Pirfenidone", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04950": {"dbids": ["DB04950"], "name": "Ranpirnase", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04959": {"dbids": ["DB04959"], "name": "HspE7", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04958": {"dbids": ["DB04958"], "name": "Epratuzumab", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08067": {"dbids": ["DB08067"], "name": "4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08066": {"dbids": ["DB08066"], "name": "N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08065": {"dbids": ["DB08065"], "name": "2-(1H-pyrazol-3-yl)-1H-benzimidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08064": {"dbids": ["DB08064"], "name": "N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08063": {"dbids": ["DB08063"], "name": "1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08062": {"dbids": ["DB08062"], "name": "3-(4-CHLOROPHENYL)-5-(METHYLTHIO)-4H-1,2,4-TRIAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08061": {"dbids": ["DB08061"], "name": "4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08060": {"dbids": ["DB08060"], "name": "4-(2-AMINOPHENYL)-4-OXOBUTANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08069": {"dbids": ["DB08069"], "name": "4-AMINO-5-(2-METHYLPHENYL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOLE-3-THIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08068": {"dbids": ["DB08068"], "name": "N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01414": {"dbids": ["DB01414"], "name": "Cefacetrile", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P02918", "drug": "DB01414"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB01414"}]}, "DB03071": {"dbids": ["DB03071", "EXPT02146"], "name": "4-Methylidene-5-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03070": {"dbids": ["DB03070", "EXPT02840"], "name": "Selenazole-4-Carboxyamide-Adenine Dinucleotide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03073": {"dbids": ["DB03073", "EXPT00177"], "name": "3-Methoxybenzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03072": {"dbids": ["DB03072", "EXPT01494"], "name": "2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03075": {"dbids": ["DB03075", "EXPT02642"], "name": "(Diphosphono)Aminophosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03074": {"dbids": ["DB03074", "EXPT02651"], "name": "7-Deaza-7-Cyano-Guanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03077": {"dbids": ["DB03077", "EXPT02049"], "name": "3-Amino-4-{3-[2-(2-Propoxy-Ethoxy)-Ethoxy]-Propylamino}-Cyclobut-3-Ene-1,2-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03076": {"dbids": ["DB03076", "EXPT02360"], "name": "AHA047", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03079": {"dbids": ["DB03079", "EXPT00084"], "name": "Alpha-Ribazole-5'-Phosphate Derivative", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03078": {"dbids": ["DB03078", "EXPT02673"], "name": "PASBN", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05929": {"dbids": ["DB05929"], "name": "GPI-0100", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05928": {"dbids": ["DB05928"], "name": "CHIR-258", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04617": {"dbids": ["DB04617"], "name": "(9S)-9-[(8-AMMONIOOCTYL)AMINO]-1,2,3,4,9,10-HEXAHYDROACRIDINIUM", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05921": {"dbids": ["DB05921"], "name": "CRA-024781", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05920": {"dbids": ["DB05920"], "name": "RTA 744", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05923": {"dbids": ["DB05923"], "name": "ECO-4601", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05922": {"dbids": ["DB05922"], "name": "Hedgehog pathway inhibitor", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05925": {"dbids": ["DB05925"], "name": "alprazolam lingual spray", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05924": {"dbids": ["DB05924"], "name": "NLX-P101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05926": {"dbids": ["DB05926"], "name": "Actyve hormone therapy", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07219": {"dbids": ["DB07219"], "name": "BENZYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02658": {"dbids": ["DB02658", "EXPT02330"], "name": "2,4-Dinitrophenyl 2-Deoxy-2-Fluoro-Beta-D-Allopyranoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02659": {"dbids": ["DB02659", "EXPT00906"], "name": "Cholic Acid", "groups": ["APPROVED"], "targets": []}, "DB02656": {"dbids": ["DB02656", "EXPT02073"], "name": "2-(4-Morpholinyl)-8-Phenyl-4h-1-Benzopyran-4-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02657": {"dbids": ["DB02657", "EXPT01610"], "name": "Glucosamine 6-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02654": {"dbids": ["DB02654", "EXPT00285"], "name": "6-Hydroxy-Flavin-Adenine Dinucleotide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02655": {"dbids": ["DB02655", "EXPT01114"], "name": "D-Aspartic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02652": {"dbids": ["DB02652", "EXPT02026"], "name": "L-[(N-Hydroxyamino)Carbonyl]Phenylalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02653": {"dbids": ["DB02653", "EXPT02775"], "name": "Delta-Bis(2,2'-Bipyridine)-(5-Methyl-2-2'-Bipyridine)-C2-Adamantane Ruthenium (Ii)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02650": {"dbids": ["DB02650", "EXPT00949"], "name": "Tri-Chloro-Acetaldehyde", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02651": {"dbids": ["DB02651", "EXPT02473"], "name": "{[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07218": {"dbids": ["DB07218"], "name": "6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08905": {"dbids": ["DB08905"], "name": "Formestane", "groups": ["APPROVED", "INVESTIGATIONAL", "WITHDRAWN"], "targets": []}, "DB09129": {"dbids": ["DB09129"], "name": "Chromic chloride", "groups": ["APPROVED"], "targets": []}, "DB09128": {"dbids": ["DB09128"], "name": "Brexpiprazole", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P08908", "drug": "DB09128"}, {"action": "PARTIAL AGONIST", "target": "P08908", "drug": "DB09128"}, {"action": "AGONIST", "target": "P14416", "drug": "DB09128"}, {"action": "PARTIAL AGONIST", "target": "P14416", "drug": "DB09128"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB09128"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB09128"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB09128"}]}, "DB09125": {"dbids": ["DB09125"], "name": "Potassium Citrate", "groups": ["APPROVED"], "targets": []}, "DB09124": {"dbids": ["DB09124"], "name": "Medrogestone", "groups": ["APPROVED"], "targets": []}, "DB09127": {"dbids": ["DB09127"], "name": "Disodium phosphate", "groups": ["APPROVED"], "targets": []}, "DB09126": {"dbids": ["DB09126"], "name": "Chorionic gonadotropin", "groups": ["APPROVED"], "targets": []}, "DB09121": {"dbids": ["DB09121"], "name": "Aurothioglucose", "groups": ["WITHDRAWN"], "targets": []}, "DB09120": {"dbids": ["DB09120"], "name": "Zucapsaicin", "groups": ["APPROVED"], "targets": []}, "DB09123": {"dbids": ["DB09123"], "name": "Dienogest", "groups": ["APPROVED"], "targets": []}, "DB09122": {"dbids": ["DB09122"], "name": "Peginterferon beta-1a", "groups": ["APPROVED"], "targets": []}, "DB08906": {"dbids": ["DB08906"], "name": "Fluticasone furoate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB08906"}]}, "DB01359": {"dbids": ["DB01359"], "name": "Penbutolol", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB01359"}, {"action": "PARTIAL AGONIST", "target": "P08588", "drug": "DB01359"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB01359"}, {"action": "PARTIAL AGONIST", "target": "P07550", "drug": "DB01359"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01359"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB01359"}]}, "DB06931": {"dbids": ["DB06931"], "name": "(1-HYDROXYNONANE-1,1-DIYL)BIS(PHOSPHONIC ACID)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01352": {"dbids": ["DB01352"], "name": "Aprobarbital", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01352"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01352"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01352"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB01352"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01352"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01352"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB01352"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB01352"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB01352"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB01352"}]}, "DB01353": {"dbids": ["DB01353"], "name": "Butethal", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01353"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01353"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01353"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB01353"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01353"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01353"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB01353"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB01353"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB01353"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB01353"}]}, "DB01351": {"dbids": ["DB01351"], "name": "Amobarbital", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01351"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01351"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01351"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB01351"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01351"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01351"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB01351"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB01351"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB01351"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB01351"}]}, "DB01356": {"dbids": ["DB01356"], "name": "Lithium", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P49841", "drug": "DB01356"}, {"action": "INHIBITOR", "target": "P29218", "drug": "DB01356"}, {"action": "INHIBITOR", "target": "O14732", "drug": "DB01356"}, {"action": "POTENTIATOR", "target": "P42263", "drug": "DB01356"}]}, "DB01357": {"dbids": ["DB01357"], "name": "Mestranol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P03372", "drug": "DB01357"}]}, "DB01354": {"dbids": ["DB01354"], "name": "Heptabarbital", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01354"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01354"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01354"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB01354"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01354"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01354"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB01354"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB01354"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB01354"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB01354"}]}, "DB01355": {"dbids": ["DB01355", "EXPT03301"], "name": "Hexobarbital", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01355"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01355"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01355"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB01355"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01355"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01355"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB01355"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB01355"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB01355"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB01355"}]}, "DB08907": {"dbids": ["DB08907"], "name": "Canagliflozin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P31639", "drug": "DB08907"}, {"action": "INHIBITOR", "target": "P13866", "drug": "DB08907"}]}, "DB08900": {"dbids": ["DB08900"], "name": "Teduglutide", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "O95838", "drug": "DB08900"}]}, "DB08418": {"dbids": ["DB08418"], "name": "(4aS,4bR,10bS,12aS)-12a-methyl-1,3-dioxo-2-(pyridin-3-ylmethyl)-1,2,3,4,4a,4b,5,6,10b,11,12,12a-dodecahydronaphtho[2,1-f]isoquinolin-8-yl sulfamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02345": {"dbids": ["DB02345", "EXPT01033"], "name": "Selenocysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08419": {"dbids": ["DB08419"], "name": "(1S)-1-(PHENOXYMETHYL)PROPYL METHYLPHOSPHONOCHLORIDOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02346": {"dbids": ["DB02346", "EXPT00139"], "name": "3'-O-N-Octanoyl-a-D-Glucopyranosyl-B-D-Fructofuranoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08416": {"dbids": ["DB08416"], "name": "(9BETA,13ALPHA,14BETA,17ALPHA)-2-METHOXYESTRA-1,3,5(10)-TRIENE-3,17-DIYL DISULFAMATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02347": {"dbids": ["DB02347", "EXPT00578"], "name": "2-Amino-3-(5-Tert-Butyl-3-(Phosphonomethoxy)-4-Isoxazolyl)Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02340": {"dbids": ["DB02340", "EXPT02839"], "name": "N-Acetyl-Serine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08901": {"dbids": ["DB08901"], "name": "Ponatinib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00519", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P11274", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P10721", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P07949", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "Q02763", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P36888", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P11362", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P21802", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P22607", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P22455", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P06239", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P12931", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P07948", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P35968", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P16234", "drug": "DB08901"}]}, "DB08414": {"dbids": ["DB08414"], "name": "6-CHLORO-2-(1-FURO[2,3-C]PYRIDIN-5-YL-ETHYLSULFANYL)-PYRIMIDIN-4-YLAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02341": {"dbids": ["DB02341", "EXPT02880"], "name": "Mdl 101,146", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02342": {"dbids": ["DB02342", "EXPT01362"], "name": "2-Methoxyestradiol", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08412": {"dbids": ["DB08412"], "name": "6-{4-[HYDROXY-(4-NITRO-PHENOXY)-PHOSPHORYL]-BUTYRYLAMINO}-HEXANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02343": {"dbids": ["DB02343", "EXPT02478"], "name": "3,6,9,12,15-Pentaoxaheptadecane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08413": {"dbids": ["DB08413"], "name": "METHYL-PHOSPHONIC ACID MONO-(4-NITRO-PHENYL) ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04728": {"dbids": ["DB04728"], "name": "Lividomycin A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04729": {"dbids": ["DB04729"], "name": "GENTAMICIN C1A", "groups": ["EXPERIMENTAL"], "targets": [{"action": "ADDUCT", "target": "P0A7S3", "drug": "DB04729"}]}, "DB04098": {"dbids": ["DB04098", "EXPT00617"], "name": "Balanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04099": {"dbids": ["DB04099", "EXPT01234"], "name": "Deamido-Nad+", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04724": {"dbids": ["DB04724"], "name": "(S)-2-((S)-3-ISOBUTYL-2,5-DIOXO-4-QUINOLIN-3-YLMETHYL-[1,4]DIAZEPAN-1YL)-N-METHYL-3-NAPHTALEN-2-YL-PROPIONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04097": {"dbids": ["DB04097", "EXPT03174"], "name": "Uridine-5'-Diphosphate-4-Deoxy-4-Fluoro-Alpha-D-Galactose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04726": {"dbids": ["DB04726"], "name": "7,8,10-TRIMETHYLBENZO[G]PTERIDINE-2,4(3H,10H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04095": {"dbids": ["DB04095", "EXPT00359"], "name": "9-Deazahypoxanthine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04720": {"dbids": ["DB04720"], "name": "S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04721": {"dbids": ["DB04721"], "name": "N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04090": {"dbids": ["DB04090", "EXPT02778"], "name": "2,5-Diaziridin-1-Yl-3-(Hydroxymethyl)-6-Methylcyclohexa-2,5-Diene-1,4-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04723": {"dbids": ["DB04723"], "name": "2-(3-GUANIDINOPHENYL)-3-MERCAPTOPROPANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08658": {"dbids": ["DB08658"], "name": "ETHYL HYDROGEN DIETHYLAMIDOPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08659": {"dbids": ["DB08659"], "name": "2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08654": {"dbids": ["DB08654"], "name": "TRANS-(1S,2S)-2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08655": {"dbids": ["DB08655"], "name": "9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08656": {"dbids": ["DB08656"], "name": "5-amino-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08657": {"dbids": ["DB08657"], "name": "2-(4-(2-((3-(5-(PYRIDIN-2-YLTHIO)THIAZOL-2-YL)UREIDO)METHYL)-1H-IMIDAZOL-4-YL)PHENOXY)ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08650": {"dbids": ["DB08650"], "name": "(1R,3S,5S,8R)-8-HYDROXY-2-OXABICYCLO[3.3.1]NON-6-ENE-3,5-DICARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08651": {"dbids": ["DB08651"], "name": "3'-THIO-THYMIDINE-5'-PHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08652": {"dbids": ["DB08652"], "name": "2-(1H-INDOL-3-YL)ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08653": {"dbids": ["DB08653"], "name": "2-(1H-INDOL-3-YL)ETHANAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00409": {"dbids": ["APRD00316", "DB00409"], "name": "Remoxipride", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB00409"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB00409"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB00409"}, {"action": "OTHER/UNKNOWN", "target": "P28223", "drug": "DB00409"}, {"action": "ANTAGONIST", "target": "Q99720", "drug": "DB00409"}]}, "DB00408": {"dbids": ["APRD00574", "DB00408"], "name": "Loxapine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB00408"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00408"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00408"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00408"}, {"action": "BINDER", "target": "P08908", "drug": "DB00408"}, {"action": "BINDER", "target": "P28222", "drug": "DB00408"}, {"action": "BINDER", "target": "P28221", "drug": "DB00408"}, {"action": "BINDER", "target": "P28566", "drug": "DB00408"}, {"action": "BINDER", "target": "P46098", "drug": "DB00408"}, {"action": "BINDER", "target": "P47898", "drug": "DB00408"}, {"action": "BINDER", "target": "P50406", "drug": "DB00408"}, {"action": "BINDER", "target": "P34969", "drug": "DB00408"}, {"action": "BINDER", "target": "P35348", "drug": "DB00408"}, {"action": "BINDER", "target": "P35368", "drug": "DB00408"}, {"action": "BINDER", "target": "P08913", "drug": "DB00408"}, {"action": "BINDER", "target": "P18089", "drug": "DB00408"}, {"action": "BINDER", "target": "P18825", "drug": "DB00408"}, {"action": "BINDER", "target": "P08588", "drug": "DB00408"}, {"action": "BINDER", "target": "P11229", "drug": "DB00408"}, {"action": "BINDER", "target": "P08172", "drug": "DB00408"}, {"action": "BINDER", "target": "P20309", "drug": "DB00408"}, {"action": "BINDER", "target": "P08173", "drug": "DB00408"}, {"action": "BINDER", "target": "P08912", "drug": "DB00408"}, {"action": "BINDER", "target": "P21728", "drug": "DB00408"}, {"action": "BINDER", "target": "P21918", "drug": "DB00408"}, {"action": "BINDER", "target": "P35462", "drug": "DB00408"}, {"action": "BINDER", "target": "P21917", "drug": "DB00408"}, {"action": "BINDER", "target": "P21918", "drug": "DB00408"}, {"action": "BINDER", "target": "P35367", "drug": "DB00408"}, {"action": "BINDER", "target": "P25021", "drug": "DB00408"}, {"action": "BINDER", "target": "Q9H3N8", "drug": "DB00408"}, {"action": "BINDER", "target": "P31645", "drug": "DB00408"}, {"action": "BINDER", "target": "P23975", "drug": "DB00408"}, {"action": "BINDER", "target": "Q01959", "drug": "DB00408"}]}, "DB06838": {"dbids": ["DB06838"], "name": "methyl L-phenylalaninate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06839": {"dbids": ["DB06839"], "name": "N-(ethoxycarbonyl)-L-leucine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00401": {"dbids": ["APRD00635", "DB00401"], "name": "Nisoldipine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q13936", "drug": "DB00401"}, {"action": "INHIBITOR", "target": "P54289", "drug": "DB00401"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB00401"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB00401"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB00401"}]}, "DB00400": {"dbids": ["APRD01004", "DB00400"], "name": "Griseofulvin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P10875", "drug": "DB00400"}, {"action": "INHIBITOR", "target": "P87066", "drug": "DB00400"}, {"action": "OTHER/UNKNOWN", "target": "Q99456", "drug": "DB00400"}]}, "DB00403": {"dbids": ["APRD00861", "DB00403"], "name": "Ceruletide", "groups": ["APPROVED"], "targets": [{"action": "INDUCER", "target": "P32238", "drug": "DB00403"}]}, "DB00402": {"dbids": ["APRD00431", "DB00402"], "name": "Eszopiclone", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00402"}, {"action": "AGONIST", "target": "P47869", "drug": "DB00402"}, {"action": "AGONIST", "target": "P34903", "drug": "DB00402"}, {"action": "AGONIST", "target": "P31644", "drug": "DB00402"}, {"action": "AGONIST", "target": "P30536", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00402"}]}, "DB00405": {"dbids": ["APRD00770", "DB00405"], "name": "Dexbrompheniramine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00405"}]}, "DB00404": {"dbids": ["APRD00280", "DB00404"], "name": "Alprazolam", "groups": ["APPROVED", "ILLICIT", "INVESTIGATIONAL"], "targets": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00404"}]}, "DB00407": {"dbids": ["APRD00803", "DB00407"], "name": "Ardeparin", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "POTENTIATOR", "target": "P01008", "drug": "DB00407"}, {"action": "AGONIST", "target": "P05546", "drug": "DB00407"}]}, "DB00406": {"dbids": ["APRD00998", "DB00406"], "name": "Gentian Violet", "groups": ["APPROVED"], "targets": []}, "DB04896": {"dbids": ["DB04896"], "name": "Milnacipran", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P31645", "drug": "DB04896"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB04896"}, {"action": "INHIBITOR", "target": "Q05586", "drug": "DB04896"}, {"action": "INHIBITOR", "target": "Q12879", "drug": "DB04896"}, {"action": "INHIBITOR", "target": "Q13224", "drug": "DB04896"}, {"action": "INHIBITOR", "target": "Q14957", "drug": "DB04896"}, {"action": "INHIBITOR", "target": "O15399", "drug": "DB04896"}, {"action": "INHIBITOR", "target": "Q8TCU5", "drug": "DB04896"}, {"action": "INHIBITOR", "target": "O60391", "drug": "DB04896"}]}, "DB04897": {"dbids": ["DB04897"], "name": "Lucinactant", "groups": ["APPROVED"], "targets": []}, "DB04894": {"dbids": ["DB04894"], "name": "Vapreotide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INDUCER", "target": "P30874", "drug": "DB04894"}, {"action": "AGONIST", "target": "P35346", "drug": "DB04894"}, {"action": "ANTAGONIST", "target": "P25103", "drug": "DB04894"}]}, "DB04895": {"dbids": ["DB04895"], "name": "Pegaptanib", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB04892": {"dbids": ["DB04892"], "name": "Phenserine", "groups": ["INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P06276", "drug": "DB04892"}]}, "DB04893": {"dbids": ["DB04893"], "name": "AZD3409", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04890": {"dbids": ["DB04890"], "name": "Bepotastine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB04890"}]}, "DB04891": {"dbids": ["DB04891"], "name": "Becocalcidiol", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04898": {"dbids": ["DB04898"], "name": "Ximelagatran", "groups": ["APPROVED", "INVESTIGATIONAL", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P00734", "drug": "DB04898"}]}, "DB04899": {"dbids": ["DB04899"], "name": "Nesiritide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "BINDER", "target": "P16066", "drug": "DB04899"}]}, "DB04548": {"dbids": ["DB04548", "EXPT01554"], "name": "4-Deoxy-D-Glucuronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04549": {"dbids": ["DB04549", "EXPT01902"], "name": "4-(Aminosulfonyl)-N-[(2,3,4-Trifluorophenyl)Methyl]-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08384": {"dbids": ["DB08384"], "name": "2-({4-[4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08385": {"dbids": ["DB08385"], "name": "4-(quinolin-3-ylmethyl)piperidine-1-carboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08382": {"dbids": ["DB08382"], "name": "2-(4-{(3S,5S)-5-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl}piperazin-1-yl)pyrimidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08383": {"dbids": ["DB08383"], "name": "4,5-bis(4-methoxyphenyl)-2-thiophen-2-yl-1H-imidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04540": {"dbids": ["DB04540", "EXPT00945"], "name": "Cholesterol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04541": {"dbids": ["DB04541", "EXPT01592"], "name": "(8ar)-Hexahydropyrrolo[1,2-a]Pyrazine-1,4-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04542": {"dbids": ["DB04542", "EXPT00601"], "name": "3'-Azido-3'-Deoxythymidine-5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04543": {"dbids": ["DB04543", "EXPT00476"], "name": "2,6-Diamino-8-(1h-Imidazol-2-Ylsulfanylmethyl)-3h-Quinazoline-4-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04544": {"dbids": ["DB04544", "EXPT01015"], "name": "1-Deoxy-1-Acetylamino-Beta-D-Gluco-2-Heptulopyranosonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04545": {"dbids": ["DB04545", "EXPT01847"], "name": "(3r,4r,5r)-5-(Hydroxymethyl)Piperidine-3,4-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04546": {"dbids": ["DB04546", "EXPT00425"], "name": "3-Deaza-Adenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04547": {"dbids": ["DB04547", "EXPT00662"], "name": "Inhibitor Bea409", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07455": {"dbids": ["DB07455"], "name": "N,N'-[biphenyl-4,4'-diyldi(2R)propane-2,1-diyl]dimethanesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04856": {"dbids": ["DB04856"], "name": "Dexloxiglumide", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07653": {"dbids": ["DB07653"], "name": "N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01903": {"dbids": ["DB01903", "EXPT00758"], "name": "5-Bromo-2'-Deoxyuridine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04857": {"dbids": ["DB04857"], "name": "Brasofensine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07657": {"dbids": ["DB07657"], "name": "PHOSPHONIC ACID 2-DODECANOYLAMINO-HEXYL ESTER PROPYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01902": {"dbids": ["DB01902", "EXPT02325"], "name": "1-Ethyl-Pyrrolidine-2,5-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07656": {"dbids": ["DB07656"], "name": "N-[4-(1-BENZOYLPIPERIDIN-4-YL)BUTYL]-3-PYRIDIN-3-YLPROPANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04421": {"dbids": ["DB04421", "EXPT02294"], "name": "Nicotinamide Adenine Dinucleotide 3-Pentanone Adduct", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07659": {"dbids": ["DB07659"], "name": "AC-(D)PHE-PRO-BOROHOMOLYS-OH", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07658": {"dbids": ["DB07658"], "name": "AC-(D)PHE-PRO-BOROLYS-OH", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04426": {"dbids": ["DB02612", "DB04426", "EXPT02108"], "name": "Alpha-Methyl-N-Acetyl-D-Glucosamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04425": {"dbids": ["DB04425", "EXPT02386"], "name": "7,8-Dihydroneopterin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04424": {"dbids": ["DB04424", "EXPT02814"], "name": "RPR128515", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06766": {"dbids": ["DB06766"], "name": "Alcaftadine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB06766"}]}, "DB06767": {"dbids": ["DB06767"], "name": "Ammonium chloride", "groups": ["APPROVED"], "targets": []}, "DB06764": {"dbids": ["DB06764"], "name": "Tetryzoline", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35348", "drug": "DB06764"}]}, "DB07301": {"dbids": ["DB07301"], "name": "9H-CARBAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06760": {"dbids": ["DB06760"], "name": "Sacrosidase", "groups": ["APPROVED"], "targets": []}, "DB06761": {"dbids": ["DB06761"], "name": "Beractant", "groups": ["APPROVED"], "targets": []}, "DB04429": {"dbids": ["DB04429", "EXPT01169"], "name": "4'-Hydroxyflavanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04855": {"dbids": ["DB04855"], "name": "Dronedarone", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35348", "drug": "DB04855"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB04855"}, {"action": "INHIBITOR", "target": "P35498", "drug": "DB04855"}, {"action": "INHIBITOR", "target": "O95069", "drug": "DB04855"}]}, "DB06769": {"dbids": ["DB06769"], "name": "Bendamustine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB02003": {"dbids": ["DB02003", "EXPT01271"], "name": "Delta-Bis(2,2'-Bipyridine)Imidazole Ruthenium (Ii)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02002": {"dbids": ["DB02002", "EXPT02725"], "name": "2-Aminoprop-2-Enamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02001": {"dbids": ["DB02001", "EXPT03102"], "name": "5-(4-Morpholin-4-Yl-Phenylsulfanyl)-2,4-Quinazolinediamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01908": {"dbids": ["DB01908", "EXPT00200"], "name": "RU85493", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02007": {"dbids": ["DB02007", "EXPT01537"], "name": "Alpha-D-Glucose-6-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02006": {"dbids": ["DB02006", "EXPT01084"], "name": "Br-Coeleneterazine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02005": {"dbids": ["DB02005", "EXPT02462"], "name": "2-Oxo-3-Pentenoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02004": {"dbids": ["DB02004", "EXPT00239"], "name": "5-(Aminomethyl)-6-(2,4-Dichlorophenyl)-2-(3,5-Dimethoxyphenyl)Pyrimidin-4-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02009": {"dbids": ["DB02009", "EXPT01995"], "name": "L-756,423", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02008": {"dbids": ["DB02008", "EXPT01503"], "name": "1-(2-Fluorobenzyl)-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07017": {"dbids": ["DB07017"], "name": "(5S)-2-{[(1S)-1-(4-fluorophenyl)ethyl]amino}-5-(1-hydroxy-1-methylethyl)-5-methyl-1,3-thiazol-4(5H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07016": {"dbids": ["DB07016"], "name": "(3R)-8-(dioxidosulfanyl)-3-methyl-1,2,3,4-tetrahydroquinoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07015": {"dbids": ["DB07015"], "name": "(3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinoxalin-2-ylcarbonyl)pyrrolidin-3-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07014": {"dbids": ["DB07014"], "name": "2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07013": {"dbids": ["DB07013"], "name": "TERT-BUTYL 4-({[4-(BUT-2-YN-1-YLAMINO)PHENYL]SULFONYL}METHYL)-4-[(HYDROXYAMINO)CARBONYL]PIPERIDINE-1-CARBOXYLATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07012": {"dbids": ["DB07012"], "name": "6-AMINO-3,7-DIHYDRO-IMIDAZO[4,5-G]QUINAZOLIN-8-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07011": {"dbids": ["DB07011"], "name": "(3S)-1-(1,3-BENZODIOXOL-5-YLMETHYL)-3-[4-(1H-IMIDAZOL-1-YL)PHENOXY]PIPERIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07010": {"dbids": ["DB07010"], "name": "N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04474": {"dbids": ["DB04474", "EXPT00103"], "name": "1-Anilino-8-Naphthalene Sulfonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07019": {"dbids": ["DB07019"], "name": "N-[(5R,14R)-5-AMINO-5,14-DIMETHYL-4-OXO-3-OXA-18-AZATRICYCLO[15.3.1.1~7,11~]DOCOSA-1(21),7(22),8,10,17,19-HEXAEN-19-YL]-N-METHYLMETHANESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07018": {"dbids": ["DB07018"], "name": "5-ETHYL-3-[(2-METHOXYETHYL)METHYLAMINO]-6-METHYL-4-(3-METHYLBENZYL)PYRIDIN-2(1H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07454": {"dbids": ["DB07454"], "name": "(R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08593": {"dbids": ["DB08593"], "name": "1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08592": {"dbids": ["DB08592"], "name": "4-{[4-({4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08591": {"dbids": ["DB08591"], "name": "5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08590": {"dbids": ["DB08590"], "name": "1-(3-HYDROXYPROPYL)-2-[(3-NITROBENZOYL)AMINO]-1H-BENZIMIDAZOL-5-YL PIVALATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04476": {"dbids": ["DB04476", "EXPT01118"], "name": "Trencam-3,2-Hopo", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08597": {"dbids": ["DB08597"], "name": "6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05740": {"dbids": ["DB05740"], "name": "RPI-78M", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07783": {"dbids": ["DB07783"], "name": "1-((1R)-1-(HYDROXYMETHYL)-3-{6-[(3-PHENYLPROPANOYL)AMINO]-1H-INDOL-1-YL}PROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08595": {"dbids": ["DB08595"], "name": "4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07782": {"dbids": ["DB07782"], "name": "4-AMINO-2-TRIFLUOROMETHYL-5-HYDROXYMETHYLPYRIMIDINE PYROPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08594": {"dbids": ["DB08594"], "name": "TERT-BUTYL 2-CYANO-2-METHYLHYDRAZINECARBOXYLATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07781": {"dbids": ["DB07781"], "name": "N-[[3-FLUORO-4-ETHOXY-PYRID-2-YL]ETHYL]-N'-[5-NITRILOMETHYL-PYRIDYL]-THIOUREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04477": {"dbids": ["DB04477", "EXPT03076"], "name": "N-1,2,3,4-Tetrahydronaphth-1-Yl-2'-[3,5-Dimethoxybenzamido]-2'-Deoxy-Adenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07780": {"dbids": ["DB07780"], "name": "FARNESYL DIPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07787": {"dbids": ["DB07787"], "name": "5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07786": {"dbids": ["DB07786"], "name": "1-((1R,2S)-1-{2-[2-(4-CHLOROPHENYL)-1,3-BENZOXAZOL-7-YL]ETHYL}-2-HYDROXYPROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06955": {"dbids": ["DB06955"], "name": "3,4-bis(7-chloro-1H-indol-3-yl)-1H-pyrrole-2,5-dicarboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08598": {"dbids": ["DB08598"], "name": "4-CHLORO-8-METHYL-7-(3-METHYL-BUT-2-ENYL)-6,7,8,9-TETRAHYDRO-2H-2,7,9A-TRIAZA-BENZO[CD]AZULENE-1-THIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07785": {"dbids": ["DB07785"], "name": "1-{(1R,2S)-2-HYDROXY-1-[2-(2-NAPHTHYLOXY)ETHYL]PROPYL}-1H-IMIDAZONE-4-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06954": {"dbids": ["DB06954"], "name": "2-(cycloheptylmethyl)-1,1-dioxido-1-benzothiophen-6-yl sulfamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07784": {"dbids": ["DB07784"], "name": "[4-(4-ACETYLAMINO-PHENYL)-3,5-DIOXO-4-AZA-TRICYCLO[5.2.2.0 2,6]UNDEC-1-YLCARBAMOYLOXY]-ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06957": {"dbids": ["DB06957"], "name": "4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04470": {"dbids": ["DB04470", "EXPT00271"], "name": "CRA_10656", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08893": {"dbids": ["DB08893"], "name": "Mirabegron", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P13945", "drug": "DB08893"}]}, "DB08890": {"dbids": ["DB08890"], "name": "Linaclotide", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P25092", "drug": "DB08890"}]}, "DB06956": {"dbids": ["DB06956"], "name": "N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08896": {"dbids": ["DB08896"], "name": "Regorafenib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P07949", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P17948", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P35968", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P35916", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P10721", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P16234", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P09619", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P11362", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P21802", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "Q02763", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "Q16832", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P04629", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P29317", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P04049", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P15056", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "Q15759", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P42685", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P00519", "drug": "DB08896"}]}, "DB08897": {"dbids": ["DB08897"], "name": "Aclidinium", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB08897"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB08897"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB08897"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB08897"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB08897"}]}, "DB08894": {"dbids": ["DB08894"], "name": "Peginesatide", "groups": ["APPROVED"], "targets": [{"action": "STIMULATOR", "target": "P19235", "drug": "DB08894"}]}, "DB08361": {"dbids": ["DB08361"], "name": "2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06951": {"dbids": ["DB06951"], "name": "(3R)-3-ethyl-N-[(4-methylphenyl)sulfonyl]-L-aspartic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08898": {"dbids": ["DB08898"], "name": "Glucarpidase", "groups": ["APPROVED"], "targets": []}, "DB08899": {"dbids": ["DB08899"], "name": "Enzalutamide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P10275", "drug": "DB08899"}]}, "DB08362": {"dbids": ["DB08362"], "name": "N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06950": {"dbids": ["DB06950"], "name": "4-chloro-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03714": {"dbids": ["DB03714", "EXPT03090"], "name": "4-Carbamoyl-4-{[6-(Difluoro-Phosphono-Methyl)-Naphthalene-2-Carbonyl]-Amino}-Butyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03716": {"dbids": ["DB03716", "EXPT00245"], "name": "5'-Fluoro-5'-Deoxyadenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03717": {"dbids": ["DB03717", "EXPT03258"], "name": "3-Hydroxy-4-(3,4,5-Trihydroxy-Tetrahydro-Pyran-2-Yloxy)-Piperidin-2-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03710": {"dbids": ["DB03710", "EXPT03224"], "name": "N5-(1-Imino-3-Butenyl)-L-Ornithine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03711": {"dbids": ["DB03711", "EXPT02062"], "name": "6-Hydroxy-6-Methyl-Heptan-3-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03712": {"dbids": ["DB03712", "EXPT00326"], "name": "RU85053", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08364": {"dbids": ["DB08364"], "name": "1-{[(1E)-(3-HYDROXY-2-METHYL-5-{[(TRIHYDROXY-LAMBDA^5^-PHOSPHANYL)OXY]METHYL}PYRIDIN-4-YL)METHYLIDENE]AMINO}UNDECAN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06952": {"dbids": ["DB06952"], "name": "(2S)-2-HYDROXY-2H-CHROMENE-2-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03718": {"dbids": ["DB03718", "EXPT03195"], "name": "6-Aza-Ump", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03719": {"dbids": ["DB03719", "EXPT02324"], "name": "N-Ethyl-5'-Carboxamido Adenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04471": {"dbids": ["DB04471", "EXPT02683"], "name": "2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08365": {"dbids": ["DB08365"], "name": "8-bromo-4-(2-chlorophenyl)-N-(2-hydroxyethyl)-6-methyl-1,3-dioxo-1,2,3,6-tetrahydropyrrolo[3,4-e]indole-7-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08367": {"dbids": ["DB08367"], "name": "(R)-2-(FORMYLOXY)-3-(PHOSPHONOOXY)PROPYL PENTANOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04472": {"dbids": ["DB04472", "EXPT02812"], "name": "(R)-1-Para-Nitro-Phenyl-2-Azido-Ethanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05718": {"dbids": ["DB05718"], "name": "Maxy-G34", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05719": {"dbids": ["DB05719"], "name": "Elesclomol", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05715": {"dbids": ["DB05715"], "name": "Genz-112638", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05712": {"dbids": ["DB05712"], "name": "AZD-9684", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05713": {"dbids": ["DB05713"], "name": "LY-517717", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05710": {"dbids": ["DB05710"], "name": "Gantacurium Chloride", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB09287": {"dbids": ["DB09287"], "name": "Polyethylene glycol", "groups": ["APPROVED"], "targets": []}, "DB06439": {"dbids": ["DB06439"], "name": "Tyloxapol", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P06858", "drug": "DB06439"}]}, "DB06918": {"dbids": ["DB06918"], "name": "2-(2-METHYLPHENYL)-1H-INDOLE-6-CARBOXIMIDAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01723": {"dbids": ["DB01723", "EXPT00532"], "name": "{3-[3-(3,4-Dimethoxy-Phenyl)-1-(1-{1-[2-(3,4,5-Trimethoxy-Phenyl)-Butyryl]-Piperidin-2yl}-Vinyloxy)-Propyl]-Phenoxy}-Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01721": {"dbids": ["DB01721", "EXPT03261"], "name": "Analogue of Indinavir Drug", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01720": {"dbids": ["DB01720", "EXPT02579"], "name": "(2z)-2-(Benzoylamino)-3-[4-(2-Bromophenoxy)Phenyl]-2-Propenoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01727": {"dbids": ["DB01727", "EXPT01834"], "name": "Isocitric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01726": {"dbids": ["DB01726", "EXPT00102"], "name": "2-Aminophenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01725": {"dbids": ["DB01725", "EXPT00301"], "name": "CRA_7806", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01724": {"dbids": ["DB01724", "EXPT03054"], "name": "Reduced Threonine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01729": {"dbids": ["DB01729", "EXPT01812"], "name": "(1s,3s,4s)-1,3,4-Triphospho-Myo-Inositol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01728": {"dbids": ["DB01728", "EXPT02544"], "name": "3-[Aminoethylphosphoryl]-[1,2-Di-Palmitoyl]-Sn-Glycerol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00092": {"dbids": ["BIOD00055", "BTD00055", "DB00092"], "name": "Alefacept", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P06729", "drug": "DB00092"}]}, "DB00093": {"dbids": ["BIOD00114", "BTD00114", "DB00093"], "name": "Felypressin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P37288", "drug": "DB00093"}]}, "DB00090": {"dbids": ["BIOD00008", "BTD00008", "DB00090"], "name": "Laronidase", "groups": ["APPROVED"], "targets": []}, "DB00091": {"dbids": ["BIOD00003", "BTD00003", "DB00091"], "name": "Cyclosporine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "BINDER", "target": "P49069", "drug": "DB00091"}, {"action": "INHIBITOR", "target": "Q96LZ3", "drug": "DB00091"}, {"action": "BINDER", "target": "P30405", "drug": "DB00091"}]}, "DB00096": {"dbids": ["BIOD00101", "BTD00101", "DB00096"], "name": "Serum albumin", "groups": ["APPROVED"], "targets": []}, "DB00097": {"dbids": ["BIOD00034", "BTD00034", "DB00097"], "name": "Choriogonadotropin alfa", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "P23945", "drug": "DB00097"}]}, "DB00094": {"dbids": ["BIOD00104", "BTD00104", "DB00094"], "name": "Urofollitropin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P23945", "drug": "DB00094"}]}, "DB00095": {"dbids": ["BIOD00074", "BTD00074", "DB00095"], "name": "Efalizumab", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTIBODY", "target": "P20701", "drug": "DB00095"}]}, "DB00098": {"dbids": ["BIOD00040", "BTD00040", "DB00098"], "name": "Anti-thymocyte Globulin (Rabbit)", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P06126", "drug": "DB00098"}, {"action": "ANTAGONIST", "target": "Q95460", "drug": "DB00098"}]}, "DB00099": {"dbids": ["BIOD00072", "BTD00072", "DB00099"], "name": "Filgrastim", "groups": ["APPROVED"], "targets": [{"action": "STIMULATOR", "target": "Q99062", "drug": "DB00099"}, {"action": "OTHER/UNKNOWN", "target": "P08246", "drug": "DB00099"}]}, "DB01556": {"dbids": ["DB01556"], "name": "Chlorphentermine", "groups": ["ILLICIT", "WITHDRAWN"], "targets": []}, "DB04398": {"dbids": ["DB04398", "EXPT01996"], "name": "Lactic Acid", "groups": ["APPROVED"], "targets": []}, "DB04395": {"dbids": ["DB04395", "EXPT00524"], "name": "Phosphoaminophosphonic Acid-Adenylate Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04394": {"dbids": ["DB04394", "EXPT02892"], "name": "3-Nitro-4-(2-Oxo-Pyrrolidin-1-Yl)-Benzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04397": {"dbids": ["DB04397", "EXPT03221"], "name": "Alpha-D-Glucose-1-Phosphate-6-Vanadate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01557": {"dbids": ["DB01557"], "name": "\u03b1-Methylfentanyl", "groups": ["ILLICIT"], "targets": []}, "DB04391": {"dbids": ["DB04391", "EXPT00444"], "name": "Aeruginosin 98-B", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04393": {"dbids": ["DB04393", "EXPT01135"], "name": "Diclosan", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04392": {"dbids": ["DB04392", "EXPT01281"], "name": "Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone]", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00898": {"dbids": ["APRD00738", "DB00898"], "name": "Ethanol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P14867", "drug": "DB00898"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00898"}, {"action": "AGONIST", "target": "P23415", "drug": "DB00898"}, {"action": "AGONIST", "target": "P23416", "drug": "DB00898"}]}, "DB00899": {"dbids": ["APRD01216", "DB00899"], "name": "Remifentanil", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB00899"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00899"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00899"}]}, "DB00678": {"dbids": ["APRD00052", "DB00678"], "name": "Losartan", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P30556", "drug": "DB00678"}]}, "DB00679": {"dbids": ["APRD00596", "DB00679"], "name": "Thioridazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB00679"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00679"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00679"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00679"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00679"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00679"}]}, "DB00676": {"dbids": ["APRD00821", "DB00676", "DB02775", "EXPT00792"], "name": "Benzyl Benzoate", "groups": ["APPROVED"], "targets": []}, "DB00677": {"dbids": ["APRD00763", "DB00677"], "name": "Isoflurophate", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P22303", "drug": "DB00677"}, {"action": "INHIBITOR", "target": "P06276", "drug": "DB00677"}]}, "DB00674": {"dbids": ["APRD00206", "DB00674", "EXPT01628"], "name": "Galantamine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P22303", "drug": "DB00674"}, {"action": "ALLOSTERIC MODULATOR", "target": "P02708", "drug": "DB00674"}, {"action": "ALLOSTERIC MODULATOR", "target": "P11230", "drug": "DB00674"}, {"action": "ALLOSTERIC MODULATOR", "target": "Q07001", "drug": "DB00674"}, {"action": "ALLOSTERIC MODULATOR", "target": "P07510", "drug": "DB00674"}, {"action": "ALLOSTERIC MODULATOR", "target": "Q04844", "drug": "DB00674"}, {"action": "ALLOSTERIC MODULATOR", "target": "Q15822", "drug": "DB00674"}, {"action": "ALLOSTERIC MODULATOR", "target": "P32297", "drug": "DB00674"}, {"action": "ALLOSTERIC MODULATOR", "target": "P43681", "drug": "DB00674"}, {"action": "ALLOSTERIC MODULATOR", "target": "P30532", "drug": "DB00674"}, {"action": "ALLOSTERIC MODULATOR", "target": "Q15825", "drug": "DB00674"}, {"action": "ALLOSTERIC MODULATOR", "target": "P36544", "drug": "DB00674"}, {"action": "ALLOSTERIC MODULATOR", "target": "Q9UGM1", "drug": "DB00674"}, {"action": "ALLOSTERIC MODULATOR", "target": "Q9GZZ6", "drug": "DB00674"}, {"action": "ALLOSTERIC MODULATOR", "target": "P17787", "drug": "DB00674"}, {"action": "ALLOSTERIC MODULATOR", "target": "Q05901", "drug": "DB00674"}, {"action": "ALLOSTERIC MODULATOR", "target": "P30926", "drug": "DB00674"}, {"action": "INHIBITOR", "target": "P06276", "drug": "DB00674"}]}, "DB00675": {"dbids": ["APRD00123", "DB00675"], "name": "Tamoxifen", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P03372", "drug": "DB00675"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00675"}, {"action": "ANTAGONIST", "target": "Q92731", "drug": "DB00675"}, {"action": "AGONIST", "target": "Q92731", "drug": "DB00675"}]}, "DB00896": {"dbids": ["APRD01220", "DB00896"], "name": "Rimexolone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00896"}]}, "DB00897": {"dbids": ["APRD00313", "DB00897"], "name": "Triazolam", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "Q9UN88", "drug": "DB00897"}, {"action": "OTHER", "target": "P30536", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00897"}]}, "DB00894": {"dbids": ["APRD00640", "DB00894"], "name": "Testolactone", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P11511", "drug": "DB00894"}]}, "DB00671": {"dbids": ["APRD00583", "DB00671"], "name": "Cefixime", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P44469", "drug": "DB00671"}]}, "DB07221": {"dbids": ["DB07221"], "name": "(2,2-DIPHOSPHONOETHYL)(DODECYL)DIMETHYLPHOSPHONIUM", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03279": {"dbids": ["DB03279", "EXPT02044"], "name": "Dodecyl-Alpha-D-Maltoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03278": {"dbids": ["DB03278", "EXPT01285"], "name": "D-Treitol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03277": {"dbids": ["DB03277", "EXPT02187"], "name": "Amylotriose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03276": {"dbids": ["DB03276", "EXPT01283"], "name": "4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03275": {"dbids": ["DB03275", "EXPT01073"], "name": "2-Amino-3-Mercapto-Propionamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03274": {"dbids": ["DB03274", "EXPT01151"], "name": "2'-5'dideoxyuridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03273": {"dbids": ["DB03273", "EXPT00442"], "name": "3'-Oxo-Adenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03272": {"dbids": ["DB03272", "EXPT02434"], "name": "4-Bromo-3-(5'-Carboxy-4'-Chloro-2'-Fluorophenyl)-1-Methyl-5-Trifluoromethyl-Pyrazol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03271": {"dbids": ["DB03271", "EXPT01698"], "name": "7,8-Dihydro-L-Biopterin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03270": {"dbids": ["DB03270", "EXPT01397"], "name": "2,6-Difluorobenzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04971": {"dbids": ["DB04971"], "name": "Reglixane", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04970": {"dbids": ["DB04970"], "name": "Lesopitron", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04973": {"dbids": ["DB04973"], "name": "LErafAON", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04972": {"dbids": ["DB04972"], "name": "Canfosfamide", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04975": {"dbids": ["DB04975"], "name": "Banoxantrone", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04974": {"dbids": ["DB04974"], "name": "AP1903", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04977": {"dbids": ["DB04977"], "name": "Aplidine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04976": {"dbids": ["DB04976"], "name": "M40403", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04979": {"dbids": ["DB04979"], "name": "AVR118", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04978": {"dbids": ["DB04978"], "name": "SP1049C", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08041": {"dbids": ["DB08041"], "name": "3-BENZYLOXYCARBONYLAMINO-2-HYDROXY-4-PHENYL-BUTYRIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08040": {"dbids": ["DB08040"], "name": "N-[(2R)-2-benzyl-4-(hydroxyamino)-4-oxobutanoyl]-L-alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08043": {"dbids": ["DB08043"], "name": "1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08042": {"dbids": ["DB08042"], "name": "N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08045": {"dbids": ["DB08045"], "name": "4-{4-[4-(3-AMINOPROPOXY)PHENYL]-1H-PYRAZOL-5-YL}-6-CHLOROBENZENE-1,3-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08044": {"dbids": ["DB08044"], "name": "(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08047": {"dbids": ["DB08047"], "name": "4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08046": {"dbids": ["DB08046"], "name": "2-chloro-5-[(1S)-1-hydroxy-3-oxo-2H-isoindol-1-yl]benzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08049": {"dbids": ["DB08049"], "name": "7,8-dihydroxy-4-phenyl-2H-chromen-2-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08048": {"dbids": ["DB08048"], "name": "4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03019": {"dbids": ["DB03019", "EXPT00924"], "name": "4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03018": {"dbids": ["DB03018", "EXPT00155"], "name": "3,4-Dimethylaniline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03013": {"dbids": ["DB03013", "EXPT00851"], "name": "Di(N-Acetyl-D-Glucosamine)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03012": {"dbids": ["DB03012", "EXPT01063"], "name": "Phenylalanine-N-Sulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03011": {"dbids": ["DB03011", "EXPT00438"], "name": "Adenosine-5'-(Dithio)Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03010": {"dbids": ["DB03010", "EXPT01349"], "name": "Epothilone B", "groups": ["EXPERIMENTAL", "INVESTIGATIONAL"], "targets": []}, "DB03016": {"dbids": ["DB03016", "EXPT00317"], "name": "CRA_1801", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03015": {"dbids": ["DB03015", "EXPT02660"], "name": "6-Hydroxy-1,6-Dihydro Purine Nucleoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02638": {"dbids": ["DB02638", "EXPT03310"], "name": "Terlipressin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P30518", "drug": "DB02638"}, {"action": "STIMULATOR", "target": "P37288", "drug": "DB02638"}]}, "DB02639": {"dbids": ["DB02639", "EXPT02256"], "name": "4-Methylumbelliferyl-Alpha-D-Glucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02630": {"dbids": ["DB02630", "EXPT02071"], "name": "L-Xylitol 5-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02631": {"dbids": ["DB02631", "EXPT00961"], "name": "5-Chloro-6-[(2-Iminopyrrolidin-1-Yl)Methyl]Pyrimidine-2,4(1h,3h)-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02632": {"dbids": ["DB02632", "EXPT00033"], "name": "1-O-[P-Nitrophenyl]-Beta-D-Galactopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02633": {"dbids": ["DB02633", "EXPT00841"], "name": "Cibacron Blue", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02635": {"dbids": ["DB02635", "EXPT01863"], "name": "N-[O-Phosphono-Pyridoxyl]-Isoleucine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02636": {"dbids": ["DB02636", "EXPT00354"], "name": "9-Hydroxy-8-Methoxy-6-Nitro-Phenanthrol[3,4-D][1,3]Dioxole-5-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02637": {"dbids": ["DB02637", "EXPT02406"], "name": "Oxaloacetate Ion", "groups": ["EXPERIMENTAL"], "targets": []}, "DB11362": {"dbids": ["DB11362"], "name": "Selexipag", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P43119", "drug": "DB11362"}]}, "DB11363": {"dbids": ["DB11363"], "name": "Alectinib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9UM73", "drug": "DB11363"}]}, "DB11366": {"dbids": ["DB11366"], "name": "Roquinimex", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB11367": {"dbids": ["DB11367"], "name": "Cefroxadine", "groups": ["APPROVED"], "targets": []}, "DB11364": {"dbids": ["DB11364"], "name": "Pidotimod", "groups": ["APPROVED"], "targets": []}, "DB11365": {"dbids": ["DB11365"], "name": "Senna glycoside", "groups": ["APPROVED"], "targets": []}, "DB07819": {"dbids": ["DB07819"], "name": "(2E)-3-(4-CHLOROPHENYL)-N-HYDROXYACRYLAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07818": {"dbids": ["DB07818"], "name": "(2E)-3-(2,4-DICHLOROPHENYL)-N-HYDROXYACRYLAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07817": {"dbids": ["DB07817"], "name": "1-{3-[(4-pyridin-2-ylpiperazin-1-yl)sulfonyl]phenyl}-3-(1,3-thiazol-2-yl)urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07816": {"dbids": ["DB07816"], "name": "N-(P-CYANOPHENYL)-N'-DIPHENYLMETHYL-GUANIDINE-ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07815": {"dbids": ["DB07815"], "name": "GIBBERELLIN A4", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07814": {"dbids": ["DB07814"], "name": "GIBBERELLIN A3", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07813": {"dbids": ["DB07813"], "name": "GLYCYLALANYL-N-2-NAPHTHYL-L-PROLINEAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07812": {"dbids": ["DB07812"], "name": "N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07811": {"dbids": ["DB07811"], "name": "N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07810": {"dbids": ["DB07810"], "name": "3-(4-HYDROXYPHENYL)-1-(2,4,6-TRIHYDROXYPHENYL)PROPAN-1-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03556": {"dbids": ["DB03556", "EXPT02539"], "name": "2-(2-{2-[2-(2-{2-[2-(2-Ethoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol, Polyethyleneglycol Peg400", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03555": {"dbids": ["DB03555", "EXPT01016"], "name": "CRA_11092", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05367": {"dbids": ["DB05367"], "name": "Actelion-1", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05366": {"dbids": ["DB05366"], "name": "CDB-2914", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05365": {"dbids": ["DB05365"], "name": "BF-200 ALA", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05364": {"dbids": ["DB05364"], "name": "ROX-888", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05363": {"dbids": ["DB05363"], "name": "LIC-477", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05362": {"dbids": ["DB05362"], "name": "SSR-126517E", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05361": {"dbids": ["DB05361"], "name": "SR-123781A", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05360": {"dbids": ["DB05360"], "name": "KW-3902", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05369": {"dbids": ["DB05369"], "name": "HZT-501", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05368": {"dbids": ["DB05368"], "name": "Ragweed pollen extract", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB04706": {"dbids": ["DB04706"], "name": "(3BETA,7BETA)-CHOLEST-5-ENE-3,7-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04707": {"dbids": ["DB04707"], "name": "HYDROXYFASUDIL", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "Q13464", "drug": "DB04707"}]}, "DB04704": {"dbids": ["DB04704"], "name": "(3BETA,20R)-CHOLEST-5-ENE-3,20-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04705": {"dbids": ["DB04705"], "name": "(3BETA)-CHOLEST-5-ENE-3,25-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04702": {"dbids": ["DB04702"], "name": "S-[(2E)-3,7-DIMETHYLOCTA-2,6-DIENYL] TRIHYDROGENTHIODIPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04703": {"dbids": ["DB04703"], "name": "HESPERIDIN", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04700": {"dbids": ["DB04700"], "name": "GLUTATHIONE SULFINATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04701": {"dbids": ["DB04701"], "name": "S-METHYL-GLUTATHIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04708": {"dbids": ["DB04708"], "name": "(S)-TETRAHYDROFURAN-3-YL (2S,3S)-4-((S)-4-((1R,3R)-3-(2-AMINO-2-OXOETHYL)-2,3-DIHYDRO-1H-INDEN-1-YL)-2-BENZYL-3-OXO-2,3-DIHYDRO-1H-PYRROL-2-YL)-3-HYDROXY-1-PHENYLBUTAN-2-YLCARBAMATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04709": {"dbids": ["DB04709"], "name": "(3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08676": {"dbids": ["DB08676"], "name": "(20S)-19,20,22,23-TETRAHYDRO-19-OXO-5H,21H-18,20-ETHANO-12,14-ETHENO-6,10-METHENOBENZ[D]IMIDAZO[4,3-L][1,6,9,13]OXATRIAZACYCLONOADECOSINE-9-CARBONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08677": {"dbids": ["DB08677"], "name": "N-(5-ISOPROPYL-THIAZOL-2-YL)-2-PYRIDIN-3-YL-ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08674": {"dbids": ["DB08674"], "name": "(20S)-19,20,21,22-TETRAHYDRO-19-OXO-5H-18,20-ETHANO-12,14-ETHENO-6,10-METHENO-18H-BENZ[D]IMIDAZO[4,3-K][1,6,9,12]OXATRIAZA-CYCLOOCTADECOSINE-9-CARBONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08675": {"dbids": ["DB08675"], "name": "(6E)-7-{6-[(1E)-OCT-1-ENYL]-2,3-DIAZABICYCLO[2.2.1]HEPT-2-EN-5-YL}HEPT-6-ENOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08672": {"dbids": ["DB08672"], "name": "4-[(3R)-3-{[2-(4-FLUOROPHENYL)-2-OXOETHYL]AMINO}BUTYL]BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08673": {"dbids": ["DB08673"], "name": "4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08670": {"dbids": ["DB08670"], "name": "METHYL N-[(2S,3R)-3-AMINO-2-HYDROXY-3-(4-ISOPROPYLPHENYL)PROPANOYL]-D-ALANYL-D-LEUCINATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08671": {"dbids": ["DB08671"], "name": "5-IMINO-4-(2-TRIFLUOROMETHYL-PHENYLAZO)-5H-PYRAZOL-3-YLAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08678": {"dbids": ["DB08678"], "name": "(4-ETHYLPHENYL)SULFAMIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08679": {"dbids": ["DB08679"], "name": "2-METHYL-FURAN-3-CARBOTHIOIC ACID [4-CHLORO-3-(3-METHYL-BUT-2-ENYLOXY)-PHENYL]-AMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00463": {"dbids": ["APRD00757", "DB00463"], "name": "Metharbital", "groups": ["WITHDRAWN"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00463"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00463"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00463"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00463"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00463"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00463"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00463"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00463"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB00463"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00463"}]}, "DB00462": {"dbids": ["APRD00314", "DB00462"], "name": "Methylscopolamine bromide", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00462"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00462"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00462"}]}, "DB00461": {"dbids": ["APRD01128", "DB00461"], "name": "Nabumetone", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00461"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00461"}]}, "DB00460": {"dbids": ["APRD01290", "DB00460"], "name": "Verteporfin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB00467": {"dbids": ["APRD00947", "DB00467"], "name": "Enoxacin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P43700", "drug": "DB00467"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB00467"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00467"}]}, "DB00466": {"dbids": ["APRD00269", "DB00466"], "name": "Picrotoxin", "groups": ["EXPERIMENTAL"], "targets": [{"action": "ANTAGONIST", "target": "P24046", "drug": "DB00466"}, {"action": "ANTAGONIST", "target": "P14867", "drug": "DB00466"}, {"action": "ANTAGONIST", "target": "P23416", "drug": "DB00466"}, {"action": "ANTAGONIST", "target": "O75311", "drug": "DB00466"}]}, "DB00465": {"dbids": ["APRD01060", "DB00465"], "name": "Ketorolac", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00465"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00465"}]}, "DB00237": {"dbids": ["APRD00752", "DB00237"], "name": "Butabarbital", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00237"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00237"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00237"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB00237"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB00237"}]}, "DB00469": {"dbids": ["APRD00011", "DB00469"], "name": "Tenoxicam", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00469"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00469"}]}, "DB00468": {"dbids": ["APRD00563", "DB00468"], "name": "Quinine", "groups": ["APPROVED"], "targets": [{"action": "OTHER", "target": "P14770", "drug": "DB00468"}, {"action": "INHIBITOR", "target": "O15554", "drug": "DB00468"}]}, "DB07514": {"dbids": ["DB07514"], "name": "3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06858": {"dbids": ["DB06858"], "name": "N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06859": {"dbids": ["DB06859"], "name": "N-ALLYL-5-AMIDINOAMINOOXY-PROPYLOXY-3-CHLORO-N-CYCLOPENTYLBENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07239": {"dbids": ["DB07239"], "name": "7-(aminomethyl)-6-(2-chlorophenyl)-1-methyl-1H-benzimidazole-5-carbonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07515": {"dbids": ["DB07515"], "name": "1-(2-{[(6-AMINO-2-METHYLPYRIDIN-3-YL)METHYL]AMINO}ETHYL)-6-CHLORO-3-[(2,2-DIFLUORO-2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06850": {"dbids": ["DB06850"], "name": "(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06851": {"dbids": ["DB06851"], "name": "N-(pyridin-3-ylmethyl)aniline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06852": {"dbids": ["DB06852"], "name": "4-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YLAMINO]-3-(1H-BENZIMIDAZOL-2-YL)-6-CHLOROQUINOLIN-2(1H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06853": {"dbids": ["DB06853"], "name": "N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06854": {"dbids": ["DB06854"], "name": "2-(2-HYDROXY-BIPHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06855": {"dbids": ["DB06855"], "name": "6-FLUORO-2-(2-HYDROXY-3-ISOBUTOXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06856": {"dbids": ["DB06856"], "name": "6-FLUORO-2-[2-HYDROXY-3-(2-METHYL-CYCLOHEXYLOXY)-PHENYL]-1H-INDOLE-5-CARBOXAMIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06857": {"dbids": ["DB06857"], "name": "N-(4-CARBAMIMIDOYL-3-CHORO-PHENYL)-2-HYDROXY-3-IODO-5-METHYL-BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04562": {"dbids": ["DB04562", "EXPT03105"], "name": "Tricarballylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04563": {"dbids": ["DB04563", "EXPT00276"], "name": "CRA_9678", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04560": {"dbids": ["DB04560", "EXPT01272"], "name": "4,7-Dioxosebacic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04561": {"dbids": ["DB04561", "EXPT00595"], "name": "4-Acetamido-2,4-Didexoy-D-Glycero-Beta-D-Galacto-Octopyranosylphosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04566": {"dbids": ["DB04566", "EXPT01874"], "name": "Inosinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04567": {"dbids": ["DB04567", "EXPT01025"], "name": "Chromophore (Gly-Tyr-Gly)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04564": {"dbids": ["DB04564", "EXPT02023"], "name": "Gluconolactone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04565": {"dbids": ["DB04565", "EXPT02962"], "name": "4-(Acetylamino)-3-[(Hydroxyacetyl)Amino]Benzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04568": {"dbids": ["DB04568", "EXPT00477"], "name": "5-Aminoimidazole Ribonucleoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04569": {"dbids": ["DB04569", "EXPT02593"], "name": "Formic Acid Benzyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07518": {"dbids": ["DB07518"], "name": "(2R)-2-ETHYL-1-HEXANESULFONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02205": {"dbids": ["DB02205", "EXPT00760"], "name": "6-(1,1-Dimethylallyl)-2-(1-Hydroxy-1-Methylethyl)-2,3-Dihydro-7h-Furo[3,2-G]Chromen-7-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07519": {"dbids": ["DB07519"], "name": "(6R)-2-amino-6-[2-(3'-methoxybiphenyl-3-yl)ethyl]-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07526": {"dbids": ["DB07526"], "name": "N-[4-({[5-(DIMETHYLAMINO)-1-NAPHTHYL]SULFONYL}AMINO)BUTYL]-3-SULFANYLPROPANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00287": {"dbids": ["APRD01271", "DB00287"], "name": "Travoprost", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P43088", "drug": "DB00287"}]}, "DB00286": {"dbids": ["APRD00396", "DB00286"], "name": "Conjugated Estrogens", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P03372", "drug": "DB00286"}]}, "DB00285": {"dbids": ["APRD00125", "DB00285"], "name": "Venlafaxine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P31645", "drug": "DB00285"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00285"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00285"}]}, "DB00284": {"dbids": ["APRD00656", "DB00284"], "name": "Acarbose", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "O43451", "drug": "DB00284"}, {"action": "INHIBITOR", "target": "P04746", "drug": "DB00284"}, {"action": "INHIBITOR", "target": "P10253", "drug": "DB00284"}, {"action": "INHIBITOR", "target": "P14410", "drug": "DB00284"}]}, "DB00283": {"dbids": ["APRD00875", "DB00283"], "name": "Clemastine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00283"}]}, "DB00282": {"dbids": ["APRD01161", "DB00282"], "name": "Pamidronate", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P14324", "drug": "DB00282"}]}, "DB00281": {"dbids": ["APRD00479", "DB00281", "DB05291"], "name": "Lidocaine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00281"}, {"action": "INHIBITOR", "target": "Q15858", "drug": "DB00281"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00281"}, {"action": "ANTAGONIST", "target": "P00533", "drug": "DB00281"}]}, "DB00280": {"dbids": ["APRD00507", "DB00280"], "name": "Disopyramide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB00280"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00280"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00280"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00280"}, {"action": "INHIBITOR", "target": "Q9NZV8", "drug": "DB00280"}, {"action": "INHIBITOR", "target": "Q9UK17", "drug": "DB00280"}]}, "DB00289": {"dbids": ["APRD00614", "DB00289"], "name": "Atomoxetine", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "Q01959", "drug": "DB00289"}, {"action": "BLOCKER", "target": "Q05586", "drug": "DB00289"}, {"action": "BLOCKER", "target": "Q12879", "drug": "DB00289"}, {"action": "BLOCKER", "target": "Q13224", "drug": "DB00289"}, {"action": "BLOCKER", "target": "Q14957", "drug": "DB00289"}, {"action": "BLOCKER", "target": "O15399", "drug": "DB00289"}, {"action": "BLOCKER", "target": "Q8TCU5", "drug": "DB00289"}, {"action": "BLOCKER", "target": "O60391", "drug": "DB00289"}]}, "DB00288": {"dbids": ["APRD00788", "DB00288"], "name": "Amcinonide", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00288"}, {"action": "AGONIST", "target": "P04083", "drug": "DB00288"}]}, "DB06700": {"dbids": ["DB06700"], "name": "Desvenlafaxine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P31645", "drug": "DB06700"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB06700"}]}, "DB06701": {"dbids": ["DB06701"], "name": "Dexmethylphenidate", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q01959", "drug": "DB06701"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB06701"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB06701"}]}, "DB06702": {"dbids": ["DB06702"], "name": "Fesoterodine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P20309", "drug": "DB06702"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB06702"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB06702"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB06702"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB06702"}]}, "DB06703": {"dbids": ["DB06703"], "name": "Gadobutrol", "groups": ["APPROVED"], "targets": []}, "DB06704": {"dbids": ["DB06704"], "name": "Iobenguane", "groups": ["APPROVED"], "targets": []}, "DB06705": {"dbids": ["DB06705"], "name": "Gadofosveset trisodium", "groups": ["APPROVED"], "targets": []}, "DB06706": {"dbids": ["DB06706"], "name": "Isometheptene", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35348", "drug": "DB06706"}, {"action": "INHIBITOR", "target": "Q05940", "drug": "DB06706"}]}, "DB06707": {"dbids": ["DB06707"], "name": "Levonordefrin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35348", "drug": "DB06707"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB06707"}]}, "DB06708": {"dbids": ["DB06708"], "name": "Lumefantrine", "groups": ["APPROVED"], "targets": []}, "DB06709": {"dbids": ["DB06709"], "name": "Methacholine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P20309", "drug": "DB06709"}]}, "DB09509": {"dbids": ["DB09509"], "name": "Samarium Sm-153 lexidronam pentasodium", "groups": ["APPROVED"], "targets": []}, "DB02029": {"dbids": ["DB02029", "EXPT00923"], "name": "N-Cyclohexyl-N'-(4-Iodophenyl)Urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02028": {"dbids": ["DB02028", "EXPT01828"], "name": "L-Alpha-Glycerophospho-D-Myo-Inositol-4,5-Bis-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02025": {"dbids": ["DB02025", "EXPT00421"], "name": "L-D-(a-Aminoadipoyl)-L-Cysteinyl-D-Valine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02024": {"dbids": ["DB02024", "EXPT01708"], "name": "3-phenylpropionic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02027": {"dbids": ["DB02027", "EXPT01253"], "name": "N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N'-Nitroguanidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02026": {"dbids": ["DB02026", "EXPT00981"], "name": "Furo[2,3d]Pyrimidine Antifolate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02021": {"dbids": ["DB02021", "EXPT01433"], "name": "Fidarestat", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P15121", "drug": "DB02021"}]}, "DB02020": {"dbids": ["DB02020", "EXPT00502"], "name": "Alrestatin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02023": {"dbids": ["DB02023", "EXPT01532"], "name": "8-Oxo-2'-Deoxy-Guanosine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02022": {"dbids": ["DB02022", "EXPT01759"], "name": "4-Amino-5-Hydroxymethyl-2-Methylpyrimidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07031": {"dbids": ["DB07031"], "name": "R-3-FLUORO-4-[2-HYDROXY-2-(5,5,8,8-TETRAMETHYL-5,6,7,8,-TETRAHYDRO-NAPHTALEN-2-YL)-ACETYLAMINO]-BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01244": {"dbids": ["APRD00727", "DB01244"], "name": "Bepridil", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "O00555", "drug": "DB01244"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB01244"}, {"action": "INHIBITOR", "target": "Q9NY47", "drug": "DB01244"}, {"action": "INHIBITOR", "target": "P05023", "drug": "DB01244"}, {"action": "INHIBITOR", "target": "P51787", "drug": "DB01244"}, {"action": "OTHER", "target": "P63316", "drug": "DB01244"}, {"action": "BINDER", "target": "P62158", "drug": "DB01244"}, {"action": "INHIBITOR", "target": "Q01064", "drug": "DB01244"}, {"action": "INHIBITOR", "target": "P54750", "drug": "DB01244"}]}, "DB07033": {"dbids": ["DB07033"], "name": "5-HYDROXY-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07032": {"dbids": ["DB07032"], "name": "2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07035": {"dbids": ["DB07035"], "name": "(2E)-3-{3-[(5-ETHYL-3-IODO-6-METHYL-2-OXO-1,2-DIHYDROPYRIDIN-4-YL)OXY]PHENYL}ACRYLONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07034": {"dbids": ["DB07034"], "name": "2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07037": {"dbids": ["DB07037"], "name": "(2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01245": {"dbids": ["APRD00696", "DB01245"], "name": "Decamethonium", "groups": ["APPROVED"], "targets": [{"action": "PARTIAL AGONIST", "target": "Q15822", "drug": "DB01245"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB01245"}]}, "DB07039": {"dbids": ["DB07039"], "name": "(2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07038": {"dbids": ["DB07038"], "name": "2-(cyclohexylamino)benzoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01246": {"dbids": ["APRD00258", "DB01246"], "name": "Alimemazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB01246"}]}, "DB01247": {"dbids": ["APRD00701", "DB01247"], "name": "Isocarboxazid", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P21397", "drug": "DB01247"}, {"action": "INHIBITOR", "target": "P27338", "drug": "DB01247"}]}, "DB07233": {"dbids": ["DB07233"], "name": "N-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}-5-methyl-D-tryptophan", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01240": {"dbids": ["APRD00949", "DB01240"], "name": "Epoprostenol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "Q9H244", "drug": "DB01240"}, {"action": "AGONIST", "target": "P43119", "drug": "DB01240"}, {"action": "INDUCER", "target": "Q16647", "drug": "DB01240"}]}, "DB01241": {"dbids": ["APRD00293", "DB01241"], "name": "Gemfibrozil", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "Q07869", "drug": "DB01241"}]}, "DB01242": {"dbids": ["APRD00253", "DB01242", "DB07600"], "name": "Clomipramine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P31645", "drug": "DB01242"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01242"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB01242"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01242"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB01242"}, {"action": "INHIBITOR", "target": "P09211", "drug": "DB01242"}]}, "DB01243": {"dbids": ["APRD00866", "DB01243"], "name": "Chloroxine", "groups": ["APPROVED"], "targets": []}, "DB02289": {"dbids": ["DB02289", "EXPT01430"], "name": "2-Aminopropanedioic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02288": {"dbids": ["DB02288", "EXPT00152"], "name": "CRA_9334", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07232": {"dbids": ["DB07232"], "name": "(2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04761": {"dbids": ["DB04761"], "name": "PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-[(PYRIDIN-3-YLMETHYL)-AMIDE]", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02281": {"dbids": ["DB02281", "EXPT01453"], "name": "Formycin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02280": {"dbids": ["DB02280", "EXPT02794"], "name": "(R)-Mandelic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02283": {"dbids": ["DB02283", "EXPT00051"], "name": "2-Phenylamino-Ethanesulfonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02282": {"dbids": ["DB02282", "EXPT02241"], "name": "5'-Deoxy-5'-Methylthioadenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02285": {"dbids": ["DB02285", "EXPT02636"], "name": "Protoporphyrin Ix", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01066": {"dbids": ["APRD00850", "DB01066"], "name": "Cefditoren", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB01066"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01066"}]}, "DB02287": {"dbids": ["DB02287", "EXPT00016"], "name": "2-(2-Hydroxy-Phenyl)-3h-Benzoimidazole-5-Carboxamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02286": {"dbids": ["DB02286", "EXPT00218"], "name": "2-Amino-3-(4-Amino-1h-Indol-3-Yl)Propanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04763": {"dbids": ["DB04763"], "name": "1-N-(4-SULFAMOYLPHENYL-ETHYL)-2,4,6-TRIMETHYLPYRIDINIUM", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04764": {"dbids": ["DB04764"], "name": "[4-(3-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-(5-PHENETHYL- PYRIDIN-3-YL)-METHANONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01061": {"dbids": ["APRD00814", "DB01061"], "name": "Azlocillin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01061"}]}, "DB03484": {"dbids": ["DB03484", "EXPT01637"], "name": "L-Alpha-Glycerophosphorylethanolamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03485": {"dbids": ["DB03485", "EXPT01400"], "name": "Alpha-D-Fucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03486": {"dbids": ["DB03486", "EXPT01632"], "name": "Phosphomethylphosphonic Acid Guanosyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03487": {"dbids": ["DB03487", "EXPT02930"], "name": "3-Aminosuccinimide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03480": {"dbids": ["DB03480", "EXPT00751"], "name": "Brequinar Analog", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03481": {"dbids": ["DB03481", "EXPT01681"], "name": "5,10-Dimethylene Tetrahydromethanopterin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03482": {"dbids": ["DB03482", "EXPT02776"], "name": "8-Demethyl-8-Dimethylamino-Flavin-Adenine-Dinucleotide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03483": {"dbids": ["DB03483", "EXPT00686"], "name": "4-Benzoylamino-4-{1-{1-Carbamoyl-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethylcarbamoyl}-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethylcarbamoyl}-Butyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01063": {"dbids": ["APRD00462", "DB01063"], "name": "Acetophenazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB01063"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01063"}]}, "DB03488": {"dbids": ["DB03488", "EXPT03157"], "name": "Uridine-5'-Diphosphate-2-Deoxy-2-Fluoro-Alpha-D-Galactose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03489": {"dbids": ["DB03489", "EXPT01966"], "name": "2-Keto-3-Deoxygluconate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00041": {"dbids": ["BIOD00082", "BTD00082", "DB00041"], "name": "Aldesleukin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P14784", "drug": "DB00041"}, {"action": "MODULATOR", "target": "P14784", "drug": "DB00041"}, {"action": "AGONIST", "target": "P01589", "drug": "DB00041"}, {"action": "MODULATOR", "target": "P01589", "drug": "DB00041"}, {"action": "AGONIST", "target": "P31785", "drug": "DB00041"}]}, "DB00040": {"dbids": ["BIOD00057", "BTD00057", "DB00040"], "name": "Glucagon recombinant", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P47871", "drug": "DB00040"}]}, "DB00043": {"dbids": ["BIOD00081", "BTD00081", "DB00043"], "name": "Omalizumab", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "Q01362", "drug": "DB00043"}]}, "DB08265": {"dbids": ["DB08265"], "name": "2-(TOLUENE-4-SULFONYL)-2H-BENZO[D][1,2,3]DIAZABORININ-1-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00042": {"dbids": ["BIOD00070", "BTD00070", "DB00042"], "name": "Botulinum Toxin Type B", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "P63027", "drug": "DB00042"}, {"action": "BINDER", "target": "P23763", "drug": "DB00042"}]}, "DB00597": {"dbids": ["APRD00992", "DB00597"], "name": "Gadoteridol", "groups": ["APPROVED"], "targets": []}, "DB00596": {"dbids": ["APRD01010", "DB00596"], "name": "Halobetasol Propionate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00596"}]}, "DB08266": {"dbids": ["DB08266"], "name": "methyl [(1E,5R)-5-{(3S)-3-[(2E,4E)-2,5-dimethylocta-2,4-dienoyl]-2,4-dioxo-3,4-dihydro-2H-pyran-6-yl}hexylidene]carbamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08878": {"dbids": ["DB08878"], "name": "Aminopterin", "groups": ["INVESTIGATIONAL", "WITHDRAWN"], "targets": []}, "DB00047": {"dbids": ["BIOD00045", "BTD00045", "DB00047", "DB01308"], "name": "Insulin Glargine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P06213", "drug": "DB00047"}, {"action": "AGONIST", "target": "P08069", "drug": "DB00047"}]}, "DB05888": {"dbids": ["DB05888"], "name": "MEM 1414", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05889": {"dbids": ["DB05889"], "name": "CMC-544", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05886": {"dbids": ["DB05886"], "name": "NV-18", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05887": {"dbids": ["DB05887"], "name": "TAFA-93", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05884": {"dbids": ["DB05884"], "name": "HCV-086", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB00046": {"dbids": ["BIOD00065", "BTD00065", "DB00046", "DB01310"], "name": "Insulin Lispro", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P06213", "drug": "DB00046"}]}, "DB05882": {"dbids": ["DB05882"], "name": "CHF 4227", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05883": {"dbids": ["DB05883"], "name": "ABX-PTH", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05880": {"dbids": ["DB05880"], "name": "MBT-0312", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05881": {"dbids": ["DB05881"], "name": "EHT 0202", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03738": {"dbids": ["DB03738", "EXPT02522"], "name": "Pantothenoylaminoethenethiol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03739": {"dbids": ["DB03739", "EXPT01388"], "name": "3-Hydroxyimino Quinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03736": {"dbids": ["DB03736", "EXPT01002"], "name": "2-Cyclopropylmethylenepropanal", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03737": {"dbids": ["DB03737", "EXPT01454"], "name": "4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03734": {"dbids": ["DB03734", "EXPT03267"], "name": "Xylarohydroxamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03735": {"dbids": ["DB03735", "EXPT02147"], "name": "9-(2-Deoxy-Beta-D-Ribofuranosyl)-6-Methylpurine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03732": {"dbids": ["DB03732", "EXPT01346"], "name": "Etheno-Nadp", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03733": {"dbids": ["DB03733", "EXPT01133"], "name": "Ethylene Dichloride", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03730": {"dbids": ["DB03730", "EXPT00159"], "name": "3,9-Dimethyladenine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03731": {"dbids": ["DB03731", "EXPT02831"], "name": "S-2-(Boronoethyl)-L-Cysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08613": {"dbids": ["DB08613"], "name": "2,2,2-TRIFLUORO-1-{5-[(3-PHENYL-5,6-DIHYDROIMIDAZO[1,2-A]PYRAZIN-7(8H)-YL)CARBONYL]THIOPHEN-2-YL}ETHANE-1,1-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05087": {"dbids": ["DB05087"], "name": "Ganaxolone", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05084": {"dbids": ["DB05084"], "name": "BA058", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05082": {"dbids": ["DB05082"], "name": "ARX201", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05083": {"dbids": ["DB05083"], "name": "TMC278", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05080": {"dbids": ["DB05080"], "name": "OBE101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05081": {"dbids": ["DB05081"], "name": "JB991", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08617": {"dbids": ["DB08617"], "name": "4-(2,2,2-TRIFLUOROETHYL)-L-PHENYLALANINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05088": {"dbids": ["DB05088"], "name": "Tetrathiomolybdate", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05089": {"dbids": ["DB05089"], "name": "VPM4001", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05778": {"dbids": ["DB05778"], "name": "Col-118", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05779": {"dbids": ["DB05779"], "name": "oglufanide disodium", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05771": {"dbids": ["DB05771"], "name": "LLL-3348", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05772": {"dbids": ["DB05772"], "name": "Rob 803", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05773": {"dbids": ["DB05773"], "name": "ado-trastuzumab emtansine", "groups": ["APPROVED"], "targets": [{"action": "ANTIBODY", "target": "P04626", "drug": "DB05773"}]}, "DB05774": {"dbids": ["DB05774"], "name": "IMC-11F8", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05775": {"dbids": ["DB05775"], "name": "CRx-401", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05776": {"dbids": ["DB05776"], "name": "IC41", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05777": {"dbids": ["DB05777"], "name": "ART-123", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB07524": {"dbids": ["DB07524"], "name": "N-phenyl-1H-pyrrolo[2,3-b]pyridin-3-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06876": {"dbids": ["DB06876"], "name": "N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06877": {"dbids": ["DB06877"], "name": "N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06878": {"dbids": ["DB06878"], "name": "1-[(2R)-2-aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06879": {"dbids": ["DB06879"], "name": "5-(4'-AMINO-1'-ETHYL-5',8'-DIFLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLINE]-1-YLCARBONYL)PICOLINONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06274": {"dbids": ["DB06274"], "name": "Alvimopan", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35372", "drug": "DB06274"}, {"action": "ANTAGONIST", "target": "P41145", "drug": "DB06274"}, {"action": "ANTAGONIST", "target": "P41143", "drug": "DB06274"}]}, "DB01144": {"dbids": ["APRD00131", "DB01144", "DB07948"], "name": "Diclofenamide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00915", "drug": "DB01144"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB01144"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB01144"}, {"action": "INHIBITOR", "target": "P43166", "drug": "DB01144"}]}, "DB06928": {"dbids": ["DB06928"], "name": "(2S)-2-{[HYDROXY(4-IODOBENZYL)PHOSPHORYL]METHYL}PENTANEDIOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09083": {"dbids": ["DB09083"], "name": "Ivabradine", "groups": ["APPROVED"], "targets": []}, "DB09080": {"dbids": ["DB09080"], "name": "Olodaterol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P07550", "drug": "DB09080"}]}, "DB09081": {"dbids": ["DB09081"], "name": "Idebenone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB09086": {"dbids": ["DB09086"], "name": "Eugenol", "groups": ["APPROVED"], "targets": []}, "DB09087": {"dbids": ["DB09087"], "name": "Potassium alum", "groups": ["APPROVED"], "targets": []}, "DB09084": {"dbids": ["DB09084"], "name": "Benzydamine", "groups": ["APPROVED"], "targets": []}, "DB09085": {"dbids": ["DB09085"], "name": "Tetracaine", "groups": ["APPROVED"], "targets": []}, "DB09088": {"dbids": ["DB09088"], "name": "Amylocaine", "groups": ["WITHDRAWN"], "targets": []}, "DB09089": {"dbids": ["DB09089"], "name": "Trimebutine", "groups": ["APPROVED"], "targets": []}, "DB01709": {"dbids": ["DB01709", "EXPT00143"], "name": "2-Phosphoglyceric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01708": {"dbids": ["DB01708", "DB06593", "EXPT00519"], "name": "Dehydroepiandrosterone", "groups": ["NUTRACEUTICAL"], "targets": [{"action": "ACTIVATOR", "target": "Q07869", "drug": "DB01708"}, {"action": "BINDER", "target": "P03372", "drug": "DB01708"}, {"action": "AGONIST", "target": "Q99720", "drug": "DB01708"}, {"action": "ACTIVATOR", "target": "Q92731", "drug": "DB01708"}, {"action": "ACTIVATOR", "target": "O75469", "drug": "DB01708"}, {"action": "ACTIVATOR", "target": "Q14994", "drug": "DB01708"}, {"action": "ANTAGONIST", "target": "P14867", "drug": "DB01708"}, {"action": "ANTAGONIST", "target": "P47869", "drug": "DB01708"}, {"action": "ANTAGONIST", "target": "P34903", "drug": "DB01708"}, {"action": "ANTAGONIST", "target": "P48169", "drug": "DB01708"}, {"action": "ANTAGONIST", "target": "P31644", "drug": "DB01708"}, {"action": "ANTAGONIST", "target": "Q16445", "drug": "DB01708"}, {"action": "ANTAGONIST", "target": "P18505", "drug": "DB01708"}, {"action": "ANTAGONIST", "target": "P47870", "drug": "DB01708"}, {"action": "ANTAGONIST", "target": "P28472", "drug": "DB01708"}, {"action": "ANTAGONIST", "target": "O14764", "drug": "DB01708"}, {"action": "ANTAGONIST", "target": "P78334", "drug": "DB01708"}, {"action": "ANTAGONIST", "target": "Q8N1C3", "drug": "DB01708"}, {"action": "ANTAGONIST", "target": "P18507", "drug": "DB01708"}, {"action": "ANTAGONIST", "target": "Q99928", "drug": "DB01708"}, {"action": "ANTAGONIST", "target": "O00591", "drug": "DB01708"}, {"action": "ANTAGONIST", "target": "Q9UN88", "drug": "DB01708"}, {"action": "AGONIST", "target": "Q05586", "drug": "DB01708"}, {"action": "AGONIST", "target": "Q12879", "drug": "DB01708"}, {"action": "AGONIST", "target": "Q13224", "drug": "DB01708"}, {"action": "AGONIST", "target": "Q14957", "drug": "DB01708"}, {"action": "AGONIST", "target": "O15399", "drug": "DB01708"}, {"action": "AGONIST", "target": "Q8TCU5", "drug": "DB01708"}, {"action": "AGONIST", "target": "O60391", "drug": "DB01708"}]}, "DB01259": {"dbids": ["DB01259", "DB02584"], "name": "Lapatinib", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P00533", "drug": "DB01259"}, {"action": "ANTAGONIST", "target": "P04626", "drug": "DB01259"}]}, "DB01705": {"dbids": ["DB01705", "EXPT00620"], "name": "Bis(5-Amidino-Benzimidazolyl)Methane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01704": {"dbids": ["DB01704", "EXPT02925"], "name": "2,4-Dihydroxy-Trans Cinnamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01707": {"dbids": ["DB01707", "EXPT02003"], "name": "L-Alfa-Lysophosphatidylcholine, Lauroyl", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01706": {"dbids": ["DB01706", "EXPT00642"], "name": "2-Bromo-6-Chloro-Purine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01701": {"dbids": ["DB01701", "EXPT00992"], "name": "1,2-Dichloro-Propane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01700": {"dbids": ["DB01700", "EXPT00407"], "name": "Aicar", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01703": {"dbids": ["DB01703", "EXPT01419"], "name": "N-(2-Ferrocenylethyl)Maleimide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01702": {"dbids": ["DB01702", "EXPT01200", "EXPT01685"], "name": "2-(3,4-Dihydroxyphenyl)Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00078": {"dbids": ["BIOD00069", "BTD00069", "DB00078"], "name": "Ibritumomab", "groups": ["APPROVED"], "targets": [{"action": "ANTIBODY", "target": "P11836", "drug": "DB00078"}]}, "DB00074": {"dbids": ["BIOD00073", "BTD00073", "DB00074"], "name": "Basiliximab", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTIBODY", "target": "P01589", "drug": "DB00074"}, {"action": "ANTIBODY", "target": "P14784", "drug": "DB00074"}]}, "DB00075": {"dbids": ["BIOD00005", "BTD00005", "DB00075"], "name": "Muromonab", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "BINDER", "target": "P07766", "drug": "DB00075"}]}, "DB00076": {"dbids": ["BIOD00027", "BIOD00046", "BTD00027", "BTD00046", "DB00076"], "name": "Digoxin Immune Fab (Ovine)", "groups": ["APPROVED"], "targets": []}, "DB00070": {"dbids": ["BIOD00022", "BTD00022", "DB00070"], "name": "Hyaluronidase", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P01137", "drug": "DB00070"}]}, "DB00071": {"dbids": ["BIOD00031", "BTD00031", "DB00071"], "name": "Insulin, porcine", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "P06213", "drug": "DB00071"}]}, "DB00072": {"dbids": ["BIOD00098", "BTD00098", "DB00072"], "name": "Trastuzumab", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTIBODY", "target": "P04626", "drug": "DB00072"}]}, "DB00073": {"dbids": ["BIOD00014", "BTD00014", "DB00073"], "name": "Rituximab", "groups": ["APPROVED"], "targets": [{"action": "ANTIBODY", "target": "P11836", "drug": "DB00073"}]}, "DB00618": {"dbids": ["APRD00272", "DB00618"], "name": "Demeclocycline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A7X3", "drug": "DB00618"}, {"action": "INHIBITOR", "target": "P0A7V8", "drug": "DB00618"}]}, "DB00619": {"dbids": ["APRD01028", "DB00619", "DB03261", "EXPT02967"], "name": "Imatinib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "A9UF02", "drug": "DB00619"}, {"action": "ANTAGONIST", "target": "P10721", "drug": "DB00619"}, {"action": "MULTITARGET", "target": "P10721", "drug": "DB00619"}, {"action": "INHIBITOR", "target": "O43519", "drug": "DB00619"}, {"action": "ANTAGONIST", "target": "P04629", "drug": "DB00619"}, {"action": "ANTAGONIST", "target": "P07333", "drug": "DB00619"}, {"action": "ANTAGONIST", "target": "P16234", "drug": "DB00619"}, {"action": "ANTAGONIST", "target": "Q08345", "drug": "DB00619"}, {"action": "INHIBITOR", "target": "P00519", "drug": "DB00619"}, {"action": "ANTAGONIST", "target": "P09619", "drug": "DB00619"}]}, "DB00610": {"dbids": ["APRD00555", "DB00610"], "name": "Metaraminol", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P35348", "drug": "DB00610"}]}, "DB00611": {"dbids": ["APRD00835", "DB00611"], "name": "Butorphanol", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P41145", "drug": "DB00611"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00611"}, {"action": "PARTIAL ANTAGONIST", "target": "P35372", "drug": "DB00611"}]}, "DB00612": {"dbids": ["APRD00257", "DB00612"], "name": "Bisoprolol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB00612"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00612"}]}, "DB00613": {"dbids": ["APRD00796", "DB00613"], "name": "Amodiaquine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P50135", "drug": "DB00613"}]}, "DB00614": {"dbids": ["APRD00988", "DB00614"], "name": "Furazolidone", "groups": ["APPROVED"], "targets": []}, "DB00615": {"dbids": ["APRD00094", "DB00615"], "name": "Rifabutin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A7Z4", "drug": "DB00615"}, {"action": "INHIBITOR", "target": "P0A8V2", "drug": "DB00615"}, {"action": "INHIBITOR", "target": "P0A8T7", "drug": "DB00615"}, {"action": "OTHER/UNKNOWN", "target": "P07900", "drug": "DB00615"}, {"action": "OTHER/UNKNOWN", "target": "P14625", "drug": "DB00615"}]}, "DB00616": {"dbids": ["APRD00027", "DB00616"], "name": "Candoxatril", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P08473", "drug": "DB00616"}, {"action": "INHIBITOR", "target": "P12821", "drug": "DB00616"}]}, "DB00617": {"dbids": ["APRD00236", "DB00617"], "name": "Paramethadione", "groups": ["APPROVED"], "targets": [{"action": "SUPPRESSOR", "target": "Q9P0X4", "drug": "DB00617"}]}, "DB03259": {"dbids": ["DB03259", "EXPT00743"], "name": "2',6'-Dichloro-Biphenyl-2,6-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03258": {"dbids": ["DB03258", "EXPT01137"], "name": "2'-Deoxycytidine-5'-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03251": {"dbids": ["DB03251", "EXPT02826"], "name": "RWJ-51084", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03250": {"dbids": ["DB03250", "EXPT03046"], "name": "2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Benzothiazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03253": {"dbids": ["DB03253", "EXPT02476"], "name": "(2s)-Pyrrolidin-2-Ylmethylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03252": {"dbids": ["DB03252", "EXPT01219"], "name": "D-Lysine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03255": {"dbids": ["DB03255", "EXPT01917"], "name": "Phenol", "groups": ["APPROVED", "EXPERIMENTAL"], "targets": []}, "DB03254": {"dbids": ["DB03254", "EXPT02601"], "name": "4-Phenyl-1h-Imidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03257": {"dbids": ["DB03257", "EXPT00403"], "name": "5-[1-(Acetylamino)-3-Methylbutyl]-2,5-Anhydro-3,4-Dideoxy-4-(Methoxycarbonyl)Pentonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03256": {"dbids": ["DB03256", "EXPT01470"], "name": "5-Formyl-5,6,7,8-Tetrahydrofolate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04919": {"dbids": ["DB04919"], "name": "Alfimeprase", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04918": {"dbids": ["DB04918"], "name": "Ceftobiprole", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04912": {"dbids": ["DB04912"], "name": "Stannsoporfin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04911": {"dbids": ["DB04911"], "name": "Oritavancin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB04910": {"dbids": ["DB04910"], "name": "Oxibendazole", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04917": {"dbids": ["DB04917"], "name": "Renzapride", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04915": {"dbids": ["DB04915"], "name": "Phenoxodiol", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04914": {"dbids": ["DB04914"], "name": "G17DT", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08029": {"dbids": ["DB08029"], "name": "N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08028": {"dbids": ["DB08028"], "name": "BUT-3-ENYL-[5-(4-CHLORO-PHENYL)-3,6-DIHYDRO-[1,3,4]THIADIAZIN-2-YLIDENE]-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08023": {"dbids": ["DB08023"], "name": "N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08022": {"dbids": ["DB08022"], "name": "(2S)-1,3-benzothiazol-2-yl{2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}ethanenitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08021": {"dbids": ["DB08021"], "name": "5-bromo-N-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08020": {"dbids": ["DB08020"], "name": "(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08027": {"dbids": ["DB08027"], "name": "1-(3-chloro-4-methylphenyl)-3-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)thio]ethyl}urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08026": {"dbids": ["DB08026"], "name": "2-{4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]piperidin-1-yl}-N-methylacetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08025": {"dbids": ["DB08025"], "name": "N-{2'-[(4-FLUOROPHENYL)AMINO]-4,4'-BIPYRIDIN-2-YL}-4-METHOXYCYCLOHEXANECARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08024": {"dbids": ["DB08024"], "name": "1-[2-(S)-AMINO-3-BIPHENYL-4-YL-PROPIONYL]-PYRROLIDINE-2-(S)-CARBONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03035": {"dbids": ["DB03035", "EXPT01762"], "name": "1,8-Di-Hydroxy-4-Nitro-Anthraquinone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03034": {"dbids": ["DB03034", "EXPT03256"], "name": "Dextrofloxacine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03037": {"dbids": ["DB03037", "EXPT02410"], "name": "Oxidized Acetyl Dithranol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03031": {"dbids": ["DB03031", "EXPT01276"], "name": "Adamantane-1-Carboxylic Acid-5-Dimethylamino-Naphthalene-1-Sulfonylamino-Octyl-Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03030": {"dbids": ["DB03030", "EXPT00269"], "name": "4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03033": {"dbids": ["DB03033", "EXPT02236"], "name": "1-Methyloxy-4-Sulfone-Benzene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03032": {"dbids": ["DB03032", "EXPT01665"], "name": "S-Octylglutathione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03039": {"dbids": ["DB03039", "EXPT01900"], "name": "4-(Aminosulfonyl)-N-[(2,5-Difluorophenyl)Methyl]-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03038": {"dbids": ["DB03038", "EXPT02074"], "name": "LY341770", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02344": {"dbids": ["DB02344", "EXPT02908"], "name": "O-Sialic Acid (Chair Conformation)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02613": {"dbids": ["DB02613", "EXPT01149"], "name": "Decylamine-N,N-Dimethyl-N-Oxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02610": {"dbids": ["DB02610", "EXPT01425"], "name": "N-(2,3,4,5,6-Pentaflouro-Benzyl)-4-Sulfamoyl-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02611": {"dbids": ["DB02611", "EXPT00607"], "name": "Balanol Analog 1", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02616": {"dbids": ["DB02616", "EXPT01481"], "name": "FR117016", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02617": {"dbids": ["DB02617", "EXPT02560"], "name": "1-(N-Imidazolyl)-2-Hydroxy-2-(2,3-Dichlorophenyl)Octane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02614": {"dbids": ["DB02614", "EXPT00712"], "name": "1(R)-1-Acetamido-2-(3-Carboxyphenyl)Ethyl Boronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02615": {"dbids": ["DB02615", "EXPT00338", "EXPT00478"], "name": "Compound 19", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02618": {"dbids": ["DB02618", "EXPT02323"], "name": "Ethyl Dimethyl Ammonio Propane Sulfonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02619": {"dbids": ["DB02619", "EXPT00648"], "name": "Bromo-Dodecanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02348": {"dbids": ["DB02348", "EXPT01478"], "name": "Fluoro-Phosphite Ion", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02349": {"dbids": ["DB02349", "EXPT02346"], "name": "Nicotinamide-Adenine-Dinucleotide-5-Hydroxy-4-Oxonorvaline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01564": {"dbids": ["DB01564"], "name": "Calusterone", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB07839": {"dbids": ["DB07839"], "name": "N~2~-1,3-BENZOXAZOL-2-YL-3-CYCLOHEXYL-N-{2-[(4-METHOXYPHENYL)AMINO]ETHYL}-L-ALANINAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07838": {"dbids": ["DB07838"], "name": "(Z)-3-BENZYL-5-(2-HYDROXY-3-NITROBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08568": {"dbids": ["DB08568"], "name": "(2S)-1-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}-3-PHENYLPROPAN-2-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07831": {"dbids": ["DB07831"], "name": "2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07830": {"dbids": ["DB07830"], "name": "(4R,5R)-5-AMINO-1-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07833": {"dbids": ["DB07833"], "name": "N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07832": {"dbids": ["DB07832"], "name": "4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07835": {"dbids": ["DB07835"], "name": "N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07834": {"dbids": ["DB07834"], "name": "N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07837": {"dbids": ["DB07837"], "name": "[4-(5-naphthalen-2-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl]acetic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07836": {"dbids": ["DB07836"], "name": "1-DECYL-3-TRIFLUORO ETHYL-SN-GLYCERO-2-PHOSPHOMETHANOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08566": {"dbids": ["DB08566"], "name": "D-1-NAPHTHYL-2-ACETAMIDO-ETHANE BORONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08567": {"dbids": ["DB08567"], "name": "(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08564": {"dbids": ["DB08564"], "name": "(2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08565": {"dbids": ["DB08565"], "name": "L-1-NAPHTHYL-2-ACETAMIDO-ETHANE BORONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05003": {"dbids": ["DB05003"], "name": "Imexon", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08560": {"dbids": ["DB08560"], "name": "3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08561": {"dbids": ["DB08561"], "name": "BENZYL 6-BENZYL-5,7-DIOXO-6,7-DIHYDRO-5H-[1,3]THIAZOLO[3,2-C]PYRIMIDINE-2-CARBOXYLATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05341": {"dbids": ["DB05341"], "name": "C1-INH", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05340": {"dbids": ["DB05340"], "name": "ATL-2502", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05343": {"dbids": ["DB05343"], "name": "ONO-2506", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05342": {"dbids": ["DB05342"], "name": "SP-01A", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05345": {"dbids": ["DB05345"], "name": "SO-101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05344": {"dbids": ["DB05344"], "name": "NT-501", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05346": {"dbids": ["DB05346"], "name": "WL-1002", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05349": {"dbids": ["DB05349"], "name": "autologousadipose stem cell therapy", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05348": {"dbids": ["DB05348"], "name": "autologous fibroblast transplant", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB09350": {"dbids": ["DB09350"], "name": "Piperonyl butoxide", "groups": ["APPROVED"], "targets": []}, "DB01064": {"dbids": ["APRD00182", "DB01064"], "name": "Isoprenaline", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P08588", "drug": "DB01064"}, {"action": "AGONIST", "target": "P07550", "drug": "DB01064"}, {"action": "AGONIST", "target": "P13945", "drug": "DB01064"}, {"action": "INDUCER", "target": "P28482", "drug": "DB01064"}, {"action": "AGONIST", "target": "P27986", "drug": "DB01064"}, {"action": "AGONIST", "target": "O00459", "drug": "DB01064"}, {"action": "AGONIST", "target": "Q92569", "drug": "DB01064"}, {"action": "ACTIVATOR", "target": "Q4ZHU6", "drug": "DB01064"}]}, "DB01065": {"dbids": ["APRD00742", "DB01065", "DB08189"], "name": "Melatonin", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "AGONIST", "target": "P48039", "drug": "DB01065"}, {"action": "AGONIST", "target": "P49286", "drug": "DB01065"}, {"action": "ANTAGONIST", "target": "P03372", "drug": "DB01065"}, {"action": "AGONIST", "target": "Q92753", "drug": "DB01065"}, {"action": "INHIBITOR", "target": "P05164", "drug": "DB01065"}, {"action": "INHIBITOR", "target": "P11678", "drug": "DB01065"}]}, "DB04762": {"dbids": ["DB04762"], "name": "N-PYRIDOXYL-D-GLUTAMIC ACID-5'-MONOPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01067": {"dbids": ["APRD00436", "DB01067"], "name": "Glipizide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q09428", "drug": "DB01067"}, {"action": "AGONIST", "target": "P37231", "drug": "DB01067"}]}, "DB01060": {"dbids": ["APRD00248", "DB01060"], "name": "Amoxicillin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01060"}]}, "DB04765": {"dbids": ["DB04765"], "name": "N-PYRIDOXYL-2-METHYL-L-GLUTAMIC ACID-5'-MONOPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01062": {"dbids": ["APRD00427", "DB01062"], "name": "Oxybutynin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P20309", "drug": "DB01062"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01062"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01062"}]}, "DB04767": {"dbids": ["DB04767"], "name": "N-[1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-3-METHYLSULFANYL-PROPYL]-3-HYDROXY-2-PROPOXYAMINO-BUTYRAMID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04768": {"dbids": ["DB04768"], "name": "Pyrithiamine Pyrophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04769": {"dbids": ["DB04769"], "name": "5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07238": {"dbids": ["DB07238"], "name": "5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01068": {"dbids": ["APRD00054", "DB01068"], "name": "Clonazepam", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01068"}, {"action": "OTHER/UNKNOWN", "target": "P30536", "drug": "DB01068"}]}, "DB01069": {"dbids": ["APRD00601", "DB01069"], "name": "Promethazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB01069"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01069"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01069"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01069"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01069"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01069"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB01069"}, {"action": "UNKNOWN", "target": "P35348", "drug": "DB01069"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01069"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB01069"}]}, "DB08610": {"dbids": ["DB08610"], "name": "N-(2-AMINOETHYL)-2-{3-CHLORO-4-[(4-ISOPROPYLBENZYL)OXY]PHENYL} ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07237": {"dbids": ["DB07237"], "name": "{4-[(2R)-pyrrolidin-2-ylmethoxy]phenyl}(4-thiophen-3-ylphenyl)methanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08612": {"dbids": ["DB08612"], "name": "1,1,1-TRIFLUORO-3-(OCTYLTHIO)ACETONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01786": {"dbids": ["DB01786", "EXPT01109"], "name": "D-Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08614": {"dbids": ["DB08614"], "name": "3-[[(METHYLAMINO)SULFONYL]AMINO]-2-OXO-6-PHENYL-N-[3,3,3-TRIFLUORO-1-(1-METHYLETHYL)-2-OXOPHENYL]-1(2H)-PYRIDINE ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08615": {"dbids": ["DB08615"], "name": "2-[4-(DIMETHYLAMINO)PHENYL]-6-HYDROXY-3-METHYL-1,3-BENZOTHIAZOL-3-IUM", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07236": {"dbids": ["DB07236"], "name": "3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08618": {"dbids": ["DB08618"], "name": "3-(HYDROXY-PHENYL-PHOSPHINOYLOXY)-8-METHYL-8-AZA-BICYCLO[3.2.1]OCTANE-2-CARBOXYLIC ACID METHYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08619": {"dbids": ["DB08619"], "name": "TESTOSTERONE HEMISUCCINATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07235": {"dbids": ["DB07235"], "name": "N-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01780": {"dbids": ["DB01780", "EXPT01498"], "name": "Fusicoccin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06872": {"dbids": ["DB06872"], "name": "1-((2-HYDROXYETHOXY)METHYL)-5-(PHENYLTHIO)PYRIMIDINE-2,4(1H,3H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06873": {"dbids": ["DB06873"], "name": "1-((2-HYDROXYETHOXY)METHYL)-5-(3-(BENZYLOXY)BENZYL)PYRIMIDINE-2,4(1H,3H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06870": {"dbids": ["DB06870"], "name": "17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06871": {"dbids": ["DB06871"], "name": "17-METHYL-17-ALPHA-DIHYDROEQUILENIN", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00449": {"dbids": ["APRD00930", "DB00449"], "name": "Dipivefrin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35348", "drug": "DB00449"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00449"}, {"action": "AGONIST", "target": "P07550", "drug": "DB00449"}, {"action": "POTENTIATOR", "target": "P06276", "drug": "DB00449"}]}, "DB00448": {"dbids": ["APRD00077", "DB00448"], "name": "Lansoprazole", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P20648", "drug": "DB00448"}]}, "DB06874": {"dbids": ["DB06874"], "name": "(6-[4-(AMINOMETHYL)-2,6-DIMETHYLPHENOXY]-2-{[4-(AMINOMETHYL)PHENYL]AMINO}-5-BROMOPYRIMIDIN-4-YL)METHANOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06875": {"dbids": ["DB06875"], "name": "3-(3-FLUORO-4-HYDROXYPHENYL)-7-HYDROXY-1-NAPHTHONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00445": {"dbids": ["APRD00361", "DB00445"], "name": "Epirubicin", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "O14646", "drug": "DB00445"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00445"}]}, "DB00444": {"dbids": ["APRD00649", "DB00444"], "name": "Teniposide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P11388", "drug": "DB00444"}]}, "DB00447": {"dbids": ["APRD01077", "DB00447"], "name": "Loracarbef", "groups": ["WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00447"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB00447"}]}, "DB00446": {"dbids": ["APRD00862", "DB00446", "EXPT00942"], "name": "Chloramphenicol", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0ADY7", "drug": "DB00446"}, {"action": "ANTAGONIST", "target": "P24093", "drug": "DB00446"}, {"action": "OTHER", "target": "P08174", "drug": "DB00446"}]}, "DB00441": {"dbids": ["APRD00201", "DB00441"], "name": "Gemcitabine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23921", "drug": "DB00441"}, {"action": "INHIBITOR", "target": "P04818", "drug": "DB00441"}, {"action": "INHIBITOR", "target": "P30085", "drug": "DB00441"}]}, "DB00440": {"dbids": ["APRD00103", "DB00440"], "name": "Trimethoprim", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P04818", "drug": "DB00440"}, {"action": "INHIBITOR", "target": "P00374", "drug": "DB00440"}]}, "DB00443": {"dbids": ["APRD00513", "DB00443"], "name": "Betamethasone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00443"}]}, "DB00442": {"dbids": ["APRD00948", "DB00442"], "name": "Entecavir", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB07231": {"dbids": ["DB07231"], "name": "N-({(2S,3S)-3-[(BENZYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07230": {"dbids": ["DB07230"], "name": "3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04588": {"dbids": ["DB04588"], "name": "N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04584": {"dbids": ["DB04584"], "name": "Phenyldehydroalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04585": {"dbids": ["DB04585"], "name": "DEHYDRO-2(S)-AMINO-6-BORONOHEXANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04586": {"dbids": ["DB04586"], "name": "2-bromophenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04587": {"dbids": ["DB04587"], "name": "2'-O-BUTYL-5-METHYLURIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04580": {"dbids": ["DB04580"], "name": "1-Methyl-2-quinolone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04581": {"dbids": ["DB04581"], "name": "1-benzylimidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04582": {"dbids": ["DB04582"], "name": "IMAZAQUIN", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04583": {"dbids": ["DB04583"], "name": "5-(AMINOCARBONYL)-1,1':4',1''-TERPHENYL-3-CARBOXYLICACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01143": {"dbids": ["APRD00021", "DB01143"], "name": "Amifostine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INDUCER", "target": "P10696", "drug": "DB01143"}, {"action": "INDUCER", "target": "P22413", "drug": "DB01143"}]}, "DB07581": {"dbids": ["DB07581"], "name": "5-AMINO-6-CYCLOHEXYL-4-HYDROXY-2-ISOPROPYL-HEXANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07580": {"dbids": ["DB07580"], "name": "BIS-1,2-{[(Z)-2CARBOXY-2-METHYL-1,3-DIOXANE]-5-YLOXYCARBONYL}-PIPERAZINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07583": {"dbids": ["DB07583"], "name": "(4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07582": {"dbids": ["DB07582"], "name": "N-[(2R,3S)-1-((2S)-2-{[(CYCLOPENTYLAMINO)CARBONYL]AMINO}-3-METHYLBUTANOYL)-2-(1-FORMYL-1-CYCLOBUTYL)PYRROLIDINYL]CYCLOPROPANECARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07585": {"dbids": ["DB07585"], "name": "5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07584": {"dbids": ["DB07584"], "name": "N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00919": {"dbids": ["APRD01232", "DB00919"], "name": "Spectinomycin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A7S3", "drug": "DB00919"}]}, "DB00918": {"dbids": ["APRD00169", "DB00918"], "name": "Almotriptan", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P28222", "drug": "DB00918"}, {"action": "AGONIST", "target": "P28221", "drug": "DB00918"}]}, "DB00917": {"dbids": ["APRD00927", "DB00917"], "name": "Dinoprostone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P43116", "drug": "DB00917"}, {"action": "AGONIST", "target": "P34995", "drug": "DB00917"}, {"action": "AGONIST", "target": "P43115", "drug": "DB00917"}, {"action": "AGONIST", "target": "P35408", "drug": "DB00917"}]}, "DB00916": {"dbids": ["APRD00631", "DB00916"], "name": "Metronidazole", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "O25608", "drug": "DB00916"}, {"action": "INHIBITOR", "target": "P29166", "drug": "DB00916"}]}, "DB00915": {"dbids": ["APRD00787", "DB00915"], "name": "Amantadine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P21430", "drug": "DB00915"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00915"}, {"action": "AGONIST", "target": "P14416", "drug": "DB00915"}]}, "DB00914": {"dbids": ["APRD00511", "DB00914"], "name": "Phenformin", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "ACTIVATOR", "target": "Q13131", "drug": "DB00914"}, {"action": "INHIBITOR", "target": "Q15842", "drug": "DB00914"}]}, "DB00913": {"dbids": ["APRD00741", "DB00913"], "name": "Anileridine", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB00913"}]}, "DB00912": {"dbids": ["APRD00439", "DB00912"], "name": "Repaglinide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q09428", "drug": "DB00912"}, {"action": "AGONIST", "target": "P37231", "drug": "DB00912"}]}, "DB00911": {"dbids": ["APRD01260", "DB00911"], "name": "Tinidazole", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB00910": {"dbids": ["APRD01165", "DB00910"], "name": "Paricalcitol", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P11473", "drug": "DB00910"}]}, "DB08038": {"dbids": ["DB08038"], "name": "L-alanyl-N-[(1S,2R)-1-benzyl-2-hydroxypropyl]-L-alaninamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08039": {"dbids": ["DB08039"], "name": "(3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06728": {"dbids": ["DB06728"], "name": "Aniline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06729": {"dbids": ["DB06729"], "name": "Sulfaphenazole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0AC13", "drug": "DB06729"}]}, "DB03938": {"dbids": ["DB03938", "EXPT02469"], "name": "Deacetoxycephalosporin-C", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03939": {"dbids": ["DB03939", "EXPT01777"], "name": "4-Hydroxy-3,4-Dihydro-1h-Pyrimidin-2-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09526": {"dbids": ["DB09526"], "name": "Hydroquinone", "groups": ["APPROVED"], "targets": []}, "DB03934": {"dbids": ["DB03934", "EXPT03292"], "name": "Protoporphyrin Ix Containing Zn", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03935": {"dbids": ["DB03935", "EXPT01845"], "name": "1,4-Dideoxy-O2-Sulfo-Glucuronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03936": {"dbids": ["DB03936", "EXPT02797"], "name": "1-Deoxy-Ribofuranose-5'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03937": {"dbids": ["DB03937", "EXPT01316"], "name": "Erythose-4-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03930": {"dbids": ["DB03930", "EXPT00689"], "name": "4-Methyl-Pyrroline-5-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03931": {"dbids": ["DB03931", "EXPT01633"], "name": "Diguanosine-5'-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03932": {"dbids": ["DB03932", "EXPT00387"], "name": "LFA703", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03933": {"dbids": ["DB03933", "EXPT02805"], "name": "C-1027 Aromatized Chromophore", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07059": {"dbids": ["DB07059"], "name": "N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOXAZIN-4-YL]ETHYL}ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07058": {"dbids": ["DB07058"], "name": "5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06723": {"dbids": ["DB06723"], "name": "Aluminum hydroxide", "groups": ["APPROVED"], "targets": []}, "DB07053": {"dbids": ["DB07053"], "name": "2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07052": {"dbids": ["DB07052"], "name": "5'-S-ethyl-5'-thioadenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07051": {"dbids": ["DB07051"], "name": "3,5-DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07050": {"dbids": ["DB07050"], "name": "5-[(phenylsulfonyl)amino]-1,3,4-thiadiazole-2-sulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07057": {"dbids": ["DB07057"], "name": "(3S)-1-(2-hydroxyphenyl)-5-oxopyrrolidine-3-carboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06720": {"dbids": ["DB06720"], "name": "Velaglucerase alfa", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB07055": {"dbids": ["DB07055"], "name": "2-[2-(1H-tetrazol-5-yl)ethyl]-1H-isoindole-1,3(2H)-dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07054": {"dbids": ["DB07054"], "name": "(2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06726": {"dbids": ["DB06726"], "name": "Bufuralol", "groups": ["EXPERIMENTAL", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB06726"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB06726"}, {"action": "ANTAGONIST", "target": "P13945", "drug": "DB06726"}]}, "DB06727": {"dbids": ["DB06727"], "name": "Sparteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06724": {"dbids": ["DB06724"], "name": "Calcium carbonate", "groups": ["APPROVED"], "targets": []}, "DB06725": {"dbids": ["DB06725"], "name": "Lornoxicam", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23219", "drug": "DB06725"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB06725"}]}, "DB06186": {"dbids": ["DB06186"], "name": "Ipilimumab", "groups": ["APPROVED"], "targets": []}, "DB00231": {"dbids": ["APRD00676", "DB00231"], "name": "Temazepam", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "Q9UN88", "drug": "DB00231"}, {"action": "OTHER", "target": "P30536", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00231"}]}, "DB05578": {"dbids": ["DB05578"], "name": "Ramucirumab", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P35968", "drug": "DB05578"}]}, "DB03758": {"dbids": ["DB03758", "EXPT02763"], "name": "Radicicol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03759": {"dbids": ["DB03759", "EXPT01239"], "name": "Dnqx", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03750": {"dbids": ["DB03750", "EXPT01947"], "name": "Isovaleric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03751": {"dbids": ["DB03751", "EXPT01115"], "name": "2'deoxy-Thymidine-5'-Diphospho-Alpha-D-Glucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03752": {"dbids": ["DB03752", "EXPT01934"], "name": "P-(2'-Iodo-5'-Thenoyl)Hydrotropic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03753": {"dbids": ["DB03753", "EXPT01438"], "name": "Flurbiprofen Methyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03754": {"dbids": ["DB03754", "EXPT03072"], "name": "Tris", "groups": ["APPROVED"], "targets": []}, "DB03755": {"dbids": ["DB03755", "EXPT00417"], "name": "Adenosine-5'-[Beta, Gamma-Methylene]Tetraphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03756": {"dbids": ["DB03756", "EXPT01798"], "name": "Docosa-4,7,10,13,16,19-Hexaenoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03757": {"dbids": ["DB03757", "EXPT00619"], "name": "(Tert-Butyloxycarbonyl)-Alanyl-Alanyl-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07667": {"dbids": ["DB07667"], "name": "2-((3',5'-DIMETHYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05752": {"dbids": ["DB05752"], "name": "ALKS 27", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05753": {"dbids": ["DB05753"], "name": "VSF-173", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05750": {"dbids": ["DB05750"], "name": "AVE-1625", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05751": {"dbids": ["DB05751"], "name": "RP01", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05756": {"dbids": ["DB05756"], "name": "PAC-113", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05757": {"dbids": ["DB05757"], "name": "DNB-001", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05754": {"dbids": ["DB05754"], "name": "IPH 1101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05755": {"dbids": ["DB05755"], "name": "BF-37", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08588": {"dbids": ["DB08588"], "name": "2-({2-[(3R)-3-AMINOPIPERIDIN-1-YL]-4-OXOQUINAZOLIN-3(4H)-YL}METHYL)BENZONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08589": {"dbids": ["DB08589"], "name": "SYRINGATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05758": {"dbids": ["DB05758"], "name": "CYT007-TNFQb", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05759": {"dbids": ["DB05759"], "name": "IMC-A12", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01165": {"dbids": ["APRD00502", "DB01165"], "name": "Ofloxacin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P43702", "drug": "DB01165"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB01165"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB01165"}]}, "DB01164": {"dbids": ["APRD00840", "DB01164"], "name": "Calcium Chloride", "groups": ["APPROVED"], "targets": []}, "DB01166": {"dbids": ["APRD00155", "DB01166"], "name": "Cilostazol", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14432", "drug": "DB01166"}]}, "DB07056": {"dbids": ["DB07056"], "name": "2-(6-{[(3-chloro-2-methylphenyl)sulfonyl]amino}pyridin-2-yl)-N,N-diethylacetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01169": {"dbids": ["APRD00171", "DB01169"], "name": "Arsenic trioxide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INDUCER", "target": "O14920", "drug": "DB01169"}, {"action": "INHIBITOR", "target": "Q16881", "drug": "DB01169"}, {"action": "INDUCER", "target": "P05412", "drug": "DB01169"}, {"action": "ANTAGONIST", "target": "P24385", "drug": "DB01169"}, {"action": "INDUCER", "target": "P27361", "drug": "DB01169"}, {"action": "INDUCER", "target": "P28482", "drug": "DB01169"}, {"action": "INDUCER", "target": "P31749", "drug": "DB01169"}]}, "DB01168": {"dbids": ["APRD00695", "DB01168"], "name": "Procarbazine", "groups": ["APPROVED"], "targets": []}, "DB04660": {"dbids": ["DB04660"], "name": "Glycerylphosphorylcholine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02407": {"dbids": ["DB02407", "EXPT00955"], "name": "6-O-Cyclohexylmethyl Guanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02406": {"dbids": ["DB02406", "DB04344", "EXPT02547"], "name": "N-Valeric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02405": {"dbids": ["DB02405", "EXPT00749"], "name": "12-Bromododecanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02404": {"dbids": ["DB02404", "EXPT02540"], "name": "1-Deoxy-1-Thio-Heptaethylene Glycol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02403": {"dbids": ["DB02403", "EXPT00067"], "name": "2-Fluoroaniline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02402": {"dbids": ["DB02402", "EXPT02228"], "name": "5-(4-Methoxyphenoxy)-2,4-Quinazolinediamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02401": {"dbids": ["DB02401", "EXPT02463"], "name": "4-Hydroxy-1,2,5-Oxadiazole-3-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02400": {"dbids": ["DB02400", "EXPT00341"], "name": "5-Methoxy-1,2-Dimethyl-3-(4-Nitrophenoxymethyl)Indole-4,7-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02409": {"dbids": ["DB02409", "EXPT00106"], "name": "(1r,4s)-2-Azabornane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02408": {"dbids": ["DB02408", "EXPT02083"], "name": "(3s)-3-Amino-1-(Cyclopropylamino)Heptane-2,2-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08175": {"dbids": ["DB08175"], "name": "(2E,4E)-11-METHOXY-3,7,11-TRIMETHYLDODECA-2,4-DIENOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08174": {"dbids": ["DB08174"], "name": "5-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO) CYCLOPENTYL)THIOPHENE-2-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09068": {"dbids": ["DB09068"], "name": "Vortioxetine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P31645", "drug": "DB09068"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB09068"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB09068"}, {"action": "PARTIAL AGONIST", "target": "P28222", "drug": "DB09068"}, {"action": "AGONIST", "target": "P08908", "drug": "DB09068"}, {"action": "LIGAND", "target": "P08588", "drug": "DB09068"}]}, "DB09069": {"dbids": ["DB09069"], "name": "Trimetazidine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P09110", "drug": "DB09069"}]}, "DB09065": {"dbids": ["DB09065"], "name": "Cobicistat", "groups": ["APPROVED"], "targets": []}, "DB09067": {"dbids": ["DB09067"], "name": "Corticorelin", "groups": ["APPROVED"], "targets": []}, "DB09060": {"dbids": ["DB09060"], "name": "Avibactam", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P62593", "drug": "DB09060"}, {"action": "INHIBITOR", "target": "Q9L5C7", "drug": "DB09060"}, {"action": "INHIBITOR", "target": "Q93CA2", "drug": "DB09060"}, {"action": "INHIBITOR", "target": "P0AD63", "drug": "DB09060"}, {"action": "INHIBITOR", "target": "P0A9Z7", "drug": "DB09060"}, {"action": "INHIBITOR", "target": "P0AD64", "drug": "DB09060"}, {"action": "INHIBITOR", "target": "A0A023W3H0", "drug": "DB09060"}, {"action": "INHIBITOR", "target": "Q9F663", "drug": "DB09060"}, {"action": "INHIBITOR", "target": "Q9EXV5", "drug": "DB09060"}, {"action": "INHIBITOR", "target": "P37321", "drug": "DB09060"}]}, "DB11194": {"dbids": ["DB11194"], "name": "Pyruvate", "groups": ["APPROVED"], "targets": []}, "DB09063": {"dbids": ["DB09063"], "name": "Ceritinib", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q9UM73", "drug": "DB09063"}]}, "DB01279": {"dbids": ["DB01279"], "name": "Galsulfase", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB01278": {"dbids": ["DB01278"], "name": "Pramlintide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P30988", "drug": "DB01278"}, {"action": "AGONIST", "target": "O60894", "drug": "DB01278"}, {"action": "AGONIST", "target": "O60895", "drug": "DB01278"}, {"action": "AGONIST", "target": "O60896", "drug": "DB01278"}]}, "DB01271": {"dbids": ["DB01271"], "name": "Idursulfase", "groups": ["APPROVED"], "targets": []}, "DB01270": {"dbids": ["DB01270"], "name": "Ranibizumab", "groups": ["APPROVED"], "targets": []}, "DB01273": {"dbids": ["DB01273"], "name": "Varenicline", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "PARTIAL AGONIST", "target": "P43681", "drug": "DB01273"}, {"action": "AGONIST", "target": "P36544", "drug": "DB01273"}, {"action": "PARTIAL AGONIST", "target": "P32297", "drug": "DB01273"}, {"action": "PARTIAL AGONIST", "target": "Q15825", "drug": "DB01273"}]}, "DB01272": {"dbids": ["DB01272"], "name": "Alglucosidase alfa", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "P20645", "drug": "DB01272"}]}, "DB01275": {"dbids": ["DB01275"], "name": "Hydralazine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q16853", "drug": "DB01275"}, {"action": "INHIBITOR", "target": "P13674", "drug": "DB01275"}]}, "DB01274": {"dbids": ["DB01274"], "name": "Arformoterol", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P07550", "drug": "DB01274"}]}, "DB01277": {"dbids": ["DB01277"], "name": "Mecasermin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P08069", "drug": "DB01277"}]}, "DB01276": {"dbids": ["DB01276"], "name": "Exenatide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P43220", "drug": "DB01276"}]}, "DB00588": {"dbids": ["APRD00065", "DB00588"], "name": "Fluticasone Propionate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00588"}, {"action": "AGONIST", "target": "P06401", "drug": "DB00588"}, {"action": "INHIBITOR", "target": "P47712", "drug": "DB00588"}, {"action": "ANTAGONIST", "target": "P08235", "drug": "DB00588"}]}, "DB00589": {"dbids": ["APRD00636", "DB00589"], "name": "Lisuride", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P14416", "drug": "DB00589"}, {"action": "AGONIST", "target": "P35462", "drug": "DB00589"}, {"action": "AGONIST", "target": "P21917", "drug": "DB00589"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00589"}, {"action": "ANTAGONIST", "target": "P21918", "drug": "DB00589"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00589"}, {"action": "AGONIST", "target": "P28221", "drug": "DB00589"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB00589"}, {"action": "AGONIST", "target": "P28223", "drug": "DB00589"}, {"action": "AGONIST", "target": "P28335", "drug": "DB00589"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00589"}, {"action": "OTHER/UNKNOWN", "target": "P08913", "drug": "DB00589"}, {"action": "OTHER/UNKNOWN", "target": "P18089", "drug": "DB00589"}, {"action": "OTHER/UNKNOWN", "target": "P18825", "drug": "DB00589"}]}, "DB00580": {"dbids": ["APRD00183", "DB00580", "DB07576"], "name": "Valdecoxib", "groups": ["INVESTIGATIONAL", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00580"}]}, "DB00581": {"dbids": ["APRD01063", "DB00581"], "name": "Lactulose", "groups": ["APPROVED"], "targets": [{"action": "OTHER", "target": "P06864", "drug": "DB00581"}]}, "DB00582": {"dbids": ["APRD00543", "DB00582"], "name": "Voriconazole", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P10613", "drug": "DB00582"}, {"action": "INHIBITOR", "target": "P10613", "drug": "DB00582"}]}, "DB00583": {"dbids": ["APRD01070", "DB00583"], "name": "L-Carnitine", "groups": ["APPROVED"], "targets": [{"action": "ACTIVATOR", "target": "P50416", "drug": "DB00583"}]}, "DB00584": {"dbids": ["APRD00510", "DB00584"], "name": "Enalapril", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P12821", "drug": "DB00584"}]}, "DB00585": {"dbids": ["APRD00706", "DB00585"], "name": "Nizatidine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P25021", "drug": "DB00585"}]}, "DB00586": {"dbids": ["APRD00527", "DB00586"], "name": "Diclofenac", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00586"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00586"}, {"action": "POTENTIATOR", "target": "P09917", "drug": "DB00586"}, {"action": "INHIBITOR", "target": "P35499", "drug": "DB00586"}, {"action": "INHIBITOR", "target": "P78348", "drug": "DB00586"}, {"action": "OTHER", "target": "O43526", "drug": "DB00586"}, {"action": "OTHER", "target": "O43525", "drug": "DB00586"}, {"action": "INHIBITOR", "target": "P14555", "drug": "DB00586"}]}, "DB00587": {"dbids": ["APRD00637", "DB00587"], "name": "Cinalukast", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q9Y271", "drug": "DB00587"}]}, "DB05912": {"dbids": ["DB05912"], "name": "REN-850", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01183": {"dbids": ["APRD00025", "DB01183"], "name": "Naloxone", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35372", "drug": "DB01183"}, {"action": "ANTAGONIST", "target": "P41143", "drug": "DB01183"}, {"action": "ANTAGONIST", "target": "P41145", "drug": "DB01183"}, {"action": "OTHER/UNKNOWN", "target": "P16220", "drug": "DB01183"}, {"action": "ANTAGONIST", "target": "P03372", "drug": "DB01183"}, {"action": "OTHER/UNKNOWN", "target": "P03372", "drug": "DB01183"}, {"action": "INHIBITOR", "target": "O00206", "drug": "DB01183"}]}, "DB01182": {"dbids": ["APRD00261", "DB01182"], "name": "Propafenone", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB01182"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB01182"}]}, "DB01181": {"dbids": ["APRD00007", "DB01181"], "name": "Ifosfamide", "groups": ["APPROVED"], "targets": []}, "DB01180": {"dbids": ["APRD00112", "DB01180"], "name": "Rescinnamine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P12821", "drug": "DB01180"}]}, "DB01187": {"dbids": ["APRD01312", "DB01187"], "name": "Iophendylate", "groups": ["APPROVED"], "targets": []}, "DB01186": {"dbids": ["APRD00663", "DB01186"], "name": "Pergolide", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "AGONIST", "target": "P14416", "drug": "DB01186"}, {"action": "AGONIST", "target": "P35462", "drug": "DB01186"}, {"action": "AGONIST", "target": "P21917", "drug": "DB01186"}, {"action": "AGONIST", "target": "P08908", "drug": "DB01186"}, {"action": "AGONIST", "target": "P41595", "drug": "DB01186"}, {"action": "AGONIST", "target": "P28223", "drug": "DB01186"}, {"action": "AGONIST", "target": "P28221", "drug": "DB01186"}, {"action": "AGONIST", "target": "P18089", "drug": "DB01186"}, {"action": "AGONIST", "target": "P08913", "drug": "DB01186"}, {"action": "AGONIST", "target": "P18825", "drug": "DB01186"}, {"action": "AGONIST", "target": "P21918", "drug": "DB01186"}, {"action": "AGONIST", "target": "P21728", "drug": "DB01186"}, {"action": "AGONIST", "target": "P28222", "drug": "DB01186"}, {"action": "AGONIST", "target": "P28335", "drug": "DB01186"}, {"action": "AGONIST", "target": "P35348", "drug": "DB01186"}, {"action": "AGONIST", "target": "P35368", "drug": "DB01186"}, {"action": "AGONIST", "target": "P25100", "drug": "DB01186"}]}, "DB01185": {"dbids": ["APRD00981", "DB01185"], "name": "Fluoxymesterone", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P10275", "drug": "DB01185"}, {"action": "ANTAGONIST", "target": "P03372", "drug": "DB01185"}, {"action": "ANTAGONIST", "target": "P16471", "drug": "DB01185"}, {"action": "ANTAGONIST", "target": "P04150", "drug": "DB01185"}]}, "DB01184": {"dbids": ["APRD00418", "DB01184"], "name": "Domperidone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB01184"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB01184"}]}, "DB01189": {"dbids": ["APRD00907", "DB01189"], "name": "Desflurane", "groups": ["APPROVED"], "targets": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01189"}, {"action": "AGONIST", "target": "P23415", "drug": "DB01189"}, {"action": "ANTAGONIST", "target": "P42261", "drug": "DB01189"}, {"action": "INDUCER", "target": "Q09470", "drug": "DB01189"}, {"action": "INHIBITOR", "target": "P98194", "drug": "DB01189"}, {"action": "OTHER/UNKNOWN", "target": "P30049", "drug": "DB01189"}, {"action": "UNKNOWN", "target": "P03886", "drug": "DB01189"}]}, "DB01188": {"dbids": ["APRD00871", "DB01188"], "name": "Ciclopirox", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "BINDER", "target": "P05023", "drug": "DB01188"}]}, "DB00781": {"dbids": ["APRD01190", "DB00781"], "name": "Polymyxin B Sulfate", "groups": ["APPROVED"], "targets": []}, "DB01989": {"dbids": ["DB01989", "EXPT02604"], "name": "Carbobenzoxy-Pro-Lys-Phe-Y(Po2)-Ala-Pro-Ome", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01988": {"dbids": ["DB01988", "EXPT00289"], "name": "6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01983": {"dbids": ["DB01983", "EXPT00396"], "name": "2(S)-Amino-6-Boronohexanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01982": {"dbids": ["DB01982", "EXPT02116"], "name": "D-Mannuronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01981": {"dbids": ["DB01981", "EXPT01183"], "name": "3,6-Anhydro-D-Galactose-2-Sulfate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01980": {"dbids": ["DB01980", "EXPT01920"], "name": "Para-Iodo-D-Phenylalanine Hydroxamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01987": {"dbids": ["DB01987", "EXPT03031", "EXPT03093"], "name": "Thiamin Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01986": {"dbids": ["DB01986", "EXPT01445"], "name": "3-Fluoro-2-Methyl-Aniline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01985": {"dbids": ["DB01985", "EXPT00382"], "name": "N-Alpha-L-Acetyl-Arginine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01984": {"dbids": ["DB01984", "EXPT01214"], "name": "4-[2-(3-Benzyloxycarbonylamino-4-Cyclohexyl-1-Hydroxy-2-Oxo-Butylamino)-5-Guanidino-Pentanoylamino]-4-(1-Carboxy-2-Cyclohexyl-Ethylcarbamoyl)-Butyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00056": {"dbids": ["BIOD00077", "BTD00077", "DB00056"], "name": "Gemtuzumab ozogamicin", "groups": ["APPROVED", "INVESTIGATIONAL", "WITHDRAWN"], "targets": [{"action": "ANTIBODY", "target": "P20138", "drug": "DB00056"}]}, "DB00057": {"dbids": ["BIOD00108", "BTD00108", "DB00057"], "name": "Satumomab Pendetide", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB00054": {"dbids": ["BIOD00041", "BTD00041", "DB00054"], "name": "Abciximab", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P05106", "drug": "DB00054"}, {"action": "ANTAGONIST", "target": "P08514", "drug": "DB00054"}]}, "DB00055": {"dbids": ["BIOD00068", "BTD00068", "DB00055"], "name": "Drotrecogin alfa", "groups": ["APPROVED", "INVESTIGATIONAL", "WITHDRAWN"], "targets": [{"action": "MULTITARGET", "target": "P00451", "drug": "DB00055"}, {"action": "MULTITARGET", "target": "P12259", "drug": "DB00055"}]}, "DB00052": {"dbids": ["BIOD00086", "BTD00086", "DB00052"], "name": "Somatropin recombinant", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "BINDER", "target": "P10912", "drug": "DB00052"}]}, "DB00053": {"dbids": ["BIOD00026", "BTD00026", "DB00053"], "name": "Imiglucerase", "groups": ["APPROVED"], "targets": []}, "DB00050": {"dbids": ["APRD00686", "BIOD00115", "BTD00115", "DB00050"], "name": "Cetrorelix", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P30968", "drug": "DB00050"}]}, "DB00051": {"dbids": ["BIOD00049", "BTD00049", "DB00051"], "name": "Adalimumab", "groups": ["APPROVED"], "targets": [{"action": "ANTIBODY", "target": "P01375", "drug": "DB00051"}]}, "DB00058": {"dbids": ["BIOD00002", "BTD00002", "DB00058"], "name": "Alpha-1-proteinase inhibitor", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P08246", "drug": "DB00058"}]}, "DB00059": {"dbids": ["BIOD00079", "BTD00079", "DB00059"], "name": "Pegaspargase", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB03233": {"dbids": ["DB03233", "EXPT02401"], "name": "Phosphoric Acid Mono-[3-Amino-5-(5-Methyl-2,4-Dioxo-3,4-Dihydro-2h-Pyrimidin-1-Yl)-Tetrahydro-Furan-2-Ylmethyl] Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03232": {"dbids": ["DB03232", "EXPT00337"], "name": "2-[(2e,6e,10e,14e,18e,22e,26e)-3,7,11,15,19,23,27,31-Octamethyldotriaconta-2,6,10,14,18,22,26,30-Octaenyl]Phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03231": {"dbids": ["DB03231", "EXPT02670"], "name": "3-(5-Amino-7-Hydroxy-[1,2,3]Triazolo[4,5-D]Pyrimidin-2-Yl)-N-[2-(2-(Hydroxymethyl-Phenylsulfanyl)-Benzyl]-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03230": {"dbids": ["DB03230", "EXPT02666"], "name": "Adenosine-5'-Propylphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03237": {"dbids": ["DB03237", "EXPT01611"], "name": "2,3-Dihydroxy-5-Oxo-Hexanedioate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03236": {"dbids": ["DB03236", "EXPT00060"], "name": "(2s)-4-(Beta-Alanylamino)-2-Aminobutanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03235": {"dbids": ["DB03235", "EXPT01954"], "name": "N-{3-[4-(3-Amino-Propyl)-Piperazin-1-Yl]-Propyl}-3-Nitro-5-(Galactopyranosyl)-Alpha-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03234": {"dbids": ["DB03234", "EXPT02736"], "name": "(4'-{[Allyl(Methyl)Amino]Methyl}-1,1'-Biphenyl-4-Yl)(4-Bromophenyl)Methanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03239": {"dbids": ["DB03239", "EXPT02474"], "name": "3',5'-Dinitro-N-Acetyl-L-Thyronine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03238": {"dbids": ["DB03238", "EXPT00238"], "name": "3,5-Difluoroaniline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04934": {"dbids": ["DB04934"], "name": "Benzoxazinorifamycin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04937": {"dbids": ["DB04937"], "name": "GV1001", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04936": {"dbids": ["DB04936"], "name": "Tagatose", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04931": {"dbids": ["DB04931"], "name": "EPT1647", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04930": {"dbids": ["DB04930"], "name": "Permethrin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P35498", "drug": "DB04930"}]}, "DB04933": {"dbids": ["DB04933"], "name": "Eritoran", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04240": {"dbids": ["DB04240", "EXPT01305"], "name": "1,2-Hydro-1-Oxy-3,4-Hydro-3-(1-Methoxy-2-Oxy-3,4-Dihydroxypentyl)-8,9-Dihydroxy-7-(Sec-Butyl)-Anthracene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04938": {"dbids": ["DB04938"], "name": "Ospemifene", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P03372", "drug": "DB04938"}, {"action": "AGONIST", "target": "P03372", "drug": "DB04938"}]}, "DB04249": {"dbids": ["DB04249", "EXPT01728"], "name": "Zinc Substituted Heme C", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04248": {"dbids": ["DB04248", "EXPT00613"], "name": "Beta-1,4-Galactotrioside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08005": {"dbids": ["DB08005"], "name": "4-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-N-ethylpiperidine-1-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08004": {"dbids": ["DB08004"], "name": "(2S)-2-{[3-(3-aminophenyl)imidazo[1,2-b]pyridazin-6-yl]amino}-3-methylbutan-1-ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08007": {"dbids": ["DB08007"], "name": "(2R)-3-{[(BENZYLAMINO)CARBONYL]AMINO}-2-HYDROXYPROPANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08006": {"dbids": ["DB08006"], "name": "N-anthracen-2-yl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08001": {"dbids": ["DB08001"], "name": "5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08000": {"dbids": ["DB08000"], "name": "2-(CARBOXYMETHYL)-1-OXO-1,2-DIHYDRONAPHTHO[1,2-D]ISOTHIAZOLE-4-CARBOXYLIC ACID 3,3-DIOXIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08003": {"dbids": ["DB08003"], "name": "ISOTHIAZOLIDINONE ANALOG", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08009": {"dbids": ["DB08009"], "name": "5-[(E)-(5-CHLORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]-N-[2-(DIETHYLAMINO)ETHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08008": {"dbids": ["DB08008"], "name": "5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00632": {"dbids": ["APRD00933", "DB00632"], "name": "Docosanol", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INTERCALATION", "target": "P03200", "drug": "DB00632"}, {"action": "INTERCALATION", "target": "P68344", "drug": "DB00632"}]}, "DB00633": {"dbids": ["APRD00578", "DB00633"], "name": "Dexmedetomidine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P08913", "drug": "DB00633"}]}, "DB00630": {"dbids": ["APRD00561", "DB00630"], "name": "Alendronate", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P14324", "drug": "DB00630"}, {"action": "INHIBITOR", "target": "P29074", "drug": "DB00630"}, {"action": "INHIBITOR", "target": "Q13332", "drug": "DB00630"}, {"action": "INHIBITOR", "target": "P23469", "drug": "DB00630"}, {"action": "INHIBITOR", "target": "P38606", "drug": "DB00630"}]}, "DB00631": {"dbids": ["APRD00878", "DB00631", "DB07554"], "name": "Clofarabine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P09884", "drug": "DB00631"}, {"action": "INHIBITOR", "target": "P23921", "drug": "DB00631"}]}, "DB00636": {"dbids": ["APRD00879", "DB00636"], "name": "Clofibrate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "Q07869", "drug": "DB00636"}]}, "DB00637": {"dbids": ["APRD00585", "DB00637"], "name": "Astemizole", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00637"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00637"}]}, "DB00634": {"dbids": ["APRD00452", "DB00634"], "name": "Sulfacetamide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0AC13", "drug": "DB00634"}, {"action": "INHIBITOR", "target": "P0C002", "drug": "DB00634"}, {"action": "INHIBITOR", "target": "P53848", "drug": "DB00634"}]}, "DB00635": {"dbids": ["APRD00340", "DB00635"], "name": "Prednisone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00635"}, {"action": "LIGAND", "target": "P28845", "drug": "DB00635"}]}, "DB00638": {"dbids": ["APRD01034", "DB00638"], "name": "Inulin", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "BINDER", "target": "Q9F0I5", "drug": "DB00638"}]}, "DB00639": {"dbids": ["APRD00834", "DB00639"], "name": "Butoconazole", "groups": ["APPROVED"], "targets": []}, "DB03589": {"dbids": ["DB03589", "EXPT02110"], "name": "Alpha-Ketomalonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03588": {"dbids": ["DB03588", "EXPT01167"], "name": "Diphenylacetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03585": {"dbids": ["DB03585", "EXPT02440"], "name": "Oxyphenbutazone", "groups": ["WITHDRAWN"], "targets": []}, "DB03584": {"dbids": ["DB03584", "EXPT02895"], "name": "4-Deoxy-4-Thio-Beta-D-Glucopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03587": {"dbids": ["DB03587", "EXPT02707"], "name": "Pyruvoyl Group", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03586": {"dbids": ["DB03586", "EXPT03266"], "name": "5(R)-5-Fluoro-Beta-D-Xylopyranosyl-Enzyme Intermediate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03581": {"dbids": ["DB03581", "EXPT01538"], "name": "Glucose-6-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06060": {"dbids": ["DB06060"], "name": "ADX-48621", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03583": {"dbids": ["DB03583", "EXPT02828"], "name": "(2e,3s)-3-Hydroxy-5'-[(4-Hydroxypiperidin-1-Yl)Sulfonyl]-3-Methyl-1,3-Dihydro-2,3'-Biindol-2'(1'h)-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03582": {"dbids": ["DB03582", "EXPT02981"], "name": "N~2~-Succinylornithine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02988": {"dbids": ["DB02988", "EXPT01942"], "name": "Imino-Tryptophan", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02989": {"dbids": ["DB02989", "EXPT00346"], "name": "CRA_10972", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02982": {"dbids": ["DB02982", "EXPT00738"], "name": "Bombykol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02983": {"dbids": ["DB02983", "EXPT02614"], "name": "Para-Mercury-Benzenesulfonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02980": {"dbids": ["DB02980", "EXPT03057"], "name": "Thymidine-5'-(Dithio)Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02981": {"dbids": ["DB02981", "EXPT02715"], "name": "Vitamin B6 Complexed with 2-Amino-Hexanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02986": {"dbids": ["DB02986", "EXPT03089"], "name": "N-(2-Thienylmethyl)-2,5-Thiophenedisulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02987": {"dbids": ["DB02987", "EXPT03271"], "name": "Cysteine-S-Acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02984": {"dbids": ["DB02984", "EXPT02240"], "name": "4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02985": {"dbids": ["DB02985", "EXPT00334"], "name": "8-Iodo-Guanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09234": {"dbids": ["DB09234"], "name": "Darodipine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02182": {"dbids": ["DB02182", "EXPT01721"], "name": "Hybrid Between B and C Type Hemes (Protoporphyrin Ixcontaining Fe)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02183": {"dbids": ["DB02183", "EXPT00440"], "name": "Adenosine-5'-Ditungstate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02180": {"dbids": ["DB02180", "EXPT02264"], "name": "Myristoyl-Coa", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02181": {"dbids": ["DB02181", "EXPT01184"], "name": "2'-Deoxyguanosine-5'-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02186": {"dbids": ["DB02186", "EXPT02335"], "name": "N-Acetyl-D-Galactosamine 6-Sulfate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02187": {"dbids": ["DB02187", "EXPT01355"], "name": "Equilin", "groups": ["APPROVED"], "targets": []}, "DB02184": {"dbids": ["DB02184", "EXPT01293"], "name": "(2s,3s)-1,4-Dimercaptobutane-2,3-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02185": {"dbids": ["DB02185", "EXPT01700"], "name": "2,4-Dihydroxy-7-(Methyloxy)-2h-1,4-Benzoxazin-3(4h)-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02188": {"dbids": ["DB02188", "EXPT02216"], "name": "N-Methylmesoporphyrin Containing Copper", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02189": {"dbids": ["DB02189", "EXPT01104"], "name": "2',3'-Dideoxyadenosine-5'-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09237": {"dbids": ["DB09237"], "name": "Levamlodipine", "groups": ["APPROVED"], "targets": []}, "DB09236": {"dbids": ["DB09236"], "name": "Lacidipine", "groups": ["APPROVED"], "targets": []}, "DB02368": {"dbids": ["DB02368", "EXPT02432"], "name": "N-Acetyl-L-Citrulline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02369": {"dbids": ["DB02369", "EXPT00160"], "name": "3-Aza-2,3-Dihydrogeranyl Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02366": {"dbids": ["DB02366", "EXPT00299"], "name": "CRA_10762", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02367": {"dbids": ["DB02367", "EXPT00010"], "name": "(1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02364": {"dbids": ["DB02364", "EXPT02876"], "name": "2-Amino-3-(Diethoxy-Phosphoryloxy)-Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02365": {"dbids": ["DB02365", "EXPT02592"], "name": "1,10-Phenanthroline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02362": {"dbids": ["DB02362", "EXPT02486"], "name": "4-Aminobenzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02363": {"dbids": ["DB02363", "EXPT00588"], "name": "2'-Monophosphoadenosine-5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02360": {"dbids": ["DB02360", "EXPT01984"], "name": "Bis-Napthyl Beta-Ketophosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02361": {"dbids": ["DB02361", "EXPT02865"], "name": "S-Methyl Thiocysteine Group", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09231": {"dbids": ["DB09231"], "name": "Benidipine", "groups": ["APPROVED"], "targets": []}, "DB08877": {"dbids": ["DB08877"], "name": "Ruxolitinib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23458", "drug": "DB08877"}, {"action": "INHIBITOR", "target": "O60674", "drug": "DB08877"}]}, "DB09230": {"dbids": ["DB09230"], "name": "Azelnidipine", "groups": ["APPROVED"], "targets": []}, "DB08870": {"dbids": ["DB08870"], "name": "Brentuximab vedotin", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "P28908", "drug": "DB08870"}]}, "DB07853": {"dbids": ["DB07853"], "name": "[4-({4-[(5-CYCLOPROPYL-1H-PYRAZOL-3-YL)AMINO]QUINAZOLIN-2-YL}IMINO)CYCLOHEXA-2,5-DIEN-1-YL]ACETONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07852": {"dbids": ["DB07852"], "name": "1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07851": {"dbids": ["DB07851"], "name": "(3R,4S)-1-(3,4-DIMETHOXYPHENYL)-3-(3-METHYLPHENYL)PIPERIDIN-4-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07850": {"dbids": ["DB07850"], "name": "(1R,2S)-2-(5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)cyclohexanecarboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07857": {"dbids": ["DB07857"], "name": "(2R)-2-(4-CHLOROPHENYL)-2-[4-(1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07856": {"dbids": ["DB07856"], "name": "6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07855": {"dbids": ["DB07855"], "name": "(S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07854": {"dbids": ["DB07854"], "name": "N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07859": {"dbids": ["DB07859"], "name": "4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07858": {"dbids": ["DB07858"], "name": "(2S)-2-(4-CHLOROPHENYL)-2-[4-(1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09233": {"dbids": ["DB09233"], "name": "Cronidipine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08871": {"dbids": ["DB08871"], "name": "Eribulin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB02335": {"dbids": ["DB02335", "EXPT00587"], "name": "2-Aminothiazoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09232": {"dbids": ["DB09232"], "name": "Cilnidipine", "groups": ["APPROVED"], "targets": []}, "DB02334": {"dbids": ["DB02334", "EXPT00192"], "name": "(R)-2-Hydroxy-3-Sulfopropanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07466": {"dbids": ["DB07466"], "name": "(1R)-2-PHENYLACETAMIDO-2-(3-CARBOXYPHENYL)ETHYL BORONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05329": {"dbids": ["DB05329"], "name": "MDX-1379", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05328": {"dbids": ["DB05328"], "name": "VGV-1", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07467": {"dbids": ["DB07467"], "name": "4-chloro-N-[(2S)-2-methyl-2,3-dihydro-1H-indol-1-yl]-3-sulfamoylbenzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05322": {"dbids": ["DB05322"], "name": "INGN 201", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05321": {"dbids": ["DB05321"], "name": "PEG-uricase", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05320": {"dbids": ["DB05320"], "name": "ATG-Fresenius S", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05327": {"dbids": ["DB05327"], "name": "AS-3201", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05326": {"dbids": ["DB05326"], "name": "INKP-102", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05325": {"dbids": ["DB05325"], "name": "INGN 225", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05324": {"dbids": ["DB05324"], "name": "HuMax-EGFr", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07465": {"dbids": ["DB07465"], "name": "(1S,3S,5S)-2-{(2S)-2-amino-2-[(1R,3S,5R,7S)-3-hydroxytricyclo[3.3.1.1~3,7~]dec-1-yl]acetyl}-2-azabicyclo[3.1.0]hexane-3-carbonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07462": {"dbids": ["DB07462"], "name": "(3,4-DIHYDROXY-2-NITROPHENYL)(PHENYL)METHANONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07463": {"dbids": ["DB07463"], "name": "(3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(butylsulfanyl)methyl]pyrrolidin-3-ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07460": {"dbids": ["DB07460"], "name": "2-({5-CHLORO-2-[(2-METHOXY-4-MORPHOLIN-4-YLPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)-N-METHYLBENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07461": {"dbids": ["DB07461"], "name": "3-AMINO-3-BENZYL-9-CARBOXAMIDE[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08469": {"dbids": ["DB08469"], "name": "tert-butyl 4-(3-thiophen-2-yl-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08468": {"dbids": ["DB08468"], "name": "2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08463": {"dbids": ["DB08463"], "name": "(2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07468": {"dbids": ["DB07468"], "name": "(3aS)-3a-hydroxy-5-methyl-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08462": {"dbids": ["DB08462"], "name": "N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07469": {"dbids": ["DB07469"], "name": "(3aS)-3a-hydroxy-7-methyl-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08461": {"dbids": ["DB08461"], "name": "3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04748": {"dbids": ["DB04748"], "name": "OXIMINOARYLSULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04749": {"dbids": ["DB04749"], "name": "2-(3-OXO-PROPYLSULFANYLCARBONYL)-ETHANETHIOLATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04038": {"dbids": ["DB04038", "EXPT01357"], "name": "Ergosterol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04039": {"dbids": ["DB04039", "EXPT02034"], "name": "3-Oxo-Pentadecanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01048": {"dbids": ["APRD00216", "DB01048"], "name": "Abacavir", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q72547", "drug": "DB01048"}]}, "DB01049": {"dbids": ["APRD00711", "DB01049", "DB01287"], "name": "Ergoloid mesylate", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08913", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB01049"}, {"action": "INHIBITOR", "target": "O94956", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P28221", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P28566", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P30939", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "O95264", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "Q8WXA8", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "Q70Z44", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "A5X5Y0", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "Q13639", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01049"}, {"action": "AGONIST", "target": "P21728", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01049"}, {"action": "AGONIST", "target": "P14416", "drug": "DB01049"}, {"action": "AGONIST", "target": "P14867", "drug": "DB01049"}, {"action": "AGONIST", "target": "P47869", "drug": "DB01049"}, {"action": "AGONIST", "target": "P34903", "drug": "DB01049"}, {"action": "AGONIST", "target": "P48169", "drug": "DB01049"}, {"action": "AGONIST", "target": "P31644", "drug": "DB01049"}, {"action": "AGONIST", "target": "Q16445", "drug": "DB01049"}, {"action": "AGONIST", "target": "P18505", "drug": "DB01049"}, {"action": "AGONIST", "target": "P47870", "drug": "DB01049"}, {"action": "AGONIST", "target": "P28472", "drug": "DB01049"}, {"action": "AGONIST", "target": "O14764", "drug": "DB01049"}, {"action": "AGONIST", "target": "P78334", "drug": "DB01049"}, {"action": "AGONIST", "target": "Q8N1C3", "drug": "DB01049"}, {"action": "AGONIST", "target": "P18507", "drug": "DB01049"}, {"action": "AGONIST", "target": "Q99928", "drug": "DB01049"}, {"action": "AGONIST", "target": "O00591", "drug": "DB01049"}, {"action": "AGONIST", "target": "Q9UN88", "drug": "DB01049"}]}, "DB01514": {"dbids": ["DB01514"], "name": "Furazabol", "groups": ["ILLICIT"], "targets": []}, "DB01515": {"dbids": ["DB01515"], "name": "Benzoylecgonine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01516": {"dbids": ["DB01516"], "name": "3,4,5-Trimethoxyamphetamine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB04037": {"dbids": ["DB04037", "EXPT00852"], "name": "N,N-Bis(4-Chlorobenzyl)-1h-1,2,3,4-Tetraazol-5-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01510": {"dbids": ["DB01510"], "name": "Dehydrochloromethyltestosterone", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01511": {"dbids": ["DB01511"], "name": "Delorazepam", "groups": ["APPROVED", "ILLICIT"], "targets": []}, "DB01512": {"dbids": ["DB01512"], "name": "Hydromorphinol", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01513": {"dbids": ["DB01513"], "name": "17Alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB08638": {"dbids": ["DB08638"], "name": "2-AMINO-3-(1-HYDROPEROXY-1H-INDOL-3-YL)PROPAN-1-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08639": {"dbids": ["DB08639"], "name": "4-[4-(2,4,6-TRIMETHYL-PHENYLAMINO)-PYRIMIDIN-2-YLAMINO]-BENZONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08465": {"dbids": ["DB08465"], "name": "2-(3-AMINO-2,5,6-TRIMETHOXYPHENYL)ETHYL 5-CHLORO-2,4-DIHYDROXYBENZOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08632": {"dbids": ["DB08632"], "name": "1,3,5-BENZENETRICARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08633": {"dbids": ["DB08633"], "name": "(CHLOROACETYL)CARBAMIC ACID (3R,4S,5S,5R)-5-METHOXY-4-[(2R,3R)-2-METHYL-3-(3-METHYL-2-BUTENYL)OXIRANYL]-1-OXASPIRO[2.5]OCT-6-YL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08464": {"dbids": ["DB08464"], "name": "METHYL 3-CHLORO-2-{3-[(2,5-DIHYDROXY-4-METHOXYPHENYL)AMINO]-3-OXOPROPYL}-4,6-DIHYDROXYBENZOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08636": {"dbids": ["DB08636"], "name": "(3E)-4-(2-HYDROXYPHENYL)-2-OXOBUT-3-ENOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08637": {"dbids": ["DB08637"], "name": "4-(2-METHOXYPHENYL)-2-OXOBUT-3-ENOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08634": {"dbids": ["DB08634"], "name": "6-BENZYL-1-BENZYLOXYMETHYL-5-ISOPROPYL URACIL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08635": {"dbids": ["DB08635"], "name": "N-(TRANS-4'-NITRO-4-STILBENYL)-N-METHYL-5-AMINO-PENTANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06898": {"dbids": ["DB06898"], "name": "4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03305": {"dbids": ["DB03305", "EXPT01862"], "name": "N5-Iminoethyl-L-Ornithine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06894": {"dbids": ["DB06894"], "name": "1-DODECANOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06896": {"dbids": ["DB06896"], "name": "1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06897": {"dbids": ["DB06897"], "name": "3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06890": {"dbids": ["DB06890"], "name": "(2R)-2-PHENYL-N-PYRIDIN-4-YLBUTANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06891": {"dbids": ["DB06891"], "name": "5-{[(4-AMINO-3-CHLORO-5-FLUOROPHENYL)SULFONYL]AMINO}-1,3,4-THIADIAZOLE-2-SULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06892": {"dbids": ["DB06892"], "name": "(5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06893": {"dbids": ["DB06893"], "name": "1-DECANE-SULFONIC-ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07942": {"dbids": ["DB07942"], "name": "2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06228": {"dbids": ["DB06228"], "name": "Rivaroxaban", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P00742", "drug": "DB06228"}]}, "DB04517": {"dbids": ["DB04517", "EXPT01256"], "name": "Dipyrromethane Cofactor", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04516": {"dbids": ["DB04516", "EXPT01174"], "name": "2-Deoxy-Glucitol-6-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04847": {"dbids": ["DB04847"], "name": "FG-4592", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04514": {"dbids": ["DB04514", "EXPT03158"], "name": "Phosphoric Acid-2'-[2'-Deoxy-Uridine]Ester-5'-Guanosine Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04513": {"dbids": ["DB04513", "EXPT03246"], "name": "N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04512": {"dbids": ["DB04512", "EXPT02668"], "name": "2-Isobutyl-3-Methoxypyrazine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04430": {"dbids": ["DB04430", "EXPT01502"], "name": "3-(4-Phenylamino-Phenylamino)-2-(1h-Tetrazol-5-Yl)-Acrylonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04511": {"dbids": ["DB04511", "EXPT02922"], "name": "N-Succinyl Methionine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04431": {"dbids": ["DB04431", "EXPT03218"], "name": "4-Epi-Vancosaminyl Derivative of Vancomycin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04510": {"dbids": ["DB04510", "EXPT00187"], "name": "3-Phosphoglyceric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04432": {"dbids": ["DB04432", "EXPT00266"], "name": "ZK-805623", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00939": {"dbids": ["APRD01090", "DB00939"], "name": "Meclofenamic acid", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23219", "drug": "DB00939"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00939"}, {"action": "INHIBITOR", "target": "P09917", "drug": "DB00939"}, {"action": "OTHER", "target": "O43526", "drug": "DB00939"}, {"action": "OTHER", "target": "O43525", "drug": "DB00939"}]}, "DB00938": {"dbids": ["APRD00277", "DB00938"], "name": "Salmeterol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P07550", "drug": "DB00938"}]}, "DB07647": {"dbids": ["DB07647"], "name": "(2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00931": {"dbids": ["APRD00137", "DB00931"], "name": "Methacycline", "groups": ["APPROVED"], "targets": []}, "DB00930": {"dbids": ["APRD00883", "DB00930"], "name": "Colesevelam", "groups": ["APPROVED"], "targets": []}, "DB00933": {"dbids": ["APRD00610", "DB00933"], "name": "Mesoridazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P28223", "drug": "DB00933"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00933"}]}, "DB00932": {"dbids": ["APRD01306", "DB00932"], "name": "Tipranavir", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q72874", "drug": "DB00932"}]}, "DB00935": {"dbids": ["APRD01158", "DB00935"], "name": "Oxymetazoline", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35348", "drug": "DB00935"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00935"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00935"}, {"action": "BINDER", "target": "P18089", "drug": "DB00935"}, {"action": "AGONIST", "target": "P35368", "drug": "DB00935"}, {"action": "AGONIST", "target": "P25100", "drug": "DB00935"}]}, "DB00934": {"dbids": ["APRD00747", "DB00934"], "name": "Maprotiline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23975", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00934"}, {"action": "BINDER", "target": "P28223", "drug": "DB00934"}, {"action": "BINDER", "target": "P28335", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00934"}, {"action": "BINDER", "target": "P14416", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB00934"}]}, "DB00937": {"dbids": ["APRD00919", "DB00937"], "name": "Diethylpropion", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "INHIBITOR", "target": "P23975", "drug": "DB00937"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00937"}]}, "DB00936": {"dbids": ["APRD01605", "DB00936"], "name": "Salicylic acid", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23219", "drug": "DB00936"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00936"}, {"action": "INHIBITOR", "target": "Q04828", "drug": "DB00936"}]}, "DB03916": {"dbids": ["DB03916", "EXPT03239"], "name": "4-{2-[4-(2-Aminoethyl)Piperazin-1-Yl]Pyridin-4-Yl}-N-(3-Chloro-4-Methylphenyl)Pyrimidin-2-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03917": {"dbids": ["DB03917", "EXPT01372"], "name": "N-Ethyl Retinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03914": {"dbids": ["DB03914", "EXPT01021"], "name": "[2-(1-Amino-2-Hydroxy-Propyl)-4-(1h-Indol-3-Ylmethylene)-5-Oxo-4,5-Dihydro-Imidazol-1-Yl]-Acetaldehyde", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03915": {"dbids": ["DB03915", "EXPT00482"], "name": "2-Amino-3-Ketobutyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03912": {"dbids": ["DB03912", "EXPT02624"], "name": "4'-Phosphopantetheine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03913": {"dbids": ["DB03913", "EXPT01381"], "name": "Coenzyme F420", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03910": {"dbids": ["DB03910", "EXPT00164"], "name": "S,S'-(1,3-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03911": {"dbids": ["DB03911", "EXPT02070"], "name": "L-Xylopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07642": {"dbids": ["DB07642"], "name": "5-{[1-(2-fluorobenzyl)piperidin-4-yl]methoxy}quinazoline-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04437": {"dbids": ["DB04437", "EXPT02382"], "name": "Cysteine-Methylene-Carbamoyl-1,10-Phenanthroline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03918": {"dbids": ["DB03918", "EXPT00702"], "name": "6s-5,6,7,8-Tetrahydrobiopterin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03919": {"dbids": ["DB03919", "EXPT02149"], "name": "Ethyl-Carbamic Acid Methyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04438": {"dbids": ["DB04438", "EXPT00784"], "name": "BVDU-MP", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09548": {"dbids": ["DB09548"], "name": "Ioflupane I-123", "groups": ["APPROVED"], "targets": []}, "DB07640": {"dbids": ["DB07640"], "name": "2-decyl-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04439": {"dbids": ["DB04439", "EXPT00411"], "name": "Modified Acarbose Pentasaccharide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09543": {"dbids": ["DB09543"], "name": "Methyl salicylate", "groups": ["APPROVED"], "targets": []}, "DB09542": {"dbids": ["DB09542"], "name": "Sodium phosphate, dibasic, anhydrous", "groups": ["APPROVED"], "targets": []}, "DB09541": {"dbids": ["DB09541"], "name": "Sodium ascorbate", "groups": ["APPROVED"], "targets": []}, "DB07641": {"dbids": ["DB07641"], "name": "DECYL(DIMETHYL)PHOSPHINE OXIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09546": {"dbids": ["DB09546"], "name": "Iobenguane sulfate I-123", "groups": ["APPROVED"], "targets": []}, "DB09545": {"dbids": ["DB09545"], "name": "Choline fenofibrate", "groups": ["APPROVED"], "targets": []}, "DB07075": {"dbids": ["DB07075"], "name": "3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07074": {"dbids": ["DB07074"], "name": "6-CARBAMIMIDOYL-4-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-NAPHTHALENE-2-CARBOXYLIC ACID METHYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07077": {"dbids": ["DB07077"], "name": "(R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENYL)GUANIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07076": {"dbids": ["DB07076"], "name": "6-[(Z)-AMINO(IMINO)METHYL]-N-[3-(CYCLOPENTYLOXY)PHENYL]-2-NAPHTHAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07071": {"dbids": ["DB07071"], "name": "(R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENETHYL)GUANIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07070": {"dbids": ["DB07070"], "name": "(2S)-2-{3-[({[2-fluoro-4-(trifluoromethyl)phenyl]carbonyl}amino)methyl]-4-methoxybenzyl}butanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07073": {"dbids": ["DB07073"], "name": "5,5-dimethyl-2-morpholin-4-yl-5,6-dihydro-1,3-benzothiazol-7(4H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07072": {"dbids": ["DB07072"], "name": "(1S,2R,5S)-5-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-2-(2,4,5-TRIFLUOROPHENYL)CYCLOHEXANAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00960": {"dbids": ["APRD00678", "DB00960"], "name": "Pindolol", "groups": ["APPROVED"], "targets": [{"action": "PARTIAL AGONIST", "target": "P08588", "drug": "DB00960"}, {"action": "PARTIAL AGONIST", "target": "P07550", "drug": "DB00960"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00960"}, {"action": "OTHER/UNKNOWN", "target": "P28222", "drug": "DB00960"}]}, "DB07079": {"dbids": ["DB07079"], "name": "3-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}propane-1-thiol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07078": {"dbids": ["DB07078"], "name": "(3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08351": {"dbids": ["DB08351"], "name": "N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08723": {"dbids": ["DB08723"], "name": "5-(5-(2,6-DICHLORO-4-(4,5-DIHYDRO-2-OXAZOLY)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08580": {"dbids": ["DB08580"], "name": "4-bromo-2-{[(2R)-2-(2-chlorobenzyl)pyrrolidin-1-yl]carbonyl}aniline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08581": {"dbids": ["DB08581"], "name": "4-[(4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}phenyl)amino]-4-oxobutanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08582": {"dbids": ["DB08582"], "name": "N-(4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}phenyl)-4-morpholin-4-yl-4-oxobutanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08583": {"dbids": ["DB08583"], "name": "2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08729": {"dbids": ["DB08729"], "name": "5-ethoxy-4-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)thiophene-2-sulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08584": {"dbids": ["DB08584"], "name": "6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}quinoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08585": {"dbids": ["DB08585"], "name": "S-[2-({N-[(2S)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alanyl}amino)ethyl] hexanethioate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07790": {"dbids": ["DB07790"], "name": "N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08586": {"dbids": ["DB08586"], "name": "S-[2-({N-[(2S)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alanyl}amino)ethyl] octanethioate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07791": {"dbids": ["DB07791"], "name": "4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08587": {"dbids": ["DB08587"], "name": "SINAPINATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07792": {"dbids": ["DB07792"], "name": "(S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07793": {"dbids": ["DB07793"], "name": "(2S)-N-[(3S)-1-(2-AMINO-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-2-CHLORO-2H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07794": {"dbids": ["DB07794"], "name": "5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07795": {"dbids": ["DB07795"], "name": "3,7,3',4'-TETRAHYDROXYFLAVONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05510": {"dbids": ["DB05510"], "name": "Huperzine-A", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05511": {"dbids": ["DB05511"], "name": "CF-101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05512": {"dbids": ["DB05512"], "name": "MM-093", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08834": {"dbids": ["DB08834"], "name": "Tauroursodeoxycholic acid", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB08835": {"dbids": ["DB08835"], "name": "Spaglumic Acid", "groups": ["APPROVED"], "targets": []}, "DB08836": {"dbids": ["DB08836"], "name": "Temocapril", "groups": ["EXPERIMENTAL", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P12821", "drug": "DB08836"}]}, "DB08837": {"dbids": ["DB08837"], "name": "Tetraethylammonium", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P0A334", "drug": "DB08837"}, {"action": "AGONIST", "target": "Q9UGM1", "drug": "DB08837"}, {"action": "INHIBITOR", "target": "Q9UGM1", "drug": "DB08837"}, {"action": "INHIBITOR", "target": "Q08460", "drug": "DB08837"}]}, "DB08838": {"dbids": ["DB08838"], "name": "Agmatine", "groups": ["EXPERIMENTAL", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P18825", "drug": "DB08838"}, {"action": "AGONIST", "target": "Q9Y2I1", "drug": "DB08838"}, {"action": "ANTAGONIST", "target": "P02708", "drug": "DB08838"}, {"action": "ANTAGONIST", "target": "Q05586", "drug": "DB08838"}, {"action": "ANTAGONIST", "target": "P48048", "drug": "DB08838"}, {"action": "ANTAGONIST", "target": "Q00975", "drug": "DB08838"}, {"action": "AGONIST", "target": "Q9UHC3", "drug": "DB08838"}]}, "DB07797": {"dbids": ["DB07797"], "name": "N-[[3-FLUORO-4-ETHOXY-PYRID-2-YL]ETHYL]-N'-[5-CHLORO-PYRIDYL]-THIOUREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03772": {"dbids": ["DB03772", "EXPT01217"], "name": "2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,5-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03773": {"dbids": ["DB03773", "EXPT01536"], "name": "6-Deoxy-Alpha-D-Glucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03770": {"dbids": ["DB03770", "EXPT01741"], "name": "N-Hydroxyguanidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03771": {"dbids": ["DB03771", "EXPT02740"], "name": "Allyl-{4-[3-(4-Bromo-Phenyl)-Benzofuran-6-Yloxy]-but-2-Enyl}-Methyl-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03776": {"dbids": ["DB03776", "EXPT00138"], "name": "Lactaldehyde", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03777": {"dbids": ["DB03777", "EXPT00703"], "name": "Rbt205 Inhibitor", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03774": {"dbids": ["DB03774", "EXPT01861"], "name": "Glutamyl Group", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03775": {"dbids": ["DB03775", "EXPT01280"], "name": "D-Dethiobiotin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06946": {"dbids": ["DB06946"], "name": "(2S,3S)-3-(4-fluorophenyl)-2,3-dihydroxypropanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03779": {"dbids": ["DB03779", "EXPT02268"], "name": "Glucosaminyl-(Alpha-6)-D-Myo-Inositol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06947": {"dbids": ["DB06947"], "name": "1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07435": {"dbids": ["DB07435"], "name": "1,2,3-TRIHYDROXY-1,2,3,4-TETRAHYDROBENZO[A]PYRENE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00888": {"dbids": ["APRD00249", "DB00888"], "name": "Mechlorethamine", "groups": ["APPROVED"], "targets": []}, "DB01924": {"dbids": ["DB01924", "EXPT00700"], "name": "Benzhydroxamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06948": {"dbids": ["DB06948"], "name": "2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06949": {"dbids": ["DB06949"], "name": "N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]naphthalene-2-carbohydrazide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08535": {"dbids": ["DB08535"], "name": "3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01927": {"dbids": ["DB01927", "EXPT01265"], "name": "Duroquinone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02797": {"dbids": ["DB02797", "EXPT02380"], "name": "3-Nitrophenylboronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02796": {"dbids": ["DB02796", "EXPT00357"], "name": "9-Deazainosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02795": {"dbids": ["DB02795", "EXPT00523"], "name": "P-Anisic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02794": {"dbids": ["DB02794", "EXPT00025"], "name": "N-[5'-O-Phosphono-Ribofuranosyl]-2-[2-Hydroxy-2-[4-[Glutamic Acid]-N-Carbonylphenyl]-3-[2-Amino-4-Hydroxy-Quinazolin-6-Yl]-Propanylamino]-Acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02793": {"dbids": ["DB02793", "EXPT01933"], "name": "Isochorismic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02792": {"dbids": ["DB02792", "EXPT01122"], "name": "Deglucobalhimycin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08534": {"dbids": ["DB08534"], "name": "5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02790": {"dbids": ["DB02790", "EXPT03199"], "name": "Phenyl-Uridine-5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01926": {"dbids": ["DB01926", "EXPT00951"], "name": "Carboxymycobactin S", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02799": {"dbids": ["DB02799", "EXPT02140"], "name": "N-[2-(1-Maleimidyl)Ethyl]-7-Diethylaminocoumarin-3-Carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02798": {"dbids": ["DB02798", "EXPT00399"], "name": "Alpha-Methylene Adenosine Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02421": {"dbids": ["DB02421", "EXPT03175"], "name": "Uridine-5'-Diphosphate-Mannose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02420": {"dbids": ["DB02420", "EXPT02051"], "name": "[[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid,", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02423": {"dbids": ["DB02423", "EXPT02603"], "name": "Thiopyrophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02422": {"dbids": ["DB02422", "EXPT02920"], "name": "Methyl-2-S-(Alpha-D-Mannopyranosyl)-2-Thio-Alpha-D-Mannopyranoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02425": {"dbids": ["DB02425", "EXPT00974"], "name": "Hexadecyl Octanoate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02424": {"dbids": ["DB02424", "EXPT01571"], "name": "Geldanamycin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02427": {"dbids": ["DB02427", "EXPT00983"], "name": "2,4-Diamino-6-[N-(2',5'-Dimethoxybenzyl)-N-Methylamino]Quinazoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02426": {"dbids": ["DB02426", "EXPT01071"], "name": "Carboxyatractyloside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01920": {"dbids": ["DB01920", "EXPT00031"], "name": "1-O-[O-Nitrophenyl]-Beta-D-Galactopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02428": {"dbids": ["DB02428", "DB08452", "EXPT02730"], "name": "Quinaldic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08531": {"dbids": ["DB08531"], "name": "5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01923": {"dbids": ["DB01923", "EXPT02069"], "name": "L-Xylulose 5-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09046": {"dbids": ["DB09046"], "name": "Metreleptin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P48357", "drug": "DB09046"}]}, "DB09047": {"dbids": ["DB09047"], "name": "Finafloxacin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P43700", "drug": "DB09047"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB09047"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB09047"}]}, "DB09045": {"dbids": ["DB09045"], "name": "Dulaglutide", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P43220", "drug": "DB09045"}]}, "DB09042": {"dbids": ["DB09042"], "name": "Tedizolid Phosphate", "groups": ["APPROVED"], "targets": []}, "DB09043": {"dbids": ["DB09043"], "name": "Albiglutide", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P43220", "drug": "DB09043"}]}, "DB09040": {"dbids": ["DB09040"], "name": "Efinaconazole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P50859", "drug": "DB09040"}]}, "DB09041": {"dbids": ["DB09041"], "name": "Tavaborole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9HGT2", "drug": "DB09041"}]}, "DB08530": {"dbids": ["DB08530"], "name": "7-BENZYL-1,3-DIMETHYL-8-PIPERAZIN-1-YL-3,7-DIHYDRO-PURINE-2,6-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09049": {"dbids": ["DB09049"], "name": "Naloxegol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35372", "drug": "DB09049"}]}, "DB01213": {"dbids": ["APRD00985", "DB01213"], "name": "Fomepizole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P07327", "drug": "DB01213"}, {"action": "INHIBITOR", "target": "P00325", "drug": "DB01213"}, {"action": "INHIBITOR", "target": "P00326", "drug": "DB01213"}, {"action": "INHIBITOR", "target": "P04040", "drug": "DB01213"}]}, "DB01212": {"dbids": ["APRD00395", "DB01212"], "name": "Ceftriaxone", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB01212"}]}, "DB01211": {"dbids": ["APRD00181", "DB01211"], "name": "Clarithromycin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A7J6", "drug": "DB01211"}]}, "DB01210": {"dbids": ["APRD00165", "DB01210"], "name": "Levobunolol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P07550", "drug": "DB01210"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB01210"}]}, "DB01217": {"dbids": ["APRD00016", "DB01217"], "name": "Anastrozole", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P11511", "drug": "DB01217"}]}, "DB01216": {"dbids": ["APRD00632", "DB01216", "DB07774"], "name": "Finasteride", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P31213", "drug": "DB01216"}, {"action": "INHIBITOR", "target": "P18405", "drug": "DB01216"}, {"action": "INHIBITOR", "target": "P51857", "drug": "DB01216"}]}, "DB01215": {"dbids": ["APRD00955", "DB01215"], "name": "Estazolam", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01215"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01215"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01215"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01215"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB01215"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB01215"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB01215"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB01215"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB01215"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB01215"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB01215"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB01215"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB01215"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB01215"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB01215"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01215"}]}, "DB01214": {"dbids": ["APRD00668", "DB01214"], "name": "Metipranolol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P07550", "drug": "DB01214"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB01214"}]}, "DB01219": {"dbids": ["APRD00901", "DB01219"], "name": "Dantrolene", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P21817", "drug": "DB01219"}]}, "DB01218": {"dbids": ["APRD00419", "DB01218"], "name": "Halofantrine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q12809", "drug": "DB01218"}, {"action": "INHIBITOR", "target": "P46925", "drug": "DB01218"}]}, "DB04485": {"dbids": ["DB04485", "EXPT03053"], "name": "Deoxythymidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04484": {"dbids": ["DB04484", "EXPT02590"], "name": "L-Phenylalaninol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04487": {"dbids": ["DB04487", "EXPT02181"], "name": "N-Methylleucine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04486": {"dbids": ["DB04486", "EXPT01745"], "name": "(2s)-2,8-Diaminooctanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04481": {"dbids": ["DB04481", "EXPT02232"], "name": "Meso-Erythritol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04480": {"dbids": ["DB04480", "EXPT00236"], "name": "3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04483": {"dbids": ["DB04483", "EXPT02121"], "name": "2-Deoxy-2-Fluoro-Beta-D-Mannose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04482": {"dbids": ["DB04482", "EXPT00957"], "name": "Cmp-2-Keto-3-Deoxy-Octulosonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04489": {"dbids": ["DB04489", "EXPT01581"], "name": "Guanidinoethylmercaptosuccinic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04488": {"dbids": ["DB04488", "EXPT01675"], "name": "(6r,7r)-3-[(Acetyloxy)Methyl]-7-{[(6s)-6-(Glycylamino)-7-Oxido-7-Oxoheptanoyl]Amino}-8-Oxo-5-Thia-1-Azabicyclo[4.2.0]Octane-2-Carboxylate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08795": {"dbids": ["DB08795"], "name": "Azidocillin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB08795"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB08795"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB08795"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB08795"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB08795"}]}, "DB08794": {"dbids": ["DB08794"], "name": "Ethyl biscoumacetate", "groups": ["WITHDRAWN"], "targets": []}, "DB08797": {"dbids": ["DB08797"], "name": "Salicylamide", "groups": ["APPROVED"], "targets": []}, "DB08796": {"dbids": ["DB08796"], "name": "Pipazethate", "groups": ["APPROVED"], "targets": []}, "DB08791": {"dbids": ["DB08791"], "name": "1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08790": {"dbids": ["DB08790"], "name": "1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08792": {"dbids": ["DB08792"], "name": "Diloxanide", "groups": ["APPROVED"], "targets": []}, "DB08799": {"dbids": ["DB08799"], "name": "Antazoline", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB08799"}]}, "DB08798": {"dbids": ["DB08798"], "name": "Sulfamoxole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q27738", "drug": "DB08798"}]}, "DB00030": {"dbids": ["BIOD00105", "BTD00105", "DB00030", "DB01383"], "name": "Insulin Regular", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P06213", "drug": "DB00030"}]}, "DB00031": {"dbids": ["BIOD00019", "BTD00019", "DB00031"], "name": "Tenecteplase", "groups": ["APPROVED"], "targets": [{"action": "ACTIVATOR", "target": "P00747", "drug": "DB00031"}]}, "DB00032": {"dbids": ["BIOD00018", "BTD00018", "DB00032"], "name": "Menotropins", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "P23945", "drug": "DB00032"}]}, "DB00033": {"dbids": ["BIOD00017", "BTD00017", "DB00033"], "name": "Interferon gamma-1b", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "BINDER", "target": "P15260", "drug": "DB00033"}, {"action": "BINDER", "target": "P38484", "drug": "DB00033"}]}, "DB00034": {"dbids": ["BIOD00012", "BIOD00095", "BTD00012", "BTD00095", "DB00034", "DB00037"], "name": "Interferon Alfa-2a, Recombinant", "groups": ["APPROVED"], "targets": []}, "DB00035": {"dbids": ["BIOD00061", "BIOD00112", "BTD00061", "BTD00112", "DB00035"], "name": "Desmopressin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P30518", "drug": "DB00035"}]}, "DB00036": {"dbids": ["BIOD00006", "BTD00006", "DB00036"], "name": "Coagulation factor VIIa", "groups": ["APPROVED"], "targets": []}, "DB06930": {"dbids": ["DB06930"], "name": "N-[amino(imino)methyl]-2-(2,5-diphenyl-1H-pyrrol-1-yl)acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00038": {"dbids": ["BIOD00021", "BTD00021", "DB00038"], "name": "Oprelvekin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "Q14626", "drug": "DB00038"}]}, "DB00039": {"dbids": ["BIOD00042", "BTD00042", "DB00039"], "name": "Palifermin", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "P21802", "drug": "DB00039"}]}, "DB06939": {"dbids": ["DB06939"], "name": "N-(TRANS-4-{(1S,2S)-2-AMINO-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-1-METHYL-3-OXOPROPYL}CYCLOHEXYL)-N-METHYLACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06938": {"dbids": ["DB06938"], "name": "4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03219": {"dbids": ["DB03219", "EXPT01268"], "name": "11-Deoxy-Beta-Rhodomycin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03218": {"dbids": ["DB03218", "EXPT00600"], "name": "N-Acetyl-N'-Beta-D-Glucopyranosyl Urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03215": {"dbids": ["DB03215", "EXPT02957"], "name": "(2s,5s)-5-Carboxymethylproline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03214": {"dbids": ["DB03214", "EXPT02068"], "name": "Vinylglycine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03217": {"dbids": ["DB03217", "EXPT01817"], "name": "DPI59", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03216": {"dbids": ["DB03216", "EXPT00427"], "name": "(1'r,2's)-9-(2-Hydroxy-3'-Keto-Cyclopenten-1-Yl)Adenine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03211": {"dbids": ["DB03211", "EXPT01081"], "name": "(3-Formyl-but-3-Enyl)-Phosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03210": {"dbids": ["DB03210", "EXPT00463"], "name": "4-Aminohydrocinnamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03213": {"dbids": ["DB03213", "EXPT00623"], "name": "Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03212": {"dbids": ["DB03212", "EXPT01307"], "name": "4-Deoxyglucarate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04261": {"dbids": ["DB04261", "EXPT02453"], "name": "Carbamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04260": {"dbids": ["DB04260", "EXPT01684"], "name": "9-(5,5-Difluoro-5-Phosphonopentyl)Guanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04263": {"dbids": ["DB04263", "EXPT01586"], "name": "G418", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04262": {"dbids": ["DB04262", "EXPT02791"], "name": "3-(7-Hydroxy-8-Ribityllumazine-6-Yl) Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04265": {"dbids": ["DB04265", "EXPT02915"], "name": "Beta-Sialic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04264": {"dbids": ["DB04264", "EXPT02347"], "name": "(10R)-10-Formyl-5,8,10-Trideazafolic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04267": {"dbids": ["DB04267", "EXPT02530"], "name": "Dipicolinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04266": {"dbids": ["DB04266", "EXPT01888"], "name": "5-(6-D-Ribitylamino-2,4-Dihydroxypyrimidin-5-Yl)-1-Pentyl-Phosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04269": {"dbids": ["DB04269", "EXPT01047"], "name": "Cyclotheonamide A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04268": {"dbids": ["DB04268", "EXPT03186"], "name": "Methylumbelliferyl Chitotriose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08539": {"dbids": ["DB08539"], "name": "3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07688": {"dbids": ["DB07688"], "name": "4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07689": {"dbids": ["DB07689"], "name": "METHYL 1-(4-{[(2,4-DIAMINOPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)PIPERIDINE-4-CARBOXYLATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07683": {"dbids": ["DB07683"], "name": "N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07680": {"dbids": ["DB07680"], "name": "[(1S)-1-(5-CHLORO-1-BENZOTHIEN-3-YL)-2-(2-NAPHTHYLAMINO)-2-OXOETHYL]PHOSPHONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07681": {"dbids": ["DB07681"], "name": "DODECANESULFONATE ION", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07686": {"dbids": ["DB07686"], "name": "4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07687": {"dbids": ["DB07687"], "name": "4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07684": {"dbids": ["DB07684"], "name": "5-(DIMETHYLAMINO)-2-NAPHTHALENESULFONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07685": {"dbids": ["DB07685"], "name": "4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08538": {"dbids": ["DB08538"], "name": "N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07436": {"dbids": ["DB07436"], "name": "N-(1-PHENYL-PROPYL)-FORMAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09327": {"dbids": ["DB09327"], "name": "Tegafur-uracil", "groups": ["APPROVED"], "targets": []}, "DB09326": {"dbids": ["DB09326"], "name": "Ammonia N-13", "groups": ["APPROVED"], "targets": []}, "DB09325": {"dbids": ["DB09325"], "name": "Sodium fluoride", "groups": ["APPROVED"], "targets": []}, "DB09324": {"dbids": ["DB09324"], "name": "Sulbactam", "groups": ["APPROVED"], "targets": []}, "DB02168": {"dbids": ["DB02168", "EXPT00741"], "name": "Bromopurine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02169": {"dbids": ["DB02169", "EXPT02429"], "name": "9,10-Deepithio-9,10-Didehydroacanthifolicin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02164": {"dbids": ["DB02164", "EXPT01464"], "name": "N-Sulfo-Flavin Mononucleotide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02165": {"dbids": ["DB02165", "EXPT03289"], "name": "Zinc Trihydroxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02166": {"dbids": ["DB02166", "EXPT02661"], "name": "Propidium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02167": {"dbids": ["DB02167", "EXPT02000"], "name": "N,N-Dimethyl-L-Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02160": {"dbids": ["DB02160", "EXPT01074"], "name": "S-Butyryl-Cystein", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02161": {"dbids": ["DB02161", "EXPT01792"], "name": "Hydroxy-Phenyl-Acetic Acid 8-Methyl-8-Aza-Bicyclo[3.2.1]Oct-3-Yl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02162": {"dbids": ["DB02162", "EXPT00240"], "name": "5'-O-(N-Ethyl-Sulfamoyl)Adenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02163": {"dbids": ["DB02163", "EXPT03265"], "name": "2,5-Xylidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09321": {"dbids": ["DB09321"], "name": "Zinc oxide", "groups": ["APPROVED"], "targets": []}, "DB09320": {"dbids": ["DB09320"], "name": "Procaine benzylpenicillin", "groups": ["APPROVED"], "targets": []}, "DB07252": {"dbids": ["DB07252"], "name": "3-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08895": {"dbids": ["DB08895"], "name": "Tofacitinib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "O60674", "drug": "DB08895"}, {"action": "INHIBITOR", "target": "P23458", "drug": "DB08895"}, {"action": "INHIBITOR", "target": "P52333", "drug": "DB08895"}]}, "DB02308": {"dbids": ["DB02308", "EXPT01310"], "name": "4-(1,3,2-Dioxaborolan-2-Yloxy)Butan-1-Aminium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02309": {"dbids": ["DB02309", "EXPT03260"], "name": "5--Monophosphate-9-Beta-D-Ribofuranosyl Xanthine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09329": {"dbids": ["DB09329"], "name": "Antihemophilic Factor (Recombinant), PEGylated", "groups": ["APPROVED"], "targets": []}, "DB02300": {"dbids": ["DB02300", "EXPT02131"], "name": "Calcipotriol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11473", "drug": "DB02300"}]}, "DB02301": {"dbids": ["DB02301", "EXPT03070"], "name": "5,10-Methylene-6-Hydrofolic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02302": {"dbids": ["DB02302", "EXPT00132"], "name": "N3, N4-Dimethylarginine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02303": {"dbids": ["DB02303", "EXPT01839"], "name": "(5s)-5-Iododihydro-2,4(1h,3h)-Pyrimidinedione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02304": {"dbids": ["DB02304", "EXPT01314"], "name": "Prostaglandin B2", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02305": {"dbids": ["DB02305", "EXPT01556"], "name": "4,5-Dehydro-D-Glucuronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02306": {"dbids": ["DB02306", "EXPT01000"], "name": "Palmitoyl-Linoleoyl Phosphatidylcholine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02307": {"dbids": ["DB02307", "EXPT01770"], "name": "N-(1-Carboxy-3-Phenylpropyl)Phenylalanyl-Alpha-Asparagine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07431": {"dbids": ["DB07431"], "name": "(3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07879": {"dbids": ["DB07879"], "name": "N-hydroxy-5-[(3-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)carbonyl]thiophene-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07878": {"dbids": ["DB07878"], "name": "N-[(1S)-1-{1-[(1R,3E)-1-ACETYLPENT-3-EN-1-YL]-1H-1,2,3-TRIAZOL-4-YL}-1,2-DIMETHYLPROPYL]BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07875": {"dbids": ["DB07875"], "name": "5-Chloro-thiophene-2-carboxylic acid ((3S,4S)-1-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-methyl}-4-hydroxy-pyrrolidin-3-yl)-amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07874": {"dbids": ["DB07874"], "name": "(6S)-2-amino-6-(3'-methoxybiphenyl-3-yl)-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07877": {"dbids": ["DB07877"], "name": "8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07876": {"dbids": ["DB07876"], "name": "(S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07871": {"dbids": ["DB07871"], "name": "6-CHLORO-4-(CYCLOHEXYLOXY)-3-ISOPROPYLQUINOLIN-2(1H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07870": {"dbids": ["DB07870"], "name": "(2S)-2-(4-{[3-CHLORO-5-(TRIFLUOROMETHYL)PYRIDIN-2-YL]OXY}PHENOXY)PROPANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07873": {"dbids": ["DB07873"], "name": "(1-HYDROXYDODECANE-1,1-DIYL)BIS(PHOSPHONIC ACID)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07872": {"dbids": ["DB07872"], "name": "5-chloro-N-[(3R)-1-(2-{[2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl]amino}-2-oxoethyl)pyrrolidin-3-yl]thiophene-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07169": {"dbids": ["DB07169"], "name": "5R-(3,4-DICHLOROPHENYLMETHYL)-3-(2-THIOPHENESULFONYLAMINO)-4-OXO-2-THIONOTHIAZOLIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07168": {"dbids": ["DB07168"], "name": "[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino)phenyl]acetonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05657": {"dbids": ["DB05657"], "name": "TZP-101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05304": {"dbids": ["DB05304"], "name": "WX-G250", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05307": {"dbids": ["DB05307"], "name": "CHF-1512", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05654": {"dbids": ["DB05654"], "name": "ZK-Epothilone", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05301": {"dbids": ["DB05301"], "name": "LAX-101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05652": {"dbids": ["DB05652"], "name": "VTP-201227", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05651": {"dbids": ["DB05651"], "name": "MGCD-0103", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05302": {"dbids": ["DB05302"], "name": "naltrexone depot", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05309": {"dbids": ["DB05309"], "name": "TP-508", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05308": {"dbids": ["DB05308"], "name": "ANX-510", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05659": {"dbids": ["DB05659"], "name": "faropenem medoxomil", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05658": {"dbids": ["DB05658"], "name": "SPL-7013", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07430": {"dbids": ["DB07430"], "name": "(10R)-10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01028": {"dbids": ["APRD00744", "DB01028"], "name": "Methoxyflurane", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P14867", "drug": "DB01028"}, {"action": "ANTAGONIST", "target": "P42261", "drug": "DB01028"}, {"action": "AGONIST", "target": "P23415", "drug": "DB01028"}, {"action": "INHIBITOR", "target": "P98194", "drug": "DB01028"}, {"action": "INDUCER", "target": "Q09470", "drug": "DB01028"}, {"action": "UNKNOWN", "target": "P30049", "drug": "DB01028"}, {"action": "UNKNOWN", "target": "P03886", "drug": "DB01028"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01028"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01028"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01028"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01028"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01028"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01028"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01028"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01028"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01028"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01028"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01028"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01028"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01028"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01028"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01028"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01028"}]}, "DB01029": {"dbids": ["APRD00413", "DB01029"], "name": "Irbesartan", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P30556", "drug": "DB01029"}, {"action": "OTHER/UNKNOWN", "target": "P05412", "drug": "DB01029"}]}, "DB01020": {"dbids": ["APRD00528", "DB01020"], "name": "Isosorbide Mononitrate", "groups": ["APPROVED"], "targets": [{"action": "INDUCER", "target": "P33402", "drug": "DB01020"}]}, "DB01021": {"dbids": ["APRD00031", "DB01021"], "name": "Trichlormethiazide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q13621", "drug": "DB01021"}, {"action": "INHIBITOR", "target": "P05023", "drug": "DB01021"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB01021"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB01021"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB01021"}]}, "DB01022": {"dbids": ["APRD00464", "DB01022"], "name": "Phylloquinone", "groups": ["APPROVED"], "targets": [{"action": "INDUCER", "target": "P38435", "drug": "DB01022"}, {"action": "AGONIST", "target": "P02818", "drug": "DB01022"}]}, "DB01023": {"dbids": ["APRD00374", "DB01023"], "name": "Felodipine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q13936", "drug": "DB01023"}, {"action": "INHIBITOR", "target": "P54289", "drug": "DB01023"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB01023"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB01023"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB01023"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB01023"}, {"action": "INHIBITOR", "target": "Q9NY47", "drug": "DB01023"}, {"action": "OTHER", "target": "P62158", "drug": "DB01023"}, {"action": "INHIBITOR", "target": "Q01064", "drug": "DB01023"}, {"action": "INHIBITOR", "target": "P54750", "drug": "DB01023"}, {"action": "ANTAGONIST", "target": "P08235", "drug": "DB01023"}, {"action": "OTHER", "target": "P02585", "drug": "DB01023"}, {"action": "OTHER", "target": "P63316", "drug": "DB01023"}]}, "DB01024": {"dbids": ["APRD01603", "DB01024", "EXPT02208"], "name": "Mycophenolic acid", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P20839", "drug": "DB01024"}, {"action": "INHIBITOR", "target": "P12268", "drug": "DB01024"}]}, "DB01025": {"dbids": ["APRD00795", "DB01025"], "name": "Amlexanox", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P80511", "drug": "DB01025"}, {"action": "ANTAGONIST", "target": "Q99584", "drug": "DB01025"}, {"action": "ANTAGONIST", "target": "P08700", "drug": "DB01025"}, {"action": "INHIBITOR", "target": "P05230", "drug": "DB01025"}]}, "DB01026": {"dbids": ["APRD00401", "DB01026"], "name": "Ketoconazole", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P10613", "drug": "DB01026"}, {"action": "BINDER", "target": "P10275", "drug": "DB01026"}]}, "DB00715": {"dbids": ["DB00715"], "name": "Paroxetine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P31645", "drug": "DB00715"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00715"}, {"action": "OTHER/UNKNOWN", "target": "P28223", "drug": "DB00715"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00715"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00715"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00715"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00715"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00715"}]}, "DB00714": {"dbids": ["APRD00531", "DB00714"], "name": "Apomorphine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P35462", "drug": "DB00714"}, {"action": "AGONIST", "target": "P21917", "drug": "DB00714"}, {"action": "AGONIST", "target": "P14416", "drug": "DB00714"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00714"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00714"}, {"action": "AGONIST", "target": "P28335", "drug": "DB00714"}, {"action": "AGONIST", "target": "P21918", "drug": "DB00714"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00714"}, {"action": "AGONIST", "target": "P28223", "drug": "DB00714"}, {"action": "AGONIST", "target": "P41595", "drug": "DB00714"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00714"}, {"action": "AGONIST", "target": "P21728", "drug": "DB00714"}, {"action": "AGONIST", "target": "P28221", "drug": "DB00714"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00714"}, {"action": "AGONIST", "target": "Q9NYX4", "drug": "DB00714"}]}, "DB00717": {"dbids": ["APRD00679", "DB00717"], "name": "Norethindrone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P06401", "drug": "DB00717"}]}, "DB00716": {"dbids": ["APRD01137", "DB00716"], "name": "Nedocromil", "groups": ["APPROVED"], "targets": [{"action": "SUPPRESSOR", "target": "Q9Y271", "drug": "DB00716"}, {"action": "ANTAGONIST", "target": "Q9NS75", "drug": "DB00716"}, {"action": "ANTAGONIST", "target": "P21462", "drug": "DB00716"}, {"action": "UNKNOWN", "target": "Q13258", "drug": "DB00716"}]}, "DB00711": {"dbids": ["APRD00918", "DB00711"], "name": "Diethylcarbamazine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P09917", "drug": "DB00711"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00711"}]}, "DB00710": {"dbids": ["APRD00231", "DB00710", "DB04635"], "name": "Ibandronate", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P14324", "drug": "DB00710"}]}, "DB00713": {"dbids": ["APRD01149", "DB00713"], "name": "Oxacillin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00713"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB00713"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB00713"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB00713"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB00713"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB00713"}]}, "DB00244": {"dbids": ["APRD01098", "DB00244"], "name": "Mesalazine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00244"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00244"}, {"action": "INHIBITOR", "target": "P09917", "drug": "DB00244"}, {"action": "AGONIST", "target": "P37231", "drug": "DB00244"}, {"action": "INHIBITOR", "target": "O15111", "drug": "DB00244"}, {"action": "INHIBITOR", "target": "O14920", "drug": "DB00244"}]}, "DB07569": {"dbids": ["DB07569"], "name": "CIS-4-METHYL-N-[(1S)-3-(METHYLSULFANYL)-1-(PYRIDIN-4-YLCARBAMOYL)PROPYL]CYCLOHEXANECARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06864": {"dbids": ["DB06864"], "name": "2-(3-CARBOXYPROPIONYL)-6-HYDROXY-CYCLOHEXA-2,4-DIENE CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07568": {"dbids": ["DB07568"], "name": "(2S)-2-[(2,1,3-BENZOTHIADIAZOL-4-YLSULFONYL)AMINO]-2-PHENYL-N-PYRIDIN-4-YLACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04016": {"dbids": ["DB04016", "EXPT02424"], "name": "2-[3-({Methyl[1-(2-Naphthoyl)Piperidin-4-Yl]Amino}Carbonyl)-2-Naphthyl]-1-(1-Naphthyl)-2-Oxoethylphosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04017": {"dbids": ["DB04017", "EXPT02182"], "name": "N-Methyl-N-Propargyl-3-(2,4-Dichlorophenoxy)Propylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04014": {"dbids": ["DB04014", "EXPT00590"], "name": "Alsterpaullone", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P06493", "drug": "DB04014"}]}, "DB04015": {"dbids": ["DB04015", "EXPT02222"], "name": "Methionine Phosphinate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01532": {"dbids": ["DB01532"], "name": "\u03b1-Methylacetylfentanyl", "groups": ["ILLICIT"], "targets": []}, "DB04013": {"dbids": ["DB04013", "EXPT01017"], "name": "1-Deoxy-1-Methoxycarbamido-Beta-D-Gluco-2-Heptulopyranosonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01530": {"dbids": ["DB01530"], "name": "3Alpha,17beta-dihydroxy-5alpha-androstane", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01531": {"dbids": ["DB01531"], "name": "Desomorphine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01538": {"dbids": ["DB01538"], "name": "Acetyldihydrocodeine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01539": {"dbids": ["DB01539"], "name": "1-Piperidinocyclohexanecarbonitrile", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB00777": {"dbids": ["APRD00339", "DB00777"], "name": "Propiomazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00777"}]}, "DB00776": {"dbids": ["APRD01308", "DB00776"], "name": "Oxcarbazepine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB00776"}]}, "DB00775": {"dbids": ["APRD00304", "DB00775"], "name": "Tirofiban", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08514", "drug": "DB00775"}, {"action": "ANTAGONIST", "target": "P05106", "drug": "DB00775"}]}, "DB00950": {"dbids": ["APRD00349", "DB00950"], "name": "Fexofenadine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00950"}]}, "DB00773": {"dbids": ["APRD00239", "DB00773"], "name": "Etoposide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P11388", "drug": "DB00773"}, {"action": "INHIBITOR", "target": "Q02880", "drug": "DB00773"}]}, "DB00772": {"dbids": ["APRD01081", "DB00772"], "name": "Malathion", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P06276", "drug": "DB00772"}]}, "DB00955": {"dbids": ["APRD00232", "DB00955"], "name": "Netilmicin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A7S3", "drug": "DB00955"}]}, "DB00954": {"dbids": ["APRD00931", "DB00954"], "name": "Dirithromycin", "groups": ["APPROVED"], "targets": []}, "DB00959": {"dbids": ["APRD00342", "DB00959"], "name": "Methylprednisolone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00959"}]}, "DB00958": {"dbids": ["APRD00466", "DB00958"], "name": "Carboplatin", "groups": ["APPROVED"], "targets": []}, "DB00779": {"dbids": ["APRD01133", "DB00779"], "name": "Nalidixic Acid", "groups": ["APPROVED"], "targets": []}, "DB00778": {"dbids": ["APRD01305", "DB00778"], "name": "Roxithromycin", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P0A7J6", "drug": "DB00778"}]}, "DB03970": {"dbids": ["DB03970", "EXPT03247"], "name": "(6,7-Dihydro-5h-Cyclopenta[D]Imidazo[2,1-B]Thiazol-2-Yl]-4,7-Dihydro[1,4]Thiazepine-3,6-Dicarboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03971": {"dbids": ["DB03971", "EXPT00291"], "name": "Acarbose Derived Hexasaccharide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03972": {"dbids": ["DB03972", "EXPT02966"], "name": "2-Amino-4h-1,3-Benzoxathiin-4-Ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03973": {"dbids": ["DB03973", "EXPT02995"], "name": "3-{2,6,8-Trioxo-9-[(2r,3r,4r)-2,3,4,5-Tetrahydroxypentyl]-1,2,3,6,8,9-Hexahydro-7h-Purin-7-Yl}Propyl Dihydrogen Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03974": {"dbids": ["DB03974", "EXPT01779"], "name": "L-Homoarginine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03975": {"dbids": ["DB03975", "EXPT02124"], "name": "Mercuribenzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03976": {"dbids": ["DB03976", "EXPT01937"], "name": "Phosphorylisopropane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03977": {"dbids": ["DB03977", "EXPT02087"], "name": "N-Trimethyllysine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03978": {"dbids": ["DB03978", "EXPT03134"], "name": "Tyrosinal", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03979": {"dbids": ["DB03979", "EXPT01177"], "name": "1-[Glycerolylphosphonyl]-2-[8-(2-Hexyl-Cyclopropyl)-Octanal-1-Yl]-3-[Hexadecanal-1-Yl]-Glycerol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09568": {"dbids": ["DB09568"], "name": "Omega-3-carboxylic acids", "groups": ["APPROVED"], "targets": []}, "DB06168": {"dbids": ["DB06168"], "name": "Canakinumab", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "BINDER", "target": "P01584", "drug": "DB06168"}]}, "DB07099": {"dbids": ["DB07099"], "name": "N-[4-(benzyloxy)phenyl]glycinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07098": {"dbids": ["DB07098"], "name": "4-bromo-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07097": {"dbids": ["DB07097"], "name": "4-tert-butyl-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07096": {"dbids": ["DB07096"], "name": "6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07095": {"dbids": ["DB07095"], "name": "(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07094": {"dbids": ["DB07094"], "name": "1-(2,2'-bithiophen-5-yl)methanamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07093": {"dbids": ["DB07093"], "name": "{3-[(5-CHLORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL}ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07092": {"dbids": ["DB07092"], "name": "(2S,3S)-3-AMINO-4-(3,3-DIFLUOROPYRROLIDIN-1-YL)-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-6-YLCYCLOHEXYL)BUTANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07091": {"dbids": ["DB07091"], "name": "(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07090": {"dbids": ["DB07090"], "name": "(3S)-N-(3-CHLORO-2-METHYLPHENYL)-1-CYCLOHEXYL-5-OXOPYRROLIDINE-3-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07432": {"dbids": ["DB07432"], "name": "[[(3R,4R,5S,6R)-3-(butanoylamino)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-ylidene]amino] N-phenylcarbamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01497": {"dbids": ["DB01497"], "name": "Etorphine", "groups": ["ILLICIT"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB01497"}, {"action": "AGONIST", "target": "P41143", "drug": "DB01497"}, {"action": "AGONIST", "target": "P41145", "drug": "DB01497"}, {"action": "AGONIST", "target": "P41146", "drug": "DB01497"}, {"action": "AGONIST", "target": "O60858", "drug": "DB01497"}]}, "DB04759": {"dbids": ["DB04759"], "name": "PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-(3-METHYL-BENZYLAMIDE)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04758": {"dbids": ["DB04758"], "name": "2-[2-ETHANESULFONYLAMINO-3-(1H-INDOL-3-YL)-PROPIONYLAMINO]-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIM IDOYL-BENZYLAMIDE)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01057": {"dbids": ["APRD00942", "DB01057"], "name": "Echothiophate", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P06276", "drug": "DB01057"}]}, "DB01496": {"dbids": ["DB01496"], "name": "Barbituric acid derivative", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01496"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01496"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01496"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB01496"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01496"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01496"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB01496"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB01496"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB01496"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB01496"}]}, "DB04028": {"dbids": ["DB04028", "EXPT03143"], "name": "Tyvelose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08214": {"dbids": ["DB08214"], "name": "4-(1H-IMIDAZOL-1-YL)PHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04755": {"dbids": ["DB04755"], "name": "PROPYL-1-PHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08216": {"dbids": ["DB08216"], "name": "2-((3'-TERTBUTYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08217": {"dbids": ["DB08217"], "name": "2,2,5,5-TETRAMETHYL-3-(SULFANYLMETHYL)-2,5-DIHYDRO-1H-PYRROL-1-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08210": {"dbids": ["DB08210"], "name": "2-AMINO-4-FLUORO-5-[(1-METHYL-1H-IMIDAZOL-2-YL)SULFANYL]-N-(1,3-THIAZOL-2-YL)BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08211": {"dbids": ["DB08211"], "name": "5-bromo-3-(pyrrolidin-1-ylsulfonyl)-1H-indole-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08212": {"dbids": ["DB08212"], "name": "1-[2-(3-ACETYL-2-HYDROXY-6-METHOXY-PHENYL)-CYCLOPROPYL]-3-(5-CYANO-PYRIDIN-2-YL)-THIOUREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04026": {"dbids": ["DB04026", "EXPT02685"], "name": "Pseudotropine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08218": {"dbids": ["DB08218"], "name": "HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01505": {"dbids": ["DB01505"], "name": "Etoxeridine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB09218": {"dbids": ["DB09218"], "name": "Clonixin", "groups": ["APPROVED"], "targets": []}, "DB08818": {"dbids": ["DB08818"], "name": "Hyaluronic acid", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "O14594", "drug": "DB08818"}, {"action": "BINDER", "target": "P13611", "drug": "DB08818"}, {"action": "BINDER", "target": "Q07021", "drug": "DB08818"}, {"action": "BINDER", "target": "P10915", "drug": "DB08818"}, {"action": "BINDER", "target": "Q96S86", "drug": "DB08818"}, {"action": "BINDER", "target": "Q86UW8", "drug": "DB08818"}, {"action": "BINDER", "target": "Q14520", "drug": "DB08818"}, {"action": "BINDER", "target": "Q6UX15", "drug": "DB08818"}, {"action": "BINDER", "target": "Q8WWQ8", "drug": "DB08818"}, {"action": "BINDER", "target": "P98066", "drug": "DB08818"}, {"action": "BINDER", "target": "Q9BZV3", "drug": "DB08818"}, {"action": "BINDER", "target": "Q5JVS0", "drug": "DB08818"}]}, "DB04756": {"dbids": ["DB04756"], "name": "2-[3,5-DICHLORO-4-(2-{2-[2(2-MERCAPTOETHOXY)ETHOXY]ETHOXY}ETHOXY)PHENYLAMINO]BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05828": {"dbids": ["DB05828"], "name": "LU-31130", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05829": {"dbids": ["DB05829"], "name": "Preotact", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ACTIVATOR", "target": "Q03431", "drug": "DB05829"}, {"action": "ACTIVATOR", "target": "P49190", "drug": "DB05829"}]}, "DB01499": {"dbids": ["DB01499"], "name": "Alphameprodine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB05824": {"dbids": ["DB05824"], "name": "CNS-5161", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05825": {"dbids": ["DB05825"], "name": "NCX 1015", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05826": {"dbids": ["DB05826"], "name": "Prolease-r-hFSH", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05827": {"dbids": ["DB05827"], "name": "G207", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05820": {"dbids": ["DB05820"], "name": "DP-b99", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05821": {"dbids": ["DB05821"], "name": "DP-VPA", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05822": {"dbids": ["DB05822"], "name": "NCX 4016", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01502": {"dbids": ["DB01502"], "name": "Diampromide", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB03798": {"dbids": ["DB03798", "EXPT01134"], "name": "2'-Deoxycytidine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03799": {"dbids": ["DB03799", "EXPT02158"], "name": "Trifluoromethionine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03794": {"dbids": ["DB03794", "EXPT01440"], "name": "Trifluoroalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03795": {"dbids": ["DB03795", "EXPT01981"], "name": "2-Dehydropantoate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03796": {"dbids": ["DB03796", "EXPT01393", "EXPT02607"], "name": "Palmitic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03797": {"dbids": ["DB03797", "EXPT02317"], "name": "3-Aminomethyl-Pyridinium-Adenine-Dinucleotide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03790": {"dbids": ["DB03790", "EXPT02437"], "name": "S-Dioxymethionine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03791": {"dbids": ["DB03791", "EXPT00345"], "name": "(3-{3-[[2-Chloro-3-(Trifluoromethyl)Benzyl](2,2-Diphenylethyl)Amino]Propoxy}Phenyl)Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03792": {"dbids": ["DB03792", "EXPT03241"], "name": "5-Amino-1h-Pyrimidine-2,4-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03793": {"dbids": ["DB03793", "EXPT00675"], "name": "Benzoic Acid", "groups": ["APPROVED"], "targets": []}, "DB01498": {"dbids": ["DB01498"], "name": "Alphamethadol", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB07505": {"dbids": ["DB07505"], "name": "N-({(3R,4R)-4-[(benzyloxy)methyl]pyrrolidin-3-yl}methyl)-N-(2-methylpropyl)benzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08993": {"dbids": ["DB08993"], "name": "Enviomycin", "groups": ["APPROVED"], "targets": []}, "DB02449": {"dbids": ["DB02449", "EXPT01260"], "name": "3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02448": {"dbids": ["DB02448", "EXPT03028"], "name": "N-Tridecanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02443": {"dbids": ["DB02443", "EXPT02130"], "name": "Methicillin Acyl-Serine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02442": {"dbids": ["DB02442", "EXPT02935"], "name": "Dioxyselenocysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02441": {"dbids": ["DB02441", "EXPT00650"], "name": "2-Butyl-5,6-Dihydro-1h-Imidazo[4,5-D]Pyridazine-4,7-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02447": {"dbids": ["DB02447", "EXPT01598"], "name": "3,8,9,10-Tetrahydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02446": {"dbids": ["DB02446", "EXPT01737"], "name": "Glutamine Hydroxamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02445": {"dbids": ["DB02445", "EXPT00457"], "name": "2-Deoxy-2-Amino Glucitol-6-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05796": {"dbids": ["DB05796"], "name": "SLV 306", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05797": {"dbids": ["DB05797"], "name": "TNX-901", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05794": {"dbids": ["DB05794"], "name": "recombinant human relaxin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05795": {"dbids": ["DB05795"], "name": "YKP-10A", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05792": {"dbids": ["DB05792"], "name": "SR 31747", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05793": {"dbids": ["DB05793"], "name": "PRO-542", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05790": {"dbids": ["DB05790"], "name": "SR 140333", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05791": {"dbids": ["DB05791"], "name": "Perflubron emulsion", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06885": {"dbids": ["DB06885"], "name": "3-[({(1E)-[2-(trifluoromethyl)phenyl]methylidene}amino)oxy]propanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05798": {"dbids": ["DB05798"], "name": "GEM-231", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05799": {"dbids": ["DB05799"], "name": "NOX-100", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06884": {"dbids": ["DB06884"], "name": "4-HYDROXY-N'-(4-ISOPROPYLBENZYL)BENZOHYDRAZIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06883": {"dbids": ["DB06883"], "name": "1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06882": {"dbids": ["DB06882"], "name": "1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09020": {"dbids": ["DB09020"], "name": "Bisacodyl", "groups": ["APPROVED"], "targets": []}, "DB09021": {"dbids": ["DB09021"], "name": "Benzoctamine", "groups": ["APPROVED"], "targets": []}, "DB09022": {"dbids": ["DB09022"], "name": "Benfluorex", "groups": ["WITHDRAWN"], "targets": []}, "DB09023": {"dbids": ["DB09023"], "name": "Benactyzine", "groups": ["WITHDRAWN"], "targets": []}, "DB09024": {"dbids": ["DB09024"], "name": "Follitropin Alpha", "groups": ["APPROVED"], "targets": []}, "DB06881": {"dbids": ["DB06881"], "name": "(1Z)-2-HYDROXY-3-OXOHEX-1-EN-1-YL DIHYDROGEN PHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09026": {"dbids": ["DB01258", "DB09026"], "name": "Aliskiren", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P00797", "drug": "DB09026"}]}, "DB09027": {"dbids": ["DB09027"], "name": "Ledipasvir", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q5L478", "drug": "DB09027"}]}, "DB09028": {"dbids": ["DB09028"], "name": "Cytisine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P43681", "drug": "DB09028"}, {"action": "AGONIST", "target": "P36544", "drug": "DB09028"}, {"action": "AGONIST", "target": "P32297", "drug": "DB09028"}, {"action": "AGONIST", "target": "Q15825", "drug": "DB09028"}]}, "DB09029": {"dbids": ["DB09029"], "name": "Secukinumab", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q16552", "drug": "DB09029"}]}, "DB06880": {"dbids": ["DB06880"], "name": "(1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-PROP-1-YN-1-YLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02761": {"dbids": ["DB02761", "EXPT01038"], "name": "S-Mercaptocysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01239": {"dbids": ["APRD00718", "DB01239"], "name": "Chlorprothixene", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB01239"}]}, "DB01238": {"dbids": ["APRD00638", "DB01238"], "name": "Aripiprazole", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P28223", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01238"}, {"action": "PARTIAL AGONIST", "target": "P14416", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01238"}, {"action": "PARTIAL AGONIST", "target": "P08908", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P28221", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P28566", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01238"}, {"action": "PARTIAL AGONIST", "target": "P21728", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P21918", "drug": "DB01238"}, {"action": "PARTIAL AGONIST", "target": "P21918", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB01238"}, {"action": "PARTIAL AGONIST", "target": "P35462", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB01238"}, {"action": "PARTIAL AGONIST", "target": "P21917", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB01238"}, {"action": "OTHER/UNKNOWN", "target": "P18825", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB01238"}]}, "DB01235": {"dbids": ["APRD00309", "DB01235", "EXPT01107"], "name": "Levodopa", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P21728", "drug": "DB01235"}, {"action": "AGONIST", "target": "P21918", "drug": "DB01235"}, {"action": "AGONIST", "target": "P14416", "drug": "DB01235"}, {"action": "AGONIST", "target": "P35462", "drug": "DB01235"}, {"action": "AGONIST", "target": "P21917", "drug": "DB01235"}]}, "DB01234": {"dbids": ["APRD00674", "DB01234"], "name": "Dexamethasone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB01234"}, {"action": "STIMULATOR", "target": "P51843", "drug": "DB01234"}, {"action": "AGONIST", "target": "P04083", "drug": "DB01234"}, {"action": "NEGATIVE MODULATOR", "target": "P35228", "drug": "DB01234"}]}, "DB01237": {"dbids": ["APRD00710", "DB01237"], "name": "Bromodiphenhydramine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB01237"}]}, "DB01236": {"dbids": ["APRD00219", "DB01236"], "name": "Sevoflurane", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P14867", "drug": "DB01236"}, {"action": "AGONIST", "target": "P23415", "drug": "DB01236"}, {"action": "ANTAGONIST", "target": "P42261", "drug": "DB01236"}, {"action": "INDUCER", "target": "Q09470", "drug": "DB01236"}, {"action": "INHIBITOR", "target": "P98194", "drug": "DB01236"}, {"action": "OTHER/UNKNOWN", "target": "P30049", "drug": "DB01236"}, {"action": "UNKNOWN", "target": "P03886", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01236"}]}, "DB01231": {"dbids": ["APRD00929", "DB01231"], "name": "Diphenidol", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB01231"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01231"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01231"}]}, "DB01230": {"dbids": ["APRD01169", "DB01230"], "name": "Pemoline", "groups": ["ILLICIT", "WITHDRAWN"], "targets": []}, "DB01233": {"dbids": ["APRD00665", "DB01233"], "name": "Metoclopramide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB01233"}, {"action": "AGONIST", "target": "P11229", "drug": "DB01233"}, {"action": "AGONIST", "target": "Q13639", "drug": "DB01233"}, {"action": "AGONIST", "target": "P46098", "drug": "DB01233"}]}, "DB01232": {"dbids": ["APRD00623", "DB01232"], "name": "Saquinavir", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q72874", "drug": "DB01232"}]}, "DB01491": {"dbids": ["DB01491"], "name": "Dipipanone", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01490": {"dbids": ["DB01490"], "name": "Aminorex", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01493": {"dbids": ["DB01493"], "name": "Ethylestrenol", "groups": ["WITHDRAWN"], "targets": []}, "DB01495": {"dbids": ["DB01495"], "name": "Dichloralphenazone", "groups": ["ILLICIT"], "targets": []}, "DB01494": {"dbids": ["DB01494"], "name": "Chloral betaine", "groups": ["ILLICIT", "WITHDRAWN"], "targets": []}, "DB04469": {"dbids": ["DB04469", "EXPT00210"], "name": "1-(4-Methoxyphenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04468": {"dbids": ["DB04468", "EXPT02425"], "name": "Afimoxifene", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01947": {"dbids": ["DB01947", "EXPT00096"], "name": "RU78262", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04466": {"dbids": ["DB04466", "EXPT02953"], "name": "SR12813", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04465": {"dbids": ["DB04465", "EXPT02005"], "name": "Lactose", "groups": ["APPROVED"], "targets": []}, "DB04464": {"dbids": ["DB04464", "EXPT01455"], "name": "N-Formylmethionine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04463": {"dbids": ["DB04463", "EXPT00389"], "name": "3-(4-Amino-1-Tert-Butyl-1h-Pyrazolo[3,4-D]Pyrimidin-3-Yl)Phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04462": {"dbids": ["DB04462", "EXPT03020"], "name": "Tetrabromo-2-Benzotriazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04461": {"dbids": ["DB04461", "EXPT00993"], "name": "Coproporphyrin Iii", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04460": {"dbids": ["DB04460", "EXPT02811"], "name": "(C8-S)-Hydantocidin 5'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08779": {"dbids": ["DB08779"], "name": "2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08778": {"dbids": ["DB08778"], "name": "[4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08777": {"dbids": ["DB08777"], "name": "5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06695": {"dbids": ["DB06695"], "name": "Dabigatran etexilate", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00734", "drug": "DB06695"}]}, "DB08775": {"dbids": ["DB08775"], "name": "BENZOYL-TYROSINE-ALANINE-METHYL KETONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08774": {"dbids": ["DB08774"], "name": "1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08773": {"dbids": ["DB08773"], "name": "RALOXIFENE CORE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08772": {"dbids": ["DB08772"], "name": "3,4-DIHYDRO-4-OXO-3-((5-TRIFLUOROMETHYL-2-BENZOTHIAZOLYL)METHYL)-1-PHTHALAZINE ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08771": {"dbids": ["DB08771"], "name": "(5R)-2-[(2-fluorophenyl)amino]-5-(1-methylethyl)-1,3-thiazol-4(5H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08770": {"dbids": ["DB08770"], "name": "4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06911": {"dbids": ["DB06911"], "name": "D-leucyl-N-(3-chlorobenzyl)-L-prolinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06910": {"dbids": ["DB06910"], "name": "[4-R-(4-ALPHA,6-BETA,7-BETA]-HEXAHYDRO-5,6-DI(HYDROXY)-1,3-DI(ALLYL)-4,7-BISPHENYLMETHYL)-2H-1,3-DIAZEPINONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00018": {"dbids": ["BIOD00023", "BTD00023", "DB00018"], "name": "Interferon alfa-n3", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P17181", "drug": "DB00018"}, {"action": "AGONIST", "target": "P48551", "drug": "DB00018"}]}, "DB00019": {"dbids": ["BIOD00094", "BTD00094", "DB00019"], "name": "Pegfilgrastim", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "Q99062", "drug": "DB00019"}]}, "DB00548": {"dbids": ["APRD00812", "DB00548", "EXPT00598"], "name": "Azelaic Acid", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P66010", "drug": "DB00548"}, {"action": "INHIBITOR", "target": "P51857", "drug": "DB00548"}, {"action": "INHIBITOR", "target": "P31213", "drug": "DB00548"}, {"action": "INHIBITOR", "target": "P14679", "drug": "DB00548"}, {"action": "INHIBITOR", "target": "P00582", "drug": "DB00548"}]}, "DB00549": {"dbids": ["APRD00377", "DB00549"], "name": "Zafirlukast", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "Q9Y271", "drug": "DB00549"}]}, "DB06917": {"dbids": ["DB06917"], "name": "(4-fluorophenyl)(pyridin-4-yl)methanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06916": {"dbids": ["DB06916"], "name": "N-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-1-[2-(1H-IMIDAZOL-1-YL)-6-METHYLPYRIMIDIN-4-YL]-D-PROLINAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00012": {"dbids": ["BIOD00032", "BTD00032", "DB00012"], "name": "Darbepoetin alfa", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P19235", "drug": "DB00012"}]}, "DB00013": {"dbids": ["BIOD00030", "BTD00030", "DB00013"], "name": "Urokinase", "groups": ["APPROVED", "INVESTIGATIONAL", "WITHDRAWN"], "targets": [{"action": "ACTIVATOR", "target": "P00747", "drug": "DB00013"}]}, "DB00010": {"dbids": ["BIOD00033", "BTD00033", "DB00010"], "name": "Sermorelin", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "AGONIST", "target": "Q02643", "drug": "DB00010"}]}, "DB00011": {"dbids": ["BIOD00096", "BTD00096", "DB00011", "DB00084"], "name": "Interferon alfa-n1", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P48551", "drug": "DB00011"}, {"action": "AGONIST", "target": "P17181", "drug": "DB00011"}]}, "DB00016": {"dbids": ["BIOD00103", "BTD00103", "DB00016"], "name": "Epoetin alfa", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P19235", "drug": "DB00016"}]}, "DB00017": {"dbids": ["BIOD00025", "BTD00025", "DB00017"], "name": "Salmon Calcitonin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P30988", "drug": "DB00017"}]}, "DB00014": {"dbids": ["BIOD00113", "BTD00113", "DB00014"], "name": "Goserelin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P22888", "drug": "DB00014"}, {"action": "AGONIST", "target": "P30968", "drug": "DB00014"}]}, "DB00015": {"dbids": ["BIOD00013", "BTD00013", "DB00015"], "name": "Reteplase", "groups": ["APPROVED"], "targets": [{"action": "ACTIVATOR", "target": "P00747", "drug": "DB00015"}]}, "DB07387": {"dbids": ["DB07387"], "name": "3-(BUTYLSULPHONYL)-PROPANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03899": {"dbids": ["DB03899", "EXPT02695"], "name": "9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03898": {"dbids": ["DB03898", "EXPT00910"], "name": "3-Chloro-4-Hydroxyphenylglycine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03893": {"dbids": ["DB03893", "EXPT02928"], "name": "Thionicotinamide-Adenine-Dinucleotide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03892": {"dbids": ["DB03892", "EXPT00563"], "name": "5-N-Allyl-Arginine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03891": {"dbids": ["DB03891", "EXPT01880"], "name": "1,5-Bis(N-Benzyloxycarbonyl-L-Leucinyl)Carbohydrazide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03890": {"dbids": ["DB03890", "EXPT00265"], "name": "N-[2-(1-Formyl-2-Methyl-Propyl)-1-(4-Piperidin-1-Yl-but-2-Enoyl)-Pyrrolidin-3-Yl]-Methanesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03897": {"dbids": ["DB03897", "EXPT01773"], "name": "Hydroxyphenyl Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03896": {"dbids": ["DB03896", "EXPT00188"], "name": "Triphospate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03895": {"dbids": ["DB03895", "EXPT02168"], "name": "Malachite Green", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03894": {"dbids": ["DB03894", "EXPT02818"], "name": "N-Propargyl-1(S)-Aminoindan", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04209": {"dbids": ["DB04209", "EXPT01162"], "name": "Dequadin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04208": {"dbids": ["DB04208", "EXPT02225"], "name": "3-(3,4-Dimethoxyphenyl)Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04203": {"dbids": ["DB04203", "EXPT00515"], "name": "3-Mercuri-4-Aminobenzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04202": {"dbids": ["DB04202", "EXPT01760"], "name": "Isoformononetin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04201": {"dbids": ["DB04201", "EXPT01691"], "name": "Histidyl-Adenosine Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04200": {"dbids": ["DB04200", "EXPT02118"], "name": "Matairesinol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04207": {"dbids": ["DB04207", "EXPT02906"], "name": "N-(5-Amino-5-Carboxypentyl)Glutamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04206": {"dbids": ["DB04206", "EXPT03111"], "name": "Nz2-Tryptophan", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04205": {"dbids": ["DB04205", "EXPT03055"], "name": "Thymidine-3',5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04204": {"dbids": ["DB04204", "EXPT01422"], "name": "[(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07381": {"dbids": ["DB03954", "DB07381"], "name": "S-Atrolactic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07380": {"dbids": ["DB07380"], "name": "1,1,1-TRIFLUORO-3-ACETAMIDO-4-PHENYL BUTAN-2-ONE(N-ACETYL-L-PHENYLALANYL TRIFLUOROMETHYL KETONE)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09316": {"dbids": ["DB09316"], "name": "Thallous Chloride", "groups": ["APPROVED"], "targets": []}, "DB07389": {"dbids": ["DB07389"], "name": "N-[2-(6-AMINO-4-METHYLPYRIDIN-2-YL)ETHYL]-4-CYANOBENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07388": {"dbids": ["DB07388"], "name": "ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09317": {"dbids": ["DB09317"], "name": "Synthetic Conjugated Estrogens, A", "groups": ["APPROVED"], "targets": []}, "DB02146": {"dbids": ["DB02146", "EXPT00579"], "name": "Atrazine Glutathione Conjugate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02147": {"dbids": ["DB02147", "EXPT03213"], "name": "Cyclo-Tetrametavanadate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02144": {"dbids": ["DB02144", "EXPT02597"], "name": "1,2-Diacyl-Sn-Glycero-3-Phosphoinositol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02145": {"dbids": ["DB02145", "EXPT00068"], "name": "Butan-1-Ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02142": {"dbids": ["DB02142", "EXPT02621"], "name": "Pyridoxamine-5'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02143": {"dbids": ["DB02143", "EXPT01853"], "name": "N-Isopropyl-N'-Hydroxyguanidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02140": {"dbids": ["DB02140", "EXPT00812"], "name": "N1-(1-Dimethylcarbamoyl-2-Phenyl-Ethyl)-2-Oxo-N4-(2-Pyridin-2-Yl-Ethyl)-Succinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02141": {"dbids": ["DB02141", "EXPT00205"], "name": "S,S'-(1,4-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02148": {"dbids": ["DB02148", "EXPT02881"], "name": "3-Amino-4-Oxybenzyl-2-Butanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09222": {"dbids": ["DB09222"], "name": "Fibrinogen Concentrate (Human)", "groups": ["APPROVED"], "targets": []}, "DB09315": {"dbids": ["DB09315"], "name": "Xenon-133", "groups": ["APPROVED"], "targets": []}, "DB03093": {"dbids": ["DB03093", "EXPT02693"], "name": "8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03092": {"dbids": ["DB03092", "EXPT01756"], "name": "5-Hydroxymethyl-Chonduritol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03091": {"dbids": ["DB03091", "EXPT01619"], "name": "4-Amido-4-Carbamoyl-Butyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03090": {"dbids": ["DB03090", "EXPT02676"], "name": "Ethylaminobenzylmethylcarbonyl Group", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03097": {"dbids": ["DB03097", "EXPT02617"], "name": "Pmp-Hydroxyisoxazole, Pyridoxamine-5-Phosphate-Hydroxyisoxazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03096": {"dbids": ["DB03096", "EXPT01341"], "name": "N-Aminoethylmorpholine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03095": {"dbids": ["DB03095", "EXPT03069"], "name": "Tetramethylammonium Ion", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03094": {"dbids": ["DB03094", "EXPT00055"], "name": "3,5-Dihydro-5-Methylidene-4h-Imidazol-4-On", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09235": {"dbids": ["DB09235"], "name": "Efonidipine", "groups": ["APPROVED"], "targets": []}, "DB03099": {"dbids": ["DB03099", "EXPT03191"], "name": "5-Amino 6-Nitro Uracil", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03098": {"dbids": ["DB03098", "EXPT02237"], "name": "[Methylseleno]Acetate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02854": {"dbids": ["DB02854", "EXPT00443"], "name": "Aetiocholanolone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02855": {"dbids": ["DB02855", "EXPT00003"], "name": "N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02856": {"dbids": ["DB02856", "EXPT01337"], "name": "Methyl-Carbamic Acid Ethyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02857": {"dbids": ["DB02857", "EXPT01622"], "name": "Guanosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02850": {"dbids": ["DB02850", "EXPT00327"], "name": "(1-Tert-Butyl-5-Hydroxy-1h-Pyrazol-4-Yl)-(6-Methanesulfonyl-4'-Methoxy-2-Methyl-Biphenyl-3-Yl)-Methanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02851": {"dbids": ["DB02851", "EXPT03025"], "name": "Thiocamphor", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02852": {"dbids": ["DB02852", "EXPT01248"], "name": "Domoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02853": {"dbids": ["DB02853", "EXPT01259"], "name": "D-Proline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02328": {"dbids": ["DB02328", "EXPT01727"], "name": "2-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Imino]-5-Phosphono-Pent-3-Enoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02329": {"dbids": ["DB02329", "EXPT00848"], "name": "Carbenoxolone", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P28845", "drug": "DB02329"}]}, "DB02858": {"dbids": ["DB02858", "EXPT01371"], "name": "3-(4-Benzenesulfonyl-Thiophene-2-Sulfonylamino)-Phenylboronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02859": {"dbids": ["DB02859", "EXPT02829"], "name": "Soraphen A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09313": {"dbids": ["DB09313"], "name": "Ioxaglic acid", "groups": ["APPROVED"], "targets": []}, "DB09310": {"dbids": ["DB09310"], "name": "Coagulation Factor XIII A-Subunit (Recombinant)", "groups": ["APPROVED"], "targets": []}, "DB08519": {"dbids": ["DB08519"], "name": "N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05495": {"dbids": ["DB05495"], "name": "PG-530742", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05494": {"dbids": ["DB05494"], "name": "CP-4055", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05496": {"dbids": ["DB05496"], "name": "TRX4", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05491": {"dbids": ["DB05491"], "name": "ATN-161", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05490": {"dbids": ["DB05490"], "name": "T131", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05493": {"dbids": ["DB05493"], "name": "NX-1207", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05492": {"dbids": ["DB05492", "DB08290"], "name": "Epicept NP-1", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05499": {"dbids": ["DB05499"], "name": "TAK-428", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05498": {"dbids": ["DB05498"], "name": "KW-7158", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03637": {"dbids": ["DB03637", "EXPT02563"], "name": "Guanidine-3-Propanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03636": {"dbids": ["DB03636", "EXPT01617"], "name": "Glycinamid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03635": {"dbids": ["DB03635", "EXPT01359"], "name": "Ethanesulfonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03634": {"dbids": ["DB03634", "EXPT01335"], "name": "1,3-Di(N-Propyloxy-a-Mannopyranosyl)-Carbomyl 5-Methyazido-Benzene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03633": {"dbids": ["DB03633", "EXPT02056"], "name": "Lpc-Ether", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03632": {"dbids": ["DB03632", "EXPT02754"], "name": "Argifin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03631": {"dbids": ["DB03631", "EXPT03144"], "name": "3-(4-Hydroxy-3-Imino-6-Oxo-Cyclohexa-1,4-Dienyl)-Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03630": {"dbids": ["DB03630", "EXPT01829"], "name": "2-Iodobenzylthio Group", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01547": {"dbids": ["DB01547"], "name": "Drotebanol", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB03639": {"dbids": ["DB03639", "EXPT01555"], "name": "1-Guanidinium-7-Aminoheptane", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P49366", "drug": "DB03639"}]}, "DB03638": {"dbids": ["DB03638", "EXPT00898"], "name": "Cytidyl-2'-5'-Phospho-Guanosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08513": {"dbids": ["DB08513"], "name": "[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08512": {"dbids": ["DB08512"], "name": "6-amino-2-[(1-naphthylmethyl)amino]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08511": {"dbids": ["DB08511"], "name": "6-amino-2-methyl-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08510": {"dbids": ["DB08510"], "name": "5-ALPHA-PREGNANE-3-BETA-OL-HEMISUCCINATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08517": {"dbids": ["DB08517"], "name": "(2S)-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-2,3-dihydro-4H-chromen-4-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08516": {"dbids": ["DB08516"], "name": "(S)-(+)-2-[4-(FLUOROBENZYLOXY-BENZYLAMINO)PROPIONAMIDE]", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05671": {"dbids": ["DB05671"], "name": "AC-100", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05675": {"dbids": ["DB05675"], "name": "EP-2104R", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08515": {"dbids": ["DB08515"], "name": "(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05676": {"dbids": ["DB05676"], "name": "Apremilast", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "Q08499", "drug": "DB05676"}, {"action": "ANTAGONIST", "target": "P27815", "drug": "DB05676"}, {"action": "ANTAGONIST", "target": "Q07343", "drug": "DB05676"}]}, "DB05679": {"dbids": ["DB05679"], "name": "Ustekinumab", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB04246": {"dbids": ["DB04246", "EXPT00268"], "name": "CRA_23653", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04245": {"dbids": ["DB04245", "EXPT01768"], "name": "2-Hydroxy-3-Amino-4-Phenyl Butane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04244": {"dbids": ["DB04244", "EXPT01807"], "name": "1-[2-(3-Biphenyl)-4-Methylvaleryl)]Amino-3-(2-Pyridylsulfonyl)Amino-2-Propanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04243": {"dbids": ["DB04243", "EXPT00254"], "name": "5-Methyluridine 5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04242": {"dbids": ["DB04242", "EXPT02580"], "name": "P-Hydroxybenzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01820": {"dbids": ["DB01820", "EXPT00349"], "name": "Compound 12, N-Acetyl-4-[(Carboxycarbonyl)(2-Carboxyphenyl)Amino]-N-Pentyl-1-Napthylalaniamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04241": {"dbids": ["DB04241", "EXPT02361"], "name": "N-Pyridoxyl-2-Methylalanine-5-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01821": {"dbids": ["DB01821", "EXPT01252"], "name": "L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04932": {"dbids": ["DB04932"], "name": "Defibrotide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB01822": {"dbids": ["DB01822", "EXPT01282"], "name": "Dithiane Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07224": {"dbids": ["DB07224"], "name": "N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ALANINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01823": {"dbids": ["DB01823", "EXPT01612"], "name": "Beta-D-Glucopyranose Spirohydantoin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07225": {"dbids": ["DB07225"], "name": "N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ISOLEUCINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01824": {"dbids": ["DB01824", "EXPT00182"], "name": "(3s)-Tetrahydrofuran-3-Yl (1r,2s)-3-[4-((1r)-2-{[(S)-Amino(Hydroxy)Methyl]Oxy}-2,3-Dihydro-1h-Inden-1-Yl)-2-Benzyl-3-Oxopyrrolidin-2-Yl]-1-Benzyl-2-Hydroxypropylcarbamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07226": {"dbids": ["DB07226"], "name": "N-[4-(2-CHLOROPHENYL)-1,3-DIOXO-1,2,3,6-TETRAHYDROPYRROLO[3,4-C]CARBAZOL-9-YL]FORMAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01825": {"dbids": ["DB01825", "EXPT02114"], "name": "2-Amino-8-Methylquinazolin-4(3h)-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02393": {"dbids": ["DB02393", "EXPT01415"], "name": "D-Gluco-2,5-Anhydro-1-Deoxy-1-Phosphonohexitol-6-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07227": {"dbids": ["DB07227"], "name": "4-[(5-{[4-(3-CHLOROPHENYL)-3-OXOPIPERAZIN-1-YL]METHYL}-1H-IMIDAZOL-1-YL)METHYL]BENZONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01826": {"dbids": ["DB01826", "EXPT02302"], "name": "N-Butyl Isocyanide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07220": {"dbids": ["DB07220"], "name": "N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01827": {"dbids": ["DB01827", "EXPT00667"], "name": "2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02391": {"dbids": ["DB02391", "EXPT01667"], "name": "2-Amino-7-[2-(2-Hydroxy-1-Hydroxymethyl-Ethylamino)-Ethyl]-1,7-Dihydro-Purin-6-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00901": {"dbids": ["APRD00827", "DB00901"], "name": "Bitolterol", "groups": ["WITHDRAWN"], "targets": []}, "DB07222": {"dbids": ["DB07222"], "name": "(3S)-N-(5-CHLORO-2-METHYLPHENYL)-1-CYCLOHEXYL-5-OXOPYRROLIDINE-3-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02397": {"dbids": ["DB02397", "EXPT03081"], "name": "O-(2-Acetamido-2-Deoxy-Alpha-D-Galactopyranosyl)-L-Serine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07223": {"dbids": ["DB07223"], "name": "METHYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02396": {"dbids": ["DB02396", "EXPT01370"], "name": "Methylethylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02395": {"dbids": ["DB02395", "EXPT01312"], "name": "3-Hydroxymethyl-5-Aziridinyl-1methyl-2-[1h-Indole-4,7-Dione]-Propanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02394": {"dbids": ["DB02394", "EXPT02443"], "name": "Oxiranpseudoglucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08034": {"dbids": ["DB08034"], "name": "(E)-3,4-DIHYDROXY-N'-[(2-METHOXYNAPHTHALEN-1-YL)METHYLENE]BENZOHYDRAZIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04070": {"dbids": ["DB04070", "EXPT01153"], "name": "6-Deoxyerythronolide B", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01551": {"dbids": ["DB01551"], "name": "Dihydrocodeine", "groups": ["APPROVED", "ILLICIT"], "targets": []}, "DB01000": {"dbids": ["APRD00892", "DB01000"], "name": "Cyclacillin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01000"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB01000"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB01000"}, {"action": "INHIBITOR", "target": "C1KC03", "drug": "DB01000"}]}, "DB01001": {"dbids": ["APRD00553", "DB01001"], "name": "Salbutamol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P07550", "drug": "DB01001"}, {"action": "AGONIST", "target": "P08588", "drug": "DB01001"}]}, "DB01006": {"dbids": ["APRD01066", "DB01006"], "name": "Letrozole", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P11511", "drug": "DB01006"}]}, "DB01007": {"dbids": ["APRD01262", "DB01007"], "name": "Tioconazole", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P10613", "drug": "DB01007"}, {"action": "INHIBITOR", "target": "Q16850", "drug": "DB01007"}]}, "DB01004": {"dbids": ["APRD00263", "DB01004", "EXPT01540"], "name": "Ganciclovir", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P04293", "drug": "DB01004"}, {"action": "INDUCER", "target": "P03176", "drug": "DB01004"}]}, "DB01005": {"dbids": ["APRD00023", "DB01005"], "name": "Hydroxyurea", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23921", "drug": "DB01005"}]}, "DB01558": {"dbids": ["DB01558"], "name": "Bromazepam", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "Q9UN88", "drug": "DB01558"}]}, "DB01559": {"dbids": ["DB01559"], "name": "Clotiazepam", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB01559"}]}, "DB01008": {"dbids": ["APRD00664", "DB01008"], "name": "Busulfan", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB01009": {"dbids": ["APRD01059", "DB01009", "DB05823"], "name": "Ketoprofen", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23219", "drug": "DB01009"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB01009"}, {"action": "OTHER", "target": "P25024", "drug": "DB01009"}]}, "DB00751": {"dbids": ["APRD00043", "DB00751"], "name": "Epinastine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00751"}, {"action": "ANTAGONIST", "target": "P25021", "drug": "DB00751"}, {"action": "UNKNOWN", "target": "P35348", "drug": "DB00751"}, {"action": "UNKNOWN", "target": "P08913", "drug": "DB00751"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00751"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00751"}]}, "DB00750": {"dbids": ["APRD00180", "DB00750"], "name": "Prilocaine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB00750"}]}, "DB00753": {"dbids": ["APRD00212", "DB00753"], "name": "Isoflurane", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P14867", "drug": "DB00753"}, {"action": "INHIBITOR", "target": "P98194", "drug": "DB00753"}, {"action": "AGONIST", "target": "P23415", "drug": "DB00753"}, {"action": "ANTAGONIST", "target": "P42261", "drug": "DB00753"}, {"action": "INDUCER", "target": "Q09470", "drug": "DB00753"}, {"action": "UNKNOWN", "target": "P30049", "drug": "DB00753"}, {"action": "OTHER/UNKNOWN", "target": "P62158", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00753"}]}, "DB00752": {"dbids": ["APRD00645", "DB00752"], "name": "Tranylcypromine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P21397", "drug": "DB00752"}, {"action": "INHIBITOR", "target": "P27338", "drug": "DB00752"}]}, "DB00755": {"dbids": ["APRD00362", "DB00755", "NUTR00051"], "name": "Tretinoin", "groups": ["APPROVED", "INVESTIGATIONAL", "NUTRACEUTICAL"], "targets": [{"action": "AGONIST", "target": "P28702", "drug": "DB00755"}, {"action": "AGONIST", "target": "P48443", "drug": "DB00755"}, {"action": "AGONIST", "target": "P13631", "drug": "DB00755"}, {"action": "AGONIST", "target": "P49788", "drug": "DB00755"}]}, "DB00754": {"dbids": ["APRD00962", "DB00754"], "name": "Ethotoin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB00754"}]}, "DB00209": {"dbids": ["APRD00393", "DB00209"], "name": "Trospium", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00209"}]}, "DB00208": {"dbids": ["APRD01257", "DB00208"], "name": "Ticlopidine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q9H244", "drug": "DB00208"}]}, "DB00207": {"dbids": ["APRD00397", "DB00207"], "name": "Azithromycin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P60725", "drug": "DB00207"}, {"action": "INHIBITOR", "target": "P61177", "drug": "DB00207"}]}, "DB00974": {"dbids": ["APRD01327", "DB00974"], "name": "Edetic Acid", "groups": ["APPROVED"], "targets": []}, "DB00205": {"dbids": ["APRD00599", "DB00205"], "name": "Pyrimethamine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00374", "drug": "DB00205"}, {"action": "INHIBITOR", "target": "P13922", "drug": "DB00205"}]}, "DB00204": {"dbids": ["APRD00367", "DB00204"], "name": "Dofetilide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q12809", "drug": "DB00204"}, {"action": "INHIBITOR", "target": "O95069", "drug": "DB00204"}, {"action": "INHIBITOR", "target": "Q14500", "drug": "DB00204"}]}, "DB00203": {"dbids": ["APRD00556", "DB00203"], "name": "Sildenafil", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "O76074", "drug": "DB00203"}, {"action": "INHIBITOR", "target": "P18545", "drug": "DB00203"}, {"action": "INHIBITOR", "target": "Q13956", "drug": "DB00203"}]}, "DB00202": {"dbids": ["APRD00159", "DB00202"], "name": "Succinylcholine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "Q9GZZ6", "drug": "DB00202"}, {"action": "AGONIST", "target": "Q693P7", "drug": "DB00202"}, {"action": "AGONIST", "target": "P11229", "drug": "DB00202"}, {"action": "AGONIST", "target": "P08172", "drug": "DB00202"}, {"action": "AGONIST", "target": "P20309", "drug": "DB00202"}]}, "DB00201": {"dbids": ["APRD00673", "DB00201"], "name": "Caffeine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P30542", "drug": "DB00201"}, {"action": "MULTITARGET", "target": "P30542", "drug": "DB00201"}, {"action": "ANTAGONIST", "target": "P29274", "drug": "DB00201"}, {"action": "MULTITARGET", "target": "P29274", "drug": "DB00201"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "P54750", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "Q01064", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "Q14123", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "Q9Y233", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "P27815", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "Q07343", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "Q08493", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "Q08499", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "Q9NP56", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "O00408", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "Q14432", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "Q13370", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "O76074", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "P51160", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "Q9HCR9", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "Q13946", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "O60658", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "O95263", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "O76083", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "P16499", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "P35913", "drug": "DB00201"}]}, "DB00200": {"dbids": ["APRD01022", "DB00200"], "name": "Hydroxocobalamin", "groups": ["APPROVED"], "targets": [{"action": "COFACTOR", "target": "Q99707", "drug": "DB00200"}, {"action": "COFACTOR", "target": "P22033", "drug": "DB00200"}, {"action": "OTHER", "target": "Q9UBK8", "drug": "DB00200"}, {"action": "OTHER/UNKNOWN", "target": "Q8IVH4", "drug": "DB00200"}, {"action": "OTHER", "target": "P20061", "drug": "DB00200"}, {"action": "OTHER", "target": "Q9BXJ7", "drug": "DB00200"}, {"action": "OTHER", "target": "O60494", "drug": "DB00200"}, {"action": "OTHER", "target": "Q96EY8", "drug": "DB00200"}, {"action": "OTHER/UNKNOWN", "target": "Q9Y4U1", "drug": "DB00200"}]}, "DB03958": {"dbids": ["DB03958", "EXPT01655"], "name": "7-methyl-guanosine-5'-triphosphate-5'-guanosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03959": {"dbids": ["DB03959", "EXPT02898"], "name": "N,O6-Disulfo-Glucosamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03952": {"dbids": ["DB03952", "EXPT01123"], "name": "9-(6-Deoxy-Beta-D-Allofuranosyl)-6-Methylpurine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03953": {"dbids": ["DB03953", "EXPT02866"], "name": "L-Thiocitrulline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03950": {"dbids": ["DB03950", "EXPT02860"], "name": "(S)-N-(3-Indol-1-Yl-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03951": {"dbids": ["DB03951", "EXPT00050"], "name": "16g", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03956": {"dbids": ["DB03956", "EXPT01809"], "name": "D-Myo-Inositol-2,4,5-Trisphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03957": {"dbids": ["DB03957", "EXPT01488"], "name": "SP2456", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03955": {"dbids": ["DB03955", "EXPT01145"], "name": "1,5-Dideoxy-1,5-Imino-D-Mannitol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09536": {"dbids": ["DB09536"], "name": "Titanium dioxide", "groups": ["APPROVED"], "targets": []}, "DB09537": {"dbids": ["DB09537"], "name": "Iodine povacrylex", "groups": ["APPROVED"], "targets": []}, "DB09534": {"dbids": ["DB09534"], "name": "Ecamsule", "groups": ["APPROVED"], "targets": []}, "DB04694": {"dbids": ["DB04694"], "name": "2,6-anhydro-3-deoxy-3-fluoronononic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04695": {"dbids": ["DB04695"], "name": "FARNESYL THIOPYROPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04696": {"dbids": ["DB04696"], "name": "4-CHLORO-3',3''-DIBROMOPHENOL-1,8-NAPHTHALEIN", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04697": {"dbids": ["DB04697"], "name": "TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04690": {"dbids": ["DB04690"], "name": "Camptothecin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04691": {"dbids": ["DB04691"], "name": "2'-O-[1-ETHYL-1H-IMIDAZOL)] THYMIDINE-5'-MONOPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04692": {"dbids": ["DB04692"], "name": "(E)-(S)-4-[(S)-2-((S)-2-TERT-BUTOXYCARBONYLAMINO-3-METHYL-BUTYRYLAMINO)-2-PHENYL-ACETYLAMINO]-5-(2-OXO-PYRROLIDIN-3-YL)-PENT-2-ENOIC ACID ETHYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04693": {"dbids": ["DB04693"], "name": "(13S)-13-METHYLDODECAHYDRO-1H-CYCLOPENTA[A]PHENANTHRENE-3,17(2H,4H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04698": {"dbids": ["DB04698"], "name": "N-(1,4-DIHYDRO-5H-TETRAZOL-5-YLIDENE)-9-OXO-9H-XANTHENE-2-SULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04699": {"dbids": ["DB04699"], "name": "4-Butyrolactone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08184": {"dbids": ["DB08184"], "name": "2-(2-METHYLPHENYL)-1H-INDOLE-5-CARBOXIMIDAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08185": {"dbids": ["DB08185"], "name": "2-METHYLTHIO-N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08186": {"dbids": ["DB08186"], "name": "(3E)-4-(1-METHYL-1H-INDOL-3-YL)BUT-3-EN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08187": {"dbids": ["DB08187"], "name": "METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08180": {"dbids": ["DB08180"], "name": "2-[METHYL-(5-GERANYL-4-METHYL-PENT-3-ENYL)-AMINO]-ETHYL-DIPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08181": {"dbids": ["DB08181"], "name": "2-((3'-METHYL-4'-HYDROXYPHENYL)AZO)BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08182": {"dbids": ["DB08182"], "name": "4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08183": {"dbids": ["DB08183"], "name": "3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08188": {"dbids": ["DB08188"], "name": "6-BENZYL-1-ETHOXYMETHYL-5-ISOPROPYL URACIL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03408": {"dbids": ["DB03408", "EXPT00168"], "name": "Gamma-Glutamylcysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03409": {"dbids": ["DB03409", "EXPT02426"], "name": "Octahydroindole-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06698": {"dbids": ["DB06698"], "name": "Betahistine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35367", "drug": "DB06698"}, {"action": "ANTAGONIST", "target": "Q9Y5N1", "drug": "DB06698"}]}, "DB06699": {"dbids": ["DB06699"], "name": "Degarelix", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P30968", "drug": "DB06699"}]}, "DB03404": {"dbids": ["DB03404", "EXPT01720"], "name": "Hemin", "groups": ["APPROVED"], "targets": []}, "DB03405": {"dbids": ["DB03405", "EXPT02520"], "name": "1-[N[(Phenylmethoxy)Carbonyl]-L-Leucyl-4-[[N/N-[(Phenylmethoxy)Carbonyl]-/Nl-Leucyl]Amino]-3-Pyrrolidinone/N", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03406": {"dbids": ["DB03406", "EXPT02101"], "name": "O1-Methyl-4-Deoxy-4-Thio-Alpha-D-Glucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03407": {"dbids": ["DB03407", "EXPT00222"], "name": "4-Nitrocatechol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03400": {"dbids": ["DB03400", "EXPT02648"], "name": "3-(P-Tolyl)Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03401": {"dbids": ["DB03401", "EXPT01811"], "name": "D-Myo-Inositol-1,4,5-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03402": {"dbids": ["DB03402", "EXPT01989"], "name": "1,2-Di-1-(3,7,11,15-Tetramethyl-Hexadecane)-Sn-Glycero-3-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03403": {"dbids": ["DB03403", "EXPT00796"], "name": "Cytidine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08238": {"dbids": ["DB08238"], "name": "5-AMINO-NAPHTALENE-2-MONOSULFONATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06064": {"dbids": ["DB06064"], "name": "KAI-1455", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08236": {"dbids": ["DB08236"], "name": "(2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08237": {"dbids": ["DB08237"], "name": "2'-deoxy-N-(naphthalen-1-ylmethyl)guanosine 5'-(dihydrogen phosphate)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08234": {"dbids": ["DB08234"], "name": "5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08235": {"dbids": ["DB08235"], "name": "N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08232": {"dbids": ["DB08232"], "name": "{5-(5-AMINO-1H-PYRROLO[3,2-B]PYRIDIN-2-YL)-6-HYDROXY-3'-NITRO-BIPHENYL-3-YL]-ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08233": {"dbids": ["DB08233"], "name": "6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07382": {"dbids": ["DB07382"], "name": "N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08231": {"dbids": ["DB08231"], "name": "MYRISTIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06066": {"dbids": ["DB06066"], "name": "ARD-07", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06061": {"dbids": ["DB06061"], "name": "AZD-8330", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06063": {"dbids": ["DB06063"], "name": "CAM-2029", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06062": {"dbids": ["DB06062"], "name": "XOMA 052", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07611": {"dbids": ["DB07611"], "name": "DECANE-1-THIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04679": {"dbids": ["DB04679"], "name": "H TYPE I TRISACCHARIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07041": {"dbids": ["DB07041"], "name": "N-[2-(2,4-diaminopyrido[2,3-d]pyrimidin-7-yl)-2-methylpropyl]-4-phenoxybenzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09272": {"dbids": ["DB09272"], "name": "Eluxadoline", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB09272"}, {"action": "ANTAGONIST", "target": "P41143", "drug": "DB09272"}, {"action": "AGONIST", "target": "P41145", "drug": "DB09272"}]}, "DB05806": {"dbids": ["DB05806"], "name": "BNP 1350", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04672": {"dbids": ["DB04672"], "name": "cyclic 3',5'-thymidine monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05804": {"dbids": ["DB05804"], "name": "dehydroepiandrosterone sulfate", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05805": {"dbids": ["DB05805"], "name": "NS-2359", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05802": {"dbids": ["DB05802"], "name": "MLN-02", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05803": {"dbids": ["DB05803"], "name": "ISIS 14803", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05800": {"dbids": ["DB05800"], "name": "beta alethine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04673": {"dbids": ["DB04673"], "name": "4-[(5-CHLOROINDOL-2-YL)SULFONYL]-2-(2-METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL)PYRIMIDIN-2-YL]CARBONYL]PIPERAZINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07047": {"dbids": ["DB07047"], "name": "2',4'-DICHLORO-4-HYDROXY-1,1'-BIPHENYL-3-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05808": {"dbids": ["DB05808"], "name": "PI-88", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05809": {"dbids": ["DB05809"], "name": "TA-CIN", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04671": {"dbids": ["DB04671"], "name": "L-CYSTEIN-S-1-(IMINOMETHYL)-L-ORNITHINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04676": {"dbids": ["DB04676"], "name": "Dansyllysine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04677": {"dbids": ["DB04677"], "name": "N-METHYL-N-[(1R)-1-METHYL-2-PHENYLETHYL]PROP-2-EN-1-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02465": {"dbids": ["DB02465", "EXPT02119"], "name": "Methoxy arachidonyl fluorophosphonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02464": {"dbids": ["DB02464", "EXPT00400"], "name": "Benzylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02467": {"dbids": ["DB02467", "EXPT02173"], "name": "S-Oxymethionine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02466": {"dbids": ["DB02466", "EXPT00042"], "name": "4-[3-Oxo-3-(5,5,8,8-Tetramethyl-5,6,7,8-Tetrahydro-Naphthalen-2-Yl)-Propenyl]-Benzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02461": {"dbids": ["DB02461", "EXPT01078"], "name": "S-Methyl Phosphocysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02460": {"dbids": ["DB02460", "EXPT00986"], "name": "Hydrogenobyrinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02463": {"dbids": ["DB02463", "EXPT00018"], "name": "2-(2-Hydroxy-Phenyl)-1h-Indole-5-Carboxamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02462": {"dbids": ["DB02462", "EXPT01399"], "name": "Thiocoumarin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04675": {"dbids": ["DB04675"], "name": "(2S,5R,8S,11R,12S,15S,18S,19S,E)-8-ISOBUTYL-18-((5S,6S)-6-METHOXY-3,5-DIMETHYL-7-PHENYLHEPTYL)-1,2,5,12,15,19-HEXAMETHYL-3,6,9,13,16,20,25-HEPTAOXO-1,4,7,10,14,17,21-HEPTAAZACYCLOPENTACOS-21-ENE-11,22-DICARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02469": {"dbids": ["DB02469", "EXPT01106"], "name": "4,6-Dideoxy-4-Amino-Beta-D-Glucopyranoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02468": {"dbids": ["DB02468", "EXPT00073"], "name": "12-Phenylheme", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08169": {"dbids": ["DB08169"], "name": "(2Z)-N-biphenyl-4-yl-2-cyano-3-cyclopropyl-3-hydroxyprop-2-enamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09277": {"dbids": ["DB09277"], "name": "Choline C 11", "groups": ["APPROVED"], "targets": []}, "DB09008": {"dbids": ["DB09008"], "name": "Cephaloridine", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB09009": {"dbids": ["DB09009"], "name": "Articaine", "groups": ["APPROVED"], "targets": []}, "DB09276": {"dbids": ["DB09276"], "name": "Sodium aurothiomalate", "groups": ["APPROVED"], "targets": []}, "DB07610": {"dbids": ["DB07610"], "name": "NAPHTHALENE-1,2-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09003": {"dbids": ["DB09003"], "name": "Clocapramine", "groups": ["APPROVED"], "targets": []}, "DB09000": {"dbids": ["DB09000"], "name": "Cyamemazine", "groups": ["APPROVED"], "targets": []}, "DB09001": {"dbids": ["DB09001"], "name": "Barbexaclone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09006": {"dbids": ["DB09006"], "name": "Clinofibrate", "groups": ["APPROVED"], "targets": []}, "DB08160": {"dbids": ["DB08160"], "name": "(2S)-2-AMINO-4-(METHYLSULFANYL)-1-(1,3-THIAZOL-2-YL)BUTANE-1,1-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09004": {"dbids": ["DB09004"], "name": "Clobutinol", "groups": ["WITHDRAWN"], "targets": []}, "DB09117": {"dbids": ["DB09117"], "name": "Paraldehyde", "groups": ["APPROVED"], "targets": []}, "DB08410": {"dbids": ["DB08410"], "name": "PARA-NITROBENZYL GLUTARYL GLYCINIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08161": {"dbids": ["DB08161"], "name": "(S)-2-(MERCAPTOMETHYL)-5-PHENYLPENTANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08411": {"dbids": ["DB08411"], "name": "PARA-NITROPHENYL PHOSPHONOBUTANOYL L-ALANINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09278": {"dbids": ["DB09278"], "name": "Activated charcoal", "groups": ["APPROVED"], "targets": []}, "DB05114": {"dbids": ["DB05114"], "name": "EHC18", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05115": {"dbids": ["DB05115"], "name": "NN344", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05116": {"dbids": ["DB05116"], "name": "NB1011", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05117": {"dbids": ["DB05117"], "name": "IGN301", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05110": {"dbids": ["DB05110"], "name": "VIR201", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05111": {"dbids": ["DB05111"], "name": "Fontolizumab", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05112": {"dbids": ["DB05112"], "name": "AP5280", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05113": {"dbids": ["DB05113"], "name": "105AD7", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05118": {"dbids": ["DB05118"], "name": "R1204", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05119": {"dbids": ["DB05119"], "name": "Rilapladib", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01969": {"dbids": ["DB01969", "EXPT00982"], "name": "Trifluoroacetonyl Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01968": {"dbids": ["DB01968", "EXPT03035"], "name": "2-Thioethenamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04199": {"dbids": ["DB04199", "EXPT01744"], "name": "1-Monohexanoyl-2-Hydroxy-Sn-Glycero-3-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04198": {"dbids": ["DB04198", "EXPT01452"], "name": "Formycin B", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01961": {"dbids": ["DB01961", "EXPT00809"], "name": "Cytidine-3'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01960": {"dbids": ["DB01960", "EXPT02090", "EXPT02143"], "name": "7n-Methyl-8-Hydroguanosine-5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01963": {"dbids": ["DB01963", "EXPT02504"], "name": "Phenylethane Boronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04442": {"dbids": ["DB04442", "EXPT00015"], "name": "2-(2-Oxo-1,2-Dihydro-Pyridin-3-Yl)-1h-Benzoimidazole-5-Carboxamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01965": {"dbids": ["DB01965", "EXPT01299"], "name": "2'-Deoxyuridine 5'-Alpha,Beta-Imido-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01964": {"dbids": ["DB01964", "EXPT00487"], "name": "AL5424", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01967": {"dbids": ["DB01967", "EXPT03238"], "name": "N-{3-[(7ar,12as,12bs)-7-Oxo-1,3,4,6,7,7a,12a,12b-Octahydroindolo[2,3-a]Quinolizin-12(2h)-Yl]Propyl}Propane-2-Sulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01966": {"dbids": ["DB01966", "EXPT02546"], "name": "Di-Stearoyl-3-Sn-Phosphatidylethanolamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00566": {"dbids": ["APRD01236", "DB00566"], "name": "Succimer", "groups": ["APPROVED"], "targets": []}, "DB00567": {"dbids": ["APRD00250", "DB00567"], "name": "Cephalexin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00567"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB00567"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB00567"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB00567"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB00567"}]}, "DB00564": {"dbids": ["APRD00337", "DB00564"], "name": "Carbamazepine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB00564"}]}, "DB00565": {"dbids": ["APRD00874", "DB00565"], "name": "Cisatracurium besylate", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q15822", "drug": "DB00565"}]}, "DB00562": {"dbids": ["APRD00728", "DB00562"], "name": "Benzthiazide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P55017", "drug": "DB00562"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00562"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00562"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00562"}, {"action": "INHIBITOR", "target": "Q16790", "drug": "DB00562"}, {"action": "INHIBITOR", "target": "O43570", "drug": "DB00562"}]}, "DB00563": {"dbids": ["APRD00353", "DB00563"], "name": "Methotrexate", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00374", "drug": "DB00563"}]}, "DB00560": {"dbids": ["APRD01307", "DB00560"], "name": "Tigecycline", "groups": ["APPROVED"], "targets": [{"action": "ADDUCT", "target": "P0A7X3", "drug": "DB00560"}, {"action": "ADDUCT", "target": "P0A7S3", "drug": "DB00560"}, {"action": "ADDUCT", "target": "P0A7S9", "drug": "DB00560"}, {"action": "ADDUCT", "target": "P0AG59", "drug": "DB00560"}, {"action": "ADDUCT", "target": "P0A7U3", "drug": "DB00560"}]}, "DB00561": {"dbids": ["APRD00935", "DB00561"], "name": "Doxapram", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "O14649", "drug": "DB00561"}, {"action": "INHIBITOR", "target": "Q9NPC2", "drug": "DB00561"}]}, "DB08751": {"dbids": ["DB08751"], "name": "N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08750": {"dbids": ["DB08750"], "name": "1-[4-(AMINOMETHYL)BENZOYL]-5'-FLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLIN]-4'-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08753": {"dbids": ["DB08753"], "name": "4-{(1E)-3-OXO-3-[(2-PHENYLETHYL)AMINO]PROP-1-EN-1-YL}-1,2-PHENYLENE DIACETATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08752": {"dbids": ["DB08752"], "name": "N-[(1S)-2-[(4-cyano-1-methylpiperidin-4-yl)amino]-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08755": {"dbids": ["DB08755"], "name": "N-[(1S)-2-{[(1R)-2-(benzyloxy)-1-cyano-1-methylethyl]amino}-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08754": {"dbids": ["DB08754"], "name": "(2E)-3-(3,4-DIHYDROXYPHENYL)-N-[2-(4-HYDROXYPHENYL)ETHYL]ACRYLAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00568": {"dbids": ["APRD00332", "DB00568"], "name": "Cinnarizine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00568"}, {"action": "INHIBITOR", "target": "Q13936", "drug": "DB00568"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB00568"}, {"action": "INHIBITOR", "target": "O60840", "drug": "DB00568"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB00568"}, {"action": "INHIBITOR", "target": "O43497", "drug": "DB00568"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB00568"}, {"action": "INHIBITOR", "target": "Q9P0X4", "drug": "DB00568"}, {"action": "OTHER/UNKNOWN", "target": "P14416", "drug": "DB00568"}, {"action": "BINDER", "target": "P21728", "drug": "DB00568"}, {"action": "BINDER", "target": "P21918", "drug": "DB00568"}, {"action": "BINDER", "target": "P11229", "drug": "DB00568"}, {"action": "BINDER", "target": "P08172", "drug": "DB00568"}, {"action": "BINDER", "target": "P20309", "drug": "DB00568"}, {"action": "BINDER", "target": "P08173", "drug": "DB00568"}, {"action": "BINDER", "target": "P08912", "drug": "DB00568"}]}, "DB00569": {"dbids": ["APRD00500", "DB00569"], "name": "Fondaparinux sodium", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "POTENTIATOR", "target": "P01008", "drug": "DB00569"}, {"action": "INHIBITOR", "target": "P00742", "drug": "DB00569"}]}, "DB06979": {"dbids": ["DB06979"], "name": "5-(dodecylthio)-1H-1,2,3-triazole-4-carboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06978": {"dbids": ["DB06978"], "name": "N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]-4-methoxybenzohydrazide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09336": {"dbids": ["DB09336"], "name": "Technetium Tc 99m nofetumomab merpentan", "groups": ["APPROVED"], "targets": []}, "DB06973": {"dbids": ["DB06973"], "name": "4,4'-PROPANE-2,2-DIYLDIPHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06972": {"dbids": ["DB06972"], "name": "7A-[(4-cyanophenyl)methyl]-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7A-tetrahydro-1H-pyrrolo[1,2-A]pyrrole-7-carbonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06971": {"dbids": ["DB06971"], "name": "N-{2-[(4'-CYANO-1,1'-BIPHENYL-4-YL)OXY]ETHYL}-N'-HYDROXY-N-METHYLUREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06970": {"dbids": ["DB06970"], "name": "2-CHLORO-N-(3-CYANO-5,6-DIHYDRO-4H-CYCLOPENTA[B]THIOPHEN-2-YL)-5-DIETHYLSULFAMOYL-BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06977": {"dbids": ["DB06977"], "name": "(2S)-1-{[5-(1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}-3-[(7AS)-7AH-INDOL-3-YL]PROPAN-2-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06976": {"dbids": ["DB06976"], "name": "1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06974": {"dbids": ["DB06974"], "name": "5-hydroxy-4-(7-methoxy-1,1-dioxido-2H-1,2,4-benzothiadiazin-3-yl)-2-(3-methylbutyl)-6-phenylpyridazin-3(2H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04225": {"dbids": ["DB04225", "EXPT02144"], "name": "N-Methyldehydrobutyrine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01616": {"dbids": ["DB01616"], "name": "Alverine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08908", "drug": "DB01616"}]}, "DB01615": {"dbids": ["DB01615"], "name": "Aceprometazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB01615"}]}, "DB04226": {"dbids": ["DB04226", "EXPT01543"], "name": "Dihydro-Acarbose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01613": {"dbids": ["DB01613"], "name": "Erythrityl Tetranitrate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P16066", "drug": "DB01613"}, {"action": "AGONIST", "target": "P20594", "drug": "DB01613"}]}, "DB01612": {"dbids": ["DB01612"], "name": "Amyl Nitrite", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P16066", "drug": "DB01612"}]}, "DB01611": {"dbids": ["DB01611"], "name": "Hydroxychloroquine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q9NYK1", "drug": "DB01611"}, {"action": "ANTAGONIST", "target": "Q9NR96", "drug": "DB01611"}]}, "DB01610": {"dbids": ["DB01610"], "name": "Valganciclovir", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB04999": {"dbids": ["DB04999"], "name": "MBO7133", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04998": {"dbids": ["DB04998"], "name": "AGRO100", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04229": {"dbids": ["DB04229", "EXPT03274"], "name": "7,10,13-Tri(Carboxymethyl)-5,15-Dioxo-4,7,10,13,16-Pentaaza-1,19-Dithianonadecane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04228": {"dbids": ["DB04228", "EXPT01095"], "name": "(2r)-Amino(3,5-Dihydroxyphenyl)Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01619": {"dbids": ["DB01619"], "name": "Phenindamine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB01619"}]}, "DB01618": {"dbids": ["DB01618"], "name": "Molindone", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB01618"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01618"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01618"}, {"action": "OTHER/UNKNOWN", "target": "P11229", "drug": "DB01618"}]}, "DB09254": {"dbids": ["DB09254"], "name": "Caroxazone", "groups": ["WITHDRAWN"], "targets": []}, "DB09253": {"dbids": ["DB09253"], "name": "Safrazine", "groups": ["WITHDRAWN"], "targets": []}, "DB09252": {"dbids": ["DB09252"], "name": "Pivhydrazine", "groups": ["WITHDRAWN"], "targets": []}, "DB00690": {"dbids": ["APRD00983", "DB00690"], "name": "Flurazepam", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "Q9UN88", "drug": "DB00690"}]}, "DB00691": {"dbids": ["APRD01120", "DB00691"], "name": "Moexipril", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P12821", "drug": "DB00691"}, {"action": "INHIBITOR", "target": "Q9BYF1", "drug": "DB00691"}]}, "DB00692": {"dbids": ["APRD00615", "DB00692"], "name": "Phentolamine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08913", "drug": "DB00692"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00692"}]}, "DB00693": {"dbids": ["APRD00979", "DB00693", "DB07777", "EXPT01447"], "name": "Fluorescein", "groups": ["APPROVED"], "targets": [{"action": "OTHER", "target": "P06310", "drug": "DB00693"}]}, "DB00694": {"dbids": ["APRD00521", "DB00694"], "name": "Daunorubicin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P11388", "drug": "DB00694"}, {"action": "INHIBITOR", "target": "Q02880", "drug": "DB00694"}]}, "DB00695": {"dbids": ["APRD00608", "DB00695", "DB07799"], "name": "Furosemide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q13621", "drug": "DB00695"}]}, "DB00696": {"dbids": ["APRD00677", "DB00696"], "name": "Ergotamine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P28221", "drug": "DB00696"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00696"}, {"action": "AGONIST", "target": "P28223", "drug": "DB00696"}, {"action": "AGONIST", "target": "P14416", "drug": "DB00696"}, {"action": "PARTIAL AGONIST", "target": "P35348", "drug": "DB00696"}, {"action": "PARTIAL AGONIST", "target": "P35368", "drug": "DB00696"}, {"action": "PARTIAL AGONIST", "target": "P25100", "drug": "DB00696"}, {"action": "PARTIAL AGONIST", "target": "P08913", "drug": "DB00696"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00696"}, {"action": "PARTIAL AGONIST", "target": "P18089", "drug": "DB00696"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00696"}, {"action": "AGONIST", "target": "P21728", "drug": "DB00696"}, {"action": "AGONIST", "target": "P21918", "drug": "DB00696"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00696"}, {"action": "AGONIST", "target": "P30939", "drug": "DB00696"}, {"action": "AGONIST", "target": "P28335", "drug": "DB00696"}]}, "DB00697": {"dbids": ["APRD00128", "DB00697"], "name": "Tizanidine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P08913", "drug": "DB00697"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00697"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00697"}, {"action": "AGONIST", "target": "Q9Y2I1", "drug": "DB00697"}]}, "DB00698": {"dbids": ["APRD00191", "DB00698"], "name": "Nitrofurantoin", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P52647", "drug": "DB00698"}, {"action": "POTENTIATOR", "target": "P17117", "drug": "DB00698"}]}, "DB00699": {"dbids": ["APRD00617", "DB00699"], "name": "Nicergoline", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35348", "drug": "DB00699"}]}, "DB09250": {"dbids": ["DB09250"], "name": "Pheniprazine", "groups": ["WITHDRAWN"], "targets": []}, "DB07596": {"dbids": ["DB07596"], "name": "(17beta)-17-(cyanomethyl)-2-methoxyestra-1(10),2,4-trien-3-yl sulfamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09331": {"dbids": ["DB09331"], "name": "Daratumumab", "groups": ["APPROVED"], "targets": []}, "DB09259": {"dbids": ["DB09259"], "name": "Reviparin", "groups": ["APPROVED"], "targets": []}, "DB09258": {"dbids": ["DB09258"], "name": "Bemiparin", "groups": ["APPROVED"], "targets": []}, "DB02120": {"dbids": ["DB02120", "EXPT00413"], "name": "6-Amino-4-Hydroxymethyl-Cyclohex-4-Ene-1,2,3-Triol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02121": {"dbids": ["DB02121", "EXPT00722"], "name": "Butyramide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02122": {"dbids": ["DB02122", "EXPT01822"], "name": "4-iodo-acetamido phenylboronic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02123": {"dbids": ["DB02123", "EXPT00909"], "name": "Glycochenodeoxycholic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02124": {"dbids": ["DB02124", "EXPT01743"], "name": "(2s,3s)-Trans-2,3-Dihydro-3-Hydroxyanthranilic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02125": {"dbids": ["DB02125", "EXPT00435"], "name": "Adamantanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02126": {"dbids": ["DB02126", "EXPT00919"], "name": "4-Carboxycinnamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02127": {"dbids": ["DB02127", "EXPT01207"], "name": "Methylphosphonic Acid Diisopropyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02128": {"dbids": ["DB02128", "EXPT02467"], "name": "[1-(3-Hydroxy-2-Oxo-1-Phenethyl-Propylcarbamoyl)2-Phenyl-Ethyl]-Carbamic Acid Pyridin-4-Ylmethyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02129": {"dbids": ["DB02129", "EXPT01249"], "name": "Dihydroorotic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07754": {"dbids": ["DB07754"], "name": "N-({(1R)-1-carboxy-2-[(4-fluorobenzyl)sulfanyl]ethyl}carbamoyl)-L-glutamic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07755": {"dbids": ["DB07755"], "name": "(2S)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07756": {"dbids": ["DB07756"], "name": "1-[3-({[(4-AMINO-5-FLUORO-2-METHYLQUINOLIN-3-YL)METHYL]THIO}METHYL)PHENYL]-2,2,2-TRIFLUOROETHANE-1,1-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07757": {"dbids": ["DB07757"], "name": "(9aS)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07750": {"dbids": ["DB07750"], "name": "(2R)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07751": {"dbids": ["DB07751"], "name": "(2S)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07753": {"dbids": ["DB07753"], "name": "3',5'-DIFLUOROBIPHENYL-4-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07758": {"dbids": ["DB07758"], "name": "5-(2,5-DICHLOROPHENYL)-2-FUROIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07759": {"dbids": ["DB07759"], "name": "5-[2-(TRIFLUOROMETHYL)PHENYL]-2-FUROIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06594": {"dbids": ["DB06594"], "name": "Agomelatine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P28335", "drug": "DB06594"}, {"action": "AGONIST", "target": "P48039", "drug": "DB06594"}, {"action": "AGONIST", "target": "P49286", "drug": "DB06594"}]}, "DB06590": {"dbids": ["DB06590"], "name": "Ceftaroline fosamil", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB02698": {"dbids": ["DB02698", "EXPT00744"], "name": "N-(M-Trifluoromethylphenyl) Phenoxazine-4,6-Dicarboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02699": {"dbids": ["DB02699", "EXPT02464"], "name": "4-Oxoretinol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02878": {"dbids": ["DB02878", "EXPT02503"], "name": "3-(2-Aminoethyl)-4-(Aminomethyl)Heptanedioic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02879": {"dbids": ["DB02879", "EXPT02535"], "name": "2,3-Di-O-Sulfo-Alpha-D-Glucopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02692": {"dbids": ["DB02692", "EXPT00691"], "name": "(6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02693": {"dbids": ["DB02693", "EXPT01093"], "name": "(4s,5s)-1,2-Dithiane-4,5-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02690": {"dbids": ["DB02690", "EXPT02396"], "name": "NU1025", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02691": {"dbids": ["DB02691", "EXPT01558"], "name": "N-Cholylglycine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02696": {"dbids": ["DB02696", "EXPT03171"], "name": "6-Aminohexyl-Uridine-C1,5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02697": {"dbids": ["DB02697", "EXPT01693"], "name": "Hydroxyaminovaline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02694": {"dbids": ["DB02694", "EXPT02493"], "name": "Pantoyl Adenylate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02695": {"dbids": ["DB02695", "EXPT02444"], "name": "O1-Pentyl-Mannose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02230": {"dbids": ["DB02230", "EXPT01868"], "name": "Immucillin-G", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05479": {"dbids": ["DB05479"], "name": "CZEN 002", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05478": {"dbids": ["DB05478"], "name": "Pradefovir Mesylate", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05477": {"dbids": ["DB05477"], "name": "Dendritic cell therapy", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05476": {"dbids": ["DB05476"], "name": "WX-UK1", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05475": {"dbids": ["DB05475"], "name": "SCV-07", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05474": {"dbids": ["DB05474"], "name": "T487", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05473": {"dbids": ["DB05473"], "name": "QR-334", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05472": {"dbids": ["DB05472"], "name": "omega interferon", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05471": {"dbids": ["DB05471"], "name": "SGN-30", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05470": {"dbids": ["DB05470"], "name": "VX-702", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03611": {"dbids": ["DB03611", "EXPT00504"], "name": "L-2-Amino-4-Methoxy-Cis-but-3-Enoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03610": {"dbids": ["DB03610", "EXPT01405"], "name": "Alpha,Alpha,Alpha-Trifluoro-P-Cresol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03613": {"dbids": ["DB03613", "EXPT00209"], "name": "4-Hydroxyphenacyl Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03612": {"dbids": ["DB03612", "EXPT00172"], "name": "3-Hydroxybutyryl-Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03615": {"dbids": ["DB03615", "EXPT02786"], "name": "Ribostamycin", "groups": ["APPROVED"], "targets": []}, "DB03614": {"dbids": ["DB03614", "EXPT00979"], "name": "Co-Methylcobalamin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03617": {"dbids": ["DB03617", "EXPT00392"], "name": "Modified Acarbose Hexasaccharide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03616": {"dbids": ["DB03616", "EXPT01959"], "name": "Kabiramide C", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03619": {"dbids": ["DB03619", "EXPT01194"], "name": "Deoxycholic Acid", "groups": ["APPROVED"], "targets": []}, "DB03618": {"dbids": ["DB03618", "EXPT02354"], "name": "2-(Acetylamino)-2-Deoxy-4-O-Beta-D-Galactopyranosyl-Alpha-D-Glucopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09339": {"dbids": ["DB09339"], "name": "Indium (111In) imciromab", "groups": ["WITHDRAWN"], "targets": []}, "DB08822": {"dbids": ["DB08822"], "name": "Azilsartan medoxomil", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P30556", "drug": "DB08822"}]}, "DB08820": {"dbids": ["DB05989", "DB08820"], "name": "Ivacaftor", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P13569", "drug": "DB08820"}]}, "DB08827": {"dbids": ["DB08827"], "name": "Lomitapide", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P55157", "drug": "DB08827"}]}, "DB08826": {"dbids": ["DB08826"], "name": "Deferiprone", "groups": ["APPROVED"], "targets": []}, "DB07413": {"dbids": ["DB07413"], "name": "5'-S-[2-(decylamino)ethyl]-5'-thioadenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07412": {"dbids": ["DB07412"], "name": "1-biphenyl-2-ylmethanamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07411": {"dbids": ["DB07411"], "name": "PHENYLALANINE BORONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07410": {"dbids": ["DB07410"], "name": "[2-(3-DIBENZOFURAN-4-YL-PHENYL)-1-HYDROXY-1-PHOSPHONO-ETHYL]-PHOSPHONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07416": {"dbids": ["DB07416"], "name": "(2S)-2-(BUTYRYLOXY)-3-HYDROXYPROPYL NONANOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08478": {"dbids": ["DB08478"], "name": "N-[2-chloro-5-(trifluoromethyl)phenyl]imidodicarbonimidic diamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08828": {"dbids": ["DB08828"], "name": "Vismodegib", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q99835", "drug": "DB08828"}]}, "DB07415": {"dbids": ["DB07415"], "name": "4-[(1S)-1-(3-fluoro-4-methoxyphenyl)-2-(2-methoxy-5-nitrophenyl)ethyl]-1H-imidazol-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08479": {"dbids": ["DB08479"], "name": "N-(3,5-dimethoxyphenyl)imidodicarbonimidic diamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07414": {"dbids": ["DB07414"], "name": "(5S)-1-benzyl-3-(1,1-dioxido-1,2-benzisothiazol-3-yl)-4-hydroxy-5-(1-methylethyl)-1,5-dihydro-2H-pyrrol-2-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07419": {"dbids": ["DB07419"], "name": "(2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06317": {"dbids": ["DB06317"], "name": "Elotuzumab", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07418": {"dbids": ["DB07418"], "name": "bis(4-nitrophenyl) hydrogen phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08470": {"dbids": ["DB08470"], "name": "3-(4-fluorophenyl)-5-phenyl-4H-1,2,4-triazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08471": {"dbids": ["DB08471"], "name": "1-(thiophen-2-ylacetyl)-4-(3-thiophen-2-yl-1,2,4-oxadiazol-5-yl)piperidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08472": {"dbids": ["DB08472"], "name": "(3R)-N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08473": {"dbids": ["DB08473"], "name": "5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08474": {"dbids": ["DB08474"], "name": "3-(CARBOXYAMIDE(2-CARBOXYAMIDE-2-TERTBUTYLETHYL))PENTAN", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08475": {"dbids": ["DB08475"], "name": "[(4R)-2,2-DIMETHYL-1,3-DIOXOLAN-4-YL]METHYL HYDROGEN HEX-5-ENYLPHOSPHONATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08476": {"dbids": ["DB08476"], "name": "3-AMINO-AZACYCLOTRIDECAN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08477": {"dbids": ["DB08477"], "name": "5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06237": {"dbids": ["DB06237"], "name": "Avanafil", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "O76074", "drug": "DB06237"}]}, "DB07967": {"dbids": ["DB07967"], "name": "9-CYCLOPENTYL-6-[2-(3-IMIDAZOL-1-YL-PROPOXY)-PHENYLAMINO]-9H-PURINE-2-CARBONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07966": {"dbids": ["DB07966"], "name": "[4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07965": {"dbids": ["DB07965"], "name": "6-(CYCLOHEXYLAMINO)-9-[2-(4-METHYLPIPERAZIN-1-YL)-ETHYL]-9H-PURINE-2-CARBONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07964": {"dbids": ["DB07964"], "name": "(3S)-4-{[4-(BUT-2-YNYLOXY)PHENYL]SULFONYL}-N-HYDROXY-2,2-DIMETHYLTHIOMORPHOLINE-3-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07963": {"dbids": ["DB07963"], "name": "N-[(2',4'-DIFLUORO-4-HYDROXY-5-IODOBIPHENYL-3-YL)CARBONYL]-BETA-ALANINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07962": {"dbids": ["DB07962"], "name": "METHYL N-[(2',4'-DIFLUORO-4-HYDROXY-5-IODOBIPHENYL-3-YL)CARBONYL]-BETA-ALANINATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07961": {"dbids": ["DB07961"], "name": "1-(4-CYANO-PHENYL)-3-[2-(2,6-DICHLORO-PHENYL)-1-IMINO-ETHYL]-THIOUREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07960": {"dbids": ["DB07960"], "name": "5-ACETAMIDO-5,6-DIHYDRO-4-HYDROXY-6-ISOBUTOXY-4H-PYRAN-2-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07969": {"dbids": ["DB07969"], "name": "3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07968": {"dbids": ["DB07968"], "name": "N-(2-CHLORO-4-FLUOROBENZOYL)-N'-(5-HYDROXY-2-METHOXYPHENYL)UREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04852": {"dbids": ["DB04852"], "name": "Implitapide", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04853": {"dbids": ["DB04853"], "name": "Binodenoson", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04850": {"dbids": ["DB04850"], "name": "AZD2563", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01578": {"dbids": ["DB01578"], "name": "Metrizamide", "groups": ["APPROVED"], "targets": []}, "DB01579": {"dbids": ["DB01579"], "name": "Phendimetrazine", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P35348", "drug": "DB01579"}, {"action": "NEGATIVE MODULATOR", "target": "P23975", "drug": "DB01579"}, {"action": "AGONIST", "target": "P35368", "drug": "DB01579"}]}, "DB01572": {"dbids": ["DB01572"], "name": "17Alpha-methyl-delta1-dihydrotestosterone", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01573": {"dbids": ["DB01573"], "name": "Benzylmorphine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01570": {"dbids": ["DB01570"], "name": "Ohmefentanyl", "groups": ["ILLICIT"], "targets": []}, "DB01571": {"dbids": ["DB01571"], "name": "3-Methylfentanyl", "groups": ["ILLICIT"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB01571"}, {"action": "AGONIST", "target": "P41143", "drug": "DB01571"}, {"action": "AGONIST", "target": "P41145", "drug": "DB01571"}]}, "DB01576": {"dbids": ["DB01576"], "name": "Dextroamphetamine", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "INDUCER", "target": "Q05940", "drug": "DB01576"}, {"action": "NEGATIVE MODULATOR", "target": "P23975", "drug": "DB01576"}, {"action": "NEGATIVE MODULATOR", "target": "Q01959", "drug": "DB01576"}, {"action": "AGONIST", "target": "Q96RJ0", "drug": "DB01576"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01576"}]}, "DB01577": {"dbids": ["DB01577"], "name": "Methamphetamine", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "NEGATIVE MODULATOR", "target": "Q01959", "drug": "DB01577"}, {"action": "NEGATIVE MODULATOR", "target": "P31645", "drug": "DB01577"}, {"action": "NEGATIVE MODULATOR", "target": "P23975", "drug": "DB01577"}, {"action": "INHIBITOR", "target": "Q05940", "drug": "DB01577"}, {"action": "INHIBITOR", "target": "P54219", "drug": "DB01577"}, {"action": "AGONIST", "target": "Q96RJ0", "drug": "DB01577"}, {"action": "AGONIST", "target": "P08913", "drug": "DB01577"}, {"action": "AGONIST", "target": "P18089", "drug": "DB01577"}, {"action": "AGONIST", "target": "P18825", "drug": "DB01577"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB01577"}, {"action": "INHIBITOR", "target": "P27338", "drug": "DB01577"}]}, "DB01574": {"dbids": ["DB01574"], "name": "Attapulgite", "groups": ["APPROVED"], "targets": []}, "DB01575": {"dbids": ["DB01575"], "name": "Kaolin", "groups": ["APPROVED"], "targets": []}, "DB00229": {"dbids": ["APRD00855", "DB00229"], "name": "Cefotiam", "groups": ["APPROVED"], "targets": [{"action": "INDUCER", "target": "Q8XJ01", "drug": "DB00229"}]}, "DB00228": {"dbids": ["APRD00234", "DB00228"], "name": "Enflurane", "groups": ["APPROVED"], "targets": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00228"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00228"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00228"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00228"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00228"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00228"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00228"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00228"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00228"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00228"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00228"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00228"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00228"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00228"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00228"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00228"}, {"action": "AGONIST", "target": "P23415", "drug": "DB00228"}, {"action": "AGONIST", "target": "P48167", "drug": "DB00228"}, {"action": "INHIBITOR", "target": "O15554", "drug": "DB00228"}, {"action": "INDUCER", "target": "Q09470", "drug": "DB00228"}, {"action": "INHIBITOR", "target": "P98194", "drug": "DB00228"}, {"action": "ANTAGONIST", "target": "P42261", "drug": "DB00228"}, {"action": "OTHER/UNKNOWN", "target": "P30049", "drug": "DB00228"}]}, "DB00739": {"dbids": ["APRD01012", "DB00739"], "name": "Hetacillin", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB00739"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB00739"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00739"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB00739"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB00739"}]}, "DB00738": {"dbids": ["APRD00303", "DB00738", "EXPT02625"], "name": "Pentamidine", "groups": ["APPROVED"], "targets": [{"action": "OTHER", "target": "O14717", "drug": "DB00738"}]}, "DB04854": {"dbids": ["DB03786", "DB04854"], "name": "Febuxostat", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P47989", "drug": "DB04854"}]}, "DB00221": {"dbids": ["APRD00750", "DB00221"], "name": "Isoetarine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P08588", "drug": "DB00221"}, {"action": "AGONIST", "target": "P07550", "drug": "DB00221"}]}, "DB00220": {"dbids": ["APRD00003", "DB00220"], "name": "Nelfinavir", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "O90777", "drug": "DB00220"}]}, "DB00223": {"dbids": ["APRD00921", "DB00223"], "name": "Diflorasone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00223"}]}, "DB00222": {"dbids": ["APRD00381", "DB00222"], "name": "Glimepiride", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14654", "drug": "DB00222"}, {"action": "INHIBITOR", "target": "P48048", "drug": "DB00222"}, {"action": "INDUCER", "target": "Q09428", "drug": "DB00222"}]}, "DB00225": {"dbids": ["APRD00990", "DB00225"], "name": "Gadodiamide", "groups": ["APPROVED"], "targets": []}, "DB00224": {"dbids": ["APRD00069", "DB00224"], "name": "Indinavir", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q72874", "drug": "DB00224"}]}, "DB00227": {"dbids": ["APRD00370", "DB00227"], "name": "Lovastatin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P04035", "drug": "DB00227"}, {"action": "OTHER/UNKNOWN", "target": "P20701", "drug": "DB00227"}, {"action": "OTHER", "target": "Q92769", "drug": "DB00227"}]}, "DB00226": {"dbids": ["APRD01006", "DB00226"], "name": "Guanadrel", "groups": ["APPROVED"], "targets": [{"action": "PARTIAL AGONIST", "target": "P23975", "drug": "DB00226"}]}, "DB07633": {"dbids": ["DB07633"], "name": "octyl 3-deoxy-2-O-(6-deoxy-alpha-L-galactopyranosyl)-beta-D-xylo-hexopyranoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07632": {"dbids": ["DB07632"], "name": "5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01929": {"dbids": ["DB01929", "EXPT00950"], "name": "5-Chloryl-2,4,6-Quinazolinetriamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07631": {"dbids": ["DB07631"], "name": "N-DODECYL-N,N-DIMETHYLGLYCINATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01384": {"dbids": ["DB01384"], "name": "Paramethasone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB01384"}]}, "DB07630": {"dbids": ["DB07630"], "name": "N-((1R,2R)-2-(5-CHLORO-1H-INDOLE-2-CARBOXAMIDO)CYCLOHEXYL)-5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01439": {"dbids": ["DB01439"], "name": "3-Methylthiofentanyl", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB01439"}, {"action": "AGONIST", "target": "P41143", "drug": "DB01439"}, {"action": "AGONIST", "target": "P41145", "drug": "DB01439"}]}, "DB07637": {"dbids": ["DB07637"], "name": "3,5 DIBROMOTYROSINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01438": {"dbids": ["DB01438"], "name": "Phenazopyridine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35498", "drug": "DB01438"}]}, "DB07636": {"dbids": ["DB07636"], "name": "5-HEPTYL-6-HYDROXY-1,3-BENZOTHIAZOLE-4,7-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01437": {"dbids": ["DB01437"], "name": "Glutethimide", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P14867", "drug": "DB01437"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01437"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01437"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01437"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01437"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01437"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01437"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01437"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01437"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01437"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01437"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01437"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01437"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01437"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01437"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01437"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01437"}]}, "DB07635": {"dbids": ["DB07635"], "name": "bis(4-hydroxyphenyl)methanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01436": {"dbids": ["DB01436"], "name": "Alfacalcidol", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "AGONIST", "target": "P11473", "drug": "DB01436"}]}, "DB07634": {"dbids": ["DB07634"], "name": "(2,6-DIMETHYL-PHENOXY)-ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04407": {"dbids": ["DB04407", "EXPT00929"], "name": "4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04154": {"dbids": ["DB04154", "EXPT00933"], "name": "N-Methyl-N-[3-(6-Phenyl[1,2,4]Triazolo[4,3-B]Pyridazin-3-Yl)Phenyl]Acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01433": {"dbids": ["DB01433"], "name": "Methadyl Acetate", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB01433"}]}, "DB04152": {"dbids": ["DB04152", "EXPT01825"], "name": "2-Amino-3-(3-Hydroxy-7,8-Dihydro-6h-Cyclohepta[D]-4-Isoxazolyl)Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01431": {"dbids": ["DB01431"], "name": "Allylestrenol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P06401", "drug": "DB01431"}, {"action": "AGONIST", "target": "P03372", "drug": "DB01431"}]}, "DB01430": {"dbids": ["DB01430"], "name": "Almitrine", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "P05023", "drug": "DB01430"}]}, "DB08345": {"dbids": ["DB08345"], "name": "4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03426": {"dbids": ["DB03426", "EXPT01176"], "name": "Digalactosyl Diacyl Glycerol (Dgdg)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03427": {"dbids": ["DB03427", "EXPT00577"], "name": "Delta-(L-Alpha-Aminoadipoyl)-L-Cysteinyl-D-Vinylglycine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03424": {"dbids": ["DB03424", "EXPT00673"], "name": "Bestatin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03425": {"dbids": ["DB03425", "EXPT02986"], "name": "2s,4r-4-Methylglutamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03422": {"dbids": ["DB03422", "EXPT03153"], "name": "1,3-Thiazole-4-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03423": {"dbids": ["DB03423", "EXPT02843"], "name": "S-Adenosyl-L-Homoselenocysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03420": {"dbids": ["DB03420", "EXPT01624"], "name": "2,4-Deoxy-4-Guanidino-5-N-Acetyl-Neuraminic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03421": {"dbids": ["DB03421", "EXPT01806"], "name": "2-Phenethyl-2,3-Dihydro-Phthalazine-1,4-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03428": {"dbids": ["DB03428", "EXPT02974"], "name": "SU9516", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "Q00535", "drug": "DB03428"}, {"action": "BINDER", "target": "P06493", "drug": "DB03428"}, {"action": "INHIBITOR", "target": "P24941", "drug": "DB03428"}]}, "DB03429": {"dbids": ["DB03429", "EXPT00874"], "name": "Cardiolipin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08258": {"dbids": ["DB08258"], "name": "6-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEXANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08259": {"dbids": ["DB08259"], "name": "7-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEPTANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08437": {"dbids": ["DB08437"], "name": "Puromycin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08250": {"dbids": ["DB08250"], "name": "(5S)-5-(3-AMINOPROPYL)-3-(2,5-DIFLUOROPHENYL)-N-ETHYL-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08251": {"dbids": ["DB08251"], "name": "4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08252": {"dbids": ["DB08252"], "name": "2-((4'-HYDROXYNAPHTHYL)-AZO)BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08253": {"dbids": ["DB08253"], "name": "NAM NAPTHYLAMINOALANINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08254": {"dbids": ["DB08254"], "name": "2-NAPHTHALENESULFONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08255": {"dbids": ["DB08255"], "name": "(3AR,5R,6S,7R,7AR)-5-(HYDROXYMETHYL)-2-PROPYL-5,6,7,7A-TETRAHYDRO-3AH-PYRANO[3,2-D][1,3]THIAZOLE-6,7-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08256": {"dbids": ["DB08256"], "name": "N-[(CYCLOHEXYLAMINO)CARBONYL]GLYCINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08257": {"dbids": ["DB08257"], "name": "4-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}BUTANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06366": {"dbids": ["DB06366"], "name": "Pertuzumab", "groups": ["APPROVED"], "targets": [{"action": "ANTIBODY", "target": "P04626", "drug": "DB06366"}]}, "DB08430": {"dbids": ["DB08430"], "name": "PARA-NITROPHENYL 1-THIO-BETA-D-GLUCOPYRANOSIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08431": {"dbids": ["DB08431"], "name": "[(3R,4S)-4-HYDROXY-3-METHYL-2-OXOHEXYL]PHOSPHONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08432": {"dbids": ["DB08432"], "name": "THYMIDINE-5'-THIOPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02226": {"dbids": ["DB02226", "EXPT03146"], "name": "3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-4-Yl]Hexyl]-Phenanthridinium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09257": {"dbids": ["DB09257"], "name": "Gimeracil", "groups": ["APPROVED"], "targets": []}, "DB05860": {"dbids": ["DB05860"], "name": "PEG-Infergen", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05861": {"dbids": ["DB05861"], "name": "TASQ", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05862": {"dbids": ["DB05862"], "name": "ISV-403", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05863": {"dbids": ["DB05863"], "name": "TRX1", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05864": {"dbids": ["DB05864"], "name": "PPI-2458", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05865": {"dbids": ["DB05865"], "name": "VIT-100", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05866": {"dbids": ["DB05866"], "name": "ETC-1001", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05867": {"dbids": ["DB05867"], "name": "99mTc-14 F7 Mab", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05868": {"dbids": ["DB05868"], "name": "BILN 2061", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05869": {"dbids": ["DB05869"], "name": "CTI-01", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB09256": {"dbids": ["DB09256"], "name": "Tegafur", "groups": ["APPROVED"], "targets": []}, "DB02489": {"dbids": ["DB02489", "EXPT00360"], "name": "9-Methylguanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02488": {"dbids": ["DB02488", "EXPT01009"], "name": "1-(2-Ethanone)-2-Hydroxy-2-(1-Amino-2-Methyl-2-Ethanol)-4-(2-Dimethyl)Ethane-Imidazoline-5-One;Chromophore (Thr-Leu-Gly)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02486": {"dbids": ["DB02486", "EXPT01723"], "name": "2-Hydroxyethyl Disulfide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02485": {"dbids": ["DB02485", "EXPT02309"], "name": "Cytidine-5'-Monophosphate-5-N-Acetylneuraminic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02484": {"dbids": ["DB02484", "EXPT00805"], "name": "Cytidine 5'-Diphosphoglycerol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02483": {"dbids": ["DB02483", "EXPT01343"], "name": "Etheno-Nad", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02482": {"dbids": ["DB02482", "EXPT03092"], "name": "Phosphonothreonine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02481": {"dbids": ["DB02481", "EXPT00729"], "name": "N-Benzylformamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02480": {"dbids": ["DB02480", "EXPT02854"], "name": "(S)-4-Bromo-3-Hydroxy-3-Methylbutyl Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05730": {"dbids": ["DB05730"], "name": "PMI-001", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05284": {"dbids": ["DB05284"], "name": "CA4P", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05285": {"dbids": ["DB05285"], "name": "SB-249553", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05280": {"dbids": ["DB05280"], "name": "SLV 308", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05281": {"dbids": ["DB05281"], "name": "S-8184", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05282": {"dbids": ["DB05282"], "name": "MCC", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05283": {"dbids": ["DB05283"], "name": "HIIP", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05288": {"dbids": ["DB05288"], "name": "anecortave acetate", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05289": {"dbids": ["DB05289"], "name": "MPC-7869", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB09251": {"dbids": ["DB09251"], "name": "Phenoxypropazine", "groups": ["WITHDRAWN"], "targets": []}, "DB08439": {"dbids": ["DB08439"], "name": "Parecoxib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB08439"}]}, "DB05138": {"dbids": ["DB05138"], "name": "AdPEDF", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05139": {"dbids": ["DB05139"], "name": "CR002", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05136": {"dbids": ["DB05136"], "name": "Bavituximab", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05137": {"dbids": ["DB05137"], "name": "Lobeline", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05134": {"dbids": ["DB05134"], "name": "CNF1010", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05135": {"dbids": ["DB05135"], "name": "Vibriolysin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05132": {"dbids": ["DB05132"], "name": "ND1251", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05133": {"dbids": ["DB05133"], "name": "VP025", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05130": {"dbids": ["DB05130"], "name": "INCB3284", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05131": {"dbids": ["DB05131"], "name": "TTP889", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB00546": {"dbids": ["APRD00724", "DB00546"], "name": "Adinazolam", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB00546"}]}, "DB04423": {"dbids": ["DB04423", "EXPT02513"], "name": "Coproporphyrin I Containing Co(Iii)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04422": {"dbids": ["DB04422", "EXPT01710"], "name": "2-Amino-4-Mercapto-Butyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01901": {"dbids": ["DB01901", "EXPT02871"], "name": "Sucrose Octasulfate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04427": {"dbids": ["DB04427", "EXPT03234"], "name": "3-[[N-[4-Methyl-Piperazinyl]Carbonyl]-Phenylalaninyl-Amino]-5-Phenyl-Pentane-1-Sulfonic Acid Benzyloxy-Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01906": {"dbids": ["DB01906", "EXPT00372"], "name": "3-(5-Amino-7-Hydroxy-[1,2,3]Triazolo[4,5-D]Pyrimidin-2-Yl)-Benzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01905": {"dbids": ["DB01905", "EXPT00017"], "name": "2-(2-Hydroxy-5-Methoxy-Phenyl)-1h-Benzoimidazole-5-Carboxamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01904": {"dbids": ["DB01904", "EXPT03268"], "name": "D-Xylitol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01909": {"dbids": ["DB01909", "EXPT00422"], "name": "Alpha-Cyclodextrin (Cyclohexa-Amylose)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04428": {"dbids": ["DB04428", "EXPT02682"], "name": "Tungstopterin Cofactor", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08733": {"dbids": ["DB08733"], "name": "(2R,3R)-N^1^-[(1S)-2,2-DIMETHYL-1-(METHYLCARBAMOYL)PROPYL]-N^4^-HYDROXY-2-(2-METHYLPROPYL)-3-{[(1,3-THIAZOL-2-YLCARBONYL)AMINO]METHYL}BUTANEDIAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08732": {"dbids": ["DB08732"], "name": "NALPHA-[(BENZYLOXY)CARBONYL]-N-[(1R)-4-HYDROXY-1-METHYL-2-OXOBUTYL]-L-PHENYLALANINAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08731": {"dbids": ["DB08731"], "name": "2-[(1R)-2-carboxy-1-(naphthalen-1-ylmethyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08730": {"dbids": ["DB08730"], "name": "3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08737": {"dbids": ["DB08737"], "name": "(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08736": {"dbids": ["DB08736"], "name": "4-HYDROXY-3-[(1S,3S)-3-HYDROXY-1-PHENYLBUTYL]-2H-CHROMEN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08735": {"dbids": ["DB08735"], "name": "4-HYDROXY-3-[(1S,3R)-3-HYDROXY-1-PHENYLBUTYL]-2H-CHROMEN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08734": {"dbids": ["DB08734"], "name": "6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08739": {"dbids": ["DB08739"], "name": "2-{3-[(2S)-4,4-difluoro-2-(pyrrolidin-1-ylcarbonyl)pyrrolidin-1-yl]-3-oxopropyl}-isoindole-1,3(2H)-dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08738": {"dbids": ["DB08738"], "name": "1-{3-oxo-3-[(2S)-2-(pyrrolidin-1-ylcarbonyl)pyrrolidin-1-yl]propyl}-3-phenylquinoxalin-2(1H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00500": {"dbids": ["APRD01268", "DB00500"], "name": "Tolmetin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00500"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00500"}]}, "DB00501": {"dbids": ["APRD00568", "DB00501"], "name": "Cimetidine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P25021", "drug": "DB00501"}]}, "DB00502": {"dbids": ["APRD00538", "DB00502"], "name": "Haloperidol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB00502"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00502"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB00502"}, {"action": "OTHER/UNKNOWN", "target": "P28223", "drug": "DB00502"}, {"action": "INVERSE AGONIST", "target": "P35462", "drug": "DB00502"}]}, "DB00503": {"dbids": ["APRD00312", "DB00503"], "name": "Ritonavir", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q72874", "drug": "DB00503"}]}, "DB00504": {"dbids": ["APRD00733", "DB00504"], "name": "Levallorphan", "groups": ["APPROVED"], "targets": [{"action": "PARTIAL AGONIST", "target": "P35372", "drug": "DB00504"}]}, "DB00505": {"dbids": ["APRD00286", "DB00505"], "name": "Tridihexethyl", "groups": ["WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P20309", "drug": "DB00505"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00505"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00505"}]}, "DB06953": {"dbids": ["DB06953"], "name": "2-CHLORO-5-(3-CHLORO-PHENYL)-6-[(4-CYANO-PHENYL)-(3-METHYL-3H-IMIDAZOL-4-YL)- METHOXYMETHYL]-NICOTINONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00507": {"dbids": ["APRD00558", "DB00507"], "name": "Nitazoxanide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P94692", "drug": "DB00507"}]}, "DB00508": {"dbids": ["APRD00465", "DB00508"], "name": "Triflupromazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P21728", "drug": "DB00508"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00508"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB00508"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00508"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00508"}]}, "DB00509": {"dbids": ["APRD00911", "DB00509"], "name": "Dextrothyroxine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P10827", "drug": "DB00509"}, {"action": "AGONIST", "target": "P10828", "drug": "DB00509"}]}, "DB06959": {"dbids": ["DB06959"], "name": "(1S)-2-(1H-INDOL-3-YL)-1-{[(5-ISOQUINOLIN-6-YLPYRIDIN-3-YL)OXY]METHYL}ETHYLAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06958": {"dbids": ["DB06958"], "name": "5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01631": {"dbids": ["DB01631", "EXPT02376"], "name": "Methyl Nonanoate (Ester)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01630": {"dbids": ["DB01630", "EXPT01815"], "name": "SC-74020", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01633": {"dbids": ["DB01633", "EXPT01406"], "name": "Deoxy-2-Fluoro-B-D-Cellotrioside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01632": {"dbids": ["DB01632", "EXPT02663"], "name": "Alpha-Phosphoribosylpyrophosphoric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01635": {"dbids": ["DB01635", "EXPT00133"], "name": "2,2-Dimethylthiazolidine-4-Carboxylic Acid;(Dmt)Thiazolidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01634": {"dbids": ["DB01634", "EXPT02499"], "name": "2-Oxy-4-Hydroxy-5-(2-Hydrazinopyridine)Phenylalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01637": {"dbids": ["DB01637", "EXPT00556"], "name": "3,7,11,15-Tetramethyl-Hexadecan-1-Ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01636": {"dbids": ["DB01636", "EXPT00859"], "name": "Clorocruoro Hem", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01639": {"dbids": ["DB01639", "EXPT02223"], "name": "N-Methyl-Pyridoxal-5'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01638": {"dbids": ["DB01638", "EXPT02939"], "name": "D-Sorbitol", "groups": ["APPROVED"], "targets": []}, "DB08089": {"dbids": ["DB08089"], "name": "6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08088": {"dbids": ["DB08088"], "name": "2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08085": {"dbids": ["DB08085"], "name": "1-(4-HEXYLPHENYL)PROP-2-EN-1-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08084": {"dbids": ["DB08084"], "name": "IDD594", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08087": {"dbids": ["DB08087"], "name": "4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08086": {"dbids": ["DB08086"], "name": "N-[12-(1H-imidazol-1-yl)dodecanoyl]-L-leucine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08081": {"dbids": ["DB08081"], "name": "3-OXO-OCTANOIC ACID (2-OXO-TETRAHYDRO-FURAN-3-YL)-AMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08080": {"dbids": ["DB08080"], "name": "LATRUNCULIN B", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08083": {"dbids": ["DB08083"], "name": "2-(1,3-thiazol-4-yl)-1H-benzimidazole-5-sulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08082": {"dbids": ["DB08082"], "name": "N-(2-AMINOETHYL)-P-CHLOROBENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07192": {"dbids": ["DB07192"], "name": "(3S)-N-(3-BROMOPHENYL)-1-CYCLOHEXYL-5-OXOPYRROLIDINE-3-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07193": {"dbids": ["DB07193"], "name": "(2R,3R)-7-(methylsulfonyl)-3-(2,4,5-trifluorophenyl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07190": {"dbids": ["DB07190"], "name": "3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07191": {"dbids": ["DB07191"], "name": "4-({6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]PYRIMIDIN-4-YL}OXY)-3,5-DIMETHYLBENZONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07196": {"dbids": ["DB07196"], "name": "N-methyl-1-(2-thiophen-2-ylphenyl)methanamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07197": {"dbids": ["DB07197"], "name": "4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07194": {"dbids": ["DB07194"], "name": "2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07195": {"dbids": ["DB07195"], "name": "4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07198": {"dbids": ["DB07198"], "name": "5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07199": {"dbids": ["DB07199"], "name": "(2S,4S,5R)-1-(4-TERT-BUTYLBENZOYL)-2-ISOBUTYL-5-(1,3-THIAZOL-2-YL)PYRROLIDINE-2,4-DICARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09425": {"dbids": ["DB09425"], "name": "Indium in-111 pentetate disodium", "groups": ["APPROVED"], "targets": []}, "DB09420": {"dbids": ["DB09420"], "name": "Sodium iodide I-123", "groups": ["APPROVED"], "targets": []}, "DB09421": {"dbids": ["DB09421"], "name": "Protirelin", "groups": ["APPROVED"], "targets": []}, "DB03859": {"dbids": ["DB03859", "EXPT01644"], "name": "1-Thio-Beta-D-Glucopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03858": {"dbids": ["DB03858", "EXPT01030"], "name": "S-Acetonylcysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03857": {"dbids": ["DB03857", "EXPT02958"], "name": "1,4-Deoxy-1,4-Dithio-Beta-D-Glucopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03856": {"dbids": ["DB03856", "EXPT01229"], "name": "Alpha-Difluoromethylornithine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03855": {"dbids": ["DB03855", "EXPT03133"], "name": "L-Threonohydroxamate 4-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03854": {"dbids": ["DB03854", "EXPT02275"], "name": "Pentane-1,5-Diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03853": {"dbids": ["DB03853", "EXPT02816"], "name": "Azo-Dye Hapten", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03852": {"dbids": ["DB03852", "EXPT00969"], "name": "Eucalyptol", "groups": ["NUTRACEUTICAL"], "targets": []}, "DB03851": {"dbids": ["DB03851", "EXPT01028"], "name": "Carbazole Butanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03850": {"dbids": ["DB03850", "EXPT01955"], "name": "Jaspisamide A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02108": {"dbids": ["DB02108", "EXPT00447"], "name": "2-Aminoethanimidic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02109": {"dbids": ["DB02109", "EXPT01711"], "name": "Hadacidin", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "Q9U8D3", "drug": "DB02109"}]}, "DB09335": {"dbids": ["DB09335"], "name": "Alatrofloxacin", "groups": ["WITHDRAWN"], "targets": []}, "DB02102": {"dbids": ["DB02102", "DB02886", "EXPT00197"], "name": "DMP450", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02103": {"dbids": ["DB02103", "EXPT00881"], "name": "2-Chlorodideoxyadenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02100": {"dbids": ["DB02100", "EXPT00507"], "name": "Methyl alpha-galactoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02101": {"dbids": ["DB02101", "EXPT01435", "EXPT01436"], "name": "Fidarestat(Stereoisomer)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02106": {"dbids": ["DB02106", "EXPT00196"], "name": "[3,5-Dibromo-4-(4-Hydroxy-3-Phenethylcarbamoyl-Phenoxy)-Phenyl]-Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02107": {"dbids": ["DB02107", "EXPT00128"], "name": "Leucine - Reduced Carbonyl", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02104": {"dbids": ["DB02104", "EXPT00976"], "name": "2,4-Diamino-5-Methyl-6-[(3,4,5-Trimethoxy-N-Methylanilino)Methyl]Pyrido[2,3-D]Pyrimidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02105": {"dbids": ["DB02105", "EXPT01233"], "name": "3,5-Dinitrocatechol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09337": {"dbids": ["DB09337"], "name": "Medical air", "groups": ["APPROVED"], "targets": []}, "DB07778": {"dbids": ["DB07778"], "name": "FAMOXADONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07779": {"dbids": ["DB07779"], "name": "N-({(2S)-1-[(3R)-3-AMINO-4-(2-FLUOROPHENYL)BUTANOYL]PYRROLIDIN-2-YL}METHYL)BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07776": {"dbids": ["DB07776"], "name": "2-PHENYL-4H-CHROMEN-4-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09330": {"dbids": ["DB09330"], "name": "Osimertinib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00533", "drug": "DB09330"}]}, "DB07775": {"dbids": ["DB07775"], "name": "3',5'-DIBROMO-2',4,4',6'-TETRAHYDROXY AURONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07772": {"dbids": ["DB07772"], "name": "(1R)-1-{[(4'-METHOXY-1,1'-BIPHENYL-4-YL)SULFONYL]AMINO}-2-METHYLPROPYLPHOSPHONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07773": {"dbids": ["DB07773"], "name": "5-FLUOROINDOLE PROPANOL PHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07770": {"dbids": ["DB07770"], "name": "5-(4-FLUOROPHENYL)-3-{[(4-METHYLPHENYL)SULFONYL]AMINO}THIOPHENE-2-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07771": {"dbids": ["DB07771"], "name": "[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09332": {"dbids": ["DB09332"], "name": "Kappadione", "groups": ["APPROVED"], "targets": []}, "DB09333": {"dbids": ["DB09333"], "name": "Ipodate", "groups": ["APPROVED"], "targets": []}, "DB02818": {"dbids": ["DB02818", "EXPT01948"], "name": "Iodo-Willardiine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02819": {"dbids": ["DB02819", "EXPT02793"], "name": "Mono-[3,4-Dihydroxy-5-(5-Methyl-Benzoimidazol-1-Yl)-Tetrahydor-Furan-2-Ylmethyl] Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02810": {"dbids": ["DB02810", "EXPT02170"], "name": "N-(2-Acetamido)Iminodiacetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02811": {"dbids": ["DB02811", "EXPT01161"], "name": "Diethylphosphono Group", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02812": {"dbids": ["DB02812", "EXPT00391"], "name": "(2s,4r)-1-Acetyl-N-[(1s)-4-[(Aminoiminomethyl)Amino]-1-(2-Benzothiazolylcarbonyl)Butyl]-4-Hydroxy-2-Pyrrolidinecarboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02813": {"dbids": ["DB02813", "EXPT01570"], "name": "2-Acetamido-2-Deoxy-D-Glucono-1,5-Lactone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02814": {"dbids": ["DB02814", "EXPT02276"], "name": "3'-Deazo-Thiamin Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02816": {"dbids": ["DB02816", "EXPT01416"], "name": "7-(1-Methyl-1,2,3-Triazol-4-Yl)-6-Formyl-2,7-Dihydro-[1,4]Thiazepine-3-Carboxylic Acid, Brl42715, C6-(N1-Methyl-1,2,3-Triazolylmethylene)Penem", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02817": {"dbids": ["DB02817", "EXPT00826"], "name": "5-Exo-Hydroxycamphor", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05459": {"dbids": ["DB05459"], "name": "ABT-874", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05458": {"dbids": ["DB05458"], "name": "ABT-089", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05451": {"dbids": ["DB05451"], "name": "P54", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05450": {"dbids": ["DB05450"], "name": "PYM50028", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05452": {"dbids": ["DB05452"], "name": "PH-284", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05455": {"dbids": ["DB05455"], "name": "SR 121463", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05454": {"dbids": ["DB05454"], "name": "SR 57667", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05457": {"dbids": ["DB05457"], "name": "OSI-7904L", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05456": {"dbids": ["DB05456"], "name": "ETC-588", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03679": {"dbids": ["DB03679", "EXPT03112"], "name": "2-Hydroxy-Tryptophan", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03678": {"dbids": ["DB03678", "EXPT03193"], "name": "(6,7-Difluoro-Quinazolin-4-Yl)-(1-Methyl-2,2-Diphenyl-Ethyl)-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03673": {"dbids": ["DB03673", "EXPT03063"], "name": "Beta(2-Thienyl)Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03672": {"dbids": ["DB03672", "EXPT00297"], "name": "9-N-Phenylmethylamino-Tacrine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03671": {"dbids": ["DB03671", "EXPT01244"], "name": "4-(3,12,14-Trihydroxy-10,13-Dimethyl-Hexadecahydro-Cyclopenta[a]Phenanthren-17-Yl)-5h-Furan-2-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03670": {"dbids": ["DB03670", "EXPT02452"], "name": "2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03677": {"dbids": ["DB03677", "EXPT00878"], "name": "N-Cyclohexyl-N'-Decylurea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03676": {"dbids": ["DB03676", "EXPT00825"], "name": "Cystein-S-Yl Cacodylate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03675": {"dbids": ["DB03675", "EXPT01232"], "name": "2,3-Dihydroxy-Valerianic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05630": {"dbids": ["DB05630"], "name": "Sodium stibogluconate", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P11387", "drug": "DB05630"}]}, "DB07174": {"dbids": ["DB07174"], "name": "6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-4-(3-METHOXYPROPYL)-2,2-DIMETHYL-2H-1,4-BENZOXAZIN-3(4H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07175": {"dbids": ["DB07175"], "name": "N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07176": {"dbids": ["DB07176"], "name": "5-aminonaphthalene-1-sulfonic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07177": {"dbids": ["DB07177"], "name": "(5E,13E)-11-HYDROXY-9,15-DIOXOPROSTA-5,13-DIEN-1-OIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07170": {"dbids": ["DB07170"], "name": "5'-FLUORO-2',5'-DIDEOXYADENOSINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07171": {"dbids": ["DB07171"], "name": "5-(2-hydroxyethyl)nonane-1,9-diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07172": {"dbids": ["DB07172"], "name": "(5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07173": {"dbids": ["DB07173"], "name": "7-(5-DEOXY-BETA-D-RIBOFURANOSYL)-5-IODO-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08557": {"dbids": ["DB08557"], "name": "2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08556": {"dbids": ["DB08556"], "name": "5'-ACETYL-4-{[(2,4-DIMETHYLPHENYL)SULFONYL]AMINO}-2,2'-BITHIOPHENE-5-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00702": {"dbids": ["APRD01026", "DB00702"], "name": "Icodextrin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB00703": {"dbids": ["APRD00740", "DB00703"], "name": "Methazolamide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00915", "drug": "DB00703"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00703"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00703"}, {"action": "INHIBITOR", "target": "P43166", "drug": "DB00703"}]}, "DB00700": {"dbids": ["APRD00707", "DB00700"], "name": "Eplerenone", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08235", "drug": "DB00700"}]}, "DB07941": {"dbids": ["DB07941"], "name": "3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl}-N,4-dimethylbenzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07940": {"dbids": ["DB07940"], "name": "9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07943": {"dbids": ["DB07943"], "name": "2-{4-[5-(4-chlorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxoethanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00701": {"dbids": ["APRD00605", "DB00701"], "name": "Amprenavir", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q72874", "drug": "DB00701"}]}, "DB07945": {"dbids": ["DB07945"], "name": "5-(3-carbamoylbenzyl)-5,6,7,8,9,10-hexahydrocyclohepta[b]indole-4-carboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07944": {"dbids": ["DB07944"], "name": "N-{3-METHYL-5-[2-(PYRIDIN-4-YLAMINO)-ETHOXY]-PHENYL}-BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07947": {"dbids": ["DB07947"], "name": "ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07946": {"dbids": ["DB07946"], "name": "N-[2-({[amino(imino)methyl]amino}oxy)ethyl]-2-{6-chloro-3-[(2,2-difluoro-2-phenylethyl)amino]-2-fluorophenyl}acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07949": {"dbids": ["DB07949"], "name": "({[(3E)-2'-OXO-2',7'-DIHYDRO-2,3'-BIINDOL-3(7H)-YLIDENE]AMINO}OXY)ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00706": {"dbids": ["APRD00036", "DB00706"], "name": "Tamsulosin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P35348", "drug": "DB00706"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00706"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00706"}]}, "DB00707": {"dbids": ["APRD00078", "DB00707"], "name": "Porfimer", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "OTHER/UNKNOWN", "target": "P01130", "drug": "DB00707"}, {"action": "ANTAGONIST", "target": "P12314", "drug": "DB00707"}]}, "DB00704": {"dbids": ["APRD00005", "DB00704", "DB05067"], "name": "Naltrexone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P41143", "drug": "DB00704"}, {"action": "ANTAGONIST", "target": "P35372", "drug": "DB00704"}, {"action": "ANTAGONIST", "target": "P41145", "drug": "DB00704"}, {"action": "ANTAGONIST", "target": "Q5T1J1", "drug": "DB00704"}]}, "DB09058": {"dbids": ["DB09058"], "name": "Prothrombin complex concentrate", "groups": ["APPROVED"], "targets": []}, "DB00705": {"dbids": ["APRD00149", "DB00705", "DB08563"], "name": "Delavirdine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q72547", "drug": "DB00705"}]}, "DB07578": {"dbids": ["DB07578"], "name": "3-[4-(2-METHYL-IMIDAZO[4,5-C]PYRIDIN-1-YL)BENZYL]-3H-BENZOTHIAZOL-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07579": {"dbids": ["DB07579"], "name": "BIS-1,2-{[(Z)-2-CARBOXY-2-METHYL-1,3-DIOXANE]-5-YLOXYCARBAMOYL}-ETHANE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09007": {"dbids": ["DB09007"], "name": "Chlorphenoxamine", "groups": ["WITHDRAWN"], "targets": []}, "DB02591": {"dbids": ["DB02591", "EXPT01222"], "name": "5,6-Dimethylbenzimidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02590": {"dbids": ["DB02590", "EXPT00394"], "name": "Abequose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02593": {"dbids": ["DB02593", "EXPT00011"], "name": "7,8-Dihydroxy-1-Methoxy-3-Methyl-10-Oxo-4,10-Dihydro-1h,3h-Pyrano[4,3-B]Chromene-9-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02592": {"dbids": ["DB02592", "EXPT01018"], "name": "Carbaphosphonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02595": {"dbids": ["DB02595", "EXPT00715"], "name": "Bulgecin A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02594": {"dbids": ["DB02594", "EXPT01140"], "name": "2'-Deoxycytidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06155": {"dbids": ["DB06155"], "name": "Rimonabant", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P21554", "drug": "DB06155"}]}, "DB02597": {"dbids": ["DB02597", "EXPT03060"], "name": "[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06626": {"dbids": ["DB06626"], "name": "Axitinib", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P17948", "drug": "DB06626"}, {"action": "INHIBITOR", "target": "P35968", "drug": "DB06626"}, {"action": "INHIBITOR", "target": "P35916", "drug": "DB06626"}]}, "DB02596": {"dbids": ["DB02596", "EXPT00539"], "name": "Alpha,Beta-Methyleneadenosine-5'-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06151": {"dbids": ["DB06151"], "name": "Acetylcysteine", "groups": ["APPROVED"], "targets": [{"action": "LIGAND", "target": "Q03154", "drug": "DB06151"}, {"action": "INHIBITOR", "target": "O15111", "drug": "DB06151"}, {"action": "INHIBITOR", "target": "O14920", "drug": "DB06151"}, {"action": "STIMULATOR", "target": "P48637", "drug": "DB06151"}, {"action": "ACTIVATOR", "target": "Q9UPY5", "drug": "DB06151"}, {"action": "ACTIVATOR", "target": "Q13224", "drug": "DB06151"}, {"action": "ACTIVATOR", "target": "Q05586", "drug": "DB06151"}, {"action": "ACTIVATOR", "target": "Q12879", "drug": "DB06151"}, {"action": "ACTIVATOR", "target": "O15399", "drug": "DB06151"}, {"action": "ACTIVATOR", "target": "Q8TCU5", "drug": "DB06151"}]}, "DB06150": {"dbids": ["DB06150"], "name": "Sulfadimethoxine", "groups": ["APPROVED"], "targets": []}, "DB00243": {"dbids": ["APRD01300", "DB00243"], "name": "Ranolazine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB00243"}, {"action": "INHIBITOR", "target": "Q15858", "drug": "DB00243"}]}, "DB00242": {"dbids": ["APRD00260", "DB00242"], "name": "Cladribine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P23921", "drug": "DB00242"}, {"action": "INHIBITOR", "target": "P31350", "drug": "DB00242"}, {"action": "INHIBITOR", "target": "Q7LG56", "drug": "DB00242"}, {"action": "INHIBITOR", "target": "P09884", "drug": "DB00242"}, {"action": "INHIBITOR", "target": "Q07864", "drug": "DB00242"}, {"action": "INHIBITOR", "target": "P56282", "drug": "DB00242"}, {"action": "INHIBITOR", "target": "Q9NRF9", "drug": "DB00242"}, {"action": "INHIBITOR", "target": "Q9NR33", "drug": "DB00242"}, {"action": "INDUCER", "target": "P00491", "drug": "DB00242"}]}, "DB00241": {"dbids": ["APRD00266", "DB00241"], "name": "Butalbital", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00241"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00241"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00241"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00241"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00241"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00241"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00241"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00241"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB00241"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00241"}]}, "DB00240": {"dbids": ["APRD00783", "DB00240"], "name": "Alclometasone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00240"}]}, "DB00247": {"dbids": ["APRD00463", "DB00247"], "name": "Methysergide", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P41595", "drug": "DB00247"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00247"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00247"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00247"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00247"}, {"action": "BINDER", "target": "P28222", "drug": "DB00247"}, {"action": "BINDER", "target": "P30939", "drug": "DB00247"}, {"action": "BINDER", "target": "P28566", "drug": "DB00247"}]}, "DB00246": {"dbids": ["APRD00540", "DB00246"], "name": "Ziprasidone", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P21918", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P28221", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P28566", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00246"}]}, "DB00245": {"dbids": ["APRD00748", "DB00245"], "name": "Benzatropine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00245"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00245"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00245"}]}, "DB00712": {"dbids": ["APRD00753", "DB00712"], "name": "Flurbiprofen", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P23219", "drug": "DB00712"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00712"}]}, "DB00249": {"dbids": ["APRD00504", "DB00249", "DB03778", "EXPT01835"], "name": "Idoxuridine", "groups": ["APPROVED"], "targets": [{"action": "UNKNOWN", "target": "Q9QNF7", "drug": "DB00249"}]}, "DB00248": {"dbids": ["APRD00836", "DB00248"], "name": "Cabergoline", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P14416", "drug": "DB00248"}, {"action": "AGONIST", "target": "P41595", "drug": "DB00248"}, {"action": "AGONIST", "target": "P35462", "drug": "DB00248"}, {"action": "AGONIST", "target": "P28223", "drug": "DB00248"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00248"}, {"action": "AGONIST", "target": "P28221", "drug": "DB00248"}, {"action": "AGONIST", "target": "P21917", "drug": "DB00248"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00248"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00248"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB00248"}, {"action": "AGONIST", "target": "P21918", "drug": "DB00248"}, {"action": "AGONIST", "target": "P21728", "drug": "DB00248"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00248"}, {"action": "AGONIST", "target": "P28335", "drug": "DB00248"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00248"}, {"action": "BINDER", "target": "P35348", "drug": "DB00248"}, {"action": "BINDER", "target": "P35368", "drug": "DB00248"}, {"action": "BINDER", "target": "P25100", "drug": "DB00248"}, {"action": "BINDER", "target": "P08588", "drug": "DB00248"}, {"action": "BINDER", "target": "P07550", "drug": "DB00248"}, {"action": "AGONIST", "target": "P21728", "drug": "DB00248"}, {"action": "AGONIST", "target": "P21918", "drug": "DB00248"}]}, "DB00719": {"dbids": ["APRD00810", "DB00719"], "name": "Azatadine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00719"}]}, "DB00718": {"dbids": ["APRD00781", "DB00718"], "name": "Adefovir Dipivoxil", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "OTHER", "target": "P24024", "drug": "DB00718"}]}, "DB03440": {"dbids": ["DB03440", "EXPT00027"], "name": "N-Hexadecanoylglycine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03441": {"dbids": ["DB03441", "EXPT00709"], "name": "2-Benzyl-3-Iodopropanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03442": {"dbids": ["DB03442", "EXPT00150"], "name": "2-[5-Hydroxy-3-Methyl-1-(2-Methyl-4-Sulfo-Phenyl)-1h-Pyrazol-4-Ylazo]-4-Sulfo-Benzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03443": {"dbids": ["DB03443", "EXPT00740"], "name": "Bis(5-Amidino-Benzimidazolyl)Methanone Zinc", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03444": {"dbids": ["DB03444", "EXPT00759"], "name": "(3e)-6'-Bromo-2,3'-Biindole-2',3(1h,1'h)-Dione 3-Oxime", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03445": {"dbids": ["DB03445", "EXPT03016"], "name": "Tazobactam Trans-Enamine Intermediate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03446": {"dbids": ["DB03446", "EXPT00470"], "name": "3-Benzylaminocarbonylphenyl-Alpha-D-Galactoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03447": {"dbids": ["DB03447", "EXPT03196"], "name": "Uridylyl-2'-5'-Phospho-Adenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03448": {"dbids": ["DB03448", "EXPT03183"], "name": "2'-Deoxyuridine 3'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03449": {"dbids": ["DB03449", "EXPT00560"], "name": "N-(4-(2-((3-Chlorophenylmethyl)Amino)Ethyl)Phenyl)-2-Thiophecarboxamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01518": {"dbids": ["DB01518"], "name": "Benzethidine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB08272": {"dbids": ["DB08272"], "name": "(4S)-4-(2-NAPHTHYLMETHYL)-D-GLUTAMIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08273": {"dbids": ["DB08273"], "name": "4-HYDROXY-5-IODO-3-NITROPHENYLACETYL-EPSILON-AMINOCAPROIC ACID ANION", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08270": {"dbids": ["DB08270"], "name": "N-(2-AMINOETHYL)-N~2~-{(1S)-1-[4'-(AMINOSULFONYL)BIPHENYL-4-YL]-2,2,2-TRIFLUOROETHYL}-L-LEUCINAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08271": {"dbids": ["DB08271"], "name": "N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08276": {"dbids": ["DB08276"], "name": "N-METHYL O-NITROPHENYL AMINOETHYLDIPHOSPHATE BERYLLIUM TRIFLUORIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08277": {"dbids": ["DB08277"], "name": "2-(2-CHLORO-4-FLUOROPHENOXY)-2-METHYL-N-[(1R,2S,3S,5S,7S)-5-(METHYLSULFONYL)-2-ADAMANTYL]PROPANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08274": {"dbids": ["DB08274"], "name": "6,7,8,9-TETRAHYDRO-4-HYDROXY-3-(1-PHENYLPROPYL)CYCLOHEPTA[B]PYRAN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08275": {"dbids": ["DB08275"], "name": "N-DODECANOYL-L-TYROSINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08278": {"dbids": ["DB08278"], "name": "1-(2-CYCLOPROPYLETHYL)-3-(1,1-DIOXIDO-2H-1,2,4-BENZOTHIADIAZIN-3-YL)-6-FLUORO-4-HYDROXYQUINOLIN-2(1H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08279": {"dbids": ["DB08279"], "name": "3-{ISOPROPYL[(TRANS-4-METHYLCYCLOHEXYL)CARBONYL]AMINO}-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04034": {"dbids": ["DB04034", "EXPT00260"], "name": "Ribulose-5-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04035": {"dbids": ["DB04035", "EXPT00840"], "name": "Pinacol[[2-Amino-Alpha-(1-Carboxy-1-Methylethoxyimino)-4-Thiazoleacetyl]Amino]Methaneboronate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04036": {"dbids": ["DB04036", "EXPT00989"], "name": "Coenzyme a Persulfide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04741": {"dbids": ["DB04741"], "name": "Myxothiazol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04030": {"dbids": ["DB04030", "EXPT00323"], "name": "1,3,4,9-Tetrahydro-2-(Hydroxybenzoyl)-9-[(4-Hydroxyphenyl)Methyl]-6-Methoxy-2h-Pyrido[3,4-B]Indole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04031": {"dbids": ["DB04031", "EXPT02982"], "name": "Serine Vanadate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06985": {"dbids": ["DB06985"], "name": "2-[({4-[2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)amino]benzoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04032": {"dbids": ["DB04032", "EXPT01125"], "name": "Adamantane-1-Carboxylic Acid-5-Dimethylamino-Naphthalene-1-Sulfonylamino-Butyl-Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04033": {"dbids": ["DB04033", "EXPT03282"], "name": "Z-Ala Prolinal", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00867": {"dbids": ["APRD00541", "DB00867"], "name": "Ritodrine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P07550", "drug": "DB00867"}]}, "DB00866": {"dbids": ["APRD00736", "DB00866"], "name": "Alprenolol", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB00866"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00866"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00866"}]}, "DB00865": {"dbids": ["APRD00759", "DB00865"], "name": "Benzphetamine", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "INDUCER", "target": "Q05940", "drug": "DB00865"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00865"}, {"action": "AGONIST", "target": "P35348", "drug": "DB00865"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00865"}]}, "DB00864": {"dbids": ["APRD00276", "DB00864", "EXPT01437"], "name": "Tacrolimus", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P62942", "drug": "DB00864"}]}, "DB00863": {"dbids": ["APRD00254", "DB00863"], "name": "Ranitidine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P25021", "drug": "DB00863"}]}, "DB00862": {"dbids": ["APRD00699", "DB00862"], "name": "Vardenafil", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "O76074", "drug": "DB00862"}, {"action": "ALLOSTERIC MODULATOR", "target": "P18545", "drug": "DB00862"}, {"action": "ALLOSTERIC MODULATOR", "target": "Q13956", "drug": "DB00862"}]}, "DB00861": {"dbids": ["APRD00922", "DB00861", "DB06895"], "name": "Diflunisal", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00861"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00861"}]}, "DB00860": {"dbids": ["APRD00197", "DB00860"], "name": "Prednisolone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00860"}]}, "DB00869": {"dbids": ["APRD00577", "DB00869", "DB04507"], "name": "Dorzolamide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00918", "drug": "DB00869"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00869"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00869"}]}, "DB00868": {"dbids": ["APRD00629", "DB00868"], "name": "Benzonatate", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q14524", "drug": "DB00868"}]}, "DB02719": {"dbids": ["DB02719", "EXPT00842"], "name": "C-(1-Hydrogyl-Beta-D-Glucopyranosyl) Formamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02718": {"dbids": ["DB02718", "EXPT01428"], "name": "5-Formyl-6-Hydrofolic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02717": {"dbids": ["DB02717", "EXPT01056"], "name": "Cellotetraose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02716": {"dbids": ["DB02716", "EXPT02167"], "name": "7-Methyl-Guanosine-5'-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02715": {"dbids": ["DB02715", "EXPT00473"], "name": "Compound 18", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02714": {"dbids": ["DB02714", "EXPT03160"], "name": "3'-Uridinemonophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02713": {"dbids": ["DB02713", "EXPT00379"], "name": "Acetylamino-Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02712": {"dbids": ["DB02712", "EXPT03309"], "name": "Sorbinil", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P15121", "drug": "DB02712"}]}, "DB02711": {"dbids": ["DB02711", "EXPT03117"], "name": "4-{2,6,8-Trioxo-9-[(2s,3r,4r)-2,3,4,5-Tetrahydroxypentyl]-1,2,3,6,8,9-Hexahydro-7h-Purin-7-Yl}Butyl Dihydrogen Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02710": {"dbids": ["DB02710", "EXPT01126"], "name": "2,3,-Dihydroxybenzoylserine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08631": {"dbids": ["DB08631"], "name": "N-(4-CHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05848": {"dbids": ["DB05848"], "name": "humanized SMART Anti-IL-12 Antibody", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05849": {"dbids": ["DB05849"], "name": "NCX 950", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05842": {"dbids": ["DB05842"], "name": "AI-850", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05843": {"dbids": ["DB05843"], "name": "trans NV-04", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05840": {"dbids": ["DB05840"], "name": "AGI-1096", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05841": {"dbids": ["DB05841"], "name": "AI-128", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05846": {"dbids": ["DB05846"], "name": "Mito-4509", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05847": {"dbids": ["DB05847"], "name": "heat-activated liposome technology", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05844": {"dbids": ["DB05844"], "name": "MX-1094", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05845": {"dbids": ["DB05845"], "name": "NV-07a", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB09389": {"dbids": ["DB09389"], "name": "Norgestrel", "groups": ["APPROVED"], "targets": []}, "DB09381": {"dbids": ["DB09381"], "name": "Estrogens, esterified", "groups": ["APPROVED"], "targets": []}, "DB06899": {"dbids": ["DB06899"], "name": "N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOTHIAZIN-4-YL]ETHYL}ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08708": {"dbids": ["DB08708"], "name": "N-cyclohexyl-3-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazin-6-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08939": {"dbids": ["DB08939"], "name": "Letosteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05158": {"dbids": ["DB05158"], "name": "PM02734", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05159": {"dbids": ["DB05159"], "name": "CCX915", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05150": {"dbids": ["DB05150"], "name": "CAD106", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05151": {"dbids": ["DB05151"], "name": "TST10088", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05152": {"dbids": ["DB05152"], "name": "NGX267", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05153": {"dbids": ["DB05153"], "name": "XL184", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05154": {"dbids": ["DB05154"], "name": "PA824", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05155": {"dbids": ["DB05155"], "name": "CR665", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05156": {"dbids": ["DB05156"], "name": "SL017", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05157": {"dbids": ["DB05157"], "name": "KC706", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01381": {"dbids": ["DB01381"], "name": "Ginkgo biloba", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "INHIBITOR", "target": "P23975", "drug": "DB01381"}, {"action": "INHIBITOR", "target": "P14555", "drug": "DB01381"}, {"action": "ANTAGONIST", "target": "P23415", "drug": "DB01381"}, {"action": "NEGATIVE MODULATOR", "target": "P14867", "drug": "DB01381"}, {"action": "NEGATIVE MODULATOR", "target": "P47870", "drug": "DB01381"}, {"action": "NEGATIVE MODULATOR", "target": "P18507", "drug": "DB01381"}]}, "DB01380": {"dbids": ["DB01380"], "name": "Cortisone acetate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB01380"}]}, "DB01382": {"dbids": ["DB01382"], "name": "Glycodiazine", "groups": ["APPROVED"], "targets": [{"action": "OTHER/UNKNOWN", "target": "P48048", "drug": "DB01382"}, {"action": "INDUCER", "target": "Q09428", "drug": "DB01382"}]}, "DB04409": {"dbids": ["DB04409", "EXPT02393"], "name": "Naphthalene Trisulfonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01928": {"dbids": ["DB01928", "EXPT01795"], "name": "Huperaine A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04159": {"dbids": ["DB04159", "EXPT01793"], "name": "Beta-Hydroxytryptophane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04158": {"dbids": ["DB04158", "EXPT00373"], "name": "6-(Adenosine Tetraphosphate-Methyl)-7,8-Dihydropterin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01925": {"dbids": ["DB01925", "EXPT00742"], "name": "2'-Chloro-Biphenyl-2,3-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01388": {"dbids": ["DB01388"], "name": "Mibefradil", "groups": ["WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "O43497", "drug": "DB01388"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB01388"}, {"action": "INHIBITOR", "target": "Q13936", "drug": "DB01388"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB01388"}, {"action": "INHIBITOR", "target": "O60840", "drug": "DB01388"}, {"action": "INHIBITOR", "target": "Q9P0X4", "drug": "DB01388"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB01388"}, {"action": "INHIBITOR", "target": "Q02641", "drug": "DB01388"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB01388"}, {"action": "INHIBITOR", "target": "P54284", "drug": "DB01388"}, {"action": "INHIBITOR", "target": "O00305", "drug": "DB01388"}]}, "DB01435": {"dbids": ["DB01435"], "name": "Antipyrine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB01435"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB01435"}]}, "DB01434": {"dbids": ["DB01434"], "name": "19-norandrostenedione", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01921": {"dbids": ["DB01921", "EXPT02054"], "name": "Xylose-Derived Lactam Oxime", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01432": {"dbids": ["DB01432"], "name": "Cholestyramine", "groups": ["APPROVED"], "targets": []}, "DB04151": {"dbids": ["DB04151", "EXPT01748"], "name": "4-Methyl-Histidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01922": {"dbids": ["DB01922", "EXPT01998"], "name": "Maltosyl-Alpha (1,4)-D-Gluconhydroximo-1,5-Lactam", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08719": {"dbids": ["DB08719"], "name": "5-(5-(6-CHLORO-4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)PENTYL)-3-METHYL ISOXAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08718": {"dbids": ["DB08718"], "name": "4-(3-ethylthiophen-2-yl)benzene-1,2-diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08715": {"dbids": ["DB08715"], "name": "2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2-METHYL-4-ISOXAZOLYL]-PHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08714": {"dbids": ["DB08714"], "name": "2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[4-METHYL-2H-TETRAZOL-2-YL]-PHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08717": {"dbids": ["DB08717"], "name": "[(2S)-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-2-yl]acetic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08711": {"dbids": ["DB08711"], "name": "VANILLATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08710": {"dbids": ["DB08710"], "name": "(5Z)-5-[(5-ETHYL-2-FURYL)METHYLENE]-2-{[(S)-(4-FLUOROPHENYL)(1H-TETRAZOL-5-YL)METHYL]AMINO}-1,3-THIAZOL-4(5H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08713": {"dbids": ["DB08713"], "name": "2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2N-METHYL-2H-TETRAZOL-5-YL]-PHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08712": {"dbids": ["DB08712"], "name": "11-[(MERCAPTOCARBONYL)OXY]UNDECANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00528": {"dbids": ["APRD00193", "DB00528"], "name": "Lercanidipine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q06432", "drug": "DB00528"}]}, "DB00529": {"dbids": ["APRD00669", "DB00529"], "name": "Foscarnet", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P08546", "drug": "DB00529"}, {"action": "INHIBITOR", "target": "P04293", "drug": "DB00529"}]}, "DB00522": {"dbids": ["APRD00818", "DB00522"], "name": "Bentiromide", "groups": ["WITHDRAWN"], "targets": [{"action": "LIGAND", "target": "P05981", "drug": "DB00522"}]}, "DB00523": {"dbids": ["APRD00017", "DB00523"], "name": "Alitretinoin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P10276", "drug": "DB00523"}, {"action": "AGONIST", "target": "P19793", "drug": "DB00523"}, {"action": "AGONIST", "target": "P10826", "drug": "DB00523"}, {"action": "AGONIST", "target": "P28702", "drug": "DB00523"}, {"action": "AGONIST", "target": "P13631", "drug": "DB00523"}, {"action": "AGONIST", "target": "P48443", "drug": "DB00523"}]}, "DB00520": {"dbids": ["APRD00199", "DB00520"], "name": "Caspofungin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "A2QLK4", "drug": "DB00520"}]}, "DB00521": {"dbids": ["APRD00195", "DB00521"], "name": "Carteolol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P07550", "drug": "DB00521"}, {"action": "PARTIAL AGONIST", "target": "P08588", "drug": "DB00521"}]}, "DB00526": {"dbids": ["APRD00186", "DB00526"], "name": "Oxaliplatin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB00527": {"dbids": ["APRD00915", "DB00527"], "name": "Cinchocaine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00527"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00527"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB00527"}]}, "DB00524": {"dbids": ["APRD01109", "DB00524"], "name": "Metolazone", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P55017", "drug": "DB00524"}]}, "DB00525": {"dbids": ["APRD01607", "DB00525"], "name": "Tolnaftate", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q92206", "drug": "DB00525"}]}, "DB07394": {"dbids": ["DB07394"], "name": "AUROVERTIN B", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01659": {"dbids": ["DB01659", "EXPT02716"], "name": "3-(1,10-Phenanthrol-2-Yl)-L-Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01658": {"dbids": ["DB01658", "EXPT02273"], "name": "1'-Deazo-Thiamin Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07395": {"dbids": ["DB07395"], "name": "4-[3-(2-Chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01653": {"dbids": ["DB01653", "EXPT02399"], "name": "(5z)-5-(1h-Indol-3-Ylmethylene)-4h-Imidazol-4-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01652": {"dbids": ["DB01652", "EXPT00637"], "name": "4-Hydroxybenzoyl Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01651": {"dbids": ["DB01651", "EXPT00869"], "name": "Methyl 4,6-O-[(1r)-1-Carboxyethylidene]-Beta-D-Galactopyranoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01650": {"dbids": ["DB01650", "EXPT00123"], "name": "trans-2-hydroxycinnamic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01657": {"dbids": ["DB01657", "EXPT03142"], "name": "2-Amino-3-[4-Hydroxy-6-Oxo-3-(2-Phenyl-Cyclopropylimino)-Cyclohexa-1,4-Dienyl]-Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01656": {"dbids": ["DB01656", "EXPT02802"], "name": "Roflumilast", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q08499", "drug": "DB01656"}, {"action": "INHIBITOR", "target": "P27815", "drug": "DB01656"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB01656"}, {"action": "INHIBITOR", "target": "Q08493", "drug": "DB01656"}]}, "DB01655": {"dbids": ["DB01655", "EXPT02022"], "name": "L-Guluronic Acid 6-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07397": {"dbids": ["DB07397"], "name": "(5S)-5-(2-amino-2-oxoethyl)-4-oxo-N-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methyl]-3,4,5,6,7,8-hexahydro[1]benzothieno[2,3-d]pyrimidine-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07390": {"dbids": ["DB07390"], "name": "2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07391": {"dbids": ["DB07391"], "name": "(2S)-2-AMINO-1-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)PROPAN-1-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07392": {"dbids": ["DB07392"], "name": "2-CHLORO-4-ISOPROPYLAMINO-6-ETHYLAMINO -1,3,5-TRIAZINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07393": {"dbids": ["DB07393"], "name": "2-(2-PHENYL-3-PYRIDIN-2-YL-4,5,6,7-TETRAHYDRO-2H-ISOPHOSPHINDOL-1-YL)PYRIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07398": {"dbids": ["DB07398"], "name": "2-[(CYCLOPROPYLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07178": {"dbids": ["DB07178"], "name": "5-PENTYL-2-PHENOXYPHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07179": {"dbids": ["DB07179"], "name": "3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00388": {"dbids": ["APRD00365", "DB00388"], "name": "Phenylephrine", "groups": ["APPROVED"], "targets": []}, "DB00389": {"dbids": ["APRD00503", "DB00389"], "name": "Carbimazole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P07202", "drug": "DB00389"}]}, "DB00386": {"dbids": ["APRD00786", "DB00386"], "name": "Alseroxylon", "groups": ["WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "Q05940", "drug": "DB00386"}]}, "DB00387": {"dbids": ["APRD00383", "DB00387"], "name": "Procyclidine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00387"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00387"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00387"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00387"}]}, "DB00384": {"dbids": ["APRD00079", "DB00384"], "name": "Triamterene", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P51170", "drug": "DB00384"}, {"action": "INHIBITOR", "target": "P37088", "drug": "DB00384"}, {"action": "INHIBITOR", "target": "P51168", "drug": "DB00384"}, {"action": "INHIBITOR", "target": "P51172", "drug": "DB00384"}]}, "DB00385": {"dbids": ["APRD00662", "DB00385"], "name": "Valrubicin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P11388", "drug": "DB00385"}]}, "DB00382": {"dbids": ["APRD00690", "DB00382"], "name": "Tacrine", "groups": ["WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P22303", "drug": "DB00382"}, {"action": "INHIBITOR", "target": "P06276", "drug": "DB00382"}]}, "DB00383": {"dbids": ["APRD00399", "DB00383"], "name": "Oxyphencyclimine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P20309", "drug": "DB00383"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00383"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00383"}]}, "DB00380": {"dbids": ["APRD00090", "DB00380", "DB02444"], "name": "Dexrazoxane", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P11388", "drug": "DB00380"}]}, "DB00381": {"dbids": ["APRD00520", "DB00381"], "name": "Amlodipine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q13936", "drug": "DB00381"}, {"action": "INHIBITOR", "target": "P54289", "drug": "DB00381"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB00381"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB00381"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB00381"}, {"action": "INHIBITOR", "target": "Q00975", "drug": "DB00381"}, {"action": "INHIBITOR", "target": "Q8IZS8", "drug": "DB00381"}, {"action": "INHIBITOR", "target": "Q6TME4", "drug": "DB00381"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00381"}]}, "DB03879": {"dbids": ["DB03879", "EXPT02163"], "name": "Alpha-L-Methyl-Fucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03878": {"dbids": ["DB03878", "EXPT02657"], "name": "N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09408": {"dbids": ["DB09408"], "name": "Sodium gluconate", "groups": ["APPROVED"], "targets": []}, "DB09409": {"dbids": ["DB09409"], "name": "Magnesium acetate tetrahydrate", "groups": ["APPROVED"], "targets": []}, "DB03871": {"dbids": ["DB03871", "EXPT02061"], "name": "Lambda-Bis(2,2'-Bipyridine)Imidazole Ruthenium (Ii)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03870": {"dbids": ["DB03870", "EXPT01971"], "name": "Ara-Alpha(1,3)-Xyl", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03873": {"dbids": ["DB03873", "EXPT00376"], "name": "N-(5,5,8,8-Tetramethyl-5,8-Dihydro-Naphthalen-2-Yl)-Terephthalamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03872": {"dbids": ["DB03872", "EXPT00876"], "name": "2,3-Dideoxyfucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03875": {"dbids": ["DB03875", "EXPT01269"], "name": "Delta-Bis(2,2'-Bipyridine)-(5-Methyl-2-2'-Bipyridine)-C9-Adamantane Ruthenium (Ii)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03874": {"dbids": ["DB03874", "EXPT02951"], "name": "(4e,8e,12z,16z)-N,N,4,8,13,17,21-Heptamethyldocosa-4,8,12,16,20-Pentaen-1-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03877": {"dbids": ["DB03877", "EXPT00489"], "name": "AL4623", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03876": {"dbids": ["DB03876", "EXPT01363"], "name": "Thieno[2,3-B]Pyridine-2-Carboxamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07718": {"dbids": ["DB07718"], "name": "3-(4-HYDROXY-PHENYL)PYRUVIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07719": {"dbids": ["DB07719"], "name": "3(R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID TERT-BUTYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07710": {"dbids": ["DB07710"], "name": "PHENYLALANYLAMINODI(ETHYLOXY)ETHYL BENZENESULFONAMIDEAMINOCARBONYLBENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07711": {"dbids": ["DB07711"], "name": "(2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07712": {"dbids": ["DB07712"], "name": "3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07713": {"dbids": ["DB07713"], "name": "(1S)-1-{[(4'-METHOXY-1,1'-BIPHENYL-4-YL)SULFONYL]AMINO}-2-METHYLPROPYLPHOSPHONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07714": {"dbids": ["DB07714"], "name": "6-(3-METHYL-1,4-DIOXO-1,4-DIHYDRONAPHTHALEN-2-YL)HEXANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07715": {"dbids": ["DB07715"], "name": "3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07716": {"dbids": ["DB07716"], "name": "(4Z)-2,8:7,12:11,15:14,18:17,22-PENTAANHYDRO-4,5,6,9,10,13,19,20,21-NONADEOXY-D-ARABINO-D-ALLO-D-ALLO-DOCOSA-4,9,20-TRIENITOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07717": {"dbids": ["DB07717"], "name": "(5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03389": {"dbids": ["DB03389", "EXPT03270"], "name": "alpha-D-Xylopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03388": {"dbids": ["DB03388", "EXPT01957"], "name": "3-[(2,4-Dichlorobenzoyl)(Isopropyl)Amino]-5-Phenylthiophene-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03383": {"dbids": ["DB03383", "EXPT00907"], "name": "5-Chloro-1h-Indole-2-Carboxylic Acid [1-(4-Fluorobenzyl)-2-(4-Hydroxypiperidin-1yl)-2-Oxoethyl]Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03382": {"dbids": ["DB03382", "EXPT01041"], "name": "S-Oxy Cysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03381": {"dbids": ["DB03381", "EXPT02611"], "name": "Hexadecanal", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03380": {"dbids": ["DB03380", "EXPT03135"], "name": "L-Tyrosinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03387": {"dbids": ["DB03387", "EXPT01751"], "name": "N-Hydroxy-N-Isopropyloxamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03386": {"dbids": ["DB03386", "EXPT00213"], "name": "4-Fluorotryptophane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03385": {"dbids": ["DB03385", "EXPT00221"], "name": "4-Methylimidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03384": {"dbids": ["DB03384", "EXPT01514"], "name": "Fica", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05433": {"dbids": ["DB05433"], "name": "rGLP-1", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05432": {"dbids": ["DB05432"], "name": "DAS-431 IV", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05431": {"dbids": ["DB05431"], "name": "MLN-977", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05430": {"dbids": ["DB05430"], "name": "VLTS-589", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05437": {"dbids": ["DB05437"], "name": "RIGScan CR49", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05436": {"dbids": ["DB05436"], "name": "RK-0202", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05435": {"dbids": ["DB05435"], "name": "TNX-355", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05434": {"dbids": ["DB05434"], "name": "ABT-510", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05439": {"dbids": ["DB05439"], "name": "IDD-1", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05438": {"dbids": ["DB05438"], "name": "IDM-4", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03127": {"dbids": ["DB03127", "EXPT00669"], "name": "Benzamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03126": {"dbids": ["DB03126", "EXPT02204"], "name": "Mant-Adp", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03125": {"dbids": ["DB03125", "EXPT03114"], "name": "2,4-Diamino-5-(3,4,5-Trimethoxy-Benzyl)-Pyrimidin-1-Ium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03124": {"dbids": ["DB03124", "EXPT00045"], "name": "5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03651": {"dbids": ["DB03651", "EXPT03078"], "name": "2,4,6-Trinitrophenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03650": {"dbids": ["DB03650", "EXPT02029"], "name": "(3e)-3-[(4-Hydroxyphenyl)Imino]-1h-Indol-2(3h)-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03121": {"dbids": ["DB03121", "EXPT01810"], "name": "1-Benzyl-5-Methoxy-2-Methyl-1h-Indol-3-Yl)-Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03120": {"dbids": ["DB03120", "EXPT03125"], "name": "Para-Toluene Sulfonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03659": {"dbids": ["DB03659", "EXPT02080"], "name": "Butylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03658": {"dbids": ["DB03658", "EXPT00594"], "name": "2-{1-[2-Amino-2-(4-Hydroxy-Phenyl)-Acetylamino]-2-Oxo-Ethyl}-5,5-Dimethyl-Thiazolidine-4-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03129": {"dbids": ["DB03129", "EXPT02858"], "name": "[3-(1,3,2-Dioxaborolan-2-Yloxy)Propyl]Guanidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03128": {"dbids": ["DB03128", "EXPT00412"], "name": "Acetylcholine", "groups": ["APPROVED"], "targets": []}, "DB03655": {"dbids": ["DB03655", "EXPT00645"], "name": "Bcx-1812", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03654": {"dbids": ["DB03654", "EXPT02654"], "name": "S,S-Propylthiocysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03657": {"dbids": ["DB03657", "EXPT01010"], "name": "1-Deoxy-1-Methoxycarbamido-Beta-D-Glucopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02380": {"dbids": ["DB02380", "EXPT00134"], "name": "2'-Deoxyinosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02381": {"dbids": ["DB02381", "EXPT02371"], "name": "Nor-N-Omega-Hydroxy-L-Arginine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02382": {"dbids": ["DB02382", "EXPT02312"], "name": "Namn", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02383": {"dbids": ["DB02383", "EXPT03082"], "name": "Tolrestat", "groups": ["WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P15121", "drug": "DB02383"}]}, "DB02384": {"dbids": ["DB02384", "EXPT01432"], "name": "(E)-2-Fluoro-P-Hydroxycinnamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02385": {"dbids": ["DB02385", "EXPT02326"], "name": "Neopterin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02834": {"dbids": ["DB02834", "EXPT01836"], "name": "IDD552", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02835": {"dbids": ["DB02835", "EXPT01519"], "name": "Alpha-D-Glucose 1,6-Bisphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02388": {"dbids": ["DB02388", "EXPT00330"], "name": "Cyclohexyl-{4-[5-(3,4-Dichlorophenyl)-2-Piperidin-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02838": {"dbids": ["DB02838", "EXPT00141"], "name": "3,4-Dihydro-2h-Pyrrolium-5-Carboxylate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02839": {"dbids": ["DB02839", "EXPT01241"], "name": "2,4-Dihydroxybenzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08502": {"dbids": ["DB08502"], "name": "5-(3,5-DICHLOROPHENYL)THIO-4-ISOPROPYL-1-(PYRIDIN-4-YL-METHYL)-1H-IMIDAZOL-2-YL-METHYL CARBAMATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08503": {"dbids": ["DB08503"], "name": "(3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05389": {"dbids": ["DB05389"], "name": "WF10", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB03653": {"dbids": ["DB03653", "EXPT03273"], "name": "5-{[Ethyl(Methyl)Amino]Methyl}-2-Methyl-5,6-Dihydropyrimidin-4-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05385": {"dbids": ["DB05385"], "name": "PRO 2000", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05384": {"dbids": ["DB05384"], "name": "polyacrylic acid", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05387": {"dbids": ["DB05387"], "name": "AE-941", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05386": {"dbids": ["DB05386"], "name": "recombinant human GM-CSF", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05381": {"dbids": ["DB05381"], "name": "histamine dihydrochloride", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05380": {"dbids": ["DB05380"], "name": "Skeletal targeted radiotherapy", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05383": {"dbids": ["DB05383"], "name": "pimagedine HCl", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05382": {"dbids": ["DB05382"], "name": "molecular iodine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08506": {"dbids": ["DB08506"], "name": "N-{(2S)-3-[(1R)-1-aminoethyl](hydroxy)phosphoryl-2-benzylpropanoyl}-L-phenylalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04295": {"dbids": ["DB04295", "EXPT00789"], "name": "N-Benzoyl-N'-Beta-D-Glucopyranosyl Urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02524": {"dbids": ["DB02524", "EXPT00019"], "name": "Spiro(2,4,6-Trinitrobenzene[1,2a]-2o',3o'-Methylene-Adenine-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02525": {"dbids": ["DB02525", "EXPT01656"], "name": "D-Galactohydroximo-1,5-Lactam", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02526": {"dbids": ["DB02526", "EXPT00270"], "name": "CRA_10655", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02527": {"dbids": ["DB02527", "EXPT00959"], "name": "Cyclic Adenosine Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02520": {"dbids": ["DB02520", "EXPT01132"], "name": "Diethylcarbamodithioic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02521": {"dbids": ["DB02521", "EXPT01448"], "name": "2,5,7-Trihydroxynaphthoquinone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02522": {"dbids": ["DB02522", "EXPT02646"], "name": "Phosphonopyruvate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02523": {"dbids": ["DB02523", "EXPT00380"], "name": "5'-[[2-(Aminooxy)Ethyl]Methylsulfonio]-5'-Deoxy-Adenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02528": {"dbids": ["DB02528", "EXPT02402"], "name": "Tetrazolyl Histidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02529": {"dbids": ["DB02529", "EXPT01524"], "name": "5-N-Acetyl-4-Amino-6-Diethylcarboxamide-4,5-Dihydro-2h-Pyran-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04257": {"dbids": ["DB04257", "EXPT02495"], "name": "Palmitoleic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04250": {"dbids": ["DB04250", "EXPT00639"], "name": "Butyrylthiocholine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04251": {"dbids": ["DB04251", "EXPT02177"], "name": "Monoisopropyl Ester Phosphonic Acid Group", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07478": {"dbids": ["DB07478"], "name": "1,1'-BIPHENYL-3,4-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04252": {"dbids": ["DB04252", "EXPT02310"], "name": "N-Carbamoyl-L-Aspartate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09227": {"dbids": ["DB09227"], "name": "Barnidipine", "groups": ["APPROVED"], "targets": []}, "DB04253": {"dbids": ["DB04253", "EXPT00837"], "name": "CB1954", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07211": {"dbids": ["DB07211"], "name": "(2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07210": {"dbids": ["DB07210"], "name": "3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07213": {"dbids": ["DB07213"], "name": "(5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02832": {"dbids": ["DB02832", "EXPT02954"], "name": "Siroheme", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07212": {"dbids": ["DB07212"], "name": "N-(7-CARBAMIMIDOYL-NAPHTHALEN-1-YL)-3-HYDROXY-2-METHYL-BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02833": {"dbids": ["DB02833", "EXPT00930"], "name": "[4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07215": {"dbids": ["DB07215"], "name": "2-METHYL-2-(4-{[({4-METHYL-2-[4-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL}CARBONYL)AMINO]METHYL}PHENOXY)PROPANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02830": {"dbids": ["DB02830", "EXPT01487"], "name": "FR236913", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01815": {"dbids": ["DB01815", "EXPT02041"], "name": "Nz-(Dicarboxymethyl)Lysine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07929": {"dbids": ["DB07929"], "name": "N-(TERT-BUTYL)-3,5-DIMETHYL-N'-[(5-METHYL-2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)CARBONYL]BENZOHYDRAZIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02831": {"dbids": ["DB02831", "EXPT00124"], "name": "Dihydrogenphosphate Ion", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07217": {"dbids": ["DB07217"], "name": "N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01814": {"dbids": ["DB01814", "EXPT02033"], "name": "2-Tridecanoyloxy-Pentadecanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07923": {"dbids": ["DB07923"], "name": "octyl alpha-L-altropyranoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02836": {"dbids": ["DB02836", "EXPT01643"], "name": "Guanosine 5'-Diphosphate 2':3'-Cyclic Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07921": {"dbids": ["DB07921"], "name": "2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07216": {"dbids": ["DB07216"], "name": "(11S)-8-CHLORO-11-[1-(METHYLSULFONYL)PIPERIDIN-4-YL]-6-PIPERAZIN-1-YL-11H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07927": {"dbids": ["DB07927"], "name": "3-{[(4-CARBOXY-2-HYDROXYANILINE]SULFONYL}THIOPHENE-2-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01817": {"dbids": ["DB01817", "EXPT00445"], "name": "Threonine-Aspartic Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07925": {"dbids": ["DB07925"], "name": "4-(2-HYDROXYPHENYLSULFINYL)-BUTYLPHOSPHONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02837": {"dbids": ["DB02837", "DB03377", "EXPT01646"], "name": "O4-Sulfonylgalactose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01816": {"dbids": ["DB01816", "EXPT01055"], "name": "(1s,6s,7r,8r,8ar)-1,6,7,8-Tetrahydroxyindolizidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02386": {"dbids": ["DB02386", "EXPT02610"], "name": "Leucine Phosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01811": {"dbids": ["DB01811", "EXPT00174"], "name": "3h-Indole-5,6-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02387": {"dbids": ["DB02387", "EXPT01333"], "name": "3-Hydroxyphenylalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01810": {"dbids": ["DB01810", "EXPT00058"], "name": "[1-(1-Methyl-4,5-Dioxo-Pent-2-Enylcarbamoyl)-2-Phenyl-Ethyl]-Carbamic Acid Benzyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01813": {"dbids": ["DB01813", "EXPT02576", "EXPT02638"], "name": "Pyridoxyl-Glutamic Acid-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01812": {"dbids": ["DB01812", "EXPT00370"], "name": "Adenosine-3'-5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07552": {"dbids": ["DB07552"], "name": "2-CHLORO-4-ETHYLAMINO-6-(R(+)-2'-CYANO-4-BUTYLAMINO)-1,3,5-TRIAZINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07553": {"dbids": ["DB07553"], "name": "9,9,9-TRIFLUORO-8-OXO-N-PHENYLNONANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04233": {"dbids": ["DB04233", "EXPT00817"], "name": "(Hydroxyethyloxy)Tri(Ethyloxy)Octane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04364": {"dbids": ["DB04364", "EXPT01701"], "name": "R,3-Hydroxybutan-2-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04365": {"dbids": ["DB04365", "EXPT03296"], "name": "Arecoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04366": {"dbids": ["DB04366", "EXPT00161"], "name": "3'-Deoxy 3'-Amino Adenosine-5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04367": {"dbids": ["DB04367", "EXPT01124"], "name": "Debromohymenialdisine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04360": {"dbids": ["DB04360", "EXPT00787"], "name": "Benzo[B]Thiophene-2-Boronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04361": {"dbids": ["DB04361", "EXPT01715"], "name": "Methylhydrazine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04362": {"dbids": ["DB04362", "EXPT00469"], "name": "Adenosine Diphosphate 5-(Beta-Ethyl)-4-Methyl-Thiazole-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04363": {"dbids": ["DB04363", "EXPT02129"], "name": "Mesobiliverdin Iv Alpha", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04368": {"dbids": ["DB04368", "EXPT00629"], "name": "Bb-3497", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "Q9HBH1", "drug": "DB04368"}]}, "DB04369": {"dbids": ["DB04369", "EXPT02853"], "name": "1,3,2-Dioxaborolan-2-Ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00269": {"dbids": ["APRD00715", "DB00269"], "name": "Chlorotrianisene", "groups": ["WITHDRAWN"], "targets": [{"action": "AGONIST", "target": "P03372", "drug": "DB00269"}]}, "DB00268": {"dbids": ["APRD00302", "DB00268"], "name": "Ropinirole", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P35462", "drug": "DB00268"}, {"action": "AGONIST", "target": "P14416", "drug": "DB00268"}, {"action": "AGONIST", "target": "P21917", "drug": "DB00268"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00268"}, {"action": "AGONIST", "target": "P28221", "drug": "DB00268"}, {"action": "AGONIST", "target": "P41595", "drug": "DB00268"}, {"action": "AGONIST", "target": "P21728", "drug": "DB00268"}, {"action": "AGONIST", "target": "P21918", "drug": "DB00268"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00268"}, {"action": "AGONIST", "target": "P28223", "drug": "DB00268"}, {"action": "AGONIST", "target": "P28335", "drug": "DB00268"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00268"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00268"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00268"}]}, "DB00265": {"dbids": ["APRD00211", "DB00265"], "name": "Crotamiton", "groups": ["APPROVED"], "targets": []}, "DB00264": {"dbids": ["APRD00208", "DB00264"], "name": "Metoprolol", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB00264"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00264"}]}, "DB00267": {"dbids": ["APRD00851", "DB00267"], "name": "Cefmenoxime", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB00267"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB00267"}]}, "DB00266": {"dbids": ["APRD00761", "DB00266"], "name": "Dicoumarol", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9BQB6", "drug": "DB00266"}, {"action": "INHIBITOR", "target": "P15559", "drug": "DB00266"}, {"action": "INHIBITOR", "target": "Q08257", "drug": "DB00266"}]}, "DB00261": {"dbids": ["APRD00798", "DB00261"], "name": "Anagrelide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14432", "drug": "DB00261"}]}, "DB00260": {"dbids": ["APRD00894", "DB00260", "DB03123"], "name": "Cycloserine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A6J8", "drug": "DB00260"}, {"action": "INHIBITOR", "target": "Q9L888", "drug": "DB00260"}]}, "DB00263": {"dbids": ["APRD00595", "DB00263"], "name": "Sulfisoxazole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0AC13", "drug": "DB00263"}]}, "DB00262": {"dbids": ["APRD00006", "DB00262"], "name": "Carmustine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00390", "drug": "DB00262"}]}, "DB03468": {"dbids": ["DB03468", "EXPT02913"], "name": "1,2,3,4-Tetrahydro-Isoquinoline-7-Sulfonic Acid Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03469": {"dbids": ["DB03469", "EXPT01189"], "name": "Heme D", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03462": {"dbids": ["DB03462", "EXPT03032"], "name": "Thymine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03460": {"dbids": ["DB03460", "EXPT03252"], "name": "Violaxanthin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03461": {"dbids": ["DB03461", "EXPT02293"], "name": "2'-Monophosphoadenosine 5'-Diphosphoribose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03466": {"dbids": ["DB03466", "EXPT00057"], "name": "BMS184394", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03467": {"dbids": ["DB03467", "EXPT02295"], "name": "Naringenin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03464": {"dbids": ["DB03464", "EXPT01459"], "name": "Formycin-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03465": {"dbids": ["DB03465", "EXPT02490"], "name": "2-Phospho-D-Glyceric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08298": {"dbids": ["DB08298"], "name": "(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08299": {"dbids": ["DB08299"], "name": "4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08294": {"dbids": ["DB08294"], "name": "2-(4-HYDROXY-3-NITROPHENYL)ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08295": {"dbids": ["DB08295"], "name": "4-HYDROXY-3-NITROPHENYLACETYL-EPSILON-AMINOCAPROIC ACID ANION", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08296": {"dbids": ["DB08296"], "name": "5-(PARA-NITROPHENYL PHOSPHONATE)-PENTANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08297": {"dbids": ["DB08297"], "name": "ORTHONITROPHENYL-BETA-D-FUCOPYRANOSIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08291": {"dbids": ["DB08291"], "name": "N-(3-AMINOPROPYL)-2-NITROBENZENAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07472": {"dbids": ["DB07472"], "name": "(R)-(+)9B-(3-METHYL)PHENYL-2,3-DIHYDROTHIAZOLO[2,3-A]ISOINDOL-5(9BH)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08293": {"dbids": ["DB08293"], "name": "(5E)-12-CHLORO-13,15-DIHYDROXY-4,7,8,9-TETRAHYDRO-2-BENZOXACYCLOTRIDECINE-1,10(3H,11H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06073": {"dbids": ["DB06073"], "name": "CTS-21166", "groups": ["INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P56817", "drug": "DB06073"}]}, "DB06070": {"dbids": ["DB06070"], "name": "SNX-5422", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06071": {"dbids": ["DB06071"], "name": "DTS-201", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06077": {"dbids": ["DB06077"], "name": "ITI-007", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB00841": {"dbids": ["APRD00122", "DB00841"], "name": "Dobutamine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P08588", "drug": "DB00841"}, {"action": "AGONIST", "target": "P07550", "drug": "DB00841"}]}, "DB00840": {"dbids": ["APRD01023", "DB00840"], "name": "Hydroxypropyl cellulose", "groups": ["APPROVED"], "targets": []}, "DB00843": {"dbids": ["APRD00039", "DB00843"], "name": "Donepezil", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P22303", "drug": "DB00843"}, {"action": "OTHER/UNKNOWN", "target": "P28223", "drug": "DB00843"}]}, "DB00842": {"dbids": ["APRD01152", "DB00842"], "name": "Oxazepam", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "Q9UN88", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00842"}]}, "DB00845": {"dbids": ["APRD00278", "DB00845"], "name": "Clofazimine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q5L2G3", "drug": "DB00845"}]}, "DB00844": {"dbids": ["APRD01132", "DB00844"], "name": "Nalbuphine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P41145", "drug": "DB00844"}, {"action": "ANTAGONIST", "target": "P35372", "drug": "DB00844"}, {"action": "ANTAGONIST", "target": "P41143", "drug": "DB00844"}]}, "DB00847": {"dbids": ["APRD00896", "DB00847"], "name": "Cysteamine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "BINDER", "target": "P61278", "drug": "DB00847"}, {"action": "OTHER/UNKNOWN", "target": "P49146", "drug": "DB00847"}]}, "DB00846": {"dbids": ["APRD00982", "DB00846"], "name": "Flurandrenolide", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00846"}]}, "DB00849": {"dbids": ["APRD00047", "DB00849"], "name": "Methylphenobarbital", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00849"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00849"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00849"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00849"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00849"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00849"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00849"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00849"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB00849"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB00849"}]}, "DB00848": {"dbids": ["APRD01067", "DB00848"], "name": "Levamisole", "groups": ["WITHDRAWN"], "targets": [{"action": "AGONIST", "target": "P32297", "drug": "DB00848"}, {"action": "INHIBITOR", "target": "P10696", "drug": "DB00848"}, {"action": "ACTIVATOR", "target": "Q23022", "drug": "DB00848"}, {"action": "ACTIVATOR", "target": "Q9N587", "drug": "DB00848"}, {"action": "ACTIVATOR", "target": "Q27218", "drug": "DB00848"}, {"action": "ACTIVATOR", "target": "P48181", "drug": "DB00848"}]}, "DB07474": {"dbids": ["DB07474"], "name": "3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04235": {"dbids": ["DB04235", "EXPT03223"], "name": "4-Amino Hexanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02738": {"dbids": ["DB02738", "EXPT00244"], "name": "Adenosine-5'-Pentaphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07538": {"dbids": ["DB07538"], "name": "4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02731": {"dbids": ["DB02731", "EXPT01342"], "name": "Thimerosal", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02730": {"dbids": ["DB02730", "EXPT02093"], "name": "4-Methylthio-Alpha-D-Mannose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02733": {"dbids": ["DB02733", "EXPT02705"], "name": "Purvalanol", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P28482", "drug": "DB02733"}, {"action": "INHIBITOR", "target": "P27361", "drug": "DB02733"}]}, "DB02732": {"dbids": ["DB02732", "EXPT02284"], "name": "Nicotinamide Adenine Dinucleotide Acetone Adduct", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02735": {"dbids": ["DB02735", "EXPT00503"], "name": "2-Amino-3-Oxo-4-Sulfo-Butyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02734": {"dbids": ["DB02734", "EXPT02117"], "name": "4-Deoxy-D-Mannuronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02736": {"dbids": ["DB02736", "EXPT00414"], "name": "Acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07539": {"dbids": ["DB07539"], "name": "4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04072": {"dbids": ["DB04072", "EXPT02174"], "name": "Alpha-Methylisocitric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04073": {"dbids": ["DB04073", "EXPT00043"], "name": "N-{3-[4-(3-Amino-Propyl)-Piperazin-1-Yl]-Propyl}-3-Nitro-5-(Galactopyranosyl)-Beta-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07534": {"dbids": ["DB07534"], "name": "4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04074": {"dbids": ["DB04074", "EXPT01974"], "name": "Alpha-ketoisovalerate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07535": {"dbids": ["DB07535"], "name": "2-amino-6-[2-(1H-indol-6-yl)ethyl]pyrimidin-4(3H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08386": {"dbids": ["DB08386"], "name": "2-{[4-(4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04075": {"dbids": ["DB04075", "EXPT02356"], "name": "N-Acetyl-L-Glutamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07536": {"dbids": ["DB07536"], "name": "N-{(1S,2R)-2-hydroxy-1-[(hydroxyamino)carbonyl]propyl}-4-{[4-(morpholin-4-ylmethyl)phenyl]ethynyl}benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05172": {"dbids": ["DB05172"], "name": "AT3022", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05173": {"dbids": ["DB05173"], "name": "PTC299", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05170": {"dbids": ["DB05170"], "name": "Benzimate", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05171": {"dbids": ["DB05171"], "name": "E2012", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05176": {"dbids": ["DB05176"], "name": "CMX001", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05177": {"dbids": ["DB05177"], "name": "DG051", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05174": {"dbids": ["DB05174"], "name": "CX501", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08455": {"dbids": ["DB08455"], "name": "9-(4-HYDROXY-2,6-DIMETHYL-PHENYL)-3,7-DIMETHYL-NONA-4,6,8-TRIENOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05178": {"dbids": ["DB05178"], "name": "DLO6001", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05179": {"dbids": ["DB05179"], "name": "DLO6002", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08908": {"dbids": ["DB08908"], "name": "Dimethyl fumarate", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "BINDER", "target": "Q14145", "drug": "DB08908"}]}, "DB04076": {"dbids": ["DB04076", "EXPT01767"], "name": "Hypoxanthine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07537": {"dbids": ["DB07537"], "name": "N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04077": {"dbids": ["DB04077", "EXPT01027"], "name": "Glycerol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04179": {"dbids": ["DB04179", "EXPT00790"], "name": "Benzofuran", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04178": {"dbids": ["DB04178", "EXPT02512"], "name": "Di-Stearoyl-3-Sn-Phosphatidylcholine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07530": {"dbids": ["DB07530"], "name": "(1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04171": {"dbids": ["DB04171", "EXPT01211"], "name": "D-Isovaline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04170": {"dbids": ["DB04170", "EXPT00699"], "name": "4-Bromo-3-Hydroxy-3-Methyl Butyl Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04173": {"dbids": ["DB04173", "EXPT01495"], "name": "Fructose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04172": {"dbids": ["DB04172", "EXPT03181"], "name": "[2,4,6-Triisopropyl-Phenylsulfonyl-L-[3-Amidino-Phenylalanine]]-Piperazine-N'-Beta-Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04175": {"dbids": ["DB04175", "EXPT00939"], "name": "Mdl-29951", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04174": {"dbids": ["DB04174", "EXPT03170"], "name": "3'-1-Carboxy-1-Phosphonooxy-Ethoxy-Uridine-Diphosphate-N-Acetylglucosamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04177": {"dbids": ["DB04177", "EXPT01294"], "name": "4-(3,14-Dihydroxy-10,13-Dimethyl-Hexadecahydro-Cyclopenta[a]Phenanthren-17-Yl)-5h-Furan-2-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04176": {"dbids": ["DB04176", "EXPT02620"], "name": "Phosporic Acid Mono-[3,4-Dihydroxy-5-(5-Methoxy-Benzoimidazol-1-Yl)-Tetrahydro-Furan-2-Ylmethyl] Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06999": {"dbids": ["DB06999"], "name": "N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06998": {"dbids": ["DB06998"], "name": "[(5R)-5-(2,3-dibromo-5-ethoxy-4-hydroxybenzyl)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07531": {"dbids": ["DB07531"], "name": "4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06991": {"dbids": ["DB06991"], "name": "N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06990": {"dbids": ["DB06990"], "name": "4-[(1E,7E)-8-(2,6-DIOXO-1,2,3,6-TETRAHYDROPYRIMIDIN-4-YL)-3,6-DIOXA-2,7-DIAZAOCTA-1,7-DIEN-1-YL]BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06993": {"dbids": ["DB06993"], "name": "(2S,3S)-4-cyclopropyl-3-{(3R,5R)-3-[2-fluoro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazolidin-5-yl}-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06992": {"dbids": ["DB06992"], "name": "(3,3-dimethylpiperidin-1-yl)(6-(3-fluoro-4-methylphenyl)pyridin-2-yl)methanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06995": {"dbids": ["DB06995"], "name": "N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06994": {"dbids": ["DB06994"], "name": "(2S,3S)-3-{3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06997": {"dbids": ["DB06997"], "name": "2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06996": {"dbids": ["DB06996"], "name": "D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07532": {"dbids": ["DB07532"], "name": "N-hexanoyl-L-homoserine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09244": {"dbids": ["DB09244"], "name": "Pirlindole", "groups": ["APPROVED"], "targets": []}, "DB09245": {"dbids": ["DB09245"], "name": "Toloxatone", "groups": ["APPROVED"], "targets": []}, "DB09246": {"dbids": ["DB09246"], "name": "Benmoxin", "groups": ["WITHDRAWN"], "targets": []}, "DB00797": {"dbids": ["APRD00170", "DB00797"], "name": "Tolazoline", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35348", "drug": "DB00797"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00797"}, {"action": "AGONIST", "target": "P35367", "drug": "DB00797"}, {"action": "AGONIST", "target": "P25021", "drug": "DB00797"}, {"action": "BINDER", "target": "P18825", "drug": "DB00797"}, {"action": "BINDER", "target": "P18089", "drug": "DB00797"}]}, "DB04157": {"dbids": ["DB04157", "EXPT02588"], "name": "N-[(Aminooxy)Carbonyl]Aniline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09247": {"dbids": ["DB09247"], "name": "Iproclozide", "groups": ["WITHDRAWN"], "targets": []}, "DB09240": {"dbids": ["DB09240"], "name": "Niludipine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07533": {"dbids": ["DB07533"], "name": "4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09241": {"dbids": ["DB09241"], "name": "Methylene blue", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB09242": {"dbids": ["DB09242"], "name": "Moxonidine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "Q9Y2I1", "drug": "DB09242"}]}, "DB09243": {"dbids": ["DB09243"], "name": "Hydracarbazine", "groups": ["APPROVED"], "targets": []}, "DB04156": {"dbids": ["DB04156", "EXPT00678"], "name": "Aspartate Beryllium Trifluoride", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07156": {"dbids": ["DB07156"], "name": "(4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07157": {"dbids": ["DB07157"], "name": "(5R,6S,8S)-8-[3-(AMINOMETHYL)PHENYL]-6-HYDROXY-5-ISOPROPYL-3-OXO-1-PHENYL-2,7-DIOXA-4-AZA-6-PHOSPHANONAN-9-OIC ACID 6-OXIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07154": {"dbids": ["DB07154"], "name": "(3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-METHYL-1,4-DIAZEPAN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07155": {"dbids": ["DB07155"], "name": "(3S)-1-CYCLOHEXYL-5-OXO-N-PHENYLPYRROLIDINE-3-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07152": {"dbids": ["DB07152"], "name": "N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07153": {"dbids": ["DB07153"], "name": "6-methyl-5-[3-methyl-3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07150": {"dbids": ["DB07150"], "name": "4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07151": {"dbids": ["DB07151"], "name": "4-(4-hydroxy-3-methylphenyl)-6-phenylpyrimidin-2(5H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09248": {"dbids": ["DB09248"], "name": "Mebanazine", "groups": ["WITHDRAWN"], "targets": []}, "DB04155": {"dbids": ["DB04155", "EXPT00118"], "name": "2-Fluoro-2-Deoxy-Beta-D-Galactopyranosyl-Beta-D-Glucopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07159": {"dbids": ["DB07159"], "name": "6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07488": {"dbids": ["DB07488"], "name": "{(2Z)-4-AMINO-2-[(4-METHOXYPHENYL)IMINO]-2,3-DIHYDRO-1,3-THIAZOL-5-YL}(4-METHOXYPHENYL)METHANONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07489": {"dbids": ["DB07489"], "name": "{[4-AMINO-2-(3-CHLOROANILINO)-1,3-THIAZOL-5-YL](4-FLUOROPHENYL)METHANONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07480": {"dbids": ["DB07480"], "name": "4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07481": {"dbids": ["DB07481"], "name": "tert-butyl [(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl]carbamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07482": {"dbids": ["DB07482"], "name": "(2R)-N-[(2R)-2-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-N-[(5R)-5-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-L-PROLINAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07483": {"dbids": ["DB07483"], "name": "1,1'-BIPHENYL-2-SULFINIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07484": {"dbids": ["DB07484"], "name": "(2R)-4,4-dihydroxy-5-nitro-2-(phenylmethyl)pentanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07485": {"dbids": ["DB07485"], "name": "4,4'-cyclohexane-1,1-diyldiphenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07486": {"dbids": ["DB07486"], "name": "3-({4-[(1E)-3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-2,3-bis(trifluoromethyl)phenyl}sulfanyl)aniline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07487": {"dbids": ["DB07487"], "name": "(6-METHYL-3,4-DIHYDRO-2H-CHROMEN-2-YL)METHYLPHOSPHINATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03813": {"dbids": ["DB03813", "EXPT01103"], "name": "2-Decenoyl N-Acetyl Cysteamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03812": {"dbids": ["DB03812", "EXPT02992"], "name": "3-{2,6,8-Trioxo-9-[(2s,3r,4r)-2,3,4,5-Tetrahydroxypentyl]-1,2,3,6,8,9-Hexahydro-7h-Purin-7-Yl}Propyl Dihydrogen Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03811": {"dbids": ["DB03811", "EXPT01786"], "name": "Histidinol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03810": {"dbids": ["DB03810", "EXPT02042"], "name": "(3r)-3-Methyl-L-Glutamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03817": {"dbids": ["DB03817", "EXPT01102"], "name": "2,4-Diaminobutyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03816": {"dbids": ["DB03816", "EXPT00119"], "name": "Difluoromethionine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03815": {"dbids": ["DB03815", "EXPT01465"], "name": "Fucitol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03814": {"dbids": ["DB03814", "EXPT02154"], "name": "2-(N-Morpholino)-Ethanesulfonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03819": {"dbids": ["DB03819", "EXPT02900"], "name": "Salicylhydroxamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03818": {"dbids": ["DB03818", "EXPT03085"], "name": "N-[Tosyl-D-Prolinyl]Amino-Ethanethiol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04283": {"dbids": ["DB04283", "EXPT00735"], "name": "2-Bromo-6-Hydroxy-Purine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01674": {"dbids": ["DB01674", "EXPT00211"], "name": "[2-(1-Amino-2-Hydroxy-Propyl)-4-(4-Fluoro-1h-Indol-3-Ylmethyl)-5-Hydroxy-Imidazol-1-Yl]-Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01677": {"dbids": ["DB01677", "EXPT01460", "EXPT01511"], "name": "Fumarate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01676": {"dbids": ["DB01676", "EXPT03079"], "name": "Trinitrotoluene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04287": {"dbids": ["DB04287", "EXPT00701"], "name": "(S)-5-(4-Benzyloxy-Phenyl)-4-(7-Phenyl-Heptanoylamino)-Pentanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04286": {"dbids": ["DB04286", "EXPT02787"], "name": "beta-D-Ribopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04285": {"dbids": ["DB04285", "EXPT02484"], "name": "{4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01672": {"dbids": ["DB01672", "EXPT01121"], "name": "2,3-Dihydroxy-Benzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04289": {"dbids": ["DB04289", "EXPT01584"], "name": "Genz-10850", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04288": {"dbids": ["DB04288", "EXPT01808"], "name": "2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01679": {"dbids": ["DB01679", "EXPT02471"], "name": "Propyl Trihydrogen Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01678": {"dbids": ["DB01678", "EXPT00280"], "name": "RU84687", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00104": {"dbids": ["BIOD00088", "BTD00088", "DB00104"], "name": "Octreotide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "BINDER", "target": "P30874", "drug": "DB00104"}]}, "DB00105": {"dbids": ["BIOD00066", "BTD00066", "DB00105"], "name": "Interferon Alfa-2b, Recombinant", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "P48551", "drug": "DB00105"}, {"action": "BINDER", "target": "P17181", "drug": "DB00105"}]}, "DB00106": {"dbids": ["BIOD00051", "BTD00051", "DB00106"], "name": "Abarelix", "groups": ["APPROVED", "INVESTIGATIONAL", "WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P30968", "drug": "DB00106"}]}, "DB00107": {"dbids": ["BIOD00016", "BTD00016", "DB00107"], "name": "Oxytocin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P30559", "drug": "DB00107"}, {"action": "BINDER", "target": "P01178", "drug": "DB00107"}]}, "DB00100": {"dbids": ["BIOD00038", "BTD00038", "DB00100"], "name": "Coagulation Factor IX", "groups": ["APPROVED"], "targets": [{"action": "ACTIVATOR", "target": "P00742", "drug": "DB00100"}, {"action": "LIGAND", "target": "P03951", "drug": "DB00100"}, {"action": "LIGAND", "target": "P08709", "drug": "DB00100"}, {"action": "COFACTOR", "target": "P00451", "drug": "DB00100"}]}, "DB07737": {"dbids": ["DB07737"], "name": "(2S)-4-(4-fluorobenzyl)-N-(3-sulfanylpropyl)piperazine-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00102": {"dbids": ["BIOD00053", "BTD00053", "DB00102"], "name": "Becaplermin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB00103": {"dbids": ["BIOD00075", "BTD00075", "DB00103"], "name": "Agalsidase beta", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB04153": {"dbids": ["DB04153", "EXPT00464"], "name": "S-Hydroxymethyl Glutathione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07739": {"dbids": ["DB07739"], "name": "(3R)-3-(FLUOROMETHYL)-7-(THIOMORPHOLIN-4-YLSULFONYL)-1,2,3,4-TETRAHYDROISOQUINOLINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00108": {"dbids": ["BIOD00083", "BTD00083", "DB00108"], "name": "Natalizumab", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTIBODY", "target": "P13612", "drug": "DB00108"}]}, "DB00109": {"dbids": ["BIOD00106", "BTD00106", "DB00109"], "name": "Enfuvirtide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB06285": {"dbids": ["DB06285"], "name": "Teriparatide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "BINDER", "target": "Q03431", "drug": "DB06285"}]}, "DB06287": {"dbids": ["DB06287"], "name": "Temsirolimus", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P42345", "drug": "DB06287"}]}, "DB06283": {"dbids": ["DB06283"], "name": "Ziconotide", "groups": ["APPROVED"], "targets": []}, "DB06282": {"dbids": ["DB06282"], "name": "Levocetirizine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB06282"}, {"action": "INHIBITOR", "target": "P35367", "drug": "DB06282"}]}, "DB06288": {"dbids": ["DB06288"], "name": "Amisulpride", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB06288"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB06288"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB06288"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB06288"}]}, "DB04827": {"dbids": ["DB04827"], "name": "Ethyl carbamate", "groups": ["WITHDRAWN"], "targets": []}, "DB04826": {"dbids": ["DB04826"], "name": "Thenalidine", "groups": ["WITHDRAWN"], "targets": []}, "DB04825": {"dbids": ["DB04825"], "name": "Prenylamine", "groups": ["WITHDRAWN"], "targets": []}, "DB04824": {"dbids": ["DB04824"], "name": "Phenolphthalein", "groups": ["WITHDRAWN"], "targets": []}, "DB04823": {"dbids": ["DB04823"], "name": "Oxyphenisatin", "groups": ["WITHDRAWN"], "targets": []}, "DB04822": {"dbids": ["DB04822"], "name": "Oxeladin", "groups": ["WITHDRAWN"], "targets": []}, "DB04821": {"dbids": ["DB04821"], "name": "Nomifensine", "groups": ["WITHDRAWN"], "targets": []}, "DB04820": {"dbids": ["DB04820"], "name": "Nialamide", "groups": ["WITHDRAWN"], "targets": []}, "DB04829": {"dbids": ["DB04829"], "name": "Lysergic Acid Diethylamide", "groups": ["ILLICIT", "WITHDRAWN"], "targets": []}, "DB04828": {"dbids": ["DB04828"], "name": "Zomepirac", "groups": ["WITHDRAWN"], "targets": []}, "DB08337": {"dbids": ["DB08337"], "name": "TERT-BUTYL [(1S)-2-METHYL-1-(1,3,4-OXADIAZOL-2-YL)PROPYL]CARBAMATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08336": {"dbids": ["DB08336"], "name": "TERT-BUTYL [(1R)-2-METHYL-1-(1,3,4-OXADIAZOL-2-YL)PROPYL]CARBAMATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08335": {"dbids": ["DB08335"], "name": "4-HYDROXYBENZALDEHYDE O-(3,3-DIMETHYLBUTANOYL)OXIME", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08334": {"dbids": ["DB08334"], "name": "3-FLUORO-4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08333": {"dbids": ["DB08333"], "name": "4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08332": {"dbids": ["DB08332"], "name": "[2'-CARBOXYLETHYL]-10-METHYL-ANTHRACENE ENDOPEROXIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08331": {"dbids": ["DB08331"], "name": "N-1H-imidazol-2-yl-N'-[4-(1H-imidazol-2-ylamino)phenyl]benzene-1,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08330": {"dbids": ["DB08330"], "name": "METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08339": {"dbids": ["DB08339"], "name": "6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}-8-METHYLPYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08338": {"dbids": ["DB08338"], "name": "19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05419": {"dbids": ["DB05419"], "name": "ADX-10061", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05418": {"dbids": ["DB05418"], "name": "GW 597599", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07439": {"dbids": ["DB07439"], "name": "1-((2-HYDROXYETHOXY)METHYL)-5-(3-(BENZYLOXY)BENZYL)-6-HYDROXYPYRIMIDINE-2,4(1H,3H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05415": {"dbids": ["DB05415"], "name": "OSI-461", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05414": {"dbids": ["DB05414"], "name": "ERA-923", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05417": {"dbids": ["DB05417"], "name": "GW 468816", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05416": {"dbids": ["DB05416"], "name": "GW 501516", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05411": {"dbids": ["DB05411"], "name": "VB2-011", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05410": {"dbids": ["DB05410"], "name": "NCX 1022", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05413": {"dbids": ["DB05413"], "name": "T-1249", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05412": {"dbids": ["DB05412"], "name": "SCIO-469", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03101": {"dbids": ["DB03101", "EXPT02743"], "name": "Ribose-1-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03100": {"dbids": ["DB03100", "EXPT00288"], "name": "6-Nitroindazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03103": {"dbids": ["DB03103", "EXPT03136"], "name": "Thymidine-5'- Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03102": {"dbids": ["DB03102", "EXPT02439"], "name": "2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03105": {"dbids": ["DB03105", "EXPT01193"], "name": "5-Hydroxy Norvaline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03104": {"dbids": ["DB03104", "EXPT00321"], "name": "RU82129", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03107": {"dbids": ["DB03107", "EXPT00624"], "name": "Beta-Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03106": {"dbids": ["DB03106", "EXPT01892"], "name": "Myo-Inositol", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "O14735", "drug": "DB03106"}]}, "DB03109": {"dbids": ["DB03109", "EXPT02281"], "name": "N-Acetyl-D-Allosamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03108": {"dbids": ["DB03108", "EXPT01166"], "name": "4-Phospho-D-Erythronate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08445": {"dbids": ["DB08445"], "name": "(3R,4S)-1-[6-(6-METHOXYPYRIDIN-3-YL)PYRIMIDIN-4-YL]-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08444": {"dbids": ["DB08444"], "name": "3-[2-bromo-4-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-methylbenzonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08447": {"dbids": ["DB08447"], "name": "3-{3-[(DIMETHYLAMINO)METHYL]-1H-INDOL-7-YL}PROPAN-1-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08446": {"dbids": ["DB08446"], "name": "3-[6-bromo-2-fluoro-3-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-chlorobenzonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08441": {"dbids": ["DB08441"], "name": "6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08440": {"dbids": ["DB08440"], "name": "N-1,10-phenanthrolin-5-ylacetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08830": {"dbids": ["DB08830"], "name": "Dehydroascorbic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08443": {"dbids": ["DB08443"], "name": "2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08831": {"dbids": ["DB08831"], "name": "2-deoxyglucose", "groups": ["EXPERIMENTAL", "INVESTIGATIONAL"], "targets": []}, "DB08442": {"dbids": ["DB08442"], "name": "4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07400": {"dbids": ["DB07400"], "name": "1-ETHOXYCARBONYL-D-PHE-PRO-2(4-AMINOBUTYL)HYDRAZINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07401": {"dbids": ["DB07401"], "name": "METHYL (2Z)-2-(2-{[6-(2-CYANOPHENOXY)PYRIMIDIN-4-YL]OXY}PHENYL)-3-METHOXYACRYLATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08449": {"dbids": ["DB08449"], "name": "2-(3-((4,5,7-trifluorobenzo[d]thiazol-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)acetic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07402": {"dbids": ["DB07402"], "name": "Azapropazone", "groups": ["WITHDRAWN"], "targets": []}, "DB08448": {"dbids": ["DB08448"], "name": "(4aS)-5-[(2,4-diaminopteridin-6-yl)methyl]-4a,5-dihydro-2H-dibenzo[b,f]azepin-8-ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06804": {"dbids": ["DB06804"], "name": "Nonoxynol-9", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB06803": {"dbids": ["DB06803"], "name": "Niclosamide", "groups": ["APPROVED"], "targets": []}, "DB06802": {"dbids": ["DB06802"], "name": "Nepafenac", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23219", "drug": "DB06802"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB06802"}]}, "DB07406": {"dbids": ["DB07406"], "name": "(4R)-N-[4-({[2-(DIMETHYLAMINO)ETHYL]AMINO}CARBONYL)-1,3-THIAZOL-2-YL]-4-METHYL-1-OXO-2,3,4,9-TETRAHYDRO-1H-BETA-CARBOLINE-6-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06800": {"dbids": ["DB06800"], "name": "Methylnaltrexone", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35372", "drug": "DB06800"}, {"action": "ANTAGONIST", "target": "P41145", "drug": "DB06800"}]}, "DB07408": {"dbids": ["DB07408"], "name": "5-(2-NITROPHENYL)-2-FUROIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07409": {"dbids": ["DB07409"], "name": "(1-HYDROXY-1-PHOSPHONO-2-[1,1';4',1'']TERPHENYL-3-YL-ETHYL)-PHOSPHONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07434": {"dbids": ["DB07434"], "name": "HONH-BENZYLMALONYL-L-ALANYLGLYCINE-P-NITROANILIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02508": {"dbids": ["DB02508", "EXPT01922"], "name": "Isopentyl Pyrophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02509": {"dbids": ["DB02509", "EXPT01466"], "name": "Farnesol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02506": {"dbids": ["DB02506", "EXPT00428"], "name": "2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02507": {"dbids": ["DB02507", "EXPT02984"], "name": "4-Hydroxy-3-[(1s)-3-Oxo-1-Phenylbutyl]-2h-Chromen-2-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02504": {"dbids": ["DB02504", "EXPT00335"], "name": "[3-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Propyl-]-Phosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02505": {"dbids": ["DB02505", "EXPT01851"], "name": "N-(R-Carboxy-Ethyl)-Alpha-(S)-(2-Phenylethyl)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02502": {"dbids": ["DB02502", "EXPT00333"], "name": "8-Hydroxy-2'-Deoxyguanosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02503": {"dbids": ["DB02503", "EXPT01061"], "name": "4-(Carboxyvin-2-Yl)Phenylboronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02500": {"dbids": ["DB02500", "EXPT00866"], "name": "6-(Dihydroxy-Isobutyl)-Thymine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02501": {"dbids": ["DB02501", "EXPT02979"], "name": "N~2~-Succinylarginine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07437": {"dbids": ["DB07437"], "name": "1-((2-HYDROXYETHOXY)METHYL)-5-BENZYLPYRIMIDINE-2,4(1H,3H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07570": {"dbids": ["DB07570"], "name": "3-CYCLOHEXYL-1-(2-MORPHOLIN-4-YL-2-OXOETHYL)-2-PHENYL-1H-INDOLE-6-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03985": {"dbids": ["DB03985", "EXPT02759"], "name": "R-azabisabolene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03984": {"dbids": ["DB03984", "EXPT00813"], "name": "Morpholine-4-Carboxylic Acid [1-(2-Benzylsulfanyl-1-Formyl-Ethylcarbamoyl)-2-Phenyl-Ethyl]-Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07905": {"dbids": ["DB07905"], "name": "(1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07907": {"dbids": ["DB07907"], "name": "(2S)-2-HYDROXYOCTANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07906": {"dbids": ["DB07906"], "name": "[(3R)-7-NITRO-1,2,3,4-TETRAHYDROISOQUINOLIN-3-YL]METHANOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07901": {"dbids": ["DB07901"], "name": "5-CHLORO-6-METHYL-N-(2-PHENYLETHYL)-2-PYRIDIN-2-YLPYRIMIDIN-4-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07571": {"dbids": ["DB07571"], "name": "N~2~-[(BENZYLOXY)CARBONYL]-N-[(1S,2S)-2-HYDROXY-1-(4-HYDROXYBENZYL)PROPYL]-L-LEUCINAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07903": {"dbids": ["DB07903"], "name": "3-[(2,2-DIMETHYLPROPANOYL)AMINO]-N-1,3-THIAZOL-2-YLPYRIDINE-2-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07902": {"dbids": ["DB07902"], "name": "TERT-BUTYL {2-[(1,3-THIAZOL-2-YLAMINO)CARBONYL]PYRIDIN-3-YL}CARBAMATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07909": {"dbids": ["DB07909"], "name": "(1S,2S,5S)2-(4-GLUTARIDYLBENZYL)-5-PHENYL-1-CYCLOHEXANOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07908": {"dbids": ["DB07908"], "name": "7-HYDROXY-4-METHYL-3-(2-HYDROXY-ETHYL)COUMARIN", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03989": {"dbids": ["DB03989", "EXPT00500"], "name": "D-Allopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07928": {"dbids": ["DB07928"], "name": "N-(2-OXOTETRAHYDROFURAN-3-YL)OCTANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06204": {"dbids": ["DB06204"], "name": "Tapentadol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB06204"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB06204"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB06204"}]}, "DB06207": {"dbids": ["DB06207"], "name": "Silodosin", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35348", "drug": "DB06207"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB06207"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB06207"}]}, "DB06206": {"dbids": ["DB06206"], "name": "Sugammadex", "groups": ["APPROVED"], "targets": []}, "DB06201": {"dbids": ["DB06201"], "name": "Rufinamide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P41594", "drug": "DB06201"}, {"action": "MODULATOR", "target": "Q15858", "drug": "DB06201"}]}, "DB06203": {"dbids": ["DB06203"], "name": "Alogliptin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P27487", "drug": "DB06203"}]}, "DB07922": {"dbids": ["DB07922"], "name": "N-oxo-2-(phenylsulfonylamino)ethanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06750": {"dbids": ["DB06750"], "name": "Ginsenoside Rg1", "groups": ["NUTRACEUTICAL"], "targets": []}, "DB07573": {"dbids": ["DB07573"], "name": "(2S)-1-(2,5-dimethylphenoxy)-3-morpholin-4-ylpropan-2-ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01088": {"dbids": ["APRD01027", "DB01088"], "name": "Iloprost", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P43119", "drug": "DB01088"}, {"action": "AGONIST", "target": "P34995", "drug": "DB01088"}, {"action": "INDUCER", "target": "P27815", "drug": "DB01088"}, {"action": "INDUCER", "target": "Q07343", "drug": "DB01088"}, {"action": "INDUCER", "target": "Q08493", "drug": "DB01088"}, {"action": "INDUCER", "target": "Q08499", "drug": "DB01088"}, {"action": "OTHER/UNKNOWN", "target": "P00750", "drug": "DB01088"}]}, "DB01089": {"dbids": ["APRD00906", "DB01089"], "name": "Deserpidine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q05940", "drug": "DB01089"}]}, "DB01082": {"dbids": ["APRD00412", "DB01082"], "name": "Streptomycin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A7S3", "drug": "DB01082"}]}, "DB01083": {"dbids": ["APRD00255", "DB01083"], "name": "Orlistat", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P16233", "drug": "DB01083"}, {"action": "INHIBITOR", "target": "P07098", "drug": "DB01083"}, {"action": "INHIBITOR", "target": "P49327", "drug": "DB01083"}]}, "DB01080": {"dbids": ["APRD00282", "DB01080"], "name": "Vigabatrin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "Q9UBS5", "drug": "DB01080"}, {"action": "INHIBITOR", "target": "P80404", "drug": "DB01080"}]}, "DB01081": {"dbids": ["APRD00366", "DB01081"], "name": "Diphenoxylate", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB01081"}, {"action": "AGONIST", "target": "P41143", "drug": "DB01081"}]}, "DB01086": {"dbids": ["APRD00539", "DB01086"], "name": "Benzocaine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB01086"}]}, "DB01087": {"dbids": ["APRD00604", "DB01087"], "name": "Primaquine", "groups": ["APPROVED"], "targets": [{"action": "OTHER/UNKNOWN", "target": "P08729", "drug": "DB01087"}, {"action": "INHIBITOR", "target": "P16083", "drug": "DB01087"}]}, "DB01084": {"dbids": ["APRD00946", "DB01084"], "name": "Emedastine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB01084"}]}, "DB01085": {"dbids": ["APRD00382", "DB01085"], "name": "Pilocarpine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P20309", "drug": "DB01085"}, {"action": "AGONIST", "target": "P11229", "drug": "DB01085"}, {"action": "AGONIST", "target": "P08172", "drug": "DB01085"}]}, "DB07433": {"dbids": ["DB07433"], "name": "(TERT-BUTYLOXYCARBONYL)-ALANYL-AMINO ETHYL-FORMAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05041": {"dbids": ["DB05041"], "name": "RP101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07924": {"dbids": ["DB07924"], "name": "octyl beta-D-galactopyranoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07574": {"dbids": ["DB07574"], "name": "2-MERCAPTO-N-[1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDRO-BENZO[A]HEPTALEN-7-YL]ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04418": {"dbids": ["DB04418", "EXPT00146"], "name": "Adenylosuccinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01882": {"dbids": ["DB01882", "EXPT02085"], "name": "(2s)-2-Amino-4-(Methylsulfanyl)-1-Pyridin-2-Ylbutane-1,1-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01883": {"dbids": ["DB01883", "EXPT02874"], "name": "N-(Sulfanylacetyl)Tyrosylprolylmethioninamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01880": {"dbids": ["DB01880", "EXPT01188"], "name": "3,4-Dihydroxycinnamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01881": {"dbids": ["DB01881", "EXPT02229"], "name": "2-Methylpentane-1,2,4-Triol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01887": {"dbids": ["DB01887", "EXPT00659"], "name": "Inhibitor BEA369", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01884": {"dbids": ["DB01884", "EXPT00369"], "name": "2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01885": {"dbids": ["DB01885", "EXPT00035"], "name": "D-Galctopyranosyl-1-On", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01888": {"dbids": ["DB01888", "EXPT01046"], "name": "4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01889": {"dbids": ["DB01889", "EXPT00580"], "name": "16,17-Androstene-3-Ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07575": {"dbids": ["DB07575"], "name": "2,4-DIAMINO-1,5-DIPHENYL-3-HYDROXYPENTANE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01429": {"dbids": ["DB01429"], "name": "Aprindine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB01429"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB01429"}]}, "DB01396": {"dbids": ["DB01396"], "name": "Digitoxin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P05023", "drug": "DB01396"}]}, "DB01397": {"dbids": ["DB01397"], "name": "Magnesium salicylate", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB01397"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB01397"}]}, "DB01394": {"dbids": ["DB01394"], "name": "Colchicine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9H4B7", "drug": "DB01394"}, {"action": "INHIBITOR", "target": "P07437", "drug": "DB01394"}]}, "DB04147": {"dbids": ["DB04147", "EXPT02013"], "name": "Lauryl Dimethylamine-N-Oxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04140": {"dbids": ["DB04140", "EXPT00633"], "name": "1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01393": {"dbids": ["DB01393", "DB08380"], "name": "Bezafibrate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "Q07869", "drug": "DB01393"}, {"action": "AGONIST", "target": "Q03181", "drug": "DB01393"}, {"action": "AGONIST", "target": "P37231", "drug": "DB01393"}]}, "DB04618": {"dbids": ["DB04618"], "name": "4,6-DIDEOXY-4-{[4-[(4-O-HEXOPYRANOSYLHEXOPYRANOSYL)OXY]-5,6-DIHYDROXY-3-(HYDROXYMETHYL)CYCLOHEX-2-EN-1-YL]AMINO}HEXOPYRANOSYL-(1->4)HEXOPYRANOSYL-(1->4)HEXOPYRANOSE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01390": {"dbids": ["DB01390"], "name": "Sodium bicarbonate", "groups": ["APPROVED"], "targets": []}, "DB04348": {"dbids": ["DB04348", "EXPT03023"], "name": "Taurocholic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04349": {"dbids": ["DB04349", "EXPT02573"], "name": "S-1,2-Propanediol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04614": {"dbids": ["DB04614"], "name": "(R)-tacrine(10)-hupyridone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04615": {"dbids": ["DB04615"], "name": "(S)-tacrine(10)-hupyridone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04616": {"dbids": ["DB04616"], "name": "TACRINE(8)-4-AMINOQUINOLINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04143": {"dbids": ["DB04143", "EXPT01850"], "name": "Indole-3-Glycerol Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04610": {"dbids": ["DB04610"], "name": "7,8-dihydro-6-hydroxymethyl-7-methyl-7-[2-phenylethyl]-pterin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04343": {"dbids": ["DB04343", "EXPT01614"], "name": "Glyoxalate, Glyoxylate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04612": {"dbids": ["DB04612"], "name": "N-METHYLALANYL-3-METHYLVALYL-4-PHENOXY-N-(1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)PROLINAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04613": {"dbids": ["DB04613"], "name": "(E)-(4S,6S)-6-((S)-2-{(S)-2-[(FURAN-2-CARBONYL)-AMINO]-3-METHYL-BUTYRYLAMINO}-3-METHYL-BUTYRYLAMINO)-8-METHYL-5-OXO-4-((R)-2-OXO-PYRROLIDIN-3-YLMETHYL)-NON-2-ENOIC ACID ETHYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08108": {"dbids": ["DB08108"], "name": "N-({6-[(4-CYANOBENZYL)OXY]NAPHTHALEN-2-YL}SULFONYL)-D-GLUTAMIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08109": {"dbids": ["DB08109"], "name": "(1S,4R,7AR)-4-BUTOXY-1-[(1R)-1-FORMYLPROPYL]-2,4,5,6,7,7A-HEXAHYDRO-1H-ISOINDOLE-3-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08104": {"dbids": ["DB08104"], "name": "N-(3,5-dibromo-4-hydroxyphenyl)benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08105": {"dbids": ["DB08105"], "name": "N-[(6-BUTOXYNAPHTHALEN-2-YL)SULFONYL]-L-GLUTAMIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08106": {"dbids": ["DB08106"], "name": "N-[(6-BUTOXYNAPHTHALEN-2-YL)SULFONYL]-D-GLUTAMIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08107": {"dbids": ["DB08107"], "name": "N-{[6-(PENTYLOXY)NAPHTHALEN-2-YL]SULFONYL}-D-GLUTAMIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08100": {"dbids": ["DB08100"], "name": "2,6-dimethyl-4-[(E)-2-phenylethenyl]phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08101": {"dbids": ["DB08101"], "name": "2,6-dibromo-4-[(E)-2-phenylethenyl]phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08102": {"dbids": ["DB08102"], "name": "3,5-dibromobiphenyl-4-ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08103": {"dbids": ["DB08103"], "name": "2,6-dibromo-4-phenoxyphenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07459": {"dbids": ["DB07459"], "name": "4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06886": {"dbids": ["DB06886"], "name": "N-BENZYLOXYCARBONYL-ALA-PRO-3-AMINO-4-PHENYL-BUTAN-2-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07458": {"dbids": ["DB07458"], "name": "3-(1H-INDOL-3-YL)-4-{1-[2-(1-METHYLPYRROLIDIN-2-YL)ETHYL]-1H-INDOL-3-YL}-1H-PYRROLE-2,5-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08701": {"dbids": ["DB08701"], "name": "2-(3-BROMOPHENYL)-6-[(2-HYDROXYETHYL)AMINO]-1H-BENZO[DE]ISOQUINOLINE-1,3(2H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07457": {"dbids": ["DB07457"], "name": "3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07456": {"dbids": ["DB07456"], "name": "3-(1H-INDOL-3-YL)-4-(1-{2-[(2S)-1-METHYLPYRROLIDINYL]ETHYL}-1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00829": {"dbids": ["APRD00642", "DB00829", "DB07699"], "name": "Diazepam", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "Q9UN88", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P30536", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00829"}]}, "DB00828": {"dbids": ["APRD00987", "DB00828"], "name": "Fosfomycin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A749", "drug": "DB00828"}]}, "DB00823": {"dbids": ["APRD00760", "DB00823"], "name": "Ethynodiol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P06401", "drug": "DB00823"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00823"}]}, "DB00822": {"dbids": ["APRD00767", "DB00822"], "name": "Disulfiram", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P05091", "drug": "DB00822"}, {"action": "INHIBITOR", "target": "P09172", "drug": "DB00822"}]}, "DB00821": {"dbids": ["APRD00849", "DB00821"], "name": "Carprofen", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00821"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00821"}]}, "DB00820": {"dbids": ["APRD00071", "DB00820"], "name": "Tadalafil", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "O76074", "drug": "DB00820"}, {"action": "INHIBITOR", "target": "Q9HCR9", "drug": "DB00820"}]}, "DB00827": {"dbids": ["APRD00873", "DB00827"], "name": "Cinoxacin", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P43700", "drug": "DB00827"}]}, "DB00826": {"dbids": ["APRD01136", "DB00826"], "name": "Natamycin", "groups": ["APPROVED"], "targets": []}, "DB00825": {"dbids": ["APRD01604", "DB00825"], "name": "Menthol", "groups": ["APPROVED"], "targets": [{"action": "INDUCER", "target": "Q7Z2W7", "drug": "DB00825"}, {"action": "INDUCER", "target": "O75762", "drug": "DB00825"}, {"action": "INDUCER", "target": "Q8NET8", "drug": "DB00825"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00825"}]}, "DB00824": {"dbids": ["APRD00273", "DB00824"], "name": "Enprofylline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P27815", "drug": "DB00824"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB00824"}, {"action": "ANTAGONIST", "target": "P29275", "drug": "DB00824"}]}, "DB06616": {"dbids": ["DB06616"], "name": "Bosutinib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P11274", "drug": "DB06616"}, {"action": "INHIBITOR", "target": "P00519", "drug": "DB06616"}, {"action": "INHIBITOR", "target": "P08631", "drug": "DB06616"}, {"action": "INHIBITOR", "target": "P12931", "drug": "DB06616"}, {"action": "INHIBITOR", "target": "P24941", "drug": "DB06616"}, {"action": "INHIBITOR", "target": "Q02750", "drug": "DB06616"}, {"action": "INHIBITOR", "target": "P36507", "drug": "DB06616"}, {"action": "INHIBITOR", "target": "Q9Y2U5", "drug": "DB06616"}, {"action": "INHIBITOR", "target": "Q13555", "drug": "DB06616"}]}, "DB06614": {"dbids": ["DB06614"], "name": "Peramivir", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB06612": {"dbids": ["DB06612"], "name": "Mepolizumab", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P05113", "drug": "DB06612"}]}, "DB02753": {"dbids": ["DB02753", "EXPT02929"], "name": "Selenoinosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02752": {"dbids": ["DB02752", "EXPT03095"], "name": "Tosyl-D-Proline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02751": {"dbids": ["DB02751", "EXPT02364"], "name": "N-[Amino(Imino)Methyl]Glycine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02750": {"dbids": ["DB02750", "EXPT00956"], "name": "S-(Methylmercury)-L-Cysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02757": {"dbids": ["DB02757", "EXPT02727"], "name": "Pyrazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02756": {"dbids": ["DB02756", "EXPT02722"], "name": "1,2,5,6-Tetrahydro-4h-Pyrrolo(3,2,1-Ij)Quinolin-4-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02755": {"dbids": ["DB02755", "EXPT02479"], "name": "1-3 Sugar Ring of Pentamannosyl 6-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02970": {"dbids": ["DB02970", "EXPT02667"], "name": "2-Propyl-Aniline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02759": {"dbids": ["DB02759", "EXPT01671"], "name": "4-Methylumbelliferyl Chitobiose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02758": {"dbids": ["DB02758", "EXPT01908"], "name": "Indolylpropionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02979": {"dbids": ["DB02979", "EXPT02394"], "name": "N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02978": {"dbids": ["DB02978", "EXPT01755"], "name": "Beta-Hydroxyleucine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07453": {"dbids": ["DB07453"], "name": "2-PHENYL-4H-BENZO[H]CHROMEN-4-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08128": {"dbids": ["DB08128"], "name": "(1S,4R,9S)-5-(trifluoromethyl)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-9-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07452": {"dbids": ["DB07452"], "name": "2,6-diamino-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08129": {"dbids": ["DB08129"], "name": "(1R)-2-amino-1-[3-(trifluoromethyl)phenyl]ethanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07451": {"dbids": ["DB07451"], "name": "1-(5-BROMO-PYRIDIN-2-YL)-3-[2-(6-FLUORO-2-HYDROXY-3-PROPIONYL-PHENYL)-CYCLOPROPYL]-UREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07450": {"dbids": ["DB07450"], "name": "2[4-BROMO-2-FLUOROPHENYL)METHYL]-6-FLUOROSPIRO[ISOQUINOLINE-4-(1H),3'-PYRROLIDINE]-1,2',3,5'(2H)-TETRONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01644": {"dbids": ["DB01644", "EXPT01800"], "name": "3,6-Dihydroxy-Xanthene-9-Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05198": {"dbids": ["DB05198"], "name": "CYC116", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05199": {"dbids": ["DB05199"], "name": "LX1031", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08928": {"dbids": ["DB08928"], "name": "Arsthinol", "groups": ["APPROVED"], "targets": []}, "DB08929": {"dbids": ["DB08929"], "name": "MK-8931", "groups": ["INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P56817", "drug": "DB08929"}]}, "DB05194": {"dbids": ["DB05194"], "name": "KB002", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05195": {"dbids": ["DB05195"], "name": "ADC4022", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05196": {"dbids": ["DB05196"], "name": "ACR325", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05197": {"dbids": ["DB05197"], "name": "Sofalcone", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05190": {"dbids": ["DB05190"], "name": "XL281", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05191": {"dbids": ["DB05191"], "name": "Atl146e", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05192": {"dbids": ["DB05192"], "name": "MB07811", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05193": {"dbids": ["DB05193"], "name": "R7128", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07615": {"dbids": ["DB07615"], "name": "Tranilast", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB07614": {"dbids": ["DB07614"], "name": "PHENYL-5-(1H-PYRAZOL-3-YL)-1,3-THIAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB11064": {"dbids": ["DB11064"], "name": "Homosalate", "groups": ["APPROVED"], "targets": []}, "DB11062": {"dbids": ["DB11062"], "name": "Octisalate", "groups": ["APPROVED"], "targets": []}, "DB07617": {"dbids": ["DB07617"], "name": "N-METHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01473": {"dbids": ["DB01473"], "name": "Betaprodine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01472": {"dbids": ["DB01472", "EXPT03303"], "name": "4-Methoxyamphetamine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": [{"action": "INHIBITOR", "target": "Q01959", "drug": "DB01472"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB01472"}, {"action": "INHIBITOR", "target": "Q05940", "drug": "DB01472"}, {"action": "AGONIST", "target": "P35348", "drug": "DB01472"}, {"action": "AGONIST", "target": "P08913", "drug": "DB01472"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB01472"}, {"action": "INHIBITOR", "target": "P27338", "drug": "DB01472"}]}, "DB04111": {"dbids": ["DB04111", "EXPT00727"], "name": "Balhimycin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04110": {"dbids": ["DB04110", "EXPT02314"], "name": "2-Nitro-P-Cresol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01477": {"dbids": ["DB01477"], "name": "Codeine methylbromide", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01476": {"dbids": ["DB01476"], "name": "Haloxazolam", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB04115": {"dbids": ["DB04115", "EXPT00672"], "name": "Berberine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04114": {"dbids": ["DB04114", "EXPT01796"], "name": "3-Chloro-9-Ethyl-6,7,8,9,10,11-Hexahydro-7,11-Methanocycloocta[B]Quinolin-12-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09190": {"dbids": ["DB09190"], "name": "Talopram", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09191": {"dbids": ["DB09191"], "name": "Talsupram", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04119": {"dbids": ["DB04119", "EXPT03019"], "name": "Hexatantalum Dodecabromide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04118": {"dbids": ["DB04118", "EXPT01087"], "name": "N-Coeleneterazine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09194": {"dbids": ["DB09194"], "name": "Etoperidone", "groups": ["APPROVED"], "targets": []}, "DB09195": {"dbids": ["DB09195"], "name": "Lorpiprazole", "groups": ["APPROVED"], "targets": []}, "DB09196": {"dbids": ["DB09196"], "name": "Lubazodone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09197": {"dbids": ["DB09197"], "name": "Mepiprazole", "groups": ["APPROVED"], "targets": []}, "DB07130": {"dbids": ["DB07130"], "name": "4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07131": {"dbids": ["DB07131"], "name": "(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07132": {"dbids": ["DB07132"], "name": "1-{2-OXO-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-5-YL}UREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07133": {"dbids": ["DB07133"], "name": "D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07134": {"dbids": ["DB07134"], "name": "5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07135": {"dbids": ["DB07135"], "name": "(2S,3S)-3-AMINO-4-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-5-YLCYCLOHEXYL)BUTANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07136": {"dbids": ["DB07136"], "name": "(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-{(R)-HYDROXY[(1R)-2-METHYL-1-{[(3-PHENYLPROPYL)SULFONYL]AMINO}PROPYL]PHOSPHORYL}PROPANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07137": {"dbids": ["DB07137"], "name": "(2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07138": {"dbids": ["DB07138"], "name": "5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)sulfanyl]-6H-pyrimido[1,6-b]pyridazin-6-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07139": {"dbids": ["DB07139"], "name": "3-[5-(3-nitrophenyl)thiophen-2-yl]propanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07616": {"dbids": ["DB07616"], "name": "4-{[4-(4-fluoro-3-methylphenyl)-1,3-thiazol-2-yl]amino}-2-hydroxybenzoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03839": {"dbids": ["DB03839", "EXPT01295"], "name": "D-Tyrosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03835": {"dbids": ["DB03835", "EXPT01602"], "name": "N-(8,9,10-Trihydroxy-7-Hydroxymethyl-2,4-Dioxo-6-Oxa-1,3-Diaza-Spiro[4.5]Dec-3-Yl-Acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03834": {"dbids": ["DB03834", "EXPT03014"], "name": "Tazobactam Intermediate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03837": {"dbids": ["DB03837", "EXPT00801"], "name": "Morpholine-4-Carboxylic Acid (1-(3-Benzenesulfonyl-1-Phenethylallylcarbamoyl)-3-Methylbutyl)-Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03836": {"dbids": ["DB03836", "EXPT03027"], "name": "1,3,5-Trichloro-Benzene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03831": {"dbids": ["DB03831", "EXPT02220"], "name": "1-Monooleoyl-Rac-Glycerol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03830": {"dbids": ["DB03830", "EXPT02528"], "name": "Phosphorylated Dihydropteroate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03833": {"dbids": ["DB03833", "EXPT02680"], "name": "2-Prolyl-5-Tert-Butyl-[1,3,4]Oxadiazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03832": {"dbids": ["DB03832", "EXPT02414"], "name": "3-Carboxy-N,N,N-Trimethyl-2-(Octanoyloxy)Propan-1-Aminium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01699": {"dbids": ["DB01699", "EXPT01579"], "name": "(4e)-4-Aminohex-4-Enoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01698": {"dbids": ["DB01698", "EXPT02824"], "name": "Rutin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01697": {"dbids": ["DB01697", "EXPT01054"], "name": "Cellotriose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01696": {"dbids": ["DB01696", "EXPT03202"], "name": "7,9-Dihydro-1h-Purine-2,6,8(3h)-Trione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01695": {"dbids": ["DB01695", "EXPT00226"], "name": "N-Hydroxy-4-Phosphono-Butanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01694": {"dbids": ["DB01694", "EXPT03007"], "name": "D-tartaric acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01693": {"dbids": ["DB01693", "EXPT02825"], "name": "Ribavirin Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01692": {"dbids": ["DB01692", "EXPT01292"], "name": "Dithioerythritol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01691": {"dbids": ["DB01691", "EXPT01841"], "name": "Indole Naphthyridinone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01690": {"dbids": ["DB01690", "EXPT00618"], "name": "Bis(Adenosine)-5'-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09301": {"dbids": ["DB09301"], "name": "Chondroitin sulfate", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00128": {"dbids": ["DB00128", "EXPT01823", "NUTR00016"], "name": "L-Aspartic Acid", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00129": {"dbids": ["DB00129", "NUTR00043"], "name": "L-Ornithine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00126": {"dbids": ["APRD00084", "DB00126", "EXPT00568", "NUTR00001"], "name": "Vitamin C", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "ACTIVATOR", "target": "Q02809", "drug": "DB00126"}]}, "DB00127": {"dbids": ["DB00127", "DB02564", "EXPT02947", "NUTR00055"], "name": "Spermine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "LIGAND", "target": "P52788", "drug": "DB00127"}, {"action": "LIGAND", "target": "Q9NWM0", "drug": "DB00127"}, {"action": "PRODUCT OF", "target": "P11926", "drug": "DB00127"}]}, "DB00125": {"dbids": ["DB00125", "NUTR00014"], "name": "L-Arginine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00122": {"dbids": ["DB00122", "NUTR00020"], "name": "Choline", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "PRODUCT OF", "target": "Q9Y5K3", "drug": "DB00122"}, {"action": "PRODUCT OF", "target": "P22303", "drug": "DB00122"}, {"action": "PRODUCT OF", "target": "P49585", "drug": "DB00122"}, {"action": "PRODUCT OF", "target": "O14939", "drug": "DB00122"}, {"action": "PRODUCT OF", "target": "P06276", "drug": "DB00122"}, {"action": "PRODUCT OF", "target": "Q13393", "drug": "DB00122"}, {"action": "PRODUCT OF", "target": "Q8TCT1", "drug": "DB00122"}]}, "DB00123": {"dbids": ["DB00123", "NUTR00037"], "name": "L-Lysine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00120": {"dbids": ["DB00120", "NUTR00044"], "name": "L-Phenylalanine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "BINDER", "target": "P07101", "drug": "DB00120"}]}, "DB00121": {"dbids": ["DB00121", "NUTR00019"], "name": "Biotin", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB06733": {"dbids": ["DB06733"], "name": "Bafilomycin A1", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P38606", "drug": "DB06733"}]}, "DB09302": {"dbids": ["DB09302"], "name": "Alirocumab", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q8NBP7", "drug": "DB09302"}]}, "DB09305": {"dbids": ["DB09305"], "name": "Aptazapine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09304": {"dbids": ["DB09304"], "name": "Setiptiline", "groups": ["APPROVED"], "targets": []}, "DB03505": {"dbids": ["DB03505", "EXPT01267"], "name": "2,6-Diaminoquinazolin-4(3h)-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07613": {"dbids": ["DB07613"], "name": "3-phenyl-5-(1H-pyrazol-3-yl)isoxazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09307": {"dbids": ["DB09307"], "name": "Oxaprotiline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03504": {"dbids": ["DB03504", "EXPT02698"], "name": "9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09306": {"dbids": ["DB09306"], "name": "Metralindole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02429": {"dbids": ["DB02429", "EXPT01895"], "name": "4-(Aminosulfonyl)-N-[(4-Fluorophenyl)Methyl]-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03506": {"dbids": ["DB03506", "EXPT00355"], "name": "9-Deazaadenine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09308": {"dbids": ["DB09308"], "name": "Solithromycin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03501": {"dbids": ["DB03501", "EXPT01576"], "name": "Uridine Diphosphate Galactose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03052": {"dbids": ["DB03052", "EXPT03297"], "name": "Dazoxiben", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P24557", "drug": "DB03052"}]}, "DB07612": {"dbids": ["DB07612"], "name": "6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03503": {"dbids": ["DB03503", "EXPT01521"], "name": "4-Acetyl-4-Guanidino-6-Methyl(Propyl)Carboxamide-4,5-Dihydro-2h-Pyran-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03349": {"dbids": ["DB03349", "EXPT00332"], "name": "8-Bromo-Adenosine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03348": {"dbids": ["DB03348", "EXPT01794"], "name": "Huperzine B", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03347": {"dbids": ["DB03347", "EXPT03038"], "name": "Triethyl Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03346": {"dbids": ["DB03346", "EXPT02524"], "name": "3,5,3',5'-Tetrachloro-Biphenyl-4,4'-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03345": {"dbids": ["DB03131", "DB03345", "EXPT02882"], "name": "Beta-Mercaptoethanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03344": {"dbids": ["DB03344", "EXPT01818"], "name": "Inositol-(1,3,4,5,6)-Pentakisphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03343": {"dbids": ["DB03343", "EXPT03039"], "name": "Malate Like Intermediate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03342": {"dbids": ["DB03342", "EXPT02961"], "name": "4-(Acetylamino)-3-Guanidinobenzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03341": {"dbids": ["DB03341", "EXPT00819"], "name": "Coa-S-Acetyl 5-Bromotryptamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03340": {"dbids": ["DB03340", "EXPT00448"], "name": "3-[(1-Amino-2-Carboxy-Ethyl)-Hydroxy-Phosphinoyl]-2-Methyl-Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04801": {"dbids": ["DB04801"], "name": "(11E)-OCTADEC-11-ENOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04800": {"dbids": ["DB04800"], "name": "1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04803": {"dbids": ["DB04803"], "name": "Verdoheme", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04802": {"dbids": ["DB04802"], "name": "D-ERITHRO-2,3-DIAMINO-BUTYRIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04805": {"dbids": ["DB04805"], "name": "Virginiamycin factor S1", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04804": {"dbids": ["DB04804"], "name": "L-threo-2,3-diamino-butyric acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04807": {"dbids": ["DB04807"], "name": "4-NITROPHENYL-(6-S-ALPHA-D-XYLOPYRANOSYL)-BETA-D-GLUCOPYRANOSIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04806": {"dbids": ["DB04806"], "name": "(5-BROMO-4-CHLORO-3-INDOLYL)-A-D-MANNOSE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04809": {"dbids": ["DB04809"], "name": "SALOPHEN-10-PROPIONATE IRON CHELATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04808": {"dbids": ["DB04808"], "name": "Neamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08310": {"dbids": ["DB08310"], "name": "N-[(2R)-2-{[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl}hexyl]-N-hydroxyformamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08313": {"dbids": ["DB08313"], "name": "nocodazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08312": {"dbids": ["DB08312"], "name": "6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08315": {"dbids": ["DB08315"], "name": "2-AMINO-N,N-BIS(PHENYLMETHYL)-1,3-OXAZOLE-5-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08314": {"dbids": ["DB08314"], "name": "(2-AMINO-1,3-OXAZOL-5-YL)-(3-BROMOPHENYL)METHANONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08317": {"dbids": ["DB08317"], "name": "5-methyl-6-phenylquinazoline-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08316": {"dbids": ["DB08316"], "name": "4-amino-7,7-dimethyl-7,8-dihydroquinazolin-5(6H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08319": {"dbids": ["DB08319"], "name": "2'-HYDROXY-1,1'-BIPHENYL-2-SULFINIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08318": {"dbids": ["DB08318"], "name": "6-(2-phenoxyethoxy)-1,3,5-triazine-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05305": {"dbids": ["DB05305"], "name": "Cintredekin Besudotox", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03699": {"dbids": ["DB03699", "EXPT02863"], "name": "Succinyl-Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03698": {"dbids": ["DB03698", "EXPT02142"], "name": "5-Mercaptoethanol-2-Decenoyl-Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03169": {"dbids": ["DB03169", "EXPT01758"], "name": "(S)-Hmg-Coa", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03168": {"dbids": ["DB03168", "EXPT02318"], "name": "Nicotinamide Adenine Dinucleotide Cyclohexanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03691": {"dbids": ["DB03691", "EXPT02790"], "name": "WRR-112", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03690": {"dbids": ["DB03690", "EXPT02526"], "name": "(Z,Z)-4-Hydroxy-N,N,N-Trimethyl-10-Oxo-7-[(1-Oxo-9-Octadecenyl)Oxy]-3,5,9-Trioxa-4-Phosphaheptacos-18-En-1-Aminium-4-Oxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03161": {"dbids": ["DB03161", "EXPT03034"], "name": "Thymidine-5'-Diphospho-Beta-D-Xylose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03160": {"dbids": ["DB03160", "EXPT01960"], "name": "N-Pyridoxyl-7-Keto-8-Aminopelargonic Acid-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03695": {"dbids": ["DB03695", "EXPT02259"], "name": "6-(2,5-Dimethoxy-Benzyl)-5-Methyl-Pyrido[2,3-D]Pyrimidine-2,4-Diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03694": {"dbids": ["DB03694", "EXPT03208"], "name": "N-Phenylthiourea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03697": {"dbids": ["DB03697", "EXPT02838"], "name": "4-Sulfonamide-[1-(4-Aminobutane)]Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03164": {"dbids": ["DB03164", "EXPT02082"], "name": "6-Amino-1-Methylpurine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06757": {"dbids": ["DB06757"], "name": "Manganese", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB07493": {"dbids": ["DB07493"], "name": "(2Z)-5'-BROMO-2,3'-BIINDOLE-2',3(1H,1'H)-DIONE AMMONIATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07492": {"dbids": ["DB07492"], "name": "BROMAMPHENICOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07491": {"dbids": ["DB07491"], "name": "5-amino-2,4,6-tribromobenzene-1,3-dicarboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07490": {"dbids": ["DB07490"], "name": "2-[1-(4-CHLORO-PHENYL)-ETHYL]-4,6-DINITRO-PHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07497": {"dbids": ["DB07497"], "name": "5-(HEXAHYDRO-2-OXO-1H-THIENO[3,4-D]IMIDAZOL-6-YL)PENTANAL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06756": {"dbids": ["DB06756"], "name": "Glycine betaine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB07496": {"dbids": ["DB07496"], "name": "1,3-DIPHENYLUREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01420": {"dbids": ["DB01420"], "name": "Testosterone Propionate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P10275", "drug": "DB01420"}]}, "DB07495": {"dbids": ["DB07495"], "name": "5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07494": {"dbids": ["DB07494"], "name": "(3-EXO)-3-(10,11-DIHYDRO-5H-DIBENZO[A,D][7]ANNULEN-5-YLOXY)-8,8-DIMETHYL-8-AZONIABICYCLO[3.2.1]OCTANE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02568": {"dbids": ["DB02568", "DB07442", "EXPT03305"], "name": "Peldesine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02569": {"dbids": ["DB02569", "EXPT01096"], "name": "2',3'-Dehydro-2',3'-Deoxy-Thymidine 5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03860": {"dbids": ["DB03860", "EXPT00529"], "name": "N-Butyl-11-[(7r,8r,9s,13s,14s,17s)-3,17-Dihydroxy-13-Methyl-7,8,9,11,12,13,14,15,16,17-Decahydro-6h-Cyclopenta[a]Phenanthren-7-Yl]-N-Methylundecanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02560": {"dbids": ["DB02560", "EXPT00938"], "name": "D-Para-Chlorophenyl-1-Acteamidoboronic Acid Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02561": {"dbids": ["DB02561", "EXPT00649"], "name": "Beta-D-Fructopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02562": {"dbids": ["DB02562", "EXPT01676"], "name": "Quinonoid 7,8-Tetrahydrobiopterin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02563": {"dbids": ["DB02563", "EXPT01799"], "name": "Hexanoyl-Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09204": {"dbids": ["DB09204"], "name": "Arotinolol", "groups": ["APPROVED"], "targets": []}, "DB02565": {"dbids": ["DB02565", "EXPT00611"], "name": "4-Dimethylamino-N-(6-Hydroxycarbamoyethyl)Benzamide-N-Hydroxy-7-(4-Dimethyla Minobenzoyl)Aminoheptanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02566": {"dbids": ["DB02566", "EXPT02731"], "name": "8-Hydroxy-4-(1-Hydroxyethyl)Quinoline-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02567": {"dbids": ["DB02567", "EXPT02468"], "name": "PD173955", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05692": {"dbids": ["DB05692"], "name": "SCH-530348", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05694": {"dbids": ["DB05694"], "name": "NBI-56418", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB09166": {"dbids": ["DB09166"], "name": "Etizolam", "groups": ["APPROVED"], "targets": []}, "DB11294": {"dbids": ["DB11294"], "name": "Coccidioides immitis spherule", "groups": ["APPROVED"], "targets": []}, "DB05275": {"dbids": ["DB05275"], "name": "transdermal testosterone gel", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB09048": {"dbids": ["DB09048"], "name": "Netupitant", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P25103", "drug": "DB09048"}]}, "DB07549": {"dbids": ["DB07549"], "name": "2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-3-METHYL-6-PYRIDINYL)METHYL]ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07548": {"dbids": ["DB07548"], "name": "2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-6-PYRIDINYL)METHYL]ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06751": {"dbids": ["DB06751"], "name": "Drotaverine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P27815", "drug": "DB06751"}, {"action": "INHIBITOR", "target": "Q13936", "drug": "DB06751"}]}, "DB05276": {"dbids": ["DB05276"], "name": "Hepatitis B immune globulin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB05903": {"dbids": ["DB05903"], "name": "KOS-1584", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07545": {"dbids": ["DB07545"], "name": "N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05273": {"dbids": ["DB05273"], "name": "Samarium (153sm) lexidronam", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB07544": {"dbids": ["DB07544"], "name": "N'-(5-CHLOROBENZOFURAN-2-CARBONYL)-2-(TRIFLUOROMETHYL)BENZENESULFONOHYDRAZIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07547": {"dbids": ["DB07547"], "name": "5-(4-CYANOPHENYL)-3-{[(2-METHYLPHENYL)SULFONYL]AMINO}THIOPHENE-2-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05037": {"dbids": ["DB05037"], "name": "AT7519", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05036": {"dbids": ["DB05036"], "name": "Grn163l", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05035": {"dbids": ["DB05035"], "name": "KB2115", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05034": {"dbids": ["DB05034"], "name": "Ularitide", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05033": {"dbids": ["DB05033"], "name": "INCB7839", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05032": {"dbids": ["DB05032"], "name": "REV131", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05031": {"dbids": ["DB05031"], "name": "XP19986", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05030": {"dbids": ["DB05030"], "name": "XL880", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07541": {"dbids": ["DB07541"], "name": "4-(dihydroxyboranyl)-2-({[4-(phenylsulfonyl)thiophen-2-yl]sulfonyl}amino)benzoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05039": {"dbids": ["DB05039"], "name": "Indacaterol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P07550", "drug": "DB05039"}]}, "DB05038": {"dbids": ["DB05038"], "name": "Anatibant", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07543": {"dbids": ["DB07543"], "name": "(2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07542": {"dbids": ["DB07542"], "name": "5-AMINO-6-CYCLOHEXYL-4-HYDROXY-2-ISOBUTYL-HEXANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07517": {"dbids": ["DB07517"], "name": "3-CARBOXY-4-METHYL-5-PROPYL-2-FURANPROPIONIC", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06867": {"dbids": ["DB06867"], "name": "3,6,9,12,15,18-HEXAOXAICOSANE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07724": {"dbids": ["DB07724"], "name": "3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06148": {"dbids": ["DB06148"], "name": "Mianserin", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08913", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB06148"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB06148"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB06148"}, {"action": "BINDER", "target": "Q9H3N8", "drug": "DB06148"}, {"action": "BLOCKER", "target": "P08908", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB06148"}, {"action": "BINDER", "target": "P41595", "drug": "DB06148"}, {"action": "BINDER", "target": "P30939", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB06148"}, {"action": "BINDER", "target": "P35462", "drug": "DB06148"}, {"action": "AGONIST", "target": "P41145", "drug": "DB06148"}, {"action": "BINDER", "target": "Q01959", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB06148"}, {"action": "BINDER", "target": "P50406", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB06148"}, {"action": "BINDER", "target": "P21728", "drug": "DB06148"}, {"action": "BINDER", "target": "P21918", "drug": "DB06148"}]}, "DB06149": {"dbids": ["DB06149"], "name": "Teicoplanin", "groups": ["APPROVED"], "targets": []}, "DB01868": {"dbids": ["DB01868", "EXPT02767"], "name": "Glycyl-L-a-Aminopimelyl-E-(D-2-Aminoethyl)Phosphonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01864": {"dbids": ["DB01864", "EXPT01651"], "name": "5'-Guanosine-Diphosphate-Monothiophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01865": {"dbids": ["DB01865", "EXPT00597"], "name": "3-(6-Aminopyridin-3-Yl)-N-Methyl-N-[(1-Methyl-1h-Indol-2-Yl)Methyl]Acrylamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01866": {"dbids": ["DB01866", "EXPT00095"], "name": "RU79256", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01860": {"dbids": ["DB01860", "EXPT00163"], "name": "Cordycepin Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01861": {"dbids": ["DB01861", "EXPT01669"], "name": "Glucose-Uridine-C1,5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01862": {"dbids": ["DB01862", "EXPT01924"], "name": "1-(Isopropylthio)-Beta-Galactopyranside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01863": {"dbids": ["DB01863", "DB03265", "EXPT01943"], "name": "Inositol 1,3,4,5-Tetrakisphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07723": {"dbids": ["DB07723"], "name": "3-(5-methoxy-1H-indol-3-yl)propanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07722": {"dbids": ["DB07722"], "name": "3-(4-NITRO-PHENOXY)-PROPAN-1-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06636": {"dbids": ["DB06636"], "name": "Isavuconazonium", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB04636": {"dbids": ["DB04636"], "name": "Glutamine t-butyl ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04637": {"dbids": ["DB04637"], "name": "6-Bromo-1-hexanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04634": {"dbids": ["DB04634"], "name": "N-BENZYLOXYCARBONYL-L-SERINE-BETALACTONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06637": {"dbids": ["DB06637"], "name": "Dalfampridine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q09470", "drug": "DB06637"}, {"action": "ANTAGONIST", "target": "P16389", "drug": "DB06637"}, {"action": "ANTAGONIST", "target": "P22001", "drug": "DB06637"}, {"action": "ANTAGONIST", "target": "P22459", "drug": "DB06637"}, {"action": "ANTAGONIST", "target": "P22460", "drug": "DB06637"}, {"action": "ANTAGONIST", "target": "P17658", "drug": "DB06637"}, {"action": "ANTAGONIST", "target": "Q96RP8", "drug": "DB06637"}, {"action": "ANTAGONIST", "target": "Q16322", "drug": "DB06637"}, {"action": "ANTAGONIST", "target": "Q14721", "drug": "DB06637"}, {"action": "ANTAGONIST", "target": "Q92953", "drug": "DB06637"}, {"action": "ANTAGONIST", "target": "P48547", "drug": "DB06637"}, {"action": "ANTAGONIST", "target": "Q96PR1", "drug": "DB06637"}, {"action": "ANTAGONIST", "target": "Q14003", "drug": "DB06637"}, {"action": "ANTAGONIST", "target": "Q9NSA2", "drug": "DB06637"}, {"action": "ANTAGONIST", "target": "Q9NZV8", "drug": "DB06637"}, {"action": "ANTAGONIST", "target": "Q9UK17", "drug": "DB06637"}]}, "DB04632": {"dbids": ["DB04632"], "name": "4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04633": {"dbids": ["DB04633"], "name": "N-ethyl-N-[3-(propylamino)propyl]propane-1,3-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04630": {"dbids": ["DB04630"], "name": "Aldosterone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04631": {"dbids": ["DB04631"], "name": "Atpenin A5", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04638": {"dbids": ["DB04638"], "name": "2,5-DI-(TERT-BUTYL)-1,4,BENZOHYDROQUINONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04639": {"dbids": ["DB04639"], "name": "Biphenylalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04328": {"dbids": ["DB04328", "EXPT02832"], "name": "Shikimate-3-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04329": {"dbids": ["DB04329", "EXPT01938"], "name": "Isoquinoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08124": {"dbids": ["DB08124"], "name": "3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08125": {"dbids": ["DB08125"], "name": "4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08122": {"dbids": ["DB08122"], "name": "N-METHYL-4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06144": {"dbids": ["DB06144"], "name": "Sertindole", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB06144"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB06144"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB06144"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB06144"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB06144"}]}, "DB08120": {"dbids": ["DB08120"], "name": "6,8-DIMERCAPTO-OCTANOIC ACID AMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08121": {"dbids": ["DB08121"], "name": "(2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04320": {"dbids": ["DB04320", "EXPT00755"], "name": "2-Bromo-2-Propene-1-Ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04321": {"dbids": ["DB04321", "EXPT01724"], "name": "N-Hexylphosphonate Ethyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04322": {"dbids": ["DB04322", "EXPT01990"], "name": "LY249543", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04323": {"dbids": ["DB04323", "EXPT00242"], "name": "2-Amino-3-(Cystein-S-Yl)-Isoxazolidin-5-Yl-Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04324": {"dbids": ["DB04324", "EXPT02454"], "name": "Ovalicin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04325": {"dbids": ["DB04325", "EXPT02542"], "name": "2-Phenylethylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04326": {"dbids": ["DB04326", "EXPT00026"], "name": "1,3-Dihydroxyacetonephosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04327": {"dbids": ["DB04327", "EXPT02690"], "name": "Phosphatidylethanolamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07513": {"dbids": ["DB07513"], "name": "7-[(3-CHLOROBENZYL)OXY]-4-[(METHYLAMINO)METHYL]-2H-CHROMEN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01529": {"dbids": ["DB01529"], "name": "Dextromoramide", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB04008": {"dbids": ["DB04008", "EXPT00628"], "name": "Bis(5-Amidino-Benzimidazolyl)Methane Zinc", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07510": {"dbids": ["DB07510"], "name": "3-fluoro-6-(4-fluorophenyl)-2-hydroxy-6-oxohexa-2,4-dienoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08669": {"dbids": ["DB08669"], "name": "METHYL N-[(2S,3R)-3-AMINO-2-HYDROXY-3-(4-METHYLPHENYL)PROPANOYL]-D-ALANYL-D-LEUCINATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01521": {"dbids": ["DB01521"], "name": "Clostebol", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB07511": {"dbids": ["DB07511"], "name": "4-(4-methyl-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)benzonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01520": {"dbids": ["DB01520"], "name": "Tenocyclidine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": [{"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB01520"}, {"action": "ANTAGONIST", "target": "O60391", "drug": "DB01520"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB01520"}, {"action": "ANTAGONIST", "target": "Q14957", "drug": "DB01520"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB01520"}, {"action": "ANTAGONIST", "target": "O15399", "drug": "DB01520"}, {"action": "ANTAGONIST", "target": "Q693P7", "drug": "DB01520"}]}, "DB01523": {"dbids": ["DB01523"], "name": "Clonitazene", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01522": {"dbids": ["DB01522"], "name": "Betacetylmethadol", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01525": {"dbids": ["DB01525"], "name": "Ecgonine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01524": {"dbids": ["DB01524"], "name": "5-Androstenediol", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB00805": {"dbids": ["APRD00735", "DB00805"], "name": "Minaprine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P21397", "drug": "DB00805"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB00805"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00805"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00805"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB00805"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00805"}, {"action": "AGONIST", "target": "P21728", "drug": "DB00805"}, {"action": "AGONIST", "target": "P14416", "drug": "DB00805"}, {"action": "AGONIST", "target": "P11229", "drug": "DB00805"}]}, "DB00804": {"dbids": ["APRD00113", "DB00804"], "name": "Dicyclomine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00804"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00804"}]}, "DB00807": {"dbids": ["APRD00522", "DB00807"], "name": "Proparacaine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00807"}]}, "DB00806": {"dbids": ["APRD00121", "DB00806"], "name": "Pentoxifylline", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q07343", "drug": "DB00806"}, {"action": "ANTAGONIST", "target": "P30542", "drug": "DB00806"}, {"action": "INHIBITOR", "target": "O76074", "drug": "DB00806"}, {"action": "INHIBITOR", "target": "P27815", "drug": "DB00806"}, {"action": "ANTAGONIST", "target": "P29274", "drug": "DB00806"}, {"action": "INHIBITOR", "target": "P21589", "drug": "DB00806"}]}, "DB00801": {"dbids": ["APRD01009", "DB00801"], "name": "Halazepam", "groups": ["APPROVED", "ILLICIT", "WITHDRAWN"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00801"}]}, "DB04007": {"dbids": ["DB04007", "EXPT03244"], "name": "Bromo-WR99210", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00803": {"dbids": ["APRD00886", "DB00803"], "name": "Colistin", "groups": ["APPROVED"], "targets": []}, "DB00802": {"dbids": ["APRD00726", "DB00802"], "name": "Alfentanil", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB00802"}]}, "DB04006": {"dbids": ["DB04006", "EXPT02612"], "name": "[2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00809": {"dbids": ["APRD00287", "DB00809"], "name": "Tropicamide", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08173", "drug": "DB00809"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00809"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00809"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00809"}]}, "DB00808": {"dbids": ["APRD01031", "DB00808"], "name": "Indapamide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P51787", "drug": "DB00808"}, {"action": "INHIBITOR", "target": "P15382", "drug": "DB00808"}]}, "DB07679": {"dbids": ["DB07679"], "name": "(9S,12S)-9-(1-methylethyl)-7,10-dioxo-2-oxa-8,11-diazabicyclo[12.2.2]octadeca-1(16),14,17-triene-12-carboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07678": {"dbids": ["DB07678"], "name": "(9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06674": {"dbids": ["DB06674"], "name": "golimumab", "groups": ["APPROVED"], "targets": [{"action": "ANTIBODY", "target": "P01375", "drug": "DB06674"}]}, "DB06678": {"dbids": ["DB06678"], "name": "Esmirtazapine", "groups": ["INVESTIGATIONAL"], "targets": [{"action": "INVERSE AGONIST", "target": "P35367", "drug": "DB06678"}, {"action": "INVERSE AGONIST", "target": "P28223", "drug": "DB06678"}, {"action": "INVERSE AGONIST", "target": "P41595", "drug": "DB06678"}, {"action": "INVERSE AGONIST", "target": "P28335", "drug": "DB06678"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB06678"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB06678"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB06678"}]}, "DB02951": {"dbids": ["DB02951", "EXPT00190"], "name": "3-Hydroxypyruvic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02950": {"dbids": ["DB02950", "EXPT01757"], "name": "Hymenialdisine", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "Q00535", "drug": "DB02950"}, {"action": "INHIBITOR", "target": "P24941", "drug": "DB02950"}]}, "DB02953": {"dbids": ["DB02953", "EXPT00769"], "name": "2-Thiomethyl-3-Phenylpropanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02952": {"dbids": ["DB02952", "EXPT00471"], "name": "Alpha-Aminoisobutyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02955": {"dbids": ["DB02955", "EXPT02762"], "name": "Ricinoleic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02954": {"dbids": ["DB02954", "EXPT01687"], "name": "(Carboxyhydroxyamino)Ethanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02957": {"dbids": ["DB02957", "EXPT02436"], "name": "Orotidine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02956": {"dbids": ["DB02956", "EXPT02669"], "name": "Pentasulfide-Sulfur", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02959": {"dbids": ["DB02959", "EXPT01780"], "name": "Oxitriptan", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB02958": {"dbids": ["DB02958", "EXPT02238"], "name": "Selenomethionine Selenoxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02777": {"dbids": ["DB02777", "EXPT02605"], "name": "Diundecyl Phosphatidyl Choline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02776": {"dbids": ["DB02776", "EXPT01716"], "name": "1-Hexadecanosulfonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02770": {"dbids": ["DB02770", "EXPT00315"], "name": "7-Alpha-D-Ribofuranosyl-2-Aminopurine-5'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02773": {"dbids": ["DB02773", "EXPT00156"], "name": "(3-Chloro-4-Propoxy-Phenyl)-Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02772": {"dbids": ["DB02772", "EXPT02977"], "name": "Sucrose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08292": {"dbids": ["DB08292"], "name": "(5Z)-12-CHLORO-13,15-DIHYDROXY-4,7,8,9-TETRAHYDRO-2-BENZOXACYCLOTRIDECINE-1,10(3H,11H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03574": {"dbids": ["DB03574", "EXPT01403"], "name": "Ferricrocin-Iron", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03575": {"dbids": ["DB03575", "EXPT03307"], "name": "Phencyclidine", "groups": ["ILLICIT"], "targets": [{"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB03575"}]}, "DB03576": {"dbids": ["DB03576", "EXPT03066"], "name": "N-Pyridoxyl-Threonine-5-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03577": {"dbids": ["DB03577", "EXPT00105"], "name": "Alpha-Benzyl-Aminobenzyl-Phosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03570": {"dbids": ["DB03570", "EXPT00030"], "name": "Tris-Hydroxymethyl-Methyl-Ammonium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03571": {"dbids": ["DB03571", "EXPT00198"], "name": "3-(5-Amino-7-Hydroxy-[1,2,3]Triazolo[4,5-D]Pyrimidin-2-Yl)-N-(3,5-Dichlorobenzyl)-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03572": {"dbids": ["DB03572", "EXPT01484"], "name": "FR230513", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03573": {"dbids": ["DB03573", "EXPT02751"], "name": "WRR-99", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03578": {"dbids": ["DB03578", "EXPT02721"], "name": "Pyruvamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03579": {"dbids": ["DB03579", "EXPT02870"], "name": "Pyridoxyl-N,O-Cycloserylamide-5-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05209": {"dbids": ["DB05209"], "name": "SYM001", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08239": {"dbids": ["DB08239"], "name": "(2S)-4-(2,5-DIFLUOROPHENYL)-N-METHYL-2-PHENYL-N-PIPERIDIN-4-YL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05204": {"dbids": ["DB05204"], "name": "XL418", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05205": {"dbids": ["DB05205"], "name": "CX157", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05206": {"dbids": ["DB05206"], "name": "PS433540", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05207": {"dbids": ["DB05207"], "name": "SD118", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05200": {"dbids": ["DB05200"], "name": "AT2220", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05201": {"dbids": ["DB05201"], "name": "V24343", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05202": {"dbids": ["DB05202"], "name": "ARC1779", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05203": {"dbids": ["DB05203"], "name": "SPP1148", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04742": {"dbids": ["DB04742"], "name": "NITROCEFIN", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08497": {"dbids": ["DB08497"], "name": "(1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08494": {"dbids": ["DB08494"], "name": "S-{2-[(2-chloro-4-sulfamoylphenyl)amino]-2-oxoethyl} 6-methyl-3,4-dihydroquinoline-1(2H)-carbothioate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08495": {"dbids": ["DB08495"], "name": "4-({4-[(6-CHLORO-1-BENZOTHIEN-2-YL)SULFONYL]-2-OXOPIPERAZIN-1-YL}METHYL)BENZENECARBOXIMIDAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08492": {"dbids": ["DB08492"], "name": "(2E)-3-(2-OCT-1-YN-1-YLPHENYL)ACRYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08493": {"dbids": ["DB08493"], "name": "5-METHYL-3-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.013,18]NONADECA-12(19),13,15,17-TETRAEN-10-YLCARBAMOYL)-HEXANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08490": {"dbids": ["DB08490"], "name": "4-[4-(4-CHLORO-PHENOXY)-BENZENESULFONYLMETHYL]-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08491": {"dbids": ["DB08491"], "name": "N-HYDROXY-2-[4-(4-PHENOXY-BENZENESULFONYL)-TETRAHYDRO-PYRAN-4-YL]-ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04743": {"dbids": ["DB04743"], "name": "Nimesulide", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB04743"}]}, "DB08498": {"dbids": ["DB08498"], "name": "(1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08499": {"dbids": ["DB08499"], "name": "N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08948": {"dbids": ["DB08948"], "name": "Iodamide", "groups": ["WITHDRAWN"], "targets": []}, "DB08940": {"dbids": ["DB08940"], "name": "Kebuzone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08941": {"dbids": ["DB08941"], "name": "Isoxsuprine", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB08942": {"dbids": ["DB08942"], "name": "Isoxicam", "groups": ["WITHDRAWN"], "targets": []}, "DB08943": {"dbids": ["DB08943"], "name": "Isoconazole", "groups": ["APPROVED"], "targets": []}, "DB08944": {"dbids": ["DB08944"], "name": "Isoaminile", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB08946": {"dbids": ["DB08946"], "name": "Iopanoic acid", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB08947": {"dbids": ["DB08947"], "name": "Iopamidol", "groups": ["APPROVED"], "targets": []}, "DB04740": {"dbids": ["DB04740"], "name": "MOXALACTAM (HYDROLYZED)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04746": {"dbids": ["DB04746"], "name": "(10E,12Z)-octadeca-10,12-dienoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04747": {"dbids": ["DB04747"], "name": "11-TRANS-13-TRANS-15-CIS-OCTADECATRIENOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04744": {"dbids": ["DB04744"], "name": "2-HYDROXY-1,4-NAPHTHOQUINONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB11083": {"dbids": ["DB11083"], "name": "Sodium phosphate, dibasic", "groups": ["APPROVED"], "targets": []}, "DB04139": {"dbids": ["DB04139", "EXPT01776"], "name": "6-Hydroxypropylthymine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04138": {"dbids": ["DB04138", "EXPT00668"], "name": "2,4-Dinitro,5-[Bis(2-Bromoethyl)Amino]-N-(2',3'-Dioxopropyl)Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01329": {"dbids": ["DB01329"], "name": "Cefoperazone", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0AD68", "drug": "DB01329"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB01329"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB01329"}, {"action": "INHIBITOR", "target": "Q07806", "drug": "DB01329"}, {"action": "INHIBITOR", "target": "Q9X6W0", "drug": "DB01329"}, {"action": "INHIBITOR", "target": "P08506", "drug": "DB01329"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB01329"}, {"action": "INHIBITOR", "target": "P0AEB2", "drug": "DB01329"}, {"action": "INHIBITOR", "target": "P24228", "drug": "DB01329"}]}, "DB01328": {"dbids": ["DB01328"], "name": "Cefonicid", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P02918", "drug": "DB01328"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB01328"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB01328"}, {"action": "INHIBITOR", "target": "P24228", "drug": "DB01328"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB01328"}]}, "DB01455": {"dbids": ["DB01455"], "name": "19-Nor-5-androstenediol", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01454": {"dbids": ["DB01454"], "name": "3,4-Methylenedioxymethamphetamine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": [{"action": "NEGATIVE MODULATOR", "target": "P31645", "drug": "DB01454"}, {"action": "INHIBITOR", "target": "Q05940", "drug": "DB01454"}, {"action": "NEGATIVE MODULATOR", "target": "Q01959", "drug": "DB01454"}, {"action": "AGONIST", "target": "P28223", "drug": "DB01454"}, {"action": "AGONIST", "target": "P41595", "drug": "DB01454"}, {"action": "AGONIST", "target": "P28335", "drug": "DB01454"}, {"action": "NEGATIVE MODULATOR", "target": "P23975", "drug": "DB01454"}]}, "DB04137": {"dbids": ["DB04137", "EXPT01660"], "name": "Guanosine-5'-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04136": {"dbids": ["DB04136", "EXPT02059"], "name": "Lysophosphotidylserine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04131": {"dbids": ["DB04131", "EXPT00485"], "name": "10-(4-Dimethylamino-5-Hydroxy-6-Methyl-Tetrahydro-Pyran-2-Yloxy)-8-Ethyl-1,8,11-Trihydroxy-7,8,9,10-Tetrahydro-Naphthacene-5,12-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04130": {"dbids": ["DB04130", "EXPT00256"], "name": "5-Methoxybenzimidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04133": {"dbids": ["DB04133", "EXPT00884"], "name": "Degraded Cephaloridine", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB04133"}]}, "DB04132": {"dbids": ["DB04132", "EXPT01664"], "name": "S-Hexylglutathione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04745": {"dbids": ["DB04745"], "name": "2-OXOQUINOLINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07118": {"dbids": ["DB07118"], "name": "7-hydroxy-4-methyl-2H-chromen-2-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07119": {"dbids": ["DB07119"], "name": "1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00328": {"dbids": ["APRD00109", "DB00328"], "name": "Indomethacin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P23219", "drug": "DB00328"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00328"}, {"action": "INHIBITOR", "target": "P14555", "drug": "DB00328"}, {"action": "INHIBITOR", "target": "Q8N8N7", "drug": "DB00328"}, {"action": "ACTIVATOR", "target": "P37231", "drug": "DB00328"}, {"action": "INHIBITOR", "target": "Q04760", "drug": "DB00328"}, {"action": "OTHER/UNKNOWN", "target": "Q9Y5Y4", "drug": "DB00328"}, {"action": "AGONIST", "target": "Q07869", "drug": "DB00328"}]}, "DB07449": {"dbids": ["DB07449"], "name": "N-[(1S)-1-(AMINOCARBONYL)-4-(ETHANIMIDOYLAMINO)BUTYL]BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00498": {"dbids": ["APRD00166", "DB00498"], "name": "Phenindione", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9BQB6", "drug": "DB00498"}]}, "DB00499": {"dbids": ["APRD00984", "DB00499"], "name": "Flutamide", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P10275", "drug": "DB00499"}, {"action": "AGONIST", "target": "P35869", "drug": "DB00499"}]}, "DB00324": {"dbids": ["APRD00980", "DB00324"], "name": "Fluorometholone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00324"}]}, "DB00325": {"dbids": ["APRD01143", "DB00325"], "name": "Nitroprusside", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P16066", "drug": "DB00325"}]}, "DB00326": {"dbids": ["APRD00841", "DB00326"], "name": "Calcium Gluceptate", "groups": ["APPROVED"], "targets": []}, "DB00327": {"dbids": ["APRD01021", "DB00327"], "name": "Hydromorphone", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB00327"}, {"action": "PARTIAL AGONIST", "target": "P41143", "drug": "DB00327"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00327"}]}, "DB00320": {"dbids": ["APRD00476", "DB00320"], "name": "Dihydroergotamine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P28221", "drug": "DB00320"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00320"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00320"}, {"action": "AGONIST", "target": "P41595", "drug": "DB00320"}]}, "DB00321": {"dbids": ["APRD00227", "DB00321"], "name": "Amitriptyline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23975", "drug": "DB00321"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00321"}, {"action": "INHIBITOR", "target": "P08908", "drug": "DB00321"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00321"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00321"}, {"action": "AGONIST", "target": "P04629", "drug": "DB00321"}, {"action": "AGONIST", "target": "Q16620", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00321"}, {"action": "INHIBITOR", "target": "O43526", "drug": "DB00321"}, {"action": "INHIBITOR", "target": "Q09470", "drug": "DB00321"}, {"action": "INHIBITOR", "target": "Q9NZV8", "drug": "DB00321"}, {"action": "INHIBITOR", "target": "Q9UK17", "drug": "DB00321"}, {"action": "BLOCKER", "target": "P25021", "drug": "DB00321"}, {"action": "BINDER", "target": "Q9H3N8", "drug": "DB00321"}, {"action": "AGONIST", "target": "Q99720", "drug": "DB00321"}, {"action": "BINDER", "target": "P28335", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00321"}, {"action": "BINDER", "target": "P28221", "drug": "DB00321"}, {"action": "BINDER", "target": "P35372", "drug": "DB00321"}, {"action": "BINDER", "target": "P28222", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB00321"}, {"action": "BINDER", "target": "P08588", "drug": "DB00321"}, {"action": "BINDER", "target": "P07550", "drug": "DB00321"}, {"action": "BINDER", "target": "P13945", "drug": "DB00321"}]}, "DB00322": {"dbids": ["APRD00692", "DB00322"], "name": "Floxuridine", "groups": ["APPROVED"], "targets": []}, "DB00323": {"dbids": ["APRD00445", "DB00323"], "name": "Tolcapone", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P21964", "drug": "DB00323"}]}, "DB00148": {"dbids": ["DB00148", "NUTR00022"], "name": "Creatine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "LIGAND", "target": "P06732", "drug": "DB00148"}, {"action": "LIGAND", "target": "P12532", "drug": "DB00148"}, {"action": "LIGAND", "target": "P12277", "drug": "DB00148"}, {"action": "LIGAND", "target": "P17540", "drug": "DB00148"}, {"action": "PRODUCT OF", "target": "Q14353", "drug": "DB00148"}]}, "DB00149": {"dbids": ["DB00149", "NUTR00033"], "name": "L-Leucine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00140": {"dbids": ["APRD00626", "DB00140", "EXPT02760", "NUTR00010"], "name": "Riboflavin", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "LIGAND", "target": "Q969G6", "drug": "DB00140"}, {"action": "OTHER", "target": "P0AFU8", "drug": "DB00140"}, {"action": "PRODUCT OF", "target": "P30043", "drug": "DB00140"}]}, "DB00141": {"dbids": ["DB00141", "NUTR00040"], "name": "N-Acetyl-D-glucosamine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "ACTIVATOR", "target": "P54802", "drug": "DB00141"}]}, "DB00142": {"dbids": ["DB00142", "NUTR00027"], "name": "L-Glutamic Acid", "groups": ["NUTRACEUTICAL"], "targets": []}, "DB00143": {"dbids": ["DB00143", "EXPT01650", "NUTR00029"], "name": "Glutathione", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "COFACTOR", "target": "P36969", "drug": "DB00143"}, {"action": "COFACTOR", "target": "P59796", "drug": "DB00143"}, {"action": "COFACTOR", "target": "Q96SL4", "drug": "DB00143"}, {"action": "COFACTOR", "target": "P07203", "drug": "DB00143"}, {"action": "COFACTOR", "target": "P18283", "drug": "DB00143"}, {"action": "COFACTOR", "target": "O75715", "drug": "DB00143"}, {"action": "COFACTOR", "target": "P22352", "drug": "DB00143"}]}, "DB00144": {"dbids": ["DB00144", "NUTR00048"], "name": "Phosphatidylserine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00145": {"dbids": ["DB00145", "NUTR00028"], "name": "Glycine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "ANTAGONIST", "target": "Q12879", "drug": "DB00145"}]}, "DB00146": {"dbids": ["APRD00428", "DB00146", "NUTR00006"], "name": "Calcidiol", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "AGONIST", "target": "P11473", "drug": "DB00146"}]}, "DB00147": {"dbids": ["DB00147", "NUTR00049"], "name": "Pyridoxal", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB04791": {"dbids": ["DB04791"], "name": "2-O-(4'-AMIDINOPHENYL)-5-O-(3''-AMIDINOPHENYL)-1,4:3,6-DIANHYDRO-D-SORBITOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04790": {"dbids": ["DB04790"], "name": "2,5-bis-o-{3-[amino(imino)methyl]phenyl}-1,4:3,6-dianhydro-d-glucitol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04793": {"dbids": ["DB04793"], "name": "2-O-(3'-AMIDINOPHENYL)-5-O-(4''-AMIDINOPHENYL}-1,4:3,6-DIANHYDRO-D-SORBITOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04792": {"dbids": ["DB04792"], "name": "2,5-O,O-BIS-{4',4''-AMIDINOPHENYL}-1,4:3,6-DIANHYDRO-D-SORBITOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04795": {"dbids": ["DB04795"], "name": "Thenoyltrifluoroacetone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04794": {"dbids": ["DB04794"], "name": "Bifonazole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P10613", "drug": "DB04794"}]}, "DB04797": {"dbids": ["DB04797"], "name": "Triazolopyridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04796": {"dbids": ["DB04796"], "name": "Inecalcitol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04799": {"dbids": ["DB04799"], "name": "5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04798": {"dbids": ["DB04798"], "name": "THIO-ATPA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08537": {"dbids": ["DB08537"], "name": "3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08536": {"dbids": ["DB08536"], "name": "3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05723": {"dbids": ["DB05723"], "name": "ALKS 29", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05722": {"dbids": ["DB05722"], "name": "CGC-11047", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08533": {"dbids": ["DB08533"], "name": "3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08532": {"dbids": ["DB08532"], "name": "6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03369": {"dbids": ["DB03369", "EXPT00353"], "name": "9-Aminophenanthrene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03368": {"dbids": ["DB03368", "EXPT01778"], "name": "5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06799": {"dbids": ["DB06146", "DB06799"], "name": "Hexamethylenetetramine", "groups": ["APPROVED"], "targets": []}, "DB03361": {"dbids": ["DB03361", "EXPT01719"], "name": "2-{(9as)-9a-[(1s)-1-Hydroxyethyl]-2,7-Dimethyl-9a,10-Dihydro-5h-Pyrimido[4,5-D][1,3]Thiazolo[3,2-a]Pyrimidin-8-Yl}Ethyl Trihydrogen Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03360": {"dbids": ["DB03360", "EXPT02279"], "name": "N-Acetylproline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03363": {"dbids": ["DB03363", "EXPT00368"], "name": "3-Acetylpyridine Adenine Dinucleotide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03362": {"dbids": ["DB03362", "EXPT02189"], "name": "N-Dimethyl-Lysine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03365": {"dbids": ["DB03365", "EXPT01289"], "name": "4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03364": {"dbids": ["DB03364", "EXPT00877"], "name": "N-Carbamyl-D-Methionine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03367": {"dbids": ["DB03367", "EXPT02553"], "name": "PF-00356231", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06794": {"dbids": ["DB06794"], "name": "Lodoxamide", "groups": ["APPROVED"], "targets": []}, "DB06937": {"dbids": ["DB06937"], "name": "4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04869": {"dbids": ["DB04869"], "name": "Olcegepant", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04868": {"dbids": ["DB04868"], "name": "Nilotinib", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P00519", "drug": "DB04868"}, {"action": "ANTAGONIST", "target": "P10721", "drug": "DB04868"}]}, "DB06936": {"dbids": ["DB06936"], "name": "N-(4-carbamimidoylbenzyl)-1-(4-methylpentanoyl)-L-prolinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04863": {"dbids": ["DB04863"], "name": "Lefradafiban", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04862": {"dbids": ["DB04862"], "name": "Merimepodib", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04861": {"dbids": ["DB04861"], "name": "Nebivolol", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB04861"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB04861"}]}, "DB04860": {"dbids": ["DB04860"], "name": "Isatoribine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04867": {"dbids": ["DB04867"], "name": "Lintitript", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04866": {"dbids": ["DB04866"], "name": "Halofuginone", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04980": {"dbids": ["DB04980"], "name": "Lemuteporfin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04864": {"dbids": ["DB04864"], "name": "Huperzine A", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08379": {"dbids": ["DB08379"], "name": "6-(4-chloro-2-fluoro-3-phenoxybenzyl)pyridazin-3(2H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06934": {"dbids": ["DB06934"], "name": "(1R)-3-chloro-1-phenylpropan-1-ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08373": {"dbids": ["DB08373"], "name": "4,4'-BIS([H]METHYLSULFONYL)-2,2',5,5'-TETRACHLOROBIPHENYL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06933": {"dbids": ["DB06933"], "name": "N-(tert-butyl)-4-[5-(pyridin-2-ylamino)quinolin-3-yl]benzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08371": {"dbids": ["DB08371"], "name": "PARA-(BENZOYL)-PHENYLALANINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08370": {"dbids": ["DB08370"], "name": "S-(4-BROMOBENZYL)CYSTEINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08377": {"dbids": ["DB08377"], "name": "PARA-NITROPHENYL PHOSPHONOBUTANOYL D-ALANINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08376": {"dbids": ["DB08376"], "name": "(2R)-3-(phosphonooxy)propane-1,2-diyl diheptanoate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08375": {"dbids": ["DB08375"], "name": "PCNOTAXIME GROUP", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06932": {"dbids": ["DB06932"], "name": "10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01033": {"dbids": ["APRD01096", "DB01033"], "name": "Mercaptopurine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00492", "drug": "DB01033"}, {"action": "INHIBITOR", "target": "P20839", "drug": "DB01033"}, {"action": "INHIBITOR", "target": "P12268", "drug": "DB01033"}]}, "DB03144": {"dbids": ["DB03144", "EXPT01692"], "name": "N-Omega-Hydroxy-L-Arginine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03147": {"dbids": ["DB03147", "EXPT01391"], "name": "Flavin adenine dinucleotide", "groups": ["APPROVED"], "targets": []}, "DB03146": {"dbids": ["DB03146", "EXPT02575"], "name": "2-Deazo-6-Thiophosphate Guanosine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03141": {"dbids": ["DB03141", "EXPT00690"], "name": "3-({5-Benzyl-6-Hydroxy-2,4-Bis-(4-Hydroxy-Benzyl)-3-Oxo-[1,2,4]-Triazepane-1-Sulfonyl)-Benzonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03140": {"dbids": ["DB03140", "EXPT00208"], "name": "4-Carboxyphenylboronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03143": {"dbids": ["DB03143", "EXPT01376"], "name": "Nonan-1-Ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03142": {"dbids": ["DB02769", "DB03142", "EXPT00554"], "name": "Alpha-L-Arabinose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03149": {"dbids": ["DB03149", "EXPT02591"], "name": "Phenylalanylmethane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03148": {"dbids": ["DB03148", "EXPT00363", "EXPT00533"], "name": "Phosphomethylphosphonic Acid Adenosyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01032": {"dbids": ["APRD00167", "DB01032"], "name": "Probenecid", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q4U2R8", "drug": "DB01032"}, {"action": "INHIBITOR", "target": "Q9NSA0", "drug": "DB01032"}, {"action": "INHIBITOR", "target": "Q8TCC7", "drug": "DB01032"}, {"action": "ANTAGONIST", "target": "Q96RD7", "drug": "DB01032"}]}, "DB02890": {"dbids": ["DB02890", "EXPT00724"], "name": "6-Hydroxyuridine-5'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03642": {"dbids": ["DB03642", "EXPT00107"], "name": "Benzofuran-2-Carboxylic Acid {(S)-3-Methyl-1-[3-Oxo-1-(Pyridin-2-Ylsulfonyl)Azepan-4-Ylcarbamoyl]Butyl}Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02892": {"dbids": ["DB02892", "EXPT00136"], "name": "L-2-Amino-6-Methylene-Pimelic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02893": {"dbids": ["DB02893", "EXPT02150"], "name": "D-Methionine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02894": {"dbids": ["DB02894", "EXPT02924"], "name": "Sulfamic Acid 2,3-O-(1-Methylethylidene)-4,5-O-Sulfonyl-Beta-Fructopyranose Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02895": {"dbids": ["DB02895", "EXPT00480"], "name": "3-(Prop-2-Ene-1-Sulfinyl)-Propene-1-Thiol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02896": {"dbids": ["DB02896", "EXPT02248"], "name": "Methylthioinosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03643": {"dbids": ["DB03643", "EXPT01013"], "name": "CRA_1144", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02898": {"dbids": ["DB02898", "EXPT03189"], "name": "5-{[(2-Amino-9h-Purin-6-Yl)Oxy]Methyl}-2-Pyrrolidinone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02899": {"dbids": ["DB02899", "EXPT01067"], "name": "N-Carboxymethionine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03136": {"dbids": ["DB03136", "EXPT01360"], "name": "4-Iodobenzo[B]Thiophene-2-Carboxamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03137": {"dbids": ["DB03137", "EXPT02704"], "name": "8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03646": {"dbids": ["DB03646", "EXPT01991"], "name": "1,2-Di-1-(3,7,11,15-Tetramethyl-Hexadecane)-Sn-Glycerol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01031": {"dbids": ["APRD00959", "DB01031"], "name": "Ethinamate", "groups": ["APPROVED", "ILLICIT", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P00915", "drug": "DB01031"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB01031"}]}, "DB07206": {"dbids": ["DB07206"], "name": "6-[2-(1H-INDOL-6-YL)ETHYL]PYRIDIN-2-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03644": {"dbids": ["DB03644", "EXPT00171"], "name": "3-Hydroxyanthranilic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07207": {"dbids": ["DB07207"], "name": "2-(4-HYDROXY-5-PHENYL-1H-PYRAZOL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03645": {"dbids": ["DB03645", "EXPT02491"], "name": "Phosphonoacetohydroxamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07204": {"dbids": ["DB07204"], "name": "(1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07205": {"dbids": ["DB07205"], "name": "N6-ISOPENTENYL-ADENOSINE-5'-MONOPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07202": {"dbids": ["DB07202"], "name": "6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01030": {"dbids": ["APRD00687", "DB01030"], "name": "Topotecan", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P11387", "drug": "DB01030"}, {"action": "INHIBITOR", "target": "Q969P6", "drug": "DB01030"}]}, "DB07203": {"dbids": ["DB07203"], "name": "6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02098": {"dbids": ["DB02098", "EXPT00366"], "name": "Adenosine-2'-5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02099": {"dbids": ["DB02099", "EXPT02848"], "name": "S-azabisabolene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07200": {"dbids": ["DB07200"], "name": "(2S,4S,5R)-2-ISOBUTYL-5-(2-THIENYL)-1-[4-(TRIFLUOROMETHYL)BENZOYL]PYRROLIDINE-2,4-DICARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02090": {"dbids": ["DB02090", "EXPT02835"], "name": "A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02091": {"dbids": ["DB02091", "EXPT00925"], "name": "4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02092": {"dbids": ["DB02092", "EXPT00941"], "name": "Cholesteryl Linoleate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02093": {"dbids": ["DB02093", "EXPT02496"], "name": "5-Phospho-D-Arabinohydroxamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02094": {"dbids": ["DB02094", "EXPT01048"], "name": "N-2-Thiophen-2-Yl-Acetamide Boronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02095": {"dbids": ["DB02095", "EXPT01935"], "name": "Isatin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02096": {"dbids": ["DB02096", "EXPT01483"], "name": "FR221647", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02097": {"dbids": ["DB02097", "EXPT01051"], "name": "Cytidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01037": {"dbids": ["APRD00525", "DB01037"], "name": "Selegiline", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P27338", "drug": "DB01037"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB01037"}]}, "DB08911": {"dbids": ["DB08911"], "name": "Trametinib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q02750", "drug": "DB08911"}, {"action": "INHIBITOR", "target": "P36507", "drug": "DB08911"}]}, "DB04985": {"dbids": ["DB04985"], "name": "PCK3145", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB02542": {"dbids": ["DB02542", "EXPT02018"], "name": "(4s)-5-Fluoro-L-Leucine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02543": {"dbids": ["DB02543", "EXPT02717"], "name": "Pyrrole-2-Carboxylate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02540": {"dbids": ["DB02540", "EXPT02348"], "name": "(10S)-10-Formyl-5,8,10-Trideazafolic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02541": {"dbids": ["DB02541", "EXPT00214"], "name": "4-Hydroxybutan-1-Aminium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02546": {"dbids": ["DB02546", "EXPT02902"], "name": "Vorinostat", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q13547", "drug": "DB02546"}, {"action": "INHIBITOR", "target": "Q92769", "drug": "DB02546"}, {"action": "INHIBITOR", "target": "O15379", "drug": "DB02546"}, {"action": "INHIBITOR", "target": "Q9UBN7", "drug": "DB02546"}]}, "DB02547": {"dbids": ["DB02547", "EXPT01574"], "name": "Guanosine-5'-Diphosphate-Rhamnose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02544": {"dbids": ["DB02544", "EXPT02750"], "name": "N-(6-{[3-(4-Bromophenyl)-1,2-Benzisothiazol-6-Yl]Oxy}Hexyl)-N-Methylprop-2-En-1-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02545": {"dbids": ["DB02545", "EXPT01424"], "name": "Fexaramine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07248": {"dbids": ["DB07248"], "name": "7-PYRIDIN-2-YL-N-(3,4,5-TRIMETHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02548": {"dbids": ["DB02548", "EXPT02834"], "name": "Sorbitol 6-phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02549": {"dbids": ["DB02549", "EXPT00591"], "name": "3'-O-Acetylthymidine-5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02238": {"dbids": ["DB02238", "EXPT01977"], "name": "4-(Methylsulfanyl)-2-Oxobutanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02239": {"dbids": ["DB02239", "EXPT02901"], "name": "Laevulinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01035": {"dbids": ["APRD00509", "DB01035"], "name": "Procainamide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB01035"}, {"action": "OTHER", "target": "P26358", "drug": "DB01035"}]}, "DB07249": {"dbids": ["DB07249"], "name": "N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01034": {"dbids": ["APRD00703", "DB01034"], "name": "Cerulenin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A953", "drug": "DB01034"}, {"action": "INHIBITOR", "target": "P0AAI5", "drug": "DB01034"}, {"action": "INHIBITOR", "target": "P0A6R0", "drug": "DB01034"}, {"action": "INHIBITOR", "target": "P49327", "drug": "DB01034"}]}, "DB01802": {"dbids": ["DB01802", "EXPT00307"], "name": "(4r)-7aza-7,8-Dihydrolimonene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01803": {"dbids": ["DB01803", "EXPT01369"], "name": "2-(Trimethylammonium)Ethyl Thiol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01800": {"dbids": ["DB01800", "EXPT01034"], "name": "N,4-Dihydroxy-N-Oxo-3-(Sulfooxy)Benzenaminium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01807": {"dbids": ["DB01807", "EXPT01987"], "name": "N-[(3z)-5-Tert-Butyl-2-Phenyl-1,2-Dihydro-3h-Pyrazol-3-Ylidene]-N'-(4-Chlorophenyl)Urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01804": {"dbids": ["DB01804", "EXPT00367"], "name": "2-Ammoniobut-3-Enoate, 2-Amino-3-Butenoate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01805": {"dbids": ["DB01805", "EXPT02178"], "name": "Monoisopropylphosphorylserine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05011": {"dbids": ["DB05011"], "name": "EG004", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05010": {"dbids": ["DB05010"], "name": "SGS742", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05013": {"dbids": ["DB05013"], "name": "Ingenol Mebutate", "groups": ["APPROVED"], "targets": [{"action": "LIGAND", "target": "Q05655", "drug": "DB05013"}, {"action": "LIGAND", "target": "P17252", "drug": "DB05013"}]}, "DB05012": {"dbids": ["DB05012"], "name": "XEN2174", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05015": {"dbids": ["DB05015"], "name": "Belinostat", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB05014": {"dbids": ["DB05014"], "name": "XL999", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05017": {"dbids": ["DB05017"], "name": "YSIL6", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05016": {"dbids": ["DB05016"], "name": "Ataluren", "groups": ["APPROVED"], "targets": []}, "DB05019": {"dbids": ["DB05019"], "name": "LC16M8", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05018": {"dbids": ["DB05018"], "name": "Migalastat", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01846": {"dbids": ["DB01846", "EXPT00829"], "name": "Oxidized Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01847": {"dbids": ["DB01847", "EXPT00879"], "name": "N-Carbamyl-D-Valine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01844": {"dbids": ["DB01844", "EXPT01224"], "name": "Dimethylformamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01842": {"dbids": ["DB01842", "EXPT02498"], "name": "3'-Phosphate-Adenosine-5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01843": {"dbids": ["DB01843", "EXPT01596"], "name": "3-Amino-8,9,10-Trihydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01840": {"dbids": ["DB01840", "EXPT01100"], "name": "2-Deoxy-D-Glucitol 6-(E)-Vinylhomophosphonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01841": {"dbids": ["DB01841", "EXPT01604"], "name": "4,6-Dideoxyglucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07242": {"dbids": ["DB07242"], "name": "(4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01848": {"dbids": ["DB01848", "EXPT01831"], "name": "Isocitrate Calcium Complex", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01849": {"dbids": ["DB01849", "EXPT01296"], "name": "3,4-Dihydrouracil", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06410": {"dbids": ["DB06410"], "name": "Doxercalciferol", "groups": ["APPROVED"], "targets": []}, "DB07639": {"dbids": ["DB07639"], "name": "3-(7-DIAMINOMETHYL-NAPHTHALEN-2-YL)-PROPIONIC ACID ETHYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07243": {"dbids": ["DB07243"], "name": "(3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04650": {"dbids": ["DB04650"], "name": "5-[(3AS,4R,6AR)-2-OXOHEXAHYDRO-1H-THIENO[3,4-D]IMIDAZOL-4-YL]PENTANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04651": {"dbids": ["DB04651"], "name": "BIOTINOL-5-AMP", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04300": {"dbids": ["DB04300", "EXPT01814"], "name": "(1s,3r,4r,6s)-1,3,4,6-Tetrapkisphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04653": {"dbids": ["DB04653"], "name": "CBZ-LEU-LEU-TYR-CH2F", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04306": {"dbids": ["DB04306", "EXPT03100"], "name": "5-[(4-Methylphenyl)Sulfanyl]-2,4-Quinazolinediamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01151": {"dbids": ["APRD00022", "DB01151", "DB07682"], "name": "Desipramine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23975", "drug": "DB01151"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB01151"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01151"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB01151"}, {"action": "OTHER", "target": "P08588", "drug": "DB01151"}, {"action": "INHIBITOR", "target": "P17405", "drug": "DB01151"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01151"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01151"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01151"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB01151"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01151"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01151"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01151"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01151"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB01151"}, {"action": "BINDER", "target": "P08908", "drug": "DB01151"}, {"action": "BINDER", "target": "P28335", "drug": "DB01151"}, {"action": "BINDER", "target": "P14416", "drug": "DB01151"}, {"action": "BINDER", "target": "P08913", "drug": "DB01151"}, {"action": "BINDER", "target": "P18089", "drug": "DB01151"}, {"action": "BINDER", "target": "P18825", "drug": "DB01151"}]}, "DB04656": {"dbids": ["DB04656"], "name": "1,3,4-TRIHYDROXY-5-(3-PHENOXYPROPYL)-CYCLOHEXANE-1-CARBOXYLIC A CID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04657": {"dbids": ["DB04657"], "name": "Carboxin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04658": {"dbids": ["DB04658"], "name": "(1S,2R,3S,4R,5S)-8-AZABICYCLO[3.2.1]OCTANE-1,2,3,4-TETROL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04659": {"dbids": ["DB04659"], "name": "(1S,2S,3R,4S,5S)-2,3,4-TRIHYDROXY-5-(HYDROXYMETHYL)CYCLOHEXYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04308": {"dbids": ["DB04308", "EXPT01178"], "name": "(2r)-Amino(4-Hydroxyphenyl)Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01158": {"dbids": ["APRD00830", "DB01158"], "name": "Bretylium", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P05023", "drug": "DB01158"}]}, "DB01159": {"dbids": ["APRD00598", "DB01159", "DB02330", "EXPT01754"], "name": "Halothane", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "O14649", "drug": "DB01159"}, {"action": "BINDER", "target": "Q9NPC2", "drug": "DB01159"}, {"action": "INHIBITOR", "target": "Q12791", "drug": "DB01159"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB01159"}, {"action": "ANTAGONIST", "target": "O60391", "drug": "DB01159"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB01159"}, {"action": "ALLOSTERIC MODULATOR", "target": "P23415", "drug": "DB01159"}, {"action": "OTHER", "target": "P08100", "drug": "DB01159"}, {"action": "INHIBITOR", "target": "P48051", "drug": "DB01159"}, {"action": "INHIBITOR", "target": "P48549", "drug": "DB01159"}, {"action": "INHIBITOR", "target": "P03886", "drug": "DB01159"}, {"action": "INHIBITOR", "target": "O15554", "drug": "DB01159"}, {"action": "OTHER/UNKNOWN", "target": "P30049", "drug": "DB01159"}, {"action": "OTHER/UNKNOWN", "target": "P98194", "drug": "DB01159"}, {"action": "OTHER/UNKNOWN", "target": "P14867", "drug": "DB01159"}, {"action": "OTHER/UNKNOWN", "target": "P59768", "drug": "DB01159"}, {"action": "OTHER/UNKNOWN", "target": "Q6W5P4", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01159"}]}, "DB08140": {"dbids": ["DB08140"], "name": "5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08141": {"dbids": ["DB08141"], "name": "4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06412": {"dbids": ["DB06412"], "name": "Oxymetholone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB08143": {"dbids": ["DB08143"], "name": "5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID ((3S,4S)-4-FLUORO- 1-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYLCARBAMOYL]-METHYL}-PYRROLIDIN-3-YL)-AMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08144": {"dbids": ["DB08144"], "name": "6-(2,6-dibromophenyl)pyrido[2,3-d]pyrimidine-2,7-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08145": {"dbids": ["DB08145"], "name": "6-(2,6-DIMETHOXYPHENYL)PYRIDO[2,3-D]PYRIMIDINE-2,7-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08146": {"dbids": ["DB08146"], "name": "7-(2,5-dihydropyrrol-1-yl)-6-phenyl-pyrido[6,5-d]pyrimidin-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08147": {"dbids": ["DB08147"], "name": "4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08148": {"dbids": ["DB08148"], "name": "1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08149": {"dbids": ["DB08149"], "name": "1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09552": {"dbids": ["DB09552"], "name": "Thonzonium bromide", "groups": ["APPROVED"], "targets": []}, "DB00799": {"dbids": ["APRD01246", "DB00799"], "name": "Tazarotene", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P10276", "drug": "DB00799"}, {"action": "AGONIST", "target": "P28702", "drug": "DB00799"}, {"action": "AGONIST", "target": "P13631", "drug": "DB00799"}, {"action": "AGONIST", "target": "P10826", "drug": "DB00799"}]}, "DB00798": {"dbids": ["APRD00214", "DB00798"], "name": "Gentamicin", "groups": ["APPROVED"], "targets": [{"action": "ADDUCT", "target": "P0A7S3", "drug": "DB00798"}, {"action": "OTHER/UNKNOWN", "target": "P98164", "drug": "DB00798"}]}, "DB07241": {"dbids": ["DB07241"], "name": "7-carboxy-5-hydroxy-12,13-dihydro-6H-indolo[2,3-a]pyrrolo[3,4-c]carbazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00795": {"dbids": ["APRD00152", "DB00795", "DB08518"], "name": "Sulfasalazine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P09917", "drug": "DB00795"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00795"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00795"}, {"action": "AGONIST", "target": "P37231", "drug": "DB00795"}, {"action": "INHIBITOR", "target": "O15111", "drug": "DB00795"}, {"action": "INHIBITOR", "target": "O14920", "drug": "DB00795"}, {"action": "INHIBITOR", "target": "Q9UPY5", "drug": "DB00795"}, {"action": "INHIBITOR", "target": "P24752", "drug": "DB00795"}, {"action": "ANTAGONIST", "target": "P24557", "drug": "DB00795"}, {"action": "ANTAGONIST", "target": "P04054", "drug": "DB00795"}]}, "DB00794": {"dbids": ["APRD00549", "DB00794"], "name": "Primidone", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00794"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00794"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00794"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00794"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00794"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00794"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00794"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00794"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB00794"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00794"}]}, "DB04193": {"dbids": ["DB04193", "EXPT01782"], "name": "L-Homoserine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00796": {"dbids": ["APRD00420", "DB00796"], "name": "Candesartan", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P30556", "drug": "DB00796"}]}, "DB00791": {"dbids": ["APRD00130", "DB00791"], "name": "Uracil mustard", "groups": ["APPROVED"], "targets": []}, "DB00790": {"dbids": ["APRD01178", "DB00790"], "name": "Perindopril", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P12821", "drug": "DB00790"}]}, "DB00793": {"dbids": ["APRD01011", "DB00793"], "name": "Haloprogin", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB00792": {"dbids": ["APRD00689", "DB00792"], "name": "Tripelennamine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00792"}]}, "DB04408": {"dbids": ["DB04408", "EXPT00912"], "name": "Ncs-Chromophore", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07246": {"dbids": ["DB07246"], "name": "(2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07063": {"dbids": ["DB07063"], "name": "{3-[(4,5,7-TRIFLUORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-1H-INDOL-1-YL}ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07247": {"dbids": ["DB07247"], "name": "[2'-HYDROXY-3'-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-BIPHENYL-3-YLMETHYL]-UREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07065": {"dbids": ["DB07065"], "name": "5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07244": {"dbids": ["DB07244"], "name": "5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04190": {"dbids": ["DB04190", "EXPT00664"], "name": "Inhibitor Bea425", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07369": {"dbids": ["DB07369"], "name": "N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07651": {"dbids": ["DB07651"], "name": "N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07650": {"dbids": ["DB07650"], "name": "DECYL FORMATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04405": {"dbids": ["DB04405", "EXPT01160"], "name": "2-[2-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Ethyl]-4-(4'-Ethoxy-1,1'-Biphenyl-4-Yl)-4-Oxobutanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07652": {"dbids": ["DB07652"], "name": "1-[2-DEOXYRIBOFURANOSYL]-2,4-DIFLUORO-5-METHYL-BENZENE-5'MONOPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07655": {"dbids": ["DB07655"], "name": "3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07654": {"dbids": ["DB07654"], "name": "(5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07309": {"dbids": ["DB07309"], "name": "5-BROMO-2-{[(4-CHLOROPHENYL)SULFONYL]AMINO}BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07308": {"dbids": ["DB07308"], "name": "5-(2-CHLOROBENZYL)-2-FUROIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07307": {"dbids": ["DB07307"], "name": "N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07306": {"dbids": ["DB07306"], "name": "ETHYL 4-[(4-CHLOROPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07305": {"dbids": ["DB07305"], "name": "5-(2-CHLORO-4-NITROPHENYL)-2-FUROIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07304": {"dbids": ["DB07304"], "name": "5-[2-(TRIFLUOROMETHOXY)PHENYL]-2-FUROIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07303": {"dbids": ["DB07303"], "name": "N~3~-[3-(5-METHOXYPYRIDIN-3-YL)BENZYL]PYRIDINE-2,3-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07302": {"dbids": ["DB07302"], "name": "(9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07245": {"dbids": ["DB07245"], "name": "6-[2-(3'-METHOXYBIPHENYL-3-YL)ETHYL]PYRIDIN-2-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07300": {"dbids": ["DB07300"], "name": "2-(1H-imidazol-1-yl)-9-methoxy-8-(2-methoxyethoxy)benzo[c][2,7]naphthyridin-4-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04197": {"dbids": ["DB04197", "EXPT00467"], "name": "Descarboxy-nor-N(Omega)-Hydroxy-L-Arginine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07368": {"dbids": ["DB07368"], "name": "4-(METHYLSULFONYL)BENZENECARBOXIMIDAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04404": {"dbids": ["DB04404", "EXPT00509"], "name": "Allosamizoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06650": {"dbids": ["DB06650"], "name": "Ofatumumab", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06655": {"dbids": ["DB06655"], "name": "Liraglutide", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P43220", "drug": "DB06655"}]}, "DB04196": {"dbids": ["DB04196", "EXPT02678"], "name": "Pteroic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02938": {"dbids": ["DB02938", "EXPT02907"], "name": "Heptanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02933": {"dbids": ["DB02933", "EXPT02244"], "name": "5'-Deoxy-5'-(Methylthio)-Tubercidin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02932": {"dbids": ["DB02932", "EXPT00064"], "name": "(2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02931": {"dbids": ["DB02931", "EXPT00990"], "name": "Coa-S-Acetyl Tryptamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02930": {"dbids": ["DB02930", "EXPT00458"], "name": "Phosphothiophosphoric Acid-Adenylate Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02937": {"dbids": ["DB02937", "EXPT00589"], "name": "Gamma-Arsono-Beta, Gamma-Methyleneadenosine-5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02936": {"dbids": ["DB02936", "EXPT00286"], "name": "4-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Butyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02935": {"dbids": ["DB02935", "EXPT02086"], "name": "1-Methoxy-2-(2-Methoxyethoxy)Ethane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02934": {"dbids": ["DB02934", "EXPT03003"], "name": "9-(6-Deoxy-Alpha-L-Talofuranosyl)-6-Methylpurine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04760": {"dbids": ["DB04760"], "name": "PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-(4-FLUORO-3-METHYL-BENZYLAMIDE)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04195": {"dbids": ["DB04195", "EXPT01677"], "name": "Heptulose-2-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04406": {"dbids": ["DB04406", "EXPT02615"], "name": "3-(Phosphonomethyl)Pyridine-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04194": {"dbids": ["DB04194", "EXPT01052"], "name": "Chitotriose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07365": {"dbids": ["DB07365"], "name": "NAPHTHALEN-2-YL-3-ALANINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04401": {"dbids": ["DB04401", "EXPT00767"], "name": "[Formylmethyl]Trimethyl-Ammonium, N,N,N-Trimethylammonium Acetaldehyde", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01337": {"dbids": ["DB01337"], "name": "Pancuronium", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q15822", "drug": "DB01337"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01337"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01337"}]}, "DB01933": {"dbids": ["DB01933", "EXPT03167"], "name": "7-Hydroxystaurosporine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07364": {"dbids": ["DB07364"], "name": "6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03558": {"dbids": ["DB03558", "EXPT03087"], "name": "Sp-876", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03559": {"dbids": ["DB03559", "EXPT01065"], "name": "Cyclohexylformamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04400": {"dbids": ["DB03271", "DB04400", "EXPT01697"], "name": "7,8-Dihydrobiopterin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03557": {"dbids": ["DB03557", "EXPT02927"], "name": "N-{1-[5-(1-Carbamoyl-2-Mercapto-Ethylcarbamoyl)-Pentylcarbamoyl]-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethyl}-3-{2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Acetylamino}-Succinamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03554": {"dbids": ["DB03554", "EXPT01946"], "name": "5-Iodouracil", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01330": {"dbids": ["DB01330"], "name": "Cefotetan", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB01330"}]}, "DB03552": {"dbids": ["DB03552", "EXPT02254"], "name": "Meta-Tyrosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03553": {"dbids": ["DB03553", "EXPT01668"], "name": "Glutaric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03550": {"dbids": ["DB03550", "EXPT01909"], "name": "Isopenicillin N", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03551": {"dbids": ["DB03551", "EXPT01206"], "name": "4'-Deaza-1'-Aza-2'-Deoxy-1'-(9-Methylene)-Immucillin-H, (3r,4r)-N-[9-Deazahypoxanthin-9-Yl)Methyl]-4-Hydroxymethyl-Pyrrolidin-3-Ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05226": {"dbids": ["DB05226"], "name": "BTA9881", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05227": {"dbids": ["DB05227"], "name": "APD791", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05224": {"dbids": ["DB05224"], "name": "REP8839", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05225": {"dbids": ["DB05225"], "name": "AM103", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05222": {"dbids": ["DB05222"], "name": "KB001", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05223": {"dbids": ["DB05223"], "name": "SB939", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05220": {"dbids": ["DB05220"], "name": "MLN8237", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01331": {"dbids": ["DB01331", "EXPT00897"], "name": "Cefoxitin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P08506", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "P0AEB2", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "P0AFI5", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "P24228", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB01331"}]}, "DB05228": {"dbids": ["DB05228"], "name": "RDEA806", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05229": {"dbids": ["DB05229"], "name": "Beraprost", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01332": {"dbids": ["DB01332"], "name": "Ceftizoxime", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q53707", "drug": "DB01332"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB01332"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB01332"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB01332"}]}, "DB07361": {"dbids": ["DB07361"], "name": "1-(3-chlorophenyl)-3-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08962": {"dbids": ["DB08962"], "name": "Glibornuride", "groups": ["WITHDRAWN"], "targets": []}, "DB08960": {"dbids": ["DB08960"], "name": "Hexamethonium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08961": {"dbids": ["DB08961"], "name": "Azosemide", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08966": {"dbids": ["DB08966"], "name": "Fursultiamine", "groups": ["APPROVED"], "targets": []}, "DB08967": {"dbids": ["DB08967"], "name": "Dimetotiazine", "groups": ["APPROVED"], "targets": []}, "DB08964": {"dbids": ["DB08964"], "name": "Gemeprost", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB08965": {"dbids": ["DB08965"], "name": "Fusafungine", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB08968": {"dbids": ["DB08968"], "name": "Fominoben", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB08969": {"dbids": ["DB08969"], "name": "Flurothyl", "groups": ["WITHDRAWN"], "targets": []}, "DB07360": {"dbids": ["DB07360"], "name": "1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07884": {"dbids": ["DB07884"], "name": "ISOPROPYL (2S)-2-ETHYL-7-FLUORO-3-OXO-3,4-DIHYDROQUINOXALINE-1(2H)-CARBOXYLATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07885": {"dbids": ["DB07885"], "name": "(S)-4-ISOPROPOXYCARBONYL-6-METHOXY-3-METHYLTHIOMETHYL-3,4-DIHYDROQUINOXALIN-2(1H)-THIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07887": {"dbids": ["DB07887"], "name": "(R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)BENZYL)GUANIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07880": {"dbids": ["DB07880"], "name": "2-((4'-HYDROXYPHENYL)-AZO)BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07881": {"dbids": ["DB07881"], "name": "N-{[2-({[1-(4-CARBOXYBUTANOYL)AMINO]-2-PHENYLETHYL}-HYDROXYPHOSPHINYL)OXY]ACETYL}-2-PHENYLETHYLAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07882": {"dbids": ["DB07882"], "name": "4-{4-[2-(1A,7A-DIMETHYL-4-OXY-OCTAHYDRO-1-OXA-4-AZA-CYCLOPROPA[A]NAPHTHALEN-4-YL) -ACETYLAMINO]-PHENYLCARBAMOYL}-BUTYRIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07883": {"dbids": ["DB07883"], "name": "(2-AMINO-3-PHENYL-BICYCLO[2.2.1]HEPT-2-YL)-PHENYL-METHANONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07888": {"dbids": ["DB07888"], "name": "3-(4-HYDROXYPHENYL)-4,5-DIHYDRO-5-ISOXAZOLE-ACETIC ACID METHYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07889": {"dbids": ["DB07889"], "name": "1-(DIMETHYLAMINO)-3-(4-{{4-(2-METHYLIMIDAZO[1,2-A]PYRIDIN-3-YL)PYRIMIDIN-2-YL]AMINO}PHENOXY)PROPAN-2-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09271": {"dbids": ["DB09271"], "name": "Cimetropium Bromide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09270": {"dbids": ["DB09270"], "name": "Coenzyme Q10", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09273": {"dbids": ["DB09273"], "name": "Doxofylline", "groups": ["APPROVED"], "targets": []}, "DB04643": {"dbids": ["DB04643"], "name": "4-{3-CHLORO-4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-PHENOXY}-BUTYRIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02512": {"dbids": ["DB02512", "EXPT00120"], "name": "1,6-Fructose Diphosphate (Linear Form)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09275": {"dbids": ["DB09275"], "name": "Bismuth Subcitrate", "groups": ["APPROVED"], "targets": []}, "DB09274": {"dbids": ["DB09274"], "name": "Artesunate", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P04926", "drug": "DB09274"}]}, "DB09158": {"dbids": ["DB09158"], "name": "Trypan blue", "groups": ["APPROVED"], "targets": []}, "DB09159": {"dbids": ["DB09159"], "name": "Trisodium citrate dihydrate", "groups": ["APPROVED"], "targets": []}, "DB09154": {"dbids": ["DB09154"], "name": "Sodium Citrate", "groups": ["APPROVED"], "targets": []}, "DB09155": {"dbids": ["DB09155"], "name": "Helium", "groups": ["APPROVED"], "targets": []}, "DB09156": {"dbids": ["DB09156"], "name": "Iopromide", "groups": ["APPROVED"], "targets": []}, "DB09157": {"dbids": ["DB09157"], "name": "Carbon dioxide", "groups": ["APPROVED"], "targets": []}, "DB09150": {"dbids": ["DB09150"], "name": "Fludeoxyglucose (18F)", "groups": ["APPROVED"], "targets": []}, "DB09151": {"dbids": ["DB09151"], "name": "Flutemetamol (18F)", "groups": ["APPROVED"], "targets": []}, "DB09152": {"dbids": ["DB09152"], "name": "Nitrogen", "groups": ["APPROVED"], "targets": []}, "DB09153": {"dbids": ["DB09153"], "name": "Sodium Chloride", "groups": ["APPROVED"], "targets": []}, "DB01309": {"dbids": ["DB01309"], "name": "Insulin Glulisine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P06213", "drug": "DB01309"}]}, "DB09279": {"dbids": ["DB09279"], "name": "Fimasartan", "groups": ["APPROVED"], "targets": []}, "DB02518": {"dbids": ["DB02518", "EXPT00596"], "name": "N-Acetylalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01301": {"dbids": ["DB01301"], "name": "Rolitetracycline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A7X3", "drug": "DB01301"}]}, "DB01303": {"dbids": ["DB01303"], "name": "Oxtriphylline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14432", "drug": "DB01303"}, {"action": "INHIBITOR", "target": "P27815", "drug": "DB01303"}, {"action": "ANTAGONIST", "target": "P29274", "drug": "DB01303"}, {"action": "ANTAGONIST", "target": "P30542", "drug": "DB01303"}, {"action": "ACTIVATOR", "target": "Q92769", "drug": "DB01303"}]}, "DB01307": {"dbids": ["DB01307"], "name": "Insulin Detemir", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P06213", "drug": "DB01307"}]}, "DB01306": {"dbids": ["DB01306"], "name": "Insulin Aspart", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P06213", "drug": "DB01306"}]}, "DB04641": {"dbids": ["DB04641"], "name": "3,7-DIHYDROXYNAPHTHALENE-2-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09484": {"dbids": ["DB09484"], "name": "Sodium monofluorophosphate", "groups": ["APPROVED"], "targets": []}, "DB09485": {"dbids": ["DB09485"], "name": "Cysteine hydrochloride", "groups": ["APPROVED"], "targets": []}, "DB09481": {"dbids": ["DB09481"], "name": "Magnesium carbonate", "groups": ["APPROVED"], "targets": []}, "DB09488": {"dbids": ["DB09488"], "name": "Acrivastine", "groups": ["APPROVED"], "targets": []}, "DB07920": {"dbids": ["DB07920"], "name": "N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04646": {"dbids": ["DB04646"], "name": "Dibromothymoquinone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00306": {"dbids": ["APRD01333", "DB00306"], "name": "Talbutal", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00306"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00306"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00306"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00306"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00306"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00306"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00306"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00306"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB00306"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00306"}]}, "DB00307": {"dbids": ["APRD00114", "DB00307"], "name": "Bexarotene", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P19793", "drug": "DB00307"}, {"action": "AGONIST", "target": "P28702", "drug": "DB00307"}, {"action": "AGONIST", "target": "P48443", "drug": "DB00307"}]}, "DB00304": {"dbids": ["APRD00762", "DB00304"], "name": "Desogestrel", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P06401", "drug": "DB00304"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00304"}]}, "DB00305": {"dbids": ["APRD00284", "DB00305"], "name": "Mitomycin", "groups": ["APPROVED"], "targets": []}, "DB00302": {"dbids": ["APRD01270", "DB00302", "EXPT00508"], "name": "Tranexamic Acid", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00747", "drug": "DB00302"}]}, "DB00303": {"dbids": ["APRD00952", "DB00303"], "name": "Ertapenem", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P44469", "drug": "DB00303"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB00303"}, {"action": "INHIBITOR", "target": "P45059", "drug": "DB00303"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB00303"}, {"action": "INHIBITOR", "target": "P24228", "drug": "DB00303"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB00303"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB00303"}, {"action": "INHIBITOR", "target": "P08506", "drug": "DB00303"}]}, "DB00300": {"dbids": ["APRD01248", "DB00300"], "name": "Tenofovir", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q72547", "drug": "DB00300"}]}, "DB00301": {"dbids": ["APRD00609", "DB00301"], "name": "Flucloxacillin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB00301"}]}, "DB08683": {"dbids": ["DB08683"], "name": "REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08682": {"dbids": ["DB08682"], "name": "1-METHYL ETHYL 1-CHLORO-5-[[(5,6DIHYDRO-2-METHYL-1,4-OXATHIIN-3-YL)CARBONYL]AMINO]BENZOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08681": {"dbids": ["DB08681"], "name": "1-METHYL ETHYL 2-CHLORO-5-[[[(1-METHYLETHOXY)THIOOXO]METHYL]AMINO]-BENZOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08680": {"dbids": ["DB08680"], "name": "N-[4-CLORO-3-(T-BUTYLOXOME)PHENYL-2-METHYL-3-FURAN-CARBOTHIAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08687": {"dbids": ["DB08687"], "name": "N-[(1-CHLORO-4-HYDROXYISOQUINOLIN-3-YL)CARBONYL]GLYCINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08686": {"dbids": ["DB08686"], "name": "5,6,7,8,9,10-HEXAHYDRO-4-HYDROXY-3-(1-PHENYLPROPYL)CYCLOOCTA[B]PYRAN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00308": {"dbids": ["APRD01025", "DB00308"], "name": "Ibutilide", "groups": ["APPROVED"], "targets": [{"action": "ACTIVATOR", "target": "Q13936", "drug": "DB00308"}, {"action": "ACTIVATOR", "target": "Q02641", "drug": "DB00308"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00308"}, {"action": "ACTIVATOR", "target": "P54289", "drug": "DB00308"}, {"action": "ACTIVATOR", "target": "Q06432", "drug": "DB00308"}, {"action": "INHIBITOR", "target": "O00180", "drug": "DB00308"}, {"action": "INHIBITOR", "target": "Q9Y257", "drug": "DB00308"}, {"action": "INHIBITOR", "target": "Q9H252", "drug": "DB00308"}, {"action": "INHIBITOR", "target": "Q9NS40", "drug": "DB00308"}, {"action": "INHIBITOR", "target": "Q14654", "drug": "DB00308"}]}, "DB00309": {"dbids": ["APRD00392", "DB00309"], "name": "Vindesine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9H4B7", "drug": "DB00309"}]}, "DB03303": {"dbids": ["DB03303", "EXPT02959"], "name": "D-2-Keto-3-Deoxygluconate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03302": {"dbids": ["DB03302", "EXPT02586"], "name": "4,5,6,7-Tetrachloro-3h-Isobenzofuran-1-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03301": {"dbids": ["DB03301", "EXPT02077"], "name": "2-Allyl-6-Methyl-Phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03300": {"dbids": ["DB03300", "EXPT02136"], "name": "Pterin Cytosine Dinucleotide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03307": {"dbids": ["DB03307", "EXPT03161"], "name": "4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03306": {"dbids": ["DB03306", "EXPT00147"], "name": "RU78300", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04645": {"dbids": ["DB04645"], "name": "5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03304": {"dbids": ["DB03304", "EXPT02659"], "name": "7-Deaza-7-Aminomethyl-Guanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03309": {"dbids": ["DB03309", "EXPT02344"], "name": "N-Cyclohexyltaurine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03308": {"dbids": ["DB03308", "EXPT02048"], "name": "L-Leucyl-Hydroxylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04845": {"dbids": ["DB04845"], "name": "Ixabepilone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q13509", "drug": "DB04845"}]}, "DB04844": {"dbids": ["DB04844"], "name": "Tetrabenazine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q05940", "drug": "DB04844"}, {"action": "INHIBITOR", "target": "P14416", "drug": "DB04844"}]}, "DB04515": {"dbids": ["DB04515", "EXPT02263"], "name": "6-Deoxy-2-O-Methyl-Alpha-L-Galactopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04846": {"dbids": ["DB04846"], "name": "Celiprolol", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB04846"}, {"action": "AGONIST", "target": "P07550", "drug": "DB04846"}]}, "DB04841": {"dbids": ["DB04841"], "name": "Flunarizine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "O43497", "drug": "DB04841"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB04841"}, {"action": "INHIBITOR", "target": "Q9P0X4", "drug": "DB04841"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB04841"}]}, "DB04840": {"dbids": ["DB04840"], "name": "Debrisoquin", "groups": ["APPROVED"], "targets": [{"action": "INDUCER", "target": "P23975", "drug": "DB04840"}]}, "DB04843": {"dbids": ["DB04843"], "name": "Mepenzolate", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB04843"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB04843"}]}, "DB04842": {"dbids": ["DB04842"], "name": "Fluspirilene", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB04842"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB04842"}, {"action": "INHIBITOR", "target": "Q06432", "drug": "DB04842"}]}, "DB07926": {"dbids": ["DB07926"], "name": "N-[3-(N'-HYDROXYCARBOXAMIDO)-2-(2-METHYLPROPYL)-PROPANOYL]-O-TYROSINE-N-METHYLAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04849": {"dbids": ["DB04849"], "name": "AZD2171", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04848": {"dbids": ["DB04848"], "name": "AZD0947", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04519": {"dbids": ["DB04519", "EXPT02413"], "name": "Caprylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04518": {"dbids": ["DB04518", "EXPT00928"], "name": "3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08355": {"dbids": ["DB08355"], "name": "1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08354": {"dbids": ["DB08354"], "name": "2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04254": {"dbids": ["DB04254", "EXPT02703"], "name": "8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08356": {"dbids": ["DB08356"], "name": "4-[4-(4-methoxyphenyl)-5-methyl-1H-pyrazol-3-yl]benzene-1,3-diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04644": {"dbids": ["DB04644"], "name": "4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08350": {"dbids": ["DB08350"], "name": "5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08353": {"dbids": ["DB08353"], "name": "2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08352": {"dbids": ["DB08352"], "name": "6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08359": {"dbids": ["DB08359"], "name": "2-PHENYLAMINO-4-METHYL-5-ACETYL THIAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08358": {"dbids": ["DB08358"], "name": "2-(2-QUINOLIN-3-YLPYRIDIN-4-YL)-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00162": {"dbids": ["APRD00486", "DB00162", "NUTR00007"], "name": "Vitamin A", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00163": {"dbids": ["DB00163", "EXPT03227", "NUTR00061"], "name": "Vitamin E", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00160": {"dbids": ["DB00160", "NUTR00013"], "name": "L-Alanine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "INHIBITOR", "target": "P80404", "drug": "DB00160"}]}, "DB00161": {"dbids": ["DB00161", "NUTR00060"], "name": "L-Valine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00166": {"dbids": ["DB00166", "NUTR00035"], "name": "Lipoic Acid", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB00167": {"dbids": ["DB00167", "NUTR00031"], "name": "L-Isoleucine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB07796": {"dbids": ["DB07796"], "name": "(3ASR,4RS,8ASR,8BRS)-4-(2-(4-FLUOROBENZYL)-1,3-DIOXODEACAHYDROPYRROLO[3,4-A] PYRROLIZIN-4-YL)BENZAMIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00165": {"dbids": ["APRD00204", "DB00165", "NUTR00002"], "name": "Pyridoxine", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "LIGAND", "target": "O00764", "drug": "DB00165"}]}, "DB07798": {"dbids": ["DB07798"], "name": "(3R)-3-(FLUOROMETHYL)-N-(3,3,3-TRIFLUOROPROPYL)-1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00168": {"dbids": ["DB00168", "NUTR00046"], "name": "Aspartame", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "INDUCER", "target": "Q8NER1", "drug": "DB00168"}, {"action": "AGONIST", "target": "Q8TE23", "drug": "DB00168"}]}, "DB00169": {"dbids": ["APRD00506", "DB00169", "NUTR00008"], "name": "Cholecalciferol", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": [{"action": "AGONIST", "target": "P11473", "drug": "DB00169"}]}, "DB08202": {"dbids": ["DB08202"], "name": "4-({[(4-METHYLPIPERAZIN-1-YL)AMINO]CARBONOTHIOYL}AMINO)BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04256": {"dbids": ["DB04256", "EXPT02133"], "name": "4-(1-Amino-1-Carboxy-Ethyl)-Benzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08904": {"dbids": ["DB08904"], "name": "Certolizumab pegol", "groups": ["APPROVED"], "targets": [{"action": "NEUTRALIZER", "target": "P01375", "drug": "DB08904"}]}, "DB08453": {"dbids": ["DB08453"], "name": "2-NONYL-4-HYDROXYQUINOLINE N-OXIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08450": {"dbids": ["DB08450"], "name": "N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08451": {"dbids": ["DB08451"], "name": "N-(QUINOLIN-8-YL)METHANESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08456": {"dbids": ["DB08456"], "name": "3-{[(2,2,5,5-TETRAMETHYL-1-OXO-4-PHENYL-2,5-DIHYDRO-1H-PYRROLIUM-3-YL)METHYL]DISULFANYL}-D-ALANINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08457": {"dbids": ["DB08457"], "name": "4-(3,5-DIMETHYLPHENOXY)-5-(FURAN-2-YLMETHYLSULFANYLMETHYL)-3-IODO-6-METHYLPYRIDIN-2(1H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06147": {"dbids": ["DB06147"], "name": "Sulfathiazole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q27738", "drug": "DB06147"}]}, "DB08454": {"dbids": ["DB08454"], "name": "N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08903": {"dbids": ["DB08903"], "name": "Bedaquiline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P63691", "drug": "DB08903"}]}, "DB01059": {"dbids": ["APRD00469", "DB01059"], "name": "Norfloxacin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P43702", "drug": "DB01059"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB01059"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB01059"}]}, "DB08458": {"dbids": ["DB08458"], "name": "(4-BROMOPHENYL)[4-({(2E)-4-[CYCLOPROPYL(METHYL)AMINO]BUT-2-ENYL}OXY)PHENYL]METHANONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08808": {"dbids": ["DB08808"], "name": "Bupranolol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB08808"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB08808"}, {"action": "ANTAGONIST", "target": "P13945", "drug": "DB08808"}]}, "DB08459": {"dbids": ["DB08459"], "name": "3-chloro-5-[2-chloro-5-(1H-pyrazolo[3,4-b]pyridin-3-ylmethoxy)phenoxy]benzonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06069": {"dbids": ["DB06069"], "name": "XMT-1001", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB09468": {"dbids": ["DB09468"], "name": "Sodium phosphate, dibasic, heptahydrate", "groups": ["APPROVED"], "targets": []}, "DB08909": {"dbids": ["DB08909"], "name": "Glycerol Phenylbutyrate", "groups": ["APPROVED"], "targets": []}, "DB07105": {"dbids": ["DB07105"], "name": "2-[2-(4-CHLORO-PHENYLSULFANYL)-ACETYLAMINO]-3-(4-GUANIDINO-PHENYL)-PROPIONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08805": {"dbids": ["DB08805"], "name": "Metiamide", "groups": ["EXPERIMENTAL"], "targets": [{"action": "ANTAGONIST", "target": "P25021", "drug": "DB08805"}]}, "DB08804": {"dbids": ["DB08804"], "name": "Nandrolone decanoate", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P10275", "drug": "DB08804"}]}, "DB06810": {"dbids": ["DB06810"], "name": "Plicamycin", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB01058": {"dbids": ["APRD01196", "DB01058", "EXPT02728"], "name": "Praziquantel", "groups": ["APPROVED"], "targets": []}, "DB08807": {"dbids": ["DB08807"], "name": "Bopindolol", "groups": ["APPROVED"], "targets": [{"action": "PARTIAL AGONIST", "target": "P08588", "drug": "DB08807"}, {"action": "PARTIAL AGONIST", "target": "P07550", "drug": "DB08807"}]}, "DB06811": {"dbids": ["DB06811"], "name": "Polidocanol", "groups": ["APPROVED"], "targets": []}, "DB08806": {"dbids": ["DB08806"], "name": "Roxatidine acetate", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P25021", "drug": "DB08806"}]}, "DB06812": {"dbids": ["DB06812"], "name": "Povidone-iodine", "groups": ["APPROVED"], "targets": []}, "DB05833": {"dbids": ["DB05833"], "name": "lymphotoxin beta receptor", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06813": {"dbids": ["DB06813"], "name": "Pralatrexate", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00374", "drug": "DB06813"}, {"action": "INHIBITOR", "target": "P04818", "drug": "DB06813"}]}, "DB07104": {"dbids": ["DB07104"], "name": "4-amino-N-[4-(benzyloxy)phenyl]butanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08800": {"dbids": ["DB07523", "DB08800"], "name": "Chloropyramine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB08800"}]}, "DB00427": {"dbids": ["APRD00306", "DB00427"], "name": "Triprolidine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00427"}]}, "DB08803": {"dbids": ["DB08803"], "name": "Tymazoline", "groups": ["APPROVED"], "targets": []}, "DB02218": {"dbids": ["DB02218", "EXPT00405"], "name": "N-[4-Hydroxymethyl-Cyclohexan-6-Yl-1,2,3-Triol]-4,6-Dideoxy-4-Aminoglucopyranoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02219": {"dbids": ["DB02219", "EXPT01070"], "name": "3-Cyclohexyl-1-Propylsulfonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02216": {"dbids": ["DB02216", "EXPT01076", "EXPT02919"], "name": "S-Methylcysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02217": {"dbids": ["DB02217", "EXPT01255"], "name": "Dpb-T", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02214": {"dbids": ["DB02214", "EXPT02766"], "name": "6,7-Dioxo-5h-8-Ribitylaminolumazine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02215": {"dbids": ["DB02215", "EXPT01441"], "name": "Furoyl-Leucine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02213": {"dbids": ["DB02213", "EXPT01541"], "name": "Metanitrophenyl-Alpha-D-Galactoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02210": {"dbids": ["DB02210", "EXPT01731"], "name": "Hexane-1,6-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02211": {"dbids": ["DB02211", "EXPT02792"], "name": "N-Methyl-N-Propargyl-1(R)-Aminoindan", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00424": {"dbids": ["APRD00607", "DB00424"], "name": "Hyoscyamine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00424"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00424"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00424"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00424"}]}, "DB00423": {"dbids": ["APRD01102", "DB00423"], "name": "Methocarbamol", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00915", "drug": "DB00423"}]}, "DB00422": {"dbids": ["APRD00657", "DB00422"], "name": "Methylphenidate", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q01959", "drug": "DB00422"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00422"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00422"}]}, "DB00421": {"dbids": ["APRD01234", "DB00421"], "name": "Spironolactone", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08235", "drug": "DB00421"}, {"action": "ANTAGONIST", "target": "P10275", "drug": "DB00421"}, {"action": "AGONIST", "target": "P06401", "drug": "DB00421"}, {"action": "ANTAGONIST", "target": "P04150", "drug": "DB00421"}, {"action": "ANTAGONIST", "target": "P19099", "drug": "DB00421"}, {"action": "ANTAGONIST", "target": "P18405", "drug": "DB00421"}, {"action": "ANTAGONIST", "target": "P31213", "drug": "DB00421"}, {"action": "ANTAGONIST", "target": "Q9H8P0", "drug": "DB00421"}, {"action": "BINDER", "target": "P04278", "drug": "DB00421"}]}, "DB07260": {"dbids": ["DB07260"], "name": "N-benzyl-4-[(2R)-pyrrolidin-2-ylmethoxy]aniline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00352": {"dbids": ["APRD00290", "DB00352"], "name": "Tioguanine", "groups": ["APPROVED"], "targets": []}, "DB07343": {"dbids": ["DB07343"], "name": "4-[4-AMINO-6-(2,6-DICHLORO-PHENOXY)-[1,3,5]TRIAZIN-2-YLAMINO]-BENZONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01155": {"dbids": ["APRD00053", "DB01155"], "name": "Gemifloxacin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P43702", "drug": "DB01155"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB01155"}]}, "DB07342": {"dbids": ["DB07342"], "name": "1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06218": {"dbids": ["DB06218"], "name": "Lacosamide", "groups": ["APPROVED"], "targets": []}, "DB06219": {"dbids": ["DB06219"], "name": "Dalbavancin", "groups": ["APPROVED"], "targets": []}, "DB07261": {"dbids": ["DB07261"], "name": "THIENO[3,2-B]PYRIDINE-2-SULFONIC ACID [1-(1-AMINO-ISOQUINOLIN-7-YLMETHYL)-2-OXO-PYRROLDIN-3-YL]-AMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07347": {"dbids": ["DB07347"], "name": "4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07346": {"dbids": ["DB07346"], "name": "4-(2-aminoethyl)-2-ethylphenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01156": {"dbids": ["APRD00621", "DB01156"], "name": "Bupropion", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q01959", "drug": "DB01156"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB01156"}, {"action": "ANTAGONIST", "target": "P32297", "drug": "DB01156"}]}, "DB07345": {"dbids": ["DB07345"], "name": "4-(2-aminoethyl)-2-cyclohexylphenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07344": {"dbids": ["DB07344"], "name": "3,6,9,12,15-PENTAOXAHEPTADECAN-1-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03996": {"dbids": ["DB03996", "EXPT01994"], "name": "3-[(5s)-1-Acetyl-3-(2-Chlorophenyl)-4,5-Dihydro-1h-Pyrazol-5-Yl]Phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07262": {"dbids": ["DB07262"], "name": "1-{[N-(1-IMINO-GUANIDINO-METHYL)]SULFANYLMETHYL}-3-TRIFLUOROMETHYL-BENZENE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03333": {"dbids": ["DB03333", "EXPT02975"], "name": "(4-sulfamoyl-phenyl)-thiocarbamic acid O-(2-thiophen-3-yl-ethyl) ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03994": {"dbids": ["DB03994", "EXPT01366"], "name": "Ethanolamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01157": {"dbids": ["APRD00268", "DB01157"], "name": "Trimetrexate", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P00374", "drug": "DB01157"}]}, "DB03331": {"dbids": ["DB03331", "EXPT02362"], "name": "N-Naphthalen-1-Ylmethyl-2'-[3,5-Dimethoxybenzamido]-2'-Deoxy-Adenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03992": {"dbids": ["DB03992", "EXPT01128"], "name": "3-(Benzoylamino)-L-Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03993": {"dbids": ["DB03993", "EXPT00220"], "name": "4-Methyl Valeric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07263": {"dbids": ["DB07263"], "name": "[{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06742": {"dbids": ["DB06742"], "name": "Ambroxol", "groups": ["APPROVED"], "targets": []}, "DB03335": {"dbids": ["DB03335", "EXPT00069"], "name": "1-Bromopropane-2-Ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07932": {"dbids": ["DB07932"], "name": "dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05079": {"dbids": ["DB05079"], "name": "HY10275", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05078": {"dbids": ["DB05078"], "name": "AER001", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05073": {"dbids": ["DB05073"], "name": "SRT501", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05072": {"dbids": ["DB05072"], "name": "AV608", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05071": {"dbids": ["DB05071"], "name": "ACE393", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05070": {"dbids": ["DB05070"], "name": "ADX10059", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05077": {"dbids": ["DB05077"], "name": "SLV319", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05076": {"dbids": ["DB03922", "DB05076"], "name": "Fenretinide", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05075": {"dbids": ["DB05075"], "name": "TG100801", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08514": {"dbids": ["DB08514"], "name": "6-amino-2-[(thiophen-2-ylmethyl)amino]-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07264": {"dbids": ["DB07264"], "name": "(S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01792": {"dbids": ["DB01792", "EXPT00547"], "name": "Adenylyl-3'-5'-Phospho-Uridine-3'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01793": {"dbids": ["DB01793", "EXPT00277"], "name": "I-5", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01790": {"dbids": ["DB01790", "EXPT02808", "EXPT02940"], "name": "Sp-Adenosine-3',5'-Cyclic-Monophosphorothioate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01791": {"dbids": ["DB01791", "EXPT02600"], "name": "Piclamilast", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01796": {"dbids": ["DB01796", "EXPT02391"], "name": "Quinolinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01797": {"dbids": ["DB01797", "EXPT01014"], "name": "(2r)-2-(Aminomethyl)-2,4-Dihydroxy-5-Oxo-3-(2-Oxoethyl)-2,5-Dihydro-1h-Imidazol-3-Ium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01794": {"dbids": ["DB01794", "EXPT02688"], "name": "bis(molybdopterin)tungsten cofactor", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01795": {"dbids": ["DB01795", "EXPT02505"], "name": "Phenyl Boronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01828": {"dbids": ["DB01828", "EXPT02363"], "name": "Methylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01829": {"dbids": ["DB01829", "EXPT01129"], "name": "Desulfo-Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01798": {"dbids": ["DB01798", "EXPT02470"], "name": "Ethyl Dihydrogen Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01799": {"dbids": ["DB01799", "EXPT01334"], "name": "4-Hydroxy-3-Methyl Butyl Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07265": {"dbids": ["DB07265"], "name": "3-(9-HYDROXY-1,3-DIOXO-4-PHENYL-2,3-DIHYDROPYRROLO[3,4-C]CARBAZOL-6(1H)-YL)PROPANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01152": {"dbids": ["APRD00843", "DB01152"], "name": "Candicidin", "groups": ["WITHDRAWN"], "targets": []}, "DB07597": {"dbids": ["DB07597"], "name": "CIS-(1R,2S)-2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07266": {"dbids": ["DB07266"], "name": "8-ethyl-3,10,10-trimethyl-4,5,6,8,10,12-hexahydropyrazolo[4',3':6,7]cyclohepta[1,2-b]pyrrolo[2,3-f]indol-9(1H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01411": {"dbids": ["DB01411"], "name": "Pranlukast", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q9Y271", "drug": "DB01411"}, {"action": "OTHER/UNKNOWN", "target": "P01375", "drug": "DB01411"}, {"action": "ANTAGONIST", "target": "P05113", "drug": "DB01411"}, {"action": "OTHER/UNKNOWN", "target": "P12724", "drug": "DB01411"}, {"action": "OTHER/UNKNOWN", "target": "P19838", "drug": "DB01411"}, {"action": "OTHER/UNKNOWN", "target": "Q02817", "drug": "DB01411"}]}, "DB01256": {"dbids": ["DB01256"], "name": "Retapamulin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9A1X4", "drug": "DB01256"}]}, "DB01410": {"dbids": ["DB01410"], "name": "Ciclesonide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB01410"}]}, "DB07594": {"dbids": ["DB07594"], "name": "4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01413": {"dbids": ["DB01413"], "name": "Cefepime", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0AD65", "drug": "DB01413"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB01413"}, {"action": "INHIBITOR", "target": "Q51504", "drug": "DB01413"}, {"action": "INHIBITOR", "target": "Q9X6V3", "drug": "DB01413"}]}, "DB04678": {"dbids": ["DB04678"], "name": "H TYPE II TRISACCHARIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01412": {"dbids": ["DB01412"], "name": "Theobromine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P30542", "drug": "DB01412"}, {"action": "ANTAGONIST", "target": "P29274", "drug": "DB01412"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB01412"}]}, "DB01178": {"dbids": ["APRD00865", "DB01178"], "name": "Chlormezanone", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "AGONIST", "target": "P30536", "drug": "DB01178"}]}, "DB01179": {"dbids": ["APRD01189", "DB01179", "DB08417"], "name": "Podofilox", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P11388", "drug": "DB01179"}, {"action": "INHIBITOR", "target": "P68366", "drug": "DB01179"}, {"action": "INHIBITOR", "target": "P07437", "drug": "DB01179"}]}, "DB01176": {"dbids": ["APRD00061", "DB01176"], "name": "Cyclizine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB01176"}, {"action": "INHIBITOR", "target": "P49888", "drug": "DB01176"}]}, "DB01177": {"dbids": ["APRD00126", "DB01177"], "name": "Idarubicin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P11388", "drug": "DB01177"}]}, "DB01174": {"dbids": ["APRD00184", "DB01174"], "name": "Phenobarbital", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "Q05586", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "Q14957", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "O15399", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "O60391", "drug": "DB01174"}]}, "DB01175": {"dbids": ["APRD00683", "DB01175"], "name": "Escitalopram", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P31645", "drug": "DB01175"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB01175"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB01175"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01175"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01175"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01175"}]}, "DB01172": {"dbids": ["APRD00026", "DB01172"], "name": "Kanamycin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A7S3", "drug": "DB01172"}]}, "DB01173": {"dbids": ["APRD00097", "DB01173"], "name": "Orphenadrine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "O15399", "drug": "DB01173"}, {"action": "ANTAGONIST", "target": "Q05586", "drug": "DB01173"}, {"action": "ANTAGONIST", "target": "O60391", "drug": "DB01173"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB01173"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01173"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB01173"}, {"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB01173"}]}, "DB01170": {"dbids": ["APRD01007", "DB01170"], "name": "Guanethidine", "groups": ["APPROVED"], "targets": [{"action": "INDUCER", "target": "P23975", "drug": "DB01170"}]}, "DB01171": {"dbids": ["APRD00603", "DB01171"], "name": "Moclobemide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P21397", "drug": "DB01171"}]}, "DB08168": {"dbids": ["DB08168"], "name": "7-AMINO-4-METHYL-CHROMEN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01255": {"dbids": ["DB01255"], "name": "Lisdexamfetamine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q01959", "drug": "DB01255"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01255"}]}, "DB09462": {"dbids": ["DB09462"], "name": "Glycerin", "groups": ["APPROVED"], "targets": []}, "DB08162": {"dbids": ["DB08162"], "name": "5-(1,4-DIAZEPAN-1-SULFONYL)ISOQUINOLINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08163": {"dbids": ["DB08163"], "name": "5'-{[4-(aminooxy)butyl](methyl)amino}-5'-deoxy-8-ethenyladenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07595": {"dbids": ["DB07595"], "name": "(5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01416": {"dbids": ["DB01416"], "name": "Cefpodoxime", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0AD68", "drug": "DB01416"}]}, "DB08166": {"dbids": ["DB08166"], "name": "(4R)-7-chloro-9-methyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08167": {"dbids": ["DB08167"], "name": "3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-IUM", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08164": {"dbids": ["DB08164"], "name": "(3R,4R)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-3-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08165": {"dbids": ["DB08165"], "name": "indane-5-sulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB11122": {"dbids": ["DB11122"], "name": "Dextran 40", "groups": ["APPROVED"], "targets": []}, "DB07592": {"dbids": ["DB07592"], "name": "(1R)-2-METHYL-1-(PHENYLMETHYL)PROPYL[(1S)-1-FORMYLPENTYL]CARBAMATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07593": {"dbids": ["DB07593"], "name": "1-(PHENYLMETHYL)CYCLOPENTYL[(1S)-1-FORMYLPENTYL]CARBAMATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06176": {"dbids": ["DB06176"], "name": "Romidepsin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07590": {"dbids": ["DB07590"], "name": "S-[3-(3,4-DICHLOROPHENYL)-3-OXOPROPYL]-L-CYSTEINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07329": {"dbids": ["DB07329"], "name": "1-[N-4'-NITROBENZYL-N-4'-CARBOXYBUTYLAMINO]METHYLPHOSPHONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07328": {"dbids": ["DB07328"], "name": "METHYL 4-{[({[(2R,5S)-5-{[(2S)-2-(AMINOMETHYL)PYRROLIDIN-1-YL]CARBONYL}PYRROLIDIN-2-YL]METHYL}AMINO)CARBONYL]AMINO}BENZOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07591": {"dbids": ["DB07591"], "name": "N1-CYCLOPENTYL-N2-(THIAZOL-2-YL)OXALAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07638": {"dbids": ["DB07638"], "name": "(3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07321": {"dbids": ["DB07321"], "name": "2,5-DICHLORO-N-[5-METHOXY-7-(6-METHOXYPYRIDIN-3-YL)-1,3-BENZOXAZOL-2-YL]BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07320": {"dbids": ["DB07320"], "name": "4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07323": {"dbids": ["DB07323"], "name": "2-[({2-[(1Z)-3-(DIMETHYLAMINO)PROP-1-ENYL]-4-FLUOROPHENYL}SULFONYL)AMINO]-5,6,7,8-TETRAHYDRONAPHTHALENE-1-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07322": {"dbids": ["DB07322"], "name": "2-[(PHENYLSULFONYL)AMINO]-5,6,7,8-TETRAHYDRONAPHTHALENE-1-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07325": {"dbids": ["DB07325"], "name": "N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07324": {"dbids": ["DB07324"], "name": "3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07327": {"dbids": ["DB07327"], "name": "(2-ACETYL-5-METHYLANILINO)(2,6-DIBROMOPHENYL)ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07326": {"dbids": ["DB07326"], "name": "6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07341": {"dbids": ["DB07341"], "name": "octyl 3-amino-3-deoxy-2-O-(2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)-beta-D-galactopyranoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01614": {"dbids": ["DB01614"], "name": "Acepromazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB01614"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01614"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01614"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01614"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01614"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01614"}]}, "DB01094": {"dbids": ["APRD00117", "DB01094"], "name": "Hesperetin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35610", "drug": "DB01094"}, {"action": "INHIBITOR", "target": "O75908", "drug": "DB01094"}, {"action": "ANTAGONIST", "target": "P55157", "drug": "DB01094"}]}, "DB07340": {"dbids": ["DB07340"], "name": "N~6~-cyclohexyl-N~2~-(4-morpholin-4-ylphenyl)-9H-purine-2,6-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01092": {"dbids": ["APRD00135", "DB01092"], "name": "Ouabain", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P05023", "drug": "DB01092"}]}, "DB03539": {"dbids": ["DB03539", "EXPT02280"], "name": "2-(Acetylamino)-2-Deoxy-6-O-Methyl-Alpha-D-Allopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03530": {"dbids": ["DB03530", "EXPT00836"], "name": "Acylated Ceftazidime", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03531": {"dbids": ["DB03531", "EXPT01389"], "name": "Flavin-Adenine Dinucleotide-N5-Isobutyl Ketone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03532": {"dbids": ["DB03532", "EXPT01527"], "name": "Phosphomethylphosphonic Acid Guanylate Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03533": {"dbids": ["DB03533", "EXPT01607"], "name": "Glycoluril", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03534": {"dbids": ["DB03534", "EXPT03283"], "name": "3-[(Acetyl-Methyl-Amino)-Methyl]-4-Amino-N-Methyl-N-(1-Methyl-1h-Indol-2-Ylmethyl)-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03535": {"dbids": ["DB03535", "EXPT03293"], "name": "Z-Pro-Prolinal", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03536": {"dbids": ["DB03536", "EXPT03294"], "name": "Benzoyl-Arginine-Alanine-Methyl Ketone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03537": {"dbids": ["DB03537", "EXPT01042"], "name": "[4-(4-Hydroxy-Benzyl)-2-(2-Hydroxy-1-Methyl-Ethyl)-5-Oxo-Imidazolidin-1-Yl]-Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02915": {"dbids": ["DB02915", "EXPT00927"], "name": "4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(4-Trifluoromethyl-Phenyl)-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02914": {"dbids": ["DB02914", "EXPT00525"], "name": "(6e)-6-[(2e,4e,6e)-3,7-Dimethylnona-2,4,6,8-Tetraenylidene]-1,5,5-Trimethylcyclohexene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02917": {"dbids": ["DB02917", "EXPT02343"], "name": "N-Hydroxy-4-(Methyl{[5-(2-Pyridinyl)-2-Thienyl]Sulfonyl}Amino)Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02916": {"dbids": ["DB02916", "EXPT02043"], "name": "[(2r,3s,4r,5r)-5-(6-Amino-9h-Purin-9-Yl)-3,4-Dihydroxytetrahydro-2-Furanyl]Methyl Sulfamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02911": {"dbids": ["DB02911", "EXPT00536"], "name": "2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02910": {"dbids": ["DB02910", "EXPT00977"], "name": "Octanoyl-Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02912": {"dbids": ["DB02912", "EXPT00059"], "name": "Propionyl Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02919": {"dbids": ["DB02919", "EXPT01286"], "name": "2,4-Diamino-6-[N-(3',4',5'-Trimethoxybenzyl)-N-Methylamino]Pyrido[2,3-D]Pyrimidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02918": {"dbids": ["DB02918", "EXPT03284"], "name": "6-(4-Difluoromethoxy-3-Methoxy-Phenyl)-2h-Pyridazin-3-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05240": {"dbids": ["DB05240"], "name": "XL147", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05241": {"dbids": ["DB05241"], "name": "XL765", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05242": {"dbids": ["DB05242"], "name": "eiRNA", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05243": {"dbids": ["DB05243"], "name": "XL019", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05244": {"dbids": ["DB05244"], "name": "G4544", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05245": {"dbids": ["DB05245"], "name": "Silver sulfadiazine", "groups": ["APPROVED"], "targets": []}, "DB05246": {"dbids": ["DB05246"], "name": "Methsuximide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "O43497", "drug": "DB05246"}]}, "DB05248": {"dbids": ["DB05248", "EXPT00838"], "name": "5-bromo-cytidinemonophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05249": {"dbids": ["DB05249"], "name": "FavId", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB00491": {"dbids": ["APRD01117", "DB00491"], "name": "Miglitol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "O43451", "drug": "DB00491"}, {"action": "INHIBITOR", "target": "O43451", "drug": "DB00491"}, {"action": "ANTAGONIST", "target": "P10253", "drug": "DB00491"}, {"action": "ANTAGONIST", "target": "Q14697", "drug": "DB00491"}, {"action": "ANTAGONIST", "target": "Q8TET4", "drug": "DB00491"}]}, "DB06209": {"dbids": ["DB06209"], "name": "Prasugrel", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q9H244", "drug": "DB06209"}]}, "DB01015": {"dbids": ["APRD00076", "DB01015"], "name": "Sulfamethoxazole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0AC13", "drug": "DB01015"}, {"action": "INHIBITOR", "target": "P08192", "drug": "DB01015"}]}, "DB01014": {"dbids": ["APRD00141", "DB01014"], "name": "Balsalazide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P37231", "drug": "DB01014"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB01014"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB01014"}, {"action": "INHIBITOR", "target": "P09917", "drug": "DB01014"}]}, "DB08988": {"dbids": ["DB08988"], "name": "Ethoheptazine", "groups": ["WITHDRAWN"], "targets": []}, "DB08989": {"dbids": ["DB08989"], "name": "Etamivan", "groups": ["WITHDRAWN"], "targets": []}, "DB08984": {"dbids": ["DB08984"], "name": "Etofenamate", "groups": ["APPROVED"], "targets": []}, "DB08985": {"dbids": ["DB08985"], "name": "Etilefrine", "groups": ["WITHDRAWN"], "targets": []}, "DB08986": {"dbids": ["DB08986"], "name": "Etifoxine", "groups": ["WITHDRAWN"], "targets": []}, "DB08987": {"dbids": ["DB08987"], "name": "Etidocaine", "groups": ["APPROVED"], "targets": []}, "DB08980": {"dbids": ["DB08980"], "name": "Fendiline", "groups": ["WITHDRAWN"], "targets": []}, "DB08981": {"dbids": ["DB08981"], "name": "Fenbufen", "groups": ["APPROVED"], "targets": []}, "DB08982": {"dbids": ["DB08982"], "name": "Etozoline", "groups": ["APPROVED"], "targets": []}, "DB08983": {"dbids": ["DB08983"], "name": "Etofibrate", "groups": ["APPROVED"], "targets": []}, "DB01017": {"dbids": ["APRD00547", "DB01017"], "name": "Minocycline", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P0A7X3", "drug": "DB01017"}, {"action": "INHIBITOR", "target": "P0A7V8", "drug": "DB01017"}, {"action": "MODULATOR", "target": "P01584", "drug": "DB01017"}, {"action": "INHIBITOR", "target": "P09917", "drug": "DB01017"}, {"action": "INHIBITOR", "target": "P14780", "drug": "DB01017"}, {"action": "INHIBITOR", "target": "P15692", "drug": "DB01017"}, {"action": "NEGATIVE MODULATOR", "target": "P29466", "drug": "DB01017"}, {"action": "NEGATIVE MODULATOR", "target": "P42574", "drug": "DB01017"}, {"action": "NEGATIVE MODULATOR", "target": "P99999", "drug": "DB01017"}]}, "DB02667": {"dbids": ["DB02667", "EXPT00608"], "name": "Factor IIIm", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02666": {"dbids": ["DB02666", "EXPT02810"], "name": "(C8-R)-Hydantocidin 5'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02665": {"dbids": ["DB02665", "EXPT03088"], "name": "Trans-2-Phenylcyclopropylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02664": {"dbids": ["DB02664", "EXPT00775"], "name": "1-Butane Boronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02663": {"dbids": ["DB02663", "EXPT02645"], "name": "2-Amino-4-(Hydroxymethyl-Phosphinyl)Butanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02662": {"dbids": ["DB02662", "EXPT00329"], "name": "Novo Nordisk a/S Compound", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02661": {"dbids": ["DB02661", "EXPT00592"], "name": "Adenosine-5'-Diphosphate-2',3'-Vanadate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02660": {"dbids": ["DB02660", "EXPT01434"], "name": "Filaminast", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02669": {"dbids": ["DB02669", "EXPT03062"], "name": "RB106", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02668": {"dbids": ["DB02668", "EXPT01956"], "name": "Je-2147, Ag1776, Kni-764", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08368": {"dbids": ["DB08368"], "name": "OCTANE-1,3,5,7-TETRACARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06205": {"dbids": ["DB06205"], "name": "Hyaluronidase (Human Recombinant)", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P01137", "drug": "DB06205"}]}, "DB08369": {"dbids": ["DB08369"], "name": "1-(biphenyl-4-ylmethyl)-1H-imidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB11330": {"dbids": ["DB11330"], "name": "Factor IX complex", "groups": ["APPROVED"], "targets": []}, "DB01010": {"dbids": ["APRD00944", "DB01010"], "name": "Edrophonium", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P22303", "drug": "DB01010"}, {"action": "INHIBITOR", "target": "P06276", "drug": "DB01010"}]}, "DB01898": {"dbids": ["DB01898", "EXPT02151"], "name": "2s,3r-2-Amino-3-Methylpentanedioic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06907": {"dbids": ["DB06907"], "name": "2-(2,6-DICHLOROPHENYL)-1,3-BENZOXAZOLE-6-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01013": {"dbids": ["APRD00876", "DB01013"], "name": "Clobetasol propionate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB01013"}]}, "DB09177": {"dbids": ["DB09177"], "name": "4-fluorofentanyl", "groups": ["ILLICIT"], "targets": []}, "DB09174": {"dbids": ["DB09174"], "name": "Lofentanil", "groups": ["ILLICIT"], "targets": []}, "DB09175": {"dbids": ["DB09175"], "name": "Mirfentanil", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09172": {"dbids": ["DB09172"], "name": "Brifentanil", "groups": ["ILLICIT"], "targets": []}, "DB09173": {"dbids": ["DB09173"], "name": "Butyrfentanyl", "groups": ["ILLICIT"], "targets": []}, "DB09170": {"dbids": ["DB09170"], "name": "\u03b2-Hydroxythiofentanyl", "groups": ["ILLICIT"], "targets": []}, "DB09171": {"dbids": ["DB09171"], "name": "\u03b2-Methylfentanyl", "groups": ["ILLICIT"], "targets": []}, "DB09178": {"dbids": ["DB09178"], "name": "Phenaridine", "groups": ["ILLICIT"], "targets": []}, "DB09179": {"dbids": ["DB09179"], "name": "R-30490", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01363": {"dbids": ["DB01363"], "name": "Ephedra", "groups": ["APPROVED", "NUTRACEUTICAL", "WITHDRAWN"], "targets": [{"action": "NEGATIVE MODULATOR", "target": "Q01959", "drug": "DB01363"}, {"action": "NEGATIVE MODULATOR", "target": "P23975", "drug": "DB01363"}, {"action": "AGONIST", "target": "P08913", "drug": "DB01363"}, {"action": "AGONIST", "target": "P18089", "drug": "DB01363"}, {"action": "AGONIST", "target": "P18825", "drug": "DB01363"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB01363"}, {"action": "INHIBITOR", "target": "P27338", "drug": "DB01363"}, {"action": "AGONIST", "target": "P08588", "drug": "DB01363"}, {"action": "AGONIST", "target": "P07550", "drug": "DB01363"}, {"action": "AGONIST", "target": "P13945", "drug": "DB01363"}, {"action": "NEGATIVE MODULATOR", "target": "P31645", "drug": "DB01363"}, {"action": "INHIBITOR", "target": "Q05940", "drug": "DB01363"}, {"action": "INHIBITOR", "target": "P54219", "drug": "DB01363"}]}, "DB01362": {"dbids": ["DB01362"], "name": "Iohexol", "groups": ["APPROVED"], "targets": []}, "DB01361": {"dbids": ["DB01361"], "name": "Troleandomycin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P49228", "drug": "DB01361"}, {"action": "INHIBITOR", "target": "P60723", "drug": "DB01361"}]}, "DB01367": {"dbids": ["DB01367", "EXPT02758"], "name": "Rasagiline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P27338", "drug": "DB01367"}, {"action": "ACTIVATOR", "target": "P10415", "drug": "DB01367"}]}, "DB01366": {"dbids": ["DB01366"], "name": "Procaterol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P07550", "drug": "DB01366"}]}, "DB01365": {"dbids": ["DB01365"], "name": "Mephentermine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35348", "drug": "DB01365"}, {"action": "AGONIST", "target": "P35368", "drug": "DB01365"}, {"action": "AGONIST", "target": "P25100", "drug": "DB01365"}, {"action": "AGONIST", "target": "P08913", "drug": "DB01365"}, {"action": "AGONIST", "target": "P18089", "drug": "DB01365"}, {"action": "AGONIST", "target": "P18825", "drug": "DB01365"}, {"action": "AGONIST", "target": "P08588", "drug": "DB01365"}, {"action": "AGONIST", "target": "P07550", "drug": "DB01365"}, {"action": "AGONIST", "target": "P13945", "drug": "DB01365"}]}, "DB01364": {"dbids": ["DB01364"], "name": "Ephedrine", "groups": ["APPROVED"], "targets": [{"action": "INVERSE AGONIST", "target": "P23975", "drug": "DB01364"}, {"action": "INHIBITOR", "target": "Q05940", "drug": "DB01364"}]}, "DB01012": {"dbids": ["APRD00872", "DB01012"], "name": "Cinacalcet", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P41180", "drug": "DB01012"}]}, "DB01369": {"dbids": ["DB01369"], "name": "Quinupristin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A7J6", "drug": "DB01369"}, {"action": "INHIBITOR", "target": "P61177", "drug": "DB01369"}]}, "DB05655": {"dbids": ["DB05655"], "name": "TD-5108", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05306": {"dbids": ["DB05306"], "name": "Alferminogene Tadenovec", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05300": {"dbids": ["DB05300"], "name": "PTI-801", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05303": {"dbids": ["DB05303"], "name": "OMS-103HP", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05650": {"dbids": ["DB05650"], "name": "OT-551", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01587": {"dbids": ["DB01587"], "name": "Ketazolam", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P30536", "drug": "DB01587"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01587"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB01587"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB01587"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB01587"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB01587"}]}, "DB01586": {"dbids": ["DB01586"], "name": "Ursodeoxycholic acid", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INDUCER", "target": "P52895", "drug": "DB01586"}]}, "DB01584": {"dbids": ["DB01584"], "name": "Thyroglobulin", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB01583": {"dbids": ["DB01583"], "name": "Liotrix", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P10827", "drug": "DB01583"}, {"action": "AGONIST", "target": "P10828", "drug": "DB01583"}]}, "DB01582": {"dbids": ["DB01582"], "name": "Sulfamethazine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0AC13", "drug": "DB01582"}]}, "DB01581": {"dbids": ["DB01581"], "name": "Sulfamerazine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0AC13", "drug": "DB01581"}]}, "DB01580": {"dbids": ["DB01580"], "name": "Oxprenolol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB01580"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB01580"}]}, "DB01589": {"dbids": ["DB01589"], "name": "Quazepam", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01589"}]}, "DB01588": {"dbids": ["DB01588"], "name": "Prazepam", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01588"}]}, "DB03512": {"dbids": ["DB03512", "EXPT03211"], "name": "Uridine-2',3'-Vanadate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09318": {"dbids": ["DB09318"], "name": "Synthetic Conjugated Estrogens, B", "groups": ["APPROVED"], "targets": []}, "DB03513": {"dbids": ["DB03513", "EXPT00151"], "name": "(S)-2-Amino-3-(4h-Selenolo[3,2-B]-Pyrrol-6-Yl)-Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03510": {"dbids": ["DB03510", "EXPT01873"], "name": "6-O-Phosphoryl Inosine Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00360": {"dbids": ["APRD01297", "DB00360"], "name": "Tetrahydrobiopterin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "COFACTOR", "target": "P29474", "drug": "DB00360"}, {"action": "COFACTOR", "target": "P00439", "drug": "DB00360"}, {"action": "COFACTOR", "target": "P07101", "drug": "DB00360"}, {"action": "COFACTOR", "target": "P17752", "drug": "DB00360"}]}, "DB00361": {"dbids": ["APRD00101", "DB00361"], "name": "Vinorelbine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P07437", "drug": "DB00361"}]}, "DB00362": {"dbids": ["APRD01301", "DB00362"], "name": "Anidulafungin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "A2QLK4", "drug": "DB00362"}]}, "DB00363": {"dbids": ["APRD00470", "DB00363"], "name": "Clozapine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P28221", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P28566", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "Q9H3N8", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00363"}, {"action": "UNKNOWN", "target": "Q9NYX4", "drug": "DB00363"}]}, "DB00364": {"dbids": ["APRD01238", "DB00364"], "name": "Sucralfate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P09038", "drug": "DB00364"}, {"action": "INDUCER", "target": "P01133", "drug": "DB00364"}, {"action": "ANTAGONIST", "target": "P02671", "drug": "DB00364"}, {"action": "ANTAGONIST", "target": "P02675", "drug": "DB00364"}, {"action": "ANTAGONIST", "target": "P02679", "drug": "DB00364"}]}, "DB00365": {"dbids": ["APRD01003", "DB00365"], "name": "Grepafloxacin", "groups": ["WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P43700", "drug": "DB00365"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB00365"}]}, "DB00366": {"dbids": ["APRD00937", "DB00366"], "name": "Doxylamine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00366"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00366"}]}, "DB00367": {"dbids": ["APRD00106", "APRD00754", "DB00367", "DB00506"], "name": "Levonorgestrel", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "BINDER", "target": "P06401", "drug": "DB00367"}, {"action": "INHIBITOR", "target": "P18405", "drug": "DB00367"}, {"action": "OTHER", "target": "P03372", "drug": "DB00367"}, {"action": "AGONIST", "target": "P10275", "drug": "DB00367"}]}, "DB00368": {"dbids": ["APRD01299", "DB00368"], "name": "Norepinephrine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35348", "drug": "DB00368"}, {"action": "AGONIST", "target": "P35368", "drug": "DB00368"}, {"action": "AGONIST", "target": "P25100", "drug": "DB00368"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00368"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00368"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00368"}, {"action": "AGONIST", "target": "P08588", "drug": "DB00368"}, {"action": "AGONIST", "target": "P07550", "drug": "DB00368"}, {"action": "AGONIST", "target": "P13945", "drug": "DB00368"}, {"action": "INHIBITOR", "target": "P00439", "drug": "DB00368"}, {"action": "BINDER", "target": "Q05940", "drug": "DB00368"}, {"action": "BINDER", "target": "P54219", "drug": "DB00368"}]}, "DB00369": {"dbids": ["APRD00148", "DB00369"], "name": "Cidofovir", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P08546", "drug": "DB00369"}]}, "DB09314": {"dbids": ["DB09314"], "name": "Technetium Tc-99m sodium pertechnetate", "groups": ["APPROVED"], "targets": []}, "DB06809": {"dbids": ["DB06809"], "name": "Plerixafor", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P61073", "drug": "DB06809"}]}, "DB03041": {"dbids": ["DB03041", "EXPT03177"], "name": "Udp-Glucuronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03981": {"dbids": ["DB03981", "EXPT03166"], "name": "1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03980": {"dbids": ["DB03980", "EXPT02850"], "name": "4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03983": {"dbids": ["DB03983", "EXPT02249"], "name": "(Molybdopterin-S,S)-Dioxo-Thio-Molybdenum(V)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03982": {"dbids": ["DB03982", "EXPT00306"], "name": "Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03329": {"dbids": ["DB03329", "EXPT02724"], "name": "2-Pyridinethiol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03328": {"dbids": ["DB03328", "EXPT02214"], "name": "dioxothiomolybdenum(VI) ion", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03987": {"dbids": ["DB03987", "EXPT00988"], "name": "2,4-Diamino-6-[N-(3',5'-Dimethoxybenzyl)-N-Methylamino]Pyrido[2,3-D]Pyrimidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03986": {"dbids": ["DB03986", "EXPT01451"], "name": "6-Methyl-Formycin A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03325": {"dbids": ["DB03325", "EXPT03277"], "name": "Tyrosyladenylate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03988": {"dbids": ["DB03988", "EXPT02078"], "name": "2,6-Diamino-Hexanoic Acid Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03327": {"dbids": ["DB03327", "EXPT01879"], "name": "{1-[(3-Hydroxy-Methyl-5-Phosphonooxy-Methyl-Pyridin-4-Ylmethyl)-Amino]-Ethyl}-Phosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03326": {"dbids": ["DB03326", "EXPT00901"], "name": "deoxycytidylyl-3',5'-guanosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03321": {"dbids": ["DB03321", "EXPT00202"], "name": "4-Amino-2-Deoxy-2,3-Dehydro-N-Neuraminic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03320": {"dbids": ["DB03320", "EXPT01238"], "name": "3-Amino-Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03323": {"dbids": ["DB03323", "EXPT02111"], "name": "Maltose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03322": {"dbids": ["DB03322", "EXPT02931"], "name": "1-(Isopropylamino)-3-(1-Naphthyloxy)-2-Propanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04531": {"dbids": ["DB04531", "EXPT00643"], "name": "Benzylcysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04530": {"dbids": ["DB04530", "EXPT00954"], "name": "S,S-(2-Hydroxyethyl)Thiocysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04533": {"dbids": ["DB04533", "EXPT00100"], "name": "2-Amino-P-Cresol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04532": {"dbids": ["DB04532", "EXPT01882"], "name": "Indole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04534": {"dbids": ["DB04534", "EXPT00255"], "name": "5-Nitroindazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04537": {"dbids": ["DB04537", "EXPT02063"], "name": "L-Tryptophanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04539": {"dbids": ["DB04539", "EXPT01639"], "name": "Glyphosate", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "Q9S400", "drug": "DB04539"}]}, "DB04538": {"dbids": ["DB04538", "EXPT00179"], "name": "2s,3s-3-Methylaspartic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09311": {"dbids": ["DB09311"], "name": "Polycarbophil calcium", "groups": ["APPROVED"], "targets": []}, "DB00188": {"dbids": ["APRD00828", "DB00188", "DB07475"], "name": "Bortezomib", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q13200", "drug": "DB00188"}, {"action": "ANTAGONIST", "target": "P20618", "drug": "DB00188"}, {"action": "ANTAGONIST", "target": "P28074", "drug": "DB00188"}, {"action": "ANTAGONIST", "target": "P49721", "drug": "DB00188"}, {"action": "INHIBITOR", "target": "Q99460", "drug": "DB00188"}]}, "DB00189": {"dbids": ["APRD00958", "DB00189"], "name": "Ethchlorvynol", "groups": ["APPROVED", "ILLICIT", "WITHDRAWN"], "targets": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00189"}]}, "DB00184": {"dbids": ["APRD00200", "DB00184", "DB09463", "EXPT02315"], "name": "Nicotine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P43681", "drug": "DB00184"}, {"action": "AGONIST", "target": "P36544", "drug": "DB00184"}, {"action": "AGONIST", "target": "P17787", "drug": "DB00184"}, {"action": "AGONIST", "target": "Q15822", "drug": "DB00184"}, {"action": "AGONIST", "target": "P32297", "drug": "DB00184"}, {"action": "AGONIST", "target": "P30532", "drug": "DB00184"}, {"action": "AGONIST", "target": "Q15825", "drug": "DB00184"}, {"action": "AGONIST", "target": "Q9UGM1", "drug": "DB00184"}, {"action": "AGONIST", "target": "Q9GZZ6", "drug": "DB00184"}, {"action": "AGONIST", "target": "Q05901", "drug": "DB00184"}, {"action": "AGONIST", "target": "P30926", "drug": "DB00184"}]}, "DB00185": {"dbids": ["APRD00224", "DB00185"], "name": "Cevimeline", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P20309", "drug": "DB00185"}, {"action": "AGONIST", "target": "P11229", "drug": "DB00185"}]}, "DB00186": {"dbids": ["APRD00116", "DB00186"], "name": "Lorazepam", "groups": ["APPROVED"], "targets": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00186"}, {"action": "OTHER", "target": "P30536", "drug": "DB00186"}]}, "DB00187": {"dbids": ["APRD00954", "DB00187"], "name": "Esmolol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB00187"}]}, "DB00180": {"dbids": ["APRD00976", "DB00180"], "name": "Flunisolide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00180"}]}, "DB00181": {"dbids": ["APRD00551", "DB00181"], "name": "Baclofen", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "Q9UBS5", "drug": "DB00181"}, {"action": "AGONIST", "target": "O75899", "drug": "DB00181"}]}, "DB00182": {"dbids": ["APRD00480", "DB00182"], "name": "Amphetamine", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "INHIBITOR", "target": "Q05940", "drug": "DB00182"}, {"action": "NEGATIVE MODULATOR", "target": "Q01959", "drug": "DB00182"}, {"action": "AGONIST", "target": "Q16568", "drug": "DB00182"}, {"action": "AGONIST", "target": "Q96RJ0", "drug": "DB00182"}, {"action": "STIMULATOR", "target": "P23975", "drug": "DB00182"}, {"action": "AGONIST", "target": "P35348", "drug": "DB00182"}, {"action": "AGONIST", "target": "P35368", "drug": "DB00182"}, {"action": "AGONIST", "target": "P25100", "drug": "DB00182"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00182"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00182"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00182"}, {"action": "AGONIST", "target": "P08588", "drug": "DB00182"}, {"action": "AGONIST", "target": "P07550", "drug": "DB00182"}, {"action": "AGONIST", "target": "P13945", "drug": "DB00182"}, {"action": "BINDER", "target": "P14416", "drug": "DB00182"}, {"action": "BINDER", "target": "P31645", "drug": "DB00182"}]}, "DB00183": {"dbids": ["APRD01172", "DB00183"], "name": "Pentagastrin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P32239", "drug": "DB00183"}]}, "DB03189": {"dbids": ["DB03189", "EXPT02191"], "name": "Cu-Cyclam", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03188": {"dbids": ["DB03188", "EXPT01645"], "name": "4-Thio-Beta-D-Glucopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03181": {"dbids": ["DB03181", "EXPT02554"], "name": "2-[4-(4-Hydroxy-3-Isopropyl-Phenoxy)-3,5-Dimethyl-Phenyl]-2h-[1,2,4]Triazine-3,5-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03180": {"dbids": ["DB03180", "EXPT00037"], "name": "4,5-Dimethyl-1,2-Phenylenediamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03183": {"dbids": ["DB03183", "EXPT00243"], "name": "1-(4-Aminophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03182": {"dbids": ["DB03182", "EXPT01407"], "name": "Alpha-Fluoro-Carboxymethyldethia Coenzyme a Complex", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03185": {"dbids": ["DB03185", "EXPT00750"], "name": "1-Beta-Ribofuranosyl-1,3-Diazepinone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03184": {"dbids": ["DB03184", "EXPT03249"], "name": "5-Amino-3-Methyl-Pyrrolidine-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03187": {"dbids": ["DB03187", "EXPT02450"], "name": "6-(Hydroxyethyldithio)-8-(Aminomethylthio)Octanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03186": {"dbids": ["DB03186", "EXPT02700"], "name": "U-Pi-a-Pi", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06829": {"dbids": ["DB06829"], "name": "4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08363": {"dbids": ["DB08363"], "name": "1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07158": {"dbids": ["DB07158"], "name": "5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09285": {"dbids": ["DB09285"], "name": "Morniflumate", "groups": ["APPROVED"], "targets": []}, "DB00984": {"dbids": ["APRD00134", "DB00984"], "name": "Nandrolone phenpropionate", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P10275", "drug": "DB00984"}]}, "DB00985": {"dbids": ["APRD00924", "DB00985"], "name": "Dimenhydrinate", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00985"}]}, "DB00986": {"dbids": ["APRD01000", "DB00986"], "name": "Glycopyrrolate", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00986"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00986"}, {"action": "BINDER", "target": "P08172", "drug": "DB00986"}]}, "DB00987": {"dbids": ["APRD00499", "DB00987"], "name": "Cytarabine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P06746", "drug": "DB00987"}]}, "DB00980": {"dbids": ["APRD01213", "DB00980"], "name": "Ramelteon", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "MULTITARGET", "target": "P48039", "drug": "DB00980"}, {"action": "MULTITARGET", "target": "P49286", "drug": "DB00980"}]}, "DB00981": {"dbids": ["APRD00406", "DB00981"], "name": "Physostigmine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P22303", "drug": "DB00981"}]}, "DB00982": {"dbids": ["APRD00140", "DB00982"], "name": "Isotretinoin", "groups": ["APPROVED"], "targets": [{"action": "OTHER/UNKNOWN", "target": "P10276", "drug": "DB00982"}]}, "DB00983": {"dbids": ["APRD00641", "DB00983"], "name": "Formoterol", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P07550", "drug": "DB00983"}]}, "DB00988": {"dbids": ["APRD00085", "DB00988"], "name": "Dopamine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P14416", "drug": "DB00988"}, {"action": "AGONIST", "target": "P21728", "drug": "DB00988"}, {"action": "AGONIST", "target": "P21918", "drug": "DB00988"}, {"action": "AGONIST", "target": "P35462", "drug": "DB00988"}, {"action": "AGONIST", "target": "P21917", "drug": "DB00988"}, {"action": "INDUCER", "target": "Q01959", "drug": "DB00988"}, {"action": "LIGAND", "target": "P09172", "drug": "DB00988"}, {"action": "BINDER", "target": "P08908", "drug": "DB00988"}, {"action": "BINDER", "target": "P34969", "drug": "DB00988"}, {"action": "AGONIST", "target": "P21728", "drug": "DB00988"}, {"action": "AGONIST", "target": "P21918", "drug": "DB00988"}]}, "DB00989": {"dbids": ["APRD00321", "DB00989"], "name": "Rivastigmine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P22303", "drug": "DB00989"}, {"action": "INHIBITOR", "target": "P06276", "drug": "DB00989"}]}, "DB06828": {"dbids": ["DB06828"], "name": "5-[2-(1H-pyrrol-1-yl)ethoxy]-1H-indole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04357": {"dbids": ["DB04357", "EXPT00546"], "name": "Pteric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04356": {"dbids": ["DB04356", "EXPT00356"], "name": "9-Deazaguanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04359": {"dbids": ["DB04359", "EXPT03236"], "name": "Vinylsulphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02058": {"dbids": ["DB02058", "EXPT02973"], "name": "SU4984", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02059": {"dbids": ["DB02059", "EXPT00544"], "name": "Adenosine-5-Diphosphoribose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02054": {"dbids": ["DB02054", "EXPT01542"], "name": "Gabaculine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02055": {"dbids": ["DB02055", "EXPT02297"], "name": "N-Butyl-Benzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02056": {"dbids": ["DB02056", "EXPT02562"], "name": "(5e,13e)-9,15-Dihydroxy-11-Oxoprosta-5,13-Dien-1-Oicacid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02057": {"dbids": ["DB02057", "EXPT00513"], "name": "AMPA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02051": {"dbids": ["DB02051", "EXPT03233"], "name": "3-[N-[Benzyloxycarbonyl]-Phenylalaninyl-Amino]-5-Phenyl-Pentane-1-Sulfonic Acid 4-Nitro-Phenyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02052": {"dbids": ["DB02052", "EXPT01949"], "name": "Indirubin-3'-Monoxime", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "Q00535", "drug": "DB02052"}, {"action": "BINDER", "target": "P06493", "drug": "DB02052"}, {"action": "INHIBITOR", "target": "P24941", "drug": "DB02052"}]}, "DB02053": {"dbids": ["DB02053", "EXPT02747"], "name": "Ribose-5-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06042": {"dbids": ["DB06042"], "name": "ZEN-012", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06914": {"dbids": ["DB06914"], "name": "1-({2-[2-(4-CHLOROPHENYL)ETHYL]-1,3-DIOXOLAN-2-YL}METHYL)-1H-IMIDAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02586": {"dbids": ["DB02586", "EXPT01261"], "name": "4,7-Dimethyl-[1,10]Phenanthroline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02587": {"dbids": ["DB02587", "EXPT01467"], "name": "Forskolin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02585": {"dbids": ["DB02585", "EXPT00206"], "name": "4-(Hydroxymethyl)Benzamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02582": {"dbids": ["DB02582", "EXPT00870"], "name": "D-(L-a-Aminoadipoyl)-L-Cysteinyl-D-Isodehydrovaline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02583": {"dbids": ["DB02583", "EXPT02658"], "name": "N6-(2,5-Dimethoxy-Benzyl)-N6-Methyl-Pyrido[2,3-D]Pyrimidine-2,4,6-Triamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02580": {"dbids": ["DB02580", "EXPT02566"], "name": "1-(2-Methoxy-Ethoxy)-2-{2-[2-(2-Methoxy-Ethoxy]-Ethoxy}-Ethane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02581": {"dbids": ["DB02581", "EXPT01491"], "name": "5-[2,3-Dichloro-4-(5-{1-[2-(2-Guanidino-4-Methyl-Pentanoylamino)-Acetyl]-Piperidin-4-Yl}-1-Methyl-1h-Pyrazol-3-Yl)-Phenoxymethyl]-Furan-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02588": {"dbids": ["DB02588", "EXPT02215"], "name": "Moxalactam Derivative", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02589": {"dbids": ["DB02589", "EXPT01939"], "name": "Se-Ethyl-Isoselenourea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02278": {"dbids": ["DB02278", "EXPT02803"], "name": "7,8-Dihydro-7,7-Dimethyl-6-Hydroxypterin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02279": {"dbids": ["DB02279", "EXPT00053"], "name": "Benzoylformic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02270": {"dbids": ["DB02270", "EXPT01279"], "name": "Dimethylallyl S-Thiolodiphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02271": {"dbids": ["DB02271", "EXPT02345"], "name": "S-(2-Oxo)Pentadecylcoa", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02272": {"dbids": ["DB02272", "EXPT02507"], "name": "Porphobilinogen", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02273": {"dbids": ["DB02273", "EXPT01192"], "name": "2,6-Dimethyl-7-Octen-2-Ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02274": {"dbids": ["DB02274", "EXPT01962"], "name": "7-Keto-8-Aminopelargonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02275": {"dbids": ["DB02275", "EXPT02508"], "name": "[2-Aminomethyl-5-Oxo-4-(4-Oxo-Cyclohexa-2,5-Dienylmethyl)-4,5-Dihydro-Imidazol-1-Yl] -Acetaldehyde", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02276": {"dbids": ["DB02276", "EXPT02185"], "name": "(S)-2-(Phosphonoxy)Caproyl-L-Leucyl-P-Nitroanilide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02277": {"dbids": ["DB02277", "EXPT00726"], "name": "1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08116": {"dbids": ["DB08116"], "name": "(3R)-4-{[(3,4-dihydroxyphenyl)acetyl]oxy}-N-(2-formylindolizin-3-yl)-3-sulfino-D-valine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09293": {"dbids": ["DB09293"], "name": "Sodium Iodide I-131", "groups": ["APPROVED"], "targets": []}, "DB08114": {"dbids": ["DB08114"], "name": "5-benzyl-1,3-thiazol-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09291": {"dbids": ["DB09291"], "name": "Rolapitant", "groups": ["APPROVED"], "targets": []}, "DB07989": {"dbids": ["DB07989"], "name": "2-(ACETYL-HYDROXY-AMINO)-4-METHYL-PENTANOIC ACID METHYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07988": {"dbids": ["DB07988"], "name": "2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07985": {"dbids": ["DB07985"], "name": "+/-METHYL 4-(AMINOIMINOMETHYL)-BETA-[3- INH (AMINOIMINO)PHENYL]BENZENE PENTANOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07984": {"dbids": ["DB07984"], "name": "2-[1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYL-1H-INDOL-3-YL]-N-[(1S)-1-(HYDROXYMETHYL)PROPYL]ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07987": {"dbids": ["DB07987"], "name": "[2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07986": {"dbids": ["DB07986"], "name": "[4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07981": {"dbids": ["DB07981"], "name": "2-[1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYL-1H-INDOL-3-YL]-N-[(1R)-1-(HYDROXYMETHYL)PROPYL]ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07980": {"dbids": ["DB07980"], "name": "(2E)-1-[(6-chloropyridin-3-yl)methyl]-N-nitroimidazolidin-2-imine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07983": {"dbids": ["DB07983"], "name": "1-(4-IODOBENZOYL)-5-METHOXY-2-METHYL INDOLE-3-ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07982": {"dbids": ["DB07982"], "name": "2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01675": {"dbids": ["DB01675", "EXPT00129"], "name": "Methacrylyl-Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09295": {"dbids": ["DB09295"], "name": "Talniflumate", "groups": ["APPROVED"], "targets": []}, "DB04282": {"dbids": ["DB04282", "EXPT01525"], "name": "2-Deoxy-2fluoro-Glucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09294": {"dbids": ["DB09294"], "name": "Sodium lactate", "groups": ["APPROVED"], "targets": []}, "DB04234": {"dbids": ["DB04234", "EXPT02267"], "name": "N2-({[(4-Bromophenyl)Methyl]Oxy}Carbonyl)-N1-[(1s)-1-Formylpentyl]-L-Leucinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04281": {"dbids": ["DB04281", "EXPT00451"], "name": "2-[4-(4-Chlorophenyl)Cyclohexylidene]-3,4-Dihydroxy-1(2h)-Naphthalenone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05914": {"dbids": ["DB05914"], "name": "mesenchymal stem cells", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04280": {"dbids": ["DB04280", "EXPT01146"], "name": "((2r,3s,5r)-3-Hydroxy-5-(4-Hydroxy-2-Oxo-3,4-Dihydropyrimidin-1(2h)-Yl)-Tetrahydrofuran-2-Yl)Methyldihydrogen Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05263": {"dbids": ["DB05263"], "name": "Caprospinol", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01671": {"dbids": ["DB01671", "EXPT01738"], "name": "4-(Hydroxymercury)Benzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05260": {"dbids": ["DB05260"], "name": "Gallium nitrate", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P31350", "drug": "DB05260"}, {"action": "INHIBITOR", "target": "P21281", "drug": "DB05260"}, {"action": "ANTAGONIST", "target": "P02818", "drug": "DB05260"}, {"action": "INHIBITOR", "target": "Q9S427", "drug": "DB05260"}, {"action": "ANTAGONIST", "target": "P01584", "drug": "DB05260"}]}, "DB01670": {"dbids": ["DB01670", "EXPT00225"], "name": "Propyl Acetate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01673": {"dbids": ["DB01673", "EXPT03184"], "name": "Uridine-5'-Diphosphate-N-Acetylmuramoyl-L-Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05910": {"dbids": ["DB05910"], "name": "ALS-357", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04284": {"dbids": ["DB04284", "EXPT02506"], "name": "Proline Betaine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05055": {"dbids": ["DB05055"], "name": "RG2417", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05054": {"dbids": ["DB05054"], "name": "AN0128", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05057": {"dbids": ["DB05057"], "name": "Erdosteine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05056": {"dbids": ["DB05056"], "name": "EGS21", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05051": {"dbids": ["DB05051"], "name": "BZL101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05050": {"dbids": ["DB05050"], "name": "ADL5859", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05053": {"dbids": ["DB05053"], "name": "MB07803", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05052": {"dbids": ["DB05052"], "name": "MF101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05265": {"dbids": ["DB05265"], "name": "Ecabet", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "Q8NFA2", "drug": "DB05265"}, {"action": "INHIBITOR", "target": "P18314", "drug": "DB05265"}]}, "DB05059": {"dbids": ["DB05059"], "name": "ILY101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05058": {"dbids": ["DB05058"], "name": "AN2690", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07551": {"dbids": ["DB07551"], "name": "2-CHLORO-4-ETHYLAMINO-6-(S(-)-2'-CYANO-4-BUTYLAMINO)-1,3,5-TRIAZINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07556": {"dbids": ["DB07556"], "name": "N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07557": {"dbids": ["DB07557"], "name": "(5BETA)-PREGNANE-3,20-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07555": {"dbids": ["DB07555"], "name": "1-(2-nitrophenyl)-2,2,2-trifluoroethyl]-arsenocholine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07732": {"dbids": ["DB07732"], "name": "2-[(2-NAPHTHYLSULFONYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01808": {"dbids": ["DB01808", "EXPT01089"], "name": "Thiarsahydroxy-Cysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01809": {"dbids": ["DB01809", "EXPT02633"], "name": "1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01778": {"dbids": ["DB01778", "EXPT00087"], "name": "8-Amino-1,3-Dimethyl-3,7-Dihydropurine-2,6-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01779": {"dbids": ["DB01779", "EXPT01526"], "name": "Glycerol-2-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07733": {"dbids": ["DB07733"], "name": "1-METHYL-3-TRIFLUOROMETHYL-1H-THIENO[2,3-C]PYRAZOLE-5-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)-AMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01774": {"dbids": ["DB01774", "EXPT00437"], "name": "Adenosine-5'-Monophosphate Glucopyranosyl-Monophosphate Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01775": {"dbids": ["DB01775", "EXPT00122"], "name": "Dihydroxyacetone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01776": {"dbids": ["DB01776", "EXPT01026"], "name": "M-Cresol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01777": {"dbids": ["DB01777", "EXPT00818"], "name": "Coa-S-Trimethylene-Acetyl-Tryptamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01806": {"dbids": ["DB01806", "EXPT00481"], "name": "10-{4-Dimethylamino-5-[4-Hydroxy-6-Methyl-5-(6-Methyl-5-Oxo-Tetrahydro-Pyran-2-Yloxy)-Tetrahydro-Pyrane-2-Yloxy]-6-Methyl-Tetrahydro-Pyran-2-Yloxy}-8-Ethyl-1,8,11-Trihydroxy-7,8,9,10-Tetrahydro-Naphthacene-5,12-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01771": {"dbids": ["DB01771", "EXPT00350"], "name": "CRA_10991", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01772": {"dbids": ["DB01772", "EXPT01170"], "name": "3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01773": {"dbids": ["DB01773", "EXPT03200"], "name": "4-[3-Carboxymethyl-3-(4-Phosphonooxy-Benzyl)-Ureido]-4-[(3-Cyclohexyl-Propyl)-Methyl-Carbamoyl]Butyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07731": {"dbids": ["DB07731"], "name": "4-[(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYL]PHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07736": {"dbids": ["DB07736"], "name": "(2S)-4-(4-fluorobenzyl)-N-(2-sulfanylethyl)piperazine-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07734": {"dbids": ["DB07734"], "name": "N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07735": {"dbids": ["DB07735"], "name": "N-[1-(2,6-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07738": {"dbids": ["DB07738"], "name": "N-[1-(5-bromo-2,3-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01118": {"dbids": ["APRD00288", "DB01118"], "name": "Amiodarone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q12809", "drug": "DB01118"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB01118"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB01118"}, {"action": "INHIBITOR", "target": "Q9NY47", "drug": "DB01118"}]}, "DB01119": {"dbids": ["APRD00914", "DB01119"], "name": "Diazoxide", "groups": ["APPROVED"], "targets": [{"action": "INDUCER", "target": "Q14654", "drug": "DB01119"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB01119"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB01119"}, {"action": "OTHER", "target": "P05023", "drug": "DB01119"}, {"action": "OTHER", "target": "Q12791", "drug": "DB01119"}, {"action": "UNKNOWN", "target": "P55017", "drug": "DB01119"}]}, "DB01110": {"dbids": ["APRD01115", "DB01110"], "name": "Miconazole", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P10613", "drug": "DB01110"}, {"action": "INHIBITOR", "target": "P29474", "drug": "DB01110"}, {"action": "INHIBITOR", "target": "P35228", "drug": "DB01110"}, {"action": "INHIBITOR", "target": "Q12791", "drug": "DB01110"}, {"action": "INHIBITOR", "target": "Q16558", "drug": "DB01110"}, {"action": "INHIBITOR", "target": "Q9Y691", "drug": "DB01110"}, {"action": "INHIBITOR", "target": "Q9NPA1", "drug": "DB01110"}, {"action": "INHIBITOR", "target": "Q86W47", "drug": "DB01110"}, {"action": "INHIBITOR", "target": "O15554", "drug": "DB01110"}, {"action": "INHIBITOR", "target": "Q92952", "drug": "DB01110"}, {"action": "INHIBITOR", "target": "Q9H2S1", "drug": "DB01110"}, {"action": "INHIBITOR", "target": "Q9UGI6", "drug": "DB01110"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB01110"}, {"action": "INHIBITOR", "target": "Q9H252", "drug": "DB01110"}, {"action": "INHIBITOR", "target": "Q9NS40", "drug": "DB01110"}]}, "DB01111": {"dbids": ["APRD00885", "DB01111"], "name": "Colistimethate", "groups": ["APPROVED"], "targets": []}, "DB01112": {"dbids": ["APRD00285", "DB01112"], "name": "Cefuroxime", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01112"}]}, "DB01113": {"dbids": ["APRD00628", "DB01113", "DB07725"], "name": "Papaverine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q07343", "drug": "DB01113"}, {"action": "INHIBITOR", "target": "Q9Y233", "drug": "DB01113"}]}, "DB01114": {"dbids": ["APRD00001", "DB01114", "DB09440"], "name": "Chlorphenamine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB01114"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB01114"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB01114"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB01114"}]}, "DB01115": {"dbids": ["APRD00590", "DB01115"], "name": "Nifedipine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q13936", "drug": "DB01115"}, {"action": "INHIBITOR", "target": "P54289", "drug": "DB01115"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB01115"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB01115"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB01115"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB01115"}, {"action": "INHIBITOR", "target": "Q09470", "drug": "DB01115"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB01115"}]}, "DB01116": {"dbids": ["APRD00044", "DB01116"], "name": "Trimethaphan", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q9GZZ6", "drug": "DB01116"}]}, "DB01117": {"dbids": ["APRD00805", "DB01117"], "name": "Atovaquone", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q02768", "drug": "DB01117"}, {"action": "INHIBITOR", "target": "Q08210", "drug": "DB01117"}, {"action": "INHIBITOR", "target": "Q02127", "drug": "DB01117"}]}, "DB11101": {"dbids": ["DB11101"], "name": "Lysine", "groups": ["APPROVED"], "targets": []}, "DB09407": {"dbids": ["DB09407"], "name": "Magnesium chloride", "groups": ["APPROVED"], "targets": []}, "DB07677": {"dbids": ["DB07677"], "name": "2-methyl-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07201": {"dbids": ["DB07201"], "name": "(2S)-3-[(9H-fluoren-9-ylideneamino)oxy]-2-methylpropanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00647": {"dbids": ["APRD00548", "DB00647"], "name": "Dextropropoxyphene", "groups": ["APPROVED", "ILLICIT", "WITHDRAWN"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB00647"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00647"}, {"action": "ANTAGONIST", "target": "P41145", "drug": "DB00647"}]}, "DB00646": {"dbids": ["APRD01146", "DB00646"], "name": "Nystatin", "groups": ["APPROVED"], "targets": []}, "DB00645": {"dbids": ["APRD00940", "DB00645"], "name": "Dyclonine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00645"}]}, "DB00644": {"dbids": ["APRD01001", "DB00644"], "name": "Gonadorelin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P30968", "drug": "DB00644"}, {"action": "AGONIST", "target": "Q96P88", "drug": "DB00644"}]}, "DB00643": {"dbids": ["APRD01086", "DB00643"], "name": "Mebendazole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q71U36", "drug": "DB00643"}, {"action": "INHIBITOR", "target": "P68371", "drug": "DB00643"}]}, "DB00642": {"dbids": ["APRD00573", "DB00642", "EXPT02075"], "name": "Pemetrexed", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P04818", "drug": "DB00642"}, {"action": "INHIBITOR", "target": "P31939", "drug": "DB00642"}, {"action": "INHIBITOR", "target": "P00374", "drug": "DB00642"}, {"action": "INHIBITOR", "target": "P22102", "drug": "DB00642"}]}, "DB00641": {"dbids": ["APRD00104", "DB00641"], "name": "Simvastatin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P04035", "drug": "DB00641"}, {"action": "OTHER", "target": "P05107", "drug": "DB00641"}]}, "DB00640": {"dbids": ["APRD00132", "DB00640"], "name": "Adenosine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P29274", "drug": "DB00640"}, {"action": "AGONIST", "target": "P29275", "drug": "DB00640"}, {"action": "AGONIST", "target": "P0DMS8", "drug": "DB00640"}, {"action": "AGONIST", "target": "P30542", "drug": "DB00640"}]}, "DB07349": {"dbids": ["DB07349"], "name": "(1S)-2-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-1-[(PENTANOYLOXY)METHYL]ETHYL OCTANOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07348": {"dbids": ["DB07348"], "name": "1,6,7,8,9,11A,12,13,14,14A-DECAHYDRO-1,13-DIHYDROXY-6-METHYL-4H-CYCLOPENT[F]OXACYCLOTRIDECIN-4-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07619": {"dbids": ["DB07619"], "name": "N-cyclopropyl-N-(trans-4-pyridin-3-ylcyclohexyl)-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07618": {"dbids": ["DB07618"], "name": "2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00649": {"dbids": ["APRD00440", "DB00649"], "name": "Stavudine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q72547", "drug": "DB00649"}]}, "DB00648": {"dbids": ["APRD00494", "DB00648"], "name": "Mitotane", "groups": ["APPROVED"], "targets": [{"action": "INDUCER", "target": "P15538", "drug": "DB00648"}, {"action": "UNKNOWN", "target": "P10109", "drug": "DB00648"}]}, "DB07675": {"dbids": ["DB07675"], "name": "(2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09189": {"dbids": ["DB09189"], "name": "Daledalin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09188": {"dbids": ["DB09188"], "name": "Amedalin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09525": {"dbids": ["DB09525"], "name": "Sodium phosphate, monobasic, monohydrate", "groups": ["APPROVED"], "targets": []}, "DB07672": {"dbids": ["DB07672"], "name": "TRANS-2-(DIMETHYLPHENYLSILYL)-PIPERIDINE-N-OXIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03044": {"dbids": ["DB03044", "EXPT00616"], "name": "1-(5-Tert-Butyl-2-P-Tolyl-2h-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl]-Urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03045": {"dbids": ["DB03045", "EXPT00046"], "name": "Pantothenyl-Aminoethanol-Acetate Pivalic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03046": {"dbids": ["DB03046", "EXPT03180"], "name": "7-Methoxy-8-[1-(Methylsulfonyl)-1h-Pyrazol-4-Yl]Naphthalene-2-Carboximidamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03047": {"dbids": ["DB03047", "EXPT01352"], "name": "L-Alpha-Phosphatidyl-Beta-Oleoyl-Gamma-Palmitoyl-Phosphatidylethanolamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03040": {"dbids": ["DB03040", "EXPT02390"], "name": "Nitrilotriacetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03517": {"dbids": ["DB03517", "EXPT02243"], "name": "[Methylthio]Acetate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03042": {"dbids": ["DB03042", "EXPT02485"], "name": "5-Phosphoarabinonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03043": {"dbids": ["DB03043", "EXPT00092"], "name": "(S)-2-Amino-3-(6h-Selenolo[2,3-B]-Pyrrol-4-Yl)-Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04622": {"dbids": ["DB04622"], "name": "N-ACETYLHISTAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03518": {"dbids": ["DB03518", "EXPT02156"], "name": "(R)-Mevalonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03519": {"dbids": ["DB03519", "EXPT00144"], "name": "2-Amino-Pentanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03048": {"dbids": ["DB03048", "EXPT03164"], "name": "6-Carboxymethyluracil", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03049": {"dbids": ["DB03049", "EXPT01043"], "name": "S-Selanyl Cysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07208": {"dbids": ["DB07208"], "name": "(8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05268": {"dbids": ["DB05268"], "name": "iCo-007", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05269": {"dbids": ["DB05269"], "name": "AST-120", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB05918": {"dbids": ["DB05918"], "name": "LS11", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05919": {"dbids": ["DB05919"], "name": "DDP-200", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05262": {"dbids": ["DB05262"], "name": "Oxypurinol", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05915": {"dbids": ["DB05915"], "name": "MYO-029", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05916": {"dbids": ["DB05916"], "name": "CT-011", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05917": {"dbids": ["DB05917"], "name": "EP-1572", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05266": {"dbids": ["DB05266"], "name": "Ibudilast", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P27815", "drug": "DB05266"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB05266"}, {"action": "INHIBITOR", "target": "Q08493", "drug": "DB05266"}, {"action": "INHIBITOR", "target": "Q08499", "drug": "DB05266"}, {"action": "INHIBITOR", "target": "Q14432", "drug": "DB05266"}]}, "DB05911": {"dbids": ["DB05911"], "name": "RUS 3108", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05264": {"dbids": ["DB05264"], "name": "NPI 32101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05913": {"dbids": ["DB05913"], "name": "OSI-930", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04624": {"dbids": ["DB04624"], "name": "DERIVATIVE OF AKLANONIC ACID METHYL ESTER (AAME)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07209": {"dbids": ["DB07209"], "name": "(8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07997": {"dbids": ["DB07997"], "name": "N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02641": {"dbids": ["DB02641", "EXPT01772"], "name": "Heptanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02640": {"dbids": ["DB02640", "EXPT01509"], "name": "Fumagillin", "groups": ["EXPERIMENTAL"], "targets": [{"action": "LIGAND", "target": "P50579", "drug": "DB02640"}]}, "DB02643": {"dbids": ["DB02643", "EXPT00799"], "name": "N-Dodecyl-N,N-Dimethyl-3-Ammonio-1-Propanesulfonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02642": {"dbids": ["DB02642", "EXPT01473"], "name": "[[N-(Benzyloxycarbonyl)Amino]Methyl]Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02645": {"dbids": ["DB02645", "EXPT01323"], "name": "3,4-Epoxybutyl-Alpha-D-Glucopyranoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02644": {"dbids": ["DB02644", "EXPT00162"], "name": "N-Omega-Propyl-L-Arginine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02647": {"dbids": ["DB02647", "EXPT02278"], "name": "N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02646": {"dbids": ["DB02646", "EXPT02372"], "name": "Nitrosoethane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02649": {"dbids": ["DB02649", "EXPT02184"], "name": "3-Amino-3-Oxopropanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02648": {"dbids": ["DB02648", "EXPT00038"], "name": "(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06920": {"dbids": ["DB06920"], "name": "(2R,4R)-N~1~-(4-CHLOROPHENYL)-N~2~-[2-FLUORO-4-(2-OXOPYRIDIN-1(2H)-YL)PHENYL]-4-METHOXYPYRROLIDINE-1,2-DICARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06921": {"dbids": ["DB06921"], "name": "(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-[(R)-HYDROXY{(1R)-2-METHYL-1-[(PHENYLSULFONYL)AMINO]PROPYL}PHOSPHORYL]PROPANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06922": {"dbids": ["DB06922"], "name": "2-[(1R)-1-carboxy-2-naphthalen-1-ylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09110": {"dbids": ["DB09110"], "name": "Mesna", "groups": ["APPROVED"], "targets": []}, "DB09111": {"dbids": ["DB09111"], "name": "Pentastarch", "groups": ["APPROVED"], "targets": []}, "DB09112": {"dbids": ["DB09112"], "name": "Sodium Nitrite", "groups": ["APPROVED"], "targets": []}, "DB09113": {"dbids": ["DB09113"], "name": "Poractant alfa", "groups": ["APPROVED"], "targets": []}, "DB09114": {"dbids": ["DB09114"], "name": "Colfosceril palmitate", "groups": ["APPROVED"], "targets": []}, "DB09115": {"dbids": ["DB09115"], "name": "Diiodohydroxyquinoline", "groups": ["APPROVED"], "targets": []}, "DB09116": {"dbids": ["DB09116"], "name": "Calcium carbimide", "groups": ["APPROVED"], "targets": []}, "DB06923": {"dbids": ["DB06923"], "name": "2-(3-METHYLPHENYL)-1H-INDOLE-5-CARBOXIMIDAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09118": {"dbids": ["DB09118"], "name": "Stiripentol", "groups": ["APPROVED"], "targets": []}, "DB09119": {"dbids": ["DB09119"], "name": "Eslicarbazepine acetate", "groups": ["APPROVED"], "targets": []}, "DB09185": {"dbids": ["DB09185"], "name": "Viloxazine", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB01349": {"dbids": ["DB01349"], "name": "Tasosartan", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P30556", "drug": "DB01349"}, {"action": "ANTAGONIST", "target": "P50052", "drug": "DB01349"}]}, "DB01348": {"dbids": ["DB01348"], "name": "Spirapril", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P12821", "drug": "DB01348"}]}, "DB01345": {"dbids": ["DB01345"], "name": "Potassium", "groups": ["APPROVED"], "targets": []}, "DB01344": {"dbids": ["DB01344"], "name": "Polystyrene sulfonate", "groups": ["APPROVED"], "targets": []}, "DB01347": {"dbids": ["DB01347"], "name": "Saprisartan", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P30556", "drug": "DB01347"}]}, "DB01346": {"dbids": ["DB01346"], "name": "Quinidine barbiturate", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01346"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01346"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB01346"}, {"action": "INHIBITOR", "target": "O00180", "drug": "DB01346"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB01346"}]}, "DB01341": {"dbids": ["DB01341"], "name": "Dihydroquinidine barbiturate", "groups": ["EXPERIMENTAL"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01341"}]}, "DB01340": {"dbids": ["DB01340"], "name": "Cilazapril", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P12821", "drug": "DB01340"}]}, "DB01342": {"dbids": ["DB01342"], "name": "Forasartan", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P30556", "drug": "DB01342"}]}, "DB09184": {"dbids": ["DB09184"], "name": "Edivoxetine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08937": {"dbids": ["DB08937"], "name": "TAS-102", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04081": {"dbids": ["DB04081", "EXPT02251"], "name": "(4s-Trans)-4-(Methylamino)-5,6-Dihydro-6-Methyl-4h-Thieno(2,3-B)Thiopyran-2-Sulfonamide-7,7-Dioxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04080": {"dbids": ["DB04080", "EXPT00305"], "name": "RU78191", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04083": {"dbids": ["DB04083", "EXPT02040"], "name": "N'-Pyridoxyl-Lysine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04082": {"dbids": ["DB04082", "EXPT01158"], "name": "Decyloxy-Methanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04085": {"dbids": ["DB04085", "EXPT02445"], "name": "1-[Pyrrol-1-Yl-2,5-Dione-Methoxymethyl]-Pyrrole-2,5-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04084": {"dbids": ["DB04084", "EXPT02107"], "name": "2-Deoxy-2-Fluoro-Alpha-D-Mannose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04087": {"dbids": ["DB04087", "EXPT01769"], "name": "Open Form of 2'-Deoxy-Ribofuranose-5'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04086": {"dbids": ["DB04086", "EXPT01130"], "name": "2',4'-Dinitrophenyl-2deoxy-2-Fluro-B-D-Cellobioside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04089": {"dbids": ["DB04089", "EXPT00488"], "name": "AL5300", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04736": {"dbids": ["DB04736"], "name": "2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE(BETA1-4)-2-ACETAMIDO-1,6-ANHYDRO-3-O-[(R)-1-CARBOXYETHYL]-2-DEOXY-BETA-D-GLUCOPYRANOSE-L-ALANYL-GAMMA-D-GLUTAMYL-MESO-DIAMINOPIMELYL-D-ALANINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04735": {"dbids": ["DB04735"], "name": "MONOGALACTOSYL-DIACYLGLYCEROL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04734": {"dbids": ["DB04734"], "name": "Citraconic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04733": {"dbids": ["DB04733"], "name": "1,6-DI-O-PHOSPHONO-D-MANNITOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04732": {"dbids": ["DB04732"], "name": "N-(4-MORPHOLINE)CARBONYL-B-(1-NAPHTHYL)-L-ALANINE-L-LEUCINE BORONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04731": {"dbids": ["DB04731"], "name": "1-ACETYL-2-LYSO-SN-GLYCERO-3-PHOSPHOETHANOLAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08522": {"dbids": ["DB08522"], "name": "4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08649": {"dbids": ["DB08649"], "name": "(1S)-1-AMINO-2-(1H-INDOL-3-YL)ETHANOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08523": {"dbids": ["DB08523"], "name": "[HYDROXY(3-PHENYLPROPYL)AMINO]METHANOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08647": {"dbids": ["DB08647"], "name": "TRAZEOLIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08646": {"dbids": ["DB08646"], "name": "TRW3-(2-AMINO-3-HYDROXY-PROPYL)-6-(N'-CYCLOHEXYL-HYDRAZINO)OCTAHYDRO-INDOL-7-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08645": {"dbids": ["DB08645"], "name": "6-CHLORO-3-(DICHLOROMETHYL)-3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-7-SULFONAMIDE 1,1-DIOXIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08644": {"dbids": ["DB08644"], "name": "{1-[2-(1-FORMYL-PROPYL)-3-METHANESULFONYLAMINO-PYRROLIDINE-1-CARBONYL]-2-METHYL-PROPYL}-CARBAMIC ACID TERT-BUTYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08643": {"dbids": ["DB08643"], "name": "2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05736": {"dbids": ["DB05736"], "name": "MIV-701", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08641": {"dbids": ["DB08641"], "name": "(2S,3S)-3-FORMYL-2-({[(4-NITROPHENYL)SULFONYL]AMINO}METHYL)PENTANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08640": {"dbids": ["DB08640"], "name": "(2S,3S)-3-FORMYL-2-({[(4-METHYLPHENYL)SULFONYL]AMINO}METHYL)PENTANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06820": {"dbids": ["DB06820"], "name": "Sulconazole", "groups": ["APPROVED"], "targets": []}, "DB00348": {"dbids": ["APRD01141", "DB00348"], "name": "Nitisinone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P32754", "drug": "DB00348"}]}, "DB00349": {"dbids": ["APRD00307", "DB00349"], "name": "Clobazam", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00349"}]}, "DB00438": {"dbids": ["APRD00857", "DB00438"], "name": "Ceftazidime", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0AD68", "drug": "DB00438"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00438"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB00438"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB00438"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB00438"}, {"action": "INHIBITOR", "target": "Q9X6W0", "drug": "DB00438"}, {"action": "INHIBITOR", "target": "Q9X6V3", "drug": "DB00438"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB00438"}, {"action": "INHIBITOR", "target": "P72161", "drug": "DB00438"}]}, "DB00439": {"dbids": ["APRD00102", "DB00439"], "name": "Cerivastatin", "groups": ["WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P04035", "drug": "DB00439"}]}, "DB06827": {"dbids": ["DB06827"], "name": "Viomycin", "groups": ["APPROVED"], "targets": []}, "DB06826": {"dbids": ["DB06826"], "name": "Unoprostone", "groups": ["APPROVED"], "targets": []}, "DB00434": {"dbids": ["APRD00033", "DB00434"], "name": "Cyproheptadine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00434"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00434"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00434"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00434"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00434"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00434"}]}, "DB00435": {"dbids": ["APRD01142", "DB00435"], "name": "Nitric Oxide", "groups": ["APPROVED"], "targets": [{"action": "INDUCER", "target": "P33402", "drug": "DB00435"}]}, "DB00340": {"dbids": ["APRD01101", "DB00340"], "name": "Metixene", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00340"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00340"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00340"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00340"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00340"}]}, "DB00341": {"dbids": ["APRD00630", "DB00341"], "name": "Cetirizine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00341"}]}, "DB00346": {"dbids": ["APRD00490", "DB00346"], "name": "Alfuzosin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P35348", "drug": "DB00346"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00346"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00346"}]}, "DB00347": {"dbids": ["APRD00315", "DB00347"], "name": "Trimethadione", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "O43497", "drug": "DB00347"}]}, "DB00432": {"dbids": ["APRD01275", "DB00432"], "name": "Trifluridine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P04818", "drug": "DB00432"}]}, "DB00433": {"dbids": ["APRD00624", "DB00433"], "name": "Prochlorperazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB00433"}]}, "DB06779": {"dbids": ["DB06779"], "name": "Dalteparin", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P01008", "drug": "DB06779"}, {"action": "INHIBITOR", "target": "P15692", "drug": "DB06779"}, {"action": "INHIBITOR", "target": "P10646", "drug": "DB06779"}, {"action": "INHIBITOR", "target": "P16109", "drug": "DB06779"}]}, "DB08938": {"dbids": ["DB08938"], "name": "Magaldrate", "groups": ["WITHDRAWN"], "targets": []}, "DB05732": {"dbids": ["DB05732"], "name": "Strontium malonate", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06771": {"dbids": ["DB06771"], "name": "Besifloxacin", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P43702", "drug": "DB06771"}, {"action": "ANTAGONIST", "target": "P72525", "drug": "DB06771"}, {"action": "ANTAGONIST", "target": "P43700", "drug": "DB06771"}, {"action": "ANTAGONIST", "target": "P72524", "drug": "DB06771"}]}, "DB06770": {"dbids": ["DB06770"], "name": "Benzyl alcohol", "groups": ["APPROVED"], "targets": []}, "DB06773": {"dbids": ["DB06773"], "name": "Human calcitonin", "groups": ["APPROVED"], "targets": []}, "DB06772": {"dbids": ["DB06772"], "name": "Cabazitaxel", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "P68366", "drug": "DB06772"}, {"action": "BINDER", "target": "Q9H4B7", "drug": "DB06772"}]}, "DB06775": {"dbids": ["DB06775"], "name": "Carglumic Acid", "groups": ["APPROVED"], "targets": [{"action": "ALLOSTERIC MODULATOR", "target": "P31327", "drug": "DB06775"}]}, "DB06774": {"dbids": ["DB06774"], "name": "Capsaicin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "Q8NER1", "drug": "DB06774"}]}, "DB06777": {"dbids": ["DB06777"], "name": "Chenodeoxycholic acid", "groups": ["APPROVED"], "targets": [{"action": "OTHER", "target": "Q96RI1", "drug": "DB06777"}]}, "DB04889": {"dbids": ["DB04889"], "name": "Bicifadine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04888": {"dbids": ["DB04888"], "name": "Bifeprunox", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04559": {"dbids": ["DB04559", "EXPT02578"], "name": "N-(Chlorophenyl)-N'-Hydroxyguanidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04881": {"dbids": ["DB04881"], "name": "Elacridar", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04880": {"dbids": ["DB04880"], "name": "Enoximone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q14432", "drug": "DB04880"}]}, "DB04551": {"dbids": ["DB04551", "EXPT01395"], "name": "Fructose-1,6-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04550": {"dbids": ["DB04550", "EXPT01250"], "name": "Delta-Bis(2,2'-Bipyridine)Imidazole Osmium (Ii)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04557": {"dbids": ["DB04557", "EXPT00409"], "name": "Arachidonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04884": {"dbids": ["DB04884"], "name": "Dapoxetine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04555": {"dbids": ["DB04555", "EXPT00868"], "name": "Cytidine-5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04554": {"dbids": ["DB04554", "EXPT00401"], "name": "8-Bromoadenosine-5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08399": {"dbids": ["DB08399"], "name": "PICEATANNOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01536": {"dbids": ["DB01536", "DB07386", "EXPT00569"], "name": "4-Androstenedione", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": [{"action": "INDUCER", "target": "P14061", "drug": "DB01536"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14060", "drug": "DB01536"}, {"action": "INDUCER", "target": "Q00441", "drug": "DB01536"}, {"action": "INDUCER", "target": "P42330", "drug": "DB01536"}]}, "DB08529": {"dbids": ["DB08529"], "name": "(6E,11E)-HEPTADECA-6,11-DIENE-9,9-DIYLBIS(PHOSPHONIC ACID)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01537": {"dbids": ["DB01537"], "name": "4-Bromo-2,5-dimethoxyphenethylamine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB08391": {"dbids": ["DB08391"], "name": "6,7-DIMETHOXY-4-[(3R)-3-(QUINOXALIN-2-YLOXY)PYRROLIDIN-1-YL]QUINAZOLINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08390": {"dbids": ["DB08390"], "name": "(6S)-6-CYCLOPENTYL-6-[2-(3-FLUORO-4-ISOPROPOXYPHENYL)ETHYL]-4-HYDROXY-5,6-DIHYDRO-2H-PYRAN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08393": {"dbids": ["DB08393"], "name": "2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08392": {"dbids": ["DB08392"], "name": "2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08395": {"dbids": ["DB08395"], "name": "2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01534": {"dbids": ["DB01534"], "name": "Chlorhexadol", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB08397": {"dbids": ["DB08397"], "name": "6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08396": {"dbids": ["DB08396"], "name": "4-{[(Z)-(5-OXO-2-PHENYL-1,3-OXAZOL-4(5H)-YLIDENE)METHYL]AMINO}BUTANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01535": {"dbids": ["DB01535"], "name": "Carfentanil", "groups": ["ILLICIT"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB01535"}, {"action": "AGONIST", "target": "P41143", "drug": "DB01535"}, {"action": "AGONIST", "target": "P41145", "drug": "DB01535"}]}, "DB04012": {"dbids": ["DB04012", "EXPT03124"], "name": "(3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Leucine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01533": {"dbids": ["DB01533"], "name": "Diethylthiambutene", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB04010": {"dbids": ["DB04010", "EXPT00788"], "name": "2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04011": {"dbids": ["DB04011", "EXPT00636"], "name": "2'-(4-Dimethylaminophenyl)-5-(4-Methyl-1-Piperazinyl)-2,5'-Bi-Benzimidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00005": {"dbids": ["BIOD00052", "BTD00052", "DB00005"], "name": "Etanercept", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTIBODY", "target": "P01375", "drug": "DB00005"}]}, "DB00004": {"dbids": ["BIOD00084", "BTD00084", "DB00004"], "name": "Denileukin diftitox", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "BINDER", "target": "P01589", "drug": "DB00004"}, {"action": "AGONIST", "target": "P14784", "drug": "DB00004"}]}, "DB00007": {"dbids": ["BIOD00009", "BTD00009", "DB00007"], "name": "Leuprolide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P30968", "drug": "DB00007"}]}, "DB00006": {"dbids": ["BIOD00076", "BTD00076", "DB00006"], "name": "Bivalirudin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P00734", "drug": "DB00006"}]}, "DB07288": {"dbids": ["DB07288"], "name": "N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07289": {"dbids": ["DB07289"], "name": "5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07286": {"dbids": ["DB07286"], "name": "2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00001": {"dbids": ["BIOD00024", "BTD00024", "DB00001"], "name": "Lepirudin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00734", "drug": "DB00001"}]}, "DB07284": {"dbids": ["DB07284"], "name": "N~3~-(3-PYRIDIN-3-YLBENZYL)PYRIDINE-2,3-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07285": {"dbids": ["DB07285"], "name": "(3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07282": {"dbids": ["DB07282"], "name": "3-({[(1Z)-(2-methoxyphenyl)methylidene]amino}oxy)propanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07283": {"dbids": ["DB07283"], "name": "9-benzyl-2,3,4,9-tetrahydro-1H-carbazole-8-carboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07280": {"dbids": ["DB07280"], "name": "5-[4-(DIMETHYLAMINO)PHENYL]-6-[(6-MORPHOLIN-4-YLPYRIDIN-3-YL)ETHYNYL]PYRIMIDIN-4-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06929": {"dbids": ["DB06929"], "name": "1-butanoyl-N-(4-carbamimidoylbenzyl)-L-prolinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00003": {"dbids": ["BIOD00001", "BTD00001", "DB00003"], "name": "Dornase alfa", "groups": ["APPROVED"], "targets": []}, "DB00002": {"dbids": ["BIOD00071", "BTD00071", "DB00002"], "name": "Cetuximab", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P00533", "drug": "DB00002"}]}, "DB02076": {"dbids": ["DB02076", "EXPT00290"], "name": "6-Phosphogluconic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02077": {"dbids": ["DB02077", "EXPT01254"], "name": "L-N(Omega)-Nitroarginine-(4r)-Amino-L-Proline Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02074": {"dbids": ["DB02074", "EXPT00670"], "name": "Butenoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02075": {"dbids": ["DB02075", "EXPT01929"], "name": "(1s)-1(9-Deazahypoxanthin-9yl)1,4-Dideoxy-1,4-Imino-D-Ribitol-5-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02072": {"dbids": ["DB02072", "EXPT00987"], "name": "2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02073": {"dbids": ["DB02073", "EXPT00714"], "name": "Biliverdine Ix Alpha", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02070": {"dbids": ["DB02070", "EXPT01985"], "name": "L-2-Amino-4-[2-Aminophenyl]-4-Oxobutanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02071": {"dbids": ["DB02071", "EXPT03240"], "name": "WAY-151693", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00951": {"dbids": ["APRD01055", "DB00951", "EXPT01940"], "name": "Isoniazid", "groups": ["APPROVED"], "targets": [{"action": "OTHER/UNKNOWN", "target": "Q08129", "drug": "DB00951"}, {"action": "ADDUCT", "target": "P0A5Y6", "drug": "DB00951"}]}, "DB02078": {"dbids": ["DB02078", "EXPT02565"], "name": "1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02079": {"dbids": ["DB02079", "EXPT00528"], "name": "(Aminooxy)Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00774": {"dbids": ["APRD01020", "DB00774"], "name": "Hydroflumethiazide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q13621", "drug": "DB00774"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00774"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00774"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00774"}, {"action": "INHIBITOR", "target": "Q16790", "drug": "DB00774"}, {"action": "INHIBITOR", "target": "O43570", "drug": "DB00774"}, {"action": "OTHER/UNKNOWN", "target": "P05023", "drug": "DB00774"}, {"action": "OTHER/UNKNOWN", "target": "Q12791", "drug": "DB00774"}]}, "DB00957": {"dbids": ["APRD00569", "DB00957"], "name": "Norgestimate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P06401", "drug": "DB00957"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00957"}]}, "DB00956": {"dbids": ["APRD00591", "DB00956", "DB09475"], "name": "Hydrocodone", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB00956"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00956"}]}, "DB00771": {"dbids": ["APRD00737", "DB00771"], "name": "Clidinium", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00771"}]}, "DB00770": {"dbids": ["APRD00785", "DB00770"], "name": "Alprostadil", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P43116", "drug": "DB00770"}, {"action": "AGONIST", "target": "P34995", "drug": "DB00770"}]}, "DB06480": {"dbids": ["DB06480"], "name": "Prucalopride", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "Q13639", "drug": "DB06480"}]}, "DB07279": {"dbids": ["DB07279"], "name": "N-ETHYL-N-ISOPROPYL-3-METHYL-5-{[(2S)-2-(PYRIDIN-4-YLAMINO)PROPYL]OXY}BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02252": {"dbids": ["DB02252", "EXPT02599"], "name": "Iodophenyl", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02253": {"dbids": ["DB02253", "EXPT00185"], "name": "(1r)-4-[(1e,3e,5e,7z,9e,11z,13e,15e)-17-Hydroxy-3,7,12,16-Tetramethylheptadeca-1,3,5,7,9,11,13,15-Octaen-1-Yl]-3,5,5-Trimethylcyclohex-3-En-1-Ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02250": {"dbids": ["DB02250", "EXPT02192"], "name": "Cu-Bicyclam", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02251": {"dbids": ["DB02251", "EXPT02448"], "name": "O-Succinylbenzoate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02256": {"dbids": ["DB02256", "EXPT01300"], "name": "2'-Deoxyuridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02257": {"dbids": ["DB02257", "EXPT00655"], "name": "N-Bromoacetyl-Aminoethyl Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02254": {"dbids": ["DB02254", "EXPT01504"], "name": "Trifluoro-thiamin phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02255": {"dbids": ["DB02255", "EXPT01618"], "name": "GM6001", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09288": {"dbids": ["DB09288"], "name": "Propacetamol", "groups": ["APPROVED"], "targets": []}, "DB09289": {"dbids": ["DB09289"], "name": "Tianeptine", "groups": ["APPROVED"], "targets": []}, "DB02258": {"dbids": ["DB02258", "EXPT00094"], "name": "SR11254", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02259": {"dbids": ["DB02259", "EXPT00331"], "name": "3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08689": {"dbids": ["DB08689"], "name": "UBIQUINONE-1", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08688": {"dbids": ["DB08688"], "name": "undecan-2-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08885": {"dbids": ["DB08885"], "name": "Aflibercept", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "P15692", "drug": "DB08885"}, {"action": "BINDER", "target": "P49763", "drug": "DB08885"}, {"action": "BINDER", "target": "P49765", "drug": "DB08885"}]}, "DB08884": {"dbids": ["DB08884"], "name": "Gadoxetate", "groups": ["APPROVED"], "targets": []}, "DB08887": {"dbids": ["DB08887"], "name": "Icosapent ethyl", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB08886": {"dbids": ["DB08886"], "name": "Asparaginase Erwinia chrysanthemi", "groups": ["APPROVED"], "targets": []}, "DB08881": {"dbids": ["DB08881"], "name": "Vemurafenib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P15056", "drug": "DB08881"}]}, "DB08880": {"dbids": ["DB08880"], "name": "Teriflunomide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q02127", "drug": "DB08880"}]}, "DB08883": {"dbids": ["DB08883"], "name": "Perampanel", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P42261", "drug": "DB08883"}]}, "DB08882": {"dbids": ["DB08882"], "name": "Linagliptin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P27487", "drug": "DB08882"}]}, "DB08802": {"dbids": ["DB08802"], "name": "Isothipendyl", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB08802"}]}, "DB08888": {"dbids": ["DB08888"], "name": "Ocriplasmin", "groups": ["APPROVED"], "targets": [{"action": "CLEAVAGE", "target": "P02751", "drug": "DB08888"}, {"action": "LIGAND", "target": "P01023", "drug": "DB08888"}, {"action": "LIGAND", "target": "P08697", "drug": "DB08888"}]}, "DB03707": {"dbids": ["DB03707", "EXPT02689"], "name": "S-Ethyl-N-Phenyl-Isothiourea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03706": {"dbids": ["DB03706", "EXPT01354"], "name": "1-Hydroxy-2-S-Glutathionyl-3-Para-Nitrophenoxy-Propane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03705": {"dbids": ["DB03705", "EXPT00278"], "name": "6-Methylamino-5-Nitroisocytosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03704": {"dbids": ["DB03704", "EXPT00021"], "name": "12-Hydroxydodecanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03703": {"dbids": ["DB03703", "EXPT01066"], "name": "Cyclohexanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03702": {"dbids": ["DB03702", "EXPT01482"], "name": "2-[4-[[(S)-1-[[(S)-2-[[(Rs)-3,3,3-Trifluoro-1-Isopropyl-2-Oxopropyl]Aminocarbonyl]Pyrrolidin-1-Yl-]Carbonyl]-2-Methylpropyl]Aminocarbonyl]Benzoylamino]Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03701": {"dbids": ["DB03701", "EXPT03312"], "name": "Vanoxerine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03700": {"dbids": ["DB03700", "EXPT01284"], "name": "D-Threonine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03709": {"dbids": ["DB03709", "EXPT00641"], "name": "Bicine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03708": {"dbids": ["DB03708", "EXPT00441"], "name": "Adenosine-5'-Phosphosulfate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01743": {"dbids": ["DB01743", "EXPT02706"], "name": "Pyoverdine-Chromophore", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09564": {"dbids": ["DB09564"], "name": "Insulin degludec", "groups": ["APPROVED"], "targets": []}, "DB01745": {"dbids": ["DB01745", "EXPT01410"], "name": "N-Alpha-(2-Naphthylsulfonyl)-N(3-Amidino-L-Phenylalaninyl)Isopipecolinic Acid Methyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09567": {"dbids": ["DB09567"], "name": "Olive oil", "groups": ["APPROVED"], "targets": []}, "DB01744": {"dbids": ["DB01744", "EXPT00827"], "name": "Camphor", "groups": ["APPROVED"], "targets": []}, "DB05705": {"dbids": ["DB05705"], "name": "ALS-08", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01747": {"dbids": ["DB01747", "EXPT01001"], "name": "Coprogen", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05708": {"dbids": ["DB05708"], "name": "GTS-21", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01746": {"dbids": ["DB01746", "EXPT01216"], "name": "D-Leucine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09560": {"dbids": ["DB09560"], "name": "Filgrastim-sndz", "groups": ["APPROVED"], "targets": []}, "DB09563": {"dbids": ["DB09563"], "name": "Choline C-11", "groups": ["APPROVED"], "targets": []}, "DB09562": {"dbids": ["DB09562"], "name": "Flutemetamol F-18", "groups": ["APPROVED"], "targets": []}, "DB07383": {"dbids": ["DB07383"], "name": "N-(1-BENZYL-3,3,3-TRIFLUORO-2,2-DIHYDROXY-PROPYL)-ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01288": {"dbids": ["DB01288"], "name": "Fenoterol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P07550", "drug": "DB01288"}, {"action": "AGONIST", "target": "P08588", "drug": "DB01288"}, {"action": "AGONIST", "target": "P13945", "drug": "DB01288"}]}, "DB01289": {"dbids": ["DB01289"], "name": "Glisoxepide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q15842", "drug": "DB01289"}]}, "DB01280": {"dbids": ["DB01280"], "name": "Nelarabine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P09884", "drug": "DB01280"}]}, "DB01281": {"dbids": ["DB01281"], "name": "Abatacept", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P33681", "drug": "DB01281"}, {"action": "ANTAGONIST", "target": "P42081", "drug": "DB01281"}]}, "DB01282": {"dbids": ["DB01282"], "name": "Carbetocin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P30559", "drug": "DB01282"}]}, "DB01283": {"dbids": ["DB01283"], "name": "Lumiracoxib", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB01283"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB01283"}]}, "DB01284": {"dbids": ["DB01284"], "name": "Cosyntropin", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q01718", "drug": "DB01284"}]}, "DB01285": {"dbids": ["DB01285"], "name": "Corticotropin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "Q01718", "drug": "DB01285"}, {"action": "AGONIST", "target": "P06850", "drug": "DB01285"}]}, "DB01756": {"dbids": ["DB01756", "EXPT01163"], "name": "D-4-Phosphoerythronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01754": {"dbids": ["DB01754", "EXPT02028"], "name": "3,4-Dihydroxy-1-Methylquinolin-2(1h)-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01755": {"dbids": ["DB01755", "EXPT01859"], "name": "N-[Isoleucinyl]-N'-[Adenosyl]-Diaminosufone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01752": {"dbids": ["DB01752", "EXPT02842"], "name": "S-Adenosyl-L-Homocysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01753": {"dbids": ["DB01753", "EXPT02418"], "name": "4-Oxo-Nicotinamide-Adenine Dinucleotide Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01750": {"dbids": ["DB01750", "EXPT02353"], "name": "Naphthalen-1-Yl-Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01751": {"dbids": ["DB01751", "EXPT02994"], "name": "3,3',5,5'-Tetraiodothyroacetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01758": {"dbids": ["DB01758", "EXPT01951"], "name": "3-Iodo-Tyrosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01759": {"dbids": ["DB01759", "EXPT01978"], "name": "5-Hydroxy-2-(Hydroxymethyl)-4h-Pyran-4-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00085": {"dbids": ["BIOD00067", "BTD00067", "DB00085"], "name": "Pancrelipase", "groups": ["APPROVED"], "targets": []}, "DB00087": {"dbids": ["BIOD00109", "BTD00109", "DB00087"], "name": "Alemtuzumab", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTIBODY", "target": "P31358", "drug": "DB00087"}]}, "DB00086": {"dbids": ["BIOD00028", "BTD00028", "DB00086"], "name": "Streptokinase", "groups": ["APPROVED"], "targets": [{"action": "ACTIVATOR", "target": "P00747", "drug": "DB00086"}, {"action": "CLEAVAGE", "target": "P25116", "drug": "DB00086"}]}, "DB00081": {"dbids": ["BIOD00085", "BTD00085", "DB00081"], "name": "Tositumomab", "groups": ["APPROVED"], "targets": [{"action": "ANTIBODY", "target": "P11836", "drug": "DB00081"}]}, "DB00080": {"dbids": ["BIOD00111", "BTD00111", "DB00080"], "name": "Daptomycin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB00083": {"dbids": ["BIOD00092", "BTD00092", "DB00083"], "name": "Botulinum Toxin Type A", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P60880", "drug": "DB00083"}]}, "DB00082": {"dbids": ["BIOD00044", "BTD00044", "DB00082"], "name": "Pegvisomant", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P10912", "drug": "DB00082"}]}, "DB00089": {"dbids": ["BIOD00080", "BTD00080", "DB00089"], "name": "Capromab", "groups": ["APPROVED"], "targets": [{"action": "OTHER/UNKNOWN", "target": "Q04609", "drug": "DB00089"}]}, "DB00088": {"dbids": ["BIOD00037", "BTD00037", "DB00088"], "name": "Alglucerase", "groups": ["APPROVED"], "targets": []}, "DB09422": {"dbids": ["DB09422"], "name": "Soybean oil", "groups": ["APPROVED"], "targets": []}, "DB01132": {"dbids": ["APRD00653", "DB01132"], "name": "Pioglitazone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P37231", "drug": "DB01132"}]}, "DB01133": {"dbids": ["APRD01259", "DB01133"], "name": "Tiludronate", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P38606", "drug": "DB01133"}, {"action": "INHIBITOR", "target": "P18031", "drug": "DB01133"}]}, "DB01130": {"dbids": ["APRD01197", "DB01130"], "name": "Prednicarbate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB01130"}]}, "DB01131": {"dbids": ["APRD00188", "DB01131"], "name": "Proguanil", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00374", "drug": "DB01131"}, {"action": "INHIBITOR", "target": "P13922", "drug": "DB01131"}]}, "DB01136": {"dbids": ["APRD00091", "DB01136"], "name": "Carvedilol", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB01136"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01136"}, {"action": "INHIBITOR", "target": "O95298", "drug": "DB01136"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB01136"}, {"action": "OTHER", "target": "P15692", "drug": "DB01136"}, {"action": "OTHER", "target": "P16860", "drug": "DB01136"}, {"action": "OTHER", "target": "P17302", "drug": "DB01136"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB01136"}, {"action": "INHIBITOR", "target": "P19320", "drug": "DB01136"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB01136"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01136"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB01136"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB01136"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01136"}, {"action": "INHIBITOR", "target": "P16581", "drug": "DB01136"}, {"action": "MODULATOR", "target": "Q16665", "drug": "DB01136"}]}, "DB01137": {"dbids": ["APRD00477", "DB01137", "DB06085"], "name": "Levofloxacin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P43702", "drug": "DB01137"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB01137"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB01137"}]}, "DB01134": {"dbids": ["APRD00709", "DB01134"], "name": "Desoxycorticosterone Pivalate", "groups": ["EXPERIMENTAL"], "targets": [{"action": "AGONIST", "target": "P08235", "drug": "DB01134"}]}, "DB01135": {"dbids": ["APRD00934", "DB01135", "DB01334"], "name": "Doxacurium chloride", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q15822", "drug": "DB01135"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01135"}]}, "DB01138": {"dbids": ["APRD00620", "DB01138"], "name": "Sulfinpyrazone", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q92887", "drug": "DB01138"}, {"action": "INHIBITOR", "target": "P33527", "drug": "DB01138"}]}, "DB01139": {"dbids": ["APRD00860", "DB01139"], "name": "Cefapirin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01139"}]}, "DB08685": {"dbids": ["DB08685"], "name": "1-(1,4-dimethyl-1,2,3,4-tetrahydroquinoxalin-6-yl)methanamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00661": {"dbids": ["APRD00335", "DB00661"], "name": "Verapamil", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q13936", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "O60840", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "Q02641", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "P54284", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "O00305", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "Q9P0X4", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "O43497", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "Q00975", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "O00555", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00661"}, {"action": "OTHER", "target": "Q14524", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "Q14654", "drug": "DB00661"}, {"action": "OTHER/UNKNOWN", "target": "P31645", "drug": "DB00661"}]}, "DB00660": {"dbids": ["APRD00514", "DB00660"], "name": "Metaxalone", "groups": ["APPROVED"], "targets": []}, "DB00663": {"dbids": ["APRD00975", "DB00663"], "name": "Flumethasone Pivalate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00663"}]}, "DB00662": {"dbids": ["APRD01277", "DB00662"], "name": "Trimethobenzamide", "groups": ["APPROVED"], "targets": []}, "DB00665": {"dbids": ["APRD00150", "DB00665"], "name": "Nilutamide", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P10275", "drug": "DB00665"}]}, "DB00664": {"dbids": ["APRD00517", "DB00664"], "name": "Sulfametopyrazine", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "Q27738", "drug": "DB00664"}]}, "DB00667": {"dbids": ["APRD01015", "DB00667"], "name": "Histamine Phosphate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35367", "drug": "DB00667"}, {"action": "AGONIST", "target": "P25021", "drug": "DB00667"}, {"action": "AGONIST", "target": "Q9Y5N1", "drug": "DB00667"}, {"action": "AGONIST", "target": "Q9H3N8", "drug": "DB00667"}]}, "DB00666": {"dbids": ["APRD01129", "DB00666"], "name": "Nafarelin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P30968", "drug": "DB00666"}, {"action": "AGONIST", "target": "Q96P88", "drug": "DB00666"}]}, "DB00669": {"dbids": ["APRD00379", "DB00669"], "name": "Sumatriptan", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P28221", "drug": "DB00669"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00669"}, {"action": "AGONIST", "target": "P30939", "drug": "DB00669"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00669"}]}, "DB00884": {"dbids": ["APRD00410", "DB00884", "DB02782"], "name": "Risedronate", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P14324", "drug": "DB00884"}]}, "DB00887": {"dbids": ["APRD00294", "DB00887"], "name": "Bumetanide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q13621", "drug": "DB00887"}, {"action": "INHIBITOR", "target": "P55011", "drug": "DB00887"}, {"action": "INHIBITOR", "target": "Q9UP95", "drug": "DB00887"}, {"action": "INHIBITOR", "target": "Q9H2X9", "drug": "DB00887"}, {"action": "ANTAGONIST", "target": "P13569", "drug": "DB00887"}]}, "DB00886": {"dbids": ["APRD00443", "DB00886"], "name": "Omapatrilat", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB00881": {"dbids": ["APRD00523", "DB00881"], "name": "Quinapril", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P12821", "drug": "DB00881"}]}, "DB00880": {"dbids": ["APRD00721", "DB00880"], "name": "Chlorothiazide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P55017", "drug": "DB00880"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00880"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00880"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00880"}]}, "DB00883": {"dbids": ["APRD00455", "DB00883"], "name": "Isosorbide Dinitrate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P16066", "drug": "DB00883"}]}, "DB00882": {"dbids": ["APRD00880", "DB00882"], "name": "Clomifene", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P03372", "drug": "DB00882"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00882"}]}, "DB08684": {"dbids": ["DB08684"], "name": "O-DECYL HYDROGEN THIOCARBONATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07588": {"dbids": ["DB07588"], "name": "3,4-DI-1H-INDOL-3-YL-1H-PYRROLE-2,5-DICARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03283": {"dbids": ["DB03283", "EXPT01510"], "name": "beta-L-fucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03280": {"dbids": ["DB03280", "EXPT02996"], "name": "P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03281": {"dbids": ["DB03281", "EXPT01247"], "name": "2'-Deoxymaltose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03286": {"dbids": ["DB03286", "EXPT00899"], "name": "C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03287": {"dbids": ["DB03287", "EXPT02640"], "name": "4-(2-Amino-Ethoxy)-2-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Amino]-but-3-Enoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03284": {"dbids": ["DB03284", "EXPT01544"], "name": "2,6-Anhydro-3-Deoxy-D-Erythro-Hex-2-Enonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03285": {"dbids": ["DB03285", "EXPT01707"], "name": "2',4,4'-Trihydroxychalcone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03288": {"dbids": ["DB03288", "EXPT00098"], "name": "5-Chloro-1h-Indole-2-Carboxylic Acid{[Cyclopentyl-(2-Hydroxy-Ethyl)-Carbamoyl]-Methyl}-Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03289": {"dbids": ["DB03289", "EXPT01083"], "name": "Thiarsa Dihydroxy Cysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01426": {"dbids": ["DB01426"], "name": "Ajmaline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB01426"}]}, "DB04946": {"dbids": ["DB04946"], "name": "Iloperidone", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P28223", "drug": "DB04946"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB04946"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB04946"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB04946"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB04946"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB04946"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB04946"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB04946"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB04946"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB04946"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB04946"}]}, "DB04947": {"dbids": ["DB04947"], "name": "Altropane", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04940": {"dbids": ["DB04940"], "name": "E7389", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04941": {"dbids": ["DB04941"], "name": "Crofelemer", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P13569", "drug": "DB04941"}, {"action": "ANTAGONIST", "target": "Q5XXA6", "drug": "DB04941"}]}, "DB04942": {"dbids": ["DB04942"], "name": "Tamibarotene", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P10276", "drug": "DB04942"}, {"action": "AGONIST", "target": "P10826", "drug": "DB04942"}]}, "DB04943": {"dbids": ["DB04943"], "name": "LX201", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04948": {"dbids": ["DB04948"], "name": "Lofexidine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P08913", "drug": "DB04948"}]}, "DB04949": {"dbids": ["DB04949"], "name": "Pexelizumab", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08074": {"dbids": ["DB08074"], "name": "3-(3-methylbut-2-en-1-yl)-3H-purin-6-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08075": {"dbids": ["DB08075"], "name": "4-(2-amino-1,3-thiazol-4-yl)pyrimidin-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08076": {"dbids": ["DB08076"], "name": "4-[1-(2,6-dichlorobenzyl)-2-methyl-1H-imidazol-4-yl]pyrimidin-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08077": {"dbids": ["DB08077"], "name": "2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08070": {"dbids": ["DB08070"], "name": "2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08071": {"dbids": ["DB08071"], "name": "(2S)-1-methyl-2-[(2S,4R)-2-methyl-4-phenylpentyl]piperidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08072": {"dbids": ["DB08072"], "name": "4-(2-AMINOETHOXY)-3,5-DICHLORO-N-[3-(1-METHYLETHOXY)PHENYL]BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08073": {"dbids": ["DB08073"], "name": "(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08078": {"dbids": ["DB08078"], "name": "{4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy}acetic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08079": {"dbids": ["DB08079"], "name": "7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01427": {"dbids": ["DB01427"], "name": "Amrinone", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14432", "drug": "DB01427"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB01427"}, {"action": "INHIBITOR", "target": "P01375", "drug": "DB01427"}]}, "DB03068": {"dbids": ["DB03068", "EXPT03280"], "name": "Zebularine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03069": {"dbids": ["DB03069", "EXPT01072"], "name": "Cytidine-5'-Diphospho-Beta-D-Xylose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03066": {"dbids": ["DB03066", "EXPT01215"], "name": "D-Lactic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03067": {"dbids": ["DB03067", "EXPT00062"], "name": "4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03064": {"dbids": ["DB03064", "EXPT01195"], "name": "3-Decyl-2,5-Dioxo-4-Hydroxy-3-Pyrroline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03065": {"dbids": ["DB03065", "EXPT00312"], "name": "7-Nitroindazole-2-Carboxamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03062": {"dbids": ["DB03062", "EXPT02748"], "name": "(1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-Methanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03063": {"dbids": ["DB03063", "EXPT01332"], "name": "N-(1-Benzyl-3-{[3-(1,3-Dioxo-1,3-Dihydro-Isoindol-2-Yl)-Propionyl]-[2-(Hexahydro-Benzo[1,3]Dioxol-5-Yl)-Ethyl]-Amino}-2-Hydroxy-Propyl)-4-Benzyloxy-3,5-Dimethoxy-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03060": {"dbids": ["DB03060", "EXPT02032"], "name": "Sri-9662", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03061": {"dbids": ["DB03061", "EXPT02365"], "name": "(R)-N-(1-Methyl-Hexyl)-Formamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01421": {"dbids": ["DB01421"], "name": "Paromomycin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q5SHN7", "drug": "DB01421"}]}, "DB01562": {"dbids": ["DB01562"], "name": "1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01422": {"dbids": ["DB01422"], "name": "Nitroxoline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P50579", "drug": "DB01422"}]}, "DB01509": {"dbids": ["DB01509"], "name": "3,4-Methylenedioxyamphetamine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB02629": {"dbids": ["DB02629", "EXPT00657", "EXPT00661"], "name": "Inhibitor Bea403", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02628": {"dbids": ["DB02628", "EXPT00351"], "name": "1-[3,3-Dimethyl-2-(2-Methylamino-Propionylamino)-Butyryl]-Pyrrolidine-2-Carboxylic Acid(1,2,3,4-Tetrahydro-Naphthalen-1-Yl)-Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02623": {"dbids": ["DB02623", "EXPT01626"], "name": "Aminophosphonic Acid-Guanylate Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02622": {"dbids": ["DB02622", "EXPT02412"], "name": "2-(Oxalyl-Amino)-Benzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02621": {"dbids": ["DB02621", "EXPT02004"], "name": "Latrunculin A", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P68133", "drug": "DB02621"}]}, "DB02620": {"dbids": ["DB02620", "EXPT00344"], "name": "Sp7343-Sp7964", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02627": {"dbids": ["DB02627", "EXPT00647"], "name": "4,4'-Biphenyldiboronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02626": {"dbids": ["DB02626", "EXPT02556"], "name": "Phenylferricrocin-Iron", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02625": {"dbids": ["DB02625", "EXPT00756"], "name": "(2r)-2-{[Formyl(Hydroxy)Amino]Methyl}Hexanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02624": {"dbids": ["DB02624", "EXPT01784"], "name": "Homoserine Lactone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05930": {"dbids": ["DB05930"], "name": "SB-559448", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08917": {"dbids": ["DB08917"], "name": "Ferric Carboxymaltose", "groups": ["APPROVED"], "targets": []}, "DB09139": {"dbids": ["DB09139"], "name": "Technetium Tc 99m Oxidronate", "groups": ["APPROVED"], "targets": []}, "DB09132": {"dbids": ["DB09132"], "name": "Gadoteric acid", "groups": ["APPROVED"], "targets": []}, "DB09133": {"dbids": ["DB09133"], "name": "Iothalamic acid", "groups": ["APPROVED"], "targets": []}, "DB09130": {"dbids": ["DB09130"], "name": "Copper", "groups": ["APPROVED"], "targets": []}, "DB09131": {"dbids": ["DB09131"], "name": "Cupric Chloride", "groups": ["APPROVED"], "targets": []}, "DB09136": {"dbids": ["DB09136"], "name": "Isosulfan blue", "groups": ["APPROVED"], "targets": []}, "DB09137": {"dbids": ["DB09137"], "name": "Technetium Tc 99m Mebrofenin", "groups": ["APPROVED"], "targets": []}, "DB09134": {"dbids": ["DB09134"], "name": "Ioversol", "groups": ["APPROVED"], "targets": []}, "DB09135": {"dbids": ["DB09135"], "name": "Ioxilan", "groups": ["APPROVED"], "targets": []}, "DB09268": {"dbids": ["DB09268"], "name": "Sodium picosulfate", "groups": ["APPROVED"], "targets": []}, "DB09269": {"dbids": ["DB09269"], "name": "Phenylacetic acid", "groups": ["APPROVED"], "targets": []}, "DB08916": {"dbids": ["DB08916"], "name": "Afatinib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00533", "drug": "DB08916"}, {"action": "INHIBITOR", "target": "P04626", "drug": "DB08916"}, {"action": "INHIBITOR", "target": "Q15303", "drug": "DB08916"}]}, "DB09266": {"dbids": ["DB09266"], "name": "Technetium Tc-99m tilmanocept", "groups": ["APPROVED"], "targets": []}, "DB09267": {"dbids": ["DB09267"], "name": "Strontium ranelate", "groups": ["APPROVED"], "targets": []}, "DB09264": {"dbids": ["DB09264"], "name": "Idarucizumab", "groups": ["APPROVED"], "targets": []}, "DB09265": {"dbids": ["DB09265"], "name": "Lixisenatide", "groups": ["APPROVED"], "targets": []}, "DB07228": {"dbids": ["DB07228"], "name": "1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09262": {"dbids": ["DB09262"], "name": "Imidafenacin", "groups": ["APPROVED"], "targets": []}, "DB08915": {"dbids": ["DB08483", "DB08915"], "name": "Aleglitazar", "groups": ["INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "Q07869", "drug": "DB08915"}, {"action": "AGONIST", "target": "P37231", "drug": "DB08915"}]}, "DB09263": {"dbids": ["DB09263"], "name": "Patiromer", "groups": ["APPROVED"], "targets": []}, "DB01503": {"dbids": ["DB01503"], "name": "1-Androstenediol", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB09260": {"dbids": ["DB09260"], "name": "Parnaparin", "groups": ["APPROVED"], "targets": []}, "DB09261": {"dbids": ["DB09261"], "name": "Certoparin", "groups": ["APPROVED"], "targets": []}, "DB07229": {"dbids": ["DB07229"], "name": "3-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-5-METHOXY-1,1'-BIPHENYL-2-OLATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08914": {"dbids": ["DB08914"], "name": "Insulin, isophane", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P06213", "drug": "DB08914"}]}, "DB08913": {"dbids": ["DB05677", "DB08913"], "name": "Radium Ra 223 Dichloride", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB04719": {"dbids": ["DB04719"], "name": "DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04718": {"dbids": ["DB04718"], "name": "(2S,3S,4R,5R,6R)-5-Amino-2-(Aminomethyl)-6-((2R,3R,4R,5S)-5-((1R,2R,3S,5R,6S)-3,5-Diamino-2-((2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)-tetrahydro-2H-pyran-2-yloxy)-6-hydroxycyclohexyloxy)-2-(hydroxymethyl)-4-(2-((R)-piperidin-3-ylmethylamin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04711": {"dbids": ["DB04711"], "name": "Iodipamide", "groups": ["APPROVED"], "targets": []}, "DB04710": {"dbids": ["DB04710"], "name": "(E)-(S)-4-[(S)-4-METHYL-2-((S)-3-METHYL-2{(S)-2-[(5-METHYL-ISOXAZOLE-3- CARBONYL)-AMINO]-PROPIONYLAMINO}-BUTYRYLAMINO)-PENTANOYLAMINO]-5-((S)-2- OXO-PYRROLIDIN-3-YL)-PENT-2-ENOIC ACID ETHYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04713": {"dbids": ["DB04713"], "name": "4-IODOPHENYLALANINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04712": {"dbids": ["DB04712"], "name": "ANILINOMETHYL GLUCO-PHENYLIMIDAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04715": {"dbids": ["DB04715"], "name": "IMIDAZOPYRIDAZIN 1", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04714": {"dbids": ["DB04714"], "name": "ISOPENTENYL PYROPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04717": {"dbids": ["DB04717"], "name": "2''-O-[N-(3-(aminopropyl)2-aminoethyl]paromomycin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04716": {"dbids": ["DB04716"], "name": "2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00416": {"dbids": ["APRD01318", "DB00416"], "name": "Metocurine Iodide", "groups": ["WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "Q15822", "drug": "DB00416"}]}, "DB00417": {"dbids": ["APRD00423", "DB00417", "DB08415"], "name": "Phenoxymethylpenicillin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q53707", "drug": "DB00417"}]}, "DB00414": {"dbids": ["APRD00773", "DB00414"], "name": "Acetohexamide", "groups": ["WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P48048", "drug": "DB00414"}]}, "DB00415": {"dbids": ["APRD00320", "DB00415"], "name": "Ampicillin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB00415"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB00415"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00415"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB00415"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB00415"}]}, "DB00412": {"dbids": ["APRD00403", "DB00412"], "name": "Rosiglitazone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P37231", "drug": "DB00412"}, {"action": "INHIBITOR", "target": "O60488", "drug": "DB00412"}]}, "DB00413": {"dbids": ["APRD00156", "DB00413"], "name": "Pramipexole", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P35462", "drug": "DB00413"}, {"action": "AGONIST", "target": "P14416", "drug": "DB00413"}, {"action": "AGONIST", "target": "P21917", "drug": "DB00413"}, {"action": "UNKNOWN", "target": "P18089", "drug": "DB00413"}, {"action": "UNKNOWN", "target": "P08908", "drug": "DB00413"}, {"action": "UNKNOWN", "target": "P28221", "drug": "DB00413"}, {"action": "PARTIAL AGONIST", "target": "P08913", "drug": "DB00413"}, {"action": "UNKNOWN", "target": "P28222", "drug": "DB00413"}, {"action": "UNKNOWN", "target": "P28223", "drug": "DB00413"}, {"action": "UNKNOWN", "target": "P41595", "drug": "DB00413"}, {"action": "UNKNOWN", "target": "P28335", "drug": "DB00413"}, {"action": "UNKNOWN", "target": "P18825", "drug": "DB00413"}, {"action": "UNKNOWN", "target": "P21728", "drug": "DB00413"}, {"action": "UNKNOWN", "target": "P21918", "drug": "DB00413"}]}, "DB00410": {"dbids": ["APRD00162", "DB00410"], "name": "Mupirocin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P41972", "drug": "DB00410"}]}, "DB00411": {"dbids": ["APRD00845", "DB00411", "DB02487"], "name": "Carbachol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P11229", "drug": "DB00411"}, {"action": "AGONIST", "target": "P08172", "drug": "DB00411"}, {"action": "AGONIST", "target": "Q15822", "drug": "DB00411"}]}, "DB08661": {"dbids": ["DB08661"], "name": "1-(2,5-dideoxy-5-pyrrolidin-1-yl-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08660": {"dbids": ["DB08660"], "name": "1,2,5,8-tetrahydroxyanthracene-9,10-dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08663": {"dbids": ["DB08663"], "name": "4-HYDROXY-7-METHOXY-3-(1-PHENYL-PROPYL)-CHROMEN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08662": {"dbids": ["DB08662"], "name": "3-[1-(4-BROMO-PHENYL)-2-METHYL-PROPYL]-4-HYDROXY-CHROMEN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08665": {"dbids": ["DB08665"], "name": "6,11-DIHYDRO-11-ETHYL-6-METHYL-9-NITRO-5H-PYRIDO[2,3-B][1,5]BENZODIAZEPIN-5-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08664": {"dbids": ["DB08664"], "name": "({3-[1-(4-HYDROXY-2-OXO-2H-CHROMEN-3-YL)-PROPYL]-PHENYLCARBAMOYL}-METHYL)-CARBAMIC ACID TERT-BUTYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00418": {"dbids": ["APRD00497", "DB00418"], "name": "Secobarbital", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00418"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00418"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00418"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00418"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00418"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "Q05586", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "Q14957", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "O15399", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "O60391", "drug": "DB00418"}]}, "DB00419": {"dbids": ["APRD01118", "DB00419"], "name": "Miglustat", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q16739", "drug": "DB00419"}]}, "DB06849": {"dbids": ["DB06849"], "name": "1-[1'-(3-phenylacryloyl)spiro[1-benzofuran-3,4'-piperidin]-5-yl]methanamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06848": {"dbids": ["DB06848"], "name": "1-(1'-{[3-(methylsulfanyl)-2-benzothiophen-1-yl]carbonyl}spiro[1-benzofuran-3,4'-piperidin]-5-yl)methanamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06843": {"dbids": ["DB06843"], "name": "2',5'-DIDEOXY-ADENOSINE 3'-MONOPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06842": {"dbids": ["DB06842"], "name": "(4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06841": {"dbids": ["DB06841"], "name": "D-phenylalanyl-N-[(1S)-4-{[amino(iminio)methyl]amino}-1-(chloroacetyl)butyl]-L-prolinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06840": {"dbids": ["DB06840"], "name": "diethyl [(1R)-1,5-diaminopentyl]boronate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06847": {"dbids": ["DB06847"], "name": "5-[(3S)-3-(2-methoxybiphenyl-4-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06846": {"dbids": ["DB06846"], "name": "7-[3-(4-FLUORO-PHENYL)-1-ISOPROPYL-1H-INDOL-2-YL]-3,5-DIHYDROXY-HEPTANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06845": {"dbids": ["DB06845"], "name": "(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06844": {"dbids": ["DB06844"], "name": "4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04575": {"dbids": ["DB04575"], "name": "Quinestrol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P03372", "drug": "DB04575"}, {"action": "MODULATOR", "target": "P03372", "drug": "DB04575"}]}, "DB04574": {"dbids": ["DB04574"], "name": "Estropipate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P03372", "drug": "DB04574"}, {"action": "AGONIST", "target": "Q92731", "drug": "DB04574"}]}, "DB04577": {"dbids": ["DB04577"], "name": "1-(1-phenylcyclopentyl)methylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04576": {"dbids": ["DB04576"], "name": "Fleroxacin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P11388", "drug": "DB04576"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB04576"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB04576"}]}, "DB04571": {"dbids": ["DB04571"], "name": "Trioxsalen", "groups": ["APPROVED"], "targets": []}, "DB04739": {"dbids": ["DB04739"], "name": "4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04573": {"dbids": ["DB04573", "DB05375", "EXPT01361"], "name": "Estriol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P03372", "drug": "DB04573"}, {"action": "AGONIST", "target": "Q92731", "drug": "DB04573"}]}, "DB04572": {"dbids": ["DB04572"], "name": "Thiotepa", "groups": ["APPROVED"], "targets": []}, "DB04738": {"dbids": ["DB04738"], "name": "Motuporin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04579": {"dbids": ["DB04579"], "name": "N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04578": {"dbids": ["DB04578"], "name": "(S)-2-[(R)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04737": {"dbids": ["DB04737"], "name": "(S)-HYDROXY(PHENYL)ACETONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04088": {"dbids": ["DB04088", "EXPT00193"], "name": "N-(Allyloxycarbonyl)-4-[N-(Carboxy-Formyl)-2-(Benzoic Acid)-Amino]-L-Phenylalaninyl-Amino-Butyloxy-(6-Hydroxy-Benzoic Acid Methyl Ester)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08910": {"dbids": ["DB08910"], "name": "Pomalidomide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q96SW2", "drug": "DB08910"}, {"action": "INHIBITOR", "target": "P01375", "drug": "DB08910"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB08910"}]}, "DB08215": {"dbids": ["DB08215"], "name": "2-T-BUTYLAMINO-4-ETHYLAMINO-6-METHYLTHIO-S-TRIAZINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08213": {"dbids": ["DB08213"], "name": "1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01002": {"dbids": ["APRD00110", "DB01002"], "name": "Levobupivacaine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB01002"}]}, "DB01460": {"dbids": ["DB01460"], "name": "Diethyltryptamine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB08648": {"dbids": ["DB08648"], "name": "8-HYDROXY-2-OXA-BICYCLO[3.3.1]NON-6-ENE-3,5-DICARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08219": {"dbids": ["DB08219"], "name": "4-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06713": {"dbids": ["DB06713"], "name": "Norelgestromin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P06401", "drug": "DB06713"}]}, "DB06712": {"dbids": ["DB06712"], "name": "Nilvadipine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q13936", "drug": "DB06712"}, {"action": "INHIBITOR", "target": "P54289", "drug": "DB06712"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB06712"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB06712"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB06712"}, {"action": "INHIBITOR", "target": "Q8IZS8", "drug": "DB06712"}]}, "DB06711": {"dbids": ["DB06711"], "name": "Naphazoline", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35348", "drug": "DB06711"}, {"action": "AGONIST", "target": "P08913", "drug": "DB06711"}]}, "DB06710": {"dbids": ["DB06710"], "name": "Methyltestosterone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P10275", "drug": "DB06710"}]}, "DB06717": {"dbids": ["DB06717"], "name": "Fosaprepitant", "groups": ["APPROVED"], "targets": []}, "DB06716": {"dbids": ["DB05279", "DB06716"], "name": "Fospropofol", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POTENTIATOR", "target": "P47870", "drug": "DB06716"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB06716"}]}, "DB06715": {"dbids": ["DB06715"], "name": "Potassium Iodide", "groups": ["APPROVED"], "targets": []}, "DB06714": {"dbids": ["DB06714"], "name": "Propylhexedrine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "Q96RJ0", "drug": "DB06714"}]}, "DB06719": {"dbids": ["DB06719"], "name": "Buserelin", "groups": ["APPROVED"], "targets": []}, "DB06718": {"dbids": ["DB06718"], "name": "Stanozolol", "groups": ["APPROVED"], "targets": []}, "DB01461": {"dbids": ["DB01461"], "name": "Dimenoxadol", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB02010": {"dbids": ["DB02010", "EXPT02970", "EXPT02972"], "name": "Staurosporine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02011": {"dbids": ["DB02011", "EXPT02497"], "name": "N-(Phosphonoacetyl)-L-Ornithine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02013": {"dbids": ["DB02013", "EXPT01417"], "name": "Monoazido-Mu-Oxo-Diiron", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02014": {"dbids": ["DB02014", "EXPT00090"], "name": "Compound 9", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02015": {"dbids": ["DB02015", "EXPT01190"], "name": "Dihydrofolic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02016": {"dbids": ["DB02016", "EXPT02749"], "name": "R048-8071", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02017": {"dbids": ["DB02017", "EXPT01837"], "name": "Imidazole-Derived Cellobiose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02018": {"dbids": ["DB02018", "EXPT00537"], "name": "Amido Phenyl Pyruvic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02019": {"dbids": ["DB02019", "EXPT00432"], "name": "Acetyl Dithranol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08936": {"dbids": ["DB08936"], "name": "Chlorcyclizine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB08936"}]}, "DB02337": {"dbids": ["DB02337", "EXPT00843"], "name": "S-(D-Carboxybutyl)-L-Homocysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08642": {"dbids": ["DB08642"], "name": "(2R,6S)-6-{[methyl(3,4,5-trimethoxyphenyl)amino]methyl}-1,2,5,6,7,8-hexahydroquinazoline-2,4-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07004": {"dbids": ["DB07004"], "name": "2-[(5-hex-1-yn-1-ylfuran-2-yl)carbonyl]-N-methylhydrazinecarbothioamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07005": {"dbids": ["DB07005"], "name": "D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07006": {"dbids": ["DB07006"], "name": "9-HYDROXY-6-(3-HYDROXYPROPYL)-4-(2-METHOXYPHENYL)PYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02336": {"dbids": ["DB02336", "EXPT00328"], "name": "RU83876", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07000": {"dbids": ["DB07000"], "name": "N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07001": {"dbids": ["DB07001"], "name": "(3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07002": {"dbids": ["DB07002"], "name": "4-({4-[(4-methoxypyridin-2-yl)amino]piperidin-1-yl}carbonyl)benzonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07003": {"dbids": ["DB07003"], "name": "(2S)-2-methyl-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02331": {"dbids": ["DB02331", "EXPT00040"], "name": "(2s)-2-[(5-Benzofuran-2-Yl-Thiophen-2-Ylmethyl)-(2,4-Dichloro-Benzoyl)-Amino]-3-Phenyl-Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07008": {"dbids": ["DB07008"], "name": "4-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]PYRIMIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07009": {"dbids": ["DB07009"], "name": "2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02841": {"dbids": ["DB02841", "EXPT02299"], "name": "[(2-Ethoxy-1-Naphthoyl)Amino]Methylboronic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02332": {"dbids": ["DB02332", "EXPT01392"], "name": "Flavin-N7 Protonated-Adenine Dinucleotide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06823": {"dbids": ["DB06823"], "name": "Tiopronin", "groups": ["APPROVED"], "targets": []}, "DB06822": {"dbids": ["DB06822"], "name": "Tinzaparin", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P01008", "drug": "DB06822"}, {"action": "INHIBITOR", "target": "P13612", "drug": "DB06822"}, {"action": "BINDER", "target": "P48061", "drug": "DB06822"}]}, "DB08813": {"dbids": ["DB08813"], "name": "Nadroparin", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P01008", "drug": "DB08813"}, {"action": "INHIBITOR", "target": "P16109", "drug": "DB08813"}, {"action": "INHIBITOR", "target": "P01100", "drug": "DB08813"}, {"action": "INHIBITOR", "target": "P01106", "drug": "DB08813"}]}, "DB06825": {"dbids": ["DB06825"], "name": "Triptorelin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P30968", "drug": "DB06825"}]}, "DB08810": {"dbids": ["DB08810"], "name": "Cinitapride", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P08908", "drug": "DB08810"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB08810"}, {"action": "AGONIST", "target": "Q13639", "drug": "DB08810"}]}, "DB06824": {"dbids": ["DB06824"], "name": "Triethylenetetramine", "groups": ["APPROVED"], "targets": []}, "DB08811": {"dbids": ["DB08811"], "name": "Tofisopam", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P27815", "drug": "DB08811"}, {"action": "INHIBITOR", "target": "Q9Y233", "drug": "DB08811"}, {"action": "INHIBITOR", "target": "Q14432", "drug": "DB08811"}, {"action": "INHIBITOR", "target": "O00408", "drug": "DB08811"}]}, "DB08816": {"dbids": ["DB08816"], "name": "Ticagrelor", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9H244", "drug": "DB08816"}]}, "DB00342": {"dbids": ["APRD00606", "DB00342"], "name": "Terfenadine", "groups": ["WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00342"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00342"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00342"}, {"action": "BINDER", "target": "P11229", "drug": "DB00342"}, {"action": "BINDER", "target": "P08912", "drug": "DB00342"}, {"action": "BINDER", "target": "P08173", "drug": "DB00342"}, {"action": "BINDER", "target": "P08172", "drug": "DB00342"}]}, "DB08814": {"dbids": ["DB08814"], "name": "Triflusal", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P23219", "drug": "DB08814"}, {"action": "ANTAGONIST", "target": "P19838", "drug": "DB08814"}, {"action": "AGONIST", "target": "P35228", "drug": "DB08814"}, {"action": "ANTAGONIST", "target": "Q9Y233", "drug": "DB08814"}]}, "DB00343": {"dbids": ["APRD00473", "DB00343"], "name": "Diltiazem", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q06432", "drug": "DB00343"}]}, "DB08815": {"dbids": ["DB08815"], "name": "Lurasidone", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB08815"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB08815"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB08815"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB08815"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB08815"}]}, "DB00436": {"dbids": ["APRD00666", "DB00436"], "name": "Bendroflumethiazide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P55017", "drug": "DB00436"}, {"action": "INDUCER", "target": "Q12791", "drug": "DB00436"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00436"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00436"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00436"}]}, "DB07900": {"dbids": ["DB07900"], "name": "3-FORMYL-2-HYDROXY-5-METHYL-HEXANOIC ACID HYDROXYAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03497": {"dbids": ["DB03497", "EXPT02449"], "name": "O-Sulfo-L-Serine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03496": {"dbids": ["DB03496", "EXPT00998"], "name": "Flavopiridol", "groups": ["EXPERIMENTAL", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P24941", "drug": "DB03496"}]}, "DB03495": {"dbids": ["DB03495", "EXPT01820"], "name": "4,6-Dideoxy-4-{[4,5,6-Trihydroxy-3-(Hydroxymethyl)Cyclohex-2-En-1-Yl]Amino}-Alpha-D-Lyxo-Hexopyranosyl-(1->4)-Alpha-D-Threo-Hexopyranosyl-(1->6)-Alpha-L-Threo-Hexopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00437": {"dbids": ["APRD00435", "DB00437", "DB03027"], "name": "Allopurinol", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P47989", "drug": "DB00437"}]}, "DB03493": {"dbids": ["DB03493", "EXPT02164"], "name": "7-Methylguanosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03492": {"dbids": ["DB03492", "EXPT02053"], "name": "Lambda-Bis(2,2'-Bipyridine)Imidazole Osmium (Ii)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03491": {"dbids": ["DB03491", "EXPT01179"], "name": "2'-Deoxyguanosine-5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03490": {"dbids": ["DB03490", "EXPT02030"], "name": "3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00430": {"dbids": ["APRD00856", "DB00430"], "name": "Cefpiramide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0AD68", "drug": "DB00430"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB00430"}, {"action": "INHIBITOR", "target": "Q07806", "drug": "DB00430"}, {"action": "INHIBITOR", "target": "Q9X6W0", "drug": "DB00430"}, {"action": "INHIBITOR", "target": "P08506", "drug": "DB00430"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB00430"}, {"action": "INHIBITOR", "target": "C1KC03", "drug": "DB00430"}]}, "DB03499": {"dbids": ["DB03499", "EXPT02188"], "name": "Malate Ion", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00431": {"dbids": ["APRD01072", "DB00431"], "name": "Lindane", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P18505", "drug": "DB00431"}, {"action": "ANTAGONIST", "target": "P23415", "drug": "DB00431"}, {"action": "ANTAGONIST", "target": "P23416", "drug": "DB00431"}, {"action": "ANTAGONIST", "target": "O75311", "drug": "DB00431"}, {"action": "ANTAGONIST", "target": "P48167", "drug": "DB00431"}]}, "DB01003": {"dbids": ["APRD00336", "DB01003"], "name": "Cromoglicic acid", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q12791", "drug": "DB01003"}, {"action": "ANTAGONIST", "target": "P25815", "drug": "DB01003"}]}, "DB00344": {"dbids": ["APRD00441", "DB00344"], "name": "Protriptyline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23975", "drug": "DB00344"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00344"}]}, "DB00345": {"dbids": ["APRD00792", "DB00345"], "name": "Aminohippurate", "groups": ["APPROVED"], "targets": []}, "DB07350": {"dbids": ["DB07350"], "name": "(2E)-N-hydroxy-3-[1-methyl-4-(phenylacetyl)-1H-pyrrol-2-yl]prop-2-enamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07351": {"dbids": ["DB07351"], "name": "O-(((1R)-((N-(PHENYL-METHOXY-CARBONYL)-ALANYL)-AMINO)METHYL)HYDROXYPHOSPHINYL)3-L-PHENYLLACTATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07352": {"dbids": ["DB07352"], "name": "5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05891": {"dbids": ["DB05891"], "name": "HD-O", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05890": {"dbids": ["DB05890"], "name": "VEGF-AS", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05892": {"dbids": ["DB05892"], "name": "RI 624", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05895": {"dbids": ["DB05895"], "name": "HGS-TR2J", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05894": {"dbids": ["DB05894"], "name": "GT 389-255", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05897": {"dbids": ["DB05897"], "name": "rhIGFBP-3", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05896": {"dbids": ["DB05896"], "name": "Sirna-027", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05899": {"dbids": ["DB05899"], "name": "IT-101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05898": {"dbids": ["DB05898"], "name": "CERE-110", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08865": {"dbids": ["DB08865"], "name": "Crizotinib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9UM73", "drug": "DB08865"}, {"action": "INHIBITOR", "target": "P08581", "drug": "DB08865"}]}, "DB08864": {"dbids": ["DB08864"], "name": "Rilpivirine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q72547", "drug": "DB08864"}, {"action": "AGONIST", "target": "O75469", "drug": "DB08864"}]}, "DB08862": {"dbids": ["DB08862"], "name": "Cholecystokinin", "groups": ["APPROVED"], "targets": []}, "DB07355": {"dbids": ["DB07355"], "name": "3-(heptyloxy)benzoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03721": {"dbids": ["DB03721", "EXPT02909"], "name": "O-Sialic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03720": {"dbids": ["DB03720", "EXPT01127"], "name": "Z-Dehydrobutyrine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03723": {"dbids": ["DB03723", "EXPT03108"], "name": "2'-Deoxy-Thymidine-Beta-L-Rhamnose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03722": {"dbids": ["DB03722", "EXPT01196"], "name": "3,4-Dihydro-5-Methyl-Isoquinolinone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03725": {"dbids": ["DB03725", "EXPT01659"], "name": "Phosphomethylphosphonic Acid-Guanylate Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03724": {"dbids": ["DB03724", "EXPT03250"], "name": "(1s,2s)-1-Amino-1-(1,3-Thiazol-2-Yl)Propan-2-Ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03727": {"dbids": ["DB03727", "EXPT00070"], "name": "Coproporphyrin I", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03726": {"dbids": ["DB03726", "EXPT02482"], "name": "Purine Riboside-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03729": {"dbids": ["DB03729", "EXPT00052"], "name": "2-Amino-5-Hydroxy-Benzimidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03728": {"dbids": ["DB03728", "EXPT00054"], "name": "4-Chlorobenzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07357": {"dbids": ["DB07357"], "name": "4-AMINO-2-HEXYLOXY-6-HYDROXYMETHYL-TETRAHYDRO-PYRAN-3,5-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05099": {"dbids": ["DB05099"], "name": "Ancrod", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05098": {"dbids": ["DB05098"], "name": "Leptin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05769": {"dbids": ["DB05769"], "name": "LCP-AtorFen", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05768": {"dbids": ["DB05768"], "name": "Alkaline Phosphatase", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05091": {"dbids": ["DB05091"], "name": "M0002", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05090": {"dbids": ["DB05090"], "name": "FP0011", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05093": {"dbids": ["DB05093"], "name": "AX200", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05092": {"dbids": ["DB05092"], "name": "CDP323", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05767": {"dbids": ["DB05767"], "name": "HMPL-004", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05766": {"dbids": ["DB05766"], "name": "ACP-104", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05765": {"dbids": ["DB05765"], "name": "ATX-201", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05764": {"dbids": ["DB05764"], "name": "ABT-263", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04553": {"dbids": ["DB04553", "EXPT00126"], "name": "2-Oxobutanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04552": {"dbids": ["DB04552", "EXPT02331"], "name": "Niflumic Acid", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P04054", "drug": "DB04552"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB04552"}, {"action": "INDUCER", "target": "P51800", "drug": "DB04552"}]}, "DB04883": {"dbids": ["DB04883"], "name": "Darusentan", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04882": {"dbids": ["DB04882"], "name": "Edotecarin", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04885": {"dbids": ["DB04885"], "name": "Cilansetron", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04556": {"dbids": ["DB04556", "EXPT02841"], "name": "3-[(1s)-1-(Dimethylamino)Ethyl]Phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04887": {"dbids": ["DB04887"], "name": "Brecanavir", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04886": {"dbids": ["DB04886"], "name": "Calanolide A", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08398": {"dbids": ["DB08398"], "name": "2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09095": {"dbids": ["DB09095"], "name": "Difluocortolone", "groups": ["APPROVED"], "targets": []}, "DB09094": {"dbids": ["DB09094"], "name": "Podophyllin", "groups": ["APPROVED"], "targets": []}, "DB09097": {"dbids": ["DB09097"], "name": "Quinagolide", "groups": ["APPROVED"], "targets": []}, "DB09096": {"dbids": ["DB09096"], "name": "Benzoyl peroxide", "groups": ["APPROVED"], "targets": []}, "DB09091": {"dbids": ["DB09091"], "name": "Tixocortol", "groups": ["APPROVED"], "targets": []}, "DB09090": {"dbids": ["DB09090"], "name": "Pinaverium", "groups": ["APPROVED"], "targets": []}, "DB09093": {"dbids": ["DB09093"], "name": "Chlortetracycline", "groups": ["APPROVED"], "targets": []}, "DB09092": {"dbids": ["DB09092"], "name": "Xanthinol", "groups": ["APPROVED"], "targets": []}, "DB09099": {"dbids": ["DB09099"], "name": "Somatostatin", "groups": ["APPROVED"], "targets": []}, "DB09098": {"dbids": ["DB09098"], "name": "Somatrem", "groups": ["WITHDRAWN"], "targets": []}, "DB01731": {"dbids": ["DB01731", "EXPT03245"], "name": "(S)-Wiskostatin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01732": {"dbids": ["DB01732", "EXPT00460"], "name": "(4r,5s,6s,7r)-1,3-Dibenzyl-4,7-Bis(Phenoxymethyl)-5,6-Dihydroxy-1,3 Diazepan-2-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01733": {"dbids": ["DB01733", "EXPT02551"], "name": "L-Phospholactate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01734": {"dbids": ["DB01734", "EXPT00298"], "name": "3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01735": {"dbids": ["DB01735", "EXPT00806"], "name": "3-Chloroalaninate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01736": {"dbids": ["DB01736", "EXPT02014"], "name": "[3-(Dodecanoylamino)Propyl](Hydroxy)Dimethylammonium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01737": {"dbids": ["DB01737", "EXPT00521"], "name": "Nalpha-(2-Naphthylsulfonylglycyl)-3-Amidino-D,L-Phenylalanine-Isopropylester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01738": {"dbids": ["DB01738", "DB04403", "EXPT02671"], "name": "O-Phosphoethanolamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01739": {"dbids": ["DB01739", "EXPT01856"], "name": "Allo-Isoleucine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00069": {"dbids": ["BIOD00062", "BTD00062", "DB00069"], "name": "Interferon alfacon-1", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "P17181", "drug": "DB00069"}, {"action": "BINDER", "target": "P48551", "drug": "DB00069"}]}, "DB00068": {"dbids": ["BIOD00078", "BTD00078", "DB00068"], "name": "Interferon beta-1b", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P17181", "drug": "DB00068"}, {"action": "AGONIST", "target": "P48551", "drug": "DB00068"}]}, "DB00067": {"dbids": ["BIOD00110", "BTD00110", "DB00067"], "name": "Vasopressin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P30518", "drug": "DB00067"}]}, "DB00066": {"dbids": ["BIOD00064", "BIOD00099", "BTD00064", "BTD00099", "DB00066"], "name": "Follitropin beta", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P23945", "drug": "DB00066"}]}, "DB00065": {"dbids": ["BIOD00004", "BTD00004", "DB00065"], "name": "Infliximab", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P01375", "drug": "DB00065"}]}, "DB00064": {"dbids": ["BIOD00089", "BTD00089", "DB00064"], "name": "Serum albumin iodonated", "groups": ["APPROVED"], "targets": []}, "DB00063": {"dbids": ["BIOD00063", "BTD00063", "DB00063"], "name": "Eptifibatide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB00062": {"dbids": ["BIOD00059", "BTD00059", "DB00062"], "name": "Human Serum Albumin", "groups": ["APPROVED"], "targets": []}, "DB00061": {"dbids": ["BIOD00100", "BTD00100", "DB00061"], "name": "Pegademase bovine", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "P62993", "drug": "DB00061"}]}, "DB00060": {"dbids": ["BIOD00093", "BTD00093", "DB00060"], "name": "Interferon beta-1a", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P17181", "drug": "DB00060"}]}, "DB00206": {"dbids": ["APRD00472", "DB00206"], "name": "Reserpine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q05940", "drug": "DB00206"}]}, "DB04388": {"dbids": ["DB04388", "EXPT00821"], "name": "4-Carboxy-4-Aminobutanal", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04389": {"dbids": ["DB04389", "EXPT01824"], "name": "Ado-P-Ch2-P-Ps-Ado", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04382": {"dbids": ["DB04382", "EXPT00111"], "name": "2-Deoxy-Beta-D-Galactose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04383": {"dbids": ["DB04383", "EXPT03230"], "name": "L-Valinol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04380": {"dbids": ["DB04380", "EXPT00066"], "name": "Diureido-Acetate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04381": {"dbids": ["DB04381", "EXPT01020"], "name": "Crotonaldehyde", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04386": {"dbids": ["DB04386", "EXPT00886"], "name": "4,6-O-(1-Carboxyethylidene)-Beta-D-Glucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04387": {"dbids": ["DB04387", "EXPT00905"], "name": "1-Hydroxy-2-Amino-3-Cyclohexylpropane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04384": {"dbids": ["DB04384", "EXPT01749"], "name": "Fe-Mesopone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04385": {"dbids": ["DB04385", "EXPT01050"], "name": "3-Deazacytidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00609": {"dbids": ["APRD00961", "DB00609"], "name": "Ethionamide", "groups": ["APPROVED"], "targets": [{"action": "ADDUCT", "target": "P0A5Y6", "drug": "DB00609"}, {"action": "OTHER/UNKNOWN", "target": "Q08129", "drug": "DB00609"}]}, "DB00608": {"dbids": ["APRD00468", "DB00608"], "name": "Chloroquine", "groups": ["APPROVED"], "targets": []}, "DB00603": {"dbids": ["APRD00627", "DB00603"], "name": "Medroxyprogesterone Acetate", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P06401", "drug": "DB00603"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00603"}]}, "DB00602": {"dbids": ["APRD01058", "DB00602"], "name": "Ivermectin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "O75311", "drug": "DB00602"}, {"action": "AGONIST", "target": "P28472", "drug": "DB00602"}]}, "DB00601": {"dbids": ["APRD01073", "DB00601", "DB08769"], "name": "Linezolid", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB00600": {"dbids": ["APRD01121", "DB00600"], "name": "Monobenzone", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P14679", "drug": "DB00600"}]}, "DB00607": {"dbids": ["APRD01130", "DB00607", "DB08269"], "name": "Nafcillin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB00607"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB00607"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB00607"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00607"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB00607"}]}, "DB00606": {"dbids": ["APRD00895", "DB00606", "EXPT01082"], "name": "Cyclothiazide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P54710", "drug": "DB00606"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00606"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00606"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00606"}]}, "DB00605": {"dbids": ["APRD01243", "DB00605"], "name": "Sulindac", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00605"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00605"}, {"action": "INHIBITOR", "target": "P15121", "drug": "DB00605"}, {"action": "INHIBITOR", "target": "P27361", "drug": "DB00605"}, {"action": "NEGATIVE MODULATOR", "target": "Q03181", "drug": "DB00605"}, {"action": "ANTAGONIST", "target": "Q9Y5Y4", "drug": "DB00605"}]}, "DB00604": {"dbids": ["APRD00454", "DB00604"], "name": "Cisapride", "groups": ["APPROVED", "INVESTIGATIONAL", "WITHDRAWN"], "targets": [{"action": "AGONIST", "target": "Q13639", "drug": "DB00604"}, {"action": "AGONIST", "target": "P46098", "drug": "DB00604"}, {"action": "AGONIST", "target": "P28223", "drug": "DB00604"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00604"}]}, "DB03268": {"dbids": ["DB03268", "EXPT00063"], "name": "RU82197", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03269": {"dbids": ["DB03269", "EXPT00449"], "name": "4-Deoxy-4-((5-Hydroxymethyl-2,3,4-Trihydroxycyclohex-5,6-Enyl)Amino)Fructose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03264": {"dbids": ["DB03264", "EXPT01131"], "name": "Dodecyl-Coa", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03266": {"dbids": ["DB03266", "EXPT02681"], "name": "Pentanedial", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03267": {"dbids": ["DB03267", "EXPT03126"], "name": "1-Allyl-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03260": {"dbids": ["DB03260", "EXPT00049"], "name": "1,6-Diaminohexane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03262": {"dbids": ["DB03262", "EXPT01890"], "name": "Al-6619, [2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide,2-(3-Hydroxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide]", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03263": {"dbids": ["DB03263", "EXPT03022"], "name": "Thiocellobiose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04968": {"dbids": ["DB04968"], "name": "PH94B", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04969": {"dbids": ["DB04969"], "name": "NV1020", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04967": {"dbids": ["DB04967"], "name": "Lucanthone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P11388", "drug": "DB04967"}, {"action": "INHIBITOR", "target": "P27695", "drug": "DB04967"}, {"action": "INHIBITOR", "target": "P11387", "drug": "DB04967"}]}, "DB04964": {"dbids": ["DB04964"], "name": "Oregovomab", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04962": {"dbids": ["DB04962"], "name": "Bectumomab", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04963": {"dbids": ["DB04963"], "name": "rhGAD65", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04960": {"dbids": ["DB04960"], "name": "R115777", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04961": {"dbids": ["DB04961"], "name": "Troxacitabine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08058": {"dbids": ["DB08058"], "name": "4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08059": {"dbids": ["DB08059"], "name": "(1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08056": {"dbids": ["DB08056"], "name": "N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08057": {"dbids": ["DB08057"], "name": "N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08054": {"dbids": ["DB08054"], "name": "1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08055": {"dbids": ["DB08055"], "name": "N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08052": {"dbids": ["DB08052"], "name": "1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08053": {"dbids": ["DB08053"], "name": "1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08050": {"dbids": ["DB08050"], "name": "5-PHENYL-2-KETO-VALERIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08051": {"dbids": ["DB08051"], "name": "(2R)-4-(2-BENZOYL-1,2-DIAZEPAN-1-YL)-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06038": {"dbids": ["DB06038"], "name": "ITMN-191", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06039": {"dbids": ["DB06039"], "name": "PA-1050040", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03008": {"dbids": ["DB03008", "EXPT01670"], "name": "5-Fluoro-Beta-L-Gulosyl Fluoride", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03009": {"dbids": ["DB03009", "EXPT00609"], "name": "2-[(2-Oxo-2-Piperidin-1-Ylethyl)Thio]-6-(Trifluoromethyl)Pyrimidin-4(1h)-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03000": {"dbids": ["DB03000", "EXPT00545"], "name": "9-Hydroxypropyladenine, S-Isomer", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03001": {"dbids": ["DB03001", "EXPT02596"], "name": "Peridinin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03002": {"dbids": ["DB03002", "EXPT01906"], "name": "4-Iodophenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03003": {"dbids": ["DB03003", "EXPT01662"], "name": "Glutathione Sulfonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03004": {"dbids": ["DB03004", "EXPT00419"], "name": "1-[(1s)-Carboxy-2-(Methylsulfinyl)Ethyl]-(3r)-[(5s)-5-Amino-5-Carboxypentanamido]-(4r)-Sulfanylazetidin-2-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03005": {"dbids": ["DB03005", "EXPT03147"], "name": "3,8-Diamino-6-Phenyl-5-[6-[1-[2-[(1,2,3,4-Tetrahydro-9-Acridinyl)Amino]Ethyl]-1h-1,2,3-Triazol-5-Yl]Hexyl]-Phenanthridinium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03006": {"dbids": ["DB03006", "EXPT00575"], "name": "4-Aminophenylarsonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03007": {"dbids": ["DB03007", "EXPT02441"], "name": "9r,13r-Opda", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07240": {"dbids": ["DB07240"], "name": "3-[(9H-fluoren-9-ylideneamino)oxy]propanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02357": {"dbids": ["DB02357", "EXPT02145"], "name": "Methyl-O3-(Alpha-D-Mannose)-Alpha-D-Mannose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02356": {"dbids": ["DB02356", "EXPT01855"], "name": "4-Imidazolmethylene-5-Imidazolone Chromophore", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02355": {"dbids": ["DB02355", "EXPT03009"], "name": "Adenosine-5'-Rp-Alpha-Thio-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02354": {"dbids": ["DB02354", "EXPT02739"], "name": "4-{[1-Methyl-5-(2-Methyl-Benzoimidazol-1-Ylmethyl)-1h-Benzoimidazol-2-Ylmethyl]-Amino}-Benzamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02353": {"dbids": ["DB02353", "EXPT01679"], "name": "Heparin Disaccharide Iii-S", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02352": {"dbids": ["DB02352", "EXPT00176"], "name": "3-(Benzyloxy)Pyridin-2-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02351": {"dbids": ["DB02351", "EXPT03302"], "name": "Hirulog", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P00734", "drug": "DB02351"}]}, "DB02350": {"dbids": ["DB02350", "EXPT02193"], "name": "N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02609": {"dbids": ["DB02609", "EXPT00231"], "name": "4-Hydroxy-L-Threonine-5-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02608": {"dbids": ["DB02608", "EXPT00937"], "name": "N-Acetyl-P-Nitrophenylserinol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02359": {"dbids": ["DB02359", "EXPT02697"], "name": "9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02358": {"dbids": ["DB02358", "EXPT01992"], "name": "LY374571", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07287": {"dbids": ["DB07287"], "name": "2-(2,4-DICHLOROPHENOXY)-5-(PYRIDIN-2-YLMETHYL)PHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07281": {"dbids": ["DB07281"], "name": "N~3~-BENZYLPYRIDINE-2,3-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07167": {"dbids": ["DB07167"], "name": "5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07809": {"dbids": ["DB07809"], "name": "4-({[4-(3-METHYLBENZOYL)PYRIDIN-2-YL]AMINO}METHYL)BENZENECARBOXIMIDAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07804": {"dbids": ["DB07804"], "name": "5-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1H-1,2,4-TRIAZOLE-3-SULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07805": {"dbids": ["DB07805"], "name": "3-CHLORO-2,2-DIMETHYL-N-[4-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07806": {"dbids": ["DB07806"], "name": "(2R,4S)-2-[(R)-BENZYLCARBAMOYL-PHENYLACETYL-METHYL]-5,5-DIMETHYL-THIAZOLIDINE-4-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07807": {"dbids": ["DB07807"], "name": "(3R,4R,5R)-5-(HYDROXYMETHYL)-1-(3-PHENYLPROPYL)PIPERIDINE-3,4-DIOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07800": {"dbids": ["DB07800"], "name": "N-(2-(((5-CHLORO-2-PYRIDINYL)AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07801": {"dbids": ["DB07801"], "name": "N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07802": {"dbids": ["DB07802"], "name": "3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07803": {"dbids": ["DB07803"], "name": "2-phenyl-1H-imidazole-4-carboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05374": {"dbids": ["DB05374"], "name": "CDX-110", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05376": {"dbids": ["DB05376"], "name": "MAX-002", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05377": {"dbids": ["DB05377"], "name": "K101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05370": {"dbids": ["DB05370"], "name": "NOVA-22007", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05371": {"dbids": ["DB05371"], "name": "ACR-16", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05372": {"dbids": ["DB05372"], "name": "CP-945598", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05378": {"dbids": ["DB05378"], "name": "CB-01-11", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05379": {"dbids": ["DB05379"], "name": "APL-202", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06791": {"dbids": ["DB06791"], "name": "Lanreotide", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P30874", "drug": "DB06791"}, {"action": "AGONIST", "target": "P35346", "drug": "DB06791"}]}, "DB01406": {"dbids": ["DB01406"], "name": "Danazol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P03372", "drug": "DB01406"}, {"action": "AGONIST", "target": "P10275", "drug": "DB01406"}, {"action": "AGONIST", "target": "P06401", "drug": "DB01406"}, {"action": "NEGATIVE MODULATOR", "target": "P30968", "drug": "DB01406"}, {"action": "NEGATIVE MODULATOR", "target": "Q96P88", "drug": "DB01406"}, {"action": "INHIBITOR", "target": "P13500", "drug": "DB01406"}]}, "DB01407": {"dbids": ["DB01407"], "name": "Clenbuterol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P07550", "drug": "DB01407"}, {"action": "AGONIST", "target": "P08588", "drug": "DB01407"}, {"action": "AGONIST", "target": "P13945", "drug": "DB01407"}, {"action": "STIMULATOR", "target": "P01138", "drug": "DB01407"}, {"action": "OTHER/UNKNOWN", "target": "P01375", "drug": "DB01407"}]}, "DB04164": {"dbids": ["DB04164", "EXPT01105"], "name": "1,4-Deoxy-4-((5-Hydroxymethyl-2,3,4-Trihydroxycyclohex-5-Enyl)Amino)Fructose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01405": {"dbids": ["DB01405"], "name": "Temafloxacin", "groups": ["WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P43700", "drug": "DB01405"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB01405"}]}, "DB04163": {"dbids": ["DB04163", "EXPT03099"], "name": "5-Phenylsulfanyl-2,4-Quinazolinediamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04773": {"dbids": ["DB04773"], "name": "METHYL (3R)-3-{[(3R)-3-{[(3R)-3-HYDROXYBUTANOYL]OXY}BUTANOYL]OXY}BUTANOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01076": {"dbids": ["APRD00055", "DB01076"], "name": "Atorvastatin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P04035", "drug": "DB01076"}, {"action": "INHIBITOR", "target": "P27487", "drug": "DB01076"}, {"action": "AGONIST", "target": "P35869", "drug": "DB01076"}]}, "DB04771": {"dbids": ["DB04771"], "name": "1-GUANIDINO-4-(N-NITRO-BENZOYLAMINO-L-LEUCYL-L-PROLYLAMINO)BUTANE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01074": {"dbids": ["APRD00107", "DB01074"], "name": "Perhexiline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P50416", "drug": "DB01074"}, {"action": "INHIBITOR", "target": "P23786", "drug": "DB01074"}]}, "DB01073": {"dbids": ["APRD00594", "DB01073"], "name": "Fludarabine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23921", "drug": "DB01073"}, {"action": "INHIBITOR", "target": "P09884", "drug": "DB01073"}, {"action": "AGONIST", "target": "P27707", "drug": "DB01073"}]}, "DB01072": {"dbids": ["APRD00804", "DB01072"], "name": "Atazanavir", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q72874", "drug": "DB01072"}]}, "DB01071": {"dbids": ["APRD00386", "DB01071"], "name": "Mequitazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB01071"}]}, "DB04774": {"dbids": ["DB04774"], "name": "Reidispongiolide A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04779": {"dbids": ["DB04779"], "name": "ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04778": {"dbids": ["DB04778"], "name": "SC45647", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01079": {"dbids": ["APRD00096", "DB01079"], "name": "Tegaserod", "groups": ["INVESTIGATIONAL", "WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "Q13639", "drug": "DB01079"}, {"action": "PARTIAL AGONIST", "target": "Q13639", "drug": "DB01079"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB01079"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01079"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01079"}]}, "DB01078": {"dbids": ["APRD00909", "DB01078"], "name": "Deslanoside", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P05023", "drug": "DB01078"}]}, "DB08603": {"dbids": ["DB08603"], "name": "N-[(1S)-5-amino-1-(chloroacetyl)pentyl]-4-methylbenzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08602": {"dbids": ["DB08602"], "name": "3-(2,6-difluorophenyl)-2-(methylthio)quinazolin-4(3H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08601": {"dbids": ["DB08601"], "name": "tributylstannanyl", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08600": {"dbids": ["DB08600"], "name": "5-CHLORO-8-METHYL-7-(3-METHYL-BUT-2-ENYL)-6,7,8,9-TETRAHYDRO-2H-2,7,9A-TRIAZA-BENZO[CD]AZULENE-1-THIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08607": {"dbids": ["DB08607"], "name": "(5R)-5-(4-{[(2R)-6-HYDROXY-2,5,7,8-TETRAMETHYL-3,4-DIHYDRO-2H-CHROMEN-2-YL]METHOXY}BENZYL)-1,3-THIAZOLIDINE-2,4-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08606": {"dbids": ["DB08606"], "name": "(3R,4S)-1-[(4-AMINO-5H-PYRROLO[3,2-D]PYRIMIDIN-7-YL)METHYL]-4-[(METHYLSULFANYL)METHYL]PYRROLIDIN-3-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08605": {"dbids": ["DB08605"], "name": "6-METHYL-2(PROPANE-1-SULFONYL)-2H-THIENO[3,2-D][1,2,3]DIAZABORININ-1-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08604": {"dbids": ["DB08604"], "name": "Triclosan", "groups": ["APPROVED"], "targets": []}, "DB08609": {"dbids": ["DB08609"], "name": "(N-{4-[(ETHYLANILINO)SULFONYL]-2-METHYLPHENYL}-3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPANAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08608": {"dbids": ["DB08608"], "name": "4-({(2R,5S)-2,5-DIMETHYL-4-[(2R)-3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPANOYL]PIPERAZIN-1-YL}CARBONYL)BENZONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09181": {"dbids": ["DB09181"], "name": "Trefentanil", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00470": {"dbids": ["APRD00571", "DB00470"], "name": "Dronabinol", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P21554", "drug": "DB00470"}, {"action": "AGONIST", "target": "P34972", "drug": "DB00470"}]}, "DB00471": {"dbids": ["APRD00434", "DB00471"], "name": "Montelukast", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q9Y271", "drug": "DB00471"}, {"action": "OTHER/UNKNOWN", "target": "P09917", "drug": "DB00471"}]}, "DB00472": {"dbids": ["APRD00530", "DB00472"], "name": "Fluoxetine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P31645", "drug": "DB00472"}]}, "DB00473": {"dbids": ["APRD01014", "DB00473"], "name": "Hexylcaine", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB00473"}, {"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00473"}]}, "DB00474": {"dbids": ["APRD00058", "DB00474"], "name": "Methohexital", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14867", "drug": "DB00474"}]}, "DB00475": {"dbids": ["APRD00682", "DB00475"], "name": "Chlordiazepoxide", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00475"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00475"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00475"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00475"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00475"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00475"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00475"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00475"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00475"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00475"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00475"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00475"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00475"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00475"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00475"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00475"}]}, "DB00476": {"dbids": ["APRD00060", "DB00476"], "name": "Duloxetine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P31645", "drug": "DB00476"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00476"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00476"}]}, "DB00477": {"dbids": ["APRD00482", "DB00477"], "name": "Chlorpromazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB00477"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00477"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00477"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00477"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00477"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00477"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00477"}, {"action": "BINDER", "target": "P21917", "drug": "DB00477"}, {"action": "BINDER", "target": "P28335", "drug": "DB00477"}, {"action": "BINDER", "target": "P28223", "drug": "DB00477"}, {"action": "BINDER", "target": "P41595", "drug": "DB00477"}, {"action": "BINDER", "target": "P28335", "drug": "DB00477"}, {"action": "BINDER", "target": "P02763", "drug": "DB00477"}, {"action": "BINDER", "target": "P19652", "drug": "DB00477"}, {"action": "BINDER", "target": "P50406", "drug": "DB00477"}, {"action": "BINDER", "target": "P34969", "drug": "DB00477"}, {"action": "BINDER", "target": "Q9H3N8", "drug": "DB00477"}]}, "DB00478": {"dbids": ["APRD01219", "DB00478"], "name": "Rimantadine", "groups": ["APPROVED"], "targets": [{"action": "OTHER/UNKNOWN", "target": "P21430", "drug": "DB00478"}]}, "DB00479": {"dbids": ["APRD00550", "DB00479"], "name": "Amikacin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A7S3", "drug": "DB00479"}]}, "DB06869": {"dbids": ["DB06869"], "name": "1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06868": {"dbids": ["DB06868"], "name": "N-(3-chlorobenzyl)-1-(4-methylpentanoyl)-L-prolinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04168": {"dbids": ["DB04168", "EXPT00347"], "name": "2-Amino-5-Bromo-6-Phenylpyrimidin-4-Ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04169": {"dbids": ["DB04169", "EXPT01263"], "name": "3,5-Diaminophthalhydrazide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06554": {"dbids": ["DB06554"], "name": "Gaboxadol", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04599": {"dbids": ["DB04599"], "name": "Aniracetam", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04598": {"dbids": ["DB04598"], "name": "2-AMINO-4-CHLORO-3-HYDROXYBENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04597": {"dbids": ["DB04597"], "name": "[4,6-O-(1-CARBOXYETHYLIDENE)-BETA-D-MANNOSE]", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04596": {"dbids": ["DB04596"], "name": "4,6-O-(1-CARBOXYETHYLIDENE)-BETA-D-MANNOSE-(1->4)-BETA-D-GLUCURONIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04595": {"dbids": ["DB04595"], "name": "(E)-(4S,6S)-8-METHYL-6-((S)-3-METHYL-2-{(S)-2-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-PROPIONYLAMINO}-BUTYRYLAMINO)-5-OXO-4-((R)-2-OXO-PYRROLIDIN-3-YLMETHYL)-NON-2-ENOIC ACID BENZYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04594": {"dbids": ["DB04594"], "name": "3-hydroxyglutaric acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04593": {"dbids": ["DB04593"], "name": "3-({1-[3-CARBAMIMIDOYL-1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-PROPYLCARBAMOYL]-2-METHYL-BUTYLSULFAMOYL}-METHYL)-BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04592": {"dbids": ["DB04592"], "name": "3-Bromo-3-buten-1-ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04591": {"dbids": ["DB04591"], "name": "N-{2,2-DIFLUORO-2-[(2R)-PIPERIDIN-2-YL]ETHYL}-2-[2-(1H-1,2,4-TRIAZOL-1-YL)BENZYL][1,3]OXAZOLO[4,5-C]PYRIDIN-4-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04590": {"dbids": ["DB04590"], "name": "(2R)-({4-[AMINO(IMINO)METHYL]PHENYL}AMINO){5-ETHOXY-2-FLUORO-3-[(3R)-TETRAHYDROFURAN-3-YLOXY]PHENYL}ACETICACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00294": {"dbids": ["APRD00766", "DB00294"], "name": "Etonogestrel", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P06401", "drug": "DB00294"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00294"}]}, "DB00295": {"dbids": ["APRD00215", "DB00295"], "name": "Morphine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB00295"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00295"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00295"}]}, "DB00296": {"dbids": ["APRD00492", "DB00296"], "name": "Ropivacaine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00296"}]}, "DB00297": {"dbids": ["APRD00247", "DB00297"], "name": "Bupivacaine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00297"}, {"action": "OTHER/UNKNOWN", "target": "P34995", "drug": "DB00297"}]}, "DB00290": {"dbids": ["APRD00453", "DB00290", "EXPT00718"], "name": "Bleomycin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P18858", "drug": "DB00290"}, {"action": "INHIBITOR", "target": "P49916", "drug": "DB00290"}]}, "DB00291": {"dbids": ["APRD00115", "DB00291"], "name": "Chlorambucil", "groups": ["APPROVED"], "targets": []}, "DB00292": {"dbids": ["APRD00965", "DB00292"], "name": "Etomidate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P14867", "drug": "DB00292"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00292"}]}, "DB00293": {"dbids": ["APRD00430", "DB00293", "EXPT01092"], "name": "Raltitrexed", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P04818", "drug": "DB00293"}, {"action": "ANTAGONIST", "target": "Q05932", "drug": "DB00293"}]}, "DB00298": {"dbids": ["APRD00902", "DB00298"], "name": "Dapiprazole", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35348", "drug": "DB00298"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00298"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00298"}]}, "DB00299": {"dbids": ["APRD00041", "DB00299", "DB01730"], "name": "Penciclovir", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P04293", "drug": "DB00299"}, {"action": "INDUCER", "target": "P06478", "drug": "DB00299"}]}, "DB09517": {"dbids": ["DB09517"], "name": "Sodium ferric gluconate complex", "groups": ["APPROVED"], "targets": []}, "DB09510": {"dbids": ["DB09510"], "name": "Urea C-13", "groups": ["APPROVED"], "targets": []}, "DB06738": {"dbids": ["DB06738"], "name": "Ketobemidone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB06738"}, {"action": "AGONIST", "target": "P41145", "drug": "DB06738"}, {"action": "AGONIST", "target": "P41143", "drug": "DB06738"}, {"action": "ANTAGONIST", "target": "Q05586", "drug": "DB06738"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB06738"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB06738"}, {"action": "ANTAGONIST", "target": "Q14957", "drug": "DB06738"}, {"action": "ANTAGONIST", "target": "O15399", "drug": "DB06738"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB06738"}, {"action": "ANTAGONIST", "target": "O60391", "drug": "DB06738"}]}, "DB03929": {"dbids": ["DB03929", "EXPT01275"], "name": "D-Serine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03928": {"dbids": ["DB03928", "EXPT00861"], "name": "Carboxymethylthio-3-(3-Chlorophenyl)-1,2,4-Oxadiazol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03927": {"dbids": ["DB03927", "EXPT02774"], "name": "Glycyl-L-Alpha-Amino-Epsilon-Pimelyl-D-Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03926": {"dbids": ["DB03926", "EXPT00531"], "name": "5-Alpha-Androstane-3-Beta,17-Alpha-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03925": {"dbids": ["DB03925", "EXPT00279"], "name": "ONO-6818", "groups": ["EXPERIMENTAL", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P08246", "drug": "DB03925"}]}, "DB03924": {"dbids": ["DB03924", "EXPT02206"], "name": "5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03923": {"dbids": ["DB03923", "EXPT01489"], "name": "Feruloyl Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06730": {"dbids": ["DB06730"], "name": "Gestodene", "groups": ["APPROVED"], "targets": []}, "DB03921": {"dbids": ["DB03921", "EXPT02712"], "name": "4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03920": {"dbids": ["DB03920", "EXPT01110"], "name": "N-Methyl-Alpha-Beta-Dehydroalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02038": {"dbids": ["DB02038", "EXPT01138"], "name": "D-Pyridoxyl-N,O-Cycloserylamide-5-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02039": {"dbids": ["DB02039", "EXPT02873"], "name": "S-Acetyl-Cysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02032": {"dbids": ["DB02032", "EXPT02137"], "name": "1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02033": {"dbids": ["DB02033", "EXPT01894"], "name": "N-(3-Cyclopropyl(5,6,7,8,9,10-Hexahydro-2-Oxo-2h-Cycloocta[B]Pyran-3-Yl)Methyl)Phenylbenzensulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02030": {"dbids": ["DB02030", "EXPT02761"], "name": "Alpha-Ribazole-5'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02031": {"dbids": ["DB02031", "EXPT03050"], "name": "(6s)-5,6,7,8-Tetrahydrofolate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02036": {"dbids": ["DB02036", "EXPT01627"], "name": "2-(3,4-Dihydro-3-Oxo-2h-Benzo[B][1,4]Thiazin-2-Yl)-N-Hydroxyacetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02037": {"dbids": ["DB02037", "EXPT01148"], "name": "2,4-Diamino-4,6-Dihydroxypyrimidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02034": {"dbids": ["DB02034", "EXPT02983"], "name": "Swainsonine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02035": {"dbids": ["DB02035", "EXPT01783"], "name": "1-Hexadecylsulfonyl Fluoride", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04346": {"dbids": ["DB04346", "EXPT02502"], "name": "(2r,4s)-2-Methyl-2,3,3,4-Tetrahydroxytetrahydrofuran", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06887": {"dbids": ["DB06887"], "name": "3(S)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID TERT-BUTYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07028": {"dbids": ["DB07028"], "name": "(2-{[(4-BROMO-2-FLUOROBENZYL)AMINO]CARBONYL}-5-CHLOROPHENOXY)ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04347": {"dbids": ["DB04347", "EXPT01191"], "name": "3-Dehydroshikimate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07026": {"dbids": ["DB07026"], "name": "(1S,5S,7R)-N~7~-(BIPHENYL-4-YLMETHYL)-N~3~-HYDROXY-6,8-DIOXA-3-AZABICYCLO[3.2.1]OCTANE-3,7-DICARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07027": {"dbids": ["DB07027"], "name": "D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07024": {"dbids": ["DB07024"], "name": "2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07025": {"dbids": ["DB07025"], "name": "3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07022": {"dbids": ["DB07022"], "name": "3-HYDROXYPROPYL 3-[({7-[AMINO(IMINO)METHYL]-1-NAPHTHYL}AMINO)CARBONYL]BENZENESULFONATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07023": {"dbids": ["DB07023"], "name": "(1R)-2-{[AMINO(IMINO)METHYL]AMINO}-1-{4-[(4R)-4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL]PHENYL}ETHYL NICOTINATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07020": {"dbids": ["DB07020"], "name": "N-{3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenyl}furan-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07021": {"dbids": ["DB07021"], "name": "(7R,8R)-8-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydroimidazo[1,2-a:4,5-c']dipyridin-7-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04345": {"dbids": ["DB04345", "EXPT02065"], "name": "7,8-dimethylalloxazine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04342": {"dbids": ["DB04342", "EXPT02261"], "name": "7-((Carboxy(4-Hydroxyphenyl)Acetyl)Amino)-7-Methoxy-(3-((1-Methyl-1h-Tetrazol-5-Yl)Thio)Methyl)-8-Oxo-5-Oxa-1-Azabicyclo[4.2.0]Oct-2-Ene-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04340": {"dbids": ["DB04340", "EXPT00140"], "name": "2-[(Dioxidophosphino)Oxy]Benzoate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04341": {"dbids": ["DB04341", "EXPT01551"], "name": "S-(3-Iodobenzyl)Glutathione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06193": {"dbids": ["DB06193"], "name": "Pixantrone", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06196": {"dbids": ["DB06196"], "name": "Icatibant", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P30411", "drug": "DB06196"}, {"action": "INHIBITOR", "target": "P15144", "drug": "DB06196"}]}, "DB01785": {"dbids": ["DB01785", "EXPT01221"], "name": "Dimethylallyl Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09280": {"dbids": ["DB09280"], "name": "Lumacaftor", "groups": ["INVESTIGATIONAL"], "targets": [{"action": "MODULATOR", "target": "P13569", "drug": "DB09280"}]}, "DB09281": {"dbids": ["DB09281"], "name": "Magnesium Trisilicate", "groups": ["APPROVED"], "targets": []}, "DB09282": {"dbids": ["DB09282"], "name": "Molsidomine", "groups": ["APPROVED"], "targets": []}, "DB08848": {"dbids": ["DB08848"], "name": "Guvacine", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "Q9NSD5", "drug": "DB08848"}, {"action": "INHIBITOR", "target": "P30531", "drug": "DB08848"}, {"action": "INHIBITOR", "target": "P48066", "drug": "DB08848"}, {"action": "INHIBITOR", "target": "P48065", "drug": "DB08848"}]}, "DB01784": {"dbids": ["DB01784", "EXPT01396"], "name": "4-Flourobenzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09283": {"dbids": ["DB09283"], "name": "Trapidil", "groups": ["APPROVED"], "targets": []}, "DB08841": {"dbids": ["DB08841"], "name": "Tyramine", "groups": ["INVESTIGATIONAL", "NUTRACEUTICAL"], "targets": []}, "DB09284": {"dbids": ["DB09284"], "name": "Imolamine", "groups": ["APPROVED"], "targets": []}, "DB08842": {"dbids": ["DB08842"], "name": "Acetylcarnitine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB08844": {"dbids": ["DB01696", "DB08844"], "name": "Uric Acid", "groups": ["EXPERIMENTAL", "INVESTIGATIONAL"], "targets": []}, "DB08847": {"dbids": ["DB08847"], "name": "Hydroxyproline", "groups": ["APPROVED", "EXPERIMENTAL"], "targets": []}, "DB08846": {"dbids": ["DB08846"], "name": "Ellagic Acid", "groups": ["INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P00915", "drug": "DB08846"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB08846"}, {"action": "INHIBITOR", "target": "P07451", "drug": "DB08846"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB08846"}, {"action": "INHIBITOR", "target": "P35218", "drug": "DB08846"}, {"action": "INHIBITOR", "target": "Q9Y2D0", "drug": "DB08846"}, {"action": "INHIBITOR", "target": "P23280", "drug": "DB08846"}, {"action": "INHIBITOR", "target": "P43166", "drug": "DB08846"}, {"action": "INHIBITOR", "target": "Q16790", "drug": "DB08846"}, {"action": "INHIBITOR", "target": "O43570", "drug": "DB08846"}, {"action": "INHIBITOR", "target": "Q9ULX7", "drug": "DB08846"}, {"action": "INHIBITOR", "target": "P68400", "drug": "DB08846"}, {"action": "INHIBITOR, COMPETITIVE", "target": "P17612", "drug": "DB08846"}, {"action": "INHIBITOR, COMPETITIVE", "target": "P17252", "drug": "DB08846"}, {"action": "INHIBITOR, COMPETITIVE", "target": "P05771", "drug": "DB08846"}, {"action": "INHIBITOR", "target": "P43405", "drug": "DB08846"}, {"action": "INHIBITOR", "target": "Q14534", "drug": "DB08846"}]}, "DB01662": {"dbids": ["DB01662", "EXPT02407"], "name": "Trans-O-Hydroxy-Alpha-Methyl Cinnamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03749": {"dbids": ["DB03749", "EXPT00195"], "name": "4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03748": {"dbids": ["DB03748", "EXPT02744"], "name": "Methyl-[4-(4-Piperidine-1-Ylmethyl-Phenyl)-Cyclohexyl]-Carbaminic Acid-(4-Chlorophenyl)-Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09286": {"dbids": ["DB09286"], "name": "Pipamperone", "groups": ["APPROVED"], "targets": []}, "DB01663": {"dbids": ["DB01663", "EXPT02060"], "name": "Lambda-Bis(2,2'-Bipyridine)-(5-Methyl-2-2'-Bipyridine)-C9-Adamantane Ruthenium (Ii)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03742": {"dbids": ["DB03742", "EXPT01315"], "name": "Compound 4-D", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03741": {"dbids": ["DB03741", "EXPT02918"], "name": "2-Methylbutanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03740": {"dbids": ["DB03740", "EXPT02319"], "name": "2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03747": {"dbids": ["DB03747", "EXPT02338"], "name": "3ar,5r,6s,7r,7ar-5-Hydroxymethyl-2-Methyl-5,6,7,7a-Tetrahydro-3ah-Pyrano[3,2-D]Thiazole-6,7-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03746": {"dbids": ["DB03746", "EXPT01198"], "name": "3-Amino-4,5-Dihydroxy-Cyclohex-1-Enecarboxylate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03745": {"dbids": ["DB03745", "EXPT00375"], "name": "Arabinose-5-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03744": {"dbids": ["DB03744", "EXPT00293"], "name": "Cp403700, (S)-1-{2-[(5-Chloro-1h-Indole-2-Carbonyl)-Amino]-3-Phenyl-Propionyl}-Azetidine-3-Carboxylate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02296": {"dbids": ["DB02296", "EXPT01910"], "name": "1-Hydroxy-3-Methylbutane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02297": {"dbids": ["DB02297", "EXPT00917"], "name": "2-Amino-6-Chloropyrazine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02294": {"dbids": ["DB02294", "EXPT01666"], "name": "(5r,6s,7s,8s)-5-Hydroxymethyl-6,7,8-Trihydroxy-Tetrazolo[1,5-a]Piperidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02295": {"dbids": ["DB02295", "EXPT00474"], "name": "N-[3-(Dimethylamino)Propyl]-2-({[4-({[4-(Formylamino)-1-Methyl-1h-Pyrrol-2-Yl]Carbonyl}Amino)-1-Methyl-1h-Pyrrol-2-Yl]Carbonyl}Amino)-5-Isopropyl-1,3-Thiazole-4-Carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02292": {"dbids": ["DB02292", "EXPT00273"], "name": "6-Oxo-8,9,10,11-Tetrahydro-7h-Cyclohepta[C][1]Benzopyran-3-O-Sulfamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02293": {"dbids": ["DB02293", "EXPT01993"], "name": "2,3-Di-O-Phytanly-3-Sn-Glycero-1-Phosphoryl-3'-Sn-Glycerol-1'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02290": {"dbids": ["DB02290", "EXPT02997"], "name": "3-{2,6,8-Trioxo-9-[(2s,3s,4r)-2,3,4,5-Tetrahydroxypentyl]-1,2,3,6,8,9-Hexahydro-7h-Purin-7-Yl}Propyl Dihydrogen Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01666": {"dbids": ["DB01666", "EXPT01854"], "name": "D-Myo-Inositol-Hexasulphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02298": {"dbids": ["DB02298", "EXPT00683"], "name": "5-Hydroxyamino-3-Methyl-Pyrrolidine-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02299": {"dbids": ["DB02299", "EXPT00385"], "name": "Arginineamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05745": {"dbids": ["DB05745"], "name": "CHR-2797", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05744": {"dbids": ["DB05744"], "name": "CRx-139", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05747": {"dbids": ["DB05747"], "name": "R-851", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05746": {"dbids": ["DB05746"], "name": "PF-03187207", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05741": {"dbids": ["DB05741"], "name": "AGS-005", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01664": {"dbids": ["DB01664", "EXPT02903"], "name": "(S)-Des-Me-Ampa", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05743": {"dbids": ["DB05743"], "name": "MAP-0004", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05742": {"dbids": ["DB05742"], "name": "AGS-004", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07558": {"dbids": ["DB07558"], "name": "2-ACETYLAMINO-4-METHYL-PENTANOIC ACID [1-(1-FORMYL-PENTYLCARBAMOYL)-3-METHYL-BUTYL]-AMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08599": {"dbids": ["DB08599"], "name": "N-[(4-methoxyphenyl)sulfonyl]-D-alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01665": {"dbids": ["DB01665", "EXPT00097"], "name": "ZK-800270", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05749": {"dbids": ["DB05749"], "name": "MPI-674", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05748": {"dbids": ["DB05748"], "name": "NB-002", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01401": {"dbids": ["DB01401"], "name": "Trisalicylate-choline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23219", "drug": "DB01401"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB01401"}]}, "DB01783": {"dbids": ["DB01783", "EXPT02501"], "name": "Pantothenic acid", "groups": ["NUTRACEUTICAL"], "targets": []}, "DB01782": {"dbids": ["DB01782", "EXPT00232"], "name": "2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07559": {"dbids": ["DB07559"], "name": "(2Z)-2-cyano-N-(2,2'-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09079": {"dbids": ["DB09079"], "name": "Nintedanib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P17948", "drug": "DB09079"}, {"action": "INHIBITOR", "target": "P35968", "drug": "DB09079"}, {"action": "INHIBITOR", "target": "P35916", "drug": "DB09079"}, {"action": "INHIBITOR", "target": "P11362", "drug": "DB09079"}, {"action": "INHIBITOR", "target": "P21802", "drug": "DB09079"}, {"action": "INHIBITOR", "target": "P22607", "drug": "DB09079"}, {"action": "INHIBITOR", "target": "P36888", "drug": "DB09079"}, {"action": "INHIBITOR", "target": "P06239", "drug": "DB09079"}, {"action": "INHIBITOR", "target": "P07948", "drug": "DB09079"}, {"action": "INHIBITOR", "target": "P12931", "drug": "DB09079"}]}, "DB09078": {"dbids": ["DB09078"], "name": "Lenvatinib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P17948", "drug": "DB09078"}, {"action": "INHIBITOR", "target": "P35968", "drug": "DB09078"}, {"action": "INHIBITOR", "target": "P35916", "drug": "DB09078"}, {"action": "INHIBITOR", "target": "P11362", "drug": "DB09078"}, {"action": "INHIBITOR", "target": "P21802", "drug": "DB09078"}, {"action": "INHIBITOR", "target": "P22607", "drug": "DB09078"}, {"action": "INHIBITOR", "target": "P22455", "drug": "DB09078"}, {"action": "INHIBITOR", "target": "P10721", "drug": "DB09078"}]}, "DB09077": {"dbids": ["DB09077"], "name": "Dinutuximab", "groups": ["APPROVED"], "targets": []}, "DB09076": {"dbids": ["DB09076"], "name": "Umeclidinium", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB09076"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB09076"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB09076"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB09076"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB09076"}]}, "DB09075": {"dbids": ["DB09075"], "name": "Edoxaban", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00742", "drug": "DB09075"}]}, "DB09074": {"dbids": ["DB09074"], "name": "Olaparib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P09874", "drug": "DB09074"}, {"action": "INHIBITOR", "target": "Q9UGN5", "drug": "DB09074"}, {"action": "INHIBITOR", "target": "Q9Y6F1", "drug": "DB09074"}]}, "DB09073": {"dbids": ["DB09073"], "name": "Palbociclib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P11802", "drug": "DB09073"}, {"action": "INHIBITOR", "target": "Q00534", "drug": "DB09073"}]}, "DB09072": {"dbids": ["DB09072"], "name": "Sodium oxybate", "groups": ["APPROVED"], "targets": []}, "DB09071": {"dbids": ["DB09071"], "name": "Tasimelteon", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P48039", "drug": "DB09071"}, {"action": "AGONIST", "target": "P49286", "drug": "DB09071"}]}, "DB01718": {"dbids": ["DB01718", "EXPT00048"], "name": "Cetyl-Trimethyl-Ammonium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01719": {"dbids": ["DB01719", "EXPT03067"], "name": "Thio-Maltopentaose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01248": {"dbids": ["APRD00932", "DB01248"], "name": "Docetaxel", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "BINDER", "target": "O75469", "drug": "DB01248"}]}, "DB01249": {"dbids": ["DB01249"], "name": "Iodixanol", "groups": ["APPROVED"], "targets": []}, "DB01712": {"dbids": ["DB01712", "EXPT02976"], "name": "(3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Phenylalanine Ethyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01713": {"dbids": ["DB01713", "EXPT03173"], "name": "Udp-Alpha-D-Xylopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01710": {"dbids": ["DB01710", "EXPT02632"], "name": "Porphyrin Fe(Iii)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01711": {"dbids": ["DB01711", "EXPT02555"], "name": "2,3,4,5,6-Pentafluorobenzyl Alcohol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01716": {"dbids": ["DB01716", "EXPT00972"], "name": "2-Propenyl-N-Acetyl-Neuramic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01717": {"dbids": ["DB01717", "EXPT00535"], "name": "Bis(Adenosine)-5'-Pentaphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01714": {"dbids": ["DB01714", "EXPT02190"], "name": "N-Methyl-Lysine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01715": {"dbids": ["DB01715", "EXPT01237"], "name": "7,8-Diamino-Nonanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00049": {"dbids": ["BIOD00090", "BTD00090", "DB00049"], "name": "Rasburicase", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB00048": {"dbids": ["BIOD00010", "BTD00010", "DB00048"], "name": "Collagenase clostridium histolyticum", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB00599": {"dbids": ["APRD00660", "DB00599"], "name": "Thiopental", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB00599"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00599"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00599"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00599"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00599"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00599"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00599"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00599"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB00599"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB00599"}, {"action": "INHIBITOR", "target": "O00519", "drug": "DB00599"}]}, "DB00598": {"dbids": ["APRD01062", "DB00598"], "name": "Labetalol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB00598"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00598"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00598"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00598"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00598"}]}, "DB00593": {"dbids": ["APRD00318", "DB00593"], "name": "Ethosuximide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "O43497", "drug": "DB00593"}]}, "DB00592": {"dbids": ["APRD00225", "DB00592"], "name": "Piperazine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P28472", "drug": "DB00592"}]}, "DB00591": {"dbids": ["APRD00977", "DB00591"], "name": "Fluocinolone Acetonide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00591"}]}, "DB00590": {"dbids": ["APRD00474", "DB00590"], "name": "Doxazosin", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35348", "drug": "DB00590"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00590"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00590"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00590"}, {"action": "INHIBITOR", "target": "Q9H252", "drug": "DB00590"}, {"action": "INHIBITOR", "target": "Q9NS40", "drug": "DB00590"}]}, "DB00045": {"dbids": ["BIOD00054", "BTD00054", "DB00045"], "name": "OspA lipoprotein", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "OTHER/UNKNOWN", "target": "O60603", "drug": "DB00045"}]}, "DB00044": {"dbids": ["BIOD00056", "BTD00056", "DB00044"], "name": "Lutropin alfa", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P22888", "drug": "DB00044"}]}, "DB00595": {"dbids": ["APRD00019", "DB00595"], "name": "Oxytetracycline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A7X3", "drug": "DB00595"}, {"action": "INHIBITOR", "target": "P0A7V8", "drug": "DB00595"}]}, "DB00594": {"dbids": ["APRD00790", "DB00594", "EXPT00514"], "name": "Amiloride", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P37088", "drug": "DB00594"}, {"action": "INHIBITOR", "target": "P51168", "drug": "DB00594"}, {"action": "INHIBITOR", "target": "P51170", "drug": "DB00594"}, {"action": "INHIBITOR", "target": "P51172", "drug": "DB00594"}, {"action": "INHIBITOR", "target": "P19801", "drug": "DB00594"}, {"action": "INHIBITOR", "target": "Q16515", "drug": "DB00594"}, {"action": "INHIBITOR", "target": "P78348", "drug": "DB00594"}, {"action": "INHIBITOR", "target": "P19634", "drug": "DB00594"}, {"action": "INHIBITOR", "target": "P00749", "drug": "DB00594"}]}, "DB06935": {"dbids": ["DB06935"], "name": "2',6'-DIFLUOROBIPHENYL-4-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03246": {"dbids": ["DB03246", "EXPT00555"], "name": "Beta-L-Arabinose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03247": {"dbids": ["DB03247", "EXPT01458"], "name": "Riboflavin Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03244": {"dbids": ["DB03244", "EXPT03000"], "name": "(S)-2-[4-(Aminomethyl)-1h-1,2,3-Triazol-1-Yl]-4-Methylpentanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03245": {"dbids": ["DB03245", "EXPT02298"], "name": "S-4-Nitrobutyryl-Coa", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03242": {"dbids": ["DB03242", "EXPT01548"], "name": "P-Aminophenyl-Alpha-D-Galactopyranoside", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03243": {"dbids": ["DB03243", "EXPT01394"], "name": "4-Fluorobenzylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03240": {"dbids": ["DB03240", "EXPT01007"], "name": "(S)-2-Amino-3-(1,3,5,7-Pentahydro-2,4-Dioxo-Cyclopenta[E]Pyrimidin-1-Yl) Proionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03241": {"dbids": ["DB03241", "EXPT02081"], "name": "1-Amino-1-Carbonyl Pentane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03248": {"dbids": ["DB03248", "EXPT02552"], "name": "2-(Phosphonooxy)Butanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03249": {"dbids": ["DB03249", "EXPT02991"], "name": "2'-O-Methyl-3'-Methyl-3'-Deoxy-Arabinofuranosyl-Thymine-5'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00547": {"dbids": ["APRD00910", "DB00547"], "name": "Desoximetasone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00547"}]}, "DB04908": {"dbids": ["DB04908"], "name": "Flibanserin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P08908", "drug": "DB04908"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB04908"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB04908"}]}, "DB04909": {"dbids": ["DB04909"], "name": "Sitamaquine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04900": {"dbids": ["DB04900"], "name": "Thymalfasin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB04901": {"dbids": ["DB04901"], "name": "Galiximab", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04902": {"dbids": ["DB04902"], "name": "AZD6140", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04903": {"dbids": ["DB04903"], "name": "Pagoclone", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04904": {"dbids": ["DB04904"], "name": "Amolimogene", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04905": {"dbids": ["DB04905"], "name": "Tesmilifene", "groups": ["INVESTIGATIONAL"], "targets": [{"action": "INDUCER", "target": "P08183", "drug": "DB04905"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB04905"}]}, "DB04906": {"dbids": ["DB04906"], "name": "ISA247", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04907": {"dbids": ["DB04907"], "name": "EG009", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB00625": {"dbids": ["APRD00059", "DB00625", "DB07709"], "name": "Efavirenz", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q72547", "drug": "DB00625"}]}, "DB00624": {"dbids": ["APRD00433", "DB00624"], "name": "Testosterone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P10275", "drug": "DB00624"}]}, "DB00627": {"dbids": ["APRD00536", "DB00627", "NUTR00042"], "name": "Niacin", "groups": ["APPROVED", "INVESTIGATIONAL", "NUTRACEUTICAL"], "targets": [{"action": "AGONIST", "target": "P49019", "drug": "DB00627"}, {"action": "AGONIST", "target": "Q8TDS4", "drug": "DB00627"}, {"action": "BINDER", "target": "Q15274", "drug": "DB00627"}, {"action": "BINDER", "target": "P40261", "drug": "DB00627"}]}, "DB00626": {"dbids": ["APRD00816", "DB00626"], "name": "Bacitracin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P14735", "drug": "DB00626"}, {"action": "INHIBITOR", "target": "P01023", "drug": "DB00626"}]}, "DB00621": {"dbids": ["APRD01151", "DB00621"], "name": "Oxandrolone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P10275", "drug": "DB00621"}]}, "DB00620": {"dbids": ["APRD00422", "DB00620"], "name": "Triamcinolone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00620"}]}, "DB00623": {"dbids": ["APRD00633", "DB00623"], "name": "Fluphenazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB00623"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00623"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB00623"}]}, "DB00622": {"dbids": ["APRD00088", "DB00622"], "name": "Nicardipine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q13936", "drug": "DB00622"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB00622"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB00622"}, {"action": "INHIBITOR", "target": "P54289", "drug": "DB00622"}, {"action": "INHIBITOR", "target": "P54750", "drug": "DB00622"}, {"action": "INHIBITOR", "target": "Q01064", "drug": "DB00622"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00622"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00622"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00622"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00622"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00622"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00622"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00622"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00622"}, {"action": "OTHER/UNKNOWN", "target": "P62158", "drug": "DB00622"}]}, "DB08030": {"dbids": ["DB08030"], "name": "3-[(4'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08031": {"dbids": ["DB08031"], "name": "N-[(13-CYCLOHEXYL-6,7-DIHYDROINDOLO[1,2-D][1,4]BENZOXAZEPIN-10-YL)CARBONYL]-2-METHYL-L-ALANINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08032": {"dbids": ["DB08032"], "name": "N,N-DIETHYL-2-[(2-THIENYLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08033": {"dbids": ["DB08033"], "name": "(5R)-N,N-DIETHYL-5-METHYL-2-[(THIOPHEN-2-YLCARBONYL)AMINO]-4,5,6,7-TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00629": {"dbids": ["APRD00487", "DB00629"], "name": "Guanabenz", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P08913", "drug": "DB00629"}, {"action": "BINDER", "target": "P18089", "drug": "DB00629"}]}, "DB00628": {"dbids": ["APRD00881", "DB00628"], "name": "Clorazepate", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00628"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00628"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00628"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00628"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00628"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00628"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00628"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00628"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00628"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00628"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00628"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00628"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00628"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00628"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00628"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00628"}, {"action": "AGONIST", "target": "P30536", "drug": "DB00628"}]}, "DB08036": {"dbids": ["DB08036"], "name": "6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08037": {"dbids": ["DB08037"], "name": "(2S)-4-(2,5-difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03022": {"dbids": ["DB03022", "EXPT02990"], "name": "3-{2,6,8-Trioxo-9-[(2r,3s,4r)-2,3,4,5-Tetrahydroxypentyl]-1,2,3,6,8,9-Hexahydro-7h-Purin-7-Yl}Propyl Dihydrogen Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03023": {"dbids": ["DB03023", "EXPT02634"], "name": "1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03020": {"dbids": ["DB03020", "EXPT00966"], "name": "5-Beta-D-Ribofuranosylnicotinamide Adenine Dinucleotide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03021": {"dbids": ["DB03021", "EXPT03182"], "name": "Ulapualide A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03026": {"dbids": ["DB03026", "EXPT02570"], "name": "Phosphoglycolohydroxamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03024": {"dbids": ["DB03024", "EXPT01750"], "name": "2-Methyl-3-(2-Aminothiazolo)Propanal", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03025": {"dbids": ["DB03025", "EXPT00184"], "name": "1-Octen-3-Ol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06058": {"dbids": ["DB06058"], "name": "XTL-6865", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03028": {"dbids": ["DB03028", "EXPT03110"], "name": "1h-Benoximidazole-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09223": {"dbids": ["DB09223"], "name": "Blonanserin", "groups": ["APPROVED"], "targets": []}, "DB02999": {"dbids": ["DB02999", "EXPT02735"], "name": "Quisqualate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02998": {"dbids": ["DB02998", "EXPT02741"], "name": "Methyltrienolone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02995": {"dbids": ["DB02995", "EXPT01690"], "name": "Cyclohexylammonium Ion", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02994": {"dbids": ["DB02994", "EXPT00823"], "name": "Hydroxydimethylarsine Oxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02996": {"dbids": ["DB02996", "EXPT02916"], "name": "2-(Thiomethylene)-4-Methylpentanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02991": {"dbids": ["DB02991", "EXPT03044"], "name": "S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02990": {"dbids": ["DB02990", "EXPT03058"], "name": "C16-Fatty-Acyl-Substrate-Mimic", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02993": {"dbids": ["DB02993", "EXPT02210"], "name": "8-Methyl-9-Oxoguanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02992": {"dbids": ["DB02992", "EXPT01682"], "name": "1-Deoxy-6-O-Phosphono-1-[(Phosphonomethyl)Amino]-L-Threo-Hexitol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07234": {"dbids": ["DB07234"], "name": "3-{[(1R)-1-phenylethyl]amino}-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09220": {"dbids": ["DB09220"], "name": "Nicorandil", "groups": ["APPROVED"], "targets": []}, "DB02195": {"dbids": ["DB02195", "EXPT01476"], "name": "3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02194": {"dbids": ["DB02194", "EXPT01057"], "name": "8-Benzyl-2-Hydroxy-2-(4-Hydroxy-Benzyl)-6-(4-Hydroxy-Phenyl)-2h-Imidazo[1,2-a]Pyrazin-3-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02197": {"dbids": ["DB02197", "EXPT01717"], "name": "4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02196": {"dbids": ["DB02196", "EXPT03169"], "name": "Uridine-Diphosphate-N-Acetylgalactosamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02191": {"dbids": ["DB02191", "EXPT01928"], "name": "(7as,12ar,12bs)-1,2,3,4,7a,12,12a,12b-Octahydroindolo[2,3-a]Quinolizin-7(6h)-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02190": {"dbids": ["DB02190", "EXPT02465"], "name": "2-Oxalosuccinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02193": {"dbids": ["DB02193", "EXPT00728"], "name": "2-(2-Hydroxy-Phenyl)-1h-Benzoimidazole-5-Carboxamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02192": {"dbids": ["DB02192", "EXPT02549"], "name": "2-Phenyl-Ethanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02199": {"dbids": ["DB02199", "EXPT01729"], "name": "1,3-Dedimethyl-1,3-Divinyl Heme", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02198": {"dbids": ["DB02198", "EXPT00753"], "name": "2-Bromoacetyl Group", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08889": {"dbids": ["DB08889"], "name": "Carfilzomib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P28074", "drug": "DB08889"}, {"action": "INHIBITOR", "target": "P28062", "drug": "DB08889"}, {"action": "INHIBITOR", "target": "P20618", "drug": "DB08889"}, {"action": "INHIBITOR", "target": "P28065", "drug": "DB08889"}, {"action": "INHIBITOR", "target": "P49721", "drug": "DB08889"}, {"action": "INHIBITOR", "target": "P40306", "drug": "DB08889"}]}, "DB09226": {"dbids": ["DB09226"], "name": "RP5063", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB02371": {"dbids": ["DB02371", "EXPT02328"], "name": "2-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Ethanesulfonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02370": {"dbids": ["DB02370", "EXPT02135"], "name": "Nz-(1-Carboxyethyl)-Lysine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02373": {"dbids": ["DB02373", "EXPT00516"], "name": "Adenosine Monotungstate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02372": {"dbids": ["DB02372", "EXPT03272"], "name": "2,5-Dimethylpyrimidin-4-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02375": {"dbids": ["DB02375", "EXPT02265"], "name": "Myricetin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02374": {"dbids": ["DB02374", "EXPT03259"], "name": "Xylose-Derived Imidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02377": {"dbids": ["DB02377", "EXPT01672"], "name": "Guanine", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P30793", "drug": "DB02377"}]}, "DB02376": {"dbids": ["DB02376", "EXPT01630"], "name": "D-Gluconhydroximo-1,5-Lactam", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02379": {"dbids": ["DB02379", "EXPT00455", "EXPT00685", "EXPT01603"], "name": "Beta-D-Glucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02378": {"dbids": ["DB02378", "EXPT02196"], "name": "MMI-175", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09224": {"dbids": ["DB09224"], "name": "Melperone", "groups": ["APPROVED"], "targets": []}, "DB09225": {"dbids": ["DB09225"], "name": "Zotepine", "groups": ["APPROVED"], "targets": []}, "DB07826": {"dbids": ["DB07826"], "name": "2-[4-chloro-2-(phenylcarbonyl)phenoxy]-N-phenylacetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07827": {"dbids": ["DB07827"], "name": "4-{[1-METHYL-2,4-DIOXO-6-(3-PHENYLPROP-1-YN-1-YL)-1,4-DIHYDROQUINAZOLIN-3(2H)-YL]METHYL}BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07824": {"dbids": ["DB07824"], "name": "4-ethyl-5-methyl-2-(1H-tetrazol-5-yl)-1,2-dihydro-3H-pyrazol-3-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07825": {"dbids": ["DB07825"], "name": "(3S)-1-(4-acetylphenyl)-5-oxopyrrolidine-3-carboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07822": {"dbids": ["DB07822"], "name": "(1R)-1,2,2-TRIMETHYLPROPYL (S)-METHYLPHOSPHINATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07823": {"dbids": ["DB07823"], "name": "(2S)-2-[(3aR,4R,7S,7aS)-1,3-dioxooctahydro-2H-4,7-methanoisoindol-2-yl]propanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07820": {"dbids": ["DB07820"], "name": "6-(3',5'-DIMETHYLBENZYL)-1-ETHOXYMETHYL-5-ISOPROPYLURACIL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07821": {"dbids": ["DB07821"], "name": "(1R)-1,2,2-TRIMETHYLPROPYL (R)-METHYLPHOSPHINATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07829": {"dbids": ["DB07829"], "name": "4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07425": {"dbids": ["DB07425"], "name": "{4-[4-hydroxy-3-(1-methylethyl)benzyl]-3,5-dimethylphenoxy}acetic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09082": {"dbids": ["DB09082"], "name": "Vilanterol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P07550", "drug": "DB09082"}]}, "DB05358": {"dbids": ["DB05358"], "name": "TAK-491", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05359": {"dbids": ["DB05359"], "name": "VEC-162", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05356": {"dbids": ["DB05356"], "name": "EUR-1008", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05357": {"dbids": ["DB05357"], "name": "grass pollen extract", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05354": {"dbids": ["DB05354"], "name": "intranasal morphine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05352": {"dbids": ["DB05352"], "name": "Fx-1006A", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05353": {"dbids": ["DB05353"], "name": "CMC 001", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05350": {"dbids": ["DB05350"], "name": "AP-1034", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05351": {"dbids": ["DB05351"], "name": "TAK-390MR", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB01949": {"dbids": ["DB01949", "EXPT00776"], "name": "2-Amino-N,3,3-Trimethylbutanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09229": {"dbids": ["DB09229"], "name": "Aranidipine", "groups": ["APPROVED"], "targets": []}, "DB01948": {"dbids": ["DB01948", "EXPT00157"], "name": "1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04839": {"dbids": ["DB04839"], "name": "Cyproterone acetate", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P10275", "drug": "DB04839"}]}, "DB04467": {"dbids": ["DB04467", "EXPT02529", "EXPT02532", "EXPT02635"], "name": "Pyridoxyl-Alanine-5-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01946": {"dbids": ["DB01946", "EXPT00704"], "name": "3-[1-(3-Aminopropyl)-1h-Indol-3-Yl]-4-(1-Methyl-1h-Indol-3-Yl)-1h-Pyrrole-2,5-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08879": {"dbids": ["DB08879"], "name": "Belimumab", "groups": ["APPROVED"], "targets": [{"action": "NEUTRALIZER", "target": "Q9Y275", "drug": "DB08879"}]}, "DB01945": {"dbids": ["DB01945", "EXPT02272"], "name": "4-Carbamoyl-1-Beta-D-Ribofuranosyl-Imidazolium-5-Olate-5'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01944": {"dbids": ["DB01944", "EXPT00711"], "name": "(S)-blebbistatin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01942": {"dbids": ["DB01942", "EXPT01461"], "name": "Formic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08327": {"dbids": ["DB08327"], "name": "2-(3,6-DIHYDROXYPHENYL)ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01941": {"dbids": ["DB01941", "EXPT02021"], "name": "6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-Tetrahydronaphthalen-2-Yl)Cyclopropyl]Pyridine-3-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01940": {"dbids": ["DB01940", "EXPT00646"], "name": "Balanol Analog 2", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01051": {"dbids": ["APRD00694", "DB01051"], "name": "Novobiocin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A0K8", "drug": "DB01051"}]}, "DB01050": {"dbids": ["APRD00372", "DB01050"], "name": "Ibuprofen", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB01050"}, {"action": "MODULATOR", "target": "P10415", "drug": "DB01050"}, {"action": "MODULATOR", "target": "P07204", "drug": "DB01050"}, {"action": "NEGATIVE MODULATOR", "target": "P00750", "drug": "DB01050"}, {"action": "BINDER", "target": "P12104", "drug": "DB01050"}, {"action": "ACTIVATOR", "target": "P37231", "drug": "DB01050"}, {"action": "INHIBITOR", "target": "P13569", "drug": "DB01050"}]}, "DB01053": {"dbids": ["APRD00646", "DB01053"], "name": "Benzylpenicillin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q2FGH1", "drug": "DB01053"}]}, "DB01055": {"dbids": ["APRD00647", "DB01055"], "name": "Mimosine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P34896", "drug": "DB01055"}, {"action": "INHIBITOR", "target": "P13500", "drug": "DB01055"}, {"action": "INHIBITOR", "target": "P14679", "drug": "DB01055"}]}, "DB01054": {"dbids": ["APRD00421", "DB01054"], "name": "Nitrendipine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q13936", "drug": "DB01054"}, {"action": "INHIBITOR", "target": "P54289", "drug": "DB01054"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB01054"}, {"action": "INHIBITOR", "target": "Q06432", "drug": "DB01054"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB01054"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB01054"}, {"action": "INHIBITOR", "target": "Q9NY47", "drug": "DB01054"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB01054"}]}, "DB04029": {"dbids": ["DB04029", "EXPT02329"], "name": "Phenylalanine Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01056": {"dbids": ["APRD01266", "DB01056"], "name": "Tocainide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB01056"}]}, "DB04027": {"dbids": ["DB04027", "EXPT01113"], "name": "D-Arginine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01506": {"dbids": ["DB01506"], "name": "1-Phenylcyclohexylamine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB04757": {"dbids": ["DB04757"], "name": "GUANOSINE-2',3'-O-METHYLIDENEPHOSPHONATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04024": {"dbids": ["DB04024", "EXPT00371"], "name": "N'-L-Seryl-3'-Amino-(3'-Deoxy)-Adenosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04023": {"dbids": ["DB04023", "EXPT01577"], "name": "Guanosine 5'-(Trihydrogen Diphosphate), P'-D-Mannopyranosyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04022": {"dbids": ["DB04022", "EXPT01534"], "name": "Guanosine-5',3'-Tetraphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04021": {"dbids": ["DB04021", "EXPT02157"], "name": "MF268", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04020": {"dbids": ["DB04020", "EXPT02212"], "name": "4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08629": {"dbids": ["DB08629"], "name": "N1-(2-AMINO-4-METHYLPENTYL)OCTAHYDRO-PYRROLO[1,2-A] PYRIMIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08628": {"dbids": ["DB08628"], "name": "(5R)-5-[(1E)-BUTA-1,3-DIENYL]-4-HYDROXY-3,5-DIMETHYLTHIOPHEN-2(5H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08624": {"dbids": ["DB08624"], "name": "BENZOTHIAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08627": {"dbids": ["DB08627"], "name": "(5R)-4-HYDROXY-3,5-DIMETHYL-5-[(1E,3E)-2-METHYLPENTA-1,3-DIENYL]THIOPHEN-2(5H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08626": {"dbids": ["DB01654", "DB08626"], "name": "Thiorphan", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "P08473", "drug": "DB08626"}]}, "DB08621": {"dbids": ["DB08621"], "name": "Thiamphenicol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08620": {"dbids": ["DB08620"], "name": "{(2Z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08623": {"dbids": ["DB08623"], "name": "2-[CARBOXY-(2-THIOPHEN-2-YL-ACETYLAMINO)-METHYL]-5-METHYLENE-5,6-DIHYDRO-2H-[1,3]THIAZINE-4-CARBOXYLIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08622": {"dbids": ["DB08622"], "name": "4-(4-CHLORO-PHENYL)-1-{3-[2-(4-FLUORO-PHENYL)-[1,3]DITHIOLAN-2-YL]-PROPYL}-PIPERIDIN-4-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00458": {"dbids": ["APRD00672", "DB00458", "DB08002"], "name": "Imipramine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23975", "drug": "DB00458"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00458"}, {"action": "INHIBITOR", "target": "Q9NZV8", "drug": "DB00458"}, {"action": "INHIBITOR", "target": "Q9UK17", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00458"}, {"action": "BINDER", "target": "P28335", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00458"}, {"action": "BINDER", "target": "P21728", "drug": "DB00458"}, {"action": "BINDER", "target": "P21918", "drug": "DB00458"}, {"action": "BINDER", "target": "P14416", "drug": "DB00458"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00458"}, {"action": "ACTIVATOR", "target": "P08908", "drug": "DB00458"}, {"action": "BINDER", "target": "P50406", "drug": "DB00458"}]}, "DB00459": {"dbids": ["APRD00778", "DB00459"], "name": "Acitretin", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P19793", "drug": "DB00459"}, {"action": "AGONIST", "target": "P10276", "drug": "DB00459"}, {"action": "AGONIST", "target": "P10826", "drug": "DB00459"}, {"action": "AGONIST", "target": "P13631", "drug": "DB00459"}, {"action": "AGONIST", "target": "P28702", "drug": "DB00459"}, {"action": "AGONIST", "target": "P48443", "drug": "DB00459"}, {"action": "AGONIST", "target": "P09455", "drug": "DB00459"}]}, "DB06889": {"dbids": ["DB06889"], "name": "3-(1H-tetrazol-5-ylmethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06888": {"dbids": ["DB06888"], "name": "(13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00452": {"dbids": ["APRD00618", "DB00452"], "name": "Framycetin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A7S3", "drug": "DB00452"}, {"action": "ANTAGONIST", "target": "P61073", "drug": "DB00452"}]}, "DB00453": {"dbids": ["APRD00343", "DB00453"], "name": "Clomocycline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A7V8", "drug": "DB00453"}, {"action": "INHIBITOR", "target": "P0A7X3", "drug": "DB00453"}]}, "DB00450": {"dbids": ["APRD00939", "DB00450"], "name": "Droperidol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB00450"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00450"}]}, "DB00451": {"dbids": ["APRD00235", "DB00451", "EXPT02993"], "name": "Levothyroxine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P10827", "drug": "DB00451"}, {"action": "AGONIST", "target": "P10828", "drug": "DB00451"}]}, "DB00456": {"dbids": ["APRD00859", "DB00456", "EXPT00946"], "name": "Cefalotin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P15555", "drug": "DB00456"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB00456"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB00456"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00456"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB00456"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB00456"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB00456"}, {"action": "POTENTIATOR", "target": "P00811", "drug": "DB00456"}]}, "DB00457": {"dbids": ["APRD00020", "DB00457"], "name": "Prazosin", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35348", "drug": "DB00457"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00457"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00457"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00457"}, {"action": "INHIBITOR", "target": "Q9H252", "drug": "DB00457"}, {"action": "INHIBITOR", "target": "Q9NS40", "drug": "DB00457"}, {"action": "BINDER", "target": "P08913", "drug": "DB00457"}, {"action": "BINDER", "target": "P18089", "drug": "DB00457"}]}, "DB00454": {"dbids": ["APRD00074", "DB00454"], "name": "Pethidine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q05586", "drug": "DB00454"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB00454"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB00454"}, {"action": "ANTAGONIST", "target": "Q14957", "drug": "DB00454"}, {"action": "ANTAGONIST", "target": "O15399", "drug": "DB00454"}, {"action": "BINDER", "target": "P11229", "drug": "DB00454"}, {"action": "BINDER", "target": "P08172", "drug": "DB00454"}, {"action": "BINDER", "target": "P20309", "drug": "DB00454"}, {"action": "BINDER", "target": "P08173", "drug": "DB00454"}, {"action": "BINDER", "target": "P08912", "drug": "DB00454"}, {"action": "AGONIST", "target": "P35372", "drug": "DB00454"}, {"action": "BINDING", "target": "P31645", "drug": "DB00454"}]}, "DB00455": {"dbids": ["APRD00384", "DB00455"], "name": "Loratadine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00455"}]}, "DB08776": {"dbids": ["DB08776"], "name": "N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02977": {"dbids": ["DB02977", "EXPT03015"], "name": "PNU177836", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02976": {"dbids": ["DB02976", "EXPT03197"], "name": "Uridine-5'-Monophosphate 2-Deoxy-2-Fluoro-Galactopyranosyl-Monophosphate Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02975": {"dbids": ["DB02975", "EXPT01578"], "name": "Ge2270a", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02974": {"dbids": ["DB02974", "EXPT01008"], "name": "4-(4-Chlorophenyl)Imidazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02973": {"dbids": ["DB02973", "EXPT00008"], "name": "4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02972": {"dbids": ["DB02972", "EXPT02626"], "name": "1-Benzyl-(R)-Propylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01543": {"dbids": ["DB01543"], "name": "13Beta-ethyl-17beta-hydroxygon-4-en-3-one", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB02971": {"dbids": ["DB02971", "EXPT00593"], "name": "2-Amino-4-(2-Amino-Ethoxy)-Butyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01542": {"dbids": ["DB01542"], "name": "Allylprodine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB02754": {"dbids": ["DB02754", "EXPT02694"], "name": "9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04061": {"dbids": ["DB04061", "EXPT01849"], "name": "Alpha-Amino-2-Indanacetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01540": {"dbids": ["DB01540"], "name": "17alpha-methyl-4-hydroxynandrolone", "groups": ["ILLICIT"], "targets": []}, "DB01011": {"dbids": ["APRD01111", "DB01011", "EXPT02271"], "name": "Metyrapone", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P15538", "drug": "DB01011"}, {"action": "OTHER/UNKNOWN", "target": "P00183", "drug": "DB01011"}]}, "DB04066": {"dbids": ["DB04066", "EXPT01706"], "name": "Para-Coumaric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01545": {"dbids": ["DB01545"], "name": "Ethyl loflazepate", "groups": ["APPROVED", "ILLICIT"], "targets": []}, "DB01544": {"dbids": ["DB01544"], "name": "Flunitrazepam", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "AGONIST", "target": "P30536", "drug": "DB01544"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01544"}, {"action": "AGONIST", "target": "P48169", "drug": "DB01544"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01544"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01544"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01544"}]}, "DB00544": {"dbids": ["APRD00516", "DB00544", "EXPT03204"], "name": "Fluorouracil", "groups": ["APPROVED"], "targets": [{"action": "OTHER/UNKNOWN", "target": "P04818", "drug": "DB00544"}]}, "DB00908": {"dbids": ["APRD00136", "DB00908"], "name": "Quinidine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB00908"}, {"action": "INHIBITOR", "target": "O00180", "drug": "DB00908"}, {"action": "INHIBITOR", "target": "Q9Y257", "drug": "DB00908"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00908"}]}, "DB00909": {"dbids": ["APRD00004", "DB00909"], "name": "Zonisamide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P35498", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q99250", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q9NY46", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P35499", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q15858", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q9UI33", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q07699", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "O60939", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q9NY72", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q8IWT1", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "O43497", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q9P0X4", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P07451", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P35218", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q9Y2D0", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P23280", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P43166", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P35219", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q16790", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q9NS85", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "O75493", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "O43570", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q8N1Q1", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q9ULX7", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P27338", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB00909"}]}, "DB07598": {"dbids": ["DB07598"], "name": "2,3,6A,7,8,9-HEXAHYDRO-11H-[1,4]DIOXINO[2,3-G]PYRROLO[2,1-B][1,3]BENZOXAZIN-11-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00545": {"dbids": ["APRD00380", "DB00545"], "name": "Pyridostigmine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P22303", "drug": "DB00545"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB00545"}, {"action": "ANTAGONIST", "target": "P06276", "drug": "DB00545"}]}, "DB00904": {"dbids": ["APRD00481", "DB00904"], "name": "Ondansetron", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P46098", "drug": "DB00904"}, {"action": "AGONIST", "target": "Q13639", "drug": "DB00904"}, {"action": "OTHER/UNKNOWN", "target": "P35372", "drug": "DB00904"}, {"action": "OTHER/UNKNOWN", "target": "P08908", "drug": "DB00904"}, {"action": "OTHER/UNKNOWN", "target": "P28222", "drug": "DB00904"}]}, "DB00905": {"dbids": ["APRD00826", "DB00905", "DB06863"], "name": "Bimatoprost", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P43088", "drug": "DB00905"}, {"action": "AGONIST", "target": "P34995", "drug": "DB00905"}, {"action": "AGONIST", "target": "P43115", "drug": "DB00905"}]}, "DB00906": {"dbids": ["APRD00344", "DB00906"], "name": "Tiagabine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P30531", "drug": "DB00906"}]}, "DB00907": {"dbids": ["APRD00080", "DB00907"], "name": "Cocaine", "groups": ["APPROVED", "ILLICIT"], "targets": [{"action": "INHIBITOR", "target": "Q01959", "drug": "DB00907"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00907"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00907"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00907"}, {"action": "INHIBITOR", "target": "Q9UI33", "drug": "DB00907"}, {"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00907"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00907"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00907"}]}, "DB00900": {"dbids": ["APRD00240", "DB00900", "DB02392"], "name": "Didanosine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q72547", "drug": "DB00900"}]}, "DB04069": {"dbids": ["DB04069", "EXPT01270"], "name": "5,6-Dihydro-Benzo[H]Cinnolin-3-Ylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00902": {"dbids": ["APRD00713", "DB00902"], "name": "Methdilazine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00902"}]}, "DB00903": {"dbids": ["APRD00251", "DB00903"], "name": "Ethacrynic acid", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P05023", "drug": "DB00903"}, {"action": "INHIBITOR", "target": "Q13621", "drug": "DB00903"}]}, "DB04068": {"dbids": ["DB04068", "EXPT01512"], "name": "Fudp", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00540": {"dbids": ["APRD00602", "DB00540"], "name": "Nortriptyline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23975", "drug": "DB00540"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00540"}, {"action": "BINDER", "target": "P50406", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P13945", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00540"}, {"action": "BINDER", "target": "O00264", "drug": "DB00540"}, {"action": "BINDER", "target": "Q99720", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P08909", "drug": "DB00540"}]}, "DB00543": {"dbids": ["APRD00142", "DB00543"], "name": "Amoxapine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23975", "drug": "DB00543"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P14867", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB00543"}, {"action": "BINDER", "target": "Q9H3N8", "drug": "DB00543"}, {"action": "BINDER", "target": "P14867", "drug": "DB00543"}, {"action": "BINDER", "target": "P47869", "drug": "DB00543"}, {"action": "BINDER", "target": "P34903", "drug": "DB00543"}, {"action": "BINDER", "target": "P48169", "drug": "DB00543"}, {"action": "BINDER", "target": "P31644", "drug": "DB00543"}, {"action": "BINDER", "target": "Q16445", "drug": "DB00543"}, {"action": "BINDER", "target": "P18505", "drug": "DB00543"}, {"action": "BINDER", "target": "P47870", "drug": "DB00543"}, {"action": "BINDER", "target": "P28472", "drug": "DB00543"}, {"action": "BINDER", "target": "O14764", "drug": "DB00543"}, {"action": "BINDER", "target": "P78334", "drug": "DB00543"}, {"action": "BINDER", "target": "Q8N1C3", "drug": "DB00543"}, {"action": "BINDER", "target": "P18507", "drug": "DB00543"}, {"action": "BINDER", "target": "Q99928", "drug": "DB00543"}, {"action": "BINDER", "target": "O00591", "drug": "DB00543"}, {"action": "BINDER", "target": "Q9UN88", "drug": "DB00543"}, {"action": "BINDER", "target": "Q01959", "drug": "DB00543"}]}, "DB00541": {"dbids": ["APRD00495", "DB00541"], "name": "Vincristine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P07437", "drug": "DB00541"}, {"action": "INHIBITOR", "target": "P68366", "drug": "DB00541"}]}, "DB03909": {"dbids": ["DB03909", "EXPT00416"], "name": "Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03908": {"dbids": ["DB03908", "EXPT00665"], "name": "Inhibitor Bea322", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00542": {"dbids": ["APRD00063", "DB00542"], "name": "Benazepril", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P12821", "drug": "DB00542"}]}, "DB09539": {"dbids": ["DB09539"], "name": "Omega-3-acid ethyl esters", "groups": ["APPROVED"], "targets": []}, "DB03901": {"dbids": ["DB03901", "EXPT00900"], "name": "5-Oxo-Pyrrolidine-2-Carbaldehyde", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03900": {"dbids": ["DB03900", "EXPT03021"], "name": "2-Methyl-2-Propanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03903": {"dbids": ["DB03903", "EXPT02780"], "name": "Tmr", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03902": {"dbids": ["DB02737", "DB03902", "EXPT02457"], "name": "Oxalic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03905": {"dbids": ["DB03905", "EXPT02869"], "name": "Succinamide-Coa", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03904": {"dbids": ["DB03904", "EXPT03203"], "name": "Urea", "groups": ["APPROVED"], "targets": []}, "DB03907": {"dbids": ["DB03907", "EXPT00934"], "name": "N-{3-[5-(6-Amino-Purin-9-Yl)-3,4-Dihydroxy-Tetrahydro-Furan-2-Yl]-Allyl}-2,3-Dihydroxy-5-Nitro-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03906": {"dbids": ["DB03906", "EXPT00117"], "name": "2-Phenylheme", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00940": {"dbids": ["APRD00751", "DB00940"], "name": "Methantheline", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00940"}, {"action": "ANTAGONIST", "target": "P25021", "drug": "DB00940"}]}, "DB00941": {"dbids": ["APRD01013", "DB00941"], "name": "Hexafluronium", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P06276", "drug": "DB00941"}]}, "DB00942": {"dbids": ["APRD00731", "DB00942"], "name": "Cycrimine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11229", "drug": "DB00942"}]}, "DB07048": {"dbids": ["DB07048"], "name": "N-[(2R)-5-(aminosulfonyl)-2,3-dihydro-1H-inden-2-yl]-2-propylpentanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07049": {"dbids": ["DB07049"], "name": "(2R)-1-[(4-tert-butylphenyl)sulfonyl]-2-methyl-4-(4-nitrophenyl)piperazine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00943": {"dbids": ["APRD00562", "DB00943"], "name": "Zalcitabine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q72547", "drug": "DB00943"}]}, "DB07040": {"dbids": ["DB07040"], "name": "2-amino-7-fluoro-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00944": {"dbids": ["APRD00905", "DB00944"], "name": "Demecarium", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P22303", "drug": "DB00944"}, {"action": "INHIBITOR", "target": "P06276", "drug": "DB00944"}]}, "DB07042": {"dbids": ["DB07042"], "name": "7-amino-2-tert-butyl-4-{[2-(1H-imidazol-4-yl)ethyl]amino}pyrido[2,3-d]pyrimidine-6-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07043": {"dbids": ["DB07043"], "name": "7-amino-2-tert-butyl-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrido[2,3-d]pyrimidine-6-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07044": {"dbids": ["DB07044"], "name": "3-bromo-N'-[(1E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylidene]benzohydrazide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07045": {"dbids": ["DB07045"], "name": "(2R,3R,4S,5R)-2-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07046": {"dbids": ["DB07046"], "name": "2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00945": {"dbids": ["APRD00264", "DB00945", "EXPT00475"], "name": "Acetylsalicylic acid", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P23219", "drug": "DB00945"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00945"}, {"action": "INHIBITOR", "target": "Q04828", "drug": "DB00945"}, {"action": "ACTIVATOR", "target": "Q13131", "drug": "DB00945"}, {"action": "ACTIVATOR", "target": "P54646", "drug": "DB00945"}, {"action": "ACTIVATOR", "target": "Q9Y478", "drug": "DB00945"}, {"action": "ACTIVATOR", "target": "O43741", "drug": "DB00945"}, {"action": "ACTIVATOR", "target": "P54619", "drug": "DB00945"}, {"action": "ACTIVATOR", "target": "Q9UGJ0", "drug": "DB00945"}, {"action": "ACTIVATOR", "target": "Q9UGI9", "drug": "DB00945"}, {"action": "ACETYLATION", "target": "P04637", "drug": "DB00945"}, {"action": "BINDING", "target": "P11021", "drug": "DB00945"}, {"action": "ANTAGONIST", "target": "Q00653", "drug": "DB00945"}, {"action": "ANTAGONIST", "target": "P19838", "drug": "DB00945"}]}, "DB00946": {"dbids": ["APRD00228", "DB00946"], "name": "Phenprocoumon", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9BQB6", "drug": "DB00946"}]}, "DB00947": {"dbids": ["APRD00654", "DB00947"], "name": "Fulvestrant", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P03372", "drug": "DB00947"}]}, "DB07268": {"dbids": ["DB07268"], "name": "2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07269": {"dbids": ["DB07269"], "name": "(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-[(R)-[(1R)-1-{[(BENZYLOXY)CARBONYL]AMINO}-2-METHYLPROPYL](HYDROXY)PHOSPHORYL]PROPANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01932": {"dbids": ["DB01932", "EXPT00253"], "name": "5-Methylpyrrole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09348": {"dbids": ["DB09348"], "name": "beta-Propiolactone", "groups": ["APPROVED"], "targets": []}, "DB08823": {"dbids": ["DB08823"], "name": "Spinosad", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB05502": {"dbids": ["DB05502"], "name": "AG-858", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05501": {"dbids": ["DB05501"], "name": "AMD-070", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05500": {"dbids": ["DB05500"], "name": "AVN-944", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05507": {"dbids": ["DB05507"], "name": "VX-765", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05506": {"dbids": ["DB05506"], "name": "ISIS 113715", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05505": {"dbids": ["DB05505"], "name": "NM-702", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08824": {"dbids": ["DB08824"], "name": "Ioflupane I 123", "groups": ["APPROVED"], "targets": []}, "DB05509": {"dbids": ["DB05509"], "name": "LI-301", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05508": {"dbids": ["DB05508"], "name": "PTI-901", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB03765": {"dbids": ["DB03765", "EXPT00808"], "name": "Cytidine-2'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03764": {"dbids": ["DB03764", "EXPT00216"], "name": "4-Hydroperoxy-2-Methoxy-Phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03767": {"dbids": ["DB03767", "EXPT00719"], "name": "Morpholine-4-Carboxylic Acid [1s-(2-Benzyloxy-1r-Cyano-Ethylcarbamoyl)-3-Methyl-Butyl]Amide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03766": {"dbids": ["DB03766", "EXPT02641"], "name": "Propanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03761": {"dbids": ["DB03761", "EXPT03176"], "name": "5-Fluoro-2'-Deoxyuridine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03760": {"dbids": ["DB03760", "EXPT02769"], "name": "Dihydrolipoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03763": {"dbids": ["DB03763", "EXPT00252"], "name": "5-Methyl-2'-Deoxypseudouridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03769": {"dbids": ["DB03769", "EXPT01152"], "name": "D-Eritadenine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03768": {"dbids": ["DB03768", "EXPT01695"], "name": "N-[2-Hydroxy-2-(8-Isopropyl-6,9-Dioxo-2-Oxa-7,10-Diaza-Bicyclo[11.2.2]Heptadeca-1(16),13(17),14-Trien-11-Yl)-Ethyl]-N-(3-Methyl-Butyl)-Benzenesulfonamide,Inhibitor 3", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01930": {"dbids": ["DB01930", "EXPT02489"], "name": "2,4-Dihydroxy-3,3-Dimethyl-Butyrate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01931": {"dbids": ["DB01931", "EXPT01212"], "name": "Dcka, 5,7-Dichlorokynurenic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08520": {"dbids": ["DB08520"], "name": "(21S)-1AZA-4,4-DIMETHYL-6,19-DIOXA-2,3,7,20-TETRAOXOBICYCLO[19.4.0] PENTACOSANE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01936": {"dbids": ["DB01936", "EXPT02783"], "name": "Ribose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08521": {"dbids": ["DB08521"], "name": "4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07550": {"dbids": ["DB07550"], "name": "2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(1-OXIDO-2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUOROPHENYL)METHYL]ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01937": {"dbids": ["DB01937", "EXPT00121"], "name": "Guanosine-2'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08526": {"dbids": ["DB08526"], "name": "CARBOBENZYLOXY-(L)-LEUCINYL-(L)LEUCINYL METHOXYMETHYLKETONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01934": {"dbids": ["DB01934", "EXPT00564"], "name": "N-Methyl-N-(10-Methylundecanoyl)-D-Seryl-L-Alanyl-N~1~-[(7s,10s,13s)-13-Carboxy-3,18-Dihydroxy-10-Methyl-8,11-Dioxo-9,12-Diazatricyclo[13.3.1.1~2,6~]Icosa-1(19),2(20),3,5,15,17-Hexaen-7-Yl]-N~1~-Methylglycinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02414": {"dbids": ["DB02414", "EXPT00911"], "name": "(3s,8ar)-3-(1h-Imidazol-5-Ylmethyl)Hexahydropyrrolo[1,2-a]Pyrazine-1,4-Dione", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02415": {"dbids": ["DB02415", "EXPT02420"], "name": "N-Octyl-2-Hydroxyethyl Sulfoxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02416": {"dbids": ["DB02416", "EXPT02813"], "name": "2-Ribofuranosyl-3-Iodo-2,3-Dihydro-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02417": {"dbids": ["DB02417", "EXPT03018"], "name": "2,4,6-Tribromophenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02410": {"dbids": ["DB02410", "EXPT01790"], "name": "2-Acetyl-3-[(4-Amino-2-Methyl-5-Pyrimidinyl)Methyl]-4-Methyl-5-(4,6,6-Trihydroxy-3,5-Dioxa-4,6-Diphosphahex-1-Yl)Thiazolium Inner Salt P,P'-Dioxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02411": {"dbids": ["DB02411", "EXPT01696"], "name": "2-(11-{2-[Benzenesulfonyl-(3-Methyl-Butyl)-Amino]-1-Hydroxy-Ethyl}-6,9-Dioxo-2-Oxa-7,10-Diaza-Bicyclo[11.2.2]Heptadeca-1(16),13(17),14-Trien-8-Yl)-Acetamide, Inhibitor 2", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02412": {"dbids": ["DB02412", "EXPT02719"], "name": "Tetrahydropyran", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02413": {"dbids": ["DB02413", "EXPT02417"], "name": "Hydroxyethylcysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02418": {"dbids": ["DB02418", "EXPT00773"], "name": "(R,R)-2,3-Butanediol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02419": {"dbids": ["DB02419", "EXPT01313"], "name": "Ethyl Oxo(Piperidin-1-Yl)Acetate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08527": {"dbids": ["DB08527"], "name": "1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01935": {"dbids": ["DB01935", "EXPT02817"], "name": "3-{[(1r)-1-Benzyl-2-Sulfanylethyl]Amino}-3-Oxopropanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08524": {"dbids": ["DB08524"], "name": "2-(3-BENZOYLPHENOXY)ETHYL(HYDROXY)FORMAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01266": {"dbids": ["DB01266"], "name": "Sinecatechins", "groups": ["APPROVED", "NUTRACEUTICAL"], "targets": []}, "DB01267": {"dbids": ["DB01267"], "name": "Paliperidone", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P28223", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01267"}, {"action": "AGONIST", "target": "P35367", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P28221", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB01267"}, {"action": "AGONIST", "target": "P18825", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01267"}]}, "DB01264": {"dbids": ["DB01264", "EXPT00002"], "name": "Darunavir", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q72874", "drug": "DB01264"}]}, "DB01265": {"dbids": ["DB01265"], "name": "Telbivudine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": []}, "DB01262": {"dbids": ["DB01262"], "name": "Decitabine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P26358", "drug": "DB01262"}]}, "DB01263": {"dbids": ["DB01263"], "name": "Posaconazole", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P10613", "drug": "DB01263"}]}, "DB01260": {"dbids": ["DB01260"], "name": "Desonide", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB01260"}]}, "DB01261": {"dbids": ["DB01261", "DB07214"], "name": "Sitagliptin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P27487", "drug": "DB01261"}]}, "DB09051": {"dbids": ["DB09051"], "name": "Elosulfase alfa", "groups": ["APPROVED"], "targets": []}, "DB09050": {"dbids": ["DB09050"], "name": "Ceftolozane", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9X6W0", "drug": "DB09050"}, {"action": "INHIBITOR", "target": "Q51504", "drug": "DB09050"}]}, "DB09053": {"dbids": ["DB09053"], "name": "Ibrutinib", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q06187", "drug": "DB09053"}]}, "DB09052": {"dbids": ["DB09052"], "name": "Blinatumomab", "groups": ["APPROVED"], "targets": [{"action": "ACTIVATOR", "target": "P15391", "drug": "DB09052"}, {"action": "ACTIVATOR", "target": "P04234", "drug": "DB09052"}]}, "DB08525": {"dbids": ["DB08525"], "name": "HYDROXY[3-(6-METHYLPYRIDIN-2-YL)PROPYL]FORMAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09054": {"dbids": ["DB09054"], "name": "Idelalisib", "groups": ["APPROVED"], "targets": []}, "DB01268": {"dbids": ["DB01268", "DB07417"], "name": "Sunitinib", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P09619", "drug": "DB01268"}, {"action": "ANTAGONIST", "target": "P17948", "drug": "DB01268"}, {"action": "ANTAGONIST", "target": "P10721", "drug": "DB01268"}, {"action": "MULTITARGET", "target": "P35968", "drug": "DB01268"}, {"action": "ANTAGONIST", "target": "P35916", "drug": "DB01268"}, {"action": "MULTITARGET", "target": "P36888", "drug": "DB01268"}, {"action": "OTHER/UNKNOWN", "target": "P07333", "drug": "DB01268"}, {"action": "ANTAGONIST", "target": "P16234", "drug": "DB01268"}]}, "DB01269": {"dbids": ["DB01269"], "name": "Panitumumab", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "SUPPRESSOR", "target": "P00533", "drug": "DB01269"}]}, "DB01190": {"dbids": ["APRD00566", "DB01190"], "name": "Clindamycin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A7J6", "drug": "DB01190"}]}, "DB01191": {"dbids": ["APRD00648", "DB01191"], "name": "Dexfenfluramine", "groups": ["APPROVED", "ILLICIT", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "P31645", "drug": "DB01191"}, {"action": "AGONIST", "target": "P28335", "drug": "DB01191"}]}, "DB01192": {"dbids": ["APRD00158", "DB01192"], "name": "Oxymorphone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB01192"}, {"action": "ANTAGONIST", "target": "P41143", "drug": "DB01192"}]}, "DB01193": {"dbids": ["APRD00772", "DB01193"], "name": "Acebutolol", "groups": ["APPROVED"], "targets": [{"action": "PARTIAL AGONIST", "target": "P08588", "drug": "DB01193"}, {"action": "PARTIAL AGONIST", "target": "P07550", "drug": "DB01193"}]}, "DB01194": {"dbids": ["APRD00475", "DB01194"], "name": "Brinzolamide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00918", "drug": "DB01194"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB01194"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB01194"}, {"action": "INHIBITOR", "target": "P35218", "drug": "DB01194"}]}, "DB01195": {"dbids": ["APRD00129", "DB01195"], "name": "Flecainide", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB01195"}, {"action": "INHIBITOR", "target": "P35499", "drug": "DB01195"}]}, "DB01196": {"dbids": ["APRD00625", "DB01196"], "name": "Estramustine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P11137", "drug": "DB01196"}, {"action": "ANTAGONIST", "target": "P78559", "drug": "DB01196"}, {"action": "AGONIST", "target": "P03372", "drug": "DB01196"}, {"action": "OTHER/UNKNOWN", "target": "Q92731", "drug": "DB01196"}]}, "DB01197": {"dbids": ["APRD00164", "DB01197"], "name": "Captopril", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P12821", "drug": "DB01197"}, {"action": "INHIBITOR", "target": "P08253", "drug": "DB01197"}, {"action": "INHIBITOR", "target": "P14780", "drug": "DB01197"}]}, "DB01198": {"dbids": ["APRD00356", "DB01198"], "name": "Zopiclone", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P14867", "drug": "DB01198"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01198"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01198"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01198"}, {"action": "AGONIST", "target": "P30536", "drug": "DB01198"}]}, "DB01199": {"dbids": ["APRD00176", "DB01199"], "name": "Tubocurarine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q15822", "drug": "DB01199"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB01199"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB01199"}]}, "DB07086": {"dbids": ["DB07086"], "name": "4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08528": {"dbids": ["DB08528"], "name": "2-AMINO-6-(3,5-DIMETHYLPHENYL)SULFONYLBENZONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01998": {"dbids": ["DB01998", "EXPT02980"], "name": "2-[3,4-Dihydroxy-2-Hydroxymethyl-5-(2-Hydroxy-Nonyl)-Tetrahydro-Furan-2-Yloxy]-6-Hydroxymethyl-Tetra Hydro-Pyran-3,4,5-Triol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01999": {"dbids": ["DB01999", "EXPT02891"], "name": "5,10,15,20-Tetrakis(4-Sulpfonatophenyl)-21h,23h-Porphine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01990": {"dbids": ["DB01990", "EXPT00810"], "name": "Cholesterol-Sulfate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01991": {"dbids": ["DB01991", "EXPT03132"], "name": "Tu-514", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01992": {"dbids": ["DB01992", "EXPT00991"], "name": "Coenzyme A", "groups": ["NUTRACEUTICAL"], "targets": []}, "DB01993": {"dbids": ["DB01993", "EXPT02531"], "name": "N-(5'-Phosphopyridoxyl)-D-Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01994": {"dbids": ["DB01994", "EXPT02650"], "name": "2-(Pyrido[1,2-E]Purin-4-Yl)Amino-Ethanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01995": {"dbids": ["DB01995", "EXPT00251"], "name": "5-Methylcytidine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01996": {"dbids": ["DB01996", "EXPT00181"], "name": "3-Methylpyridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01997": {"dbids": ["DB01997", "EXPT01883"], "name": "3-Bromo-7-Nitroindazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00023": {"dbids": ["BIOD00011", "BTD00011", "DB00023"], "name": "Asparaginase", "groups": ["APPROVED"], "targets": []}, "DB00022": {"dbids": ["BIOD00048", "BTD00048", "DB00022"], "name": "Peginterferon alfa-2b", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P17181", "drug": "DB00022"}, {"action": "AGONIST", "target": "P48551", "drug": "DB00022"}]}, "DB00021": {"dbids": ["BIOD00039", "BTD00039", "DB00021"], "name": "Secretin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P47872", "drug": "DB00021"}]}, "DB00020": {"dbids": ["BIOD00035", "BTD00035", "DB00020"], "name": "Sargramostim", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P15509", "drug": "DB00020"}, {"action": "AGONIST", "target": "P26951", "drug": "DB00020"}, {"action": "AGONIST", "target": "P32927", "drug": "DB00020"}, {"action": "AGONIST", "target": "P34741", "drug": "DB00020"}]}, "DB00027": {"dbids": ["BIOD00036", "BTD00036", "DB00027"], "name": "Gramicidin D", "groups": ["APPROVED"], "targets": []}, "DB00026": {"dbids": ["BIOD00060", "BTD00060", "DB00026"], "name": "Anakinra", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14778", "drug": "DB00026"}]}, "DB00025": {"dbids": ["BIOD00029", "BTD00029", "DB00025"], "name": "Antihemophilic Factor (Recombinant)", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ACTIVATOR", "target": "P00742", "drug": "DB00025"}, {"action": "COFACTOR", "target": "P00740", "drug": "DB00025"}, {"action": "BINDER", "target": "P04275", "drug": "DB00025"}, {"action": "ANTAGONIST", "target": "O14832", "drug": "DB00025"}, {"action": "BINDER", "target": "P07307", "drug": "DB00025"}, {"action": "CHAPERONE", "target": "P11021", "drug": "DB00025"}, {"action": "CHAPERONE", "target": "P27797", "drug": "DB00025"}, {"action": "CHAPERONE", "target": "P27824", "drug": "DB00025"}, {"action": "CHAPERONE", "target": "P49257", "drug": "DB00025"}, {"action": "MODULATOR", "target": "Q07954", "drug": "DB00025"}, {"action": "MODULATOR", "target": "Q8NI22", "drug": "DB00025"}]}, "DB00024": {"dbids": ["BIOD00020", "BTD00020", "DB00024"], "name": "Thyrotropin Alfa", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P16473", "drug": "DB00024"}]}, "DB00029": {"dbids": ["BIOD00102", "BTD00102", "DB00029"], "name": "Anistreplase", "groups": ["APPROVED"], "targets": [{"action": "ACTIVATOR", "target": "P00747", "drug": "DB00029"}]}, "DB00028": {"dbids": ["BIOD00091", "BTD00091", "DB00028"], "name": "Intravenous Immunoglobulin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P12314", "drug": "DB00028"}, {"action": "ANTAGONIST", "target": "Q92637", "drug": "DB00028"}, {"action": "ANTAGONIST", "target": "P12318", "drug": "DB00028"}, {"action": "ANTAGONIST", "target": "P31994", "drug": "DB00028"}, {"action": "ANTAGONIST", "target": "P31995", "drug": "DB00028"}, {"action": "ANTAGONIST", "target": "P08637", "drug": "DB00028"}, {"action": "ANTAGONIST", "target": "O75015", "drug": "DB00028"}, {"action": "BINDER", "target": "P01024", "drug": "DB00028"}, {"action": "BINDER", "target": "P0C0L4", "drug": "DB00028"}, {"action": "BINDER", "target": "P0C0L5", "drug": "DB00028"}, {"action": "BINDER", "target": "P01031", "drug": "DB00028"}]}, "DB03220": {"dbids": ["DB03220", "EXPT01485"], "name": "FR233623", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03221": {"dbids": ["DB03221", "EXPT00491"], "name": "AL7099A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03222": {"dbids": ["DB03222", "EXPT01288"], "name": "2'-Deoxyadenosine 5'-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03223": {"dbids": ["DB03223", "EXPT01142"], "name": "Diphthamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03224": {"dbids": ["DB03224", "EXPT01735"], "name": "2-Formyl-Protoporphryn Ix", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03225": {"dbids": ["DB03225", "EXPT01290"], "name": "D-Tryptophan", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03226": {"dbids": ["DB03226", "EXPT01368"], "name": "Trifluoroethanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03227": {"dbids": ["DB03227", "EXPT02366"], "name": "Nicotinamide Mononucleotide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03228": {"dbids": ["DB03228", "EXPT02926"], "name": "5-[Bis-2(Chloro-Ethyl)-Amino]-2,4-Dintro-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03229": {"dbids": ["DB03229", "EXPT00985"], "name": "2-Oxo-4-Methylpentanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04922": {"dbids": ["DB04922"], "name": "XP13512", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04255": {"dbids": ["DB04255", "EXPT00660"], "name": "Inhibitor Bea388", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04920": {"dbids": ["DB04920"], "name": "Clevidipine", "groups": ["APPROVED"], "targets": []}, "DB04921": {"dbids": ["DB04921"], "name": "MBP8298", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04926": {"dbids": ["DB04926"], "name": "Neramexane", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04927": {"dbids": ["DB04927"], "name": "NM100060", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04924": {"dbids": ["DB04924"], "name": "Itopride", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04925": {"dbids": ["DB04925"], "name": "Desmoteplase", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04928": {"dbids": ["DB04928"], "name": "XP12B", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04929": {"dbids": ["DB04929"], "name": "DG031", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04258": {"dbids": ["DB04258", "EXPT01322"], "name": "Seocalcitol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04259": {"dbids": ["DB04259", "EXPT00313"], "name": "7n-Methyl-8-Hydroguanosine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08012": {"dbids": ["DB08012"], "name": "(METHYLPYRIDAZINE PIPERIDINE ETHYLOXYPHENYL)ETHYLACETATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08013": {"dbids": ["DB08013"], "name": "(METHYLPYRIDAZINE PIPERIDINE PROPYLOXYPHENYL)ETHYLACETATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08010": {"dbids": ["DB08010"], "name": "(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08011": {"dbids": ["DB08011"], "name": "(3E)-5-fluoro-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-1H-indole-2,3-dione 3-oxime", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08016": {"dbids": ["DB08016"], "name": "4-(6-CHLORO-2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL) BUTYL PHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08017": {"dbids": ["DB08017"], "name": "3-METHOXY-6-[4-(3-METHYLPHENYL)-1-PIPERAZINYL]PYRIDAZINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08014": {"dbids": ["DB08014"], "name": "(METHYLPYRIDAZINE PIPERIDINE BUTYLOXYPHENYL)ETHYLACETATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08015": {"dbids": ["DB08015"], "name": "(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-phenyl-1H-indole-2,3-dione 3-oxime", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08018": {"dbids": ["DB08018"], "name": "N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08019": {"dbids": ["DB08019"], "name": "N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07698": {"dbids": ["DB07698"], "name": "3-(3-aminophenyl)-N-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-5-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07695": {"dbids": ["DB07695"], "name": "N-(3,5-dibromo-4-hydroxyphenyl)-4-hydroxy-3,5-dimethylbenzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07694": {"dbids": ["DB07694"], "name": "2,5-dichloro-N-(3,5-dibromo-4-hydroxyphenyl)benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07697": {"dbids": ["DB07697"], "name": "1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07696": {"dbids": ["DB07696"], "name": "methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07691": {"dbids": ["DB07691"], "name": "2-({[3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)phenyl]carbonyl}amino)benzoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07690": {"dbids": ["DB07690"], "name": "(3ALPHA,5BETA,12ALPHA)-3,12-DIHYDROXYCHOLAN-24-OIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07693": {"dbids": ["DB07693"], "name": "N-(3,5-dibromo-4-hydroxyphenyl)-2,6-dimethylbenzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07692": {"dbids": ["DB07692"], "name": "1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03598": {"dbids": ["DB03598", "EXPT01889"], "name": "Al-6629, [2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide,2-(3-Methoxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide]", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03599": {"dbids": ["DB03599", "EXPT01648"], "name": "4-Thio-D-Glucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03592": {"dbids": ["DB03592", "EXPT02619"], "name": "Pterin-6-Yl-Methyl-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03593": {"dbids": ["DB03593", "EXPT01539"], "name": "N7-Methyl-Guanosine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03590": {"dbids": ["DB03590", "EXPT00541"], "name": "2,6-Diaminopimelic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03591": {"dbids": ["DB03591", "EXPT00322"], "name": "RU82209", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03596": {"dbids": ["DB03596", "EXPT02851"], "name": "N-[2-(1h-Indol-5-Yl)-Butyl]-4-Sulfamoyl-Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03597": {"dbids": ["DB03597", "EXPT01826"], "name": "Gamma-Glutamyl[S-(2-Iodobenzyl)Cysteinyl]Glycine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03594": {"dbids": ["DB03594", "EXPT03109"], "name": "1,2,4-Triazole", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03595": {"dbids": ["DB03595", "EXPT00302"], "name": "CRA_9785", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08869": {"dbids": ["DB08869"], "name": "Tesamorelin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "BINDER", "target": "Q02643", "drug": "DB08869"}]}, "DB02179": {"dbids": ["DB02179", "EXPT02421"], "name": "O-Trifluoromethylphenyl Anthranilic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02178": {"dbids": ["DB02178", "EXPT01801"], "name": "Phenylacetaldehyde", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02177": {"dbids": ["DB02177", "EXPT01986"], "name": "1-Acetyl-4-(4-{4-[(2-Ethoxyphenyl)Thio]-3-Nitrophenyl}Pyridin-2-Yl)Piperazine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02176": {"dbids": ["DB02176", "EXPT02104"], "name": "Mercury Acetate Ion", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02175": {"dbids": ["DB02175", "EXPT02179"], "name": "Malonic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02174": {"dbids": ["DB02174", "EXPT01181"], "name": "D-Glutamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02173": {"dbids": ["DB02173", "EXPT01165"], "name": "Co(Iii)-(Deuteroporphyrin Ix)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02172": {"dbids": ["DB02172", "EXPT01205"], "name": "2,5-Dideoxy-2,5-Imino-D-Glucitol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02171": {"dbids": ["DB02171", "EXPT01474"], "name": "D-Fructose-6-Phosphate (Open Form)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02170": {"dbids": ["DB02170", "EXPT02205"], "name": "1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08192": {"dbids": ["DB08192"], "name": "2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02319": {"dbids": ["DB02319", "EXPT02403"], "name": "5,6-Dihydroxy-Nadp", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02318": {"dbids": ["DB02318", "EXPT01456"], "name": "2-Deoxy-2-Fluoro-Alpha-D-Mannosyl Fluoride", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02313": {"dbids": ["DB02313", "EXPT00453"], "name": "4-{2-(4-Fluoro-Benzyl)-6-Methyl-5-[(5-Methyl-Isoxazole-3-Carbonyl)-Amino]-4-Oxo-Heptanoylamino}-5-(2-Oxo-Pyrrolidin-3-Yl)-Pentanoic Acid Ethyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02312": {"dbids": ["DB02312", "EXPT00688"], "name": "Beta-Galactose-6-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02311": {"dbids": ["DB02311", "EXPT01278"], "name": "Methyl Methylsulfinylmethyl Sulfide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02310": {"dbids": ["DB02310", "EXPT03080"], "name": "3,5,6,8-Tetramethyl-N-Methyl Phenanthrolinium", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02317": {"dbids": ["DB02317", "EXPT01595"], "name": "Alpha-D-Galactose-1-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02316": {"dbids": ["DB02316", "EXPT00274"], "name": "1-(5-Carboxypentyl)-5-[(2,6-Dichlorobenzyl)Oxy]-1 H-Indole-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02315": {"dbids": ["DB02315", "DB04536", "EXPT02518"], "name": "Cyclic Guanosine Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02314": {"dbids": ["DB02314", "EXPT03165"], "name": "Uridine-5'-Diphosphate-N-Acetylmuramoyl-L-Alanine-D-Glutamate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09221": {"dbids": ["DB09221"], "name": "Polaprezinc", "groups": ["APPROVED"], "targets": []}, "DB07840": {"dbids": ["DB07840"], "name": "(E)-[4-(3,5-difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07841": {"dbids": ["DB07841"], "name": "GERANYLGERANYL DIPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07842": {"dbids": ["DB07842"], "name": "(2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07843": {"dbids": ["DB07843"], "name": "5-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1-BENZOTHIOPHENE-2-SULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07844": {"dbids": ["DB07844"], "name": "6-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1-BENZOTHIOPHENE-2-SULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07845": {"dbids": ["DB07845"], "name": "2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07846": {"dbids": ["DB07846"], "name": "1S,3AS,8AS-TRIMETHYL-1-OXIDO-1,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL 2-ETHYLPHENYLCARBAMATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07847": {"dbids": ["DB07847"], "name": "6-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-(4-MORPHOLINYL)-2-OXO ETHYL]-2-OXO-3-PYRROLIDINYL}-2-NAPHTHALENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07848": {"dbids": ["DB07848"], "name": "5-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-5-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-SULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07849": {"dbids": ["DB07849"], "name": "S-NONYL-CYSTEINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07516": {"dbids": ["DB07516"], "name": "(2Z,4E)-3-chloro-2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09219": {"dbids": ["DB09219"], "name": "Bisoxatin", "groups": ["APPROVED"], "targets": []}, "DB02578": {"dbids": ["DB02578", "EXPT02773"], "name": "Glycyl-L-Alpha-Amino-Epsilon-Pimelyl-D-Alanyl-D-Alanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05338": {"dbids": ["DB05338"], "name": "atamestane-plus-toremifene", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05339": {"dbids": ["DB05339"], "name": "MN-305", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05330": {"dbids": ["DB05330"], "name": "ALTU-135", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05331": {"dbids": ["DB05331"], "name": "doxorubicin TransDrug", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05332": {"dbids": ["DB05332"], "name": "Romiplostim", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P40238", "drug": "DB05332"}]}, "DB05333": {"dbids": ["DB05333"], "name": "TC-5231", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05335": {"dbids": ["DB05335"], "name": "ketoprofen transdermal patch", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05336": {"dbids": ["DB05336"], "name": "ETI-204", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05337": {"dbids": ["DB05337"], "name": "SOT-107", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB09213": {"dbids": ["DB09213"], "name": "Dexibuprofen", "groups": ["APPROVED"], "targets": []}, "DB11166": {"dbids": ["DB11166"], "name": "Antithrombin III", "groups": ["APPROVED"], "targets": []}, "DB09212": {"dbids": ["DB09212"], "name": "Loxoprofen", "groups": ["APPROVED"], "targets": []}, "DB09211": {"dbids": ["DB09211"], "name": "Limaprost", "groups": ["APPROVED"], "targets": []}, "DB09210": {"dbids": ["DB09210"], "name": "Piracetam", "groups": ["APPROVED"], "targets": []}, "DB09217": {"dbids": ["DB09217"], "name": "Firocoxib", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09216": {"dbids": ["DB09216"], "name": "Tolfenamic Acid", "groups": ["APPROVED"], "targets": []}, "DB08860": {"dbids": ["DB06514", "DB08860"], "name": "Pitavastatin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P04035", "drug": "DB08860"}]}, "DB06689": {"dbids": ["DB06689"], "name": "Ethanolamine Oleate", "groups": ["APPROVED"], "targets": [{"action": "ACTIVATOR", "target": "P00748", "drug": "DB06689"}]}, "DB06688": {"dbids": ["DB06688"], "name": "Sipuleucel-T", "groups": ["APPROVED"], "targets": []}, "DB09214": {"dbids": ["DB09214"], "name": "Dexketoprofen", "groups": ["APPROVED"], "targets": []}, "DB06130": {"dbids": ["DB06130"], "name": "FAV-201", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04009": {"dbids": ["DB04009", "EXPT01714"], "name": "Dimethyl Propionate Ester Heme", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01528": {"dbids": ["DB01528"], "name": "4-Methyl-2,5-dimethoxyamphetamine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01039": {"dbids": ["APRD00405", "DB01039"], "name": "Fenofibrate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "Q07869", "drug": "DB01039"}, {"action": "INHIBITOR", "target": "O43923", "drug": "DB01039"}]}, "DB01038": {"dbids": ["APRD00848", "DB01038"], "name": "Carphenazine", "groups": ["WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB01038"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01038"}, {"action": "ANTAGONIST", "target": "P21918", "drug": "DB01038"}]}, "DB04001": {"dbids": ["DB04001", "EXPT02409"], "name": "6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04000": {"dbids": ["DB04000", "EXPT00785"], "name": "Bromo-Willardiine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04003": {"dbids": ["DB04003", "EXPT00855"], "name": "(4-{2-Acetylamino-2-[1-(3-Carbamoyl-4-Cyclohexylmethoxy-Phenyl)-Ethylcarbamoyl}-Ethyl}-2-Phosphono-Phenoxy)-Acetic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04002": {"dbids": ["DB04002", "EXPT02964"], "name": "4-Sulfonamide-[4-(Thiomethylaminobutane)]Benzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04005": {"dbids": ["DB04005", "EXPT03210"], "name": "Uridine 5'-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04004": {"dbids": ["DB04004", "EXPT00694"], "name": "2,6-Diamino-8-(2-Dimethylaminoethylsulfanylmethyl)-3h-Quinazolin-4-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01527": {"dbids": ["DB01527"], "name": "Clortermine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01526": {"dbids": ["DB01526"], "name": "4-Androstenediol", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB11245": {"dbids": ["DB11245"], "name": "Pyroglutamate", "groups": ["APPROVED"], "targets": []}, "DB04096": {"dbids": ["DB04096", "EXPT00398"], "name": "5-Amino-5-Deoxy-Cellobiono-1,5-Lactam", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07396": {"dbids": ["DB07396"], "name": "1-{2-[3-(2-Chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04725": {"dbids": ["DB04725"], "name": "Licofelone", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB04094": {"dbids": ["DB04094", "EXPT00777"], "name": "4-Hydroxy-2-Butanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04727": {"dbids": ["DB04727"], "name": "N-(4-{4-AMINO-6-[4-(METHYLOXY)PHENYL]FURO[2,3-D]PYRIMIDIN-5-YL}PHENYL)-N'-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]UREA", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04092": {"dbids": ["DB04092", "EXPT00584"], "name": "Apstatin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04093": {"dbids": ["DB04093", "EXPT03190"], "name": "Undecanal", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04722": {"dbids": ["DB04722"], "name": "2-(3-CHLORO-6-{[2,2-DIFLUORO-2-(1-OXIDOPYRIDIN-2-YL)ETHYL]AMINO}-1-OXIDOPYRIDIN-2-YL)-N-[1-(3-CHLOROPHENYL)ETHYL]ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04091": {"dbids": ["DB04091", "EXPT02160"], "name": "Alpha-L-1-Methyl-Fucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00926": {"dbids": ["APRD00966", "DB00926"], "name": "Etretinate", "groups": ["WITHDRAWN"], "targets": [{"action": "AGONIST", "target": "P10276", "drug": "DB00926"}, {"action": "AGONIST", "target": "P19793", "drug": "DB00926"}, {"action": "AGONIST", "target": "P10826", "drug": "DB00926"}, {"action": "AGONIST", "target": "P48443", "drug": "DB00926"}, {"action": "AGONIST", "target": "P28702", "drug": "DB00926"}, {"action": "AGONIST", "target": "P13631", "drug": "DB00926"}]}, "DB00927": {"dbids": ["APRD00296", "DB00927"], "name": "Famotidine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P25021", "drug": "DB00927"}]}, "DB00924": {"dbids": ["APRD00213", "DB00924"], "name": "Cyclobenzaprine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P28223", "drug": "DB00924"}]}, "DB00925": {"dbids": ["APRD00651", "DB00925"], "name": "Phenoxybenzamine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35348", "drug": "DB00925"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00925"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB00925"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00925"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB00925"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00925"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00925"}]}, "DB00922": {"dbids": ["APRD01296", "DB00922"], "name": "Levosimendan", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "POTENTIATOR", "target": "P63316", "drug": "DB00922"}, {"action": "INDUCER", "target": "Q14654", "drug": "DB00922"}, {"action": "INDUCER", "target": "Q15842", "drug": "DB00922"}, {"action": "INHIBITOR", "target": "Q14432", "drug": "DB00922"}]}, "DB00923": {"dbids": ["APRD00853", "DB00923"], "name": "Ceforanide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q70KI2", "drug": "DB00923"}]}, "DB00920": {"dbids": ["APRD01061", "DB00920"], "name": "Ketotifen", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00920"}, {"action": "INHIBITOR", "target": "P27815", "drug": "DB00920"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB00920"}, {"action": "INHIBITOR", "target": "Q08499", "drug": "DB00920"}, {"action": "INHIBITOR", "target": "Q08493", "drug": "DB00920"}, {"action": "INHIBITOR", "target": "Q13946", "drug": "DB00920"}, {"action": "INHIBITOR", "target": "Q9NP56", "drug": "DB00920"}, {"action": "INHIBITOR", "target": "O60658", "drug": "DB00920"}, {"action": "INHIBITOR", "target": "O95263", "drug": "DB00920"}, {"action": "INHIBITOR", "target": "P52209", "drug": "DB00920"}]}, "DB00921": {"dbids": ["APRD00670", "DB00921"], "name": "Buprenorphine", "groups": ["APPROVED", "ILLICIT", "INVESTIGATIONAL"], "targets": [{"action": "PARTIAL AGONIST", "target": "P35372", "drug": "DB00921"}, {"action": "ANTAGONIST", "target": "P41145", "drug": "DB00921"}, {"action": "ANTAGONIST", "target": "P41143", "drug": "DB00921"}]}, "DB08226": {"dbids": ["DB08226"], "name": "Myxopyronin B", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00928": {"dbids": ["APRD00809", "DB00928"], "name": "Azacitidine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P26358", "drug": "DB00928"}]}, "DB00929": {"dbids": ["APRD00037", "DB00929"], "name": "Misoprostol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P43115", "drug": "DB00929"}, {"action": "AGONIST", "target": "P43116", "drug": "DB00929"}, {"action": "AGONIST", "target": "P35408", "drug": "DB00929"}]}, "DB03963": {"dbids": ["DB03963", "EXPT00832"], "name": "S-(Dimethylarsenic)Cysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03962": {"dbids": ["DB03962", "EXPT02303"], "name": "Nicotinamide 8-Bromo-Adenine Dinucleotide Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03961": {"dbids": ["DB03961", "EXPT00871"], "name": "2c-Methyl-D-Erythritol 2,4-Cyclodiphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03960": {"dbids": ["DB03960", "EXPT01088"], "name": "Cp-Coeleneterazine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03967": {"dbids": ["DB03967", "EXPT02877"], "name": "Dodecyl Sulfate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03966": {"dbids": ["DB03966", "EXPT00847"], "name": "Clorobiocin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03964": {"dbids": ["DB03964", "EXPT00582"], "name": "4-Hydroxy-Aconitate Ion", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03969": {"dbids": ["DB03969", "EXPT02282"], "name": "3-Acetyl Pyridine Adenine Dinucleotide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03968": {"dbids": ["DB03968", "EXPT01911"], "name": "1-Methyl-2-Oxy-5,5-Dimethyl Pyrrolidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09559": {"dbids": ["DB09559"], "name": "Necitumumab", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P00533", "drug": "DB09559"}]}, "DB00975": {"dbids": ["APRD00360", "DB00975"], "name": "Dipyridamole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9Y233", "drug": "DB00975"}, {"action": "INHIBITOR", "target": "P00813", "drug": "DB00975"}, {"action": "INHIBITOR", "target": "O76074", "drug": "DB00975"}, {"action": "INHIBITOR", "target": "P27815", "drug": "DB00975"}]}, "DB09555": {"dbids": ["DB09555"], "name": "Dexchlorpheniramine maleate", "groups": ["APPROVED"], "targets": []}, "DB07062": {"dbids": ["DB07062"], "name": "N-{3-[4-hydroxy-1-(3-methylbutyl)-2-oxo-1,2-dihydropyrrolo[1,2-b]pyridazin-3-yl]-1,1-dioxido-2H-1,2,4-benzothiadiazin-7-yl}methanesulfonamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02322": {"dbids": ["DB02322", "EXPT01674"], "name": "Heparin Disaccharide I-S", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07060": {"dbids": ["DB07060"], "name": "3-(INDOL-3-YL) LACTATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07061": {"dbids": ["DB07061"], "name": "1-(CYCLOHEXYLAMINO)-3-(6-METHYL-3,4-DIHYDRO-1H-CARBAZOL-9(2H)-YL)PROPAN-2-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07066": {"dbids": ["DB07066"], "name": "2-CHLORO-N-[(3R)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07067": {"dbids": ["DB07067"], "name": "(2S,3S)-3-{3-[4-(METHYLSULFONYL)PHENYL]-1,2,4-OXADIAZOL-5-YL}-1-OXO-1-PYRROLIDIN-1-YLBUTAN-2-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07064": {"dbids": ["DB07064"], "name": "(4R)-4-(3-HYDROXYPHENYL)-N,N,7,8-TETRAMETHYL-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02323": {"dbids": ["DB02323", "EXPT01802"], "name": "EM-1745", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07068": {"dbids": ["DB07068"], "name": "(4-{4-[(TERT-BUTOXYCARBONYL)AMINO]-2,2-BIS(ETHOXYCARBONYL)BUTYL}PHENYL)SULFAMIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07069": {"dbids": ["DB07069"], "name": "3-Hydroxyhippuric acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02320": {"dbids": ["DB02320", "EXPT02300"], "name": "1-N-Acetyl-Beta-D-Glucosamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08926": {"dbids": ["DB08926"], "name": "Acediasulfone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02321": {"dbids": ["DB02321", "EXPT02779"], "name": "5-(3-Amino-4,4-Dihyroxy-Butylsulfanylmethyl)-Tetrahydro-Furan-2,3,4-Triol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08927": {"dbids": ["DB08927"], "name": "Amperozide", "groups": ["EXPERIMENTAL"], "targets": [{"action": "ANTAGONIST", "target": "P28223", "drug": "DB08927"}]}, "DB02326": {"dbids": ["DB02326", "DB07904", "EXPT01761"], "name": "1-Hydroxyamine-2-Isobutylmalonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08924": {"dbids": ["DB08924"], "name": "Amfecloral", "groups": ["APPROVED"], "targets": []}, "DB02327": {"dbids": ["DB02327", "EXPT02598"], "name": "2-[2-(2-Hydroxy-Ethoxy)-Ethoxy]-Ethanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08925": {"dbids": ["DB08925"], "name": "Adrafinil", "groups": ["WITHDRAWN"], "targets": []}, "DB02324": {"dbids": ["DB02324", "EXPT00249"], "name": "5-Iodo-2'-Deoxyuridine-5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08922": {"dbids": ["DB08922"], "name": "Perospirone", "groups": ["APPROVED"], "targets": []}, "DB02325": {"dbids": ["DB02325", "DB04402", "EXPT01912"], "name": "Isopropyl Alcohol", "groups": ["APPROVED"], "targets": []}, "DB08923": {"dbids": ["DB08923"], "name": "Epoetin Zeta", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P19235", "drug": "DB08923"}]}, "DB06836": {"dbids": ["DB06836"], "name": "N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06837": {"dbids": ["DB06837"], "name": "(2R)-N~4~-hydroxy-2-(3-hydroxybenzyl)-N~1~-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07604": {"dbids": ["DB07604"], "name": "(6AR,11AS,11BR)-10-ACETYL-9-HYDROXY-7,7-DIMETHYL-2,6,6A,7,11A,11B-HEXAHYDRO-11H-PYRROLO[1',2':2,3]ISOINDOLO[4,5,6-CD]INDOL-11-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06834": {"dbids": ["DB06834"], "name": "N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06835": {"dbids": ["DB06835"], "name": "(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-{(S)-HYDROXY[(1R)-2-METHYL-1-{[(2-PHENYLETHYL)SULFONYL]AMINO}PROPYL]PHOSPHORYL}PROPANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08387": {"dbids": ["DB08387"], "name": "2-{[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06832": {"dbids": ["DB06832"], "name": "2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06833": {"dbids": ["DB06833"], "name": "1-CYCLOHEXYL-N-{[1-(4-METHYLPHENYL)-1H-INDOL-3-YL]METHYL}METHANAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08207": {"dbids": ["DB08207"], "name": "2-(3,5-DIMETHYLPHENYL)-1,3-BENZOXAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08206": {"dbids": ["DB08206"], "name": "4-(1,3-BENZOXAZOL-2-YL)-2,6-DIBROMOPHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08205": {"dbids": ["DB08205"], "name": "4-(1,3-BENZOXAZOL-2-YL)-2,6-DIMETHYLPHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08204": {"dbids": ["DB08204"], "name": "3-DIPHENOL-6-NITRO-3H-BENZO[DE]ISOCHROMEN-1-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08203": {"dbids": ["DB08203"], "name": "7-[2-METHOXY-1-(METHOXYMETHYL)ETHYL]-7H-PYRROLO[3,2-F] QUINAZOLINE-1,3-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06830": {"dbids": ["DB06830"], "name": "(1-HYDROXYHEPTANE-1,1-DIYL)BIS(PHOSPHONIC ACID)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08201": {"dbids": ["DB08201"], "name": "(1S)-MENTHYL HEXYL PHOSPHONATE GROUP", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08200": {"dbids": ["DB08200"], "name": "(1R)-MENTHYL HEXYL PHOSPHONATE GROUP", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06831": {"dbids": ["DB06831"], "name": "2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08209": {"dbids": ["DB08209"], "name": "2-(4-DIMETHYLAMINOPHENYL)DIAZENYLBENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08208": {"dbids": ["DB08208"], "name": "2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08809": {"dbids": ["DB08809"], "name": "Dichloroacetic Acid", "groups": ["EXPERIMENTAL"], "targets": [{"action": "INHIBITOR", "target": "Q15118", "drug": "DB08809"}]}, "DB05528": {"dbids": ["DB05528"], "name": "Mipomersen", "groups": ["APPROVED"], "targets": []}, "DB05839": {"dbids": ["DB05839"], "name": "BG-777", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05838": {"dbids": ["DB05838"], "name": "OPC-51803", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05837": {"dbids": ["DB05837"], "name": "OSI-7836", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05836": {"dbids": ["DB05836"], "name": "AG-702", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05835": {"dbids": ["DB05835"], "name": "NS-3728", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05834": {"dbids": ["DB05834"], "name": "OC-1012", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05521": {"dbids": ["DB05521"], "name": "Telaprevir", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "B0B3C9", "drug": "DB05521"}]}, "DB05832": {"dbids": ["DB05832"], "name": "PPI-1019", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05831": {"dbids": ["DB05831"], "name": "ING-1", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05830": {"dbids": ["DB05830"], "name": "7a-methyl-19-nortestosterone", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06335": {"dbids": ["DB06335"], "name": "Saxagliptin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P27487", "drug": "DB06335"}]}, "DB03789": {"dbids": ["DB03789", "EXPT01226"], "name": "2,3-Dimethylimidazolium Ion", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03788": {"dbids": ["DB03788", "EXPT01522"], "name": "GC-24", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03787": {"dbids": ["DB03787", "EXPT02011"], "name": "L-Pyridoxyl-N,O-Cycloserylamide-5-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00889": {"dbids": ["APRD01002", "DB00889"], "name": "Granisetron", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P46098", "drug": "DB00889"}]}, "DB03785": {"dbids": ["DB03785", "EXPT02067"], "name": "(3r,5r)-7-((1r,2r,6s,8r,8as)-2,6-Dimethyl-8-{[(2r)-2-Methylbutanoyl]Oxy}-1,2,6,7,8,8a-Hexahydronaphthalen-1-Yl)-3,5-Dihydroxyheptanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03784": {"dbids": ["DB03784", "EXPT01336"], "name": "Elaidoylamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03783": {"dbids": ["DB03783", "DB08243", "EXPT03306"], "name": "Phenacetin", "groups": ["WITHDRAWN"], "targets": []}, "DB03782": {"dbids": ["DB03782", "EXPT00454"], "name": "N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03781": {"dbids": ["DB03781", "EXPT01094"], "name": "2-[4-(2,4-Dichlorophenoxy)Phenoxy]Propanoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03780": {"dbids": ["DB03780", "EXPT00551"], "name": "2-Aminoquinazolin-4(3h)-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00885": {"dbids": ["APRD00394", "DB00885"], "name": "Pemirolast", "groups": ["APPROVED"], "targets": []}, "DB00668": {"dbids": ["APRD00450", "DB00668", "EXPT00496"], "name": "Epinephrine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35348", "drug": "DB00668"}, {"action": "AGONIST", "target": "P35368", "drug": "DB00668"}, {"action": "AGONIST", "target": "P08588", "drug": "DB00668"}, {"action": "AGONIST", "target": "P07550", "drug": "DB00668"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00668"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00668"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00668"}, {"action": "ANTAGONIST", "target": "P00439", "drug": "DB00668"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00668"}, {"action": "AGONIST", "target": "P13945", "drug": "DB00668"}, {"action": "ANTAGONIST", "target": "P01375", "drug": "DB00668"}]}, "DB07367": {"dbids": ["DB07367"], "name": "(3Z,5S,6R,7S,8S,8aR)-3-(octylimino)hexahydro[1,3]oxazolo[3,4-a]pyridine-5,6,7,8-tetrol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05789": {"dbids": ["DB05789"], "name": "MX6", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07366": {"dbids": ["DB07366"], "name": "2-[N'-(4-AMINO-BUTYL)-HYDRAZINOCARBONYL]-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05781": {"dbids": ["DB05781"], "name": "AC-1202", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05780": {"dbids": ["DB05780"], "name": "ATX-101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05785": {"dbids": ["DB05785"], "name": "LGD-1550", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05787": {"dbids": ["DB05787"], "name": "LM-609", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05786": {"dbids": ["DB05786"], "name": "MGI-114", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB07363": {"dbids": ["DB07363"], "name": "THIOPHENE-2,5-DISULFONIC ACID 2-AMIDE-5-(4-METHYL-BENZYLAMIDE)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09338": {"dbids": ["DB09338"], "name": "Mersalyl", "groups": ["APPROVED"], "targets": []}, "DB07362": {"dbids": ["DB07362"], "name": "1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02784": {"dbids": ["DB02784", "EXPT01429"], "name": "N-[4-(2-{2-[3-(2-Bromo-Acetylamino)-Propionylamino]-3-Hydroxy-Propionylamino}-Ethyl)-Phenyl]-Oxalamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02785": {"dbids": ["DB02785", "EXPT00175"], "name": "N-[2(S)-Cyclopentyl-1(R)-Hydroxy-3(R)Methyl]-5-[(2(S)-Tertiary-Butylamino-Carbonyl)-4-(N1-(2)-(N-Methylpiperazinyl)-3-Chloro-Pyrazinyl-5-Carbonyl)-Piperazino]-4(S)-Hydroxy-2(R)-Phenylmethyl-Pentanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02786": {"dbids": ["DB02786", "EXPT01387"], "name": "2-Anhydro-3-Fluoro-Quinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02787": {"dbids": ["DB02787", "EXPT02197"], "name": "N-Acetylmannosaminitol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02780": {"dbids": ["DB02780", "EXPT00644"], "name": "Beta-3-Cysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02781": {"dbids": ["DB02781", "EXPT01022"], "name": "4-{(Z)-[2-[3-(Methylsulfanyl)Propanoyl]-5-Oxo-1-(2-Oxoethyl)-1,5-Dihydro-4h-Imidazol-4-Ylidene]Methyl}Benzenolate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02783": {"dbids": ["DB02783", "EXPT01857"], "name": "4'-Deoxy-4'-Acetylyamino-Pyridoxal-5'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02788": {"dbids": ["DB02788", "EXPT01702"], "name": "S,3-Hydroxybutan-2-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02789": {"dbids": ["DB02789", "EXPT02608"], "name": "Pregnenolone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04944": {"dbids": ["DB04944"], "name": "Acadesine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB02438": {"dbids": ["DB02438", "EXPT00180"], "name": "3-O-Methylfructose in Linear Form", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02436": {"dbids": ["DB02436", "EXPT01899"], "name": "2-{4-[(2s)-2-[({[(1s)-1-Carboxy-2-Phenylethyl]Amino}Carbonyl)Amino]-3-Oxo-3-(Pentylamino)Propyl]Phenoxy}Malonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02437": {"dbids": ["DB02437", "EXPT02012"], "name": "(5r)-5-Amino-6-Hydroxyhexylcarbamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02434": {"dbids": ["DB02434", "EXPT00230"], "name": "4-(2-Thienyl)Butyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02435": {"dbids": ["DB02435", "EXPT00505"], "name": "Aminomethylcyclohexane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02432": {"dbids": ["DB02432", "EXPT00339"], "name": "RU90395", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02433": {"dbids": ["DB02433", "EXPT02492"], "name": "{[(2,2-Dihydroxy-Ethyl)-(2,3,4,5-Tetrahydroxy-6-Phosphonooxy-Hexyl)-Amino]-Methyl}-Phosphonic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02430": {"dbids": ["DB02430", "EXPT02998"], "name": "Trehalose-6-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02431": {"dbids": ["DB02431", "EXPT01053"], "name": "Cytidine-5'-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08388": {"dbids": ["DB08388"], "name": "5-(2-ETHOXYETHYL)-5-[4-(4-FLUOROPHENOXY)PHENOXY]PYRIMIDINE-2,4,6(1H,3H,5H)-TRIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08389": {"dbids": ["DB08389"], "name": "6,7-DIMETHOXY-4-[(3R)-3-(2-NAPHTHYLOXY)PYRROLIDIN-1-YL]QUINAZOLINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09033": {"dbids": ["DB09033"], "name": "Vedolizumab", "groups": ["APPROVED"], "targets": [{"action": "ANTIBODY", "target": "P13612", "drug": "DB09033"}, {"action": "ANTIBODY", "target": "P26010", "drug": "DB09033"}]}, "DB09031": {"dbids": ["DB09031"], "name": "Miltefosine", "groups": ["APPROVED"], "targets": []}, "DB09030": {"dbids": ["DB09030"], "name": "Vorapaxar", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P25116", "drug": "DB09030"}]}, "DB09037": {"dbids": ["DB09037"], "name": "Pembrolizumab", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q15116", "drug": "DB09037"}, {"action": "ANTIBODY", "target": "Q15116", "drug": "DB09037"}]}, "DB09036": {"dbids": ["DB09036"], "name": "Siltuximab", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P05231", "drug": "DB09036"}, {"action": "ANTIBODY", "target": "P05231", "drug": "DB09036"}]}, "DB09035": {"dbids": ["DB09035"], "name": "Nivolumab", "groups": ["APPROVED"], "targets": [{"action": "ANTIBODY", "target": "Q15116", "drug": "DB09035"}]}, "DB09034": {"dbids": ["DB09034"], "name": "Suvorexant", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "O43613", "drug": "DB09034"}, {"action": "ANTAGONIST", "target": "O43614", "drug": "DB09034"}]}, "DB09039": {"dbids": ["DB09039"], "name": "Eliglustat", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q16739", "drug": "DB09039"}]}, "DB09038": {"dbids": ["DB09038"], "name": "Empagliflozin", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P31639", "drug": "DB09038"}, {"action": "INHIBITOR", "target": "P31639", "drug": "DB09038"}]}, "DB01200": {"dbids": ["APRD00622", "DB01200"], "name": "Bromocriptine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P14416", "drug": "DB01200"}, {"action": "AGONIST", "target": "P35462", "drug": "DB01200"}, {"action": "AGONIST", "target": "P28221", "drug": "DB01200"}, {"action": "AGONIST", "target": "P08913", "drug": "DB01200"}, {"action": "AGONIST", "target": "P08908", "drug": "DB01200"}, {"action": "AGONIST", "target": "P18825", "drug": "DB01200"}, {"action": "AGONIST", "target": "P18089", "drug": "DB01200"}, {"action": "AGONIST", "target": "P41595", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB01200"}, {"action": "AGONIST", "target": "P28223", "drug": "DB01200"}, {"action": "AGONIST", "target": "P28222", "drug": "DB01200"}, {"action": "AGONIST", "target": "P28335", "drug": "DB01200"}, {"action": "AGONIST", "target": "P21918", "drug": "DB01200"}, {"action": "AGONIST", "target": "P21728", "drug": "DB01200"}, {"action": "AGONIST", "target": "P35348", "drug": "DB01200"}, {"action": "AGONIST", "target": "P35368", "drug": "DB01200"}, {"action": "AGONIST", "target": "P25100", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB01200"}]}, "DB01201": {"dbids": ["APRD01217", "DB01201"], "name": "Rifapentine", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P0A674", "drug": "DB01201"}]}, "DB01202": {"dbids": ["APRD01068", "DB01202"], "name": "Levetiracetam", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "Q7L0J3", "drug": "DB01202"}, {"action": "INHIBITOR", "target": "Q00975", "drug": "DB01202"}]}, "DB01203": {"dbids": ["APRD00301", "DB01203"], "name": "Nadolol", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P08588", "drug": "DB01203"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB01203"}]}, "DB01204": {"dbids": ["APRD00371", "DB01204"], "name": "Mitoxantrone", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P11388", "drug": "DB01204"}]}, "DB01205": {"dbids": ["APRD00974", "DB01205"], "name": "Flumazenil", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14867", "drug": "DB01205"}, {"action": "ANTAGONIST", "target": "P18507", "drug": "DB01205"}, {"action": "ANTAGONIST", "target": "P31644", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01205"}]}, "DB01206": {"dbids": ["APRD00292", "DB01206"], "name": "Lomustine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q9H169", "drug": "DB01206"}]}, "DB01207": {"dbids": ["APRD00271", "DB01207"], "name": "Ridogrel", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P21731", "drug": "DB01207"}, {"action": "INHIBITOR", "target": "P24557", "drug": "DB01207"}]}, "DB01208": {"dbids": ["APRD01231", "DB01208"], "name": "Sparfloxacin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P43702", "drug": "DB01208"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB01208"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB01208"}]}, "DB01209": {"dbids": ["APRD00912", "DB01209"], "name": "Dezocine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB01209"}, {"action": "ANTAGONIST", "target": "P41145", "drug": "DB01209"}]}, "DB09255": {"dbids": ["DB09255"], "name": "Dextran", "groups": ["APPROVED"], "targets": []}, "DB04492": {"dbids": ["DB04492", "EXPT02336"], "name": "2-(Acetylamino)-2-Deoxy-4-O-Sulfo-Alpha-D-Galactopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04493": {"dbids": ["DB04493", "EXPT01383"], "name": "Fructose-6-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04490": {"dbids": ["DB04490", "EXPT02713"], "name": "3-(Mercaptomethylene)Pyridine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04491": {"dbids": ["DB04491", "EXPT01171"], "name": "Diisopropylphosphono Group", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04496": {"dbids": ["DB04496", "EXPT02772"], "name": "4-Phospho-D-Erythronohydroxamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04497": {"dbids": ["DB04497", "EXPT00548"], "name": "2'-Monophosphoadenosine-5'-Diphosphoribose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04494": {"dbids": ["DB04494", "EXPT02435"], "name": "Mo(Vi)(=O)(Oh)2 Cluster", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04495": {"dbids": ["DB04495", "EXPT00324"], "name": "RU81843", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04498": {"dbids": ["DB04498", "EXPT00566"], "name": "Aspartate Semialdehyde", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04499": {"dbids": ["DB04499", "EXPT02820"], "name": "R-Styrene Oxide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08782": {"dbids": ["DB08782"], "name": "4-(2-AMINOETHYL)BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08783": {"dbids": ["DB08783"], "name": "(4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08780": {"dbids": ["DB08780"], "name": "6-MORPHOLIN-4-YL-9H-PURINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08781": {"dbids": ["DB08781"], "name": "1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08786": {"dbids": ["DB08786"], "name": "4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08787": {"dbids": ["DB08787"], "name": "4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08784": {"dbids": ["DB08784"], "name": "2-(4-CHLORO-PHENYLAMINO)-NICOTINIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08785": {"dbids": ["DB08785"], "name": "4-METHYL-2H-CHROMEN-2-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08788": {"dbids": ["DB08788"], "name": "3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08789": {"dbids": ["DB08789"], "name": "2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06924": {"dbids": ["DB06924"], "name": "(2R)-2-benzyl-3-nitropropanoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06925": {"dbids": ["DB06925"], "name": "3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06926": {"dbids": ["DB06926"], "name": "(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06927": {"dbids": ["DB06927"], "name": "[5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00009": {"dbids": ["BIOD00050", "BTD00050", "DB00009"], "name": "Alteplase", "groups": ["APPROVED"], "targets": [{"action": "ACTIVATOR", "target": "P00747", "drug": "DB00009"}]}, "DB00008": {"dbids": ["BIOD00043", "BTD00043", "DB00008"], "name": "Peginterferon alfa-2a", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P48551", "drug": "DB00008"}, {"action": "AGONIST", "target": "P17181", "drug": "DB00008"}]}, "DB00559": {"dbids": ["APRD00829", "DB00559"], "name": "Bosentan", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P25101", "drug": "DB00559"}, {"action": "ANTAGONIST", "target": "P24530", "drug": "DB00559"}]}, "DB00558": {"dbids": ["APRD00378", "DB00558"], "name": "Zanamivir", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P06818", "drug": "DB00558"}, {"action": "INHIBITOR", "target": "P27907", "drug": "DB00558"}, {"action": "INHIBITOR", "target": "Q9Y3R4", "drug": "DB00558"}]}, "DB00557": {"dbids": ["APRD00688", "DB00557"], "name": "Hydroxyzine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00557"}]}, "DB00556": {"dbids": ["APRD01177", "DB00556"], "name": "Perflutren", "groups": ["APPROVED"], "targets": []}, "DB00555": {"dbids": ["APRD00570", "DB00555"], "name": "Lamotrigine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "Q99250", "drug": "DB00555"}]}, "DB00554": {"dbids": ["APRD01187", "DB00554"], "name": "Piroxicam", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00554"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00554"}]}, "DB00553": {"dbids": ["APRD00157", "DB00553"], "name": "Methoxsalen", "groups": ["APPROVED"], "targets": []}, "DB00552": {"dbids": ["APRD00202", "DB00552"], "name": "Pentostatin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P00813", "drug": "DB00552"}]}, "DB00551": {"dbids": ["APRD00774", "DB00551", "EXPT01688"], "name": "Acetohydroxamic Acid", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P18314", "drug": "DB00551"}, {"action": "INHIBITOR", "target": "P39900", "drug": "DB00551"}]}, "DB00550": {"dbids": ["APRD00297", "DB00550"], "name": "Propylthiouracil", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P07202", "drug": "DB00550"}]}, "DB03208": {"dbids": ["DB03208", "EXPT01589"], "name": "Beta-1,2,3,4,6-Penta-O-Galloyl-D-Glucopyranose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03209": {"dbids": ["DB03209", "EXPT02456"], "name": "Oteracil", "groups": ["APPROVED"], "targets": []}, "DB03202": {"dbids": ["DB03202", "EXPT03043"], "name": "2-[5-Methanesulfonylamino-2-(4-Aminophenyl)-6-Oxo-1,6-Dihydro-1-Pyrimidinyl]-N-(3,3,3-Trifluoro-1-Isopropyl-2-Oxopropyl)Acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03203": {"dbids": ["DB03203", "EXPT02945"], "name": "Sphingosine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03200": {"dbids": ["DB03200", "EXPT00316"], "name": "7-Alpha-D-Ribofuranosyl-Purine-5'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03201": {"dbids": ["DB03201", "EXPT01139"], "name": "D-Cysteine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03206": {"dbids": ["DB03206", "EXPT01227", "EXPT01236", "EXPT02374"], "name": "1-Deoxynojirimycin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03207": {"dbids": ["DB03207", "EXPT00763"], "name": "2-(Biphenyl-4-Sulfonyl)-1,2,3,4-Tetrahydro-Isoquinoline-3-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03204": {"dbids": ["DB03204", "EXPT02389"], "name": "5-(Aminomethyl)-2-Methylpyrimidin-4-Amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03205": {"dbids": ["DB03205", "EXPT02652"], "name": "Pyrroloquinoline Quinone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04278": {"dbids": ["DB04278", "EXPT02368"], "name": "2-[2-(2-Cyclohexyl-2-Guanidino-Acetylamino)-Acetylamino]-N-(3-Mercapto-Propyl)-Propionamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04279": {"dbids": ["DB04279", "EXPT01919"], "name": "3-Isopropylmalic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04276": {"dbids": ["DB04276", "EXPT01317"], "name": "N-[N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-Butyl]-Guanidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04277": {"dbids": ["DB04277", "EXPT01384"], "name": "Fructose -6-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04274": {"dbids": ["DB04274", "EXPT01141"], "name": "5,4'-Dideoxyflavanone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04275": {"dbids": ["DB04275", "EXPT00570"], "name": "N-Acetyl Serotonin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04272": {"dbids": ["DB04272", "EXPT00922"], "name": "Citric Acid", "groups": ["NUTRACEUTICAL"], "targets": []}, "DB04273": {"dbids": ["DB04273", "EXPT02072"], "name": "8,9-Dichloro-2,3,4,5-Tetrahydro-1h-Benzo[C]Azepine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04270": {"dbids": ["DB04270", "EXPT03276"], "name": "(S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04271": {"dbids": ["DB04271", "EXPT01155"], "name": "3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02159": {"dbids": ["DB02159", "EXPT02574"], "name": "R-1,2-Propanediol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02158": {"dbids": ["DB02158", "EXPT02247"], "name": "(1s)-1-(9-Deazaadenin-9-Yl)-1,4,5-Trideoxy-1,4-Imino-5-Methylthio-D-Ribitol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02151": {"dbids": ["DB02151", "EXPT02221"], "name": "Methionine Phosphonate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02153": {"dbids": ["DB02153", "EXPT01032"], "name": "3-Sulfinoalanine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02152": {"dbids": ["DB02152", "EXPT01983"], "name": "K-252a", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02155": {"dbids": ["DB02155", "EXPT00615"], "name": "Balanol Analog 8", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02154": {"dbids": ["DB02154", "EXPT00654"], "name": "2,3-Bis-Benzo[1,3]Dioxol-5-Ylmethyl-Succinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02156": {"dbids": ["DB02156", "EXPT02950"], "name": "Sulfopyruvate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02847": {"dbids": ["DB02847", "EXPT03122"], "name": "(2s,3r)-1-Amino-2-Methylbutane-2,3-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02846": {"dbids": ["DB02846", "EXPT02664"], "name": "Thioproline", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02845": {"dbids": ["DB02845", "DB04390", "EXPT02226"], "name": "Methylphosphinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02844": {"dbids": ["DB02844", "EXPT00386"], "name": "S-Adenosyl-1,8-Diamino-3-Thiooctane", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02843": {"dbids": ["DB02843", "EXPT01520"], "name": "Alpha-D-Glucose-1-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02842": {"dbids": ["DB02842", "EXPT00308"], "name": "Aminacrine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02333": {"dbids": ["DB02333", "EXPT01301"], "name": "Deoxyuridine-5'-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02840": {"dbids": ["DB02840", "EXPT00204"], "name": "4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02339": {"dbids": ["DB02339", "EXPT02742"], "name": "Allyl-{6-[3-(4-Bromo-Phenyl)-Benzofuran-6-Yloxy]-Hexyl-}-Methyl-Amin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02338": {"dbids": ["DB02338", "EXPT02321"], "name": "Nadph Dihydro-Nicotinamide-Adenine-Dinucleotidephosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02849": {"dbids": ["DB02849", "EXPT00257"], "name": "N-Pyridoxyl-1-Amino-Cyclopropanecarboxylic Acid-5-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02848": {"dbids": ["DB02848", "EXPT02557"], "name": "{4-[3-(6,7-Diethoxy-Quinazolin-4-Ylamino)-Phenyl]-Thiazol-2-Yl}-Methanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08508": {"dbids": ["DB08508"], "name": "N-BENZOYL-D-ALANINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08509": {"dbids": ["DB08509"], "name": "1-[6-(2-CHLORO-4-METHYXYPHENOXY)-HEXYL]-IMIDAZOLE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07868": {"dbids": ["DB07868"], "name": "6-CHLORO-4-(CYCLOHEXYLSULFANYL)-3-PROPYLQUINOLIN-2(1H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07869": {"dbids": ["DB07869"], "name": "6-CHLORO-4-(CYCLOHEXYLSULFINYL)-3-PROPYLQUINOLIN-2(1H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07862": {"dbids": ["DB07862"], "name": "7-(1-ETHYL-PROPYL)-7H-PYRROLO-[3,2-F]QUINAZOLINE-1,3-DIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07863": {"dbids": ["DB07863"], "name": "2-chloro-5-nitro-N-phenylbenzamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07860": {"dbids": ["DB07860"], "name": "(2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07861": {"dbids": ["DB07861"], "name": "(2R)-N-hydroxy-3-naphthalen-2-yl-2-[(naphthalen-2-ylsulfonyl)amino]propanamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07866": {"dbids": ["DB07866"], "name": "(5S)-2-(cyclooctylamino)-5-methyl-5-propyl-1,3-thiazol-4(5H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07867": {"dbids": ["DB07867"], "name": "6-CHLORO-4-(CYCLOHEXYLOXY)-3-PROPYLQUINOLIN-2(1H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07864": {"dbids": ["DB07864"], "name": "4-[(CYCLOPROPYLETHYNYL)OXY]-6-FLUORO-3-ISOPROPYLQUINOLIN-2(1H)-ONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07865": {"dbids": ["DB07865"], "name": "3-(1H-tetrazol-5-ylamino)cyclohex-2-en-1-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07730": {"dbids": ["DB07730"], "name": "5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05312": {"dbids": ["DB05312"], "name": "NVS antibody", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05313": {"dbids": ["DB05313"], "name": "MP4", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05310": {"dbids": ["DB05310"], "name": "FP-1096", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05311": {"dbids": ["DB05311"], "name": "Ecallantide", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P03952", "drug": "DB05311"}]}, "DB05316": {"dbids": ["DB05316"], "name": "Pimavanserin", "groups": ["INVESTIGATIONAL"], "targets": [{"action": "INVERSE AGONIST", "target": "P28223", "drug": "DB05316"}]}, "DB05317": {"dbids": ["DB05317"], "name": "TAK-475", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05314": {"dbids": ["DB05314"], "name": "DN-101", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05315": {"dbids": ["DB05315"], "name": "MC-1", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05318": {"dbids": ["DB05318"], "name": "NGX-4010", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05319": {"dbids": ["DB05319"], "name": "oportuzumab monatox", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05649": {"dbids": ["DB05649"], "name": "NTx-265", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06768": {"dbids": ["DB06768"], "name": "Ammonium lactate", "groups": ["APPROVED"], "targets": []}, "DB02000": {"dbids": ["DB02000", "EXPT00947"], "name": "Gamma-Phenyl-Butyric Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04113": {"dbids": ["DB04113", "EXPT01477"], "name": "N-Formylpiperidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04112": {"dbids": ["DB04112", "EXPT01881"], "name": "1-Octadecyl-2-Acetamido-2-Deoxy-Sn-Glycerol-3-Phosphoethylmethyl Sulfide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01471": {"dbids": ["DB01471"], "name": "Bolasterone", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01470": {"dbids": ["DB01470"], "name": "\u03b1-methylthiofentanyl", "groups": ["ILLICIT"], "targets": []}, "DB04117": {"dbids": ["DB04117", "EXPT01108"], "name": "4-(N,N-Dimethylamino)Cinnamoyl-Coa", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04116": {"dbids": ["DB04116", "EXPT01999"], "name": "Allolactose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01475": {"dbids": ["DB01475"], "name": "Dioxaphetyl butyrate", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB08500": {"dbids": ["DB08500"], "name": "(3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01474": {"dbids": ["DB01474"], "name": "17Alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01479": {"dbids": ["DB01479"], "name": "17Alpha-methyl-3alpha,17beta-dihydroxy-5alpha-androstane", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01478": {"dbids": ["DB01478"], "name": "desmethylprodine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB08501": {"dbids": ["DB08501"], "name": "DIETHYL PROPANE-1,3-DIYLBISCARBAMATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00953": {"dbids": ["APRD00008", "DB00953"], "name": "Rizatriptan", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P28221", "drug": "DB00953"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00953"}, {"action": "AGONIST", "target": "P30939", "drug": "DB00953"}]}, "DB09372": {"dbids": ["DB09372"], "name": "Tannic acid", "groups": ["APPROVED"], "targets": []}, "DB00952": {"dbids": ["APRD00220", "DB00952"], "name": "Naratriptan", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P28221", "drug": "DB00952"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00952"}, {"action": "AGONIST", "target": "P30939", "drug": "DB00952"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00952"}]}, "DB09374": {"dbids": ["DB09374"], "name": "Indocyanine green", "groups": ["APPROVED"], "targets": []}, "DB07267": {"dbids": ["DB07267"], "name": "2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06016": {"dbids": ["DB06016"], "name": "Cariprazine", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35462", "drug": "DB06016"}, {"action": "PARTIAL AGONIST", "target": "P35462", "drug": "DB06016"}, {"action": "AGONIST", "target": "P14416", "drug": "DB06016"}, {"action": "PARTIAL AGONIST", "target": "P14416", "drug": "DB06016"}, {"action": "AGONIST", "target": "P08908", "drug": "DB06016"}, {"action": "PARTIAL AGONIST", "target": "P08908", "drug": "DB06016"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB06016"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB06016"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB06016"}]}, "DB04063": {"dbids": ["DB04063", "EXPT00130"], "name": "2-Methylleucine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04062": {"dbids": ["DB04062", "EXPT01401"], "name": "Beta-D-Fucose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01541": {"dbids": ["DB01541"], "name": "Boldenone", "groups": ["ILLICIT"], "targets": [{"action": "AGONIST", "target": "P10275", "drug": "DB01541"}]}, "DB01016": {"dbids": ["APRD00233", "DB01016"], "name": "Glyburide", "groups": ["APPROVED"], "targets": [{"action": "MODULATOR", "target": "Q09428", "drug": "DB01016"}, {"action": "INHIBITOR", "target": "P48048", "drug": "DB01016"}, {"action": "INHIBITOR", "target": "P48544", "drug": "DB01016"}, {"action": "MODULATOR", "target": "O60706", "drug": "DB01016"}, {"action": "INHIBITOR", "target": "O95342", "drug": "DB01016"}, {"action": "INHIBITOR", "target": "O95477", "drug": "DB01016"}, {"action": "ANTAGONIST", "target": "P13569", "drug": "DB01016"}, {"action": "MODULATOR", "target": "Q14654", "drug": "DB01016"}]}, "DB04067": {"dbids": ["DB04067", "EXPT00207"], "name": "4-Hydroxybenzyl Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01546": {"dbids": ["DB01546"], "name": "Alpha-ethyltryptamine", "groups": ["ILLICIT", "INVESTIGATIONAL", "WITHDRAWN"], "targets": []}, "DB04065": {"dbids": ["DB04065", "EXPT00857"], "name": "N-Cyclopentyl-N-Cyclobutylformamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04064": {"dbids": ["DB04064", "EXPT02339"], "name": "Nogalaviketone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01549": {"dbids": ["DB01549"], "name": "Rolicyclidine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": []}, "DB01548": {"dbids": ["DB01548"], "name": "Diprenorphine", "groups": ["EXPERIMENTAL", "ILLICIT"], "targets": [{"action": "ANTAGONIST", "target": "P35372", "drug": "DB01548"}, {"action": "ANTAGONIST", "target": "P41143", "drug": "DB01548"}, {"action": "ANTAGONIST", "target": "P41145", "drug": "DB01548"}]}, "DB01019": {"dbids": ["APRD00051", "DB01019"], "name": "Bethanechol", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P08172", "drug": "DB01019"}]}, "DB01018": {"dbids": ["APRD00075", "DB01018"], "name": "Guanfacine", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "AGONIST", "target": "P08913", "drug": "DB01018"}, {"action": "BINDER", "target": "P18089", "drug": "DB01018"}]}, "DB08504": {"dbids": ["DB08504"], "name": "6-(4-{(1S,2S)-2-AMINO-1-[(DIMETHYLAMINO)CARBONYL]-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-3-OXOPROPYL}PHENYL)-1H-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-4-IUM", "groups": ["EXPERIMENTAL"], "targets": []}, "DB00764": {"dbids": ["APRD00289", "DB00764"], "name": "Mometasone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00764"}]}, "DB00765": {"dbids": ["APRD01112", "DB00765"], "name": "Metyrosine", "groups": ["APPROVED"], "targets": [{"action": "BINDER", "target": "P07101", "drug": "DB00765"}]}, "DB00766": {"dbids": ["APRD00049", "DB00766"], "name": "Clavulanate", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P00807", "drug": "DB00766"}]}, "DB00767": {"dbids": ["APRD00820", "DB00767"], "name": "Benzquinamide", "groups": ["WITHDRAWN"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00767"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00767"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00767"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00767"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00767"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00767"}]}, "DB00760": {"dbids": ["APRD01097", "DB00760", "EXPT02153"], "name": "Meropenem", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P24228", "drug": "DB00760"}]}, "DB00761": {"dbids": ["APRD01322", "DB00761"], "name": "Potassium Chloride", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "BINDER", "target": "Q13621", "drug": "DB00761"}]}, "DB00762": {"dbids": ["APRD00579", "DB00762"], "name": "Irinotecan", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P11387", "drug": "DB00762"}, {"action": "INHIBITOR", "target": "Q969P6", "drug": "DB00762"}]}, "DB00763": {"dbids": ["APRD00002", "DB00763"], "name": "Methimazole", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P07202", "drug": "DB00763"}]}, "DB00948": {"dbids": ["APRD01113", "DB00948"], "name": "Mezlocillin", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB00948"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00948"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB00948"}]}, "DB00949": {"dbids": ["APRD00505", "DB00949"], "name": "Felbamate", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q13224", "drug": "DB00949"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00949"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB00949"}]}, "DB00768": {"dbids": ["APRD00310", "DB00768"], "name": "Olopatadine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P35367", "drug": "DB00768"}, {"action": "ANTAGONIST", "target": "P23297", "drug": "DB00768"}, {"action": "ANTAGONIST", "target": "P80511", "drug": "DB00768"}, {"action": "OTHER/UNKNOWN", "target": "P04271", "drug": "DB00768"}, {"action": "OTHER/UNKNOWN", "target": "Q99584", "drug": "DB00768"}, {"action": "ANTAGONIST", "target": "P29034", "drug": "DB00768"}]}, "DB00769": {"dbids": ["APRD01018", "DB00769"], "name": "Hydrocortamate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P04150", "drug": "DB00769"}]}, "DB08505": {"dbids": ["DB08505"], "name": "methyl 4-bromo-N-[8-(hydroxyamino)-8-oxooctanoyl]-L-phenylalaninate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09570": {"dbids": ["DB09570"], "name": "Ixazomib", "groups": ["APPROVED"], "targets": []}, "DB09571": {"dbids": ["DB09571"], "name": "Levomethamphetamine", "groups": ["APPROVED"], "targets": []}, "DB03949": {"dbids": ["DB03949", "EXPT03061"], "name": "(2-Sulfanyl-3-Phenylpropanoyl)-Phe-Tyr", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03948": {"dbids": ["DB03948", "EXPT01004"], "name": "6-Chloropurine Riboside, 5'-Monophosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03945": {"dbids": ["DB03945", "EXPT02629"], "name": "Phosphocholine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03944": {"dbids": ["DB03944", "EXPT01339"], "name": "5-[1-(3,4-Dimethoxy-Benzoyl)-1,2,3,4-Tetrahydro-Quinolin-6-Yl]-6-Methyl-3,6-Dihydro-[1,3,4]Thiadiazin-2-One", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03947": {"dbids": ["DB03947", "EXPT03263"], "name": "D-Xylulose", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03946": {"dbids": ["DB03946", "EXPT01187"], "name": "3,4-Dihydroxybenzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03941": {"dbids": ["DB03941", "EXPT01353"], "name": "Heptanyl-P-Phenol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03940": {"dbids": ["DB03940", "EXPT02460"], "name": "Oxamic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03943": {"dbids": ["DB03943", "EXPT01274"], "name": "D-Asparagine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03942": {"dbids": ["DB03942", "EXPT02523"], "name": "Carboxylic PRPP", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07088": {"dbids": ["DB07088"], "name": "(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07089": {"dbids": ["DB07089"], "name": "N-[amino(imino)methyl]-2-[2-(2-chlorophenyl)-4-(4-propoxyphenyl)-3-thienyl]acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07084": {"dbids": ["DB07084"], "name": "N-(6,7,9,10,17,18,20,21-octahydrodibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecin-2-yl)acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07085": {"dbids": ["DB07085"], "name": "2-{[N-(2-ACETYL-5-CHLORO-4-FLUOROPHENYL)GLYCYL]AMINO}BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06403": {"dbids": ["DB06403"], "name": "Ambrisentan", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P25101", "drug": "DB06403"}, {"action": "ANTAGONIST", "target": "P24530", "drug": "DB06403"}]}, "DB07087": {"dbids": ["DB07087"], "name": "4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07080": {"dbids": ["DB07080"], "name": "N-(2,2,2-TRIFLUOROETHYL)-N-{4-[2,2,2-TRIFLUORO-1-HYDROXY-1-(TRIFLUOROMETHYL)ETHYL]PHENYL}BENZENESULFONAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07081": {"dbids": ["DB07081"], "name": "(2R)-4-[(8R)-8-METHYL-2-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[1,5-A]PYRAZIN-7(8H)-YL]-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07082": {"dbids": ["DB07082"], "name": "1,1,1,3,3,3-HEXAFLUORO-2-{4-[(2,2,2-TRIFLUOROETHYL)AMINO]PHENYL}PROPAN-2-OL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB07083": {"dbids": ["DB07083"], "name": "beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04332": {"dbids": ["DB04332", "EXPT01367"], "name": "2-{2-[2-2-(Methoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04623": {"dbids": ["DB04623"], "name": "2-ETHOXYETHYL (2S,3S)-4-((S)-2-BENZYL-3-OXO-4-((3AR,8R,8AS)-2-OXO-3,3A,8,8A-TETRAHYDRO-2H-INDENO[1,2-D]OXAZOL-8-YL)-2,3-DIHYDRO-1H-PYRROL-2-YL)-3-HYDROXY-1-PHENYLBUTAN-2-YLCARBAMATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04687": {"dbids": ["DB04687"], "name": "DIMETHYL THIOPHOSPHATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04686": {"dbids": ["DB04686"], "name": "CHROMOPHORE (ASP-TYR-GLY)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04685": {"dbids": ["DB04685"], "name": "1-{(2S,5S)-4-FLUORO-5-[(TRITYLOXY)METHYL]TETRAHYDROFURAN-2-YL}PYRIMIDINE-2,4(1H,3H)-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04684": {"dbids": ["DB04684"], "name": "BIS(HEXAMETHYLENE)TRIAMINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04683": {"dbids": ["DB04683"], "name": "(2R)-3-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-2-[(9E)-HEXADEC-9-ENOYLOXY]PROPYL (9E)-OCTADEC-9-ENOATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04682": {"dbids": ["DB04682"], "name": "Octylphenoxy polyethoxyethanol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04681": {"dbids": ["DB04681"], "name": "BETA-METHYLLACTOSIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04680": {"dbids": ["DB04680"], "name": "GALACTOSE GREASE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01976": {"dbids": ["DB01976", "EXPT00518"], "name": "Aminoanthracene", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04689": {"dbids": ["DB04689"], "name": "2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04688": {"dbids": ["DB04688"], "name": "ECGONINE METHYL ESTER", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08197": {"dbids": ["DB08197"], "name": "(5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08196": {"dbids": ["DB08196"], "name": "2-((3',5'-DIMETHOXY-4'-HYDROXYPHENYL)AZO)BENZOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08195": {"dbids": ["DB08195"], "name": "(1R)-2-[(CYANOMETHYL)AMINO]-1-({[2-(DIFLUOROMETHOXY)BENZYL]SULFONYL}METHYL)-2-OXOETHYL MORPHOLINE-4-CARBOXYLATE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08194": {"dbids": ["DB08194"], "name": "4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08193": {"dbids": ["DB08193"], "name": "2-(3-NITROPHENYL)ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04335": {"dbids": ["DB04335", "EXPT02378"], "name": "Inosine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB08191": {"dbids": ["DB08191"], "name": "4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08190": {"dbids": ["DB08190"], "name": "N-[2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl]acetamide", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04334": {"dbids": ["DB04334", "EXPT03094"], "name": "6-hydroxydopa quinone", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04018": {"dbids": ["DB04018", "EXPT01925"], "name": "S-Isopropyl-Isothiourea", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08199": {"dbids": ["DB08199"], "name": "N-[(BENZYLOXY)CARBONYL]-L-CYSTEINYLGLYCINE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08198": {"dbids": ["DB08198"], "name": "[(4R)-4-(3-HYDROXYPHENYL)-1,6-DIMETHYL-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL](PHENYL)METHANONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB01977": {"dbids": ["DB01977", "EXPT00275"], "name": "6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB06681": {"dbids": ["DB06681"], "name": "Belatacept", "groups": ["APPROVED"], "targets": []}, "DB06684": {"dbids": ["DB06684"], "name": "Vilazodone", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P08908", "drug": "DB06684"}]}, "DB03419": {"dbids": ["DB03419", "EXPT03201"], "name": "Uracil", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03418": {"dbids": ["DB03418", "EXPT01144"], "name": "Diacetyldeuteroheme", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03417": {"dbids": ["DB03417", "EXPT00047"], "name": "1-(4-Tert-Butylcarbamoyl-Piperazine-1-Carbonyl)-3-(3-Guanidino-Propyl)-4-Oxo-Azetidine-2-Carboxylic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03416": {"dbids": ["DB03416", "EXPT03096"], "name": "Thiamin Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03415": {"dbids": ["DB03415", "EXPT01029"], "name": "3-Thiaoctanoyl-Coenzyme A", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03414": {"dbids": ["DB03414", "EXPT02038"], "name": "5-Thio-a/B-D-Mannopyranosylamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03413": {"dbids": ["DB03413", "EXPT01297"], "name": "Deoxyuridine-5'-Diphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03412": {"dbids": ["DB03412", "EXPT02015"], "name": "6-Hydroxy-L-Norleucine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03411": {"dbids": ["DB03411", "EXPT01875"], "name": "2-Hydroxymethyl-Pyrrolidine-3,4-Diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB03410": {"dbids": ["DB03410", "EXPT00215"], "name": "4-hydroxycoumarin", "groups": ["EXPERIMENTAL"], "targets": []}, "DB04231": {"dbids": ["DB04231", "EXPT01867"], "name": "Tetra(Imidazole)Diaquacopper (I)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08221": {"dbids": ["DB08221"], "name": "N-{4-METHYL-3-[(3-PYRIMIDIN-4-YLPYRIDIN-2-YL)AMINO]PHENYL}-3-(TRIFLUOROMETHYL)BENZAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08220": {"dbids": ["DB08220"], "name": "(8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08223": {"dbids": ["DB08223"], "name": "N-{(1S,2R)-1-BENZYL-3-[(CYCLOPROPYLMETHYL)(2-FURYLSULFONYL)AMINO]-2-HYDROXYPROPYL}-N'-METHYLSUCCINAMIDE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08222": {"dbids": ["DB08222"], "name": "METHOXYUNDECYLPHOSPHINIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08224": {"dbids": ["DB08224"], "name": "(1S,7S,8S,8AR)-1,2,3,7,8,8A-HEXAHYDRO-7-METHYL-8-[2-[(2R,4R)-TETRAHYDRO-4-HY DROXY-6-OXO-2H-PYRAN-2-YL]ETHYL]-1-NAPHTHALENOL", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08227": {"dbids": ["DB08227"], "name": "1-(1-HYDROXY-2,2,6,6-TETRAMETHYLPIPERIDIN-4-YL)PYRROLIDINE-2,5-DIONE", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08130": {"dbids": ["DB08130"], "name": "N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08229": {"dbids": ["DB08229"], "name": "[N-(3-DIBENZYLCARBAMOYL-OXIRANECARBONYL)-HYDRAZINO]-ACETIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08228": {"dbids": ["DB08228"], "name": "5,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one", "groups": ["EXPERIMENTAL"], "targets": []}, "DB05819": {"dbids": ["DB05819"], "name": "NBI-6024", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05818": {"dbids": ["DB05818"], "name": "SGN-15", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB09449": {"dbids": ["DB09449"], "name": "Sodium phosphate", "groups": ["APPROVED"], "targets": []}, "DB05811": {"dbids": ["DB05811"], "name": "HSV-2 theracine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05810": {"dbids": ["DB05810"], "name": "99mTc-glucarate", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05813": {"dbids": ["DB05813"], "name": "autologous activated macrophage therapy", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05812": {"dbids": ["DB05812"], "name": "Abiraterone", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "P05093", "drug": "DB05812"}]}, "DB05815": {"dbids": ["DB05815"], "name": "GnRH pharmaccine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05814": {"dbids": ["DB05814"], "name": "GPI-1485", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05817": {"dbids": ["DB05817"], "name": "VNP 40101M", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB05816": {"dbids": ["DB05816"], "name": "intranasal apomorphine", "groups": ["INVESTIGATIONAL"], "targets": []}, "DB06402": {"dbids": ["DB06402"], "name": "Telavancin", "groups": ["APPROVED"], "targets": []}, "DB08460": {"dbids": ["DB08460"], "name": "3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridin-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08467": {"dbids": ["DB08467"], "name": "6-(2,3,4,5,6,7-HEXAHYDRO-2,4,4-TRIMETHYL-1-METYLENEINDEN-2-YL)-3-METHYLHEXA-2,4-DIENOIC ACID", "groups": ["EXPERIMENTAL"], "targets": []}, "DB08466": {"dbids": ["DB08466"], "name": "5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02458": {"dbids": ["DB02458", "DB04412", "EXPT01572"], "name": "Glutathione S-(2,4 Dinitrobenzene)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02459": {"dbids": ["DB02459", "EXPT01553"], "name": "4-Guanidinobenzoic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02450": {"dbids": ["DB02450", "EXPT00786"], "name": "2-Benzo[1,3]Dioxol-5-Ylmethyl-3-Benzyl-Succinic Acid", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02452": {"dbids": ["DB02452", "EXPT03131"], "name": "Thymidine-5'-Triphosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02453": {"dbids": ["DB02453", "EXPT02857"], "name": "Trihydroxyantimonite(Iii)", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02454": {"dbids": ["DB02454", "EXPT01386"], "name": "5-(6-Amino-9h-Purin-9-Yl)-4-Hydroxytetrahydrofuran-3-Yl Dihydrogen Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02455": {"dbids": ["DB02455", "EXPT01443"], "name": "Fluoresceinylthioureido", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02456": {"dbids": ["DB02456", "EXPT00831"], "name": "Cytosine Arabinose-5'-Phosphate", "groups": ["EXPERIMENTAL"], "targets": []}, "DB02457": {"dbids": ["DB02457", "EXPT00797"], "name": "Undecyl-Phosphinic Acid Butyl Ester", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09019": {"dbids": ["DB09019"], "name": "Bromhexine", "groups": ["APPROVED"], "targets": []}, "DB09018": {"dbids": ["DB09018"], "name": "Bromopride", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P14416", "drug": "DB09018"}]}, "DB09015": {"dbids": ["DB09015"], "name": "Potassium Canrenoate", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB09014": {"dbids": ["DB09014"], "name": "Captodiame", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "ANTAGONIST", "target": "P28335", "drug": "DB09014"}, {"action": "AGONIST", "target": "Q99720", "drug": "DB09014"}, {"action": "AGONIST", "target": "P35462", "drug": "DB09014"}]}, "DB09017": {"dbids": ["DB09017"], "name": "Brotizolam", "groups": ["APPROVED", "WITHDRAWN"], "targets": []}, "DB09016": {"dbids": ["DB09016"], "name": "Butriptyline", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P31645", "drug": "DB09016"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB09016"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB09016"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB09016"}]}, "DB09010": {"dbids": ["DB09010"], "name": "Carmofur", "groups": ["WITHDRAWN"], "targets": []}, "DB09013": {"dbids": ["DB09013"], "name": "Befunolol", "groups": ["EXPERIMENTAL"], "targets": []}, "DB09012": {"dbids": ["DB09012"], "name": "Carbazochrome", "groups": ["APPROVED", "INVESTIGATIONAL", "WITHDRAWN"], "targets": []}, "DB01228": {"dbids": ["APRD00613", "DB01228"], "name": "Encainide", "groups": ["APPROVED", "WITHDRAWN"], "targets": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB01228"}]}, "DB01229": {"dbids": ["APRD00259", "DB01229", "DB05261", "DB05927"], "name": "Paclitaxel", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q9H4B7", "drug": "DB01229"}, {"action": "INHIBITOR", "target": "P10415", "drug": "DB01229"}, {"action": "INDUCER", "target": "O75469", "drug": "DB01229"}]}, "DB01222": {"dbids": ["APRD00442", "DB01222"], "name": "Budesonide", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P04150", "drug": "DB01222"}]}, "DB01223": {"dbids": ["APRD00329", "DB01223"], "name": "Aminophylline", "groups": ["APPROVED"], "targets": [{"action": "INHIBITOR", "target": "Q14432", "drug": "DB01223"}, {"action": "ANTAGONIST", "target": "P30542", "drug": "DB01223"}, {"action": "ANTAGONIST", "target": "P0DMS8", "drug": "DB01223"}, {"action": "ACTIVATOR", "target": "Q92769", "drug": "DB01223"}]}, "DB01220": {"dbids": ["APRD01218", "DB01220"], "name": "Rifaximin", "groups": ["APPROVED", "INVESTIGATIONAL"], "targets": [{"action": "INHIBITOR", "target": "P0A8V2", "drug": "DB01220"}, {"action": "AGONIST", "target": "O75469", "drug": "DB01220"}]}, "DB01221": {"dbids": ["APRD00493", "DB01221"], "name": "Ketamine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P25103", "drug": "DB01221"}, {"action": "AGONIST", "target": "P14416", "drug": "DB01221"}, {"action": "PARTIAL AGONIST", "target": "P14416", "drug": "DB01221"}, {"action": "BINDER", "target": "P41143", "drug": "DB01221"}, {"action": "AGONIST", "target": "P41145", "drug": "DB01221"}, {"action": "BINDER", "target": "P35372", "drug": "DB01221"}, {"action": "BINDER", "target": "P11229", "drug": "DB01221"}, {"action": "BINDER", "target": "P08172", "drug": "DB01221"}, {"action": "BINDER", "target": "P20309", "drug": "DB01221"}, {"action": "BINDER", "target": "P08173", "drug": "DB01221"}, {"action": "BINDER", "target": "P08912", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P28221", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P28566", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P30939", "drug": "DB01221"}]}, "DB01226": {"dbids": ["APRD01119", "DB01226"], "name": "Mivacurium", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "Q15822", "drug": "DB01226"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01226"}, {"action": "PARTIAL AGONIST", "target": "P08172", "drug": "DB01226"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01226"}]}, "DB01227": {"dbids": ["APRD00745", "DB01227"], "name": "Levomethadyl Acetate", "groups": ["APPROVED"], "targets": [{"action": "AGONIST", "target": "P35372", "drug": "DB01227"}, {"action": "OTHER/UNKNOWN", "target": "P30926", "drug": "DB01227"}, {"action": "ANTAGONIST", "target": "P32297", "drug": "DB01227"}]}, "DB01224": {"dbids": ["APRD00675", "DB01224"], "name": "Quetiapine", "groups": ["APPROVED"], "targets": [{"action": "ANTAGONIST", "target": "P28223", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01224"}, {"action": "OTHER/UNKNOWN", "target": "P28222", "drug": "DB01224"}, {"action": "OTHER/UNKNOWN", "target": "P28221", "drug": "DB01224"}, {"action": "OTHER/UNKNOWN", "target": "P28566", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01224"}, {"action": "OTHER/UNKNOWN", "target": "P46098", "drug": "DB01224"}, {"action": "OTHER/UNKNOWN", "target": "P50406", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P21918", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB01224"}]}, "DB01225": {"dbids": ["APRD00068", "DB01225"], "name": "Enoxaparin", "groups": ["APPROVED"], "targets": [{"action": "POTENTIATOR", "target": "P01008", "drug": "DB01225"}, {"action": "INHIBITOR", "target": "P00742", "drug": "DB01225"}]}}, "proteins": {"Q96I99": {"specific_function": "Catalyzes the GTP-dependent ligation of succinate and CoA to form succinyl-CoA.", "general_function": "Succinate-coa ligase (gdp-forming) activity", "gene_names": ["SUCLG2"], "name": "Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial", "drug_actions": []}, "O85465": {"general_function": "Cellulase activity", "gene_names": ["cel5A"], "name": "Endoglucanase 5A", "drug_actions": []}, "P31749": {"specific_function": "AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development. Phosphorylates STK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its: kinase activity, nuclear translocation, autophosphorylation and ability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its: cleavage, kinase activity, autophosphorylation at Thr-180, binding to RASSF1 and nuclear translocation. Phosphorylates SRPK2 and enhances its kinase activity towards SRSF2 and ACIN1 and promotes its nuclear translocation. Phosphorylates RAF1 at 'Ser-259' and negatively regulates its activity. Phosphorylation of BAD stimulates its pro-apoptotic activity. Phosphorylates KAT6A at 'Thr-369' and this phosphorylation inhibits the interaction of KAT6A with PML and negatively regulates its acetylation activity towards p53/TP53.AKT1-specific substrates have been recently identified, including palladin (PALLD), which phosphorylation modulates cytoskeletal organization and cell motility; prohibitin (PHB), playing an important role in cell metabolism and proliferation; and CDKN1A, for which phosphorylation at 'Thr-145' induces its release from CDK2 and cytoplasmic relocalization. These recent findings indicate that the AKT1 isoform has a more specific role in cell motility and proliferation. Phosphorylates CLK2 thereby controlling cell survival to ionizing radiation.", "general_function": "Protein serine/threonine/tyrosine kinase activity", "gene_names": ["AKT1"], "name": "RAC-alpha serine/threonine-protein kinase", "drug_actions": [{"action": "INDUCER", "target": "P31749", "drug": "DB01169"}]}, "P30613": {"specific_function": "Plays a key role in glycolysis.", "general_function": "Pyruvate kinase activity", "gene_names": ["PKLR"], "name": "Pyruvate kinase PKLR", "drug_actions": []}, "P31213": {"specific_function": "Converts testosterone (T) into 5-alpha-dihydrotestosterone (DHT) and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.", "name": "3-oxo-5-alpha-steroid 4-dehydrogenase 2", "drug_actions": [{"action": "ANTAGONIST", "target": "P31213", "drug": "DB00421"}, {"action": "INHIBITOR", "target": "P31213", "drug": "DB00548"}, {"action": "INHIBITOR", "target": "P31213", "drug": "DB01126"}, {"action": "INHIBITOR", "target": "P31213", "drug": "DB01216"}], "general_function": "Sterol 5-alpha reductase activity", "in_complexes": ["3-oxo-5-alpha-steroid 4-dehydrogenase"], "gene_names": ["SRD5A2"]}, "P34995": {"specific_function": "Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system. May play a role as an important modulator of renal function. Implicated the smooth muscle contractile response to PGE2 in various tissues.", "general_function": "Prostaglandin e receptor activity", "gene_names": ["PTGER1"], "name": "Prostaglandin E2 receptor EP1 subtype", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "P34995", "drug": "DB00297"}, {"action": "AGONIST", "target": "P34995", "drug": "DB00429"}, {"action": "AGONIST", "target": "P34995", "drug": "DB00770"}, {"action": "AGONIST", "target": "P34995", "drug": "DB00905"}, {"action": "AGONIST", "target": "P34995", "drug": "DB00917"}, {"action": "AGONIST", "target": "P34995", "drug": "DB01088"}]}, "P83453": {"specific_function": "Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr).", "general_function": "Tyrosine-trna ligase activity", "gene_names": ["tyrS"], "name": "Tyrosine--tRNA ligase", "drug_actions": []}, "Q97QE9": {"general_function": "Involved in nucleotidyltransferase activity", "gene_names": ["licC"], "name": "LicC protein", "drug_actions": []}, "P97253": {"specific_function": "Antenna complexes are light-harvesting systems, which transfer the excitation energy to the reaction centers.", "general_function": "Metal ion binding", "gene_names": ["A1"], "name": "Light-harvesting protein B-800/850 alpha chain", "drug_actions": []}, "P60880": {"specific_function": "t-SNARE involved in the molecular regulation of neurotransmitter release. May play an important role in the synaptic function of specific neuronal systems. Associates with proteins involved in vesicle docking and membrane fusion. Regulates plasma membrane recycling through its interaction with CENPF. Modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1 in pancreatic beta cells.", "general_function": "Syntaxin-1 binding", "gene_names": ["SNAP25"], "name": "Synaptosomal-associated protein 25", "drug_actions": [{"action": "INHIBITOR", "target": "P60880", "drug": "DB00083"}]}, "P20932": {"specific_function": "Reduction of (S)-mandelate to benzoylformate.", "general_function": "Fmn binding", "gene_names": ["mdlB"], "name": "(S)-mandelate dehydrogenase", "drug_actions": []}, "P45844": {"specific_function": "Transporter involved in macrophage lipid homeostasis. Is an active component of the macrophage lipid export complex. Could also be involved in intracellular lipid transport processes. The role in cellular lipid homeostasis may not be limited to macrophages.", "general_function": "Toxin transporter activity", "gene_names": ["ABCG1"], "name": "ATP-binding cassette sub-family G member 1", "drug_actions": []}, "P33527": {"specific_function": "Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.", "general_function": "Transporter activity", "gene_names": ["ABCC1"], "name": "Multidrug resistance-associated protein 1", "drug_actions": [{"action": "INHIBITOR", "target": "P33527", "drug": "DB01138"}]}, "P06715": {"specific_function": "Maintains high levels of reduced glutathione in the cytosol.", "general_function": "Nadp binding", "gene_names": ["gor"], "name": "Glutathione reductase", "drug_actions": [{"action": "INHIBITOR", "target": "P06715", "drug": "DB00336"}]}, "P06716": {"specific_function": "This colicin is a channel-forming colicin. This class of transmembrane toxins depolarize the cytoplasmic membrane, leading to dissipation of cellular energy.Colicins are polypeptide toxins produced by and active against E.coli and closely related bacteria.", "gene_names": ["cia"], "name": "Colicin-Ia", "drug_actions": []}, "P06710": {"specific_function": "DNA polymerase III is a complex, multichain enzyme responsible for most of the replicative synthesis in bacteria. This DNA polymerase also exhibits 3' to 5' exonuclease activity.Isoform tau: serves as a scaffold to help in the dimerization of the core complex.Isoform gamma: seems to interact with the delta subunit. to transfer the beta subunit on the DNA.", "general_function": "Nucleoside-triphosphatase activity", "gene_names": ["dnaX"], "name": "DNA polymerase III subunit tau", "drug_actions": []}, "Q9HYX1": {"general_function": "N-acetyltransferase activity", "gene_names": [], "name": "Uncharacterized protein", "drug_actions": []}, "P16435": {"specific_function": "This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5.", "general_function": "Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen", "gene_names": ["POR"], "name": "NADPH--cytochrome P450 reductase", "drug_actions": []}, "P0A5R0": {"specific_function": "ATP + (R)-pantoate + beta-alanine = AMP + diphosphate + (R)-pantothenate", "general_function": "Coenzyme transport and metabolism", "gene_names": ["panC"], "name": "Pantothenate synthetase", "drug_actions": []}, "O34002": {"specific_function": "Involved in the catabolism of short chain fatty acids (SCFA) via the tricarboxylic acid (TCA)(acetyl degradation route) and via the 2-methylcitrate cycle I (propionate degradation route). Catalyzes the Claisen condensation of propionyl-CoA and oxaloacetate (OAA) to yield (2S,3S)-2-methylcitrate (2-MC) and CoA. Also catalyzes the condensation of oxaloacetate with acetyl-CoA but with a lower specificity.", "general_function": "Citrate synthase activity", "gene_names": ["gltA"], "name": "2-methylcitrate synthase", "drug_actions": []}, "P84077": {"specific_function": "GTP-binding protein that functions as an allosteric activator of the cholera toxin catalytic subunit, an ADP-ribosyltransferase. Involved in protein trafficking among different compartments. Modulates vesicle budding and uncoating within the Golgi complex. Deactivation induces the redistribution of the entire Golgi complex to the endoplasmic reticulum, suggesting a crucial role in protein trafficking. In its GTP-bound form, its triggers the association with coat proteins with the Golgi membrane. The hydrolysis of ARF1-bound GTP, which is mediated by ARFGAPs proteins, is required for dissociation of coat proteins from Golgi membranes and vesicles. The GTP-bound form interacts with PICK1 to limit PICK1-mediated inhibition of Arp2/3 complex activity; the function is linked to AMPA receptor (AMPAR) trafficking, regulation of synaptic plasicity of excitatory synapses and spine shrinkage during long-term depression (LTD).", "general_function": "Receptor signaling protein activity", "gene_names": ["ARF1"], "name": "ADP-ribosylation factor 1", "drug_actions": []}, "Q9KL51": {"general_function": "6-phosphogluconolactonase activity", "gene_names": [], "name": "DevB protein", "drug_actions": []}, "P23919": {"specific_function": "Catalyzes the conversion of dTMP to dTDP.", "general_function": "Uridylate kinase activity", "gene_names": ["DTYMK"], "name": "Thymidylate kinase", "drug_actions": []}, "Q9BUF5": {"specific_function": "Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity).", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["TUBB6"], "name": "Tubulin beta-6 chain", "drug_actions": []}, "Q4KH25": {"general_function": "Porin activity", "gene_names": [], "name": "Outer membrane porin, OprD family", "drug_actions": []}, "P31101": {"specific_function": "Catalyzes the reduction of hydroxylamine to form NH(3) and H(2)O.", "general_function": "Metal ion binding", "gene_names": ["hcp"], "name": "Hydroxylamine reductase", "drug_actions": []}, "P01589": {"specific_function": "Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T cells.", "general_function": "Interleukin-2 receptor activity", "gene_names": ["IL2RA"], "name": "Interleukin-2 receptor subunit alpha", "drug_actions": [{"action": "BINDER", "target": "P01589", "drug": "DB00004"}, {"action": "AGONIST", "target": "P01589", "drug": "DB00041"}, {"action": "MODULATOR", "target": "P01589", "drug": "DB00041"}, {"action": "ANTIBODY", "target": "P01589", "drug": "DB00074"}, {"action": "ANTIBODY", "target": "P01589", "drug": "DB00111"}]}, "Q00535": {"specific_function": "Proline-directed serine/threonine-protein kinase essential for neuronal cell cycle arrest and differentiation and may be involved in apoptotic cell death in neuronal diseases by triggering abortive cell cycle re-entry. Interacts with D1 and D3-type G1 cyclins. Phosphorylates SRC, NOS3, VIM/vimentin, p35/CDK5R1, MEF2A, SIPA1L1, SH3GLB1, PXN, PAK1, MCAM/MUC18, SEPT5, SYN1, DNM1, AMPH, SYNJ1, CDK16, RAC1, RHOA, CDC42, TONEBP/NFAT5, MAPT/TAU, MAP1B, histone H1, p53/TP53, HDAC1, APEX1, PTK2/FAK1, huntingtin/HTT, ATM, MAP2, NEFH and NEFM. Regulates several neuronal development and physiological processes including neuronal survival, migration and differentiation, axonal and neurite growth, synaptogenesis, oligodendrocyte differentiation, synaptic plasticity and neurotransmission, by phosphorylating key proteins. Activated by interaction with CDK5R1 (p35) and CDK5R2 (p39), especially in post-mitotic neurons, and promotes CDK5R1 (p35) expression in an autostimulation loop. Phosphorylates many downstream substrates such as Rho and Ras family small GTPases (e.g. PAK1, RAC1, RHOA, CDC42) or microtubule-binding proteins (e.g. MAPT/TAU, MAP2, MAP1B), and modulates actin dynamics to regulate neurite growth and/or spine morphogenesis. Phosphorylates also exocytosis associated proteins such as MCAM/MUC18, SEPT5, SYN1, and CDK16/PCTAIRE1 as well as endocytosis associated proteins such as DNM1, AMPH and SYNJ1 at synaptic terminals. In the mature central nervous system (CNS), regulates neurotransmitter movements by phosphorylating substrates associated with neurotransmitter release and synapse plasticity; synaptic vesicle exocytosis, vesicles fusion with the presynaptic membrane, and endocytosis. Promotes cell survival by activating anti-apoptotic proteins BCL2 and STAT3, and negatively regulating of JNK3/MAPK10 activity. Phosphorylation of p53/TP53 in response to genotoxic and oxidative stresses enhances its stabilization by preventing ubiquitin ligase-mediated proteasomal degradation, and induces transactivation of p53/TP53 target genes, thus regulating apoptosis. Phosphorylation of p35/CDK5R1 enhances its stabilization by preventing calpain-mediated proteolysis producing p25/CDK5R1 and avoiding ubiquitin ligase-mediated proteasomal degradation. During aberrant cell-cycle activity and DNA damage, p25/CDK5 activity elicits cell-cycle activity and double-strand DNA breaks that precedes neuronal death by deregulating HDAC1. DNA damage triggered phosphorylation of huntingtin/HTT in nuclei of neurons protects neurons against polyglutamine expansion as well as DNA damage mediated toxicity. Phosphorylation of PXN reduces its interaction with PTK2/FAK1 in matrix-cell focal adhesions (MCFA) during oligodendrocytes (OLs) differentiation. Negative regulator of Wnt/beta-catenin signaling pathway. Activator of the GAIT (IFN-gamma-activated inhibitor of translation) pathway, which suppresses expression of a post-transcriptional regulon of proinflammatory genes in myeloid cells; phosphorylates the linker domain of glutamyl-prolyl tRNA synthetase (EPRS) in a IFN-gamma-dependent manner, the initial event in assembly of the GAIT complex. Phosphorylation of SH3GLB1 is required for autophagy induction in starved neurons. Phosphorylation of TONEBP/NFAT5 in response to osmotic stress mediates its rapid nuclear localization. MEF2 is inactivated by phosphorylation in nucleus in response to neurotoxin, thus leading to neuronal apoptosis. APEX1 AP-endodeoxyribonuclease is repressed by phosphorylation, resulting in accumulation of DNA damage and contributing to neuronal death. NOS3 phosphorylation down regulates NOS3-derived nitrite (NO) levels. SRC phosphorylation mediates its ubiquitin-dependent degradation and thus leads to cytoskeletal reorganization. May regulate endothelial cell migration and angiogenesis via the modulation of lamellipodia formation. Involved in dendritic spine morphogenesis by mediating the EFNA1-EPHA4 signaling. The complex p35/CDK5 participates in the regulation of the circadian clock by modulating the function of CLOCK protein: phosphorylates CLOCK at 'Thr-451' and 'Thr-461' and regulates the transcriptional activity of the CLOCK-ARNTL/BMAL1 heterodimer in association with altered stability and subcellular distribution.", "general_function": "Tau-protein kinase activity", "gene_names": ["CDK5"], "name": "Cyclin-dependent-like kinase 5", "drug_actions": [{"action": "INHIBITOR", "target": "Q00535", "drug": "DB02052"}, {"action": "INHIBITOR", "target": "Q00535", "drug": "DB02116"}, {"action": "INHIBITOR", "target": "Q00535", "drug": "DB02950"}, {"action": "INHIBITOR", "target": "Q00535", "drug": "DB03428"}]}, "Q00534": {"specific_function": "Serine/threonine-protein kinase involved in the control of the cell cycle and differentiation; promotes G1/S transition. Phosphorylates pRB/RB1 and NPM1. Interacts with D-type G1 cyclins during interphase at G1 to form a pRB/RB1 kinase and controls the entrance into the cell cycle. Involved in initiation and maintenance of cell cycle exit during cell differentiation; prevents cell proliferation and regulates negatively cell differentiation, but is required for the proliferation of specific cell types (e.g. erythroid and hematopoietic cells). Essential for cell proliferation within the dentate gyrus of the hippocampus and the subventricular zone of the lateral ventricles. Required during thymocyte development. Promotes the production of newborn neurons, probably by modulating G1 length. Promotes, at least in astrocytes, changes in patterns of gene expression, changes in the actin cytoskeleton including loss of stress fibers, and enhanced motility during cell differentiation. Prevents myeloid differentiation by interfering with RUNX1 and reducing its transcription transactivation activity, but promotes proliferation of normal myeloid progenitors. Delays senescence. Promotes the proliferation of beta-cells in pancreatic islets of Langerhans. May play a role in the centrosome organization during the cell cycle phases (PubMed:23918663).", "general_function": "Cyclin-dependent protein serine/threonine kinase activity", "gene_names": ["CDK6"], "name": "Cyclin-dependent kinase 6", "drug_actions": [{"action": "INHIBITOR", "target": "Q00534", "drug": "DB09073"}]}, "Q00536": {"specific_function": "Protein kinase that plays a role in vesicle-mediated transport processes and exocytosis. Regulates GH1 release by brain neurons. Phosphorylates NSF, and thereby regulates NSF oligomerization. Required for normal spermatogenesis. Regulates neuron differentiation and dendrite development (By similarity). Plays a role in the regulation of insulin secretion in response to changes in blood glucose levels. Can phosphorylate CCNY at 'Ser-336' (in vitro).", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["CDK16"], "name": "Cyclin-dependent kinase 16", "drug_actions": []}, "P51671": {"specific_function": "In response to the presence of allergens, this protein directly promotes the accumulation of eosinophils, a prominent feature of allergic inflammatory reactions. Binds to CCR3.", "general_function": "Chemokine activity", "gene_names": ["CCL11"], "name": "Eotaxin", "drug_actions": []}, "P13100": {"general_function": "Thymidylate synthase activity", "gene_names": ["THYA"], "name": "Thymidylate synthase", "drug_actions": []}, "O00244": {"specific_function": "Binds and deliver cytosolic copper to the copper ATPase proteins. May be important in cellular antioxidant defense.", "general_function": "Metallochaperone activity", "gene_names": ["ATOX1"], "name": "Copper transport protein ATOX1", "drug_actions": []}, "Q83QN9": {"specific_function": "Essential cell division protein that stabilizes the FtsZ protofilaments by cross-linking them and that serves as a cytoplasmic membrane anchor for the Z ring. Also required for the recruitment to the septal ring of downstream cell division proteins.", "gene_names": ["zipA"], "name": "Cell division protein ZipA", "drug_actions": []}, "Q3JUV5": {"general_function": "Magnesium ion binding", "gene_names": ["ppa"], "name": "Inorganic pyrophosphatase", "drug_actions": []}, "Q6FEW8": {"general_function": "Phosphoenolpyruvate-protein phosphotransferase activity", "gene_names": ["ptsP"], "name": "Phosphoenolpyruvate-protein phosphotransferase", "drug_actions": []}, "Q7DHH4": {"general_function": "Transferase activity, transferring glycosyl groups", "gene_names": ["mecA"], "name": "MecA", "drug_actions": []}, "Q9UBM7": {"specific_function": "Production of cholesterol by reduction of C7-C8 double bond of 7-dehydrocholesterol (7-DHC).", "general_function": "7-dehydrocholesterol reductase activity", "gene_names": ["DHCR7"], "name": "7-dehydrocholesterol reductase", "drug_actions": []}, "O92972": {"specific_function": "Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).E1 and E2 glycoproteins form a heterodimer that is involved in virus attachment to the host cell, virion internalization through clathrin-dependent endocytosis and fusion with host membrane. E1/E2 heterodimer binds to human LDLR, CD81 and SCARB1/SR-BI receptors, but this binding is not sufficient for infection, some additional liver specific cofactors may be needed. The fusion function may possibly be carried by E1. E2 inhibits human EIF2AK2/PKR activation, preventing the establishment of an antiviral state. E2 is a viral ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on liver sinusoidal endothelial cells and macrophage-like cells of lymph node sinuses. These interactions allow capture of circulating HCV particles by these cells and subsequent transmission to permissive cells. DCs act as sentinels in various tissues where they entrap pathogens and convey them to local lymphoid tissue or lymph node for establishment of immunity. Capture of circulating HCV particles by these SIGN+ cells may facilitate virus infection of proximal hepatocytes and lymphocyte subpopulations and may be essential for the establishment of persistent infection (By similarity).P7 seems to be a heptameric ion channel protein (viroporin) and is inhibited by the antiviral drug amantadine. Also inhibited by long-alkyl-chain iminosugar derivatives. Essential for infectivity (By similarity).Protease NS2-3 is a cysteine protease responsible for the autocatalytic cleavage of NS2-NS3. Seems to undergo self-inactivation following maturation (By similarity).NS3 displays three enzymatic activities: serine protease, NTPase and RNA helicase. NS3 serine protease, in association with NS4A, is responsible for the cleavages of NS3-NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also prevents phosphorylation of human IRF3, thus preventing the establishment of dsRNA induced antiviral state. NS3 RNA helicase binds to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA stable secondary structure in the template strand. Cleaves and inhibits the host antiviral protein MAVS (By similarity).NS4B induces a specific membrane alteration that serves as a scaffold for the virus replication complex. This membrane alteration gives rise to the so-called ER-derived membranous web that contains the replication complex (By similarity).NS5A is a component of the replication complex involved in RNA-binding. Its interaction with Human VAPB may target the viral replication complex to vesicles. Down-regulates viral IRES translation initiation. Mediates interferon resistance, presumably by interacting with and inhibiting human EIF2AK2/PKR. Seems to inhibit apoptosis by interacting with BIN1 and FKBP8. The hyperphosphorylated form of NS5A is an inhibitor of viral replication (By similarity).NS5B is an RNA-dependent RNA polymerase that plays an essential role in the virus replication.", "general_function": "Zinc ion binding", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P21673": {"specific_function": "Enzyme which catalyzes the acetylation of polyamines. Substrate specificity: norspermidine = spermidine >> spermine > N(1)-acetylspermine > putrescine. This highly regulated enzyme allows a fine attenuation of the intracellular concentration of polyamines. Also involved in the regulation of polyamine transport out of cells. Acts on 1,3-diaminopropane, 1,5-diaminopentane, putrescine, spermidine (forming N(1)- and N(8)-acetylspermidine), spermine, N(1)-acetylspermidine and N(8)-acetylspermidine.", "general_function": "Diamine n-acetyltransferase activity", "gene_names": ["SAT1"], "name": "Diamine acetyltransferase 1", "drug_actions": []}, "P30291": {"specific_function": "Acts as a negative regulator of entry into mitosis (G2 to M transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed CDK1 before the onset of mitosis by mediating phosphorylation of CDK1 on 'Tyr-15'. Specifically phosphorylates and inactivates cyclin B1-complexed CDK1 reaching a maximum during G2 phase and a minimum as cells enter M phase. Phosphorylation of cyclin B1-CDK1 occurs exclusively on 'Tyr-15' and phosphorylation of monomeric CDK1 does not occur. Its activity increases during S and G2 phases and decreases at M phase when it is hyperphosphorylated. A correlated decrease in protein level occurs at M/G1 phase, probably due to its degradation.", "general_function": "Protein tyrosine kinase activity", "gene_names": ["WEE1"], "name": "Wee1-like protein kinase", "drug_actions": []}, "P07711": {"specific_function": "Important for the overall degradation of proteins in lysosomes.", "general_function": "Serpin family protein binding", "gene_names": ["CTSL"], "name": "Cathepsin L1", "drug_actions": []}, "Q88K39": {"general_function": "Glutamin-(asparagin-)ase activity", "gene_names": ["ansB"], "name": "Glutaminase-asparaginase", "drug_actions": []}, "Q99933": {"specific_function": "Inhibits the chaperone activity of HSP70/HSC70 by promoting substrate release. Inhibits the pro-apoptotic function of PPP1R15A, and has anti-apoptotic activity. Markedly increases the anti-cell death function of BCL2 induced by various stimuli.", "general_function": "Receptor signaling protein activity", "gene_names": ["BAG1"], "name": "BAG family molecular chaperone regulator 1", "drug_actions": []}, "Q07699": {"specific_function": "Crucial in the assembly, expression, and functional modulation of the heterotrimeric complex of the sodium channel. The subunit beta-1 can modulate multiple alpha subunit isoforms from brain, skeletal muscle, and heart. Its association with neurofascin may target the sodium channels to the nodes of Ranvier of developing axons and retain these channels at the nodes in mature myelinated axons.Isoform 2: Cell adhesion molecule that plays a critical role in neuronal migration and pathfinding during brain development. Stimulates neurite outgrowth.", "name": "Sodium channel subunit beta-1", "drug_actions": [{"action": "INHIBITOR", "target": "Q07699", "drug": "DB00909"}], "general_function": "Voltage-gated sodium channel activity involved in purkinje myocyte action potential", "in_complexes": ["Sodium channel protein"], "gene_names": ["SCN1B"]}, "P40429": {"specific_function": "Associated with ribosomes but is not required for canonical ribosome function and has extra-ribosomal functions. Component of the GAIT (gamma interferon-activated inhibitor of translation) complex which mediates interferon-gamma-induced transcript-selective translation inhibition in inflammation processes. Upon interferon-gamma activation and subsequent phosphorylation dissociates from the ribosome and assembles into the GAIT complex which binds to stem loop-containing GAIT elements in the 3'-UTR of diverse inflammatory mRNAs (such as ceruplasmin) and suppresses their translation. In the GAIT complex interacts with m7G cap-bound eIF4G at or near the eIF3-binding site and blocks the recruitment of the 43S ribosomal complex. Involved in methylation of rRNA.", "general_function": "Structural constituent of ribosome", "gene_names": ["RPL13A"], "name": "60S ribosomal protein L13a", "drug_actions": []}, "Q08638": {"general_function": "Beta-glucosidase activity", "gene_names": ["bglA"], "name": "Beta-glucosidase A", "drug_actions": []}, "P39377": {"specific_function": "Catalyzes the hydrolytic cleavage of a subset of L-isoaspartyl (L-beta-aspartyl) dipeptides. Used to degrade proteins damaged by L-isoaspartyl residues formation. The best substrate for the enzyme reported thus far is iso-Asp-Leu.", "general_function": "Zinc ion binding", "gene_names": ["iadA"], "name": "Isoaspartyl dipeptidase", "drug_actions": []}, "Q13838": {"specific_function": "Involved in nuclear export of spliced and unspliced mRNA. Assembling component of the TREX complex which is thought to couple mRNA transcription, processing and nuclear export, and specifically associates with spliced mRNA and not with unspliced pre-mRNA. TREX is recruited to spliced mRNAs by a transcription-independent mechanism, binds to mRNA upstream of the exon-junction complex (EJC) and is recruited in a splicing- and cap-dependent manner to a region near the 5' end of the mRNA where it functions in mRNA export to the cytoplasm via the TAP/NFX1 pathway. May undergo several rounds of ATP hydrolysis during assembly of TREX to drive subsequent loading of components such as ALYREF/THOC and CHTOP onto mRNA. The TREX complex is essential for the export of Kaposi's sarcoma-associated herpesvirus (KSHV) intronless mRNAs and infectious virus production. Also associates with pre-mRNA independent of ALYREF/THOC4 and the THO complex. Involved in the nuclear export of intronless mRNA; the ATP-bound form is proposed to recruit export adapter ALYREF/THOC4 to intronless mRNA; its ATPase activity is cooperatively stimulated by RNA and ALYREF/THOC4 and ATP hydrolysis is thought to trigger the dissociation from RNA to allow the association of ALYREF/THOC4 and the NXF1-NXT1 heterodimer. Involved in transcription elongation and genome stability.Splice factor that is required for the first ATP-dependent step in spliceosome assembly and for the interaction of U2 snRNP with the branchpoint. Has both RNA-stimulated ATP binding/hydrolysis activity and ATP-dependent RNA unwinding activity. Even with the stimulation of RNA, the ATPase activity is weak. Can only hydrolyze ATP but not other NTPs. The RNA stimulation of ATPase activity does not have a strong preference for the sequence and length of the RNA. However, ssRNA stimulates the ATPase activity much more strongly than dsRNA. Can unwind 5' or 3' overhangs or blunt end RNA duplexes in vitro. The ATPase and helicase activities are not influenced by U2AF2; the effect of ALYREF/THOC4 is reported conflictingly with [PubMed:23299939] reporting a stimulatory effect.", "general_function": "U6 snrna binding", "gene_names": ["DDX39B"], "name": "Spliceosome RNA helicase DDX39B", "drug_actions": []}, "P0AB77": {"specific_function": "Catalyzes the cleavage of 2-amino-3-ketobutyrate to glycine and acetyl-CoA.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["kbl"], "name": "2-amino-3-ketobutyrate coenzyme A ligase", "drug_actions": []}, "P0AB74": {"specific_function": "Catalytic subunit of the tagatose-1,6-bisphosphate aldolase KbaYZ, which catalyzes the reversible aldol condensation of dihydroxyacetone phosphate (DHAP or glycerone-phosphate) with glyceraldehyde 3-phosphate (G3P) to produce tagatose 1,6-bisphosphate (TBP). Requires KbaZ subunit for full activity and stability.", "general_function": "Zinc ion binding", "gene_names": ["kbaY"], "name": "D-tagatose-1,6-bisphosphate aldolase subunit KbaY", "drug_actions": []}, "Q9XB59": {"specific_function": "Catalyzes the Fe(2+) and alpha-ketoglutarate-dependent conversion of (3S,5S)-carbapenam to (5R)-carbapenem, an essential step in carbapenem antibiotic biosynthesis.", "general_function": "Metal ion binding", "gene_names": ["carC"], "name": "(5R)-carbapenem-3-carboxylate synthase", "drug_actions": []}, "P08842": {"specific_function": "Conversion of sulfated steroid precursors to estrogens during pregnancy.", "general_function": "Sulfuric ester hydrolase activity", "gene_names": ["STS"], "name": "Steryl-sulfatase", "drug_actions": []}, "P03891": {"specific_function": "Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["MT-ND2"], "name": "NADH-ubiquinone oxidoreductase chain 2", "drug_actions": [{"action": "BINDER", "target": "P03891", "drug": "DB00157"}]}, "P29717": {"specific_function": "Major glucan 1,3-beta-glucosidase required for cell wall integrity. Beta-glucanases participate in the metabolism of beta-glucan, the main structural component of the cell wall. Can also function biosynthetically as a transglycosylase. Functions to deliver glucan from the cell to the extracellular matrix. Does not appear to impact cell wall glucan content of biofilm cells, nor is it necessary for filamentation or biofilm formation. Involved in cell-substrate and cell-cell adhesion. Adhesion to host-cell surfaces is the first critical step during mucosal infection. XOG1 is target of human antimicrobial peptide LL-37 for inhibition of cell adhesion.", "general_function": "Transferase activity", "gene_names": ["XOG1"], "name": "Glucan 1,3-beta-glucosidase", "drug_actions": []}, "P14210": {"specific_function": "Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerization.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["HGF"], "name": "Hepatocyte growth factor", "drug_actions": []}, "P49788": {"specific_function": "Inhibitor of the cytoplasmic carboxypeptidase AGBL2, may regulate the alpha-tubulin tyrosination cycle.", "gene_names": ["RARRES1"], "name": "Retinoic acid receptor responder protein 1", "drug_actions": [{"action": "AGONIST", "target": "P49788", "drug": "DB00755"}]}, "P03897": {"specific_function": "Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["MT-ND3"], "name": "NADH-ubiquinone oxidoreductase chain 3", "drug_actions": [{"action": "BINDER", "target": "P03897", "drug": "DB00157"}]}, "Q53ET4": {"specific_function": "Interconversion of serine and glycine.", "general_function": "Pyridoxal phosphate binding", "gene_names": [], "name": "Serine hydroxymethyltransferase", "drug_actions": [{"action": "COFACTOR", "target": "Q53ET4", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q53ET4", "drug": "DB00116"}]}, "P02768": {"specific_function": "Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.", "general_function": "Toxic substance binding", "gene_names": ["ALB"], "name": "Serum albumin", "drug_actions": []}, "P20645": {"specific_function": "Transport of phosphorylated lysosomal enzymes from the Golgi complex and the cell surface to lysosomes. Lysosomal enzymes bearing phosphomannosyl residues bind specifically to mannose-6-phosphate receptors in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelyosomal compartment where the low pH mediates the dissociation of the complex.", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["M6PR"], "name": "Cation-dependent mannose-6-phosphate receptor", "drug_actions": [{"action": "BINDER", "target": "P20645", "drug": "DB01272"}]}, "Q59675": {"specific_function": "Endo-acting xylanase which specifically cleaves internal linkages on the xylan backbone, releasing xylooligosaccharides. Is able to hydrolyze oat spelt xylan, the arabinoxylans from wheat and rye, and glucuronoxylan. Also displays very low activity against xylooligosaccharides. During the xylan degradation process, Xyn10C may act on the soluble xylans and long xylooligosaccharides products released by the secreted xylanases Xyn11A, Xyn11B and Xyn10A.", "general_function": "Endo-1,4-beta-xylanase activity", "gene_names": ["xyn10C"], "name": "Endo-beta-1,4-xylanase Xyn10C", "drug_actions": []}, "P78348": {"specific_function": "Isoform 2 and isoform 3 function as proton-gated sodium channels; they are activated by a drop of the extracellular pH and then become rapidly desensitized. The channel generates a biphasic current with a fast inactivating and a slow sustained phase. Has high selectivity for sodium ions and can also transport lithium ions with high efficiency. Isoform 2 can also transport potassium, but with lower efficiency. It is nearly impermeable to the larger rubidium and cesium ions. Isoform 3 can also transport calcium ions. Mediates glutamate-independent Ca(2+) entry into neurons upon acidosis. This Ca(2+) overloading is toxic for cortical neurons and may be in part responsible for ischemic brain injury. Heteromeric channel assembly seems to modulate channel properties. Functions as a postsynaptic proton receptor that influences intracellular Ca(2+) concentration and calmodulin-dependent protein kinase II phosphorylation and thereby the density of dendritic spines. Modulates activity in the circuits underlying innate fear.Isoform 1 does not display proton-gated cation channel activity.", "general_function": "Ligand-gated sodium channel activity", "gene_names": ["ASIC1"], "name": "Acid-sensing ion channel 1", "drug_actions": [{"action": "INHIBITOR", "target": "P78348", "drug": "DB00586"}, {"action": "INHIBITOR", "target": "P78348", "drug": "DB00594"}]}, "P09373": {"general_function": "Formate c-acetyltransferase activity", "gene_names": ["pflB"], "name": "Formate acetyltransferase 1", "drug_actions": []}, "P02760": {"specific_function": "Inter-alpha-trypsin inhibitor inhibits trypsin, plasmin, and lysosomal granulocytic elastase. Inhibits calcium oxalate crystallization.Trypstatin is a trypsin inhibitor.", "general_function": "Small molecule binding", "gene_names": ["AMBP"], "name": "Protein AMBP", "drug_actions": []}, "P02763": {"in_complexes": ["alpha1-acid glycoprotein"], "specific_function": "Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.", "gene_names": ["ORM1"], "name": "Alpha-1-acid glycoprotein 1", "drug_actions": [{"action": "BINDER", "target": "P02763", "drug": "DB00477"}, {"action": "BINDER", "target": "P02763", "drug": "DB00497"}, {"action": "BINDER", "target": "P02763", "drug": "DB01041"}]}, "P52477": {"specific_function": "The periplasmic linker component of the MexAB-OprM efflux system that confers multidrug resistance. Also functions as the major efflux pump for n-hexane and p-xylene efflux. Over-expression of the pump increases antibiotic and solvent efflux capacities. Required for assembly of the MexA/MexB/OprM complex. Implicated in the secretion of the siderophore pyoverdine.The ability to export antibiotics and solvents is dramatically decreased in the presence of the proton conductor carbonyl cyanide m-chlorophenylhydrazone (CCCP), showing that an energized inner membrane is required for efflux. It is thought that the MexB subunit is a proton antiporter.", "general_function": "Drug transmembrane transporter activity", "gene_names": ["mexA"], "name": "Multidrug resistance protein MexA", "drug_actions": []}, "P23008": {"specific_function": "VP0 precursor is a component of immature procapsids (By similarity)", "general_function": "Involved in structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P35094": {"specific_function": "Antenna complexes are light-harvesting systems, which transfer the excitation energy to the reaction centers.", "general_function": "Metal ion binding", "gene_names": [], "name": "Light-harvesting protein B-800/820 beta chain", "drug_actions": []}, "Q7L266": {"specific_function": "Has both L-asparaginase and beta-aspartyl peptidase activity. May be involved in the production of L-aspartate, which can act as an excitatory neurotransmitter in some brain regions. Is highly active with L-Asp beta-methyl ester. Besides, has catalytic activity toward beta-aspartyl dipeptides and their methyl esters, including beta-L-Asp-L-Phe, beta-L-Asp-L-Phe methyl ester (aspartame), beta-L-Asp-L-Ala, beta-L-Asp-L-Leu and beta-L-Asp-L-Lys. Does not have aspartylglucosaminidase activity and is inactive toward GlcNAc-L-Asn. Likewise, has no activity toward glutamine.", "general_function": "Beta-aspartyl-peptidase activity", "gene_names": ["ASRGL1"], "name": "Isoaspartyl peptidase/L-asparaginase", "drug_actions": []}, "P10275": {"specific_function": "Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.", "general_function": "Zinc ion binding", "gene_names": ["AR"], "name": "Androgen receptor", "drug_actions": [{"action": "AGONIST", "target": "P10275", "drug": "DB00367"}, {"action": "ANTAGONIST", "target": "P10275", "drug": "DB00421"}, {"action": "ANTAGONIST", "target": "P10275", "drug": "DB00499"}, {"action": "AGONIST", "target": "P10275", "drug": "DB00621"}, {"action": "AGONIST", "target": "P10275", "drug": "DB00624"}, {"action": "ANTAGONIST", "target": "P10275", "drug": "DB00665"}, {"action": "AGONIST", "target": "P10275", "drug": "DB00687"}, {"action": "AGONIST", "target": "P10275", "drug": "DB00858"}, {"action": "AGONIST", "target": "P10275", "drug": "DB00984"}, {"action": "BINDER", "target": "P10275", "drug": "DB01026"}, {"action": "ANTAGONIST", "target": "P10275", "drug": "DB01128"}, {"action": "AGONIST", "target": "P10275", "drug": "DB01185"}, {"action": "ANTAGONIST", "target": "P10275", "drug": "DB01395"}, {"action": "AGONIST", "target": "P10275", "drug": "DB01406"}, {"action": "AGONIST", "target": "P10275", "drug": "DB01420"}, {"action": "AGONIST", "target": "P10275", "drug": "DB01481"}, {"action": "AGONIST", "target": "P10275", "drug": "DB01541"}, {"action": "ANTAGONIST", "target": "P10275", "drug": "DB04839"}, {"action": "AGONIST", "target": "P10275", "drug": "DB06710"}, {"action": "AGONIST", "target": "P10275", "drug": "DB08804"}, {"action": "INHIBITOR", "target": "P10275", "drug": "DB08899"}]}, "P10276": {"specific_function": "Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis. Has a role in the survival of early spermatocytes at the beginning prophase of meiosis. In Sertoli cells, may promote the survival and development of early meiotic prophase spermatocytes. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function (By similarity). Regulates expression of target genes in a ligand-dependent manner by recruiting chromatin complexes containing KMT2E/MLL5. Mediates retinoic acid-induced granulopoiesis.", "general_function": "Zinc ion binding", "gene_names": ["RARA"], "name": "Retinoic acid receptor alpha", "drug_actions": [{"action": "AGONIST", "target": "P10276", "drug": "DB00210"}, {"action": "AGONIST", "target": "P10276", "drug": "DB00459"}, {"action": "AGONIST", "target": "P10276", "drug": "DB00523"}, {"action": "AGONIST", "target": "P10276", "drug": "DB00799"}, {"action": "AGONIST", "target": "P10276", "drug": "DB00926"}, {"action": "OTHER/UNKNOWN", "target": "P10276", "drug": "DB00982"}, {"action": "AGONIST", "target": "P10276", "drug": "DB04942"}]}, "Q9Y2U5": {"specific_function": "Component of a protein kinase signal transduction cascade. Regulates the JNK and ERK5 pathways by phosphorylating and activating MAP2K5 and MAP2K7 (By similarity). Plays a role in caveolae kiss-and-run dynamics.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["MAP3K2"], "name": "Mitogen-activated protein kinase kinase kinase 2", "drug_actions": [{"action": "INHIBITOR", "target": "Q9Y2U5", "drug": "DB06616"}]}, "Q9UJ70": {"specific_function": "Converts endogenous N-acetylglucosamine (GlcNAc), a major component of complex carbohydrates, from lysosomal degradation or nutritional sources into GlcNAc 6-phosphate. Involved in the N-glycolylneuraminic acid (Neu5Gc) degradation pathway: although human is not able to catalyze formation of Neu5Gc due to the inactive CMAHP enzyme, Neu5Gc is present in food and must be degraded. Also has ManNAc kinase activity.", "general_function": "N-acylmannosamine kinase activity", "gene_names": ["NAGK"], "name": "N-acetyl-D-glucosamine kinase", "drug_actions": []}, "P00943": {"specific_function": "Involved in the gluconeogenesis. Catalyzes stereospecifically the conversion of dihydroxyacetone phosphate (DHAP) to D-glyceraldehyde-3-phosphate (G3P).", "general_function": "Triose-phosphate isomerase activity", "gene_names": ["tpiA"], "name": "Triosephosphate isomerase", "drug_actions": []}, "P20618": {"specific_function": "The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity.", "general_function": "Threonine-type endopeptidase activity", "gene_names": ["PSMB1"], "name": "Proteasome subunit beta type-1", "drug_actions": [{"action": "ANTAGONIST", "target": "P20618", "drug": "DB00188"}, {"action": "INHIBITOR", "target": "P20618", "drug": "DB08889"}]}, "P00947": {"general_function": "Steroid delta-isomerase activity", "gene_names": ["ksi"], "name": "Steroid Delta-isomerase", "drug_actions": []}, "P52270": {"general_function": "Triose-phosphate isomerase activity", "gene_names": [], "name": "Triosephosphate isomerase, glycosomal", "drug_actions": []}, "P09172": {"specific_function": "Conversion of dopamine to noradrenaline.", "general_function": "L-ascorbic acid binding", "gene_names": ["DBH"], "name": "Dopamine beta-hydroxylase", "drug_actions": [{"action": "INHIBITOR", "target": "P09172", "drug": "DB00822"}, {"action": "LIGAND", "target": "P09172", "drug": "DB00988"}]}, "P07515": {"specific_function": "General (non sugar-specific) component of the phosphoenolpyruvate-dependent sugar phosphotransferase system (sugar PTS). This major carbohydrate active-transport system catalyzes the phosphorylation of incoming sugar substrates concomitantly with their translocation across the cell membrane. The phosphoryl group from phosphoenolpyruvate (PEP) is transferred to the phosphoryl carrier protein HPr by enzyme I. Phospho-HPr then transfers it to the permease (enzymes II/III).P-Ser-HPr interacts with the catabolite control protein A (CcpA), forming a complex that binds to DNA at the catabolite response elements cre, operator sites preceding a large number of catabolite-regulated genes. Thus, P-Ser-HPr is a corepressor in carbon catabolite repression (CCR), a mechanism that allows bacteria to coordinate and optimize the utilization of available carbon sources. P-Ser-HPr also plays a role in inducer exclusion, in which it probably interacts with several non-PTS permeases and inhibits their transport activity (By similarity).", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["ptsH"], "name": "Phosphocarrier protein HPr", "drug_actions": []}, "Q08188": {"specific_function": "Catalyzes the calcium-dependent formation of isopeptide cross-links between glutamine and lysine residues in various proteins, as well as the conjugation of polyamines to proteins. Involved in the formation of the cornified envelope (CE), a specialized component consisting of covalent cross-links of proteins beneath the plasma membrane of terminally differentiated keratinocytes. Catalyzes small proline-rich proteins (SPRR1 and SPRR2) and LOR cross-linking to form small interchain oligomers, which are further cross-linked by TGM1 onto the growing CE scaffold (By similarity). In hair follicles, involved in cross-linking structural proteins to hardening the inner root sheath.", "general_function": "Transferase activity, transferring acyl groups", "gene_names": ["TGM3"], "name": "Protein-glutamine gamma-glutamyltransferase E", "drug_actions": []}, "Q96T66": {"specific_function": "Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP. Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency. Can use triazofurin monophosphate (TrMP) as substrate. Can also use GTP and ITP as nucleotide donors. Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD(+). For the pyrophosphorolytic activity, can use NAD(+), NADH, NaAD, nicotinic acid adenine dinucleotide phosphate (NHD), nicotinamide guanine dinucleotide (NGD) as substrates. Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and NaADP(+). Protects against axonal degeneration following injury.", "general_function": "Nicotinate-nucleotide adenylyltransferase activity", "gene_names": ["NMNAT3"], "name": "Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 3", "drug_actions": []}, "O00408": {"specific_function": "Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.Isoform PDE2A2: Regulates Mitochondrial cAMP Levels and Respiration.", "name": "cGMP-dependent 3',5'-cyclic phosphodiesterase", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "O00408", "drug": "DB00201"}, {"action": "INHIBITOR", "target": "O00408", "drug": "DB08811"}], "general_function": "Tpr domain binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE2A"]}, "P01709": {"general_function": "Antigen binding", "gene_names": [], "name": "Ig lambda chain V-II region MGC", "drug_actions": []}, "Q2LU76": {"gene_names": [], "name": "Hypothetical cytosolic protein", "drug_actions": []}, "P10478": {"general_function": "Xylan endo-1,3-beta-xylosidase activity", "gene_names": ["xynZ"], "name": "Endo-1,4-beta-xylanase Z", "drug_actions": []}, "P61313": {"general_function": "Structural constituent of ribosome", "gene_names": ["RPL15"], "name": "60S ribosomal protein L15", "drug_actions": []}, "P03960": {"specific_function": "Part of the high-affinity ATP-driven potassium transport (or Kdp) system, which catalyzes the hydrolysis of ATP coupled with the electrogenic transport of potassium into the cytoplasm (PubMed:2849541, PubMed:8499455, PubMed:23930894). This subunit is responsible for energy coupling to the transport system (PubMed:16354672).", "general_function": "Potassium-transporting atpase activity", "gene_names": ["kdpB"], "name": "Potassium-transporting ATPase ATP-binding subunit", "drug_actions": []}, "Q13907": {"specific_function": "Catalyzes the 1,3-allylic rearrangement of the homoallylic substrate isopentenyl (IPP) to its highly electrophilic allylic isomer, dimethylallyl diphosphate (DMAPP).", "general_function": "Metal ion binding", "gene_names": ["IDI1"], "name": "Isopentenyl-diphosphate Delta-isomerase 1", "drug_actions": []}, "P83844": {"specific_function": "Acts on ADP-mannose and ADP-glucose as well as ADP-ribose. Prevents glycogen biosynthesis. The reaction catalyzed by this enzyme is a limiting step of the gluconeogenic process (By similarity).", "general_function": "Metal ion binding", "gene_names": ["nudF"], "name": "ADP-ribose pyrophosphatase", "drug_actions": []}, "P02746": {"specific_function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.", "gene_names": ["C1QB"], "name": "Complement C1q subcomponent subunit B", "drug_actions": []}, "P35247": {"specific_function": "Contributes to the lung's defense against inhaled microorganisms, organic antigens and toxins. Interacts with compounds such as bacterial lipopolysaccharides, oligosaccharides and fatty acids and modulates leukocyte action in immune response. May participate in the extracellular reorganization or turnover of pulmonary surfactant. Binds strongly maltose residues and to a lesser extent other alpha-glucosyl moieties.", "general_function": "Carbohydrate binding", "gene_names": ["SFTPD"], "name": "Pulmonary surfactant-associated protein D", "drug_actions": []}, "Q3IWB0": {"specific_function": "Catalyzes the non-oxidative deamination of L-tyrosine. Has very low phenylalanine ammonia-lyase activity (in vitro).", "general_function": "Tyrosine ammonia-lyase activity", "gene_names": ["hutH"], "name": "Tyrosine ammonia-lyase", "drug_actions": []}, "P35241": {"specific_function": "Probably plays a crucial role in the binding of the barbed end of actin filaments to the plasma membrane.", "general_function": "Protein kinase a binding", "gene_names": ["RDX"], "name": "Radixin", "drug_actions": []}, "P35243": {"specific_function": "Seems to be implicated in the pathway from retinal rod guanylate cyclase to rhodopsin. May be involved in the inhibition of the phosphorylation of rhodopsin in a calcium-dependent manner. The calcium-bound recoverin prolongs the photoresponse.", "general_function": "Calcium sensitive guanylate cyclase activator activity", "gene_names": ["RCVRN"], "name": "Recoverin", "drug_actions": []}, "O75438": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFB1"], "name": "NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 1", "drug_actions": []}, "P11124": {"specific_function": "Rna-dependent RNA polymerase part of the packaging complex that packages the viral RNA segments, replicate them into a double-stranded form and transcribe them.", "general_function": "Rna-directed rna polymerase activity", "gene_names": ["P2"], "name": "RNA-directed RNA polymerase", "drug_actions": []}, "P08620": {"specific_function": "Plays an important role in the regulation of embryonic development, cell proliferation, and cell differentiation. Required for normal limb and cardiac valve development during embryogenesis.", "general_function": "Heparin binding", "gene_names": ["FGF4"], "name": "Fibroblast growth factor 4", "drug_actions": [{"action": "INHIBITOR", "target": "P08620", "drug": "DB00686"}]}, "Q01118": {"specific_function": "Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient.", "name": "Sodium channel protein type 7 subunit alpha", "drug_actions": [], "general_function": "Voltage-gated sodium channel activity", "in_complexes": ["Sodium channel protein"], "gene_names": ["SCN7A"]}, "P0C5C2": {"gene_names": ["cmaA1"], "name": "Cyclopropane mycolic acid synthase 1", "drug_actions": []}, "P01031": {"specific_function": "Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed:8182049). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.", "general_function": "Receptor binding", "gene_names": ["C5"], "name": "Complement C5", "drug_actions": [{"action": "BINDER", "target": "P01031", "drug": "DB00028"}, {"action": "ANTIBODY", "target": "P01031", "drug": "DB01257"}]}, "Q44048": {"general_function": "Metal ion binding", "gene_names": ["mndD"], "name": "3,4-dihydroxyphenylacetate 2,3-dioxygenase", "drug_actions": []}, "Q88H32": {"general_function": "Nucleotide binding", "gene_names": [], "name": "Ornithine cyclodeaminase", "drug_actions": []}, "Q9UK17": {"specific_function": "Pore-forming (alpha) subunit of voltage-gated rapidly inactivating A-type potassium channels. May contribute to I(To) current in heart and I(Sa) current in neurons. Channel properties are modulated by interactions with other alpha subunits and with regulatory subunits.", "general_function": "Metal ion binding", "gene_names": ["KCND3"], "name": "Potassium voltage-gated channel subfamily D member 3", "drug_actions": [{"action": "INHIBITOR", "target": "Q9UK17", "drug": "DB00280"}, {"action": "INHIBITOR", "target": "Q9UK17", "drug": "DB00321"}, {"action": "INHIBITOR", "target": "Q9UK17", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "Q9UK17", "drug": "DB06637"}]}, "P02749": {"specific_function": "Binds to various kinds of negatively charged substances such as heparin, phospholipids, and dextran sulfate. May prevent activation of the intrinsic blood coagulation cascade by binding to phospholipids on the surface of damaged cells.", "general_function": "Phospholipid binding", "gene_names": ["APOH"], "name": "Beta-2-glycoprotein 1", "drug_actions": []}, "P16006": {"specific_function": "Supplies the nucleotide substrate for thymidylate synthetase.", "general_function": "Zinc ion binding", "gene_names": ["CD"], "name": "Deoxycytidylate deaminase", "drug_actions": []}, "Q92831": {"specific_function": "Functions as a histone acetyltransferase (HAT) to promote transcriptional activation. Has significant histone acetyltransferase activity with core histones (H3 and H4), and also with nucleosome core particles. Also acetylates non-histone proteins, such as ACLY. Inhibits cell-cycle progression and counteracts the mitogenic activity of the adenoviral oncoprotein E1A. In case of HIV-1 infection, it is recruited by the viral protein Tat. Regulates Tat's transactivating activity and may help inducing chromatin remodeling of proviral genes. Acts as a circadian transcriptional coactivator which enhances the activity of the circadian transcriptional activators: NPAS2-ARNTL/BMAL1 and CLOCK-ARNTL/BMAL1 heterodimers.", "general_function": "Transcription factor binding", "gene_names": ["KAT2B"], "name": "Histone acetyltransferase KAT2B", "drug_actions": []}, "P17931": {"specific_function": "Galactose-specific lectin which binds IgE. May mediate with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. Together with DMBT1, required for terminal differentiation of columnar epithelial cells during early embryogenesis (By similarity). In the nucleus: acts as a pre-mRNA splicing factor. Involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells.", "general_function": "Poly(a) rna binding", "gene_names": ["LGALS3"], "name": "Galectin-3", "drug_actions": []}, "P17936": {"specific_function": "IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Also exhibits IGF-independent antiproliferative and apoptotic effects mediated by its receptor TMEM219/IGFBP-3R.", "general_function": "Protein tyrosine phosphatase activator activity", "gene_names": ["IGFBP3"], "name": "Insulin-like growth factor-binding protein 3", "drug_actions": []}, "Q9A1X4": {"gene_names": ["rplC"], "name": "50S ribosomal protein L3", "drug_actions": [{"action": "INHIBITOR", "target": "Q9A1X4", "drug": "DB01256"}]}, "Q07982": {"general_function": "Glucose-fructose oxidoreductase activity", "gene_names": ["gfo"], "name": "Glucose--fructose oxidoreductase", "drug_actions": []}, "P09850": {"general_function": "Endo-1,4-beta-xylanase activity", "gene_names": ["xlnA"], "name": "Endo-1,4-beta-xylanase", "drug_actions": []}, "P06280": {"general_function": "Receptor binding", "gene_names": ["GLA"], "name": "Alpha-galactosidase A", "drug_actions": []}, "Q99884": {"specific_function": "Terminates the action of proline by its high affinity sodium-dependent reuptake into presynaptic terminals.", "general_function": "Neurotransmitter:sodium symporter activity", "gene_names": ["SLC6A7"], "name": "Sodium-dependent proline transporter", "drug_actions": []}, "P21695": {"general_function": "Nad binding", "gene_names": ["GPD1"], "name": "Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic", "drug_actions": []}, "Q46822": {"specific_function": "Catalyzes the 1,3-allylic rearrangement of the homoallylic substrate isopentenyl (IPP) to its highly electrophilic allylic isomer, dimethylallyl diphosphate (DMAPP).", "general_function": "Metal ion binding", "gene_names": ["idi"], "name": "Isopentenyl-diphosphate Delta-isomerase", "drug_actions": []}, "P19480": {"specific_function": "Serves to protect the cell against DNA damage by alkyl hydroperoxides. It can use either NADH or NADPH as electron donor for direct reduction of redox dyes or of alkyl hydroperoxides when combined with the AhpC protein.", "general_function": "Protein disulfide oxidoreductase activity", "gene_names": ["ahpF"], "name": "Alkyl hydroperoxide reductase subunit F", "drug_actions": []}, "P43457": {"specific_function": "Involved in ATP-driven sodium extrusion.", "general_function": "Hydrogen ion transmembrane transporter activity", "gene_names": ["ntpK"], "name": "V-type sodium ATPase subunit K", "drug_actions": []}, "Q99643": {"specific_function": "Membrane-anchoring subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q).", "general_function": "Succinate dehydrogenase activity", "gene_names": ["SDHC"], "name": "Succinate dehydrogenase cytochrome b560 subunit, mitochondrial", "drug_actions": []}, "Q9UGN5": {"specific_function": "Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks.", "general_function": "Nad+ adp-ribosyltransferase activity", "gene_names": ["PARP2"], "name": "Poly [ADP-ribose] polymerase 2", "drug_actions": [{"action": "INHIBITOR", "target": "Q9UGN5", "drug": "DB09074"}]}, "O43570": {"specific_function": "Reversible hydration of carbon dioxide.", "general_function": "Zinc ion binding", "gene_names": ["CA12"], "name": "Carbonic anhydrase 12", "drug_actions": [{"action": "INHIBITOR", "target": "O43570", "drug": "DB00562"}, {"action": "INHIBITOR", "target": "O43570", "drug": "DB00774"}, {"action": "INHIBITOR", "target": "O43570", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "O43570", "drug": "DB00999"}, {"action": "INHIBITOR", "target": "O43570", "drug": "DB08846"}]}, "Q02761": {"specific_function": "Component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is a respiratory chain that generates an electrochemical potential coupled to ATP synthesis.", "general_function": "Ubiquinol-cytochrome-c reductase activity", "gene_names": ["petB"], "name": "Cytochrome b", "drug_actions": []}, "Q9X242": {"specific_function": "May play a role in 30S ribosomal subunit biogenesis. Unusual circulary permuted GTPase that catalyzes rapid hydrolysis of GTP with a slow catalytic turnover.", "general_function": "Metal ion binding", "gene_names": ["rsgA"], "name": "Putative ribosome biogenesis GTPase RsgA", "drug_actions": []}, "Q96AE4": {"specific_function": "Regulates MYC expression by binding to a single-stranded far-upstream element (FUSE) upstream of the MYC promoter. May act both as activator and repressor of transcription.", "general_function": "Transcriptional activator activity, rna polymerase ii distal enhancer sequence-specific binding", "gene_names": ["FUBP1"], "name": "Far upstream element-binding protein 1", "drug_actions": []}, "O75380": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFS6"], "name": "NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial", "drug_actions": []}, "Q7MUW6": {"specific_function": "Serine proteinase. Releases tripeptides from the free amino terminus of proteins. Has a requirement for Pro in the P1 position, but is inactivated by Pro in the P1' position.", "general_function": "Serine-type peptidase activity", "gene_names": ["ptpA"], "name": "Prolyl tripeptidyl peptidase", "drug_actions": []}, "O75891": {"general_function": "Methyltransferase activity", "gene_names": ["ALDH1L1"], "name": "Cytosolic 10-formyltetrahydrofolate dehydrogenase", "drug_actions": [{"action": "COFACTOR", "target": "O75891", "drug": "DB00116"}]}, "Q9HYN5": {"general_function": "Metal ion binding", "gene_names": ["lecB"], "name": "Fucose-binding lectin PA-IIL", "drug_actions": []}, "P04035": {"specific_function": "Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including ubiquinone and geranylgeranyl proteins.", "general_function": "Nadph binding", "gene_names": ["HMGCR"], "name": "3-hydroxy-3-methylglutaryl-coenzyme A reductase", "drug_actions": [{"action": "INHIBITOR", "target": "P04035", "drug": "DB00175"}, {"action": "INHIBITOR", "target": "P04035", "drug": "DB00227"}, {"action": "INHIBITOR", "target": "P04035", "drug": "DB00439"}, {"action": "INHIBITOR", "target": "P04035", "drug": "DB00641"}, {"action": "INHIBITOR", "target": "P04035", "drug": "DB01076"}, {"action": "INHIBITOR", "target": "P04035", "drug": "DB01095"}, {"action": "INHIBITOR", "target": "P04035", "drug": "DB01098"}, {"action": "INHIBITOR", "target": "P04035", "drug": "DB06693"}, {"action": "INHIBITOR", "target": "P04035", "drug": "DB08860"}]}, "Q9BXA1": {"general_function": "Transaminase activity", "gene_names": [], "name": "Hepatic peroxysomal alanine:glyoxylate aminotransferase", "drug_actions": [{"action": "COFACTOR", "target": "Q9BXA1", "drug": "DB00114"}]}, "O75899": {"specific_function": "Component of a heterodimeric G-protein coupled receptor for GABA, formed by GABBR1 and GABBR2. Within the heterodimeric GABA receptor, only GABBR1 seems to bind agonists, while GABBR2 mediates coupling to G proteins. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase, stimulates phospholipase A2, activates potassium channels, inactivates voltage-dependent calcium-channels and modulates inositol phospholipid hydrolysis. Plays a critical role in the fine-tuning of inhibitory synaptic transmission. Pre-synaptic GABA receptor inhibits neurotransmitter release by down-regulating high-voltage activated calcium channels, whereas postsynaptic GABA receptor decreases neuronal excitability by activating a prominent inwardly rectifying potassium (Kir) conductance that underlies the late inhibitory postsynaptic potentials. Not only implicated in synaptic inhibition but also in hippocampal long-term potentiation, slow wave sleep, muscle relaxation and antinociception.", "general_function": "G-protein coupled gaba receptor activity", "gene_names": ["GABBR2"], "name": "Gamma-aminobutyric acid type B receptor subunit 2", "drug_actions": [{"action": "AGONIST", "target": "O75899", "drug": "DB00181"}, {"action": "AGONIST", "target": "O75899", "drug": "DB08891"}, {"action": "AGONIST", "target": "O75899", "drug": "DB08892"}]}, "Q9X2W8": {"general_function": "Photoreceptor activity", "gene_names": ["pph"], "name": "PPH", "drug_actions": []}, "Q9BXA5": {"specific_function": "Receptor for succinate.", "general_function": "G-protein coupled receptor activity", "gene_names": ["SUCNR1"], "name": "Succinate receptor 1", "drug_actions": []}, "Q92637": {"specific_function": "May bind to the Fc region of immunoglobulins gamma with a low affinity compared to FCGR1A. May function in the humoral immune response.", "general_function": "Immunoglobulin receptor activity", "gene_names": ["FCGR1B"], "name": "High affinity immunoglobulin gamma Fc receptor IB", "drug_actions": [{"action": "ANTAGONIST", "target": "Q92637", "drug": "DB00028"}]}, "P55017": {"specific_function": "Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.", "general_function": "Transporter activity", "gene_names": ["SLC12A3"], "name": "Solute carrier family 12 member 3", "drug_actions": [{"action": "INHIBITOR", "target": "P55017", "drug": "DB00436"}, {"action": "INHIBITOR", "target": "P55017", "drug": "DB00524"}, {"action": "INHIBITOR", "target": "P55017", "drug": "DB00562"}, {"action": "INHIBITOR", "target": "P55017", "drug": "DB00880"}, {"action": "INHIBITOR", "target": "P55017", "drug": "DB00999"}, {"action": "UNKNOWN", "target": "P55017", "drug": "DB01119"}, {"action": "INHIBITOR", "target": "P55017", "drug": "DB01324"}, {"action": "INHIBITOR", "target": "P55017", "drug": "DB01325"}]}, "P00720": {"specific_function": "Endolysin with lysozyme activity that degrades host peptidoglycans and participates with the holin and spanin proteins in the sequential events which lead to the programmed host cell lysis releasing the mature viral particles. Once the holin has permeabilized the host cell membrane, the endolysin can reach the periplasm and break down the peptidoglycan layer.", "general_function": "Lysozyme activity", "gene_names": ["E"], "name": "Endolysin", "drug_actions": []}, "P09391": {"specific_function": "Rhomboid-type serine protease that catalyzes intramembrane proteolysis.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["glpG"], "name": "Rhomboid protease GlpG", "drug_actions": []}, "O60760": {"specific_function": "Bifunctional enzyme which catalyzes both the conversion of PGH2 to PGD2, a prostaglandin involved in smooth muscle contraction/relaxation and a potent inhibitor of platelet aggregation, and the conjugation of glutathione with a wide range of aryl halides and organic isothiocyanates. Also exhibits low glutathione-peroxidase activity towards cumene hydroperoxide.", "general_function": "Protein homodimerization activity", "gene_names": ["HPGDS"], "name": "Hematopoietic prostaglandin D synthase", "drug_actions": []}, "P0A333": {"specific_function": "Acts as a pH-gated potassium ion channel; changing the cytosolic pH from 7 to 4 opens the channel.", "general_function": "Voltage-gated potassium channel activity", "gene_names": ["kcsA"], "name": "pH-gated potassium channel KcsA", "drug_actions": []}, "P23222": {"specific_function": "Putative oxygen sensor; modulates the activity of FixJ, a transcriptional activator of nitrogen fixation fixK gene. FixL probably acts as a kinase that phosphorylates FixJ.", "general_function": "Phosphorelay sensor kinase activity", "gene_names": ["fixL"], "name": "Sensor protein FixL", "drug_actions": []}, "P62714": {"specific_function": "PP2A can modulate the activity of phosphorylase B kinase casein kinase 2, mitogen-stimulated S6 kinase, and MAP-2 kinase.", "general_function": "Protein serine/threonine phosphatase activity", "gene_names": ["PPP2CB"], "name": "Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform", "drug_actions": []}, "Q4W8W1": {"general_function": "Pyrroline-5-carboxylate reductase activity", "gene_names": ["P5CR2"], "name": "Pyrroline-5-carboxylate reductase", "drug_actions": []}, "Q05901": {"specific_function": "After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.", "general_function": "Drug binding", "gene_names": ["CHRNB3"], "name": "Neuronal acetylcholine receptor subunit beta-3", "drug_actions": [{"action": "AGONIST", "target": "Q05901", "drug": "DB00184"}, {"action": "ALLOSTERIC MODULATOR", "target": "Q05901", "drug": "DB00674"}]}, "Q15185": {"specific_function": "Cytosolic prostaglandin synthase that catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2) (PubMed:10922363). Molecular chaperone that localizes to genomic response elements in a hormone-dependent manner and disrupts receptor-mediated transcriptional activation, by promoting disassembly of transcriptional regulatory complexes (PubMed:11274138, PubMed:12077419). Facilitates HIF alpha proteins hydroxylation via interaction with EGLN1/PHD2, leading to recruit EGLN1/PHD2 to the HSP90 pathway (PubMed:24711448).", "general_function": "Unfolded protein binding", "gene_names": ["PTGES3"], "name": "Prostaglandin E synthase 3", "drug_actions": []}, "P17596": {"specific_function": "The fumarate reductase enzyme complex is required for fumarate respiration using formate or sulfide as electron donor.", "general_function": "Succinate dehydrogenase (ubiquinone) activity", "gene_names": ["frdB"], "name": "Fumarate reductase iron-sulfur subunit", "drug_actions": []}, "P0A733": {"general_function": "Methylglyoxal synthase activity", "gene_names": ["mgsA"], "name": "Methylglyoxal synthase", "drug_actions": []}, "P17735": {"specific_function": "Transaminase involved in tyrosine breakdown. Converts tyrosine to p-hydroxyphenylpyruvate. Can catalyze the reverse reaction, using glutamic acid, with 2-oxoglutarate as cosubstrate (in vitro). Has much lower affinity and transaminase activity towards phenylalanine.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["TAT"], "name": "Tyrosine aminotransferase", "drug_actions": [{"action": "COFACTOR", "target": "P17735", "drug": "DB00114"}]}, "P20035": {"specific_function": "Converts guanine to guanosine monophosphate, and hypoxanthine to inosine monophosphate. Transfers the 5-phosphoribosyl group from 5-phosphoribosylpyrophosphate onto the purine. Works with guanine, hypoxanthine and xanthine. Plays a central role in the generation of purine nucleotides through the purine salvage pathway.", "general_function": "Xanthine phosphoribosyltransferase activity", "gene_names": ["LACZ"], "name": "Hypoxanthine-guanine-xanthine phosphoribosyltransferase", "drug_actions": []}, "P08048": {"specific_function": "Probable transcriptional activator. Binds to the consensus sequence 5'-AGGCCY-3'.", "general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": ["ZFY"], "name": "Zinc finger Y-chromosomal protein", "drug_actions": []}, "Q05586": {"specific_function": "NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (By similarity).", "name": "Glutamate receptor ionotropic, NMDA 1", "drug_actions": [{"action": "BLOCKER", "target": "Q05586", "drug": "DB00289"}, {"action": "ANTAGONIST", "target": "Q05586", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "Q05586", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "Q05586", "drug": "DB00454"}, {"action": "ANTAGONIST", "target": "Q05586", "drug": "DB00659"}, {"action": "BINDER", "target": "Q05586", "drug": "DB01043"}, {"action": "ANTAGONIST", "target": "Q05586", "drug": "DB01173"}, {"action": "ANTAGONIST", "target": "Q05586", "drug": "DB01174"}, {"action": "AGONIST", "target": "Q05586", "drug": "DB01708"}, {"action": "INHIBITOR", "target": "Q05586", "drug": "DB04896"}, {"action": "ACTIVATOR", "target": "Q05586", "drug": "DB06151"}, {"action": "ANTAGONIST", "target": "Q05586", "drug": "DB06738"}, {"action": "ANTAGONIST", "target": "Q05586", "drug": "DB06741"}, {"action": "ANTAGONIST", "target": "Q05586", "drug": "DB08838"}, {"action": "ANTAGONIST", "target": "Q05586", "drug": "DB08954"}], "general_function": "Voltage-gated cation channel activity", "in_complexes": ["Glutamate (NMDA) receptor", "NMDA receptor"], "gene_names": ["GRIN1"]}, "Q9NPF7": {"specific_function": "Associates with IL12B to form the IL-23 interleukin, a heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 may constitute with IL-17 an acute response to infection in peripheral tissues. IL-23 binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory rather than naive T-cells and promotes production of proinflammatory cytokines. IL-23 induces autoimmune inflammation and thus may be responsible for autoimmune inflammatory diseases and may be important for tumorigenesis.", "gene_names": ["IL23A"], "name": "Interleukin-23 subunit alpha", "drug_actions": []}, "P25774": {"specific_function": "Thiol protease. Key protease responsible for the removal of the invariant chain from MHC class II molecules. The bond-specificity of this proteinase is in part similar to the specificities of cathepsin L and cathepsin N.", "general_function": "Proteoglycan binding", "gene_names": ["CTSS"], "name": "Cathepsin S", "drug_actions": []}, "Q05581": {"general_function": "Iron ion binding", "gene_names": ["cs1"], "name": "Clavaminate synthase 1", "drug_actions": []}, "P49354": {"specific_function": "Essential subunit of both the farnesyltransferase and the geranylgeranyltransferase complex. Contributes to the transfer of a farnesyl or geranylgeranyl moiety from farnesyl or geranylgeranyl diphosphate to a cysteine at the fourth position from the C-terminus of several proteins having the C-terminal sequence Cys-aliphatic-aliphatic-X. May positively regulate neuromuscular junction development downstream of MUSK via its function in RAC1 prenylation and activation.", "general_function": "Rab geranylgeranyltransferase activity", "gene_names": ["FNTA"], "name": "Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha", "drug_actions": []}, "P25779": {"specific_function": "Hydrolyzes chromogenic peptides at the carboxyl Arg or Lys; requires at least one more amino acid, preferably Arg, Phe, Val or Leu, between the terminal Arg or Lys and the amino-blocking group.The cysteine protease may play an important role in the development and differentiation of the parasites at several stages of their life cycle.", "general_function": "Cysteine-type endopeptidase activity", "gene_names": [], "name": "Cruzipain", "drug_actions": []}, "O94903": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["PROSC"], "name": "Proline synthase co-transcribed bacterial homolog protein", "drug_actions": [{"action": "COFACTOR", "target": "O94903", "drug": "DB00114"}]}, "P0C1V1": {"specific_function": "Lyses erythrocytes and many other mammalian cells.", "gene_names": ["hld"], "name": "Delta-hemolysin", "drug_actions": []}, "P11226": {"specific_function": "Calcium-dependent lectin involved in innate immune defense. Binds mannose, fucose and N-acetylglucosamine on different microorganisms and activates the lectin complement pathway. Binds to late apoptotic cells, as well as to apoptotic blebs and to necrotic cells, but not to early apoptotic cells, facilitating their uptake by macrophages. May bind DNA.", "general_function": "Receptor binding", "gene_names": ["MBL2"], "name": "Mannose-binding protein C", "drug_actions": []}, "Q6UWM7": {"general_function": "Hydrolase activity, hydrolyzing o-glycosyl compounds", "gene_names": ["LCTL"], "name": "Lactase-like protein", "drug_actions": []}, "P54548": {"specific_function": "Zinc phosphodiesterase, which displays some tRNA 3'-processing endonuclease activity. Probably involved in tRNA maturation, by removing a 3'-trailer from precursor tRNA.", "general_function": "Zinc ion binding", "gene_names": ["rnz"], "name": "Ribonuclease Z", "drug_actions": []}, "P96558": {"specific_function": "Catalyzes the attachment of 4-epi-vancosamine from a TDP donor to the beta-OH-Tyr-6 of the aglycone cosubstrate in the biosynthesis of glycopeptide antibiotic chloroeremomycin, a member of the vancomycin group of antibiotics. Strongly prefers devancoaminyl-vancomycin (DVV) as substrate rather than the heptapeptide vancomycin aglycone (AGV). Acts downstream of GtfB.", "general_function": "Transferase activity, transferring hexosyl groups", "gene_names": ["gtfA"], "name": "dTDP-epi-vancosaminyltransferase", "drug_actions": [{"action": "OTHER", "target": "P96558", "drug": "DB00512"}]}, "Q13126": {"specific_function": "Catalyzes the reversible phosphorylation of S-methyl-5'-thioadenosine (MTA) to adenine and 5-methylthioribose-1-phosphate. Involved in the breakdown of MTA, a major by-product of polyamine biosynthesis. Responsible for the first step in the methionine salvage pathway after MTA has been generated from S-adenosylmethionine. Has broad substrate specificity with 6-aminopurine nucleosides as preferred substrates.", "general_function": "S-methyl-5-thioadenosine phosphorylase activity", "gene_names": ["MTAP"], "name": "S-methyl-5'-thioadenosine phosphorylase", "drug_actions": []}, "Q2YY41": {"general_function": "Coenzyme transport and metabolism", "gene_names": ["dfrB"], "name": "Dihydrofolate reductase", "drug_actions": []}, "P30411": {"specific_function": "Receptor for bradykinin. It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system.", "general_function": "Type 1 angiotensin receptor binding", "gene_names": ["BDKRB2"], "name": "B2 bradykinin receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "P30411", "drug": "DB06196"}]}, "P02941": {"specific_function": "Receptor for the attractant L-aspartate and related amino and dicarboxylic acids. Tar mediates taxis away from the repellents cobalt and nickel. Unlike in E.coli tar, it does not mediates maltose taxis.Chemotactic-signal transducers respond to changes in the concentration of attractants and repellents in the environment, transduce a signal from the outside to the inside of the cell, and facilitate sensory adaptation through the variation of the level of methylation. Attractants increase the level of methylation while repellents decrease the level of methylation, the methyl groups are added by the methyltransferase CheR and removed by the methylesterase CheB.", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["tar"], "name": "Methyl-accepting chemotaxis protein II", "drug_actions": []}, "O43246": {"specific_function": "Involved in the transport of the cationic amino acids (arginine, lysine and ornithine).", "general_function": "L-ornithine transmembrane transporter activity", "gene_names": ["SLC7A4"], "name": "Cationic amino acid transporter 4", "drug_actions": []}, "Q9NRF9": {"specific_function": "Forms a complex with DNA polymerase epsilon subunit CHRAC1 and binds naked DNA, which is then incorporated into chromatin, aided by the nucleosome-remodeling activity of ISWI/SNF2H and ACF1.", "general_function": "Dna-directed dna polymerase activity", "gene_names": ["POLE3"], "name": "DNA polymerase epsilon subunit 3", "drug_actions": [{"action": "INHIBITOR", "target": "Q9NRF9", "drug": "DB00242"}]}, "Q9RC92": {"specific_function": "Catalyzes the hydrolysis of oligosaccharides with unsaturated glucuronyl residues at the non-reducing terminal, to a sugar or an amino sugar, and an unsaturated D-glucuronic acid (GlcA), which is nonenzymatically converted immediately to alpha-keto acid.", "general_function": "Hydrolase activity, acting on glycosyl bonds", "gene_names": ["ugl"], "name": "Unsaturated glucuronyl hydrolase", "drug_actions": []}, "Q7WUJ1": {"general_function": "Protein tyrosine phosphatase activity", "gene_names": ["phyA"], "name": "Myo-inositol hexaphosphate phosphohydrolase", "drug_actions": []}, "P0A590": {"specific_function": "ATP + L-glutamate + NH(3) = ADP + phosphate + L-glutamine", "general_function": "Involved in glutamate-ammonia ligase activity", "gene_names": ["glnA1"], "name": "Glutamine synthetase 1", "drug_actions": []}, "Q9KKU4": {"general_function": "Metal ion binding", "gene_names": [], "name": "Organic hydroperoxide resistance protein, putative", "drug_actions": []}, "P02930": {"specific_function": "Outer membrane channel, which is required for the function of several efflux systems such as AcrAB-TolC, AcrEF-TolC, EmrAB-TolC and MacAB-TolC. These systems are involved in export of antibiotics and other toxic compounds from the cell. TolC is also involved in import of colicin E1 into the cells.", "general_function": "Porin activity", "gene_names": ["tolC"], "name": "Outer membrane protein TolC", "drug_actions": []}, "P35568": {"specific_function": "May mediate the control of various cellular processes by insulin. When phosphorylated by the insulin receptor binds specifically to various cellular proteins containing SH2 domains such as phosphatidylinositol 3-kinase p85 subunit or GRB2. Activates phosphatidylinositol 3-kinase when bound to the regulatory p85 subunit (By similarity).", "general_function": "Transmembrane receptor protein tyrosine kinase adaptor activity", "gene_names": ["IRS1"], "name": "Insulin receptor substrate 1", "drug_actions": []}, "P15428": {"specific_function": "Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells.", "general_function": "Protein homodimerization activity", "gene_names": ["HPGD"], "name": "15-hydroxyprostaglandin dehydrogenase [NAD(+)]", "drug_actions": []}, "P0A6I9": {"specific_function": "Catalyzes the phosphorylation of the 3'-hydroxyl group of dephosphocoenzyme A to form coenzyme A.", "general_function": "Dephospho-coa kinase activity", "gene_names": ["coaE"], "name": "Dephospho-CoA kinase", "drug_actions": []}, "O68601": {"general_function": "Nitrite reductase (no-forming) activity", "gene_names": ["nir"], "name": "Copper-containing nitrite reductase", "drug_actions": []}, "O68600": {"general_function": "Catalytic activity", "gene_names": ["fcbB"], "name": "4-chlorobenzoyl CoA dehalogenase", "drug_actions": []}, "P0AEE5": {"specific_function": "This protein is involved in the active transport of galactose and glucose. It plays a role in the chemotaxis towards the two sugars by interacting with the trg chemoreceptor.", "general_function": "Metal ion binding", "gene_names": ["mglB"], "name": "D-galactose-binding periplasmic protein", "drug_actions": []}, "Q81L49": {"general_function": "Hydrolase activity", "gene_names": ["srtB"], "name": "Sortase", "drug_actions": []}, "Q96Q83": {"specific_function": "Dioxygenase that repairs alkylated DNA containing 1-methyladenine (1meA) and 3-methylcytosine (3meC) by oxidative demethylation. Has a strong preference for single-stranded DNA. Able to process alkylated 3mC within double-stranded regions via its interaction with ASCC3, which promotes DNA unwinding to generate single-stranded substrate needed for ALKHB3. May also act on RNA. Requires molecular oxygen, alpha-ketoglutarate and iron.", "general_function": "L-ascorbic acid binding", "gene_names": ["ALKBH3"], "name": "Alpha-ketoglutarate-dependent dioxygenase alkB homolog 3", "drug_actions": []}, "P31992": {"specific_function": "Can use enol isomers of phenylpyruvate, 2-hydroxy-2,4-pentadienoate and (p-hydroxyphenyl)pyruvate as substrates.", "general_function": "Intramolecular oxidoreductase activity, interconverting keto- and enol-groups", "gene_names": ["pptA"], "name": "Tautomerase PptA", "drug_actions": []}, "P26466": {"specific_function": "Involved in the transport of maltose and maltodextrins. Does not act as a receptor for phages.", "general_function": "Maltose transporting porin activity", "gene_names": ["lamB"], "name": "Maltoporin", "drug_actions": []}, "Q9Y6I3": {"specific_function": "Binds to membranes enriched in phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2). Modifies membrane curvature and facilitates the formation of clathrin-coated invaginations (By similarity). Regulates receptor-mediated endocytosis.", "general_function": "Lipid binding", "gene_names": ["EPN1"], "name": "Epsin-1", "drug_actions": []}, "O43424": {"specific_function": "Receptor for glutamate. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists.", "general_function": "Scaffold protein binding", "gene_names": ["GRID2"], "name": "Glutamate receptor ionotropic, delta-2", "drug_actions": []}, "P45066": {"specific_function": "Cell wall formation.", "general_function": "Udp-n-acetylmuramate-l-alanine ligase activity", "gene_names": ["murC"], "name": "UDP-N-acetylmuramate--L-alanine ligase", "drug_actions": []}, "Q9ULX7": {"specific_function": "Reversible hydration of carbon dioxide.", "general_function": "Metal ion binding", "gene_names": ["CA14"], "name": "Carbonic anhydrase 14", "drug_actions": [{"action": "INHIBITOR", "target": "Q9ULX7", "drug": "DB00819"}, {"action": "INHIBITOR", "target": "Q9ULX7", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q9ULX7", "drug": "DB08846"}]}, "Q9UNX3": {"general_function": "Structural constituent of ribosome", "gene_names": ["RPL26L1"], "name": "60S ribosomal protein L26-like 1", "drug_actions": []}, "Q83JC4": {"specific_function": "This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis.", "general_function": "Translation elongation factor activity", "gene_names": ["tufA"], "name": "Elongation factor Tu", "drug_actions": []}, "Q9HCR9": {"specific_function": "Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides cAMP and cGMP. Catalyzes the hydrolysis of both cAMP and cGMP to 5'-AMP and 5'-GMP, respectively.", "name": "Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "Q9HCR9", "drug": "DB00201"}, {"action": "INHIBITOR", "target": "Q9HCR9", "drug": "DB00820"}], "general_function": "Metal ion binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE11A"]}, "P31995": {"specific_function": "Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells.", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["FCGR2C"], "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "drug_actions": [{"action": "ANTAGONIST", "target": "P31995", "drug": "DB00028"}]}, "Q16850": {"specific_function": "Catalyzes C14-demethylation of lanosterol; it transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol.", "general_function": "Sterol 14-demethylase activity", "gene_names": ["CYP51A1"], "name": "Lanosterol 14-alpha demethylase", "drug_actions": [{"action": "INHIBITOR", "target": "Q16850", "drug": "DB01007"}, {"action": "INHIBITOR", "target": "Q16850", "drug": "DB01167"}]}, "Q16853": {"specific_function": "Cell adhesion protein that participates in lymphocyte extravasation and recirculation by mediating the binding of lymphocytes to peripheral lymph node vascular endothelial cells in an L-selectin-independent fashion. Has semicarbazide-sensitive (SSAO) monoamine oxidase activity. May play a role in adipogenesis.", "general_function": "Tryptamine:oxygen oxidoreductase (deaminating) activity", "gene_names": ["AOC3"], "name": "Membrane primary amine oxidase", "drug_actions": [{"action": "INHIBITOR", "target": "Q16853", "drug": "DB00780"}, {"action": "INHIBITOR", "target": "Q16853", "drug": "DB01275"}]}, "P99999": {"specific_function": "Electron carrier protein. The oxidized form of the cytochrome c heme group can accept an electron from the heme group of the cytochrome c1 subunit of cytochrome reductase. Cytochrome c then transfers this electron to the cytochrome oxidase complex, the final protein carrier in the mitochondrial electron-transport chain.Plays a role in apoptosis. Suppression of the anti-apoptotic members or activation of the pro-apoptotic members of the Bcl-2 family leads to altered mitochondrial membrane permeability resulting in release of cytochrome c into the cytosol. Binding of cytochrome c to Apaf-1 triggers the activation of caspase-9, which then accelerates apoptosis by activating other caspases.", "general_function": "Metal ion binding", "gene_names": ["CYCS"], "name": "Cytochrome c", "drug_actions": [{"action": "NEGATIVE MODULATOR", "target": "P99999", "drug": "DB01017"}]}, "P04626": {"specific_function": "Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth.", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["ERBB2"], "name": "Receptor tyrosine-protein kinase erbB-2", "drug_actions": [{"action": "ANTIBODY", "target": "P04626", "drug": "DB00072"}, {"action": "ANTAGONIST", "target": "P04626", "drug": "DB01259"}, {"action": "ANTIBODY", "target": "P04626", "drug": "DB05773"}, {"action": "ANTIBODY", "target": "P04626", "drug": "DB06366"}, {"action": "INHIBITOR", "target": "P04626", "drug": "DB08916"}]}, "Q16857": {"general_function": "Iron ion binding", "gene_names": ["CDO-1"], "name": "Cysteine dioxygenase", "drug_actions": []}, "P0AGC3": {"specific_function": "Murein-degrading enzyme. Catalyzes the cleavage of the glycosidic bonds between N-acetylmuramic acid and N-acetylglucosamine residues in peptidoglycan. May play a role in recycling of muropeptides during cell elongation and/or cell division.", "general_function": "Lytic transglycosylase activity", "gene_names": ["slt"], "name": "Soluble lytic murein transglycosylase", "drug_actions": []}, "P06864": {"specific_function": "The wild-type enzyme is an ineffective lactase. Two classes of point mutations dramatically improve activity of the enzyme.", "general_function": "Carbohydrate binding", "gene_names": ["ebgA"], "name": "Evolved beta-galactosidase subunit alpha", "drug_actions": [{"action": "OTHER", "target": "P06864", "drug": "DB00581"}]}, "P04629": {"specific_function": "Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand, it can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axonal extension through NTRK1 but has no effect on neuron survival. Upon dimeric NGF ligand-binding, undergoes homodimerization, autophosphorylation and activation. Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation. Through SHC1 and FRS2 activates a GRB2-Ras-MAPK cascade that regulates cell differentiation and survival. Through PLCG1 controls NF-Kappa-B activation and the transcription of genes involved in cell survival. Through SHC1 and SH2B1 controls a Ras-PI3 kinase-AKT1 signaling cascade that is also regulating survival. In absence of ligand and activation, may promote cell death, making the survival of neurons dependent on trophic factors.Isoform TrkA-III is resistant to NGF, constitutively activates AKT1 and NF-kappa-B and is unable to activate the Ras-MAPK signaling cascade. Antagonizes the anti-proliferative NGF-NTRK1 signaling that promotes neuronal precursors differentiation. Isoform TrkA-III promotes angiogenesis and has oncogenic activity when overexpressed.", "general_function": "Transmembrane receptor protein tyrosine kinase activity", "gene_names": ["NTRK1"], "name": "High affinity nerve growth factor receptor", "drug_actions": [{"action": "AGONIST", "target": "P04629", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P04629", "drug": "DB00619"}, {"action": "INHIBITOR", "target": "P04629", "drug": "DB08896"}]}, "P15925": {"specific_function": "Conversion of folates to polyglutamate derivatives. It prefers 5,10-methylenetetrahydrofolate, rather than 10-formyltetrahydrofolate as folate substrate.", "general_function": "Tetrahydrofolylpolyglutamate synthase activity", "gene_names": ["fgs"], "name": "Folylpolyglutamate synthase", "drug_actions": []}, "P26640": {"general_function": "Valine-trna ligase activity", "gene_names": ["VARS"], "name": "Valine--tRNA ligase", "drug_actions": []}, "Q5VZ30": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["GAD2"], "name": "Glutamate decarboxylase 2 (Pancreatic islets and brain, 65kDa)", "drug_actions": [{"action": "COFACTOR", "target": "Q5VZ30", "drug": "DB00114"}]}, "Q9WZD5": {"general_function": "Endodeoxyribonuclease activity, producing 5'-phosphomonoesters", "gene_names": [], "name": "Putative deoxyribonuclease YcfH", "drug_actions": []}, "P49302": {"specific_function": "Forms an icosahedral capsid with a T=7 symmetry and a 40 nm diameter. The capsid is composed of 72 pentamers linked to each other by disulfide bonds and associated with VP2 or VP3 proteins. Interacts with terminal alpha(2,3)-linked sialic acids on the cell surface to provide virion attachment to target cell. This attachment induces virion internalization predominantly through caveolin-mediated endocytosis. Once attached, the virion is internalized by caveolin-mediated endocytosis and traffics to the endoplasmic reticulum. Inside the endoplasmic reticulum, the protein folding machinery isomerizes VP1 interpentamer disulfide bonds, thereby triggering initial uncoating. Next, the virion uses the endoplasmic reticulum-associated degradation machinery to probably translocate in the cytosol before reaching the nucleus. Nuclear entry of the viral DNA involves the selective exposure and importin recognition of VP2/Vp3 nuclear localization signal. In late phase of infection, neo-synthesized VP1 encapsulates replicated genomic DNA in the nucleus, and participates in rearranging nucleosomes around the viral DNA (By similarity).", "general_function": "Structural molecule activity", "gene_names": [], "name": "Capsid protein VP1", "drug_actions": []}, "Q99460": {"specific_function": "Acts as a regulatory subunit of the 26 proteasome which is involved in the ATP-dependent degradation of ubiquitinated proteins.", "general_function": "Enzyme regulator activity", "gene_names": ["PSMD1"], "name": "26S proteasome non-ATPase regulatory subunit 1", "drug_actions": [{"action": "INHIBITOR", "target": "Q99460", "drug": "DB00188"}]}, "Q9RHZ6": {"general_function": "Maltose transmembrane transporter activity", "gene_names": ["malE"], "name": "Maltose binding protein", "drug_actions": []}, "Q13231": {"specific_function": "Degrades chitin, chitotriose and chitobiose. May participate in the defense against nematodes and other pathogens. Isoform 3 has no enzymatic activity.", "general_function": "Endochitinase activity", "gene_names": ["CHIT1"], "name": "Chitotriosidase-1", "drug_actions": []}, "Q96RQ9": {"specific_function": "Lysosomal L-amino-acid oxidase with highest specific activity with phenylalanine. May play a role in lysosomal antigen processing and presentation (By similarity).", "general_function": "L-amino-acid oxidase activity", "gene_names": ["IL4I1"], "name": "L-amino-acid oxidase", "drug_actions": []}, "Q79G13": {"general_function": "Cellulase activity", "gene_names": ["celA1"], "name": "Possible cellulase CelA1 (Endoglucanase) (Endo-1,4-beta-glucanase) (FI-cmcase) (Carboxymethyl cellulase)", "drug_actions": []}, "P30872": {"specific_function": "Receptor for somatostatin with higher affinity for somatostatin-14 than -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins.", "general_function": "Somatostatin receptor activity", "gene_names": ["SSTR1"], "name": "Somatostatin receptor type 1", "drug_actions": []}, "Q8TCT1": {"specific_function": "Phosphatase that has a high activity toward phosphoethanolamine (PEA) and phosphocholine (PCho). Involved in the generation of inorganic phosphate for bone mineralization.", "general_function": "Pyrophosphatase activity", "gene_names": ["PHOSPHO1"], "name": "Phosphoethanolamine/phosphocholine phosphatase", "drug_actions": [{"action": "PRODUCT OF", "target": "Q8TCT1", "drug": "DB00122"}]}, "P19079": {"specific_function": "This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis.", "general_function": "Zinc ion binding", "gene_names": ["cdd"], "name": "Cytidine deaminase", "drug_actions": []}, "Q14749": {"specific_function": "Catalyzes the methylation of glycine by using S-adenosylmethionine (AdoMet) to form N-methylglycine (sarcosine) with the concomitant production of S-adenosylhomocysteine (AdoHcy). Possible crucial role in the regulation of tissue concentration of AdoMet and of metabolism of methionine.", "general_function": "Glycine n-methyltransferase activity", "gene_names": ["GNMT"], "name": "Glycine N-methyltransferase", "drug_actions": [{"action": "COFACTOR", "target": "Q14749", "drug": "DB00118"}]}, "P10915": {"specific_function": "Stabilizes the aggregates of proteoglycan monomers with hyaluronic acid in the extracellular cartilage matrix.", "general_function": "Hyaluronic acid binding", "gene_names": ["HAPLN1"], "name": "Hyaluronan and proteoglycan link protein 1", "drug_actions": [{"action": "BINDER", "target": "P10915", "drug": "DB08818"}]}, "P41145": {"specific_function": "G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions.", "general_function": "Opioid receptor activity", "gene_names": ["OPRK1"], "name": "Kappa-type opioid receptor", "drug_actions": [{"action": "AGONIST", "target": "P41145", "drug": "DB00193"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00295"}, {"action": "PARTIAL AGONIST", "target": "P41145", "drug": "DB00318"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00321"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00327"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00370"}, {"action": "ACTIVATOR", "target": "P41145", "drug": "DB00396"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00497"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00514"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00611"}, {"action": "ANTAGONIST", "target": "P41145", "drug": "DB00647"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00652"}, {"action": "ANTAGONIST", "target": "P41145", "drug": "DB00704"}, {"action": "OTHER", "target": "P41145", "drug": "DB00708"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00813"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00825"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00836"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00844"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00854"}, {"action": "AGONIST", "target": "P41145", "drug": "DB00899"}, {"action": "ANTAGONIST", "target": "P41145", "drug": "DB00921"}, {"action": "ANTAGONIST", "target": "P41145", "drug": "DB01183"}, {"action": "ANTAGONIST", "target": "P41145", "drug": "DB01209"}, {"action": "AGONIST", "target": "P41145", "drug": "DB01221"}, {"action": "AGONIST", "target": "P41145", "drug": "DB01439"}, {"action": "AGONIST", "target": "P41145", "drug": "DB01452"}, {"action": "AGONIST", "target": "P41145", "drug": "DB01497"}, {"action": "AGONIST", "target": "P41145", "drug": "DB01535"}, {"action": "ANTAGONIST", "target": "P41145", "drug": "DB01548"}, {"action": "AGONIST", "target": "P41145", "drug": "DB01565"}, {"action": "AGONIST", "target": "P41145", "drug": "DB01571"}, {"action": "AGONIST", "target": "P41145", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P41145", "drug": "DB06274"}, {"action": "AGONIST", "target": "P41145", "drug": "DB06738"}, {"action": "ANTAGONIST", "target": "P41145", "drug": "DB06800"}, {"action": "AGONIST", "target": "P41145", "drug": "DB09272"}]}, "P41146": {"specific_function": "G-protein coupled opioid receptor that functions as receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception and the perception of pain. Plays a role in the regulation of locomotor activity by the neuropeptide nociceptin.", "general_function": "Nociceptin receptor activity", "gene_names": ["OPRL1"], "name": "Nociceptin receptor", "drug_actions": [{"action": "AGONIST", "target": "P41146", "drug": "DB01497"}]}, "Q15761": {"specific_function": "Receptor for neuropeptide Y and peptide YY. The activity of this receptor is mediated by G proteins that inhibit adenylate cyclase activity. Seems to be associated with food intake. Could be involved in feeding disorders.", "general_function": "Peptide yy receptor activity", "gene_names": ["NPY5R"], "name": "Neuropeptide Y receptor type 5", "drug_actions": []}, "P10912": {"specific_function": "Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway (By similarity).The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling.Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling.", "general_function": "Protein kinase binding", "gene_names": ["GHR"], "name": "Growth hormone receptor", "drug_actions": [{"action": "BINDER", "target": "P10912", "drug": "DB00052"}, {"action": "ANTAGONIST", "target": "P10912", "drug": "DB00082"}]}, "O14788": {"specific_function": "Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy.", "general_function": "Tumor necrosis factor receptor superfamily binding", "gene_names": ["TNFSF11"], "name": "Tumor necrosis factor ligand superfamily member 11", "drug_actions": [{"action": "INHIBITOR", "target": "O14788", "drug": "DB00480"}, {"action": "ANTIBODY", "target": "O14788", "drug": "DB06643"}]}, "P40943": {"general_function": "Endo-1,4-beta-xylanase activity", "gene_names": [], "name": "Endo-1,4-beta-xylanase", "drug_actions": []}, "Q02054": {"specific_function": "Acyl carrier protein.", "gene_names": [], "name": "Actinorhodin polyketide synthase acyl carrier protein", "drug_actions": []}, "P23743": {"specific_function": "Upon cell stimulation converts the second messenger diacylglycerol into phosphatidate, initiating the resynthesis of phosphatidylinositols and attenuating protein kinase C activity.", "general_function": "Phospholipid binding", "gene_names": ["DGKA"], "name": "Diacylglycerol kinase alpha", "drug_actions": []}, "P22619": {"specific_function": "Methylamine dehydrogenase carries out the oxidation of methylamine. Electrons are passed from methylamine dehydrogenase to amicyanin.", "general_function": "Methylamine dehydrogenase (amicyanin) activity", "gene_names": ["mauA"], "name": "Methylamine dehydrogenase light chain", "drug_actions": []}, "P66010": {"general_function": "Thioredoxin-disulfide reductase activity", "gene_names": ["trxB"], "name": "Thioredoxin reductase", "drug_actions": [{"action": "INHIBITOR", "target": "P66010", "drug": "DB00548"}]}, "A6PZ59": {"general_function": "Ammonium transmembrane transporter activity", "gene_names": ["RHD"], "name": "Rhesus blood group D antigen", "drug_actions": []}, "Q57193": {"gene_names": ["ctxB"], "name": "Cholera enterotoxin B subunit", "drug_actions": []}, "Q60FT7": {"general_function": "Penicillin binding", "gene_names": ["pbp3"], "name": "PBP3", "drug_actions": [{"action": "INHIBITOR", "target": "Q60FT7", "drug": "DB00535"}]}, "Q46220": {"general_function": "Nucleotide binding", "gene_names": [], "name": "Iota toxin component Ia", "drug_actions": []}, "P16088": {"specific_function": "During replicative cycle of retroviruses, the reverse-transcribed viral DNA is integrated into the host chromosome by the viral integrase enzyme. RNase H activity is associated with the reverse transcriptase.", "general_function": "Zinc ion binding", "gene_names": ["pol"], "name": "Pol polyprotein", "drug_actions": []}, "Q96KG9": {"specific_function": "Regulates COPI-mediated retrograde traffic. Has no detectable kinase activity in vitro.Isoform 6 acts as transcriptional activator. It binds to three different types of GC-rich DNA binding sites (box-A, -B and -C) in the beta-polymerase promoter region. It also binds to the TERT promoter region.", "general_function": "Protein tyrosine kinase activity", "gene_names": ["SCYL1"], "name": "N-terminal kinase-like protein", "drug_actions": []}, "P49411": {"specific_function": "This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis.", "general_function": "Translation elongation factor activity", "gene_names": ["TUFM"], "name": "Elongation factor Tu, mitochondrial", "drug_actions": []}, "P48147": {"specific_function": "Cleaves peptide bonds on the C-terminal side of prolyl residues within peptides that are up to approximately 30 amino acids long.", "general_function": "Serine-type peptidase activity", "gene_names": ["PREP"], "name": "Prolyl endopeptidase", "drug_actions": []}, "P04825": {"specific_function": "Aminopeptidase N is involved in the degradation of intracellular peptides generated by protein breakdown during normal growth as well as in response to nutrient starvation.", "general_function": "Zinc ion binding", "gene_names": ["pepN"], "name": "Aminopeptidase N", "drug_actions": []}, "P16083": {"specific_function": "The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis.", "general_function": "Nadph dehydrogenase (quinone) activity", "gene_names": ["NQO2"], "name": "Ribosyldihydronicotinamide dehydrogenase [quinone]", "drug_actions": [{"action": "INHIBITOR", "target": "P16083", "drug": "DB01087"}]}, "Q99519": {"specific_function": "Catalyzes the removal of sialic acid (N-acetylneuraminic acid) moities from glycoproteins and glycolipids. To be active, it is strictly dependent on its presence in the multienzyme complex. Appears to have a preference for alpha 2-3 and alpha 2-6 sialyl linkage.", "general_function": "Exo-alpha-sialidase activity", "gene_names": ["NEU1"], "name": "Sialidase-1", "drug_actions": [{"action": "INHIBITOR", "target": "Q99519", "drug": "DB00198"}]}, "Q9P289": {"specific_function": "Mediator of cell growth. Modulates apoptosis.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["STK26"], "name": "Serine/threonine-protein kinase 26", "drug_actions": []}, "P54368": {"specific_function": "Ornithine decarboxylase (ODC) antizyme protein that negatively regulates ODC activity and intracellular polyamine biosynthesis and uptake by binding to and targeting ODC1 for degradation (PubMed:17900240). Stabilizes AZIN2 by interfering with its ubiquitination. Also inhibits cellular uptake of polyamines by inactivating the polyamine uptake transporter. SMAD1/OAZ1/PSMB4 complex mediates the degradation of the CREBBP/EP300 repressor SNIP1. Involved in the translocation of AZNI2 from ER-Golgi intermediate compartment (ERGIC) to the cytosol.", "general_function": "Ornithine decarboxylase inhibitor activity", "gene_names": ["OAZ1"], "name": "Ornithine decarboxylase antizyme 1", "drug_actions": []}, "P49419": {"specific_function": "Multifunctional enzyme mediating important protective effects. Metabolizes betaine aldehyde to betaine, an important cellular osmolyte and methyl donor. Protects cells from oxidative stress by metabolizing a number of lipid peroxidation-derived aldehydes. Involved in lysine catabolism.", "general_function": "L-aminoadipate-semialdehyde dehydrogenase activity", "gene_names": ["ALDH7A1"], "name": "Alpha-aminoadipic semialdehyde dehydrogenase", "drug_actions": []}, "P10340": {"specific_function": "Low-potential electron donor to a number of redox enzymes.", "general_function": "Fmn binding", "gene_names": ["isiB"], "name": "Flavodoxin", "drug_actions": []}, "P21980": {"specific_function": "Catalyzes the cross-linking of proteins and the conjugation of polyamines to proteins.", "general_function": "Protein-glutamine gamma-glutamyltransferase activity", "gene_names": ["TGM2"], "name": "Protein-glutamine gamma-glutamyltransferase 2", "drug_actions": []}, "Q45135": {"general_function": "Metal ion binding", "gene_names": [], "name": "Homoprotocatechuate 2,3-dioxygenase", "drug_actions": []}, "O60664": {"specific_function": "Required for the transport of mannose 6-phosphate receptors (MPR) from endosomes to the trans-Golgi network.", "gene_names": ["PLIN3"], "name": "Perilipin-3", "drug_actions": []}, "P62491": {"specific_function": "The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different set of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion. That Rab regulates endocytic recycling. Acts as a major regulator of membrane delivery during cytokinesis. Together with MYO5B and RAB8A participates in epithelial cell polarization. Together with RAB3IP, RAB8A, the exocyst complex, PARD3, PRKCI, ANXA2, CDC42 and DNMBP promotes transcytosis of PODXL to the apical membrane initiation sites (AMIS), apical surface formation and lumenogenesis. Together with MYO5B participates in CFTR trafficking to the plasma membrane and TF (Transferrin) recycling in nonpolarized cells. Required in a complex with MYO5B and RAB11FIP2 for the transport of NPC1L1 to the plasma membrane. Participates in the sorting and basolateral transport of CDH1 from the Golgi apparatus to the plasma membrane. Regulates the recycling of FCGRT (receptor of Fc region of monomeric Ig G) to basolateral membranes. May also play a role in melanosome transport and release from melanocytes.", "general_function": "Syntaxin binding", "gene_names": ["RAB11A"], "name": "Ras-related protein Rab-11A", "drug_actions": []}, "P15692": {"specific_function": "Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.", "general_function": "Vascular endothelial growth factor receptor binding", "gene_names": ["VEGFA"], "name": "Vascular endothelial growth factor A", "drug_actions": [{"action": "INHIBITOR", "target": "P15692", "drug": "DB01017"}, {"action": "OTHER/UNKNOWN", "target": "P15692", "drug": "DB01120"}, {"action": "OTHER", "target": "P15692", "drug": "DB01136"}, {"action": "INHIBITOR", "target": "P15692", "drug": "DB05294"}, {"action": "INHIBITOR", "target": "P15692", "drug": "DB06779"}, {"action": "BINDER", "target": "P15692", "drug": "DB08885"}]}, "P11511": {"specific_function": "Catalyzes the formation of aromatic C18 estrogens from C19 androgens.", "general_function": "Oxygen binding", "gene_names": ["CYP19A1"], "name": "Aromatase", "drug_actions": [{"action": "INHIBITOR", "target": "P11511", "drug": "DB00357"}, {"action": "INHIBITOR", "target": "P11511", "drug": "DB00894"}, {"action": "INHIBITOR", "target": "P11511", "drug": "DB00990"}, {"action": "ANTAGONIST", "target": "P11511", "drug": "DB01006"}, {"action": "INHIBITOR", "target": "P11511", "drug": "DB01217"}]}, "P20581": {"gene_names": [], "name": "Uncharacterized protein PA1000", "drug_actions": []}, "Q0S9X1": {"general_function": "Metal ion binding", "gene_names": [], "name": "Catechol 2,3-dioxygenase", "drug_actions": []}, "Q79MP6": {"general_function": "Zinc ion binding", "gene_names": ["blaIMP-1"], "name": "Beta-lactamase", "drug_actions": []}, "P01857": {"general_function": "Immunoglobulin receptor binding", "gene_names": ["IGHG1"], "name": "Ig gamma-1 chain C region", "drug_actions": []}, "Q16270": {"specific_function": "Binds IGF-I and IGF-II with a relatively low affinity. Stimulates prostacyclin (PGI2) production. Stimulates cell adhesion.", "gene_names": ["IGFBP7"], "name": "Insulin-like growth factor-binding protein 7", "drug_actions": []}, "P20586": {"general_function": "Monooxygenase activity", "gene_names": ["pobA"], "name": "p-hydroxybenzoate hydroxylase", "drug_actions": []}, "Q9BY32": {"specific_function": "Pyrophosphatase that hydrolyzes the non-canonical purine nucleotides inosine triphosphate (ITP), deoxyinosine triphosphate (dITP) as well as 2'-deoxy-N-6-hydroxylaminopurine triposphate (dHAPTP) and xanthosine 5'-triphosphate (XTP) to their respective monophosphate derivatives. The enzyme does not distinguish between the deoxy- and ribose forms. Probably excludes non-canonical purines from RNA and DNA precursor pools, thus preventing their incorporation into RNA and DNA and avoiding chromosomal lesions.", "general_function": "Xtp diphosphatase activity", "gene_names": ["ITPA"], "name": "Inosine triphosphate pyrophosphatase", "drug_actions": []}, "P35626": {"specific_function": "Specifically phosphorylates the agonist-occupied form of the beta-adrenergic and closely related receptors.", "general_function": "Protein kinase activity", "gene_names": ["ADRBK2"], "name": "Beta-adrenergic receptor kinase 2", "drug_actions": []}, "P03367": {"specific_function": "Gag-Pol polyprotein and Gag polyprotein may regulate their own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, Gag-Pol and Gag would promote translation, whereas at high concentration, the polyproteins encapsidate genomic RNA and then shutt off translation (By similarity).Matrix protein p17 targets Gag and Gag-pol polyproteins to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus (By similarity). Matrix protein is part of the pre-integration complex. Implicated in the release from host cell mediated by Vpu. Binds to RNA (By similarity).Capsid protein p24: Forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion. Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry (By similarity). Host restriction factors such as TRIM5-alpha or TRIMCyp bind retroviral capsids and cause premature capsid disassembly, leading to blocks in reverse transcription. Capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species. Host PIN1 apparently facilitates the virion uncoating. On the other hand, interactions with PDZD8 or CYPA stabilize the capsid.Nucleocapsid protein p7 encapsulates and protects viral dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its zinc fingers. Acts as a nucleic acid chaperone which is involved in rearangement of nucleic acid secondary structure during gRNA retrotranscription. Also facilitates template switch leading to recombination. As part of the polyprotein, participates to gRNA dimerization, packaging, tRNA incorporation and virion assembly.The aspartyl protease mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane. Cleavages take place as an ordered, step-wise cascade to yield mature proteins. This process is called maturation. Displays maximal activity during the budding process just prior to particle release from the cell. Also cleaves Nef and Vif, probably concomitantly with viral structural proteins on maturation of virus particles. Hydrolyzes host EIF4GI and PABP1 in order to shut off the capped cellular mRNA translation. The resulting inhibition of cellular protein synthesis serves to ensure maximal viral gene expression and to evade host immune response (By similarity).Reverse transcriptase/ribonuclease H (RT) is a multifunctional enzyme that converts the viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for two polypurine tracts (PPTs) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPTs that have not been removed by RNase H as primers. PPTs and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends (By similarity).Integrase: Catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration.", "general_function": "Zinc ion binding", "gene_names": ["gag-pol"], "name": "Gag-Pol polyprotein", "drug_actions": []}, "P50391": {"specific_function": "Receptor for neuropeptide Y and peptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is PP, PP (2-36) and [Ile-31, Gln-34] PP > [Pro-34] PYY > PYY and [Leu-31, Pro-34] NPY > NPY > PYY (3-36) and NPY (2-36) > PP (13-36) > PP (31-36) > NPY free acid.", "general_function": "Peptide yy receptor activity", "gene_names": ["NPY4R"], "name": "Neuropeptide Y receptor type 4", "drug_actions": []}, "Q9S427": {"general_function": "Protein tyrosine phosphatase activity", "gene_names": ["PPI"], "name": "Protein-tyrosine-phosphatase", "drug_actions": [{"action": "INHIBITOR", "target": "Q9S427", "drug": "DB05260"}]}, "P30041": {"specific_function": "Involved in redox regulation of the cell. Can reduce H(2)O(2) and short chain organic, fatty acid, and phospholipid hydroperoxides. May play a role in the regulation of phospholipid turnover as well as in protection against oxidative injury.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["PRDX6"], "name": "Peroxiredoxin-6", "drug_actions": []}, "P06441": {"specific_function": "Capsid proteins VP1, VP2, and VP3 form a closed capsid enclosing the viral positive strand RNA genome. All these proteins contain a beta-sheet structure called beta-barrel jelly roll. Together they form an icosahedral capsid (T=3) composed of 60 copies of each VP1, VP2, and VP3, with a diameter of approximately 300 Angstroms. VP1 is situated at the 12 fivefold axes, whereas VP2 and VP3 are located at the quasi-sixfold axes. The capsid interacts with HAVCR1 to provide virion attachment to target cell (By similarity).Protein VP0: VP0 precursor is a component of immature procapsids. The N-terminal domain of VP0, protein VP4, is needed for the assembly of 12 pentamers into the icosahedral structure. Unlike other picornaviruses, HAV VP4 does not seem to be myristoylated and has not been detected in mature virions, supposedly owing to its small size (By similarity).VP1-2A precursor is a component of immature procapsids and corresponds to an extended form of the structural protein VP1. The C-terminal domain of VP1-2A, protein 2A, acts as an assembly signal that allows multimerization of VP1-2A and formation of pentamers of VP1-VP2-VP3 trimers. It is proteolytically removed from the precursor by a host protease and does not seem to be found in mature particles (By similarity).Protein 2B and 2BC precursor affect membrane integrity and cause an increase in membrane permeability.Protein 2C: Associates with and induces structural rearrangements of intracellular membranes. It displays RNA-binding, nucleotide binding and NTPase activities (By similarity).Protein 3A, via its hydrophobic domain, serves as membrane anchor to the 3AB and 3ABC precursors.The 3AB precursor interacts with the 3CD precursor and with RNA structures found at both the 5'- and 3'-termini of the viral genome. Since the 3AB precursor contains the hydrophobic domain 3A, it probably anchors the whole viral replicase complex to intracellular membranes on which viral RNA synthesis occurs (By similarity).The 3ABC precursor is targeted to the mitochondrial membrane where protease 3C activity cleaves and inhibits the host antiviral protein MAVS, thereby disrupting activation of IRF3 through the IFIH1/MDA5 pathway. In vivo, the protease activity of 3ABC precursor is more efficient in cleaving the 2BC precursor than that of protein 3C. The 3ABC precursor may therefore play a role in the proteolytic processing of the polyprotein (By similarity).Protein 3B is covalently linked to the 5'-end of both the positive-strand and negative-strand genomic RNAs. It acts as a genome-linked replication primer (By similarity).Protease 3C: cysteine protease that generates mature viral proteins from the precursor polyprotein. In addition to its proteolytic activity, it binds to viral RNA, and thus influences viral genome replication. RNA and substrate bind cooperatively to the protease. Also cleaves host proteins such as PCBP2 (By similarity).RNA-directed RNA polymerase 3D-POL replicates genomic and antigenomic RNA by recognizing replications specific signals.", "general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P41789": {"specific_function": "Member of the two-component regulatory system NtrB/NtrC involved in the activation of nitrogen assimilatory genes such as GlnA. NtrC is phosphorylated by NtrB and interacts with sigma-54.", "general_function": "Sequence-specific dna binding", "gene_names": ["glnG"], "name": "Nitrogen regulation protein NR(I)", "drug_actions": []}, "P49773": {"specific_function": "Hydrolyzes purine nucleotide phosphoramidates with a single phosphate group, including adenosine 5'monophosphoramidate (AMP-NH2), adenosine 5'monophosphomorpholidate (AMP-morpholidate) and guanosine 5'monophosphomorpholidate (GMP-morpholidate). Hydrolyzes lysyl-AMP (AMP-N-epsilon-(N-alpha-acetyl lysine methyl ester)) generated by lysine tRNA ligase, as well as Met-AMP, His-AMP and Asp-AMP, lysyl-GMP (GMP-N-epsilon-(N-alpha-acetyl lysine methyl ester)) and AMP-N-alanine methyl ester. Can also convert adenosine 5'-O-phosphorothioate and guanosine 5'-O-phosphorothioate to the corresponding nucleoside 5'-O-phosphates with concomitant release of hydrogen sulfide. In addition, functions as scaffolding protein that modulates transcriptional activation by the LEF1/TCF1-CTNNB1 complex and by the complex formed with MITF and CTNNB1. Modulates p53/TP53 levels and p53/TP53-mediated apoptosis. Modulates proteasomal degradation of target proteins by the SCF (SKP2-CUL1-F-box protein) E3 ubiquitin-protein ligase complex.", "general_function": "Protein kinase c binding", "gene_names": ["HINT1"], "name": "Histidine triad nucleotide-binding protein 1", "drug_actions": [{"action": "PRODUCT OF", "target": "P49773", "drug": "DB00131"}]}, "P40306": {"specific_function": "The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides.", "general_function": "Threonine-type endopeptidase activity", "gene_names": ["PSMB10"], "name": "Proteasome subunit beta type-10", "drug_actions": [{"action": "INHIBITOR", "target": "P40306", "drug": "DB08889"}]}, "Q9NS40": {"specific_function": "Pore-forming (alpha) subunit of voltage-gated potassium channel. Channel properties may be modulated by cAMP and subunit assembly.", "general_function": "Voltage-gated potassium channel activity", "gene_names": ["KCNH7"], "name": "Potassium voltage-gated channel subfamily H member 7", "drug_actions": [{"action": "INHIBITOR", "target": "Q9NS40", "drug": "DB00308"}, {"action": "INHIBITOR", "target": "Q9NS40", "drug": "DB00457"}, {"action": "INHIBITOR", "target": "Q9NS40", "drug": "DB00590"}, {"action": "INHIBITOR", "target": "Q9NS40", "drug": "DB01110"}, {"action": "INHIBITOR", "target": "Q9NS40", "drug": "DB01162"}]}, "P0A6A8": {"specific_function": "Carrier of the growing fatty acid chain in fatty acid biosynthesis.", "general_function": "Phosphopantetheine binding", "gene_names": ["acpP"], "name": "Acyl carrier protein", "drug_actions": []}, "Q02127": {"specific_function": "Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor.", "general_function": "Ubiquinone binding", "gene_names": ["DHODH"], "name": "Dihydroorotate dehydrogenase (quinone), mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "Q02127", "drug": "DB01097"}, {"action": "INHIBITOR", "target": "Q02127", "drug": "DB01117"}, {"action": "INHIBITOR", "target": "Q02127", "drug": "DB08880"}]}, "P19080": {"specific_function": "Catalyzes the Claisen rearrangement of chorismate to prephenate. Probably involved in the aromatic amino acid biosynthesis.", "general_function": "Chorismate mutase activity", "gene_names": ["aroH"], "name": "Chorismate mutase AroH", "drug_actions": []}, "P01106": {"specific_function": "Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes.", "general_function": "Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding", "gene_names": ["MYC"], "name": "Myc proto-oncogene protein", "drug_actions": [{"action": "INHIBITOR", "target": "P01106", "drug": "DB08813"}]}, "O15528": {"specific_function": "Catalyzes the conversion of 25-hydroxyvitamin D3 (25(OH)D) to 1-alpha,25-dihydroxyvitamin D3 (1,25(OH)2D) plays an important role in normal bone growth, calcium metabolism, and tissue differentiation.", "general_function": "Iron ion binding", "gene_names": ["CYP27B1"], "name": "25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial", "drug_actions": []}, "Q16678": {"specific_function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compounds to their activated forms, including polycyclic aromatic hydrocarbons. Promotes angiogenesis by removing cellular oxygenation products, thereby decreasing oxidative stress, release of antiangiogenic factor THBS2, then allowing endothelial cells migration, cell adhesion and capillary morphogenesis. These changes are concommitant with the endothelial nitric oxide synthase activity and nitric oxide synthesis. Plays an important role in the regulation of perivascular cell proliferation, migration, and survival through modulation of the intracellular oxidative state and NF-kappa-B expression and/or activity, during angiogenesis. Contributes to oxidative homeostasis and ultrastructural organization and function of trabecular meshwork tissue through modulation of POSTN expression.", "general_function": "Oxygen binding", "gene_names": ["CYP1B1"], "name": "Cytochrome P450 1B1", "drug_actions": []}, "Q5XXA6": {"specific_function": "Calcium-activated chloride channel (CaCC) which plays a role in transepithelial anion transport and smooth muscle contraction. Required for the normal functioning of the interstitial cells of Cajal (ICCs) which generate electrical pacemaker activity in gastrointestinal smooth muscles. Acts as a major contributor to basal and stimulated chloride conductance in airway epithelial cells and plays an important role in tracheal cartilage development.", "general_function": "Voltage-gated chloride channel activity", "gene_names": ["ANO1"], "name": "Anoctamin-1", "drug_actions": [{"action": "ANTAGONIST", "target": "Q5XXA6", "drug": "DB04941"}]}, "Q16671": {"specific_function": "On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for anti-Muellerian hormone.", "general_function": "Transforming growth factor beta receptor activity, type ii", "gene_names": ["AMHR2"], "name": "Anti-Muellerian hormone type-2 receptor", "drug_actions": []}, "Q5SJ76": {"specific_function": "One of the primary rRNA binding proteins, it binds directly to 16S rRNA where it helps nucleate assembly of the platform of the 30S subunit by binding and bridging several RNA helices of the 16S rRNA.Forms an intersubunit bridge (bridge B4) with the 23S rRNA of the 50S subunit in the ribosome.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsO"], "name": "30S ribosomal protein S15", "drug_actions": []}, "Q56268": {"specific_function": "Catalyzes the oxidation of 3-carboxy-2-hydroxy-4-methylpentanoate (3-isopropylmalate) to 3-carboxy-4-methyl-2-oxopentanoate. The product decarboxylates to 4-methyl-2 oxopentanoate. Can also use D-malate and L-malate, with lower efficiency.", "general_function": "Nad binding", "gene_names": ["leuB"], "name": "3-isopropylmalate dehydrogenase", "drug_actions": []}, "Q06110": {"specific_function": "Binds non-covalently to a chromophore which is the cytotoxic and mutagenic component of the antibiotic. The chromophore binds to DNA as a weak intercalator and causes single- and double-strand breaks.", "general_function": "Dna binding", "gene_names": ["cagA"], "name": "Antitumor antibiotic C-1027 apoprotein", "drug_actions": []}, "P30419": {"specific_function": "Adds a myristoyl group to the N-terminal glycine residue of certain cellular and viral proteins.", "general_function": "Glycylpeptide n-tetradecanoyltransferase activity", "gene_names": ["NMT1"], "name": "Glycylpeptide N-tetradecanoyltransferase 1", "drug_actions": []}, "P65728": {"specific_function": "ATP + a protein = ADP + a phosphoprotein", "general_function": "Involved in ATP binding", "gene_names": ["pknG"], "name": "Serine/threonine-protein kinase PknG", "drug_actions": []}, "P59676": {"specific_function": "Penicillin-binding proteins (PBPs) function in the late steps of murein biosynthesis. Beta-lactams inactivate the PBPs by acylating an essential serine residue in the active site of these proteins.", "general_function": "Penicillin binding", "gene_names": ["pbpX"], "name": "Penicillin-binding protein 2X", "drug_actions": []}, "P07650": {"specific_function": "The enzymes which catalyze the reversible phosphorolysis of pyrimidine nucleosides are involved in the degradation of these compounds and in their utilization as carbon and energy sources, or in the rescue of pyrimidine bases for nucleotide synthesis.", "general_function": "Thymidine phosphorylase activity", "gene_names": ["deoA"], "name": "Thymidine phosphorylase", "drug_actions": []}, "P17117": {"specific_function": "Reduction of nitroaromatic compounds using NADH. Reduces nitrofurazone by a ping-pong bi-bi mechanism possibly to generate a two-electron transfer product. Major component of the oxygen-insensitive nitroreductase activity in E.coli.", "general_function": "Oxidoreductase activity, acting on nad(p)h, nitrogenous group as acceptor", "gene_names": ["nfsA"], "name": "Oxygen-insensitive NADPH nitroreductase", "drug_actions": [{"action": "POTENTIATOR", "target": "P17117", "drug": "DB00698"}]}, "P30197": {"specific_function": "Catalyzes the removal of two reducing equivalents (oxidative decarboxylation) from the cysteine residue of the C-terminal meso-lanthionine of epidermin to form a --C==C-- double bond.", "general_function": "Lyase activity", "gene_names": ["epiD"], "name": "Epidermin decarboxylase", "drug_actions": []}, "Q96EN8": {"specific_function": "Sulfurates the molybdenum cofactor. Sulfation of molybdenum is essential for xanthine dehydrogenase (XDH) and aldehyde oxidase (ADO) enzymes in which molybdenum cofactor is liganded by 1 oxygen and 1 sulfur atom in active form. In vitro, the C-terminal domain is able to reduce N-hydroxylated prodrugs, such as benzamidoxime.", "general_function": "Transferase activity", "gene_names": ["MOCOS"], "name": "Molybdenum cofactor sulfurase", "drug_actions": [{"action": "COFACTOR", "target": "Q96EN8", "drug": "DB00114"}]}, "O67648": {"specific_function": "Involved in the biosynthesis of lipid A, a phosphorylated glycolipid that anchors the lipopolysaccharide to the outer membrane of the cell.", "general_function": "Udp-3-o-[3-hydroxymyristoyl] n-acetylglucosamine deacetylase activity", "gene_names": ["lpxC"], "name": "UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase", "drug_actions": []}, "P0AD68": {"specific_function": "Essential cell division protein that is required for the synthesis of peptidoglycan at the division septum (PubMed:1103132, PubMed:9614966). Catalyzes the synthesis of cross-linked peptidoglycan from the lipid-linked precursors (PubMed:7030331). Required for localization of FtsN (PubMed:9282742).", "general_function": "Peptidoglycan glycosyltransferase activity", "gene_names": ["ftsI"], "name": "Peptidoglycan synthase FtsI", "drug_actions": [{"action": "INHIBITOR", "target": "P0AD68", "drug": "DB00267"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB00274"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB00303"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB00430"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB00438"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB01327"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB01328"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB01329"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB01332"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB01413"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB01415"}, {"action": "INHIBITOR", "target": "P0AD68", "drug": "DB01416"}]}, "Q03181": {"specific_function": "Ligand-activated transcription factor. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-linoleic acid and eicosapentanoic acid. Once activated by a ligand, the receptor binds to promoter elements of target genes. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the acyl-CoA oxidase gene. Decreases expression of NPC1L1 once activated by a ligand.", "general_function": "Zinc ion binding", "gene_names": ["PPARD"], "name": "Peroxisome proliferator-activated receptor delta", "drug_actions": [{"action": "AGONIST", "target": "Q03181", "drug": "DB00159"}, {"action": "AGONIST", "target": "Q03181", "drug": "DB00374"}, {"action": "NEGATIVE MODULATOR", "target": "Q03181", "drug": "DB00605"}, {"action": "AGONIST", "target": "Q03181", "drug": "DB01393"}]}, "P10644": {"specific_function": "Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["PRKAR1A"], "name": "cAMP-dependent protein kinase type I-alpha regulatory subunit", "drug_actions": []}, "P0AD65": {"specific_function": "Cell wall formation; PBP-2 is responsible for the determination of the rod shape of the cell. It synthesizes cross-linked peptidoglycan from lipid intermediates.", "general_function": "Serine-type d-ala-d-ala carboxypeptidase activity", "gene_names": ["mrdA"], "name": "Penicillin-binding protein 2", "drug_actions": [{"action": "INHIBITOR", "target": "P0AD65", "drug": "DB00303"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB00438"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB00948"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB01163"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB01327"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB01328"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB01329"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB01413"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB01415"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB01598"}, {"action": "ANTAGONIST", "target": "P0AD65", "drug": "DB06211"}, {"action": "INHIBITOR", "target": "P0AD65", "drug": "DB06211"}]}, "P10646": {"specific_function": "Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma.", "general_function": "Serine-type endopeptidase inhibitor activity", "gene_names": ["TFPI"], "name": "Tissue factor pathway inhibitor", "drug_actions": [{"action": "INHIBITOR", "target": "P10646", "drug": "DB06779"}]}, "O15067": {"specific_function": "Phosphoribosylformylglycinamidine synthase involved in the purines biosynthetic pathway. Catalyzes the ATP-dependent conversion of formylglycinamide ribonucleotide (FGAR) and glutamine to yield formylglycinamidine ribonucleotide (FGAM) and glutamate (By similarity).", "general_function": "Phosphoribosylformylglycinamidine synthase activity", "gene_names": ["PFAS"], "name": "Phosphoribosylformylglycinamidine synthase", "drug_actions": []}, "P48551": {"specific_function": "Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.", "general_function": "Type i interferon receptor activity", "gene_names": ["IFNAR2"], "name": "Interferon alpha/beta receptor 2", "drug_actions": [{"action": "AGONIST", "target": "P48551", "drug": "DB00008"}, {"action": "AGONIST", "target": "P48551", "drug": "DB00011"}, {"action": "AGONIST", "target": "P48551", "drug": "DB00018"}, {"action": "AGONIST", "target": "P48551", "drug": "DB00022"}, {"action": "AGONIST", "target": "P48551", "drug": "DB00068"}, {"action": "BINDER", "target": "P48551", "drug": "DB00069"}, {"action": "BINDER", "target": "P48551", "drug": "DB00105"}]}, "P48552": {"specific_function": "Modulates transcriptional activation by steroid receptors such as NR3C1, NR3C2 and ESR1. Also modulates transcriptional repression by nuclear hormone receptors. Positive regulator of the circadian clock gene expression: stimulates transcription of ARNTL/BMAL1, CLOCK and CRY1 by acting as a coactivator for RORA and RORC.", "general_function": "Transcription corepressor activity", "gene_names": ["NRIP1"], "name": "Nuclear receptor-interacting protein 1", "drug_actions": []}, "P17050": {"specific_function": "Removes terminal alpha-N-acetylgalactosamine residues from glycolipids and glycopeptides. Required for the breakdown of glycolipids.", "general_function": "Protein homodimerization activity", "gene_names": ["NAGA"], "name": "Alpha-N-acetylgalactosaminidase", "drug_actions": []}, "P0A5S4": {"specific_function": "ATP + a protein = ADP + a phosphoprotein", "general_function": "Involved in penicillin binding", "gene_names": ["pknB"], "name": "Serine/threonine-protein kinase PknB", "drug_actions": []}, "P83849": {"general_function": "Oxidoreductase activity, acting on the aldehyde or oxo group of donors, nad or nadp as acceptor", "gene_names": [], "name": "1-pyrroline-5-carboxylate dehydrogenase", "drug_actions": []}, "Q58L87": {"general_function": "Dna binding", "gene_names": ["lfrR"], "name": "TetR family transcriptional regulator", "drug_actions": []}, "P01834": {"general_function": "Immunoglobulin receptor binding", "gene_names": ["IGKC"], "name": "Ig kappa chain C region", "drug_actions": []}, "P41143": {"specific_function": "G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine.", "general_function": "Opioid receptor activity", "gene_names": ["OPRD1"], "name": "Delta-type opioid receptor", "drug_actions": [{"action": "AGONIST", "target": "P41143", "drug": "DB00193"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00295"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00318"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00321"}, {"action": "PARTIAL AGONIST", "target": "P41143", "drug": "DB00327"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00333"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00497"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00514"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00611"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00647"}, {"action": "ANTAGONIST", "target": "P41143", "drug": "DB00704"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00708"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00813"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00836"}, {"action": "ANTAGONIST", "target": "P41143", "drug": "DB00844"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00854"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00899"}, {"action": "ANTAGONIST", "target": "P41143", "drug": "DB00921"}, {"action": "AGONIST", "target": "P41143", "drug": "DB00956"}, {"action": "AGONIST", "target": "P41143", "drug": "DB01081"}, {"action": "ANTAGONIST", "target": "P41143", "drug": "DB01183"}, {"action": "ANTAGONIST", "target": "P41143", "drug": "DB01192"}, {"action": "BINDER", "target": "P41143", "drug": "DB01221"}, {"action": "AGONIST", "target": "P41143", "drug": "DB01439"}, {"action": "AGONIST", "target": "P41143", "drug": "DB01444"}, {"action": "AGONIST", "target": "P41143", "drug": "DB01452"}, {"action": "AGONIST", "target": "P41143", "drug": "DB01497"}, {"action": "AGONIST", "target": "P41143", "drug": "DB01535"}, {"action": "ANTAGONIST", "target": "P41143", "drug": "DB01548"}, {"action": "AGONIST", "target": "P41143", "drug": "DB01565"}, {"action": "AGONIST", "target": "P41143", "drug": "DB01571"}, {"action": "ANTAGONIST", "target": "P41143", "drug": "DB06274"}, {"action": "AGONIST", "target": "P41143", "drug": "DB06738"}, {"action": "ANTAGONIST", "target": "P41143", "drug": "DB09272"}]}, "P19438": {"specific_function": "Receptor for TNFSF2/TNF-alpha and homotrimeric TNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes to the induction of non-cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase.", "general_function": "Tumor necrosis factor-activated receptor activity", "gene_names": ["TNFRSF1A"], "name": "Tumor necrosis factor receptor superfamily member 1A", "drug_actions": []}, "P68400": {"specific_function": "Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection. May act as a regulatory node which integrates and coordinates numerous signals leading to an appropriate cellular response. During mitosis, functions as a component of the p53/TP53-dependent spindle assembly checkpoint (SAC) that maintains cyclin-B-CDK1 activity and G2 arrest in response to spindle damage. Also required for p53/TP53-mediated apoptosis, phosphorylating 'Ser-392' of p53/TP53 following UV irradiation. Can also negatively regulate apoptosis. Phosphorylates the caspases CASP9 and CASP2 and the apoptotic regulator NOL3. Phosphorylation protects CASP9 from cleavage and activation by CASP8, and inhibits the dimerization of CASP2 and activation of CASP8. Regulates transcription by direct phosphorylation of RNA polymerases I, II, III and IV. Also phosphorylates and regulates numerous transcription factors including NF-kappa-B, STAT1, CREB1, IRF1, IRF2, ATF1, SRF, MAX, JUN, FOS, MYC and MYB. Phosphorylates Hsp90 and its co-chaperones FKBP4 and CDC37, which is essential for chaperone function. Regulates Wnt signaling by phosphorylating CTNNB1 and the transcription factor LEF1. Acts as an ectokinase that phosphorylates several extracellular proteins. During viral infection, phosphorylates various proteins involved in the viral life cycles of EBV, HSV, HBV, HCV, HIV, CMV and HPV. Phosphorylates PML at 'Ser-565' and primes it for ubiquitin-mediated degradation. Plays an important role in the circadian clock function by phosphorylating ARNTL/BMAL1 at 'Ser-90' which is pivotal for its interaction with CLOCK and which controls CLOCK nuclear entry (PubMed:11239457, PubMed:11704824, PubMed:16193064, PubMed:19188443, PubMed:20625391, PubMed:22406621). Phosphorylates CCAR2 at 'Thr-454' in gastric carcinoma tissue (PubMed:24962073).", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["CSNK2A1"], "name": "Casein kinase II subunit alpha", "drug_actions": [{"action": "INHIBITOR", "target": "P68400", "drug": "DB08846"}]}, "P07098": {"general_function": "Triglyceride lipase activity", "gene_names": ["LIPF"], "name": "Gastric triacylglycerol lipase", "drug_actions": [{"action": "INHIBITOR", "target": "P07098", "drug": "DB01083"}]}, "Q9RUZ0": {"specific_function": "May play a role in fatty acid biosynthesis.", "general_function": "Metal ion binding", "gene_names": [], "name": "Citrate lyase subunit beta-like protein", "drug_actions": []}, "O95749": {"specific_function": "Catalyzes the trans-addition of the three molecules of IPP onto DMAPP to form geranylgeranyl pyrophosphate, an important precursor of carotenoids and geranylated proteins.", "general_function": "Metal ion binding", "gene_names": ["GGPS1"], "name": "Geranylgeranyl pyrophosphate synthase", "drug_actions": [{"action": "INHIBITOR", "target": "O95749", "drug": "DB00399"}]}, "P22983": {"specific_function": "Catalyzes the reversible phosphorylation of pyruvate and phosphate. In E.histolytica and C.symbiosus, PPDK functions in the direction of ATP synthesis.", "general_function": "Pyruvate, phosphate dikinase activity", "gene_names": ["ppdK"], "name": "Pyruvate, phosphate dikinase", "drug_actions": []}, "P83689": {"specific_function": "Acts as a blue-light photoreceptor and photo-protectant. Essential for inhibiting damaged induced by excess blue-green light via a process known as non-photochemical quenching (NPQ). Binding carotenoids improves OCP's intrinsic photoprotectant activity by broadening its absorption spectrum and facilitating the dissipation of absorbed energy (PubMed:15751975). In the dark or dim light the stable inactive form (OCP-O) is orange, upon illumination with blue-green light it converts to a metastable active red form (OCP-R), inducing energy dissipation, quenching cellular fluorescence via NPQ (By similarity).", "general_function": "Photoreceptor activity", "gene_names": [], "name": "Orange carotenoid-binding protein", "drug_actions": []}, "P37231": {"specific_function": "Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of ARNTL/BMAL1 in the blood vessels (By similarity).", "general_function": "Zinc ion binding", "gene_names": ["PPARG"], "name": "Peroxisome proliferator-activated receptor gamma", "drug_actions": [{"action": "AGONIST", "target": "P37231", "drug": "DB00159"}, {"action": "AGONIST", "target": "P37231", "drug": "DB00197"}, {"action": "AGONIST", "target": "P37231", "drug": "DB00244"}, {"action": "ACTIVATOR", "target": "P37231", "drug": "DB00328"}, {"action": "AGONIST", "target": "P37231", "drug": "DB00412"}, {"action": "AGONIST", "target": "P37231", "drug": "DB00731"}, {"action": "AGONIST", "target": "P37231", "drug": "DB00795"}, {"action": "AGONIST", "target": "P37231", "drug": "DB00912"}, {"action": "PARTIAL AGONIST", "target": "P37231", "drug": "DB00966"}, {"action": "AGONIST", "target": "P37231", "drug": "DB01014"}, {"action": "ACTIVATOR", "target": "P37231", "drug": "DB01050"}, {"action": "AGONIST", "target": "P37231", "drug": "DB01067"}, {"action": "AGONIST", "target": "P37231", "drug": "DB01132"}, {"action": "AGONIST", "target": "P37231", "drug": "DB01252"}, {"action": "AGONIST", "target": "P37231", "drug": "DB01393"}, {"action": "AGONIST", "target": "P37231", "drug": "DB08915"}]}, "P41052": {"specific_function": "Murein-degrading enzyme. Catalyzes the cleavage of the glycosidic bonds between N-acetylmuramic acid and N-acetylglucosamine residues in peptidoglycan. May play a role in recycling of muropeptides during cell elongation and/or cell division.", "general_function": "Lytic transglycosylase activity", "gene_names": ["mltB"], "name": "Membrane-bound lytic murein transglycosylase B", "drug_actions": []}, "P69905": {"specific_function": "Involved in oxygen transport from the lung to the various peripheral tissues.", "general_function": "Oxygen transporter activity", "gene_names": ["HBA1"], "name": "Hemoglobin subunit alpha", "drug_actions": [{"action": "ANTAGONIST", "target": "P69905", "drug": "DB00358"}, {"action": "ACTIVATOR", "target": "P69905", "drug": "DB00893"}]}, "P69903": {"specific_function": "Involved in the catabolism of oxalate and in the adapatation to low pH via the induction of the oxalate-dependent acid tolerance response (ATR). Catalyzes the transfer of the CoA moiety from formyl-CoA to oxalate (By similarity).", "general_function": "Formyl-coa transferase activity", "gene_names": ["frc"], "name": "Formyl-CoA:oxalate CoA-transferase", "drug_actions": []}, "P30519": {"specific_function": "Heme oxygenase cleaves the heme ring at the alpha methene bridge to form biliverdin. Biliverdin is subsequently converted to bilirubin by biliverdin reductase. Under physiological conditions, the activity of heme oxygenase is highest in the spleen, where senescent erythrocytes are sequestrated and destroyed. Heme oxygenase 2 could be implicated in the production of carbon monoxide in brain where it could act as a neurotransmitter.", "general_function": "Metal ion binding", "gene_names": ["HMOX2"], "name": "Heme oxygenase 2", "drug_actions": []}, "P30518": {"specific_function": "Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.", "general_function": "Vasopressin receptor activity", "gene_names": ["AVPR2"], "name": "Vasopressin V2 receptor", "drug_actions": [{"action": "AGONIST", "target": "P30518", "drug": "DB00035"}, {"action": "AGONIST", "target": "P30518", "drug": "DB00067"}, {"action": "ANTAGONIST", "target": "P30518", "drug": "DB00872"}, {"action": "AGONIST", "target": "P30518", "drug": "DB02638"}, {"action": "ANTAGONIST", "target": "P30518", "drug": "DB06212"}]}, "Q9BZV2": {"specific_function": "Mediates high affinity thiamine uptake, propably via a proton anti-port mechanism. Has no folate transport activity.", "general_function": "Thiamine uptake transmembrane transporter activity", "gene_names": ["SLC19A3"], "name": "Thiamine transporter 2", "drug_actions": []}, "Q9BZV3": {"specific_function": "Chondroitin sulfate- and hyaluronan-binding proteoglycan involved in the organization of interphotoreceptor matrix; may participate in the maturation and maintenance of the light-sensitive photoreceptor outer segment. Binds heparin.", "general_function": "Hyaluronic acid binding", "gene_names": ["IMPG2"], "name": "Interphotoreceptor matrix proteoglycan 2", "drug_actions": [{"action": "BINDER", "target": "Q9BZV3", "drug": "DB08818"}]}, "P08697": {"specific_function": "Serine protease inhibitor. The major targets of this inhibitor are plasmin and trypsin, but it also inactivates matriptase-3/TMPRSS7 and chymotrypsin.", "general_function": "Serine-type endopeptidase inhibitor activity", "gene_names": ["SERPINF2"], "name": "Alpha-2-antiplasmin", "drug_actions": [{"action": "LIGAND", "target": "P08697", "drug": "DB08888"}]}, "P0AB71": {"specific_function": "Catalyzes the aldol condensation of dihydroxyacetone phosphate (DHAP or glycerone-phosphate) with glyceraldehyde 3-phosphate (G3P) to form fructose 1,6-bisphosphate (FBP) in gluconeogenesis and the reverse reaction in glycolysis.", "general_function": "Zinc ion binding", "gene_names": ["fbaA"], "name": "Fructose-bisphosphate aldolase class 2", "drug_actions": []}, "Q9F5I8": {"specific_function": "Hydrolyzes iota-carrageenans, sulfated 1,3-alpha-1,4-beta galactans from red algal cell walls, with an inversion of anomeric configuration. Also active against hybrid iota-/nu-carrageenan, not active against kappa- or lambda-carrageenans.", "general_function": "Iota-carrageenase activity", "gene_names": ["cgiA"], "name": "Iota-carrageenase", "drug_actions": []}, "P05062": {"general_function": "Phosphatidylcholine binding", "gene_names": ["ALDOB"], "name": "Fructose-bisphosphate aldolase B", "drug_actions": []}, "P0ACQ4": {"specific_function": "Hydrogen peroxide sensor. Activates the expression of a regulon of hydrogen peroxide-inducible genes such as katG, gor, ahpC, ahpF, oxyS (a regulatory RNA), dps, fur and grxA. OxyR expression is negatively autoregulated by binding to a 43 bp region upstream of its own coding sequence. OxyR is inactivated by reduction of its essential disulfide bond by the product of GrxA, itself positively regulated by OxyR. Has also a positive regulatory effect on the production of surface proteins that control the colony morphology and auto-aggregation ability.", "general_function": "Transcription factor activity, bacterial-type rna polymerase core promoter proximal region sequence-specific binding", "gene_names": ["oxyR"], "name": "Hydrogen peroxide-inducible genes activator", "drug_actions": []}, "P51606": {"specific_function": "Catalyzes the interconversion of N-acetylglucosamine to N-acetylmannosamine. Binds to renin forming a protein complex called high molecular weight (HMW) renin and inhibits renin activity. Involved in the N-glycolylneuraminic acid (Neu5Gc) degradation pathway: although human is not able to catalyze formation of Neu5Gc due to the inactive CMAHP enzyme, Neu5Gc is present in food and must be degraded.", "general_function": "N-acylglucosamine 2-epimerase activity", "gene_names": ["RENBP"], "name": "N-acylglucosamine 2-epimerase", "drug_actions": []}, "P25103": {"specific_function": "This is a receptor for the tachykinin neuropeptide substance P. It is probably associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: substance P > substance K > neuromedin-K.", "general_function": "Tachykinin receptor activity", "gene_names": ["TACR1"], "name": "Substance-P receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "P25103", "drug": "DB00673"}, {"action": "ANTAGONIST", "target": "P25103", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P25103", "drug": "DB04894"}, {"action": "ANTAGONIST", "target": "P25103", "drug": "DB09048"}]}, "Q9Y296": {"specific_function": "May play a role in vesicular transport from endoplasmic reticulum to Golgi.", "general_function": "Rab guanyl-nucleotide exchange factor activity", "gene_names": ["TRAPPC4"], "name": "Trafficking protein particle complex subunit 4", "drug_actions": []}, "P25100": {"specific_function": "This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.", "name": "Alpha-1D adrenergic receptor", "drug_actions": [{"action": "AGONIST", "target": "P25100", "drug": "DB00182"}, {"action": "AGONIST", "target": "P25100", "drug": "DB00211"}, {"action": "BINDER", "target": "P25100", "drug": "DB00248"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00298"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00346"}, {"action": "AGONIST", "target": "P25100", "drug": "DB00368"}, {"action": "BINDER", "target": "P25100", "drug": "DB00370"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00457"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00543"}, {"action": "AGONIST", "target": "P25100", "drug": "DB00575"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00590"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00598"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00622"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00668"}, {"action": "PARTIAL AGONIST", "target": "P25100", "drug": "DB00696"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00706"}, {"action": "BINDER", "target": "P25100", "drug": "DB00723"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00925"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB00934"}, {"action": "AGONIST", "target": "P25100", "drug": "DB00935"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB01136"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB01151"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB01162"}, {"action": "AGONIST", "target": "P25100", "drug": "DB01186"}, {"action": "AGONIST", "target": "P25100", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB01224"}, {"action": "AGONIST", "target": "P25100", "drug": "DB01365"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P25100", "drug": "DB06207"}, {"action": "AGONIST", "target": "P25100", "drug": "DB06262"}, {"action": "AGONIST", "target": "P25100", "drug": "DB06694"}, {"action": "PARTIAL AGONIST", "target": "P25100", "drug": "DB09202"}], "general_function": "Alpha1-adrenergic receptor activity", "in_complexes": ["Alpha adrenergic receptor", "Alpha-1 adrenergic receptor"], "gene_names": ["ADRA1D"]}, "P95780": {"specific_function": "Catalyzes the dehydration of dTDP-D-glucose to form dTDP-6-deoxy-D-xylo-4-hexulose via a three-step process involving oxidation, dehydration and reduction.", "general_function": "Dtdp-glucose 4,6-dehydratase activity", "gene_names": ["rmlB"], "name": "dTDP-glucose 4,6-dehydratase", "drug_actions": []}, "P03886": {"specific_function": "Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["MT-ND1"], "name": "NADH-ubiquinone oxidoreductase chain 1", "drug_actions": [{"action": "BINDER", "target": "P03886", "drug": "DB00157"}, {"action": "UNKNOWN", "target": "P03886", "drug": "DB01028"}, {"action": "INHIBITOR", "target": "P03886", "drug": "DB01159"}, {"action": "UNKNOWN", "target": "P03886", "drug": "DB01189"}, {"action": "UNKNOWN", "target": "P03886", "drug": "DB01236"}]}, "P0AFI7": {"specific_function": "Catalyzes the oxidation of either pyridoxine 5'-phosphate (PNP) or pyridoxamine 5'-phosphate (PMP) into pyridoxal 5'-phosphate (PLP).", "general_function": "Pyridoxamine-phosphate oxidase activity", "gene_names": ["pdxH"], "name": "Pyridoxine/pyridoxamine 5'-phosphate oxidase", "drug_actions": []}, "Q9XB61": {"specific_function": "Involved in the biosynthesis of carbapenam-3-carboxylate, a beta-lactam antibiotic of the carbapenem class. Catalyzes the ATP-dependent formation of (3S,5S)-carbapenam-3-carboxylate from (2S,5S)-5-carboxymethylproline.", "general_function": "Atp binding", "gene_names": ["carA"], "name": "Carbapenam-3-carboxylate synthase", "drug_actions": []}, "P0AFI2": {"specific_function": "Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule. MukB stimulates the relaxation activity of topoisomerase IV and also has a modest effect on decatenation.", "general_function": "Dna topoisomerase type ii (atp-hydrolyzing) activity", "gene_names": ["parC"], "name": "DNA topoisomerase 4 subunit A", "drug_actions": [{"action": "INHIBITOR", "target": "P0AFI2", "drug": "DB00817"}]}, "Q52437": {"general_function": "Oxidoreductase activity", "gene_names": ["bphA4"], "name": "Ferredoxin reductase", "drug_actions": []}, "P94548": {"specific_function": "Transcriptional regulator in fatty acid degradation. Represses transcription of genes required for fatty acid transport and beta-oxidation, including acdA, fadA, fadB, fadE, fadF, fadG, fadH, fadM, fadN, lcfA and lcfB. Binding of FadR to DNA is specifically inhibited by long chain fatty acyl-CoA compounds of 14-20 carbon atoms in length.", "general_function": "Dna binding", "gene_names": ["fadR"], "name": "Fatty acid metabolism regulator protein", "drug_actions": []}, "P98066": {"specific_function": "Possibly involved in cell-cell and cell-matrix interactions during inflammation and tumorigenesis.", "general_function": "Hyaluronic acid binding", "gene_names": ["TNFAIP6"], "name": "Tumor necrosis factor-inducible gene 6 protein", "drug_actions": [{"action": "BINDER", "target": "P98066", "drug": "DB08818"}]}, "Q47Q21": {"gene_names": ["menC"], "name": "o-succinylbenzoate synthase", "drug_actions": []}, "P36952": {"specific_function": "Tumor suppressor. It blocks the growth, invasion, and metastatic properties of mammary tumors. As it does not undergo the S (stressed) to R (relaxed) conformational transition characteristic of active serpins, it exhibits no serine protease inhibitory activity.", "general_function": "Serine-type endopeptidase inhibitor activity", "gene_names": ["SERPINB5"], "name": "Serpin B5", "drug_actions": []}, "P29274": {"specific_function": "Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.", "general_function": "Identical protein binding", "gene_names": ["ADORA2A"], "name": "Adenosine receptor A2a", "drug_actions": [{"action": "ANTAGONIST", "target": "P29274", "drug": "DB00201"}, {"action": "MULTITARGET", "target": "P29274", "drug": "DB00201"}, {"action": "ANTAGONIST", "target": "P29274", "drug": "DB00277"}, {"action": "ANTAGONIST", "target": "P29274", "drug": "DB00358"}, {"action": "AGONIST", "target": "P29274", "drug": "DB00640"}, {"action": "ANTAGONIST", "target": "P29274", "drug": "DB00651"}, {"action": "ANTAGONIST", "target": "P29274", "drug": "DB00806"}, {"action": "ANTAGONIST", "target": "P29274", "drug": "DB01303"}, {"action": "ANTAGONIST", "target": "P29274", "drug": "DB01412"}, {"action": "AGONIST", "target": "P29274", "drug": "DB06213"}]}, "P29275": {"specific_function": "Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.", "general_function": "G-protein coupled adenosine receptor activity", "gene_names": ["ADORA2B"], "name": "Adenosine receptor A2b", "drug_actions": [{"action": "ANTAGONIST", "target": "P29275", "drug": "DB00277"}, {"action": "AGONIST", "target": "P29275", "drug": "DB00640"}, {"action": "ANTAGONIST", "target": "P29275", "drug": "DB00824"}]}, "Q9Y2Z4": {"specific_function": "Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr).", "general_function": "Tyrosine-trna ligase activity", "gene_names": ["YARS2"], "name": "Tyrosine--tRNA ligase, mitochondrial", "drug_actions": []}, "Q5SLQ0": {"specific_function": "Located on the back of the platform of the 30S subunit where it stabilizes the close packing of several RNA helices of the 16S rRNA. Forms part of the Shine-Dalgarno cleft in the 70S ribosome, where it probably interacts with the Shine-Dalgarno helix.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsR"], "name": "30S ribosomal protein S18", "drug_actions": []}, "P13000": {"specific_function": "Catalyzes a mechanistically unusual reaction, the ATP-dependent insertion of CO2 between the N7 and N8 nitrogen atoms of 7,8-diaminopelargonic acid (DAPA) to form an ureido ring. Only CTP can partially replace ATP while diaminobiotin is only 37% as effective as 7,8-diaminopelargonic acid.", "general_function": "Magnesium ion binding", "gene_names": ["bioD1"], "name": "ATP-dependent dethiobiotin synthetase BioD 1", "drug_actions": []}, "Q6W5P4": {"specific_function": "G-protein coupled receptor for neuropeptide S (NPS) (PubMed:16790440). Promotes mobilization of intracellular Ca(2+) stores (PubMed:16790440). Inhibits cell growth in response to NPS binding (PubMed:15947423). Involved in pathogenesis of asthma and other IgE-mediated diseases.", "general_function": "Vasopressin receptor activity", "gene_names": ["NPSR1"], "name": "Neuropeptide S receptor", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "Q6W5P4", "drug": "DB01159"}]}, "P78352": {"specific_function": "Interacts with the cytoplasmic tail of NMDA receptor subunits and shaker-type potassium channels. Required for synaptic plasticity associated with NMDA receptor signaling. Overexpression or depletion of DLG4 changes the ratio of excitatory to inhibitory synapses in hippocampal neurons. May reduce the amplitude of ASIC3 acid-evoked currents by retaining the channel intracellularly. May regulate the intracellular trafficking of ADR1B (By similarity).", "general_function": "Scaffold protein binding", "gene_names": ["DLG4"], "name": "Disks large homolog 4", "drug_actions": []}, "P09148": {"general_function": "Zinc ion binding", "gene_names": ["galT"], "name": "Galactose-1-phosphate uridylyltransferase", "drug_actions": []}, "Q9BZZ2": {"specific_function": "Acts as an endocytic receptor mediating clathrin dependent endocytosis. Macrophage-restricted adhesion molecule that mediates sialic-acid dependent binding to lymphocytes, including granulocytes, monocytes, natural killer cells, B-cells and CD8 T-cells. Preferentially binds to alpha-2,3-linked sialic acid (By similarity). Binds to SPN/CD43 on T-cells (By similarity). May play a role in hemopoiesis.", "general_function": "Carbohydrate binding", "gene_names": ["SIGLEC1"], "name": "Sialoadhesin", "drug_actions": []}, "Q9BVM4": {"specific_function": "Contributes to degradation of proteins cross-linked by transglutaminases. Degrades the cross-link between a lysine and a glutamic acid residue from two proteins that have been cross-linked by transglutaminases. Catalyzes the formation of 5-oxoproline from L-gamma-glutamyl-L-epsilon-lysine. Inactive with L-gamma-glutamyl-alpha-amino acid substrates such as L-gamma-glutamyl-L-alpha-cysteine and L-gamma-glutamyl-L-alpha-alanine.", "general_function": "Gamma-glutamylcyclotransferase activity", "gene_names": ["GGACT"], "name": "Gamma-glutamylaminecyclotransferase", "drug_actions": []}, "P09012": {"specific_function": "Component of the spliceosomal U1 snRNP, which is essential for recognition of the pre-mRNA 5' splice-site and the subsequent assembly of the spliceosome. U1 snRNP is the first snRNP to interact with pre-mRNA. This interaction is required for the subsequent binding of U2 snRNP and the U4/U6/U5 tri-snRNP. SNRPA binds stem loop II of U1 snRNA. In a snRNP-free form (SF-A) may be involved in coupled pre-mRNA splicing and polyadenylation process. May bind preferentially to the 5'-UGCAC-3' motif on RNAs.", "general_function": "U1 snrna binding", "gene_names": ["SNRPA"], "name": "U1 small nuclear ribonucleoprotein A", "drug_actions": []}, "Q9KVB4": {"gene_names": [], "name": "Uncharacterized protein", "drug_actions": []}, "P14900": {"specific_function": "Cell wall formation. Catalyzes the addition of glutamate to the nucleotide precursor UDP-N-acetylmuramoyl-L-alanine (UMA).", "general_function": "Udp-n-acetylmuramoylalanine-d-glutamate ligase activity", "gene_names": ["murD"], "name": "UDP-N-acetylmuramoylalanine--D-glutamate ligase", "drug_actions": []}, "P27907": {"specific_function": "Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells (By similarity).", "general_function": "Metal ion binding", "gene_names": ["NA"], "name": "Neuraminidase", "drug_actions": [{"action": "INHIBITOR", "target": "P27907", "drug": "DB00558"}]}, "P09147": {"specific_function": "Involved in the metabolism of galactose. Catalyzes the conversion of UDP-galactose (UDP-Gal) to UDP-glucose (UDP-Glc) through a mechanism involving the transient reduction of NAD. It is only active on UDP-galactose and UDP-glucose.", "general_function": "Udp-glucose 4-epimerase activity", "gene_names": ["galE"], "name": "UDP-glucose 4-epimerase", "drug_actions": []}, "P24347": {"specific_function": "May play an important role in the progression of epithelial malignancies.", "general_function": "Zinc ion binding", "gene_names": ["MMP11"], "name": "Stromelysin-3", "drug_actions": [{"action": "ANTAGONIST", "target": "P24347", "drug": "DB00786"}]}, "P11998": {"specific_function": "Catalyzes the formation of 6,7-dimethyl-8-ribityllumazine by condensation of 5-amino-6-(D-ribitylamino)uracil with 3,4-dihydroxy-2-butanone 4-phosphate. This is the penultimate step in the biosynthesis of riboflavin. Is able to use the non-natural R enantiomer of 3,4-dihydroxy-2-butanone 4-phosphate as a substrate, but with less efficiency than the natural S enantiomer. Cannot use unphosphorylated 3,4-dihydroxy-2-butanone, 3,4-dihydroxy-2-butanone 3-phosphate or diacetyl as substrates.", "general_function": "Transferase activity", "gene_names": ["ribH"], "name": "6,7-dimethyl-8-ribityllumazine synthase", "drug_actions": []}, "Q9HCD5": {"specific_function": "Nuclear receptor coregulator that can have both coactivator and corepressor functions. Interacts with nuclear receptors for steroids (ESR1 and ESR2) independently of the steroid binding domain (AF-2) of the ESR receptors, and with the orphan nuclear receptor NR1D2. Involved in the coactivation of nuclear steroid receptors (ER) as well as the corepression of MYC in response to 17-beta-estradiol (E2).", "general_function": "Poly(a) rna binding", "gene_names": ["NCOA5"], "name": "Nuclear receptor coactivator 5", "drug_actions": []}, "P0AC13": {"specific_function": "Catalyzes the condensation of para-aminobenzoate (pABA) with 6-hydroxymethyl-7,8-dihydropterin diphosphate (DHPt-PP) to form 7,8-dihydropteroate (H2Pte), the immediate precursor of folate derivatives.", "general_function": "Metal ion binding", "gene_names": ["folP"], "name": "Dihydropteroate synthase", "drug_actions": [{"action": "INHIBITOR", "target": "P0AC13", "drug": "DB00259"}, {"action": "INHIBITOR", "target": "P0AC13", "drug": "DB00263"}, {"action": "INHIBITOR", "target": "P0AC13", "drug": "DB00576"}, {"action": "INHIBITOR", "target": "P0AC13", "drug": "DB00634"}, {"action": "INHIBITOR", "target": "P0AC13", "drug": "DB01015"}, {"action": "INHIBITOR", "target": "P0AC13", "drug": "DB01298"}, {"action": "INHIBITOR", "target": "P0AC13", "drug": "DB01581"}, {"action": "INHIBITOR", "target": "P0AC13", "drug": "DB01582"}, {"action": "INHIBITOR", "target": "P0AC13", "drug": "DB06729"}]}, "O15217": {"specific_function": "Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. This isozyme has a high catalytic efficiency with 4-hydroxyalkenals such as 4-hydroxynonenal (4-HNE).", "general_function": "Protein homodimerization activity", "gene_names": ["GSTA4"], "name": "Glutathione S-transferase A4", "drug_actions": []}, "Q15375": {"specific_function": "Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Among GPI-anchored ephrin-A ligands, EFNA5 is a cognate/functional ligand for EPHA7 and their interaction regulates brain development modulating cell-cell adhesion and repulsion. Has a repellent activity on axons and is for instance involved in the guidance of corticothalamic axons and in the proper topographic mapping of retinal axons to the colliculus. May also regulate brain development through a caspase(CASP3)-dependent proapoptotic activity. Forward signaling may result in activation of components of the ERK signaling pathway including MAP2K1, MAP2K2, MAPK1 AND MAPK3 which are phosphorylated upon activation of EPHA7.", "general_function": "Protein tyrosine kinase activity", "gene_names": ["EPHA7"], "name": "Ephrin type-A receptor 7", "drug_actions": []}, "P53611": {"specific_function": "Catalyzes the transfer of a geranylgeranyl moiety from geranylgeranyl diphosphate to both cysteines of Rab proteins with the C-terminal sequence -XXCC, -XCXC and -CCXX, such as RAB1A, RAB3A, RAB5A and RAB7A.", "general_function": "Zinc ion binding", "gene_names": ["RABGGTB"], "name": "Geranylgeranyl transferase type-2 subunit beta", "drug_actions": []}, "Q5SID9": {"general_function": "Transferase activity, transferring pentosyl groups", "gene_names": [], "name": "Purine nucleoside phosphorylase", "drug_actions": []}, "P07478": {"specific_function": "In the ileum, may be involved in defensin processing, including DEFA5.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["PRSS2"], "name": "Trypsin-2", "drug_actions": []}, "P77444": {"specific_function": "Cysteine desulfurases mobilize the sulfur from L-cysteine to yield L-alanine, an essential step in sulfur metabolism for biosynthesis of a variety of sulfur-containing biomolecules. Component of the suf operon, which is activated and required under specific conditions such as oxidative stress and iron limitation. Acts as a potent selenocysteine lyase in vitro, that mobilizes selenium from L-selenocysteine. Selenocysteine lyase activity is however unsure in vivo.", "general_function": "Selenocysteine lyase activity", "gene_names": ["sufS"], "name": "Cysteine desulfurase", "drug_actions": []}, "P29474": {"specific_function": "Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets.Isoform eNOS13C: Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by forming heterodimers with isoform 1.", "general_function": "Tetrahydrobiopterin binding", "gene_names": ["NOS3"], "name": "Nitric oxide synthase, endothelial", "drug_actions": [{"action": "COFACTOR", "target": "P29474", "drug": "DB00360"}, {"action": "INHIBITOR", "target": "P29474", "drug": "DB01110"}]}, "P29475": {"specific_function": "Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter. Probably has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such SRR.", "general_function": "Tetrahydrobiopterin binding", "gene_names": ["NOS1"], "name": "Nitric oxide synthase, brain", "drug_actions": []}, "Q9Y617": {"specific_function": "Catalyzes the reversible conversion of 3-phosphohydroxypyruvate to phosphoserine and of 3-hydroxy-2-oxo-4-phosphonooxybutanoate to phosphohydroxythreonine.", "general_function": "O-phospho-l-serine:2-oxoglutarate aminotransferase activity", "gene_names": ["PSAT1"], "name": "Phosphoserine aminotransferase", "drug_actions": [{"action": "COFACTOR", "target": "Q9Y617", "drug": "DB00114"}]}, "P09546": {"specific_function": "Oxidizes proline to glutamate for use as a carbon and nitrogen source and also function as a transcriptional repressor of the put operon.", "general_function": "Transcriptional repressor activity, bacterial-type rna polymerase core promoter proximal region sequence-specific binding", "gene_names": ["putA"], "name": "Bifunctional protein PutA", "drug_actions": []}, "P49789": {"specific_function": "Cleaves P(1)-P(3)-bis(5'-adenosyl) triphosphate (Ap3A) to yield AMP and ADP. Can also hydrolyze P(1)-P(4)-bis(5'-adenosyl) tetraphosphate (Ap4A), but has extremely low activity with ATP. Modulates transcriptional activation by CTNNB1 and thereby contributes to regulate the expression of genes essential for cell proliferation and survival, such as CCND1 and BIRC5. Plays a role in the induction of apoptosis via SRC and AKT1 signaling pathways. Inhibits MDM2-mediated proteasomal degradation of p53/TP53 and thereby plays a role in p53/TP53-mediated apoptosis. Induction of apoptosis depends on the ability of FHIT to bind P(1)-P(3)-bis(5'-adenosyl) triphosphate or related compounds, but does not require its catalytic activity, it may in part come from the mitochondrial form, which sensitizes the low-affinity Ca(2+) transporters, enhancing mitochondrial calcium uptake. Functions as tumor suppressor.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["FHIT"], "name": "Bis(5'-adenosyl)-triphosphatase", "drug_actions": []}, "Q08751": {"specific_function": "Hydrolyzes pullulan efficiently but only a small amount of starch. Endohydrolysis of 1,4-alpha-glucosidic linkages in pullulan to form panose. Cleaves also (1-6)-alpha-glucosidic linkages to form maltotriose.", "general_function": "Neopullulanase activity", "gene_names": ["tvaII"], "name": "Neopullulanase 2", "drug_actions": []}, "P07477": {"specific_function": "Has activity against the synthetic substrates Boc-Phe-Ser-Arg-Mec, Boc-Leu-Thr-Arg-Mec, Boc-Gln-Ala-Arg-Mec and Boc-Val-Pro-Arg-Mec. The single-chain form is more active than the two-chain form against all of these substrates.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["PRSS1"], "name": "Trypsin-1", "drug_actions": []}, "O33245": {"specific_function": "Component of the proteasome core, a large protease complex with broad specificity involved in protein turnover. The M.tuberculosis proteasome is able to cleave oligopeptides not only after hydrophobic but also after basic, acidic and small neutral residues. Identified substrates of the M.tuberculosis proteasome are the pupylated fabD, panB and mpa proteins. One function of the proteasome is to contribute to M.tuberculosis ability to resist killing by host macrophages, since the core proteasome is essential for persistence of the pathogen during the chronic phase of infection in mice. The mechanism of protection against bactericidal chemistries of the host's immune reponse probably involves the degradation of proteins that are irreversibly oxidized, nitrated, or nitrosated", "general_function": "Posttranslational modification, protein turnover, chaperones", "gene_names": ["prcB"], "name": "Proteasome subunit beta", "drug_actions": []}, "O33244": {"general_function": "Involved in threonine endopeptidase activity", "gene_names": ["prcA"], "name": "Proteasome subunit alpha", "drug_actions": []}, "P32929": {"specific_function": "Catalyzes the last step in the trans-sulfuration pathway from methionine to cysteine. Has broad substrate specificity. Converts cystathionine to cysteine, ammonia and 2-oxobutanoate. Converts two cysteine molecules to lanthionine and hydrogen sulfide. Can also accept homocysteine as substrate. Specificity depends on the levels of the endogenous substrates. Generates the endogenous signaling molecule hydrogen sulfide (H2S), and so contributes to the regulation of blood pressure. Acts as a cysteine-protein sulfhydrase by mediating sulfhydration of target proteins: sulfhydration consists of converting -SH groups into -SSH on specific cysteine residues of target proteins such as GAPDH, PTPN1 and NF-kappa-B subunit RELA, thereby regulating their function.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["CTH"], "name": "Cystathionine gamma-lyase", "drug_actions": [{"action": "COFACTOR", "target": "P32929", "drug": "DB00114"}]}, "P08149": {"specific_function": "Synthesis of cross-linked peptidoglycan from the lipid intermediates.", "general_function": "Penicillin binding", "gene_names": ["penA"], "name": "Penicillin-binding protein 2", "drug_actions": [{"action": "INHIBITOR", "target": "P08149", "drug": "DB00535"}]}, "Q54527": {"gene_names": ["rdmB"], "name": "Aclacinomycin 10-hydroxylase RdmB", "drug_actions": []}, "Q6TME4": {"in_complexes": ["Voltage-dependent calcium channel"], "general_function": "High voltage-gated calcium channel activity", "gene_names": ["CACNB1"], "name": "Voltage-dependent L-type calcium channel subunit beta-1", "drug_actions": [{"action": "INHIBITOR", "target": "Q6TME4", "drug": "DB00381"}]}, "Q92731": {"specific_function": "Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner (PubMed:20074560). Isoform beta-cx lacks ligand binding ability and has no or only very low ere binding activity resulting in the loss of ligand-dependent transactivation ability. DNA-binding by ESR1 and ESR2 is rapidly lost at 37 degrees Celsius in the absence of ligand while in the presence of 17 beta-estradiol and 4-hydroxy-tamoxifen loss in DNA-binding at elevated temperature is more gradual.", "general_function": "Zinc ion binding", "gene_names": ["ESR2"], "name": "Estrogen receptor beta", "drug_actions": [{"action": "AGONIST", "target": "Q92731", "drug": "DB00255"}, {"action": "AGONIST", "target": "Q92731", "drug": "DB00481"}, {"action": "ANTAGONIST", "target": "Q92731", "drug": "DB00675"}, {"action": "AGONIST", "target": "Q92731", "drug": "DB00675"}, {"action": "AGONIST", "target": "Q92731", "drug": "DB00783"}, {"action": "ALLOSTERIC MODULATOR", "target": "Q92731", "drug": "DB01108"}, {"action": "OTHER/UNKNOWN", "target": "Q92731", "drug": "DB01196"}, {"action": "ACTIVATOR", "target": "Q92731", "drug": "DB01708"}, {"action": "AGONIST", "target": "Q92731", "drug": "DB03882"}, {"action": "AGONIST", "target": "Q92731", "drug": "DB04573"}, {"action": "AGONIST", "target": "Q92731", "drug": "DB04574"}]}, "Q9UGM1": {"specific_function": "Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding induces a conformation change that leads to the opening of an ion-conducting channel across the plasma membrane (PubMed:11752216, PubMed:25282151). The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane (PubMed:11752216, PubMed:25282151). In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma. May also regulate keratinocyte adhesion (PubMed:11021840).", "general_function": "Calcium channel activity", "gene_names": ["CHRNA9"], "name": "Neuronal acetylcholine receptor subunit alpha-9", "drug_actions": [{"action": "AGONIST", "target": "Q9UGM1", "drug": "DB00184"}, {"action": "ALLOSTERIC MODULATOR", "target": "Q9UGM1", "drug": "DB00674"}, {"action": "AGONIST", "target": "Q9UGM1", "drug": "DB08837"}, {"action": "INHIBITOR", "target": "Q9UGM1", "drug": "DB08837"}]}, "Q54528": {"gene_names": ["rdmC"], "name": "Aclacinomycin methylesterase RdmC", "drug_actions": []}, "P08631": {"specific_function": "Non-receptor tyrosine-protein kinase found in hematopoietic cells that transmits signals from cell surface receptors and plays an important role in the regulation of innate immune responses, including neutrophil, monocyte, macrophage and mast cell functions, phagocytosis, cell survival and proliferation, cell adhesion and migration. Acts downstream of receptors that bind the Fc region of immunoglobulins, such as FCGR1A and FCGR2A, but also CSF3R, PLAUR, the receptors for IFNG, IL2, IL6 and IL8, and integrins, such as ITGB1 and ITGB2. During the phagocytic process, mediates mobilization of secretory lysosomes, degranulation, and activation of NADPH oxidase to bring about the respiratory burst. Plays a role in the release of inflammatory molecules. Promotes reorganization of the actin cytoskeleton and actin polymerization, formation of podosomes and cell protrusions. Inhibits TP73-mediated transcription activation and TP73-mediated apoptosis. Phosphorylates CBL in response to activation of immunoglobulin gamma Fc region receptors. Phosphorylates ADAM15, BCR, ELMO1, FCGR2A, GAB1, GAB2, RAPGEF1, STAT5B, TP73, VAV1 and WAS.", "general_function": "Receptor binding", "gene_names": ["HCK"], "name": "Tyrosine-protein kinase HCK", "drug_actions": [{"action": "INHIBITOR", "target": "P08631", "drug": "DB06616"}]}, "Q9UGM6": {"general_function": "Tryptophan-trna ligase activity", "gene_names": ["WARS2"], "name": "Tryptophan--tRNA ligase, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "Q9UGM6", "drug": "DB00150"}]}, "P01137": {"specific_function": "Multifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. Can promote either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. At high concentrations, leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression, favoring Treg cell development. At low concentrations in concert with IL-6 and IL-21, leads to expression of the IL-17 and IL-23 receptors, favoring differentiation to Th17 cells.", "general_function": "Type iii transforming growth factor beta receptor binding", "gene_names": ["TGFB1"], "name": "Transforming growth factor beta-1", "drug_actions": [{"action": "INHIBITOR", "target": "P01137", "drug": "DB00070"}, {"action": "INHIBITOR", "target": "P01137", "drug": "DB06205"}]}, "P32927": {"specific_function": "High affinity receptor for interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor.", "general_function": "Receptor activity", "gene_names": ["CSF2RB"], "name": "Cytokine receptor common subunit beta", "drug_actions": [{"action": "AGONIST", "target": "P32927", "drug": "DB00020"}]}, "Q5SKH7": {"general_function": "Sulfate adenylyltransferase (atp) activity", "gene_names": [], "name": "ATP sulfurylase (Sulfate adenylyltransferase)", "drug_actions": []}, "Q9X0L5": {"general_function": "Transaminase activity", "gene_names": [], "name": "Aminotransferase, putative", "drug_actions": []}, "Q97NR6": {"gene_names": ["SP_1951"], "name": "Putative uncharacterized protein", "drug_actions": []}, "O60603": {"specific_function": "Cooperates with LY96 to mediate the innate immune response to bacterial lipoproteins and other microbial cell wall components. Cooperates with TLR1 or TLR6 to mediate the innate immune response to bacterial lipoproteins or lipopeptides (PubMed:17889651). Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. May also promote apoptosis in response to lipoproteins (PubMed:10426996). Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B.burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR6 (PubMed:11441107). Acts as a receptor for M.tuberculosis lipoproteins LprA, LprG, LpqH and PhoS1 (pstS1), some lipoproteins are dependent on other coreceptors (TLR1, CD14 and/or CD36).The lipoproteins act as agonists to modulate antigen presenting cell functions in response to the pathogen (PubMed:19362712). Forms activation clusters composed of several receptors depending on the ligand, these clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway. Forms the cluster TLR2:TLR6:CD14:CD36 in response to diacylated lipopeptides and TLR2:TLR1:CD14 in response to triacylated lipopeptides (PubMed:16880211).", "general_function": "Triacyl lipopeptide binding", "gene_names": ["TLR2"], "name": "Toll-like receptor 2", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "O60603", "drug": "DB00045"}]}, "O25928": {"specific_function": "Involved in unsaturated fatty acids biosynthesis. Catalyzes the dehydration of short chain beta-hydroxyacyl-ACPs and long chain saturated and unsaturated beta-hydroxyacyl-ACPs.", "general_function": "3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase activity", "gene_names": ["fabZ"], "name": "3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ", "drug_actions": []}, "P20138": {"specific_function": "Putative adhesion molecule of myelomonocytic-derived cells that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. Induces apoptosis in acute myeloid leukemia (in vitro).", "general_function": "Receptor activity", "gene_names": ["CD33"], "name": "Myeloid cell surface antigen CD33", "drug_actions": [{"action": "ANTIBODY", "target": "P20138", "drug": "DB00056"}]}, "P00533": {"specific_function": "Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.Isoform 2 may act as an antagonist of EGF action.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["EGFR"], "name": "Epidermal growth factor receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "P00533", "drug": "DB00002"}, {"action": "ANTAGONIST", "target": "P00533", "drug": "DB00281"}, {"action": "ANTAGONIST", "target": "P00533", "drug": "DB00317"}, {"action": "ANTAGONIST", "target": "P00533", "drug": "DB00530"}, {"action": "ANTAGONIST", "target": "P00533", "drug": "DB01259"}, {"action": "SUPPRESSOR", "target": "P00533", "drug": "DB01269"}, {"action": "INHIBITOR", "target": "P00533", "drug": "DB05294"}, {"action": "INHIBITOR", "target": "P00533", "drug": "DB08916"}, {"action": "INHIBITOR", "target": "P00533", "drug": "DB09330"}, {"action": "ANTAGONIST", "target": "P00533", "drug": "DB09559"}]}, "P51843": {"specific_function": "Orphan nuclear receptor. Component of a cascade required for the development of the hypothalamic-pituitary-adrenal-gonadal axis. Acts as a coregulatory protein that inhibits the transcriptional activity of other nuclear receptors through heterodimeric interactions. May also have a role in the development of the embryo and in the maintenance of embryonic stem cell pluripotency (By similarity).", "general_function": "Transcription factor binding", "gene_names": ["NR0B1"], "name": "Nuclear receptor subfamily 0 group B member 1", "drug_actions": [{"action": "STIMULATOR", "target": "P51843", "drug": "DB01234"}]}, "Q8MU52": {"specific_function": "Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. May also function as a storage protein or ligandin for parasitotoxic ferriprotoporphyrin IX (hemin).", "general_function": "Glutathione transferase activity", "gene_names": ["GST"], "name": "Glutathione S-transferase", "drug_actions": []}, "Q9UKM7": {"specific_function": "Involved in glycoprotein quality control targeting of misfolded glycoproteins for degradation. It primarily trims a single alpha-1,2-linked mannose residue from Man(9)GlcNAc(2) to produce Man(8)GlcNAc(2), but at high enzyme concentrations, as found in the ER quality control compartment (ERQC), it further trims the carbohydrates to Man(5-6)GlcNAc(2).", "general_function": "Mannosyl-oligosaccharide 1,2-alpha-mannosidase activity", "gene_names": ["MAN1B1"], "name": "Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase", "drug_actions": []}, "P20132": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["SDS"], "name": "L-serine dehydratase/L-threonine deaminase", "drug_actions": [{"action": "COFACTOR", "target": "P20132", "drug": "DB00114"}]}, "P10384": {"specific_function": "Involved in translocation of long-chain fatty acids across the outer membrane. It is a receptor for the bacteriophage T2. FadL may form a specific channel.", "general_function": "Long-chain fatty acid transporting porin activity", "gene_names": ["fadL"], "name": "Long-chain fatty acid transport protein", "drug_actions": []}, "Q08289": {"specific_function": "The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.", "name": "Voltage-dependent L-type calcium channel subunit beta-2", "drug_actions": [{"action": "INHIBITOR", "target": "Q08289", "drug": "DB00270"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB00381"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB00393"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB00401"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB00622"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB01023"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB01054"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB01115"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB01388"}, {"action": "INHIBITOR", "target": "Q08289", "drug": "DB06712"}], "general_function": "Voltage-gated calcium channel activity", "in_complexes": ["Voltage-dependent calcium channel"], "gene_names": ["CACNB2"]}, "P08700": {"specific_function": "Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages.This CSF induces granulocytes, macrophages, mast cells, stem cells, erythroid cells, eosinophils and megakaryocytes.", "general_function": "Interleukin-3 receptor binding", "gene_names": ["IL3"], "name": "Interleukin-3", "drug_actions": [{"action": "ANTAGONIST", "target": "P08700", "drug": "DB01025"}]}, "P01009": {"specific_function": "Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin.Short peptide from AAT: reversible chymotrypsin inhibitor. It also inhibits elastase, but not trypsin. Its major physiological function is the protection of the lower respiratory tract against proteolytic destruction by human leukocyte elastase (HLE).", "general_function": "Serine-type endopeptidase inhibitor activity", "gene_names": ["SERPINA1"], "name": "Alpha-1-antitrypsin", "drug_actions": []}, "P01008": {"specific_function": "Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory activity is greatly enhanced in the presence of heparin.", "general_function": "Serine-type endopeptidase inhibitor activity", "gene_names": ["SERPINC1"], "name": "Antithrombin-III", "drug_actions": [{"action": "POTENTIATOR", "target": "P01008", "drug": "DB00407"}, {"action": "POTENTIATOR", "target": "P01008", "drug": "DB00569"}, {"action": "POTENTIATOR", "target": "P01008", "drug": "DB01109"}, {"action": "POTENTIATOR", "target": "P01008", "drug": "DB01225"}, {"action": "POTENTIATOR", "target": "P01008", "drug": "DB06271"}, {"action": "POTENTIATOR", "target": "P01008", "drug": "DB06779"}, {"action": "POTENTIATOR", "target": "P01008", "drug": "DB06822"}, {"action": "POTENTIATOR", "target": "P01008", "drug": "DB08813"}]}, "O43923": {"general_function": "Zinc ion binding", "gene_names": ["mmp20"], "name": "Matrix metalloproteinase-25", "drug_actions": [{"action": "INHIBITOR", "target": "O43923", "drug": "DB01039"}]}, "P28593": {"specific_function": "Trypanothione is the parasite analog of glutathione; this enzyme is the equivalent of glutathione reductase.", "general_function": "Trypanothione-disulfide reductase activity", "gene_names": ["TPR"], "name": "Trypanothione reductase", "drug_actions": []}, "P08709": {"specific_function": "Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium.", "general_function": "Serine-type peptidase activity", "gene_names": ["F7"], "name": "Coagulation factor VII", "drug_actions": [{"action": "LIGAND", "target": "P08709", "drug": "DB00100"}, {"action": "ACTIVATOR", "target": "P08709", "drug": "DB00170"}]}, "Q01581": {"specific_function": "This enzyme condenses acetyl-CoA with acetoacetyl-CoA to form HMG-CoA, which is the substrate for HMG-CoA reductase.", "general_function": "Organic acid binding", "gene_names": ["HMGCS1"], "name": "Hydroxymethylglutaryl-CoA synthase, cytoplasmic", "drug_actions": []}, "Q05315": {"specific_function": "Regulates immune responses through the recognition of cell-surface glycans. Essential for the anergy and suppressive function of CD25-positive regulatory T-cells (Treg).", "general_function": "Cysteine-type endopeptidase activity involved in apoptotic process", "gene_names": ["CLC"], "name": "Galectin-10", "drug_actions": []}, "P39639": {"specific_function": "Part of the bacABCDE operon responsible for the biosynthesis of bacilysin.", "gene_names": ["bacB"], "name": "Bacilysin biosynthesis protein BacB", "drug_actions": []}, "P43155": {"specific_function": "Carnitine acetylase is specific for short chain fatty acids. Carnitine acetylase seems to affect the flux through the pyruvate dehydrogenase complex. It may be involved as well in the transport of acetyl-CoA into mitochondria.", "general_function": "Receptor binding", "gene_names": ["CRAT"], "name": "Carnitine O-acetyltransferase", "drug_actions": []}, "Q01362": {"specific_function": "High affinity receptor that binds to the Fc region of immunoglobulins epsilon. Aggregation of FCER1 by multivalent antigens is required for the full mast cell response, including the release of preformed mediators (such as histamine) by degranulation and de novo production of lipid mediators and cytokines. Also mediates the secretion of important lymphokines. Binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators responsible for the manifestations of allergy.", "general_function": "Ige receptor activity", "gene_names": ["MS4A2"], "name": "High affinity immunoglobulin epsilon receptor subunit beta", "drug_actions": [{"action": "ANTAGONIST", "target": "Q01362", "drug": "DB00043"}]}, "P72030": {"specific_function": "Arabinosyl transferase responsible for the polymerization of arabinose into the arabinan of arabinogalactan", "general_function": "Involved in transferase activity, transferring pentosyl groups", "gene_names": ["embB"], "name": "Probable arabinosyltransferase B", "drug_actions": [{"action": "INHIBITOR", "target": "P72030", "drug": "DB00330"}]}, "Q13002": {"specific_function": "Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. May be involved in the transmission of light information from the retina to the hypothalamus. Modulates cell surface expression of NETO2 (By similarity).", "general_function": "Kainate selective glutamate receptor activity", "gene_names": ["GRIK2"], "name": "Glutamate receptor ionotropic, kainate 2", "drug_actions": [{"action": "ANTAGONIST", "target": "Q13002", "drug": "DB00237"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB00241"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB00306"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB00463"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB00599"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB00794"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB00849"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB01351"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB01352"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB01353"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB01354"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB01355"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB01483"}, {"action": "ANTAGONIST", "target": "Q13002", "drug": "DB01496"}]}, "Q9FA38": {"specific_function": "Catalyzes the condensation of formaldehyde with tetrahydromethanopterin (H(4)MPT) to 5,10-methylenetetrahydromethanopterin, a reaction which also proceeds spontaneously, but at a lower rate than that of the enzyme-catalyzed reaction. Is an essential enzyme for methylotrophic energy metabolism and formaldehyde detoxification of this bacterium.", "general_function": "Carbon-nitrogen lyase activity", "gene_names": ["fae"], "name": "5,6,7,8-tetrahydromethanopterin hydro-lyase", "drug_actions": []}, "P96416": {"gene_names": ["Rv0233"], "name": "R2-like ligand binding oxidase", "drug_actions": []}, "O75390": {"general_function": "Poly(a) rna binding", "gene_names": ["CS"], "name": "Citrate synthase, mitochondrial", "drug_actions": []}, "P0A8X2": {"gene_names": ["yceI"], "name": "Protein YceI", "drug_actions": []}, "Q47PU3": {"specific_function": "Catalyzes a Baeyer-Villiger oxidation reaction, i.e. the insertion of an oxygen atom into a carbon-carbon bond adjacent to a carbonyl, which converts ketones to esters. Is most efficient with phenylacetone as substrate, leading to the formation of benzyl acetate. Can also oxidize other aromatic ketones (benzylacetone, alpha-methylphenylacetone and 4-hydroxyacetophenone), some aliphatic ketones (dodecan-2-one and bicyclohept-2-en-6-one) and sulfides (e.g. methyl 4-tolylsulfide).", "general_function": "Phenylacetone monooxygenase activity", "gene_names": ["pamO"], "name": "Phenylacetone monooxygenase", "drug_actions": []}, "P35499": {"specific_function": "This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. This sodium channel may be present in both denervated and innervated skeletal muscle.", "name": "Sodium channel protein type 4 subunit alpha", "drug_actions": [{"action": "INHIBITOR", "target": "P35499", "drug": "DB00586"}, {"action": "INHIBITOR", "target": "P35499", "drug": "DB00818"}, {"action": "INHIBITOR", "target": "P35499", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P35499", "drug": "DB01195"}], "general_function": "Voltage-gated sodium channel activity", "in_complexes": ["Sodium channel protein"], "gene_names": ["SCN4A"]}, "P35498": {"specific_function": "Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient.", "name": "Sodium channel protein type 1 subunit alpha", "drug_actions": [{"action": "INHIBITOR", "target": "P35498", "drug": "DB00252"}, {"action": "INHIBITOR", "target": "P35498", "drug": "DB00273"}, {"action": "INHIBITOR", "target": "P35498", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P35498", "drug": "DB01121"}, {"action": "INHIBITOR", "target": "P35498", "drug": "DB01438"}, {"action": "OTHER/UNKNOWN", "target": "P35498", "drug": "DB01595"}, {"action": "INHIBITOR", "target": "P35498", "drug": "DB04855"}, {"action": "INHIBITOR", "target": "P35498", "drug": "DB04930"}], "general_function": "Voltage-gated sodium channel activity", "in_complexes": ["Sodium channel protein"], "gene_names": ["SCN1A"]}, "P14550": {"specific_function": "Catalyzes the NADPH-dependent reduction of a variety of aromatic and aliphatic aldehydes to their corresponding alcohols. Catalyzes the reduction of mevaldate to mevalonic acid and of glyceraldehyde to glycerol. Has broad substrate specificity. In vitro substrates include succinic semialdehyde, 4-nitrobenzaldehyde, 1,2-naphthoquinone, methylglyoxal, and D-glucuronic acid. Plays a role in the activation of procarcinogens, such as polycyclic aromatic hydrocarbon trans-dihydrodiols, and in the metabolism of various xenobiotics and drugs, including the anthracyclines doxorubicin (DOX) and daunorubicin (DAUN).", "general_function": "L-glucuronate reductase activity", "gene_names": ["AKR1A1"], "name": "Alcohol dehydrogenase [NADP(+)]", "drug_actions": []}, "P09038": {"specific_function": "Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.", "general_function": "Ligand-dependent nuclear receptor transcription coactivator activity", "gene_names": ["FGF2"], "name": "Fibroblast growth factor 2", "drug_actions": [{"action": "AGONIST", "target": "P09038", "drug": "DB00364"}, {"action": "ANTAGONIST", "target": "P09038", "drug": "DB00686"}, {"action": "OTHER/UNKNOWN", "target": "P09038", "drug": "DB00877"}]}, "P23219": {"specific_function": "Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the generation of thromboxane A2 (TXA2), which promotes platelet activation and aggregation, vasoconstriction and proliferation of vascular smooth muscle cells.", "general_function": "Prostaglandin-endoperoxide synthase activity", "gene_names": ["PTGS1"], "name": "Prostaglandin G/H synthase 1", "drug_actions": [{"action": "INHIBITOR", "target": "P23219", "drug": "DB00154"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00159"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00244"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00316"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00328"}, {"action": "INDUCER", "target": "P23219", "drug": "DB00350"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00461"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00465"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00469"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00500"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00554"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00573"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00586"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00605"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00711"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00712"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00749"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00784"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00788"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00795"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00812"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00814"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00821"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00861"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00870"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00936"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00939"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00945"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00963"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB00991"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB01009"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB01014"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB01283"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB01397"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB01398"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB01399"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB01401"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB01419"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB01435"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB01600"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB01892"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB02709"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB06725"}, {"action": "INHIBITOR", "target": "P23219", "drug": "DB06802"}, {"action": "ANTAGONIST", "target": "P23219", "drug": "DB08814"}]}, "O60779": {"specific_function": "High-affinity transporter for the intake of thiamine.", "general_function": "Thiamine uptake transmembrane transporter activity", "gene_names": ["SLC19A2"], "name": "Thiamine transporter 1", "drug_actions": [{"action": "BINDER", "target": "O60779", "drug": "DB00152"}]}, "P20261": {"general_function": "Triglyceride lipase activity", "gene_names": ["LIP1"], "name": "Lipase 1", "drug_actions": []}, "P15509": {"specific_function": "Low affinity receptor for granulocyte-macrophage colony-stimulating factor. Transduces a signal that results in the proliferation, differentiation, and functional activation of hematopoietic cells.", "general_function": "Receptor activity", "gene_names": ["CSF2RA"], "name": "Granulocyte-macrophage colony-stimulating factor receptor subunit alpha", "drug_actions": [{"action": "AGONIST", "target": "P15509", "drug": "DB00020"}]}, "P27915": {"specific_function": "Capsid protein C self-assembles to form an icosahedral capsid about 30 nm in diameter. The capsid encapsulates the genomic RNA.prM acts as a chaperone for envelope protein E during intracellular virion assembly by masking and inactivating envelope protein E fusion peptide. prM is matured in the last step of virion assembly, presumably to avoid catastrophic activation of the viral fusion peptide induced by the acidic pH of the trans-Golgi network. After cleavage by host furin, the pr peptide is released in the extracellular medium and small envelope protein M and envelope protein E homodimers are dissociated.Envelope protein E binding to host cell surface receptor is followed by virus internalization through clathrin-mediated endocytosis. Envelope protein E is subsequently involved in membrane fusion between virion and host late endosomes. Synthesized as a homodimer with prM which acts as a chaperone for envelope protein E. After cleavage of prM, envelope protein E dissociate from small envelope protein M and homodimerizes.Non-structural protein 1 is involved in virus replication and regulation of the innate immune response. Soluble and membrane-associated NS1 may activate human complement and induce host vascular leakage. This effect might explain the clinical manifestations of dengue hemorrhagic fever and dengue shock syndrome.Non-structural protein 2A may be involved viral RNA replication and capsid assembly.Non-structural protein 2B is a required cofactor for the serine protease function of NS3.Serine protease NS3 displays three enzymatic activities: serine protease, NTPase and RNA helicase. NS3 serine protease, in association with NS2B, performs its autocleavage and cleaves the polyprotein at dibasic sites in the cytoplasm: C-prM, NS2A-NS2B, NS2B-NS3, NS3-NS4A, NS4A-2K and NS4B-NS5. NS3 RNA helicase binds RNA and unwinds dsRNA in the 3' to 5' direction (By similarity).Non-structural protein 4A induces host endoplasmic reticulum membrane rearrangements leading to the formation of virus-induced membranous vesicles hosting the dsRNA and polymerase, functioning as a replication complex. NS4A might also regulate the ATPase activity of the NS3 helicase.Peptide 2k functions as a signal peptide for NS4B and is required for the interferon antagonism activity of the latter.Non-structural protein 4B inhibits interferon (IFN)-induced host STAT1 phosphorylation and nuclear translocation, thereby preventing the establishment of cellular antiviral state by blocking the IFN-alpha/beta pathway.RNA-directed RNA polymerase NS5 replicates the viral (+) and (-) genome, and performs the capping of genomes in the cytoplasm. NS5 methylates viral RNA cap at guanine N-7 and ribose 2'-O positions. Besides its role in genome replication, also prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) signaling pathway. Inhibits host TYK2 and STAT2 phosphorylation, thereby preventing activation of JAK-STAT signaling pathway (By similarity).", "general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "Q819K2": {"specific_function": "Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions.", "general_function": "Peptide deformylase activity", "gene_names": ["def2"], "name": "Peptide deformylase 2", "drug_actions": []}, "P15502": {"specific_function": "Major structural protein of tissues such as aorta and nuchal ligament, which must expand rapidly and recover completely. Molecular determinant of the late arterial morphogenesis, stabilizing arterial structure by regulating proliferation and organization of vascular smooth muscle (By similarity).", "general_function": "Extracellular matrix structural constituent", "gene_names": ["ELN"], "name": "Elastin", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "P15502", "drug": "DB00533"}]}, "P42790": {"general_function": "Serine-type endopeptidase activity", "gene_names": ["pcp"], "name": "Pseudomonalisin", "drug_actions": []}, "Q59FK2": {"general_function": "Lyase activity", "gene_names": [], "name": "Selenocysteine lyase variant", "drug_actions": [{"action": "COFACTOR", "target": "Q59FK2", "drug": "DB00114"}]}, "P27695": {"specific_function": "Multifunctional protein that plays a central role in the cellular response to oxidative stress. The two major activities of APEX1 in DNA repair and redox regulation of transcriptional factors. Functions as a apurinic/apyrimidinic (AP) endodeoxyribonuclease in the DNA base excision repair (BER) pathway of DNA lesions induced by oxidative and alkylating agents. Initiates repair of AP sites in DNA by catalyzing hydrolytic incision of the phosphodiester backbone immediately adjacent to the damage, generating a single-strand break with 5'-deoxyribose phosphate and 3'-hydroxyl ends. Does also incise at AP sites in the DNA strand of DNA/RNA hybrids, single-stranded DNA regions of R-loop structures, and single-stranded RNA molecules. Has a 3'-5' exoribonuclease activity on mismatched deoxyribonucleotides at the 3' termini of nicked or gapped DNA molecules during short-patch BER. Possesses a DNA 3' phosphodiesterase activity capable of removing lesions (such as phosphoglycolate) blocking the 3' side of DNA strand breaks. May also play a role in the epigenetic regulation of gene expression by participating in DNA demethylation. Acts as a loading factor for POLB onto non-incised AP sites in DNA and stimulates the 5'-terminal deoxyribose 5'-phosphate (dRp) excision activity of POLB. Plays a role in the protection from granzymes-mediated cellular repair leading to cell death. Also involved in the DNA cleavage step of class switch recombination (CSR). On the other hand, APEX1 also exerts reversible nuclear redox activity to regulate DNA binding affinity and transcriptional activity of transcriptional factors by controlling the redox status of their DNA-binding domain, such as the FOS/JUN AP-1 complex after exposure to IR. Involved in calcium-dependent down-regulation of parathyroid hormone (PTH) expression by binding to negative calcium response elements (nCaREs). Together with HNRNPL or the dimer XRCC5/XRCC6, associates with nCaRE, acting as an activator of transcriptional repression. Stimulates the YBX1-mediated MDR1 promoter activity, when acetylated at Lys-6 and Lys-7, leading to drug resistance. Acts also as an endoribonuclease involved in the control of single-stranded RNA metabolism. Plays a role in regulating MYC mRNA turnover by preferentially cleaving in between UA and CA dinucleotides of the MYC coding region determinant (CRD). In association with NMD1, plays a role in the rRNA quality control process during cell cycle progression. Associates, together with YBX1, on the MDR1 promoter. Together with NPM1, associates with rRNA. Binds DNA and RNA.", "general_function": "Uracil dna n-glycosylase activity", "gene_names": ["APEX1"], "name": "DNA-(apurinic or apyrimidinic site) lyase", "drug_actions": [{"action": "INHIBITOR", "target": "P27695", "drug": "DB04967"}]}, "P27696": {"general_function": "Thiamine pyrophosphate binding", "gene_names": ["budB"], "name": "Acetolactate synthase, catabolic", "drug_actions": []}, "P24182": {"specific_function": "This protein is a component of the acetyl coenzyme A carboxylase complex; first, biotin carboxylase catalyzes the carboxylation of the carrier protein and then the transcarboxylase transfers the carboxyl group to form malonyl-CoA.", "general_function": "Metal ion binding", "gene_names": ["accC"], "name": "Biotin carboxylase", "drug_actions": []}, "P27693": {"general_function": "Serine-type endopeptidase activity", "gene_names": [], "name": "Alkaline protease", "drug_actions": []}, "P15879": {"specific_function": "ADP-ribosylates eukaryotic Rho and Rac proteins on an asparagine residue.", "general_function": "Transferase activity, transferring pentosyl groups", "gene_names": ["C3"], "name": "Mono-ADP-ribosyltransferase C3", "drug_actions": []}, "P0AGG2": {"specific_function": "Can hydrolyze a broad range of acyl-CoA thioesters. Its physiological function is not known.", "general_function": "Acyl-coa hydrolase activity", "gene_names": ["tesB"], "name": "Acyl-CoA thioesterase 2", "drug_actions": []}, "Q14353": {"general_function": "Methyltransferase activity", "gene_names": ["GAMT"], "name": "Guanidinoacetate N-methyltransferase", "drug_actions": [{"action": "PRODUCT OF", "target": "Q14353", "drug": "DB00148"}]}, "P17291": {"specific_function": "One of the primary rRNA binding proteins, it binds directly to 3'-end of the 16S rRNA where it nucleates assembly of the head domain of the 30S subunit. Is located at the subunit interface close to the decoding center. Binds mRNA and the E site tRNA blocking its exit path in the ribosome. This blockage implies that this section of the ribosome must be able to move to release the deacetylated tRNA.", "general_function": "Trna binding", "gene_names": ["rpsG"], "name": "30S ribosomal protein S7", "drug_actions": []}, "P00441": {"specific_function": "Destroys radicals which are normally produced within the cells and which are toxic to biological systems.", "general_function": "Zinc ion binding", "gene_names": ["SOD1"], "name": "Superoxide dismutase [Cu-Zn]", "drug_actions": []}, "Q9LCC8": {"gene_names": ["daaA"], "name": "D-Amino acid amidase", "drug_actions": []}, "Q53464": {"specific_function": "Catalyzes the hydrolytic dehalogenation of small (S)-2-haloalkanoic acids to yield the corresponding (R)-2-hydroxyalkanoic acids. Acts on acids of short chain lengths, C(2) to C(4), with inversion of configuration at C-2.", "general_function": "(s)-2-haloacid dehalogenase activity", "gene_names": [], "name": "(S)-2-haloacid dehalogenase", "drug_actions": []}, "P75792": {"specific_function": "Catalyzes the hydrolysis of sugar phosphate to sugar and inorganic phosphate. Has a wide substrate specificity catalyzing the hydrolysis of ribose-5-phosphate, glucose-6-phosphate, fructose-1-phosphate, acetyl-phosphate, glycerol-1-phosphate, glycerol-2-phosphate, 2-deoxy-glucose-6-phosphate, mannose-6-phosphate and fructose-6-phosphate. Appears to have a low level of phosphotransferase activity using monophosphates as the phosphate donor.", "general_function": "Sugar-phosphatase activity", "gene_names": ["ybiV"], "name": "Sugar phosphatase YbiV", "drug_actions": []}, "O43252": {"specific_function": "Bifunctional enzyme with both ATP sulfurylase and APS kinase activity, which mediates two steps in the sulfate activation pathway. The first step is the transfer of a sulfate group to ATP to yield adenosine 5'-phosphosulfate (APS), and the second step is the transfer of a phosphate group from ATP to APS yielding 3'-phosphoadenylylsulfate (PAPS: activated sulfate donor used by sulfotransferase). In mammals, PAPS is the sole source of sulfate; APS appears to be only an intermediate in the sulfate-activation pathway. Also involved in the biosynthesis of sulfated L-selectin ligands in endothelial cells.", "general_function": "Sulfate adenylyltransferase (atp) activity", "gene_names": ["PAPSS1"], "name": "Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1", "drug_actions": []}, "Q49184": {"specific_function": "Catalyzes the condensation of para-aminobenzoate (pABA) with 6-hydroxymethyl-7,8-dihydropterin diphosphate (DHPt-PP) to form 7,8-dihydropteroate (H2Pte), the immediate precursor of folate derivatives (By similarity). Implicated in resistance to sulfonamide (PubMed:2163027).", "general_function": "Metal ion binding", "gene_names": ["sulI"], "name": "Dihydropteroate synthase type-1", "drug_actions": [{"action": "INHIBITOR", "target": "Q49184", "drug": "DB00891"}]}, "P32745": {"specific_function": "Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase.", "general_function": "Somatostatin receptor activity", "gene_names": ["SSTR3"], "name": "Somatostatin receptor type 3", "drug_actions": []}, "Q99497": {"specific_function": "Protein deglycase that repairs methylglyoxal- and glyoxal-glycated amino acids and proteins, and releases repaired proteins and lactate or glycolate, respectively. Deglycates cysteines, arginines and lysines residues in proteins, and thus reactivates these proteins by reversing glycation by glyoxals. Acts on early glycation intermediates (hemithioacetals and aminocarbinols), preventing the formation of advanced glycation endproducts (AGE) (PubMed:25416785). Plays an important role in cell protection against oxidative stress and cell death acting as oxidative stress sensor and redox-sensitive chaperone and protease; functions probably related to its primary function (PubMed:17015834, PubMed:20304780, PubMed:18711745, PubMed:12796482, PubMed:19229105, PubMed:25416785). It is involved in neuroprotective mechanisms like the stabilization of NFE2L2 and PINK1 proteins, male fertility as a positive regulator of androgen signaling pathway as well as cell growth and transformation through, for instance, the modulation of NF-kappa-B signaling pathway (PubMed:12612053, PubMed:15502874, PubMed:14749723, PubMed:17015834, PubMed:21097510, PubMed:18711745). Its involvement in protein repair could also explain other unrelated functions. Eliminates hydrogen peroxide and protects cells against hydrogen peroxide-induced cell death (PubMed:16390825). Required for correct mitochondrial morphology and function as well as for autophagy of dysfunctional mitochondria (PubMed:19229105, PubMed:16632486). Plays a role in regulating expression or stability of the mitochondrial uncoupling proteins SLC25A14 and SLC25A27 in dopaminergic neurons of the substantia nigra pars compacta and attenuates the oxidative stress induced by calcium entry into the neurons via L-type channels during pacemaking (PubMed:18711745). Regulates astrocyte inflammatory responses, may modulate lipid rafts-dependent endocytosis in astrocytes and neuronal cells (PubMed:23847046). Binds to a number of mRNAs containing multiple copies of GG or CC motifs and partially inhibits their translation but dissociates following oxidative stress (PubMed:18626009). Metal-binding protein able to bind copper as well as toxic mercury ions, enhances the cell protection mechanism against induced metal toxicity (PubMed:23792957).", "general_function": "Ubiquitin-specific protease binding", "gene_names": ["PARK7"], "name": "Protein deglycase DJ-1", "drug_actions": []}, "P00269": {"specific_function": "Rubredoxin is a small nonheme, iron protein lacking acid-labile sulfide. Its single Fe, chelated to 4 Cys, functions as an electron acceptor and may also stabilize the conformation of the molecule.Electron acceptor for cytoplasmic lactate dehydrogenase.", "general_function": "Iron ion binding", "gene_names": ["rub"], "name": "Rubredoxin", "drug_actions": []}, "P14174": {"specific_function": "Pro-inflammatory cytokine. Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.", "general_function": "Receptor binding", "gene_names": ["MIF"], "name": "Macrophage migration inhibitory factor", "drug_actions": []}, "Q84CU3": {"general_function": "Nucleotide binding", "gene_names": ["ndx4"], "name": "ADP-ribose pyrophosphatase", "drug_actions": []}, "Q5NUL3": {"specific_function": "Receptor for medium and long-chain free fatty acids (FFAs). Signals via a G(q)/G(11)-coupled pathway. Acts as a receptor for omega-3 fatty acids and mediates robust anti-inflammatory effects, particularly in macrophages and fat cells. The anti-inflammatory effects involve inhibition of TAK1 through a beta-arrestin 2 (ARRB2)/TAB1-dependent effect, but independent of the G(q)/G(11)-coupled pathway. Mediates potent insulin sensitizing and antidiabetic effects by repressing macrophage-induced tissue inflammation. May mediate the taste of fatty acids. Mediates FFA-induced inhibition of apoptosis in enteroendocrine cells. May play a role in the regulation of adipocyte development and differentiation.", "general_function": "Taste receptor activity", "gene_names": ["FFAR4"], "name": "Free fatty acid receptor 4", "drug_actions": []}, "P54886": {"specific_function": "Bifunctional enzyme that converts glutamate to glutamate 5-semialdehyde, an intermediate in the biosynthesis of proline, ornithine and arginine.", "general_function": "Poly(a) rna binding", "gene_names": ["ALDH18A1"], "name": "Delta-1-pyrroline-5-carboxylate synthase", "drug_actions": []}, "Q13131": {"specific_function": "Catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin. Regulates lipid synthesis by phosphorylating and inactivating lipid metabolic enzymes such as ACACA, ACACB, GYS1, HMGCR and LIPE; regulates fatty acid and cholesterol synthesis by phosphorylating acetyl-CoA carboxylase (ACACA and ACACB) and hormone-sensitive lipase (LIPE) enzymes, respectively. Regulates insulin-signaling and glycolysis by phosphorylating IRS1, PFKFB2 and PFKFB3. AMPK stimulates glucose uptake in muscle by increasing the translocation of the glucose transporter SLC2A4/GLUT4 to the plasma membrane, possibly by mediating phosphorylation of TBC1D4/AS160. Regulates transcription and chromatin structure by phosphorylating transcription regulators involved in energy metabolism such as CRTC2/TORC2, FOXO3, histone H2B, HDAC5, MEF2C, MLXIPL/ChREBP, EP300, HNF4A, p53/TP53, SREBF1, SREBF2 and PPARGC1A. Acts as a key regulator of glucose homeostasis in liver by phosphorylating CRTC2/TORC2, leading to CRTC2/TORC2 sequestration in the cytoplasm. In response to stress, phosphorylates 'Ser-36' of histone H2B (H2BS36ph), leading to promote transcription. Acts as a key regulator of cell growth and proliferation by phosphorylating TSC2, RPTOR and ATG1/ULK1: in response to nutrient limitation, negatively regulates the mTORC1 complex by phosphorylating RPTOR component of the mTORC1 complex and by phosphorylating and activating TSC2. In response to nutrient limitation, promotes autophagy by phosphorylating and activating ATG1/ULK1. AMPK also acts as a regulator of circadian rhythm by mediating phosphorylation of CRY1, leading to destabilize it. May regulate the Wnt signaling pathway by phosphorylating CTNNB1, leading to stabilize it. Also has tau-protein kinase activity: in response to amyloid beta A4 protein (APP) exposure, activated by CAMKK2, leading to phosphorylation of MAPT/TAU; however the relevance of such data remains unclear in vivo. Also phosphorylates CFTR, EEF2K, KLC1, NOS3 and SLC12A1.", "name": "5'-AMP-activated protein kinase catalytic subunit alpha-1", "drug_actions": [{"action": "ACTIVATOR", "target": "Q13131", "drug": "DB00131"}, {"action": "ACTIVATOR", "target": "Q13131", "drug": "DB00914"}, {"action": "ACTIVATOR", "target": "Q13131", "drug": "DB00945"}], "general_function": "Tau-protein kinase activity", "in_complexes": ["5'-AMP-activated protein kinase"], "gene_names": ["PRKAA1"]}, "P53609": {"specific_function": "Catalyzes the transfer of a geranyl-geranyl moiety from geranyl-geranyl pyrophosphate to a cysteine at the fourth position from the C-terminus of proteins having the C-terminal sequence Cys-aliphatic-aliphatic-X. Known substrates include RAC1, RAC2, RAP1A and RAP1B.", "general_function": "Zinc ion binding", "gene_names": ["PGGT1B"], "name": "Geranylgeranyl transferase type-1 subunit beta", "drug_actions": []}, "Q5T1J1": {"gene_names": ["SIGMAR1"], "name": "HCG20471, isoform CRA_c", "drug_actions": [{"action": "AGONIST", "target": "Q5T1J1", "drug": "DB00514"}, {"action": "ANTAGONIST", "target": "Q5T1J1", "drug": "DB00704"}]}, "P05653": {"specific_function": "DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.", "general_function": "Dna topoisomerase type ii (atp-hydrolyzing) activity", "gene_names": ["gyrA"], "name": "DNA gyrase subunit A", "drug_actions": []}, "P28838": {"specific_function": "Presumably involved in the processing and regular turnover of intracellular proteins. Catalyzes the removal of unsubstituted N-terminal amino acids from various peptides.", "general_function": "Metalloexopeptidase activity", "gene_names": ["LAP3"], "name": "Cytosol aminopeptidase", "drug_actions": []}, "P0A876": {"specific_function": "Specifically methylates guanosine-37 in various tRNAs.", "general_function": "Trna (guanine(37)-n(1))-methyltransferase activity", "gene_names": ["trmD"], "name": "tRNA (guanine-N(1)-)-methyltransferase", "drug_actions": []}, "P41972": {"specific_function": "Catalyzes the attachment of isoleucine to tRNA(Ile). As IleRS can inadvertently accommodate and process structurally similar amino acids such as valine, to avoid such errors it has two additional distinct tRNA(Ile)-dependent editing activities. One activity is designated as 'pretransfer' editing and involves the hydrolysis of activated Val-AMP. The other activity is designated 'posttransfer' editing and involves deacylation of mischarged Val-tRNA(Ile) (By similarity).", "general_function": "Zinc ion binding", "gene_names": ["ileS"], "name": "Isoleucine--tRNA ligase", "drug_actions": [{"action": "INHIBITOR", "target": "P41972", "drug": "DB00410"}]}, "Q04609": {"specific_function": "Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. In the intestine, required for the uptake of folate. In the brain, modulates excitatory neurotransmission through the hydrolysis of the neuropeptide, N-aceylaspartylglutamate (NAAG), thereby releasing glutamate. Isoform PSM-4 and isoform PSM-5 would appear to be physiologically irrelevant. Involved in prostate tumor progression.Also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC.", "general_function": "Tetrahydrofolyl-poly(glutamate) polymer binding", "gene_names": ["FOLH1"], "name": "Glutamate carboxypeptidase 2", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "Q04609", "drug": "DB00089"}]}, "Q9UI09": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFA12"], "name": "NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12", "drug_actions": []}, "P23368": {"general_function": "Oxaloacetate decarboxylase activity", "gene_names": ["ME2"], "name": "NAD-dependent malic enzyme, mitochondrial", "drug_actions": []}, "Q5F2I3": {"specific_function": "Catalyzes the reduction of nitrite to ammonia, consuming six electrons in the process (PubMed:16500161, PubMed:22281743). Has very low activity toward hydroxylamine (PubMed:16500161). Has even lower activity toward sulfite (PubMed:16500161, PubMed:22281743). Sulfite reductase activity is maximal at neutral pH (PubMed:20944237).", "general_function": "Nitrite reductase (cytochrome, ammonia-forming) activity", "gene_names": ["nir"], "name": "Cytochrome c-552", "drug_actions": []}, "P20964": {"specific_function": "Necessary for the transition from vegetative growth to stage 0 or stage II of sporulation, but sporulation subsequent to these stages is unaffected at 45 degrees Celsius. This ts effect is probably due solely to the E-79 mutation. Required for expression of early sporulation genes, further suggesting a role in the induction of sporulation. Depletion effects on sporulation can be partially suppressed by missense mutations in spo0A. Strains depleted for obg stop growing after about 3 hours and do not induce the sigma-B factor following ethanol stress. It cofractionates with the ribosome and upstream stress response regulators RsbR, RsbS and RsbT in size fractionation columns, suggesting the ribosome might serve as a possible mediator of the activity of obg and the stress induction of sigma-B. In glycerol gradients partially associates with ribosomes; this is stabilized by a nonhydrolyzable GTP-analog and to a lesser extent GTP and GDP.An essential GTPase which binds GTP, GDP and possibly (p)ppGpp with moderate affinity, with high nucleotide exchange rates and a fairly low GTP hydrolysis rate. Plays a role in control of the cell cycle, stress response, ribosome biogenesis and in those bacteria that undergo differentiation, in morphogenesis control.", "general_function": "Magnesium ion binding", "gene_names": ["obg"], "name": "GTPase Obg", "drug_actions": []}, "Q01698": {"specific_function": "This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis.", "general_function": "Translation elongation factor activity", "gene_names": ["tuf"], "name": "Elongation factor Tu", "drug_actions": []}, "Q9X266": {"general_function": "Threonine aldolase activity", "gene_names": [], "name": "L-allo-threonine aldolase", "drug_actions": []}, "Q9RN68": {"specific_function": "May form part of a transmembrane redox complex through which electrons are transferred to the cytoplasm for reduction of sulfate.", "general_function": "Metal ion binding", "gene_names": [], "name": "Nine-heme cytochrome c", "drug_actions": []}, "P23367": {"specific_function": "This protein is involved in the repair of mismatches in DNA. It is required for dam-dependent methyl-directed DNA mismatch repair. May act as a \"molecular matchmaker\", a protein that promotes the formation of a stable complex between two or more DNA-binding proteins in an ATP-dependent manner without itself being part of the final effector complex. The ATPase activity of MutL is stimulated by DNA.", "general_function": "Mismatched dna binding", "gene_names": ["mutL"], "name": "DNA mismatch repair protein MutL", "drug_actions": []}, "P37610": {"specific_function": "Catalyzes the conversion of taurine and alpha ketoglutarate to sulfite, aminoacetaldehyde and succinate. Required for the utilization of taurine (2-aminoethanesulfonic acid) as an alternative sulfur source. Pentane-sulfonic acid, 3-(N-morpholino)propanesulfonic acid and 1,3-dioxo-2-isoindolineethanesulfonic acid are also substrates for this enzyme.", "general_function": "Taurine dioxygenase activity", "gene_names": ["tauD"], "name": "Alpha-ketoglutarate-dependent taurine dioxygenase", "drug_actions": []}, "Q8GI16": {"specific_function": "Part of the multicomponent carbazole 1,9a-dioxygenase (CARDO), that converts carbazole (CAR) into 2-aminobiphenyl-2,3-diol. Acts as a mediator in the electron transfer from CarAd to CarAa.", "general_function": "Metal ion binding", "gene_names": ["carAc"], "name": "Ferredoxin CarAc", "drug_actions": []}, "P0AEJ4": {"specific_function": "Member of the two-component regulatory system EnvZ/OmpR involved in the regulation of osmoregulation (genes ompF and ompC). EnvZ functions as a membrane-associated protein kinase that phosphorylates OmpR in response to environmental signals.", "general_function": "Phosphorelay sensor kinase activity", "gene_names": ["envZ"], "name": "Osmolarity sensor protein EnvZ", "drug_actions": []}, "O43704": {"specific_function": "Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of many hormones, neurotransmitters, drugs and xenobiotic compounds. Sulfonation increases the water solubility of most compounds, and therefore their renal excretion, but it can also result in bioactivation to form active metabolites. Sulfates dopamine, small phenols such as 1-naphthol and p-nitrophenol and thyroid hormones, including 3,3'-diiodothyronine, triidothyronine, reverse triiodothyronine and thyroxine.", "general_function": "Sulfotransferase activity", "gene_names": ["SULT1B1"], "name": "Sulfotransferase family cytosolic 1B member 1", "drug_actions": []}, "P09669": {"specific_function": "This protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport.", "general_function": "Cytochrome-c oxidase activity", "gene_names": ["COX6C"], "name": "Cytochrome c oxidase subunit 6C", "drug_actions": []}, "P27302": {"specific_function": "Catalyzes the reversible transfer of a two-carbon ketol group from sedoheptulose-7-phosphate to glyceraldehyde-3-phosphate, producing xylulose-5-phosphate and ribose-5-phosphate. Catalyzes the transfer of a two-carbon ketol group from a ketose donor to an aldose acceptor, via a covalent intermediate with the cofactor thiamine pyrophosphate.", "general_function": "Transketolase activity", "gene_names": ["tktA"], "name": "Transketolase 1", "drug_actions": []}, "Q72497": {"general_function": "Zinc ion binding", "gene_names": ["gag"], "name": "Gag polyprotein", "drug_actions": []}, "Q14643": {"specific_function": "Intracellular channel that mediates calcium release from the endoplasmic reticulum following stimulation by inositol 1,4,5-trisphosphate. Involved in the regulation of epithelial secretion of electrolytes and fluid through the interaction with AHCYL1 (By similarity). Plays a role in ER stress-induced apoptosis. Cytoplasmic calcium released from the ER triggers apoptosis by the activation of CaM kinase II, eventually leading to the activation of downstream apoptosis pathways (By similarity).", "name": "Inositol 1,4,5-trisphosphate receptor type 1", "drug_actions": [], "general_function": "Phosphatidylinositol binding", "in_complexes": ["Inositol 1,4,5-trisphosphate receptor"], "gene_names": ["ITPR1"]}, "Q9KEQ1": {"general_function": "Hydrolase activity", "gene_names": [], "name": "Acyl-CoA hydrolase", "drug_actions": []}, "Q14721": {"specific_function": "Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain, but also in the pancreas and cardiovascular system. Contributes to the regulation of the action potential (AP) repolarization, duration and frequency of repetitive AP firing in neurons, muscle cells and endocrine cells and plays a role in homeostatic attenuation of electrical excitability throughout the brain (PubMed:23161216). Plays also a role in the regulation of exocytosis independently of its electrical function (By similarity). Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane. Homotetrameric channels mediate a delayed-rectifier voltage-dependent outward potassium current that display rapid activation and slow inactivation in response to membrane depolarization (PubMed:8081723, PubMed:1283219, PubMed:10484328, PubMed:12560340, PubMed:19074135, PubMed:19717558, PubMed:24901643). Can form functional homotetrameric and heterotetrameric channels that contain variable proportions of KCNB2; channel properties depend on the type of alpha subunits that are part of the channel (By similarity). Can also form functional heterotetrameric channels with other alpha subunits that are non-conducting when expressed alone, such as KCNF1, KCNG1, KCNG3, KCNG4, KCNH1, KCNH2, KCNS1, KCNS2, KCNS3 and KCNV1, creating a functionally diverse range of channel complexes (PubMed:10484328, PubMed:11852086, PubMed:12060745, PubMed:19074135, PubMed:19717558, PubMed:24901643). Heterotetrameric channel activity formed with KCNS3 show increased current amplitude with the threshold for action potential activation shifted towards more negative values in hypoxic-treated pulmonary artery smooth muscle cells (By similarity). Channel properties are also modulated by cytoplasmic ancillary beta subunits such as AMIGO1, KCNE1, KCNE2 and KCNE3, slowing activation and inactivation rate of the delayed rectifier potassium channels (By similarity). In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Major contributor to the slowly inactivating delayed-rectifier voltage-gated potassium current in neurons of the central nervous system, sympathetic ganglion neurons, neuroendocrine cells, pancreatic beta cells, cardiomyocytes and smooth muscle cells. Mediates the major part of the somatodendritic delayed-rectifier potassium current in hippocampal and cortical pyramidal neurons and sympathetic superior cervical ganglion (CGC) neurons that acts to slow down periods of firing, especially during high frequency stimulation. Plays a role in the induction of long-term potentiation (LTP) of neuron excitability in the CA3 layer of the hippocampus (By similarity). Contributes to the regulation of glucose-induced action potential amplitude and duration in pancreatic beta cells, hence limiting calcium influx and insulin secretion (PubMed:23161216). Plays a role in the regulation of resting membrane potential and contraction in hypoxia-treated pulmonary artery smooth muscle cells. May contribute to the regulation of the duration of both the action potential of cardiomyocytes and the heart ventricular repolarization QT interval. Contributes to the pronounced pro-apoptotic potassium current surge during neuronal apoptotic cell death in response to oxidative injury. May confer neuroprotection in response to hypoxia/ischemic insults by suppressing pyramidal neurons hyperexcitability in hippocampal and cortical regions (By similarity). Promotes trafficking of KCNG3, KCNH1 and KCNH2 to the cell surface membrane, presumably by forming heterotetrameric channels with these subunits (PubMed:12060745). Plays a role in the calcium-dependent recruitment and release of fusion-competent vesicles from the soma of neurons, neuroendocrine and glucose-induced pancreatic beta cells by binding key components of the fusion machinery in a pore-independent manner (By similarity).", "general_function": "Ubiquitin-like protein binding", "gene_names": ["KCNB1"], "name": "Potassium voltage-gated channel subfamily B member 1", "drug_actions": [{"action": "ANTAGONIST", "target": "Q14721", "drug": "DB06637"}]}, "A2QLK4": {"specific_function": "Catalytic subunit of the 1,3-beta-glucan synthase. Synthesizes 1,3-beta-glucan, a major structural component of the cell wall. Involved in cell wall synthesis, maintenance and cell wall remodeling (By similarity).", "general_function": "1,3-beta-d-glucan synthase activity", "gene_names": ["fksA"], "name": "1,3-beta-glucan synthase component FKS1", "drug_actions": [{"action": "INHIBITOR", "target": "A2QLK4", "drug": "DB00362"}, {"action": "INHIBITOR", "target": "A2QLK4", "drug": "DB00520"}, {"action": "INHIBITOR", "target": "A2QLK4", "drug": "DB01141"}]}, "P45563": {"specific_function": "The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate. This protein can degrade all purine nucleosides including xanthosine, inosine and guanosine, but cannot cleave adenosine, deoxyadenosine or hypoxanthine arabinoside. Has a preference for the neutral over the monoanionic form of xanthosine.", "general_function": "Purine-nucleoside phosphorylase activity", "gene_names": ["xapA"], "name": "Purine nucleoside phosphorylase 2", "drug_actions": []}, "Q99456": {"specific_function": "May play a unique role in maintaining the normal corneal epithelial function. Together with KRT3, essential for the maintenance of corneal epithelium integrity (By similarity).", "general_function": "Structural molecule activity", "gene_names": ["KRT12"], "name": "Keratin, type I cytoskeletal 12", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "Q99456", "drug": "DB00400"}]}, "P04632": {"specific_function": "Regulatory subunit of the calcium-regulated non-lysosomal thiol-protease which catalyzes limited proteolysis of substrates involved in cytoskeletal remodeling and signal transduction.", "general_function": "Calcium-dependent cysteine-type endopeptidase activity", "gene_names": ["CAPNS1"], "name": "Calpain small subunit 1", "drug_actions": []}, "Q9N587": {"specific_function": "Acetylcholine receptor.", "general_function": "Acetylcholine-gated cation channel activity", "gene_names": ["unc-63"], "name": "Acetylcholine receptor subunit alpha-type unc-63", "drug_actions": [{"action": "ACTIVATOR", "target": "Q9N587", "drug": "DB00848"}]}, "P04637": {"gene_names": ["TP53"], "name": "Cellular tumor antigen p53", "drug_actions": [{"action": "ACETYLATION", "target": "P04637", "drug": "DB00945"}]}, "P54965": {"specific_function": "The enzyme catalyzes the degradation of conjugated bile acids in the mammalian gut.", "general_function": "Choloylglycine hydrolase activity", "gene_names": ["cbh"], "name": "Choloylglycine hydrolase", "drug_actions": []}, "Q05486": {"specific_function": "Multifunctional enzyme that converts the viral RNA genome into dsDNA in viral cytoplasmic capsids. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3'- to 5'-endonucleasic mode. Neo-synthesized pregenomic RNA (pgRNA) are encapsidated together with the P protein, and reverse-transcribed inside the nucleocapsid. Initiation of reverse-transcription occurs first by binding the epsilon loop on the pgRNA genome, and is initiated by protein priming, thereby the 5'-end of (-)DNA is covalently linked to P protein. Partial (+)DNA is synthesized from the (-)DNA template and generates the relaxed circular DNA (RC-DNA) genome. After budding and infection, the RC-DNA migrates in the nucleus, and is converted into a plasmid-like covalently closed circular DNA (cccDNA). The activity of P protein does not seem to be necessary for cccDNA generation, and is presumably released from (+)DNA by host nuclear DNA repair machinery (By similarity).", "general_function": "Rna-dna hybrid ribonuclease activity", "gene_names": ["P"], "name": "Protein P", "drug_actions": [{"action": "INHIBITOR", "target": "Q05486", "drug": "DB00709"}]}, "Q9FBC5": {"general_function": "Nucleotide binding", "gene_names": ["fabK"], "name": "Putative enoyl-(Acyl-carrier-protein) reductase II", "drug_actions": []}, "P44783": {"specific_function": "Rhomboid-type serine protease that catalyzes intramembrane proteolysis.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["glpG"], "name": "Rhomboid protease GlpG", "drug_actions": []}, "Q9H4G4": {"general_function": "Protein homodimerization activity", "gene_names": ["GLIPR2"], "name": "Golgi-associated plant pathogenesis-related protein 1", "drug_actions": []}, "Q7DB61": {"gene_names": [], "name": "GrlR", "drug_actions": []}, "P0AEX9": {"specific_function": "Involved in the high-affinity maltose membrane transport system MalEFGK. Initial receptor for the active transport of and chemotaxis toward maltooligosaccharides.", "general_function": "Transporter activity", "gene_names": ["malE"], "name": "Maltose-binding periplasmic protein", "drug_actions": []}, "P03355": {"specific_function": "Gag-Pol polyprotein plays a role in budding and is processed by the viral protease during virion maturation outside the cell. During budding, it recruits, in a PPXY-dependent or independent manner, Nedd4-like ubiquitin ligases that conjugate ubiquitin molecules to Gag, or to Gag binding host factors. Interaction with HECT ubiquitin ligases probably link the viral protein to the host ESCRT pathway and facilitate release.Matrix protein p15 targets Gag and gag-pol polyproteins to the plasma membrane via a multipartite membrane binding signal, that includes its myristoylated N-terminus. Also mediates nuclear localization of the preintegration complex (By similarity).Capsid protein p30 forms the spherical core of the virion that encapsulates the genomic RNA-nucleocapsid complex.Nucleocapsid protein p10 is involved in the packaging and encapsidation of two copies of the genome. Binds with high affinity to conserved UCUG elements within the packaging signal, located near the 5'-end of the genome. This binding is dependent on genome dimerization.The aspartyl protease mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane. Cleavages take place as an ordered, step-wise cascade to yield mature proteins. This process is called maturation. Displays maximal activity during the budding process just prior to particle release from the cell.Reverse transcriptase/ribonuclease H (RT) is a multifunctional enzyme that converts the viral dimeric RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA binds to the primer-binding site (PBS) situated at the 5' end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for a polypurine tract (PPT) situated at the 5' end of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPT that has not been removed by RNase H as primers. PPT and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends (By similarity).Integrase catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step that requires cell division, the PIC enters cell nucleus. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The last step is viral DNA integration into host chromosome.", "general_function": "Zinc ion binding", "gene_names": ["gag-pol"], "name": "Gag-Pol polyprotein", "drug_actions": []}, "P11217": {"specific_function": "Phosphorylase is an important allosteric enzyme in carbohydrate metabolism. Enzymes from different sources differ in their regulatory mechanisms and in their natural substrates. However, all known phosphorylases share catalytic and structural properties.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["PYGM"], "name": "Glycogen phosphorylase, muscle form", "drug_actions": [{"action": "COFACTOR", "target": "P11217", "drug": "DB00114"}]}, "Q96LZ3": {"specific_function": "Regulatory subunit of calcineurin, a calcium-dependent, calmodulin stimulated protein phosphatase. Confers calcium sensitivity (By similarity).", "general_function": "Calcium ion binding", "gene_names": ["PPP3R2"], "name": "Calcineurin subunit B type 2", "drug_actions": [{"action": "INHIBITOR", "target": "Q96LZ3", "drug": "DB00091"}]}, "Q99928": {"specific_function": "GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.", "name": "Gamma-aminobutyric acid receptor subunit gamma-3", "drug_actions": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00228"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00475"}, {"action": "BINDER", "target": "Q99928", "drug": "DB00543"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB00546"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00628"}, {"action": "POSITIVE MODULATOR", "target": "Q99928", "drug": "DB00659"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB00690"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00794"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00818"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01028"}, {"action": "AGONIST", "target": "Q99928", "drug": "DB01049"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01205"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01437"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q99928", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "Q99928", "drug": "DB01595"}, {"action": "ANTAGONIST", "target": "Q99928", "drug": "DB01708"}], "general_function": "Inhibitory extracellular ligand-gated ion channel activity", "in_complexes": ["GABA-A receptor (anion channel)"], "gene_names": ["GABRG3"]}, "P77674": {"specific_function": "Catalyzes the oxidation of 1-pyrroline, which is spontaneously formed from 4-aminobutanal, leading to 4-aminobutanoate (GABA). Can also oxidize n-alkyl medium-chain aldehydes, but with a lower catalytic efficiency.", "general_function": "Nad binding", "gene_names": ["prr"], "name": "Gamma-aminobutyraldehyde dehydrogenase", "drug_actions": []}, "O60391": {"specific_function": "NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine.", "name": "Glutamate receptor ionotropic, NMDA 3B", "drug_actions": [{"action": "BLOCKER", "target": "O60391", "drug": "DB00289"}, {"action": "ANTAGONIST", "target": "O60391", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "O60391", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "O60391", "drug": "DB00659"}, {"action": "ANTAGONIST", "target": "O60391", "drug": "DB01159"}, {"action": "ANTAGONIST", "target": "O60391", "drug": "DB01173"}, {"action": "ANTAGONIST", "target": "O60391", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "O60391", "drug": "DB01520"}, {"action": "AGONIST", "target": "O60391", "drug": "DB01708"}, {"action": "INHIBITOR", "target": "O60391", "drug": "DB04896"}, {"action": "ANTAGONIST", "target": "O60391", "drug": "DB06738"}, {"action": "ANTAGONIST", "target": "O60391", "drug": "DB06741"}], "general_function": "Nmda glutamate receptor activity", "in_complexes": ["Glutamate (NMDA) receptor", "NMDA receptor"], "gene_names": ["GRIN3B"]}, "Q13224": {"specific_function": "NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an irreversible neuronal death (By similarity).", "name": "Glutamate receptor ionotropic, NMDA 2B", "drug_actions": [{"action": "BLOCKER", "target": "Q13224", "drug": "DB00289"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB00454"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB00502"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB00659"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB00949"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB01043"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB01520"}, {"action": "AGONIST", "target": "Q13224", "drug": "DB01708"}, {"action": "INHIBITOR", "target": "Q13224", "drug": "DB04896"}, {"action": "ACTIVATOR", "target": "Q13224", "drug": "DB06151"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB06738"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB06741"}, {"action": "ANTAGONIST", "target": "Q13224", "drug": "DB08954"}], "general_function": "Zinc ion binding", "in_complexes": ["Glutamate (NMDA) receptor", "NMDA receptor"], "gene_names": ["GRIN2B"]}, "Q9WZK0": {"specific_function": "Reversibly transfers an adenylyl group from ATP to 4'-phosphopantetheine, yielding dephospho-CoA (dPCoA) and pyrophosphate.", "general_function": "Pantetheine-phosphate adenylyltransferase activity", "gene_names": ["coaD"], "name": "Phosphopantetheine adenylyltransferase", "drug_actions": []}, "Q8TCU5": {"specific_function": "NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity).", "name": "Glutamate receptor ionotropic, NMDA 3A", "drug_actions": [{"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00193"}, {"action": "BLOCKER", "target": "Q8TCU5", "drug": "DB00289"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00333"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00392"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00514"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00659"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00721"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00898"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00915"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB00949"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB01043"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB01159"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB01161"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB01173"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB01520"}, {"action": "AGONIST", "target": "Q8TCU5", "drug": "DB01708"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB03575"}, {"action": "INHIBITOR", "target": "Q8TCU5", "drug": "DB04896"}, {"action": "ACTIVATOR", "target": "Q8TCU5", "drug": "DB06151"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB06738"}, {"action": "ANTAGONIST", "target": "Q8TCU5", "drug": "DB06741"}], "general_function": "Protein phosphatase 2a binding", "in_complexes": ["Glutamate (NMDA) receptor", "NMDA receptor"], "gene_names": ["GRIN3A"]}, "P01877": {"specific_function": "Ig alpha is the major immunoglobulin class in body secretions. It may serve both to defend against local infection and to prevent access of foreign antigens to the general immunologic system.", "general_function": "Antigen binding", "gene_names": ["IGHA2"], "name": "Ig alpha-2 chain C region", "drug_actions": []}, "Q8N142": {"specific_function": "Component of the purine nucleotide cycle (PNC), which interconverts IMP and AMP to regulate the nucleotide levels in various tissues, and which contributes to glycolysis and ammoniagenesis. Catalyzes the first committed step in the biosynthesis of AMP from IMP (By similarity).", "general_function": "Phosphate ion binding", "gene_names": ["ADSSL1"], "name": "Adenylosuccinate synthetase isozyme 1", "drug_actions": []}, "P22188": {"specific_function": "Catalyzes the addition of meso-diaminopimelic acid to the nucleotide precursor UDP-N-acetylmuramoyl-L-alanyl-D-glutamate (UMAG) in the biosynthesis of bacterial cell-wall peptidoglycan. Is also able to use many meso-diaminopimelate analogs as substrates, although much less efficiently, but not L-lysine.", "general_function": "Udp-n-acetylmuramoylalanyl-d-glutamate-2,6-diaminopimelate ligase activity", "gene_names": ["murE"], "name": "UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--2,6-diaminopimelate ligase", "drug_actions": []}, "Q96P88": {"specific_function": "Putative receptor for gonadotropin releasing hormone II (GnRH II) which is most probably non-functional.", "general_function": "Gonadotropin-releasing hormone receptor activity", "gene_names": ["GNRHR2"], "name": "Putative gonadotropin-releasing hormone II receptor", "drug_actions": [{"action": "AGONIST", "target": "Q96P88", "drug": "DB00644"}, {"action": "AGONIST", "target": "Q96P88", "drug": "DB00666"}, {"action": "NEGATIVE MODULATOR", "target": "Q96P88", "drug": "DB01406"}]}, "P19992": {"general_function": "Androstan-3-alpha,17-beta-diol dehydrogenase activity", "gene_names": [], "name": "3-alpha-(or 20-beta)-hydroxysteroid dehydrogenase", "drug_actions": []}, "P20823": {"specific_function": "Transcriptional activator that regulates the tissue specific expression of multiple genes, especially in pancreatic islet cells and in liver. Required for the expression of several liver specific genes. Binds to the inverted palindrome 5'-GTTAATNATTAAC-3'.", "general_function": "Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding", "gene_names": ["HNF1A"], "name": "Hepatocyte nuclear factor 1-alpha", "drug_actions": []}, "P40939": {"specific_function": "Bifunctional subunit.", "general_function": "Nad binding", "gene_names": ["HADHA"], "name": "Trifunctional enzyme subunit alpha, mitochondrial", "drug_actions": []}, "Q9HA77": {"general_function": "Metal ion binding", "gene_names": ["CARS2"], "name": "Probable cysteine--tRNA ligase, mitochondrial", "drug_actions": []}, "Q9NY72": {"specific_function": "Modulates channel gating kinetics. Causes unique persistent sodium currents. Inactivates the sodium channel opening more slowly than the subunit beta-1. Its association with neurofascin may target the sodium channels to the nodes of Ranvier of developing axons and retain these channels at the nodes in mature myelinated axons (By similarity).", "name": "Sodium channel subunit beta-3", "drug_actions": [{"action": "INHIBITOR", "target": "Q9NY72", "drug": "DB00909"}], "general_function": "Voltage-gated sodium channel activity involved in cardiac muscle cell action potential", "in_complexes": ["Sodium channel protein"], "gene_names": ["SCN3B"]}, "Q9HVJ6": {"gene_names": [], "name": "Probable outer membrane protein", "drug_actions": []}, "Q8GN86": {"general_function": "Nucleotide binding", "gene_names": [], "name": "4-chlorobenzoyl CoA ligase", "drug_actions": []}, "O14939": {"specific_function": "May have a role in signal-induced cytoskeletal regulation and/or endocytosis.", "general_function": "Phospholipase d activity", "gene_names": ["PLD2"], "name": "Phospholipase D2", "drug_actions": [{"action": "PRODUCT OF", "target": "O14939", "drug": "DB00122"}]}, "O14936": {"specific_function": "Multidomain scaffolding protein with a role in synaptic transmembrane protein anchoring and ion channel trafficking. Contributes to neural development and regulation of gene expression via interaction with the transcription factor TBR1. Binds to cell-surface proteins, including amyloid precursor protein, neurexins and syndecans. May mediate a link between the extracellular matrix and the actin cytoskeleton via its interaction with syndecan and with the actin/spectrin-binding protein 4.1.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["CASK"], "name": "Peripheral plasma membrane protein CASK", "drug_actions": []}, "P04839": {"specific_function": "Critical component of the membrane-bound oxidase of phagocytes that generates superoxide. It is the terminal component of a respiratory chain that transfers single electrons from cytoplasmic NADPH across the plasma membrane to molecular oxygen on the exterior. Also functions as a voltage-gated proton channel that mediates the H(+) currents of resting phagocytes. It participates in the regulation of cellular pH and is blocked by zinc.", "name": "Cytochrome b-245 heavy chain", "drug_actions": [{"action": "INHIBITOR", "target": "P04839", "drug": "DB00514"}], "general_function": "Voltage-gated ion channel activity", "in_complexes": ["NADPH oxidase"], "gene_names": ["CYBB"]}, "P14598": {"specific_function": "NCF2, NCF1, and a membrane bound cytochrome b558 are required for activation of the latent NADPH oxidase (necessary for superoxide production).", "name": "Neutrophil cytosol factor 1", "drug_actions": [{"action": "INHIBITOR", "target": "P14598", "drug": "DB00514"}], "general_function": "Superoxide-generating nadph oxidase activity", "in_complexes": ["NADPH oxidase"], "gene_names": ["NCF1"]}, "O15403": {"specific_function": "Proton-linked monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate (By similarity).", "general_function": "Symporter activity", "gene_names": ["SLC16A6"], "name": "Monocarboxylate transporter 7", "drug_actions": []}, "P0A9Z7": {"specific_function": "This enzyme hydrolyzes cefotaxime, ceftazidime and other broad spectrum cephalosporins.", "general_function": "Beta-lactamase activity", "gene_names": ["bla"], "name": "Beta-lactamase SHV-2", "drug_actions": [{"action": "INHIBITOR", "target": "P0A9Z7", "drug": "DB09060"}]}, "Q88016": {"general_function": "Zinc ion binding", "gene_names": ["pol"], "name": "Pol polyprotein", "drug_actions": []}, "Q6TGC4": {"specific_function": "Catalyzes the deimination of arginine residues of proteins. May be involved in cytoskeletal reorganization in the egg and early embryo (By similarity).", "general_function": "Protein-arginine deiminase activity", "gene_names": ["PADI6"], "name": "Protein-arginine deiminase type-6", "drug_actions": []}, "Q51948": {"specific_function": "Involved in the naphthalene catabolic pathway. Catalyzes the reversible glutathione-dependent isomerization of 2-hydroxychromene-2-carboxylate (HCCA) to trans-O-hydroxybenzylidenepyruvate (THBPA).", "general_function": "Protein disulfide oxidoreductase activity", "gene_names": ["nahD"], "name": "2-hydroxychromene-2-carboxylate isomerase", "drug_actions": []}, "Q59FW3": {"general_function": "Zinc ion binding", "gene_names": [], "name": "Thyroid hormone receptor, alpha isoform 1 variant", "drug_actions": []}, "P11509": {"specific_function": "Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.", "general_function": "Steroid hydroxylase activity", "gene_names": ["CYP2A6"], "name": "Cytochrome P450 2A6", "drug_actions": []}, "P82599": {"specific_function": "Natural electron acceptor for a formate dehydrogenase.", "general_function": "Iron ion binding", "gene_names": [], "name": "Cytochrome c-553", "drug_actions": []}, "P14756": {"specific_function": "Cleaves host elastin, collagen, IgG, and several complement components as well as endogenous pro-aminopeptidase (PubMed:11533066). Autocatalyses processing of its pro-peptide (PubMed:9642203, PubMed:1744034). Processes the pro-peptide of pro-chitin-binding protein (cbpD) (PubMed:9642203). Involved in the pathogenesis of P.aeruginosa infections.", "general_function": "Metalloendopeptidase activity", "gene_names": ["lasB"], "name": "Elastase", "drug_actions": []}, "Q8II92": {"general_function": "Dutp diphosphatase activity", "gene_names": [], "name": "Deoxyuridine 5'-triphosphate nucleotidohydrolase, putative", "drug_actions": []}, "P56937": {"specific_function": "Responsible for the reduction of the keto group on the C-3 of sterols.", "general_function": "Estradiol 17-beta-dehydrogenase activity", "gene_names": ["HSD17B7"], "name": "3-keto-steroid reductase", "drug_actions": []}, "P0ACJ8": {"specific_function": "A global transcription regulator. Complexes with cyclic AMP (cAMP) which allosterically activates DNA binding (to consensus sequence 5'-AAATGTGATCTAGATCACATTT-3') to directly regulate the transcription of about 300 genes in about 200 operons and indirectly regulate the expression of about half the genome. There are 3 classes of CRP promoters; class I promoters have a single CRP-binding site upstream of the RNA polymerase (RNAP)-binding site, whereas in class II promoters the single CRP- and RNAP-binding site overlap, CRP making multiple contacts with RNAP. Class III promoters require multiple activator molecules, including at least one CRP dimer. It can act as an activator, repressor, coactivator or corepressor. Induces a severe bend in DNA (about 87 degrees), bringing upstream promoter elements into contact with RNAP. Acts as a negative regulator of its own synthesis as well as for adenylate cyclase (cyaA), which generates cAMP. High levels of active CRP are detrimental to growth (PubMed:16260780). Plays a major role in carbon catabolite repression (CCR). CCR involves cAMP, adenylate cyclase (cyaA), CRP and the EIIA-Glc component of the PTS (crr). In the presence of glucose EIIA-Glc is dephosphorylated, and does not activate adenylate cyclase, leading to reduced cAMP and thus decreased CRP activity. Also plays a role in many other processes (see PubMed:22573269).", "general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": ["crp"], "name": "cAMP-activated global transcriptional regulator CRP", "drug_actions": []}, "P17213": {"specific_function": "The cytotoxic action of BPI is limited to many species of Gram-negative bacteria; this specificity may be explained by a strong affinity of the very basic N-terminal half for the negatively charged lipopolysaccharides that are unique to the Gram-negative bacterial outer envelope. Has antibacterial activity against the Gram-nagative bacterium P.aeruginosa, this activity is inhibited by LPS from P.aeruginosa.", "general_function": "Lipopolysaccharide binding", "gene_names": ["BPI"], "name": "Bactericidal permeability-increasing protein", "drug_actions": []}, "Q14914": {"specific_function": "Functions as 15-oxo-prostaglandin 13-reductase and acts on 15-oxo-PGE1, 15-oxo-PGE2 and 15-oxo-PGE2-alpha. Has no activity towards PGE1, PGE2 and PGE2-alpha (By similarity). Catalyzes the conversion of leukotriene B4 into its biologically less active metabolite, 12-oxo-leukotriene B4. This is an initial and key step of metabolic inactivation of leukotriene B4.", "general_function": "Zinc ion binding", "gene_names": ["PTGR1"], "name": "Prostaglandin reductase 1", "drug_actions": []}, "P37088": {"specific_function": "Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical membrane of epithelial cells. Plays an essential role in electrolyte and blood pressure homeostasis, but also in airway surface liquid homeostasis, which is important for proper clearance of mucus. Controls the reabsorption of sodium in kidney, colon, lung and sweat glands. Also plays a role in taste perception.", "general_function": "Ww domain binding", "gene_names": ["SCNN1A"], "name": "Amiloride-sensitive sodium channel subunit alpha", "drug_actions": [{"action": "INHIBITOR", "target": "P37088", "drug": "DB00384"}, {"action": "INHIBITOR", "target": "P37088", "drug": "DB00594"}]}, "P60953": {"specific_function": "Plasma membrane-associated small GTPase which cycles between an active GTP-bound and an inactive GDP-bound state. In active state binds to a variety of effector proteins to regulate cellular responses. Involved in epithelial cell polarization processes. Regulates the bipolar attachment of spindle microtubules to kinetochores before chromosome congression in metaphase. Plays a role in the extension and maintenance of the formation of thin, actin-rich surface projections called filopodia. Mediates CDC42-dependent cell migration.", "general_function": "Ubiquitin protein ligase activity", "gene_names": ["CDC42"], "name": "Cell division control protein 42 homolog", "drug_actions": []}, "P50416": {"specific_function": "Catalyzes the transfer of the acyl group of long-chain fatty acid-CoA conjugates onto carnitine, an essential step for the mitochondrial uptake of long-chain fatty acids and their subsequent beta-oxidation in the mitochondrion. Plays an important role in triglyceride metabolism.", "general_function": "Carnitine o-palmitoyltransferase activity", "gene_names": ["CPT1A"], "name": "Carnitine O-palmitoyltransferase 1, liver isoform", "drug_actions": [{"action": "ACTIVATOR", "target": "P50416", "drug": "DB00583"}, {"action": "INHIBITOR", "target": "P50416", "drug": "DB01074"}]}, "Q8GGK7": {"general_function": "Metal ion binding", "gene_names": ["ppcA"], "name": "Cytochrome C", "drug_actions": []}, "P19531": {"specific_function": "Converts starch into maltose.", "general_function": "Starch binding", "gene_names": ["amyM"], "name": "Maltogenic alpha-amylase", "drug_actions": []}, "P22570": {"specific_function": "Serves as the first electron transfer protein in all the mitochondrial P450 systems. Including cholesterol side chain cleavage in all steroidogenic tissues, steroid 11-beta hydroxylation in the adrenal cortex, 25-OH-vitamin D3-24 hydroxylation in the kidney, and sterol C-27 hydroxylation in the liver.", "general_function": "Nadph-adrenodoxin reductase activity", "gene_names": ["FDXR"], "name": "NADPH:adrenodoxin oxidoreductase, mitochondrial", "drug_actions": []}, "P13901": {"specific_function": "Capsid proteins VP1, VP2, and VP3 form a closed capsid enclosing the viral positive strand RNA genome. All these proteins contain a beta-sheet structure called beta-barrel jelly roll. Together they form an icosahedral capsid (T=3) composed of 60 copies of each VP1, VP2, and VP3, with a diameter of approximately 300 Angstroms. VP1 is situated at the 12 fivefold axes, whereas VP2 and VP3 are located at the quasi-sixfold axes. The capsid interacts with HAVCR1 to provide virion attachment to target cell (By similarity).Protein VP0: VP0 precursor is a component of immature procapsids. The N-terminal domain of VP0, protein VP4, is needed for the assembly of 12 pentamers into the icosahedral structure. Unlike other picornaviruses, HAV VP4 does not seem to be myristoylated and has not been detected in mature virions, supposedly owing to its small size (By similarity).VP1-2A precursor is a component of immature procapsids and corresponds to an extended form of the structural protein VP1. The C-terminal domain of VP1-2A, protein 2A, acts as an assembly signal that allows multimerization of VP1-2A and formation of pentamers of VP1-VP2-VP3 trimers. It is proteolytically removed from the precursor by a host protease and does not seem to be found in mature particles (By similarity).Protein 2B and 2BC precursor affect membrane integrity and cause an increase in membrane permeability.Protein 2C: Associates with and induces structural rearrangements of intracellular membranes. It displays RNA-binding, nucleotide binding and NTPase activities (By similarity).Protein 3A, via its hydrophobic domain, serves as membrane anchor to the 3AB and 3ABC precursors.The 3AB precursor interacts with the 3CD precursor and with RNA structures found at both the 5'- and 3'-termini of the viral genome. Since the 3AB precursor contains the hydrophobic domain 3A, it probably anchors the whole viral replicase complex to intracellular membranes on which viral RNA synthesis occurs (By similarity).The 3ABC precursor is targeted to the mitochondrial membrane where protease 3C activity cleaves and inhibits the host antiviral protein MAVS, thereby disrupting activation of IRF3 through the IFIH1/MDA5 pathway. In vivo, the protease activity of 3ABC precursor is more efficient in cleaving the 2BC precursor than that of protein 3C. The 3ABC precursor may therefore play a role in the proteolytic processing of the polyprotein (By similarity).Protein 3B is covalently linked to the 5'-end of both the positive-strand and negative-strand genomic RNAs. It acts as a genome-linked replication primer (By similarity).Protease 3C: cysteine protease that generates mature viral proteins from the precursor polyprotein. In addition to its proteolytic activity, it binds to viral RNA, and thus influences viral genome replication. RNA and substrate bind cooperatively to the protease. Also cleaves host proteins such as PCBP2 (By similarity).RNA-directed RNA polymerase 3D-POL replicates genomic and antigenomic RNA by recognizing replications specific signals.", "general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P13900": {"specific_function": "Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host CXADR to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP2: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP3: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP4: Lies on the inner surface of the capsid shell. After binding to the host receptor, the capsid undergoes conformational changes. Capsid protein VP4 is released, Capsid protein VP1 N-terminus is externalized, and together, they shape a pore in the host membrane through which the viral genome is translocated into the host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP0: Component of immature procapsids, which is cleaved into capsid proteins VP4 and VP2 after maturation. Allows the capsid to remain inactive before the maturation step (By similarity).Protein 2A: Cysteine protease that cleaves viral polyprotein and specific host proteins. It is responsible for the cleavage between the P1 and P2 regions, first cleavage occurring in the polyprotein. Cleaves also the host translation initiation factor EIF4G1, in order to shut down the capped cellular mRNA translation. Inhibits the host nucleus-cytoplasm protein and RNA trafficking by cleaving host members of the nuclear pores (By similarity).Protein 2B: Plays an essential role in the virus replication cycle by acting as a viroporin. Creates a pore in the host reticulum endoplasmic and as a consequence releases Ca2+ in the cytoplasm of infected cell. In turn, high levels of cyctoplasmic calcium may trigger membrane trafficking and transport of viral ER-associated proteins to viroplasms, sites of viral genome replication (By similarity).Protein 2C: Induces and associates with structural rearrangements of intracellular membranes. Displays RNA-binding, nucleotide binding and NTPase activities. May play a role in virion morphogenesis and viral RNA encapsidation by interacting with the capsid protein VP3 (By similarity).Protein 3AB: Localizes the viral replication complex to the surface of membranous vesicles. Together with protein 3CD binds the Cis-Active RNA Element (CRE) which is involved in RNA synthesis initiation. Acts as a cofactor to stimulate the activity of 3D polymerase, maybe through a nucleid acid chaperone activity (By similarity).Protein 3A: Localizes the viral replication complex to the surface of membranous vesicles. It inhibits host cell endoplasmic reticulum-to-Golgi apparatus transport and causes the dissassembly of the Golgi complex, possibly through GBF1 interaction. This would result in depletion of MHC, trail receptors and IFN receptors at the host cell surface (By similarity).Viral protein genome-linked: acts as a primer for viral RNA replication and remains covalently bound to viral genomic RNA. VPg is uridylylated prior to priming replication into VPg-pUpU. The oriI viral genomic sequence may act as a template for this. The VPg-pUpU is then used as primer on the genomic RNA poly(A) by the RNA-dependent RNA polymerase to replicate the viral genome. VPg may be removed in the cytoplasm by an unknown enzyme termed \"unlinkase\". VPg is not cleaved off virion genomes because replicated genomic RNA are encapsidated at the site of replication (By similarity).Protein 3CD: Is involved in the viral replication complex and viral polypeptide maturation. It exhibits protease activity with a specificity and catalytic efficiency that is different from protease 3C. Protein 3CD lacks polymerase activity. The 3C domain in the context of protein 3CD may have an RNA binding activity (By similarity).Protease 3C: cleaves host DDX58/RIG-I and thus contributes to the inhibition of type I interferon production. Cleaves also host PABPC1 (By similarity).RNA-directed RNA polymerase: Replicates the viral genomic RNA on the surface of intracellular membranes. May form linear arrays of subunits that propagate along a strong head-to-tail interaction called interface-I. Covalently attaches UMP to a tyrosine of VPg, which is used to prime RNA synthesis. The positive stranded RNA genome is first replicated at virus induced membranous vesicles, creating a dsRNA genomic replication form. This dsRNA is then used as template to synthesize positive stranded RNA genomes. ss(+)RNA genomes are either translated, replicated or encapsidated (By similarity).", "general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "Q8RQE9": {"specific_function": "DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates.", "general_function": "Ribonucleoside binding", "gene_names": ["rpoB"], "name": "DNA-directed RNA polymerase subunit beta", "drug_actions": []}, "O94768": {"specific_function": "Phosphorylates myosin light chains (By similarity). Acts as a positive regulator of apoptosis.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["STK17B"], "name": "Serine/threonine-protein kinase 17B", "drug_actions": []}, "Q16644": {"specific_function": "Stress-activated serine/threonine-protein kinase involved in cytokines production, endocytosis, cell migration, chromatin remodeling and transcriptional regulation. Following stress, it is phosphorylated and activated by MAP kinase p38-alpha/MAPK14, leading to phosphorylation of substrates. Phosphorylates serine in the peptide sequence, Hyd-X-R-X(2)-S, where Hyd is a large hydrophobic residue. MAPKAPK2 and MAPKAPK3, share the same function and substrate specificity, but MAPKAPK3 kinase activity and level in protein expression are lower compared to MAPKAPK2. Phosphorylates HSP27/HSPB1, KRT18, KRT20, RCSD1, RPS6KA3, TAB3 and TTP/ZFP36. Mediates phosphorylation of HSP27/HSPB1 in response to stress, leading to dissociate HSP27/HSPB1 from large small heat-shock protein (sHsps) oligomers and impair their chaperone activities and ability to protect against oxidative stress effectively. Involved in inflammatory response by regulating tumor necrosis factor (TNF) and IL6 production post-transcriptionally: acts by phosphorylating AU-rich elements (AREs)-binding proteins, such as TTP/ZFP36, leading to regulate the stability and translation of TNF and IL6 mRNAs. Phosphorylation of TTP/ZFP36, a major post-transcriptional regulator of TNF, promotes its binding to 14-3-3 proteins and reduces its ARE mRNA affinity leading to inhibition of dependent degradation of ARE-containing transcript. Involved in toll-like receptor signaling pathway (TLR) in dendritic cells: required for acute TLR-induced macropinocytosis by phosphorylating and activating RPS6KA3. Also acts as a modulator of Polycomb-mediated repression.", "general_function": "Signal transducer activity", "gene_names": ["MAPKAPK3"], "name": "MAP kinase-activated protein kinase 3", "drug_actions": []}, "Q16647": {"specific_function": "Catalyzes the isomerization of prostaglandin H2 to prostacyclin (= prostaglandin I2).", "general_function": "Prostaglandin-i synthase activity", "gene_names": ["PTGIS"], "name": "Prostacyclin synthase", "drug_actions": [{"action": "INHIBITOR", "target": "Q16647", "drug": "DB00812"}, {"action": "INDUCER", "target": "Q16647", "drug": "DB01240"}]}, "P16184": {"specific_function": "Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis.", "general_function": "Nadp binding", "gene_names": [], "name": "Dihydrofolate reductase", "drug_actions": []}, "O15530": {"specific_function": "Serine/threonine kinase which acts as a master kinase, phosphorylating and activating a subgroup of the AGC family of protein kinases. Its targets include: protein kinase B (PKB/AKT1, PKB/AKT2, PKB/AKT3), p70 ribosomal protein S6 kinase (RPS6KB1), p90 ribosomal protein S6 kinase (RPS6KA1, RPS6KA2 and RPS6KA3), cyclic AMP-dependent protein kinase (PRKACA), protein kinase C (PRKCD and PRKCZ), serum and glucocorticoid-inducible kinase (SGK1, SGK2 and SGK3), p21-activated kinase-1 (PAK1), protein kinase PKN (PKN1 and PKN2). Plays a central role in the transduction of signals from insulin by providing the activating phosphorylation to PKB/AKT1, thus propagating the signal to downstream targets controlling cell proliferation and survival, as well as glucose and amino acid uptake and storage. Negatively regulates the TGF-beta-induced signaling by: modulating the association of SMAD3 and SMAD7 with TGF-beta receptor, phosphorylating SMAD2, SMAD3, SMAD4 and SMAD7, preventing the nuclear translocation of SMAD3 and SMAD4 and the translocation of SMAD7 from the nucleus to the cytoplasm in response to TGF-beta. Activates PPARG transcriptional activity and promotes adipocyte differentiation. Activates the NF-kappa-B pathway via phosphorylation of IKKB. The tyrosine phosphorylated form is crucial for the regulation of focal adhesions by angiotensin II. Controls proliferation, survival, and growth of developing pancreatic cells. Participates in the regulation of Ca(2+) entry and Ca(2+)-activated K(+) channels of mast cells. Essential for the motility of vascular endothelial cells (ECs) and is involved in the regulation of their chemotaxis. Plays a critical role in cardiac homeostasis by serving as a dual effector for cell survival and beta-adrenergic response. Plays an important role during thymocyte development by regulating the expression of key nutrient receptors on the surface of pre-T cells and mediating Notch-induced cell growth and proliferative responses. Provides negative feedback inhibition to toll-like receptor-mediated NF-kappa-B activation in macrophages. Isoform 3 is catalytically inactive.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["PDPK1"], "name": "3-phosphoinositide-dependent protein kinase 1", "drug_actions": [{"action": "INHIBITOR", "target": "O15530", "drug": "DB00482"}]}, "Q8RQE7": {"specific_function": "Promotes RNA polymerase assembly. Latches the N- and C-terminal regions of the beta' subunit thereby facilitating its interaction with the beta and alpha subunits.", "general_function": "Dna-directed rna polymerase activity", "gene_names": ["rpoZ"], "name": "DNA-directed RNA polymerase subunit omega", "drug_actions": []}, "P07864": {"specific_function": "Possible role in sperm motility.", "general_function": "L-lactate dehydrogenase activity", "gene_names": ["LDHC"], "name": "L-lactate dehydrogenase C chain", "drug_actions": []}, "P03366": {"specific_function": "Gag-Pol polyprotein: Mediates, with Gag polyrotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shutt off translation.Matrix protein p17: Targets the polyprotein to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus. Matrix protein is part of the pre-integration complex. Implicated in the release from host cell mediated by Vpu. Binds to RNA.Capsid protein p24: Forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion. Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry (By similarity). Host restriction factors such as TRIM5-alpha or TRIMCyp bind retroviral capsids and cause premature capsid disassembly, leading to blocks in reverse transcription. Capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species. Host PIN1 apparently facilitates the virion uncoating. On the other hand, interactions with PDZD8 or CYPA stabilize the capsid.Nucleocapsid protein p7: Encapsulates and protects viral dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its zinc fingers. Acts as a nucleic acid chaperone which is involved in rearangement of nucleic acid secondary structure during gRNA retrotranscription. Also facilitates template switch leading to recombination. As part of the polyprotein, participates to gRNA dimerization, packaging, tRNA incorporation and virion assembly.Protease: Aspartyl protease that mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane. Cleavages take place as an ordered, step-wise cascade to yield mature proteins. This process is called maturation. Displays maximal activity during the budding process just prior to particle release from the cell. Also cleaves Nef and Vif, probably concomitantly with viral structural proteins on maturation of virus particles. Hydrolyzes host EIF4GI and PABP1 in order to shut off the capped cellular mRNA translation. The resulting inhibition of cellular protein synthesis serves to ensure maximal viral gene expression and to evade host immune response (By similarity).Reverse transcriptase/ribonuclease H: Multifunctional enzyme that converts the viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for two polypurine tracts (PPTs) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPTs that have not been removed by RNase H as primers. PPTs and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends.Integrase: Catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration.", "general_function": "Zinc ion binding", "gene_names": ["gag-pol"], "name": "Gag-Pol polyprotein", "drug_actions": []}, "Q9NS75": {"specific_function": "Receptor for cysteinyl leukotrienes. The response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. Stimulation by BAY u9773, a partial agonist, induces specific contractions of pulmonary veins and might also have an indirect role in the relaxation of the pulmonary vascular endothelium. The rank order of affinities for the leukotrienes is LTC4 = LTD4 >> LTE4.", "general_function": "Leukotriene receptor activity", "gene_names": ["CYSLTR2"], "name": "Cysteinyl leukotriene receptor 2", "drug_actions": [{"action": "ANTAGONIST", "target": "Q9NS75", "drug": "DB00716"}]}, "O95622": {"specific_function": "Catalyzes the formation of the signaling molecule cAMP in response to G-protein signaling (PubMed:15385642, PubMed:26206488, PubMed:24700542). Mediates signaling downstream of ADRB1 (PubMed:24700542). Regulates the increase of free cytosolic Ca(2+) in response to increased blood glucose levels and contributes to the regulation of Ca(2+)-dependent insulin secretion (PubMed:24740569).", "general_function": "Protein heterodimerization activity", "gene_names": ["ADCY5"], "name": "Adenylate cyclase type 5", "drug_actions": []}, "P38606": {"specific_function": "Catalytic subunit of the peripheral V1 complex of vacuolar ATPase. V-ATPase vacuolar ATPase is responsible for acidifying a variety of intracellular compartments in eukaryotic cells.", "general_function": "Proton-transporting atpase activity, rotational mechanism", "gene_names": ["ATP6V1A"], "name": "V-type proton ATPase catalytic subunit A", "drug_actions": [{"action": "INHIBITOR", "target": "P38606", "drug": "DB00630"}, {"action": "INHIBITOR", "target": "P38606", "drug": "DB01077"}, {"action": "INHIBITOR", "target": "P38606", "drug": "DB01133"}, {"action": "INHIBITOR", "target": "P38606", "drug": "DB06733"}, {"action": "INHIBITOR", "target": "P38606", "drug": "DB06734"}]}, "P48048": {"specific_function": "In the kidney, probably plays a major role in potassium homeostasis. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. This channel is activated by internal ATP and can be blocked by external barium.", "name": "ATP-sensitive inward rectifier potassium channel 1", "drug_actions": [{"action": "INHIBITOR", "target": "P48048", "drug": "DB00217"}, {"action": "INHIBITOR", "target": "P48048", "drug": "DB00222"}, {"action": "INDUCER", "target": "P48048", "drug": "DB00350"}, {"action": "INHIBITOR", "target": "P48048", "drug": "DB00414"}, {"action": "INHIBITOR", "target": "P48048", "drug": "DB00839"}, {"action": "INHIBITOR", "target": "P48048", "drug": "DB01016"}, {"action": "INHIBITOR", "target": "P48048", "drug": "DB01124"}, {"action": "OTHER/UNKNOWN", "target": "P48048", "drug": "DB01382"}, {"action": "ANTAGONIST", "target": "P48048", "drug": "DB08838"}], "general_function": "Phosphatidylinositol-4,5-bisphosphate binding", "in_complexes": ["ATP-sensitive potassium channel"], "gene_names": ["KCNJ1"]}, "Q00975": {"specific_function": "Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1B gives rise to N-type calcium currents. N-type calcium channels belong to the 'high-voltage activated' (HVA) group and are blocked by omega-conotoxin-GVIA (omega-CTx-GVIA) and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to dihydropyridines (DHP), and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing alpha-1B subunit may play a role in directed migration of immature neurons.", "name": "Voltage-dependent N-type calcium channel subunit alpha-1B", "drug_actions": [{"action": "INHIBITOR", "target": "Q00975", "drug": "DB00381"}, {"action": "INHIBITOR", "target": "Q00975", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "Q00975", "drug": "DB00996"}, {"action": "INHIBITOR", "target": "Q00975", "drug": "DB01202"}, {"action": "ANTAGONIST", "target": "Q00975", "drug": "DB08838"}], "general_function": "Voltage-gated calcium channel activity", "in_complexes": ["Voltage-dependent calcium channel"], "gene_names": ["CACNA1B"]}, "P49327": {"specific_function": "Fatty acid synthetase catalyzes the formation of long-chain fatty acids from acetyl-CoA, malonyl-CoA and NADPH. This multifunctional protein has 7 catalytic activities and an acyl carrier protein.", "general_function": "Poly(a) rna binding", "gene_names": ["FASN"], "name": "Fatty acid synthase", "drug_actions": [{"action": "INHIBITOR", "target": "P49327", "drug": "DB01034"}, {"action": "INHIBITOR", "target": "P49327", "drug": "DB01083"}]}, "Q16881": {"specific_function": "Isoform 1 may possess glutaredoxin activity as well as thioredoxin reductase activity and induces actin and tubulin polymerization, leading to formation of cell membrane protrusions. Isoform 4 enhances the transcriptional activity of estrogen receptors alpha and beta while isoform 5 enhances the transcriptional activity of the beta receptor only. Isoform 5 also mediates cell death induced by a combination of interferon-beta and retinoic acid.", "general_function": "Thioredoxin-disulfide reductase activity", "gene_names": ["TXNRD1"], "name": "Thioredoxin reductase 1, cytoplasmic", "drug_actions": [{"action": "INHIBITOR", "target": "Q16881", "drug": "DB01169"}]}, "P63509": {"specific_function": "L-lysine + 2-oxoglutarate = 2-aminoadipate 6- semialdehyde + L-glutamate", "general_function": "Amino acid transport and metabolism", "gene_names": ["lat"], "name": "Probable L-lysine-epsilon aminotransferase", "drug_actions": []}, "P31013": {"general_function": "Tyrosine phenol-lyase activity", "gene_names": ["tpl"], "name": "Tyrosine phenol-lyase", "drug_actions": []}, "P65389": {"specific_function": "Catalyzes, together with MoaC, the conversion of 5'-GTP to cyclic pyranopterin monophosphate (cPMP or molybdopterin precursor Z).", "general_function": "Metal ion binding", "gene_names": ["moaA"], "name": "Cyclic pyranopterin monophosphate synthase", "drug_actions": []}, "P22888": {"specific_function": "Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.", "general_function": "Luteinizing hormone receptor activity", "gene_names": ["LHCGR"], "name": "Lutropin-choriogonadotropic hormone receptor", "drug_actions": [{"action": "AGONIST", "target": "P22888", "drug": "DB00014"}, {"action": "AGONIST", "target": "P22888", "drug": "DB00044"}]}, "Q03426": {"specific_function": "May be a regulatory site in cholesterol biosynthetic pathway.", "general_function": "Mevalonate kinase activity", "gene_names": ["MVK"], "name": "Mevalonate kinase", "drug_actions": []}, "P0AET8": {"specific_function": "7-alpha-dehydroxylation of cholic acid, yielding deoxycholic acid and lithocholic acid, respectively. Highest affinity with taurochenodeoxycholic acid.", "general_function": "Identical protein binding", "gene_names": ["hdhA"], "name": "7-alpha-hydroxysteroid dehydrogenase", "drug_actions": []}, "P0C6U8": {"specific_function": "The papain-like proteinase (PL-PRO) is responsible for the cleavages located at the N-terminus of replicase polyprotein. In addition, PL-PRO possesses a deubiquitinating/deISGylating activity and processes both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular substrates. Antagonizes innate immune induction of type I interferon by blocking the phosphorylation, dimerization and subsequent nuclear translocation of host IRF-3.The main proteinase 3CL-PRO is responsible for the majority of cleavages as it cleaves the C-terminus of replicase polyprotein at 11 sites. Recognizes substrates containing the core sequence [ILMVF]-Q-|-[SGACN]. Inhibited by the substrate-analog Cbz-Val-Asn-Ser-Thr-Leu-Gln-CMK (By similarity). Also contains an ADP-ribose-1''-phosphate (ADRP)-binding function.Nsp7-nsp8 hexadecamer may possibly confer processivity to the polymerase, maybe by binding to dsRNA or by producing primers utilized by the latter.Nsp9 is a ssRNA-binding protein.Non-structural protein 1: binds to the 40S ribosomal subunit and inhibits host translation. The nsp1-40S ribosome complex further induces an endonucleolytic cleavage near the 5'UTR of host mRNAs, targeting them for degradation. Viral mRNAs are not susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the presence of a 5'-end leader sequence and are therefore protected from degradation. By suppressing host gene expression, nsp1 facilitates efficient viral gene expression in infected cells and evasion from host immune response.", "general_function": "Zinc ion binding", "gene_names": [], "name": "Replicase polyprotein 1a", "drug_actions": []}, "O67931": {"specific_function": "Catalyzes the oxidation of hydrogen sulfide, with the help of a quinone. Consecutive reaction cycles lead to the accumulation of a polysulfide product on the active site Cys residues; these products are released when they exceed a critical length, typically as cyclooctasulfur.", "general_function": "Quinone binding", "gene_names": ["sqr"], "name": "Sulfide-quinone reductase", "drug_actions": []}, "P49356": {"specific_function": "Essential subunit of the farnesyltransferase complex. Catalyzes the transfer of a farnesyl moiety from farnesyl diphosphate to a cysteine at the fourth position from the C-terminus of several proteins having the C-terminal sequence Cys-aliphatic-aliphatic-X.", "general_function": "Zinc ion binding", "gene_names": ["FNTB"], "name": "Protein farnesyltransferase subunit beta", "drug_actions": []}, "Q9UHC9": {"specific_function": "Plays a major role in cholesterol homeostasis. Is critical for the uptake of cholesterol across the plasma membrane of the intestinal enterocyte. Is the direct molecular target of ezetimibe, a drug that inhibits cholesterol absorption. Lack of activity leads to multiple lipid transport defects. The protein may have a function in the transport of multiple lipids and their homeostasis, and may play a critical role in regulating lipid metabolism. Acts as a negative regulator of NPC2 and down-regulates its expression and secretion by inhibiting its maturation and accelerating its degradation.", "general_function": "Rab gtpase binding", "gene_names": ["NPC1L1"], "name": "Niemann-Pick C1-like protein 1", "drug_actions": [{"action": "INHIBITOR", "target": "Q9UHC9", "drug": "DB00973"}]}, "P47229": {"specific_function": "Catalyzes an unusual C-C bond hydrolysis of 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid (HOPDA) to produce benzoic acid and 2-hydroxy-2,4-pentadienoic acid (HPD).", "general_function": "2-hydroxy-6-oxonona-2,4-dienedioate hydrolase activity", "gene_names": ["bphD"], "name": "2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate hydrolase", "drug_actions": []}, "P47228": {"specific_function": "Shows a preference for catechols with groups immediately adjacent to the hydroxyl substituents.", "general_function": "Ferrous iron binding", "gene_names": ["bphC"], "name": "Biphenyl-2,3-diol 1,2-dioxygenase", "drug_actions": []}, "P39905": {"specific_function": "Neurotrophic factor that enhances survival and morphological differentiation of dopaminergic neurons and increases their high-affinity dopamine uptake.", "general_function": "Receptor binding", "gene_names": ["GDNF"], "name": "Glial cell line-derived neurotrophic factor", "drug_actions": []}, "P48549": {"specific_function": "This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. This receptor plays a crucial role in regulating the heartbeat.", "general_function": "G-protein activated inward rectifier potassium channel activity", "gene_names": ["KCNJ3"], "name": "G protein-activated inward rectifier potassium channel 1", "drug_actions": [{"action": "INHIBITOR", "target": "P48549", "drug": "DB01159"}]}, "P43912": {"specific_function": "Specifically methylates guanosine-37 in various tRNAs.", "general_function": "Trna (guanine(37)-n(1))-methyltransferase activity", "gene_names": ["trmD"], "name": "tRNA (guanine-N(1)-)-methyltransferase", "drug_actions": []}, "Q96EM0": {"specific_function": "Catalyzes the dehydration of trans-3-hydroxy-L-proline to Delta(1)-pyrroline-2-carboxylate (Pyr2C). May be required to degrade trans-3-hydroxy-L-proline from the diet and originating from the degradation of proteins such as collagen-IV that contain it.", "general_function": "Trans-l-3-hydroxyproline dehydratase activity", "gene_names": ["L3HYPDH"], "name": "Trans-3-hydroxy-L-proline dehydratase", "drug_actions": []}, "P25924": {"specific_function": "Multifunctional enzyme that catalyzes the SAM-dependent methylations of uroporphyrinogen III at position C-2 and C-7 to form precorrin-2 via precorrin-1. Then it catalyzes the NAD-dependent ring dehydrogenation of precorrin-2 to yield sirohydrochlorin. Finally, it catalyzes the ferrochelation of sirohydrochlorin to yield siroheme.", "general_function": "Uroporphyrin-iii c-methyltransferase activity", "gene_names": ["cysG"], "name": "Siroheme synthase", "drug_actions": []}, "Q13748": {"specific_function": "Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["TUBA3C"], "name": "Tubulin alpha-3C/D chain", "drug_actions": []}, "P48547": {"specific_function": "Mediates the voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient. Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNC2, and possibly other family members as well. Contributes to fire sustained trains of very brief action potentials at high frequency in pallidal neurons.", "general_function": "Voltage-gated potassium channel activity", "gene_names": ["KCNC1"], "name": "Potassium voltage-gated channel subfamily C member 1", "drug_actions": [{"action": "ANTAGONIST", "target": "P48547", "drug": "DB06637"}]}, "Q2QJL3": {"specific_function": "Catalyzes the conversion of N5-carboxyaminoimidazole ribonucleotide (N5-CAIR) to 4-carboxy-5-aminoimidazole ribonucleotide (CAIR).", "general_function": "5-(carboxyamino)imidazole ribonucleotide mutase activity", "gene_names": ["purE"], "name": "N5-carboxyaminoimidazole ribonucleotide mutase", "drug_actions": []}, "Q9UN76": {"specific_function": "Mediates the uptake of a broad range of neutral and cationic amino acids (with the exception of proline) in a Na(+)/Cl(-)-dependent manner.", "general_function": "Neurotransmitter:sodium symporter activity", "gene_names": ["SLC6A14"], "name": "Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+)", "drug_actions": []}, "P48544": {"specific_function": "This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by external barium.", "general_function": "G-protein activated inward rectifier potassium channel activity", "gene_names": ["KCNJ5"], "name": "G protein-activated inward rectifier potassium channel 4", "drug_actions": [{"action": "INHIBITOR", "target": "P48544", "drug": "DB01016"}]}, "O14756": {"specific_function": "NAD-dependent oxidoreductase with broad substrate specificity that shows both oxidative and reductive activity (in vitro). Has 17-beta-hydroxysteroid dehydrogenase activity towards various steroids (in vitro). Converts 5-alpha-androstan-3-alpha,17-beta-diol to androsterone and estradiol to estrone (in vitro). Has 3-alpha-hydroxysteroid dehydrogenase activity towards androsterone (in vitro). Has retinol dehydrogenase activity towards all-trans-retinol (in vitro). Can convert androsterone to epi-androsterone. Androsterone is first oxidized to 5-alpha-androstane-3,17-dione and then reduced to epi-andosterone. Can act on both C-19 and C-21 3-alpha-hydroxysteroids.", "general_function": "Testosterone dehydrogenase (nad+) activity", "gene_names": ["HSD17B6"], "name": "17-beta-hydroxysteroid dehydrogenase type 6", "drug_actions": []}, "O14757": {"specific_function": "Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest and activation of DNA repair in response to the presence of DNA damage or unreplicated DNA. May also negatively regulate cell cycle progression during unperturbed cell cycles. This regulation is achieved by a number of mechanisms that together help to preserve the integrity of the genome. Recognizes the substrate consensus sequence [R-X-X-S/T]. Binds to and phosphorylates CDC25A, CDC25B and CDC25C. Phosphorylation of CDC25A at 'Ser-178' and 'Thr-507' and phosphorylation of CDC25C at 'Ser-216' creates binding sites for 14-3-3 proteins which inhibit CDC25A and CDC25C. Phosphorylation of CDC25A at 'Ser-76', 'Ser-124', 'Ser-178', 'Ser-279' and 'Ser-293' promotes proteolysis of CDC25A. Phosphorylation of CDC25A at 'Ser-76' primes the protein for subsequent phosphorylation at 'Ser-79', 'Ser-82' and 'Ser-88' by NEK11, which is required for polyubiquitination and degradation of CDCD25A. Inhibition of CDC25 leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression. Also phosphorylates NEK6. Binds to and phosphorylates RAD51 at 'Thr-309', which promotes the release of RAD51 from BRCA2 and enhances the association of RAD51 with chromatin, thereby promoting DNA repair by homologous recombination. Phosphorylates multiple sites within the C-terminus of TP53, which promotes activation of TP53 by acetylation and promotes cell cycle arrest and suppression of cellular proliferation. Also promotes repair of DNA cross-links through phosphorylation of FANCE. Binds to and phosphorylates TLK1 at 'Ser-743', which prevents the TLK1-dependent phosphorylation of the chromatin assembly factor ASF1A. This may enhance chromatin assembly both in the presence or absence of DNA damage. May also play a role in replication fork maintenance through regulation of PCNA. May regulate the transcription of genes that regulate cell-cycle progression through the phosphorylation of histones. Phosphorylates histone H3.1 (to form H3T11ph), which leads to epigenetic inhibition of a subset of genes. May also phosphorylate RB1 to promote its interaction with the E2F family of transcription factors and subsequent cell cycle arrest.Isoform 2: Endogenous repressor of isoform 1, interacts with, and antagonizes CHK1 to promote the S to G2/M phase transition.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["CHEK1"], "name": "Serine/threonine-protein kinase Chk1", "drug_actions": []}, "O35000": {"specific_function": "Catalyzes the reversible isomerization-deamination of glucosamine 6-phosphate (GlcN6P) to form fructose 6-phosphate (Fru6P) and ammonium ion.", "general_function": "Hydrolase activity", "gene_names": ["nagB"], "name": "Glucosamine-6-phosphate deaminase 1", "drug_actions": []}, "Q7SI98": {"general_function": "Endo-1,4-beta-xylanase activity", "gene_names": [], "name": "Beta-xylanase", "drug_actions": []}, "P0AG82": {"specific_function": "Part of the ABC transporter complex PstSACB involved in phosphate import.", "general_function": "Phosphate ion transmembrane-transporting atpase activity", "gene_names": ["pstS"], "name": "Phosphate-binding protein PstS", "drug_actions": []}, "P30559": {"specific_function": "Receptor for oxytocin. The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system.", "general_function": "Vasopressin receptor activity", "gene_names": ["OXTR"], "name": "Oxytocin receptor", "drug_actions": [{"action": "AGONIST", "target": "P30559", "drug": "DB00107"}, {"action": "AGONIST", "target": "P30559", "drug": "DB01282"}]}, "P16455": {"specific_function": "Involved in the cellular defense against the biological effects of O6-methylguanine (O6-MeG) in DNA. Repairs alkylated guanine in DNA by stoichiometrically transferring the alkyl group at the O-6 position to a cysteine residue in the enzyme. This is a suicide reaction: the enzyme is irreversibly inactivated.", "general_function": "Methyltransferase activity", "gene_names": ["MGMT"], "name": "Methylated-DNA--protein-cysteine methyltransferase", "drug_actions": []}, "Q9NUB1": {"specific_function": "Important for maintaining normal body temperature during fasting and for energy homeostasis. Essential for energy expenditure under ketogenic conditions (By similarity). Converts acetate to acetyl-CoA so that it can be used for oxidation through the tricarboxylic cycle to produce ATP and CO(2).", "general_function": "Atp binding", "gene_names": ["ACSS1"], "name": "Acetyl-coenzyme A synthetase 2-like, mitochondrial", "drug_actions": [{"action": "PRODUCT OF", "target": "Q9NUB1", "drug": "DB00131"}]}, "P80040": {"specific_function": "Catalyzes the reversible oxidation of malate to oxaloacetate.", "general_function": "L-malate dehydrogenase activity", "gene_names": ["mdh"], "name": "Malate dehydrogenase", "drug_actions": []}, "Q75UV1": {"specific_function": "Specifically hydrolyzes (di)adenosine polyphosphates but not ATP or diadenosine triphosphate, generating ATP as the product. Diadenosine hexaphosphate (Ap6A) is the preferred substrate and its hydrolyzation yields 2 ATP. It is the only enzyme that symmetrically hydrolyzes Ap6A. It also hydrolyzes diadenosine pentaphosphate (Ap5A), diadenosine tetraphosphate (Ap4A), adenosine tetraphosphate (p4A) to produce ATP and ADP, ATP and AMP, ATP and inorganic orthophosphate, respectively.", "general_function": "Metal ion binding", "gene_names": ["ndx1"], "name": "Diadenosine hexaphosphate hydrolase", "drug_actions": []}, "P80511": {"specific_function": "S100A12 is a calcium-, zinc- and copper-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response. Its proinflammatory activity involves recruitment of leukocytes, promotion of cytokine and chemokine production, and regulation of leukocyte adhesion and migration. Acts as an alarmin or a danger associated molecular pattern (DAMP) molecule and stimulates innate immune cells via binding to receptor for advanced glycation endproducts (AGER). Binding to AGER activates the MAP-kinase and NF-kappa-B signaling pathways leading to production of proinflammatory cytokines and up-regulation of cell adhesion molecules ICAM1 and VCAM1. Acts as a monocyte and mast cell chemoattractant. Can stimulate mast cell degranulation and activation which generates chemokines, histamine and cytokines inducing further leukocyte recruitment to the sites of inflammation. Can inhibit the activity of matrix metalloproteinases; MMP2, MMP3 and MMP9 by chelating Zn(2+) from their active sites. Possesses filariacidal and filariastatic activity. Calcitermin possesses antifungal activity against C.albicans and is also active against E.coli and P.aeruginosa but not L.monocytogenes and S.aureus.", "general_function": "Zinc ion binding", "gene_names": ["S100A12"], "name": "Protein S100-A12", "drug_actions": [{"action": "ANTAGONIST", "target": "P80511", "drug": "DB00768"}, {"action": "ANTAGONIST", "target": "P80511", "drug": "DB01025"}]}, "P25929": {"specific_function": "Receptor for neuropeptide Y and peptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is NPY > [Pro-34] PYY, PYY and [Leu-31, Pro-34] NPY > NPY (2-36) > [Ile-31, Gln-34] PP and PYY (3-36) > PP > NPY free acid.", "general_function": "Peptide yy receptor activity", "gene_names": ["NPY1R"], "name": "Neuropeptide Y receptor type 1", "drug_actions": []}, "Q969V6": {"specific_function": "Transcriptional coactivator of serum response factor (SRF) with the potential to modulate SRF target genes. Suppresses TNF-induced cell death by inhibiting activation of caspases; its transcriptional activity is indispensable for the antiapoptotic function. It may up-regulate antiapoptotic molecules, which in turn inhibit caspase activation (By similarity).", "general_function": "Transcription regulatory region sequence-specific dna binding", "gene_names": ["MKL1"], "name": "MKL/myocardin-like protein 1", "drug_actions": []}, "Q75WK2": {"general_function": "Transaminase activity", "gene_names": [], "name": "Aminotransferase", "drug_actions": []}, "Q6YP21": {"specific_function": "Catalyzes the irreversible transamination of the L-tryptophan metabolite L-kynurenine to form kynurenic acid (KA). May catalyze the beta-elimination of S-conjugates and Se-conjugates of L-(seleno)cysteine, resulting in the cleavage of the C-S or C-Se bond (By similarity). Has transaminase activity towards L-kynurenine, tryptophan, phenylalanine, serine, cysteine, methionine, histidine, glutamine and asparagine with glyoxylate as an amino group acceptor (in vitro). Has lower activity with 2-oxoglutarate as amino group acceptor (in vitro) (By similarity).", "general_function": "Pyridoxal phosphate binding", "gene_names": ["CCBL2"], "name": "Kynurenine--oxoglutarate transaminase 3", "drug_actions": [{"action": "COFACTOR", "target": "Q6YP21", "drug": "DB00114"}]}, "P23975": {"specific_function": "Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.", "general_function": "Norepinephrine:sodium symporter activity", "gene_names": ["SLC6A2"], "name": "Sodium-dependent noradrenaline transporter", "drug_actions": [{"action": "STIMULATOR", "target": "P23975", "drug": "DB00182"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00191"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00193"}, {"action": "PARTIAL AGONIST", "target": "P23975", "drug": "DB00226"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00234"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00285"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00321"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00344"}, {"action": "BINDER", "target": "P23975", "drug": "DB00370"}, {"action": "BINDER", "target": "P23975", "drug": "DB00408"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00422"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00458"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00476"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00540"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00543"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00579"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00696"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00715"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00726"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00830"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00852"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00907"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00934"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB00937"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB01105"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB01114"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB01142"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB01149"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB01151"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB01156"}, {"action": "INDUCER", "target": "P23975", "drug": "DB01170"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB01173"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB01175"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB01242"}, {"action": "NEGATIVE MODULATOR", "target": "P23975", "drug": "DB01363"}, {"action": "INVERSE AGONIST", "target": "P23975", "drug": "DB01364"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB01381"}, {"action": "NEGATIVE MODULATOR", "target": "P23975", "drug": "DB01442"}, {"action": "NEGATIVE MODULATOR", "target": "P23975", "drug": "DB01454"}, {"action": "NEGATIVE MODULATOR", "target": "P23975", "drug": "DB01576"}, {"action": "NEGATIVE MODULATOR", "target": "P23975", "drug": "DB01577"}, {"action": "NEGATIVE MODULATOR", "target": "P23975", "drug": "DB01579"}, {"action": "INDUCER", "target": "P23975", "drug": "DB04840"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB04896"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB06148"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB06204"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB06700"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB06701"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB06707"}, {"action": "INHIBITOR", "target": "P23975", "drug": "DB08918"}]}, "Q9L9D7": {"specific_function": "Hydrolyzes cocaine to benzoate and ecgonine methyl ester, endowing the bacteria with the ability to utilize cocaine as a sole source of carbon and energy for growth, as this bacterium lives in the rhizosphere of coca plants. Also efficiently hydrolyzes cocaethylene, a more potent cocaine metabolite that has been observed in patients who concurrently abuse cocaine and alcohol. Is able to prevent cocaine-induced convulsions and lethality in rat.", "general_function": "Dipeptidyl-peptidase activity", "gene_names": ["cocE"], "name": "Cocaine esterase", "drug_actions": []}, "P12564": {"specific_function": "Attaches the virus to sialic acid-containing cell receptors and thereby initiating infection. Binding of HN protein to the receptor induces a conformational change that allows the F protein to trigger virion/cell membranes fusion (By similarity).Neuraminidase activity ensures the efficient spread of the virus by dissociating the mature virions from the neuraminic acid containing glycoproteins.", "general_function": "Exo-alpha-(2->8)-sialidase activity", "gene_names": ["HN"], "name": "Hemagglutinin-neuraminidase", "drug_actions": []}, "Q9BZW2": {"specific_function": "Sodium/sulfate cotransporter that mediates sulfate reabsorption in the kidney.", "general_function": "Sodium:sulfate symporter activity", "gene_names": ["SLC13A1"], "name": "Solute carrier family 13 member 1", "drug_actions": []}, "P0ABP8": {"specific_function": "Cleavage of guanosine or inosine to respective bases and sugar-1-phosphate molecules.", "general_function": "Purine-nucleoside phosphorylase activity", "gene_names": ["deoD"], "name": "Purine nucleoside phosphorylase DeoD-type", "drug_actions": []}, "Q10588": {"specific_function": "Synthesizes the second messagers cyclic ADP-ribose and nicotinate-adenine dinucleotide phosphate, the former a second messenger that elicits calcium release from intracellular stores. May be involved in pre-B-cell growth.", "general_function": "Transferase activity", "gene_names": ["BST1"], "name": "ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2", "drug_actions": []}, "P05019": {"specific_function": "The insulin-like growth factors, isolated from plasma, are structurally and functionally related to insulin but have a much higher growth-promoting activity. May be a physiological regulator of [1-14C]-2-deoxy-D-glucose (2DG) transport and glycogen synthesis in osteoblasts. Stimulates glucose transport in rat bone-derived osteoblastic (PyMS) cells and is effective at much lower concentrations than insulin, not only regarding glycogen and DNA synthesis but also with regard to enhancing glucose uptake. May play a role in synapse maturation.", "general_function": "Integrin binding", "gene_names": ["IGF1"], "name": "Insulin-like growth factor I", "drug_actions": []}, "Q9HTN2": {"general_function": "Atp binding", "gene_names": ["argB"], "name": "Acetylglutamate kinase", "drug_actions": []}, "P01920": {"specific_function": "Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.", "general_function": "Peptide antigen binding", "gene_names": ["HLA-DQB1"], "name": "HLA class II histocompatibility antigen, DQ beta 1 chain", "drug_actions": []}, "O25096": {"general_function": "Nad+ synthase activity", "gene_names": ["nadE"], "name": "NH(3)-dependent NAD(+) synthetase", "drug_actions": []}, "Q9Y285": {"general_function": "Trna binding", "gene_names": ["FARSA"], "name": "Phenylalanine--tRNA ligase alpha subunit", "drug_actions": []}, "P0DMS8": {"specific_function": "Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. Possible role in reproduction.", "general_function": "G-protein coupled adenosine receptor activity", "gene_names": ["ADORA3"], "name": "Adenosine receptor A3", "drug_actions": [{"action": "AGONIST", "target": "P0DMS8", "drug": "DB00640"}, {"action": "ANTAGONIST", "target": "P0DMS8", "drug": "DB01223"}]}, "Q9Y286": {"specific_function": "Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,3- and alpha-2,6-linked sialic acid. Also binds disialogangliosides (disialogalactosyl globoside, disialyl lactotetraosylceramide and disialyl GalNAc lactotetraoslylceramide). The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. Mediates inhibition of natural killer cells cytotoxicity. May play a role in hemopoiesis. Inhibits differentiation of CD34+ cell precursors towards myelomonocytic cell lineage and proliferation of leukemic myeloid cells (in vitro).", "general_function": "Receptor activity", "gene_names": ["SIGLEC7"], "name": "Sialic acid-binding Ig-like lectin 7", "drug_actions": []}, "Q9Y289": {"specific_function": "Transports pantothenate, biotin and lipoate in the presence of sodium.", "general_function": "Sodium-dependent multivitamin transmembrane transporter activity", "gene_names": ["SLC5A6"], "name": "Sodium-dependent multivitamin transporter", "drug_actions": []}, "P06608": {"general_function": "Asparaginase activity", "gene_names": ["ansB"], "name": "L-asparaginase", "drug_actions": []}, "O00264": {"specific_function": "Receptor for progesterone.", "name": "Membrane-associated progesterone receptor component 1", "drug_actions": [{"action": "BINDER", "target": "O00264", "drug": "DB00514"}, {"action": "BINDER", "target": "O00264", "drug": "DB00540"}], "general_function": "Steroid binding", "in_complexes": ["Sigma receptor"], "gene_names": ["PGRMC1"]}, "Q7D9R5": {"general_function": "Involved in cyclopropane-fatty-acyl-phospholipid synthase activity", "gene_names": ["pcaA"], "name": "Cyclopropane mycolic acid synthase 3", "drug_actions": []}, "Q9HB21": {"specific_function": "Binds specifically to phosphatidylinositol 3,4-diphosphate (PtdIns3,4P2), but not to other phosphoinositides. May recruit other proteins to the plasma membrane.", "general_function": "Phosphatidylinositol-3,4-bisphosphate binding", "gene_names": ["PLEKHA1"], "name": "Pleckstrin homology domain-containing family A member 1", "drug_actions": []}, "Q9UNI1": {"specific_function": "Acts upon elastin.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["CELA1"], "name": "Chymotrypsin-like elastase family member 1", "drug_actions": []}, "O15923": {"gene_names": ["Tcdut"], "name": "Deoxyuridine triphosphatase", "drug_actions": []}, "P17443": {"specific_function": "Cell wall formation. Catalyzes the transfer of a GlcNAc subunit on undecaprenyl-pyrophosphoryl-MurNAc-pentapeptide (lipid intermediate I) to form undecaprenyl-pyrophosphoryl-MurNAc-(pentapeptide)GlcNAc (lipid intermediate II).", "general_function": "Undecaprenyldiphospho-muramoylpentapeptide beta-n-acetylglucosaminyltransferase activity", "gene_names": ["murG"], "name": "UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase", "drug_actions": []}, "Q06124": {"specific_function": "Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus. Dephosphorylates ROCK2 at Tyr-722 resulting in stimulatation of its RhoA binding activity.", "general_function": "Sh3/sh2 adaptor activity", "gene_names": ["PTPN11"], "name": "Tyrosine-protein phosphatase non-receptor type 11", "drug_actions": []}, "Q81ZL8": {"general_function": "Nucleic acid binding", "gene_names": [], "name": "Integrase, catalytic core", "drug_actions": []}, "P0A0N5": {"specific_function": "Transcriptional repressor of qacA. Binds to IR1, an unusually long 28 bp operator, which is located downstream from the qacA promoter and overlaps its transcription start site. QacR is induced from its IR1 site by binding to one of many structurally dissimilar cationic lipophilic compounds, which are also substrates of QacA (By similarity).", "general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": ["qacR"], "name": "HTH-type transcriptional regulator QacR", "drug_actions": []}, "P0A0N4": {"specific_function": "Transcriptional repressor of qacA. Binds to IR1, an unusually long 28 bp operator, which is located downstream from the qacA promoter and overlaps its transcription start site. QacR is induced from its IR1 site by binding to one of many structurally dissimilar cationic lipophilic compounds, which are also substrates of QacA.", "general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": ["qacR"], "name": "HTH-type transcriptional regulator QacR", "drug_actions": []}, "Q13698": {"specific_function": "Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin-GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing the alpha-1S subunit play an important role in excitation-contraction coupling in skeletal muscle.", "name": "Voltage-dependent L-type calcium channel subunit alpha-1S", "drug_actions": [{"action": "INHIBITOR", "target": "Q13698", "drug": "DB00270"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB00381"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB00393"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB00401"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB00568"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB01023"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB01054"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB01115"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB01388"}, {"action": "INHIBITOR", "target": "Q13698", "drug": "DB06712"}], "general_function": "Voltage-gated calcium channel activity", "in_complexes": ["Voltage-dependent calcium channel"], "gene_names": ["CACNA1S"]}, "Q4L5E3": {"general_function": "Trna binding", "gene_names": ["pheS"], "name": "Phenylalanine--tRNA ligase alpha subunit", "drug_actions": []}, "P56556": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed to be not involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFA6"], "name": "NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6", "drug_actions": []}, "P02585": {"specific_function": "Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site for tropomyosin and Tn-C. The binding of calcium to Tn-C abolishes the inhibitory action of Tn on actin filaments.", "general_function": "Calcium ion binding", "gene_names": ["TNNC2"], "name": "Troponin C, skeletal muscle", "drug_actions": [{"action": "OTHER", "target": "P02585", "drug": "DB01023"}, {"action": "AGONIST", "target": "P02585", "drug": "DB01373"}]}, "P09152": {"specific_function": "The nitrate reductase enzyme complex allows E.coli to use nitrate as an electron acceptor during anaerobic growth. The alpha chain is the actual site of nitrate reduction.", "general_function": "Nitrate reductase activity", "gene_names": ["narG"], "name": "Respiratory nitrate reductase 1 alpha chain", "drug_actions": []}, "Q9X6W0": {"specific_function": "Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits).", "general_function": "Peptidoglycan glycosyltransferase activity", "gene_names": ["ponB"], "name": "Penicillin-binding protein 1B", "drug_actions": [{"action": "INHIBITOR", "target": "Q9X6W0", "drug": "DB00430"}, {"action": "INHIBITOR", "target": "Q9X6W0", "drug": "DB00438"}, {"action": "INHIBITOR", "target": "Q9X6W0", "drug": "DB01329"}, {"action": "INHIBITOR", "target": "Q9X6W0", "drug": "DB09050"}]}, "Q01770": {"specific_function": "Catalyzes the reduction of hydroxylamine to form NH(3) and H(2)O.", "general_function": "Metal ion binding", "gene_names": ["hcp"], "name": "Hydroxylamine reductase", "drug_actions": []}, "Q5SLP8": {"specific_function": "Located on the outer edge of the platform on the body of the 30S subunit.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsF"], "name": "30S ribosomal protein S6", "drug_actions": []}, "P78362": {"specific_function": "Serine/arginine-rich protein-specific kinase which specifically phosphorylates its substrates at serine residues located in regions rich in arginine/serine dipeptides, known as RS domains and is involved in the phosphorylation of SR splicing factors and the regulation of splicing. Promotes neuronal apoptosis by up-regulating cyclin-D1 (CCND1) expression. This is done by the phosphorylation of SRSF2, leading to the suppression of p53/TP53 phosphorylation thereby relieving the repressive effect of p53/TP53 on cyclin-D1 (CCND1) expression. Phosphorylates ACIN1, and redistributes it from the nuclear speckles to the nucleoplasm, resulting in cyclin A1 but not cyclin A2 up-regulation. Plays an essential role in spliceosomal B complex formation via the phosphorylation of DDX23/PRP28. Can mediate hepatitis B virus (HBV) core protein phosphorylation. Plays a negative role in the regulation of HBV replication through a mechanism not involving the phosphorylation of the core protein but by reducing the packaging efficiency of the pregenomic RNA (pgRNA) without affecting the formation of the viral core particles.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["SRPK2"], "name": "SRSF protein kinase 2", "drug_actions": []}, "P04229": {"specific_function": "Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route; where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules; and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments; exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides; autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs; other cells of the gastrointestinal tract; such as epithelial cells; express MHC class II molecules and CD74 and act as APCs; which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen; three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs; CD74 undergoes a sequential degradation by various proteases; including CTSS and CTSL; leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells; the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules; increased acidification produces increased proteolysis and efficient peptide loading.(Microbial infection) Acts as a receptor for Epstein-Barr virus on lymphocytes.", "general_function": "Virus receptor activity", "gene_names": ["HLA-DRB1"], "name": "HLA class II histocompatibility antigen, DRB1-1 beta chain", "drug_actions": [{"action": "BINDER", "target": "P04229", "drug": "DB05259"}]}, "Q6PEY2": {"specific_function": "Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity).", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["TUBA3E"], "name": "Tubulin alpha-3E chain", "drug_actions": []}, "Q9NRX3": {"gene_names": ["NDUFA4L2"], "name": "NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4-like 2", "drug_actions": []}, "O95342": {"specific_function": "Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.", "general_function": "Transporter activity", "gene_names": ["ABCB11"], "name": "Bile salt export pump", "drug_actions": [{"action": "INHIBITOR", "target": "O95342", "drug": "DB01016"}]}, "P09488": {"specific_function": "Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.", "general_function": "Protein homodimerization activity", "gene_names": ["GSTM1"], "name": "Glutathione S-transferase Mu 1", "drug_actions": []}, "O60551": {"specific_function": "Adds a myristoyl group to the N-terminal glycine residue of certain cellular and viral proteins.", "general_function": "Glycylpeptide n-tetradecanoyltransferase activity", "gene_names": ["NMT2"], "name": "Glycylpeptide N-tetradecanoyltransferase 2", "drug_actions": []}, "P30012": {"specific_function": "Involved in the catabolism of quinolinic acid (QA).", "general_function": "Nicotinate-nucleotide diphosphorylase (carboxylating) activity", "gene_names": ["nadC"], "name": "Nicotinate-nucleotide pyrophosphorylase [carboxylating]", "drug_actions": []}, "Q9BVJ7": {"specific_function": "Protein phosphatase that mediates dephosphorylation of proteins phosphorylated on Tyr and Ser/Thr residues. In vitro, it can dephosphorylate p44-ERK1 (MAPK3) but not p54 SAPK-beta (MAPK10) in vitro. Able to enhance activation of JNK and p38 (MAPK14).", "general_function": "Protein tyrosine/serine/threonine phosphatase activity", "gene_names": ["DUSP23"], "name": "Dual specificity protein phosphatase 23", "drug_actions": []}, "P05129": {"specific_function": "Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays diverse roles in neuronal cells and eye tissues, such as regulation of the neuronal receptors GRIA4/GLUR4 and GRIN1/NMDAR1, modulation of receptors and neuronal functions related to sensitivity to opiates, pain and alcohol, mediation of synaptic function and cell survival after ischemia, and inhibition of gap junction activity after oxidative stress. Binds and phosphorylates GRIA4/GLUR4 glutamate receptor and regulates its function by increasing plasma membrane-associated GRIA4 expression. In primary cerebellar neurons treated with the agonist 3,5-dihyidroxyphenylglycine, functions downstream of the metabotropic glutamate receptor GRM5/MGLUR5 and phosphorylates GRIN1/NMDAR1 receptor which plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. May be involved in the regulation of hippocampal long-term potentiation (LTP), but may be not necessary for the process of synaptic plasticity. May be involved in desensitization of mu-type opioid receptor-mediated G-protein activation in the spinal cord, and may be critical for the development and/or maintenance of morphine-induced reinforcing effects in the limbic forebrain. May modulate the functionality of mu-type-opioid receptors by participating in a signaling pathway which leads to the phosphorylation and degradation of opioid receptors. May also contributes to chronic morphine-induced changes in nociceptive processing. Plays a role in neuropathic pain mechanisms and contributes to the maintenance of the allodynia pain produced by peripheral inflammation. Plays an important role in initial sensitivity and tolerance to ethanol, by mediating the behavioral effects of ethanol as well as the effects of this drug on the GABA(A) receptors. During and after cerebral ischemia modulate neurotransmission and cell survival in synaptic membranes, and is involved in insulin-induced inhibition of necrosis, an important mechanism for minimizing ischemic injury. Required for the elimination of multiple climbing fibers during innervation of Purkinje cells in developing cerebellum. Is activated in lens epithelial cells upon hydrogen peroxide treatment, and phosphorylates connexin-43 (GJA1/CX43), resulting in disassembly of GJA1 gap junction plaques and inhibition of gap junction activity which could provide a protective effect against oxidative stress (By similarity). Phosphorylates p53/TP53 and promotes p53/TP53-dependent apoptosis in response to DNA damage. Involved in the phase resetting of the cerebral cortex circadian clock during temporally restricted feeding. Stabilizes the core clock component ARNTL/BMAL1 by interfering with its ubiquitination, thus suppressing its degradation, resulting in phase resetting of the cerebral cortex clock (By similarity).", "name": "Protein kinase C gamma type", "drug_actions": [], "general_function": "Zinc ion binding", "in_complexes": ["Protein kinase C"], "gene_names": ["PRKCG"]}, "P75430": {"specific_function": "Involved in folate metabolism. Catalyzes the irreversible conversion of 5-formyltetrahydrofolate (5-FTHF) to yield 5,10-methenyltetrahydrofolate.", "general_function": "Metal ion binding", "gene_names": [], "name": "5-formyltetrahydrofolate cyclo-ligase", "drug_actions": []}, "P26572": {"specific_function": "Initiates complex N-linked carbohydrate formation. Essential for the conversion of high-mannose to hybrid and complex N-glycans.", "general_function": "Metal ion binding", "gene_names": ["MGAT1"], "name": "Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase", "drug_actions": []}, "P05120": {"specific_function": "Inhibits urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct from the endothelial cell-derived PAI-1.", "general_function": "Serine-type endopeptidase inhibitor activity", "gene_names": ["SERPINB2"], "name": "Plasminogen activator inhibitor 2", "drug_actions": []}, "P05121": {"specific_function": "Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.", "general_function": "Serine-type endopeptidase inhibitor activity", "gene_names": ["SERPINE1"], "name": "Plasminogen activator inhibitor 1", "drug_actions": [{"action": "ANTAGONIST", "target": "P05121", "drug": "DB00197"}]}, "O00469": {"specific_function": "Forms hydroxylysine residues in -Xaa-Lys-Gly- sequences in collagens. These hydroxylysines serve as sites of attachment for carbohydrate units and are essential for the stability of the intermolecular collagen cross-links.", "general_function": "Procollagen-lysine 5-dioxygenase activity", "gene_names": ["PLOD2"], "name": "Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2", "drug_actions": []}, "Q9UL51": {"specific_function": "Hyperpolarization-activated ion channel exhibiting weak selectivity for potassium over sodium ions. Contributes to the native pacemaker currents in heart (If) and in neurons (Ih). Can also transport ammonium in the distal nephron. Produces a large instantaneous current. Modulated by intracellular chloride ions and pH; acidic pH shifts the activation to more negative voltages (By similarity).", "general_function": "Voltage-gated sodium channel activity", "gene_names": ["HCN2"], "name": "Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2", "drug_actions": []}, "P60339": {"specific_function": "This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis.", "general_function": "Translation elongation factor activity", "gene_names": ["tufB"], "name": "Elongation factor Tu-B", "drug_actions": []}, "O95180": {"specific_function": "Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1H gives rise to T-type calcium currents. T-type calcium channels belong to the \"low-voltage activated (LVA)\" group and are strongly blocked by nickel and mibefradil. A particularity of this type of channels is an opening at quite negative potentials, and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.", "name": "Voltage-dependent T-type calcium channel subunit alpha-1H", "drug_actions": [{"action": "INHIBITOR", "target": "O95180", "drug": "DB00270"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB00568"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB01023"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB01054"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB01115"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB01118"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB01244"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB01388"}, {"action": "INHIBITOR", "target": "O95180", "drug": "DB04841"}], "general_function": "Scaffold protein binding", "in_complexes": ["Voltage-dependent calcium channel"], "gene_names": ["CACNA1H"]}, "O95182": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Structural constituent of ribosome", "gene_names": ["NDUFA7"], "name": "NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7", "drug_actions": []}, "P43235": {"specific_function": "Closely involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation.", "general_function": "Proteoglycan binding", "gene_names": ["CTSK"], "name": "Cathepsin K", "drug_actions": []}, "P29460": {"specific_function": "Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting PBMC.Associates with IL23A to form the IL-23 interleukin, a heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 may constitute with IL-17 an acute response to infection in peripheral tissues. IL-23 binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory rather than naive T-cells and promotes production of proinflammatory cytokines. IL-23 induces autoimmune inflammation and thus may be responsible for autoimmune inflammatory diseases and may be important for tumorigenesis.", "general_function": "Protein heterodimerization activity", "gene_names": ["IL12B"], "name": "Interleukin-12 subunit beta", "drug_actions": []}, "P45880": {"specific_function": "Forms a channel through the mitochondrial outer membrane that allows diffusion of small hydrophilic molecules. The channel adopts an open conformation at low or zero membrane potential and a closed conformation at potentials above 30-40 mV. The open state has a weak anion selectivity whereas the closed state is cation-selective.", "general_function": "Voltage-gated anion channel activity", "gene_names": ["VDAC2"], "name": "Voltage-dependent anion-selective channel protein 2", "drug_actions": [{"action": "INHIBITOR", "target": "P45880", "drug": "DB01375"}]}, "P29466": {"specific_function": "Thiol protease that cleaves IL-1 beta between an Asp and an Ala, releasing the mature cytokine which is involved in a variety of inflammatory processes. Important for defense against pathogens. Cleaves and activates sterol regulatory element binding proteins (SREBPs). Can also promote apoptosis.", "general_function": "Endopeptidase activity", "gene_names": ["CASP1"], "name": "Caspase-1", "drug_actions": [{"action": "NEGATIVE MODULATOR", "target": "P29466", "drug": "DB01017"}]}, "O34974": {"specific_function": "May play a role in methionine degradation. May play a role in a sulfur salvage pathway.", "general_function": "Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen", "gene_names": ["moxC"], "name": "Putative monooxygenase MoxC", "drug_actions": []}, "P77454": {"general_function": "Glutaminase activity", "gene_names": ["glsA1"], "name": "Glutaminase 1", "drug_actions": []}, "Q9Y600": {"general_function": "Sulfinoalanine decarboxylase activity", "gene_names": ["CSAD"], "name": "Cysteine sulfinic acid decarboxylase", "drug_actions": [{"action": "COFACTOR", "target": "Q9Y600", "drug": "DB00114"}, {"action": "COFACTOR", "target": "Q9Y600", "drug": "DB00114"}]}, "Q6NXR0": {"general_function": "Hydrolase activity", "gene_names": ["IRGC"], "name": "Interferon-inducible GTPase 5", "drug_actions": []}, "P28482": {"specific_function": "Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade plays also a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation. However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis and apoptosis. Moreover, the MAPK/ERK cascade is also involved in the regulation of the endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC); as well as in the fragmentation of the Golgi apparatus during mitosis. The substrates include transcription factors (such as ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of translation (such as EIF4EBP1) and a variety of other signaling-related molecules (like ARHGEF2, DCC, FRS2 or GRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates which enable the propagation the MAPK/ERK signal to additional cytosolic and nuclear targets, thereby extending the specificity of the cascade. Mediates phosphorylation of TPR in respons to EGF stimulation. May play a role in the spindle assembly checkpoint. Phosphorylates PML and promotes its interaction with PIN1, leading to PML degradation.Acts as a transcriptional repressor. Binds to a [GC]AAA[GC] consensus sequence. Repress the expression of interferon gamma-induced genes. Seems to bind to the promoter of CCL5, DMP1, IFIH1, IFITM1, IRF7, IRF9, LAMP3, OAS1, OAS2, OAS3 and STAT1. Transcriptional activity is independent of kinase activity.", "general_function": "Rna polymerase ii carboxy-terminal domain kinase activity", "gene_names": ["MAPK1"], "name": "Mitogen-activated protein kinase 1", "drug_actions": [{"action": "INDUCER", "target": "P28482", "drug": "DB01064"}, {"action": "INDUCER", "target": "P28482", "drug": "DB01169"}, {"action": "INHIBITOR", "target": "P28482", "drug": "DB02733"}]}, "Q54089": {"specific_function": "In eubacteria ppGpp (guanosine 3'-diphosphate 5-' diphosphate) is a mediator of the stringent response that coordinates a variety of cellular activities in response to changes in nutritional abundance. This enzyme catalyzes both the formation of pppGpp which is then hydrolyzed to form ppGpp, and the hydrolysis of ppGpp. The enzyme does not simultaneously display both synthase and hydrolase activities. In the structure of residues 1-385 there are 2 conformations seen, the hydrolase-OFF/synthase-ON and hydrolase-ON/synthase-OFF, suggesting there is ligand-induced signal transmission between the 2 active sites.", "general_function": "Metal ion binding", "gene_names": ["relA"], "name": "Bifunctional (p)ppGpp synthase/hydrolase RelA", "drug_actions": []}, "Q03736": {"specific_function": "Subunits I and II form the functional core of the enzyme complex. Electrons originating in cytochrome c are transferred via heme a and Cu(A) to the binuclear center formed by heme a3 and Cu(B).", "general_function": "Cytochrome-c oxidase activity", "gene_names": ["ctaC"], "name": "Cytochrome c oxidase subunit 2", "drug_actions": []}, "Q9Y3I0": {"specific_function": "Catalytic subunit of the tRNA-splicing ligase complex that acts by directly joining spliced tRNA halves to mature-sized tRNAs by incorporating the precursor-derived splice junction phosphate into the mature tRNA as a canonical 3',5'-phosphodiester. May act as an RNA ligase with broad substrate specificity, and may function toward other RNAs.", "general_function": "Vinculin binding", "gene_names": ["RTCB"], "name": "tRNA-splicing ligase RtcB homolog", "drug_actions": []}, "Q9L888": {"specific_function": "Catalyzes the interconversion of L-alanine and D-alanine.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["alr"], "name": "Alanine racemase", "drug_actions": [{"action": "INHIBITOR", "target": "Q9L888", "drug": "DB00260"}]}, "P26827": {"specific_function": "Degrades starch to alpha-, beta-, and gamma-cyclodextrins, as well as linear sugars.", "general_function": "Starch binding", "gene_names": ["amyA"], "name": "Cyclomaltodextrin glucanotransferase", "drug_actions": []}, "P28335": {"specific_function": "G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and down-stream signaling cascades and promotes the release of Ca(2+) ions from intracellular stores. Regulates neuronal activity via the activation of short transient receptor potential calcium channels in the brain, and thereby modulates the activation of pro-opiomelacortin neurons and the release of CRH that then regulates the release of corticosterone. Plays a role in the regulation of appetite and eating behavior, responses to anxiogenic stimuli and stress. Plays a role in insulin sensitivity and glucose homeostasis.", "name": "5-hydroxytryptamine receptor 2C", "drug_actions": [{"action": "ANTAGONIST", "target": "P28335", "drug": "DB00193"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00247"}, {"action": "AGONIST", "target": "P28335", "drug": "DB00248"}, {"action": "AGONIST", "target": "P28335", "drug": "DB00268"}, {"action": "BINDER", "target": "P28335", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00370"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00408"}, {"action": "UNKNOWN", "target": "P28335", "drug": "DB00413"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00434"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00458"}, {"action": "BINDER", "target": "P28335", "drug": "DB00458"}, {"action": "BINDER", "target": "P28335", "drug": "DB00477"}, {"action": "BINDER", "target": "P28335", "drug": "DB00477"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00543"}, {"action": "AGONIST", "target": "P28335", "drug": "DB00574"}, {"action": "AGONIST", "target": "P28335", "drug": "DB00589"}, {"action": "AGONIST", "target": "P28335", "drug": "DB00656"}, {"action": "AGONIST", "target": "P28335", "drug": "DB00696"}, {"action": "AGONIST", "target": "P28335", "drug": "DB00714"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB00805"}, {"action": "BINDER", "target": "P28335", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01079"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01149"}, {"action": "BINDER", "target": "P28335", "drug": "DB01151"}, {"action": "AGONIST", "target": "P28335", "drug": "DB01186"}, {"action": "AGONIST", "target": "P28335", "drug": "DB01191"}, {"action": "AGONIST", "target": "P28335", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01242"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01392"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB01403"}, {"action": "AGONIST", "target": "P28335", "drug": "DB01454"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB06144"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB06594"}, {"action": "INVERSE AGONIST", "target": "P28335", "drug": "DB06678"}, {"action": "ANTAGONIST", "target": "P28335", "drug": "DB09014"}], "general_function": "Serotonin receptor activity", "in_complexes": ["5-hydroxytryptamine 2 receptor", "5-hydroxytryptamine receptor 2", "Serotonin Receptors"], "gene_names": ["HTR2C"]}, "P28331": {"specific_function": "Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity). This is the largest subunit of complex I and it is a component of the iron-sulfur (IP) fragment of the enzyme. It may form part of the active site crevice where NADH is oxidized.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFS1"], "name": "NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial", "drug_actions": []}, "P27958": {"specific_function": "Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).E1 and E2 glycoproteins form a heterodimer that is involved in virus attachment to the host cell, virion internalization through clathrin-dependent endocytosis and fusion with host membrane. E1/E2 heterodimer binds to human LDLR, CD81 and SCARB1/SR-BI receptors, but this binding is not sufficient for infection, some additional liver specific cofactors may be needed. The fusion function may possibly be carried by E1. E2 inhibits human EIF2AK2/PKR activation, preventing the establishment of an antiviral state. E2 is a viral ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on liver sinusoidal endothelial cells and macrophage-like cells of lymph node sinuses. These interactions allow capture of circulating HCV particles by these cells and subsequent transmission to permissive cells. DCs act as sentinels in various tissues where they entrap pathogens and convey them to local lymphoid tissue or lymph node for establishment of immunity. Capture of circulating HCV particles by these SIGN+ cells may facilitate virus infection of proximal hepatocytes and lymphocyte subpopulations and may be essential for the establishment of persistent infection (By similarity).P7 seems to be a heptameric ion channel protein (viroporin) and is inhibited by the antiviral drug amantadine (By similarity). Also inhibited by long-alkyl-chain iminosugar derivatives. Essential for infectivity.Protease NS2-3 is a cysteine protease responsible for the autocatalytic cleavage of NS2-NS3. Seems to undergo self-inactivation following maturation (By similarity).NS3 displays three enzymatic activities: serine protease, NTPase and RNA helicase. NS3 serine protease, in association with NS4A, is responsible for the cleavages of NS3-NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also prevents phosphorylation of human IRF3, thus preventing the establishment of dsRNA induced antiviral state. NS3 RNA helicase binds to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA stable secondary structure in the template strand (By similarity). Cleaves and inhibits the host antiviral protein MAVS.NS4B induces a specific membrane alteration that serves as a scaffold for the virus replication complex. This membrane alteration gives rise to the so-called ER-derived membranous web that contains the replication complex. NS4B polymerization or in protein-protein interactions activity may contribute to its function in membranous web formation.NS5A is a component of the replication complex involved in RNA-binding. Its interaction with Human VAPB may target the viral replication complex to vesicles. Down-regulates viral IRES translation initiation. Mediates interferon resistance, presumably by interacting with and inhibiting human EIF2AK2/PKR. Seems to inhibit apoptosis by interacting with BIN1 and FKBP8. The hyperphosphorylated form of NS5A is an inhibitor of viral replication (By similarity).NS5B is an RNA-dependent RNA polymerase that plays an essential role in the virus replication.", "general_function": "Zinc ion binding", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P62829": {"general_function": "Structural constituent of ribosome", "gene_names": ["RPL23"], "name": "60S ribosomal protein L23", "drug_actions": []}, "Q92830": {"specific_function": "Functions as a histone acetyltransferase (HAT) to promote transcriptional activation. Acetylation of histones gives a specific tag for epigenetic transcription activation. Has significant histone acetyltransferase activity with core histones, but not with nucleosome core particles. Also acetylates non-histone proteins, such as CEBPB (PubMed:17301242). Component of the ATAC complex, a complex with histone acetyltransferase activity on histones H3 and H4. In case of HIV-1 infection, it is recruited by the viral protein Tat. Regulates Tat's transactivating activity and may help inducing chromatin remodeling of proviral genes.", "general_function": "Transcription factor binding", "gene_names": ["KAT2A"], "name": "Histone acetyltransferase KAT2A", "drug_actions": []}, "Q96SL4": {"specific_function": "It protects esophageal epithelia from hydrogen peroxide-induced oxidative stress. It suppresses acidic bile acid-induced reactive oxigen species (ROS) and protects against oxidative DNA damage and double-strand breaks.", "general_function": "Peroxidase activity", "gene_names": ["GPX7"], "name": "Glutathione peroxidase 7", "drug_actions": [{"action": "COFACTOR", "target": "Q96SL4", "drug": "DB00143"}]}, "Q86US8": {"specific_function": "Component of the telomerase ribonucleoprotein (RNP) complex that is essential for the replication of chromosome termini. May have a general role in telomere regulation. Promotes in vitro the ability of TERT to elongate telomeres. Overexpression induces telomere uncapping, chromosomal end-to-end fusions (telomeric DNA persists at the fusion points) and did not perturb TRF2 telomeric localization. Binds to the single-stranded 5'-(GTGTGG)(4)GTGT-3' telomeric DNA, but not to a telomerase RNA template component (TER).Plays a role in nonsense-mediated mRNA decay. Is thought to provide a link to the mRNA degradation machinery as it has endonuclease activity required to initiate NMD, and to serve as an adapter for UPF1 to protein phosphatase 2A (PP2A), thereby triggering UPF1 dephosphorylation. Degrades single-stranded RNA (ssRNA), but not ssDNA or dsRNA.", "general_function": "Telomeric dna binding", "gene_names": ["SMG6"], "name": "Telomerase-binding protein EST1A", "drug_actions": []}, "P56524": {"specific_function": "Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Involved in muscle maturation via its interaction with the myocyte enhancer factors such as MEF2A, MEF2C and MEF2D. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer.", "general_function": "Zinc ion binding", "gene_names": ["HDAC4"], "name": "Histone deacetylase 4", "drug_actions": [{"action": "INHIBITOR", "target": "P56524", "drug": "DB06603"}]}, "Q84FH6": {"specific_function": "Catalyzes the Claisen rearrangement of chorismate to prephenate. Probably involved in the aromatic amino acid biosynthesis.", "general_function": "Chorismate mutase activity", "gene_names": ["aroH"], "name": "Chorismate mutase AroH", "drug_actions": []}, "P62826": {"specific_function": "GTP-binding protein involved in nucleocytoplasmic transport. Required for the import of protein into the nucleus and also for RNA export. Involved in chromatin condensation and control of cell cycle (By similarity). The complex with BIRC5/ survivin plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. Acts as a negative regulator of the kinase activity of VRK1 and VRK2.Enhances AR-mediated transactivation. Transactivation decreases as the poly-Gln length within AR increases.", "general_function": "Transcription coactivator activity", "gene_names": ["RAN"], "name": "GTP-binding nuclear protein Ran", "drug_actions": []}, "P68104": {"specific_function": "This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis. With PARP1 and TXK, forms a complex that acts as a T helper 1 (Th1) cell-specific transcription factor and binds the promoter of IFN-gamma to directly regulate its transcription, and is thus involved importantly in Th1 cytokine production.", "general_function": "Trna binding", "gene_names": ["EEF1A1"], "name": "Elongation factor 1-alpha 1", "drug_actions": []}, "P00521": {"general_function": "Non-membrane spanning protein tyrosine kinase activity", "gene_names": ["ABL"], "name": "Tyrosine-protein kinase transforming protein Abl", "drug_actions": []}, "P48507": {"general_function": "Glutamate-cysteine ligase catalytic subunit binding", "gene_names": ["GCLM"], "name": "Glutamate--cysteine ligase regulatory subunit", "drug_actions": []}, "Q9UKL6": {"specific_function": "Catalyzes the transfer of phosphatidylcholine between membranes. Binds a single lipid molecule.", "general_function": "Phosphatidylcholine transporter activity", "gene_names": ["PCTP"], "name": "Phosphatidylcholine transfer protein", "drug_actions": []}, "P0A017": {"specific_function": "Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis.", "general_function": "Nadp binding", "gene_names": ["folA"], "name": "Dihydrofolate reductase", "drug_actions": []}, "P0A6R0": {"specific_function": "Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP. Catalyzes the first condensation reaction which initiates fatty acid synthesis and may therefore play a role in governing the total rate of fatty acid production. Possesses both acetoacetyl-ACP synthase and acetyl transacylase activities. Has some substrate specificity for acetyl-CoA. Its substrate specificity determines the biosynthesis of straight-chain of fatty acids instead of branched-chain.", "general_function": "Beta-ketoacyl-acyl-carrier-protein synthase iii activity", "gene_names": ["fabH"], "name": "3-oxoacyl-[acyl-carrier-protein] synthase 3", "drug_actions": [{"action": "INHIBITOR", "target": "P0A6R0", "drug": "DB01034"}]}, "P51857": {"specific_function": "Efficiently catalyzes the reduction of progesterone, androstenedione, 17-alpha-hydroxyprogesterone and testosterone to 5-beta-reduced metabolites. The bile acid intermediates 7-alpha,12-alpha-dihydroxy-4-cholesten-3-one and 7-alpha-hydroxy-4-cholesten-3-one can also act as substrates.", "general_function": "Steroid binding", "gene_names": ["AKR1D1"], "name": "3-oxo-5-beta-steroid 4-dehydrogenase", "drug_actions": [{"action": "INHIBITOR", "target": "P51857", "drug": "DB00548"}, {"action": "INHIBITOR", "target": "P51857", "drug": "DB01216"}]}, "P05230": {"specific_function": "Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.", "general_function": "S100 protein binding", "gene_names": ["FGF1"], "name": "Fibroblast growth factor 1", "drug_actions": [{"action": "ANTAGONIST", "target": "P05230", "drug": "DB00686"}, {"action": "INHIBITOR", "target": "P05230", "drug": "DB01025"}, {"action": "INHIBITOR", "target": "P05230", "drug": "DB06589"}]}, "Q969I3": {"specific_function": "Acyltransferase which transfers an acyl group to the N-terminus of glutamine. Can use phenylacetyl-CoA as an acyl donor.", "general_function": "Glycine n-acyltransferase activity", "gene_names": ["GLYATL1"], "name": "Glycine N-acyltransferase-like protein 1", "drug_actions": []}, "O00519": {"specific_function": "Degrades bioactive fatty acid amides like oleamide, the endogenous cannabinoid, anandamide and myristic amide to their corresponding acids, thereby serving to terminate the signaling functions of these molecules. Hydrolyzes polyunsaturated substrate anandamide preferentially as compared to monounsaturated substrates.", "general_function": "Fatty acid amide hydrolase activity", "gene_names": ["FAAH"], "name": "Fatty-acid amide hydrolase 1", "drug_actions": [{"action": "INHIBITOR", "target": "O00519", "drug": "DB00599"}]}, "P51852": {"general_function": "Thiamine pyrophosphate binding", "gene_names": ["ipdC"], "name": "Indole-3-pyruvate decarboxylase", "drug_actions": []}, "P0A915": {"specific_function": "Acts as a receptor for colicin S4.", "gene_names": ["ompW"], "name": "Outer membrane protein W", "drug_actions": []}, "Q11062": {"general_function": "Secondary metabolites biosynthesis, transport and catabolism", "gene_names": ["cyp130"], "name": "Cytochrome P450 130", "drug_actions": []}, "P02743": {"specific_function": "Can interact with DNA and histones and may scavenge nuclear material released from damaged circulating cells. May also function as a calcium-dependent lectin.", "general_function": "Virion binding", "gene_names": ["APCS"], "name": "Serum amyloid P-component", "drug_actions": []}, "P02741": {"specific_function": "Displays several functions associated with host defense: it promotes agglutination, bacterial capsular swelling, phagocytosis and complement fixation through its calcium-dependent binding to phosphorylcholine. Can interact with DNA and histones and may scavenge nuclear material released from damaged circulating cells.", "general_function": "Low-density lipoprotein particle receptor binding", "gene_names": ["CRP"], "name": "C-reactive protein", "drug_actions": []}, "P02747": {"specific_function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.", "gene_names": ["C1QC"], "name": "Complement C1q subcomponent subunit C", "drug_actions": []}, "P07510": {"specific_function": "After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.", "general_function": "Channel activity", "gene_names": ["CHRNG"], "name": "Acetylcholine receptor subunit gamma", "drug_actions": [{"action": "ALLOSTERIC MODULATOR", "target": "P07510", "drug": "DB00674"}]}, "P02745": {"specific_function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.", "gene_names": ["C1QA"], "name": "Complement C1q subcomponent subunit A", "drug_actions": []}, "O95298": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFC2"], "name": "NADH dehydrogenase [ubiquinone] 1 subunit C2", "drug_actions": [{"action": "INHIBITOR", "target": "O95298", "drug": "DB01136"}]}, "O95299": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFA10"], "name": "NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial", "drug_actions": []}, "P35398": {"specific_function": "Nuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5'-AGGTCA-3' preceded by a short A-T-rich sequence. Key regulator of embryonic development, cellular differentiation, immunity, circadian rhythm as well as lipid, steroid, xenobiotics and glucose metabolism. Considered to have intrinsic transcriptional activity, have some natural ligands like oxysterols that act as agonists (25-hydroxycholesterol) or inverse agonists (7-oxygenated sterols), enhancing or repressing the transcriptional activity, respectively. Recruits distinct combinations of cofactors to target genes regulatory regions to modulate their transcriptional expression, depending on the tissue, time and promoter contexts. Regulates genes involved in photoreceptor development including OPN1SW, OPN1SM and ARR3 and skeletal muscle development with MYOD1. Required for proper cerebellum development, regulates SHH gene expression, among others, to induce granule cells proliferation as well as expression of genes involved in calcium-mediated signal transduction. Regulates the circadian expression of several clock genes, including CLOCK, ARNTL/BMAL1, NPAS2 and CRY1. Competes with NR1D1 for binding to their shared DNA response element on some clock genes such as ARNTL/BMAL1, CRY1 and NR1D1 itself, resulting in NR1D1-mediated repression or RORA-mediated activation of clock genes expression, leading to the circadian pattern of clock genes expression. Therefore influences the period length and stability of the clock. Regulates genes involved in lipid metabolism such as apolipoproteins APOA1, APOA5, APOC3 and PPARG. In liver, has specific and redundant functions with RORC as positive or negative modulator of expression of genes encoding phase I and phase II proteins involved in the metabolism of lipids, steroids and xenobiotics, such as CYP7B1 and SULT2A1. Induces a rhythmic expression of some of these genes. In addition, interplays functionally with NR1H2 and NR1H3 for the regulation of genes involved in cholesterol metabolism. Also involved in the regulation of hepatic glucose metabolism through the modulation of G6PC and PCK1. In adipose tissue, plays a role as negative regulator of adipocyte differentiation, probably acting through dual mechanisms. May suppress CEBPB-dependent adipogenesis through direct interaction and PPARG-dependent adipogenesis through competition for DNA-binding. Downstream of IL6 and TGFB and synergistically with RORC isoform 2, is implicated in the lineage specification of uncommitted CD4(+) T-helper (T(H)) cells into T(H)17 cells, antagonizing the T(H)1 program. Probably regulates IL17 and IL17F expression on T(H) by binding to the essential enhancer conserved non-coding sequence 2 (CNS2) in the IL17-IL17F locus. Involved in hypoxia signaling by interacting with and activating the transcriptional activity of HIF1A. May inhibit cell growth in response to cellular stress. May exert an anti-inflammatory role by inducing CHUK expression and inhibiting NF-kappa-B signaling.", "general_function": "Zinc ion binding", "gene_names": ["RORA"], "name": "Nuclear receptor ROR-alpha", "drug_actions": []}, "P0ABF6": {"specific_function": "This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis.", "general_function": "Zinc ion binding", "gene_names": ["cdd"], "name": "Cytidine deaminase", "drug_actions": []}, "P08514": {"specific_function": "Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. It recognizes the sequence R-G-D in a wide array of ligands. It recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial cell surface.", "general_function": "Metal ion binding", "gene_names": ["ITGA2B"], "name": "Integrin alpha-IIb", "drug_actions": [{"action": "ANTAGONIST", "target": "P08514", "drug": "DB00054"}, {"action": "ANTAGONIST", "target": "P08514", "drug": "DB00775"}]}, "P21281": {"specific_function": "Non-catalytic subunit of the peripheral V1 complex of vacuolar ATPase. V-ATPase is responsible for acidifying a variety of intracellular compartments in eukaryotic cells.", "general_function": "Proton-transporting atpase activity, rotational mechanism", "gene_names": ["ATP6V1B2"], "name": "V-type proton ATPase subunit B, brain isoform", "drug_actions": [{"action": "INHIBITOR", "target": "P21281", "drug": "DB05260"}]}, "P72024": {"specific_function": "2,3,4,5-tetrahydrodipicolinate + NAD(P)(+) = 2,3-dihydrodipicolinate + NAD(P)H", "general_function": "Amino acid transport and metabolism", "gene_names": ["dapB"], "name": "4-hydroxy-tetrahydrodipicolinate reductase", "drug_actions": []}, "P43166": {"specific_function": "Reversible hydration of carbon dioxide.", "general_function": "Zinc ion binding", "gene_names": ["CA7"], "name": "Carbonic anhydrase 7", "drug_actions": [{"action": "INHIBITOR", "target": "P43166", "drug": "DB00311"}, {"action": "INHIBITOR", "target": "P43166", "drug": "DB00703"}, {"action": "INHIBITOR", "target": "P43166", "drug": "DB00819"}, {"action": "INHIBITOR", "target": "P43166", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P43166", "drug": "DB01144"}, {"action": "INHIBITOR", "target": "P43166", "drug": "DB08846"}]}, "P03765": {"gene_names": ["ninB"], "name": "Protein ninB", "drug_actions": []}, "P49146": {"specific_function": "Receptor for neuropeptide Y and peptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is PYY > NPY > PYY (3-36) > NPY (2-36) > [Ile-31, Gln-34] PP > [Leu-31, Pro-34] NPY > PP, [Pro-34] PYY and NPY free acid.", "general_function": "Receptor activity", "gene_names": ["NPY2R"], "name": "Neuropeptide Y receptor type 2", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "P49146", "drug": "DB00847"}]}, "P08519": {"specific_function": "Apo(a) is the main constituent of lipoprotein(a) (Lp(a)). It has serine proteinase activity and is able of autoproteolysis. Inhibits tissue-type plasminogen activator 1. Lp(a) may be a ligand for megalin/Gp 330.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["LPA"], "name": "Apolipoprotein(a)", "drug_actions": [{"action": "OTHER", "target": "P08519", "drug": "DB00513"}]}, "Q6PHW0": {"specific_function": "Catalyzes the oxidative NADPH-dependent deiodination of monoiodotyrosine (L-MIT) or diiodotyrosine (L-DIT). Acts during the hydrolysis of thyroglobulin to liberate iodide, which can then reenter the hormone-producing pathways. Acts more efficiently on monoiodotyrosine than on diiodotyrosine.", "general_function": "Oxidoreductase activity", "gene_names": ["IYD"], "name": "Iodotyrosine deiodinase 1", "drug_actions": []}, "P78540": {"specific_function": "May play a role in the regulation of extra-urea cycle arginine metabolism and also in down-regulation of nitric oxide synthesis. Extrahepatic arginase functions to regulate L-arginine bioavailability to NO synthase. Since NO synthase is found in the penile corpus cavernosum smooth muscle, the clitoral corpus cavernosum and the vagina, arginase II plays a role in both male and female sexual arousal. It is therefore a potential target for the treatment of male and female sexual arousal disorders.", "general_function": "Metal ion binding", "gene_names": ["ARG2"], "name": "Arginase-2, mitochondrial", "drug_actions": []}, "Q84EX5": {"general_function": "Oxidoreductase activity", "gene_names": ["radh"], "name": "R-specific alcohol dehydrogenase", "drug_actions": []}, "Q54468": {"specific_function": "Digests the beta-1,4-glycosidic bonds in N-acetylglucosamine (GlcNAc) oligomers (mainly dimers).", "general_function": "Polysaccharide binding", "gene_names": ["chb"], "name": "Chitobiase", "drug_actions": []}, "O60701": {"specific_function": "Involved in the biosynthesis of glycosaminoglycans; hyaluronan, chondroitin sulfate, and heparan sulfate.", "general_function": "Udp-glucose 6-dehydrogenase activity", "gene_names": ["UGDH"], "name": "UDP-glucose 6-dehydrogenase", "drug_actions": []}, "O60706": {"specific_function": "Subunit of ATP-sensitive potassium channels (KATP). Can form cardiac and smooth muscle-type KATP channels with KCNJ11. KCNJ11 forms the channel pore while ABCC9 is required for activation and regulation.", "general_function": "Transporter activity", "gene_names": ["ABCC9"], "name": "ATP-binding cassette sub-family C member 9", "drug_actions": [{"action": "MODULATOR", "target": "O60706", "drug": "DB01016"}]}, "P15531": {"specific_function": "Major role in the synthesis of nucleoside triphosphates other than ATP. The ATP gamma phosphate is transferred to the NDP beta phosphate via a ping-pong mechanism, using a phosphorylated active-site intermediate. Possesses nucleoside-diphosphate kinase, serine/threonine-specific protein kinase, geranyl and farnesyl pyrophosphate kinase, histidine protein kinase and 3'-5' exonuclease activities. Involved in cell proliferation, differentiation and development, signal transduction, G protein-coupled receptor endocytosis, and gene expression. Required for neural development including neural patterning and cell fate determination. During GZMA-mediated cell death, works in concert with TREX1. NME1 nicks one strand of DNA and TREX1 removes bases from the free 3' end to enhance DNA damage and prevent DNA end reannealing and rapid repair.", "general_function": "Ribosomal small subunit binding", "gene_names": ["NME1"], "name": "Nucleoside diphosphate kinase A", "drug_actions": []}, "P0A7R5": {"specific_function": "Involved in the binding of tRNA to the ribosomes.", "general_function": "Trna binding", "gene_names": ["rpsJ"], "name": "30S ribosomal protein S10", "drug_actions": []}, "P15538": {"specific_function": "Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochrome P450 XIB.", "general_function": "Steroid 11-beta-monooxygenase activity", "gene_names": ["CYP11B1"], "name": "Cytochrome P450 11B1, mitochondrial", "drug_actions": [{"action": "INDUCER", "target": "P15538", "drug": "DB00648"}, {"action": "INHIBITOR", "target": "P15538", "drug": "DB01011"}]}, "P64767": {"general_function": "Amino acid transport and metabolism", "gene_names": ["Rv0948c"], "name": "Intracellular chorismate mutase", "drug_actions": []}, "Q99062": {"specific_function": "Receptor for granulocyte colony-stimulating factor (CSF3), essential for granulocytic maturation. Plays a crucial role in the proliferation, differientation and survival of cells along the neutrophilic lineage. In addition it may function in some adhesion or recognition events at the cell surface.", "general_function": "Receptor activity", "gene_names": ["CSF3R"], "name": "Granulocyte colony-stimulating factor receptor", "drug_actions": [{"action": "AGONIST", "target": "Q99062", "drug": "DB00019"}, {"action": "STIMULATOR", "target": "Q99062", "drug": "DB00099"}]}, "P02925": {"specific_function": "Part of the ABC transporter complex RbsABC involved in ribose import. Binds ribose. Also serves as the primary chemoreceptor for chemotaxis.", "general_function": "Monosaccharide transmembrane transporter activity", "gene_names": ["rbsB"], "name": "Ribose import binding protein RbsB", "drug_actions": []}, "A0A023W3H0": {"general_function": "Penicillin binding", "gene_names": ["OXA-48"], "name": "Class D OXA-48 carbapenemase", "drug_actions": [{"action": "INHIBITOR", "target": "A0A023W3H0", "drug": "DB09060"}]}, "P80099": {"general_function": "Metal ion binding", "gene_names": ["mgtA"], "name": "4-alpha-glucanotransferase", "drug_actions": []}, "P26010": {"specific_function": "Integrin alpha-4/beta-7 (Peyer patches-specific homing receptor LPAM-1) is an adhesion molecule that mediates lymphocyte migration and homing to gut-associated lymphoid tissue (GALT). Integrin alpha-4/beta-7 interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interacts also with VCAM1 and fibronectin, an extracellular matrix component. It recognizes one or more domains within the alternatively spliced CS-1 region of fibronectin. Interactions involves the tripeptide L-D-T in MADCAM1, and L-D-V in fibronectin. Binds to HIV-1 gp120, thereby allowing the virus to enter GALT, which is thought to be the major trigger of AIDS disease. Interaction would involve a tripeptide L-D-I in HIV-1 gp120. Integrin alpha-E/beta-7 (HML-1) is a receptor for E-cadherin.", "general_function": "Virus receptor activity", "gene_names": ["ITGB7"], "name": "Integrin beta-7", "drug_actions": [{"action": "ANTIBODY", "target": "P26010", "drug": "DB09033"}]}, "P04293": {"specific_function": "Replicates viral genomic DNA. The replication complex is composed of six viral proteins: the DNA polymerase, processivity factor, primase, primase-associated factor, helicase, and ssDNA-binding protein. Additionally, the polymerase contains an intrinsic ribonuclease H (RNase H) activity that specifically degrades RNA/DNA heteroduplexes or duplex DNA substrates in the 5' to 3' direction. Therefore, it can catalyze the excision of the RNA primers that initiate the synthesis of Okazaki fragments at a replication fork during viral DNA replication.", "general_function": "Rna-dna hybrid ribonuclease activity", "gene_names": [], "name": "DNA polymerase catalytic subunit", "drug_actions": [{"action": "INHIBITOR", "target": "P04293", "drug": "DB00299"}, {"action": "INHIBITOR", "target": "P04293", "drug": "DB00426"}, {"action": "INHIBITOR", "target": "P04293", "drug": "DB00529"}, {"action": "INHIBITOR", "target": "P04293", "drug": "DB00577"}, {"action": "INHIBITOR", "target": "P04293", "drug": "DB00787"}, {"action": "INHIBITOR", "target": "P04293", "drug": "DB01004"}]}, "P0A112": {"specific_function": "Component of the naphthalene dioxygenase (NDO) multicomponent enzyme system which catalyzes the incorporation of both atoms of molecular oxygen into naphthalene to form cis-naphthalene dihydrodiol. The beta subunit may be responsible for the substrate specificity of the enzyme.", "general_function": "Naphthalene 1,2-dioxygenase activity", "gene_names": ["ndoC"], "name": "Naphthalene 1,2-dioxygenase subunit beta", "drug_actions": []}, "P35625": {"specific_function": "Complexes with metalloproteinases (such as collagenases) and irreversibly inactivates them by binding to their catalytic zinc cofactor. May form part of a tissue-specific acute response to remodeling stimuli. Known to act on MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, MMP-14 and MMP-15.", "general_function": "Protease binding", "gene_names": ["TIMP3"], "name": "Metalloproteinase inhibitor 3", "drug_actions": []}, "P36924": {"general_function": "Starch binding", "gene_names": ["spoII"], "name": "Beta-amylase", "drug_actions": []}, "Q9H169": {"specific_function": "Exhibits microtubule-destabilizing activity.", "general_function": "Tubulin binding", "gene_names": ["STMN4"], "name": "Stathmin-4", "drug_actions": [{"action": "ANTAGONIST", "target": "Q9H169", "drug": "DB01206"}]}, "P21549": {"general_function": "Transaminase activity", "gene_names": ["AGXT"], "name": "Serine--pyruvate aminotransferase", "drug_actions": [{"action": "COFACTOR", "target": "P21549", "drug": "DB00114"}]}, "P01100": {"specific_function": "Nuclear phosphoprotein which forms a tight but non-covalently linked complex with the JUN/AP-1 transcription factor. In the heterodimer, FOS and JUN/AP-1 basic regions each seems to interact with symmetrical DNA half sites. On TGF-beta activation, forms a multimeric SMAD3/SMAD4/JUN/FOS complex at the AP1/SMAD-binding site to regulate TGF-beta-mediated signaling. Has a critical function in regulating the development of cells destined to form and maintain the skeleton. It is thought to have an important role in signal transduction, cell proliferation and differentiation. In growing cells, activates phospholipid synthesis, possibly by activating CDS1 and PI4K2A. This activity requires Tyr-dephosphorylation and association with the endoplasmic reticulum.", "name": "Proto-oncogene c-Fos", "drug_actions": [{"action": "INHIBITOR", "target": "P01100", "drug": "DB08813"}], "general_function": "Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding", "in_complexes": ["activator protein 1"], "gene_names": ["FOS"]}, "Q83P33": {"specific_function": "Plays an important role in the de novo pathway of purine nucleotide biosynthesis. Catalyzes the first committed step in the biosynthesis of AMP from IMP.", "general_function": "Magnesium ion binding", "gene_names": ["purA"], "name": "Adenylosuccinate synthetase", "drug_actions": []}, "Q8X444": {"specific_function": "Excises uracil residues from the DNA which can arise as a result of misincorporation of dUMP residues by DNA polymerase or due to deamination of cytosine.", "general_function": "Uracil dna n-glycosylase activity", "gene_names": ["ung"], "name": "Uracil-DNA glycosylase", "drug_actions": []}, "Q8NBP7": {"specific_function": "Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.", "general_function": "Very-low-density lipoprotein particle receptor binding", "gene_names": ["PCSK9"], "name": "Proprotein convertase subtilisin/kexin type 9", "drug_actions": [{"action": "INHIBITOR", "target": "Q8NBP7", "drug": "DB09302"}]}, "P62136": {"specific_function": "Protein phosphatase that associates with over 200 regulatory proteins to form highly specific holoenzymes which dephosphorylate hundreds of biological targets. Protein phosphatase 1 (PP1) is essential for cell division, and participates in the regulation of glycogen metabolism, muscle contractility and protein synthesis. Involved in regulation of ionic conductances and long-term synaptic plasticity. May play an important role in dephosphorylating substrates such as the postsynaptic density-associated Ca(2+)/calmodulin dependent protein kinase II. Component of the PTW/PP1 phosphatase complex, which plays a role in the control of chromatin structure and cell cycle progression during the transition from mitosis into interphase. Regulates NEK2 function in terms of kinase activity and centrosome number and splitting, both in the presence and absence of radiation-induced DNA damage. Regulator of neural tube and optic fissure closure, and enteric neural crest cell (ENCCs) migration during development. In balance with CSNK1D and CSNK1E, determines the circadian period length, through the regulation of the speed and rhythmicity of PER1 and PER2 phosphorylation. May dephosphorylate CSNK1D and CSNK1E. Dephosphorylates the 'Ser-418' residue of FOXP3 in regulatory T-cells (Treg) from patients with rheumatoid arthritis, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:23396208).", "general_function": "Ribonucleoprotein complex binding", "gene_names": ["PPP1CA"], "name": "Serine/threonine-protein phosphatase PP1-alpha catalytic subunit", "drug_actions": []}, "P00451": {"specific_function": "Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa.", "general_function": "Oxidoreductase activity", "gene_names": ["F8"], "name": "Coagulation factor VIII", "drug_actions": [{"action": "MULTITARGET", "target": "P00451", "drug": "DB00055"}, {"action": "COFACTOR", "target": "P00451", "drug": "DB00100"}]}, "P00450": {"specific_function": "Ceruloplasmin is a blue, copper-binding (6-7 atoms per molecule) glycoprotein. It has ferroxidase activity oxidizing Fe(2+) to Fe(3+) without releasing radical oxygen species. It is involved in iron transport across the cell membrane. Provides Cu(2+) ions for the ascorbate-mediated deaminase degradation of the heparan sulfate chains of GPC1. May also play a role in fetal lung development or pulmonary antioxidant defense (By similarity).", "general_function": "Ferroxidase activity", "gene_names": ["CP"], "name": "Ceruloplasmin", "drug_actions": []}, "Q02928": {"specific_function": "Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE).", "general_function": "Leukotriene-b4 20-monooxygenase activity", "gene_names": ["CYP4A11"], "name": "Cytochrome P450 4A11", "drug_actions": []}, "O75746": {"specific_function": "Catalyzes the calcium-dependent exchange of cytoplasmic glutamate with mitochondrial aspartate across the mitochondrial inner membrane. May have a function in the urea cycle.", "general_function": "L-glutamate transmembrane transporter activity", "gene_names": ["SLC25A12"], "name": "Calcium-binding mitochondrial carrier protein Aralar1", "drug_actions": []}, "Q8ZIV7": {"specific_function": "Plays an important role in the de novo pathway of purine nucleotide biosynthesis. Catalyzes the first committed step in the biosynthesis of AMP from IMP.", "general_function": "Magnesium ion binding", "gene_names": ["purA"], "name": "Adenylosuccinate synthetase", "drug_actions": []}, "P76270": {"specific_function": "Catalyzes the reversible oxidation-reduction of the R-enantiomer of free methionine sulfoxide to methionine. Specific for free L-methionine-(R)-S-oxide.", "general_function": "Oxidoreductase activity, acting on a sulfur group of donors, disulfide as acceptor", "gene_names": ["msrC"], "name": "Free methionine-R-sulfoxide reductase", "drug_actions": []}, "P68371": {"specific_function": "Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.", "general_function": "Unfolded protein binding", "gene_names": ["TUBB4B"], "name": "Tubulin beta-4B chain", "drug_actions": [{"action": "INHIBITOR", "target": "P68371", "drug": "DB00518"}, {"action": "INHIBITOR", "target": "P68371", "drug": "DB00643"}]}, "P22088": {"specific_function": "Catalyzes the hydrolysis of triglycerides.", "general_function": "Triglyceride lipase activity", "gene_names": ["lipA"], "name": "Lipase", "drug_actions": []}, "P39621": {"specific_function": "Glycosyltransferase implicated in the synthesis of the spore coat.", "general_function": "Transferase activity, transferring glycosyl groups", "gene_names": ["spsA"], "name": "Spore coat polysaccharide biosynthesis protein SpsA", "drug_actions": []}, "Q9NPH2": {"specific_function": "Key enzyme in myo-inositol biosynthesis pathway that catalyzes the conversion of glucose 6-phosphate to 1-myo-inositol 1-phosphate in a NAD-dependent manner. Rate-limiting enzyme in the synthesis of all inositol-containing compounds.", "general_function": "Inositol-3-phosphate synthase activity", "gene_names": ["ISYNA1"], "name": "Inositol-3-phosphate synthase 1", "drug_actions": []}, "P42768": {"specific_function": "Effector protein for Rho-type GTPases. Regulates actin filament reorganization via its interaction with the Arp2/3 complex. Important for efficient actin polymerization. Possible regulator of lymphocyte and platelet function. Mediates actin filament reorganization and the formation of actin pedestals upon infection by pathogenic bacteria.", "general_function": "Sh3 domain binding", "gene_names": ["WAS"], "name": "Wiskott-Aldrich syndrome protein", "drug_actions": []}, "Q9UE69": {"gene_names": [], "name": "5HT3 serotonin receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "Q9UE69", "drug": "DB09207"}]}, "P13866": {"specific_function": "Actively transports glucose into cells by Na(+) cotransport with a Na(+) to glucose coupling ratio of 2:1. Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capacity and a high affinity low capacity Na(+)/glucose cotransporter arranged in series along kidney proximal tubules.", "general_function": "Glucose:sodium symporter activity", "gene_names": ["SLC5A1"], "name": "Sodium/glucose cotransporter 1", "drug_actions": [{"action": "INHIBITOR", "target": "P13866", "drug": "DB08907"}]}, "P26790": {"specific_function": "Antenna complexes are light-harvesting systems, which transfer the excitation energy to the reaction centers.", "general_function": "Metal ion binding", "gene_names": [], "name": "Light-harvesting protein B-800/850 beta chain", "drug_actions": []}, "Q53547": {"specific_function": "Hydrolyzes carboxylic ester bonds with relatively broad substrate specificity.", "general_function": "Carboxylic ester hydrolase activity", "gene_names": ["estB"], "name": "Carboxylesterase 2", "drug_actions": []}, "Q92506": {"specific_function": "NAD-dependent 17-beta-hydroxysteroid dehydrogenase with highest activity towards estradiol. Has very low activity towards testosterone. The heteroteramer with CBR4 has NADH-dependent 3-ketoacyl-acyl carrier protein reductase activity. May play a role in biosynthesis of fatty acids in mitochondria.", "general_function": "Testosterone dehydrogenase (nad+) activity", "gene_names": ["HSD17B8"], "name": "Estradiol 17-beta-dehydrogenase 8", "drug_actions": []}, "Q8TC12": {"specific_function": "Exhibits an oxidoreductive catalytic activity towards retinoids. Most efficient as an NADPH-dependent retinal reductase. Displays high activity towards 9-cis and all-trans-retinol. Also involved in the metabolism of short-chain aldehydes. No steroid dehydrogenase activity detected.", "general_function": "Retinol dehydrogenase activity", "gene_names": ["RDH11"], "name": "Retinol dehydrogenase 11", "drug_actions": []}, "P09788": {"general_function": "Oxidoreductase activity, acting on ch-oh group of donors", "gene_names": ["pchF"], "name": "4-cresol dehydrogenase [hydroxylating] flavoprotein subunit", "drug_actions": []}, "P59846": {"general_function": "Atp binding", "gene_names": ["argG"], "name": "Argininosuccinate synthase", "drug_actions": []}, "Q14123": {"specific_function": "Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a high affinity for both cAMP and cGMP.", "name": "Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "Q14123", "drug": "DB00201"}], "general_function": "Metal ion binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE1C"]}, "P08192": {"specific_function": "Conversion of folates to polyglutamate derivatives.", "general_function": "Tetrahydrofolylpolyglutamate synthase activity", "gene_names": ["folC"], "name": "Bifunctional protein FolC", "drug_actions": [{"action": "INHIBITOR", "target": "P08192", "drug": "DB01015"}]}, "P00183": {"specific_function": "Involved in a camphor oxidation system.", "general_function": "Iron ion binding", "gene_names": ["camC"], "name": "Camphor 5-monooxygenase", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "P00183", "drug": "DB01011"}]}, "P23378": {"specific_function": "The glycine cleavage system catalyzes the degradation of glycine. The P protein (GLDC) binds the alpha-amino group of glycine through its pyridoxal phosphate cofactor; CO(2) is released and the remaining methylamine moiety is then transferred to the lipoamide cofactor of the H protein (GCSH).", "general_function": "Lyase activity", "gene_names": ["GLDC"], "name": "Glycine dehydrogenase (decarboxylating), mitochondrial", "drug_actions": [{"action": "COFACTOR", "target": "P23378", "drug": "DB00114"}]}, "P10114": {"specific_function": "Small GTP-binding protein which cycles between a GDP-bound inactive and a GTP-bound active form. In its active form interacts with and regulates several effectors including MAP4K4, MINK1 and TNIK. Part of a signaling complex composed of NEDD4, RAP2A and TNIK which regulates neuronal dendrite extension and arborization during development. More generally, it is part of several signaling cascades and may regulate cytoskeletal rearrangements, cell migration, cell adhesion and cell spreading.", "general_function": "Gtpase activity", "gene_names": ["RAP2A"], "name": "Ras-related protein Rap-2a", "drug_actions": []}, "Q2TU84": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["GIG18"], "name": "Aspartate aminotransferase", "drug_actions": [{"action": "COFACTOR", "target": "Q2TU84", "drug": "DB00114"}]}, "P04745": {"general_function": "Metal ion binding", "gene_names": ["AMY1A"], "name": "Alpha-amylase 1", "drug_actions": []}, "P04746": {"general_function": "Chloride ion binding", "gene_names": ["AMY2A"], "name": "Pancreatic alpha-amylase", "drug_actions": [{"action": "INHIBITOR", "target": "P04746", "drug": "DB00284"}]}, "P24666": {"specific_function": "Acts on tyrosine phosphorylated proteins, low-MW aryl phosphates and natural and synthetic acyl phosphates. Isoform 3 does not possess phosphatase activity.", "general_function": "Non-membrane spanning protein tyrosine phosphatase activity", "gene_names": ["ACP1"], "name": "Low molecular weight phosphotyrosine protein phosphatase", "drug_actions": []}, "P77872": {"specific_function": "Decomposes hydrogen peroxide into water and oxygen; serves to protect cells from the toxic effects of hydrogen peroxide.", "general_function": "Metal ion binding", "gene_names": ["katA"], "name": "Catalase", "drug_actions": []}, "P20309": {"specific_function": "The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.", "name": "Muscarinic acetylcholine receptor M3", "drug_actions": [{"action": "AGONIST", "target": "P20309", "drug": "DB00185"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00193"}, {"action": "AGONIST", "target": "P20309", "drug": "DB00202"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00280"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00332"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00340"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00342"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00376"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00383"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00387"}, {"action": "BINDER", "target": "P20309", "drug": "DB00408"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00424"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00434"}, {"action": "BINDER", "target": "P20309", "drug": "DB00454"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00462"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00496"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00505"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00517"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00543"}, {"action": "BINDER", "target": "P20309", "drug": "DB00568"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00572"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00622"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00715"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00725"}, {"action": "BINDER", "target": "P20309", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00729"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00747"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00767"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00785"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00809"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00835"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB00986"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01036"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01062"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01069"}, {"action": "AGONIST", "target": "P20309", "drug": "DB01085"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01151"}, {"action": "BINDER", "target": "P20309", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01226"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01231"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01337"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01338"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01409"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01591"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB01625"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB04843"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB06702"}, {"action": "AGONIST", "target": "P20309", "drug": "DB06709"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB08897"}, {"action": "ANTAGONIST", "target": "P20309", "drug": "DB09076"}], "general_function": "Receptor activity", "in_complexes": ["Muscarinic acetylcholine receptor"], "gene_names": ["CHRM3"]}, "P0AEK4": {"specific_function": "Catalyzes the reduction of a carbon-carbon double bond in an enoyl moiety that is covalently linked to an acyl carrier protein (ACP). Involved in the elongation cycle of fatty acid which are used in the lipid metabolism and in the biotin biosynthesis.", "general_function": "Identical protein binding", "gene_names": ["fabI"], "name": "Enoyl-[acyl-carrier-protein] reductase [NADH] FabI", "drug_actions": []}, "P0AEK7": {"specific_function": "Formate dehydrogenase allows E.coli to use formate as major electron donor during anaerobic respiration, when nitrate is used as electron acceptor. Subunit gamma is the cytochrome b556 component of the formate dehydrogenase-N, and also contains a menaquinone reduction site that receives electrons from the beta subunit (FdnH), through its hemes. Formate dehydrogenase-N is part of a system that generates proton motive force, together with the dissimilatory nitrate reductase (Nar).", "general_function": "Metal ion binding", "gene_names": ["fdnI"], "name": "Formate dehydrogenase, nitrate-inducible, cytochrome b556(Fdn) subunit", "drug_actions": []}, "Q6UX15": {"specific_function": "Receptor for hyaluronate.", "general_function": "Hyaluronic acid binding", "gene_names": ["LAYN"], "name": "Layilin", "drug_actions": [{"action": "BINDER", "target": "Q6UX15", "drug": "DB08818"}]}, "P0AEK2": {"specific_function": "Catalyzes the NADPH-dependent reduction of beta-ketoacyl-ACP substrates to beta-hydroxyacyl-ACP products, the first reductive step in the elongation cycle of fatty acid biosynthesis.", "general_function": "Nadp binding", "gene_names": ["fabG"], "name": "3-oxoacyl-[acyl-carrier-protein] reductase FabG", "drug_actions": []}, "P26221": {"general_function": "Cellulose binding", "gene_names": ["celD"], "name": "Endoglucanase E-4", "drug_actions": []}, "P08311": {"specific_function": "Serine protease with trypsin- and chymotrypsin-like specificity. Cleaves complement C3. Has antibacterial activity against the Gram-negative bacterium P.aeruginosa, antibacterial activity is inhibited by LPS from P.aeruginosa, Z-Gly-Leu-Phe-CH2Cl and phenylmethylsulfonyl fluoride.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["CTSG"], "name": "Cathepsin G", "drug_actions": []}, "Q14654": {"specific_function": "This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by extracellular barium (By similarity). Subunit of ATP-sensitive potassium channels (KATP). Can form cardiac and smooth muscle-type KATP channels with ABCC9. KCNJ11 forms the channel pore while ABCC9 is required for activation and regulation.", "name": "ATP-sensitive inward rectifier potassium channel 11", "drug_actions": [{"action": "INHIBITOR", "target": "Q14654", "drug": "DB00222"}, {"action": "INHIBITOR", "target": "Q14654", "drug": "DB00308"}, {"action": "INHIBITOR", "target": "Q14654", "drug": "DB00661"}, {"action": "INDUCER", "target": "Q14654", "drug": "DB00922"}, {"action": "MODULATOR", "target": "Q14654", "drug": "DB01016"}, {"action": "INDUCER", "target": "Q14654", "drug": "DB01119"}, {"action": "INHIBITOR", "target": "Q14654", "drug": "DB01154"}], "general_function": "Voltage-gated potassium channel activity", "in_complexes": ["ATP-sensitive potassium channel", "Mitochondrial ATP-sensitive potassium channel"], "gene_names": ["KCNJ11"]}, "Q9HCP0": {"specific_function": "Serine/threonine-protein kinase. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. It can phosphorylate a large number of proteins. Participates in Wnt signaling. Regulates fast synaptic transmission mediated by glutamate (By similarity). Phosphorylates CLSPN.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["CSNK1G1"], "name": "Casein kinase I isoform gamma-1", "drug_actions": []}, "O43681": {"specific_function": "ATPase required for the post-translational delivery of tail-anchored (TA) proteins to the endoplasmic reticulum. Recognizes and selectively binds the transmembrane domain of TA proteins in the cytosol. This complex then targets to the endoplasmic reticulum by membrane-bound receptors, where the tail-anchored protein is released for insertion. This process is regulated by ATP binding and hydrolysis. ATP binding drives the homodimer towards the closed dimer state, facilitating recognition of newly synthesized TA membrane proteins. ATP hydrolysis is required for insertion. Subsequently, the homodimer reverts towards the open dimer state, lowering its affinity for the membrane-bound receptor, and returning it to the cytosol to initiate a new round of targeting (By similarity). May be involved in insulin signaling.", "general_function": "Transporter activity", "gene_names": ["ASNA1"], "name": "ATPase ASNA1", "drug_actions": []}, "Q16878": {"specific_function": "Initiates several important metabolic pathways related to pyruvate and several sulfurate compounds including sulfate, hypotaurine and taurine. Critical regulator of cellular cysteine concentrations. Has an important role in maintaining the hepatic concentation of intracellular free cysteine within a proper narrow range.", "general_function": "Ferrous iron binding", "gene_names": ["CDO1"], "name": "Cysteine dioxygenase type 1", "drug_actions": []}, "Q9H239": {"specific_function": "Can degrade casein. Could play a role in tissues homeostasis and repair.", "general_function": "Zinc ion binding", "gene_names": ["MMP28"], "name": "Matrix metalloproteinase-28", "drug_actions": [{"action": "INHIBITOR", "target": "Q9H239", "drug": "DB00786"}]}, "P96622": {"specific_function": "Toxic component of a type II toxin-antitoxin (TA) module. Specific for 5'-UACAU-3' sequences, cleaving after the first U (PubMed:21763692). Yields cleavage products with 3' phosphate and 5' hydroxyl groups (PubMed:15882409). Cannot digest substrate with a UUdUACAUAA cleavage site (PubMed:24120662). Overexpression is toxic for cell growth (shown in E.coli), probably by inhibiting protein synthesis through the cleavage of single-stranded RNA. The toxicity is reversed by the antitoxin EndoAI. Toxin activity cannot be inhibited by MazE from E.coli. The EndoA-EndoAI complex does not seem to bind its own promoter (PubMed:24120662).", "general_function": "Rna binding", "gene_names": ["ndoA"], "name": "Endoribonuclease EndoA", "drug_actions": []}, "Q16873": {"specific_function": "Catalyzes the conjugation of leukotriene A4 with reduced glutathione to form leukotriene C4.", "general_function": "Lipid binding", "gene_names": ["LTC4S"], "name": "Leukotriene C4 synthase", "drug_actions": []}, "P45314": {"specific_function": "Involved in the biosynthesis of lipopolysaccharides (LPSs), but is not essential. Catalyzes the hydrolysis of 3-deoxy-D-manno-octulosonate 8-phosphate (KDO 8-P) to 3-deoxy-D-manno-octulosonate (KDO) and inorganic phosphate.", "general_function": "Metal ion binding", "gene_names": [], "name": "3-deoxy-D-manno-octulosonate 8-phosphate phosphatase KdsC", "drug_actions": []}, "P0ABQ0": {"specific_function": "Catalyzes two steps in the biosynthesis of coenzyme A. In the first step cysteine is conjugated to 4'-phosphopantothenate to form 4-phosphopantothenoylcysteine, in the latter compound is decarboxylated to form 4'-phosphopantotheine.", "general_function": "Phosphopantothenoylcysteine decarboxylase activity", "gene_names": ["coaBC"], "name": "Coenzyme A biosynthesis bifunctional protein CoaBC", "drug_actions": []}, "Q16877": {"specific_function": "Synthesis and degradation of fructose 2,6-bisphosphate.", "general_function": "Fructose-2,6-bisphosphate 2-phosphatase activity", "gene_names": ["PFKFB4"], "name": "6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4", "drug_actions": []}, "P46849": {"specific_function": "Catalyzes the conversion of 3'-phosphate to a 2',3'-cyclic phosphodiester at the end of RNA. The mechanism of action of the enzyme occurs in 3 steps: (A) adenylation of the enzyme by ATP; (B) transfer of adenylate to an RNA-N3'P to produce RNA-N3'PP5'A; (C) and attack of the adjacent 2'-hydroxyl on the 3'-phosphorus in the diester linkage to produce the cyclic end product. The biological role of this enzyme is unknown but it is likely to function in some aspects of cellular RNA processing.", "general_function": "Rna-3'-phosphate cyclase activity", "gene_names": ["rtcA"], "name": "RNA 3'-terminal phosphate cyclase", "drug_actions": []}, "P42328": {"specific_function": "Thermophilic NAD(+)-dependent alcohol dehydrogenase. Bears mainly an ethanol-dehydrogenase activity.", "general_function": "Zinc ion binding", "gene_names": [], "name": "Alcohol dehydrogenase", "drug_actions": []}, "Q9A5I5": {"specific_function": "Response regulator that is part of a signal transduction pathway controlling cell differentiation in the swarmer-to-stalked cell transition.Catalyzes the condensation of two GTP molecules to the cyclic dinucleotide di-GMP (c-di-GMP), which acts as a secondary messenger.", "general_function": "Signal transducer activity", "gene_names": ["pleD"], "name": "Response regulator PleD", "drug_actions": []}, "Q04707": {"specific_function": "Cell wall formation.", "general_function": "Penicillin binding", "gene_names": ["ponA"], "name": "Penicillin-binding protein 1A", "drug_actions": [{"action": "INHIBITOR", "target": "Q04707", "drug": "DB01150"}]}, "P0A1P6": {"general_function": "Glutamate-ammonia ligase activity", "gene_names": ["glnA"], "name": "Glutamine synthetase", "drug_actions": []}, "P11229": {"specific_function": "The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.", "name": "Muscarinic acetylcholine receptor M1", "drug_actions": [{"action": "AGONIST", "target": "P11229", "drug": "DB00185"}, {"action": "AGONIST", "target": "P11229", "drug": "DB00202"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00209"}, {"action": "BINDER", "target": "P11229", "drug": "DB00215"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00219"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00245"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00280"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00332"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00340"}, {"action": "BINDER", "target": "P11229", "drug": "DB00342"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00354"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00366"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00376"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00383"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00387"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00392"}, {"action": "BINDER", "target": "P11229", "drug": "DB00408"}, {"action": "AGONIST", "target": "P11229", "drug": "DB00411"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00424"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00434"}, {"action": "BINDER", "target": "P11229", "drug": "DB00454"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00462"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00496"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00505"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00508"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00517"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00543"}, {"action": "BINDER", "target": "P11229", "drug": "DB00568"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00572"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00622"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00670"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00715"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00725"}, {"action": "BINDER", "target": "P11229", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00747"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00767"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00771"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00782"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00785"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00804"}, {"action": "AGONIST", "target": "P11229", "drug": "DB00805"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00809"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00810"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00835"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00875"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00907"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00940"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00942"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00979"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB00986"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01036"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01062"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01069"}, {"action": "AGONIST", "target": "P11229", "drug": "DB01085"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01148"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01151"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01175"}, {"action": "BINDER", "target": "P11229", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01231"}, {"action": "AGONIST", "target": "P11229", "drug": "DB01233"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01409"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB01591"}, {"action": "OTHER/UNKNOWN", "target": "P11229", "drug": "DB01618"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB04843"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB06702"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB08897"}, {"action": "ANTAGONIST", "target": "P11229", "drug": "DB09076"}], "general_function": "Phosphatidylinositol phospholipase c activity", "in_complexes": ["Muscarinic acetylcholine receptor"], "gene_names": ["CHRM1"]}, "P14618": {"specific_function": "Glycolytic enzyme that catalyzes the transfer of a phosphoryl group from phosphoenolpyruvate (PEP) to ADP, generating ATP. Stimulates POU5F1-mediated transcriptional activation. Plays a general role in caspase independent cell death of tumor cells. The ratio betwween the highly active tetrameric form and nearly inactive dimeric form determines whether glucose carbons are channeled to biosynthetic processes or used for glycolytic ATP production. The transition between the 2 forms contributes to the control of glycolysis and is important for tumor cell proliferation and survival.", "general_function": "Pyruvate kinase activity", "gene_names": ["PKM"], "name": "Pyruvate kinase PKM", "drug_actions": []}, "Q05655": {"specific_function": "Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays contrasting roles in cell death and cell survival by functioning as a pro-apoptotic protein during DNA damage-induced apoptosis, but acting as an anti-apoptotic protein during cytokine receptor-initiated cell death, is involved in tumor suppression as well as survival of several cancers, is required for oxygen radical production by NADPH oxidase and acts as positive or negative regulator in platelet functional responses. Negatively regulates B cell proliferation and also has an important function in self-antigen induced B cell tolerance induction. Upon DNA damage, activates the promoter of the death-promoting transcription factor BCLAF1/Btf to trigger BCLAF1-mediated p53/TP53 gene transcription and apoptosis. In response to oxidative stress, interact with and activate CHUK/IKKA in the nucleus, causing the phosphorylation of p53/TP53. In the case of ER stress or DNA damage-induced apoptosis, can form a complex with the tyrosine-protein kinase ABL1 which trigger apoptosis independently of p53/TP53. In cytosol can trigger apoptosis by activating MAPK11 or MAPK14, inhibiting AKT1 and decreasing the level of X-linked inhibitor of apoptosis protein (XIAP), whereas in nucleus induces apoptosis via the activation of MAPK8 or MAPK9. Upon ionizing radiation treatment, is required for the activation of the apoptosis regulators BAX and BAK, which trigger the mitochondrial cell death pathway. Can phosphorylate MCL1 and target it for degradation which is sufficient to trigger for BAX activation and apoptosis. Is required for the control of cell cycle progression both at G1/S and G2/M phases. Mediates phorbol 12-myristate 13-acetate (PMA)-induced inhibition of cell cycle progression at G1/S phase by up-regulating the CDK inhibitor CDKN1A/p21 and inhibiting the cyclin CCNA2 promoter activity. In response to UV irradiation can phosphorylate CDK1, which is important for the G2/M DNA damage checkpoint activation. Can protect glioma cells from the apoptosis induced by TNFSF10/TRAIL, probably by inducing increased phosphorylation and subsequent activation of AKT1. Is highly expressed in a number of cancer cells and promotes cell survival and resistance against chemotherapeutic drugs by inducing cyclin D1 (CCND1) and hyperphosphorylation of RB1, and via several pro-survival pathways, including NF-kappa-B, AKT1 and MAPK1/3 (ERK1/2). Can also act as tumor suppressor upon mitogenic stimulation with PMA or TPA. In N-formyl-methionyl-leucyl-phenylalanine (fMLP)-treated cells, is required for NCF1 (p47-phox) phosphorylation and activation of NADPH oxidase activity, and regulates TNF-elicited superoxide anion production in neutrophils, by direct phosphorylation and activation of NCF1 or indirectly through MAPK1/3 (ERK1/2) signaling pathways. May also play a role in the regulation of NADPH oxidase activity in eosinophil after stimulation with IL5, leukotriene B4 or PMA. In collagen-induced platelet aggregation, acts a negative regulator of filopodia formation and actin polymerization by interacting with and negatively regulating VASP phosphorylation. Downstream of PAR1, PAR4 and CD36/GP4 receptors, regulates differentially platelet dense granule secretion; acts as a positive regulator in PAR-mediated granule secretion, whereas it negatively regulates CD36/GP4-mediated granule release. Phosphorylates MUC1 in the C-terminal and regulates the interaction between MUC1 and beta-catenin. The catalytic subunit phosphorylates 14-3-3 proteins (YWHAB, YWHAZ and YWHAH) in a sphingosine-dependent fashion (By similarity).", "name": "Protein kinase C delta type", "drug_actions": [{"action": "LIGAND", "target": "Q05655", "drug": "DB05013"}], "general_function": "Protein serine/threonine kinase activity", "in_complexes": ["Protein kinase C"], "gene_names": ["PRKCD"]}, "P39265": {"specific_function": "Part of the binding-protein-dependent transport system AlsBAC for D-allose.", "general_function": "Monosaccharide transmembrane transporter activity", "gene_names": ["alsB"], "name": "D-allose-binding periplasmic protein", "drug_actions": []}, "Q70I53": {"specific_function": "Exhibits significant levels of protein deacetylase activity comparable to those of eukaryotic HDACs in assays both with fluorogenic peptidic substrates and acetate-radiolabeled histones. Accepts proteins with epsilon-acetylated lysine residues and tritiated-acetate-prelabeled chicken histones as substrates. The natural substrate protein is not yet known.", "general_function": "Hydrolase activity", "gene_names": ["hdaH"], "name": "Histone deacetylase-like amidohydrolase", "drug_actions": []}, "P45799": {"specific_function": "Active on adenosine(5')triphospho(5')adenosine (Ap3A), ADP-ribose, NADH, adenosine(5')diphospho(5')adenosine (Ap2A).", "general_function": "Magnesium ion binding", "gene_names": ["nudE"], "name": "ADP compounds hydrolase NudE", "drug_actions": []}, "Q9WMX2": {"specific_function": "Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).E1 and E2 glycoproteins form a heterodimer that is involved in virus attachment to the host cell, virion internalization through clathrin-dependent endocytosis and fusion with host membrane. E1/E2 heterodimer binds to human LDLR, CD81 and SCARB1/SR-BI receptors, but this binding is not sufficient for infection, some additional liver specific cofactors may be needed. The fusion function may possibly be carried by E1. E2 inhibits human EIF2AK2/PKR activation, preventing the establishment of an antiviral state. E2 is a viral ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on liver sinusoidal endothelial cells and macrophage-like cells of lymph node sinuses. These interactions allow capture of circulating HCV particles by these cells and subsequent transmission to permissive cells. DCs act as sentinels in various tissues where they entrap pathogens and convey them to local lymphoid tissue or lymph node for establishment of immunity. Capture of circulating HCV particles by these SIGN+ cells may facilitate virus infection of proximal hepatocytes and lymphocyte subpopulations and may be essential for the establishment of persistent infection (By similarity).P7 seems to be a heptameric ion channel protein (viroporin) and is inhibited by the antiviral drug amantadine. Also inhibited by long-alkyl-chain iminosugar derivatives. Essential for infectivity (By similarity).Protease NS2-3 is a cysteine protease responsible for the autocatalytic cleavage of NS2-NS3. Seems to undergo self-inactivation following maturation (By similarity).NS3 displays three enzymatic activities: serine protease, NTPase and RNA helicase. NS3 serine protease, in association with NS4A, is responsible for the cleavages of NS3-NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3 RNA helicase binds to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA stable secondary structure in the template strand. Cleaves the host antiviral protein MAVS (By similarity). NS3/NS4A complex also prevents phosphorylation of human IRF3, thus preventing the establishment of dsRNA induced antiviral state.NS4B induces a specific membrane alteration that serves as a scaffold for the virus replication complex. This membrane alteration gives rise to the so-called ER-derived membranous web that contains the replication complex (By similarity).NS5A is a component of the replication complex involved in RNA-binding. Its interaction with Human VAPB may target the viral replication complex to vesicles. Down-regulates viral IRES translation initiation. Mediates interferon resistance, presumably by interacting with and inhibiting human EIF2AK2/PKR. Seems to inhibit apoptosis by interacting with BIN1 and FKBP8. The hyperphosphorylated form of NS5A is an inhibitor of viral replication (By similarity).NS5B is an RNA-dependent RNA polymerase that plays an essential role in the virus replication.", "general_function": "Zinc ion binding", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "Q8N159": {"specific_function": "Plays a role in the regulation of ureagenesis by producing the essential cofactor N-acetylglutamate (NAG), thus modulating carbamoylphosphate synthase I (CPSI) activity.", "general_function": "Arginine binding", "gene_names": ["NAGS"], "name": "N-acetylglutamate synthase, mitochondrial", "drug_actions": []}, "P0CG04": {"general_function": "Immunoglobulin receptor binding", "gene_names": ["IGLC1"], "name": "Ig lambda-1 chain C regions", "drug_actions": []}, "P20831": {"specific_function": "DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.", "general_function": "Dna topoisomerase type ii (atp-hydrolyzing) activity", "gene_names": ["gyrA"], "name": "DNA gyrase subunit A", "drug_actions": []}, "P26137": {"specific_function": "Binds to sialic acid-containing receptors on the cell surface, bringing about the attachment of the virus particle to the cell. This attachment induces virion internalization of about two third of the virus particles through clathrin-dependent endocytosis and about one third through a clathrin- and caveolin-independent pathway. Plays a major role in the determination of host range restriction and virulence. Class I viral fusion protein. Responsible for penetration of the virus into the cell cytoplasm by mediating the fusion of the membrane of the endocytosed virus particle with the endosomal membrane. Low pH in endosomes induces an irreversible conformational change in HA2, releasing the fusion hydrophobic peptide. Several trimers are required to form a competent fusion pore.", "gene_names": ["HA"], "name": "Hemagglutinin", "drug_actions": []}, "Q9UDR5": {"specific_function": "Bifunctional enzyme that catalyzes the first two steps in lysine degradation. The N-terminal and the C-terminal contain lysine-ketoglutarate reductase and saccharopine dehydrogenase activity, respectively.", "general_function": "Saccharopine dehydrogenase (nadp+, l-lysine-forming) activity", "gene_names": ["AASS"], "name": "Alpha-aminoadipic semialdehyde synthase, mitochondrial", "drug_actions": []}, "P19235": {"specific_function": "Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.", "general_function": "Identical protein binding", "gene_names": ["EPOR"], "name": "Erythropoietin receptor", "drug_actions": [{"action": "AGONIST", "target": "P19235", "drug": "DB00012"}, {"action": "AGONIST", "target": "P19235", "drug": "DB00016"}, {"action": "STIMULATOR", "target": "P19235", "drug": "DB08894"}, {"action": "AGONIST", "target": "P19235", "drug": "DB08923"}]}, "P66034": {"specific_function": "Riboflavin synthase is a bifunctional enzyme complex catalyzing the formation of riboflavin from 5-amino-6-(1'-D)- ribityl-amino-2,4(1H,3H)-pyrimidinedione and L-3,4-dihydrohy-2- butanone-4-phosphate via 6,7-dimethyl-8-lumazine. The beta subunit catalyzes the condensation of 5-amino-6-(1'-D)-ribityl-amino- 2,4(1H,3H)-pyrimidinedione with L-3,4-dihydrohy-2-butanone-4- phosphate yielding 6,7-dimethyl-8-lumazine", "general_function": "Coenzyme transport and metabolism", "gene_names": ["ribH"], "name": "6,7-dimethyl-8-ribityllumazine synthase", "drug_actions": []}, "P20839": {"specific_function": "Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in the development of malignancy and the growth progression of some tumors.", "name": "Inosine-5'-monophosphate dehydrogenase 1", "drug_actions": [{"action": "INHIBITOR", "target": "P20839", "drug": "DB00688"}, {"action": "INHIBITOR", "target": "P20839", "drug": "DB00811"}, {"action": "INHIBITOR", "target": "P20839", "drug": "DB01024"}, {"action": "INHIBITOR", "target": "P20839", "drug": "DB01033"}], "general_function": "Rna binding", "in_complexes": ["Inosine-5'-monophosphate dehydrogenase"], "gene_names": ["IMPDH1"]}, "P42321": {"specific_function": "Decomposes hydrogen peroxide into water and oxygen; serves to protect cells from the toxic effects of hydrogen peroxide.", "general_function": "Metal ion binding", "gene_names": ["katA"], "name": "Catalase", "drug_actions": []}, "P40925": {"general_function": "Nad binding", "gene_names": ["MDH1"], "name": "Malate dehydrogenase, cytoplasmic", "drug_actions": []}, "P33402": {"specific_function": "Has guanylyl cyclase on binding to the beta-1 subunit.Isoform 2 acts as a negative regulator of guanylyl cyclase activity as it forms non-functional heterodimers with the beta subunits.", "general_function": "Heme binding", "gene_names": ["GUCY1A2"], "name": "Guanylate cyclase soluble subunit alpha-2", "drug_actions": [{"action": "INDUCER", "target": "P33402", "drug": "DB00435"}, {"action": "INDUCER", "target": "P33402", "drug": "DB01020"}]}, "P33151": {"specific_function": "Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. This cadherin may play a important role in endothelial cell biology through control of the cohesion and organization of the intercellular junctions. It associates with alpha-catenin forming a link to the cytoskeleton. Acts in concert with KRIT1 to establish and maintain correct endothelial cell polarity and vascular lumen. These effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for activation of PRKCZ and for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction.", "general_function": "Receptor binding", "gene_names": ["CDH5"], "name": "Cadherin-5", "drug_actions": [{"action": "ANTAGONIST", "target": "P33151", "drug": "DB00480"}]}, "P52026": {"specific_function": "In addition to polymerase activity, this DNA polymerase exhibits 5' to 3' exonuclease activity.", "general_function": "Dna-directed dna polymerase activity", "gene_names": ["polA"], "name": "DNA polymerase I", "drug_actions": []}, "Q9NY65": {"specific_function": "Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["TUBA8"], "name": "Tubulin alpha-8 chain", "drug_actions": []}, "Q48436": {"specific_function": "Catalyzes the reversible reduction of (S)-acetoin to 2,3-butanediol in the presence of NADH.", "general_function": "Diacetyl reductase ((s)-acetoin forming) activity", "gene_names": ["budC"], "name": "Diacetyl reductase [(S)-acetoin forming]", "drug_actions": []}, "Q820T1": {"specific_function": "Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP. Catalyzes the first condensation reaction which initiates fatty acid synthesis and may therefore play a role in governing the total rate of fatty acid production. Possesses both acetoacetyl-ACP synthase and acetyl transacylase activities. Its substrate specificity determines the biosynthesis of branched-chain and/or straight-chain of fatty acids.", "general_function": "Beta-ketoacyl-acyl-carrier-protein synthase iii activity", "gene_names": ["fabH"], "name": "3-oxoacyl-[acyl-carrier-protein] synthase 3", "drug_actions": []}, "P22256": {"specific_function": "Catalyzes the transfer of the amino group from gamma-aminobutyrate (GABA) to alpha-ketoglutarate (KG) to yield succinic semialdehyde (SSA).", "general_function": "Pyridoxal phosphate binding", "gene_names": ["gabT"], "name": "4-aminobutyrate aminotransferase GabT", "drug_actions": []}, "O14920": {"specific_function": "Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. In addition to the NF-kappa-B inhibitors, phosphorylates several other components of the signaling pathway including NEMO/IKBKG, NF-kappa-B subunits RELA and NFKB1, as well as IKK-related kinases TBK1 and IKBKE. IKK-related kinase phosphorylations may prevent the overproduction of inflammatory mediators since they exert a negative regulation on canonical IKKs. Phosphorylates FOXO3, mediating the TNF-dependent inactivation of this pro-apoptotic transcription factor. Also phosphorylates other substrates including NCOA3, BCL10 and IRS1. Within the nucleus, acts as an adapter protein for NFKBIA degradation in UV-induced NF-kappa-B activation.", "general_function": "Scaffold protein binding", "gene_names": ["IKBKB"], "name": "Inhibitor of nuclear factor kappa-B kinase subunit beta", "drug_actions": [{"action": "INHIBITOR", "target": "O14920", "drug": "DB00244"}, {"action": "INHIBITOR", "target": "O14920", "drug": "DB00795"}, {"action": "INHIBITOR", "target": "O14920", "drug": "DB00995"}, {"action": "INDUCER", "target": "O14920", "drug": "DB01169"}, {"action": "INHIBITOR", "target": "O14920", "drug": "DB06151"}]}, "P23763": {"specific_function": "Involved in the targeting and/or fusion of transport vesicles to their target membrane.", "general_function": "Snare binding", "gene_names": ["VAMP1"], "name": "Vesicle-associated membrane protein 1", "drug_actions": [{"action": "BINDER", "target": "P23763", "drug": "DB00042"}]}, "Q13362": {"specific_function": "The B regulatory subunit might modulate substrate selectivity and catalytic activity, and also might direct the localization of the catalytic enzyme to a particular subcellular compartment. The PP2A-PPP2R5C holoenzyme may specifically dephosphorylate and activate TP53 and play a role in DNA damage-induced inhibition of cell proliferation. PP2A-PPP2R5C may also regulate the ERK signaling pathway through ERK dephosphorylation.", "general_function": "Protein phosphatase type 2a regulator activity", "gene_names": ["PPP2R5C"], "name": "Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform", "drug_actions": []}, "Q13363": {"specific_function": "Corepressor targeting diverse transcription regulators such as GLIS2 or BCL6. Has dehydrogenase activity. Involved in controlling the equilibrium between tubular and stacked structures in the Golgi complex. Functions in brown adipose tissue (BAT) differentiation.", "general_function": "Transcription factor binding", "gene_names": ["CTBP1"], "name": "C-terminal-binding protein 1", "drug_actions": []}, "P12996": {"specific_function": "Catalyzes the conversion of dethiobiotin (DTB) to biotin by the insertion of a sulfur atom into dethiobiotin via a radical-based mechanism.", "general_function": "Iron ion binding", "gene_names": ["bioB"], "name": "Biotin synthase", "drug_actions": []}, "P12995": {"specific_function": "Catalyzes the transfer of the alpha-amino group from S-adenosyl-L-methionine (SAM) to 7-keto-8-aminopelargonic acid (KAPA) to form 7,8-diaminopelargonic acid (DAPA). It is the only animotransferase known to utilize SAM as an amino donor.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["bioA"], "name": "Adenosylmethionine-8-amino-7-oxononanoate aminotransferase", "drug_actions": []}, "Q9NYK1": {"specific_function": "Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR7 is a nucleotide-sensing TLR which is activated by single-stranded RNA. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (By similarity).", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["TLR7"], "name": "Toll-like receptor 7", "drug_actions": [{"action": "AGONIST", "target": "Q9NYK1", "drug": "DB00724"}, {"action": "ANTAGONIST", "target": "Q9NYK1", "drug": "DB01611"}]}, "Q9ULZ9": {"specific_function": "Endopeptidase that degrades various components of the extracellular matrix, such as fibrin. May be involved in the activation of membrane-bound precursors of growth factors or inflammatory mediators, such as tumor necrosis factor-alpha. May also be involved in tumoral process. Not obvious if able to proteolytically activate progelatinase A. Does not hydrolyze collagen types I, II, III, IV and V, gelatin, fibronectin, laminin, decorin nor alpha1-antitrypsin.", "general_function": "Zinc ion binding", "gene_names": ["MMP17"], "name": "Matrix metalloproteinase-17", "drug_actions": [{"action": "INHIBITOR", "target": "Q9ULZ9", "drug": "DB00786"}]}, "P00691": {"general_function": "Metal ion binding", "gene_names": ["amyE"], "name": "Alpha-amylase", "drug_actions": []}, "Q9BQE3": {"specific_function": "Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.", "general_function": "Structural molecule activity", "gene_names": ["TUBA1C"], "name": "Tubulin alpha-1C chain", "drug_actions": []}, "P11086": {"specific_function": "Converts noradrenaline to adrenaline.", "general_function": "Phenylethanolamine n-methyltransferase activity", "gene_names": ["PNMT"], "name": "Phenylethanolamine N-methyltransferase", "drug_actions": []}, "Q16478": {"specific_function": "Receptor for glutamate. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists. This receptor binds kainate > quisqualate > domoate > L-glutamate >> AMPA >> NMDA = 1S,3R-ACPD.", "general_function": "Kainate selective glutamate receptor activity", "gene_names": ["GRIK5"], "name": "Glutamate receptor ionotropic, kainate 5", "drug_actions": []}, "Q97E82": {"general_function": "Magnesium ion binding", "gene_names": ["comB"], "name": "Probable 2-phosphosulfolactate phosphatase", "drug_actions": []}, "P41091": {"specific_function": "eIF-2 functions in the early steps of protein synthesis by forming a ternary complex with GTP and initiator tRNA. This complex binds to a 40S ribosomal subunit, followed by mRNA binding to form a 43S preinitiation complex. Junction of the 60S ribosomal subunit to form the 80S initiation complex is preceded by hydrolysis of the GTP bound to eIF-2 and release of an eIF-2-GDP binary complex. In order for eIF-2 to recycle and catalyze another round of initiation, the GDP bound to eIF-2 must exchange with GTP by way of a reaction catalyzed by eIF-2B.", "general_function": "Translation initiation factor activity", "gene_names": ["EIF2S3"], "name": "Eukaryotic translation initiation factor 2 subunit 3", "drug_actions": []}, "P10845": {"specific_function": "Inhibits acetylcholine release. The botulinum toxin binds with high affinity to peripheral neuronal presynaptic membrane to the secretory vesicle protein SV2. It binds directly to the largest luminal loop of SV2A, SV2B and SV2C. It is then internalized by receptor-mediated endocytosis. The C-terminus of the heavy chain (H) is responsible for the adherence of the toxin to the cell surface while the N-terminus mediates transport of the light chain from the endocytic vesicle to the cytosol. After translocation, the light chain (L) hydrolyzes the 197-Gln-|-Arg-198 bond in SNAP-25, thereby blocking neurotransmitter release. Inhibition of acetylcholine release results in flaccid paralysis, with frequent heart or respiratory failure.", "general_function": "Zinc ion binding", "gene_names": ["botA"], "name": "Botulinum neurotoxin type A", "drug_actions": []}, "P05981": {"specific_function": "Plays an essential role in cell growth and maintenance of cell morphology. May mediate the activating cleavage of HGF and MST1/HGFL. Plays a role in the proteolytic processing of ACE2.", "general_function": "Serine-type peptidase activity", "gene_names": ["HPN"], "name": "Serine protease hepsin", "drug_actions": [{"action": "LIGAND", "target": "P05981", "drug": "DB00522"}]}, "Q46730": {"general_function": "Transposase activity", "gene_names": ["tnp"], "name": "Transposase", "drug_actions": []}, "P04036": {"specific_function": "Catalyzes the conversion of 4-hydroxy-tetrahydrodipicolinate (HTPA) to tetrahydrodipicolinate. Can use both NADH and NADPH as a reductant, with NADH being twice as effective as NADPH.", "general_function": "Oxidoreductase activity, acting on ch or ch2 groups, nad or nadp as acceptor", "gene_names": ["dapB"], "name": "4-hydroxy-tetrahydrodipicolinate reductase", "drug_actions": []}, "P37093": {"specific_function": "Involved in a type II secretion system (T2SS, formerly general secretion pathway, GSP) for the export of proteins. Required for secretion of cholera toxin through the outer membrane.", "general_function": "Protein transporter activity", "gene_names": ["epsE"], "name": "Type II secretion system protein E", "drug_actions": []}, "P11712": {"specific_function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan.", "general_function": "Steroid hydroxylase activity", "gene_names": ["CYP2C9"], "name": "Cytochrome P450 2C9", "drug_actions": []}, "Q9Y2J8": {"specific_function": "Catalyzes the deimination of arginine residues of proteins.", "general_function": "Protein-arginine deiminase activity", "gene_names": ["PADI2"], "name": "Protein-arginine deiminase type-2", "drug_actions": []}, "Q9I7A8": {"specific_function": "Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions.", "general_function": "Peptide deformylase activity", "gene_names": ["def"], "name": "Peptide deformylase", "drug_actions": []}, "P11717": {"specific_function": "Transport of phosphorylated lysosomal enzymes from the Golgi complex and the cell surface to lysosomes. Lysosomal enzymes bearing phosphomannosyl residues bind specifically to mannose-6-phosphate receptors in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelyosomal compartment where the low pH mediates the dissociation of the complex. This receptor also binds IGF2. Acts as a positive regulator of T-cell coactivation, by binding DPP4.", "general_function": "Transporter activity", "gene_names": ["IGF2R"], "name": "Cation-independent mannose-6-phosphate receptor", "drug_actions": []}, "Q9UJT1": {"specific_function": "In the elongating spermatid it is associated with the manchette, a specialized microtubule system present during reshaping of the sperm head.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["TUBD1"], "name": "Tubulin delta chain", "drug_actions": [{"action": "ADDUCT", "target": "Q9UJT1", "drug": "DB00570"}]}, "Q9UJT0": {"general_function": "Structural constituent of cytoskeleton", "gene_names": ["TUBE1"], "name": "Tubulin epsilon chain", "drug_actions": [{"action": "ADDUCT", "target": "Q9UJT0", "drug": "DB00570"}]}, "P40859": {"specific_function": "Catalyzes the oxidative demethylation of sarcosine. Can also oxidize other secondary amino acids such as N-methyl-L-alanine.", "general_function": "Sarcosine oxidase activity", "gene_names": ["soxA"], "name": "Monomeric sarcosine oxidase", "drug_actions": []}, "Q9ZGH3": {"general_function": "Oxidoreductase activity", "gene_names": ["desIV"], "name": "dTDP-glucose 4,6-dehydratase", "drug_actions": []}, "Q57265": {"general_function": "Metal ion binding", "gene_names": ["synC"], "name": "Capsule biosynthesis protein", "drug_actions": []}, "P69167": {"specific_function": "Androstan-3-alpha,17-beta-diol + NAD(+) = 17- beta-hydroxyandrostan-3-one + NADH", "general_function": "Lipid transport and metabolism", "gene_names": ["fabG3"], "name": "3-alpha-(or 20-beta)-hydroxysteroid dehydrogenase", "drug_actions": []}, "Q9WYH8": {"specific_function": "Catalyzes the condensation of phosphoenolpyruvate (PEP) and D-erythrose-4-phosphate (E4P) giving rise to 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP).", "general_function": "Aldehyde-lyase activity", "gene_names": ["aroF"], "name": "Phospho-2-dehydro-3-deoxyheptonate aldolase", "drug_actions": []}, "P23560": {"specific_function": "During development, promotes the survival and differentiation of selected neuronal populations of the peripheral and central nervous systems. Participates in axonal growth, pathfinding and in the modulation of dendritic growth and morphology. Major regulator of synaptic transmission and plasticity at adult synapses in many regions of the CNS. The versatility of BDNF is emphasized by its contribution to a range of adaptive neuronal responses including long-term potentiation (LTP), long-term depression (LTD), certain forms of short-term synaptic plasticity, as well as homeostatic regulation of intrinsic neuronal excitability.", "general_function": "Neurotrophin trkb receptor binding", "gene_names": ["BDNF"], "name": "Brain-derived neurotrophic factor", "drug_actions": []}, "Q9KFR4": {"general_function": "Starch binding", "gene_names": [], "name": "Alpha-amylase G-6", "drug_actions": []}, "Q8N1Q1": {"specific_function": "Reversible hydration of carbon dioxide.", "general_function": "Zinc ion binding", "gene_names": ["CA13"], "name": "Carbonic anhydrase 13", "drug_actions": [{"action": "INHIBITOR", "target": "Q8N1Q1", "drug": "DB00909"}]}, "P03176": {"specific_function": "In latent infection, may allow the virus to be reactivated and to grow in cells lacking a high concentration of phosphorylated nucleic acid precursors, such as nerve cells that do not replicate their genome.", "general_function": "Thymidine kinase activity", "gene_names": ["TK"], "name": "Thymidine kinase", "drug_actions": [{"action": "POTENTIATOR", "target": "P03176", "drug": "DB00787"}, {"action": "INDUCER", "target": "P03176", "drug": "DB01004"}]}, "Q16651": {"specific_function": "Possesses a trypsin-like cleavage specificity with a preference for poly-basic substrates. Stimulates epithelial sodium channel (ENaC) activity through activating cleavage of the gamma subunits (SCNN1G).", "general_function": "Serine-type peptidase activity", "gene_names": ["PRSS8"], "name": "Prostasin", "drug_actions": []}, "P62658": {"specific_function": "One of the primary rRNA binding proteins, it binds specifically to the 5'-end of 16S ribosomal RNA.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsQ"], "name": "30S ribosomal protein S17", "drug_actions": []}, "C3T8E2": {"specific_function": "Multidrug efflux pump that functions probably as a Na(+)/drug antiporter.", "general_function": "Drug transmembrane transporter activity", "gene_names": ["mdtK"], "name": "Multidrug resistance protein MdtK", "drug_actions": []}, "Q16654": {"specific_function": "Kinase that plays a key role in regulation of glucose and fatty acid metabolism and homeostasis via phosphorylation of the pyruvate dehydrogenase subunits PDHA1 and PDHA2. This inhibits pyruvate dehydrogenase activity, and thereby regulates metabolite flux through the tricarboxylic acid cycle, down-regulates aerobic respiration and inhibits the formation of acetyl-coenzyme A from pyruvate. Inhibition of pyruvate dehydrogenase decreases glucose utilization and increases fat metabolism in response to prolonged fasting and starvation. Plays an important role in maintaining normal blood glucose levels under starvation, and is involved in the insulin signaling cascade. Via its regulation of pyruvate dehydrogenase activity, plays an important role in maintaining normal blood pH and in preventing the accumulation of ketone bodies under starvation. In the fed state, mediates cellular responses to glucose levels and to a high-fat diet. Regulates both fatty acid oxidation and de novo fatty acid biosynthesis. Plays a role in the generation of reactive oxygen species. Protects detached epithelial cells against anoikis. Plays a role in cell proliferation via its role in regulating carbohydrate and fatty acid metabolism.", "general_function": "Pyruvate dehydrogenase (acetyl-transferring) kinase activity", "gene_names": ["PDK4"], "name": "[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial", "drug_actions": []}, "P38940": {"specific_function": "Hydrolyzes pullulan efficiently but only a small amount of starch. Endohydrolysis of 1,4-alpha-glucosidic linkages in pullulan to form panose. Cleaves also (1-6)-alpha-glucosidic linkages to form maltotriose.", "general_function": "Neopullulanase activity", "gene_names": ["nplT"], "name": "Neopullulanase", "drug_actions": []}, "P22352": {"specific_function": "Protects cells and enzymes from oxidative damage, by catalyzing the reduction of hydrogen peroxide, lipid peroxides and organic hydroperoxide, by glutathione.", "general_function": "Transcription factor binding", "gene_names": ["GPX3"], "name": "Glutathione peroxidase 3", "drug_actions": [{"action": "COFACTOR", "target": "P22352", "drug": "DB00143"}]}, "P69856": {"specific_function": "Outer membrane channel protein allowing the entry of N-acetylneuraminic acid (Neu5Ac, the most abundant sialic acid on host cell surfaces) into the bacteria (Probable). NanC proteins form high-conductance channels which are open at low membrane potentials and which have a weak anion selectivity.", "general_function": "Sialic acid transmembrane transporter activity", "gene_names": ["nanC"], "name": "Probable N-acetylneuraminic acid outer membrane channel protein NanC", "drug_actions": []}, "Q14541": {"specific_function": "Transcription factor. Has a lower transcription activation potential than HNF4-alpha.", "general_function": "Zinc ion binding", "gene_names": ["HNF4G"], "name": "Hepatocyte nuclear factor 4-gamma", "drug_actions": []}, "P03371": {"specific_function": "During replicative cycle of retroviruses, the reverse-transcribed viral DNA is integrated into the host chromosome by the viral integrase enzyme. RNase H activity is associated with the reverse transcriptase.", "general_function": "Zinc ion binding", "gene_names": ["pol"], "name": "Pol polyprotein", "drug_actions": []}, "P48058": {"specific_function": "Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate.", "general_function": "Ionotropic glutamate receptor activity", "gene_names": ["GRIA4"], "name": "Glutamate receptor 4", "drug_actions": []}, "P03372": {"specific_function": "Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform 1.", "general_function": "Zinc ion binding", "gene_names": ["ESR1"], "name": "Estrogen receptor", "drug_actions": [{"action": "AGONIST", "target": "P03372", "drug": "DB00255"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00269"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00286"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00294"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00304"}, {"action": "OTHER", "target": "P03372", "drug": "DB00367"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00396"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00481"}, {"action": "MODULATOR", "target": "P03372", "drug": "DB00539"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00603"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00655"}, {"action": "ANTAGONIST", "target": "P03372", "drug": "DB00675"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00675"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00783"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00823"}, {"action": "ANTAGONIST", "target": "P03372", "drug": "DB00882"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00882"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00890"}, {"action": "ANTAGONIST", "target": "P03372", "drug": "DB00947"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00957"}, {"action": "AGONIST", "target": "P03372", "drug": "DB00977"}, {"action": "ANTAGONIST", "target": "P03372", "drug": "DB01065"}, {"action": "ALLOSTERIC MODULATOR", "target": "P03372", "drug": "DB01108"}, {"action": "ANTAGONIST", "target": "P03372", "drug": "DB01183"}, {"action": "OTHER/UNKNOWN", "target": "P03372", "drug": "DB01183"}, {"action": "ANTAGONIST", "target": "P03372", "drug": "DB01185"}, {"action": "AGONIST", "target": "P03372", "drug": "DB01196"}, {"action": "AGONIST", "target": "P03372", "drug": "DB01357"}, {"action": "AGONIST", "target": "P03372", "drug": "DB01406"}, {"action": "AGONIST", "target": "P03372", "drug": "DB01431"}, {"action": "BINDER", "target": "P03372", "drug": "DB01708"}, {"action": "AGONIST", "target": "P03372", "drug": "DB04573"}, {"action": "AGONIST", "target": "P03372", "drug": "DB04574"}, {"action": "AGONIST", "target": "P03372", "drug": "DB04575"}, {"action": "MODULATOR", "target": "P03372", "drug": "DB04575"}, {"action": "ANTAGONIST", "target": "P03372", "drug": "DB04938"}, {"action": "AGONIST", "target": "P03372", "drug": "DB04938"}, {"action": "ANTAGONIST", "target": "P03372", "drug": "DB06401"}, {"action": "AGONIST", "target": "P03372", "drug": "DB06401"}]}, "Q9X6R4": {"general_function": "Serine-type exopeptidase activity", "gene_names": [], "name": "Prolyl endopeptidase", "drug_actions": []}, "Q8AAK6": {"general_function": "Hydrolase activity, hydrolyzing o-glycosyl compounds", "gene_names": [], "name": "Beta-mannosidase", "drug_actions": []}, "P12758": {"specific_function": "Catalyzes the reversible phosphorylytic cleavage of uridine and deoxyuridine to uracil and ribose- or deoxyribose-1-phosphate. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis.", "general_function": "Uridine phosphorylase activity", "gene_names": ["udp"], "name": "Uridine phosphorylase", "drug_actions": []}, "P11409": {"specific_function": "This methylase recognizes the double-stranded sequence CAGCTG, causes specific methylation on C-4 on both strands, and protects the DNA from cleavage by the PvuII endonuclease.", "general_function": "Site-specific dna-methyltransferase (cytosine-n4-specific) activity", "gene_names": ["pvuIIM"], "name": "Modification methylase PvuII", "drug_actions": []}, "Q9NS85": {"specific_function": "Does not have a catalytic activity.", "gene_names": ["CA10"], "name": "Carbonic anhydrase-related protein 10", "drug_actions": [{"action": "INHIBITOR", "target": "Q9NS85", "drug": "DB00909"}]}, "P0A6M2": {"specific_function": "Required for disulfide bond formation in some periplasmic proteins such as PhoA or OmpA. Acts by oxidizing the DsbA protein. PhoP-regulated transcription is redox-sensitive, being activated when the periplasm becomes more reducing (deletion of dsbA/dsbB, treatment with dithiothreitol). MgrB acts between DsbA/DsbB and PhoP/PhoQ in this pathway.", "general_function": "Protein disulfide oxidoreductase activity", "gene_names": ["dsbB"], "name": "Disulfide bond formation protein B", "drug_actions": []}, "P35030": {"specific_function": "Digestive protease specialized for the degradation of trypsin inhibitors. In the ileum, may be involved in defensin processing, including DEFA5.", "general_function": "Serine-type peptidase activity", "gene_names": ["PRSS3"], "name": "Trypsin-3", "drug_actions": []}, "P00722": {"general_function": "Magnesium ion binding", "gene_names": ["lacZ"], "name": "Beta-galactosidase", "drug_actions": []}, "P22891": {"specific_function": "Appears to assist hemostasis by binding thrombin and promoting its association with phospholipid vesicles. Inhibits activity of the coagulation protease factor Xa in the presence of SERPINA10, calcium and phospholipids.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["PROZ"], "name": "Vitamin K-dependent protein Z", "drug_actions": [{"action": "ACTIVATOR", "target": "P22891", "drug": "DB00170"}]}, "P10844": {"specific_function": "Botulinum toxin acts by inhibiting neurotransmitter release. It binds to peripheral neuronal synapses, is internalized and moves by retrograde transport up the axon into the spinal cord where it can move between postsynaptic and presynaptic neurons. It inhibits neurotransmitter release by acting as a zinc endopeptidase that cleaves the '76-Gln-|-Phe-77' bond of synaptobrevin-2.", "general_function": "Zinc ion binding", "gene_names": ["botB"], "name": "Botulinum neurotoxin type B", "drug_actions": []}, "P22894": {"specific_function": "Can degrade fibrillar type I, II, and III collagens.", "general_function": "Zinc ion binding", "gene_names": ["MMP8"], "name": "Neutrophil collagenase", "drug_actions": [{"action": "INHIBITOR", "target": "P22894", "drug": "DB00786"}]}, "Q65HB5": {"general_function": "Involved in penicillin binding", "gene_names": ["pbpA"], "name": "Penicillin-binding protein 2A", "drug_actions": [{"action": "ANTAGONIST", "target": "Q65HB5", "drug": "DB00689"}]}, "Q9KU37": {"specific_function": "Plays a role in peptidoglycan recycling by cleaving the terminal beta-1,4-linked N-acetylglucosamine (GlcNAc) from peptide-linked peptidoglycan fragments, giving rise to free GlcNAc, anhydro-N-acetylmuramic acid and anhydro-N-acetylmuramic acid-linked peptides. Plays a role in beta-lactam antibiotic resistance via its role in generating anhydro-N-acetylmuramic acid-linked peptides; these peptides function as signaling molecules that induce high-level expression of the beta-lactamase AmpC.", "general_function": "Beta-n-acetylhexosaminidase activity", "gene_names": ["nagZ"], "name": "Beta-hexosaminidase", "drug_actions": []}, "P80188": {"specific_function": "Iron-trafficking protein involved in multiple processes such as apoptosis, innate immunity and renal development. Binds iron through association with 2,5-dihydroxybenzoic acid (2,5-DHBA), a siderophore that shares structural similarities with bacterial enterobactin, and delivers or removes iron from the cell, depending on the context. Iron-bound form (holo-24p3) is internalized following binding to the SLC22A17 (24p3R) receptor, leading to release of iron and subsequent increase of intracellular iron concentration. In contrast, association of the iron-free form (apo-24p3) with the SLC22A17 (24p3R) receptor is followed by association with an intracellular siderophore, iron chelation and iron transfer to the extracellular medium, thereby reducing intracellular iron concentration. Involved in apoptosis due to interleukin-3 (IL3) deprivation: iron-loaded form increases intracellular iron concentration without promoting apoptosis, while iron-free form decreases intracellular iron levels, inducing expression of the proapoptotic protein BCL2L11/BIM, resulting in apoptosis. Involved in innate immunity, possibly by sequestrating iron, leading to limit bacterial growth.", "general_function": "Transporter activity", "gene_names": ["LCN2"], "name": "Neutrophil gelatinase-associated lipocalin", "drug_actions": []}, "P49888": {"specific_function": "Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of estradiol and estrone. May play a role in the regulation of estrogen receptor activity by metabolizing free estradiol. Maximally sulfates beta-estradiol and estrone at concentrations of 20 nM. Also sulfates dehydroepiandrosterone, pregnenolone, ethinylestradiol, equalenin, diethylstilbesterol and 1-naphthol, at significantly higher concentrations; however, cortisol, testosterone and dopamine are not sulfated.", "general_function": "Sulfotransferase activity", "gene_names": ["SULT1E1"], "name": "Estrogen sulfotransferase", "drug_actions": [{"action": "INHIBITOR", "target": "P49888", "drug": "DB01176"}]}, "O60942": {"specific_function": "Bifunctional mRNA-capping enzyme exhibiting RNA 5'-triphosphatase activity in the N-terminal part and mRNA guanylyltransferase activity in the C-terminal part. Catalyzes the first two steps of cap formation: by removing the gamma-phosphate from the 5'-triphosphate end of nascent mRNA to yield a diphosphate end, and by transferring the gmp moiety of GTP to the 5'-diphosphate terminus.", "general_function": "Triphosphatase activity", "gene_names": ["RNGTT"], "name": "mRNA-capping enzyme", "drug_actions": []}, "Q14831": {"specific_function": "G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.", "general_function": "Voltage-gated calcium channel activity", "gene_names": ["GRM7"], "name": "Metabotropic glutamate receptor 7", "drug_actions": []}, "Q96NX5": {"specific_function": "Calcium/calmodulin-dependent protein kinase belonging to a proposed calcium-triggered signaling cascade. In vitro phosphorylates transcription factor CREB1 (By similarity).", "general_function": "Calmodulin-dependent protein kinase activity", "gene_names": ["CAMK1G"], "name": "Calcium/calmodulin-dependent protein kinase type 1G", "drug_actions": []}, "Q14833": {"specific_function": "G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling inhibits adenylate cyclase activity.", "general_function": "Group iii metabotropic glutamate receptor activity", "gene_names": ["GRM4"], "name": "Metabotropic glutamate receptor 4", "drug_actions": []}, "Q14832": {"specific_function": "G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling inhibits adenylate cyclase activity.", "general_function": "Group ii metabotropic glutamate receptor activity", "gene_names": ["GRM3"], "name": "Metabotropic glutamate receptor 3", "drug_actions": []}, "P23945": {"specific_function": "Receptor for follicle-stimulating hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Induces cAMP production through the activation of PI3K-AKT and SRC-ERK1/2 signaling pathways.", "general_function": "G-protein coupled peptide receptor activity", "gene_names": ["FSHR"], "name": "Follicle-stimulating hormone receptor", "drug_actions": [{"action": "BINDER", "target": "P23945", "drug": "DB00032"}, {"action": "AGONIST", "target": "P23945", "drug": "DB00066"}, {"action": "AGONIST", "target": "P23945", "drug": "DB00094"}, {"action": "BINDER", "target": "P23945", "drug": "DB00097"}, {"action": "ANTAGONIST", "target": "P23945", "drug": "DB04786"}]}, "P23946": {"specific_function": "Major secreted protease of mast cells with suspected roles in vasoactive peptide generation, extracellular matrix degradation, and regulation of gland secretion.", "general_function": "Serine-type peptidase activity", "gene_names": ["CMA1"], "name": "Chymase", "drug_actions": []}, "O14746": {"specific_function": "Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Catalyzes the RNA-dependent extension of 3'-chromosomal termini with the 6-nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The catalytic cycle involves primer binding, primer extension and release of product once the template boundary has been reached or nascent product translocation followed by further extension. More active on substrates containing 2 or 3 telomeric repeats. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. Modulates Wnt signaling. Plays important roles in aging and antiapoptosis.", "general_function": "Trna binding", "gene_names": ["TERT"], "name": "Telomerase reverse transcriptase", "drug_actions": [{"action": "INHIBITOR", "target": "O14746", "drug": "DB00495"}]}, "O66145": {"specific_function": "Involved in the methylaspartate cycle. Catalyzes the formation of the alpha,beta-unsaturated bond by the reversible anti elimination of ammonia from L-threo-beta-methylaspartate (L-threo-(2S,3S)-3-methylaspartate) to give mesaconate (By similarity).", "general_function": "Methylaspartate ammonia-lyase activity", "gene_names": [], "name": "Methylaspartate ammonia-lyase", "drug_actions": []}, "P39023": {"specific_function": "The L3 protein is a component of the large subunit of cytoplasmic ribosomes.", "general_function": "Structural constituent of ribosome", "gene_names": ["RPL3"], "name": "60S ribosomal protein L3", "drug_actions": [{"action": "ANTAGONIST", "target": "P39023", "drug": "DB04865"}]}, "P13376": {"general_function": "Glucose-6-phosphate isomerase activity", "gene_names": ["pgiB"], "name": "Glucose-6-phosphate isomerase B", "drug_actions": []}, "P16442": {"specific_function": "This protein is the basis of the ABO blood group system. The histo-blood group ABO involves three carbohydrate antigens: A, B, and H. A, B, and AB individuals express a glycosyltransferase activity that converts the H antigen to the A antigen (by addition of UDP-GalNAc) or to the B antigen (by addition of UDP-Gal), whereas O individuals lack such activity.", "general_function": "Metal ion binding", "gene_names": ["ABO"], "name": "Histo-blood group ABO system transferase", "drug_actions": []}, "P16444": {"specific_function": "Hydrolyzes a wide range of dipeptides. Implicated in the renal metabolism of glutathione and its conjugates. Converts leukotriene D4 to leukotriene E4; it may play an important role in the regulation of leukotriene activity.", "general_function": "Zinc ion binding", "gene_names": ["DPEP1"], "name": "Dipeptidase 1", "drug_actions": [{"action": "INHIBITOR", "target": "P16444", "drug": "DB01597"}]}, "Q9NZK7": {"specific_function": "PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Has a preference for arachidonic-containing phospholipids.", "general_function": "Phospholipase a2 activity", "gene_names": ["PLA2G2E"], "name": "Group IIE secretory phospholipase A2", "drug_actions": [{"action": "UNKNOWN", "target": "Q9NZK7", "drug": "DB00233"}]}, "P07071": {"general_function": "Ribonucleoside-triphosphate reductase activity", "gene_names": ["NRDD"], "name": "Anaerobic ribonucleoside-triphosphate reductase", "drug_actions": []}, "P23786": {"general_function": "Carnitine o-palmitoyltransferase activity", "gene_names": ["CPT2"], "name": "Carnitine O-palmitoyltransferase 2, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "P23786", "drug": "DB01074"}]}, "P50406": {"specific_function": "This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through the regulation of CDK5 activity (By similarity). Is an activator of TOR signaling (PubMed:23027611).", "name": "5-hydroxytryptamine receptor 6", "drug_actions": [{"action": "ANTAGONIST", "target": "P50406", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB00363"}, {"action": "BINDER", "target": "P50406", "drug": "DB00408"}, {"action": "BINDER", "target": "P50406", "drug": "DB00458"}, {"action": "BINDER", "target": "P50406", "drug": "DB00477"}, {"action": "BINDER", "target": "P50406", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB01049"}, {"action": "BINDER", "target": "P50406", "drug": "DB01142"}, {"action": "OTHER/UNKNOWN", "target": "P50406", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB04946"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB06144"}, {"action": "BINDER", "target": "P50406", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P50406", "drug": "DB06216"}], "general_function": "Serotonin receptor activity", "in_complexes": ["Serotonin Receptors"], "gene_names": ["HTR6"]}, "P37700": {"specific_function": "The biological conversion of cellulose to glucose generally requires three types of hydrolytic enzymes: (1) Endoglucanases which cut internal beta-1,4-glucosidic bonds; (2) Exocellobiohydrolases that cut the dissaccharide cellobiose from the non-reducing end of the cellulose polymer chain; (3) Beta-1,4-glucosidases which hydrolyze the cellobiose and other short cello-oligosaccharides to glucose.", "general_function": "Cellulose binding", "gene_names": ["celCCG"], "name": "Endoglucanase G", "drug_actions": []}, "Q16099": {"specific_function": "Receptor for glutamate. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists.", "general_function": "Kainate selective glutamate receptor activity", "gene_names": ["GRIK4"], "name": "Glutamate receptor ionotropic, kainate 4", "drug_actions": []}, "P19883": {"specific_function": "Binds directly to activin and functions as an activin antagonist. Specific inhibitor of the biosynthesis and secretion of pituitary follicle stimulating hormone (FSH).", "general_function": "Signal transducer activity", "gene_names": ["FST"], "name": "Follistatin", "drug_actions": []}, "P69923": {"specific_function": "Converts the aldose L-fucose into the corresponding ketose L-fuculose.", "general_function": "Manganese ion binding", "gene_names": ["fucI"], "name": "L-fucose isomerase", "drug_actions": []}, "P69924": {"specific_function": "Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. R2 contains the tyrosyl radical required for catalysis.", "general_function": "Ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor", "gene_names": ["nrdB"], "name": "Ribonucleoside-diphosphate reductase 1 subunit beta", "drug_actions": []}, "P31133": {"specific_function": "Required for the activity of the bacterial periplasmic transport system of putrescine. Polyamine binding protein.", "general_function": "Putrescine-importing atpase activity", "gene_names": ["potF"], "name": "Putrescine-binding periplasmic protein", "drug_actions": []}, "P56122": {"specific_function": "Catalyzes the anti-1,4-elimination of the C-3 phosphate and the C-6 proR hydrogen from 5-enolpyruvylshikimate-3-phosphate (EPSP) to yield chorismate, which is the branch point compound that serves as the starting substrate for the three terminal pathways of aromatic amino acid biosynthesis. This reaction introduces a second double bond into the aromatic ring system.", "general_function": "Fmn binding", "gene_names": ["aroC"], "name": "Chorismate synthase", "drug_actions": []}, "O60493": {"specific_function": "Phosphoinositide-binding protein required for multivesicular body formation. Specifically binds phosphatidylinositol 3-phosphate (PtdIns(P3)). Also can bind phosphatidylinositol 4-phosphate (PtdIns(P4)), phosphatidylinositol 5-phosphate (PtdIns(P5)) and phosphatidylinositol 3,5-biphosphate (PtdIns(3,5)P2) (By similarity). Plays a role in protein transport between cellular compartments. Together with RAB7A facilitates endosome membrane association of the retromer cargo-selective subcomplex (CSC/VPS). May in part act as component of the SNX3-retromer complex which mediates the retrograde endosome-to-TGN transport of WLS distinct from the SNX-BAR retromer pathway (PubMed:21725319, PubMed:24344282). Promotes stability and cell surface expression of epithelial sodium channel (ENAC) subunits SCNN1A and SCNN1G (By similarity). Not involved in EGFR degradation. Involved in the regulation of phagocytosis in dendritic cells possibly by regulating EEA1 recruitment to the nascent phagosomes (PubMed:23237080). Involved in iron homeostasis through regulation of endocytic recycling of the transferrin receptor TFRC presumably by delivering the tranferrin:transferrin receptor complex to recycling endosomes; the function may involve the CSC retromer subcomplex (By similarity). In the case of Salmonella enterica infection plays arole in maturation of the Salmonella-containing vacuole (SCV) and promotes recruitment of LAMP1 to SCVs (PubMed:20482551).", "general_function": "Protein phosphatase binding", "gene_names": ["SNX3"], "name": "Sorting nexin-3", "drug_actions": []}, "Q9UBN7": {"specific_function": "Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes (By similarity). Plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer.In addition to its protein deacetylase activity, plays a key role in the degradation of misfolded proteins: when misfolded proteins are too abundant to be degraded by the chaperone refolding system and the ubiquitin-proteasome, mediates the transport of misfolded proteins to a cytoplasmic juxtanuclear structure called aggresome. Probably acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy.", "general_function": "Zinc ion binding", "gene_names": ["HDAC6"], "name": "Histone deacetylase 6", "drug_actions": [{"action": "INHIBITOR", "target": "Q9UBN7", "drug": "DB02546"}, {"action": "INHIBITOR", "target": "Q9UBN7", "drug": "DB06603"}]}, "O06934": {"general_function": "Involved in oxidoreductase activity", "gene_names": ["glf"], "name": "UDP-galactopyranose mutase", "drug_actions": []}, "O60494": {"specific_function": "Cotransporter which plays a role in lipoprotein, vitamin and iron metabolism, by facilitating their uptake. Binds to ALB, MB, Kappa and lambda-light chains, TF, hemoglobin, GC, SCGB1A1, APOA1, high density lipoprotein, and the GIF-cobalamin complex. The binding of all ligands requires calcium. Serves as important transporter in several absorptive epithelia, including intestine, renal proximal tubules and embryonic yolk sac. Interaction with LRP2 mediates its trafficking throughout vesicles and facilitates the uptake of specific ligands like GC, hemoglobin, ALB, TF and SCGB1A1. Interaction with AMN controls its trafficking to the plasma membrane and facilitates endocytosis of ligands. May play an important role in the development of the peri-implantation embryo through internalization of APOA1 and cholesterol. Binds to LGALS3 at the maternal-fetal interface.", "general_function": "Transporter activity", "gene_names": ["CUBN"], "name": "Cubilin", "drug_actions": [{"action": "OTHER", "target": "O60494", "drug": "DB00200"}]}, "Q26000": {"general_function": "Gtp binding", "gene_names": ["rab6"], "name": "GTPase (Rab6)", "drug_actions": []}, "Q79FX6": {"specific_function": "Catalyzes the conversion of a double bond to a cis cyclopropane ring at the distal position of an alpha mycolic acid via the transfer of a methylene group from S-adenosyl-L-methionine. MmaA2 also catalyzes the biosynthesis of the cis-cyclopropanated methoxymycolates. Cyclopropanated mycolic acids are key factors participating in cell envelope permeability, host immunomodulation and persistence.", "general_function": "Methyltransferase activity", "gene_names": ["mmaA2"], "name": "Cyclopropane mycolic acid synthase MmaA2", "drug_actions": []}, "P31151": {"general_function": "Zinc ion binding", "gene_names": ["S100A7"], "name": "Protein S100-A7", "drug_actions": []}, "P31153": {"specific_function": "Catalyzes the formation of S-adenosylmethionine from methionine and ATP.", "general_function": "Methionine adenosyltransferase activity", "gene_names": ["MAT2A"], "name": "S-adenosylmethionine synthase isoform type-2", "drug_actions": [{"action": "COFACTOR", "target": "P31153", "drug": "DB00118"}]}, "P48443": {"specific_function": "Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXRs is 9-cis retinoic acid (By similarity).", "general_function": "Zinc ion binding", "gene_names": ["RXRG"], "name": "Retinoic acid receptor RXR-gamma", "drug_actions": [{"action": "AGONIST", "target": "P48443", "drug": "DB00210"}, {"action": "AGONIST", "target": "P48443", "drug": "DB00307"}, {"action": "AGONIST", "target": "P48443", "drug": "DB00459"}, {"action": "AGONIST", "target": "P48443", "drug": "DB00523"}, {"action": "AGONIST", "target": "P48443", "drug": "DB00755"}, {"action": "AGONIST", "target": "P48443", "drug": "DB00926"}]}, "P74645": {"specific_function": "Component of the KaiABC clock protein complex, which constitutes the main circadian regulator in cyanobacteria. The KaiABC complex may act as a promoter-non-specific transcription regulator that represses transcription, possibly by acting on the state of chromosome compaction. In the complex, it decreases the phosphorylation status of KaiC. It has no effect on KaiC by itself, but instead needs the presence of both KaiA and KaiC, suggesting that it acts by antagonizing the interaction between KaiA and KaiC.", "general_function": "Identical protein binding", "gene_names": ["kaiB"], "name": "Circadian clock protein KaiB", "drug_actions": []}, "P06612": {"specific_function": "Releases the supercoiling and torsional tension of DNA, which is introduced during the DNA replication and transcription, by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(5'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 3'-OH DNA strand. The free DNA strand then undergoes passage around the unbroken strand, thus removing DNA supercoils. Finally, in the religation step, the DNA 3'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone.", "general_function": "Magnesium ion binding", "gene_names": ["topA"], "name": "DNA topoisomerase 1", "drug_actions": []}, "P30711": {"specific_function": "Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Acts on 1,2-epoxy-3-(4-nitrophenoxy)propane, phenethylisothiocyanate 4-nitrobenzyl chloride and 4-nitrophenethyl bromide. Displays glutathione peroxidase activity with cumene hydroperoxide.", "general_function": "Glutathione transferase activity", "gene_names": ["GSTT1"], "name": "Glutathione S-transferase theta-1", "drug_actions": []}, "P48448": {"general_function": "Aldehyde dehydrogenase [nad(p)+] activity", "gene_names": ["ALDH3B2"], "name": "Aldehyde dehydrogenase family 3 member B2", "drug_actions": []}, "P48449": {"specific_function": "Catalyzes the cyclization of (S)-2,3 oxidosqualene to lanosterol, a reaction that forms the sterol nucleus.", "general_function": "Lanosterol synthase activity", "gene_names": ["LSS"], "name": "Lanosterol synthase", "drug_actions": []}, "Q03721": {"specific_function": "This protein mediates the voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient.", "general_function": "Voltage-gated potassium channel activity", "gene_names": ["KCNC4"], "name": "Potassium voltage-gated channel subfamily C member 4", "drug_actions": []}, "O00217": {"specific_function": "Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity). May donate electrons to ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFS8"], "name": "NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial", "drug_actions": []}, "P16502": {"specific_function": "RNA-dependent RNA polymerase which is responsible for replication and transcription of virus RNA segments. The transcription of viral mRNAs occurs by a unique mechanism called cap-snatching. 5' methylated caps of cellular mRNAs are cleaved after 10-13 nucleotides by PA. In turn, these short capped RNAs are used as primers by PB1 for transcription of viral mRNAs. During virus replication, PB1 initiates RNA synthesis and copy vRNA into complementary RNA (cRNA) which in turn serves as a template for the production of more vRNAs.", "general_function": "Rna-directed rna polymerase activity", "gene_names": ["PB1"], "name": "RNA-directed RNA polymerase catalytic subunit", "drug_actions": [{"action": "INHIBITOR", "target": "P16502", "drug": "DB00811"}]}, "Q9UKU7": {"specific_function": "Has very high activity toward isobutyryl-CoA. Is an isobutyryl-CoA dehydrogenase that functions in valine catabolism. Plays a role in transcriptional coactivation within the ARC complex.", "general_function": "Oxidoreductase activity, acting on the ch-ch group of donors, with a flavin as acceptor", "gene_names": ["ACAD8"], "name": "Isobutyryl-CoA dehydrogenase, mitochondrial", "drug_actions": []}, "P08870": {"specific_function": "Catalyzes the transfer of a ribosyl phosphate group from 5-phosphoribose 1-diphosphate to orotate, leading to the formation of orotidine monophosphate (OMP).", "general_function": "Orotate phosphoribosyltransferase activity", "gene_names": ["pyrE"], "name": "Orotate phosphoribosyltransferase", "drug_actions": []}, "Q9Y2D1": {"specific_function": "Transcription factor that either stimulates or represses gene transcription through binding of different DNA regulatory elements such as cAMP response element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), ATF5-specific response element (ARE) (consensus: 5'-C[CT]TCT[CT]CCTT[AT]-3') but also the amino acid response element (AARE), present in many viral and cellular promoters. Critically involved, often in a cell type-dependent manner, in cell survival, proliferation, and differentiation (PubMed:10373550, PubMed:15358120, PubMed:21212266, PubMed:20654631). Its transcriptional activity is enhanced by CCND3 and slightly inhibited by CDK4 (PubMed:15358120). Important regulator of the cerebral cortex formation, functions in cerebral cortical neuroprogenitor cells to maintain proliferation and to block differentiation into neurons. Must be down-regulated in order for such cells to exit the cycle and differentiate (By similarity). Participates in the pathways by which SHH promotes cerebellar granule neuron progenitor cells proliferation (By similarity). Critical for survival of mature olfactory sensory neurons (OSN), directs expression of OSN-specific genes (By similarity). May be involved in osteogenic differentiation (PubMed:22442021). Promotes cell proliferation and survival by inducing the expression of EGR1 sinergistically with ELK1. Once acetylated by EP300, binds to ARE sequences on target genes promoters, such as BCL2 and EGR1 (PubMed:21791614). Plays an anti-apoptotic role through the transcriptional regulation of BCL2, this function seems to be cell type-dependent (By similarity). Cooperates with NR1I3/CAR in the transcritpional activation of CYP2B6 in liver (PubMed:18332083). In hepatic cells, represses CRE-dependent transcription and inhibits proliferation by blocking at G2/M phase (PubMed:22528486, PubMed:18701499). May act as a negative regulator of IL1B transduction pathway in liver (PubMed:24379400). Upon IL1B stimulus, cooperates with NLK to activate the transactivation activity of C/EBP subfamily members (PubMed:25512613). Besides its function of transcription factor, acts as a cofactor of CEBPB to activate CEBPA and promote adipocyte differentiation (PubMed:24216764). Regulates centrosome dynamics in a cell-cycle- and centriole-age-dependent manner. Forms 9-foci symmetrical ring scaffold around the mother centriole to control centrosome function and the interaction between centrioles and pericentriolar material (PubMed:26213385).", "name": "Cyclic AMP-dependent transcription factor ATF-5", "drug_actions": [], "general_function": "Tubulin binding", "in_complexes": ["activator protein 1"], "gene_names": ["ATF5"]}, "Q9Y2D0": {"specific_function": "Reversible hydration of carbon dioxide.", "general_function": "Zinc ion binding", "gene_names": ["CA5B"], "name": "Carbonic anhydrase 5B, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "Q9Y2D0", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q9Y2D0", "drug": "DB08846"}]}, "P0AFG8": {"specific_function": "Component of the pyruvate dehydrogenase (PDH) complex, that catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2).", "general_function": "Pyruvate dehydrogenase activity", "gene_names": ["aceE"], "name": "Pyruvate dehydrogenase E1 component", "drug_actions": []}, "P12429": {"specific_function": "Inhibitor of phospholipase A2, also possesses anti-coagulant properties. Also cleaves the cyclic bond of inositol 1,2-cyclic phosphate to form inositol 1-phosphate.", "general_function": "Phospholipase a2 inhibitor activity", "gene_names": ["ANXA3"], "name": "Annexin A3", "drug_actions": []}, "O00180": {"specific_function": "Ion channel that contributes to passive transmembrane potassium transport and to the regulation of the resting membrane potential in brain astrocytes, but also in kidney and in other tissues (PubMed:15820677, PubMed:21653227). Forms dimeric channels through which potassium ions pass in accordance with their electrochemical gradient. The channel is selective for K(+) ions at physiological potassium concentrations and at neutral pH, but becomes permeable to Na(+) at subphysiological K(+) levels and upon acidification of the extracellular medium (PubMed:21653227, PubMed:22431633). The homodimer has very low potassium channel activity, when expressed in heterologous systems, and can function as weakly inward rectifying potassium channel (PubMed:8605869, PubMed:8978667, PubMed:15820677, PubMed:21653227, PubMed:22431633, PubMed:23169818, PubMed:25001086). Channel activity is modulated by activation of serotonin receptors (By similarity). Heterodimeric channels containing KCNK1 and KCNK2 have much higher activity, and may represent the predominant form in astrocytes (By similarity). Heterodimeric channels containing KCNK1 and KCNK3 or KCNK9 have much higher activity (PubMed:23169818). Heterodimeric channels formed by KCNK1 and KCNK9 may contribute to halothane-sensitive currents (PubMed:23169818). Mediates outward rectifying potassium currents in dentate gyrus granule cells and contributes to the regulation of their resting membrane potential (By similarity). Contributes to the regulation of action potential firing in dentate gyrus granule cells and down-regulates their intrinsic excitability (By similarity). In astrocytes, the heterodimer formed by KCNK1 and KCNK2 is required for rapid glutamate release in response to activation of G-protein coupled receptors, such as F2R and CNR1 (By similarity). Required for normal ion and water transport in the kidney (By similarity). Contributes to the regulation of the resting membrane potential of pancreatic beta cells (By similarity). The low channel activity of homodimeric KCNK1 may be due to sumoylation (PubMed:15820677, PubMed:20498050, PubMed:23169818). The low channel activity may be due to rapid internalization from the cell membrane and retention in recycling endosomes (PubMed:19959478).", "general_function": "Sodium channel activity", "gene_names": ["KCNK1"], "name": "Potassium channel subfamily K member 1", "drug_actions": [{"action": "INHIBITOR", "target": "O00180", "drug": "DB00308"}, {"action": "INHIBITOR", "target": "O00180", "drug": "DB00908"}, {"action": "INHIBITOR", "target": "O00180", "drug": "DB01346"}]}, "Q54AI1": {"general_function": "Metal ion binding", "gene_names": ["hmuO"], "name": "Heme oxygenase", "drug_actions": []}, "Q96IY4": {"specific_function": "Cleaves C-terminal arginine or lysine residues from biologically active peptides such as kinins or anaphylatoxins in the circulation thereby regulating their activities. Down-regulates fibrinolysis by removing C-terminal lysine residues from fibrin that has already been partially degraded by plasmin.", "general_function": "Zinc ion binding", "gene_names": ["CPB2"], "name": "Carboxypeptidase B2", "drug_actions": []}, "O00187": {"specific_function": "Serum protease that plays an important role in the activation of the complement system via mannose-binding lectin. After activation by auto-catalytic cleavage it cleaves C2 and C4, leading to their activation and to the formation of C3 convertase.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["MASP2"], "name": "Mannan-binding lectin serine protease 2", "drug_actions": []}, "P02359": {"specific_function": "One of the primary rRNA binding proteins, it binds directly to 16S rRNA where it nucleates assembly of the head domain of the 30S subunit. Is located at the subunit interface close to the decoding center, where it has been shown to contact mRNA. Has been shown to contact tRNA in both the P and E sites; it probably blocks exit of the E site tRNA.Protein S7 is also a translational repressor protein; it regulates the expression of the str operon members to different degrees by binding to its mRNA.", "general_function": "Trna binding", "gene_names": ["rpsG"], "name": "30S ribosomal protein S7", "drug_actions": [{"action": "INHIBITOR", "target": "P02359", "drug": "DB00759"}]}, "P06129": {"specific_function": "Involved in the active translocation of vitamin B12 (cyanocobalamin) across the outer membrane to the periplasmic space. It derives its energy for transport by interacting with the trans-periplasmic membrane protein TonB. Is also a receptor for bacteriophages BF23 and C1, and for A and E colicins.", "general_function": "Receptor activity", "gene_names": ["btuB"], "name": "Vitamin B12 transporter BtuB", "drug_actions": []}, "P13716": {"specific_function": "Catalyzes an early step in the biosynthesis of tetrapyrroles. Binds two molecules of 5-aminolevulinate per subunit, each at a distinct site, and catalyzes their condensation to form porphobilinogen.", "general_function": "Zinc ion binding", "gene_names": ["ALAD"], "name": "Delta-aminolevulinic acid dehydratase", "drug_actions": [{"action": "INDUCER", "target": "P13716", "drug": "DB00855"}]}, "P03198": {"specific_function": "Replicates viral genomic DNA in the late phase of lytic infection, producing long concatemeric DNA. The replication complex is composed of six viral proteins: the DNA polymerase, processivity factor, primase, primase-associated factor, helicase, and ssDNA-binding protein.", "general_function": "Nucleotide binding", "gene_names": [], "name": "DNA polymerase catalytic subunit", "drug_actions": [{"action": "INHIBITOR", "target": "P03198", "drug": "DB00194"}]}, "P06210": {"specific_function": "Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host cell receptor to provide virion attachment to target host cells. This attachment induces virion internalization through clathrin- and caveolin-independent endocytosis in Hela cells and through caveolin-mediated endocytosis in brain microvascular endothelial cells. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP2: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP3: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP4: Lies on the inner surface of the capsid shell. After binding to the host receptor, the capsid undergoes conformational changes. Capsid protein VP4 is released, Capsid protein VP1 N-terminus is externalized, and together, they shape a pore in the host membrane through which the viral genome is translocated into the host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP0: Component of immature procapsids, which is cleaved into capsid proteins VP4 and VP2 after maturation. Allows the capsid to remain inactive before the maturation step (By similarity).Protein 2A: Cysteine protease that cleaves viral polyprotein and specific host proteins. It is responsible for the cleavage between the P1 and P2 regions, first cleavage occurring in the polyprotein. Cleaves also the host translation initiation factor EIF4G1, in order to shut down the capped cellular mRNA translation. Inhibits the host nucleus-cytoplasm protein and RNA trafficking by cleaving host members of the nuclear pores (By similarity).Protein 2B: Plays an essential role in the virus replication cycle by acting as a viroporin. Creates a pore in the host reticulum endoplasmic and as a consequence releases Ca2+ in the cytoplasm of infected cell. In turn, high levels of cyctoplasmic calcium may trigger membrane trafficking and transport of viral ER-associated proteins to viroplasms, sites of viral genome replication (By similarity).Protein 2C: Induces and associates with structural rearrangements of intracellular membranes. Displays RNA-binding, nucleotide binding and NTPase activities. May play a role in virion morphogenesis and viral RNA encapsidation by interacting with the capsid protein VP3 (By similarity).Protein 3AB: Localizes the viral replication complex to the surface of membranous vesicles. Together with protein 3CD binds the Cis-Active RNA Element (CRE) which is involved in RNA synthesis initiation. Acts as a cofactor to stimulate the activity of 3D polymerase, maybe through a nucleid acid chaperone activity (By similarity).Protein 3A: Localizes the viral replication complex to the surface of membranous vesicles. It inhibits host cell endoplasmic reticulum-to-Golgi apparatus transport and causes the dissassembly of the Golgi complex, possibly through GBF1 interaction. This would result in depletion of MHC, trail receptors and IFN receptors at the host cell surface (By similarity).Viral protein genome-linked: acts as a primer for viral RNA replication and remains covalently bound to viral genomic RNA. VPg is uridylylated prior to priming replication into VPg-pUpU. The oriI viral genomic sequence may act as a template for this. The VPg-pUpU is then used as primer on the genomic RNA poly(A) by the RNA-dependent RNA polymerase to replicate the viral genome. VPg may be removed in the cytoplasm by an unknown enzyme termed \"unlinkase\". VPg is not cleaved off virion genomes because replicated genomic RNA are encapsidated at the site of replication (By similarity).Protein 3CD: Is involved in the viral replication complex and viral polypeptide maturation. It exhibits protease activity with a specificity and catalytic efficiency that is different from protease 3C. Protein 3CD lacks polymerase activity. The 3C domain in the context of protein 3CD may have an RNA binding activity (By similarity).Protease 3C: cleaves host DDX58/RIG-I and thus contributes to the inhibition of type I interferon production. Cleaves also host PABPC1 (By similarity).RNA-directed RNA polymerase: Replicates the viral genomic RNA on the surface of intracellular membranes. May form linear arrays of subunits that propagate along a strong head-to-tail interaction called interface-I. Covalently attaches UMP to a tyrosine of VPg, which is used to prime RNA synthesis. The positive stranded RNA genome is first replicated at virus induced membranous vesicles, creating a dsRNA genomic replication form. This dsRNA is then used as template to synthesize positive stranded RNA genomes. ss(+)RNA genomes are either translated, replicated or encapsidated (By similarity).", "general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P14927": {"specific_function": "This is a component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is part of the mitochondrial respiratory chain. This component is involved in redox-linked proton pumping.", "gene_names": ["UQCRB"], "name": "Cytochrome b-c1 complex subunit 7", "drug_actions": []}, "P14920": {"specific_function": "Regulates the level of the neuromodulator D-serine in the brain. Has high activity towards D-DOPA and contributes to dopamine synthesis. Could act as a detoxifying agent which removes D-amino acids accumulated during aging. Acts on a variety of D-amino acids with a preference for those having small hydrophobic side chains followed by those bearing polar, aromatic, and basic groups. Does not act on acidic amino acids.", "general_function": "Receptor binding", "gene_names": ["DAO"], "name": "D-amino-acid oxidase", "drug_actions": []}, "O76054": {"specific_function": "Carrier protein. Binds to some hydrophobic molecules and promotes their transfer between the different cellular sites. Binds with high affinity to alpha-tocopherol. Also binds with a weaker affinity to other tocopherols and to tocotrienols. May have a transcriptional activatory activity via its association with alpha-tocopherol. Probably recognizes and binds some squalene structure, suggesting that it may regulate cholesterol biosynthesis by increasing the transfer of squalene to a metabolic active pool in the cell.", "general_function": "Vitamin e binding", "gene_names": ["SEC14L2"], "name": "SEC14-like protein 2", "drug_actions": []}, "O53434": {"specific_function": "Generates Z-farnesyl diphosphate (Z-FPP) from isopentenyl pyrophosphate (IPP). Z-FPP is the precursor of decaprenyl diphosphate, which has a central role in the biosynthesis of the mycobacterial cell wall", "general_function": "Lipid transport and metabolism", "gene_names": ["Rv1086"], "name": "(2Z,6E)-farnesyl diphosphate synthase", "drug_actions": []}, "Q12882": {"specific_function": "Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil.", "general_function": "Protein homodimerization activity", "gene_names": ["DPYD"], "name": "Dihydropyrimidine dehydrogenase [NADP(+)]", "drug_actions": []}, "P62942": {"specific_function": "Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand. Recruites SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. May modulate the RYR1 calcium channel activity. PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides.", "general_function": "Type i transforming growth factor beta receptor binding", "gene_names": ["FKBP1A"], "name": "Peptidyl-prolyl cis-trans isomerase FKBP1A", "drug_actions": [{"action": "POTENTIATOR", "target": "P62942", "drug": "DB00337"}, {"action": "INHIBITOR", "target": "P62942", "drug": "DB00864"}, {"action": "OTHER", "target": "P62942", "drug": "DB00877"}]}, "O33199": {"general_function": "Manganese ion binding", "gene_names": [], "name": "MutT/nudix family protein", "drug_actions": []}, "P29034": {"specific_function": "May function as calcium sensor and modulator, contributing to cellular calcium signaling. May function by interacting with other proteins, such as TPR-containing proteins, and indirectly play a role in many physiological processes. May also play a role in suppressing tumor cell growth.", "general_function": "Identical protein binding", "gene_names": ["S100A2"], "name": "Protein S100-A2", "drug_actions": [{"action": "ANTAGONIST", "target": "P29034", "drug": "DB00768"}]}, "P17846": {"specific_function": "Component of the sulfite reductase complex that catalyzes the 6-electron reduction of sulfite to sulfide. This is one of several activities required for the biosynthesis of L-cysteine from sulfate.", "general_function": "Sulfite reductase (nadph) activity", "gene_names": ["cysI"], "name": "Sulfite reductase [NADPH] hemoprotein beta-component", "drug_actions": []}, "Q69600": {"gene_names": ["S gene"], "name": "HBsAg", "drug_actions": []}, "Q93LE9": {"specific_function": "Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions (By similarity).", "general_function": "Peptide deformylase activity", "gene_names": ["def"], "name": "Peptide deformylase", "drug_actions": []}, "Q5JTZ9": {"specific_function": "Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala). Also edits incorrectly charged tRNA(Ala) via its editing domain.", "general_function": "Trna binding", "gene_names": ["AARS2"], "name": "Alanine--tRNA ligase, mitochondrial", "drug_actions": []}, "Q00169": {"specific_function": "Catalyzes the transfer of PtdIns and phosphatidylcholine between membranes.", "general_function": "Phosphatidylinositol transporter activity", "gene_names": ["PITPNA"], "name": "Phosphatidylinositol transfer protein alpha isoform", "drug_actions": []}, "O00459": {"specific_function": "Regulatory subunit of phosphoinositide-3-kinase (PI3K), a kinase that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Binds to activated (phosphorylated) protein-tyrosine kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Indirectly regulates autophagy (PubMed:23604317). Promotes nuclear translocation of XBP1 isoform 2 in a ER stress- and/or insulin-dependent manner during metabolic overloading in the liver and hence plays a role in glucose tolerance improvement (By similarity).", "general_function": "Receptor tyrosine kinase binding", "gene_names": ["PIK3R2"], "name": "Phosphatidylinositol 3-kinase regulatory subunit beta", "drug_actions": [{"action": "AGONIST", "target": "O00459", "drug": "DB01064"}]}, "O95178": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFB2"], "name": "NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial", "drug_actions": []}, "O14594": {"specific_function": "May modulate neuronal adhesion and neurite growth during development by binding to neural cell adhesion molecules (NG-CAM and N-CAM). Chondroitin sulfate proteoglycan; binds to hyaluronic acid.", "general_function": "Hyaluronic acid binding", "gene_names": ["NCAN"], "name": "Neurocan core protein", "drug_actions": [{"action": "BINDER", "target": "O14594", "drug": "DB08818"}]}, "O95190": {"specific_function": "Ornithine decarboxylase (ODC) antizyme protein that negatively regulates ODC activity and intracellular polyamine biosynthesis and uptake by binding to ODC1 without promoting its degradation (PubMed:17900240). Involved in the translocation of AZNI2 from ER-Golgi intermediate compartment (ERGIC) to the cytosol.", "general_function": "Ornithine decarboxylase inhibitor activity", "gene_names": ["OAZ2"], "name": "Ornithine decarboxylase antizyme 2", "drug_actions": []}, "Q8YSC4": {"general_function": "Ion channel activity", "gene_names": [], "name": "Bacteriorhodopsin", "drug_actions": []}, "P07451": {"specific_function": "Reversible hydration of carbon dioxide.", "general_function": "Zinc ion binding", "gene_names": ["CA3"], "name": "Carbonic anhydrase 3", "drug_actions": [{"action": "INHIBITOR", "target": "P07451", "drug": "DB00819"}, {"action": "INHIBITOR", "target": "P07451", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P07451", "drug": "DB08846"}]}, "P0AC38": {"general_function": "Aspartate ammonia-lyase activity", "gene_names": ["aspA"], "name": "Aspartate ammonia-lyase", "drug_actions": []}, "P43220": {"specific_function": "This is a receptor for glucagon-like peptide 1. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["GLP1R"], "name": "Glucagon-like peptide 1 receptor", "drug_actions": [{"action": "AGONIST", "target": "P43220", "drug": "DB01276"}, {"action": "AGONIST", "target": "P43220", "drug": "DB06655"}, {"action": "AGONIST", "target": "P43220", "drug": "DB09043"}, {"action": "AGONIST", "target": "P43220", "drug": "DB09045"}]}, "Q37875": {"specific_function": "Essential for lysis of bacterial cell wall, by showing cell wall hydrolyzing activity.", "general_function": "Lysozyme activity", "gene_names": ["17"], "name": "Lysozyme", "drug_actions": []}, "Q04844": {"specific_function": "After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.", "general_function": "Cation transmembrane transporter activity", "gene_names": ["CHRNE"], "name": "Acetylcholine receptor subunit epsilon", "drug_actions": [{"action": "ALLOSTERIC MODULATOR", "target": "Q04844", "drug": "DB00674"}]}, "Q9P0J0": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone. Involved in the interferon/all-trans-retinoic acid (IFN/RA) induced cell death. This apoptotic activity is inhibited by interaction with viral IRF1. Prevents the transactivation of STAT3 target genes. May play a role in CARD15-mediated innate mucosal responses and serve to regulate intestinal epithelial cell responses to microbes.", "general_function": "Nadh dehydrogenase activity", "gene_names": ["NDUFA13"], "name": "NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13", "drug_actions": []}, "P29323": {"specific_function": "Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Functions in axon guidance during development. Involved in the guidance of commissural axons, that form a major interhemispheric connection between the 2 temporal lobes of the cerebral cortex. Also involved in guidance of contralateral inner ear efferent growth cones at the midline and of retinal ganglion cell axons to the optic disk. In addition to axon guidance, also regulates dendritic spines development and maturation and stimulates the formation of excitatory synapses. Upon activation by EFNB1, abolishes the ARHGEF15-mediated negative regulation on excitatory synapse formation. Controls other aspects of development including angiogenesis, palate development and in inner ear development through regulation of endolymph production. Forward and reverse signaling through the EFNB2/EPHB2 complex regulate movement and adhesion of cells that tubularize the urethra and septate the cloaca. May function as a tumor suppressor.", "general_function": "Transmembrane-ephrin receptor activity", "gene_names": ["EPHB2"], "name": "Ephrin type-B receptor 2", "drug_actions": []}, "P77425": {"specific_function": "Involved in the anaerobic utilization of allantoin. Converts allantoate to (S)-ureidoglycolate and ammonia.", "general_function": "Manganese ion binding", "gene_names": ["allC"], "name": "Allantoate amidohydrolase", "drug_actions": []}, "P62837": {"specific_function": "Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-48'-linked polyubiquitination. Mediates the selective degradation of short-lived and abnormal proteins. Functions in the E6/E6-AP-induced ubiquitination of p53/TP53. Mediates ubiquitination of PEX5 and autoubiquitination of STUB1 and TRAF6. Involved in the signal-induced conjugation and subsequent degradation of NFKBIA, FBXW2-mediated GCM1 ubiquitination and degradation, MDM2-dependent degradation of p53/TP53 and the activation of MAVS in the mitochondria by DDX58/RIG-I in response to viral infection. Essential for viral activation of IRF3.", "general_function": "Ubiquitin-protein transferase activity", "gene_names": ["UBE2D2"], "name": "Ubiquitin-conjugating enzyme E2 D2", "drug_actions": []}, "P02649": {"specific_function": "Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues.", "general_function": "Very-low-density lipoprotein particle receptor binding", "gene_names": ["APOE"], "name": "Apolipoprotein E", "drug_actions": []}, "P28329": {"specific_function": "Catalyzes the reversible synthesis of acetylcholine (ACh) from acetyl CoA and choline at cholinergic synapses.", "general_function": "Choline o-acetyltransferase activity", "gene_names": ["CHAT"], "name": "Choline O-acetyltransferase", "drug_actions": []}, "P25815": {"specific_function": "May function as calcium sensor and contribute to cellular calcium signaling. In a calcium-dependent manner, functions by interacting with other proteins, such as EZR and PPP5C, and indirectly plays a role in physiological processes like the formation of microvilli in epithelial cells. May stimulate cell proliferation in an autocrine manner via activation of the receptor for activated glycation end products (RAGE).", "general_function": "Magnesium ion binding", "gene_names": ["S100P"], "name": "Protein S100-P", "drug_actions": [{"action": "ANTAGONIST", "target": "P25815", "drug": "DB01003"}]}, "P0A444": {"specific_function": "Photosystem II (PSII) is a light-driven water: plastoquinone oxidoreductase that uses light energy to abstract electrons from H(2)O, generating O(2) and a proton gradient subsequently used for ATP formation. It consists of a core antenna complex that captures photons, and an electron transfer chain that converts photonic excitation into a charge separation. The D1/D2 (PsbA/PsbA) reaction center heterodimer binds P680, the primary electron donor of PSII as well as several subsequent electron acceptors.", "general_function": "Oxidoreductase activity", "gene_names": ["psbA1"], "name": "Photosystem II protein D1 1", "drug_actions": []}, "P57059": {"specific_function": "Serine/threonine-protein kinase involved in various processes such as cell cycle regulation, gluconeogenesis and lipogenesis regulation, muscle growth and differentiation and tumor suppression. Phosphorylates HDAC4, HDAC5, PPME1, SREBF1, CRTC1/TORC1 and CRTC2/TORC2. Acts as a tumor suppressor and plays a key role in p53/TP53-dependent anoikis, a type of apoptosis triggered by cell detachment: required for phosphorylation of p53/TP53 in response to loss of adhesion and is able to suppress metastasis. Part of a sodium-sensing signaling network, probably by mediating phosphorylation of PPME1: following increases in intracellular sodium, SIK1 is activated by CaMK1 and phosphorylates PPME1 subunit of protein phosphatase 2A (PP2A), leading to dephosphorylation of sodium/potassium-transporting ATPase ATP1A1 and subsequent increase activity of ATP1A1. Acts as a regulator of muscle cells by phosphorylating and inhibiting class II histone deacetylases HDAC4 and HDAC5, leading to promote expression of MEF2 target genes in myocytes. Also required during cardiomyogenesis by regulating the exit of cardiomyoblasts from the cell cycle via down-regulation of CDKN1C/p57Kip2. Acts as a regulator of hepatic gluconeogenesis by phosphorylating and repressing the CREB-specific coactivators CRTC1/TORC1 and CRTC2/TORC2, leading to inhibit CREB activity. Also regulates hepatic lipogenesis by phosphorylating and inhibiting SREBF1. In concert with CRTC1/TORC1, regulates the light-induced entrainment of the circadian clock by attenuating PER1 induction; represses CREB-mediated transcription of PER1 by phosphorylating and deactivating CRTC1/TORC1 (By similarity).", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["SIK1"], "name": "Serine/threonine-protein kinase SIK1", "drug_actions": [{"action": "INHIBITOR", "target": "P57059", "drug": "DB08912"}]}, "P04190": {"specific_function": "Can hydrolyze carbapenem compounds.", "general_function": "Zinc ion binding", "gene_names": ["blm"], "name": "Beta-lactamase 2", "drug_actions": []}, "P71119": {"specific_function": "Allows the bacteria to use the host heme as an iron source. Involved in the oxidation of heme and subsequent release of iron from the heme moiety.", "general_function": "Metal ion binding", "gene_names": ["hmuO"], "name": "Heme oxygenase", "drug_actions": []}, "Q9UIC8": {"specific_function": "Methylates the carboxyl group of the C-terminal leucine residue of protein phosphatase 2A catalytic subunits to form alpha-leucine ester residues.", "general_function": "S-adenosylmethionine-dependent methyltransferase activity", "gene_names": ["LCMT1"], "name": "Leucine carboxyl methyltransferase 1", "drug_actions": []}, "P01595": {"general_function": "Antigen binding", "gene_names": [], "name": "Ig kappa chain V-I region Bi", "drug_actions": []}, "Q9X1T2": {"specific_function": "The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate.", "general_function": "Purine-nucleoside phosphorylase activity", "gene_names": [], "name": "Purine nucleoside phosphorylase", "drug_actions": []}, "P09238": {"specific_function": "Can degrade fibronectin, gelatins of type I, III, IV, and V; weakly collagens III, IV, and V. Activates procollagenase.", "general_function": "Zinc ion binding", "gene_names": ["MMP10"], "name": "Stromelysin-2", "drug_actions": [{"action": "ANTAGONIST", "target": "P09238", "drug": "DB00786"}]}, "P00864": {"specific_function": "Forms oxaloacetate, a four-carbon dicarboxylic acid source for the tricarboxylic acid cycle.", "general_function": "Phosphoenolpyruvate carboxylase activity", "gene_names": ["ppc"], "name": "Phosphoenolpyruvate carboxylase", "drug_actions": []}, "P09237": {"specific_function": "Degrades casein, gelatins of types I, III, IV, and V, and fibronectin. Activates procollagenase.", "general_function": "Zinc ion binding", "gene_names": ["MMP7"], "name": "Matrilysin", "drug_actions": [{"action": "ANTAGONIST", "target": "P09237", "drug": "DB00786"}]}, "Q59288": {"general_function": "Metal ion binding", "gene_names": ["cslA"], "name": "Chondroitinase-AC", "drug_actions": []}, "Q32P28": {"specific_function": "Basement membrane-associated chondroitin sulfate proteoglycan (CSPG). Has prolyl 3-hydroxylase activity catalyzing the post-translational formation of 3-hydroxyproline in -Xaa-Pro-Gly- sequences in collagens, especially types IV and V. May be involved in the secretory pathway of cells. Has growth suppressive activity in fibroblasts.", "general_function": "Protein complex binding", "gene_names": ["P3H1"], "name": "Prolyl 3-hydroxylase 1", "drug_actions": []}, "P98002": {"specific_function": "Subunit I and II form the functional core of the enzyme complex. Electrons originating in cytochrome c are transferred via heme a and Cu(A) to the binuclear center formed by heme a3 and Cu(B). This cytochrome c oxidase shows proton pump activity across the membrane in addition to the electron transfer.", "general_function": "Iron ion binding", "gene_names": ["ctaDII"], "name": "Cytochrome c oxidase subunit 1-beta", "drug_actions": []}, "P01024": {"specific_function": "C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, acts as a chemoattractant for neutrophils (By similarity). It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.C3-beta-c: Acts as a chemoattractant for neutrophils in chronic inflammation.Acylation stimulating protein: adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750).", "general_function": "Receptor binding", "gene_names": ["C3"], "name": "Complement C3", "drug_actions": [{"action": "BINDER", "target": "P01024", "drug": "DB00028"}]}, "P01023": {"specific_function": "Is able to inhibit all four classes of proteinases by a unique 'trapping' mechanism. This protein has a peptide stretch, called the 'bait region' which contains specific cleavage sites for different proteinases. When a proteinase cleaves the bait region, a conformational change is induced in the protein which traps the proteinase. The entrapped enzyme remains active against low molecular weight substrates (activity against high molecular weight substrates is greatly reduced). Following cleavage in the bait region a thioester bond is hydrolyzed and mediates the covalent binding of the protein to the proteinase.", "general_function": "Tumor necrosis factor binding", "gene_names": ["A2M"], "name": "Alpha-2-macroglobulin", "drug_actions": [{"action": "INHIBITOR", "target": "P01023", "drug": "DB00626"}, {"action": "LIGAND", "target": "P01023", "drug": "DB08888"}]}, "P00519": {"specific_function": "Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH (involved in signaling); or MAPT and PXN (microtubule-binding proteins). Phosphorylation of WASF3 is critical for the stimulation of lamellipodia formation and cell migration. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as BCAR1, CRK, CRKL, DOK1, EFS or NEDD9. Phosphorylates multiple receptor tyrosine kinases and more particularly promotes endocytosis of EGFR, facilitates the formation of neuromuscular synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and modulates the endocytosis of activated B-cell receptor complexes. Other substrates which are involved in endocytosis regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL family of ubiquitin ligases that drive receptor down-regulation and actin remodeling. Phosphorylation of CBL leads to increased EGFR stability. Involved in late-stage autophagy by regulating positively the trafficking and function of lysosomal components. ABL1 targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death. ABL1 is also translocated in the nucleus where it has DNA-binding activity and is involved in DNA-damage response and apoptosis. Many substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3, ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic pathway when the DNA damage is too severe to be repaired. Phosphorylates TP73, a primary regulator for this type of damage-induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153' and regulates its processing in the apoptotic response to DNA damage. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks. ABL1 acts also as a regulator of multiple pathological signaling cascades during infection. Several known tyrosine-phosphorylated microbial proteins have been identified as ABL1 substrates. This is the case of A36R of Vaccinia virus, Tir (translocated intimin receptor) of pathogenic E.coli and possibly Citrobacter, CagA (cytotoxin-associated gene A) of H.pylori, or AnkA (ankyrin repeat-containing protein A) of A.phagocytophilum. Pathogens can highjack ABL1 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1.", "general_function": "Syntaxin binding", "gene_names": ["ABL1"], "name": "Tyrosine-protein kinase ABL1", "drug_actions": [{"action": "INHIBITOR", "target": "P00519", "drug": "DB00171"}, {"action": "INHIBITOR", "target": "P00519", "drug": "DB00619"}, {"action": "MULTITARGET", "target": "P00519", "drug": "DB01254"}, {"action": "INHIBITOR", "target": "P00519", "drug": "DB04868"}, {"action": "INHIBITOR", "target": "P00519", "drug": "DB06616"}, {"action": "INHIBITOR", "target": "P00519", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P00519", "drug": "DB08901"}]}, "P16218": {"specific_function": "This enzyme catalyzes the endohydrolysis of 1,4-beta-glucosidic linkages in cellulose, lichenin and cereal beta-D-glucans.", "general_function": "Cellulase activity", "gene_names": ["celH"], "name": "Endoglucanase H", "drug_actions": []}, "P17900": {"specific_function": "The large binding pocket can accommodate several single chain phospholipids and fatty acids, GM2A also exhibits some calcium-independent phospholipase activity (By similarity). Binds gangliosides and stimulates ganglioside GM2 degradation. It stimulates only the breakdown of ganglioside GM2 and glycolipid GA2 by beta-hexosaminidase A. It extracts single GM2 molecules from membranes and presents them in soluble form to beta-hexosaminidase A for cleavage of N-acetyl-D-galactosamine and conversion to GM3.", "general_function": "Phospholipase activator activity", "gene_names": ["GM2A"], "name": "Ganglioside GM2 activator", "drug_actions": []}, "P00512": {"specific_function": "Catalyzes the phosphorylation of D-fructose 6-phosphate to fructose 1,6-bisphosphate by ATP, the first committing step of glycolysis.", "general_function": "Metal ion binding", "gene_names": ["pfkA"], "name": "ATP-dependent 6-phosphofructokinase", "drug_actions": []}, "P13001": {"specific_function": "The physiological role of BioH is to remove the methyl group introduced by BioC when the pimeloyl moiety is complete. It allows to synthesize pimeloyl-ACP via the fatty acid synthetic pathway through the hydrolysis of the ester bonds of pimeloyl-ACP esters. E.coli employs a methylation and demethylation strategy to allow elongation of a temporarily disguised malonate moiety to a pimelate moiety by the fatty acid synthetic enzymes. BioH shows a preference for short chain fatty acid esters (acyl chain length of up to 6 carbons) and short chain p-nitrophenyl esters. Also displays a weak thioesterase activity. Can form a complex with CoA, and may be involved in the condensation of CoA and pimelic acid into pimeloyl-CoA, a precursor in biotin biosynthesis.Catalyzes the hydrolysis of the methyl ester bond of dimethylbutyryl-S-methyl mercaptopropionate (DMB-S-MMP) to yield dimethylbutyryl mercaptopropionic acid (DMBS-MPA) during the biocatalytic conversion of simvastin acid from monacolin J acid. Can also use acyl carriers such as dimethylbutyryl-S-ethyl mercaptopropionate (DMB-S-EMP) and dimethylbutyryl-S-methyl thioglycolate (DMB-S-MTG) as the thioester substrates.", "general_function": "Pimelyl-[acyl-carrier protein] methyl ester esterase activity", "gene_names": ["bioH"], "name": "Pimeloyl-[acyl-carrier protein] methyl ester esterase", "drug_actions": []}, "Q9Y257": {"specific_function": "Exhibits outward rectification in a physiological K(+) gradient and mild inward rectification in symmetrical K(+) conditions.", "general_function": "Potassium ion leak channel activity", "gene_names": ["KCNK6"], "name": "Potassium channel subfamily K member 6", "drug_actions": [{"action": "INHIBITOR", "target": "Q9Y257", "drug": "DB00308"}, {"action": "INHIBITOR", "target": "Q9Y257", "drug": "DB00908"}]}, "P08729": {"specific_function": "Blocks interferon-dependent interphase and stimulates DNA synthesis in cells. Involved in the translational regulation of the human papillomavirus type 16 E7 mRNA (HPV16 E7).", "general_function": "Structural molecule activity", "gene_names": ["KRT7"], "name": "Keratin, type II cytoskeletal 7", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "P08729", "drug": "DB01087"}]}, "P0C0F4": {"specific_function": "Catalyzes the formation of UDP-glucuronic acid which is required for capsular hyaluronic acid synthesis.", "general_function": "Udp-glucose 6-dehydrogenase activity", "gene_names": ["hasB"], "name": "UDP-glucose 6-dehydrogenase", "drug_actions": []}, "P12998": {"specific_function": "Catalyzes the decarboxylative condensation of pimeloyl-[acyl-carrier protein] and L-alanine to produce 8-amino-7-oxononanoate (AON), [acyl-carrier protein], and carbon dioxide. Can also use pimeloyl-CoA instead of pimeloyl-ACP as substrate, but it is believed that pimeloyl-ACP rather than pimeloyl-CoA is the physiological substrate of BioF.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["bioF"], "name": "8-amino-7-oxononanoate synthase", "drug_actions": []}, "Q9Y6F1": {"specific_function": "Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. May link the DNA damage surveillance network to the mitotic fidelity checkpoint. Negatively influences the G1/S cell cycle progression without interfering with centrosome duplication. Binds DNA. May be involved in the regulation of PRC2 and PRC3 complex-dependent gene silencing.", "general_function": "Nad+ adp-ribosyltransferase activity", "gene_names": ["PARP3"], "name": "Poly [ADP-ribose] polymerase 3", "drug_actions": [{"action": "INHIBITOR", "target": "Q9Y6F1", "drug": "DB09074"}]}, "P0A910": {"specific_function": "Required for the action of colicins K and L and for the stabilization of mating aggregates in conjugation. Serves as a receptor for a number of T-even like phages. Also acts as a porin with low permeability that allows slow penetration of small solutes.", "general_function": "Structural molecule activity", "gene_names": ["ompA"], "name": "Outer membrane protein A", "drug_actions": []}, "P0A560": {"specific_function": "Arabinosyl transferase responsible for the polymerization of arabinose into the arabinan of arabinogalactan", "general_function": "Involved in transferase activity, transferring pentosyl groups", "gene_names": ["embA"], "name": "Probable arabinosyltransferase A", "drug_actions": [{"action": "INHIBITOR", "target": "P0A560", "drug": "DB00330"}]}, "Q9UKY3": {"specific_function": "Has no esterase activity.", "general_function": "Carboxylic ester hydrolase activity", "gene_names": ["CES1P1"], "name": "Putative inactive carboxylesterase 4", "drug_actions": []}, "P24474": {"general_function": "Nitrite reductase (no-forming) activity", "gene_names": ["nirS"], "name": "Nitrite reductase", "drug_actions": []}, "P22364": {"specific_function": "Primary acceptor of electrons from methylamine dehydrogenase. Passes those electrons on either a soluble cytochrome c or to pseudoazurin.", "general_function": "Electron carrier activity", "gene_names": ["mauC"], "name": "Amicyanin", "drug_actions": []}, "P08506": {"specific_function": "Removes C-terminal D-alanyl residues from sugar-peptide cell wall precursors.", "general_function": "Serine-type d-ala-d-ala carboxypeptidase activity", "gene_names": ["dacC"], "name": "D-alanyl-D-alanine carboxypeptidase DacC", "drug_actions": [{"action": "INHIBITOR", "target": "P08506", "drug": "DB00274"}, {"action": "INHIBITOR", "target": "P08506", "drug": "DB00303"}, {"action": "INHIBITOR", "target": "P08506", "drug": "DB00430"}, {"action": "INHIBITOR", "target": "P08506", "drug": "DB01329"}, {"action": "INHIBITOR", "target": "P08506", "drug": "DB01331"}]}, "Q9RN59": {"gene_names": ["snoaL"], "name": "Nogalonic acid methyl ester cyclase", "drug_actions": []}, "Q5SIH3": {"specific_function": "Binds at the top of the head of the 30S subunit. It stabilizes a number of different RNA elements and thus is important for subunit structure.", "general_function": "Rrna binding", "gene_names": ["rpsU"], "name": "30S ribosomal protein Thx", "drug_actions": []}, "P0A674": {"specific_function": "DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates", "general_function": "Transcription", "gene_names": ["rpoC"], "name": "DNA-directed RNA polymerase subunit beta'", "drug_actions": [{"action": "INHIBITOR", "target": "P0A674", "drug": "DB01201"}]}, "Q9I596": {"specific_function": "Catalyzes the cleavage of the N-acyl linkage of the ceramides (Cers) to yield sphingosine (Sph) and free fatty acid at an optimal pH of 8-9. Also catalyzes the synthesis of Cers from Sph and fatty acid.", "general_function": "Metal ion binding", "gene_names": [], "name": "Neutral ceramidase", "drug_actions": []}, "Q99835": {"specific_function": "G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor patched is thought to prevent normal inhibition by patched of smoothened (SMO). Required for the accumulation of KIF7 and GLI3 in the cilia.", "general_function": "Wnt-protein binding", "gene_names": ["SMO"], "name": "Smoothened homolog", "drug_actions": [{"action": "AGONIST", "target": "Q99835", "drug": "DB01047"}, {"action": "ANTAGONIST", "target": "Q99835", "drug": "DB08828"}, {"action": "ANTAGONIST", "target": "Q99835", "drug": "DB09143"}]}, "P32890": {"specific_function": "The biological activity of the toxin is produced by the A chain, which activates intracellular adenyl cyclase.", "gene_names": ["eltB"], "name": "Heat-labile enterotoxin B chain", "drug_actions": []}, "B0B3C9": {"general_function": "Serine-type peptidase activity", "gene_names": ["NS3/4A"], "name": "Genome polyprotein", "drug_actions": [{"action": "INHIBITOR", "target": "B0B3C9", "drug": "DB05521"}, {"action": "INHIBITOR", "target": "B0B3C9", "drug": "DB08873"}]}, "P0A7S9": {"specific_function": "Located at the top of the head of the 30S subunit, it contacts several helices of the 16S rRNA.In the E.coli 70S ribosome in the initiation state (PubMed:12809609) was modeled to contact the 23S rRNA (bridge B1a) and protein L5 of the 50S subunit (bridge B1b), connecting the 2 subunits; bridge B1a is broken in the model with bound EF-G, while the protein-protein contacts between S13 and L5 in B1b change (PubMed:12809609). The 23S rRNA contact site in bridge B1a is modeled to differ in different ribosomal states (PubMed:16272117), contacting alternately S13 or S19. In the two 3.5 angstroms resolved ribosome structures (PubMed:12859903) the contacts between L5, S13 and S19 bridge B1b are different, confirming the dynamic nature of this interaction. Bridge B1a is not visible in the crystallized ribosomes due to 23S rRNA disorder.Contacts the tRNAs in the A and P sites.The C-terminal tail plays a role in the affinity of the 30S P site for different tRNAs.", "general_function": "Trna binding", "gene_names": ["rpsM"], "name": "30S ribosomal protein S13", "drug_actions": [{"action": "ADDUCT", "target": "P0A7S9", "drug": "DB00560"}]}, "P78559": {"specific_function": "Structural protein involved in the filamentous cross-bridging between microtubules and other skeletal elements.", "general_function": "Structural molecule activity", "gene_names": ["MAP1A"], "name": "Microtubule-associated protein 1A", "drug_actions": [{"action": "ANTAGONIST", "target": "P78559", "drug": "DB01196"}]}, "P0A7S3": {"specific_function": "With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Located at the interface of the 30S and 50S subunits, it traverses the body of the 30S subunit contacting proteins on the other side and probably holding the rRNA structure together. The combined cluster of proteins S8, S12 and S17 appears to hold together the shoulder and platform of the 30S subunit (By similarity).Cryo-EM studies suggest that S12 contacts the EF-Tu bound tRNA in the A-site during codon-recognition. This contact is most likely broken as the aminoacyl-tRNA moves into the peptidyl transferase center in the 50S subunit.", "general_function": "Trna binding", "gene_names": ["rpsL"], "name": "30S ribosomal protein S12", "drug_actions": [{"action": "INHIBITOR", "target": "P0A7S3", "drug": "DB00452"}, {"action": "INHIBITOR", "target": "P0A7S3", "drug": "DB00479"}, {"action": "ADDUCT", "target": "P0A7S3", "drug": "DB00560"}, {"action": "INHIBITOR", "target": "P0A7S3", "drug": "DB00684"}, {"action": "ADDUCT", "target": "P0A7S3", "drug": "DB00798"}, {"action": "INHIBITOR", "target": "P0A7S3", "drug": "DB00919"}, {"action": "INHIBITOR", "target": "P0A7S3", "drug": "DB00955"}, {"action": "INHIBITOR", "target": "P0A7S3", "drug": "DB00994"}, {"action": "INHIBITOR", "target": "P0A7S3", "drug": "DB01082"}, {"action": "INHIBITOR", "target": "P0A7S3", "drug": "DB01172"}, {"action": "ADDUCT", "target": "P0A7S3", "drug": "DB04729"}, {"action": "INHIBITOR", "target": "P0A7S3", "drug": "DB06696"}]}, "P48051": {"specific_function": "This potassium channel may be involved in the regulation of insulin secretion by glucose and/or neurotransmitters acting through G-protein-coupled receptors. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium.", "general_function": "Inward rectifier potassium channel activity", "gene_names": ["KCNJ6"], "name": "G protein-activated inward rectifier potassium channel 2", "drug_actions": [{"action": "INHIBITOR", "target": "P48051", "drug": "DB01159"}]}, "P61889": {"specific_function": "Catalyzes the reversible oxidation of malate to oxaloacetate.", "general_function": "Oxidoreductase activity", "gene_names": ["mdh"], "name": "Malate dehydrogenase", "drug_actions": [{"action": "INHIBITOR", "target": "P61889", "drug": "DB00336"}]}, "P61888": {"specific_function": "Catalyzes the formation of dTDP-glucose, from dTTP and glucose 1-phosphate, as well as its pyrophosphorolysis.", "general_function": "Metal ion binding", "gene_names": ["rffH"], "name": "Glucose-1-phosphate thymidylyltransferase 2", "drug_actions": []}, "Q07864": {"specific_function": "Participates in DNA repair and in chromosomal DNA replication.", "general_function": "Zinc ion binding", "gene_names": ["POLE"], "name": "DNA polymerase epsilon catalytic subunit A", "drug_actions": [{"action": "INHIBITOR", "target": "Q07864", "drug": "DB00242"}]}, "P25084": {"specific_function": "Transcriptional activator of elastase structural gene (LasB). Binds to the PAI autoinducer.", "general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": ["lasR"], "name": "Transcriptional activator protein LasR", "drug_actions": []}, "P18283": {"specific_function": "Could play a major role in protecting mammals from the toxicity of ingested organic hydroperoxides. Tert-butyl hydroperoxide, cumene hydroperoxide and linoleic acid hydroperoxide but not phosphatidycholine hydroperoxide, can act as acceptors.", "general_function": "Glutathione peroxidase activity", "gene_names": ["GPX2"], "name": "Glutathione peroxidase 2", "drug_actions": [{"action": "COFACTOR", "target": "P18283", "drug": "DB00143"}]}, "Q8WX39": {"general_function": "Transporter activity", "gene_names": ["LCN9"], "name": "Epididymal-specific lipocalin-9", "drug_actions": []}, "P56690": {"specific_function": "Catalyzes the attachment of isoleucine to tRNA(Ile). As IleRS can inadvertently accommodate and process structurally similar amino acids such as valine, to avoid such errors it has two additional distinct tRNA(Ile)-dependent editing activities. One activity is designated as 'pretransfer' editing and involves the hydrolysis of activated Val-AMP. The other activity is designated 'posttransfer' editing and involves deacylation of mischarged Val-tRNA(Ile) (By similarity).", "general_function": "Zinc ion binding", "gene_names": ["ileS"], "name": "Isoleucine--tRNA ligase", "drug_actions": []}, "O68541": {"general_function": "Endo-1,4-beta-xylanase activity", "gene_names": ["xynC"], "name": "Beta-xylanase", "drug_actions": []}, "Q07869": {"specific_function": "Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2. May be required for the propagation of clock information to metabolic pathways regulated by PER2.", "general_function": "Zinc ion binding", "gene_names": ["PPARA"], "name": "Peroxisome proliferator-activated receptor alpha", "drug_actions": [{"action": "AGONIST", "target": "Q07869", "drug": "DB00328"}, {"action": "AGONIST", "target": "Q07869", "drug": "DB00636"}, {"action": "AGONIST", "target": "Q07869", "drug": "DB01039"}, {"action": "AGONIST", "target": "Q07869", "drug": "DB01241"}, {"action": "AGONIST", "target": "Q07869", "drug": "DB01393"}, {"action": "ACTIVATOR", "target": "Q07869", "drug": "DB01708"}, {"action": "AGONIST", "target": "Q07869", "drug": "DB08915"}]}, "P43003": {"specific_function": "Transports L-glutamate and also L- and D-aspartate. Essential for terminating the postsynaptic action of glutamate by rapidly removing released glutamate from the synaptic cleft. Acts as a symport by cotransporting sodium.", "general_function": "Sodium:dicarboxylate symporter activity", "gene_names": ["SLC1A3"], "name": "Excitatory amino acid transporter 1", "drug_actions": []}, "Q92753": {"specific_function": "Nuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5'-AGGTCA-3' preceded by a short A-T-rich sequence. Considered to have intrinsic transcriptional activity, have some natural ligands such as all-trans retinoic acid (ATRA) and other retinoids which act as inverse agonists repressing the transcriptional activity. Required for normal postnatal development of rod and cone photoreceptor cells. Modulates rod photoreceptors differentiation at least by inducing the transcription factor NRL-mediated pathway. In cone photoreceptor cells, regulates transcription of OPN1SW. Involved in the regulation of the period length and stability of the circadian rhythm. May control cytoarchitectural patterning of neocortical neurons during development. May act in a dose-dependent manner to regulate barrel formation upon innervation of layer IV neurons by thalamocortical axons. May play a role in the suppression of osteoblastic differentiation through the inhibition of RUNX2 transcriptional activity (By similarity).Isoform 1 is critical for hindlimb motor control and for the differentiation of amacrine and horizontal cells in the retina. Regulates the expression of PTF1A synergistically with FOXN4 (By similarity).", "general_function": "Zinc ion binding", "gene_names": ["RORB"], "name": "Nuclear receptor ROR-beta", "drug_actions": [{"action": "AGONIST", "target": "Q92753", "drug": "DB01065"}]}, "Q8UCK6": {"specific_function": "Protects DNA from oxidative damage by sequestering intracellular Fe(2+) ion and storing it in the form of Fe(3+) oxyhydroxide mineral, which can be released after reduction. It efficiently inhibits hydroxyl radical production by the Fenton reaction. Does not bind DNA.", "general_function": "Oxidoreductase activity, oxidizing metal ions", "gene_names": ["dps"], "name": "DNA protection during starvation protein", "drug_actions": []}, "P46072": {"specific_function": "Involved in bioluminescence. It is a good supplier of reduced flavin mononucleotide (FMNH2) to the bioluminescence reaction. Major FMN reductase. It is capable of using both NADH and NADPH as electron donors. As electron acceptor, FMN is the most effective, FAD is considerably effective, and riboflavin is the least effective.", "general_function": "Oxidoreductase activity", "gene_names": [], "name": "Major NAD(P)H-flavin oxidoreductase", "drug_actions": []}, "P43007": {"specific_function": "Transporter for alanine, serine, cysteine, and threonine. Exhibits sodium dependence.", "general_function": "Sodium:dicarboxylate symporter activity", "gene_names": ["SLC1A4"], "name": "Neutral amino acid transporter A", "drug_actions": []}, "P32947": {"general_function": "Triglyceride lipase activity", "gene_names": ["LIP3"], "name": "Lipase 3", "drug_actions": []}, "P43005": {"specific_function": "Transports L-glutamate, L- and D-aspartate and L-cystein (PubMed:21123949). Essential for terminating the postsynaptic action of glutamate by rapidly removing released glutamate from the synaptic cleft. Acts as a symport by cotransporting sodium. Negatively regulated by ARL6IP5 (By similarity).", "general_function": "Sodium:dicarboxylate symporter activity", "gene_names": ["SLC1A1"], "name": "Excitatory amino acid transporter 3", "drug_actions": []}, "P43004": {"specific_function": "Transports L-glutamate and also L- and D-aspartate. Essential for terminating the postsynaptic action of glutamate by rapidly removing released glutamate from the synaptic cleft. Acts as a symport by cotransporting sodium.", "general_function": "Sodium:dicarboxylate symporter activity", "gene_names": ["SLC1A2"], "name": "Excitatory amino acid transporter 2", "drug_actions": []}, "P42574": {"specific_function": "Involved in the activation cascade of caspases responsible for apoptosis execution. At the onset of apoptosis it proteolytically cleaves poly(ADP-ribose) polymerase (PARP) at a '216-Asp-|-Gly-217' bond. Cleaves and activates sterol regulatory element binding proteins (SREBPs) between the basic helix-loop-helix leucine zipper domain and the membrane attachment domain. Cleaves and activates caspase-6, -7 and -9. Involved in the cleavage of huntingtin. Triggers cell adhesion in sympathetic neurons through RET cleavage.", "general_function": "Phospholipase a2 activator activity", "gene_names": ["CASP3"], "name": "Caspase-3", "drug_actions": [{"action": "NEGATIVE MODULATOR", "target": "P42574", "drug": "DB01017"}]}, "P21554": {"specific_function": "Involved in cannabinoid-induced CNS effects. Acts by inhibiting adenylate cyclase. Could be a receptor for anandamide. Inhibits L-type Ca(2+) channel current. Isoform 2 and isoform 3 have altered ligand binding.", "general_function": "Drug binding", "gene_names": ["CNR1"], "name": "Cannabinoid receptor 1", "drug_actions": [{"action": "AGONIST", "target": "P21554", "drug": "DB00470"}, {"action": "PARTIAL AGONIST", "target": "P21554", "drug": "DB00486"}, {"action": "ANTAGONIST", "target": "P21554", "drug": "DB06155"}]}, "Q9H2P9": {"specific_function": "S-adenosyl-L-methionine-dependent methyltransferase that catalyzes four methylations of the modified target histidine residue in translation elongation factor 2 (EF-2), to form an intermediate called diphthine methyl ester. The four successive methylation reactions represent the second step of diphthamide biosynthesis.", "general_function": "Diphthine synthase activity", "gene_names": ["DPH5"], "name": "Diphthine methyl ester synthase", "drug_actions": []}, "P54577": {"specific_function": "Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr).", "general_function": "Tyrosine-trna ligase activity", "gene_names": ["YARS"], "name": "Tyrosine--tRNA ligase, cytoplasmic", "drug_actions": []}, "P68366": {"specific_function": "Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["TUBA4A"], "name": "Tubulin alpha-4A chain", "drug_actions": [{"action": "INHIBITOR", "target": "P68366", "drug": "DB00541"}, {"action": "INHIBITOR", "target": "P68366", "drug": "DB01179"}, {"action": "BINDER", "target": "P68366", "drug": "DB06772"}]}, "P68363": {"specific_function": "Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["TUBA1B"], "name": "Tubulin alpha-1B chain", "drug_actions": []}, "Q15822": {"specific_function": "After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.", "general_function": "Drug binding", "gene_names": ["CHRNA2"], "name": "Neuronal acetylcholine receptor subunit alpha-2", "drug_actions": [{"action": "AGONIST", "target": "Q15822", "drug": "DB00184"}, {"action": "AGONIST", "target": "Q15822", "drug": "DB00411"}, {"action": "ANTAGONIST", "target": "Q15822", "drug": "DB00416"}, {"action": "ANTAGONIST", "target": "Q15822", "drug": "DB00483"}, {"action": "ANTAGONIST", "target": "Q15822", "drug": "DB00514"}, {"action": "INHIBITOR", "target": "Q15822", "drug": "DB00565"}, {"action": "INHIBITOR", "target": "Q15822", "drug": "DB00657"}, {"action": "ALLOSTERIC MODULATOR", "target": "Q15822", "drug": "DB00674"}, {"action": "ANTAGONIST", "target": "Q15822", "drug": "DB00721"}, {"action": "ANTAGONIST", "target": "Q15822", "drug": "DB00728"}, {"action": "INHIBITOR", "target": "Q15822", "drug": "DB00732"}, {"action": "ANTAGONIST", "target": "Q15822", "drug": "DB00810"}, {"action": "ANTAGONIST", "target": "Q15822", "drug": "DB01135"}, {"action": "ANTAGONIST", "target": "Q15822", "drug": "DB01199"}, {"action": "ANTAGONIST", "target": "Q15822", "drug": "DB01226"}, {"action": "PARTIAL AGONIST", "target": "Q15822", "drug": "DB01245"}, {"action": "ANTAGONIST", "target": "Q15822", "drug": "DB01336"}, {"action": "ANTAGONIST", "target": "Q15822", "drug": "DB01337"}, {"action": "ANTAGONIST", "target": "Q15822", "drug": "DB01338"}, {"action": "ANTAGONIST", "target": "Q15822", "drug": "DB01339"}]}, "P02918": {"specific_function": "Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits).", "general_function": "Serine-type d-ala-d-ala carboxypeptidase activity", "gene_names": ["mrcA"], "name": "Penicillin-binding protein 1A", "drug_actions": [{"action": "INHIBITOR", "target": "P02918", "drug": "DB00274"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB00303"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB00430"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB00438"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB01327"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB01328"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB01329"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB01332"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB01333"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB01414"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB01415"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB01598"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB04570"}, {"action": "ANTAGONIST", "target": "P02918", "drug": "DB06211"}, {"action": "INHIBITOR", "target": "P02918", "drug": "DB06211"}]}, "P02919": {"specific_function": "Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits).", "general_function": "Serine-type d-ala-d-ala carboxypeptidase activity", "gene_names": ["mrcB"], "name": "Penicillin-binding protein 1B", "drug_actions": [{"action": "INHIBITOR", "target": "P02919", "drug": "DB00274"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB00303"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB00430"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB00438"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB01327"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB01328"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB01329"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB01332"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB01414"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB01415"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB01598"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB04570"}, {"action": "ANTAGONIST", "target": "P02919", "drug": "DB06211"}, {"action": "INHIBITOR", "target": "P02919", "drug": "DB06211"}]}, "P42971": {"general_function": "Penicillin binding", "gene_names": ["pbpC"], "name": "Penicillin-binding protein 3", "drug_actions": [{"action": "INHIBITOR", "target": "P42971", "drug": "DB00355"}, {"action": "INHIBITOR", "target": "P42971", "drug": "DB00493"}, {"action": "INHIBITOR", "target": "P42971", "drug": "DB01598"}, {"action": "INHIBITOR", "target": "P42971", "drug": "DB04570"}]}, "O75762": {"specific_function": "Receptor-activated non-selective cation channel involved in detection of pain and possibly also in cold perception and inner ear function (PubMed:25389312, PubMed:25855297). Has a central role in the pain response to endogenous inflammatory mediators and to a diverse array of volatile irritants, such as mustard oil, cinnamaldehyde, garlic and acrolein, an irritant from tears gas and vehicule exhaust fumes (PubMed:25389312, PubMed:20547126). Is also activated by menthol (in vitro)(PubMed:25389312). Acts also as a ionotropic cannabinoid receptor by being activated by delta(9)-tetrahydrocannabinol (THC), the psychoactive component of marijuana (PubMed:25389312). May be a component for the mechanosensitive transduction channel of hair cells in inner ear, thereby participating in the perception of sounds. Probably operated by a phosphatidylinositol second messenger system (By similarity).", "general_function": "Temperature-gated cation channel activity", "gene_names": ["TRPA1"], "name": "Transient receptor potential cation channel subfamily A member 1", "drug_actions": [{"action": "INDUCER", "target": "O75762", "drug": "DB00825"}]}, "Q9UNX9": {"specific_function": "Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. KCNJ14 gives rise to low-conductance channels with a low affinity to the channel blockers Barium and Cesium (By similarity).", "name": "ATP-sensitive inward rectifier potassium channel 14", "drug_actions": [], "general_function": "Inward rectifier potassium channel activity", "in_complexes": ["ATP-sensitive potassium channel"], "gene_names": ["KCNJ14"]}, "P0A789": {"general_function": "Aspartate carbamoyltransferase activity", "gene_names": ["pyrB"], "name": "Aspartate carbamoyltransferase catalytic chain", "drug_actions": []}, "Q9ZK53": {"specific_function": "Low-potential electron donor to a number of redox enzymes.", "general_function": "Fmn binding", "gene_names": ["fldA"], "name": "Flavodoxin", "drug_actions": []}, "Q93EK7": {"general_function": "Transferase activity, transferring glycosyl groups", "gene_names": ["lgtC"], "name": "LgtC", "drug_actions": []}, "P26789": {"specific_function": "Antenna complexes are light-harvesting systems, which transfer the excitation energy to the reaction centers.", "general_function": "Metal ion binding", "gene_names": [], "name": "Light-harvesting protein B-800/850 alpha chain", "drug_actions": []}, "P72161": {"specific_function": "Cell wall formation.", "general_function": "Serine-type d-ala-d-ala carboxypeptidase activity", "gene_names": ["pbpG"], "name": "D-alanyl-D-alanine endopeptidase", "drug_actions": [{"action": "INHIBITOR", "target": "P72161", "drug": "DB00438"}]}, "P08473": {"specific_function": "Thermolysin-like specificity, but is almost confined on acting on polypeptides of up to 30 amino acids (PubMed:15283675, PubMed:8168535). Biologically important in the destruction of opioid peptides such as Met- and Leu-enkephalins by cleavage of a Gly-Phe bond (PubMed:17101991). Able to cleave angiotensin-1, angiotensin-2 and angiotensin 1-9 (PubMed:15283675). Involved in the degradation of atrial natriuretic factor (ANF) (PubMed:2531377, PubMed:2972276). Displays UV-inducible elastase activity toward skin preelastic and elastic fibers (PubMed:20876573).", "general_function": "Zinc ion binding", "gene_names": ["MME"], "name": "Neprilysin", "drug_actions": [{"action": "INHIBITOR", "target": "P08473", "drug": "DB00616"}, {"action": "INHIBITOR", "target": "P08473", "drug": "DB02557"}, {"action": "INHIBITOR", "target": "P08473", "drug": "DB08626"}, {"action": "ANTAGONIST", "target": "P08473", "drug": "DB09292"}, {"action": "INHIBITOR", "target": "P08473", "drug": "DB09292"}]}, "Q9NRE1": {"specific_function": "May hydrolyze collagen type IV, fibronectin, fibrinogen, beta-casein, type I gelatin and alpha-1 proteinase inhibitor. Is also able to activate progelatinase B.", "general_function": "Zinc ion binding", "gene_names": ["MMP26"], "name": "Matrix metalloproteinase-26", "drug_actions": [{"action": "INHIBITOR", "target": "Q9NRE1", "drug": "DB00786"}]}, "P00644": {"specific_function": "Enzyme that catalyzes the hydrolysis of both DNA and RNA at the 5' position of the phosphodiester bond.", "general_function": "Nucleic acid binding", "gene_names": ["nuc"], "name": "Thermonuclease", "drug_actions": []}, "Q8N543": {"specific_function": "Prolyl 3-hydroxylase that catalyzes 3-hydroxylation of 'Pro-62' of small ribosomal subunit RPS23, thereby regulating protein translation termination efficiency. Involved in stress granule formation.", "general_function": "Peptidyl-proline dioxygenase activity", "gene_names": ["OGFOD1"], "name": "Prolyl 3-hydroxylase OGFOD1", "drug_actions": []}, "P00646": {"specific_function": "Inactivates ribosomes by hydrolyzing 16S RNA in 30S ribosomes at a specific site.Colicins are polypeptide toxins produced by and active against E.coli and closely related bacteria.", "general_function": "Rna binding", "gene_names": ["ceaC"], "name": "Colicin-E3", "drug_actions": []}, "P35520": {"specific_function": "Hydro-lyase catalyzing the first step of the transsulfuration pathway, where the hydroxyl group of L-serine is displaced by L-homocysteine in a beta-replacement reaction to form L-cystathionine, the precursor of L-cysteine. This catabolic route allows the elimination of L-methionine and the toxic metabolite L-homocysteine (PubMed:23981774, PubMed:20506325, PubMed:23974653). Also involved in the production of hydrogen sulfide, a gasotransmitter with signaling and cytoprotective effects on neurons (By similarity).", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["CBS"], "name": "Cystathionine beta-synthase", "drug_actions": [{"action": "COFACTOR", "target": "P35520", "drug": "DB00114"}, {"action": "ACTIVATOR", "target": "P35520", "drug": "DB00118"}]}, "P42684": {"specific_function": "Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like MYH10 (involved in movement); CTTN (involved in signaling); or TUBA1 and TUBB (microtubule subunits). Binds directly F-actin and regulates actin cytoskeletal structure through its F-actin-bundling activity. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as CRK, CRKL, DOK1 or ARHGAP35. Adhesion-dependent phosphorylation of ARHGAP35 promotes its association with RASA1, resulting in recruitment of ARHGAP35 to the cell periphery where it inhibits RHO. Phosphorylates multiple receptor tyrosine kinases like PDGFRB and other substrates which are involved in endocytosis regulation such as RIN1. In brain, may regulate neurotransmission by phosphorylating proteins at the synapse. ABL2 acts also as a regulator of multiple pathological signaling cascades during infection. Pathogens can highjack ABL2 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1.", "general_function": "Receptor binding", "gene_names": ["ABL2"], "name": "Abelson tyrosine-protein kinase 2", "drug_actions": [{"action": "INHIBITOR", "target": "P42684", "drug": "DB00171"}, {"action": "MULTITARGET", "target": "P42684", "drug": "DB01254"}]}, "P42685": {"specific_function": "Non-receptor tyrosine-protein kinase that negatively regulates cell proliferation. Positively regulates PTEN protein stability through phosphorylation of PTEN on 'Tyr-336', which in turn prevents its ubiquitination and degradation, possibly by reducing its binding to NEDD4. May function as a tumor suppressor.", "general_function": "Receptor binding", "gene_names": ["FRK"], "name": "Tyrosine-protein kinase FRK", "drug_actions": [{"action": "INHIBITOR", "target": "P42685", "drug": "DB08896"}]}, "P62617": {"specific_function": "Involved in the biosynthesis of isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), two major building blocks of isoprenoid compounds. Catalyzes the conversion of 4-diphosphocytidyl-2-C-methyl-D-erythritol 2-phosphate (CDP-ME2P) to 2-C-methyl-D-erythritol 2,4-cyclodiphosphate (ME-CPP) with a corresponding release of cytidine 5-monophosphate (CMP). Also converts 4-diphosphocytidyl-2-C-methyl-D-erythritol into 2-C-methyl-D-erythritol 3,4-cyclophosphate and CMP.", "general_function": "Zinc ion binding", "gene_names": ["ispF"], "name": "2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase", "drug_actions": []}, "P08183": {"specific_function": "Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.", "general_function": "Xenobiotic-transporting atpase activity", "gene_names": ["ABCB1"], "name": "Multidrug resistance protein 1", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "P08183", "drug": "DB04877"}, {"action": "INDUCER", "target": "P08183", "drug": "DB04905"}]}, "P04179": {"specific_function": "Destroys superoxide anion radicals which are normally produced within the cells and which are toxic to biological systems.", "general_function": "Superoxide dismutase activity", "gene_names": ["SOD2"], "name": "Superoxide dismutase [Mn], mitochondrial", "drug_actions": []}, "P24670": {"specific_function": "Involved in the third step of the chorismate pathway, which leads to the biosynthesis of aromatic amino acids. Catalyzes the cis-dehydration of 3-dehydroquinate (DHQ) and introduces the first double bond of the aromatic ring to yield 3-dehydroshikimate. The reaction involves the formation of an imine intermediate between the keto group of 3-dehydroquinate and the epsylon-amino group of Lys-170 at the active site.", "general_function": "3-dehydroquinate dehydratase activity", "gene_names": ["aroD"], "name": "3-dehydroquinate dehydratase", "drug_actions": []}, "P0A078": {"specific_function": "Removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). Requires deformylation of the N(alpha)-formylated initiator methionine before it can be hydrolyzed.", "general_function": "Metalloaminopeptidase activity", "gene_names": ["map"], "name": "Methionine aminopeptidase", "drug_actions": []}, "P0A079": {"specific_function": "Removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). Requires deformylation of the N(alpha)-formylated initiator methionine before it can be hydrolyzed.", "general_function": "Metalloaminopeptidase activity", "gene_names": ["map"], "name": "Methionine aminopeptidase", "drug_actions": []}, "P35869": {"specific_function": "Ligand-activated transcriptional activator. Binds to the XRE promoter region of genes it activates. Activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes (such as the CYP1A1 gene). Mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. Involved in cell-cycle regulation. Likely to play an important role in the development and maturation of many tissues. Regulates the circadian clock by inhibiting the basal and circadian expression of the core circadian component PER1. Inhibits PER1 by repressing the CLOCK-ARNTL/BMAL1 heterodimer mediated transcriptional activation of PER1.", "general_function": "Transcription regulatory region dna binding", "gene_names": ["AHR"], "name": "Aryl hydrocarbon receptor", "drug_actions": [{"action": "AGONIST", "target": "P35869", "drug": "DB00379"}, {"action": "AGONIST", "target": "P35869", "drug": "DB00393"}, {"action": "AGONIST", "target": "P35869", "drug": "DB00499"}, {"action": "AGONIST", "target": "P35869", "drug": "DB01076"}, {"action": "AGONIST", "target": "P35869", "drug": "DB01097"}, {"action": "AGONIST", "target": "P35869", "drug": "DB01404"}]}, "P0A076": {"specific_function": "Toxin that seems to act by forming pores in the membrane of the cell. Has a hemolytic and a leucotoxic activity (By similarity).", "gene_names": ["hlgB"], "name": "Gamma-hemolysin component B", "drug_actions": []}, "Q9X278": {"general_function": "Butyrate kinase activity", "gene_names": ["buk2"], "name": "Probable butyrate kinase 2", "drug_actions": []}, "O32393": {"general_function": "Phosphorelay sensor kinase activity", "gene_names": ["cyaC"], "name": "Adenylate cyclase", "drug_actions": []}, "Q96HD9": {"specific_function": "Plays an important role in deacetylating mercapturic acids in kidney proximal tubules. Also acts on N-acetyl-aromatic amino acids (By similarity).", "general_function": "Metal ion binding", "gene_names": ["ACY3"], "name": "N-acyl-aromatic-L-amino acid amidohydrolase (carboxylate-forming)", "drug_actions": []}, "P0A4L9": {"specific_function": "DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.", "general_function": "Magnesium ion binding", "gene_names": ["gyrB"], "name": "DNA gyrase subunit B", "drug_actions": [{"action": "INHIBITOR", "target": "P0A4L9", "drug": "DB01044"}]}, "P19424": {"general_function": "Cellulase activity", "gene_names": [], "name": "Endoglucanase", "drug_actions": []}, "P06850": {"specific_function": "Hormone regulating the release of corticotropin from pituitary gland (By similarity). Induces NLRP6 in intestinal epithelial cells, hence may influence gut microbiota profile (By similarity).", "general_function": "Receptor binding", "gene_names": ["CRH"], "name": "Corticoliberin", "drug_actions": [{"action": "AGONIST", "target": "P06850", "drug": "DB01285"}]}, "P19429": {"specific_function": "Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.", "general_function": "Troponin t binding", "gene_names": ["TNNI3"], "name": "Troponin I, cardiac muscle", "drug_actions": []}, "O31616": {"specific_function": "Catalyzes the FAD-dependent oxidative deamination of various amines and D-amino acids to yield the corresponding alpha-keto acids, ammonia/amine, and hydrogen peroxide. Oxidizes sarcosine (N-methylglycine), N-ethylglycine and glycine. Can also oxidize the herbicide glyphosate (N-phosphonomethylglycine). Displays lower activities on D-alanine, D-valine, D-proline and D-methionine. Does not act on L-amino acids and other D-amino acids. Is essential for thiamine biosynthesis since the oxidation of glycine catalyzed by ThiO generates the glycine imine intermediate (dehydroglycine) required for the biosynthesis of the thiazole ring of thiamine pyrophosphate.", "general_function": "Glycine oxidase activity", "gene_names": ["thiO"], "name": "Glycine oxidase", "drug_actions": []}, "P23458": {"specific_function": "Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway. Kinase partner for the interleukin (IL)-2 receptor.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["JAK1"], "name": "Tyrosine-protein kinase JAK1", "drug_actions": [{"action": "INHIBITOR", "target": "P23458", "drug": "DB08877"}, {"action": "INHIBITOR", "target": "P23458", "drug": "DB08895"}]}, "Q03431": {"specific_function": "This is a receptor for parathyroid hormone and for parathyroid hormone-related peptide. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and also a phosphatidylinositol-calcium second messenger system.", "general_function": "Protein self-association", "gene_names": ["PTH1R"], "name": "Parathyroid hormone/parathyroid hormone-related peptide receptor", "drug_actions": [{"action": "ACTIVATOR", "target": "Q03431", "drug": "DB05829"}, {"action": "BINDER", "target": "Q03431", "drug": "DB06285"}]}, "P06858": {"specific_function": "The primary function of this lipase is the hydrolysis of triglycerides of circulating chylomicrons and very low density lipoproteins (VLDL). Binding to heparin sulfate proteogylcans at the cell surface is vital to the function. The apolipoprotein, APOC2, acts as a coactivator of LPL activity in the presence of lipids on the luminal surface of vascular endothelium (By similarity).", "general_function": "Triglyceride lipase activity", "gene_names": ["LPL"], "name": "Lipoprotein lipase", "drug_actions": [{"action": "INHIBITOR", "target": "P06858", "drug": "DB06439"}]}, "Q8TD30": {"specific_function": "Catalyzes the reversible transamination between alanine and 2-oxoglutarate to form pyruvate and glutamate.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["GPT2"], "name": "Alanine aminotransferase 2", "drug_actions": [{"action": "COFACTOR", "target": "Q8TD30", "drug": "DB00114"}, {"action": "INHIBITOR", "target": "Q8TD30", "drug": "DB00780"}]}, "Q5PXQ6": {"specific_function": "Catalyzes the ortho-cleavage of the aromatic ring of hydroxyquinol.", "general_function": "Hydroxyquinol 1,2-dioxygenase activity", "gene_names": ["chqB"], "name": "Hydroxyquinol 1,2-dioxygenase", "drug_actions": []}, "Q9Y3R4": {"specific_function": "Catalyzes the removal of sialic acid (N-acetylneuraminic acid) moities from glycoproteins, oligosaccharides and gangliosides.", "general_function": "Exo-alpha-(2->8)-sialidase activity", "gene_names": ["NEU2"], "name": "Sialidase-2", "drug_actions": [{"action": "INHIBITOR", "target": "Q9Y3R4", "drug": "DB00198"}, {"action": "INHIBITOR", "target": "Q9Y3R4", "drug": "DB00558"}]}, "Q13200": {"specific_function": "Acts as a regulatory subunit of the 26 proteasome which is involved in the ATP-dependent degradation of ubiquitinated proteins.Binds to the intracellular domain of tumor necrosis factor type 1 receptor. The binding domain of TRAP1 and TRAP2 resides outside the death domain of TNFR1.", "general_function": "Enzyme regulator activity", "gene_names": ["PSMD2"], "name": "26S proteasome non-ATPase regulatory subunit 2", "drug_actions": [{"action": "INHIBITOR", "target": "Q13200", "drug": "DB00188"}]}, "P49336": {"specific_function": "Component of the Mediator complex, a coactivator involved in regulated gene transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. Phosphorylates the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAp II), which may inhibit the formation of a transcription initiation complex. Phosphorylates CCNH leading to down-regulation of the TFIIH complex and transcriptional repression. Recruited through interaction with MAML1 to hyperphosphorylate the intracellular domain of NOTCH, leading to its degradation.", "general_function": "Ubiquitin protein ligase activity", "gene_names": ["CDK8"], "name": "Cyclin-dependent kinase 8", "drug_actions": []}, "P96618": {"specific_function": "Transfers the 4'-phosphopantetheine moiety from coenzyme A to a Ser of fatty acid acyl-carrier-protein ACP. Also modifies the D-alanyl carrier protein but fails to recognize PCP and AcpK, an acyl carrier protein of secondary metabolism.", "general_function": "Magnesium ion binding", "gene_names": ["acpS"], "name": "Holo-[acyl-carrier-protein] synthase", "drug_actions": []}, "P46859": {"general_function": "Gluconokinase activity", "gene_names": ["gntK"], "name": "Thermoresistant gluconokinase", "drug_actions": []}, "P32169": {"specific_function": "Catalyzes the reversible cleavage of L-rhamnulose-1-phosphate to dihydroxyacetone phosphate (DHAP) and L-lactaldehyde.", "general_function": "Rhamnulose-1-phosphate aldolase activity", "gene_names": ["rhaD"], "name": "Rhamnulose-1-phosphate aldolase", "drug_actions": []}, "Q9H244": {"specific_function": "Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation.", "general_function": "Guanyl-nucleotide exchange factor activity", "gene_names": ["P2RY12"], "name": "P2Y purinoceptor 12", "drug_actions": [{"action": "ANTAGONIST", "target": "Q9H244", "drug": "DB00208"}, {"action": "AGONIST", "target": "Q9H244", "drug": "DB00374"}, {"action": "ANTAGONIST", "target": "Q9H244", "drug": "DB00758"}, {"action": "AGONIST", "target": "Q9H244", "drug": "DB01240"}, {"action": "ANTAGONIST", "target": "Q9H244", "drug": "DB06209"}, {"action": "INHIBITOR", "target": "Q9H244", "drug": "DB06441"}, {"action": "INHIBITOR", "target": "Q9H244", "drug": "DB08816"}]}, "P62623": {"specific_function": "Converts 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate into isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP). Is also involved in penicillin tolerance and control of the stringent response. Seems to directly or indirectly interact with RelA to maintain it in an inactive form during normal growth.", "general_function": "Metal ion binding", "gene_names": ["ispH"], "name": "4-hydroxy-3-methylbut-2-enyl diphosphate reductase", "drug_actions": []}, "P23416": {"specific_function": "The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).", "general_function": "Transmitter-gated ion channel activity", "gene_names": ["GLRA2"], "name": "Glycine receptor subunit alpha-2", "drug_actions": [{"action": "ANTAGONIST", "target": "P23416", "drug": "DB00431"}, {"action": "ANTAGONIST", "target": "P23416", "drug": "DB00466"}, {"action": "AGONIST", "target": "P23416", "drug": "DB00898"}]}, "P23415": {"specific_function": "The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).", "name": "Glycine receptor subunit alpha-1", "drug_actions": [{"action": "AGONIST", "target": "P23415", "drug": "DB00228"}, {"action": "ANTAGONIST", "target": "P23415", "drug": "DB00431"}, {"action": "AGONIST", "target": "P23415", "drug": "DB00753"}, {"action": "AGONIST", "target": "P23415", "drug": "DB00898"}, {"action": "AGONIST", "target": "P23415", "drug": "DB01028"}, {"action": "ALLOSTERIC MODULATOR", "target": "P23415", "drug": "DB01159"}, {"action": "AGONIST", "target": "P23415", "drug": "DB01189"}, {"action": "AGONIST", "target": "P23415", "drug": "DB01236"}, {"action": "ANTAGONIST", "target": "P23415", "drug": "DB01381"}], "general_function": "Transmitter-gated ion channel activity", "in_complexes": ["Glycine receptor (alpha-1/beta)"], "gene_names": ["GLRA1"]}, "Q8VTT5": {"specific_function": "Catalyzes the stereospecific hydrolysis of the cyclic amide bond of D-hydantoin derivatives.", "general_function": "Metal ion binding", "gene_names": ["hyuA"], "name": "D-hydantoinase", "drug_actions": []}, "Q9WZI0": {"specific_function": "Catalyzes the conversion of uracil and 5-phospho-alpha-D-ribose 1-diphosphate (PRPP) to UMP and diphosphate.", "general_function": "Uracil phosphoribosyltransferase activity", "gene_names": ["upp"], "name": "Uracil phosphoribosyltransferase", "drug_actions": []}, "Q8NER1": {"specific_function": "Ligand-activated non-selective calcium permeant cation channel involved in detection of noxious chemical and thermal stimuli. Seems to mediate proton influx and may be involved in intracellular acidosis in nociceptive neurons. Involved in mediation of inflammatory pain and hyperalgesia. Sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. Can be activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. Acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. Triggers a form of long-term depression (TRPV1-LTD) mediated by the endocannabinoid anandamine in the hippocampus and nucleus accumbens by affecting AMPA receptors endocytosis (By similarity). Activation by vanilloids, like capsaicin, and temperatures higher than 42 degrees Celsius, exhibits a time- and Ca(2+)-dependent outward rectification, followed by a long-lasting refractory state. Mild extracellular acidic pH (6.5) potentiates channel activation by noxious heat and vanilloids, whereas acidic conditions (pH <6) directly activate the channel.", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["TRPV1"], "name": "Transient receptor potential cation channel subfamily V member 1", "drug_actions": [{"action": "INDUCER", "target": "Q8NER1", "drug": "DB00159"}, {"action": "INDUCER", "target": "Q8NER1", "drug": "DB00168"}, {"action": "AGONIST", "target": "Q8NER1", "drug": "DB06774"}]}, "P11230": {"specific_function": "After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.", "general_function": "Ligand-gated ion channel activity", "gene_names": ["CHRNB1"], "name": "Acetylcholine receptor subunit beta", "drug_actions": [{"action": "ALLOSTERIC MODULATOR", "target": "P11230", "drug": "DB00674"}]}, "Q9X9L0": {"gene_names": ["mglB"], "name": "Hypothetical gliding protein", "drug_actions": []}, "P63000": {"specific_function": "Plasma membrane-associated small GTPase which cycles between active GTP-bound and inactive GDP-bound states. In its active state, binds to a variety of effector proteins to regulate cellular responses such as secretory processes, phagocytosis of apoptotic cells, epithelial cell polarization and growth-factor induced formation of membrane ruffles. Rac1 p21/rho GDI heterodimer is the active component of the cytosolic factor sigma 1, which is involved in stimulation of the NADPH oxidase activity in macrophages. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. Stimulates PKN2 kinase activity. In concert with RAB7A, plays a role in regulating the formation of RBs (ruffled borders) in osteoclasts. In glioma cells, promotes cell migration and invasion. In podocytes, promotes nuclear shuttling of NR3C2; this modulation is required for a proper kidney functioning. Required for atypical chemokine receptor ACKR2-induced LIMK1-PAK1-dependent phosphorylation of cofilin (CFL1) and for up-regulation of ACKR2 from endosomal compartment to cell membrane, increasing its efficiency in chemokine uptake and degradation. In synapses, seems to mediate the regulation of F-actin cluster formation performed by SHANK3.Isoform B has an accelerated GEF-independent GDP/GTP exchange and an impaired GTP hydrolysis, which is restored partially by GTPase-activating proteins. It is able to bind to the GTPase-binding domain of PAK but not full-length PAK in a GTP-dependent manner, suggesting that the insertion does not completely abolish effector interaction.", "name": "Ras-related C3 botulinum toxin substrate 1", "drug_actions": [{"action": "INHIBITOR", "target": "P63000", "drug": "DB00514"}], "general_function": "Thioesterase binding", "in_complexes": ["NADPH oxidase"], "gene_names": ["RAC1"]}, "P37001": {"specific_function": "PagP is required both for biosynthesis of hepta-acylated lipid A species containing palmitate and for resistance to cationic antimicrobial peptides (CAMPs). It catalyzes the transfer of a palmitate chain (16:0) from the sn-1 position of a glycerophospholipid to the free hydroxyl group of the (R)-3-hydroxymyristate chain at position 2 of lipid A (endotoxin). Modifications of lipid A with a palmitate chain allow to evade host immune defenses by resisting antimicrobial peptides and attenuating the inflammatory response to infection triggered by lipopolysaccharide through the Toll-like receptor 4 (TLR4) signal transduction pathway. Phosphatidylglycerol (PtdGro), phosphatidylethanolamine (PtdEtn), phosphatidylserine (PtdSer) and phosphatidic acid (Ptd-OH) are all effective acyl donors.", "general_function": "O-palmitoyltransferase activity", "gene_names": ["pagP"], "name": "Lipid A palmitoyltransferase PagP", "drug_actions": []}, "O94956": {"specific_function": "Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.", "general_function": "Sodium-independent organic anion transmembrane transporter activity", "gene_names": ["SLCO2B1"], "name": "Solute carrier organic anion transporter family member 2B1", "drug_actions": [{"action": "INHIBITOR", "target": "O94956", "drug": "DB01049"}]}, "P20674": {"specific_function": "This is the heme A-containing chain of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport.", "general_function": "Metal ion binding", "gene_names": ["COX5A"], "name": "Cytochrome c oxidase subunit 5A, mitochondrial", "drug_actions": []}, "Q8IVH4": {"specific_function": "Probable GTPase. May function as chaperone. May be involved in the transport of cobalamin (Cbl) into mitochondria for the final steps of adenosylcobalamin (AdoCbl) synthesis.", "general_function": "Hydrolase activity", "gene_names": ["MMAA"], "name": "Methylmalonic aciduria type A protein, mitochondrial", "drug_actions": [{"action": "COFACTOR", "target": "Q8IVH4", "drug": "DB00115"}, {"action": "OTHER/UNKNOWN", "target": "Q8IVH4", "drug": "DB00200"}]}, "Q72547": {"general_function": "Rna-dna hybrid ribonuclease activity", "gene_names": ["pol"], "name": "Reverse transcriptase/RNaseH", "drug_actions": [{"action": "INHIBITOR", "target": "Q72547", "drug": "DB00238"}, {"action": "INHIBITOR", "target": "Q72547", "drug": "DB00300"}, {"action": "INHIBITOR", "target": "Q72547", "drug": "DB00495"}, {"action": "INHIBITOR", "target": "Q72547", "drug": "DB00625"}, {"action": "INHIBITOR", "target": "Q72547", "drug": "DB00649"}, {"action": "INHIBITOR", "target": "Q72547", "drug": "DB00705"}, {"action": "INHIBITOR", "target": "Q72547", "drug": "DB00709"}, {"action": "INHIBITOR", "target": "Q72547", "drug": "DB00879"}, {"action": "INHIBITOR", "target": "Q72547", "drug": "DB00900"}, {"action": "INHIBITOR", "target": "Q72547", "drug": "DB00943"}, {"action": "INHIBITOR", "target": "Q72547", "drug": "DB01048"}, {"action": "INHIBITOR", "target": "Q72547", "drug": "DB08864"}]}, "P30926": {"specific_function": "After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.", "general_function": "Ligand-gated ion channel activity", "gene_names": ["CHRNB4"], "name": "Neuronal acetylcholine receptor subunit beta-4", "drug_actions": [{"action": "AGONIST", "target": "P30926", "drug": "DB00184"}, {"action": "ANTAGONIST", "target": "P30926", "drug": "DB00514"}, {"action": "ALLOSTERIC MODULATOR", "target": "P30926", "drug": "DB00674"}, {"action": "ANTAGONIST", "target": "P30926", "drug": "DB01090"}, {"action": "OTHER/UNKNOWN", "target": "P30926", "drug": "DB01227"}]}, "Q93PP9": {"specific_function": "Iron-storage protein, whose ferroxidase center binds Fe(2+) ions, oxidizes them by dioxygen to Fe(3+), and participates in the subsequent Fe(3+) oxide mineral core formation within the central cavity of the protein complex.", "general_function": "Ferroxidase activity", "gene_names": ["bfr"], "name": "Bacterioferritin", "drug_actions": []}, "P15086": {"general_function": "Zinc ion binding", "gene_names": ["CPB1"], "name": "Carboxypeptidase B", "drug_actions": []}, "Q15759": {"specific_function": "Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK11 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. MAPK11 functions are mostly redundant with those of MAPK14. Some of the targets are downstream kinases which are activated through phosphorylation and further phosphorylate additional targets. RPS6KA5/MSK1 and RPS6KA4/MSK2 can directly phosphorylate and activate transcription factors such as CREB1, ATF1, the NF-kappa-B isoform RELA/NFKB3, STAT1 and STAT3, but can also phosphorylate histone H3 and the nucleosomal protein HMGN1. RPS6KA5/MSK1 and RPS6KA4/MSK2 play important roles in the rapid induction of immediate-early genes in response to stress or mitogenic stimuli, either by inducing chromatin remodeling or by recruiting the transcription machinery. On the other hand, two other kinase targets, MAPKAPK2/MK2 and MAPKAPK3/MK3, participate in the control of gene expression mostly at the post-transcriptional level, by phosphorylating ZFP36 (tristetraprolin) and ELAVL1, and by regulating EEF2K, which is important for the elongation of mRNA during translation. MKNK1/MNK1 and MKNK2/MNK2, two other kinases activated by p38 MAPKs, regulate protein synthesis by phosphorylating the initiation factor EIF4E2. In the cytoplasm, the p38 MAPK pathway is an important regulator of protein turnover. For example, CFLAR is an inhibitor of TNF-induced apoptosis whose proteasome-mediated degradation is regulated by p38 MAPK phosphorylation. Ectodomain shedding of transmembrane proteins is regulated by p38 MAPKs as well. In response to inflammatory stimuli, p38 MAPKs phosphorylate the membrane-associated metalloprotease ADAM17. Such phosphorylation is required for ADAM17-mediated ectodomain shedding of TGF-alpha family ligands, which results in the activation of EGFR signaling and cell proliferation. Additional examples of p38 MAPK substrates are the FGFR1. FGFR1 can be translocated from the extracellular space into the cytosol and nucleus of target cells, and regulates processes such as rRNA synthesis and cell growth. FGFR1 translocation requires p38 MAPK activation. In the nucleus, many transcription factors are phosphorylated and activated by p38 MAPKs in response to different stimuli. Classical examples include ATF1, ATF2, ATF6, ELK1, PTPRH, DDIT3, TP53/p53 and MEF2C and MEF2A. The p38 MAPKs are emerging as important modulators of gene expression by regulating chromatin modifiers and remodelers. The promoters of several genes involved in the inflammatory response, such as IL6, IL8 and IL12B, display a p38 MAPK-dependent enrichment of histone H3 phosphorylation on 'Ser-10' (H3S10ph) in LPS-stimulated myeloid cells. This phosphorylation enhances the accessibility of the cryptic NF-kappa-B-binding sites marking promoters for increased NF-kappa-B recruitment.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["MAPK11"], "name": "Mitogen-activated protein kinase 11", "drug_actions": [{"action": "INHIBITOR", "target": "Q15759", "drug": "DB08896"}]}, "Q15758": {"specific_function": "Sodium-dependent amino acids transporter that has a broad substrate specificity, with a preference for zwitterionic amino acids. It accepts as substrates all neutral amino acids, including glutamine, asparagine, and branched-chain and aromatic amino acids, and excludes methylated, anionic, and cationic amino acids. May also be activated by insulin. Through binding of the fusogenic protein syncytin-1/ERVW-1 may mediate trophoblasts syncytialization, the spontaneous fusion of their plasma membranes, an essential process in placental development (PubMed:10708449, PubMed:23492904). Acts as a cell surface receptor for feline endogenous virus RD114, baboon M7 endogenous virus and type D simian retroviruses (PubMed:10051606, PubMed:10196349).", "general_function": "Virus receptor activity", "gene_names": ["SLC1A5"], "name": "Neutral amino acid transporter B(0)", "drug_actions": []}, "P30273": {"specific_function": "Associates with a variety of FcR alpha chains to form a functional signaling complex. Regulates several aspects of the immune response. The gamma subunit has a critical role in allowing the IgE Fc receptor to reach the cell surface. Also involved in collagen-mediated platelet activation and in neutrophil activation mediated by integrin.", "general_function": "Igg binding", "gene_names": ["FCER1G"], "name": "High affinity immunoglobulin epsilon receptor subunit gamma", "drug_actions": [{"action": "AGONIST", "target": "P30273", "drug": "DB00895"}]}, "Q0WKM4": {"general_function": "Serine o-acetyltransferase activity", "gene_names": ["cysE"], "name": "Serine acetyltransferase", "drug_actions": []}, "P12823": {"specific_function": "Capsid protein C self-assembles to form an icosahedral capsid about 30 nm in diameter. The capsid encapsulates the genomic RNA.prM acts as a chaperone for envelope protein E during intracellular virion assembly by masking and inactivating envelope protein E fusion peptide. prM is matured in the last step of virion assembly, presumably to avoid catastrophic activation of the viral fusion peptide induced by the acidic pH of the trans-Golgi network. After cleavage by host furin, the pr peptide is released in the extracellular medium and small envelope protein M and envelope protein E homodimers are dissociated.Envelope protein E binding to host cell surface receptor is followed by virus internalization through clathrin-mediated endocytosis. Envelope protein E is subsequently involved in membrane fusion between virion and host late endosomes. Synthesized as a homodimer with prM which acts as a chaperone for envelope protein E. After cleavage of prM, envelope protein E dissociate from small envelope protein M and homodimerizes.Non-structural protein 1 is involved in virus replication and regulation of the innate immune response. Soluble and membrane-associated NS1 may activate human complement and induce host vascular leakage. This effect might explain the clinical manifestations of dengue hemorrhagic fever and dengue shock syndrome.Non-structural protein 2A may be involved viral RNA replication and capsid assembly.Non-structural protein 2B is a required cofactor for the serine protease function of NS3.Serine protease NS3 displays three enzymatic activities: serine protease, NTPase and RNA helicase. NS3 serine protease, in association with NS2B, performs its autocleavage and cleaves the polyprotein at dibasic sites in the cytoplasm: C-prM, NS2A-NS2B, NS2B-NS3, NS3-NS4A, NS4A-2K and NS4B-NS5. NS3 RNA helicase binds RNA and unwinds dsRNA in the 3' to 5' direction (By similarity).Non-structural protein 4A induces host endoplasmic reticulum membrane rearrangements leading to the formation of virus-induced membranous vesicles hosting the dsRNA and polymerase, functioning as a replication complex. NS4A might also regulate the ATPase activity of the NS3 helicase.Peptide 2k functions as a signal peptide for NS4B and is required for the interferon antagonism activity of the latter.Non-structural protein 4B inhibits interferon (IFN)-induced host STAT1 phosphorylation and nuclear translocation, thereby preventing the establishment of cellular antiviral state by blocking the IFN-alpha/beta pathway.RNA-directed RNA polymerase NS5 replicates the viral (+) and (-) genome, and performs the capping of genomes in the cytoplasm. NS5 methylates viral RNA cap at guanine N-7 and ribose 2'-O positions. Besides its role in genome replication, also prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) signaling pathway. Inhibits host TYK2 and STAT2 phosphorylation, thereby preventing activation of JAK-STAT signaling pathway (By similarity).", "general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "Q9H228": {"specific_function": "Receptor for the lysosphingolipid sphingosine 1-phosphate (S1P). S1P is a bioactive lysophospholipid that elicits diverse physiological effect on most types of cells and tissues. Is coupled to both the G(i/0)alpha and G(12) subclass of heteromeric G-proteins (By similarity). May play a regulatory role in the transformation of radial glial cells into astrocytes and may affect proliferative activity of these cells.", "general_function": "Sphingosine-1-phosphate receptor activity", "gene_names": ["S1PR5"], "name": "Sphingosine 1-phosphate receptor 5", "drug_actions": [{"action": "MODULATOR", "target": "Q9H228", "drug": "DB08868"}]}, "Q9GZR5": {"specific_function": "Catalyzes the first and rate-limiting reaction of the four that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process, allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle. Condensing enzyme that specifically elongates C24:0 and C26:0 acyl-CoAs. May participate to the production of saturated and monounsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. May play a critical role in early brain and skin development.", "general_function": "Transferase activity", "gene_names": ["ELOVL4"], "name": "Elongation of very long chain fatty acids protein 4", "drug_actions": []}, "P29498": {"specific_function": "May play a role in the transport of fatty acids. Binds various fatty acids, such as arachidonic, oleic, palmitic and linolenic acid (in vitro).", "general_function": "Transporter activity", "gene_names": [], "name": "14 kDa fatty acid-binding protein", "drug_actions": []}, "Q16790": {"specific_function": "Reversible hydration of carbon dioxide. Participates in pH regulation. May be involved in the control of cell proliferation and transformation. Appears to be a novel specific biomarker for a cervical neoplasia.", "general_function": "Zinc ion binding", "gene_names": ["CA9"], "name": "Carbonic anhydrase 9", "drug_actions": [{"action": "INHIBITOR", "target": "Q16790", "drug": "DB00562"}, {"action": "INHIBITOR", "target": "Q16790", "drug": "DB00774"}, {"action": "INHIBITOR", "target": "Q16790", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q16790", "drug": "DB00999"}, {"action": "INHIBITOR", "target": "Q16790", "drug": "DB08846"}]}, "O15427": {"specific_function": "Proton-linked monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate (By similarity).", "general_function": "Symporter activity", "gene_names": ["SLC16A3"], "name": "Monocarboxylate transporter 4", "drug_actions": []}, "Q9NY59": {"specific_function": "Catalyzes the hydrolysis of sphingomyelin to form ceramide and phosphocholine. Ceramide mediates numerous cellular functions, such as apoptosis and growth arrest, and is capable of regulating these 2 cellular events independently. Also hydrolyzes sphingosylphosphocholine. Regulates the cell cycle by acting as a growth suppressor in confluent cells. Probably acts as a regulator of postnatal development and participates in bone and dentin mineralization.", "general_function": "Sphingomyelin phosphodiesterase activity", "gene_names": ["SMPD3"], "name": "Sphingomyelin phosphodiesterase 3", "drug_actions": []}, "Q16795": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Protein complex binding", "gene_names": ["NDUFA9"], "name": "NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial", "drug_actions": []}, "P15085": {"specific_function": "Carboxypeptidase that catalyzes the release of a C-terminal amino acid, but has little or no action with -Asp, -Glu, -Arg, -Lys or -Pro.", "general_function": "Zinc ion binding", "gene_names": ["CPA1"], "name": "Carboxypeptidase A1", "drug_actions": []}, "Q16798": {"general_function": "Oxaloacetate decarboxylase activity", "gene_names": ["ME3"], "name": "NADP-dependent malic enzyme, mitochondrial", "drug_actions": []}, "P16050": {"specific_function": "Non-heme iron-containing dioxygenase that catalyzes the stereo-specific peroxidation of free and esterified polyunsaturated fatty acids generating a spectrum of bioactive lipid mediators. Converts arachidonic acid into 12-hydroperoxyeicosatetraenoic acid/12-HPETE and 15-hydroperoxyeicosatetraenoic acid/15-HPETE. Also converts linoleic acid to 13-hydroperoxyoctadecadienoic acid. May also act on (12S)-hydroperoxyeicosatetraenoic acid/(12S)-HPETE to produce hepoxilin A3. Probably plays an important role in the immune and inflammatory responses. Through the oxygenation of membrane-bound phosphatidylethanolamine in macrophages may favor clearance of apoptotic cells during inflammation by resident macrophages and prevent an autoimmune response associated with the clearance of apoptotic cells by inflammatory monocytes. In parallel, may regulate actin polymerization which is crucial for several biological processes, including macrophage function. May also regulate macrophage function through regulation of the peroxisome proliferator activated receptor signaling pathway. Finally, it is also involved in the cellular response to IL13/interleukin-13. In addition to its role in the immune and inflammatory responses, may play a role in epithelial wound healing in the cornea maybe through production of lipoxin A4. May also play a role in endoplasmic reticulum stress response and the regulation of bone mass.", "general_function": "Phosphatidylinositol-4,5-bisphosphate binding", "gene_names": ["ALOX15"], "name": "Arachidonate 15-lipoxygenase", "drug_actions": []}, "Q9Y5R2": {"specific_function": "Metalloprotease that mediates cleavage of N-cadherin (CDH2) and acts as a regulator of neuro-immune interactions and neural stem cell quiescence. Involved in cell-cell interactions between nociceptive neurites and mast cells, possibly by mediating cleavage of CDH2, thereby acting as a mediator of peripheral thermal nociception and inflammatory hyperalgesia. Key regulator of neural stem cells quiescence by mediating cleavage of CDH2, affecting CDH2-mediated anchorage of neural stem cells to ependymocytes in the adult subependymal zone, leading to modulate their quiescence. May play a role in axonal growth. Able to activate progelatinase A. May also be a proteoglycanase involved in degradation of proteoglycans, such as dermatan sulfate and chondroitin sulfate proteoglycans. Cleaves partially fibronectin, but not collagen type I, nor laminin (By similarity).", "general_function": "Zinc ion binding", "gene_names": ["MMP24"], "name": "Matrix metalloproteinase-24", "drug_actions": [{"action": "INHIBITOR", "target": "Q9Y5R2", "drug": "DB00786"}]}, "Q9UHI5": {"specific_function": "Sodium-independent, high-affinity transport of small and large neutral amino acids such as alanine, serine, threonine, cysteine, phenylalanine, tyrosine, leucine, arginine and tryptophan, when associated with SLC3A2/4F2hc. Acts as an amino acid exchanger. Has higher affinity for L-phenylalanine than LAT1 but lower affinity for glutamine and serine. L-alanine is transported at physiological concentrations. Plays a role in basolateral (re)absorption of neutral amino acids. Involved in the uptake of methylmercury (MeHg) when administered as the L-cysteine or D,L-homocysteine complexes, and hence plays a role in metal ion homeostasis and toxicity. Involved in the cellular activity of small molecular weight nitrosothiols, via the stereoselective transport of L-nitrosocysteine (L-CNSO) across the transmembrane. Plays an essential role in the reabsorption of neutral amino acids from the epithelial cells to the bloodstream in the kidney.", "general_function": "Toxin transporter activity", "gene_names": ["SLC7A8"], "name": "Large neutral amino acids transporter small subunit 2", "drug_actions": []}, "P25786": {"specific_function": "The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. Mediates the lipopolysaccharide-induced signal transduction in the macrophage proteasome (By similarity). Might be involved in the anti-inflammatory response of macrophages during the interaction with C.albicans heat-inactivated cells (By similarity).", "general_function": "Threonine-type endopeptidase activity", "gene_names": ["PSMA1"], "name": "Proteasome subunit alpha type-1", "drug_actions": []}, "Q9UHI7": {"specific_function": "Sodium/ascorbate cotransporter. Mediates electrogenic uptake of vitamin C, with a stoichiometry of 2 Na(+) for each ascorbate.", "general_function": "Sodium-dependent l-ascorbate transmembrane transporter activity", "gene_names": ["SLC23A1"], "name": "Solute carrier family 23 member 1", "drug_actions": []}, "P25788": {"specific_function": "The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. Binds to the C-terminus of CDKN1A and thereby mediates its degradation. Negatively regulates the membrane trafficking of the cell-surface thromboxane A2 receptor (TBXA2R) isoform 2.", "general_function": "Threonine-type endopeptidase activity", "gene_names": ["PSMA3"], "name": "Proteasome subunit alpha type-3", "drug_actions": []}, "P25789": {"specific_function": "The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity.", "general_function": "Threonine-type endopeptidase activity", "gene_names": ["PSMA4"], "name": "Proteasome subunit alpha type-4", "drug_actions": []}, "P49424": {"specific_function": "Catalyzes the endo hydrolysis of beta-1,4-linked mannan and galactomannan, but displays little activity towards other polysaccharides located in the plant cell wall (PubMed:11382747). Preferentially hydrolyzes the larger oligosaccharides and has greater activity against non-substituted polysaccharides (PubMed:7848261) (PubMed:8973192). It displays tight specificity for mannose at both the -2 and the -1 subsites (PubMed:19441796). Appears to act in synergy with alpha-galactosidase (AgaA) to elicit hydrolysis of galactomannan (PubMed:11064195).", "general_function": "Mannan endo-1,4-beta-mannosidase activity", "gene_names": ["manA"], "name": "Mannan endo-1,4-beta-mannosidase", "drug_actions": []}, "Q13370": {"specific_function": "Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. May play a role in fat metabolism. Regulates cAMP binding of RAPGEF3. Through simultaneous binding to RAPGEF3 and PIK3R6 assembles a signaling complex in which the PI3K gamma complex is activated by RAPGEF3 and which is involved in angiogenesis.", "name": "cGMP-inhibited 3',5'-cyclic phosphodiesterase B", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "Q13370", "drug": "DB00201"}], "general_function": "Protein kinase b binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE3B"]}, "P55769": {"specific_function": "Binds to the 5'-stem-loop of U4 snRNA and may play a role in the late stage of spliceosome assembly. The protein undergoes a conformational change upon RNA-binding.", "general_function": "U4atac snrna binding", "gene_names": ["SNU13"], "name": "NHP2-like protein 1", "drug_actions": []}, "Q96BI3": {"specific_function": "Essential subunit of the gamma-secretase complex, an endoprotease complex that catalyzes the intramembrane cleavage of integral proteins such as Notch receptors and APP (beta-amyloid precursor protein). It probably represents a stabilizing cofactor for the presenilin homodimer that promotes the formation of a stable complex.", "general_function": "Endopeptidase activity", "gene_names": ["APH1A"], "name": "Gamma-secretase subunit APH-1A", "drug_actions": []}, "P61949": {"specific_function": "Low-potential electron donor to a number of redox enzymes (Potential). Involved in the reactivation of inactive cob(II)alamin in methionine synthase.", "general_function": "Fmn binding", "gene_names": ["fldA"], "name": "Flavodoxin-1", "drug_actions": []}, "Q96RP8": {"specific_function": "Mediates the voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient (By similarity).", "general_function": "Delayed rectifier potassium channel activity", "gene_names": ["KCNA7"], "name": "Potassium voltage-gated channel subfamily A member 7", "drug_actions": [{"action": "ANTAGONIST", "target": "Q96RP8", "drug": "DB06637"}]}, "Q9Z4P0": {"specific_function": "Catalyzes unidirectional fumarate reduction using artificial electron donors such as methyl viologen. The physiological reductant is unknown.", "general_function": "Succinate dehydrogenase activity", "gene_names": ["ifcA"], "name": "Fumarate reductase flavoprotein subunit", "drug_actions": []}, "P17658": {"specific_function": "Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes. Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient (PubMed:2347305, PubMed:14575698). The channel alternates between opened and closed conformations in response to the voltage difference across the membrane (PubMed:2347305, PubMed:14575698). Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA6, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel (By similarity). Channel properties are modulated by cytoplasmic beta subunits that regulate the subcellular location of the alpha subunits and promote rapid inactivation (By similarity). Homotetrameric channels display rapid activation and slow inactivation (PubMed:2347305).", "general_function": "Voltage-gated potassium channel activity", "gene_names": ["KCNA6"], "name": "Potassium voltage-gated channel subfamily A member 6", "drug_actions": [{"action": "ANTAGONIST", "target": "P17658", "drug": "DB06637"}]}, "P14735": {"specific_function": "Plays a role in the cellular breakdown of insulin, IAPP, glucagon, bradykinin, kallidin and other peptides, and thereby plays a role in intercellular peptide signaling. Degrades amyloid formed by APP and IAPP. May play a role in the degradation and clearance of naturally secreted amyloid beta-protein by neurons and microglia.(Microbial infection) The membrane-associated isoform acts as an entry receptor for varicella-zoster virus (VZV).", "general_function": "Zinc ion binding", "gene_names": ["IDE"], "name": "Insulin-degrading enzyme", "drug_actions": [{"action": "INHIBITOR", "target": "P14735", "drug": "DB00626"}]}, "P61626": {"specific_function": "Lysozymes have primarily a bacteriolytic function; those in tissues and body fluids are associated with the monocyte-macrophage system and enhance the activity of immunoagents.", "general_function": "Lysozyme activity", "gene_names": ["LYZ"], "name": "Lysozyme C", "drug_actions": []}, "Q53591": {"general_function": "Hyaluronate lyase activity", "gene_names": ["hylB"], "name": "Hyaluronate lyase", "drug_actions": []}, "Q16222": {"specific_function": "Converts UDP and GlcNAc-1-P into UDP-GlcNAc, and UDP and GalNAc-1-P into UDP-GalNAc. Isoform AGX1 has 2 to 3 times higher activity towards GalNAc-1-P, while isoform AGX2 has 8 times more activity towards GlcNAc-1-P.", "general_function": "Udp-n-acetylglucosamine diphosphorylase activity", "gene_names": ["UAP1"], "name": "UDP-N-acetylhexosamine pyrophosphorylase", "drug_actions": []}, "P81040": {"specific_function": "Diheme cytochrome c which may be involved in sulfate reduction.", "general_function": "Metal ion binding", "gene_names": [], "name": "Split-Soret cytochrome c", "drug_actions": []}, "B8DCL9": {"general_function": "Involved in response to antibiotic", "gene_names": ["LMHCC_2184"], "name": "Penicillin-binding protein 3 (Pbp 3) (Pspb20)", "drug_actions": [{"action": "INHIBITOR", "target": "B8DCL9", "drug": "DB00485"}]}, "P00751": {"specific_function": "Factor B which is part of the alternate pathway of the complement system is cleaved by factor D into 2 fragments: Ba and Bb. Bb, a serine protease, then combines with complement factor 3b to generate the C3 or C5 convertase. It has also been implicated in proliferation and differentiation of preactivated B-lymphocytes, rapid spreading of peripheral blood monocytes, stimulation of lymphocyte blastogenesis and lysis of erythrocytes. Ba inhibits the proliferation of preactivated B-lymphocytes.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["CFB"], "name": "Complement factor B", "drug_actions": []}, "P37062": {"specific_function": "Peroxidase whose active site is a redox-active cysteine-sulfenic acid.", "general_function": "Nadh peroxidase activity", "gene_names": ["npr"], "name": "NADH peroxidase", "drug_actions": []}, "P37063": {"specific_function": "Important for the aerobic growth. Decarboxylates pyruvate in four steps. The energy released is partially stored in acetyl phosphate.", "general_function": "Thiamine pyrophosphate binding", "gene_names": ["pox5"], "name": "Pyruvate oxidase", "drug_actions": []}, "Q9ULW8": {"specific_function": "Catalyzes the deimination of arginine residues of proteins.", "general_function": "Protein-arginine deiminase activity", "gene_names": ["PADI3"], "name": "Protein-arginine deiminase type-3", "drug_actions": []}, "P37672": {"specific_function": "Catalyzes the reduction of 2,3-diketo-L-gulonate in the presence of NADH, to form 3-keto-L-gulonate.", "general_function": "Oxidoreductase activity, acting on the ch-oh group of donors, nad or nadp as acceptor", "gene_names": ["dlgD"], "name": "2,3-diketo-L-gulonate reductase", "drug_actions": []}, "Q52546": {"general_function": "Dna-directed dna polymerase activity", "gene_names": ["repA"], "name": "Replication protein", "drug_actions": []}, "Q57254": {"specific_function": "Hemagglutinins of uropathogenic E.coli mediate adherence to the upper urinary tract. These adhesins bind to the Dr blood group antigen and also agglutinate human erythrocytes in the presence of D-mannose (mannose-resistant hemagglutination (MRHA)).", "gene_names": ["afaE3"], "name": "Afimbrial adhesin AFA-III", "drug_actions": []}, "Q12797": {"specific_function": "Isoform 1: specifically hydroxylates an Asp or Asn residue in certain epidermal growth factor-like (EGF) domains of a number of proteins.Isoform 8: membrane-bound Ca(2+)-sensing protein, which is a structural component of the ER-plasma membrane junctions. Isoform 8 regulates the activity of Ca(+2) released-activated Ca(+2) (CRAC) channels in T-cells.", "general_function": "Structural molecule activity", "gene_names": ["ASPH"], "name": "Aspartyl/asparaginyl beta-hydroxylase", "drug_actions": []}, "P22557": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["ALAS2"], "name": "5-aminolevulinate synthase, erythroid-specific, mitochondrial", "drug_actions": []}, "P44345": {"specific_function": "One of the primary rRNA binding proteins, this protein initially binds near the 5'-end of the 23S rRNA. It is important during the early stages of 50S assembly. It makes multiple contacts with different domains of the 23S rRNA in the assembled 50S subunit and ribosome (By similarity).Protein L4 is a both a transcriptional repressor and a translational repressor protein. It regulates transcription of the S10 operon (to which L4 belongs) by causing premature termination of transcription within the S10 leader. L4 controls the translation of the S10 operon by binding to its mRNA (By similarity).This protein when expressed in E.coli represses both transcription and translation of the endogenous S10 operon. As the H.influenzae S10 leader can be regulated in vitro by the E.coli L4 protein this strongly suggests the endogenous protein controls its own S10 operon in a similar fashion.Forms part of the polypeptide exit tunnel.", "general_function": "Structural constituent of ribosome", "gene_names": ["rplD"], "name": "50S ribosomal protein L4", "drug_actions": [{"action": "INHIBITOR", "target": "P44345", "drug": "DB01321"}]}, "Q12791": {"specific_function": "Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential. Plays a key role in controlling excitability in a number of systems, such as regulation of the contraction of smooth muscle, the tuning of hair cells in the cochlea, regulation of transmitter release, and innate immunity. In smooth muscles, its activation by high level of Ca(2+), caused by ryanodine receptors in the sarcoplasmic reticulum, regulates the membrane potential. In cochlea cells, its number and kinetic properties partly determine the characteristic frequency of each hair cell and thereby helps to establish a tonotopic map. Kinetics of KCNMA1 channels are determined by alternative splicing, phosphorylation status and its combination with modulating beta subunits. Highly sensitive to both iberiotoxin (IbTx) and charybdotoxin (CTX).", "name": "Calcium-activated potassium channel subunit alpha-1", "drug_actions": [{"action": "INDUCER", "target": "Q12791", "drug": "DB00436"}, {"action": "BINDER", "target": "Q12791", "drug": "DB00721"}, {"action": "OTHER/UNKNOWN", "target": "Q12791", "drug": "DB00774"}, {"action": "OTHER/UNKNOWN", "target": "Q12791", "drug": "DB00999"}, {"action": "INHIBITOR", "target": "Q12791", "drug": "DB01003"}, {"action": "INHIBITOR", "target": "Q12791", "drug": "DB01110"}, {"action": "OTHER", "target": "Q12791", "drug": "DB01119"}, {"action": "INHIBITOR", "target": "Q12791", "drug": "DB01159"}], "general_function": "Voltage-gated potassium channel activity", "in_complexes": ["Calcium-activated potassium channel"], "gene_names": ["KCNMA1"]}, "P48060": {"gene_names": ["GLIPR1"], "name": "Glioma pathogenesis-related protein 1", "drug_actions": []}, "P07327": {"general_function": "Zinc ion binding", "gene_names": ["ADH1A"], "name": "Alcohol dehydrogenase 1A", "drug_actions": [{"action": "INHIBITOR", "target": "P07327", "drug": "DB01213"}]}, "P09917": {"specific_function": "Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.", "general_function": "Iron ion binding", "gene_names": ["ALOX5"], "name": "Arachidonate 5-lipoxygenase", "drug_actions": [{"action": "INHIBITOR", "target": "P09917", "drug": "DB00179"}, {"action": "INHIBITOR", "target": "P09917", "drug": "DB00233"}, {"action": "INHIBITOR", "target": "P09917", "drug": "DB00244"}, {"action": "OTHER/UNKNOWN", "target": "P09917", "drug": "DB00471"}, {"action": "POTENTIATOR", "target": "P09917", "drug": "DB00586"}, {"action": "INHIBITOR", "target": "P09917", "drug": "DB00711"}, {"action": "INHIBITOR", "target": "P09917", "drug": "DB00744"}, {"action": "INHIBITOR", "target": "P09917", "drug": "DB00795"}, {"action": "INHIBITOR", "target": "P09917", "drug": "DB00939"}, {"action": "INHIBITOR", "target": "P09917", "drug": "DB01014"}, {"action": "INHIBITOR", "target": "P09917", "drug": "DB01017"}, {"action": "INHIBITOR", "target": "P09917", "drug": "DB01892"}]}, "Q8TDV5": {"specific_function": "Receptor for the endogenous fatty-acid ethanolamide oleoylethanolamide (OEA) and lysophosphatidylcholine (LPC). Functions as a glucose-dependent insulinotropic receptor. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Seems to act through a G(s) mediated pathway.", "general_function": "Phosphatidylcholine binding", "gene_names": ["GPR119"], "name": "Glucose-dependent insulinotropic receptor", "drug_actions": []}, "P15813": {"specific_function": "Antigen-presenting protein that binds self and non-self glycolipids and presents them to T-cell receptors on natural killer T-cells.", "general_function": "Receptor activity", "gene_names": ["CD1D"], "name": "Antigen-presenting glycoprotein CD1d", "drug_actions": []}, "P48067": {"specific_function": "Terminates the action of glycine by its high affinity sodium-dependent reuptake into presynaptic terminals. May play a role in regulation of glycine levels in NMDA receptor-mediated neurotransmission.", "general_function": "Neurotransmitter:sodium symporter activity", "gene_names": ["SLC6A9"], "name": "Sodium- and chloride-dependent glycine transporter 1", "drug_actions": []}, "P48068": {"specific_function": "This is a purine-specific ribonuclease.", "general_function": "Rna binding", "gene_names": [], "name": "Ribonuclease", "drug_actions": []}, "P15391": {"specific_function": "Assembles with the antigen receptor of B-lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.", "general_function": "Receptor signaling protein activity", "gene_names": ["CD19"], "name": "B-lymphocyte antigen CD19", "drug_actions": [{"action": "ACTIVATOR", "target": "P15391", "drug": "DB09052"}]}, "P0ABK9": {"specific_function": "Catalyzes the reduction of nitrite to ammonia, consuming six electrons in the process (PubMed:9593308, PubMed:11863430, PubMed:18311941, PubMed:20629638). Has very low activity toward hydroxylamine (PubMed:11863430). Has even lower activity toward sulfite (PubMed:20629638). Sulfite reductase activity is maximal at neutral pH (By similarity).", "general_function": "Nitrite reductase (cytochrome, ammonia-forming) activity", "gene_names": ["nrfA"], "name": "Cytochrome c-552", "drug_actions": []}, "Q6NSD4": {"general_function": "Glutathione peroxidase activity", "gene_names": ["GPX1"], "name": "Glutathione peroxidase", "drug_actions": []}, "Q02156": {"specific_function": "Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays essential roles in the regulation of multiple cellular processes linked to cytoskeletal proteins, such as cell adhesion, motility, migration and cell cycle, functions in neuron growth and ion channel regulation, and is involved in immune response, cancer cell invasion and regulation of apoptosis. Mediates cell adhesion to the extracellular matrix via integrin-dependent signaling, by mediating angiotensin-2-induced activation of integrin beta-1 (ITGB1) in cardiac fibroblasts. Phosphorylates MARCKS, which phosphorylates and activates PTK2/FAK, leading to the spread of cardiomyocytes. Involved in the control of the directional transport of ITGB1 in mesenchymal cells by phosphorylating vimentin (VIM), an intermediate filament (IF) protein. In epithelial cells, associates with and phosphorylates keratin-8 (KRT8), which induces targeting of desmoplakin at desmosomes and regulates cell-cell contact. Phosphorylates IQGAP1, which binds to CDC42, mediating epithelial cell-cell detachment prior to migration. In HeLa cells, contributes to hepatocyte growth factor (HGF)-induced cell migration, and in human corneal epithelial cells, plays a critical role in wound healing after activation by HGF. During cytokinesis, forms a complex with YWHAB, which is crucial for daughter cell separation, and facilitates abscission by a mechanism which may implicate the regulation of RHOA. In cardiac myocytes, regulates myofilament function and excitation coupling at the Z-lines, where it is indirectly associated with F-actin via interaction with COPB1. During endothelin-induced cardiomyocyte hypertrophy, mediates activation of PTK2/FAK, which is critical for cardiomyocyte survival and regulation of sarcomere length. Plays a role in the pathogenesis of dilated cardiomyopathy via persistent phosphorylation of troponin I (TNNI3). Involved in nerve growth factor (NFG)-induced neurite outgrowth and neuron morphological change independently of its kinase activity, by inhibition of RHOA pathway, activation of CDC42 and cytoskeletal rearrangement. May be involved in presynaptic facilitation by mediating phorbol ester-induced synaptic potentiation. Phosphorylates gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2), which reduces the response of GABA receptors to ethanol and benzodiazepines and may mediate acute tolerance to the intoxicating effects of ethanol. Upon PMA treatment, phosphorylates the capsaicin- and heat-activated cation channel TRPV1, which is required for bradykinin-induced sensitization of the heat response in nociceptive neurons. Is able to form a complex with PDLIM5 and N-type calcium channel, and may enhance channel activities and potentiates fast synaptic transmission by phosphorylating the pore-forming alpha subunit CACNA1B (CaV2.2). In prostate cancer cells, interacts with and phosphorylates STAT3, which increases DNA-binding and transcriptional activity of STAT3 and seems to be essential for prostate cancer cell invasion. Downstream of TLR4, plays an important role in the lipopolysaccharide (LPS)-induced immune response by phosphorylating and activating TICAM2/TRAM, which in turn activates the transcription factor IRF3 and subsequent cytokines production. In differentiating erythroid progenitors, is regulated by EPO and controls the protection against the TNFSF10/TRAIL-mediated apoptosis, via BCL2. May be involved in the regulation of the insulin-induced phosphorylation and activation of AKT1.", "name": "Protein kinase C epsilon type", "drug_actions": [], "general_function": "Signal transducer activity", "in_complexes": ["Protein kinase C"], "gene_names": ["PRKCE"]}, "P11413": {"specific_function": "Catalyzes the rate-limiting step of the oxidative pentose-phosphate pathway, which represents a route for the dissimilation of carbohydrates besides glycolysis. The main function of this enzyme is to provide reducing power (NADPH) and pentose phosphates for fatty acid and nucleic acid synthesis.", "general_function": "Protein homodimerization activity", "gene_names": ["G6PD"], "name": "Glucose-6-phosphate 1-dehydrogenase", "drug_actions": []}, "Q8XL08": {"specific_function": "Binds carbohydrates. Capable of hydrolyzing the glycosidic link of O-GlcNAcylated proteins. Can bind and deglycosylate O-glycosylated peptides from mammals. Can use p-nitrophenyl-beta-GlcNAc and 4-methylumbelliferone-GlcNAc as substrates (in vitro).", "general_function": "Carbohydrate binding", "gene_names": ["nagJ"], "name": "O-GlcNAcase NagJ", "drug_actions": []}, "P11411": {"specific_function": "Catalyzes the oxidation of glucose 6-phosphate to 6-phosphogluconolactone. Can utilize either NADP(+) or NAD(+).", "general_function": "Nadp binding", "gene_names": ["zwf"], "name": "Glucose-6-phosphate 1-dehydrogenase", "drug_actions": []}, "P48632": {"specific_function": "Receptor for the siderophore ferripyoverdine.", "general_function": "Receptor activity", "gene_names": ["fpvA"], "name": "Ferripyoverdine receptor", "drug_actions": []}, "Q9X1B3": {"specific_function": "Catalyzes the formation of 4-diphosphocytidyl-2-C-methyl-D-erythritol from CTP and 2-C-methyl-D-erythritol 4-phosphate (MEP).", "general_function": "2-c-methyl-d-erythritol 4-phosphate cytidylyltransferase activity", "gene_names": ["ispD"], "name": "2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase", "drug_actions": []}, "Q9RP17": {"general_function": "Porin activity", "gene_names": ["nspA"], "name": "Surface protein A", "drug_actions": []}, "P11142": {"specific_function": "Acts as a repressor of transcriptional activation. Inhibits the transcriptional coactivator activity of CITED1 on Smad-mediated transcription. Chaperone. Component of the PRP19-CDC5L complex that forms an integral part of the spliceosome and is required for activating pre-mRNA splicing. May have a scaffolding role in the spliceosome assembly as it contacts all other components of the core complex. Binds bacterial lipopolysaccharide (LPS) et mediates LPS-induced inflammatory response, including TNF secretion by monocytes. Participates in the ER-associated degradation (ERAD) quality control pathway in conjunction with J domain-containing co-chaperones and the E3 ligase CHIP.", "general_function": "Unfolded protein binding", "gene_names": ["HSPA8"], "name": "Heat shock cognate 71 kDa protein", "drug_actions": []}, "P55818": {"specific_function": "Catalyzes the dehydrogenation of methylene-H(4)MPT. Can also catalyze the reversible dehydrogenation of methylene-H(4)F with 20-fold lower catalytic efficiency.", "general_function": "Methylenetetrahydrofolate dehydrogenase (nadp+) activity", "gene_names": ["mtdA"], "name": "Bifunctional protein MdtA", "drug_actions": []}, "P13498": {"specific_function": "Critical component of the membrane-bound oxidase of phagocytes that generates superoxide. Associates with NOX3 to form a functional NADPH oxidase constitutively generating superoxide.", "name": "Cytochrome b-245 light chain", "drug_actions": [{"action": "INHIBITOR", "target": "P13498", "drug": "DB00514"}], "general_function": "Superoxide-generating nadph oxidase activity", "in_complexes": ["NADPH oxidase"], "gene_names": ["CYBA"]}, "P50052": {"specific_function": "Receptor for angiotensin II. Cooperates with MTUS1 to inhibit ERK2 activation and cell proliferation.", "general_function": "Receptor antagonist activity", "gene_names": ["AGTR2"], "name": "Type-2 angiotensin II receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "P50052", "drug": "DB01349"}]}, "Q9NQX3": {"specific_function": "Microtubule-associated protein involved in membrane protein-cytoskeleton interactions. It is thought to anchor the inhibitory glycine receptor (GLYR) to subsynaptic microtubules (By similarity). Catalyzes two steps in the biosynthesis of the molybdenum cofactor. In the first step, molybdopterin is adenylated. Subsequently, molybdate is inserted into adenylated molybdopterin and AMP is released.", "general_function": "Molybdopterin molybdotransferase activity", "gene_names": ["GPHN"], "name": "Gephyrin", "drug_actions": []}, "P96275": {"specific_function": "Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions (By similarity)", "general_function": "Translation, ribosomal structure and biogenesis", "gene_names": ["def"], "name": "Peptide deformylase", "drug_actions": []}, "P10614": {"specific_function": "Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol.", "general_function": "Sterol 14-demethylase activity", "gene_names": ["ERG11"], "name": "Lanosterol 14-alpha demethylase", "drug_actions": []}, "Q03405": {"specific_function": "Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.", "general_function": "Urokinase plasminogen activator receptor activity", "gene_names": ["PLAUR"], "name": "Urokinase plasminogen activator surface receptor", "drug_actions": []}, "Q03154": {"specific_function": "Involved in the hydrolysis of N-acylated or N-acetylated amino acids (except L-aspartate).", "general_function": "Metallopeptidase activity", "gene_names": ["ACY1"], "name": "Aminoacylase-1", "drug_actions": [{"action": "LIGAND", "target": "Q03154", "drug": "DB06151"}]}, "Q9UN19": {"specific_function": "May act as a B-cell-associated adapter that regulates B-cell antigen receptor (BCR)-signaling downstream of PI3K.", "general_function": "Phospholipid binding", "gene_names": ["DAPP1"], "name": "Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide", "drug_actions": []}, "Q06432": {"specific_function": "This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only as a multiple subunit complex.", "name": "Voltage-dependent calcium channel gamma-1 subunit", "drug_actions": [{"action": "ACTIVATOR", "target": "Q06432", "drug": "DB00308"}, {"action": "INHIBITOR", "target": "Q06432", "drug": "DB00343"}, {"action": "INHIBITOR", "target": "Q06432", "drug": "DB00528"}, {"action": "INHIBITOR", "target": "Q06432", "drug": "DB01054"}, {"action": "INHIBITOR", "target": "Q06432", "drug": "DB04842"}], "general_function": "Voltage-gated calcium channel activity", "in_complexes": ["Voltage-dependent calcium channel"], "gene_names": ["CACNG1"]}, "Q51705": {"specific_function": "Nitrous-oxide reductase is part of a bacterial respiratory system which is activated under anaerobic conditions in the presence of nitrate or nitrous oxide.", "general_function": "Nitrous-oxide reductase activity", "gene_names": ["nosZ"], "name": "Nitrous-oxide reductase", "drug_actions": []}, "P80404": {"specific_function": "Catalyzes the conversion of gamma-aminobutyrate and L-beta-aminoisobutyrate to succinate semialdehyde and methylmalonate semialdehyde, respectively. Can also convert delta-aminovalerate and beta-alanine.", "general_function": "Succinate-semialdehyde dehydrogenase binding", "gene_names": ["ABAT"], "name": "4-aminobutyrate aminotransferase, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "P80404", "drug": "DB00114"}, {"action": "INHIBITOR", "target": "P80404", "drug": "DB00119"}, {"action": "INHIBITOR", "target": "P80404", "drug": "DB00160"}, {"action": "INHIBITOR", "target": "P80404", "drug": "DB00313"}, {"action": "INHIBITOR", "target": "P80404", "drug": "DB00780"}, {"action": "INHIBITOR", "target": "P80404", "drug": "DB01080"}]}, "O60512": {"specific_function": "Responsible for the synthesis of complex-type N-linked oligosaccharides in many glycoproteins as well as the carbohydrate moieties of glycolipids.", "general_function": "N-acetyllactosamine synthase activity", "gene_names": ["B4GALT3"], "name": "Beta-1,4-galactosyltransferase 3", "drug_actions": []}, "D2YW37": {"gene_names": [], "name": "Est1e", "drug_actions": []}, "P54820": {"specific_function": "Mediates the electron transport between the cytochrome bc1 complex and cytochrome-c oxidase.", "general_function": "Metal ion binding", "gene_names": ["cycM"], "name": "Cytochrome c-552", "drug_actions": []}, "P16471": {"specific_function": "This is a receptor for the anterior pituitary hormone prolactin (PRL). Acts as a prosurvival factor for spermatozoa by inhibiting sperm capacitation through suppression of SRC kinase activation and stimulation of AKT. Isoform 4 is unable to transduce prolactin signaling. Isoform 6 is unable to transduce prolactin signaling.", "general_function": "Protein homodimerization activity", "gene_names": ["PRLR"], "name": "Prolactin receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "P16471", "drug": "DB01185"}]}, "P16473": {"specific_function": "Receptor for thyrothropin. Plays a central role in controlling thyroid cell metabolism. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Also acts as a receptor for thyrostimulin (GPA2+GPB5).", "general_function": "Thyroid-stimulating hormone receptor activity", "gene_names": ["TSHR"], "name": "Thyrotropin receptor", "drug_actions": [{"action": "AGONIST", "target": "P16473", "drug": "DB00024"}]}, "P38489": {"specific_function": "Reduction of a variety of nitroaromatic compounds using NADH (and to lesser extent NADPH) as source of reducing equivalents; two electrons are transferred. Capable of reducing nitrofurazone, quinones and the anti-tumor agent CB1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). The reduction of CB1954 results in the generation of cytotoxic species.", "general_function": "Nad(p)h nitroreductase activity", "gene_names": ["nfsB"], "name": "Oxygen-insensitive NAD(P)H nitroreductase", "drug_actions": []}, "Q8I3X4": {"general_function": "Uridine phosphorylase activity", "gene_names": [], "name": "Purine nucleotide phosphorylase, putative", "drug_actions": []}, "Q72LA5": {"general_function": "Metal ion binding", "gene_names": ["nrfC"], "name": "NrfC protein", "drug_actions": []}, "P40261": {"specific_function": "Catalyzes the N-methylation of nicotinamide and other pyridines to form pyridinium ions. This activity is important for biotransformation of many drugs and xenobiotic compounds.", "general_function": "Nicotinamide n-methyltransferase activity", "gene_names": ["NNMT"], "name": "Nicotinamide N-methyltransferase", "drug_actions": [{"action": "BINDER", "target": "P40261", "drug": "DB00627"}]}, "P50870": {"specific_function": "Inactivates the A compounds of streptogramin antibiotics by acetylation, thus providing resistance to these antibiotics.", "general_function": "Transferase activity, transferring acyl groups", "gene_names": ["vatD"], "name": "Streptogramin A acetyltransferase", "drug_actions": [{"action": "INHIBITOR", "target": "P50870", "drug": "DB01764"}]}, "Q8N5Z0": {"specific_function": "Transaminase with broad substrate specificity. Has transaminase activity towards aminoadipate, kynurenine, methionine and glutamate. Shows activity also towards tryptophan, aspartate and hydroxykynurenine. Accepts a variety of oxo-acids as amino-group acceptors, with a preference for 2-oxoglutarate, 2-oxocaproic acid, phenylpyruvate and alpha-oxo-gamma-methiol butyric acid. Can also use glyoxylate as amino-group acceptor (in vitro).", "general_function": "Pyridoxal phosphate binding", "gene_names": ["AADAT"], "name": "Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial", "drug_actions": [{"action": "COFACTOR", "target": "Q8N5Z0", "drug": "DB00114"}]}, "P01848": {"gene_names": ["TRAC"], "name": "T-cell receptor alpha chain C region", "drug_actions": []}, "P15260": {"specific_function": "Receptor for interferon gamma. Two receptors bind one interferon gamma dimer.", "general_function": "Interferon-gamma receptor activity", "gene_names": ["IFNGR1"], "name": "Interferon gamma receptor 1", "drug_actions": [{"action": "BINDER", "target": "P15260", "drug": "DB00033"}]}, "Q9UQM7": {"specific_function": "CaM-kinase II (CAMK2) is a prominent kinase in the central nervous system that may function in long-term potentiation and neurotransmitter release. Member of the NMDAR signaling complex in excitatory synapses it may regulate NMDAR-dependent potentiation of the AMPAR and synaptic plasticity (By similarity).", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["CAMK2A"], "name": "Calcium/calmodulin-dependent protein kinase type II subunit alpha", "drug_actions": []}, "Q5SII2": {"specific_function": "Specifically methylates the cytosines at positions 1400 (m5C1400), 1404 (m5C1404) and 1407 (m5C1407) of 16S rRNA. C1400, C1404 and C1407 are methylated in a 30S subunit substrate, but only C1400 and C1404 are methylated when naked 16S rRNA is the substrate. Methylation by RsmF may facilitate growth at temperatures outside the optimal growth temperature.", "general_function": "Rna binding", "gene_names": ["rsmF"], "name": "Ribosomal RNA small subunit methyltransferase F", "drug_actions": []}, "P55196": {"specific_function": "Belongs to an adhesion system, probably together with the E-cadherin-catenin system, which plays a role in the organization of homotypic, interneuronal and heterotypic cell-cell adherens junctions (AJs). Nectin- and actin-filament-binding protein that connects nectin to the actin cytoskeleton.", "general_function": "Ras gtpase binding", "gene_names": ["MLLT4"], "name": "Afadin", "drug_actions": []}, "Q13564": {"specific_function": "Regulatory subunit of the dimeric UBA3-NAE1 E1 enzyme. E1 activates NEDD8 by first adenylating its C-terminal glycine residue with ATP, thereafter linking this residue to the side chain of the catalytic cysteine, yielding a NEDD8-UBA3 thioester and free AMP. E1 finally transfers NEDD8 to the catalytic cysteine of UBE2M. Necessary for cell cycle progression through the S-M checkpoint. Overexpression of NAE1 causes apoptosis through deregulation of NEDD8 conjugation.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["NAE1"], "name": "NEDD8-activating enzyme E1 regulatory subunit", "drug_actions": []}, "P13569": {"specific_function": "Involved in the transport of chloride ions. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the SLC4A7 transporter. Can inhibit the chloride channel activity of ANO1. Plays a role in the chloride and bicarbonate homeostasis during sperm epididymal maturation and capacitation.", "general_function": "Pdz domain binding", "gene_names": ["CFTR"], "name": "Cystic fibrosis transmembrane conductance regulator", "drug_actions": [{"action": "ANTAGONIST", "target": "P13569", "drug": "DB00887"}, {"action": "ANTAGONIST", "target": "P13569", "drug": "DB01016"}, {"action": "INHIBITOR", "target": "P13569", "drug": "DB01050"}, {"action": "ANTAGONIST", "target": "P13569", "drug": "DB04941"}, {"action": "POTENTIATOR", "target": "P13569", "drug": "DB08820"}, {"action": "MODULATOR", "target": "P13569", "drug": "DB09280"}]}, "P69441": {"specific_function": "Catalyzes the reversible transfer of the terminal phosphate group between ATP and AMP. Plays an important role in cellular energy homeostasis and in adenine nucleotide metabolism.", "general_function": "Magnesium ion binding", "gene_names": ["adk"], "name": "Adenylate kinase", "drug_actions": []}, "P16152": {"specific_function": "NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione.", "general_function": "Prostaglandin-e2 9-reductase activity", "gene_names": ["CBR1"], "name": "Carbonyl reductase [NADPH] 1", "drug_actions": []}, "Q8EBR3": {"specific_function": "Involved in the biosynthesis of isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), two major building blocks of isoprenoid compounds. Catalyzes the conversion of 4-diphosphocytidyl-2-C-methyl-D-erythritol 2-phosphate (CDP-ME2P) to 2-C-methyl-D-erythritol 2,4-cyclodiphosphate (ME-CPP) with a corresponding release of cytidine 5-monophosphate (CMP) (By similarity).", "general_function": "Metal ion binding", "gene_names": ["ispF"], "name": "2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase", "drug_actions": []}, "P30542": {"specific_function": "Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.", "general_function": "Purine nucleoside binding", "gene_names": ["ADORA1"], "name": "Adenosine receptor A1", "drug_actions": [{"action": "ANTAGONIST", "target": "P30542", "drug": "DB00201"}, {"action": "MULTITARGET", "target": "P30542", "drug": "DB00201"}, {"action": "ANTAGONIST", "target": "P30542", "drug": "DB00277"}, {"action": "AGONIST", "target": "P30542", "drug": "DB00640"}, {"action": "ANTAGONIST", "target": "P30542", "drug": "DB00651"}, {"action": "ANTAGONIST", "target": "P30542", "drug": "DB00806"}, {"action": "AGONIST", "target": "P30542", "drug": "DB00996"}, {"action": "ANTAGONIST", "target": "P30542", "drug": "DB01223"}, {"action": "ANTAGONIST", "target": "P30542", "drug": "DB01303"}, {"action": "ANTAGONIST", "target": "P30542", "drug": "DB01412"}]}, "O14957": {"specific_function": "This is a component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is part of the mitochondrial respiratory chain.This protein may be closely linked to the iron-sulfur protein in the complex and function as an iron-sulfur protein binding factor.", "general_function": "Ubiquinol-cytochrome-c reductase activity", "gene_names": ["UQCR11"], "name": "Cytochrome b-c1 complex subunit 10", "drug_actions": []}, "P31639": {"specific_function": "Sodium-dependent glucose transporter. Has a Na(+) to glucose coupling ratio of 1:1.Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capacity and a high affinity low capacity Na(+)/glucose cotransporter arranged in series along kidney proximal tubules.", "general_function": "Low-affinity glucose:sodium symporter activity", "gene_names": ["SLC5A2"], "name": "Sodium/glucose cotransporter 2", "drug_actions": [{"action": "ANTAGONIST", "target": "P31639", "drug": "DB06292"}, {"action": "INHIBITOR, COMPETITIVE", "target": "P31639", "drug": "DB06292"}, {"action": "INHIBITOR", "target": "P31639", "drug": "DB08907"}, {"action": "ANTAGONIST", "target": "P31639", "drug": "DB09038"}, {"action": "INHIBITOR", "target": "P31639", "drug": "DB09038"}]}, "Q9NZV8": {"specific_function": "Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Mediates the major part of the dendritic A-type current I(SA) in brain neurons (By similarity). This current is activated at membrane potentials that are below the threshold for action potentials. It regulates neuronal excitability, prolongs the latency before the first spike in a series of action potentials, regulates the frequency of repetitive action potential firing, shortens the duration of action potentials and regulates the back-propagation of action potentials from the neuronal cell body to the dendrites. Contributes to the regulation of the circadian rhytm of action potential firing in suprachiasmatic nucleus neurons, which regulates the circadian rhythm of locomotor activity (By similarity). Functions downstream of the metabotropic glutamate receptor GRM5 and plays a role in neuronal excitability and in nociception mediated by activation of GRM5 (By similarity). Mediates the transient outward current I(to) in rodent heart left ventricle apex cells, but not in human heart, where this current is mediated by another family member. Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient (PubMed:10551270, PubMed:15454437, PubMed:14695263, PubMed:14623880, PubMed:14980201, PubMed:16934482, PubMed:24811166, PubMed:24501278). The channel alternates between opened and closed conformations in response to the voltage difference across the membrane (PubMed:11507158). Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCND2 and KCND3; channel properties depend on the type of pore-forming alpha subunits that are part of the channel. In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes. Interaction with specific isoforms of the regulatory subunits KCNIP1, KCNIP2, KCNIP3 or KCNIP4 strongly increases expression at the cell surface and thereby increases channel activity; it modulates the kinetics of channel activation and inactivation, shifts the threshold for channel activation to more negative voltage values, shifts the threshold for inactivation to less negative voltages and accelerates recovery after inactivation (PubMed:15454437, PubMed:14623880, PubMed:14980201, PubMed:19171772, PubMed:24501278, PubMed:24811166). Likewise, interaction with DPP6 or DPP10 promotes expression at the cell membrane and regulates both channel characteristics and activity (By similarity).", "general_function": "Voltage-gated potassium channel activity", "gene_names": ["KCND2"], "name": "Potassium voltage-gated channel subfamily D member 2", "drug_actions": [{"action": "INHIBITOR", "target": "Q9NZV8", "drug": "DB00280"}, {"action": "INHIBITOR", "target": "Q9NZV8", "drug": "DB00321"}, {"action": "INHIBITOR", "target": "Q9NZV8", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "Q9NZV8", "drug": "DB06637"}]}, "Q72874": {"general_function": "Aspartic-type endopeptidase activity", "gene_names": ["pol"], "name": "Pol polyprotein", "drug_actions": [{"action": "INHIBITOR", "target": "Q72874", "drug": "DB00224"}, {"action": "INHIBITOR", "target": "Q72874", "drug": "DB00503"}, {"action": "INHIBITOR", "target": "Q72874", "drug": "DB00701"}, {"action": "INHIBITOR", "target": "Q72874", "drug": "DB00932"}, {"action": "INHIBITOR", "target": "Q72874", "drug": "DB01072"}, {"action": "INHIBITOR", "target": "Q72874", "drug": "DB01232"}, {"action": "INHIBITOR", "target": "Q72874", "drug": "DB01264"}, {"action": "INHIBITOR", "target": "Q72874", "drug": "DB01319"}, {"action": "INHIBITOR", "target": "Q72874", "drug": "DB01601"}]}, "O60488": {"specific_function": "Activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially uses arachidonate and eicosapentaenoate as substrates.", "general_function": "Very long-chain fatty acid-coa ligase activity", "gene_names": ["ACSL4"], "name": "Long-chain-fatty-acid--CoA ligase 4", "drug_actions": [{"action": "INDUCER", "target": "O60488", "drug": "DB00159"}, {"action": "INHIBITOR", "target": "O60488", "drug": "DB00197"}, {"action": "INHIBITOR", "target": "O60488", "drug": "DB00412"}]}, "Q00796": {"specific_function": "Converts sorbitol to fructose. Part of the polyol pathway that plays an important role in sperm physiology. May play a role in the sperm motility by providing an energetic source for sperm.", "general_function": "Zinc ion binding", "gene_names": ["SORD"], "name": "Sorbitol dehydrogenase", "drug_actions": []}, "O25323": {"general_function": "Endonuclease activity", "gene_names": [], "name": "Endonuclease III", "drug_actions": []}, "Q98GN8": {"specific_function": "Cyclic nucleotide-regulated potassium channel activated by cAMP.", "general_function": "Voltage-gated potassium channel activity", "gene_names": [], "name": "Cyclic nucleotide-gated potassium channel mll3241", "drug_actions": []}, "P16519": {"specific_function": "Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues. Responsible for the release of glucagon from proglucagon in pancreatic A cells.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["PCSK2"], "name": "Neuroendocrine convertase 2", "drug_actions": []}, "P39841": {"general_function": "Zinc ion binding", "gene_names": ["yvyI"], "name": "Putative mannose-6-phosphate isomerase YvyI", "drug_actions": []}, "P0A115": {"specific_function": "Ring cleavage of cyclic ester dienelactone to produce maleylacetate.", "general_function": "Carboxymethylenebutenolidase activity", "gene_names": ["clcD"], "name": "Carboxymethylenebutenolidase", "drug_actions": []}, "Q9UQL6": {"specific_function": "Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Involved in muscle maturation by repressing transcription of myocyte enhancer MEF2C. During muscle differentiation, it shuttles into the cytoplasm, allowing the expression of myocyte enhancer factors. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer.", "general_function": "Transcription factor binding", "gene_names": ["HDAC5"], "name": "Histone deacetylase 5", "drug_actions": [{"action": "INHIBITOR", "target": "Q9UQL6", "drug": "DB06603"}]}, "P01906": {"specific_function": "Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.", "general_function": "Mhc class ii receptor activity", "gene_names": ["HLA-DQA2"], "name": "HLA class II histocompatibility antigen, DQ alpha 2 chain", "drug_actions": []}, "O00204": {"specific_function": "Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of many hormones, neurotransmitters, drugs and xenobiotic compounds. Sulfonation increases the water solubility of most compounds, and therefore their renal excretion, but it can also result in bioactivation to form active metabolites. Sulfates hydroxysteroids like DHEA. Isoform 1 preferentially sulfonates cholesterol, and isoform 2 avidly sulfonates pregnenolone but not cholesterol.", "general_function": "Steroid sulfotransferase activity", "gene_names": ["SULT2B1"], "name": "Sulfotransferase family cytosolic 2B member 1", "drug_actions": []}, "P37288": {"specific_function": "Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behaviors, including affiliation and attachment.", "general_function": "Vasopressin receptor activity", "gene_names": ["AVPR1A"], "name": "Vasopressin V1a receptor", "drug_actions": [{"action": "AGONIST", "target": "P37288", "drug": "DB00093"}, {"action": "ANTAGONIST", "target": "P37288", "drug": "DB00872"}, {"action": "STIMULATOR", "target": "P37288", "drug": "DB02638"}, {"action": "ANTAGONIST", "target": "P37288", "drug": "DB06212"}]}, "P10721": {"specific_function": "Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the AKT1 signaling pathway by phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Activated KIT also transmits signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3, STAT5A and STAT5B. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KIT signaling is modulated by protein phosphatases, and by rapid internalization and degradation of the receptor. Activated KIT promotes phosphorylation of the protein phosphatases PTPN6/SHP-1 and PTPRU, and of the transcription factors STAT1, STAT3, STAT5A and STAT5B. Promotes phosphorylation of PIK3R1, CBL, CRK (isoform Crk-II), LYN, MAPK1/ERK2 and/or MAPK3/ERK1, PLCG1, SRC and SHC1.", "general_function": "Transmembrane receptor protein tyrosine kinase activity", "gene_names": ["KIT"], "name": "Mast/stem cell growth factor receptor Kit", "drug_actions": [{"action": "ANTAGONIST", "target": "P10721", "drug": "DB00398"}, {"action": "ANTAGONIST", "target": "P10721", "drug": "DB00619"}, {"action": "MULTITARGET", "target": "P10721", "drug": "DB00619"}, {"action": "ANTAGONIST", "target": "P10721", "drug": "DB01254"}, {"action": "ANTAGONIST", "target": "P10721", "drug": "DB01268"}, {"action": "ANTAGONIST", "target": "P10721", "drug": "DB04868"}, {"action": "INHIBITOR", "target": "P10721", "drug": "DB06589"}, {"action": "INHIBITOR", "target": "P10721", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P10721", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P10721", "drug": "DB09078"}]}, "Q9H2M3": {"specific_function": "Involved in the regulation of homocysteine metabolism. Converts homocysteine to methionine using S-methylmethionine (SMM) as a methyl donor.", "general_function": "Zinc ion binding", "gene_names": ["BHMT2"], "name": "S-methylmethionine--homocysteine S-methyltransferase BHMT2", "drug_actions": [{"action": "PRODUCT OF", "target": "Q9H2M3", "drug": "DB00134"}]}, "Q8WTS6": {"specific_function": "Histone methyltransferase that specifically monomethylates 'Lys-4' of histone H3. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation. Plays a central role in the transcriptional activation of genes such as collagenase or insulin. Recruited by IPF1/PDX-1 to the insulin promoter, leading to activate transcription. Has also methyltransferase activity toward non-histone proteins such as p53/TP53, TAF10, and possibly TAF7 by recognizing and binding the [KR]-[STA]-K in substrate proteins. Monomethylates 'Lys-189' of TAF10, leading to increase the affinity of TAF10 for RNA polymerase II. Monomethylates 'Lys-372' of p53/TP53, stabilizing p53/TP53 and increasing p53/TP53-mediated transcriptional activation.", "general_function": "Protein-lysine n-methyltransferase activity", "gene_names": ["SETD7"], "name": "Histone-lysine N-methyltransferase SETD7", "drug_actions": []}, "Q07412": {"general_function": "Triose-phosphate isomerase activity", "gene_names": ["TPI"], "name": "Triosephosphate isomerase", "drug_actions": []}, "P05893": {"specific_function": "Matrix protein p17 targets Gag and Gag-Pol polyproteins to the plasma membrane via a multipartite membrane binding signal, that includes its myristoylated N-terminus. Also mediates nuclear localization of the preintegration complex. Implicated in the release from host cell mediated by Vpu (By similarity).Capsid protein p24 forms the conical core of the virus that encapsulates the genomic RNA-nucleocapsid complex.Nucleocapsid protein p7 encapsulates and protects viral dimeric unspliced (genomic) RNA. Binds these RNAs through its zinc fingers (By similarity).p6-gag plays a role in budding of the assembled particle by interacting with the host class E VPS proteins TSG101 and PDCD6IP/AIP1.", "general_function": "Zinc ion binding", "gene_names": ["gag"], "name": "Gag polyprotein", "drug_actions": []}, "Q8NW68": {"general_function": "Threonine-trna ligase activity", "gene_names": ["thrS"], "name": "Threonine--tRNA ligase", "drug_actions": []}, "P25024": {"specific_function": "Receptor to interleukin-8, which is a powerful neutrophils chemotactic factor. Binding of IL-8 to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activate a phosphatidylinositol-calcium second messenger system. This receptor binds to IL-8 with a high affinity and to MGSA (GRO) with a low affinity.", "general_function": "Interleukin-8 receptor activity", "gene_names": ["CXCR1"], "name": "C-X-C chemokine receptor type 1", "drug_actions": [{"action": "OTHER", "target": "P25024", "drug": "DB01009"}]}, "Q9HB40": {"specific_function": "May be involved in vascular wall and kidney homeostasis.", "general_function": "Serine-type carboxypeptidase activity", "gene_names": ["SCPEP1"], "name": "Retinoid-inducible serine carboxypeptidase", "drug_actions": []}, "P25021": {"specific_function": "The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) signaling pathway (By similarity).", "general_function": "Histamine receptor activity", "gene_names": ["HRH2"], "name": "Histamine H2 receptor", "drug_actions": [{"action": "AGONIST", "target": "P25021", "drug": "DB00272"}, {"action": "BLOCKER", "target": "P25021", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P25021", "drug": "DB00334"}, {"action": "BINDER", "target": "P25021", "drug": "DB00408"}, {"action": "ANTAGONIST", "target": "P25021", "drug": "DB00501"}, {"action": "ANTAGONIST", "target": "P25021", "drug": "DB00585"}, {"action": "AGONIST", "target": "P25021", "drug": "DB00667"}, {"action": "ANTAGONIST", "target": "P25021", "drug": "DB00751"}, {"action": "AGONIST", "target": "P25021", "drug": "DB00797"}, {"action": "ANTAGONIST", "target": "P25021", "drug": "DB00863"}, {"action": "ANTAGONIST", "target": "P25021", "drug": "DB00927"}, {"action": "ANTAGONIST", "target": "P25021", "drug": "DB00940"}, {"action": "ANTAGONIST", "target": "P25021", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P25021", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P25021", "drug": "DB08805"}, {"action": "ANTAGONIST", "target": "P25021", "drug": "DB08806"}]}, "Q6PKH6": {"specific_function": "Probable oxidoreductase.", "general_function": "Oxidoreductase activity", "gene_names": ["DHRS4L2"], "name": "Dehydrogenase/reductase SDR family member 4-like 2", "drug_actions": []}, "Q8DNV6": {"specific_function": "Involved in cell wall formation. Catalyzes the final step in the synthesis of UDP-N-acetylmuramoyl-pentapeptide, the precursor of murein.", "general_function": "Udp-n-acetylmuramoylalanyl-d-glutamyl-2,6-diaminopimelate-d-alanyl-d-alanine ligase activity", "gene_names": ["murF"], "name": "UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase", "drug_actions": []}, "P0ACB2": {"specific_function": "Catalyzes an early step in the biosynthesis of tetrapyrroles. Binds two molecules of 5-aminolevulinate per subunit, each at a distinct site, and catalyzes their condensation to form porphobilinogen.", "general_function": "Zinc ion binding", "gene_names": ["hemB"], "name": "Delta-aminolevulinic acid dehydratase", "drug_actions": []}, "P54646": {"specific_function": "Catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin. Regulates lipid synthesis by phosphorylating and inactivating lipid metabolic enzymes such as ACACA, ACACB, GYS1, HMGCR and LIPE; regulates fatty acid and cholesterol synthesis by phosphorylating acetyl-CoA carboxylase (ACACA and ACACB) and hormone-sensitive lipase (LIPE) enzymes, respectively. Regulates insulin-signaling and glycolysis by phosphorylating IRS1, PFKFB2 and PFKFB3. Involved in insulin receptor/INSR internalization (PubMed:25687571). AMPK stimulates glucose uptake in muscle by increasing the translocation of the glucose transporter SLC2A4/GLUT4 to the plasma membrane, possibly by mediating phosphorylation of TBC1D4/AS160. Regulates transcription and chromatin structure by phosphorylating transcription regulators involved in energy metabolism such as CRTC2/TORC2, FOXO3, histone H2B, HDAC5, MEF2C, MLXIPL/ChREBP, EP300, HNF4A, p53/TP53, SREBF1, SREBF2 and PPARGC1A. Acts as a key regulator of glucose homeostasis in liver by phosphorylating CRTC2/TORC2, leading to CRTC2/TORC2 sequestration in the cytoplasm. In response to stress, phosphorylates 'Ser-36' of histone H2B (H2BS36ph), leading to promote transcription. Acts as a key regulator of cell growth and proliferation by phosphorylating TSC2, RPTOR and ATG1/ULK1: in response to nutrient limitation, negatively regulates the mTORC1 complex by phosphorylating RPTOR component of the mTORC1 complex and by phosphorylating and activating TSC2. In response to nutrient limitation, promotes autophagy by phosphorylating and activating ATG1/ULK1. AMPK also acts as a regulator of circadian rhythm by mediating phosphorylation of CRY1, leading to destabilize it. May regulate the Wnt signaling pathway by phosphorylating CTNNB1, leading to stabilize it. Also phosphorylates CFTR, EEF2K, KLC1, NOS3 and SLC12A1. Plays an important role in the differential regulation of pro-autophagy (composed of PIK3C3, BECN1, PIK3R4 and UVRAG or ATG14) and non-autophagy (composed of PIK3C3, BECN1 and PIK3R4) complexes, in response to glucose starvation. Can inhibit the non-autophagy complex by phosphorylating PIK3C3 and can activate the pro-autophagy complex by phosphorylating BECN1 (By similarity).", "name": "5'-AMP-activated protein kinase catalytic subunit alpha-2", "drug_actions": [{"action": "ACTIVATOR", "target": "P54646", "drug": "DB00945"}], "general_function": "Protein serine/threonine/tyrosine kinase activity", "in_complexes": ["5'-AMP-activated protein kinase"], "gene_names": ["PRKAA2"]}, "Q96C36": {"specific_function": "Housekeeping enzyme that catalyzes the last step in proline biosynthesis. In some cell types, such as erythrocytes, its primary function may be the generation of NADP(+). Can utilize both NAD and NADP. Has higher affinity for NADP, but higher catalytic efficiency with NADH (PubMed:2722838, PubMed:6894153). Involved in cellular response to oxidative stress (PubMed:25865492).", "general_function": "Pyrroline-5-carboxylate reductase activity", "gene_names": ["PYCR2"], "name": "Pyrroline-5-carboxylate reductase 2", "drug_actions": []}, "Q6NS38": {"specific_function": "Dioxygenase that repairs alkylated DNA and RNA containing 1-methyladenine and 3-methylcytosine by oxidative demethylation. Can also repair alkylated DNA containing 1-ethenoadenine (in vitro). Has strong preference for double-stranded DNA. Has low efficiency with single-stranded substrates. Requires molecular oxygen, alpha-ketoglutarate and iron.", "general_function": "Ferrous iron binding", "gene_names": ["ALKBH2"], "name": "DNA oxidative demethylase ALKBH2", "drug_actions": []}, "Q9HAB3": {"specific_function": "Riboflavin transporter. Riboflavin transport is Na(+)-independent but moderately pH-sensitive. Activity is strongly inhibited by riboflavin analogs, such as lumiflavin. Weakly inhibited by flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN). In case of infection by retroviruses, acts as a cell receptor to retroviral envelopes similar to the porcine endogenous retrovirus (PERV-A).", "general_function": "Virus receptor activity", "gene_names": ["SLC52A2"], "name": "Solute carrier family 52, riboflavin transporter, member 2", "drug_actions": [{"action": "AGONIST", "target": "Q9HAB3", "drug": "DB01440"}]}, "P13702": {"specific_function": "P.mevalonii can use mevalonate as sole carbon source. With this enzyme mevalonate is deacetylated to HMG-CoA.", "general_function": "Hydroxymethylglutaryl-coa reductase activity", "gene_names": ["mvaA"], "name": "3-hydroxy-3-methylglutaryl-coenzyme A reductase", "drug_actions": []}, "P07195": {"general_function": "Nad binding", "gene_names": ["LDHB"], "name": "L-lactate dehydrogenase B chain", "drug_actions": []}, "P01850": {"gene_names": ["TRBC1"], "name": "T-cell receptor beta-1 chain C region", "drug_actions": []}, "Q03393": {"specific_function": "Involved in the biosynthesis of tetrahydrobiopterin, an essential cofactor of aromatic amino acid hydroxylases. Catalyzes the transformation of 7,8-dihydroneopterin triphosphate into 6-pyruvoyl tetrahydropterin.", "general_function": "Metal ion binding", "gene_names": ["PTS"], "name": "6-pyruvoyl tetrahydrobiopterin synthase", "drug_actions": []}, "Q45697": {"specific_function": "Catalyzes two steps in the degradation of uric acid, i.e. the oxidation of uric acid to 5-hydroxyisourate (HIU) and the stereoselective decarboxylation of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU) to (S)-allantoin (By similarity).", "general_function": "Urate oxidase activity", "gene_names": ["uao"], "name": "Uric acid degradation bifunctional protein", "drug_actions": []}, "P52687": {"specific_function": "Member of the two-component regulatory system CitA/CitB. Probably activates CitB by phosphorylation. The periplasmic domain binds H-citrate(2-), which is essential for induction of the citrate-fermentation genes.", "general_function": "Phosphorelay sensor kinase activity", "gene_names": ["citA"], "name": "Sensor histidine kinase CitA", "drug_actions": []}, "Q8TE23": {"specific_function": "Putative taste receptor. TAS1R2/TAS1R3 recognizes diverse natural and synthetic sweeteners.", "general_function": "Taste receptor activity", "gene_names": ["TAS1R2"], "name": "Taste receptor type 1 member 2", "drug_actions": [{"action": "AGONIST", "target": "Q8TE23", "drug": "DB00168"}]}, "P13036": {"specific_function": "FecA is the outer membrane receptor protein in the Fe(3+) dicitrate transport system.", "general_function": "Receptor activity", "gene_names": ["fecA"], "name": "Fe(3+) dicitrate transport protein FecA", "drug_actions": []}, "P17584": {"specific_function": "Catalyzes the NAD dependent reversible, stereospecific interconversion between 2-ketocarboxylic acids and D-2-hydroxy-carboxylic acids.", "general_function": "Oxidoreductase activity, acting on the ch-oh group of donors, nad or nadp as acceptor", "gene_names": [], "name": "D-2-hydroxyisocaproate dehydrogenase", "drug_actions": []}, "P18925": {"specific_function": "The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2). It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and lipoamide dehydrogenase (E3).", "general_function": "Flavin adenine dinucleotide binding", "gene_names": [], "name": "Dihydrolipoyl dehydrogenase", "drug_actions": []}, "Q8WWQ8": {"specific_function": "Phosphatidylserine receptor that enhances the engulfment of apoptotic cells. Hyaluronan receptor that binds to and mediates endocytosis of hyaluronic acid (HA). Acts also, in different species, as a primary systemic scavenger receptor for heparin (Hep), chondroitin sulfate (CS), dermatan sulfate (DS), nonglycosaminoglycan (GAG), acetylated low-density lipoprotein (AcLDL), pro-collagen propeptides and advanced glycation end products (AGE). May serve to maintain tissue integrity by supporting extracellular matrix turnover or it may contribute to maintaining fluidity of bodily liquids by resorption of hyaluronan. Counter receptor which plays an important role in lymphocyte recruitment in the hepatic vasculature. Binds to both Gram-positive and Gram-negative bacteria and may play a role in defense against bacterial infection. The proteolytically processed 190 kDa form also functions as an endocytosis receptor for heparin internalisation as well as HA and CS.", "general_function": "Scavenger receptor activity", "gene_names": ["STAB2"], "name": "Stabilin-2", "drug_actions": [{"action": "BINDER", "target": "Q8WWQ8", "drug": "DB08818"}]}, "Q71U36": {"specific_function": "Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.", "general_function": "Structural molecule activity", "gene_names": ["TUBA1A"], "name": "Tubulin alpha-1A chain", "drug_actions": [{"action": "INHIBITOR", "target": "Q71U36", "drug": "DB00518"}, {"action": "ADDUCT", "target": "Q71U36", "drug": "DB00570"}, {"action": "INHIBITOR", "target": "Q71U36", "drug": "DB00643"}]}, "P05108": {"specific_function": "Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.", "general_function": "Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen", "gene_names": ["CYP11A1"], "name": "Cholesterol side-chain cleavage enzyme, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "P05108", "drug": "DB00357"}]}, "Q08493": {"specific_function": "Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.", "name": "cAMP-specific 3',5'-cyclic phosphodiesterase 4C", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "Q08493", "drug": "DB00201"}, {"action": "INHIBITOR", "target": "Q08493", "drug": "DB00651"}, {"action": "INHIBITOR", "target": "Q08493", "drug": "DB00920"}, {"action": "INDUCER", "target": "Q08493", "drug": "DB01088"}, {"action": "INHIBITOR", "target": "Q08493", "drug": "DB01656"}, {"action": "INHIBITOR", "target": "Q08493", "drug": "DB05266"}], "general_function": "Metal ion binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE4C"]}, "P22413": {"specific_function": "By generating PPi, plays a role in regulating pyrophosphate levels, and functions in bone mineralization and soft tissue calcification. PPi inhibits mineralization by binding to nascent hydroxyapatite (HA) crystals, thereby preventing further growth of these crystals. Preferentially hydrolyzes ATP, but can also hydrolyze other nucleoside 5' triphosphates such as GTP, CTP, TTP and UTP to their corresponding monophosphates with release of pyrophosphate and diadenosine polyphosphates, and also 3',5'-cAMP to AMP. May also be involved in the regulation of the availability of nucleotide sugars in the endoplasmic reticulum and Golgi, and the regulation of purinergic signaling. Appears to modulate insulin sensitivity and function.", "general_function": "Zinc ion binding", "gene_names": ["ENPP1"], "name": "Ectonucleotide pyrophosphatase/phosphodiesterase family member 1", "drug_actions": [{"action": "INHIBITOR", "target": "P22413", "drug": "DB00811"}, {"action": "INDUCER", "target": "P22413", "drug": "DB01143"}]}, "P30038": {"specific_function": "Irreversible conversion of delta-1-pyrroline-5-carboxylate (P5C), derived either from proline or ornithine, to glutamate. This is a necessary step in the pathway interconnecting the urea and tricarboxylic acid cycles. The preferred substrate is glutamic gamma-semialdehyde, other substrates include succinic, glutaric and adipic semialdehydes.", "general_function": "Identical protein binding", "gene_names": ["ALDH4A1"], "name": "Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial", "drug_actions": []}, "Q9Y2Q3": {"specific_function": "Significant glutathione conjugating activity is found only with the model substrate, 1-chloro-2,4-dinitrobenzene (CDNB).", "general_function": "Receptor binding", "gene_names": ["GSTK1"], "name": "Glutathione S-transferase kappa 1", "drug_actions": []}, "Q9Y2Q0": {"specific_function": "Catalytic component of a P4-ATPase flippase complex which catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids from the outer to the inner leaflet of various membranes and ensures the maintenance of asymmetric distribution of phospholipids. Phospholipid translocation seems also to be implicated in vesicle formation and in uptake of lipid signaling molecules. In vitro, its ATPase activity is selectively and stereospecifically stimulated by phosphatidylserine (PS). The flippase complex ATP8A1:TMEM30A seems to play a role in regulation of cell migration probably involving flippase-mediated translocation of phosphatidylethanolamine (PE) at the plasma membrane. Acts as aminophospholipid translocase at the plasma membrane in neuronal cells.", "general_function": "Phospholipid-translocating atpase activity", "gene_names": ["ATP8A1"], "name": "Phospholipid-transporting ATPase IA", "drug_actions": []}, "Q08499": {"specific_function": "Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.", "name": "cAMP-specific 3',5'-cyclic phosphodiesterase 4D", "drug_actions": [{"action": "PRODUCT OF", "target": "Q08499", "drug": "DB00131"}, {"action": "INHIBITOR, COMPETITIVE", "target": "Q08499", "drug": "DB00201"}, {"action": "INHIBITOR", "target": "Q08499", "drug": "DB00651"}, {"action": "INHIBITOR", "target": "Q08499", "drug": "DB00920"}, {"action": "INDUCER", "target": "Q08499", "drug": "DB01088"}, {"action": "INHIBITOR", "target": "Q08499", "drug": "DB01656"}, {"action": "INHIBITOR", "target": "Q08499", "drug": "DB05266"}, {"action": "ANTAGONIST", "target": "Q08499", "drug": "DB05676"}], "general_function": "Ubiquitin protein ligase binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE4D"]}, "P56220": {"general_function": "2,3,4,5-tetrahydropyridine-2,6-dicarboxylate n-succinyltransferase activity", "gene_names": ["dapD"], "name": "2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase", "drug_actions": []}, "P05106": {"specific_function": "Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets (By similarity).(Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for herpes virus 8/HHV-8 (PubMed:18045938). Integrin ITGAV:ITGB3 acts as a receptor for coxsackievirus A9 (PubMed:7519807). Acts as a receptor for Hantaan virus (PubMed:9618541). Integrin ITGAV:ITGB3 acts as a receptor for cytomegalovirus/HHV-5 (PubMed:15834425). Integrin ITGA5:ITGB3 acts as a receptor for human metapneumovirus (PubMed:24478423). Integrin ITGAV:ITGB3 acts aP05556s a receptor for human parechovirus 1 (PubMed:11160695). Integrin ITGAV:ITGB3 acts as a receptor for west nile virus (PubMed:23658209). In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions (PubMed:10397733).", "general_function": "Virus receptor activity", "gene_names": ["ITGB3"], "name": "Integrin beta-3", "drug_actions": [{"action": "ANTAGONIST", "target": "P05106", "drug": "DB00054"}, {"action": "ANTAGONIST", "target": "P05106", "drug": "DB00775"}]}, "O95363": {"specific_function": "Is responsible for the charging of tRNA(Phe) with phenylalanine in mitochondrial translation. To a lesser extent, also catalyzes direct attachment of m-Tyr (an oxidized version of Phe) to tRNA(Phe), thereby opening the way for delivery of the misacylated tRNA to the ribosome and incorporation of ROS-damaged amino acid into proteins.", "general_function": "Trna binding", "gene_names": ["FARS2"], "name": "Phenylalanine--tRNA ligase, mitochondrial", "drug_actions": []}, "P15259": {"specific_function": "Interconversion of 3- and 2-phosphoglycerate with 2,3-bisphosphoglycerate as the primer of the reaction. Can also catalyze the reaction of EC 5.4.2.4 (synthase) and EC 3.1.3.13 (phosphatase), but with a reduced activity.", "general_function": "Phosphoglycerate mutase activity", "gene_names": ["PGAM2"], "name": "Phosphoglycerate mutase 2", "drug_actions": []}, "P17707": {"specific_function": "Essential for biosynthesis of the polyamines spermidine and spermine. Promotes maintenance and self-renewal of embryonic stem cells, by maintaining spermine levels (By similarity).", "general_function": "Putrescine binding", "gene_names": ["AMD1"], "name": "S-adenosylmethionine decarboxylase proenzyme", "drug_actions": [{"action": "COFACTOR", "target": "P17707", "drug": "DB00118"}]}, "Q00987": {"specific_function": "E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in stabilizing p53/TP53. Also component of the TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA damage response pathways. Mediates ubiquitination and subsequent proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R and SNAI1 and promotes them to proteasomal degradation.", "general_function": "Zinc ion binding", "gene_names": ["MDM2"], "name": "E3 ubiquitin-protein ligase Mdm2", "drug_actions": []}, "O95168": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFB4"], "name": "NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4", "drug_actions": []}, "O95169": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFB8"], "name": "NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial", "drug_actions": []}, "O95167": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFA3"], "name": "NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3", "drug_actions": []}, "P06132": {"specific_function": "Catalyzes the decarboxylation of four acetate groups of uroporphyrinogen-III to yield coproporphyrinogen-III.", "general_function": "Uroporphyrinogen decarboxylase activity", "gene_names": ["UROD"], "name": "Uroporphyrinogen decarboxylase", "drug_actions": []}, "P0AC41": {"specific_function": "Two distinct, membrane-bound, FAD-containing enzymes are responsible for the catalysis of fumarate and succinate interconversion; the fumarate reductase is used in anaerobic growth, and the succinate dehydrogenase is used in aerobic growth.", "general_function": "Succinate dehydrogenase activity", "gene_names": ["sdhA"], "name": "Succinate dehydrogenase flavoprotein subunit", "drug_actions": []}, "P24310": {"specific_function": "This protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport.", "general_function": "Cytochrome-c oxidase activity", "gene_names": ["COX7A1"], "name": "Cytochrome c oxidase subunit 7A1, mitochondrial", "drug_actions": []}, "P24311": {"specific_function": "This protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport. Plays a role in proper central nervous system (CNS) development in vertebrates.", "general_function": "Cytochrome-c oxidase activity", "gene_names": ["COX7B"], "name": "Cytochrome c oxidase subunit 7B, mitochondrial", "drug_actions": []}, "P0AC44": {"specific_function": "Membrane-anchoring subunit of succinate dehydrogenase (SDH).", "general_function": "Succinate dehydrogenase activity", "gene_names": ["sdhD"], "name": "Succinate dehydrogenase hydrophobic membrane anchor subunit", "drug_actions": []}, "P07686": {"specific_function": "Responsible for the degradation of GM2 gangliosides, and a variety of other molecules containing terminal N-acetyl hexosamines, in the brain and other tissues.", "general_function": "Protein homodimerization activity", "gene_names": ["HEXB"], "name": "Beta-hexosaminidase subunit beta", "drug_actions": []}, "P18858": {"specific_function": "DNA ligase that seals nicks in double-stranded DNA during DNA replication, DNA recombination and DNA repair.", "general_function": "Metal ion binding", "gene_names": ["LIG1"], "name": "DNA ligase 1", "drug_actions": [{"action": "INHIBITOR", "target": "P18858", "drug": "DB00290"}]}, "P13632": {"specific_function": "Member of the two-component regulatory system DctB/DctD involved in the transport of C4-dicarboxylates. When activated by DctB acts in conjunction with sigma-54 to activate the transcription of dctA.", "general_function": "Sequence-specific dna binding", "gene_names": ["dctD"], "name": "C4-dicarboxylate transport transcriptional regulatory protein DctD", "drug_actions": []}, "P18850": {"specific_function": "Transcription factor that acts during endoplasmic reticulum stress by activating unfolded protein response target genes. Binds DNA on the 5'-CCAC[GA]-3'half of the ER stress response element (ERSE) (5'-CCAAT-N(9)-CCAC[GA]-3') and of ERSE II (5'-ATTGG-N-CCACG-3'). Binding to ERSE requires binding of NF-Y to ERSE. Could also be involved in activation of transcription by the serum response factor.", "name": "Cyclic AMP-dependent transcription factor ATF-6 alpha", "drug_actions": [], "general_function": "Transcription factor activity, sequence-specific dna binding", "in_complexes": ["activator protein 1"], "gene_names": ["ATF6"]}, "P0AD64": {"general_function": "Beta-lactamase activity", "gene_names": ["bla"], "name": "Beta-lactamase SHV-1", "drug_actions": [{"action": "INHIBITOR", "target": "P0AD64", "drug": "DB09060"}]}, "Q08129": {"specific_function": "Bifunctional, exhibiting both a catalase and broad- spectrum peroxidase activities. May play a role in the intracellular survival of mycobacteria", "general_function": "Inorganic ion transport and metabolism", "gene_names": ["katG"], "name": "Catalase-peroxidase", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "Q08129", "drug": "DB00609"}, {"action": "OTHER/UNKNOWN", "target": "Q08129", "drug": "DB00951"}]}, "Q9NS18": {"specific_function": "Glutathione-dependent oxidoreductase that facilitates the maintenance of mitochondrial redox homeostasis upon induction of apoptosis by oxidative stress. Involved in response to hydrogen peroxide and regulation of apoptosis caused by oxidative stress. Acts as a very efficient catalyst of monothiol reactions because of its high affinity for protein glutathione-mixed disulfides. Can receive electrons not only from glutathione (GSH), but also from thioredoxin reductase supporting both monothiol and dithiol reactions. Efficiently catalyzes both glutathionylation and deglutathionylation of mitochondrial complex I, which in turn regulates the superoxide production by the complex. Overexpression decreases the susceptibility to apoptosis and prevents loss of cardiolipin and cytochrome c release.", "general_function": "Protein disulfide oxidoreductase activity", "gene_names": ["GLRX2"], "name": "Glutaredoxin-2, mitochondrial", "drug_actions": []}, "P32427": {"specific_function": "Catalyzes an anti cycloisomerization.", "general_function": "3-carboxy-cis,cis-muconate cycloisomerase activity", "gene_names": ["pcaB"], "name": "3-carboxy-cis,cis-muconate cycloisomerase", "drug_actions": []}, "P04183": {"general_function": "Zinc ion binding", "gene_names": ["TK1"], "name": "Thymidine kinase, cytosolic", "drug_actions": []}, "P78417": {"specific_function": "Exhibits glutathione-dependent thiol transferase and dehydroascorbate reductase activities. Has S-(phenacyl)glutathione reductase activity. Has also glutathione S-transferase activity. Participates in the biotransformation of inorganic arsenic and reduces monomethylarsonic acid (MMA) and dimethylarsonic acid.", "general_function": "Oxidoreductase activity", "gene_names": ["GSTO1"], "name": "Glutathione S-transferase omega-1", "drug_actions": []}, "P04181": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["OAT"], "name": "Ornithine aminotransferase, mitochondrial", "drug_actions": [{"action": "COFACTOR", "target": "P04181", "drug": "DB00114"}, {"action": "INHIBITOR", "target": "P04181", "drug": "DB02821"}]}, "P43813": {"specific_function": "DNA ligase that catalyzes the formation of phosphodiester linkages between 5'-phosphoryl and 3'-hydroxyl groups in double-stranded DNA using NAD as a coenzyme and as the energy source for the reaction. It is essential for DNA replication and repair of damaged DNA.", "general_function": "Metal ion binding", "gene_names": ["ligA"], "name": "DNA ligase", "drug_actions": []}, "Q9Y4U1": {"specific_function": "May be involved in the binding and intracellular trafficking of cobalamin (vitamin B12).", "general_function": "Cobalamin binding", "gene_names": ["MMACHC"], "name": "Methylmalonic aciduria and homocystinuria type C protein", "drug_actions": [{"action": "COFACTOR", "target": "Q9Y4U1", "drug": "DB00115"}, {"action": "OTHER/UNKNOWN", "target": "Q9Y4U1", "drug": "DB00200"}]}, "Q8GIQ0": {"general_function": "Dtdp-4-dehydrorhamnose 3,5-epimerase activity", "gene_names": ["rmlC"], "name": "dTDP-4-dehydrorhamnose 3,5-epimerase", "drug_actions": []}, "P09598": {"specific_function": "Required, with sphingomyelinase, to effect target cell lysis (hemolysis).", "general_function": "Zinc ion binding", "gene_names": ["plc"], "name": "Phospholipase C", "drug_actions": []}, "P09592": {"specific_function": "Capsid protein possesses a protease activity that results in its autocatalytic cleavage from the nascent structural protein. Following its self-cleavage, the capsid protein transiently associates with ribosomes, and within several minutes the protein binds to viral RNA and rapidly assembles into icosaedric core particles. The resulting nucleocapsid eventually associates with the cytoplasmic domain of E2 at the cell membrane, leading to budding and formation of mature virions. New virions attach to target cells, and after clathrin-mediated endocytosis their membrane fuses with the host endosomal membrane. This leads to the release of the nucleocapsid into the cytoplasm, followed by an uncoating event necessary for the genomic RNA to become accessible. The uncoating might be triggered by the interaction of capsid proteins with ribosomes. Binding of ribosomes would release the genomic RNA since the same region is genomic RNA-binding and ribosome-binding (By similarity).E3 protein's function is unknown.E2 is responsible for viral attachment to target host cell, by binding to the cell receptor. Synthesized as a p62 precursor which is processed by furin at the cell membrane just before virion budding, giving rise to E2-E1 heterodimer. The p62-E1 heterodimer is stable, whereas E2-E1 is unstable and dissociate at low pH. p62 is processed at the last step, presumably to avoid E1 fusion activation before its final export to cell surface. E2 C-terminus contains a transitory transmembrane that would be disrupted by palmitoylation, resulting in reorientation of the C-terminal tail from lumenal to cytoplasmic side. This step is critical since E2 C-terminus is involved in budding by interacting with capsid proteins. This release of E2 C-terminus in cytoplasm occurs lately in protein export, and precludes premature assembly of particles at the endoplasmic reticulum membrane (By similarity).6K is a constitutive membrane protein involved in virus glycoprotein processing, cell permeabilization, and the budding of viral particles. Disrupts the calcium homeostasis of the cell, probably at the endoplasmic reticulum level. This leads to cytoplasmic calcium elevation. Because of its lipophilic properties, the 6K protein is postulated to influence the selection of lipids that interact with the transmembrane domains of the glycoproteins, which, in turn, affects the deformability of the bilayer required for the extreme curvature that occurs as budding proceeds. Present in low amount in virions, about 3% compared to viral glycoproteins (By similarity).E1 is a class II viral fusion protein. Fusion activity is inactive as long as E1 is bound to E2 in mature virion. After virus attachment to target cell and endocytosis, acidification of the endosome would induce dissociation of E1/E2 heterodimer and concomitant trimerization of the E1 subunits. This E1 trimer is fusion active, and promotes release of viral nucleocapsid in cytoplasm after endosome and viral membrane fusion. Efficient fusion requires the presence of cholesterol and sphingolipid in the target membrane (By similarity).", "general_function": "Structural molecule activity", "gene_names": [], "name": "Structural polyprotein", "drug_actions": []}, "P31142": {"specific_function": "Transfers a sulfur ion to cyanide or to other thiol compounds. Also has weak rhodanese activity (130-fold lower). Its participation in detoxification of cyanide may be small. May be involved in the enhancement of serine sensitivity.", "general_function": "Thiosulfate sulfurtransferase activity", "gene_names": ["sseA"], "name": "3-mercaptopyruvate sulfurtransferase", "drug_actions": []}, "Q9L5C8": {"general_function": "Beta-lactamase activity", "gene_names": ["blaCTX-M-9a"], "name": "Beta-lactamase", "drug_actions": []}, "P07919": {"specific_function": "This is a component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is part of the mitochondrial respiratory chain. This protein may mediate formation of the complex between cytochromes c and c1.", "general_function": "Ubiquinol-cytochrome-c reductase activity", "gene_names": ["UQCRH"], "name": "Cytochrome b-c1 complex subunit 6, mitochondrial", "drug_actions": []}, "P00509": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["aspC"], "name": "Aspartate aminotransferase", "drug_actions": []}, "Q6WRI0": {"specific_function": "May be involved in the maintenance of osteochondroprogenitor cells pool.", "gene_names": ["IGSF10"], "name": "Immunoglobulin superfamily member 10", "drug_actions": [{"action": "COFACTOR", "target": "Q6WRI0", "drug": "DB00114"}]}, "P55809": {"specific_function": "Key enzyme for ketone body catabolism. Transfers the CoA moiety from succinate to acetoacetate. Formation of the enzyme-CoA intermediate proceeds via an unstable anhydride species formed between the carboxylate groups of the enzyme and substrate.", "general_function": "Protein homodimerization activity", "gene_names": ["OXCT1"], "name": "Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial", "drug_actions": []}, "Q5SHN3": {"specific_function": "With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone (PubMed:11014182, PubMed:11007480, PubMed:11163189, PubMed:11014183, PubMed:11511350, PubMed:11296217, PubMed:11228145, PubMed:11228145, PubMed:11283358, PubMed:11340196, PubMed:11866529). Located at the interface of the 30S and 50S subunits, it traverses the body of the 30S subunit contacting proteins on the other side and probably holding the rRNA structure together. The combined cluster of proteins S8, S12 and S17 appears to hold together the shoulder and platform of the 30S subunit (PubMed:11283358).", "general_function": "Trna binding", "gene_names": ["rpsL"], "name": "30S ribosomal protein S12", "drug_actions": []}, "P06008": {"specific_function": "The reaction center is a membrane-bound complex that mediates the initial photochemical event in the electron transfer process of photosynthesis.", "general_function": "Electron transporter, transferring electrons within the cyclic electron transport pathway of photosynthesis activity", "gene_names": ["puhA"], "name": "Reaction center protein H chain", "drug_actions": []}, "P06009": {"specific_function": "The reaction center is a membrane-bound complex that mediates the initial photochemical event in the electron transfer process of photosynthesis.", "general_function": "Metal ion binding", "gene_names": ["pufL"], "name": "Reaction center protein L chain", "drug_actions": []}, "P53985": {"specific_function": "Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. Depending on the tissue and on cicumstances, mediates the import or export of lactic acid and ketone bodies. Required for normal nutrient assimilation, increase of white adipose tissue and body weight gain when on a high-fat diet. Plays a role in cellular responses to a high-fat diet by modulating the cellular levels of lactate and pyruvate, small molecules that contribute to the regulation of central metabolic pathways and insulin secretion, with concomitant effects on plasma insulin levels and blood glucose homeostasis.", "general_function": "Symporter activity", "gene_names": ["SLC16A1"], "name": "Monocarboxylate transporter 1", "drug_actions": []}, "Q15031": {"general_function": "Leucine-trna ligase activity", "gene_names": ["LARS2"], "name": "Probable leucine--tRNA ligase, mitochondrial", "drug_actions": []}, "P35610": {"specific_function": "Catalyzes the formation of fatty acid-cholesterol esters, which are less soluble in membranes than cholesterol. Plays a role in lipoprotein assembly and dietary cholesterol absorption. In addition to its acyltransferase activity, it may act as a ligase.", "general_function": "Sterol o-acyltransferase activity", "gene_names": ["SOAT1"], "name": "Sterol O-acyltransferase 1", "drug_actions": [{"action": "INHIBITOR", "target": "P35610", "drug": "DB00973"}, {"action": "INHIBITOR", "target": "P35610", "drug": "DB01094"}]}, "P56817": {"specific_function": "Responsible for the proteolytic processing of the amyloid precursor protein (APP). Cleaves at the N-terminus of the A-beta peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase.", "general_function": "Peptidase activity", "gene_names": ["BACE1"], "name": "Beta-secretase 1", "drug_actions": [{"action": "INHIBITOR", "target": "P56817", "drug": "DB06073"}, {"action": "INHIBITOR", "target": "P56817", "drug": "DB08929"}]}, "P39662": {"specific_function": "Is involved in NO detoxification in an aerobic process, termed nitric oxide dioxygenase (NOD) reaction that utilizes O(2) and NAD(P)H to convert NO to nitrate, which protects the bacterium from various noxious nitrogen compounds. Therefore, plays a central role in the inducible response to nitrosative stress.In the presence of oxygen and NADH, FHP has NADH oxidase activity, which leads to the generation of superoxide and H(2)O(2), both in vitro and in vivo, and it has been suggested that FHP might act as an amplifier of superoxide stress. Under anaerobic conditions, FHP also exhibits nitric oxide reductase and FAD reductase activities. However, all these reactions are much lower than NOD activity.", "general_function": "Oxygen transporter activity", "gene_names": ["hmp"], "name": "Flavohemoprotein", "drug_actions": []}, "Q01718": {"specific_function": "Receptor for corticotropin (ACTH). This receptor is mediated by G proteins (G(s)) which activate adenylate cyclase (cAMP).", "general_function": "Melanocortin receptor activity", "gene_names": ["MC2R"], "name": "Adrenocorticotropic hormone receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "Q01718", "drug": "DB01284"}, {"action": "AGONIST", "target": "Q01718", "drug": "DB01285"}]}, "P0C0J0": {"specific_function": "Important streptococcal virulence factor which cleaves human fibronectin and degrades vitronectin. Also cleaves human IL1B precursor to form biologically active IL1B. Can induce apoptosis in human monocytes and epithelial cells in vitro, and reduces phagocytic activity in monocytic cells. Thus, may play a role in bacterial colonization, invasion, and inhibition of wound healing.", "general_function": "Cysteine-type peptidase activity", "gene_names": ["speB"], "name": "Streptopain", "drug_actions": []}, "Q23022": {"specific_function": "Acetylcholine receptor.", "general_function": "Acetylcholine-activated cation-selective channel activity", "gene_names": ["unc-38"], "name": "Acetylcholine receptor subunit alpha-type unc-38", "drug_actions": [{"action": "ACTIVATOR", "target": "Q23022", "drug": "DB00848"}]}, "P08069": {"specific_function": "Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.", "general_function": "Protein tyrosine kinase activity", "gene_names": ["IGF1R"], "name": "Insulin-like growth factor 1 receptor", "drug_actions": [{"action": "AGONIST", "target": "P08069", "drug": "DB00047"}, {"action": "AGONIST", "target": "P08069", "drug": "DB01277"}]}, "P22314": {"specific_function": "Catalyzes the first step in ubiquitin conjugation to mark cellular proteins for degradation through the ubiquitin-proteasome system (PubMed:1606621, PubMed:1447181). Activates ubiquitin by first adenylating its C-terminal glycine residue with ATP, and thereafter linking this residue to the side chain of a cysteine residue in E1, yielding a ubiquitin-E1 thioester and free AMP (PubMed:1447181). Essential for the formation of radiation-induced foci, timely DNA repair and for response to replication stress. Promotes the recruitment of TP53BP1 and BRCA1 at DNA damage sites (PubMed:22456334).", "general_function": "Ubiquitin-protein transferase activity", "gene_names": ["UBA1"], "name": "Ubiquitin-like modifier-activating enzyme 1", "drug_actions": []}, "P01270": {"specific_function": "PTH elevates calcium level by dissolving the salts in bone and preventing their renal excretion. Stimulates [1-14C]-2-deoxy-D-glucose (2DG) transport and glycogen synthesis in osteoblastic cells.", "general_function": "Transcription factor activity, rna polymerase ii distal enhancer sequence-specific binding", "gene_names": ["PTH"], "name": "Parathyroid hormone", "drug_actions": []}, "P0A666": {"specific_function": "Regulator of RNase E/rne, which inhibits the endonuclease activity and thereby leads to increase the half-life and abundance of RNAs. General modulator of RNA abundance. Does not have any methyltransferase activity", "general_function": "Coenzyme transport and metabolism", "gene_names": ["Rv3853"], "name": "Putative regulator of ribonuclease activity", "drug_actions": []}, "P32397": {"specific_function": "Catalyzes the 6-electron oxidation of protoporphyrinogen-IX to form protoporphyrin-IX. Also oxidizes the pathway intermediate coproporphyrinogen-III.", "general_function": "Oxygen-dependent protoporphyrinogen oxidase activity", "gene_names": ["hemY"], "name": "Protoporphyrinogen oxidase", "drug_actions": []}, "P32396": {"specific_function": "Catalyzes the ferrous insertion into protoporphyrin IX.", "general_function": "Metal ion binding", "gene_names": ["hemH"], "name": "Ferrochelatase", "drug_actions": []}, "Q9UKV0": {"specific_function": "Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Represses MEF2-dependent transcription.Isoform 3 lacks active site residues and therefore is catalytically inactive. Represses MEF2-dependent transcription by recruiting HDAC1 and/or HDAC3. Seems to inhibit skeletal myogenesis and to be involved in heart development. Protects neurons from apoptosis, both by inhibiting JUN phosphorylation by MAPK10 and by repressing JUN transcription via HDAC1 recruitment to JUN promoter.", "general_function": "Transcription factor binding", "gene_names": ["HDAC9"], "name": "Histone deacetylase 9", "drug_actions": [{"action": "INHIBITOR", "target": "Q9UKV0", "drug": "DB00313"}, {"action": "INHIBITOR", "target": "Q9UKV0", "drug": "DB06603"}]}, "P52699": {"specific_function": "Confers resistance to imipenem and broad-spectrum beta-lactams. Also hydrolyzes carbapenems.", "general_function": "Zinc ion binding", "gene_names": [], "name": "Beta-lactamase IMP-1", "drug_actions": []}, "P35354": {"specific_function": "Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. In cancer cells, PTGS2 is a key step in the production of prostaglandin E2 (PGE2), which plays important roles in modulating motility, proliferation and resistance to apoptosis.", "general_function": "Prostaglandin-endoperoxide synthase activity", "gene_names": ["PTGS2"], "name": "Prostaglandin G/H synthase 2", "drug_actions": [{"action": "INHIBITOR", "target": "P35354", "drug": "DB00159"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00233"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00244"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00316"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00328"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00461"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00465"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00469"}, {"action": "NEGATIVE MODULATOR", "target": "P35354", "drug": "DB00480"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00482"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00500"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00533"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00554"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00573"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00580"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00586"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00605"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00712"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00749"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00784"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00788"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00795"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00812"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00814"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00821"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00861"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00870"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00936"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00939"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00945"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00963"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB00991"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB01009"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB01014"}, {"action": "ANTAGONIST", "target": "P35354", "drug": "DB01041"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB01050"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB01283"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB01397"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB01398"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB01399"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB01401"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB01404"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB01419"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB01435"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB01600"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB01628"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB02709"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB04552"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB04743"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB06725"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB06802"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB08439"}, {"action": "INHIBITOR", "target": "P35354", "drug": "DB08910"}]}, "P60568": {"specific_function": "Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Can stimulate B-cells, monocytes, lymphokine-activated killer cells, natural killer cells, and glioma cells.", "general_function": "Kinase activator activity", "gene_names": ["IL2"], "name": "Interleukin-2", "drug_actions": []}, "Q7BK04": {"general_function": "Atp binding", "gene_names": ["cag-alfa"], "name": "Cag alpha", "drug_actions": []}, "P55408": {"specific_function": "Acts to antagonize TraR-dependent activation.", "gene_names": ["traM"], "name": "Probable transcriptional repressor TraM", "drug_actions": []}, "Q9Y6K9": {"specific_function": "Regulatory subunit of the IKK core complex which phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. Its binding to scaffolding polyubiquitin seems to play a role in IKK activation by multiple signaling receptor pathways. However, the specific type of polyubiquitin recognized upon cell stimulation (either 'Lys-63'-linked or linear polyubiquitin) and its functional importance is reported conflictingly. Also considered to be a mediator for TAX activation of NF-kappa-B. Could be implicated in NF-kappa-B-mediated protection from cytokine toxicity. Essential for viral activation of IRF3. Involved in TLR3- and IFIH1-mediated antiviral innate response; this function requires 'Lys-27'-linked polyubiquitination.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["IKBKG"], "name": "NF-kappa-B essential modulator", "drug_actions": []}, "P32884": {"specific_function": "Attaches the virus to sialic acid-containing cell receptors and thereby initiating infection. Binding of HN protein to the receptor induces a conformational change that allows the F protein to trigger virion/cell membranes fusion (By similarity).Neuraminidase activity ensures the efficient spread of the virus by dissociating the mature virions from the neuraminic acid containing glycoproteins.", "general_function": "Exo-alpha-(2->8)-sialidase activity", "gene_names": ["HN"], "name": "Hemagglutinin-neuraminidase", "drug_actions": []}, "P08263": {"specific_function": "Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.", "general_function": "Glutathione transferase activity", "gene_names": ["GSTA1"], "name": "Glutathione S-transferase A1", "drug_actions": []}, "P17802": {"specific_function": "Adenine glycosylase active on G-A mispairs. MutY also corrects error-prone DNA synthesis past GO lesions which are due to the oxidatively damaged form of guanine: 7,8-dihydro-8-oxoguanine (8-oxo-dGTP).", "general_function": "Metal ion binding", "gene_names": ["mutY"], "name": "Adenine DNA glycosylase", "drug_actions": []}, "P05362": {"specific_function": "ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). During leukocyte trans-endothelial migration, ICAM1 engagement promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation.(Microbial infection) Acts as a receptor for major receptor group rhinovirus A-B capsid proteins (PubMed:1968231, PubMed:2538243). Acts as a receptor for Coxsackievirus A21 capsid proteins (PubMed:11160747, PubMed:16004874, PubMed:9539703). Upon Kaposi's sarcoma-associated herpesvirus/HHV-8 infection, is degraded by viral E3 ubiquitin ligase MIR2, presumably to prevent lysis of infected cells by cytotoxic T-lymphocytes and NK cell (PubMed:11413168).", "general_function": "Virus receptor activity", "gene_names": ["ICAM1"], "name": "Intercellular adhesion molecule 1", "drug_actions": []}, "P62993": {"specific_function": "Adapter protein that provides a critical link between cell surface growth factor receptors and the Ras signaling pathway.Isoform 2 does not bind to phosphorylated epidermal growth factor receptor (EGFR) but inhibits EGF-induced transactivation of a RAS-responsive element. Isoform 2 acts as a dominant negative protein over GRB2 and by suppressing proliferative signals, may trigger active programmed cell death.", "general_function": "Sh3/sh2 adaptor activity", "gene_names": ["GRB2"], "name": "Growth factor receptor-bound protein 2", "drug_actions": [{"action": "BINDER", "target": "P62993", "drug": "DB00061"}]}, "O76082": {"specific_function": "Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.", "general_function": "Symporter activity", "gene_names": ["SLC22A5"], "name": "Solute carrier family 22 member 5", "drug_actions": []}, "O76083": {"specific_function": "Specifically hydrolyzes the second messenger cGMP, which is a key regulator of many important physiological processes. Highly specific: compared to other members of the cyclic nucleotide phosphodiesterase family, has the highest affinity and selectivity for cGMP (PubMed:9624146, PubMed:18757755, PubMed:21483814). Specifically regulates natriuretic-peptide-dependent cGMP signaling in heart, acting as a regulator of cardiac hypertrophy in myocytes and muscle. Does not regulate nitric oxide-dependent cGMP in heart (PubMed:25799991). Additional experiments are required to confirm whether its ability to hydrolyze natriuretic-peptide-dependent cGMP is specific to heart or is a general feature of the protein (Probable). In brain, involved in cognitive function, such as learning and long-term memory (By similarity).", "name": "High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "O76083", "drug": "DB00201"}], "general_function": "Metal ion binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE9A"]}, "Q79FX8": {"specific_function": "Involved in the biosynthesis of hydroxymycolate, a common precursor of oxygenated mycolic acids (methoxy-mycolate and keto-mycolate). Probably transfers a methyl group from the S-adenosylmethionine (SAM) cofactor and, subsequently or simultaneously, a water molecule onto the double bound of ethylene substrates, leading to the formation of the hydroxylated product at the distal position. Involved in the activation of the antitubercular drug thiacetazone (TAC).", "general_function": "S-adenosylmethionine-dependent methyltransferase activity", "gene_names": ["mmaA4"], "name": "Hydroxymycolate synthase MmaA4", "drug_actions": []}, "O32449": {"specific_function": "Specifically catalyzes the removal of N-terminal proline residues from peptides.", "general_function": "Aminopeptidase activity", "gene_names": ["pip"], "name": "Proline iminopeptidase", "drug_actions": []}, "P0DJI8": {"specific_function": "Major acute phase protein.", "general_function": "Heparin binding", "gene_names": ["SAA1"], "name": "Serum amyloid A-1 protein", "drug_actions": []}, "P06310": {"general_function": "Antigen binding", "gene_names": [], "name": "Ig kappa chain V-II region RPMI 6410", "drug_actions": [{"action": "OTHER", "target": "P06310", "drug": "DB00693"}]}, "Q8VUS8": {"specific_function": "Catalyzes the oxidative deamination of a wide range of aliphatic and aromatic amines.", "general_function": "Oxidoreductase activity, acting on the ch-nh2 group of donors", "gene_names": ["qhnDH"], "name": "Quinohemoprotein amine dehydrogenase subunit gamma", "drug_actions": []}, "Q8VUS7": {"gene_names": [], "name": "Quinohemoprotein amine dehydrogenase 40 kDa subunit", "drug_actions": []}, "P16860": {"specific_function": "Cardiac hormone which may function as a paracrine antifibrotic factor in the heart. Also plays a key role in cardiovascular homeostasis through natriuresis, diuresis, vasorelaxation, and inhibition of renin and aldosterone secretion. Specifically binds and stimulates the cGMP production of the NPR1 receptor. Binds the clearance receptor NPR3.", "general_function": "Receptor binding", "gene_names": ["NPPB"], "name": "Natriuretic peptides B", "drug_actions": [{"action": "OTHER", "target": "P16860", "drug": "DB01136"}]}, "Q9X0A2": {"general_function": "Oxidoreductase activity", "gene_names": [], "name": "Oxidoreductase, aldo/keto reductase family", "drug_actions": []}, "O43497": {"specific_function": "Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the \"low-voltage activated (LVA)\" group and are strongly blocked by mibefradil. A particularity of this type of channel is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.", "name": "Voltage-dependent T-type calcium channel subunit alpha-1G", "drug_actions": [{"action": "INHIBITOR", "target": "O43497", "drug": "DB00347"}, {"action": "INHIBITOR", "target": "O43497", "drug": "DB00568"}, {"action": "INHIBITOR", "target": "O43497", "drug": "DB00593"}, {"action": "INHIBITOR", "target": "O43497", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "O43497", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "O43497", "drug": "DB01388"}, {"action": "INHIBITOR", "target": "O43497", "drug": "DB04841"}, {"action": "INHIBITOR", "target": "O43497", "drug": "DB05246"}], "general_function": "Scaffold protein binding", "in_complexes": ["Voltage-dependent calcium channel"], "gene_names": ["CACNA1G"]}, "Q7CRA4": {"general_function": "Transferase activity, transferring acyl groups", "gene_names": ["pbp1b"], "name": "Penicillin-binding protein 1b", "drug_actions": [{"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB00319"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB00415"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB00456"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB00485"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB00493"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB00567"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB00607"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB00713"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB00739"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB01140"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB01163"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB01603"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB03313"}, {"action": "INHIBITOR", "target": "Q7CRA4", "drug": "DB08795"}]}, "Q44244": {"gene_names": ["Aaar"], "name": "o-succinylbenzoate synthase", "drug_actions": []}, "O31465": {"general_function": "Glutaminase activity", "gene_names": ["glsA1"], "name": "Glutaminase 1", "drug_actions": []}, "Q14032": {"specific_function": "Involved in bile acid metabolism. In liver hepatocytes catalyzes the second step in the conjugation of C24 bile acids (choloneates) to glycine and taurine before excretion into bile canaliculi. The major components of bile are cholic acid and chenodeoxycholic acid. In a first step the bile acids are converted to an acyl-CoA thioester, either in peroxisomes (primary bile acids deriving from the cholesterol pathway), or cytoplasmic at the endoplasmic reticulum (secondary bile acids). May catalyze the conjugation of primary or secondary bile acids, or both. The conjugation increases the detergent properties of bile acids in the intestine, which facilitates lipid and fat-soluble vitamin absorption. In turn, bile acids are deconjugated by bacteria in the intestine and are recycled back to the liver for reconjugation (secondary bile acids). May also act as an acyl-CoA thioesterase that regulates intracellular levels of free fatty acids. In vitro, catalyzes the hydrolysis of long- and very long-chain saturated acyl-CoAs to the free fatty acid and coenzyme A (CoASH), and conjugates glycine to these acyl-CoAs.", "general_function": "Very long chain acyl-coa hydrolase activity", "gene_names": ["BAAT"], "name": "Bile acid-CoA:amino acid N-acyltransferase", "drug_actions": []}, "P01308": {"specific_function": "Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver.", "general_function": "Protease binding", "gene_names": ["INS"], "name": "Insulin", "drug_actions": []}, "Q92569": {"specific_function": "Binds to activated (phosphorylated) protein-tyrosine kinases through its SH2 domain and regulates their kinase activity. During insulin stimulation, it also binds to IRS-1.", "general_function": "1-phosphatidylinositol-3-kinase regulator activity", "gene_names": ["PIK3R3"], "name": "Phosphatidylinositol 3-kinase regulatory subunit gamma", "drug_actions": [{"action": "AGONIST", "target": "Q92569", "drug": "DB01064"}]}, "Q9UI33": {"specific_function": "This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant sodium channel isoform. Also involved, with the contribution of the receptor tyrosine kinase NTRK2, in rapid BDNF-evoked neuronal depolarization.", "name": "Sodium channel protein type 11 subunit alpha", "drug_actions": [{"action": "INHIBITOR", "target": "Q9UI33", "drug": "DB00907"}, {"action": "INHIBITOR", "target": "Q9UI33", "drug": "DB00909"}], "general_function": "Voltage-gated sodium channel activity", "in_complexes": ["Sodium channel protein"], "gene_names": ["SCN11A"]}, "Q9UI32": {"specific_function": "Plays an important role in the regulation of glutamine catabolism. Promotes mitochondrial respiration and increases ATP generation in cells by catalyzing the synthesis of glutamate and alpha-ketoglutarate. Increases cellular anti-oxidant function via NADH and glutathione production. May play a role in preventing tumor proliferation.", "general_function": "Glutaminase activity", "gene_names": ["GLS2"], "name": "Glutaminase liver isoform, mitochondrial", "drug_actions": []}, "Q9L5C7": {"general_function": "Involved in beta-lactamase activity", "gene_names": ["blaCTX-M-14"], "name": "Beta-lactamase CTX-M", "drug_actions": [{"action": "INHIBITOR", "target": "Q9L5C7", "drug": "DB09060"}]}, "Q6ZZJ1": {"general_function": "Metal ion binding", "gene_names": ["tcp14"], "name": "Putative uncharacterized protein tcp14", "drug_actions": []}, "Q5LRQ9": {"gene_names": [], "name": "ABC transporter, periplasmic substrate-binding protein", "drug_actions": []}, "P0A793": {"specific_function": "Catalyzes the pyruvoyl-dependent decarboxylation of aspartate to produce beta-alanine.", "general_function": "Aspartate 1-decarboxylase activity", "gene_names": ["panD"], "name": "Aspartate 1-decarboxylase", "drug_actions": []}, "Q27218": {"specific_function": "Acetylcholine receptor.", "general_function": "Acetylcholine-activated cation-selective channel activity", "gene_names": ["lev-1"], "name": "Acetylcholine receptor subunit beta-type lev-1", "drug_actions": [{"action": "ACTIVATOR", "target": "Q27218", "drug": "DB00848"}]}, "P0A794": {"specific_function": "Catalyzes the complicated ring closure reaction between the two acyclic compounds 1-deoxy-D-xylulose-5-phosphate (DXP) and 3-amino-2-oxopropyl phosphate (1-amino-acetone-3-phosphate or AAP) to form pyridoxine 5'-phosphate (PNP) and inorganic phosphate.", "general_function": "Pyridoxine 5'-phosphate synthase activity", "gene_names": ["pdxJ"], "name": "Pyridoxine 5'-phosphate synthase", "drug_actions": []}, "P04164": {"specific_function": "This monoheme basic protein appears to function as an electron donor to cytochrome oxidase in T.thermophilus.", "general_function": "Metal ion binding", "gene_names": ["cycA"], "name": "Cytochrome c-552", "drug_actions": []}, "P62669": {"specific_function": "Part of the top of the head of the 30S subunit. The C-terminal region penetrates the head emerging in the P-site where it contacts tRNA (By similarity).", "general_function": "Trna binding", "gene_names": ["rpsI"], "name": "30S ribosomal protein S9", "drug_actions": []}, "Q6UWP2": {"general_function": "Oxidoreductase activity", "gene_names": ["DHRS11"], "name": "Dehydrogenase/reductase SDR family member 11", "drug_actions": []}, "P03692": {"specific_function": "Synthesizes short RNA primers for DNA replication. Unwinds the DNA at the replication forks and generates single-stranded DNA for both leading and lagging strand synthesis. The primase synthesizes short RNA primers on the lagging strand that the polymerase elongates using dNTPs.", "general_function": "Zinc ion binding", "gene_names": [], "name": "DNA primase/helicase", "drug_actions": []}, "P0A884": {"specific_function": "Provides the sole de novo source of dTMP for DNA biosynthesis. This protein also binds to its mRNA thus repressing its own translation.", "general_function": "Thymidylate synthase activity", "gene_names": ["thyA"], "name": "Thymidylate synthase", "drug_actions": []}, "P62660": {"specific_function": "Protein S19 forms a complex with S13 that binds strongly to the 16S ribosomal RNA.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsS"], "name": "30S ribosomal protein S19", "drug_actions": []}, "P62661": {"specific_function": "Binds directly to 16S ribosomal RNA.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsT"], "name": "30S ribosomal protein S20", "drug_actions": []}, "P52569": {"specific_function": "Functions as permease involved in the transport of the cationic amino acids (arginine, lysine and ornithine); the affinity for its substrates differs between isoforms created by alternative splicing. Isoform 1 functions as permease that mediates the transport of the cationic amino acids (arginine, lysine and ornithine), and it has much higher affinity for arginine than isoform 2. Isoform 2 functions as low-affinity, high capacity permease involved in the transport of the cationic amino acids (arginine, lysine and ornithine) (PubMed:9174363). May play a role in classical or alternative activation of macrophages via its role in arginine transport.", "general_function": "Low-affinity l-arginine transmembrane transporter activity", "gene_names": ["SLC7A2"], "name": "Cationic amino acid transporter 2", "drug_actions": []}, "P44886": {"general_function": "Hydrolase activity", "gene_names": [], "name": "Uncharacterized acyl-CoA thioester hydrolase HI_0827", "drug_actions": []}, "P68771": {"gene_names": ["def"], "name": "Peptide deformylase", "drug_actions": []}, "P44801": {"specific_function": "Catalyzes the NADPH-dependent formation of L-aspartate-semialdehyde (L-ASA) by the reductive dephosphorylation of L-aspartyl-4-phosphate.", "general_function": "Nadp binding", "gene_names": ["asd"], "name": "Aspartate-semialdehyde dehydrogenase", "drug_actions": []}, "Q9X286": {"specific_function": "Involved in the transcription termination process.", "general_function": "Rna binding", "gene_names": ["nusB"], "name": "N utilization substance protein B homolog", "drug_actions": []}, "Q9QNF7": {"specific_function": "In latent infection, may allow the virus to be reactivated and to grow in cells lacking a high concentration of phosphorylated nucleic acid precursors, such as nerve cells that do not replicate their genome.", "general_function": "Thymidine kinase activity", "gene_names": ["TK"], "name": "Thymidine kinase", "drug_actions": [{"action": "INDUCER", "target": "Q9QNF7", "drug": "DB00194"}, {"action": "UNKNOWN", "target": "Q9QNF7", "drug": "DB00249"}, {"action": "INDUCER", "target": "Q9QNF7", "drug": "DB00577"}]}, "Q9R381": {"specific_function": "Catalyzes the transfer of an acetyl group from acetyl-CoA to the 6'-amino group of aminoglycoside molecules conferring resistance to antibiotics containing the purpurosamine ring including amikacin, tobramycin, dibekacin and ribostamycin. Able to acetylate eukaryotic histone proteins.", "general_function": "Protein homodimerization activity", "gene_names": [], "name": "Aminoglycoside N(6')-acetyltransferase type 1", "drug_actions": []}, "P06820": {"specific_function": "Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells. Likely to plays a role in the budding process through its association with lipid rafts during intracellular transport. May additionally display a raft-association independent effect on budding. Plays a role in the determination of host range restriction on replication and virulence. Sialidase activity in late endosome/lysosome traffic seems to enhance virus replication.", "general_function": "Metal ion binding", "gene_names": ["NA"], "name": "Neuraminidase", "drug_actions": []}, "P0CG29": {"specific_function": "Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Has a sulfatase activity.", "general_function": "Glutathione transferase activity", "gene_names": ["GSTT2"], "name": "Glutathione S-transferase theta-2", "drug_actions": []}, "P72355": {"general_function": "Serine-type d-ala-d-ala carboxypeptidase activity", "gene_names": ["pbp4"], "name": "Penicillin-binding protein 4", "drug_actions": [{"action": "ANTAGONIST", "target": "P72355", "drug": "DB06211"}, {"action": "INHIBITOR", "target": "P72355", "drug": "DB06211"}]}, "P27338": {"specific_function": "Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.", "name": "Amine oxidase [flavin-containing] B", "drug_actions": [{"action": "ANTAGONIST", "target": "P27338", "drug": "DB00191"}, {"action": "INHIBITOR", "target": "P27338", "drug": "DB00752"}, {"action": "ANTAGONIST", "target": "P27338", "drug": "DB00780"}, {"action": "INHIBITOR", "target": "P27338", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P27338", "drug": "DB01037"}, {"action": "INHIBITOR", "target": "P27338", "drug": "DB01247"}, {"action": "INHIBITOR", "target": "P27338", "drug": "DB01363"}, {"action": "INHIBITOR", "target": "P27338", "drug": "DB01367"}, {"action": "INHIBITOR", "target": "P27338", "drug": "DB01442"}, {"action": "INHIBITOR", "target": "P27338", "drug": "DB01472"}, {"action": "INHIBITOR", "target": "P27338", "drug": "DB01577"}, {"action": "INHIBITOR", "target": "P27338", "drug": "DB01626"}, {"action": "INHIBITOR", "target": "P27338", "drug": "DB04832"}], "general_function": "Primary amine oxidase activity", "in_complexes": ["Monoamine oxidase"], "gene_names": ["MAOB"]}, "P00367": {"specific_function": "Mitochondrial glutamate dehydrogenase that converts L-glutamate into alpha-ketoglutarate. Plays a key role in glutamine anaplerosis by producing alpha-ketoglutarate, an important intermediate in the tricarboxylic acid cycle. May be involved in learning and memory reactions by increasing the turnover of the excitatory neurotransmitter glutamate (By similarity).", "general_function": "Nad+ binding", "gene_names": ["GLUD1"], "name": "Glutamate dehydrogenase 1, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "P00367", "drug": "DB00756"}]}, "P0A538": {"specific_function": "Cleavage of guanosine or inosine to respective bases and sugar-1-phosphate molecules", "general_function": "Nucleotide transport and metabolism", "gene_names": ["punA"], "name": "Purine nucleoside phosphorylase", "drug_actions": []}, "Q8IU85": {"specific_function": "Calcium/calmodulin-dependent protein kinase that operates in the calcium-triggered CaMKK-CaMK1 signaling cascade and, upon calcium influx, activates CREB-dependent gene transcription, regulates calcium-mediated granulocyte function and respiratory burst and promotes basal dendritic growth of hippocampal neurons. In neutrophil cells, required for cytokine-induced proliferative responses and activation of the respiratory burst. Activates the transcription factor CREB1 in hippocampal neuron nuclei. May play a role in apoptosis of erythroleukemia cells. In vitro, phosphorylates transcription factor CREM isoform Beta.", "general_function": "Calmodulin-dependent protein kinase activity", "gene_names": ["CAMK1D"], "name": "Calcium/calmodulin-dependent protein kinase type 1D", "drug_actions": []}, "Q7LG56": {"specific_function": "Plays a pivotal role in cell survival by repairing damaged DNA in a p53/TP53-dependent manner. Supplies deoxyribonucleotides for DNA repair in cells arrested at G1 or G2. Contains an iron-tyrosyl free radical center required for catalysis. Forms an active ribonucleotide reductase (RNR) complex with RRM1 which is expressed both in resting and proliferating cells in response to DNA damage.", "general_function": "Ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor", "gene_names": ["RRM2B"], "name": "Ribonucleoside-diphosphate reductase subunit M2 B", "drug_actions": [{"action": "INHIBITOR", "target": "Q7LG56", "drug": "DB00242"}]}, "P32170": {"general_function": "Manganese ion binding", "gene_names": ["rhaA"], "name": "L-rhamnose isomerase", "drug_actions": []}, "P0DJ06": {"specific_function": "Secreted aspartic peptidases (SAPs) are a group of ten acidic hydrolases considered as key virulence factors. These enzymes supply the fungus with nutrient amino acids as well as are able to degrade the selected host's proteins involved in the immune defense. Induces host inflammatory cytokine production in a proteolytic activity-independent way. Plays a role in tissue damage during superficial infection. Moreover, acts toward human hemoglobin though limited proteolysis to generate a variety of antimicrobial hemocidins, enabling to compete with the other microorganisms of the same physiological niche using the microbicidal peptides generated from the host protein.", "general_function": "Drug binding", "gene_names": ["SAP2"], "name": "Candidapepsin-2", "drug_actions": []}, "Q6IBS8": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["DDC"], "name": "DDC protein", "drug_actions": [{"action": "COFACTOR", "target": "Q6IBS8", "drug": "DB00114"}]}, "Q9H252": {"specific_function": "Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current (By similarity). Channel properties may be modulated by cAMP and subunit assembly.", "general_function": "Voltage-gated potassium channel activity", "gene_names": ["KCNH6"], "name": "Potassium voltage-gated channel subfamily H member 6", "drug_actions": [{"action": "INHIBITOR", "target": "Q9H252", "drug": "DB00308"}, {"action": "INHIBITOR", "target": "Q9H252", "drug": "DB00457"}, {"action": "INHIBITOR", "target": "Q9H252", "drug": "DB00590"}, {"action": "INHIBITOR", "target": "Q9H252", "drug": "DB01110"}, {"action": "INHIBITOR", "target": "Q9H252", "drug": "DB01162"}]}, "P08319": {"general_function": "Zinc ion binding", "gene_names": ["ADH4"], "name": "Alcohol dehydrogenase 4", "drug_actions": []}, "A0R559": {"specific_function": "Involved in the biosynthesis of isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), two major building blocks of isoprenoid compounds. Catalyzes the conversion of 4-diphosphocytidyl-2-C-methyl-D-erythritol 2-phosphate (CDP-ME2P) to 2-C-methyl-D-erythritol 2,4-cyclodiphosphate (ME-CPP) with a corresponding release of cytidine 5-monophosphate (CMP) (By similarity).", "general_function": "Nucleotide binding", "gene_names": ["ispF"], "name": "2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase", "drug_actions": []}, "Q9RQB9": {"general_function": "Metal ion binding", "gene_names": ["cycA"], "name": "Cytochrome c''", "drug_actions": []}, "Q8TED1": {"general_function": "Peroxidase activity", "gene_names": ["GPX8"], "name": "Probable glutathione peroxidase 8", "drug_actions": []}, "O14786": {"specific_function": "The membrane-bound isoform 1 is a receptor involved in the development of the cardiovascular system, in angiogenesis, in the formation of certain neuronal circuits and in organogenesis outside the nervous system. It mediates the chemorepulsant activity of semaphorins. It binds to semaphorin 3A, The PLGF-2 isoform of PGF, The VEGF-165 isoform of VEGF and VEGF-B. Coexpression with KDR results in increased VEGF-165 binding to KDR as well as increased chemotaxis. It may regulate VEGF-induced angiogenesis.The soluble isoform 2 binds VEGF-165 and appears to inhibit its binding to cells. It may also induce apoptosis by sequestering VEGF-165. May bind as well various members of the semaphorin family. Its expression has an averse effect on blood vessel number and integrity.", "general_function": "Vascular endothelial growth factor-activated receptor activity", "gene_names": ["NRP1"], "name": "Neuropilin-1", "drug_actions": []}, "P46059": {"specific_function": "Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.", "general_function": "Proton-dependent oligopeptide secondary active transmembrane transporter activity", "gene_names": ["SLC15A1"], "name": "Solute carrier family 15 member 1", "drug_actions": []}, "Q65CX5": {"specific_function": "Hydrolyzes the beta-1,4-galactan linkages of arabinogalactan type I, a pectic substance found in plants such as soybeans.", "general_function": "Metal ion binding", "gene_names": ["ganB"], "name": "Arabinogalactan endo-beta-1,4-galactanase", "drug_actions": []}, "Q8T8E9": {"general_function": "Udp-glucose 4-epimerase activity", "gene_names": ["galE"], "name": "UDP-galactose 4-epimerase", "drug_actions": []}, "P30939": {"specific_function": "G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.", "name": "5-hydroxytryptamine receptor 1F", "drug_actions": [{"action": "AGONIST", "target": "P30939", "drug": "DB00216"}, {"action": "BINDER", "target": "P30939", "drug": "DB00247"}, {"action": "AGONIST", "target": "P30939", "drug": "DB00315"}, {"action": "AGONIST", "target": "P30939", "drug": "DB00669"}, {"action": "AGONIST", "target": "P30939", "drug": "DB00696"}, {"action": "AGONIST", "target": "P30939", "drug": "DB00952"}, {"action": "AGONIST", "target": "P30939", "drug": "DB00953"}, {"action": "ANTAGONIST", "target": "P30939", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P30939", "drug": "DB01221"}, {"action": "BINDER", "target": "P30939", "drug": "DB06148"}], "general_function": "Serotonin receptor activity", "in_complexes": ["5-hydroxytryptamine receptor 1", "Serotonin Receptors"], "gene_names": ["HTR1F"]}, "Q48152": {"gene_names": ["hia"], "name": "Adhesin", "drug_actions": []}, "P87066": {"specific_function": "Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["TUB1"], "name": "Tubulin alpha chain", "drug_actions": [{"action": "INHIBITOR", "target": "P87066", "drug": "DB00400"}]}, "Q8WVQ1": {"specific_function": "Calcium-dependent nucleotidase with a preference for UDP. The order of activity with different substrates is UDP > GDP > UTP > GTP. Has very low activity towards ADP and even lower activity towards ATP. Does not hydrolyze AMP and GMP. Involved in proteoglycan synthesis.", "general_function": "Uridine-diphosphatase activity", "gene_names": ["CANT1"], "name": "Soluble calcium-activated nucleotidase 1", "drug_actions": []}, "P07998": {"specific_function": "Endonuclease that catalyzes the cleavage of RNA on the 3' side of pyrimidine nucleotides. Acts on single-stranded and double-stranded RNA.", "general_function": "Ribonuclease a activity", "gene_names": ["RNASE1"], "name": "Ribonuclease pancreatic", "drug_actions": []}, "P0A6T8": {"general_function": "Zinc ion binding", "gene_names": ["folE"], "name": "GTP cyclohydrolase 1", "drug_actions": []}, "Q5SHN7": {"specific_function": "Part of the top of the 30S subunit head.", "general_function": "Trna binding", "gene_names": ["rpsJ"], "name": "30S ribosomal protein S10", "drug_actions": [{"action": "INHIBITOR", "target": "Q5SHN7", "drug": "DB01421"}]}, "P36419": {"specific_function": "Catalyzes the attachment of glutamate to tRNA(Asp) in a two-step reaction: aspartate is first activated by ATP to form Asp-AMP and then transferred to the acceptor end of tRNA(Asp).", "general_function": "Nucleic acid binding", "gene_names": ["aspS"], "name": "Aspartate--tRNA(Asp) ligase", "drug_actions": []}, "P21817": {"specific_function": "Calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytoplasm and thereby plays a key role in triggering muscle contraction following depolarization of T-tubules. Repeated very high-level exercise increases the open probability of the channel and leads to Ca(2+) leaking into the cytoplasm. Can also mediate the release of Ca(2+) from intracellular stores in neurons, and may thereby promote prolonged Ca(2+) signaling in the brain. Required for normal embryonic development of muscle fibers and skeletal muscle. Required for normal heart morphogenesis, skin development and ossification during embryogenesis (By similarity).", "general_function": "Voltage-gated calcium channel activity", "gene_names": ["RYR1"], "name": "Ryanodine receptor 1", "drug_actions": [{"action": "ANTAGONIST", "target": "P21817", "drug": "DB01219"}, {"action": "AGONIST", "target": "P21817", "drug": "DB04786"}]}, "P82251": {"specific_function": "Involved in the high-affinity, sodium-independent transport of cystine and neutral and dibasic amino acids (system b(0,+)-like activity). Thought to be responsible for the high-affinity reabsorption of cystine in the kidney tubule.", "general_function": "Peptide antigen binding", "gene_names": ["SLC7A9"], "name": "b(0,+)-type amino acid transporter 1", "drug_actions": []}, "P41180": {"specific_function": "Senses changes in the extracellular concentration of calcium ions. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system.", "general_function": "Phosphatidylinositol phospholipase c activity", "gene_names": ["CASR"], "name": "Extracellular calcium-sensing receptor", "drug_actions": [{"action": "AGONIST", "target": "P41180", "drug": "DB01012"}]}, "P20810": {"specific_function": "Specific inhibition of calpain (calcium-dependent cysteine protease). Plays a key role in postmortem tenderization of meat and have been proposed to be involved in muscle protein degradation in living tissue.", "general_function": "Poly(a) rna binding", "gene_names": ["CAST"], "name": "Calpastatin", "drug_actions": []}, "P02943": {"specific_function": "Involved in the transport of maltose and maltodextrins, indispensable for translocation of dextrins containing more than three glucosyl moieties. A hydrophobic path (\"greasy slide\") of aromatic residues serves to guide and select the sugars for transport through the channel. Also acts as a receptor for several bacteriophages including lambda.", "general_function": "Virus receptor activity", "gene_names": ["lamB"], "name": "Maltoporin", "drug_actions": []}, "P20815": {"specific_function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.", "general_function": "Oxygen binding", "gene_names": ["CYP3A5"], "name": "Cytochrome P450 3A5", "drug_actions": []}, "P68826": {"specific_function": "Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions (By similarity).", "general_function": "Peptide deformylase activity", "gene_names": ["def"], "name": "Peptide deformylase", "drug_actions": []}, "P41439": {"specific_function": "Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate to the interior of cells. Isoform Short does not bind folate.", "general_function": "Folic acid binding", "gene_names": ["FOLR3"], "name": "Folate receptor gamma", "drug_actions": [{"action": "BINDER", "target": "P41439", "drug": "DB00158"}]}, "Q02768": {"specific_function": "Component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is a respiratory chain that generates an electrochemical potential coupled to ATP synthesis.", "general_function": "Oxidoreductase activity", "gene_names": ["MT-CYB"], "name": "Cytochrome b", "drug_actions": [{"action": "INHIBITOR", "target": "Q02768", "drug": "DB01117"}]}, "P13650": {"specific_function": "Oxidizes glucose to gluconolactone.", "general_function": "Quinoprotein glucose dehydrogenase activity", "gene_names": ["gdhB"], "name": "Quinoprotein glucose dehydrogenase B", "drug_actions": []}, "P19099": {"specific_function": "Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.", "general_function": "Steroid 11-beta-monooxygenase activity", "gene_names": ["CYP11B2"], "name": "Cytochrome P450 11B2, mitochondrial", "drug_actions": [{"action": "ANTAGONIST", "target": "P19099", "drug": "DB00421"}]}, "Q02762": {"specific_function": "Component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is a respiratory chain that generates an electrochemical potential coupled to ATP synthesis.", "general_function": "Ubiquinol-cytochrome-c reductase activity", "gene_names": ["petA"], "name": "Ubiquinol-cytochrome c reductase iron-sulfur subunit", "drug_actions": []}, "Q02763": {"specific_function": "Tyrosine-protein kinase that acts as cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. Required for normal angiogenesis and heart development during embryogenesis. Required for post-natal hematopoiesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. ANGPT1 signaling triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Signaling is modulated by ANGPT2 that has lower affinity for TEK, can promote TEK autophosphorylation in the absence of ANGPT1, but inhibits ANGPT1-mediated signaling by competing for the same binding site. Signaling is also modulated by formation of heterodimers with TIE1, and by proteolytic processing that gives rise to a soluble TEK extracellular domain. The soluble extracellular domain modulates signaling by functioning as decoy receptor for angiopoietins. TEK phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1.", "general_function": "Transmembrane receptor protein tyrosine kinase activity", "gene_names": ["TEK"], "name": "Angiopoietin-1 receptor", "drug_actions": [{"action": "INHIBITOR", "target": "Q02763", "drug": "DB05294"}, {"action": "INHIBITOR", "target": "Q02763", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "Q02763", "drug": "DB08901"}]}, "Q02760": {"specific_function": "Component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is a respiratory chain that generates an electrochemical potential coupled to ATP synthesis. c1 functions as an electron donor to cytochrome c.", "general_function": "Metal ion binding", "gene_names": ["petC"], "name": "Cytochrome c1", "drug_actions": []}, "P0A334": {"specific_function": "Acts as a pH-gated potassium ion channel; changing the cytosolic pH from 7 to 4 opens the channel, although it is not clear if this is the physiological stimulus for channel opening. Monovalent cation preference is K(+) > Rb(+) > NH4(+) >> Na(+) > Li(+).", "general_function": "Voltage-gated potassium channel activity", "gene_names": ["kcsA"], "name": "pH-gated potassium channel KcsA", "drug_actions": [{"action": "INHIBITOR", "target": "P0A334", "drug": "DB08837"}]}, "Q9NY47": {"specific_function": "The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) and possibly T-type (CACNA1G). Overexpression induces apoptosis.", "name": "Voltage-dependent calcium channel subunit alpha-2/delta-2", "drug_actions": [{"action": "INHIBITOR", "target": "Q9NY47", "drug": "DB00270"}, {"action": "INHIBITOR", "target": "Q9NY47", "drug": "DB00996"}, {"action": "INHIBITOR", "target": "Q9NY47", "drug": "DB01023"}, {"action": "INHIBITOR", "target": "Q9NY47", "drug": "DB01054"}, {"action": "INHIBITOR", "target": "Q9NY47", "drug": "DB01118"}, {"action": "INHIBITOR", "target": "Q9NY47", "drug": "DB01244"}], "general_function": "Voltage-gated calcium channel activity", "in_complexes": ["Voltage-dependent calcium channel"], "gene_names": ["CACNA2D2"]}, "Q9NY46": {"specific_function": "Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient.", "name": "Sodium channel protein type 3 subunit alpha", "drug_actions": [{"action": "INHIBITOR", "target": "Q9NY46", "drug": "DB00909"}], "general_function": "Voltage-gated sodium channel activity", "in_complexes": ["Sodium channel protein"], "gene_names": ["SCN3A"]}, "Q9NWM0": {"specific_function": "Flavoenzyme which catalyzes the oxidation of spermine to spermidine. Can also use N(1)-acetylspermine and spermidine as substrates, with different affinity depending on the isoform (isozyme) and on the experimental conditions. Plays an important role in the regulation of polyamine intracellular concentration and has the potential to act as a determinant of cellular sensitivity to the antitumor polyamine analogs. May contribute to beta-alanine production via aldehyde dehydrogenase conversion of 3-amino-propanal.", "general_function": "Spermine:oxygen oxidoreductase (spermidine-forming) activity", "gene_names": ["SMOX"], "name": "Spermine oxidase", "drug_actions": [{"action": "LIGAND", "target": "Q9NWM0", "drug": "DB00127"}]}, "Q60099": {"specific_function": "Catalyzes the hydrolytic dehalogenation of small L-2-haloalkanoic acids to yield the corresponding D-2-hydroxyalkanoic acids. Active with 2-halogenated carboxylic acids and converts only the L-isomer of 2-chloropropionic acid with inversion of configuration to produce D-lactate.", "general_function": "(s)-2-haloacid dehalogenase activity", "gene_names": ["dhlB"], "name": "(S)-2-haloacid dehalogenase", "drug_actions": []}, "P03234": {"specific_function": "Capsid scaffolding protein: Acts as a scaffold protein by binding major capsid protein VP5 in the cytoplasm, inducing the nuclear localization of both proteins. Multimerizes in the nucleus such as VP5 forms the icosahedral T=16 capsid. Autocatalytic cleavage releases the assembly protein, and subsequently abolishes interaction with major capsid protein VP5. Cleavages products are evicted from the capsid before or during DNA packaging.Assemblin: Protease that plays an essential role in virion assembly within the nucleus. Catalyzes the cleavage of the assembly protein after formation of the spherical procapsid. By that cleavage, the capsid matures and gains its icosahedral shape. The cleavage sites seem to include -Ala-|-Ser-, -Ala-|-Ala-, as well as Ala-Thr bonds. Assemblin and cleavages products are evicted from the capsid before or during DNA packaging.Assembly protein: Plays a major role in capsid assembly. Acts as a scaffold protein by binding major capsid protein VP5. Multimerizes in the nucleus such as VP5 forms the icosahedral T=16 capsid. Cleaved by assemblin after capsid completion. The cleavages products are evicted from the capsid before or during DNA packaging.", "general_function": "Serine-type endopeptidase activity", "gene_names": [], "name": "Capsid scaffolding protein", "drug_actions": []}, "P22301": {"specific_function": "Inhibits the synthesis of a number of cytokines, including IFN-gamma, IL-2, IL-3, TNF and GM-CSF produced by activated macrophages and by helper T-cells.", "general_function": "Interleukin-10 receptor binding", "gene_names": ["IL10"], "name": "Interleukin-10", "drug_actions": []}, "P07203": {"specific_function": "Protects the hemoglobin in erythrocytes from oxidative breakdown.", "general_function": "Sh3 domain binding", "gene_names": ["GPX1"], "name": "Glutathione peroxidase 1", "drug_actions": [{"action": "COFACTOR", "target": "P07203", "drug": "DB00143"}]}, "P07202": {"specific_function": "Iodination and coupling of the hormonogenic tyrosines in thyroglobulin to yield the thyroid hormones T(3) and T(4).", "general_function": "Peroxidase activity", "gene_names": ["TPO"], "name": "Thyroid peroxidase", "drug_actions": [{"action": "INHIBITOR", "target": "P07202", "drug": "DB00389"}, {"action": "INHIBITOR", "target": "P07202", "drug": "DB00550"}, {"action": "INHIBITOR", "target": "P07202", "drug": "DB00763"}]}, "P31994": {"specific_function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis.", "gene_names": ["FCGR2B"], "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "drug_actions": [{"action": "ANTAGONIST", "target": "P31994", "drug": "DB00028"}]}, "P07204": {"specific_function": "Thrombomodulin is a specific endothelial cell receptor that forms a 1:1 stoichiometric complex with thrombin. This complex is responsible for the conversion of protein C to the activated protein C (protein Ca). Once evolved, protein Ca scissions the activated cofactors of the coagulation mechanism, factor Va and factor VIIIa, and thereby reduces the amount of thrombin generated.", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["THBD"], "name": "Thrombomodulin", "drug_actions": [{"action": "MODULATOR", "target": "P07204", "drug": "DB01050"}]}, "P13073": {"specific_function": "This protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport.", "general_function": "Cytochrome-c oxidase activity", "gene_names": ["COX4I1"], "name": "Cytochrome c oxidase subunit 4 isoform 1, mitochondrial", "drug_actions": []}, "O00182": {"specific_function": "Binds galactosides (PubMed:18005988). Has high affinity for the Forssman pentasaccharide (PubMed:18005988). Ligand for HAVCR2/TIM3 (PubMed:16286920). Binding to HAVCR2 induces T-helper type 1 lymphocyte (Th1) death (PubMed:16286920). Also stimulates bactericidal activity in infected macrophages by causing macrophage activation and IL1B secretion which restricts intracellular bacterial growth (By similarity). Ligand for P4HB; the interaction retains P4HB at the cell surface of Th2 T helper cells, increasing disulfide reductase activity at the plasma membrane, altering the plasma membrane redox state and enhancing cell migration (PubMed:21670307). Ligand for CD44; the interaction enhances binding of SMAD3 to the FOXP3 promoter, leading to up-regulation of FOXP3 expression and increased induced regulatory T (iTreg) cell stability and suppressive function (By similarity). Promotes ability of mesenchymal stromal cells to suppress T-cell proliferation (PubMed:23817958). Expands regulatory T cells and induces cytotoxic T cell apoptosis following virus infection (PubMed:20209097). Activates ERK1/2 phosphorylation inducing cytokine (IL-6, IL-8, IL-12) and chemokine (CCL2) production in mast and dendritic cells (PubMed:24465902, PubMed:16116184). Inhibits degranulation and induces apoptosis of mast cells (PubMed:24465902). Induces maturation and migration of dendritic cells (PubMed:25754930, PubMed:16116184). Inhibits natural killer (NK) cell function (PubMed:23408620). Can transform NK cell phenotype from peripheral to decidual during pregnancy (PubMed:25578313). Astrocyte derived galectin-9 enhances microglial TNF production (By similarity). May play a role in thymocyte-epithelial interactions relevant to the biology of the thymus. May provide the molecular basis for urate flux across cell membranes, allowing urate that is formed during purine metabolism to efflux from cells and serving as an electrogenic transporter that plays an important role in renal and gastrointestinal urate excretion (By similarity). Highly selective to the anion urate (By similarity).Isoform 2: Acts as an eosinophil chemoattractant (PubMed:9642261). It also inhibits angiogenesis (PubMed:24333696). Suppresses IFNG production by natural killer cells (By similarity).", "general_function": "Signal transducer activity", "gene_names": ["LGALS9"], "name": "Galectin-9", "drug_actions": []}, "Q4U2R8": {"specific_function": "Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-independent uptake of p-aminohippurate (PAH), ochratoxin (OTA), acyclovir (ACV), 3'-azido-3-'deoxythymidine (AZT), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), hippurate (HA), indoleacetate (IA), indoxyl sulfate (IS) and 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF), cidofovir, adefovir, 9-(2-phosphonylmethoxyethyl) guanine (PMEG), 9-(2-phosphonylmethoxyethyl) diaminopurine (PMEDAP) and edaravone sulfate. PAH uptake is inhibited by p-chloromercuribenzenesulphonate (PCMBS), diethyl pyrocarbonate (DEPC), sulindac, diclofenac, carprofen, glutarate and okadaic acid (By similarity). PAH uptake is inhibited by benzothiazolylcysteine (BTC), S-chlorotrifluoroethylcysteine (CTFC), cysteine S-conjugates S-dichlorovinylcysteine (DCVC), furosemide, steviol, phorbol 12-myristate 13-acetate (PMA), calcium ionophore A23187, benzylpenicillin, furosemide, indomethacin, bumetamide, losartan, probenecid, phenol red, urate, and alpha-ketoglutarate.", "general_function": "Sodium-independent organic anion transmembrane transporter activity", "gene_names": ["SLC22A6"], "name": "Solute carrier family 22 member 6", "drug_actions": [{"action": "INHIBITOR", "target": "Q4U2R8", "drug": "DB01032"}]}, "Q96RQ3": {"specific_function": "Biotin-attachment subunit of the 3-methylcrotonyl-CoA carboxylase, an enzyme that catalyzes the conversion of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA, a critical step for leucine and isovaleric acid catabolism.", "general_function": "Methylcrotonoyl-coa carboxylase activity", "gene_names": ["MCCC1"], "name": "Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial", "drug_actions": []}, "Q81EE4": {"general_function": "Metal ion binding", "gene_names": [], "name": "Acyl-CoA hydrolase", "drug_actions": []}, "P29218": {"specific_function": "Responsible for the provision of inositol required for synthesis of phosphatidylinositol and polyphosphoinositides and has been implicated as the pharmacological target for lithium action in brain. Has broad substrate specificity and can use myo-inositol monophosphates, myo-inositol 1,3-diphosphate, myo-inositol 1,4-diphosphate, scyllo-inositol-phosphate, D-galactose 1-phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1-phosphate, beta-glycerophosphate, and 2'-AMP as substrates.", "general_function": "Protein homodimerization activity", "gene_names": ["IMPA1"], "name": "Inositol monophosphatase 1", "drug_actions": [{"action": "INHIBITOR", "target": "P29218", "drug": "DB01356"}]}, "O94766": {"specific_function": "Glycosaminoglycans biosynthesis. Involved in forming the linkage tetrasaccharide present in heparan sulfate and chondroitin sulfate. Transfers a glucuronic acid moiety from the uridine diphosphate-glucuronic acid (UDP-GlcUA) to the common linkage region trisaccharide Gal-beta-1,3-Gal-beta-1,4-Xyl covalently bound to a Ser residue at the glycosaminylglycan attachment site of proteoglycans. Can also play a role in the biosynthesis of l2/HNK-1 carbohydrate epitope on glycoproteins. Shows strict specificity for Gal-beta-1,3-Gal-beta-1,4-Xyl, exhibiting negligible incorporation into other galactoside substrates including Galbeta1-3Gal beta1-O-benzyl, Galbeta1-4GlcNAc and Galbeta1-4Glc. Stimulates 2-phosphoxylose phosphatase activity of PXYLP1 in presence of uridine diphosphate-glucuronic acid (UDP-GlcUA) during completion of linkage region formation.", "general_function": "Protein phosphatase activator activity", "gene_names": ["B3GAT3"], "name": "Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3", "drug_actions": []}, "O94760": {"specific_function": "Hydrolyzes N(G),N(G)-dimethyl-L-arginine (ADMA) and N(G)-monomethyl-L-arginine (MMA) which act as inhibitors of NOS. Has therefore a role in the regulation of nitric oxide generation.", "general_function": "Metal ion binding", "gene_names": ["DDAH1"], "name": "N(G),N(G)-dimethylarginine dimethylaminohydrolase 1", "drug_actions": []}, "P80192": {"specific_function": "Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Plays an important role in the cascades of cellular responses evoked by changes in the environment. Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade through the phosphorylation of MAP2K4/MKK4 and MAP2K7/MKK7 which in turn activate the JNKs. The MKK/JNK signaling pathway regulates stress response via activator protein-1 (JUN) and GATA4 transcription factors. Plays also a role in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis.", "general_function": "Protein tyrosine kinase activity", "gene_names": ["MAP3K9"], "name": "Mitogen-activated protein kinase kinase kinase 9", "drug_actions": []}, "P17169": {"specific_function": "Catalyzes the first step in hexosamine metabolism, converting fructose-6P into glucosamine-6P using glutamine as a nitrogen source.", "general_function": "Glutamine-fructose-6-phosphate transaminase (isomerizing) activity", "gene_names": ["glmS"], "name": "Glutamine--fructose-6-phosphate aminotransferase [isomerizing]", "drug_actions": []}, "P61160": {"specific_function": "Functions as ATP-binding component of the Arp2/3 complex which is involved in regulation of actin polymerization and together with an activating nucleation-promoting factor (NPF) mediates the formation of branched actin networks. Seems to contact the pointed end of the daughter actin filament.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["ACTR2"], "name": "Actin-related protein 2", "drug_actions": []}, "P40871": {"specific_function": "Activation of the carboxylate group of 2,3-dihydroxy-benzoate (DHB), via ATP-dependent PPi exchange reactions, to the acyladenylate.", "general_function": "Ligase activity", "gene_names": ["dhbE"], "name": "2,3-dihydroxybenzoate-AMP ligase", "drug_actions": []}, "Q837V6": {"specific_function": "DNA ligase that catalyzes the formation of phosphodiester linkages between 5'-phosphoryl and 3'-hydroxyl groups in double-stranded DNA using NAD as a coenzyme and as the energy source for the reaction. It is essential for DNA replication and repair of damaged DNA.", "general_function": "Metal ion binding", "gene_names": ["ligA"], "name": "DNA ligase", "drug_actions": []}, "P36896": {"specific_function": "Transmembrane serine/threonine kinase activin type-1 receptor forming an activin receptor complex with activin receptor type-2 (ACVR2A or ACVR2B). Transduces the activin signal from the cell surface to the cytoplasm and is thus regulating a many physiological and pathological processes including neuronal differentiation and neuronal survival, hair follicle development and cycling, FSH production by the pituitary gland, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. Activin is also thought to have a paracrine or autocrine role in follicular development in the ovary. Within the receptor complex, type-2 receptors (ACVR2A and/or ACVR2B) act as a primary activin receptors whereas the type-1 receptors like ACVR1B act as downstream transducers of activin signals. Activin binds to type-2 receptor at the plasma membrane and activates its serine-threonine kinase. The activated receptor type-2 then phosphorylates and activates the type-1 receptor such as ACVR1B. Once activated, the type-1 receptor binds and phosphorylates the SMAD proteins SMAD2 and SMAD3, on serine residues of the C-terminal tail. Soon after their association with the activin receptor and subsequent phosphorylation, SMAD2 and SMAD3 are released into the cytoplasm where they interact with the common partner SMAD4. This SMAD complex translocates into the nucleus where it mediates activin-induced transcription. Inhibitory SMAD7, which is recruited to ACVR1B through FKBP1A, can prevent the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. Activin signal transduction is also antagonized by the binding to the receptor of inhibin-B via the IGSF1 inhibin coreceptor. ACVR1B also phosphorylates TDP2.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["ACVR1B"], "name": "Activin receptor type-1B", "drug_actions": []}, "P36897": {"specific_function": "Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. For instance, TGFBR1 induces TRAF6 autoubiquitination which in turn results in MAP3K7 ubiquitination and activation to trigger apoptosis. Also regulates epithelial to mesenchymal transition through a SMAD-independent signaling pathway through PARD6A phosphorylation and activation.", "general_function": "Type ii transforming growth factor beta receptor binding", "gene_names": ["TGFBR1"], "name": "TGF-beta receptor type-1", "drug_actions": []}, "P21964": {"specific_function": "Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.", "general_function": "O-methyltransferase activity", "gene_names": ["COMT"], "name": "Catechol O-methyltransferase", "drug_actions": [{"action": "COFACTOR", "target": "P21964", "drug": "DB00118"}, {"action": "INHIBITOR", "target": "P21964", "drug": "DB00323"}, {"action": "INHIBITOR", "target": "P21964", "drug": "DB00494"}]}, "P15382": {"specific_function": "Ancillary protein that assembles as a beta subunit with a voltage-gated potassium channel complex of pore-forming alpha subunits. Modulates the gating kinetics and enhances stability of the channel complex. Assembled with KCNB1 modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1 (PubMed:19219384). Assembled with KCNQ1/KVLQT1 is proposed to form the slowly activating delayed rectifier cardiac potassium (IKs) channel. The outward current reaches its steady state only after 50 seconds. Assembled with KCNH2/HERG may modulate the rapidly activating component of the delayed rectifying potassium current in heart (IKr).", "general_function": "Telethonin binding", "gene_names": ["KCNE1"], "name": "Potassium voltage-gated channel subfamily E member 1", "drug_actions": [{"action": "INHIBITOR", "target": "P15382", "drug": "DB00808"}]}, "P13956": {"specific_function": "This protein produces a dimethylation of the adenine residue at position 2085 in 23S rRNA, resulting in reduced affinity between ribosomes and macrolide-lincosamide-streptogramin B antibiotics.", "general_function": "Rrna (adenine-n6,n6-)-dimethyltransferase activity", "gene_names": ["ermC'"], "name": "rRNA adenine N-6-methyltransferase", "drug_actions": []}, "Q02169": {"specific_function": "Involved in septum formation.", "gene_names": ["maf"], "name": "Septum formation protein Maf", "drug_actions": []}, "P03200": {"specific_function": "Initiates virion attachment to host B-lymphocyte cell, leading to virus entry. Acts by binding to host CR2 at the surface of B-lymphocytes, facilitating the binding of viral glycoprotein gp42 to HLA class II molecules. Attachment triggers virion-host membrane fusion and invasion of the host cell.", "gene_names": [], "name": "Envelope glycoprotein GP350", "drug_actions": [{"action": "INTERCALATION", "target": "P03200", "drug": "DB00632"}]}, "P80374": {"specific_function": "Part of the top of the head of the 30S subunit. The C-terminal region penetrates the head emerging in the P-site where it contacts tRNA.", "general_function": "Trna binding", "gene_names": ["rpsI"], "name": "30S ribosomal protein S9", "drug_actions": []}, "D6R448": {"general_function": "Penicillin binding", "gene_names": ["mecA"], "name": "Penicillin-binding protein 2", "drug_actions": []}, "P15309": {"specific_function": "A non-specific tyrosine phosphatase that dephosphorylates a diverse number of substrates under acidic conditions (pH 4-6) including alkyl, aryl, and acyl orthophosphate monoesters and phosphorylated proteins. Has lipid phosphatase activity and inactivates lysophosphatidic acid in seminal plasma.Isoform 2: the cellular form also has ecto-5'-nucleotidase activity in dorsal root ganglion (DRG) neurons. Generates adenosine from AMP which acts as a pain suppressor. Acts as a tumor suppressor of prostate cancer through dephosphorylation of ERBB2 and deactivation of MAPK-mediated signaling.", "general_function": "Thiamine phosphate phosphatase activity", "gene_names": ["ACPP"], "name": "Prostatic acid phosphatase", "drug_actions": []}, "Q7Z2W7": {"specific_function": "Receptor-activated non-selective cation channel involved in detection of sensations such as coolness, by being activated by cold temperature below 25 degrees Celsius. Activated by icilin, eucalyptol, menthol, cold and modulation of intracellular pH. Involved in menthol sensation. Permeable for monovalent cations sodium, potassium, and cesium and divalent cation calcium. Temperature sensing is tightly linked to voltage-dependent gating. Activated upon depolarization, changes in temperature resulting in graded shifts of its voltage-dependent activation curves. The chemical agonist menthol functions as a gating modifier, shifting activation curves towards physiological membrane potentials. Temperature sensitivity arises from a tenfold difference in the activation energies associated with voltage-dependent opening and closing. In prostate cancer cells, shows strong inward rectification and high calcium selectivity in contrast to its behavior in normal cells which is characterized by outward rectification and poor cationic selectivity. Plays a role in prostate cancer cell migration (PubMed:25559186). Isoform 2 and isoform 3 negatively regulate menthol- and cold-induced channel activity by stabilizing the closed state of the channel.", "general_function": "Calcium channel activity", "gene_names": ["TRPM8"], "name": "Transient receptor potential cation channel subfamily M member 8", "drug_actions": [{"action": "INDUCER", "target": "Q7Z2W7", "drug": "DB00825"}]}, "P07333": {"specific_function": "Tyrosine-protein kinase that acts as cell-surface receptor for CSF1 and IL34 and plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. Promotes the release of proinflammatory chemokines in response to IL34 and CSF1, and thereby plays an important role in innate immunity and in inflammatory processes. Plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone and tooth development. Required for normal male and female fertility, and for normal development of milk ducts and acinar structures in the mammary gland during pregnancy. Promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration, and promotes cancer cell invasion. Activates several signaling pathways in response to ligand binding. Phosphorylates PIK3R1, PLCG2, GRB2, SLA2 and CBL. Activation of PLCG2 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, that then lead to the activation of protein kinase C family members, especially PRKCD. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to activation of the AKT1 signaling pathway. Activated CSF1R also mediates activation of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1, and of the SRC family kinases SRC, FYN and YES1. Activated CSF1R transmits signals both via proteins that directly interact with phosphorylated tyrosine residues in its intracellular domain, or via adapter proteins, such as GRB2. Promotes activation of STAT family members STAT3, STAT5A and/or STAT5B. Promotes tyrosine phosphorylation of SHC1 and INPP5D/SHIP-1. Receptor signaling is down-regulated by protein phosphatases, such as INPP5D/SHIP-1, that dephosphorylate the receptor and its downstream effectors, and by rapid internalization of the activated receptor.", "general_function": "Protein homodimerization activity", "gene_names": ["CSF1R"], "name": "Macrophage colony-stimulating factor 1 receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "P07333", "drug": "DB00619"}, {"action": "OTHER/UNKNOWN", "target": "P07333", "drug": "DB01268"}]}, "P04406": {"specific_function": "Has both glyceraldehyde-3-phosphate dehydrogenase and nitrosylase activities, thereby playing a role in glycolysis and nuclear functions, respectively. Participates in nuclear events including transcription, RNA transport, DNA replication and apoptosis. Nuclear functions are probably due to the nitrosylase activity that mediates cysteine S-nitrosylation of nuclear target proteins such as SIRT1, HDAC2 and PRKDC. Modulates the organization and assembly of the cytoskeleton. Facilitates the CHP1-dependent microtubule and membrane associations through its ability to stimulate the binding of CHP1 to microtubules (By similarity). Glyceraldehyde-3-phosphate dehydrogenase is a key enzyme in glycolysis that catalyzes the first step of the pathway by converting D-glyceraldehyde 3-phosphate (G3P) into 3-phospho-D-glyceroyl phosphate. Component of the GAIT (gamma interferon-activated inhibitor of translation) complex which mediates interferon-gamma-induced transcript-selective translation inhibition in inflammation processes. Upon interferon-gamma treatment assembles into the GAIT complex which binds to stem loop-containing GAIT elements in the 3'-UTR of diverse inflammatory mRNAs (such as ceruplasmin) and suppresses their translation.", "general_function": "Peptidyl-cysteine s-nitrosylase activity", "gene_names": ["GAPDH"], "name": "Glyceraldehyde-3-phosphate dehydrogenase", "drug_actions": []}, "Q9WY54": {"specific_function": "The glycine cleavage system catalyzes the degradation of glycine.", "general_function": "Transaminase activity", "gene_names": ["gcvT"], "name": "Aminomethyltransferase", "drug_actions": []}, "P07339": {"specific_function": "Acid protease active in intracellular protein breakdown. Involved in the pathogenesis of several diseases such as breast cancer and possibly Alzheimer disease.", "general_function": "Aspartic-type endopeptidase activity", "gene_names": ["CTSD"], "name": "Cathepsin D", "drug_actions": []}, "P80376": {"specific_function": "Located on the upper part of the platform of the 30S subunit, where it bridges several disparate RNA helices of the 16S rRNA. Forms part of the Shine-Dalgarno cleft in the 70S ribosome, where it interacts both with the Shine-Dalgarno helix and mRNA.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsK"], "name": "30S ribosomal protein S11", "drug_actions": []}, "P14410": {"specific_function": "Plays an important role in the final stage of carbohydrate digestion. Isomaltase activity is specific for both alpha-1,4- and alpha-1,6-oligosaccharides.", "general_function": "Sucrose alpha-glucosidase activity", "gene_names": ["SI"], "name": "Sucrase-isomaltase, intestinal", "drug_actions": [{"action": "INHIBITOR", "target": "P14410", "drug": "DB00284"}, {"action": "INHIBITOR", "target": "P14410", "drug": "DB00747"}]}, "P11172": {"general_function": "Orotidine-5'-phosphate decarboxylase activity", "gene_names": ["UMPS"], "name": "Uridine 5'-monophosphate synthase", "drug_actions": []}, "P03302": {"specific_function": "Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host cell receptor to provide virion attachment to target host cells. This attachment induces virion internalization through clathrin- and caveolin-independent endocytosis in Hela cells and through caveolin-mediated endocytosis in brain microvascular endothelial cells. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP2: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP3: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP4: Lies on the inner surface of the capsid shell. After binding to the host receptor, the capsid undergoes conformational changes. Capsid protein VP4 is released, Capsid protein VP1 N-terminus is externalized, and together, they shape a pore in the host membrane through which the viral genome is translocated into the host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP0: Component of immature procapsids, which is cleaved into capsid proteins VP4 and VP2 after maturation. Allows the capsid to remain inactive before the maturation step (By similarity).Protein 2A: Cysteine protease that cleaves viral polyprotein and specific host proteins. It is responsible for the cleavage between the P1 and P2 regions, first cleavage occurring in the polyprotein. Cleaves also the host translation initiation factor EIF4G1, in order to shut down the capped cellular mRNA translation. Inhibits the host nucleus-cytoplasm protein and RNA trafficking by cleaving host members of the nuclear pores (By similarity).Protein 2B: Plays an essential role in the virus replication cycle by acting as a viroporin. Creates a pore in the host reticulum endoplasmic and as a consequence releases Ca2+ in the cytoplasm of infected cell. In turn, high levels of cyctoplasmic calcium may trigger membrane trafficking and transport of viral ER-associated proteins to viroplasms, sites of viral genome replication (By similarity).Protein 2C: Induces and associates with structural rearrangements of intracellular membranes. Displays RNA-binding, nucleotide binding and NTPase activities. May play a role in virion morphogenesis and viral RNA encapsidation by interacting with the capsid protein VP3 (By similarity).Protein 3AB: Localizes the viral replication complex to the surface of membranous vesicles. Together with protein 3CD binds the Cis-Active RNA Element (CRE) which is involved in RNA synthesis initiation. Acts as a cofactor to stimulate the activity of 3D polymerase, maybe through a nucleid acid chaperone activity (By similarity).Protein 3A: Localizes the viral replication complex to the surface of membranous vesicles. It inhibits host cell endoplasmic reticulum-to-Golgi apparatus transport and causes the dissassembly of the Golgi complex, possibly through GBF1 interaction. This would result in depletion of MHC, trail receptors and IFN receptors at the host cell surface (By similarity).Viral protein genome-linked: acts as a primer for viral RNA replication and remains covalently bound to viral genomic RNA. VPg is uridylylated prior to priming replication into VPg-pUpU. The oriI viral genomic sequence may act as a template for this. The VPg-pUpU is then used as primer on the genomic RNA poly(A) by the RNA-dependent RNA polymerase to replicate the viral genome. VPg may be removed in the cytoplasm by an unknown enzyme termed \"unlinkase\". VPg is not cleaved off virion genomes because replicated genomic RNA are encapsidated at the site of replication (By similarity).Protein 3CD: Is involved in the viral replication complex and viral polypeptide maturation. It exhibits protease activity with a specificity and catalytic efficiency that is different from protease 3C. Protein 3CD lacks polymerase activity. The 3C domain in the context of protein 3CD may have an RNA binding activity (By similarity).Protease 3C: cleaves host DDX58/RIG-I and thus contributes to the inhibition of type I interferon production. Cleaves also host PABPC1 (By similarity).RNA-directed RNA polymerase: Replicates the viral genomic RNA on the surface of intracellular membranes. May form linear arrays of subunits that propagate along a strong head-to-tail interaction called interface-I. Covalently attaches UMP to a tyrosine of VPg, which is used to prime RNA synthesis. The positive stranded RNA genome is first replicated at virus induced membranous vesicles, creating a dsRNA genomic replication form. This dsRNA is then used as template to synthesize positive stranded RNA genomes. ss(+)RNA genomes are either translated, replicated or encapsidated (By similarity).", "general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P14416": {"specific_function": "Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.", "general_function": "Potassium channel regulator activity", "gene_names": ["DRD2"], "name": "D(2) dopamine receptor", "drug_actions": [{"action": "BINDER", "target": "P14416", "drug": "DB00182"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00246"}, {"action": "AGONIST", "target": "P14416", "drug": "DB00248"}, {"action": "AGONIST", "target": "P14416", "drug": "DB00268"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00334"}, {"action": "AGONIST", "target": "P14416", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00363"}, {"action": "BINDER", "target": "P14416", "drug": "DB00370"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00372"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00391"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00408"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00409"}, {"action": "AGONIST", "target": "P14416", "drug": "DB00413"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00433"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00450"}, {"action": "BINDER", "target": "P14416", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00477"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00490"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00502"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00508"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00543"}, {"action": "OTHER/UNKNOWN", "target": "P14416", "drug": "DB00568"}, {"action": "AGONIST", "target": "P14416", "drug": "DB00589"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00623"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00679"}, {"action": "AGONIST", "target": "P14416", "drug": "DB00696"}, {"action": "AGONIST", "target": "P14416", "drug": "DB00714"}, {"action": "OTHER/UNKNOWN", "target": "P14416", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00777"}, {"action": "AGONIST", "target": "P14416", "drug": "DB00805"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00831"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00850"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00875"}, {"action": "AGONIST", "target": "P14416", "drug": "DB00915"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB00933"}, {"action": "BINDER", "target": "P14416", "drug": "DB00934"}, {"action": "AGONIST", "target": "P14416", "drug": "DB00988"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01038"}, {"action": "AGONIST", "target": "P14416", "drug": "DB01043"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01049"}, {"action": "AGONIST", "target": "P14416", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01063"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01069"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01100"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01142"}, {"action": "BINDER", "target": "P14416", "drug": "DB01151"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01184"}, {"action": "AGONIST", "target": "P14416", "drug": "DB01186"}, {"action": "AGONIST", "target": "P14416", "drug": "DB01200"}, {"action": "AGONIST", "target": "P14416", "drug": "DB01221"}, {"action": "PARTIAL AGONIST", "target": "P14416", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01233"}, {"action": "AGONIST", "target": "P14416", "drug": "DB01235"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01238"}, {"action": "PARTIAL AGONIST", "target": "P14416", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01392"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01425"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01614"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01618"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01621"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01622"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01623"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB01624"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB04842"}, {"action": "INHIBITOR", "target": "P14416", "drug": "DB04844"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB04946"}, {"action": "AGONIST", "target": "P14416", "drug": "DB05271"}, {"action": "AGONIST", "target": "P14416", "drug": "DB06016"}, {"action": "PARTIAL AGONIST", "target": "P14416", "drug": "DB06016"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB06144"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB06288"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB08815"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB09018"}, {"action": "AGONIST", "target": "P14416", "drug": "DB09128"}, {"action": "PARTIAL AGONIST", "target": "P14416", "drug": "DB09128"}, {"action": "ANTAGONIST", "target": "P14416", "drug": "DB09207"}]}, "P11177": {"specific_function": "The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links the glycolytic pathway to the tricarboxylic cycle.", "general_function": "Pyruvate dehydrogenase activity", "gene_names": ["PDHB"], "name": "Pyruvate dehydrogenase E1 component subunit beta, mitochondrial", "drug_actions": []}, "P61769": {"specific_function": "Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system.", "general_function": "Identical protein binding", "gene_names": ["B2M"], "name": "Beta-2-microglobulin", "drug_actions": []}, "P80371": {"specific_function": "Spans the head-body hinge region of the 30S subunit. Is loosely associated with the 30S subunit.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsB"], "name": "30S ribosomal protein S2", "drug_actions": []}, "P20963": {"specific_function": "Probable role in assembly and expression of the TCR complex as well as signal transduction upon antigen triggering.", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["CD247"], "name": "T-cell surface glycoprotein CD3 zeta chain", "drug_actions": []}, "P10600": {"specific_function": "Involved in embryogenesis and cell differentiation.", "general_function": "Type iii transforming growth factor beta receptor binding", "gene_names": ["TGFB3"], "name": "Transforming growth factor beta-3", "drug_actions": []}, "Q9P0Z9": {"specific_function": "Metabolizes sarcosine, L-pipecolic acid and L-proline.", "general_function": "Sarcosine oxidase activity", "gene_names": ["PIPOX"], "name": "Peroxisomal sarcosine oxidase", "drug_actions": []}, "P30153": {"specific_function": "The PR65 subunit of protein phosphatase 2A serves as a scaffolding molecule to coordinate the assembly of the catalytic subunit and a variable regulatory B subunit. Required for proper chromosome segregation and for centromeric localization of SGOL1 in mitosis.", "general_function": "Protein serine/threonine phosphatase activity", "gene_names": ["PPP2R1A"], "name": "Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform", "drug_actions": []}, "Q9NXE4": {"specific_function": "Catalyzes the hydrolysis of membrane sphingomyelin to form phosphorylcholine and ceramide.", "general_function": "Sphingomyelin phosphodiesterase d activity", "gene_names": ["SMPD4"], "name": "Sphingomyelin phosphodiesterase 4", "drug_actions": []}, "P10606": {"specific_function": "This protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport.", "general_function": "Metal ion binding", "gene_names": ["COX5B"], "name": "Cytochrome c oxidase subunit 5B, mitochondrial", "drug_actions": []}, "P0A6K3": {"specific_function": "Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions.", "general_function": "Zinc ion binding", "gene_names": ["def"], "name": "Peptide deformylase", "drug_actions": []}, "P37173": {"specific_function": "Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways.", "general_function": "Type iii transforming growth factor beta receptor binding", "gene_names": ["TGFBR2"], "name": "TGF-beta receptor type-2", "drug_actions": []}, "P33590": {"specific_function": "Involved in a nickel transport system, probably represents the nickel binder.", "general_function": "Transition metal ion binding", "gene_names": ["nikA"], "name": "Nickel-binding periplasmic protein", "drug_actions": []}, "P47901": {"specific_function": "Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system.", "general_function": "Vasopressin receptor activity", "gene_names": ["AVPR1B"], "name": "Vasopressin V1b receptor", "drug_actions": []}, "P77173": {"specific_function": "Essential cell division protein that stabilizes the FtsZ protofilaments by cross-linking them and that serves as a cytoplasmic membrane anchor for the Z ring (PubMed:9008158, PubMed:11847116, PubMed:22164258, PubMed:22304478, PubMed:23233671). Also required for the recruitment to the septal ring of the downstream cell division proteins FtsK, FtsQ, FtsL and FtsN (PubMed:11847116, PubMed:11948172). ZipA overproduction protects FtsZ from degradation by ClpP by preventing recognition by ClpX (PubMed:23233671). Does not affect the GTPase activity of FtsZ (PubMed:10209756).", "gene_names": ["zipA"], "name": "Cell division protein ZipA", "drug_actions": []}, "P0AEG6": {"specific_function": "Acts as a disulfide isomerase, interacting with incorrectly folded proteins to correct non-native disulfide bonds. DsbG and DsbC are part of a periplasmic reducing system that controls the level of cysteine sulfenylation, and provides reducing equivalents to rescue oxidatively damaged secreted proteins. Acts by transferring its disulfide bond to other proteins and is reduced in the process. DsbC is reoxidized by DsbD.", "general_function": "Protein disulfide oxidoreductase activity", "gene_names": ["dsbC"], "name": "Thiol:disulfide interchange protein DsbC", "drug_actions": []}, "P15273": {"specific_function": "Essential virulence determinant. This protein is a protein tyrosine phosphatase. The essential function of YopH in Yersinia pathogenesis is host-protein dephosphorylation. It contributes to the ability of the bacteria to resist phagocytosis by peritoneal macrophages.", "general_function": "Protein tyrosine phosphatase activity", "gene_names": ["yopH"], "name": "Tyrosine-protein phosphatase YopH", "drug_actions": []}, "Q6L8H2": {"specific_function": "In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated protein (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins.", "gene_names": ["KRTAP5-3"], "name": "Keratin-associated protein 5-3", "drug_actions": []}, "Q15788": {"specific_function": "Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion. Involved in the coactivation of different nuclear receptors, such as for steroids (PGR, GR and ER), retinoids (RXRs), thyroid hormone (TRs) and prostanoids (PPARs). Also involved in coactivation mediated by STAT3, STAT5A, STAT5B and STAT6 transcription factors. Displays histone acetyltransferase activity toward H3 and H4; the relevance of such activity remains however unclear. Plays a central role in creating multisubunit coactivator complexes that act via remodeling of chromatin, and possibly acts by participating in both chromatin remodeling and recruitment of general transcription factors. Required with NCOA2 to control energy balance between white and brown adipose tissues. Required for mediating steroid hormone response. Isoform 2 has a higher thyroid hormone-dependent transactivation activity than isoform 1 and isoform 3.", "general_function": "Transcription coactivator activity", "gene_names": ["NCOA1"], "name": "Nuclear receptor coactivator 1", "drug_actions": []}, "P52732": {"specific_function": "Motor protein required for establishing a bipolar spindle. Blocking of KIF11 prevents centrosome migration and arrest cells in mitosis with monoastral microtubule arrays.", "general_function": "Protein kinase binding", "gene_names": ["KIF11"], "name": "Kinesin-like protein KIF11", "drug_actions": []}, "O14764": {"specific_function": "GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.", "name": "Gamma-aminobutyric acid receptor subunit delta", "drug_actions": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00228"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00475"}, {"action": "BINDER", "target": "O14764", "drug": "DB00543"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB00546"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00628"}, {"action": "POSITIVE MODULATOR", "target": "O14764", "drug": "DB00659"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB00690"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00794"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00818"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01028"}, {"action": "AGONIST", "target": "O14764", "drug": "DB01049"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01205"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01437"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB01587"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O14764", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "O14764", "drug": "DB01595"}, {"action": "ANTAGONIST", "target": "O14764", "drug": "DB01708"}], "general_function": "Gaba-a receptor activity", "in_complexes": ["GABA-A receptor (anion channel)"], "gene_names": ["GABRD"]}, "O14763": {"specific_function": "Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Essential for ER stress-induced apoptosis.", "general_function": "Tumor necrosis factor-activated receptor activity", "gene_names": ["TNFRSF10B"], "name": "Tumor necrosis factor receptor superfamily member 10B", "drug_actions": []}, "P47872": {"specific_function": "This is a receptor for secretin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.", "general_function": "Secretin receptor activity", "gene_names": ["SCTR"], "name": "Secretin receptor", "drug_actions": [{"action": "AGONIST", "target": "P47872", "drug": "DB00021"}]}, "P12724": {"specific_function": "Cytotoxin and helminthotoxin with low-efficiency ribonuclease activity. Possesses a wide variety of biological activities. Exhibits antibacterial activity, including cytoplasmic membrane depolarization of preferentially Gram-negative, but also Gram-positive strains. Promotes E.coli outer membrane detachment, alteration of the overall cell shape and partial loss of cell content.", "general_function": "Ribonuclease activity", "gene_names": ["RNASE3"], "name": "Eosinophil cationic protein", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "P12724", "drug": "DB01411"}]}, "P47870": {"specific_function": "Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.", "name": "Gamma-aminobutyric acid receptor subunit beta-2", "drug_actions": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00228"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00475"}, {"action": "BINDER", "target": "P47870", "drug": "DB00543"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB00546"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00628"}, {"action": "POSITIVE MODULATOR", "target": "P47870", "drug": "DB00659"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB00690"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00794"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00818"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01028"}, {"action": "AGONIST", "target": "P47870", "drug": "DB01049"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01205"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01236"}, {"action": "NEGATIVE MODULATOR", "target": "P47870", "drug": "DB01381"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01437"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47870", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB01595"}, {"action": "ANTAGONIST", "target": "P47870", "drug": "DB01708"}, {"action": "POTENTIATOR", "target": "P47870", "drug": "DB06716"}], "general_function": "Inhibitory extracellular ligand-gated ion channel activity", "in_complexes": ["GABA-A receptor (anion channel)"], "gene_names": ["GABRB2"]}, "P47871": {"specific_function": "G-protein coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. Plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system.", "general_function": "Peptide hormone binding", "gene_names": ["GCGR"], "name": "Glucagon receptor", "drug_actions": [{"action": "AGONIST", "target": "P47871", "drug": "DB00040"}]}, "P80373": {"specific_function": "One of the primary rRNA binding proteins, it binds directly to 16S rRNA where it helps nucleate assembly of the body and platform of the 30S subunit. Binds mRNA in the 70S ribosome, positioning it for translation.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsD"], "name": "30S ribosomal protein S4", "drug_actions": []}, "P36673": {"specific_function": "Repressor of the treBC operon. Binds trehalose 6-phosphate as an inducer.", "general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": ["treR"], "name": "HTH-type transcriptional regulator TreR", "drug_actions": []}, "P13551": {"specific_function": "Catalyzes the GTP-dependent ribosomal translocation step during translation elongation. During this step, the ribosome changes from the pre-translocational (PRE) to the post-translocational (POST) state as the newly formed A-site-bound peptidyl-tRNA and P-site-bound deacylated tRNA move to the P and E sites, respectively. Catalyzes the coordinated movement of the two tRNA molecules, the mRNA and conformational changes in the ribosome.", "general_function": "Translation elongation factor activity", "gene_names": ["fusA"], "name": "Elongation factor G", "drug_actions": [{"action": "INHIBITOR", "target": "P13551", "drug": "DB02703"}]}, "P30556": {"specific_function": "Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.", "general_function": "Protein heterodimerization activity", "gene_names": ["AGTR1"], "name": "Type-1 angiotensin II receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "P30556", "drug": "DB00177"}, {"action": "ANTAGONIST", "target": "P30556", "drug": "DB00275"}, {"action": "ANTAGONIST", "target": "P30556", "drug": "DB00678"}, {"action": "ANTAGONIST", "target": "P30556", "drug": "DB00796"}, {"action": "ANTAGONIST", "target": "P30556", "drug": "DB00876"}, {"action": "ANTAGONIST", "target": "P30556", "drug": "DB00966"}, {"action": "ANTAGONIST", "target": "P30556", "drug": "DB01029"}, {"action": "ANTAGONIST", "target": "P30556", "drug": "DB01342"}, {"action": "ANTAGONIST", "target": "P30556", "drug": "DB01347"}, {"action": "ANTAGONIST", "target": "P30556", "drug": "DB01349"}, {"action": "ANTAGONIST", "target": "P30556", "drug": "DB08822"}]}, "P80075": {"specific_function": "Chemotactic factor that attracts monocytes, lymphocytes, basophils and eosinophils. May play a role in neoplasia and inflammatory host responses. This protein can bind heparin. The processed form MCP-2(6-76) does not show monocyte chemotactic activity, but inhibits the chemotactic effect most predominantly of CCL7, and also of CCL2 and CCL5 and CCL8.", "general_function": "Protein kinase activity", "gene_names": ["CCL8"], "name": "C-C motif chemokine 8", "drug_actions": []}, "Q92793": {"specific_function": "Acetylates histones, giving a specific tag for transcriptional activation. Also acetylates non-histone proteins, like NCOA3 and FOXO1. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1. Acts as a circadian transcriptional coactivator which enhances the activity of the circadian transcriptional activators: NPAS2-ARNTL/BMAL1 and CLOCK-ARNTL/BMAL1 heterodimers. Acetylates PCNA; acetylation promotes removal of chromatin-bound PCNA and its degradation during nucleotide excision repair (NER) (PubMed:24939902).", "general_function": "Zinc ion binding", "gene_names": ["CREBBP"], "name": "CREB-binding protein", "drug_actions": []}, "Q7AUG5": {"general_function": "Oxidoreductase activity", "gene_names": ["dehB"], "name": "2,3-dichloro-1-propanol dehalogenase", "drug_actions": []}, "Q56839": {"specific_function": "Catalyzes the reductive cleavage of the thioether linkage of 2-ketopropyl-coenzyme M, and the subsequent carboxylation of the ketopropyl cleavage product, yielding the products acetoacetate and free coenzyme M.", "general_function": "Flavin adenine dinucleotide binding", "gene_names": ["xecC"], "name": "2-oxopropyl-CoM reductase, carboxylating", "drug_actions": []}, "P25006": {"general_function": "Nitrite reductase (no-forming) activity", "gene_names": ["nirK"], "name": "Copper-containing nitrite reductase", "drug_actions": []}, "P05023": {"specific_function": "This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.", "general_function": "Steroid hormone binding", "gene_names": ["ATP1A1"], "name": "Sodium/potassium-transporting ATPase subunit alpha-1", "drug_actions": [{"action": "INHIBITOR", "target": "P05023", "drug": "DB00511"}, {"action": "OTHER/UNKNOWN", "target": "P05023", "drug": "DB00774"}, {"action": "INHIBITOR", "target": "P05023", "drug": "DB00903"}, {"action": "INHIBITOR", "target": "P05023", "drug": "DB01021"}, {"action": "INHIBITOR", "target": "P05023", "drug": "DB01078"}, {"action": "INHIBITOR", "target": "P05023", "drug": "DB01092"}, {"action": "OTHER", "target": "P05023", "drug": "DB01119"}, {"action": "INHIBITOR", "target": "P05023", "drug": "DB01158"}, {"action": "BINDER", "target": "P05023", "drug": "DB01188"}, {"action": "INHIBITOR", "target": "P05023", "drug": "DB01244"}, {"action": "BINDER", "target": "P05023", "drug": "DB01370"}, {"action": "INHIBITOR", "target": "P05023", "drug": "DB01396"}, {"action": "BINDER", "target": "P05023", "drug": "DB01430"}]}, "P62312": {"specific_function": "Component of LSm protein complexes, which are involved in RNA processing and may function in a chaperone-like manner, facilitating the efficient association of RNA processing factors with their substrates. Component of the cytoplasmic LSM1-LSM7 complex, which is thought to be involved in mRNA degradation by activating the decapping step in the 5'-to-3' mRNA decay pathway. Component of the nuclear LSM2-LSM8 complex, which is involved in splicing of nuclear mRNAs. LSM2-LSM8 associates with multiple snRNP complexes containing the U6 snRNA (U4/U6 di-snRNP, spliceosomal U4/U6.U5 tri-snRNP, and free U6 snRNP). It binds directly to the 3'-terminal U-tract of U6 snRNA and plays a role in the biogenesis and stability of the U6 snRNP and U4/U6 snRNP complexes. LSM2-LSM8 probably also is involved degradation of nuclear pre-mRNA by targeting them for decapping, and in processing of pre-tRNAs, pre-rRNAs and U3 snoRNA (By similarity).", "general_function": "Poly(a) rna binding", "gene_names": ["LSM6"], "name": "U6 snRNA-associated Sm-like protein LSm6", "drug_actions": []}, "P05020": {"general_function": "Zinc ion binding", "gene_names": ["pyrC"], "name": "Dihydroorotase", "drug_actions": [{"action": "INHIBITOR", "target": "P05020", "drug": "DB02262"}]}, "Q9NSA2": {"specific_function": "Pore-forming (alpha) subunit of voltage-gated rapidly inactivating A-type potassium channels. May contribute to I(To) current in heart and I(Sa) current in neurons. Channel properties are modulated by interactions with other alpha subunits and with regulatory subunits.", "general_function": "Metal ion binding", "gene_names": ["KCND1"], "name": "Potassium voltage-gated channel subfamily D member 1", "drug_actions": [{"action": "ANTAGONIST", "target": "Q9NSA2", "drug": "DB06637"}]}, "Q9NSA0": {"specific_function": "Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.", "general_function": "Sodium-independent organic anion transmembrane transporter activity", "gene_names": ["SLC22A11"], "name": "Solute carrier family 22 member 11", "drug_actions": [{"action": "INHIBITOR", "target": "Q9NSA0", "drug": "DB01032"}]}, "Q9NP56": {"specific_function": "Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in the control of cAMP-mediated neural activity and cAMP metabolism in the brain.", "name": "cAMP-specific 3',5'-cyclic phosphodiesterase 7B", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "Q9NP56", "drug": "DB00201"}, {"action": "INHIBITOR", "target": "Q9NP56", "drug": "DB00651"}, {"action": "INHIBITOR", "target": "Q9NP56", "drug": "DB00920"}], "general_function": "Metal ion binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE7B"]}, "Q46509": {"general_function": "Metal ion binding", "gene_names": ["mop"], "name": "Aldehyde oxidoreductase", "drug_actions": []}, "P0AE18": {"specific_function": "Removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). Requires deformylation of the N(alpha)-formylated initiator methionine before it can be hydrolyzed.", "general_function": "Metalloaminopeptidase activity", "gene_names": ["map"], "name": "Methionine aminopeptidase", "drug_actions": []}, "P45984": {"specific_function": "Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death. Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK9/JNK2. In turn, MAPK9/JNK2 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional activity. In response to oxidative or ribotoxic stresses, inhibits rRNA synthesis by phosphorylating and inactivating the RNA polymerase 1-specific transcription initiation factor RRN3. Promotes stressed cell apoptosis by phosphorylating key regulatory factors including TP53 and YAP1. In T-cells, MAPK8 and MAPK9 are required for polarized differentiation of T-helper cells into Th1 cells. Upon T-cell receptor (TCR) stimulation, is activated by CARMA1, BCL10, MAP2K7 and MAP3K7/TAK1 to regulate JUN protein levels. Plays an important role in the osmotic stress-induced epithelial tight-junctions disruption. When activated, promotes beta-catenin/CTNNB1 degradation and inhibits the canonical Wnt signaling pathway. Participates also in neurite growth in spiral ganglion neurons. Phosphorylates the CLOCK-ARNTL/BMAL1 heterodimer and plays a role in the regulation of the circadian clock (PubMed:22441692).MAPK9 isoforms display different binding patterns: alpha-1 and alpha-2 preferentially bind to JUN, whereas beta-1 and beta-2 bind to ATF2. However, there is no correlation between binding and phosphorylation, which is achieved at about the same efficiency by all isoforms. JUNB is not a substrate for JNK2 alpha-2, and JUND binds only weakly to it.", "general_function": "Transcription factor binding", "gene_names": ["MAPK9"], "name": "Mitogen-activated protein kinase 9", "drug_actions": []}, "P06632": {"specific_function": "Catalyzes the reduction of 2,5-diketo-D-gluconic acid (25DKG) to 2-keto-L-gulonic acid (2KLG). 5-keto-D-fructose and dihydroxyacetone can also serve as substrates. 25DKGR-A exhibits a greater selectivity for the substrate and higher thermal stability than 25DKGR-B.", "general_function": "Oxidoreductase activity", "gene_names": ["dkgA"], "name": "2,5-diketo-D-gluconic acid reductase A", "drug_actions": []}, "Q8GB52": {"general_function": "Serine-type endopeptidase activity", "gene_names": [], "name": "Extracellular subtilisin-like serine proteinase", "drug_actions": []}, "P26392": {"specific_function": "Catalyzes the reduction of dTDP-6-deoxy-L-lyxo-4-hexulose to yield dTDP-L-rhamnose. RmlD uses NADH and NADPH nearly equally well.", "general_function": "Metal ion binding", "gene_names": ["rfbD"], "name": "dTDP-4-dehydrorhamnose reductase", "drug_actions": []}, "P0AE12": {"specific_function": "Catalyzes the hydrolysis of the N-glycosidic bond of AMP to form adenine and ribose 5-phosphate. Involved in regulation of AMP concentrations.", "general_function": "Amp nucleosidase activity", "gene_names": ["amn"], "name": "AMP nucleosidase", "drug_actions": []}, "P45983": {"specific_function": "Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death. Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK8/JNK1. In turn, MAPK8/JNK1 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN, JDP2 and ATF2 and thus regulates AP-1 transcriptional activity. Phosphorylates the replication licensing factor CDT1, inhibiting the interaction between CDT1 and the histone H4 acetylase HBO1 to replication origins. Loss of this interaction abrogates the acetylation required for replication initiation. Promotes stressed cell apoptosis by phosphorylating key regulatory factors including p53/TP53 and Yes-associates protein YAP1. In T-cells, MAPK8 and MAPK9 are required for polarized differentiation of T-helper cells into Th1 cells. Contributes to the survival of erythroid cells by phosphorylating the antagonist of cell death BAD upon EPO stimulation. Mediates starvation-induced BCL2 phosphorylation, BCL2 dissociation from BECN1, and thus activation of autophagy. Phosphorylates STMN2 and hence regulates microtubule dynamics, controlling neurite elongation in cortical neurons. In the developing brain, through its cytoplasmic activity on STMN2, negatively regulates the rate of exit from multipolar stage and of radial migration from the ventricular zone. Phosphorylates several other substrates including heat shock factor protein 4 (HSF4), the deacetylase SIRT1, ELK1, or the E3 ligase ITCH. Phosphorylates the CLOCK-ARNTL/BMAL1 heterodimer and plays a role in the regulation of the circadian clock (PubMed:22441692).JNK1 isoforms display different binding patterns: beta-1 preferentially binds to c-Jun, whereas alpha-1, alpha-2, and beta-2 have a similar low level of binding to both c-Jun or ATF2. However, there is no correlation between binding and phosphorylation, which is achieved at about the same efficiency by all isoforms.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["MAPK8"], "name": "Mitogen-activated protein kinase 8", "drug_actions": []}, "Q8NMG3": {"general_function": "Dna binding", "gene_names": [], "name": "Transcriptional regulator", "drug_actions": []}, "Q84II6": {"general_function": "Oxidoreductase activity", "gene_names": ["carAa"], "name": "Terminal oxygenase component of carbazole", "drug_actions": []}, "P23827": {"specific_function": "General inhibitor of pancreatic serine proteases: inhibits chymotrypsin, trypsin, elastases, factor X, kallikrein as well as a variety of other proteases. The strength of inhibition does not appear to be correlated with a particular protease specificity.", "general_function": "Serine-type endopeptidase inhibitor activity", "gene_names": ["eco"], "name": "Ecotin", "drug_actions": []}, "P48664": {"specific_function": "Transports L-glutamate and also L- and D-aspartate. Seems to act as a symport by cotransporting sodium.", "general_function": "Sodium:dicarboxylate symporter activity", "gene_names": ["SLC1A6"], "name": "Excitatory amino acid transporter 4", "drug_actions": []}, "P31434": {"specific_function": "Can catalyze the transfer of alpha-xylosyl residue from alpha-xyloside to xylose, glucose, mannose, fructose, maltose, isomaltose, nigerose, kojibiose, sucrose and trehalose.", "general_function": "Xyloglucan 1,6-alpha-xylosidase activity", "gene_names": ["yicI"], "name": "Alpha-xylosidase", "drug_actions": []}, "P38038": {"specific_function": "Component of the sulfite reductase complex that catalyzes the 6-electron reduction of sulfite to sulfide. This is one of several activities required for the biosynthesis of L-cysteine from sulfate. The flavoprotein component catalyzes the electron flow from NADPH -> FAD -> FMN to the hemoprotein component.", "general_function": "Sulfite reductase (nadph) activity", "gene_names": ["cysJ"], "name": "Sulfite reductase [NADPH] flavoprotein alpha-component", "drug_actions": []}, "Q94655": {"specific_function": "Maintains high levels of reduced glutathione in the cytosol.", "general_function": "Glutathione-disulfide reductase activity", "gene_names": ["GR2"], "name": "Glutathione reductase", "drug_actions": []}, "Q81F54": {"gene_names": [], "name": "Glyoxalase family protein", "drug_actions": []}, "P0ACC7": {"specific_function": "Catalyzes the last two sequential reactions in the de novo biosynthetic pathway for UDP-N-acetylglucosamine (UDP-GlcNAc). The C-terminal domain catalyzes the transfer of acetyl group from acetyl coenzyme A to glucosamine-1-phosphate (GlcN-1-P) to produce N-acetylglucosamine-1-phosphate (GlcNAc-1-P), which is converted into UDP-GlcNAc by the transfer of uridine 5-monophosphate (from uridine 5-triphosphate), a reaction catalyzed by the N-terminal domain.", "general_function": "Udp-n-acetylglucosamine diphosphorylase activity", "gene_names": ["glmU"], "name": "Bifunctional protein GlmU", "drug_actions": []}, "Q96C24": {"specific_function": "Modulates exocytosis of dense-core granules and secretion of hormones in the pancreas and the pituitary. Interacts with vesicles containing negatively charged phospholipids in a Ca(2+)-independent manner (By similarity).", "general_function": "Zinc ion binding", "gene_names": ["SYTL4"], "name": "Synaptotagmin-like protein 4", "drug_actions": []}, "P0ACC1": {"specific_function": "Methylates the class 1 translation termination release factors RF1/PrfA and RF2/PrfB on the glutamine residue of the universally conserved GGQ motif, i.e. on 'Gln-235' in RF1 and on 'Gln-252' in RF2.", "general_function": "S-adenosylmethionine-dependent methyltransferase activity", "gene_names": ["prmC"], "name": "Release factor glutamine methyltransferase", "drug_actions": []}, "Q9P2R7": {"specific_function": "Catalyzes the ATP-dependent ligation of succinate and CoA to form succinyl-CoA.", "general_function": "Succinate-coa ligase (adp-forming) activity", "gene_names": ["SUCLA2"], "name": "Succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial", "drug_actions": []}, "P04150": {"specific_function": "Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth. Involved in chromatin remodeling. May play a negative role in adipogenesis through the regulation of lipolytic and antilipogenic genes expression.", "general_function": "Zinc ion binding", "gene_names": ["NR3C1"], "name": "Glucocorticoid receptor", "drug_actions": [{"action": "AGONIST", "target": "P04150", "drug": "DB00180"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00223"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00240"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00253"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00288"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00324"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00351"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00394"}, {"action": "ANTAGONIST", "target": "P04150", "drug": "DB00421"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00443"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00547"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00588"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00591"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00596"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00620"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00635"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00663"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00687"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00741"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00764"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00769"}, {"action": "ANTAGONIST", "target": "P04150", "drug": "DB00834"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00838"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00846"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00860"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00873"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00896"}, {"action": "AGONIST", "target": "P04150", "drug": "DB00959"}, {"action": "AGONIST", "target": "P04150", "drug": "DB01013"}, {"action": "AGONIST", "target": "P04150", "drug": "DB01047"}, {"action": "AGONIST", "target": "P04150", "drug": "DB01130"}, {"action": "ANTAGONIST", "target": "P04150", "drug": "DB01185"}, {"action": "ANTAGONIST", "target": "P04150", "drug": "DB01222"}, {"action": "AGONIST", "target": "P04150", "drug": "DB01234"}, {"action": "AGONIST", "target": "P04150", "drug": "DB01260"}, {"action": "AGONIST", "target": "P04150", "drug": "DB01380"}, {"action": "AGONIST", "target": "P04150", "drug": "DB01384"}, {"action": "AGONIST", "target": "P04150", "drug": "DB01410"}, {"action": "AGONIST", "target": "P04150", "drug": "DB06781"}, {"action": "ANTAGONIST", "target": "P04150", "drug": "DB08867"}, {"action": "AGONIST", "target": "P04150", "drug": "DB08906"}]}, "P31040": {"specific_function": "Flavoprotein (FP) subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q). Can act as a tumor suppressor.", "general_function": "Succinate dehydrogenase activity", "gene_names": ["SDHA"], "name": "Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial", "drug_actions": []}, "Q60053": {"specific_function": "Endohydrolysis of 1,4-alpha-glucosidic linkages in pullulan to form panose. Also hydrolyzes cyclodextrins.", "general_function": "Neopullulanase activity", "gene_names": ["tvaI"], "name": "Neopullulanase 1", "drug_actions": []}, "P05113": {"specific_function": "Factor that induces terminal differentiation of late-developing B-cells to immunoglobulin secreting cells.", "general_function": "Interleukin-5 receptor binding", "gene_names": ["IL5"], "name": "Interleukin-5", "drug_actions": [{"action": "ANTAGONIST", "target": "P05113", "drug": "DB01411"}, {"action": "ANTAGONIST", "target": "P05113", "drug": "DB06612"}]}, "P09104": {"specific_function": "Has neurotrophic and neuroprotective properties on a broad spectrum of central nervous system (CNS) neurons. Binds, in a calcium-dependent manner, to cultured neocortical neurons and promotes cell survival (By similarity).", "general_function": "Phosphopyruvate hydratase activity", "gene_names": ["ENO2"], "name": "Gamma-enolase", "drug_actions": []}, "P09455": {"specific_function": "Intracellular transport of retinol.", "general_function": "Transporter activity", "gene_names": ["RBP1"], "name": "Retinol-binding protein 1", "drug_actions": [{"action": "AGONIST", "target": "P09455", "drug": "DB00459"}]}, "Q54873": {"general_function": "Hyaluronate lyase activity", "gene_names": [], "name": "Hyaluronate lyase", "drug_actions": []}, "O76074": {"specific_function": "Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:9714779, PubMed:15489334). Specifically regulates nitric-oxide-generated cGMP (PubMed:15489334).", "name": "cGMP-specific 3',5'-cyclic phosphodiesterase", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "O76074", "drug": "DB00201"}, {"action": "INHIBITOR", "target": "O76074", "drug": "DB00203"}, {"action": "INHIBITOR", "target": "O76074", "drug": "DB00277"}, {"action": "INHIBITOR", "target": "O76074", "drug": "DB00806"}, {"action": "INHIBITOR", "target": "O76074", "drug": "DB00820"}, {"action": "INHIBITOR", "target": "O76074", "drug": "DB00862"}, {"action": "INHIBITOR", "target": "O76074", "drug": "DB00975"}, {"action": "INHIBITOR", "target": "O76074", "drug": "DB06237"}, {"action": "INHIBITOR", "target": "O76074", "drug": "DB06267"}], "general_function": "Metal ion binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE5A"]}, "Q5LI27": {"general_function": "Aspartate carbamoyltransferase activity", "gene_names": [], "name": "Putative ornithine carbamoyltransferase", "drug_actions": []}, "P06126": {"specific_function": "Antigen-presenting protein that binds self and non-self lipid and glycolipid antigens and presents them to T-cell receptors on natural killer T-cells.", "general_function": "Lipopeptide binding", "gene_names": ["CD1A"], "name": "T-cell surface glycoprotein CD1a", "drug_actions": [{"action": "INHIBITOR", "target": "P06126", "drug": "DB00098"}]}, "O60858": {"specific_function": "E3 ubiquitin ligase involved in the retrotranslocation and turnover of membrane and secretory proteins from the ER through a set of processes named ER-associated degradation (ERAD). This process acts on misfolded proteins as well as in the regulated degradation of correctly folded proteins. Enhances ionizing radiation-induced p53/TP53 stability and apoptosis via ubiquitinating MDM2 and AKT1 and decreasing AKT1 kinase activity through MDM2 and AKT1 proteasomal degradation. Regulates ER stress-induced autophagy, and may act as a tumor suppressor.", "general_function": "Zinc ion binding", "gene_names": ["TRIM13"], "name": "E3 ubiquitin-protein ligase TRIM13", "drug_actions": [{"action": "AGONIST", "target": "O60858", "drug": "DB01497"}, {"action": "AGONIST", "target": "O60858", "drug": "DB01565"}]}, "Q9RYU4": {"specific_function": "It seems to function in response to environmental stress when various electron transfer chains are affected or when the environment is highly oxidizing. It reduces quinones to the hydroquinone state to prevent interaction of the semiquinone with O2 and production of superoxide (By similarity).", "general_function": "Nad(p)h dehydrogenase (quinone) activity", "gene_names": [], "name": "NAD(P)H dehydrogenase (quinone)", "drug_actions": []}, "O00305": {"specific_function": "The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.", "name": "Voltage-dependent L-type calcium channel subunit beta-4", "drug_actions": [{"action": "INHIBITOR", "target": "O00305", "drug": "DB00393"}, {"action": "INHIBITOR", "target": "O00305", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "O00305", "drug": "DB01388"}], "general_function": "Voltage-gated calcium channel activity", "in_complexes": ["Voltage-dependent calcium channel"], "gene_names": ["CACNB4"]}, "Q5HEB7": {"specific_function": "Cell wall formation.", "general_function": "Manganese ion binding", "gene_names": ["ddl"], "name": "D-alanine--D-alanine ligase", "drug_actions": []}, "P04324": {"specific_function": "Factor of infectivity and pathogenicity, required for optimal virus replication. Alters numerous pathways of T-lymphocytes function and down-regulates immunity surface molecules in order to evade host defense and increase viral infectivity. Alters the functionality of other immunity cells, like dendritic cells, monocytes/macrophages and NK cells.In infected CD4(+) T-lymphocytes, down-regulates the surface MHC-I, mature MHC-II, CD4, CD28, CCR5 and CXCR4 molecules. Mediates internalization and degradation of host CD4 through the interaction of with the cytoplasmic tail of CD4, the recruitment of AP-2 (clathrin adapter protein complex 2), internalization through clathrin coated pits, and subsequent transport to endosomes and lysosomes for degradation. Diverts host MHC-I molecules to the trans-Golgi network-associated endosomal compartments by an endocytic pathway to finally target them for degradation. MHC-I down-regulation may involve AP-1 (clathrin adapter protein complex 1) or possibly Src family kinase-ZAP70/Syk-PI3K cascade recruited by PACS2. In consequence infected cells are masked for immune recognition by cytotoxic T-lymphocytes. Decreasing the number of immune receptors also prevents reinfection by more HIV particles (superinfection).Bypasses host T-cell signaling by inducing a transcriptional program nearly identical to that of anti-CD3 cell activation. Interaction with TCR-zeta chain up-regulates the Fas ligand (FasL). Increasing surface FasL molecules and decreasing surface MHC-I molecules on infected CD4(+) cells send attacking cytotoxic CD8+ T-lymphocytes into apoptosis.Plays a role in optimizing the host cell environment for viral replication without causing cell death by apoptosis. Protects the infected cells from apoptosis in order to keep them alive until the next virus generation is ready to strike. Inhibits the Fas and TNFR-mediated death signals by blocking MAP3K5/ASK1. Decreases the half-life of TP53, protecting the infected cell against p53-mediated apoptosis. Inhibits the apoptotic signals regulated by the Bcl-2 family proteins through the formation of a Nef/PI3-kinase/PAK2 complex that leads to activation of PAK2 and induces phosphorylation of Bad.Extracellular Nef protein targets CD4(+) T-lymphocytes for apoptosis by interacting with CXCR4 surface receptors.", "general_function": "Thioesterase binding", "gene_names": ["nef"], "name": "Protein Nef", "drug_actions": []}, "Q9R5V5": {"specific_function": "Catalyzes the cleavage of the glycosidic bond of 2'-deoxyribonucleosides and the transfer of the deoxyribosyl moiety to an acceptor purine or pyrimidine base.", "general_function": "Nucleoside deoxyribosyltransferase activity", "gene_names": ["ntd"], "name": "Nucleoside deoxyribosyltransferase", "drug_actions": []}, "P21796": {"specific_function": "Forms a channel through the mitochondrial outer membrane and also the plasma membrane. The channel at the outer mitochondrial membrane allows diffusion of small hydrophilic molecules; in the plasma membrane it is involved in cell volume regulation and apoptosis. It adopts an open conformation at low or zero membrane potential and a closed conformation at potentials above 30-40 mV. The open state has a weak anion selectivity whereas the closed state is cation-selective (PubMed:11845315, PubMed:18755977, PubMed:20230784, PubMed:8420959). May participate in the formation of the permeability transition pore complex (PTPC) responsible for the release of mitochondrial products that triggers apoptosis (PubMed:15033708, PubMed:25296756).", "general_function": "Voltage-gated anion channel activity", "gene_names": ["VDAC1"], "name": "Voltage-dependent anion-selective channel protein 1", "drug_actions": [{"action": "INHIBITOR", "target": "P21796", "drug": "DB01375"}]}, "Q873X9": {"specific_function": "Major secreted chitinase involved in the degradation of chitin, a component of the cell walls of fungi and exoskeletal elements of some animals (including worms and arthropods). Plays a role in the morphogenesis and autolysis (By similarity).", "general_function": "Chitinase activity", "gene_names": ["chiB1"], "name": "Endochitinase B1", "drug_actions": []}, "Q9UMX2": {"specific_function": "Ornithine decarboxylase (ODC) antizyme protein that negatively regulates ODC activity and intracellular polyamine biosynthesis and uptake by binding to ODC1 without promoting its degradation (PubMed:17900240). Stabilizes AZIN2 by interfering with its ubiquitination. Involved in the translocation of AZNI2 from ER-Golgi intermediate compartment (ERGIC) to the cytosol. Probably plays a key role in spermatogenesis by regulating the intracellular concentration of polyamines in haploid germ cells.", "general_function": "Putrescine transmembrane transporter activity", "gene_names": ["OAZ3"], "name": "Ornithine decarboxylase antizyme 3", "drug_actions": []}, "P0A6Y5": {"specific_function": "Redox regulated molecular chaperone. Protects both thermally unfolding and oxidatively damaged proteins from irreversible aggregation. Plays an important role in the bacterial defense system toward oxidative stress.", "general_function": "Identical protein binding", "gene_names": ["hslO"], "name": "33 kDa chaperonin", "drug_actions": []}, "Q9X1F0": {"gene_names": [], "name": "Glycerol uptake operon antiterminator regulatory protein", "drug_actions": []}, "Q13956": {"specific_function": "Participates in processes of transmission and amplification of the visual signal. cGMP-PDEs are the effector molecules in G-protein-mediated phototransduction in vertebrate rods and cones.", "general_function": "Enzyme inhibitor activity", "gene_names": ["PDE6H"], "name": "Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma", "drug_actions": [{"action": "INHIBITOR", "target": "Q13956", "drug": "DB00203"}, {"action": "ALLOSTERIC MODULATOR", "target": "Q13956", "drug": "DB00862"}]}, "Q59931": {"general_function": "Glyceraldehyde-3-phosphate dehydrogenase (nadp+) (phosphorylating) activity", "gene_names": ["gapN"], "name": "NADP-dependent glyceraldehyde-3-phosphate dehydrogenase", "drug_actions": []}, "P0A592": {"specific_function": "Binds oxygen cooperatively with very high affinity (P(50) = 0.013 mmHg at 20 degrees Celsius) because of a fast combination (25 microM(-1).s(-1)) and a slow dissociation (0.2 s(- 1)) rate", "general_function": "Involved in oxygen binding", "gene_names": ["glbN"], "name": "Group 1 truncated hemoglobin GlbN", "drug_actions": []}, "P24300": {"specific_function": "Involved in D-xylose catabolism.", "general_function": "Xylose isomerase activity", "gene_names": ["xylA"], "name": "Xylose isomerase", "drug_actions": []}, "O75865": {"specific_function": "May play a role in vesicular transport during the biogenesis of melanosomes.", "gene_names": ["TRAPPC6A"], "name": "Trafficking protein particle complex subunit 6A", "drug_actions": []}, "P18848": {"specific_function": "Transcriptional activator. Binds the cAMP response element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), a sequence present in many viral and cellular promoters. Cooperates with FOXO1 in osteoblasts to regulate glucose homeostasis through suppression of beta-cell production and decrease in insulin production (By similarity). It binds to a Tax-responsive enhancer element in the long terminal repeat of HTLV-I. Regulates the induction of DDIT3/CHOP and asparagine synthetase (ASNS) in response to endoplasmic reticulum (ER) stress. In concert with DDIT3/CHOP, activates the transcription of TRIB3 and promotes ER stress-induced neuronal apoptosis by regulating the transcriptional induction of BBC3/PUMA. Activates transcription of SIRT4. Regulates the circadian expression of the core clock component PER2 and the serotonin transporter SLC6A4. Binds in a circadian time-dependent manner to the cAMP response elements (CRE) in the SLC6A4 and PER2 promoters and periodically activates the transcription of these genes. During ER stress response, activates the transcription of NLRP1, possibly in concert with other factors (PubMed:26086088).", "name": "Cyclic AMP-dependent transcription factor ATF-4", "drug_actions": [], "general_function": "Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding", "in_complexes": ["activator protein 1"], "gene_names": ["ATF4"]}, "P49841": {"specific_function": "Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis. May also mediate the development of insulin resistance by regulating activation of transcription factors. Regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. In Wnt signaling, GSK3B forms a multimeric complex with APC, AXIN1 and CTNNB1/beta-catenin and phosphorylates the N-terminus of CTNNB1 leading to its degradation mediated by ubiquitin/proteasomes. Phosphorylates JUN at sites proximal to its DNA-binding domain, thereby reducing its affinity for DNA. Phosphorylates NFATC1/NFATC on conserved serine residues promoting NFATC1/NFATC nuclear export, shutting off NFATC1/NFATC gene regulation, and thereby opposing the action of calcineurin. Phosphorylates MAPT/TAU on 'Thr-548', decreasing significantly MAPT/TAU ability to bind and stabilize microtubules. MAPT/TAU is the principal component of neurofibrillary tangles in Alzheimer disease. Plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. Phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. Probably regulates NF-kappa-B (NFKB1) at the transcriptional level and is required for the NF-kappa-B-mediated anti-apoptotic response to TNF-alpha (TNF/TNFA). Negatively regulates replication in pancreatic beta-cells, resulting in apoptosis, loss of beta-cells and diabetes. Through phosphorylation of the anti-apoptotic protein MCL1, may control cell apoptosis in response to growth factors deprivation. Phosphorylates MUC1 in breast cancer cells, decreasing the interaction of MUC1 with CTNNB1/beta-catenin. Is necessary for the establishment of neuronal polarity and axon outgrowth. Phosphorylates MARK2, leading to inhibit its activity. Phosphorylates SIK1 at 'Thr-182', leading to sustain its activity. Phosphorylates ZC3HAV1 which enhances its antiviral activity. Phosphorylates SNAI1, leading to its BTRC-triggered ubiquitination and proteasomal degradation. Phosphorylates SFPQ at 'Thr-687' upon T-cell activation. Phosphorylates NR1D1 st 'Ser-55' and 'Ser-59' and stabilizes it by protecting it from proteasomal degradation. Regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2. Phosphorylates CLOCK AT 'Ser-427' and targets it for proteasomal degradation. Phosphorylates ARNTL/BMAL1 at 'Ser-17' and 'Ser-21' and primes it for ubiquitination and proteasomal degradation. Phosphorylates OGT at 'Ser-3' or 'Ser-4' which positively regulates its activity. Phosphorylates MYCN in neuroblastoma cells which may promote its degradation (PubMed:24391509).", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["GSK3B"], "name": "Glycogen synthase kinase-3 beta", "drug_actions": [{"action": "INHIBITOR", "target": "P49841", "drug": "DB01356"}]}, "P18843": {"specific_function": "Catalyzes a key step in NAD biosynthesis, transforming deamido-NAD into NAD by a two-step reaction.", "general_function": "Nad+ synthase activity", "gene_names": ["nadE"], "name": "NH(3)-dependent NAD(+) synthetase", "drug_actions": []}, "P56696": {"specific_function": "Probably important in the regulation of neuronal excitability. May underlie a potassium current involved in regulating the excitability of sensory cells of the cochlea. KCNQ4 channels are blocked by linopirdin, XE991 and bepridil, whereas clofilium is without significant effect. Muscarinic agonist oxotremorine-M strongly suppress KCNQ4 current in CHO cells in which cloned KCNQ4 channels were coexpressed with M1 muscarinic receptors.", "general_function": "Potassium channel activity", "gene_names": ["KCNQ4"], "name": "Potassium voltage-gated channel subfamily KQT member 4", "drug_actions": []}, "Q4W9V8": {"general_function": "Serine-type peptidase activity", "gene_names": [], "name": "Polyhydroxybutyrate depolymerase, putative", "drug_actions": []}, "P18847": {"specific_function": "This protein binds the cAMP response element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), a sequence present in many viral and cellular promoters. Represses transcription from promoters with ATF sites. It may repress transcription by stabilizing the binding of inhibitory cofactors at the promoter. Isoform 2 activates transcription presumably by sequestering inhibitory cofactors away from the promoters.", "name": "Cyclic AMP-dependent transcription factor ATF-3", "drug_actions": [], "general_function": "Transcriptional repressor activity, rna polymerase ii core promoter proximal region sequence-specific binding", "in_complexes": ["activator protein 1"], "gene_names": ["ATF3"]}, "P18846": {"specific_function": "This protein binds the cAMP response element (CRE) (consensus: 5'-GTGACGT[AC][AG]-3'), a sequence present in many viral and cellular promoters. Binds to the Tax-responsive element (TRE) of HTLV-I. Mediates PKA-induced stimulation of CRE-reporter genes. Represses the expression of FTH1 and other antioxidant detoxification genes. Triggers cell proliferation and transformation.", "name": "Cyclic AMP-dependent transcription factor ATF-1", "drug_actions": [], "general_function": "Transcriptional activator activity, rna polymerase ii transcription regulatory region sequence-specific binding", "in_complexes": ["activator protein 1"], "gene_names": ["ATF1"]}, "Q9Y478": {"specific_function": "Non-catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin. Beta non-catalytic subunit acts as a scaffold on which the AMPK complex assembles, via its C-terminus that bridges alpha (PRKAA1 or PRKAA2) and gamma subunits (PRKAG1, PRKAG2 or PRKAG3).", "name": "5'-AMP-activated protein kinase subunit beta-1", "drug_actions": [{"action": "ACTIVATOR", "target": "Q9Y478", "drug": "DB00131"}, {"action": "INDUCER", "target": "Q9Y478", "drug": "DB00331"}, {"action": "ACTIVATOR", "target": "Q9Y478", "drug": "DB00945"}], "general_function": "Protein kinase activity", "in_complexes": ["5'-AMP-activated protein kinase"], "gene_names": ["PRKAB1"]}, "P32418": {"specific_function": "Mediates the exchange of one Ca(2+) ion against three to four Na(+) ions across the cell membrane, and thereby contributes to the regulation of cytoplasmic Ca(2+) levels and Ca(2+)-dependent cellular processes (PubMed:1374913, PubMed:11241183, PubMed:1476165). Contributes to Ca(2+) transport during excitation-contraction coupling in muscle. In a first phase, voltage-gated channels mediate the rapid increase of cytoplasmic Ca(2+) levels due to release of Ca(2+) stores from the endoplasmic reticulum. SLC8A1 mediates the export of Ca(2+) from the cell during the next phase, so that cytoplasmic Ca(2+) levels rapidly return to baseline. Required for normal embryonic heart development and the onset of heart contractions.", "general_function": "Ion channel binding", "gene_names": ["SLC8A1"], "name": "Sodium/calcium exchanger 1", "drug_actions": [{"action": "INHIBITOR", "target": "P32418", "drug": "DB00159"}]}, "P29166": {"general_function": "Iron ion binding", "gene_names": [], "name": "Iron hydrogenase 1", "drug_actions": [{"action": "INHIBITOR", "target": "P29166", "drug": "DB00916"}]}, "P02461": {"specific_function": "Collagen type III occurs in most soft connective tissues along with type I collagen. Involved in regulation of cortical development. Is the major ligand of GPR56 in the developing brain and binding to GPR56 inhibits neuronal migration and activates the RhoA pathway by coupling GPR56 to GNA13 and possibly GNA12.", "general_function": "Platelet-derived growth factor binding", "gene_names": ["COL3A1"], "name": "Collagen alpha-1(III) chain", "drug_actions": []}, "P43777": {"general_function": "Kinase activity", "gene_names": ["folK"], "name": "2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase", "drug_actions": []}, "Q92947": {"specific_function": "Catalyzes the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA and CO(2) in the degradative pathway of L-lysine, L-hydroxylysine, and L-tryptophan metabolism. It uses electron transfer flavoprotein as its electron acceptor. Isoform Short is inactive.", "general_function": "Oxidoreductase activity, acting on the ch-ch group of donors, with a flavin as acceptor", "gene_names": ["GCDH"], "name": "Glutaryl-CoA dehydrogenase, mitochondrial", "drug_actions": []}, "P23141": {"specific_function": "Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form cocaethylene. Displays fatty acid ethyl ester synthase activity, catalyzing the ethyl esterification of oleic acid to ethyloleate.", "general_function": "Triglyceride lipase activity", "gene_names": ["CES1"], "name": "Liver carboxylesterase 1", "drug_actions": [{"action": "OTHER", "target": "P23141", "drug": "DB00198"}]}, "Q9HU22": {"specific_function": "Catalyzes the formation of dTDP-glucose, from dTTP and glucose 1-phosphate, as well as its pyrophosphorolysis.", "general_function": "Nucleotide binding", "gene_names": ["rmlA"], "name": "Glucose-1-phosphate thymidylyltransferase", "drug_actions": []}, "Q9HU21": {"specific_function": "Catalyzes the epimerization of the C3' and C5'positions of dTDP-6-deoxy-D-xylo-4-hexulose, forming dTDP-6-deoxy-L-lyxo-4-hexulose.", "general_function": "Dtdp-4-dehydrorhamnose 3,5-epimerase activity", "gene_names": ["rmlC"], "name": "dTDP-4-dehydrorhamnose 3,5-epimerase", "drug_actions": []}, "Q66282": {"specific_function": "Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host cell receptor to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP2: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP3: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP4: Lies on the inner surface of the capsid shell. After binding to the host receptor, the capsid undergoes conformational changes. Capsid protein VP4 is released, Capsid protein VP1 N-terminus is externalized, and together, they shape a pore in the host membrane through which the viral genome is translocated into the host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP0: Component of immature procapsids, which is cleaved into capsid proteins VP4 and VP2 after maturation. Allows the capsid to remain inactive before the maturation step (By similarity).Protein 2A: Cysteine protease that cleaves viral polyprotein and specific host proteins. It is responsible for the cleavage between the P1 and P2 regions, first cleavage occurring in the polyprotein. Cleaves also the host translation initiation factor EIF4G1, in order to shut down the capped cellular mRNA translation. Inhibits the host nucleus-cytoplasm protein and RNA trafficking by cleaving host members of the nuclear pores (By similarity).Protein 2B: Plays an essential role in the virus replication cycle by acting as a viroporin. Creates a pore in the host reticulum endoplasmic and as a consequence releases Ca2+ in the cytoplasm of infected cell. In turn, high levels of cyctoplasmic calcium may trigger membrane trafficking and transport of viral ER-associated proteins to viroplasms, sites of viral genome replication (By similarity).Protein 2C: Induces and associates with structural rearrangements of intracellular membranes. Displays RNA-binding, nucleotide binding and NTPase activities. May play a role in virion morphogenesis and viral RNA encapsidation by interacting with the capsid protein VP3 (By similarity).Protein 3AB: Localizes the viral replication complex to the surface of membranous vesicles. Together with protein 3CD binds the Cis-Active RNA Element (CRE) which is involved in RNA synthesis initiation. Acts as a cofactor to stimulate the activity of 3D polymerase, maybe through a nucleid acid chaperone activity (By similarity).Protein 3A: Localizes the viral replication complex to the surface of membranous vesicles. It inhibits host cell endoplasmic reticulum-to-Golgi apparatus transport and causes the dissassembly of the Golgi complex, possibly through GBF1 interaction. This would result in depletion of MHC, trail receptors and IFN receptors at the host cell surface (By similarity).Viral protein genome-linked: acts as a primer for viral RNA replication and remains covalently bound to viral genomic RNA. VPg is uridylylated prior to priming replication into VPg-pUpU. The oriI viral genomic sequence may act as a template for this. The VPg-pUpU is then used as primer on the genomic RNA poly(A) by the RNA-dependent RNA polymerase to replicate the viral genome. VPg may be removed in the cytoplasm by an unknown enzyme termed \"unlinkase\". VPg is not cleaved off virion genomes because replicated genomic RNA are encapsidated at the site of replication (By similarity).Protein 3CD: Is involved in the viral replication complex and viral polypeptide maturation. It exhibits protease activity with a specificity and catalytic efficiency that is different from protease 3C. Protein 3CD lacks polymerase activity. The 3C domain in the context of protein 3CD may have an RNA binding activity (By similarity).Protease 3C: cleaves host DDX58/RIG-I and thus contributes to the inhibition of type I interferon production. Cleaves also host PABPC1 (By similarity).RNA-directed RNA polymerase: Replicates the viral genomic RNA on the surface of intracellular membranes. May form linear arrays of subunits that propagate along a strong head-to-tail interaction called interface-I. Covalently attaches UMP to a tyrosine of VPg, which is used to prime RNA synthesis. The positive stranded RNA genome is first replicated at virus induced membranous vesicles, creating a dsRNA genomic replication form. This dsRNA is then used as template to synthesize positive stranded RNA genomes. ss(+)RNA genomes are either translated, replicated or encapsidated (By similarity).", "general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P51800": {"specific_function": "Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport. May be important in urinary concentrating mechanisms.", "general_function": "Voltage-gated chloride channel activity", "gene_names": ["CLCNKA"], "name": "Chloride channel protein ClC-Ka", "drug_actions": [{"action": "INDUCER", "target": "P51800", "drug": "DB04552"}]}, "Q92887": {"specific_function": "Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.", "general_function": "Organic anion transmembrane transporter activity", "gene_names": ["ABCC2"], "name": "Canalicular multispecific organic anion transporter 1", "drug_actions": [{"action": "INHIBITOR", "target": "Q92887", "drug": "DB01138"}]}, "P09210": {"specific_function": "Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.", "general_function": "Glutathione transferase activity", "gene_names": ["GSTA2"], "name": "Glutathione S-transferase A2", "drug_actions": []}, "P09211": {"specific_function": "Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.", "general_function": "S-nitrosoglutathione binding", "gene_names": ["GSTP1"], "name": "Glutathione S-transferase P", "drug_actions": [{"action": "INHIBITOR", "target": "P09211", "drug": "DB01242"}]}, "P43985": {"specific_function": "Catalyzes the conversion of 5-methoxyuridine (mo5U) to uridine-5-oxyacetic acid (cmo5U) at position 34 in tRNA. May also participate in the methylation of uridine-5-oxyacetic acid (cmo5U) to uridine-5-oxyacetic acid methyl ester (mcmo5U).", "general_function": "Trna (uracil) methyltransferase activity", "gene_names": ["cmoA"], "name": "tRNA (cmo5U34)-methyltransferase", "drug_actions": []}, "Q7NSZ5": {"gene_names": [], "name": "Putative uncharacterized protein", "drug_actions": []}, "P14385": {"specific_function": "This methylase recognizes the double-stranded sequence TCGA, causes specific methylation on A-4 on both strands and protects the DNA from cleavage by the TaqI endonuclease.", "general_function": "Site-specific dna-methyltransferase (adenine-specific) activity", "gene_names": ["taqIM"], "name": "Modification methylase TaqI", "drug_actions": []}, "P0AG16": {"specific_function": "Catalyzes the formation of phosphoribosylamine from phosphoribosylpyrophosphate (PRPP) and glutamine. Can also use NH(3) in place of glutamine.", "general_function": "Transferase activity, transferring glycosyl groups", "gene_names": ["purF"], "name": "Amidophosphoribosyltransferase", "drug_actions": []}, "P04377": {"specific_function": "This soluble electron transfer copper protein is required for the inactivation of copper-containing nitrite reductase in the presence of oxygen. Serves as a direct electron donor to the nitrite reductase.", "general_function": "Electron carrier activity", "gene_names": [], "name": "Pseudoazurin", "drug_actions": []}, "Q8I814": {"general_function": "Oxidoreductase activity", "gene_names": ["ptr2"], "name": "Putative pteridine reductase 2", "drug_actions": []}, "Q9BZX2": {"specific_function": "Phosphorylates uridine and cytidine to uridine monophosphate and cytidine monophosphate. Does not phosphorylate deoxyribonucleosides or purine ribonucleosides. Can use ATP or GTP as a phosphate donor. Can also phosphorylate cytidine and uridine nucleoside analogs such as 6-azauridine, 5-fluorouridine, 4-thiouridine, 5-bromouridine, N(4)-acetylcytidine, N(4)-benzoylcytidine, 5-fluorocytidine, 2-thiocytidine, 5-methylcytidine, and N(4)-anisoylcytidine.", "general_function": "Uridine kinase activity", "gene_names": ["UCK2"], "name": "Uridine-cytidine kinase 2", "drug_actions": []}, "P06010": {"specific_function": "The reaction center is a membrane-bound complex that mediates the initial photochemical event in the electron transfer process of photosynthesis.", "general_function": "Metal ion binding", "gene_names": ["pufM"], "name": "Reaction center protein M chain", "drug_actions": []}, "O15375": {"specific_function": "Proton-linked monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate (By similarity).", "general_function": "Symporter activity", "gene_names": ["SLC16A5"], "name": "Monocarboxylate transporter 6", "drug_actions": []}, "O15374": {"specific_function": "Proton-linked monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate (By similarity).", "general_function": "Symporter activity", "gene_names": ["SLC16A4"], "name": "Monocarboxylate transporter 5", "drug_actions": []}, "O15379": {"specific_function": "Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4), and some other non-histone substrates. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Participates in the BCL6 transcriptional repressor activity by deacetylating the H3 'Lys-27' (H3K27) on enhancer elements, antagonizing EP300 acetyltransferase activity and repressing proximal gene expression. Probably participates in the regulation of transcription through its binding to the zinc-finger transcription factor YY1; increases YY1 repression activity. Required to repress transcription of the POU1F1 transcription factor. Acts as a molecular chaperone for shuttling phosphorylated NR2C1 to PML bodies for sumoylation (PubMed:21444723, PubMed:23911289). Contributes, together with XBP1 isoform 1, to the activation of NFE2L2-mediated HMOX1 transcription factor gene expression in a PI(3)K/mTORC2/Akt-dependent signaling pathway leading to endothelial cell (EC) survival under disturbed flow/oxidative stress (PubMed:25190803).", "general_function": "Transcription factor binding", "gene_names": ["HDAC3"], "name": "Histone deacetylase 3", "drug_actions": [{"action": "INHIBITOR", "target": "O15379", "drug": "DB02546"}, {"action": "INHIBITOR", "target": "O15379", "drug": "DB06603"}]}, "P0C278": {"specific_function": "Catalyzes fumarate reduction using artificial electron donors such as methyl viologen. The physiological reductant is unknown, but evidence indicates that flavocytochrome c participates in electron transfer from formate to fumarate and possibly also to trimethylamine oxide (TMAO). This enzyme is essentially unidirectional.", "general_function": "Succinate dehydrogenase activity", "gene_names": ["fccA"], "name": "Fumarate reductase flavoprotein subunit", "drug_actions": []}, "P96850": {"general_function": "Involved in biphenyl-2,3-diol 1,2-dioxygenase activity", "gene_names": ["hsaC"], "name": "Iron-dependent extradiol dioxygenase", "drug_actions": []}, "P96851": {"general_function": "Involved in hydrolase activity", "gene_names": ["hsaD"], "name": "4,5:9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oate hydrolase", "drug_actions": []}, "Q9Y271": {"specific_function": "Receptor for cysteinyl leukotrienes mediating bronchoconstriction of individuals with and without asthma. Stimulation by LTD4 results in the contraction and proliferation of smooth muscle, edema, eosinophil migration and damage to the mucus layer in the lung. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. The rank order of affinities for the leukotrienes is LTD4 >> LTE4 = LTC4 >> LTB4.", "general_function": "Leukotriene receptor activity", "gene_names": ["CYSLTR1"], "name": "Cysteinyl leukotriene receptor 1", "drug_actions": [{"action": "ANTAGONIST", "target": "Q9Y271", "drug": "DB00471"}, {"action": "ANTAGONIST", "target": "Q9Y271", "drug": "DB00549"}, {"action": "ANTAGONIST", "target": "Q9Y271", "drug": "DB00587"}, {"action": "SUPPRESSOR", "target": "Q9Y271", "drug": "DB00716"}, {"action": "ANTAGONIST", "target": "Q9Y271", "drug": "DB01411"}]}, "Q9Y275": {"specific_function": "Cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA. TNFSF13/APRIL binds to the same 2 receptors. Together, they form a 2 ligands -2 receptors pathway involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. A third B-cell specific BAFF-receptor (BAFFR/BR3) promotes the survival of mature B-cells and the B-cell response.Isoform 2 seems to inhibit isoform 1 secretion and bioactivity.Isoform 3: Acts as a transcription factor for its own parent gene, in association with NF-kappa-B p50 subunit, at least in autoimmune and proliferative B-cell diseases. The presence of Delta4BAFF is essential for soluble BAFF release by IFNG/IFN-gamma-stimulated monocytes and for B-cell survival. It can directly or indirectly regulate the differential expression of a large number of genes involved in the innate immune response and the regulation of apoptosis.", "general_function": "Receptor binding", "gene_names": ["TNFSF13B"], "name": "Tumor necrosis factor ligand superfamily member 13B", "drug_actions": [{"action": "NEUTRALIZER", "target": "Q9Y275", "drug": "DB08879"}]}, "Q9Y277": {"specific_function": "Forms a channel through the mitochondrial outer membrane that allows diffusion of small hydrophilic molecules.", "general_function": "Voltage-gated anion channel activity", "gene_names": ["VDAC3"], "name": "Voltage-dependent anion-selective channel protein 3", "drug_actions": [{"action": "INHIBITOR", "target": "Q9Y277", "drug": "DB01375"}]}, "P02792": {"specific_function": "Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a role in delivery of iron to cells. Mediates iron uptake in capsule cells of the developing kidney (By similarity).", "general_function": "Iron ion binding", "gene_names": ["FTL"], "name": "Ferritin light chain", "drug_actions": [{"action": "OTHER", "target": "P02792", "drug": "DB00893"}]}, "O00329": {"specific_function": "Phosphoinositide-3-kinase (PI3K) that phosphorylates PftdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Mediates immune responses. Plays a role in B-cell development, proliferation, migration, and function. Required for B-cell receptor (BCR) signaling. Mediates B-cell proliferation response to anti-IgM, anti-CD40 and IL4 stimulation. Promotes cytokine production in response to TLR4 and TLR9. Required for antibody class switch mediated by TLR9. Involved in the antigen presentation function of B-cells. Involved in B-cell chemotaxis in response to CXCL13 and sphingosine 1-phosphate (S1P). Required for proliferation, signaling and cytokine production of naive, effector and memory T-cells. Required for T-cell receptor (TCR) signaling. Mediates TCR signaling events at the immune synapse. Activation by TCR leads to antigen-dependent memory T-cell migration and retention to antigenic tissues. Together with PIK3CG participates in T-cell development. Contributes to T-helper cell expansion and differentiation. Required for T-cell migration mediated by homing receptors SELL/CD62L, CCR7 and S1PR1 and antigen dependent recruitment of T-cells. Together with PIK3CG is involved in natural killer (NK) cell development and migration towards the sites of inflammation. Participates in NK cell receptor activation. Have a role in NK cell maturation and cytokine production. Together with PIK3CG is involved in neutrophil chemotaxis and extravasation. Together with PIK3CG participates in neutrophil respiratory burst. Have important roles in mast-cell development and mast cell mediated allergic response. Involved in stem cell factor (SCF)-mediated proliferation, adhesion and migration. Required for allergen-IgE-induced degranulation and cytokine release. The lipid kinase activity is required for its biological function. Isoform 2 may be involved in stabilizing total RAS levels, resulting in increased ERK phosphorylation and increased PI3K activity.", "general_function": "Phosphatidylinositol-4,5-bisphosphate 3-kinase activity", "gene_names": ["PIK3CD"], "name": "Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform", "drug_actions": []}, "P02794": {"specific_function": "Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Has ferroxidase activity. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a role in delivery of iron to cells. Mediates iron uptake in capsule cells of the developing kidney (By similarity).", "general_function": "Iron ion binding", "gene_names": ["FTH1"], "name": "Ferritin heavy chain", "drug_actions": [{"action": "OTHER", "target": "P02794", "drug": "DB00893"}]}, "P09693": {"specific_function": "The CD3 complex mediates signal transduction.", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["CD3G"], "name": "T-cell surface glycoprotein CD3 gamma chain", "drug_actions": []}, "P43119": {"specific_function": "Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase.", "general_function": "Guanyl-nucleotide exchange factor activity", "gene_names": ["PTGIR"], "name": "Prostacyclin receptor", "drug_actions": [{"action": "AGONIST", "target": "P43119", "drug": "DB00374"}, {"action": "AGONIST", "target": "P43119", "drug": "DB01088"}, {"action": "ANTAGONIST", "target": "P43119", "drug": "DB01160"}, {"action": "AGONIST", "target": "P43119", "drug": "DB01240"}, {"action": "AGONIST", "target": "P43119", "drug": "DB11362"}]}, "P04083": {"specific_function": "Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process. Has anti-inflammatory activity (PubMed:8425544). Plays a role in glucocorticoid-mediated down-regulation of the early phase of the inflammatory response (By similarity). Promotes resolution of inflammation and wound healing (PubMed:25664854). Functions at least in part by activating the formyl peptide receptors and downstream signaling cascades (PubMed:15187149, PubMed:25664854). Promotes chemotaxis of granulocytes and monocytes via activation of the formyl peptide receptors (PubMed:15187149). Contributes to the adaptive immune response by enhancing signaling cascades that are triggered by T-cell activation, regulates differentiation and proliferation of activated T-cells (PubMed:17008549). Promotes the differentiation of T-cells into Th1 cells and negatively regulates differentiation into Th2 cells (PubMed:17008549). Has no effect on unstimulated T cells (PubMed:17008549). Promotes rearrangement of the actin cytoskeleton, cell polarization and cell migration (PubMed:15187149). Negatively regulates hormone exocytosis via activation of the formyl peptide receptors and reorganization of the actin cytoskeleton (PubMed:19625660). Has high affinity for Ca(2+) and can bind up to eight Ca(2+) ions (By similarity). Displays Ca(2+)-dependent binding to phospholipid membranes (PubMed:2532504, PubMed:8557678). Plays a role in the formation of phagocytic cups and phagosomes. Plays a role in phagocytosis by mediating the Ca(2+)-dependent interaction between phagosomes and the actin cytoskeleton (By similarity).", "general_function": "Structural molecule activity", "gene_names": ["ANXA1"], "name": "Annexin A1", "drug_actions": [{"action": "AGONIST", "target": "P04083", "drug": "DB00288"}, {"action": "AGONIST", "target": "P04083", "drug": "DB00741"}, {"action": "AGONIST", "target": "P04083", "drug": "DB01234"}]}, "P22303": {"specific_function": "Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.", "general_function": "Serine hydrolase activity", "gene_names": ["ACHE"], "name": "Acetylcholinesterase", "drug_actions": [{"action": "PRODUCT OF", "target": "P22303", "drug": "DB00122"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB00382"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB00483"}, {"action": "ANTAGONIST", "target": "P22303", "drug": "DB00545"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB00545"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB00674"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB00677"}, {"action": "ACTIVATOR", "target": "P22303", "drug": "DB00733"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB00805"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB00843"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB00944"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB00981"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB00989"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB01010"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB01122"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB01199"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB01245"}, {"action": "INHIBITOR", "target": "P22303", "drug": "DB01400"}, {"action": "ANTAGONIST", "target": "P22303", "drug": "DB08996"}]}, "P30920": {"general_function": "Starch binding", "gene_names": [], "name": "Cyclomaltodextrin glucanotransferase", "drug_actions": []}, "P53779": {"specific_function": "Serine/threonine-protein kinase involved in various processes such as neuronal proliferation, differentiation, migration and programmed cell death. Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK10/JNK3. In turn, MAPK10/JNK3 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional activity. Plays regulatory roles in the signaling pathways during neuronal apoptosis. Phosphorylates the neuronal microtubule regulator STMN2. Acts in the regulation of the beta-amyloid precursor protein/APP signaling during neuronal differentiation by phosphorylating APP. Participates also in neurite growth in spiral ganglion neurons. Phosphorylates the CLOCK-ARNTL/BMAL1 heterodimer and plays a role in the photic regulation of the circadian clock (PubMed:22441692).", "general_function": "Map kinase kinase activity", "gene_names": ["MAPK10"], "name": "Mitogen-activated protein kinase 10", "drug_actions": []}, "Q8N9I0": {"specific_function": "Exhibits calcium-dependent phospholipid and inositol polyphosphate binding properties (By similarity). May have a regulatory role in the membrane interactions during trafficking of synaptic vesicles at the active zone of the synapse (By similarity). Plays a role in dendrite formation by melanocytes (PubMed:23999003).", "general_function": "Syntaxin binding", "gene_names": ["SYT2"], "name": "Synaptotagmin-2", "drug_actions": []}, "P34130": {"specific_function": "Target-derived survival factor for peripheral sensory sympathetic neurons.", "general_function": "Growth factor activity", "gene_names": ["NTF4"], "name": "Neurotrophin-4", "drug_actions": []}, "O95954": {"specific_function": "Folate-dependent enzyme, that displays both transferase and deaminase activity. Serves to channel one-carbon units from formiminoglutamate to the folate pool.Binds and promotes bundling of vimentin filaments originating from the Golgi.", "general_function": "Microtubule binding", "gene_names": ["FTCD"], "name": "Formimidoyltransferase-cyclodeaminase", "drug_actions": [{"action": "COFACTOR", "target": "O95954", "drug": "DB00114"}, {"action": "COFACTOR", "target": "O95954", "drug": "DB00116"}]}, "P43115": {"specific_function": "Receptor for prostaglandin E2 (PGE2); the EP3 receptor may be involved in inhibition of gastric acid secretion, modulation of neurotransmitter release in central and peripheral neurons, inhibition of sodium and water reabsorption in kidney tubulus and contraction in uterine smooth muscle. The activity of this receptor can couple to both the inhibition of adenylate cyclase mediated by G-I proteins, and to an elevation of intracellular calcium. The various isoforms have identical ligand binding properties but can interact with different second messenger systems (By similarity).", "general_function": "Rna polymerase ii transcription factor activity, ligand-activated sequence-specific dna binding", "gene_names": ["PTGER3"], "name": "Prostaglandin E2 receptor EP3 subtype", "drug_actions": [{"action": "AGONIST", "target": "P43115", "drug": "DB00905"}, {"action": "AGONIST", "target": "P43115", "drug": "DB00917"}, {"action": "AGONIST", "target": "P43115", "drug": "DB00929"}]}, "P46459": {"specific_function": "Required for vesicle-mediated transport. Catalyzes the fusion of transport vesicles within the Golgi cisternae. Is also required for transport from the endoplasmic reticulum to the Golgi stack. Seems to function as a fusion protein required for the delivery of cargo proteins to all compartments of the Golgi stack independent of vesicle origin. Interaction with AMPAR subunit GRIA2 leads to influence GRIA2 membrane cycling (By similarity).", "general_function": "Syntaxin-1 binding", "gene_names": ["NSF"], "name": "Vesicle-fusing ATPase", "drug_actions": []}, "P43116": {"specific_function": "Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. The subsequent raise in intracellular cAMP is responsible for the relaxing effect of this receptor on smooth muscle.", "general_function": "Prostaglandin e receptor activity", "gene_names": ["PTGER2"], "name": "Prostaglandin E2 receptor EP2 subtype", "drug_actions": [{"action": "AGONIST", "target": "P43116", "drug": "DB00770"}, {"action": "AGONIST", "target": "P43116", "drug": "DB00917"}, {"action": "AGONIST", "target": "P43116", "drug": "DB00929"}]}, "P35346": {"specific_function": "Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Increases cell growth inhibition activity of SSTR2 following heterodimerization.", "general_function": "Somatostatin receptor activity", "gene_names": ["SSTR5"], "name": "Somatostatin receptor type 5", "drug_actions": [{"action": "AGONIST", "target": "P35346", "drug": "DB04894"}, {"action": "AGONIST", "target": "P35346", "drug": "DB06791"}]}, "P00797": {"specific_function": "Renin is a highly specific endopeptidase, whose only known function is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of blood pressure and increased sodium retention by the kidney.", "general_function": "Receptor binding", "gene_names": ["REN"], "name": "Renin", "drug_actions": [{"action": "INHIBITOR", "target": "P00797", "drug": "DB00212"}, {"action": "INHIBITOR", "target": "P00797", "drug": "DB03395"}, {"action": "INHIBITOR", "target": "P00797", "drug": "DB09026"}]}, "Q9X0P2": {"gene_names": [], "name": "Uncharacterized protein", "drug_actions": []}, "O60733": {"specific_function": "Catalyzes the release of fatty acids from phospholipids. It has been implicated in normal phospholipid remodeling, nitric oxide-induced or vasopressin-induced arachidonic acid release and in leukotriene and prostaglandin production. May participate in fas mediated apoptosis and in regulating transmembrane ion flux in glucose-stimulated B-cells. Has a role in cardiolipin (CL) deacylation. Required for both speed and directionality of monocyte MCP1/CCL2-induced chemotaxis through regulation of F-actin polymerization at the pseudopods.Isoform ankyrin-iPLA2-1 and isoform ankyrin-iPLA2-2, which lack the catalytic domain, are probably involved in the negative regulation of iPLA2 activity.", "general_function": "Phospholipase a2 activity", "gene_names": ["PLA2G6"], "name": "85/88 kDa calcium-independent phospholipase A2", "drug_actions": [{"action": "INHIBITOR", "target": "O60733", "drug": "DB01103"}]}, "Q14520": {"specific_function": "Cleaves the alpha-chain at multiple sites and the beta-chain between 'Lys-53' and 'Lys-54' but not the gamma-chain of fibrinogen and therefore does not initiate the formation of the fibrin clot and does not cause the fibrinolysis directly. It does not cleave (activate) prothrombin and plasminogen but converts the inactive single chain urinary plasminogen activator (pro-urokinase) to the active two chain form. Activates coagulation factor VII.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["HABP2"], "name": "Hyaluronan-binding protein 2", "drug_actions": [{"action": "BINDER", "target": "Q14520", "drug": "DB08818"}]}, "P35348": {"specific_function": "This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.", "name": "Alpha-1A adrenergic receptor", "drug_actions": [{"action": "AGONIST", "target": "P35348", "drug": "DB00182"}, {"action": "AGONIST", "target": "P35348", "drug": "DB00211"}, {"action": "BINDER", "target": "P35348", "drug": "DB00215"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00246"}, {"action": "BINDER", "target": "P35348", "drug": "DB00248"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00298"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00346"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00363"}, {"action": "AGONIST", "target": "P35348", "drug": "DB00368"}, {"action": "BINDER", "target": "P35348", "drug": "DB00370"}, {"action": "BINDER", "target": "P35348", "drug": "DB00370"}, {"action": "AGONIST", "target": "P35348", "drug": "DB00397"}, {"action": "BINDER", "target": "P35348", "drug": "DB00408"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00420"}, {"action": "AGONIST", "target": "P35348", "drug": "DB00449"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00450"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00457"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00477"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00543"}, {"action": "AGONIST", "target": "P35348", "drug": "DB00575"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00590"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00598"}, {"action": "AGONIST", "target": "P35348", "drug": "DB00610"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00622"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00656"}, {"action": "AGONIST", "target": "P35348", "drug": "DB00668"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00679"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00692"}, {"action": "PARTIAL AGONIST", "target": "P35348", "drug": "DB00696"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00699"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00706"}, {"action": "AGONIST", "target": "P35348", "drug": "DB00723"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00734"}, {"action": "UNKNOWN", "target": "P35348", "drug": "DB00751"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00797"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00831"}, {"action": "AGONIST", "target": "P35348", "drug": "DB00852"}, {"action": "AGONIST", "target": "P35348", "drug": "DB00865"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00875"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00925"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB00934"}, {"action": "AGONIST", "target": "P35348", "drug": "DB00935"}, {"action": "AGONIST", "target": "P35348", "drug": "DB00964"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01049"}, {"action": "UNKNOWN", "target": "P35348", "drug": "DB01069"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01136"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01149"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01151"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01162"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01175"}, {"action": "AGONIST", "target": "P35348", "drug": "DB01186"}, {"action": "AGONIST", "target": "P35348", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01238"}, {"action": "AGONIST", "target": "P35348", "drug": "DB01253"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01295"}, {"action": "AGONIST", "target": "P35348", "drug": "DB01365"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01403"}, {"action": "AGONIST", "target": "P35348", "drug": "DB01472"}, {"action": "AGONIST", "target": "P35348", "drug": "DB01579"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01614"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01622"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB01624"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB04855"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB04946"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB06207"}, {"action": "ANTAGONIST", "target": "P35348", "drug": "DB06216"}, {"action": "AGONIST", "target": "P35348", "drug": "DB06262"}, {"action": "AGONIST", "target": "P35348", "drug": "DB06694"}, {"action": "AGONIST", "target": "P35348", "drug": "DB06706"}, {"action": "AGONIST", "target": "P35348", "drug": "DB06707"}, {"action": "AGONIST", "target": "P35348", "drug": "DB06711"}, {"action": "AGONIST", "target": "P35348", "drug": "DB06764"}, {"action": "AGONIST", "target": "P35348", "drug": "DB09202"}], "general_function": "Protein heterodimerization activity", "in_complexes": ["Alpha adrenergic receptor", "Alpha-1 adrenergic receptor"], "gene_names": ["ADRA1A"]}, "Q26609": {"general_function": "Hexokinase activity", "gene_names": [], "name": "Hexokinase", "drug_actions": []}, "P78536": {"specific_function": "Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation (NEXT). Plays a role in the proteolytic processing of ACE2.", "general_function": "Zinc ion binding", "gene_names": ["ADAM17"], "name": "Disintegrin and metalloproteinase domain-containing protein 17", "drug_actions": []}, "P42512": {"specific_function": "High-affinity outer membrane receptor required for the transport of Fe(3+)-pyochelin.", "general_function": "Receptor activity", "gene_names": ["fptA"], "name": "Fe(3+)-pyochelin receptor", "drug_actions": []}, "P00403": {"specific_function": "Cytochrome c oxidase is the component of the respiratory chain that catalyzes the reduction of oxygen to water. Subunits 1-3 form the functional core of the enzyme complex. Subunit 2 transfers the electrons from cytochrome c via its binuclear copper A center to the bimetallic center of the catalytic subunit 1.", "general_function": "Cytochrome-c oxidase activity", "gene_names": ["MT-CO2"], "name": "Cytochrome c oxidase subunit 2", "drug_actions": []}, "P63454": {"gene_names": ["kasA"], "name": "3-oxoacyl-[acyl-carrier-protein] synthase 1", "drug_actions": []}, "P17812": {"specific_function": "This enzyme is involved in the de novo synthesis of CTP, a precursor of DNA, RNA and phospholipids. Catalyzes the ATP-dependent amination of UTP to CTP with either L-glutamine or ammonia as a source of nitrogen. This enzyme and its product, CTP, play a crucial role in the proliferation of activated lymphocytes and therefore in immunity.", "general_function": "Ctp synthase activity", "gene_names": ["CTPS1"], "name": "CTP synthase 1", "drug_actions": [{"action": "ANTAGONIST", "target": "P17812", "drug": "DB00130"}]}, "P28790": {"specific_function": "Catalyzes the final step of fatty acid oxidation in which acetyl-CoA is released and the CoA ester of a fatty acid two carbons shorter is formed.", "general_function": "Acetyl-coa c-acyltransferase activity", "gene_names": ["fadA"], "name": "3-ketoacyl-CoA thiolase", "drug_actions": []}, "O14735": {"specific_function": "Catalyzes the biosynthesis of phosphatidylinositol (PtdIns) as well as PtdIns:inositol exchange reaction. May thus act to reduce an excessive cellular PtdIns content. The exchange activity is due to the reverse reaction of PtdIns synthase and is dependent on CMP, which is tightly bound to the enzyme.", "general_function": "Manganese ion binding", "gene_names": ["CDIPT"], "name": "CDP-diacylglycerol--inositol 3-phosphatidyltransferase", "drug_actions": [{"action": "INHIBITOR", "target": "O14735", "drug": "DB03106"}]}, "P34741": {"specific_function": "Cell surface proteoglycan that bears heparan sulfate. Regulates dendritic arbor morphogenesis (By similarity).", "general_function": "Pdz domain binding", "gene_names": ["SDC2"], "name": "Syndecan-2", "drug_actions": [{"action": "AGONIST", "target": "P34741", "drug": "DB00020"}]}, "P10613": {"specific_function": "Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol.", "general_function": "Sterol 14-demethylase activity", "gene_names": ["ERG11"], "name": "Lanosterol 14-alpha demethylase", "drug_actions": [{"action": "INHIBITOR", "target": "P10613", "drug": "DB00196"}, {"action": "INHIBITOR", "target": "P10613", "drug": "DB00239"}, {"action": "ANTAGONIST", "target": "P10613", "drug": "DB00251"}, {"action": "ANTAGONIST", "target": "P10613", "drug": "DB00257"}, {"action": "INHIBITOR", "target": "P10613", "drug": "DB00257"}, {"action": "ANTAGONIST", "target": "P10613", "drug": "DB00582"}, {"action": "INHIBITOR", "target": "P10613", "drug": "DB00582"}, {"action": "ANTAGONIST", "target": "P10613", "drug": "DB01007"}, {"action": "INHIBITOR", "target": "P10613", "drug": "DB01026"}, {"action": "INHIBITOR", "target": "P10613", "drug": "DB01110"}, {"action": "ANTAGONIST", "target": "P10613", "drug": "DB01127"}, {"action": "INHIBITOR", "target": "P10613", "drug": "DB01153"}, {"action": "ANTAGONIST", "target": "P10613", "drug": "DB01263"}, {"action": "INHIBITOR", "target": "P10613", "drug": "DB04794"}, {"action": "INHIBITOR", "target": "P10613", "drug": "DB08933"}]}, "P60355": {"general_function": "Metal ion binding", "gene_names": [], "name": "Manganese catalase", "drug_actions": []}, "P74334": {"specific_function": "Cleaves a number of carotenals and carotenols in the all-trans configuration at the 15-15' double bond producing retinal or retinol, respectively. Also shows activity toward lycopenals and the corresponding alcohols. Does not cleave beta-carotene or lycopene.", "general_function": "Metal ion binding", "gene_names": [], "name": "Apocarotenoid-15,15'-oxygenase", "drug_actions": []}, "Q92952": {"specific_function": "Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to the slow component of synaptic afterhyperpolarization. The channel is blocked by apamin (By similarity).", "name": "Small conductance calcium-activated potassium channel protein 1", "drug_actions": [{"action": "BINDER", "target": "Q92952", "drug": "DB00721"}, {"action": "INHIBITOR", "target": "Q92952", "drug": "DB01110"}], "general_function": "Small conductance calcium-activated potassium channel activity", "in_complexes": ["Calcium-activated potassium channel"], "gene_names": ["KCNN1"]}, "Q92953": {"specific_function": "Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and smooth muscle cells. Channels open or close in response to the voltage difference across the membrane, letting potassium ions pass in accordance with their electrochemical gradient. Homotetrameric channels mediate a delayed-rectifier voltage-dependent outward potassium current that display rapid activation and slow inactivation in response to membrane depolarization. Can form functional homotetrameric and heterotetrameric channels that contain variable proportions of KCNB1; channel properties depend on the type of alpha subunits that are part of the channel. Can also form functional heterotetrameric channels with other alpha subunits that are non-conducting when expressed alone, such as KCNS1 and KCNS2, creating a functionally diverse range of channel complexes. In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Contributes to the delayed-rectifier voltage-gated potassium current in cortical pyramidal neurons and smooth muscle cells.", "general_function": "Protein heterodimerization activity", "gene_names": ["KCNB2"], "name": "Potassium voltage-gated channel subfamily B member 2", "drug_actions": [{"action": "ANTAGONIST", "target": "Q92953", "drug": "DB06637"}]}, "Q5UPJ7": {"specific_function": "Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr).", "general_function": "Tyrosine-trna ligase activity", "gene_names": ["YARS"], "name": "Tyrosine--tRNA ligase", "drug_actions": []}, "Q9I5F3": {"specific_function": "Catalyzes the reductive cleavage of azo bond in aromatic azo compounds to the corresponding amines. Requires NADH, but not NADPH, as an electron donor for its activity.", "general_function": "Oxidoreductase activity, acting on other nitrogenous compounds as donors", "gene_names": ["azoR1"], "name": "FMN-dependent NADH-azoreductase 1", "drug_actions": []}, "Q86YB8": {"specific_function": "Oxidoreductase involved in disulfide bond formation in the endoplasmic reticulum. Efficiently reoxidizes P4HB/PDI, the enzyme catalyzing protein disulfide formation, in order to allow P4HB to sustain additional rounds of disulfide formation. Other protein disulfide isomerase family members can also be reoxidized, but at lower rates compared to P4HB, including PDIA2 (50% of P4HB reoxidation rate), as well as PDIA3, PDIA4, PDIA6 and NXNDC12 (<10%). Following P4HB reoxidation, passes its electrons to molecular oxygen via FAD, leading to the production of reactive oxygen species (ROS) in the cell. May be involved in oxidative proinsulin folding in pancreatic cells, hence may play a role in glucose homeostasis.", "general_function": "Unfolded protein binding", "gene_names": ["ERO1B"], "name": "ERO1-like protein beta", "drug_actions": []}, "Q8VUT0": {"general_function": "Metal ion binding", "gene_names": [], "name": "Quinohemoprotein amine dehydrogenase 60 kDa subunit", "drug_actions": []}, "Q72JJ3": {"general_function": "Flavin adenine dinucleotide binding", "gene_names": [], "name": "Putative acyl-CoA dehydrogenase", "drug_actions": []}, "Q9BVG9": {"specific_function": "Catalyzes a base-exchange reaction in which the polar head group of phosphatidylethanolamine (PE) or phosphatidylcholine (PC) is replaced by L-serine. PTDSS2 is specific for phosphatatidylethanolamine and does not act on phosphatidylcholine.", "general_function": "Cdp-diacylglycerol-serine o-phosphatidyltransferase activity", "gene_names": ["PTDSS2"], "name": "Phosphatidylserine synthase 2", "drug_actions": []}, "P0A2W7": {"specific_function": "Transfers the 4'-phosphopantetheine moiety from coenzyme A to a Ser of acyl-carrier-protein.", "general_function": "Magnesium ion binding", "gene_names": ["acpS"], "name": "Holo-[acyl-carrier-protein] synthase", "drug_actions": []}, "O94925": {"specific_function": "Catalyzes the first reaction in the primary pathway for the renal catabolism of glutamine. Plays a role in maintaining acid-base homeostasis. Regulates the levels of the neurotransmitter glutamate in the brain. Isoform 2 lacks catalytic activity.", "general_function": "Glutaminase activity", "gene_names": ["GLS"], "name": "Glutaminase kidney isoform, mitochondrial", "drug_actions": []}, "Q9WYS2": {"general_function": "Oxidoreductase activity", "gene_names": [], "name": "Oxidoreductase, short chain dehydrogenase/reductase family", "drug_actions": []}, "P01730": {"specific_function": "Accessory protein for MHC class-II antigen/T-cell receptor interaction. May regulate T-cell activation. Induces the aggregation of lipid rafts.(Microbial infection) Acts as a receptor for human immunodeficiency virus-1 (PubMed:2214026, PubMed:16331979, PubMed:9641677). Down-regulated by HIV-1 Vpu (PubMed:17346169). Acts as a receptor for Human Herpes virus 7/HHV-7 (PubMed:7909607).", "general_function": "Zinc ion binding", "gene_names": ["CD4"], "name": "T-cell surface glycoprotein CD4", "drug_actions": []}, "Q57366": {"specific_function": "Catalyzes the reduction of dimethyl sulfoxide (DMSO) and trimethylamine N-oxide (TMAO) to dimethyl sulfide (DMS) and trimethylamine, respectively. The terminal DMSO reductase can also use various sulfoxides and N-oxide compounds as terminal electron acceptor in addition to DMSO and TMAO.", "general_function": "Trimethylamine-n-oxide reductase (cytochrome c) activity", "gene_names": ["dmsA"], "name": "Dimethyl sulfoxide/trimethylamine N-oxide reductase", "drug_actions": []}, "Q9X0N8": {"specific_function": "Hydrolysis of 6-phosphogluconolactone to 6-phosphogluconate.", "general_function": "6-phosphogluconolactonase activity", "gene_names": ["pgl"], "name": "6-phosphogluconolactonase", "drug_actions": []}, "P68344": {"specific_function": "Responsible for EBV binding to the CR2 receptor on human B-cells.", "gene_names": [], "name": "Envelope glycoprotein GP340", "drug_actions": [{"action": "INTERCALATION", "target": "P68344", "drug": "DB00632"}]}, "O43741": {"specific_function": "Non-catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin. Beta non-catalytic subunit acts as a scaffold on which the AMPK complex assembles, via its C-terminus that bridges alpha (PRKAA1 or PRKAA2) and gamma subunits (PRKAG1, PRKAG2 or PRKAG3).", "name": "5'-AMP-activated protein kinase subunit beta-2", "drug_actions": [{"action": "ACTIVATOR", "target": "O43741", "drug": "DB00131"}, {"action": "ACTIVATOR", "target": "O43741", "drug": "DB00945"}], "general_function": "Identical protein binding", "in_complexes": ["5'-AMP-activated protein kinase"], "gene_names": ["PRKAB2"]}, "P02931": {"specific_function": "Forms pores that allow passive diffusion of small molecules across the outer membrane. It is also a receptor for the bacteriophage T2.", "general_function": "Porin activity", "gene_names": ["ompF"], "name": "Outer membrane protein F", "drug_actions": []}, "Q15800": {"general_function": "Iron ion binding", "gene_names": ["MSMO1"], "name": "Methylsterol monooxygenase 1", "drug_actions": []}, "P61432": {"specific_function": "Cell wall formation.", "general_function": "Udp-n-acetylmuramate dehydrogenase activity", "gene_names": ["murB"], "name": "UDP-N-acetylenolpyruvoylglucosamine reductase", "drug_actions": []}, "Q9ZIV5": {"general_function": "Carbon-nitrogen ligase activity, with glutamine as amido-n-donor", "gene_names": [], "name": "Malonamidase E2", "drug_actions": []}, "P10147": {"specific_function": "Monokine with inflammatory and chemokinetic properties. Binds to CCR1, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-alpha induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV).", "general_function": "Protein kinase activity", "gene_names": ["CCL3"], "name": "C-C motif chemokine 3", "drug_actions": []}, "P04798": {"specific_function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.", "general_function": "Vitamin d 24-hydroxylase activity", "gene_names": ["CYP1A1"], "name": "Cytochrome P450 1A1", "drug_actions": []}, "P10145": {"specific_function": "IL-8 is a chemotactic factor that attracts neutrophils, basophils, and T-cells, but not monocytes. It is also involved in neutrophil activation. It is released from several cell types in response to an inflammatory stimulus. IL-8(6-77) has a 5-10-fold higher activity on neutrophil activation, IL-8(5-77) has increased activity on neutrophil activation and IL-8(7-77) has a higher affinity to receptors CXCR1 and CXCR2 as compared to IL-8(1-77), respectively.", "general_function": "Interleukin-8 receptor binding", "gene_names": ["CXCL8"], "name": "Interleukin-8", "drug_actions": [{"action": "ANTAGONIST", "target": "P10145", "drug": "DB05855"}]}, "Q9U8D3": {"specific_function": "Plays an important role in the salvage pathway for purine nucleotide biosynthesis. Catalyzes the first committed step in the biosynthesis of AMP from IMP (By similarity).", "general_function": "Metal ion binding", "gene_names": ["Adss"], "name": "Adenylosuccinate synthetase", "drug_actions": [{"action": "INHIBITOR", "target": "Q9U8D3", "drug": "DB02109"}]}, "P22234": {"general_function": "Phosphoribosylaminoimidazolesuccinocarboxamide synthase activity", "gene_names": ["PAICS"], "name": "Multifunctional protein ADE2", "drug_actions": []}, "P04792": {"specific_function": "Involved in stress resistance and actin organization.", "general_function": "Ubiquitin binding", "gene_names": ["HSPB1"], "name": "Heat shock protein beta-1", "drug_actions": []}, "P30838": {"specific_function": "ALDHs play a major role in the detoxification of alcohol-derived acetaldehyde. They are involved in the metabolism of corticosteroids, biogenic amines, neurotransmitters, and lipid peroxidation. This protein preferentially oxidizes aromatic aldehyde substrates. It may play a role in the oxidation of toxic aldehydes.", "general_function": "Benzaldehyde dehydrogenase (nad+) activity", "gene_names": ["ALDH3A1"], "name": "Aldehyde dehydrogenase, dimeric NADP-preferring", "drug_actions": []}, "P26439": {"specific_function": "3-beta-HSD is a bifunctional enzyme, that catalyzes the oxidative conversion of Delta(5)-ene-3-beta-hydroxy steroid, and the oxidative conversion of ketosteroids. The 3-beta-HSD enzymatic system plays a crucial role in the biosynthesis of all classes of hormonal steroids.", "general_function": "Steroid delta-isomerase activity", "gene_names": ["HSD3B2"], "name": "3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2", "drug_actions": [{"action": "INHIBITOR", "target": "P26439", "drug": "DB01108"}]}, "P0A3M5": {"general_function": "Penicillin binding", "gene_names": ["penA"], "name": "Penicillin-binding protein 2B", "drug_actions": [{"action": "INHIBITOR", "target": "P0A3M5", "drug": "DB01147"}, {"action": "INHIBITOR", "target": "P0A3M5", "drug": "DB01150"}]}, "Q9FD87": {"general_function": "Hydroxymethylglutaryl-coa synthase activity", "gene_names": ["mvaS"], "name": "HMG-CoA synthase", "drug_actions": []}, "P04156": {"specific_function": "Its primary physiological function is unclear. Has cytoprotective activity against internal or environmental stresses. May play a role in neuronal development and synaptic plasticity. May be required for neuronal myelin sheath maintenance. May play a role in iron uptake and iron homeostasis. Soluble oligomers are toxic to cultured neuroblastoma cells and induce apoptosis (in vitro) (PubMed:12732622, PubMed:19936054, PubMed:20564047). Association with GPC1 (via its heparan sulfate chains) targets PRNP to lipid rafts. Also provides Cu(2+) or ZN(2+) for the ascorbate-mediated GPC1 deaminase degradation of its heparan sulfate side chains (By similarity).", "general_function": "Tubulin binding", "gene_names": ["PRNP"], "name": "Major prion protein", "drug_actions": [{"action": "INHIBITOR", "target": "P04156", "drug": "DB00759"}]}, "P0A3M6": {"general_function": "Penicillin binding", "gene_names": ["penA"], "name": "Penicillin-binding protein 2B", "drug_actions": [{"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB00319"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB00415"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB00456"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB00485"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB00493"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB00567"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB00607"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB00713"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB00739"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB01066"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB01140"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB01163"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB01212"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB01603"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB03313"}, {"action": "INHIBITOR", "target": "P0A3M6", "drug": "DB08795"}]}, "P22460": {"specific_function": "Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes. Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane. Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA5, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel (PubMed:12130714). Channel properties are modulated by cytoplasmic beta subunits that regulate the subcellular location of the alpha subunits and promote rapid inactivation (PubMed:12130714). Homotetrameric channels display rapid activation and slow inactivation (PubMed:8505626, PubMed:12130714). May play a role in regulating the secretion of insulin in normal pancreatic islets. Isoform 2 exhibits a voltage-dependent recovery from inactivation and an excessive cumulative inactivation (PubMed:11524461).", "general_function": "Voltage-gated potassium channel activity involved in sa node cell action potential repolarization", "gene_names": ["KCNA5"], "name": "Potassium voltage-gated channel subfamily A member 5", "drug_actions": [{"action": "ANTAGONIST", "target": "P22460", "drug": "DB06637"}]}, "Q47NK3": {"gene_names": [], "name": "Proteinase inhibitor I4, serpin", "drug_actions": []}, "P15474": {"specific_function": "Catalyzes a trans-dehydration via an enolate intermediate.", "general_function": "3-dehydroquinate dehydratase activity", "gene_names": ["aroQ"], "name": "3-dehydroquinate dehydratase", "drug_actions": []}, "P30837": {"specific_function": "ALDHs play a major role in the detoxification of alcohol-derived acetaldehyde. They are involved in the metabolism of corticosteroids, biogenic amines, neurotransmitters, and lipid peroxidation.", "general_function": "Aldehyde dehydrogenase (nad) activity", "gene_names": ["ALDH1B1"], "name": "Aldehyde dehydrogenase X, mitochondrial", "drug_actions": []}, "Q8NEB9": {"specific_function": "Catalytic subunit of the PI3K complex that mediates formation of phosphatidylinositol 3-phosphate; different complex forms are believed to play a role in multiple membrane trafficking pathways: PI3KC3-C1 is involved in initiation of autophagosomes and PI3KC3-C2 in maturation of autophagosomes and endocytosis. Involved in regulation of degradative endocytic trafficking and required for the abcission step in cytokinesis, probably in the context of PI3KC3-C2 (PubMed:20643123, PubMed:20208530). Involved in the transport of lysosomal enzyme precursors to lysosomes. Required for transport from early to late endosomes (By similarity).", "general_function": "Protein kinase activity", "gene_names": ["PIK3C3"], "name": "Phosphatidylinositol 3-kinase catalytic subunit type 3", "drug_actions": []}, "P28161": {"specific_function": "Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.", "general_function": "Receptor binding", "gene_names": ["GSTM2"], "name": "Glutathione S-transferase Mu 2", "drug_actions": []}, "Q5L1E2": {"specific_function": "Catalyzes the enolization of 2,3-diketo-5-methylthiopentyl-1-phosphate (DK-MTP-1-P) into 2-hydroxy-3-keto-5-methylthiopentenyl-1-phosphate (HK-MTPenyl-1-P).", "general_function": "Ribulose-bisphosphate carboxylase activity", "gene_names": ["mtnW"], "name": "2,3-diketo-5-methylthiopentyl-1-phosphate enolase", "drug_actions": []}, "Q5RT80": {"general_function": "Porin activity", "gene_names": ["porB"], "name": "Outer membrane protein II", "drug_actions": []}, "P42357": {"general_function": "Histidine ammonia-lyase activity", "gene_names": ["HAL"], "name": "Histidine ammonia-lyase", "drug_actions": []}, "P00136": {"specific_function": "Participates in sulfate respiration coupled with phosphorylation by transferring electrons from the enzyme dehydrogenase to ferredoxin.", "general_function": "Metal ion binding", "gene_names": [], "name": "Cytochrome c3, 13 kDa", "drug_actions": []}, "P00137": {"specific_function": "Participates in sulfate respiration coupled with phosphorylation by transferring electrons from the enzyme dehydrogenase to ferredoxin.", "general_function": "Metal ion binding", "gene_names": ["cyd"], "name": "Cytochrome c3", "drug_actions": []}, "P00132": {"specific_function": "Participates in sulfate respiration coupled with phosphorylation by transferring electrons from the enzyme dehydrogenase to ferredoxin.", "general_function": "Metal ion binding", "gene_names": [], "name": "Cytochrome c3", "drug_actions": []}, "P19404": {"specific_function": "Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFV2"], "name": "NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial", "drug_actions": []}, "Q46079": {"specific_function": "Cleaves the glycosaminoglycan, dermatan sulfate.", "general_function": "Chondroitin b lyase activity", "gene_names": ["cslB"], "name": "Chondroitinase-B", "drug_actions": []}, "P20813": {"specific_function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.", "general_function": "Steroid hydroxylase activity", "gene_names": ["CYP2B6"], "name": "Cytochrome P450 2B6", "drug_actions": []}, "P00138": {"specific_function": "Cytochrome c' is the most widely occurring bacterial c-type cytochrome. Cytochromes c' are high-spin proteins and the heme has no sixth ligand. Their exact function is not known.", "general_function": "Iron ion binding", "gene_names": [], "name": "Cytochrome c'", "drug_actions": []}, "Q7SIB1": {"specific_function": "Catalyzes the addition and repair of the essential 3'-terminal CCA sequence in tRNAs without using a nucleic acid template. Adds these three nucleotides in the order of C, C, and A to the tRNA nucleotide-73, using CTP and ATP as substrates and producing inorganic pyrophosphate.", "general_function": "Trna cytidylyltransferase activity", "gene_names": ["cca"], "name": "CCA-adding enzyme", "drug_actions": []}, "P63027": {"specific_function": "Involved in the targeting and/or fusion of transport vesicles to their target membrane. Modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1.", "general_function": "Syntaxin-1 binding", "gene_names": ["VAMP2"], "name": "Vesicle-associated membrane protein 2", "drug_actions": [{"action": "BINDER", "target": "P63027", "drug": "DB00042"}]}, "P14625": {"specific_function": "Molecular chaperone that functions in the processing and transport of secreted proteins. When associated with CNPY3, required for proper folding of Toll-like receptors (By similarity). Functions in endoplasmic reticulum associated degradation (ERAD). Has ATPase activity.", "general_function": "Virion binding", "gene_names": ["HSP90B1"], "name": "Endoplasmin", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "P14625", "drug": "DB00615"}]}, "B8DD61": {"general_function": "Involved in serine-type D-Ala-D-Ala carboxypeptidase activity", "gene_names": ["LMHCC_2773"], "name": "D-alanyl-D-alanine carboxypeptidase DacA (DD-peptidase) (DD-carboxypeptidase) (CPase) (Penicillin-binding protein5) (PBP-5)", "drug_actions": [{"action": "INHIBITOR", "target": "B8DD61", "drug": "DB00485"}]}, "O05783": {"specific_function": "May serve as electron transfer protein and supply electrons to P450 systems", "general_function": "Amino acid transport and metabolism", "gene_names": ["fprA"], "name": "NADPH-ferredoxin reductase FprA", "drug_actions": []}, "P14621": {"specific_function": "Its physiological role is not yet clear.", "general_function": "Acylphosphatase activity", "gene_names": ["ACYP2"], "name": "Acylphosphatase-2", "drug_actions": []}, "Q05603": {"specific_function": "Catalyzes the synthesis of alpha-ribazole-5'-phosphate from nicotinate mononucleotide (NAMN) and 5,6-dimethylbenzimidazole (DMB).", "general_function": "Nicotinate-nucleotide-dimethylbenzimidazole phosphoribosyltransferase activity", "gene_names": ["cobT"], "name": "Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase", "drug_actions": []}, "Q8NET8": {"specific_function": "Putative receptor-activated non-selective calcium permeant cation channel. It is activated by innocuous (warm) temperatures and shows an increased response at noxious temperatures greater than 39 degrees Celsius. Activation exhibits an outward rectification. May associate with TRPV1 and may modulate its activity. Is a negative regulator of hair growth and cycling: TRPV3-coupled signaling suppresses keratinocyte proliferation in hair follicles and induces apoptosis and premature hair follicle regression (catagen).", "general_function": "Calcium channel activity", "gene_names": ["TRPV3"], "name": "Transient receptor potential cation channel subfamily V member 3", "drug_actions": [{"action": "INDUCER", "target": "Q8NET8", "drug": "DB00825"}]}, "O87949": {"specific_function": "Involved in the biogenesis of TorA. Acts on TorA before the insertion of the molybdenum cofactor and, as a result, probably favors a conformation of the apoenzyme that is competent for acquiring the cofactor.", "gene_names": ["torD"], "name": "Chaperone protein TorD", "drug_actions": []}, "Q02880": {"specific_function": "Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks.", "name": "DNA topoisomerase 2-beta", "drug_actions": [{"action": "INHIBITOR", "target": "Q02880", "drug": "DB00694"}, {"action": "INHIBITOR", "target": "Q02880", "drug": "DB00773"}], "general_function": "Protein kinase c binding", "in_complexes": ["DNA topoisomerase 2"], "gene_names": ["TOP2B"]}, "P53554": {"specific_function": "Catalyzes the C-C bond cleavage of fatty acid linked to acyl carrier protein (ACP) to generate pimelic acid for biotin biosynthesis. It has high affinity for long-chain fatty acids with the greatest affinity for myristic acid.", "general_function": "Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen", "gene_names": ["bioI"], "name": "Biotin biosynthesis cytochrome P450", "drug_actions": []}, "Q5SHQ5": {"specific_function": "With S4 and S12 plays an important role in translational accuracy.Located at the back of the 30S subunit body where it stabilizes the conformation of the head with respect to the body. Binds mRNA in the 70S ribosome, positioning it for translation.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsE"], "name": "30S ribosomal protein S5", "drug_actions": []}, "P23434": {"specific_function": "The glycine cleavage system catalyzes the degradation of glycine. The H protein (GCSH) shuttles the methylamine group of glycine from the P protein (GLDC) to the T protein (GCST).", "general_function": "Aminomethyltransferase activity", "gene_names": ["GCSH"], "name": "Glycine cleavage system H protein, mitochondrial", "drug_actions": []}, "P30901": {"general_function": "Nad binding", "gene_names": [], "name": "D-lactate dehydrogenase", "drug_actions": []}, "A5W4F4": {"gene_names": [], "name": "Membrane protein involved in aromatic hydrocarbon degradation", "drug_actions": []}, "O75330": {"specific_function": "Involved in cell motility. When hyaluronan binds to HMMR, the phosphorylation of a number of proteins, including PTK2/FAK1 occurs. May also be involved in cellular transformation and metastasis formation, and in regulating extracellular-regulated kinase (ERK) activity.", "general_function": "Hyaluronic acid binding", "gene_names": ["HMMR"], "name": "Hyaluronan mediated motility receptor", "drug_actions": []}, "Q81EW9": {"general_function": "Oxidoreductase activity", "gene_names": [], "name": "Nitroreductase family protein", "drug_actions": []}, "Q6NUM9": {"specific_function": "Retinol saturase carrying out the saturation of the 13-14 double bond of all-trans-retinol to produce all-trans-13,14-dihydroretinol. Has activity toward all-trans-retinol as substrate. Does not use all-trans-retinoic acid nor 9-cis, 11-cis or 13-cis-retinol isomers as substrates. May play a role in the metabolism of vitamin A (By similarity).", "general_function": "Oxidoreductase activity", "gene_names": ["RETSAT"], "name": "All-trans-retinol 13,14-reductase", "drug_actions": []}, "P49190": {"specific_function": "This is a specific receptor for parathyroid hormone. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. PTH2R may be responsible for PTH effects in a number of physiological systems. It may play a significant role in pancreatic function. PTH2R presence in neurons indicates that it may function as a neurotransmitter receptor (By similarity).", "general_function": "Parathyroid hormone receptor activity", "gene_names": ["PTH2R"], "name": "Parathyroid hormone 2 receptor", "drug_actions": [{"action": "ACTIVATOR", "target": "P49190", "drug": "DB05829"}]}, "Q5JPH6": {"specific_function": "Catalyzes the attachment of glutamate to tRNA(Glu) in a two-step reaction: glutamate is first activated by ATP to form Glu-AMP and then transferred to the acceptor end of tRNA(Glu).", "general_function": "Trna binding", "gene_names": ["EARS2"], "name": "Probable glutamate--tRNA ligase, mitochondrial", "drug_actions": []}, "P10092": {"specific_function": "CGRP induces vasodilation. It dilates a variety of vessels including the coronary, cerebral and systemic vasculature. Its abundance in the CNS also points toward a neurotransmitter or neuromodulator role.", "general_function": "Neuropeptide hormone activity", "gene_names": ["CALCB"], "name": "Calcitonin gene-related peptide 2", "drug_actions": []}, "P08306": {"specific_function": "Subunits I and II form the functional core of the enzyme complex. Electrons originating in cytochrome c are transferred via heme a and Cu(A) to the binuclear center formed by heme a3 and Cu(B).", "general_function": "Cytochrome-c oxidase activity", "gene_names": ["ctaC"], "name": "Cytochrome c oxidase subunit 2", "drug_actions": []}, "P27505": {"specific_function": "Ring cyclization and eight-electron oxidation of 3a-(2-amino-2-carboxyethyl)-4,5-dioxo-4,5,6,7,8,9-hexahydroquinoline-7,9-dicarboxylic-acid to PQQ.", "general_function": "Pyrroloquinoline-quinone synthase activity", "gene_names": ["pqqC"], "name": "Pyrroloquinoline-quinone synthase", "drug_actions": []}, "P54687": {"specific_function": "Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine.", "general_function": "L-valine transaminase activity", "gene_names": ["BCAT1"], "name": "Branched-chain-amino-acid aminotransferase, cytosolic", "drug_actions": [{"action": "COFACTOR", "target": "P54687", "drug": "DB00114"}]}, "P0A433": {"specific_function": "Has an unusual substrate specificity for synthetic organophosphate triesters and phosphorofluoridates. All of the phosphate triesters found to be substrates are synthetic compounds. The identity of any naturally occurring substrate for the enzyme is unknown. Has no detectable activity with phosphate monoesters or diesters and no activity as an esterase or protease. It catalyzes the hydrolysis of the insecticide paraoxon at a rate approaching the diffusion limit and thus appears to be optimally evolved for utilizing this synthetic substrate (By similarity).", "general_function": "Zinc ion binding", "gene_names": ["opd"], "name": "Parathion hydrolase", "drug_actions": []}, "Q6N063": {"general_function": "Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen", "gene_names": ["OGFOD2"], "name": "2-oxoglutarate and iron-dependent oxygenase domain-containing protein 2", "drug_actions": []}, "Q5MYR6": {"general_function": "Oxidoreductase activity", "gene_names": ["prx"], "name": "1-cys peroxiredoxin", "drug_actions": []}, "P21802": {"specific_function": "Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.", "general_function": "Protein tyrosine kinase activity", "gene_names": ["FGFR2"], "name": "Fibroblast growth factor receptor 2", "drug_actions": [{"action": "BINDER", "target": "P21802", "drug": "DB00039"}, {"action": "ANTAGONIST", "target": "P21802", "drug": "DB01041"}, {"action": "INHIBITOR", "target": "P21802", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P21802", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P21802", "drug": "DB09078"}, {"action": "INHIBITOR", "target": "P21802", "drug": "DB09079"}]}, "O95573": {"specific_function": "Acyl-CoA synthetases (ACSL) activates long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. ACSL3 mediates hepatic lipogenesis (By similarity). Preferentially uses myristate, laurate, arachidonate and eicosapentaenoate as substrates (By similarity). Has mainly an anabolic role in energy metabolism. Required for the incorporation of fatty acids into phosphatidylcholine, the major phospholipid located on the surface of VLDL (very low density lipoproteins).", "general_function": "Protein kinase binding", "gene_names": ["ACSL3"], "name": "Long-chain-fatty-acid--CoA ligase 3", "drug_actions": [{"action": "INDUCER", "target": "O95573", "drug": "DB00159"}]}, "P00282": {"specific_function": "Transfers electrons from cytochrome c551 to cytochrome oxidase.", "general_function": "Zinc ion binding", "gene_names": ["azu"], "name": "Azurin", "drug_actions": []}, "Q14894": {"specific_function": "Specifically catalyzes the reduction of imine bonds in brain substrates that may include cystathionine ketimine (CysK) and lanthionine ketimine (LK). Binds thyroid hormone which is a strong reversible inhibitor. Presumably involved in the regulation of the free intracellular concentration of triiodothyronine and access to its nuclear receptors.", "general_function": "Transcription corepressor activity", "gene_names": ["CRYM"], "name": "Ketimine reductase mu-crystallin", "drug_actions": []}, "Q8P9V9": {"general_function": "Oxidoreductase activity", "gene_names": [], "name": "Bacterioferritin comigratory protein", "drug_actions": []}, "P07947": {"specific_function": "Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation. Stimulation by receptor tyrosine kinases (RTKs) including EGRF, PDGFR, CSF1R and FGFR leads to recruitment of YES1 to the phosphorylated receptor, and activation and phosphorylation of downstream substrates. Upon EGFR activation, promotes the phosphorylation of PARD3 to favor epithelial tight junction assembly. Participates in the phosphorylation of specific junctional components such as CTNND1 by stimulating the FYN and FER tyrosine kinases at cell-cell contacts. Upon T-cell stimulation by CXCL12, phosphorylates collapsin response mediator protein 2/DPYSL2 and induces T-cell migration. Participates in CD95L/FASLG signaling pathway and mediates AKT-mediated cell migration. Plays a role in cell cycle progression by phosphorylating the cyclin-dependent kinase 4/CDK4 thus regulating the G1 phase. Also involved in G2/M progression and cytokinesis.", "general_function": "Receptor binding", "gene_names": ["YES1"], "name": "Tyrosine-protein kinase Yes", "drug_actions": [{"action": "INHIBITOR", "target": "P07947", "drug": "DB01254"}]}, "P07944": {"general_function": "Penicillin binding", "gene_names": ["pbp"], "name": "Beta-lactam-inducible penicillin-binding protein", "drug_actions": []}, "O06594": {"specific_function": "Nicotinate D-ribonucleotide + diphosphate + CO(2) = pyridine-2,3-dicarboxylate + 5-phospho-alpha-D-ribose 1- diphosphate", "general_function": "Coenzyme transport and metabolism", "gene_names": ["nadC"], "name": "Nicotinate-nucleotide pyrophosphorylase [carboxylating]", "drug_actions": []}, "Q53728": {"general_function": "Phospholipase d activity", "gene_names": [], "name": "Phospholipase D", "drug_actions": []}, "Q9UBT6": {"specific_function": "DNA polymerase specifically involved in DNA repair. Plays an important role in translesion synthesis, where the normal high-fidelity DNA polymerases cannot proceed and DNA synthesis stalls. Depending on the context, it inserts the correct base, but causes frequent base transitions, transversions and frameshifts. Lacks 3'-5' proofreading exonuclease activity. Forms a Schiff base with 5'-deoxyribose phosphate at abasic sites, but does not have lyase activity.", "general_function": "Metal ion binding", "gene_names": ["POLK"], "name": "DNA polymerase kappa", "drug_actions": []}, "Q9BQB6": {"specific_function": "Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development.", "general_function": "Vitamin-k-epoxide reductase (warfarin-sensitive) activity", "gene_names": ["VKORC1"], "name": "Vitamin K epoxide reductase complex subunit 1", "drug_actions": [{"action": "COFACTOR", "target": "Q9BQB6", "drug": "DB00170"}, {"action": "INHIBITOR", "target": "Q9BQB6", "drug": "DB00266"}, {"action": "INHIBITOR", "target": "Q9BQB6", "drug": "DB00498"}, {"action": "INHIBITOR", "target": "Q9BQB6", "drug": "DB00682"}, {"action": "INHIBITOR", "target": "Q9BQB6", "drug": "DB00946"}, {"action": "INHIBITOR", "target": "Q9BQB6", "drug": "DB01418"}]}, "P16070": {"specific_function": "Receptor for hyaluronic acid (HA). Mediates cell-cell and cell-matrix interactions through its affinity for HA, and possibly also through its affinity for other ligands such as osteopontin, collagens, and matrix metalloproteinases (MMPs). Adhesion with HA plays an important role in cell migration, tumor growth and progression. In cancer cells, may play an important role in invadopodia formation. Also involved in lymphocyte activation, recirculation and homing, and in hematopoiesis. Altered expression or dysfunction causes numerous pathogenic phenotypes. Great protein heterogeneity due to numerous alternative splicing and post-translational modification events. Receptor for LGALS9; the interaction enhances binding of SMAD3 to the FOXP3 promoter, leading to up-regulation of FOXP3 expression and increased induced regulatory T (iTreg) cell stability and suppressive function (By similarity).", "general_function": "Hyalurononglucosaminidase activity", "gene_names": ["CD44"], "name": "CD44 antigen", "drug_actions": []}, "P09848": {"specific_function": "LPH splits lactose in the small intestine.", "general_function": "Transferase activity", "gene_names": ["LCT"], "name": "Lactase-phlorizin hydrolase", "drug_actions": []}, "P07948": {"specific_function": "Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, responses to growth factors and cytokines, integrin signaling, but also responses to DNA damage and genotoxic agents. Functions primarily as negative regulator, but can also function as activator, depending on the context. Required for the initiation of the B-cell response, but also for its down-regulation and termination. Plays an important role in the regulation of B-cell differentiation, proliferation, survival and apoptosis, and is important for immune self-tolerance. Acts downstream of several immune receptors, including the B-cell receptor, CD79A, CD79B, CD5, CD19, CD22, FCER1, FCGR2, FCGR1A, TLR2 and TLR4. Plays a role in the inflammatory response to bacterial lipopolysaccharide. Mediates the responses to cytokines and growth factors in hematopoietic progenitors, platelets, erythrocytes, and in mature myeloid cells, such as dendritic cells, neutrophils and eosinophils. Acts downstream of EPOR, KIT, MPL, the chemokine receptor CXCR4, as well as the receptors for IL3, IL5 and CSF2. Plays an important role in integrin signaling. Regulates cell proliferation, survival, differentiation, migration, adhesion, degranulation, and cytokine release. Down-regulates signaling pathways by phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIM), that then serve as binding sites for phosphatases, such as PTPN6/SHP-1, PTPN11/SHP-2 and INPP5D/SHIP-1, that modulate signaling by dephosphorylation of kinases and their substrates. Phosphorylates LIME1 in response to CD22 activation. Phosphorylates BTK, CBL, CD5, CD19, CD72, CD79A, CD79B, CSF2RB, DOK1, HCLS1, LILRB3/PIR-B, MS4A2/FCER1B, PTK2B/PYK2, SYK and TEC. Promotes phosphorylation of SIRPA, PTPN6/SHP-1, PTPN11/SHP-2 and INPP5D/SHIP-1. Mediates phosphorylation of the BCR-ABL fusion protein. Required for rapid phosphorylation of FER in response to FCER1 activation. Mediates KIT phosphorylation. Acts as an effector of EPOR (erythropoietin receptor) in controlling KIT expression and may play a role in erythroid differentiation during the switch between proliferation and maturation. Depending on the context, activates or inhibits several signaling cascades. Regulates phosphatidylinositol 3-kinase activity and AKT1 activation. Regulates activation of the MAP kinase signaling cascade, including activation of MAP2K1/MEK1, MAPK1/ERK2, MAPK3/ERK1, MAPK8/JNK1 and MAPK9/JNK2. Mediates activation of STAT5A and/or STAT5B. Phosphorylates LPXN on 'Tyr-72'. Kinase activity facilitates TLR4-TLR6 heterodimerization and signal initiation.", "general_function": "Receptor signaling protein tyrosine kinase activity", "gene_names": ["LYN"], "name": "Tyrosine-protein kinase Lyn", "drug_actions": [{"action": "INHIBITOR", "target": "P07948", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P07948", "drug": "DB09079"}]}, "P07949": {"specific_function": "Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration.", "general_function": "Transmembrane receptor protein tyrosine kinase activity", "gene_names": ["RET"], "name": "Proto-oncogene tyrosine-protein kinase receptor Ret", "drug_actions": [{"action": "INHIBITOR", "target": "P07949", "drug": "DB00398"}, {"action": "ANTAGONIST", "target": "P07949", "drug": "DB08875"}, {"action": "INHIBITOR", "target": "P07949", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P07949", "drug": "DB08901"}]}, "P22055": {"specific_function": "Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host cell receptor to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP2: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP3: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP4: Lies on the inner surface of the capsid shell. After binding to the host receptor, the capsid undergoes conformational changes. Capsid protein VP4 is released, Capsid protein VP1 N-terminus is externalized, and together, they shape a pore in the host membrane through which the viral genome is translocated into the host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP0: Component of immature procapsids, which is cleaved into capsid proteins VP4 and VP2 after maturation. Allows the capsid to remain inactive before the maturation step (By similarity).Protein 2A: Cysteine protease that cleaves viral polyprotein and specific host proteins. It is responsible for the cleavage between the P1 and P2 regions, first cleavage occurring in the polyprotein. Cleaves also the host translation initiation factor EIF4G1, in order to shut down the capped cellular mRNA translation. Inhibits the host nucleus-cytoplasm protein and RNA trafficking by cleaving host members of the nuclear pores (By similarity).Protein 2B: Plays an essential role in the virus replication cycle by acting as a viroporin. Creates a pore in the host reticulum endoplasmic and as a consequence releases Ca2+ in the cytoplasm of infected cell. In turn, high levels of cyctoplasmic calcium may trigger membrane trafficking and transport of viral ER-associated proteins to viroplasms, sites of viral genome replication (By similarity).Protein 2C: Induces and associates with structural rearrangements of intracellular membranes. Displays RNA-binding, nucleotide binding and NTPase activities. May play a role in virion morphogenesis and viral RNA encapsidation by interacting with the capsid protein VP3 (By similarity).Protein 3AB: Localizes the viral replication complex to the surface of membranous vesicles. Together with protein 3CD binds the Cis-Active RNA Element (CRE) which is involved in RNA synthesis initiation. Acts as a cofactor to stimulate the activity of 3D polymerase, maybe through a nucleid acid chaperone activity (By similarity).Protein 3A: Localizes the viral replication complex to the surface of membranous vesicles. It inhibits host cell endoplasmic reticulum-to-Golgi apparatus transport and causes the dissassembly of the Golgi complex, possibly through GBF1 interaction. This would result in depletion of MHC, trail receptors and IFN receptors at the host cell surface (By similarity).Viral protein genome-linked: acts as a primer for viral RNA replication and remains covalently bound to viral genomic RNA. VPg is uridylylated prior to priming replication into VPg-pUpU. The oriI viral genomic sequence may act as a template for this. The VPg-pUpU is then used as primer on the genomic RNA poly(A) by the RNA-dependent RNA polymerase to replicate the viral genome. VPg may be removed in the cytoplasm by an unknown enzyme termed \"unlinkase\". VPg is not cleaved off virion genomes because replicated genomic RNA are encapsidated at the site of replication (By similarity).Protein 3CD: Is involved in the viral replication complex and viral polypeptide maturation. It exhibits protease activity with a specificity and catalytic efficiency that is different from protease 3C. Protein 3CD lacks polymerase activity. The 3C domain in the context of protein 3CD may have an RNA binding activity (By similarity).Protease 3C: cleaves host DDX58/RIG-I and thus contributes to the inhibition of type I interferon production. Cleaves also host PABPC1 (By similarity).RNA-directed RNA polymerase: Replicates the viral genomic RNA on the surface of intracellular membranes. May form linear arrays of subunits that propagate along a strong head-to-tail interaction called interface-I. Covalently attaches UMP to a tyrosine of VPg, which is used to prime RNA synthesis. The positive stranded RNA genome is first replicated at virus induced membranous vesicles, creating a dsRNA genomic replication form. This dsRNA is then used as template to synthesize positive stranded RNA genomes. ss(+)RNA genomes are either translated, replicated or encapsidated (By similarity).", "general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P49448": {"specific_function": "Important for recycling the chief excitatory neurotransmitter, glutamate, during neurotransmission.", "general_function": "Leucine binding", "gene_names": ["GLUD2"], "name": "Glutamate dehydrogenase 2, mitochondrial", "drug_actions": []}, "Q05513": {"specific_function": "Calcium- and diacylglycerol-independent serine/threonine-protein kinase that functions in phosphatidylinositol 3-kinase (PI3K) pathway and mitogen-activated protein (MAP) kinase cascade, and is involved in NF-kappa-B activation, mitogenic signaling, cell proliferation, cell polarity, inflammatory response and maintenance of long-term potentiation (LTP). Upon lipopolysaccharide (LPS) treatment in macrophages, or following mitogenic stimuli, functions downstream of PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signaling cascade independently of RAF1 activation. Required for insulin-dependent activation of AKT3, but may function as an adapter rather than a direct activator. Upon insulin treatment may act as a downstream effector of PI3K and contribute to the activation of translocation of the glucose transporter SLC2A4/GLUT4 and subsequent glucose transport in adipocytes. In EGF-induced cells, binds and activates MAP2K5/MEK5-MAPK7/ERK5 independently of its kinase activity and can activate JUN promoter through MEF2C. Through binding with SQSTM1/p62, functions in interleukin-1 signaling and activation of NF-kappa-B with the specific adapters RIPK1 and TRAF6. Participates in TNF-dependent transactivation of NF-kappa-B by phosphorylating and activating IKBKB kinase, which in turn leads to the degradation of NF-kappa-B inhibitors. In migrating astrocytes, forms a cytoplasmic complex with PARD6A and is recruited by CDC42 to function in the establishment of cell polarity along with the microtubule motor and dynein. In association with FEZ1, stimulates neuronal differentiation in PC12 cells. In the inflammatory response, is required for the T-helper 2 (Th2) differentiation process, including interleukin production, efficient activation of JAK1 and the subsequent phosphorylation and nuclear translocation of STAT6. May be involved in development of allergic airway inflammation (asthma), a process dependent on Th2 immune response. In the NF-kappa-B-mediated inflammatory response, can relieve SETD6-dependent repression of NF-kappa-B target genes by phosphorylating the RELA subunit at 'Ser-311'. Necessary and sufficient for LTP maintenance in hippocampal CA1 pyramidal cells. In vein endothelial cells treated with the oxidant peroxynitrite, phosphorylates STK11 leading to nuclear export of STK11, subsequent inhibition of PI3K/Akt signaling, and increased apoptosis. Phosphorylates VAMP2 in vitro (PubMed:17313651).", "name": "Protein kinase C zeta type", "drug_actions": [], "general_function": "Protein serine/threonine kinase activity", "in_complexes": ["Protein kinase C"], "gene_names": ["PRKCZ"]}, "Q8IUZ5": {"specific_function": "Catalyzes the pyridoxal-phosphate-dependent breakdown of 5-phosphohydroxy-L-lysine, converting it to ammonia, inorganic phosphate and 2-aminoadipate semialdehyde.", "general_function": "Transaminase activity", "gene_names": ["PHYKPL"], "name": "5-phosphohydroxy-L-lysine phospho-lyase", "drug_actions": [{"action": "COFACTOR", "target": "Q8IUZ5", "drug": "DB00114"}]}, "P04211": {"general_function": "Antigen binding", "gene_names": [], "name": "Ig lambda chain V region 4A", "drug_actions": []}, "P37023": {"specific_function": "Type I receptor for TGF-beta family ligands BMP9/GDF2 and BMP10 and important regulator of normal blood vessel development. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. May bind activin as well.", "general_function": "Transmembrane receptor protein serine/threonine kinase activity", "gene_names": ["ACVRL1"], "name": "Serine/threonine-protein kinase receptor R3", "drug_actions": []}, "Q9X0G9": {"general_function": "Ribose-5-phosphate isomerase activity", "gene_names": [], "name": "Ribose 5-phosphate isomerase B", "drug_actions": []}, "P31057": {"specific_function": "Catalyzes the reversible reaction in which hydroxymethyl group from 5,10-methylenetetrahydrofolate is tranferred onto alpha-ketoisovalerate to form ketopantoate.", "general_function": "Magnesium ion binding", "gene_names": ["panB"], "name": "3-methyl-2-oxobutanoate hydroxymethyltransferase", "drug_actions": []}, "Q96FI4": {"gene_names": ["NEIL1"], "name": "Endonuclease 8-like 1", "drug_actions": []}, "Q13315": {"specific_function": "Serine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX at double strand breaks (DSBs), thereby regulating DNA damage response mechanism. Also plays a role in pre-B cell allelic exclusion, a process leading to expression of a single immunoglobulin heavy chain allele to enforce clonality and monospecific recognition by the B-cell antigen receptor (BCR) expressed on individual B-lymphocytes. After the introduction of DNA breaks by the RAG complex on one immunoglobulin allele, acts by mediating a repositioning of the second allele to pericentromeric heterochromatin, preventing accessibility to the RAG complex and recombination of the second allele. Also involved in signal transduction and cell cycle control. May function as a tumor suppressor. Necessary for activation of ABL1 and SAPK. Phosphorylates DYRK2, CHEK2, p53/TP53, FANCD2, NFKBIA, BRCA1, CTIP, nibrin (NBN), TERF1, RAD9 and DCLRE1C. May play a role in vesicle and/or protein transport. Could play a role in T-cell development, gonad and neurological function. Plays a role in replication-dependent histone mRNA degradation. Binds DNA ends. Phosphorylation of DYRK2 in nucleus in response to genotoxic stress prevents its MDM2-mediated ubiquitination and subsequent proteasome degradation. Phosphorylates ATF2 which stimulates its function in DNA damage response.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["ATM"], "name": "Serine-protein kinase ATM", "drug_actions": []}, "P11741": {"specific_function": "Intermediary in the transfer of excitation energy from the chlorophyll to the reaction centers.", "general_function": "Metal ion binding", "gene_names": [], "name": "Bacteriochlorophyll a protein", "drug_actions": []}, "P43133": {"specific_function": "Extracellular zinc metalloprotease.", "general_function": "Metalloendopeptidase activity", "gene_names": ["nprS"], "name": "Thermolysin", "drug_actions": []}, "Q8GR64": {"specific_function": "Catalyzes the dye-linked oxidation of primary alcohols to the corresponding aldehydes and the (subsequent) oxidation of the aldehydes to carboxylic acids. Exhibits activity with longer mono-alcohols (C-4 to C-7) but not with methanol or glycerol. Reacts with 1,2-propanediol and 1,3-propanediol but not with sugar alcohols such as D-sorbitol.", "general_function": "Pyrroloquinoline quinone binding", "gene_names": ["qbdA"], "name": "Quinohemoprotein alcohol dehydrogenase ADH IIB", "drug_actions": []}, "P63316": {"specific_function": "Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site for tropomyosin and Tn-C. The binding of calcium to Tn-C abolishes the inhibitory action of Tn on actin filaments.", "general_function": "Troponin t binding", "gene_names": ["TNNC1"], "name": "Troponin C, slow skeletal and cardiac muscles", "drug_actions": [{"action": "POTENTIATOR", "target": "P63316", "drug": "DB00922"}, {"action": "OTHER", "target": "P63316", "drug": "DB01023"}, {"action": "OTHER", "target": "P63316", "drug": "DB01244"}, {"action": "AGONIST", "target": "P63316", "drug": "DB01373"}, {"action": "STIMULATOR", "target": "P63316", "drug": "DB01375"}]}, "P11387": {"specific_function": "Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then undergoes passage around the unbroken strand thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone (By similarity). Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Involved in the circadian transcription of the core circadian clock component ARNTL/BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the ARNTL/BMAL1 promoter.", "general_function": "Poly(a) rna binding", "gene_names": ["TOP1"], "name": "DNA topoisomerase 1", "drug_actions": [{"action": "INHIBITOR", "target": "P11387", "drug": "DB00762"}, {"action": "INHIBITOR", "target": "P11387", "drug": "DB01030"}, {"action": "INHIBITOR", "target": "P11387", "drug": "DB04967"}, {"action": "INHIBITOR", "target": "P11387", "drug": "DB05630"}]}, "Q05488": {"specific_function": "Catalyzes the carbon skeleton rearrangement of L-glutamate to L-threo-3-methylaspartate ((2S,3S)-3-methylaspartate).", "general_function": "Methylaspartate mutase activity", "gene_names": ["glmS"], "name": "Glutamate mutase sigma subunit", "drug_actions": []}, "P11388": {"specific_function": "Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).", "name": "DNA topoisomerase 2-alpha", "drug_actions": [{"action": "INHIBITOR", "target": "P11388", "drug": "DB00218"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00276"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00380"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00385"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00444"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00445"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00467"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00487"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00537"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00685"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00694"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00773"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00978"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB00997"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB01059"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB01137"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB01165"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB01177"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB01179"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB01204"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB01208"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB04576"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB04967"}, {"action": "INHIBITOR", "target": "P11388", "drug": "DB09047"}], "general_function": "Ubiquitin binding", "in_complexes": ["DNA topoisomerase 2"], "gene_names": ["TOP2A"]}, "Q02192": {"specific_function": "May play a role in both virulence and immunity.", "gene_names": ["bca"], "name": "C protein alpha-antigen", "drug_actions": []}, "P06493": {"specific_function": "Plays a key role in the control of the eukaryotic cell cycle by modulating the centrosome cycle as well as mitotic onset; promotes G2-M transition, and regulates G1 progress and G1-S transition via association with multiple interphase cyclins. Required in higher cells for entry into S-phase and mitosis. Phosphorylates PARVA/actopaxin, APC, AMPH, APC, BARD1, Bcl-xL/BCL2L1, BRCA2, CALD1, CASP8, CDC7, CDC20, CDC25A, CDC25C, CC2D1A, CSNK2 proteins/CKII, FZR1/CDH1, CDK7, CEBPB, CHAMP1, DMD/dystrophin, EEF1 proteins/EF-1, EZH2, KIF11/EG5, EGFR, FANCG, FOS, GFAP, GOLGA2/GM130, GRASP1, UBE2A/hHR6A, HIST1H1 proteins/histone H1, HMGA1, HIVEP3/KRC, LMNA, LMNB, LMNC, LBR, LATS1, MAP1B, MAP4, MARCKS, MCM2, MCM4, MKLP1, MYB, NEFH, NFIC, NPC/nuclear pore complex, PITPNM1/NIR2, NPM1, NCL, NUCKS1, NPM1/numatrin, ORC1, PRKAR2A, EEF1E1/p18, EIF3F/p47, p53/TP53, NONO/p54NRB, PAPOLA, PLEC/plectin, RB1, UL40/R2, RAB4A, RAP1GAP, RCC1, RPS6KB1/S6K1, KHDRBS1/SAM68, ESPL1, SKI, BIRC5/survivin, STIP1, TEX14, beta-tubulins, MAPT/TAU, NEDD1, VIM/vimentin, TK1, FOXO1, RUNX1/AML1, SIRT2 and RUNX2. CDK1/CDC2-cyclin-B controls pronuclear union in interphase fertilized eggs. Essential for early stages of embryonic development. During G2 and early mitosis, CDC25A/B/C-mediated dephosphorylation activates CDK1/cyclin complexes which phosphorylate several substrates that trigger at least centrosome separation, Golgi dynamics, nuclear envelope breakdown and chromosome condensation. Once chromosomes are condensed and aligned at the metaphase plate, CDK1 activity is switched off by WEE1- and PKMYT1-mediated phosphorylation to allow sister chromatid separation, chromosome decondensation, reformation of the nuclear envelope and cytokinesis. Inactivated by PKR/EIF2AK2- and WEE1-mediated phosphorylation upon DNA damage to stop cell cycle and genome replication at the G2 checkpoint thus facilitating DNA repair. Reactivated after successful DNA repair through WIP1-dependent signaling leading to CDC25A/B/C-mediated dephosphorylation and restoring cell cycle progression. In proliferating cells, CDK1-mediated FOXO1 phosphorylation at the G2-M phase represses FOXO1 interaction with 14-3-3 proteins and thereby promotes FOXO1 nuclear accumulation and transcription factor activity, leading to cell death of postmitotic neurons. The phosphorylation of beta-tubulins regulates microtubule dynamics during mitosis. NEDD1 phosphorylation promotes PLK1-mediated NEDD1 phosphorylation and subsequent targeting of the gamma-tubulin ring complex (gTuRC) to the centrosome, an important step for spindle formation. In addition, CC2D1A phosphorylation regulates CC2D1A spindle pole localization and association with SCC1/RAD21 and centriole cohesion during mitosis. The phosphorylation of Bcl-xL/BCL2L1 after prolongated G2 arrest upon DNA damage triggers apoptosis. In contrast, CASP8 phosphorylation during mitosis prevents its activation by proteolysis and subsequent apoptosis. This phosphorylation occurs in cancer cell lines, as well as in primary breast tissues and lymphocytes. EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing. CALD1 phosphorylation promotes Schwann cell migration during peripheral nerve regeneration.", "general_function": "Rna polymerase ii carboxy-terminal domain kinase activity", "gene_names": ["CDK1"], "name": "Cyclin-dependent kinase 1", "drug_actions": [{"action": "BINDER", "target": "P06493", "drug": "DB02052"}, {"action": "BINDER", "target": "P06493", "drug": "DB02116"}, {"action": "BINDER", "target": "P06493", "drug": "DB03428"}, {"action": "INHIBITOR", "target": "P06493", "drug": "DB04014"}]}, "P19571": {"general_function": "Glucan 1,4-alpha-maltohexaosidase activity", "gene_names": [], "name": "Glucan 1,4-alpha-maltohexaosidase", "drug_actions": []}, "P16384": {"specific_function": "Catalyzes the transfer of a dimethylallyl group onto the adenine at position 37 in tRNAs that read codons beginning with uridine, leading to the formation of N6-(dimethylallyl)adenosine (i(6)A).", "general_function": "Trna dimethylallyltransferase activity", "gene_names": ["miaA"], "name": "tRNA dimethylallyltransferase", "drug_actions": []}, "P05896": {"specific_function": "Gag-Pol polyprotein and Gag polyprotein may regulate their own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, Gag-Pol and Gag would promote translation, whereas at high concentration, the polyproteins encapsidate genomic RNA and then shutt off translation (By similarity).Matrix protein p17 has two main functions: in infected cell, it targets Gag and Gag-pol polyproteins to the plasma membrane via a multipartite membrane-binding signal, that includes its myristointegration complex. The myristoylation signal and the NLS exert conflicting influences its subcellular localization. The key regulation of these motifs might be phosphorylation of a portion of MA molecules on the C-terminal tyrosine at the time of virus maturation, by virion-associated cellular tyrosine kinase. Implicated in the release from host cell mediated by Vpu (By similarity).Capsid protein p24 forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry. Interaction with host PPIA/CYPA protects the virus from restriction by host TRIM5-alpha and from an unknown antiviral activity in host cells. This capsid restriction by TRIM5 is one of the factors which restricts SIV to the simian species (By similarity).Nucleocapsid protein p7 encapsulates and protects viral dimeric unspliced (genomic) RNA. Binds these RNAs through its zinc fingers. Facilitates rearangement of nucleic acid secondary structure during retrotranscription of genomic RNA. This capability is referred to as nucleic acid chaperone activity (By similarity).The aspartyl protease mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane. Cleavages take place as an ordered, step-wise cascade to yield mature proteins. This process is called maturation. Displays maximal activity during the budding process just prior to particle release from the cell. Also cleaves Nef and Vif, probably concomitantly with viral structural proteins on maturation of virus particles. Hydrolyzes host EIF4GI and PABP1 in order to shut off the capped cellular mRNA translation. The resulting inhibition of cellular protein synthesis serves to ensure maximal viral gene expression and to evade host immune response (By similarity).Reverse transcriptase/ribonuclease H (RT) is a multifunctional enzyme that converts the viral dimeric RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for two polypurine tracts (PPTs) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H can probably proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPTs that have not been removed by RNase H as primers. PPTs and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends (By similarity).Integrase catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the SIV genome, a 5 bp duplication of host DNA is produced at the ends of SIV integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration (By similarity).", "general_function": "Zinc ion binding", "gene_names": ["gag-pol"], "name": "Gag-Pol polyprotein", "drug_actions": []}, "P17252": {"specific_function": "Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in positive and negative regulation of cell proliferation, apoptosis, differentiation, migration and adhesion, tumorigenesis, cardiac hypertrophy, angiogenesis, platelet function and inflammation, by directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, or activating signaling cascade involving MAPK1/3 (ERK1/2) and RAP1GAP. Involved in cell proliferation and cell growth arrest by positive and negative regulation of the cell cycle. Can promote cell growth by phosphorylating and activating RAF1, which mediates the activation of the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A, which facilitates active cyclin-dependent kinase (CDK) complex formation in glioma cells. In intestinal cells stimulated by the phorbol ester PMA, can trigger a cell cycle arrest program which is associated with the accumulation of the hyper-phosphorylated growth-suppressive form of RB1 and induction of the CDK inhibitors CDKN1A and CDKN1B. Exhibits anti-apoptotic function in glioma cells and protects them from apoptosis by suppressing the p53/TP53-mediated activation of IGFBP3, and in leukemia cells mediates anti-apoptotic action by phosphorylating BCL2. During macrophage differentiation induced by macrophage colony-stimulating factor (CSF1), is translocated to the nucleus and is associated with macrophage development. After wounding, translocates from focal contacts to lamellipodia and participates in the modulation of desmosomal adhesion. Plays a role in cell motility by phosphorylating CSPG4, which induces association of CSPG4 with extensive lamellipodia at the cell periphery and polarization of the cell accompanied by increases in cell motility. Is highly expressed in a number of cancer cells where it can act as a tumor promoter and is implicated in malignant phenotypes of several tumors such as gliomas and breast cancers. Negatively regulates myocardial contractility and positively regulates angiogenesis, platelet aggregation and thrombus formation in arteries. Mediates hypertrophic growth of neonatal cardiomyocytes, in part through a MAPK1/3 (ERK1/2)-dependent signaling pathway, and upon PMA treatment, is required to induce cardiomyocyte hypertrophy up to heart failure and death, by increasing protein synthesis, protein-DNA ratio and cell surface area. Regulates cardiomyocyte function by phosphorylating cardiac troponin T (TNNT2/CTNT), which induces significant reduction in actomyosin ATPase activity, myofilament calcium sensitivity and myocardial contractility. In angiogenesis, is required for full endothelial cell migration, adhesion to vitronectin (VTN), and vascular endothelial growth factor A (VEGFA)-dependent regulation of kinase activation and vascular tube formation. Involved in the stabilization of VEGFA mRNA at post-transcriptional level and mediates VEGFA-induced cell proliferation. In the regulation of calcium-induced platelet aggregation, mediates signals from the CD36/GP4 receptor for granule release, and activates the integrin heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for adhesion. During response to lipopolysaccharides (LPS), may regulate selective LPS-induced macrophage functions involved in host defense and inflammation. But in some inflammatory responses, may negatively regulate NF-kappa-B-induced genes, through IL1A-dependent induction of NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1, which modulates EIF4G1 binding to MKNK1 and may be involved in the regulation of EIF4E phosphorylation. Phosphorylates KIT, leading to inhibition of KIT activity. Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription.", "name": "Protein kinase C alpha type", "drug_actions": [{"action": "LIGAND", "target": "P17252", "drug": "DB05013"}, {"action": "INHIBITOR, COMPETITIVE", "target": "P17252", "drug": "DB08846"}], "general_function": "Zinc ion binding", "in_complexes": ["Protein kinase C"], "gene_names": ["PRKCA"]}, "P0A9D2": {"specific_function": "Catalyzes the conjugation of reduced glutathione (GSH) to a wide number of exogenous and endogenous hydrophobic electrophiles. Shows activity toward 1-chloro-2,4-dinitrobenzene (CDNB) and ethacrynic acid. Also possesses thiol:disulfide oxidoreductase activity, using GSH to reduce bis-(2-hydroxyethyl) disulfide (HEDS). Has a low level of glutathione-dependent peroxidase activity toward cumene hydroperoxide. Is important for defense against oxidative stress, probably via its peroxidase activity.", "general_function": "Glutathione transferase activity", "gene_names": ["gstA"], "name": "Glutathione S-transferase GstA", "drug_actions": []}, "P16389": {"specific_function": "Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the cardiovascular system. Prevents aberrant action potential firing and regulates neuronal output. Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane (PubMed:19912772, PubMed:8495559, PubMed:11211111, PubMed:23769686). Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA5, KCNA6, KCNA7, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel (PubMed:8495559, PubMed:20220134). Channel properties are modulated by cytoplasmic beta subunits that regulate the subcellular location of the alpha subunits and promote rapid inactivation of delayed rectifier potassium channels. In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Homotetrameric KCNA2 forms a delayed-rectifier potassium channel that opens in response to membrane depolarization, followed by slow spontaneous channel closure (PubMed:19912772, PubMed:23769686). In contrast, a heteromultimer formed by KCNA2 and KCNA4 shows rapid inactivation (PubMed:8495559). Regulates neuronal excitability and plays a role as pacemaker in the regulation of neuronal action potentials (By similarity). KCNA2-containing channels play a presynaptic role and prevent hyperexcitability and aberrant action potential firing (By similarity). Response to toxins that are selective for KCNA2-containing potassium channels suggests that in Purkinje cells, dendritic subthreshold KCNA2-containing potassium channels prevent random spontaneous calcium spikes, suppressing dendritic hyperexcitability without hindering the generation of somatic action potentials, and thereby play an important role in motor coordination (By similarity). Plays a role in the induction of long-term potentiation of neuron excitability in the CA3 layer of the hippocampus (By similarity). May function as down-stream effector for G protein-coupled receptors and inhibit GABAergic inputs to basolateral amygdala neurons (By similarity). May contribute to the regulation of neurotransmitter release, such as gamma-aminobutyric acid (GABA) (By similarity). Contributes to the regulation of the axonal release of the neurotransmitter dopamine (By similarity). Reduced KCNA2 expression plays a role in the perception of neuropathic pain after peripheral nerve injury, but not acute pain (By similarity). Plays a role in the regulation of the time spent in non-rapid eye movement (NREM) sleep (By similarity).", "general_function": "Voltage-gated potassium channel activity", "gene_names": ["KCNA2"], "name": "Potassium voltage-gated channel subfamily A member 2", "drug_actions": [{"action": "ANTAGONIST", "target": "P16389", "drug": "DB06637"}]}, "P61177": {"specific_function": "This protein binds specifically to 23S rRNA; its binding is stimulated by other ribosomal proteins, e.g. L4, L17, and L20. It is important during the early stages of 50S assembly. It makes multiple contacts with different domains of the 23S rRNA in the assembled 50S subunit and ribosome (By similarity).The globular domain of the protein is located near the polypeptide exit tunnel on the outside of the subunit, while an extended beta-hairpin is found that lines the wall of the exit tunnel in the center of the 70S ribosome.", "general_function": "Structural constituent of ribosome", "gene_names": ["rplV"], "name": "50S ribosomal protein L22", "drug_actions": [{"action": "INHIBITOR", "target": "P61177", "drug": "DB00199"}, {"action": "INHIBITOR", "target": "P61177", "drug": "DB00207"}, {"action": "INHIBITOR", "target": "P61177", "drug": "DB01369"}]}, "P0A927": {"specific_function": "Constitutes the receptor for colicin K and phage T6, and functions as substrate-specific channel for nucleosides and deoxynucleosides.", "general_function": "Nucleoside-specific channel forming porin activity", "gene_names": ["tsx"], "name": "Nucleoside-specific channel-forming protein tsx", "drug_actions": []}, "P11766": {"specific_function": "Class-III ADH is remarkably ineffective in oxidizing ethanol, but it readily catalyzes the oxidation of long-chain primary alcohols and the oxidation of S-(hydroxymethyl) glutathione.", "general_function": "Zinc ion binding", "gene_names": ["ADH5"], "name": "Alcohol dehydrogenase class-3", "drug_actions": []}, "P25275": {"specific_function": "Catalyzes the hydrolysis of triglycerides.", "general_function": "Triglyceride lipase activity", "gene_names": ["lip"], "name": "Lipase", "drug_actions": []}, "Q9UNA0": {"specific_function": "Cleaves aggrecan, a cartilage proteoglycan, and may be involved in its turnover. May play an important role in the destruction of aggrecan in arthritic diseases. May play a role in proteolytic processing mostly during the peri-implantation period.", "general_function": "Zinc ion binding", "gene_names": ["ADAMTS5"], "name": "A disintegrin and metalloproteinase with thrombospondin motifs 5", "drug_actions": []}, "P23882": {"specific_function": "Modifies the free amino group of the aminoacyl moiety of methionyl-tRNA(fMet). The formyl group appears to play a dual role in the initiator identity of N-formylmethionyl-tRNA by: (I) promoting its recognition by IF2 and (II) impairing its binding to EFTu-GTP.", "general_function": "Methyltransferase activity", "gene_names": ["fmt"], "name": "Methionyl-tRNA formyltransferase", "drug_actions": []}, "P12497": {"specific_function": "Gag-Pol polyprotein: Mediates, with Gag polyrotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shutt off translation.Matrix protein p17: Targets the polyprotein to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus (PubMed:16840558). Matrix protein is part of the pre-integration complex. Implicated in the release from host cell mediated by Vpu. Binds to RNA.Capsid protein p24: Forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion. Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry (By similarity). Host restriction factors such as TRIM5-alpha or TRIMCyp bind retroviral capsids and cause premature capsid disassembly, leading to blocks in reverse transcription. Capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species. Host PIN1 apparently facilitates the virion uncoating (PubMed:24509437). On the other hand, interactions with PDZD8 or CYPA stabilize the capsid.Nucleocapsid protein p7: Encapsulates and protects viral dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its zinc fingers. Acts as a nucleic acid chaperone which is involved in rearangement of nucleic acid secondary structure during gRNA retrotranscription. Also facilitates template switch leading to recombination. As part of the polyprotein, participates to gRNA dimerization, packaging, tRNA incorporation and virion assembly.Protease: Aspartyl protease that mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane. Cleavages take place as an ordered, step-wise cascade to yield mature proteins. This process is called maturation. Displays maximal activity during the budding process just prior to particle release from the cell. Also cleaves Nef and Vif, probably concomitantly with viral structural proteins on maturation of virus particles. Hydrolyzes host EIF4GI and PABP1 in order to shut off the capped cellular mRNA translation. The resulting inhibition of cellular protein synthesis serves to ensure maximal viral gene expression and to evade host immune response (By similarity).Reverse transcriptase/ribonuclease H: Multifunctional enzyme that converts the viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for two polypurine tracts (PPTs) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPTs that have not been removed by RNase H as primers. PPTs and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends.Integrase: Catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration.", "general_function": "Zinc ion binding", "gene_names": ["gag-pol"], "name": "Gag-Pol polyprotein", "drug_actions": []}, "Q5SHQ2": {"specific_function": "One of the primary rRNA binding proteins, it binds directly to 16S rRNA where it helps nucleate assembly of the platform of the 30S subunit central domain. The combined cluster of proteins S8, S12 and S17 appears to hold together the shoulder and platform of the 30S subunit.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsH"], "name": "30S ribosomal protein S8", "drug_actions": []}, "P36888": {"specific_function": "Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.", "general_function": "Vascular endothelial growth factor-activated receptor activity", "gene_names": ["FLT3"], "name": "Receptor-type tyrosine-protein kinase FLT3", "drug_actions": [{"action": "ANTAGONIST", "target": "P36888", "drug": "DB00398"}, {"action": "MULTITARGET", "target": "P36888", "drug": "DB01268"}, {"action": "INHIBITOR", "target": "P36888", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P36888", "drug": "DB09079"}]}, "P13945": {"specific_function": "Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.", "name": "Beta-3 adrenergic receptor", "drug_actions": [{"action": "AGONIST", "target": "P13945", "drug": "DB00182"}, {"action": "ANTAGONIST", "target": "P13945", "drug": "DB00217"}, {"action": "BINDER", "target": "P13945", "drug": "DB00321"}, {"action": "AGONIST", "target": "P13945", "drug": "DB00368"}, {"action": "ANTAGONIST", "target": "P13945", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P13945", "drug": "DB00571"}, {"action": "AGONIST", "target": "P13945", "drug": "DB00668"}, {"action": "BINDER", "target": "P13945", "drug": "DB00726"}, {"action": "AGONIST", "target": "P13945", "drug": "DB01064"}, {"action": "AGONIST", "target": "P13945", "drug": "DB01102"}, {"action": "AGONIST", "target": "P13945", "drug": "DB01288"}, {"action": "AGONIST", "target": "P13945", "drug": "DB01363"}, {"action": "AGONIST", "target": "P13945", "drug": "DB01365"}, {"action": "AGONIST", "target": "P13945", "drug": "DB01407"}, {"action": "AGONIST", "target": "P13945", "drug": "DB06262"}, {"action": "ANTAGONIST", "target": "P13945", "drug": "DB06726"}, {"action": "ANTAGONIST", "target": "P13945", "drug": "DB08808"}, {"action": "AGONIST", "target": "P13945", "drug": "DB08893"}], "general_function": "Protein homodimerization activity", "in_complexes": ["Beta adrenergic receptor"], "gene_names": ["ADRB3"]}, "P50213": {"general_function": "Nad binding", "gene_names": ["IDH3A"], "name": "Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial", "drug_actions": []}, "O95045": {"specific_function": "Catalyzes the reversible phosphorylytic cleavage of uridine and deoxyuridine to uracil and ribose- or deoxyribose-1-phosphate. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis. Shows substrate specificity and accept uridine, deoxyuridine, and thymidine as well as the two pyrimidine nucleoside analogs 5-fluorouridine and 5-fluoro-2(')-deoxyuridine as substrates.", "general_function": "Uridine phosphorylase activity", "gene_names": ["UPP2"], "name": "Uridine phosphorylase 2", "drug_actions": []}, "P77150": {"specific_function": "Phosphorylates B6 vitamers; functions in a salvage pathway. Uses pyridoxamine, but has negligible activity toward pyridoxal and pyridoxine as substrates.", "general_function": "Zinc ion binding", "gene_names": ["pdxY"], "name": "Pyridoxamine kinase", "drug_actions": []}, "P07307": {"specific_function": "Mediates the endocytosis of plasma glycoproteins to which the terminal sialic acid residue on their complex carbohydrate moieties has been removed. The receptor recognizes terminal galactose and N-acetylgalactosamine units. After ligand binding to the receptor, the resulting complex is internalized and transported to a sorting organelle, where receptor and ligand are disassociated. The receptor then returns to the cell membrane surface.", "general_function": "Carbohydrate binding", "gene_names": ["ASGR2"], "name": "Asialoglycoprotein receptor 2", "drug_actions": [{"action": "BINDER", "target": "P07307", "drug": "DB00025"}]}, "Q5SHQ1": {"specific_function": "Required for the assembly of 30S particles and may also be responsible for determining the conformation of the 16S rRNA at the A site (By similarity). Binds 16S rRNA in center of the 30S subunit head.", "general_function": "Zinc ion binding", "gene_names": ["rpsZ"], "name": "30S ribosomal protein S14 type Z", "drug_actions": []}, "Q96NR8": {"specific_function": "Exhibits an oxidoreductive catalytic activity towards retinoids. Most efficient as an NADPH-dependent retinal reductase. Displays high activity toward 9-cis and all-trans-retinol. Also involved in the metabolism of short-chain aldehydes. No steroid dehydrogenase activity detected. Might be the key enzyme in the formation of 11-cis-retinal from 11-cis-retinol during regeneration of the cone visual pigments.", "general_function": "Retinol dehydrogenase activity", "gene_names": ["RDH12"], "name": "Retinol dehydrogenase 12", "drug_actions": []}, "P67910": {"specific_function": "Catalyzes the interconversion between ADP-D-glycero-beta-D-manno-heptose and ADP-L-glycero-beta-D-manno-heptose via an epimerization at carbon 6 of the heptose.", "general_function": "Nadp+ binding", "gene_names": ["hldD"], "name": "ADP-L-glycero-D-manno-heptose-6-epimerase", "drug_actions": []}, "P05787": {"specific_function": "Together with KRT19, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle.", "general_function": "Structural molecule activity", "gene_names": ["KRT8"], "name": "Keratin, type II cytoskeletal 8", "drug_actions": []}, "P36405": {"specific_function": "Small GTP-binding protein which cycles between an inactive GDP-bound and an active GTP-bound form, and the rate of cycling is regulated by guanine nucleotide exchange factors (GEF) and GTPase-activating proteins (GAP). Required for normal cytokinesis and cilia signaling. Requires assistance from GTPase-activating proteins (GAPs) like RP2 and PDE6D, in order to cycle between inactive GDP-bound and active GTP-bound forms. Required for targeting proteins such as NPHP3 to the ciliary membrane by releasing myristoylated NPHP3 from UNC119B cargo adapter into the cilium. Does not act as an allosteric activator of the cholera toxin catalytic subunit.", "general_function": "Microtubule binding", "gene_names": ["ARL3"], "name": "ADP-ribosylation factor-like protein 3", "drug_actions": []}, "P36683": {"specific_function": "Involved in the catabolism of short chain fatty acids (SCFA) via the tricarboxylic acid (TCA)(acetyl degradation route) and the 2-methylcitrate cycle I (propionate degradation route). Catalyzes the reversible isomerization of citrate to isocitrate via cis-aconitate. Also catalyzes the hydration of 2-methyl-cis-aconitate to yield (2R,3S)-2-methylisocitrate. The apo form of AcnB functions as a RNA-binding regulatory protein. During oxidative stress inactive AcnB apo-enzyme without iron sulfur clusters binds the acnB mRNA 3' UTRs (untranslated regions), stabilizes acnB mRNA and increases AcnB synthesis, thus mediating a post-transcriptional positive autoregulatory switch. AcnB also decreases the stability of the sodA transcript.", "general_function": "Mrna binding", "gene_names": ["acnB"], "name": "Aconitate hydratase B", "drug_actions": []}, "Q88CZ6": {"general_function": "Urocanate hydratase activity", "gene_names": ["hutU"], "name": "Urocanate hydratase", "drug_actions": []}, "P11168": {"specific_function": "Facilitative glucose transporter. This isoform likely mediates the bidirectional transfer of glucose across the plasma membrane of hepatocytes and is responsible for uptake of glucose by the beta cells; may comprise part of the glucose-sensing mechanism of the beta cell. May also participate with the Na(+)/glucose cotransporter in the transcellular transport of glucose in the small intestine and kidney.", "general_function": "Hexose transmembrane transporter activity", "gene_names": ["SLC2A2"], "name": "Solute carrier family 2, facilitated glucose transporter member 2", "drug_actions": [{"action": "LIGAND", "target": "P11168", "drug": "DB00428"}]}, "P04964": {"specific_function": "Catalyzes the reversible NADPH-dependent reductive amination of L-2-amino-6-oxopimelate, the acyclic form of L-tetrahydrodipicolinate, to generate the meso compound, D,L-2,6-diaminopimelate. Probably plays a role in lysine biosynthesis. Exhibits a high substrate specificity for meso-2,6-diaminopimelate, since L,L-2,6-diaminopimelate, D,D-2,6-diaminopimelate, L-glutamate, L-alanine, L-leucine, L-valine, L-aspartate, L-threonine, L-homoserine, L-methionine, L-lysine, L-serine, L-phenylalanine, L-tyrosine, L-tryptophan, L-ornithine, L-histidine, L-arginine, D-glutamate, and D-alanine are not substrates for the oxidative deamination reaction. Can use NAD(+) only poorly since the activity observed in the presence of NAD(+) is about 3% of that with NADP(+).", "general_function": "Diaminopimelate dehydrogenase activity", "gene_names": ["ddh"], "name": "Meso-diaminopimelate D-dehydrogenase", "drug_actions": []}, "P35749": {"specific_function": "Muscle contraction.", "general_function": "Structural constituent of muscle", "gene_names": ["MYH11"], "name": "Myosin-11", "drug_actions": []}, "O60931": {"specific_function": "Cystine/H(+) symporter thought to transport cystine out of lysosomes. Plays an important role in melanin synthesis, possibly by preventing melanosome acidification and subsequent degradation of tyrosinase TYR.", "general_function": "L-cystine transmembrane transporter activity", "gene_names": ["CTNS"], "name": "Cystinosin", "drug_actions": []}, "P0A6J8": {"specific_function": "Cell wall formation.", "general_function": "Manganese ion binding", "gene_names": ["ddlA"], "name": "D-alanine--D-alanine ligase A", "drug_actions": [{"action": "INHIBITOR", "target": "P0A6J8", "drug": "DB00260"}]}, "Q72EF4": {"general_function": "Metal ion binding", "gene_names": [], "name": "Cytochrome c-type protein", "drug_actions": []}, "Q8WXI7": {"specific_function": "Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces (By similarity)", "general_function": "Intracellular trafficking, secretion, and vesicular transport", "gene_names": ["MUC16"], "name": "Mucin-16", "drug_actions": []}, "O60939": {"specific_function": "Crucial in the assembly, expression, and functional modulation of the heterotrimeric complex of the sodium channel. The subunit beta-2 causes an increase in the plasma membrane surface area and in its folding into microvilli. Interacts with TNR may play a crucial role in clustering and regulation of activity of sodium channels at nodes of Ranvier (By similarity).", "name": "Sodium channel subunit beta-2", "drug_actions": [{"action": "INHIBITOR", "target": "O60939", "drug": "DB00909"}], "general_function": "Voltage-gated sodium channel activity involved in cardiac muscle cell action potential", "in_complexes": ["Sodium channel protein"], "gene_names": ["SCN2B"]}, "P10635": {"specific_function": "Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.", "general_function": "Steroid hydroxylase activity", "gene_names": ["CYP2D6"], "name": "Cytochrome P450 2D6", "drug_actions": []}, "P10636": {"specific_function": "Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["MAPT"], "name": "Microtubule-associated protein tau", "drug_actions": []}, "Q81C15": {"gene_names": [], "name": "Uncharacterized protein", "drug_actions": []}, "P10632": {"specific_function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme responsible for the metabolism the anti-cancer drug paclitaxel (taxol).", "general_function": "Steroid hydroxylase activity", "gene_names": ["CYP2C8"], "name": "Cytochrome P450 2C8", "drug_actions": []}, "Q6P996": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["PDXDC1"], "name": "Pyridoxal-dependent decarboxylase domain-containing protein 1", "drug_actions": [{"action": "COFACTOR", "target": "Q6P996", "drug": "DB00114"}]}, "Q5SJ28": {"specific_function": "Catalyzes a reversible aldol reaction between acetaldehyde and D-glyceraldehyde 3-phosphate to generate 2-deoxy-D-ribose 5-phosphate.", "general_function": "Deoxyribose-phosphate aldolase activity", "gene_names": ["deoC"], "name": "Deoxyribose-phosphate aldolase", "drug_actions": []}, "P50859": {"specific_function": "Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol (By similarity).", "general_function": "Sterol 14-demethylase activity", "gene_names": ["ERG11"], "name": "Lanosterol 14-alpha demethylase", "drug_actions": [{"action": "INHIBITOR", "target": "P50859", "drug": "DB01167"}, {"action": "INHIBITOR", "target": "P50859", "drug": "DB09040"}]}, "P39805": {"specific_function": "Mediates positive regulation of the glucanase operon (licST) by functioning as an antiterminator factor of transcription. Prevents termination at terminator lic-t.", "general_function": "Rna binding", "gene_names": ["licT"], "name": "Transcription antiterminator LicT", "drug_actions": []}, "P16499": {"specific_function": "This protein participates in processes of transmission and amplification of the visual signal.", "name": "Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "P16499", "drug": "DB00201"}], "general_function": "Metal ion binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE6A"]}, "Q9UBQ6": {"specific_function": "Glycosyltransferase required for the biosynthesis of heparan-sulfate and responsible for the alternating addition of beta-1-4-linked glucuronic acid (GlcA) and alpha-1-4-linked N-acetylglucosamine (GlcNAc) units to nascent heparan sulfate chains.", "general_function": "Metal ion binding", "gene_names": ["EXTL2"], "name": "Exostosin-like 2", "drug_actions": []}, "P25311": {"specific_function": "Stimulates lipid degradation in adipocytes and causes the extensive fat losses associated with some advanced cancers. May bind polyunsaturated fatty acids.", "general_function": "Ribonuclease activity", "gene_names": ["AZGP1"], "name": "Zinc-alpha-2-glycoprotein", "drug_actions": []}, "P49619": {"specific_function": "Reverses the normal flow of glycerolipid biosynthesis by phosphorylating diacylglycerol back to phosphatidic acid.", "general_function": "Diacylglycerol kinase activity", "gene_names": ["DGKG"], "name": "Diacylglycerol kinase gamma", "drug_actions": []}, "Q08828": {"specific_function": "Catalyzes the formation of the signaling molecule cAMP in response to G-protein signaling. Mediates responses to increased cellular Ca(2+)/calmodulin levels (By similarity). May be involved in regulatory processes in the central nervous system. May play a role in memory and learning. Plays a role in the regulation of the circadian rhythm of daytime contrast sensitivity probably by modulating the rhythmic synthesis of cyclic AMP in the retina (By similarity).", "general_function": "Metal ion binding", "gene_names": ["ADCY1"], "name": "Adenylate cyclase type 1", "drug_actions": [{"action": "PRODUCT OF", "target": "Q08828", "drug": "DB00131"}]}, "Q15796": {"specific_function": "Receptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases. Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD2/SMAD4 complex, activates transcription. May act as a tumor suppressor in colorectal carcinoma. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["SMAD2"], "name": "Mothers against decapentaplegic homolog 2", "drug_actions": []}, "P22939": {"general_function": "Metal ion binding", "gene_names": ["ispA"], "name": "Farnesyl diphosphate synthase", "drug_actions": []}, "O14717": {"specific_function": "Specifically methylates cytosine 38 in the anticodon loop of tRNA(Asp).", "general_function": "Trna methyltransferase activity", "gene_names": ["TRDMT1"], "name": "tRNA (cytosine(38)-C(5))-methyltransferase", "drug_actions": [{"action": "OTHER", "target": "O14717", "drug": "DB00738"}]}, "Q9NR82": {"specific_function": "Probably important in the regulation of neuronal excitability. Associates with KCNQ3 to form a potassium channel which contributes to M-type current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons. May contribute, with other potassium channels, to the molecular diversity of a heterogeneous population of M-channels, varying in kinetic and pharmacological properties, which underlie this physiologically important current. Insensitive to tetraethylammonium, but inhibited by barium, linopirdine and XE991. Activated by niflumic acid and the anticonvulsant retigabine. Muscarine suppresses KCNQ5 current in Xenopus oocytes in which cloned KCNQ5 channels were coexpressed with M(1) muscarinic receptors.", "general_function": "Voltage-gated potassium channel activity", "gene_names": ["KCNQ5"], "name": "Potassium voltage-gated channel subfamily KQT member 5", "drug_actions": []}, "Q13547": {"specific_function": "Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Deacetylates SP proteins, SP1 and SP3, and regulates their function. Component of the BRG1-RB1-HDAC1 complex, which negatively regulates the CREST-mediated transcription in resting neurons. Upon calcium stimulation, HDAC1 is released from the complex and CREBBP is recruited, which facilitates transcriptional activation. Deacetylates TSHZ3 and regulates its transcriptional repressor activity. Deacetylates 'Lys-310' in RELA and thereby inhibits the transcriptional activity of NF-kappa-B. Deacetylates NR1D2 and abrogates the effect of KAT5-mediated relieving of NR1D2 transcription repression activity. Component of a RCOR/GFI/KDM1A/HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development. Involved in CIART-mediated transcriptional repression of the circadian transcriptional activator: CLOCK-ARNTL/BMAL1 heterodimer. Required for the transcriptional repression of circadian target genes, such as PER1, mediated by the large PER complex or CRY1 through histone deacetylation.", "general_function": "Transcription regulatory region sequence-specific dna binding", "gene_names": ["HDAC1"], "name": "Histone deacetylase 1", "drug_actions": [{"action": "INHIBITOR", "target": "Q13547", "drug": "DB02546"}, {"action": "INHIBITOR", "target": "Q13547", "drug": "DB06603"}]}, "Q16698": {"specific_function": "Auxiliary enzyme of beta-oxidation. It participates in the metabolism of unsaturated fatty enoyl-CoA esters having double bonds in both even- and odd-numbered positions. Catalyzes the NADP-dependent reduction of 2,4-dienoyl-CoA to yield trans-3-enoyl-CoA.", "general_function": "Oxidoreductase activity, acting on nad(p)h", "gene_names": ["DECR1"], "name": "2,4-dienoyl-CoA reductase, mitochondrial", "drug_actions": []}, "Q16206": {"specific_function": "May be involved in cell growth. Probably acts as a terminal oxidase of plasma electron transport from cytosolic NAD(P)H via hydroquinones to acceptors at the cell surface. Hydroquinone oxidase activity alternates with a protein disulfide-thiol interchange/oxidoreductase activity which may control physical membrane displacements associated with vesicle budding or cell enlargement. The activities oscillate with a period length of 22 minutes and play a role in control of the ultradian cellular biological clock.", "general_function": "Protein disulfide oxidoreductase activity", "gene_names": ["ENOX2"], "name": "Ecto-NOX disulfide-thiol exchanger 2", "drug_actions": []}, "P15043": {"specific_function": "Involved in the RecF recombination pathway; its gene expression is under the regulation of the SOS system. It is a DNA helicase.", "general_function": "Zinc ion binding", "gene_names": ["recQ"], "name": "ATP-dependent DNA helicase RecQ", "drug_actions": []}, "P04350": {"specific_function": "Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["TUBB4A"], "name": "Tubulin beta-4A chain", "drug_actions": []}, "Q5L478": {"general_function": "Zinc ion binding", "gene_names": ["NS5A"], "name": "Nonstructural protein 5A", "drug_actions": [{"action": "INHIBITOR", "target": "Q5L478", "drug": "DB09027"}]}, "P47869": {"specific_function": "GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.", "name": "Gamma-aminobutyric acid receptor subunit alpha-2", "drug_actions": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00228"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00237"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00292"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00306"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00349"}, {"action": "AGONIST", "target": "P47869", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00371"}, {"action": "AGONIST", "target": "P47869", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00404"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00418"}, {"action": "AGONIST", "target": "P47869", "drug": "DB00425"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00475"}, {"action": "BINDER", "target": "P47869", "drug": "DB00543"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00599"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00628"}, {"action": "POSITIVE MODULATOR", "target": "P47869", "drug": "DB00659"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00690"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00753"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00794"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00818"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00849"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01028"}, {"action": "AGONIST", "target": "P47869", "drug": "DB01049"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01189"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01198"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01205"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01236"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01346"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01351"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01352"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01353"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01354"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01355"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01437"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01483"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01496"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01544"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P47869", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P47869", "drug": "DB01595"}, {"action": "ANTAGONIST", "target": "P47869", "drug": "DB01708"}], "general_function": "Inhibitory extracellular ligand-gated ion channel activity", "in_complexes": ["GABA-A receptor (anion channel)"], "gene_names": ["GABRA2"]}, "O70038": {"general_function": "Penicillin binding", "gene_names": ["pbp1b"], "name": "Penicillin-binding protein 1B", "drug_actions": []}, "Q9KQN0": {"general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": [], "name": "Transcriptional regulator, HTH_3 family", "drug_actions": []}, "Q06700": {"specific_function": "Decarboxylase subunit of the primary sodium pump glutaconyl-CoA decarboxylase (GCD).", "general_function": "Ligase activity", "gene_names": ["gcdA"], "name": "Glutaconyl-CoA decarboxylase subunit alpha", "drug_actions": []}, "Q96L21": {"specific_function": "May play a role in compensating for the inactivated X-linked gene during spermatogenesis.", "general_function": "Structural constituent of ribosome", "gene_names": ["RPL10L"], "name": "60S ribosomal protein L10-like", "drug_actions": []}, "P12236": {"specific_function": "Catalyzes the exchange of cytoplasmic ADP with mitochondrial ATP across the mitochondrial inner membrane. May participate in the formation of the permeability transition pore complex (PTPC) responsible for the release of mitochondrial products that triggers apoptosis.", "general_function": "Atp:adp antiporter activity", "gene_names": ["SLC25A6"], "name": "ADP/ATP translocase 3", "drug_actions": [{"action": "INHIBITOR", "target": "P12236", "drug": "DB00720"}]}, "O00222": {"specific_function": "G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.", "general_function": "Group iii metabotropic glutamate receptor activity", "gene_names": ["GRM8"], "name": "Metabotropic glutamate receptor 8", "drug_actions": []}, "P08244": {"specific_function": "Catalyzes the decarboxylation of orotidine 5'-monophosphate (OMP) to uridine 5'-monophosphate (UMP).", "general_function": "Orotidine-5'-phosphate decarboxylase activity", "gene_names": ["pyrF"], "name": "Orotidine 5'-phosphate decarboxylase", "drug_actions": []}, "P12235": {"specific_function": "Catalyzes the exchange of cytoplasmic ADP with mitochondrial ATP across the mitochondrial inner membrane.", "general_function": "Adenine transmembrane transporter activity", "gene_names": ["SLC25A4"], "name": "ADP/ATP translocase 1", "drug_actions": [{"action": "INHIBITOR", "target": "P12235", "drug": "DB00720"}]}, "Q07075": {"specific_function": "Appears to have a role in the catabolic pathway of the renin-angiotensin system. Probably plays a role in regulating growth and differentiation of early B-lineage cells.", "general_function": "Zinc ion binding", "gene_names": ["ENPEP"], "name": "Glutamyl aminopeptidase", "drug_actions": []}, "P0A5J4": {"specific_function": "Acetyl-CoA + H(2)O + glyoxylate = (S)-malate + CoA", "general_function": "Energy production and conversion", "gene_names": ["glcB"], "name": "Malate synthase G", "drug_actions": []}, "P69772": {"specific_function": "Flavin prenyltransferase that catalyzes the synthesis of the prenylated FMN cofactor (prenyl-FMN) for phenolic acid decarboxylase C (By similarity). Involved in the decarboxylation and detoxification of phenolic derivatives under both aerobic and anaerobic conditions (PubMed:15979273).", "general_function": "Prenyltransferase activity", "gene_names": ["ecdB"], "name": "Probable UbiX-like flavin prenyltransferase", "drug_actions": []}, "P0A5J2": {"gene_names": ["map"], "name": "Methionine aminopeptidase 2", "drug_actions": []}, "Q9UP95": {"specific_function": "Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral Cl(-) exit in NaCl absorbing epithelia (By similarity). Isoform 4 has no transport activity.", "general_function": "Protein kinase binding", "gene_names": ["SLC12A4"], "name": "Solute carrier family 12 member 4", "drug_actions": [{"action": "INHIBITOR", "target": "Q9UP95", "drug": "DB00887"}]}, "Q56748": {"gene_names": ["sud"], "name": "Sulfide dehydrogenase", "drug_actions": []}, "P0ABE7": {"specific_function": "Electron-transport protein of unknown function.", "general_function": "Iron ion binding", "gene_names": ["cybC"], "name": "Soluble cytochrome b562", "drug_actions": []}, "Q9EXV5": {"gene_names": [], "name": "Beta-lactamase CTX-M-15", "drug_actions": [{"action": "INHIBITOR", "target": "Q9EXV5", "drug": "DB09060"}]}, "Q51366": {"specific_function": "Catalyzes the conversion of GDP-D-mannose to GDP-4-dehydro-6-deoxy-D-mannose.", "general_function": "Nadp+ binding", "gene_names": ["gmd"], "name": "GDP-mannose 4,6-dehydratase", "drug_actions": []}, "P0AB91": {"specific_function": "Stereospecific condensation of phosphoenolpyruvate (PEP) and D-erythrose-4-phosphate (E4P) giving rise to 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP).", "general_function": "Identical protein binding", "gene_names": ["aroG"], "name": "Phospho-2-dehydro-3-deoxyheptonate aldolase, Phe-sensitive", "drug_actions": []}, "P0AE67": {"specific_function": "Involved in the transmission of sensory signals from the chemoreceptors to the flagellar motors. In its active (phosphorylated or acetylated) form, CheY exhibits enhanced binding to a switch component, FliM, at the flagellar motor which induces a change from counterclockwise to clockwise flagellar rotation. Overexpression of CheY in association with MotA and MotB improves motility of a ycgR disruption, suggesting there is an interaction (direct or indirect) between the c-di-GMP-binding flagellar brake protein and the flagellar stator.", "general_function": "Magnesium ion binding", "gene_names": ["cheY"], "name": "Chemotaxis protein CheY", "drug_actions": []}, "P01189": {"specific_function": "ACTH stimulates the adrenal glands to release cortisol.MSH (melanocyte-stimulating hormone) increases the pigmentation of skin by increasing melanin production in melanocytes.Beta-endorphin and Met-enkephalin are endogenous opiates.", "general_function": "Type 4 melanocortin receptor binding", "gene_names": ["POMC"], "name": "Pro-opiomelanocortin", "drug_actions": [{"action": "MODULATOR", "target": "P01189", "drug": "DB00836"}, {"action": "AGONIST", "target": "P01189", "drug": "DB01565"}]}, "P0AFB1": {"specific_function": "May be involved in cell division. May play a role in bacterial septation or regulation of cell wall degradation during cell division. Negatively controls the production of extracellular DNA (eDNA).", "gene_names": ["nlpI"], "name": "Lipoprotein NlpI", "drug_actions": []}, "P59796": {"general_function": "Glutathione peroxidase activity", "gene_names": ["GPX6"], "name": "Glutathione peroxidase 6", "drug_actions": [{"action": "COFACTOR", "target": "P59796", "drug": "DB00143"}]}, "P00148": {"specific_function": "Cytochrome c' is the most widely occurring bacterial c-type cytochrome. Cytochromes c' are high-spin proteins and the heme has no sixth ligand. Their exact function is not known.", "general_function": "Iron ion binding", "gene_names": ["cycP"], "name": "Cytochrome c'", "drug_actions": []}, "P13727": {"specific_function": "Cytotoxin and helminthotoxin. Also induces non-cytolytic histamine release from human basophils. Involved in antiparasitic defense mechanisms and immune hypersensitivity reactions. The proform acts as a proteinase inhibitor, reducing the activity of PAPPA.", "general_function": "Heparin binding", "gene_names": ["PRG2"], "name": "Bone marrow proteoglycan", "drug_actions": []}, "P13726": {"specific_function": "Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited protolysis. TF plays a role in normal hemostasis by initiating the cell-surface assembly and propagation of the coagulation protease cascade.", "general_function": "Protease binding", "gene_names": ["F3"], "name": "Tissue factor", "drug_actions": []}, "P33905": {"specific_function": "Positive regulation of conjugal transfer of Ti plasmids. TraR activates target genes in the presence of AAI and also activates traR and traI themselves.", "general_function": "Dna binding", "gene_names": ["traR"], "name": "Transcriptional activator protein TraR", "drug_actions": []}, "P06709": {"specific_function": "Acts both as a biotin--[acetyl-CoA-carboxylase] ligase and a biotin-operon repressor. In the presence of ATP, BirA activates biotin to form the BirA-biotinyl-5'-adenylate (BirA-bio-5'-AMP or holoBirA) complex. HoloBirA can either transfer the biotinyl moiety to the biotin carboxyl carrier protein (BCCP) subunit of acetyl-CoA carboxylase, or bind to the biotin operator site and inhibit transcription of the operon.", "general_function": "Dna binding", "gene_names": ["birA"], "name": "Bifunctional ligase/repressor BirA", "drug_actions": []}, "P0AAJ3": {"specific_function": "Formate dehydrogenase allows E.coli to use formate as major electron donor during anaerobic respiration, when nitrate is used as electron acceptor. The beta subunit FdnH is an electron transfer unit containing 4 iron-sulfur clusters; it serves as a conduit for electrons that are transferred from the formate oxidation site in the alpha subunit (FdnG) to the menaquinone associated with the gamma subunit (FdnI) of formate dehydrogenase-N. Formate dehydrogenase-N is part of a system that generates proton motive force, together with the dissimilatory nitrate reductase (Nar).", "general_function": "Metal ion binding", "gene_names": ["fdnH"], "name": "Formate dehydrogenase, nitrate-inducible, iron-sulfur subunit", "drug_actions": []}, "P31723": {"specific_function": "Involved in the maturation of Asn-linked oligosaccharides. Progressively trim alpha-1,2-linked mannose residues from Man(9)GlcNAc(2) to produce Man(5)GlcNAc(2).", "general_function": "Mannosyl-oligosaccharide 1,2-alpha-mannosidase activity", "gene_names": ["MSDC"], "name": "Mannosyl-oligosaccharide alpha-1,2-mannosidase", "drug_actions": []}, "Q9ULC6": {"specific_function": "Catalyzes the deimination of arginine residues of proteins.", "general_function": "Protein-arginine deiminase activity", "gene_names": ["PADI1"], "name": "Protein-arginine deiminase type-1", "drug_actions": []}, "Q9WYE2": {"general_function": "Alpha-l-fucosidase activity", "gene_names": [], "name": "Alpha-L-fucosidase, putative", "drug_actions": []}, "Q9NXA8": {"specific_function": "NAD-dependent lysine demalonylase, desuccinylase and deglutarylase that specifically removes malonyl, succinyl and glutaryl groups on target proteins (PubMed:21908771, PubMed:22076378, PubMed:24703693). Activates CPS1 and contributes to the regulation of blood ammonia levels during prolonged fasting: acts by mediating desuccinylation and deglutarylation of CPS1, thereby increasing CPS1 activity in response to elevated NAD levels during fasting (PubMed:22076378, PubMed:24703693). Activates SOD1 by mediating its desuccinylation, leading to reduced reactive oxygen species (PubMed:24140062). Modulates ketogenesis through the desuccinylation and activation of HMGCS2 (By similarity). Has weak NAD-dependent protein deacetylase activity; however this activity may not be physiologically relevant in vivo. Can deacetylate cytochrome c (CYCS) and a number of other proteins in vitro such as UOX.", "general_function": "Zinc ion binding", "gene_names": ["SIRT5"], "name": "NAD-dependent protein deacylase sirtuin-5, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "Q9NXA8", "drug": "DB04786"}]}, "P05162": {"specific_function": "This protein binds beta-galactoside. Its physiological function is not yet known.", "general_function": "Galactoside binding", "gene_names": ["LGALS2"], "name": "Galectin-2", "drug_actions": []}, "P11546": {"general_function": "6-phospho-beta-galactosidase activity", "gene_names": ["lacG"], "name": "6-phospho-beta-galactosidase", "drug_actions": []}, "P05166": {"general_function": "Propionyl-coa carboxylase activity", "gene_names": ["PCCB"], "name": "Propionyl-CoA carboxylase beta chain, mitochondrial", "drug_actions": []}, "P0AD69": {"specific_function": "Essential cell division protein that is required for the synthesis of peptidoglycan at the division septum. Catalyzes the synthesis of cross-linked peptidoglycan from the lipid-linked precursors.", "general_function": "Peptidoglycan glycosyltransferase activity", "gene_names": ["ftsI"], "name": "Peptidoglycan synthase FtsI", "drug_actions": []}, "P05164": {"specific_function": "Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.", "general_function": "Peroxidase activity", "gene_names": ["MPO"], "name": "Myeloperoxidase", "drug_actions": [{"action": "INHIBITOR", "target": "P05164", "drug": "DB00535"}, {"action": "INHIBITOR", "target": "P05164", "drug": "DB01065"}]}, "P05165": {"general_function": "Propionyl-coa carboxylase activity", "gene_names": ["PCCA"], "name": "Propionyl-CoA carboxylase alpha chain, mitochondrial", "drug_actions": []}, "P13051": {"specific_function": "Excises uracil residues from the DNA which can arise as a result of misincorporation of dUMP residues by DNA polymerase or due to deamination of cytosine.", "general_function": "Uracil dna n-glycosylase activity", "gene_names": ["UNG"], "name": "Uracil-DNA glycosylase", "drug_actions": []}, "P69178": {"specific_function": "The B subunit is responsible for the binding of the holotoxin to specific receptors on the target cell surface, such as globotriaosylceramide (Gb3) in human intestinal microvilli.", "gene_names": ["stxB"], "name": "Shiga-like toxin 1 subunit B", "drug_actions": []}, "Q939D2": {"specific_function": "Bifunctional enzyme with both catalase and broad-spectrum peroxidase activity. Displays also NADH oxidase, isoniazid hydrazine lyase and isonicotinoyl-NAD synthase activity.", "general_function": "Metal ion binding", "gene_names": ["katG"], "name": "Catalase-peroxidase", "drug_actions": []}, "P24232": {"specific_function": "Is involved in NO detoxification in an aerobic process, termed nitric oxide dioxygenase (NOD) reaction that utilizes O(2) and NAD(P)H to convert NO to nitrate, which protects the bacterium from various noxious nitrogen compounds. Therefore, plays a central role in the inducible response to nitrosative stress.In the presence of oxygen and NADH, HMP has NADH oxidase activity, which leads to the generation of superoxide and H(2)O(2), both in vitro and in vivo, and it has been suggested that HMP might act as an amplifier of superoxide stress. Under anaerobic conditions, HMP also exhibits nitric oxide reductase and FAD reductase activities. However, all these reactions are much lower than NOD activity.Various electron acceptors are also reduced by HMP in vitro, including dihydropterine, ferrisiderophores, ferric citrate, cytochrome c, nitrite, S-nitrosoglutathione, and alkylhydroperoxides. However, it is unknown if these reactions are of any biological significance in vivo.", "general_function": "Oxygen transporter activity", "gene_names": ["hmp"], "name": "Flavohemoprotein", "drug_actions": []}, "P10415": {"specific_function": "Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785).", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["BCL2"], "name": "Apoptosis regulator Bcl-2", "drug_actions": [{"action": "MODULATOR", "target": "P10415", "drug": "DB01050"}, {"action": "INHIBITOR", "target": "P10415", "drug": "DB01229"}, {"action": "ACTIVATOR", "target": "P10415", "drug": "DB01367"}]}, "P55263": {"specific_function": "ATP dependent phosphorylation of adenosine and other related nucleoside analogs to monophosphate derivatives. Serves as a potential regulator of concentrations of extracellular adenosine and intracellular adenine nucleotides.", "general_function": "Poly(a) rna binding", "gene_names": ["ADK"], "name": "Adenosine kinase", "drug_actions": [{"action": "PRODUCT OF", "target": "P55263", "drug": "DB00131"}, {"action": "ACTIVATOR", "target": "P55263", "drug": "DB00811"}]}, "P75914": {"specific_function": "Hydrolyzes p-nitrophenyl phosphate (pNPP) in vitro. Involved in the swarming motility process.", "general_function": "Zinc ion binding", "gene_names": ["ycdX"], "name": "Probable phosphatase YcdX", "drug_actions": []}, "Q96I15": {"specific_function": "Catalyzes the decomposition of L-selenocysteine to L-alanine and elemental selenium.", "general_function": "Transferase activity", "gene_names": ["SCLY"], "name": "Selenocysteine lyase", "drug_actions": [{"action": "COFACTOR", "target": "Q96I15", "drug": "DB00114"}]}, "O60840": {"specific_function": "Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1F gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin-GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA).", "name": "Voltage-dependent L-type calcium channel subunit alpha-1F", "drug_actions": [{"action": "INHIBITOR", "target": "O60840", "drug": "DB00393"}, {"action": "INHIBITOR", "target": "O60840", "drug": "DB00568"}, {"action": "INHIBITOR", "target": "O60840", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "O60840", "drug": "DB01388"}], "general_function": "Voltage-gated calcium channel activity", "in_complexes": ["Voltage-dependent calcium channel"], "gene_names": ["CACNA1F"]}, "Q9X4K7": {"general_function": "Acetyl-coa carboxylase activity", "gene_names": ["pccB"], "name": "Propionyl-CoA carboxylase complex B subunit", "drug_actions": []}, "P07658": {"specific_function": "Decomposes formic acid to hydrogen and carbon dioxide under anaerobic conditions in the absence of exogenous electron acceptors.", "general_function": "Nadh dehydrogenase activity", "gene_names": ["fdhF"], "name": "Formate dehydrogenase H", "drug_actions": []}, "Q51504": {"general_function": "Peptidoglycan glycosyltransferase activity", "gene_names": ["pbpB"], "name": "Cell division protein", "drug_actions": [{"action": "INHIBITOR", "target": "Q51504", "drug": "DB01147"}, {"action": "INHIBITOR", "target": "Q51504", "drug": "DB01413"}, {"action": "ANTAGONIST", "target": "Q51504", "drug": "DB06211"}, {"action": "INHIBITOR", "target": "Q51504", "drug": "DB06211"}, {"action": "INHIBITOR", "target": "Q51504", "drug": "DB09050"}]}, "Q15303": {"specific_function": "Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. Required for normal development of the embryonic central nervous system, especially for normal neural crest cell migration and normal axon guidance. Required for mammary gland differentiation, induction of milk proteins and lactation. Acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Ligand specificity and signaling is modulated by alternative splicing, proteolytic processing, and by the formation of heterodimers with other ERBB family members, thereby creating multiple combinations of intracellular phosphotyrosines that trigger ligand- and context-specific cellular responses. Mediates phosphorylation of SHC1 and activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the activation of phosphatidylinositol 3-kinase and AKT1 and protect cells against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate reorganization of the actin cytoskeleton and promote cell migration in response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the phosphotyrosine that mediates interaction with PIK3R1, and hence do not phosphorylate PIK3R1, do not protect cells against apoptosis, and do not promote reorganization of the actin cytoskeleton and cell migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM-A CYT-2 gives rise to the corresponding soluble intracellular domains (4ICD) that translocate to the nucleus, promote nuclear import of STAT5A, activation of STAT5A, mammary epithelium differentiation, cell proliferation and activation of gene expression. The ERBB4 soluble intracellular domains (4ICD) colocalize with STAT5A at the CSN2 promoter to regulate transcription of milk proteins during lactation. The ERBB4 soluble intracellular domains can also translocate to mitochondria and promote apoptosis.", "general_function": "Transmembrane receptor protein tyrosine kinase activity", "gene_names": ["ERBB4"], "name": "Receptor tyrosine-protein kinase erbB-4", "drug_actions": [{"action": "INHIBITOR", "target": "Q15303", "drug": "DB08916"}]}, "P29317": {"specific_function": "Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the ligand ephrin-A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation and differentiation of cells. Regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. May also participate in UV radiation-induced apoptosis and have a ligand-independent stimulatory effect on chemotactic cell migration. During development, may function in distinctive aspects of pattern formation and subsequently in development of several fetal tissues. Involved for instance in angiogenesis, in early hindbrain development and epithelial proliferation and branching morphogenesis during mammary gland development. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and interactions and be important for lens transparency development and maintenance. With ephrin-A2/EFNA2 may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis.", "general_function": "Transmembrane receptor protein tyrosine kinase activity", "gene_names": ["EPHA2"], "name": "Ephrin type-A receptor 2", "drug_actions": [{"action": "ANTAGONIST", "target": "P29317", "drug": "DB01254"}, {"action": "INHIBITOR", "target": "P29317", "drug": "DB08896"}]}, "P24394": {"specific_function": "Receptor for both interleukin 4 and interleukin 13. Couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1/IRS2.Soluble IL4R (sIL4R) inhibits IL4-mediated cell proliferation and IL5 up-regulation by T-cells.", "general_function": "Receptor signaling protein activity", "gene_names": ["IL4R"], "name": "Interleukin-4 receptor subunit alpha", "drug_actions": []}, "P55792": {"specific_function": "Catalyzes the reversible conversion of 4-hydroxybutyryl-CoA to crotonyl-CoA. The mechanism of the reaction seems to go through three steps: (1) the FAD-dependent oxidation of 4-hydroxybutyryl-CoA to 4-hydroxycrotonyl-CoA; (2) the hydroxyl group is substituted by a hydride derived from the now reduced FAD in an SN2' reaction leading to vinylacetyl-CoA; (3) isomerization to yield crotonyl-CoA.", "general_function": "Vinylacetyl-coa delta-isomerase activity", "gene_names": ["abfD"], "name": "4-hydroxybutyryl-CoA dehydratase/vinylacetyl-CoA-Delta-isomerase", "drug_actions": []}, "P45877": {"specific_function": "PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides.", "general_function": "Peptidyl-prolyl cis-trans isomerase activity", "gene_names": ["PPIC"], "name": "Peptidyl-prolyl cis-trans isomerase C", "drug_actions": []}, "P83696": {"general_function": "Oxidoreductase activity, acting on the aldehyde or oxo group of donors, nad or nadp as acceptor", "gene_names": [], "name": "Glyceraldehyde-3-phosphate dehydrogenase", "drug_actions": []}, "P0C002": {"specific_function": "Catalyzes the condensation of para-aminobenzoate (pABA) with 6-hydroxymethyl-7,8-dihydropterin diphosphate (DHPt-PP) to form 7,8-dihydropteroate (H2Pte), the immediate precursor of folate derivatives (By similarity). It is implicated in resistance to sulfonamide. The type II enzyme is stable whereas type I DHPS loses its activity rapidly.", "general_function": "Metal ion binding", "gene_names": ["sulI"], "name": "Dihydropteroate synthase type-1", "drug_actions": [{"action": "INHIBITOR", "target": "P0C002", "drug": "DB00634"}]}, "Q9Y646": {"specific_function": "Carboxypeptidase that may play an important role in the hydrolysis of circulating peptides. Catalyzes the hydrolysis of dipeptides with unsubstituted terminals into amino acids. May play a role in the liberation of thyroxine hormone from its thyroglobulin (Tg) precursor.", "general_function": "Protein homodimerization activity", "gene_names": ["CPQ"], "name": "Carboxypeptidase Q", "drug_actions": []}, "Q9BV57": {"specific_function": "Catalyzes the formation of formate and 2-keto-4-methylthiobutyrate (KMTB) from 1,2-dihydroxy-3-keto-5-methylthiopentene (DHK-MTPene). Also down-regulates cell migration mediated by MMP14. Necessary for hepatitis C virus replication in an otherwise non-permissive cell line.", "general_function": "Oxidoreductase activity", "gene_names": ["ADI1"], "name": "1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase", "drug_actions": []}, "P0AD63": {"general_function": "Beta-lactamase activity", "gene_names": ["bla"], "name": "Beta-lactamase SHV-1", "drug_actions": [{"action": "INHIBITOR", "target": "P0AD63", "drug": "DB01606"}, {"action": "INHIBITOR", "target": "P0AD63", "drug": "DB09060"}]}, "O14561": {"specific_function": "Carrier of the growing fatty acid chain in fatty acid biosynthesis in mitochondria. Accessory and non-catalytic subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), which functions in the transfer of electrons from NADH to the respiratory chain (By similarity).", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFAB1"], "name": "Acyl carrier protein, mitochondrial", "drug_actions": []}, "Q96LB9": {"specific_function": "Pattern receptor that binds to murein peptidoglycans (PGN) of Gram-positive bacteria. Has bactericidal activity towards Gram-positive bacteria. May kill Gram-positive bacteria by interfering with peptidoglycan biosynthesis. Binds also to Gram-negative bacteria, and has bacteriostatic activity towards Gram-negative bacteria. Plays a role in innate immunity.", "general_function": "Zinc ion binding", "gene_names": ["PGLYRP3"], "name": "Peptidoglycan recognition protein 3", "drug_actions": []}, "P51151": {"specific_function": "Involved in the transport of proteins between the endosomes and the trans Golgi network.", "general_function": "Gtpase activity", "gene_names": ["RAB9A"], "name": "Ras-related protein Rab-9A", "drug_actions": []}, "P40238": {"specific_function": "Receptor for thrombopoietin. May represent a regulatory molecule specific for TPO-R-dependent immune responses.", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["MPL"], "name": "Thrombopoietin receptor", "drug_actions": [{"action": "AGONIST", "target": "P40238", "drug": "DB05332"}, {"action": "AGONIST", "target": "P40238", "drug": "DB06210"}]}, "P58558": {"general_function": "Ferredoxin-nadp+ reductase activity", "gene_names": ["petH"], "name": "Ferredoxin--NADP reductase", "drug_actions": []}, "P77836": {"specific_function": "Catalyzes phosphorolysis of the pyrimidine nucleosides uridine, thymidine and 2'-deoxyuridine with the formation of the corresponding pyrimidine base and ribose-1-phosphate.", "general_function": "Pyrimidine-nucleoside phosphorylase activity", "gene_names": ["pdp"], "name": "Pyrimidine-nucleoside phosphorylase", "drug_actions": []}, "Q9NNW7": {"specific_function": "Maintains thioredoxin in a reduced state. Implicated in the defenses against oxidative stress. May play a role in redox-regulated cell signaling.", "general_function": "Thioredoxin-disulfide reductase activity", "gene_names": ["TXNRD2"], "name": "Thioredoxin reductase 2, mitochondrial", "drug_actions": []}, "P00505": {"specific_function": "Catalyzes the irreversible transamination of the L-tryptophan metabolite L-kynurenine to form kynurenic acid (KA). Plays a key role in amino acid metabolism. Important for metabolite exchange between mitochondria and cytosol. Facilitates cellular uptake of long-chain free fatty acids.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["GOT2"], "name": "Aspartate aminotransferase, mitochondrial", "drug_actions": [{"action": "COFACTOR", "target": "P00505", "drug": "DB00114"}]}, "P13612": {"specific_function": "Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. Integrin alpha-4/beta-1 recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-4/beta-7 is also a receptor for MADCAM1. It recognizes the sequence L-D-T in MADCAM1. On activated endothelial cells integrin VLA-4 triggers homotypic aggregation for most VLA-4-positive leukocyte cell lines. It may also participate in cytolytic T-cell interactions with target cells.", "general_function": "Metal ion binding", "gene_names": ["ITGA4"], "name": "Integrin alpha-4", "drug_actions": [{"action": "ANTIBODY", "target": "P13612", "drug": "DB00108"}, {"action": "INHIBITOR", "target": "P13612", "drug": "DB06822"}, {"action": "ANTIBODY", "target": "P13612", "drug": "DB09033"}]}, "P13611": {"specific_function": "May play a role in intercellular signaling and in connecting cells with the extracellular matrix. May take part in the regulation of cell motility, growth and differentiation. Binds hyaluronic acid.", "general_function": "Hyaluronic acid binding", "gene_names": ["VCAN"], "name": "Versican core protein", "drug_actions": [{"action": "BINDER", "target": "P13611", "drug": "DB08818"}]}, "Q9KX40": {"specific_function": "Acts on short-chain (C4-C6) fatty acid esters and triglycerides, including tertiary alcohol esters. Activity on p-nitrophenyl esters is generally higher than on o-nitrophenyl esters. Lacks beta-lactamase activity; it hydrolyzes the ester bond of cephalosporin substrates but there is no opening of the beta-lactam ring observed.", "general_function": "Hydrolase activity", "gene_names": ["estB"], "name": "Esterase EstB", "drug_actions": []}, "Q9Y468": {"specific_function": "Polycomb group (PcG) protein that specifically recognizes and binds mono- and dimethyllysine residues on target proteins, therey acting as a 'reader' of a network of post-translational modifications. PcG proteins maintain the transcriptionally repressive state of genes: acts as a chromatin compaction factor by recognizing and binding mono- and dimethylated histone H1b/HIST1H1E at 'Lys-26' (H1bK26me1 and H1bK26me2) and histone H4 at 'Lys-20' (H4K20me1 and H4K20me2), leading to condense chromatin and repress transcription. Recognizes and binds p53/TP53 monomethylated at 'Lys-382', leading to repress p53/TP53-target genes. Also recognizes and binds RB1/RB monomethylated at 'Lys-860'. Participates in the ETV6-mediated repression. Probably plays a role in cell proliferation. Overexpression induces multinucleated cells, suggesting that it is required to accomplish normal mitosis.", "general_function": "Zinc ion binding", "gene_names": ["L3MBTL1"], "name": "Lethal(3)malignant brain tumor-like protein 1", "drug_actions": []}, "P35754": {"specific_function": "Has a glutathione-disulfide oxidoreductase activity in the presence of NADPH and glutathione reductase. Reduces low molecular weight disulfides and proteins.", "general_function": "Protein n-terminus binding", "gene_names": ["GLRX"], "name": "Glutaredoxin-1", "drug_actions": []}, "P0A8M5": {"specific_function": "ThrS is also a translational repressor protein, it controls the translation of its own gene by binding to its mRNA.", "general_function": "Threonine-trna ligase activity", "gene_names": ["thrS"], "name": "Threonine--tRNA ligase", "drug_actions": []}, "Q86W47": {"specific_function": "Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Decreases the gating kinetics and calcium sensitivity of the KCNMA1 channel, but with fast deactivation kinetics. May decrease KCNMA1 channel openings at low calcium concentrations but increases channel openings at high calcium concentrations. Makes KCNMA1 channel resistant to 100 nM charybdotoxin (CTX) toxin concentrations.", "name": "Calcium-activated potassium channel subunit beta-4", "drug_actions": [{"action": "BINDER", "target": "Q86W47", "drug": "DB00721"}, {"action": "INHIBITOR", "target": "Q86W47", "drug": "DB01110"}], "general_function": "Potassium channel regulator activity", "in_complexes": ["Calcium-activated potassium channel"], "gene_names": ["KCNMB4"]}, "Q5KUI3": {"specific_function": "Catalyzes the conversion of uracil and 5-phospho-alpha-D-ribose 1-diphosphate (PRPP) to UMP and diphosphate.", "general_function": "Uracil phosphoribosyltransferase activity", "gene_names": ["upp"], "name": "Uracil phosphoribosyltransferase", "drug_actions": []}, "Q5KUI2": {"specific_function": "Catalyzes the reversible interconversion of serine and glycine with tetrahydrofolate (THF) serving as the one-carbon carrier. This reaction serves as the major source of one-carbon groups required for the biosynthesis of purines, thymidylate, methionine, and other important biomolecules. Also exhibits THF-independent aldolase activity toward beta-hydroxyamino acids, producing glycine and aldehydes, via a retro-aldol mechanism.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["glyA"], "name": "Serine hydroxymethyltransferase", "drug_actions": []}, "Q9X592": {"general_function": "Lyase activity", "gene_names": ["pelA"], "name": "Pectate lyase", "drug_actions": []}, "P51812": {"specific_function": "Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1. In fibroblast, is required for EGF-stimulated phosphorylation of CREB1 and histone H3 at 'Ser-10', which results in the subsequent transcriptional activation of several immediate-early genes. In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP. Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity. Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the preinitiation complex. In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation. Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway. Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function. Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression. In LPS-stimulated dendritic cells, is involved in TLR4-induced macropinocytosis, and in myeloma cells, acts as effector of FGFR3-mediated transformation signaling, after direct phosphorylation at Tyr-529 by FGFR3. Phosphorylates DAPK1.", "general_function": "Ribosomal protein s6 kinase activity", "gene_names": ["RPS6KA3"], "name": "Ribosomal protein S6 kinase alpha-3", "drug_actions": []}, "P07097": {"general_function": "Acetyl-coa c-acetyltransferase activity", "gene_names": ["phbA"], "name": "Acetyl-CoA acetyltransferase", "drug_actions": []}, "O82839": {"general_function": "Hydrolase activity, hydrolyzing o-glycosyl compounds", "gene_names": [], "name": "Amylase", "drug_actions": []}, "P18548": {"specific_function": "Catalyzes the step from penicillin N to deacetoxy-cephalosporin C.", "general_function": "L-ascorbic acid binding", "gene_names": ["cefE"], "name": "Deacetoxycephalosporin C synthase", "drug_actions": []}, "Q7WYV4": {"general_function": "Metal ion binding", "gene_names": ["udg"], "name": "Uracil-DNA glycosylase", "drug_actions": []}, "P34913": {"specific_function": "Bifunctional enzyme. The C-terminal domain has epoxide hydrolase activity and acts on epoxides (alkene oxides, oxiranes) and arene oxides. Plays a role in xenobiotic metabolism by degrading potentially toxic epoxides. Also determines steady-state levels of physiological mediators. The N-terminal domain has lipid phosphatase activity, with the highest activity towards threo-9,10-phosphonooxy-hydroxy-octadecanoic acid, followed by erythro-9,10-phosphonooxy-hydroxy-octadecanoic acid, 12-phosphonooxy-octadec-9Z-enoic acid, 12-phosphonooxy-octadec-9E-enoic acid, and p-nitrophenyl phospate.", "general_function": "Toxic substance binding", "gene_names": ["EPHX2"], "name": "Bifunctional epoxide hydrolase 2", "drug_actions": []}, "P29957": {"general_function": "Metal ion binding", "gene_names": ["amy"], "name": "Alpha-amylase", "drug_actions": []}, "P18545": {"specific_function": "Participates in processes of transmission and amplification of the visual signal. cGMP-PDEs are the effector molecules in G-protein-mediated phototransduction in vertebrate rods and cones.", "general_function": "Enzyme inhibitor activity", "gene_names": ["PDE6G"], "name": "Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma", "drug_actions": [{"action": "INHIBITOR", "target": "P18545", "drug": "DB00203"}, {"action": "ALLOSTERIC MODULATOR", "target": "P18545", "drug": "DB00862"}]}, "P0A6L6": {"specific_function": "Catalyzes the reversible aldol cleavage of N-acetylneuraminic acid (sialic acid; Neu5Ac) to form pyruvate and N-acetylmannosamine (ManNAc) via a Schiff base intermediate.", "general_function": "N-acetylneuraminate lyase activity", "gene_names": ["nanA"], "name": "N-acetylneuraminate lyase", "drug_actions": []}, "P02787": {"specific_function": "Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from sites of absorption and heme degradation to those of storage and utilization. Serum transferrin may also have a further role in stimulating cell proliferation.", "general_function": "Transferrin receptor binding", "gene_names": ["TF"], "name": "Serotransferrin", "drug_actions": []}, "Q92993": {"specific_function": "Catalytic subunit of the NuA4 histone acetyltransferase complex which is involved in transcriptional activation of select genes principally by acetylation of nucleosomal histones H4 and H2A. This modification may both alter nucleosome-DNA interactions and promote interaction of the modified histones with other proteins which positively regulate transcription. This complex may be required for the activation of transcriptional programs associated with oncogene and proto-oncogene mediated growth induction, tumor suppressor mediated growth arrest and replicative senescence, apoptosis, and DNA repair. NuA4 may also play a direct role in DNA repair when recruited to sites of DNA damage. Directly acetylates and activates ATM. Component of a SWR1-like complex that specifically mediates the removal of histone H2A.Z/H2AFZ from the nucleosome. In case of HIV-1 infection, interaction with the viral Tat protein leads to KAT5 polyubiquitination and targets it to degradation. Relieves NR1D2-mediated inhibition of APOC3 expression by acetylating NR1D2. Promotes FOXP3 acetylation and positively regulates its transcriptional repressor activity (PubMed:17360565).", "general_function": "Transcription coactivator activity", "gene_names": ["KAT5"], "name": "Histone acetyltransferase KAT5", "drug_actions": []}, "P96222": {"general_function": "Involved in DNA binding", "gene_names": ["ethR"], "name": "HTH-type transcriptional regulator EthR", "drug_actions": []}, "Q16836": {"specific_function": "Plays an essential role in the mitochondrial beta-oxidation of short chain fatty acids. Exerts it highest activity toward 3-hydroxybutyryl-CoA.", "general_function": "Nad+ binding", "gene_names": ["HADH"], "name": "Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial", "drug_actions": []}, "P19821": {"general_function": "Nucleoside binding", "gene_names": ["polA"], "name": "DNA polymerase I, thermostable", "drug_actions": []}, "O15382": {"specific_function": "Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine. May also function as a transporter of branched chain alpha-keto acids.", "general_function": "L-valine transaminase activity", "gene_names": ["BCAT2"], "name": "Branched-chain-amino-acid aminotransferase, mitochondrial", "drug_actions": [{"action": "COFACTOR", "target": "O15382", "drug": "DB00114"}]}, "P02788": {"specific_function": "Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate.Lactotransferrin is a major iron-binding and multifunctional protein found in exocrine fluids such as breast milk and mucosal secretions. Has antimicrobial activity, which depends on the extracellular cation concentration. Antimicrobial properties include bacteriostasis, which is related to its ability to sequester free iron and thus inhibit microbial growth, as well as direct bactericidal properties leading to the release of lipopolysaccharides from the bacterial outer membrane. Can also prevent bacterial biofilm development in P.aeruginosa infection. Has weak antifungal activity against C.albicans. Has anabolic, differentiating and anti-apoptotic effects on osteoblasts and can also inhibit osteoclastogenesis, possibly playing a role in the regulation of bone growth. Promotes binding of species C adenoviruses to epithelial cells, promoting adenovirus infection. Can inhibit papillomavirus infections. Stimulates the TLR4 signaling pathway leading to NF-kappa-B activation and subsequent pro-inflammatory cytokine production while also interfering with the lipopolysaccharide (LPS)-stimulated TLR4 signaling. Inhibits neutrophil granulocyte migration to sites of apoptosis, when secreted by apoptotic cells. Stimulates VEGFA-mediated endothelial cell migration and proliferation. Binds heparin, chondroitin sulfate and possibly other glycosaminoglycans (GAGs). Also binds specifically to pneumococcal surface protein A (pspA), the lipid A portion of bacterial lipopolysaccharide (LPS), lysozyme and DNA.Lactoferricin binds to the bacterial surface and is crucial for the bactericidal functions. Has some antiviral activity against papillomavirus infection. N-terminal region shows strong antifungal activity against C.albicans. Contains two BBXB heparin-binding consensus sequences that appear to form the predominate functional GAG-binding site.Kaliocin-1 has antimicrobial activity and is able to permeabilize different ions through liposomal membranes.Lactoferroxins A, B and C have opioid antagonist activity. Lactoferroxin A shows preference for mu-receptors, while lactoferroxin B and C have somewhat higher degrees of preference for kappa-receptors than for mu-receptors.The lactotransferrin transferrin-like domain 1 functions as a serine protease of the peptidase S60 family that cuts arginine rich regions. This function contributes to the antimicrobial activity.Isoform DeltaLf: transcription factor with antiproliferative properties and ability to induce cell cycle arrest. Binds to the DeltaLf response element found in the SKP1, BAX, DCPS, and SELH promoters.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["LTF"], "name": "Lactotransferrin", "drug_actions": []}, "P01768": {"general_function": "Involved in regulation of immune response", "gene_names": [], "name": "Ig heavy chain V-III region CAM", "drug_actions": []}, "P07237": {"specific_function": "This multifunctional protein catalyzes the formation, breakage and rearrangement of disulfide bonds. At the cell surface, seems to act as a reductase that cleaves disulfide bonds of proteins attached to the cell. May therefore cause structural modifications of exofacial proteins. Inside the cell, seems to form/rearrange disulfide bonds of nascent proteins. At high concentrations, functions as a chaperone that inhibits aggregation of misfolded proteins. At low concentrations, facilitates aggregation (anti-chaperone activity). May be involved with other chaperones in the structural modification of the TG precursor in hormone biogenesis. Also acts a structural subunit of various enzymes such as prolyl 4-hydroxylase and microsomal triacylglycerol transfer protein MTTP. Receptor for LGALS9; the interaction retains P4HB at the cell surface of Th2 T helper cells, increasing disulfide reductase activity at the plasma membrane, altering the plasma membrane redox state and enhancing cell migration (PubMed:21670307).", "general_function": "Protein heterodimerization activity", "gene_names": ["P4HB"], "name": "Protein disulfide-isomerase", "drug_actions": []}, "O15144": {"specific_function": "Functions as actin-binding component of the Arp2/3 complex which is involved in regulation of actin polymerization and together with an activating nucleation-promoting factor (NPF) mediates the formation of branched actin networks. Seems to contact the mother actin filament.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["ARPC2"], "name": "Actin-related protein 2/3 complex subunit 2", "drug_actions": []}, "O15145": {"specific_function": "Functions as component of the Arp2/3 complex which is involved in regulation of actin polymerization and together with an activating nucleation-promoting factor (NPF) mediates the formation of branched actin networks.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["ARPC3"], "name": "Actin-related protein 2/3 complex subunit 3", "drug_actions": []}, "O34667": {"specific_function": "Involved in the synthesis of autoinducer 2 (AI-2) which is secreted by bacteria and is used to communicate both the cell density and the metabolic potential of the environment. The regulation of gene expression in response to changes in cell density is called quorum sensing. Catalyzes the transformation of S-ribosylhomocysteine (RHC) to homocysteine (HC) and 4,5-dihydroxy-2,3-pentadione (DPD).", "general_function": "S-ribosylhomocysteine lyase activity", "gene_names": ["luxS"], "name": "S-ribosylhomocysteine lyase", "drug_actions": []}, "P29559": {"specific_function": "Lanthionine-containing peptide antibiotic (lantibiotic) active on Gram-positive bacteria. The bactericidal activity of lantibiotics is based on depolarization of energized bacterial cytoplasmic membranes, initiated by the formation of aqueous transmembrane pores.", "gene_names": ["nisZ"], "name": "Lantibiotic nisin-Z", "drug_actions": []}, "P07550": {"specific_function": "Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.", "name": "Beta-2 adrenergic receptor", "drug_actions": [{"action": "AGONIST", "target": "P07550", "drug": "DB00182"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00195"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00217"}, {"action": "AGONIST", "target": "P07550", "drug": "DB00221"}, {"action": "BINDER", "target": "P07550", "drug": "DB00248"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00264"}, {"action": "BINDER", "target": "P07550", "drug": "DB00321"}, {"action": "AGONIST", "target": "P07550", "drug": "DB00368"}, {"action": "BINDER", "target": "P07550", "drug": "DB00370"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00373"}, {"action": "AGONIST", "target": "P07550", "drug": "DB00397"}, {"action": "AGONIST", "target": "P07550", "drug": "DB00449"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00489"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00521"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00571"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00598"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00612"}, {"action": "AGONIST", "target": "P07550", "drug": "DB00668"}, {"action": "BINDER", "target": "P07550", "drug": "DB00726"}, {"action": "AGONIST", "target": "P07550", "drug": "DB00816"}, {"action": "AGONIST", "target": "P07550", "drug": "DB00841"}, {"action": "PARTIAL AGONIST", "target": "P07550", "drug": "DB00852"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB00866"}, {"action": "AGONIST", "target": "P07550", "drug": "DB00867"}, {"action": "AGONIST", "target": "P07550", "drug": "DB00871"}, {"action": "AGONIST", "target": "P07550", "drug": "DB00938"}, {"action": "PARTIAL AGONIST", "target": "P07550", "drug": "DB00960"}, {"action": "AGONIST", "target": "P07550", "drug": "DB00983"}, {"action": "AGONIST", "target": "P07550", "drug": "DB01001"}, {"action": "AGONIST", "target": "P07550", "drug": "DB01064"}, {"action": "AGONIST", "target": "P07550", "drug": "DB01102"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB01136"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB01151"}, {"action": "PARTIAL AGONIST", "target": "P07550", "drug": "DB01193"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB01203"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB01210"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB01214"}, {"action": "AGONIST", "target": "P07550", "drug": "DB01274"}, {"action": "AGONIST", "target": "P07550", "drug": "DB01288"}, {"action": "AGONIST", "target": "P07550", "drug": "DB01291"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB01295"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB01359"}, {"action": "PARTIAL AGONIST", "target": "P07550", "drug": "DB01359"}, {"action": "AGONIST", "target": "P07550", "drug": "DB01363"}, {"action": "AGONIST", "target": "P07550", "drug": "DB01365"}, {"action": "AGONIST", "target": "P07550", "drug": "DB01366"}, {"action": "AGONIST", "target": "P07550", "drug": "DB01407"}, {"action": "AGONIST", "target": "P07550", "drug": "DB01408"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB01580"}, {"action": "AGONIST", "target": "P07550", "drug": "DB04846"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB04861"}, {"action": "AGONIST", "target": "P07550", "drug": "DB05039"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB06216"}, {"action": "AGONIST", "target": "P07550", "drug": "DB06262"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB06726"}, {"action": "PARTIAL AGONIST", "target": "P07550", "drug": "DB08807"}, {"action": "ANTAGONIST", "target": "P07550", "drug": "DB08808"}, {"action": "AGONIST", "target": "P07550", "drug": "DB09080"}, {"action": "AGONIST", "target": "P07550", "drug": "DB09082"}], "general_function": "Protein homodimerization activity", "in_complexes": ["Beta adrenergic receptor"], "gene_names": ["ADRB2"]}, "P94622": {"general_function": "Metal ion binding", "gene_names": ["engF"], "name": "Endo-1,4-beta glucanase EngF", "drug_actions": []}, "P06881": {"specific_function": "CGRP induces vasodilation. It dilates a variety of vessels including the coronary, cerebral and systemic vasculature. Its abundance in the CNS also points toward a neurotransmitter or neuromodulator role. It also elevates platelet cAMP.", "general_function": "Receptor binding", "gene_names": ["CALCA"], "name": "Calcitonin gene-related peptide 1", "drug_actions": []}, "Q08210": {"specific_function": "Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor.", "general_function": "Dihydroorotate dehydrogenase activity", "gene_names": [], "name": "Dihydroorotate dehydrogenase (quinone), mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "Q08210", "drug": "DB01117"}]}, "Q01043": {"specific_function": "May be highly relevant to the process of cellular transformation and rapid T-cell proliferation effected by HVS during latent infections of T-cells in susceptible hosts.", "gene_names": ["72"], "name": "Cyclin homolog", "drug_actions": []}, "P25910": {"specific_function": "Can hydrolyze carbapenem compounds.", "general_function": "Zinc ion binding", "gene_names": ["ccrA"], "name": "Beta-lactamase type II", "drug_actions": []}, "Q9X022": {"general_function": "Oxidoreductase activity", "gene_names": [], "name": "Alcohol dehydrogenase, iron-containing", "drug_actions": []}, "Q47066": {"specific_function": "Has strong cefotaxime-hydrolyzing activity.", "general_function": "Beta-lactamase activity", "gene_names": ["bla"], "name": "Beta-lactamase Toho-1", "drug_actions": []}, "P78508": {"specific_function": "May be responsible for potassium buffering action of glial cells in the brain. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by extracellular barium and cesium (By similarity).", "name": "ATP-sensitive inward rectifier potassium channel 10", "drug_actions": [], "general_function": "Atp-activated inward rectifier potassium channel activity", "in_complexes": ["ATP-sensitive potassium channel"], "gene_names": ["KCNJ10"]}, "Q9K2N0": {"general_function": "Involved in hydrolase activity", "gene_names": ["blaVIM-2"], "name": "Beta-lactamase class B VIM-2", "drug_actions": []}, "P24425": {"specific_function": "In latent infection, may allow the virus to be reactivated and to grow in cells lacking a high concentration of phosphorylated nucleic acid precursors, such as nerve cells that do not replicate their genome.", "general_function": "Thymidine kinase activity", "gene_names": ["TK"], "name": "Thymidine kinase", "drug_actions": []}, "P00781": {"specific_function": "Subtilisin is an extracellular alkaline serine protease, it catalyzes the hydrolysis of proteins and peptide amides.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["apr"], "name": "Subtilisin DY", "drug_actions": []}, "P00780": {"specific_function": "Subtilisin is an extracellular alkaline serine protease, it catalyzes the hydrolysis of proteins and peptide amides.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["apr"], "name": "Subtilisin Carlsberg", "drug_actions": []}, "P35372": {"specific_function": "Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors. The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extend to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15. They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B. Also couples to adenylate cyclase stimulatory G alpha proteins. The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4. Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization. Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction. The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins. The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation. Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling. Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling. Endogenous ligands induce rapid desensitization, endocytosis and recycling whereas morphine induces only low desensitization and endocytosis. Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties. Involved in neurogenesis. Isoform 12 couples to GNAS and is proposed to be involved in excitatory effects. Isoform 16 and isoform 17 do not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity.", "general_function": "Voltage-gated calcium channel activity", "gene_names": ["OPRM1"], "name": "Mu-type opioid receptor", "drug_actions": [{"action": "AGONIST", "target": "P35372", "drug": "DB00193"}, {"action": "AGONIST", "target": "P35372", "drug": "DB00295"}, {"action": "PARTIAL AGONIST", "target": "P35372", "drug": "DB00318"}, {"action": "BINDER", "target": "P35372", "drug": "DB00321"}, {"action": "AGONIST", "target": "P35372", "drug": "DB00327"}, {"action": "AGONIST", "target": "P35372", "drug": "DB00333"}, {"action": "AGONIST", "target": "P35372", "drug": "DB00454"}, {"action": "AGONIST", "target": "P35372", "drug": "DB00497"}, {"action": "PARTIAL AGONIST", "target": "P35372", "drug": "DB00504"}, {"action": "AGONIST", "target": "P35372", "drug": "DB00514"}, {"action": "PARTIAL ANTAGONIST", "target": "P35372", "drug": "DB00611"}, {"action": "AGONIST", "target": "P35372", "drug": "DB00647"}, {"action": "ANTAGONIST", "target": "P35372", "drug": "DB00652"}, {"action": "ANTAGONIST", "target": "P35372", "drug": "DB00704"}, {"action": "AGONIST", "target": "P35372", "drug": "DB00708"}, {"action": "AGONIST", "target": "P35372", "drug": "DB00802"}, {"action": "AGONIST", "target": "P35372", "drug": "DB00813"}, {"action": "AGONIST", "target": "P35372", "drug": "DB00836"}, {"action": "ANTAGONIST", "target": "P35372", "drug": "DB00844"}, {"action": "AGONIST", "target": "P35372", "drug": "DB00854"}, {"action": "AGONIST", "target": "P35372", "drug": "DB00899"}, {"action": "OTHER/UNKNOWN", "target": "P35372", "drug": "DB00904"}, {"action": "AGONIST", "target": "P35372", "drug": "DB00913"}, {"action": "PARTIAL AGONIST", "target": "P35372", "drug": "DB00921"}, {"action": "AGONIST", "target": "P35372", "drug": "DB00956"}, {"action": "AGONIST", "target": "P35372", "drug": "DB01081"}, {"action": "ANTAGONIST", "target": "P35372", "drug": "DB01183"}, {"action": "AGONIST", "target": "P35372", "drug": "DB01192"}, {"action": "AGONIST", "target": "P35372", "drug": "DB01209"}, {"action": "BINDER", "target": "P35372", "drug": "DB01221"}, {"action": "AGONIST", "target": "P35372", "drug": "DB01227"}, {"action": "AGONIST", "target": "P35372", "drug": "DB01433"}, {"action": "AGONIST", "target": "P35372", "drug": "DB01439"}, {"action": "AGONIST", "target": "P35372", "drug": "DB01444"}, {"action": "AGONIST", "target": "P35372", "drug": "DB01452"}, {"action": "AGONIST", "target": "P35372", "drug": "DB01466"}, {"action": "AGONIST", "target": "P35372", "drug": "DB01497"}, {"action": "AGONIST", "target": "P35372", "drug": "DB01535"}, {"action": "ANTAGONIST", "target": "P35372", "drug": "DB01548"}, {"action": "AGONIST", "target": "P35372", "drug": "DB01565"}, {"action": "AGONIST", "target": "P35372", "drug": "DB01571"}, {"action": "AGONIST", "target": "P35372", "drug": "DB06204"}, {"action": "ANTAGONIST", "target": "P35372", "drug": "DB06274"}, {"action": "AGONIST", "target": "P35372", "drug": "DB06738"}, {"action": "ANTAGONIST", "target": "P35372", "drug": "DB06800"}, {"action": "ANTAGONIST", "target": "P35372", "drug": "DB09049"}, {"action": "AGONIST", "target": "P35372", "drug": "DB09272"}]}, "Q9Y6M9": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed to be not involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFB9"], "name": "NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9", "drug_actions": []}, "Q14994": {"specific_function": "Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes. Transactivates both the phenobarbital responsive element module of the human CYP2B6 gene and the CYP3A4 xenobiotic response element.", "general_function": "Zinc ion binding", "gene_names": ["NR1I3"], "name": "Nuclear receptor subfamily 1 group I member 3", "drug_actions": [{"action": "ACTIVATOR", "target": "Q14994", "drug": "DB01708"}]}, "P19711": {"specific_function": "Initial binding to target cell probably involves interaction of E(rns) with glycosaminoglycans. E1 and/or E2 are responsible of cell attachment with CD46 and subsequent fusion after internalization of the virion by endocytosis (Probable).P7 forms a leader sequence to properly orient NS2 in the membrane.Uncleaved NS2-3 is required for production of infectious virus.NS2 protease seems to play a vital role in viral RNA replication control and in the pathogenicity of the virus.NS3 displays three enzymatic activities: serine protease, NTPase and RNA helicase.NS4A is a cofactor for the NS3 protease activity.RNA-directed RNA polymerase NS5 replicates the viral (+) and (-) genome.", "general_function": "Serine-type exopeptidase activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "Q3J170": {"specific_function": "The reaction center is a membrane-bound complex that mediates the initial photochemical event in the electron transfer process of photosynthesis.", "general_function": "Electron transporter, transferring electrons within the cyclic electron transport pathway of photosynthesis activity", "gene_names": ["puhA"], "name": "Reaction center protein H chain", "drug_actions": []}, "P08243": {"general_function": "Protein homodimerization activity", "gene_names": ["ASNS"], "name": "Asparagine synthetase [glutamine-hydrolyzing]", "drug_actions": []}, "Q8NFW8": {"specific_function": "Catalyzes the activation of N-acetylneuraminic acid (NeuNAc) to cytidine 5'-monophosphate N-acetylneuraminic acid (CMP-NeuNAc), a substrate required for the addition of sialic acid. Has some activity toward NeuNAc, N-glycolylneuraminic acid (Neu5Gc) or 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN).", "general_function": "N-acylneuraminate cytidylyltransferase activity", "gene_names": ["CMAS"], "name": "N-acylneuraminate cytidylyltransferase", "drug_actions": []}, "P09668": {"specific_function": "Important for the overall degradation of proteins in lysosomes.", "general_function": "Thyroid hormone binding", "gene_names": ["CTSH"], "name": "Pro-cathepsin H", "drug_actions": []}, "P08246": {"specific_function": "Modifies the functions of natural killer cells, monocytes and granulocytes. Inhibits C5a-dependent neutrophil enzyme release and chemotaxis.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["ELANE"], "name": "Neutrophil elastase", "drug_actions": [{"action": "INHIBITOR", "target": "P08246", "drug": "DB00058"}, {"action": "OTHER/UNKNOWN", "target": "P08246", "drug": "DB00099"}, {"action": "INHIBITOR", "target": "P08246", "drug": "DB03925"}]}, "Q9X5N2": {"general_function": "Serine-type exopeptidase activity", "gene_names": ["pep"], "name": "Prolyl endopeptidase Pep", "drug_actions": []}, "P12104": {"specific_function": "FABP are thought to play a role in the intracellular transport of long-chain fatty acids and their acyl-CoA esters. FABP2 is probably involved in triglyceride-rich lipoprotein synthesis. Binds saturated long-chain fatty acids with a high affinity, but binds with a lower affinity to unsaturated long-chain fatty acids. FABP2 may also help maintain energy homeostasis by functioning as a lipid sensor.", "general_function": "Transporter activity", "gene_names": ["FABP2"], "name": "Fatty acid-binding protein, intestinal", "drug_actions": [{"action": "BINDER", "target": "P12104", "drug": "DB01050"}]}, "F1L7U3": {"specific_function": "Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.", "general_function": "Structural constituent of cytoskeleton", "gene_names": [], "name": "Tubulin beta-2 chain", "drug_actions": [{"action": "INHIBITOR", "target": "F1L7U3", "drug": "DB00518"}]}, "P00414": {"specific_function": "Subunits I, II and III form the functional core of the enzyme complex.", "general_function": "Cytochrome-c oxidase activity", "gene_names": ["MT-CO3"], "name": "Cytochrome c oxidase subunit 3", "drug_actions": []}, "P17538": {"general_function": "Serine-type endopeptidase activity", "gene_names": ["CTRB1"], "name": "Chymotrypsinogen B", "drug_actions": []}, "P21589": {"specific_function": "Hydrolyzes extracellular nucleotides into membrane permeable nucleosides. Exhibits AMP-, NAD-, and NMN-nucleosidase activities.", "general_function": "Nucleotide binding", "gene_names": ["NT5E"], "name": "5'-nucleotidase", "drug_actions": [{"action": "INHIBITOR", "target": "P21589", "drug": "DB00806"}]}, "Q27738": {"general_function": "Dihydropteroate synthase activity", "gene_names": [], "name": "Dihydropteroate synthetase", "drug_actions": [{"action": "INHIBITOR", "target": "Q27738", "drug": "DB00359"}, {"action": "INHIBITOR", "target": "Q27738", "drug": "DB00664"}, {"action": "INHIBITOR", "target": "Q27738", "drug": "DB01145"}, {"action": "INHIBITOR", "target": "Q27738", "drug": "DB06147"}, {"action": "INHIBITOR", "target": "Q27738", "drug": "DB08798"}]}, "O06414": {"general_function": "Involved in catalytic activity", "gene_names": ["menB"], "name": "1,4-Dihydroxy-2-naphthoyl-CoA synthase", "drug_actions": []}, "P05305": {"specific_function": "Endothelins are endothelium-derived vasoconstrictor peptides.", "general_function": "Hormone activity", "gene_names": ["EDN1"], "name": "Endothelin-1", "drug_actions": []}, "Q92769": {"specific_function": "Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and N-COR. Interacts in the late S-phase of DNA-replication with DNMT1 in the other transcriptional repressor complex composed of DNMT1, DMAP1, PCNA, CAF1. Deacetylates TSHZ3 and regulates its transcriptional repressor activity. Component of a RCOR/GFI/KDM1A/HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development. May be involved in the transcriptional repression of circadian target genes, such as PER1, mediated by CRY1 through histone deacetylation. Involved in MTA1-mediated transcriptional corepression of TFF1 and CDKN1A.", "general_function": "Transcription factor binding", "gene_names": ["HDAC2"], "name": "Histone deacetylase 2", "drug_actions": [{"action": "OTHER", "target": "Q92769", "drug": "DB00227"}, {"action": "ACTIVATOR", "target": "Q92769", "drug": "DB00277"}, {"action": "ACTIVATOR", "target": "Q92769", "drug": "DB01223"}, {"action": "ACTIVATOR", "target": "Q92769", "drug": "DB01303"}, {"action": "INHIBITOR", "target": "Q92769", "drug": "DB02546"}, {"action": "INHIBITOR", "target": "Q92769", "drug": "DB06603"}]}, "P02675": {"specific_function": "Cleaved by the protease thrombin to yield monomers which, together with fibrinogen alpha (FGA) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the antibacterial immune response via both innate and T-cell mediated pathways.", "general_function": "Structural molecule activity", "gene_names": ["FGB"], "name": "Fibrinogen beta chain", "drug_actions": [{"action": "ANTAGONIST", "target": "P02675", "drug": "DB00364"}]}, "P39086": {"specific_function": "Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. May be involved in the transmission of light information from the retina to the hypothalamus.", "general_function": "Voltage-gated cation channel activity", "gene_names": ["GRIK1"], "name": "Glutamate receptor ionotropic, kainate 1", "drug_actions": [{"action": "ANTAGONIST", "target": "P39086", "drug": "DB00273"}]}, "P02679": {"specific_function": "Together with fibrinogen alpha (FGA) and fibrinogen beta (FGB), polymerizes to form an insoluble fibrin matrix. Has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the antibacterial immune response via both innate and T-cell mediated pathways.", "general_function": "Structural molecule activity", "gene_names": ["FGG"], "name": "Fibrinogen gamma chain", "drug_actions": [{"action": "ANTAGONIST", "target": "P02679", "drug": "DB00364"}]}, "Q9GZP0": {"specific_function": "Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. Potent mitogen for cells of mesenchymal origin. Plays an important role in wound healing. Induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. Can initiate events that lead to a mesangial proliferative glomerulonephritis, including influx of monocytes and macrophages and production of extracellular matrix (By similarity).", "gene_names": ["PDGFD"], "name": "Platelet-derived growth factor D", "drug_actions": []}, "Q9X112": {"specific_function": "Catalyzes the transfer of a methyl group from 5-methyltetrahydrofolate to homocysteine resulting in methionine formation.", "general_function": "Zinc ion binding", "gene_names": ["metE"], "name": "5-methyltetrahydropteroyltriglutamate--homocysteine methyltransferase", "drug_actions": []}, "Q9H2S1": {"specific_function": "Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to the slow component of synaptic afterhyperpolarization. The channel is blocked by apamin.", "name": "Small conductance calcium-activated potassium channel protein 2", "drug_actions": [{"action": "BINDER", "target": "Q9H2S1", "drug": "DB00721"}, {"action": "INHIBITOR", "target": "Q9H2S1", "drug": "DB01110"}], "general_function": "Small conductance calcium-activated potassium channel activity", "in_complexes": ["Calcium-activated potassium channel"], "gene_names": ["KCNN2"]}, "P02929": {"specific_function": "Interacts with outer membrane receptor proteins that carry out high-affinity binding and energy dependent uptake into the periplasmic space of specific substrates such as cobalamin, and various iron compounds (such as iron dicitrate, enterochelin, aerobactin, etc.). In the absence of TonB these receptors bind their substrates but do not carry out active transport. TonB also interacts with some colicins and is involved in the energy-dependent, irreversible steps of bacteriophages phi 80 and T1 infection. It could act to transduce energy from the cytoplasmic membrane to specific energy-requiring processes in the outer membrane, resulting in the release into the periplasm of ligands bound by these outer membrane proteins. Implicated in hydroxy radical-mediated cell death induced by hydroxyurea treatment (PubMed:20005847).", "general_function": "Siderophore transmembrane transporter activity", "gene_names": ["tonB"], "name": "Protein TonB", "drug_actions": []}, "Q99798": {"specific_function": "Catalyzes the isomerization of citrate to isocitrate via cis-aconitate.", "general_function": "Iron ion binding", "gene_names": ["ACO2"], "name": "Aconitate hydratase, mitochondrial", "drug_actions": []}, "P69908": {"specific_function": "Converts glutamate to gamma-aminobutyrate (GABA), consuming one intracellular proton in the reaction. The gad system helps to maintain a near-neutral intracellular pH when cells are exposed to extremely acidic conditions. The ability to survive transit through the acidic conditions of the stomach is essential for successful colonization of the mammalian host by commensal and pathogenic bacteria.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["gadA"], "name": "Glutamate decarboxylase alpha", "drug_actions": []}, "Q9RVD6": {"specific_function": "Catalyzes the formation of 5'adenyl-Trp and tRNA(Trp) but with 5-fold less activity than TrpRS. Increases the solubility of the nitric oxide synthase oxygenase (nos), as well as its affinity for substrate L-arginine and its nitric-oxide synthase activity. The complex between trpS2 and nos catalyzes the regioselective nitration of tryptophan at the 4-position.", "general_function": "Tryptophan-trna ligase activity", "gene_names": ["trpS2"], "name": "Tryptophan--tRNA ligase 2", "drug_actions": []}, "P32754": {"specific_function": "Key enzyme in the degradation of tyrosine.", "general_function": "Metal ion binding", "gene_names": ["HPD"], "name": "4-hydroxyphenylpyruvate dioxygenase", "drug_actions": [{"action": "INHIBITOR", "target": "P32754", "drug": "DB00348"}]}, "Q5T4S7": {"specific_function": "E3 ubiquitin-protein ligase which is a component of the N-end rule pathway. Recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent degradation. Together with clathrin, forms meshwork structures involved in membrane morphogenesis and cytoskeletal organization. Regulates integrin-mediated signaling. May play a role in activation of FAK in response to cell-matrix interactions. Mediates ubiquitination of ACLY, leading to its subsequent degradation.", "general_function": "Zinc ion binding", "gene_names": ["UBR4"], "name": "E3 ubiquitin-protein ligase UBR4", "drug_actions": []}, "O43772": {"specific_function": "Mediates the transport of acylcarnitines of different length across the mitochondrial inner membrane from the cytosol to the mitochondrial matrix for their oxidation by the mitochondrial fatty acid-oxidation pathway.", "gene_names": ["SLC25A20"], "name": "Mitochondrial carnitine/acylcarnitine carrier protein", "drug_actions": []}, "P02920": {"specific_function": "Responsible for transport of beta-galactosides into the cell, with the concomitant import of a proton (symport system).", "general_function": "Sugar:proton symporter activity", "gene_names": ["lacY"], "name": "Lactose permease", "drug_actions": []}, "O43776": {"general_function": "Nucleic acid binding", "gene_names": ["NARS"], "name": "Asparagine--tRNA ligase, cytoplasmic", "drug_actions": []}, "P02924": {"specific_function": "Involved in the high-affinity L-arabinose membrane transport system. Binds with high affinity to arabinose, but can also bind D-galactose (approximately 2-fold reduction) and D-fucose (approximately 40-fold reduction).", "general_function": "Monosaccharide-transporting atpase activity", "gene_names": ["araF"], "name": "L-arabinose-binding periplasmic protein", "drug_actions": []}, "P15917": {"specific_function": "One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. LF is the lethal factor that, when associated with PA, causes death. LF is not toxic by itself. It is a protease that cleaves the N-terminal of most dual specificity mitogen-activated protein kinase kinases (MAPKKs or MAP2Ks) (except for MAP2K5). Cleavage invariably occurs within the N-terminal proline-rich region preceding the kinase domain, thus disrupting a sequence involved in directing specific protein-protein interactions necessary for the assembly of signaling complexes. There may be other cytosolic targets of LF involved in cytotoxicity. The proteasome may mediate a toxic process initiated by LF in the cell cytosol involving degradation of unidentified molecules that are essential for macrophage homeostasis. This is an early step in LeTx intoxication, but it is downstream of the cleavage by LF of MEK1 or other putative substrates. Also cleaves mouse Nlrp1b allele 1, leading to NLRP1 inflammasome activation, IL1B release and eventually host inflammatory response (PubMed:19651869).", "general_function": "Metallopeptidase activity", "gene_names": ["lef"], "name": "Lethal factor", "drug_actions": []}, "P30825": {"specific_function": "High-affinity, low capacity permease involved in the transport of the cationic amino acids (arginine, lysine and ornithine) in non-hepatic tissues. May also function as an ecotropic retroviral leukemia receptor.", "general_function": "L-ornithine transmembrane transporter activity", "gene_names": ["SLC7A1"], "name": "High affinity cationic amino acid transporter 1", "drug_actions": []}, "Q92781": {"specific_function": "Stereospecific 11-cis retinol dehydrogenase, which catalyzes the final step in the biosynthesis of 11-cis retinaldehyde, the universal chromophore of visual pigments. Also able to oxidize 9-cis-retinol and 13-cis-retinol, but not all-trans-retinol. Active in the presence of NAD as cofactor but not in the presence of NADP.", "general_function": "Retinol dehydrogenase activity", "gene_names": ["RDH5"], "name": "11-cis retinol dehydrogenase", "drug_actions": []}, "P52788": {"specific_function": "Catalyzes the production of spermine from spermidine and decarboxylated S-adenosylmethionine (dcSAM).", "general_function": "Spermine synthase activity", "gene_names": ["SMS"], "name": "Spermine synthase", "drug_actions": [{"action": "LIGAND", "target": "P52788", "drug": "DB00127"}]}, "Q01468": {"specific_function": "Catalyzes the ketonization of 2-hydroxymuconate stereoselectively to yield 2-oxo-3-hexenedioate.", "general_function": "Isomerase activity", "gene_names": ["xylH"], "name": "2-hydroxymuconate tautomerase", "drug_actions": []}, "Q05514": {"specific_function": "Involved in the methylaspartate cycle. Catalyzes the formation of the alpha,beta-unsaturated bond by the reversible anti elimination of ammonia from L-threo-beta-methylaspartate (L-threo-(2S,3S)-3-methylaspartate) to give mesaconate. It can also use L-erythro-beta-methylaspartate (L-erythro-(2S,3R)-3-methylaspartate), L-aspartate, fumarate and ethylfumarate as substrates.", "general_function": "Methylaspartate ammonia-lyase activity", "gene_names": [], "name": "Methylaspartate ammonia-lyase", "drug_actions": []}, "Q6P093": {"general_function": "Carboxylic ester hydrolase activity", "gene_names": ["AADACL2"], "name": "Arylacetamide deacetylase-like 2", "drug_actions": []}, "Q53586": {"general_function": "Metal ion binding", "gene_names": ["hpd"], "name": "4-hydroxyphenylpyruvate dioxygenase", "drug_actions": []}, "P26918": {"specific_function": "Can hydrolyze carbapenem compounds.", "general_function": "Zinc ion binding", "gene_names": ["cphA"], "name": "Beta-lactamase", "drug_actions": []}, "Q9WZX6": {"specific_function": "Specifically methylates the N4 position of cytidine in position 1402 (C1402) of 16S rRNA.", "general_function": "Rrna (cytosine-n4-)-methyltransferase activity", "gene_names": ["rsmH"], "name": "Ribosomal RNA small subunit methyltransferase H", "drug_actions": []}, "P05412": {"specific_function": "Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation.", "name": "Transcription factor AP-1", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "P05412", "drug": "DB00570"}, {"action": "OTHER/UNKNOWN", "target": "P05412", "drug": "DB01029"}, {"action": "INDUCER", "target": "P05412", "drug": "DB01169"}], "general_function": "Transcriptional activator activity, rna polymerase ii transcription factor binding", "in_complexes": ["activator protein 1"], "gene_names": ["JUN"]}, "P61713": {"specific_function": "Catalyzes the formation of 6,7-dimethyl-8-ribityllumazine by condensation of 5-amino-6-(D-ribitylamino)uracil with 3,4-dihydroxy-2-butanone 4-phosphate. This is the penultimate step in the biosynthesis of riboflavin.", "general_function": "Transferase activity", "gene_names": ["ribH2"], "name": "6,7-dimethyl-8-ribityllumazine synthase 2", "drug_actions": []}, "O53355": {"general_function": "Involved in oxidoreductase activity", "gene_names": ["lpdA"], "name": "NAD(P)H dehydrogenase (quinone)", "drug_actions": []}, "P10398": {"specific_function": "Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May also regulate the TOR signaling cascade.Isoform 2: Serves as a positive regulator of myogenic differentiation by inducing cell cycle arrest, the expression of myogenin and other muscle-specific proteins, and myotube formation.", "general_function": "Receptor signaling protein activity", "gene_names": ["ARAF"], "name": "Serine/threonine-protein kinase A-Raf", "drug_actions": []}, "P04141": {"specific_function": "Cytokine that stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes.", "general_function": "Granulocyte macrophage colony-stimulating factor receptor binding", "gene_names": ["CSF2"], "name": "Granulocyte-macrophage colony-stimulating factor", "drug_actions": []}, "P49368": {"specific_function": "Molecular chaperone; assists the folding of proteins upon ATP hydrolysis. As part of the BBS/CCT complex may play a role in the assembly of BBSome, a complex involved in ciliogenesis regulating transports vesicles to the cilia. Known to play a role, in vitro, in the folding of actin and tubulin.", "general_function": "Unfolded protein binding", "gene_names": ["CCT3"], "name": "T-complex protein 1 subunit gamma", "drug_actions": []}, "P0A9E0": {"specific_function": "This protein controls the expression of at least six genes that are involved in the transport and catabolism of L-arabinose. It regulates initiation of transcription of the araBAD operon and it also controls its own synthesis. The L-arabinose operon displays both positive and negative regulation through AraC.", "general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": ["araC"], "name": "Arabinose operon regulatory protein", "drug_actions": []}, "P06202": {"specific_function": "This protein is a component of the oligopeptide permease, a binding protein-dependent transport system, it binds peptides up to five amino acids long with high affinity.", "gene_names": ["oppA"], "name": "Periplasmic oligopeptide-binding protein", "drug_actions": []}, "P16930": {"general_function": "Metal ion binding", "gene_names": ["FAH"], "name": "Fumarylacetoacetase", "drug_actions": []}, "P16932": {"specific_function": "The dialkylglycine decarboxylase is of interest because it normally catalyzes both decarboxylation and amino transfer. It may be more properly described as a decarboxylating aminotransferase rather than an aminotransferring decarboxylase.", "general_function": "Transaminase activity", "gene_names": ["dgdA"], "name": "2,2-dialkylglycine decarboxylase", "drug_actions": []}, "Q99808": {"specific_function": "Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive (ES) to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (NBMPR) and is sodium-independent. It has a higher affinity for adenosine. Inhibited by dipyridamole and dilazep (anticancer chemotherapeutics drugs).", "general_function": "Nucleoside transmembrane transporter activity", "gene_names": ["SLC29A1"], "name": "Equilibrative nucleoside transporter 1", "drug_actions": [{"action": "INHIBITOR", "target": "Q99808", "drug": "DB00197"}]}, "Q8TET4": {"specific_function": "Has alpha-glucosidase activity.", "general_function": "Maltose alpha-glucosidase activity", "gene_names": ["GANC"], "name": "Neutral alpha-glucosidase C", "drug_actions": [{"action": "ANTAGONIST", "target": "Q8TET4", "drug": "DB00491"}]}, "P42345": {"specific_function": "Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins. Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2). Activated mTORC1 up-regulates protein synthesis by phosphorylating key regulators of mRNA translation and ribosome synthesis. This includes phosphorylation of EIF4EBP1 and release of its inhibition toward the elongation initiation factor 4E (eiF4E). Moreover, phosphorylates and activates RPS6KB1 and RPS6KB2 that promote protein synthesis by modulating the activity of their downstream targets including ribosomal protein S6, eukaryotic translation initiation factor EIF4B, and the inhibitor of translation initiation PDCD4. Stimulates the pyrimidine biosynthesis pathway, both by acute regulation through RPS6KB1-mediated phosphorylation of the biosynthetic enzyme CAD, and delayed regulation, through transcriptional enhancement of the pentose phosphate pathway which produces 5-phosphoribosyl-1-pyrophosphate (PRPP), an allosteric activator of CAD at a later step in synthesis, this function is dependent on the mTORC1 complex. Regulates ribosome synthesis by activating RNA polymerase III-dependent transcription through phosphorylation and inhibition of MAF1 an RNA polymerase III-repressor. In parallel to protein synthesis, also regulates lipid synthesis through SREBF1/SREBP1 and LPIN1. To maintain energy homeostasis mTORC1 may also regulate mitochondrial biogenesis through regulation of PPARGC1A. mTORC1 also negatively regulates autophagy through phosphorylation of ULK1. Under nutrient sufficiency, phosphorylates ULK1 at 'Ser-758', disrupting the interaction with AMPK and preventing activation of ULK1. Also prevents autophagy through phosphorylation of the autophagy inhibitor DAP. mTORC1 exerts a feedback control on upstream growth factor signaling that includes phosphorylation and activation of GRB10 a INSR-dependent signaling suppressor. Among other potential targets mTORC1 may phosphorylate CLIP1 and regulate microtubules. As part of the mTORC2 complex MTOR may regulate other cellular processes including survival and organization of the cytoskeleton. Plays a critical role in the phosphorylation at 'Ser-473' of AKT1, a pro-survival effector of phosphoinositide 3-kinase, facilitating its activation by PDK1. mTORC2 may regulate the actin cytoskeleton, through phosphorylation of PRKCA, PXN and activation of the Rho-type guanine nucleotide exchange factors RHOA and RAC1A or RAC1B. mTORC2 also regulates the phosphorylation of SGK1 at 'Ser-422'. Regulates osteoclastogensis by adjusting the expression of CEBPB isoforms (By similarity).", "general_function": "Tfiiic-class transcription factor binding", "gene_names": ["MTOR"], "name": "Serine/threonine-protein kinase mTOR", "drug_actions": [{"action": "POTENTIATOR", "target": "P42345", "drug": "DB00337"}, {"action": "INHIBITOR", "target": "P42345", "drug": "DB00877"}, {"action": "INHIBITOR", "target": "P42345", "drug": "DB01590"}, {"action": "INHIBITOR", "target": "P42345", "drug": "DB06287"}]}, "P05067": {"specific_function": "Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1.Beta-amyloid peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Beta-amyloid 42 is a more effective reductant than beta-amyloid 40. Beta-amyloid peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. Beta-APP42 may activate mononuclear phagocytes in the brain and elicit inflammatory responses. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with overexpressed HADH2 leads to oxidative stress and neurotoxicity. Also binds GPC1 in lipid rafts.Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brain.The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.N-APP binds TNFRSF21 triggering caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6).", "general_function": "Transition metal ion binding", "gene_names": ["APP"], "name": "Amyloid beta A4 protein", "drug_actions": []}, "P0AE22": {"specific_function": "Dephosphorylates several organic phosphate monoesters including 3'- and 5'-nucleotides, 2'-deoxy-5'-nucleotides, pNPP, phenyl phosphate, glycerol 2-phosphate, ribose 5-phosphate, O-phospho-L-amino acids and phytic acid, showing the highest activity with aryl phosphoesters (pNPP, phenyl phosphate and O-phospho-L-tyrosine), and to a lesser extent with 3'- and 5'-nucleotides. No activity toward ATP, phosphodiesters, glycerol-1-phosphate, glucose 1-phosphate, glucose 6-phosphate, NADP, GTP or 3',5'-cAMP, ADP or ATP. Also has a phosphotransferase activity catalyzing the transfer of low-energy phosphate groups from organic phosphate monoesters to free hydroxyl groups of various organic compounds. Capable of transferring phosphate from either pNPP or UMP to adenosine or uridine. Does not exhibit nucleotide phosphomutase activity.", "general_function": "Phosphoserine phosphatase activity", "gene_names": ["aphA"], "name": "Class B acid phosphatase", "drug_actions": []}, "O43175": {"general_function": "Phosphoglycerate dehydrogenase activity", "gene_names": ["PHGDH"], "name": "D-3-phosphoglycerate dehydrogenase", "drug_actions": []}, "Q9RZ04": {"general_function": "Metal ion binding", "gene_names": [], "name": "Agmatinase, putative", "drug_actions": []}, "P0A514": {"general_function": "Secondary metabolites biosynthesis, transport and catabolism", "gene_names": ["cyp121"], "name": "Mycocyclosin synthase", "drug_actions": []}, "P02818": {"specific_function": "Constitutes 1-2% of the total bone protein. It binds strongly to apatite and calcium.", "general_function": "Structural molecule activity", "gene_names": ["BGLAP"], "name": "Osteocalcin", "drug_actions": [{"action": "AGONIST", "target": "P02818", "drug": "DB00170"}, {"action": "AGONIST", "target": "P02818", "drug": "DB01022"}, {"action": "ANTAGONIST", "target": "P02818", "drug": "DB05260"}]}, "P0A6L0": {"specific_function": "Catalyzes a reversible aldol reaction between acetaldehyde and D-glyceraldehyde 3-phosphate to generate 2-deoxy-D-ribose 5-phosphate.", "general_function": "Lyase activity", "gene_names": ["deoC"], "name": "Deoxyribose-phosphate aldolase", "drug_actions": []}, "Q693P7": {"gene_names": ["CHRNA7"], "name": "Alpha-7 nicotinic cholinergic receptor subunit", "drug_actions": [{"action": "ANTAGONIST", "target": "Q693P7", "drug": "DB00193"}, {"action": "AGONIST", "target": "Q693P7", "drug": "DB00202"}, {"action": "ANTAGONIST", "target": "Q693P7", "drug": "DB01043"}, {"action": "ANTAGONIST", "target": "Q693P7", "drug": "DB01520"}]}, "O75306": {"specific_function": "Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["NDUFS2"], "name": "NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial", "drug_actions": []}, "P62508": {"specific_function": "Orphan receptor that acts as transcription activator in the absence of bound ligand. Binds specifically to an estrogen response element and activates reporter genes controlled by estrogen response elements (By similarity). Induces the expression of PERM1 in the skeletal muscle.", "general_function": "Zinc ion binding", "gene_names": ["ESRRG"], "name": "Estrogen-related receptor gamma", "drug_actions": [{"action": "INVERSE AGONIST", "target": "P62508", "drug": "DB00197"}, {"action": "AGONIST", "target": "P62508", "drug": "DB00255"}]}, "P03706": {"specific_function": "Endolysin with transglycosylase activity that degrades host peptidoglycans and participates with the holin and spanin proteins in the sequential events which lead to the programmed host cell lysis releasing the mature viral particles. Once the holin has permeabilized the host cell membrane, the endolysin can reach the periplasm and break down the peptidoglycan layer.", "general_function": "Lysozyme activity", "gene_names": ["R"], "name": "Endolysin", "drug_actions": []}, "P0A8Q3": {"specific_function": "Seems to be involved in the anchoring of the catalytic components of the fumarate reductase complex to the cytoplasmic membrane.", "general_function": "Succinate dehydrogenase activity", "gene_names": ["frdD"], "name": "Fumarate reductase subunit D", "drug_actions": []}, "P0A8Q0": {"specific_function": "Seems to be involved in the anchoring of the catalytic components of the fumarate reductase complex to the cytoplasmic membrane.", "general_function": "Succinate dehydrogenase activity", "gene_names": ["frdC"], "name": "Fumarate reductase subunit C", "drug_actions": []}, "P08337": {"specific_function": "Involved in the GO system responsible for removing an oxidatively damaged form of guanine (7,8-dihydro-8-oxoguanine) from DNA and the nucleotide pool. 8-oxo-dGTP is inserted opposite dA and dC residues of template DNA with almost equal efficiency thus leading to A.T to G.C transversions. MutT specifically degrades 8-oxo-dGTP to the monophosphate.", "general_function": "Manganese ion binding", "gene_names": ["mutT"], "name": "8-oxo-dGTP diphosphatase", "drug_actions": []}, "P0ABQ4": {"specific_function": "Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis.", "general_function": "Nadp binding", "gene_names": ["folA"], "name": "Dihydrofolate reductase", "drug_actions": []}, "P05771": {"specific_function": "Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase involved in various cellular processes such as regulation of the B-cell receptor (BCR) signalosome, oxidative stress-induced apoptosis, androgen receptor-dependent transcription regulation, insulin signaling and endothelial cells proliferation. Plays a key role in B-cell activation by regulating BCR-induced NF-kappa-B activation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11/CARMA1 at 'Ser-559', 'Ser-644' and 'Ser-652'. Phosphorylation induces CARD11/CARMA1 association with lipid rafts and recruitment of the BCL10-MALT1 complex as well as MAP3K7/TAK1, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. Plays a direct role in the negative feedback regulation of the BCR signaling, by down-modulating BTK function via direct phosphorylation of BTK at 'Ser-180', which results in the alteration of BTK plasma membrane localization and in turn inhibition of BTK activity. Involved in apoptosis following oxidative damage: in case of oxidative conditions, specifically phosphorylates 'Ser-36' of isoform p66Shc of SHC1, leading to mitochondrial accumulation of p66Shc, where p66Shc acts as a reactive oxygen species producer. Acts as a coactivator of androgen receptor (ANDR)-dependent transcription, by being recruited to ANDR target genes and specifically mediating phosphorylation of 'Thr-6' of histone H3 (H3T6ph), a specific tag for epigenetic transcriptional activation that prevents demethylation of histone H3 'Lys-4' (H3K4me) by LSD1/KDM1A. In insulin signaling, may function downstream of IRS1 in muscle cells and mediate insulin-dependent DNA synthesis through the RAF1-MAPK/ERK signaling cascade. May participate in the regulation of glucose transport in adipocytes by negatively modulating the insulin-stimulated translocation of the glucose transporter SLC2A4/GLUT4. Under high glucose in pancreatic beta-cells, is probably involved in the inhibition of the insulin gene transcription, via regulation of MYC expression. In endothelial cells, activation of PRKCB induces increased phosphorylation of RB1, increased VEGFA-induced cell proliferation, and inhibits PI3K/AKT-dependent nitric oxide synthase (NOS3/eNOS) regulation by insulin, which causes endothelial dysfunction. Also involved in triglyceride homeostasis (By similarity). Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription.", "name": "Protein kinase C beta type", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "P05771", "drug": "DB08846"}], "general_function": "Zinc ion binding", "in_complexes": ["Protein kinase C"], "gene_names": ["PRKCB"]}, "P46883": {"specific_function": "The enzyme prefers aromatic over aliphatic amines.", "general_function": "Tryptamine:oxygen oxidoreductase (deaminating) activity", "gene_names": ["tynA"], "name": "Primary amine oxidase", "drug_actions": []}, "P0A716": {"general_function": "3-deoxy-8-phosphooctulonate synthase activity", "gene_names": ["kdsA"], "name": "2-dehydro-3-deoxyphosphooctonate aldolase", "drug_actions": []}, "Q9WXN1": {"general_function": "Metal ion binding", "gene_names": [], "name": "Laminarinase", "drug_actions": []}, "Q8RJN8": {"general_function": "Endo-1,4-beta-xylanase activity", "gene_names": ["xyl"], "name": "Endo-1,4-beta-xylanase", "drug_actions": []}, "P14090": {"specific_function": "The biological conversion of cellulose to glucose generally requires three types of hydrolytic enzymes: (1) Endoglucanases which cut internal beta-1,4-glucosidic bonds; (2) Exocellobiohydrolases that cut the dissaccharide cellobiose from the non-reducing end of the cellulose polymer chain; (3) Beta-1,4-glucosidases which hydrolyze the cellobiose and other short cello-oligosaccharides to glucose.", "general_function": "Cellulase activity", "gene_names": ["cenC"], "name": "Endoglucanase C", "drug_actions": []}, "P63691": {"gene_names": [], "name": "ATP synthase subunit c", "drug_actions": [{"action": "INHIBITOR", "target": "P63691", "drug": "DB08903"}]}, "Q54331": {"general_function": "Polysaccharide binding", "gene_names": ["celB"], "name": "Cellulase B", "drug_actions": []}, "P14778": {"specific_function": "Receptor for IL1A, IL1B and IL1RN. After binding to interleukin-1 associates with the corecptor IL1RAP to form the high affinity interleukin-1 receptor complex which mediates interleukin-1-dependent activation of NF-kappa-B, MAPK and other pathways. Signaling involves the recruitment of adapter molecules such as TOLLIP, MYD88, and IRAK1 or IRAK2 via the respective TIR domains of the receptor/coreceptor subunits. Binds ligands with comparable affinity and binding of antagonist IL1RN prevents association with IL1RAP to form a signaling complex.", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["IL1R1"], "name": "Interleukin-1 receptor type 1", "drug_actions": [{"action": "ANTAGONIST", "target": "P14778", "drug": "DB00026"}]}, "P26358": {"specific_function": "Methylates CpG residues. Preferentially methylates hemimethylated DNA. Associates with DNA replication sites in S phase maintaining the methylation pattern in the newly synthesized strand, that is essential for epigenetic inheritance. Associates with chromatin during G2 and M phases to maintain DNA methylation independently of replication. It is responsible for maintaining methylation patterns established in development. DNA methylation is coordinated with methylation of histones. Mediates transcriptional repression by direct binding to HDAC2. In association with DNMT3B and via the recruitment of CTCFL/BORIS, involved in activation of BAG1 gene expression by modulating dimethylation of promoter histone H3 at H3K4 and H3K9.", "general_function": "Zinc ion binding", "gene_names": ["DNMT1"], "name": "DNA (cytosine-5)-methyltransferase 1", "drug_actions": [{"action": "INHIBITOR", "target": "P26358", "drug": "DB00928"}, {"action": "OTHER", "target": "P26358", "drug": "DB01035"}, {"action": "OTHER", "target": "P26358", "drug": "DB01099"}, {"action": "INHIBITOR", "target": "P26358", "drug": "DB01262"}]}, "P35408": {"specific_function": "Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. Has a relaxing effect on smooth muscle. May play an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function.", "general_function": "Prostaglandin e receptor activity", "gene_names": ["PTGER4"], "name": "Prostaglandin E2 receptor EP4 subtype", "drug_actions": [{"action": "AGONIST", "target": "P35408", "drug": "DB00917"}, {"action": "AGONIST", "target": "P35408", "drug": "DB00929"}]}, "Q8N119": {"specific_function": "May have an important and specific function in tumor progression and embryogenesis. Cleaves alpha-1-antitrypsin.", "general_function": "Zinc ion binding", "gene_names": ["MMP21"], "name": "Matrix metalloproteinase-21", "drug_actions": [{"action": "INHIBITOR", "target": "Q8N119", "drug": "DB00786"}]}, "Q59560": {"specific_function": "Required for homologous recombination (HR) and the bypass of mutagenic DNA lesions (double strand breaks, DSB) by the SOS response. Can catalyze the hydrolysis of ATP in the presence of single-stranded DNA, the ATP-dependent uptake of single-stranded DNA by duplex DNA, and the ATP-dependent hybridization of homologous single-stranded DNAs. Numerous X-ray crystals have been resolved under different conditions which indicate the flexibility of the protein, essential to its function. Gln-196 contributes to this plasticity by acting as a switch residue, which transmits the effect of nucleotide binding to the DNA-binding region.", "general_function": "Single-stranded dna binding", "gene_names": ["recA"], "name": "Protein RecA", "drug_actions": []}, "P45510": {"specific_function": "Catalyzes the phosphorylation of dihydroxyacetone.", "general_function": "Metal ion binding", "gene_names": ["dhaK"], "name": "Dihydroxyacetone kinase", "drug_actions": []}, "P0A7X3": {"specific_function": "The C-terminal tail plays a role in the affinity of the 30S P site for different tRNAs. Mutations that decrease this affinity are suppressed in the 70S ribosome.", "general_function": "Trna binding", "gene_names": ["rpsI"], "name": "30S ribosomal protein S9", "drug_actions": [{"action": "INHIBITOR", "target": "P0A7X3", "drug": "DB00254"}, {"action": "INHIBITOR", "target": "P0A7X3", "drug": "DB00256"}, {"action": "INHIBITOR", "target": "P0A7X3", "drug": "DB00453"}, {"action": "ADDUCT", "target": "P0A7X3", "drug": "DB00560"}, {"action": "INHIBITOR", "target": "P0A7X3", "drug": "DB00595"}, {"action": "INHIBITOR", "target": "P0A7X3", "drug": "DB00618"}, {"action": "INHIBITOR", "target": "P0A7X3", "drug": "DB01017"}, {"action": "INHIBITOR", "target": "P0A7X3", "drug": "DB01301"}]}, "O91734": {"specific_function": "Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host integrin ITGA2/ITGB1 to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP2: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP3: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP4: Lies on the inner surface of the capsid shell. After binding to the host receptor, the capsid undergoes conformational changes. Capsid protein VP4 is released, Capsid protein VP1 N-terminus is externalized, and together, they shape a pore in the host membrane through which the viral genome is translocated into the host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP0: Component of immature procapsids, which is cleaved into capsid proteins VP4 and VP2 after maturation. Allows the capsid to remain inactive before the maturation step (By similarity).Protein 2A: Cysteine protease that cleaves viral polyprotein and specific host proteins. It is responsible for the cleavage between the P1 and P2 regions, first cleavage occurring in the polyprotein. Cleaves also the host translation initiation factor EIF4G1, in order to shut down the capped cellular mRNA translation. Inhibits the host nucleus-cytoplasm protein and RNA trafficking by cleaving host members of the nuclear pores (By similarity).Protein 2B: Plays an essential role in the virus replication cycle by acting as a viroporin. Creates a pore in the host reticulum endoplasmic and as a consequence releases Ca2+ in the cytoplasm of infected cell. In turn, high levels of cyctoplasmic calcium may trigger membrane trafficking and transport of viral ER-associated proteins to viroplasms, sites of viral genome replication (By similarity).Protein 2C: Induces and associates with structural rearrangements of intracellular membranes. Displays RNA-binding, nucleotide binding and NTPase activities. May play a role in virion morphogenesis and viral RNA encapsidation by interacting with the capsid protein VP3 (By similarity).Protein 3AB: Localizes the viral replication complex to the surface of membranous vesicles. Together with protein 3CD binds the Cis-Active RNA Element (CRE) which is involved in RNA synthesis initiation. Acts as a cofactor to stimulate the activity of 3D polymerase, maybe through a nucleid acid chaperone activity (By similarity).Protein 3A: Localizes the viral replication complex to the surface of membranous vesicles. It inhibits host cell endoplasmic reticulum-to-Golgi apparatus transport and causes the dissassembly of the Golgi complex, possibly through GBF1 interaction. This would result in depletion of MHC, trail receptors and IFN receptors at the host cell surface (By similarity).Viral protein genome-linked: acts as a primer for viral RNA replication and remains covalently bound to viral genomic RNA. VPg is uridylylated prior to priming replication into VPg-pUpU. The oriI viral genomic sequence may act as a template for this. The VPg-pUpU is then used as primer on the genomic RNA poly(A) by the RNA-dependent RNA polymerase to replicate the viral genome. VPg may be removed in the cytoplasm by an unknown enzyme termed \"unlinkase\". VPg is not cleaved off virion genomes because replicated genomic RNA are encapsidated at the site of replication (By similarity).Protein 3CD: Is involved in the viral replication complex and viral polypeptide maturation. It exhibits protease activity with a specificity and catalytic efficiency that is different from protease 3C. Protein 3CD lacks polymerase activity. The 3C domain in the context of protein 3CD may have an RNA binding activity (By similarity).Protease 3C: cleaves host DDX58/RIG-I and thus contributes to the inhibition of type I interferon production. Cleaves also host PABPC1 (By similarity).RNA-directed RNA polymerase: Replicates the viral genomic RNA on the surface of intracellular membranes. May form linear arrays of subunits that propagate along a strong head-to-tail interaction called interface-I. Covalently attaches UMP to a tyrosine of VPg, which is used to prime RNA synthesis. The positive stranded RNA genome is first replicated at virus induced membranous vesicles, creating a dsRNA genomic replication form. This dsRNA is then used as template to synthesize positive stranded RNA genomes. ss(+)RNA genomes are either translated, replicated or encapsidated (By similarity).", "general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P20231": {"specific_function": "Tryptase is the major neutral protease present in mast cells and is secreted upon the coupled activation-degranulation response of this cell type. May play a role in innate immunity.", "general_function": "Serine-type peptidase activity", "gene_names": ["TPSB2"], "name": "Tryptase beta-2", "drug_actions": []}, "P16066": {"specific_function": "Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate cyclase activity upon binding of the ligand.", "general_function": "Protein kinase activity", "gene_names": ["NPR1"], "name": "Atrial natriuretic peptide receptor 1", "drug_actions": [{"action": "AGONIST", "target": "P16066", "drug": "DB00325"}, {"action": "AGONIST", "target": "P16066", "drug": "DB00727"}, {"action": "AGONIST", "target": "P16066", "drug": "DB00883"}, {"action": "AGONIST", "target": "P16066", "drug": "DB01612"}, {"action": "AGONIST", "target": "P16066", "drug": "DB01613"}, {"action": "BINDER", "target": "P16066", "drug": "DB04899"}]}, "O14965": {"specific_function": "Mitotic serine/threonine kinases that contributes to the regulation of cell cycle progression. Associates with the centrosome and the spindle microtubules during mitosis and plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. Required for initial activation of CDK1 at centrosomes. Phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2. Regulates KIF2A tubulin depolymerase activity. Required for normal axon formation. Plays a role in microtubule remodeling during neurite extension. Important for microtubule formation and/or stabilization. Also acts as a key regulatory component of the p53/TP53 pathway, and particularly the checkpoint-response pathways critical for oncogenic transformation of cells, by phosphorylating and stabilizing p53/TP53. Phosphorylates its own inhibitors, the protein phosphatase type 1 (PP1) isoforms, to inhibit their activity. Necessary for proper cilia disassembly prior to mitosis.", "general_function": "Protein serine/threonine/tyrosine kinase activity", "gene_names": ["AURKA"], "name": "Aurora kinase A", "drug_actions": []}, "O14964": {"specific_function": "Involved in intracellular signal transduction mediated by cytokines and growth factors. When associated with STAM, it suppresses DNA signaling upon stimulation by IL-2 and GM-CSF. Could be a direct effector of PI3-kinase in vesicular pathway via early endosomes and may regulate trafficking to early and late endosomes by recruiting clathrin. May concentrate ubiquitinated receptors within clathrin-coated regions. Involved in down-regulation of receptor tyrosine kinase via multivesicular body (MVBs) when complexed with STAM (ESCRT-0 complex). The ESCRT-0 complex binds ubiquitin and acts as sorting machinery that recognizes ubiquitinated receptors and transfers them to further sequential lysosomal sorting/trafficking processes. May contribute to the efficient recruitment of SMADs to the activin receptor complex. Involved in receptor recycling via its association with the CART complex, a multiprotein complex required for efficient transferrin receptor recycling but not for EGFR degradation.", "general_function": "Protein domain specific binding", "gene_names": ["HGS"], "name": "Hepatocyte growth factor-regulated tyrosine kinase substrate", "drug_actions": []}, "Q06609": {"specific_function": "Participates in a common DNA damage response pathway associated with the activation of homologous recombination and double-strand break repair. Binds to single and double-stranded DNA and exhibits DNA-dependent ATPase activity. Underwinds duplex DNA and forms helical nucleoprotein filaments. Part of a PALB2-scaffolded HR complex containing BRCA2 and RAD51C and which is thought to play a role in DNA repair by HR. Plays a role in regulating mitochondrial DNA copy number under conditions of oxidative stress in the presence of RAD51C and XRCC3.", "general_function": "Single-stranded dna-dependent atpase activity", "gene_names": ["RAD51"], "name": "DNA repair protein RAD51 homolog 1", "drug_actions": []}, "P60906": {"general_function": "Histidine-trna ligase activity", "gene_names": ["hisS"], "name": "Histidine--tRNA ligase", "drug_actions": []}, "Q14330": {"specific_function": "Receptor for N-arachidonyl glycine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. May contribute to regulation of the immune system.", "general_function": "G-protein coupled receptor activity", "gene_names": ["GPR18"], "name": "N-arachidonyl glycine receptor", "drug_actions": []}, "O43293": {"specific_function": "Serine/threonine kinase which is involved in the regulation of apoptosis, autophagy, transcription, translation and actin cytoskeleton reorganization. Involved in the regulation of smooth muscle contraction. Regulates both type I (caspase-dependent) apoptotic and type II (caspase-independent) autophagic cell deaths signal, depending on the cellular setting. Involved in regulation of starvation-induced autophagy. Regulates myosin phosphorylation in both smooth muscle and non-muscle cells. In smooth muscle, regulates myosin either directly by phosphorylating MYL12B and MYL9 or through inhibition of smooth muscle myosin phosphatase (SMPP1M) via phosphorylation of PPP1R12A; the inhibition of SMPP1M functions to enhance muscle responsiveness to Ca(2+) and promote a contractile state. Phosphorylates MYL12B in non-muscle cells leading to reorganization of actin cytoskeleton. Isoform 2 can phosphorylate myosin, PPP1R12A and MYL12B. Overexpression leads to condensation of actin stress fibers into thick bundles. Involved in actin filament focal adhesion dynamics. The function in both reorganization of actin cytoskeleton and focal adhesion dissolution is modulated by RhoD. Positively regulates canonical Wnt/beta-catenin signaling through interaction with NLK and TCF7L2. Phosphorylates RPL13A on 'Ser-77' upon interferon-gamma activation which is causing RPL13A release from the ribosome, RPL13A association with the GAIT complex and its subsequent involvement in transcript-selective translation inhibition. Enhances transcription from AR-responsive promoters in a hormone- and kinase-dependent manner. Involved in regulation of cell cycle progression and cell proliferation. May be a tumor suppressor.", "general_function": "Rho gtpase binding", "gene_names": ["DAPK3"], "name": "Death-associated protein kinase 3", "drug_actions": []}, "Q8N1C3": {"specific_function": "GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.", "name": "Gamma-aminobutyric acid receptor subunit gamma-1", "drug_actions": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00228"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00475"}, {"action": "BINDER", "target": "Q8N1C3", "drug": "DB00543"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB00546"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00628"}, {"action": "POSITIVE MODULATOR", "target": "Q8N1C3", "drug": "DB00659"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB00690"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00794"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00818"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01028"}, {"action": "AGONIST", "target": "Q8N1C3", "drug": "DB01049"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01205"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01437"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB01587"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q8N1C3", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "Q8N1C3", "drug": "DB01595"}, {"action": "ANTAGONIST", "target": "Q8N1C3", "drug": "DB01708"}], "general_function": "Inhibitory extracellular ligand-gated ion channel activity", "in_complexes": ["GABA-A receptor (anion channel)"], "gene_names": ["GABRG1"]}, "P23526": {"specific_function": "Adenosylhomocysteine is a competitive inhibitor of S-adenosyl-L-methionine-dependent methyl transferase reactions; therefore adenosylhomocysteinase may play a key role in the control of methylations via regulation of the intracellular concentration of adenosylhomocysteine.", "general_function": "Nad binding", "gene_names": ["AHCY"], "name": "Adenosylhomocysteinase", "drug_actions": []}, "P07225": {"specific_function": "Anticoagulant plasma protein; it is a cofactor to activated protein C in the degradation of coagulation factors Va and VIIIa. It helps to prevent coagulation and stimulating fibrinolysis.", "general_function": "Endopeptidase inhibitor activity", "gene_names": ["PROS1"], "name": "Vitamin K-dependent protein S", "drug_actions": [{"action": "ACTIVATOR", "target": "P07225", "drug": "DB00170"}, {"action": "INHIBITOR", "target": "P07225", "drug": "DB00464"}]}, "Q7SID9": {"general_function": "Oxidoreductase activity, acting on ch-oh group of donors", "gene_names": [], "name": "Oxidoreductase", "drug_actions": []}, "P09874": {"specific_function": "Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. Mediates the poly(ADP-ribosyl)ation of APLF and CHFR. Positively regulates the transcription of MTUS1 and negatively regulates the transcription of MTUS2/TIP150. With EEF1A1 and TXK, forms a complex that acts as a T-helper 1 (Th1) cell-specific transcription factor and binds the promoter of IFN-gamma to directly regulate its transcription, and is thus involved importantly in Th1 cytokine production. Required for PARP9 and DTX3L recruitment to DNA damage sites. PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites.", "general_function": "Zinc ion binding", "gene_names": ["PARP1"], "name": "Poly [ADP-ribose] polymerase 1", "drug_actions": [{"action": "BINDER", "target": "P09874", "drug": "DB02701"}, {"action": "INHIBITOR", "target": "P09874", "drug": "DB09074"}]}, "P23528": {"specific_function": "Binds to F-actin and exhibits pH-sensitive F-actin depolymerizing activity. Regulates actin cytoskeleton dynamics. Important for normal progress through mitosis and normal cytokinesis. Plays a role in the regulation of cell morphology and cytoskeletal organization. Required for the up-regulation of atypical chemokine receptor ACKR2 from endosomal compartment to cell membrane, increasing its efficiency in chemokine uptake and degradation.", "gene_names": ["CFL1"], "name": "Cofilin-1", "drug_actions": []}, "Q46444": {"specific_function": "Catalyzes the dye-linked oxidation of primary alcohols to the corresponding aldehydes and the (subsequent) oxidation of the aldehydes to carboxylic acids.", "general_function": "Oxidoreductase activity, acting on ch-oh group of donors", "gene_names": ["qheDH"], "name": "Quinohemoprotein ethanol dehydrogenase type-1", "drug_actions": []}, "P01859": {"general_function": "Immunoglobulin receptor binding", "gene_names": ["IGHG2"], "name": "Ig gamma-2 chain C region", "drug_actions": []}, "P09871": {"specific_function": "C1s B chain is a serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["C1S"], "name": "Complement C1s subcomponent", "drug_actions": []}, "P22061": {"specific_function": "Catalyzes the methyl esterification of L-isoaspartyl and D-aspartyl residues in peptides and proteins that result from spontaneous decomposition of normal L-aspartyl and L-asparaginyl residues. It plays a role in the repair and/or degradation of damaged proteins. Acts on EIF4EBP2, microtubule-associated protein 2, calreticulin, clathrin light chains a and b, Ubiquitin carboxyl-terminal hydrolase isozyme L1, phosphatidylethanolamine-binding protein 1, stathmin, beta-synuclein and alpha-synuclein.", "general_function": "Protein-l-isoaspartate (d-aspartate) o-methyltransferase activity", "gene_names": ["PCMT1"], "name": "Protein-L-isoaspartate(D-aspartate) O-methyltransferase", "drug_actions": []}, "O75015": {"specific_function": "Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.", "gene_names": ["FCGR3B"], "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "drug_actions": [{"action": "ANTAGONIST", "target": "O75015", "drug": "DB00028"}]}, "Q96MA6": {"specific_function": "Nucleoside monophosphate (NMP) kinase that catalyzes the reversible transfer of the terminal phosphate group between nucleoside triphosphates and monophosphates. Has highest activity toward AMP, and weaker activity toward dAMP, CMP and dCMP. Also displays broad nucleoside diphosphate kinase activity.", "general_function": "Nucleoside diphosphate kinase activity", "gene_names": ["AK8"], "name": "Adenylate kinase 8", "drug_actions": []}, "P28065": {"specific_function": "The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB6 by PSMB9 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues.", "general_function": "Threonine-type endopeptidase activity", "gene_names": ["PSMB9"], "name": "Proteasome subunit beta type-9", "drug_actions": [{"action": "INHIBITOR", "target": "P28065", "drug": "DB08889"}]}, "Q51990": {"general_function": "Oxidoreductase activity", "gene_names": ["morB"], "name": "Morphinone reductase", "drug_actions": []}, "Q8GR70": {"specific_function": "Catalyzes the reversible conversion of 2-phosphoglycerate into phosphoenolpyruvate. It is essential for the degradation of carbohydrates via glycolysis.", "general_function": "Phosphopyruvate hydratase activity", "gene_names": ["eno"], "name": "Enolase", "drug_actions": []}, "P26664": {"specific_function": "Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).E1 and E2 glycoproteins form a heterodimer that is involved in virus attachment to the host cell, virion internalization through clathrin-dependent endocytosis and fusion with host membrane. E1/E2 heterodimer binds to human LDLR, CD81 and SCARB1/SR-BI receptors, but this binding is not sufficient for infection, some additional liver specific cofactors may be needed. The fusion function may possibly be carried by E1. E2 inhibits human EIF2AK2/PKR activation, preventing the establishment of an antiviral state. E2 is a viral ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on liver sinusoidal endothelial cells and macrophage-like cells of lymph node sinuses. These interactions allow capture of circulating HCV particles by these cells and subsequent transmission to permissive cells. DCs act as sentinels in various tissues where they entrap pathogens and convey them to local lymphoid tissue or lymph node for establishment of immunity. Capture of circulating HCV particles by these SIGN+ cells may facilitate virus infection of proximal hepatocytes and lymphocyte subpopulations and may be essential for the establishment of persistent infection.P7 seems to be a heptameric ion channel protein (viroporin) and is inhibited by the antiviral drug amantadine. Also inhibited by long-alkyl-chain iminosugar derivatives. Essential for infectivity (By similarity).Protease NS2-3 is a cysteine protease responsible for the autocatalytic cleavage of NS2-NS3. Seems to undergo self-inactivation following maturation.NS3 displays three enzymatic activities: serine protease, NTPase and RNA helicase. NS3 serine protease, in association with NS4A, is responsible for the cleavages of NS3-NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also prevents phosphorylation of human IRF3, thus preventing the establishment of dsRNA induced antiviral state. NS3 RNA helicase binds to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA stable secondary structure in the template strand. Cleaves and inhibits the host antiviral protein MAVS (By similarity).NS4B induces a specific membrane alteration that serves as a scaffold for the virus replication complex. This membrane alteration gives rise to the so-called ER-derived membranous web that contains the replication complex (By similarity).NS5A is a component of the replication complex involved in RNA-binding. Its interaction with Human VAPB may target the viral replication complex to vesicles. Down-regulates viral IRES translation initiation. Mediates interferon resistance, presumably by interacting with and inhibiting human EIF2AK2/PKR. Seems to inhibit apoptosis by interacting with BIN1 and FKBP8. The hyperphosphorylated form of NS5A is an inhibitor of viral replication (By similarity).NS5B is an RNA-dependent RNA polymerase that plays an essential role in the virus replication.", "general_function": "Zinc ion binding", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "Q14697": {"specific_function": "Cleaves sequentially the 2 innermost alpha-1,3-linked glucose residues from the Glc(2)Man(9)GlcNAc(2) oligosaccharide precursor of immature glycoproteins.", "general_function": "Poly(a) rna binding", "gene_names": ["GANAB"], "name": "Neutral alpha-glucosidase AB", "drug_actions": [{"action": "ANTAGONIST", "target": "Q14697", "drug": "DB00491"}]}, "P36275": {"specific_function": "Stabilizes the head shell following the rearrangement of the gp7 subunits of the head shell lattice that accompanies expansion of the head.", "gene_names": ["shp"], "name": "Head decoration protein", "drug_actions": []}, "P06672": {"general_function": "Thiamine pyrophosphate binding", "gene_names": ["pdc"], "name": "Pyruvate decarboxylase", "drug_actions": []}, "Q746J6": {"general_function": "Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen", "gene_names": [], "name": "Cytochrome P450", "drug_actions": []}, "Q9BYZ2": {"general_function": "L-lactate dehydrogenase activity", "gene_names": ["LDHAL6B"], "name": "L-lactate dehydrogenase A-like 6B", "drug_actions": []}, "P06971": {"specific_function": "This receptor binds the ferrichrome-iron ligand. It interacts with the TonB protein, which is responsible for energy coupling of the ferrichrome-promoted iron transport system. Acts as a receptor for bacteriophage T5 as well as T1, phi80 and colicin M. Binding of T5 triggers the opening of a high conductance ion channel. Can also transport the antibiotic albomycin.", "general_function": "Virion binding", "gene_names": ["fhuA"], "name": "Ferrichrome-iron receptor", "drug_actions": []}, "Q836J0": {"specific_function": "Provides the (R)-glutamate required for cell wall biosynthesis.", "general_function": "Glutamate racemase activity", "gene_names": ["murI"], "name": "Glutamate racemase", "drug_actions": []}, "P36507": {"specific_function": "Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).", "general_function": "Scaffold protein binding", "gene_names": ["MAP2K2"], "name": "Dual specificity mitogen-activated protein kinase kinase 2", "drug_actions": [{"action": "INHIBITOR", "target": "P36507", "drug": "DB06616"}, {"action": "INHIBITOR", "target": "P36507", "drug": "DB08911"}]}, "P0ADA1": {"specific_function": "Hydrolyzes only long chain acyl thioesters (C12-C18). Specificity similar to chymotrypsin.", "general_function": "Phospholipase activity", "gene_names": ["tesA"], "name": "Acyl-CoA thioesterase I", "drug_actions": []}, "Q9FCA6": {"specific_function": "Catalyze oxidative C-C coupling reaction to polymerize flaviolin and form highly conjugated pigments which protect the soil bacterium from deleterious effects of UV irradiation (three isomers of biflaviolin and one triflaviolin).", "general_function": "Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen", "gene_names": ["cyp158a2"], "name": "Biflaviolin synthase CYP158A2", "drug_actions": []}, "O31158": {"general_function": "Chloride peroxidase activity", "gene_names": ["cpo"], "name": "Non-heme chloroperoxidase", "drug_actions": []}, "P19367": {"general_function": "Mannokinase activity", "gene_names": ["HK1"], "name": "Hexokinase-1", "drug_actions": []}, "O14818": {"specific_function": "The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. Plays an important role in the regulation of cell proliferation or cell cycle control, transcriptional regulation, immune and stress response, cell differentiation, and apoptosis. Interacts with some important proteins involved in transcription factor regulation, cell cycle transition, viral replication and even tumor initiation and progression. Inhibits the transactivation function of HIF-1A under both normoxic and hypoxia-mimicking conditions. The interaction with EMAP2 increases the proteasome-mediated HIF-1A degradation under the hypoxic conditions. Plays a role in hepatitis C virus internal ribosome entry site-mediated translation. Mediates nuclear translocation of the androgen receptor (AR) and thereby enhances androgen-mediated transactivation. Promotes MAVS degradation and thereby negatively regulates MAVS-mediated innate immune response.", "general_function": "Threonine-type endopeptidase activity", "gene_names": ["PSMA7"], "name": "Proteasome subunit alpha type-7", "drug_actions": []}, "Q8ZNF3": {"specific_function": "Catalyzes the conversion of UDP-4-keto-arabinose (UDP-Ara4O) to UDP-4-amino-4-deoxy-L-arabinose (UDP-L-Ara4N). The modified arabinose is attached to lipid A and is required for resistance to polymyxin and cationic antimicrobial peptides (By similarity).", "general_function": "Transaminase activity", "gene_names": ["arnB"], "name": "UDP-4-amino-4-deoxy-L-arabinose--oxoglutarate aminotransferase", "drug_actions": []}, "P36873": {"specific_function": "Protein phosphatase that associates with over 200 regulatory proteins to form highly specific holoenzymes which dephosphorylate hundreds of biological targets. Protein phosphatase 1 (PP1) is essential for cell division, and participates in the regulation of glycogen metabolism, muscle contractility and protein synthesis. Dephosphorylates RPS6KB1. Involved in regulation of ionic conductances and long-term synaptic plasticity. May play an important role in dephosphorylating substrates such as the postsynaptic density-associated Ca(2+)/calmodulin dependent protein kinase II. Component of the PTW/PP1 phosphatase complex, which plays a role in the control of chromatin structure and cell cycle progression during the transition from mitosis into interphase. In balance with CSNK1D and CSNK1E, determines the circadian period length, through the regulation of the speed and rhythmicity of PER1 and PER2 phosphorylation. May dephosphorylate CSNK1D and CSNK1E. Dephosphorylates the 'Ser-418' residue of FOXP3 in regulatory T-cells (Treg) from patients with rheumatoid arthritis, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:23396208).", "general_function": "Protein serine/threonine phosphatase activity", "gene_names": ["PPP1CC"], "name": "Serine/threonine-protein phosphatase PP1-gamma catalytic subunit", "drug_actions": []}, "P36871": {"specific_function": "This enzyme participates in both the breakdown and synthesis of glucose.", "general_function": "Phosphoglucomutase activity", "gene_names": ["PGM1"], "name": "Phosphoglucomutase-1", "drug_actions": []}, "P16870": {"specific_function": "Removes residual C-terminal Arg or Lys remaining after initial endoprotease cleavage during prohormone processing. Processes proinsulin.", "general_function": "Zinc ion binding", "gene_names": ["CPE"], "name": "Carboxypeptidase E", "drug_actions": []}, "Q16322": {"specific_function": "Mediates voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient. The channel activity is up-regulated by cAMP.", "general_function": "Intracellular cyclic nucleotide activated cation channel activity", "gene_names": ["KCNA10"], "name": "Potassium voltage-gated channel subfamily A member 10", "drug_actions": [{"action": "ANTAGONIST", "target": "Q16322", "drug": "DB06637"}]}, "P00469": {"specific_function": "Provides the sole de novo source of dTMP for DNA biosynthesis.", "general_function": "Thymidylate synthase activity", "gene_names": ["thyA"], "name": "Thymidylate synthase", "drug_actions": []}, "P04424": {"general_function": "Argininosuccinate lyase activity", "gene_names": ["ASL"], "name": "Argininosuccinate lyase", "drug_actions": []}, "A1Z199": {"gene_names": ["BCR/ABL fusion"], "name": "BCR/ABL p210 fusion protein", "drug_actions": []}, "P04958": {"specific_function": "Tetanus toxin acts by inhibiting neurotransmitter release. It binds to peripheral neuronal synapses, is internalized and moves by retrograde transport up the axon into the spinal cord where it can move between postsynaptic and presynaptic neurons. It inhibits neurotransmitter release by acting as a zinc endopeptidase that catalyzes the hydrolysis of the '76-Gln-|-Phe-77' bond of synaptobrevin-2.", "general_function": "Zinc ion binding", "gene_names": ["tetX"], "name": "Tetanus toxin", "drug_actions": []}, "P0AES4": {"specific_function": "DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.", "general_function": "Identical protein binding", "gene_names": ["gyrA"], "name": "DNA gyrase subunit A", "drug_actions": []}, "P0AES6": {"specific_function": "DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.", "general_function": "Magnesium ion binding", "gene_names": ["gyrB"], "name": "DNA gyrase subunit B", "drug_actions": [{"action": "INHIBITOR", "target": "P0AES6", "drug": "DB00817"}]}, "Q93TU6": {"specific_function": "Catalyzes the carbon-carbon bond cleavage of the bicyclic beta-diketone 6-oxocamphor via a retro-Claisen reaction to yield the optically active (2R,4S)-beta-campholinic acid. It is also able to cleave 2,2-disubstituted cyclohexa-1,3-diones such as 2-methyl-2-propylcyclohexa-1,3-dione and 2-methyl-2-butylcyclohexa-1,3-dione which result in racemic keto acid products. Transformations of the bicyclic diketone substrates bicyclo[2.2.1]heptane 2,6-dione and bicyclo[2.2.2]octane-2,6-dione yield (S)-keto acid products.", "general_function": "Hydrolase activity, acting on acid carbon-carbon bonds, in ketonic substances", "gene_names": ["camK"], "name": "6-oxocamphor hydrolase", "drug_actions": []}, "P0AES2": {"specific_function": "Catalyzes the dehydration of glucarate to 5-keto-4-deoxy-D-glucarate (5-kdGluc). Also acts on L-idarate.", "general_function": "Magnesium ion binding", "gene_names": ["gudD"], "name": "Glucarate dehydratase", "drug_actions": []}, "P0A3R9": {"specific_function": "NCS has antibiotic activity (for Gram-positive bacteria) and antitumor activity (for certain mouse tumors). NCS binds non-covalently to a chromophore which is the cytotoxic and mutagenic component of the antibiotic. The chromophore binds to DNA as a weak intercalator and causes single- and double-strand breaks.", "general_function": "Dna binding", "gene_names": ["ncsA"], "name": "Neocarzinostatin", "drug_actions": []}, "P05798": {"general_function": "Rna binding", "gene_names": ["rnaSA"], "name": "Guanyl-specific ribonuclease Sa", "drug_actions": []}, "P01116": {"specific_function": "Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Plays an important role in the regulation of cell proliferation (PubMed:23698361, PubMed:22711838).", "general_function": "Protein complex binding", "gene_names": ["KRAS"], "name": "GTPase KRas", "drug_actions": []}, "P47929": {"specific_function": "Could be involved in cell-cell and/or cell-matrix interactions necessary for normal growth control. Pro-apoptotic protein that functions intracellularly upstream of JNK activation and cytochrome c release.", "general_function": "Carbohydrate binding", "gene_names": ["LGALS7"], "name": "Galectin-7", "drug_actions": []}, "Q9KG76": {"general_function": "Glucan endo-1,4-beta-glucanase activity, c-3 substituted reducing group", "gene_names": [], "name": "BH0236 protein", "drug_actions": []}, "O60909": {"specific_function": "Responsible for the synthesis of complex-type N-linked oligosaccharides in many glycoproteins as well as the carbohydrate moieties of glycolipids. Can produce lactose.", "general_function": "N-acetyllactosamine synthase activity", "gene_names": ["B4GALT2"], "name": "Beta-1,4-galactosyltransferase 2", "drug_actions": []}, "P0AFI5": {"specific_function": "Cell wall formation. May play a specialized role in remodeling the cell wall. Specifically hydrolyzes the DD-diaminopimelate-alanine bonds in high-molecular-mass murein sacculi.", "general_function": "Serine-type d-ala-d-ala carboxypeptidase activity", "gene_names": ["pbpG"], "name": "D-alanyl-D-alanine endopeptidase", "drug_actions": [{"action": "INHIBITOR", "target": "P0AFI5", "drug": "DB01331"}]}, "P15170": {"specific_function": "Involved in translation termination in response to the termination codons UAA, UAG and UGA. Stimulates the activity of ERF1. Involved in regulation of mammalian cell growth. Component of the transient SURF complex which recruits UPF1 to stalled ribosomes in the context of nonsense-mediated decay (NMD) of mRNAs containing premature stop codons.", "general_function": "Translation release factor activity", "gene_names": ["GSPT1"], "name": "Eukaryotic peptide chain release factor GTP-binding subunit ERF3A", "drug_actions": []}, "Q71LY2": {"general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P10620": {"specific_function": "Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Has a wide substrate specificity.", "general_function": "Glutathione transferase activity", "gene_names": ["MGST1"], "name": "Microsomal glutathione S-transferase 1", "drug_actions": []}, "Q9NXG6": {"specific_function": "Catalyzes the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates HIF1A at 'Pro-402' and 'Pro-564'. May function as a cellular oxygen sensor and, under normoxic conditions, may target HIF through the hydroxylation for proteasomal degradation via the von Hippel-Lindau ubiquitination complex.", "general_function": "Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors", "gene_names": ["P4HTM"], "name": "Transmembrane prolyl 4-hydroxylase", "drug_actions": []}, "P55407": {"specific_function": "Positive regulation of conjugal transfer. TraR activates target genes in the presence of AAI and also activates traR and traI themselves (By similarity).", "general_function": "Dna binding", "gene_names": ["traR"], "name": "Probable transcriptional activator protein TraR", "drug_actions": []}, "Q13557": {"specific_function": "Calcium/calmodulin-dependent protein kinase involved in the regulation of Ca(2+) homeostatis and excitation-contraction coupling (ECC) in heart by targeting ion channels, transporters and accessory proteins involved in Ca(2+) influx into the myocyte, Ca(2+) release from the sarcoplasmic reticulum (SR), SR Ca(2+) uptake and Na(+) and K(+) channel transport. Targets also transcription factors and signaling molecules to regulate heart function. In its activated form, is involved in the pathogenesis of dilated cardiomyopathy and heart failure. Contributes to cardiac decompensation and heart failure by regulating SR Ca(2+) release via direct phosphorylation of RYR2 Ca(2+) channel on 'Ser-2808'. In the nucleus, phosphorylates the MEF2 repressor HDAC4, promoting its nuclear export and binding to 14-3-3 protein, and expression of MEF2 and genes involved in the hypertrophic program. Is essential for left ventricular remodeling responses to myocardial infarction. In pathological myocardial remodeling acts downstream of the beta adrenergic receptor signaling cascade to regulate key proteins involved in ECC. Regulates Ca(2+) influx to myocytes by binding and phosphorylating the L-type Ca(2+) channel subunit beta-2 CACNB2. In addition to Ca(2+) channels, can target and regulate the cardiac sarcolemmal Na(+) channel Nav1.5/SCN5A and the K+ channel Kv4.3/KCND3, which contribute to arrhythmogenesis in heart failure. Phosphorylates phospholamban (PLN/PLB), an endogenous inhibitor of SERCA2A/ATP2A2, contributing to the enhancement of SR Ca(2+) uptake that may be important in frequency-dependent acceleration of relaxation (FDAR) and maintenance of contractile function during acidosis. May participate in the modulation of skeletal muscle function in response to exercise, by regulating SR Ca(2+) transport through phosphorylation of PLN/PLB and triadin, a ryanodine receptor-coupling factor.", "general_function": "Titin binding", "gene_names": ["CAMK2D"], "name": "Calcium/calmodulin-dependent protein kinase type II subunit delta", "drug_actions": []}, "P13843": {"specific_function": "During virus entry, induces fusion of viral and cellular membranes leading to delivery of the nucleocapsid into the cytoplasm. The fusogenic activity is inactive untill entry into host cell endosome, where a furin-like protease cleaves off a small peptide between F1 and F2. Interacts directly with heparan sulfate and may participates in virus attachment. Furthermore, the F2 subunit was identifed as the major determinant of RSV host cell specificity. Later in infection, proteins F expressed at the plasma membrane of infected cells can mediate fusion with adjacent cells to form syncytia, a cytopathic effect that could lead to tissue necrosis. The fusion protein is also able to trigger p53-dependent apoptosis.", "gene_names": ["F"], "name": "Fusion glycoprotein F0", "drug_actions": []}, "Q13555": {"specific_function": "Calcium/calmodulin-dependent protein kinase that functions autonomously after Ca(2+)/calmodulin-binding and autophosphorylation, and is involved in sarcoplsamic reticulum Ca(2+) transport in skeletal muscle and may function in dendritic spine and synapse formation and neuronal plasticity. In slow-twitch muscles, is involved in regulation of sarcoplasmic reticulum (SR) Ca(2+) transport and in fast-twitch muscle participates in the control of Ca(2+) release from the SR through phosphorylation of the ryanodine receptor-coupling factor triadin. In neurons, may participate in the promotion of dendritic spine and synapse formation and maintenance of synaptic plasticity which enables long-term potentiation (LTP) and hippocampus-dependent learning.", "general_function": "Protein homodimerization activity", "gene_names": ["CAMK2G"], "name": "Calcium/calmodulin-dependent protein kinase type II subunit gamma", "drug_actions": [{"action": "INHIBITOR", "target": "Q13555", "drug": "DB06616"}]}, "Q13554": {"specific_function": "Calcium/calmodulin-dependent protein kinase that functions autonomously after Ca(2+)/calmodulin-binding and autophosphorylation, and is involved in dendritic spine and synapse formation, neuronal plasticity and regulation of sarcoplasmic reticulum Ca(2+) transport in skeletal muscle. In neurons, plays an essential structural role in the reorganization of the actin cytoskeleton during plasticity by binding and bundling actin filaments in a kinase-independent manner. This structural function is required for correct targeting of CaMK2A, which acts downstream of NMDAR to promote dendritic spine and synapse formation and maintain synaptic plasticity which enables long-term potentiation (LTP) and hippocampus-dependent learning. In developing hippocampal neurons, promotes arborization of the dendritic tree and in mature neurons, promotes dendritic remodeling. Participates in the modulation of skeletal muscle function in response to exercise. In slow-twitch muscles, is involved in regulation of sarcoplasmic reticulum (SR) Ca(2+) transport and in fast-twitch muscle participates in the control of Ca(2+) release from the SR through phosphorylation of triadin, a ryanodine receptor-coupling factor, and phospholamban (PLN/PLB), an endogenous inhibitor of SERCA2A/ATP2A2.", "general_function": "Protein homodimerization activity", "gene_names": ["CAMK2B"], "name": "Calcium/calmodulin-dependent protein kinase type II subunit beta", "drug_actions": []}, "P0AG59": {"specific_function": "Binds 16S rRNA, required for the assembly of 30S particles and may also be responsible for determining the conformation of the 16S rRNA at the A site.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsN"], "name": "30S ribosomal protein S14", "drug_actions": [{"action": "ADDUCT", "target": "P0AG59", "drug": "DB00560"}, {"action": "INHIBITOR", "target": "P0AG59", "drug": "DB00759"}]}, "P84887": {"specific_function": "Oxidizes primary aromatic amines and, more slowly, some long-chain aliphatic amines, but not methylamine or ethylamine. Uses azurin as an electron acceptor to transfer electrons from the reduced tryptophylquinone cofactor.", "general_function": "Aralkylamine dehydrogenase (azurin) activity", "gene_names": ["aauA"], "name": "Aralkylamine dehydrogenase light chain", "drug_actions": []}, "P22459": {"specific_function": "Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes. Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane (PubMed:19912772, PubMed:8495559). Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA5, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel (PubMed:8495559). Channel properties are modulated by cytoplasmic beta subunits that regulate the subcellular location of the alpha subunits and promote rapid inactivation. In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Homotetrameric KCNA4 forms a potassium channel that opens in response to membrane depolarization, followed by rapid spontaneous channel closure (PubMed:19912772, PubMed:8495559). Likewise, a heterotetrameric channel formed by KCNA1 and KCNA4 shows rapid inactivation (PubMed:17156368).", "general_function": "Voltage-gated potassium channel activity", "gene_names": ["KCNA4"], "name": "Potassium voltage-gated channel subfamily A member 4", "drug_actions": [{"action": "ANTAGONIST", "target": "P22459", "drug": "DB06637"}]}, "Q96GD4": {"specific_function": "Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Involved in the bipolar attachment of spindle microtubules to kinetochores and is a key regulator for the onset of cytokinesis during mitosis. Required for central/midzone spindle assembly and cleavage furrow formation. Key component of the cytokinesis checkpoint, a process required to delay abscission to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage: phosphorylates CHMP4C, leading to retain abscission-competent VPS4 (VPS4A and/or VPS4B) at the midbody ring until abscission checkpoint signaling is terminated at late cytokinesis (PubMed:22422861, PubMed:24814515). AURKB phosphorylates the CPC complex subunits BIRC5/survivin, CDCA8/borealin and INCENP. Phosphorylation of INCENP leads to increased AURKB activity. Other known AURKB substrates involved in centromeric functions and mitosis are CENPA, DES/desmin, GPAF, KIF2C, NSUN2, RACGAP1, SEPT1, VIM/vimentin, GSG2/Haspin, and histone H3. A positive feedback loop involving GSG2 and AURKB contributes to localization of CPC to centromeres. Phosphorylation of VIM controls vimentin filament segregation in cytokinetic process, whereas histone H3 is phosphorylated at 'Ser-10' and 'Ser-28' during mitosis (H3S10ph and H3S28ph, respectively). A positive feedback between GSG2 and AURKB contributes to CPC localization. AURKB is also required for kinetochore localization of BUB1 and SGOL1. Phosphorylation of p53/TP53 negatively regulates its transcriptional activity. Key regulator of active promoters in resting B- and T-lymphocytes: acts by mediating phosphorylation of H3S28ph at active promoters in resting B-cells, inhibiting RNF2/RING1B-mediated ubiquitination of histone H2A and enhancing binding and activity of the USP16 deubiquitinase at transcribed genes.", "general_function": "Protein serine/threonine/tyrosine kinase activity", "gene_names": ["AURKB"], "name": "Aurora kinase B", "drug_actions": []}, "P84888": {"specific_function": "Oxidizes primary aromatic amines and, more slowly, some long-chain aliphatic amines, but not methylamine or ethylamine. Uses azurin as an electron acceptor to transfer electrons from the reduced tryptophylquinone cofactor.", "general_function": "Aralkylamine dehydrogenase (azurin) activity", "gene_names": ["aauB"], "name": "Aralkylamine dehydrogenase heavy chain", "drug_actions": []}, "P01892": {"specific_function": "Involved in the presentation of foreign antigens to the immune system.", "general_function": "Tap binding", "gene_names": ["HLA-A"], "name": "HLA class I histocompatibility antigen, A-2 alpha chain", "drug_actions": []}, "Q96GD0": {"specific_function": "Protein serine phosphatase that dephosphorylates 'Ser-3' in cofilin and probably also dephosphorylates phospho-serine residues in DSTN. Regulates cofilin-dependent actin cytoskeleton reorganization. Required for normal progress through mitosis and normal cytokinesis. Does not dephosphorylate phospho-threonines in LIMK1. Does not dephosphorylate peptides containing phospho-tyrosine. Pyridoxal phosphate phosphatase. Has some activity towards pyridoxal 5'-phosphate (PLP), pyridoxine 5'-phosphate (PMP) and pyridoxine 5'-phosphate (PNP), with a highest activity with PLP followed by PNP.", "general_function": "Pyridoxal phosphatase activity", "gene_names": ["PDXP"], "name": "Pyridoxal phosphate phosphatase", "drug_actions": [{"action": "COFACTOR", "target": "Q96GD0", "drug": "DB00114"}]}, "Q96GD3": {"specific_function": "Associates with Polycomb group (PcG) multiprotein complexes; the complex class is required to maintain the transcriptionally repressive state of some genes.", "general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": ["SCMH1"], "name": "Polycomb protein SCMH1", "drug_actions": []}, "P06241": {"specific_function": "Non-receptor tyrosine-protein kinase that plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance. Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. Following activation by PKA, the protein subsequently associates with PTK2/FAK1, allowing PTK2/FAK1 phosphorylation, activation and targeting to focal adhesions. Involved in the regulation of cell adhesion and motility through phosphorylation of CTNNB1 (beta-catenin) and CTNND1 (delta-catenin). Regulates cytoskeletal remodeling by phosphorylating several proteins including the actin regulator WAS and the microtubule-associated proteins MAP2 and MAPT. Promotes cell survival by phosphorylating AGAP2/PIKE-A and preventing its apoptotic cleavage. Participates in signal transduction pathways that regulate the integrity of the glomerular slit diaphragm (an essential part of the glomerular filter of the kidney) by phosphorylating several slit diaphragm components including NPHS1, KIRREL and TRPC6. Plays a role in neural processes by phosphorylating DPYSL2, a multifunctional adapter protein within the central nervous system, ARHGAP32, a regulator for Rho family GTPases implicated in various neural functions, and SNCA, a small pre-synaptic protein. Participates in the downstream signaling pathways that lead to T-cell differentiation and proliferation following T-cell receptor (TCR) stimulation. Also participates in negative feedback regulation of TCR signaling through phosphorylation of PAG1, thereby promoting interaction between PAG1 and CSK and recruitment of CSK to lipid rafts. CSK maintains LCK and FYN in an inactive form. Promotes CD28-induced phosphorylation of VAV1.", "general_function": "Protein tyrosine kinase activity", "gene_names": ["FYN"], "name": "Tyrosine-protein kinase Fyn", "drug_actions": [{"action": "MULTITARGET", "target": "P06241", "drug": "DB01254"}]}, "O33407": {"specific_function": "Esterase whose enzymatic activity is required for rhamnolipid production, all kinds of cell motility (swimming, swarming, and twitching), and biofilm formation; the exact role of EstA in these processes is unclear. In vitro, has pronounced esterase activities towards p-nitrophenyl esters of short acyl chain length (C4-C6) and Tween detergents. Also shows relatively high activity towards beta-naphthyl butyrate, whereas its activities towards triacylglycerols and acyls-CoA are negligible.", "general_function": "Lipase activity", "gene_names": ["estA"], "name": "Esterase EstA", "drug_actions": []}, "P22695": {"specific_function": "This is a component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is part of the mitochondrial respiratory chain. The core protein 2 is required for the assembly of the complex.", "general_function": "Zinc ion binding", "gene_names": ["UQCRC2"], "name": "Cytochrome b-c1 complex subunit 2, mitochondrial", "drug_actions": []}, "P22694": {"specific_function": "Mediates cAMP-dependent signaling triggered by receptor binding to GPCRs. PKA activation regulates diverse cellular processes such as cell proliferation, the cell cycle, differentiation and regulation of microtubule dynamics, chromatin condensation and decondensation, nuclear envelope disassembly and reassembly, as well as regulation of intracellular transport mechanisms and ion flux. Regulates the abundance of compartmentalized pools of its regulatory subunits through phosphorylation of PJA2 which binds and ubiquitinates these subunits, leading to their subsequent proteolysis.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["PRKACB"], "name": "cAMP-dependent protein kinase catalytic subunit beta", "drug_actions": []}, "Q53119": {"general_function": "Fad binding", "gene_names": ["appA"], "name": "AppA protein", "drug_actions": []}, "Q9NR97": {"specific_function": "Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.", "general_function": "Single-stranded rna binding", "gene_names": ["TLR8"], "name": "Toll-like receptor 8", "drug_actions": [{"action": "AGONIST", "target": "Q9NR97", "drug": "DB00724"}]}, "Q9NR96": {"specific_function": "Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR9 is a nucleotide-sensing TLR which is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Controls lymphocyte response to Helicobacter infection.", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["TLR9"], "name": "Toll-like receptor 9", "drug_actions": [{"action": "ANTAGONIST", "target": "Q9NR96", "drug": "DB01611"}]}, "P03023": {"specific_function": "Repressor of the lactose operon. Binds allolactose as an inducer.", "general_function": "Transcriptional repressor activity, bacterial-type rna polymerase core promoter proximal region sequence-specific binding", "gene_names": ["lacI"], "name": "Lactose operon repressor", "drug_actions": []}, "O75976": {"general_function": "Zinc ion binding", "gene_names": ["CPD"], "name": "Carboxypeptidase D", "drug_actions": []}, "P0AFU8": {"specific_function": "Catalyzes the dismutation of two molecules of 6,7-dimethyl-8-ribityllumazine, resulting in the formation of riboflavin and 5-amino-6-(D-ribitylamino)uracil.", "general_function": "Riboflavin synthase activity", "gene_names": ["ribC"], "name": "Riboflavin synthase", "drug_actions": [{"action": "OTHER", "target": "P0AFU8", "drug": "DB00140"}]}, "P60900": {"specific_function": "The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity.", "general_function": "Threonine-type endopeptidase activity", "gene_names": ["PSMA6"], "name": "Proteasome subunit alpha type-6", "drug_actions": []}, "P16608": {"specific_function": "The alpha subunit is responsible for the aldol cleavage of indoleglycerol phosphate to indole and glyceraldehyde 3-phosphate.", "general_function": "Tryptophan synthase activity", "gene_names": ["trpA"], "name": "Tryptophan synthase alpha chain", "drug_actions": []}, "Q16740": {"specific_function": "Protease component of the Clp complex that cleaves peptides and various proteins in an ATP-dependent process. Has low peptidase activity in the absence of CLPX. The Clp complex can degrade CSN1S1, CSN2 and CSN3, as well as synthetic peptides (in vitro) and may be responsible for a fairly general and central housekeeping function rather than for the degradation of specific substrates.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["CLPP"], "name": "ATP-dependent Clp protease proteolytic subunit, mitochondrial", "drug_actions": []}, "P11021": {"specific_function": "Probably plays a role in facilitating the assembly of multimeric protein complexes inside the endoplasmic reticulum. Involved in the correct folding of proteins and degradation of misfolded proteins via its interaction with DNAJC10, probably to facilitate the release of DNAJC10 from its substrate.", "general_function": "Unfolded protein binding", "gene_names": ["HSPA5"], "name": "78 kDa glucose-regulated protein", "drug_actions": [{"action": "CHAPERONE", "target": "P11021", "drug": "DB00025"}, {"action": "BINDING", "target": "P11021", "drug": "DB00945"}]}, "P15056": {"specific_function": "Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Phosphorylates MAP2K1, and thereby contributes to the MAP kinase signal transduction pathway.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["BRAF"], "name": "Serine/threonine-protein kinase B-raf", "drug_actions": [{"action": "INHIBITOR", "target": "P15056", "drug": "DB00398"}, {"action": "INHIBITOR", "target": "P15056", "drug": "DB08881"}, {"action": "INHIBITOR", "target": "P15056", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P15056", "drug": "DB08912"}]}, "Q8RQE8": {"specific_function": "DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates.", "general_function": "Dna-directed rna polymerase activity", "gene_names": ["rpoC"], "name": "DNA-directed RNA polymerase subunit beta'", "drug_actions": []}, "P50440": {"specific_function": "Catalyzes the biosynthesis of guanidinoacetate, the immediate precursor of creatine. Creatine plays a vital role in energy metabolism in muscle tissues. May play a role in embryonic and central nervous system development. May be involved in the response to heart failure by elevating local creatine synthesis.", "general_function": "Glycine amidinotransferase activity", "gene_names": ["GATM"], "name": "Glycine amidinotransferase, mitochondrial", "drug_actions": []}, "Q06241": {"specific_function": "Catalyzes hydrolysis of the D-alanyl-D-alanine dipeptide.", "general_function": "Zinc ion binding", "gene_names": ["vanX"], "name": "D-alanyl-D-alanine dipeptidase", "drug_actions": []}, "P11759": {"specific_function": "Catalyzes the oxidation of guanosine diphospho-D-mannose (GDP-D-mannose) to GDP-D-mannuronic acid, a precursor for alginate polymerization. The alginate layer causes a mucoid phenotype and provides a protective barrier against host immune defenses and antibiotics.", "general_function": "Udp-glucose 6-dehydrogenase activity", "gene_names": ["algD"], "name": "GDP-mannose 6-dehydrogenase", "drug_actions": []}, "P37059": {"specific_function": "Capable of catalyzing the interconversion of testosterone and androstenedione, as well as estradiol and estrone. Also has 20-alpha-HSD activity. Uses NADH while EDH17B3 uses NADPH.", "general_function": "Testosterone dehydrogenase (nad+) activity", "gene_names": ["HSD17B2"], "name": "Estradiol 17-beta-dehydrogenase 2", "drug_actions": []}, "P37058": {"specific_function": "Favors the reduction of androstenedione to testosterone. Uses NADPH while the two other EDH17B enzymes use NADH.", "general_function": "Testosterone 17-beta-dehydrogenase (nadp+) activity", "gene_names": ["HSD17B3"], "name": "Testosterone 17-beta-dehydrogenase 3", "drug_actions": []}, "P0AB87": {"specific_function": "Catalyzes the cleavage of L-fuculose 1-phosphate to glycerone phosphate and L-lactaldehyde.", "general_function": "Zinc ion binding", "gene_names": ["fucA"], "name": "L-fuculose phosphate aldolase", "drug_actions": []}, "Q15825": {"specific_function": "After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.", "general_function": "Acetylcholine-activated cation-selective channel activity", "gene_names": ["CHRNA6"], "name": "Neuronal acetylcholine receptor subunit alpha-6", "drug_actions": [{"action": "AGONIST", "target": "Q15825", "drug": "DB00184"}, {"action": "ALLOSTERIC MODULATOR", "target": "Q15825", "drug": "DB00674"}, {"action": "PARTIAL AGONIST", "target": "Q15825", "drug": "DB01273"}, {"action": "AGONIST", "target": "Q15825", "drug": "DB09028"}]}, "P0AB80": {"specific_function": "Acts on leucine, isoleucine and valine.", "general_function": "L-valine transaminase activity", "gene_names": ["ilvE"], "name": "Branched-chain-amino-acid aminotransferase", "drug_actions": []}, "Q8WWL2": {"specific_function": "Acts as an actin nucleation factor, remains associated with the slow-growing pointed end of the new filament. Involved in intracellular vesicle transport along actin fibers, providing a novel link between actin cytoskeleton dynamics and intracellular transport. Required for asymmetric spindle positioning and asymmetric cell division during meiosis. Required for normal formation of the cleavage furrow and for polar body extrusion during female germ cell meiosis.", "gene_names": ["SPIRE2"], "name": "Protein spire homolog 2", "drug_actions": []}, "P0C0T5": {"specific_function": "Involved in the removal of murein from the sacculus. May also facilitate integration of nascent murein strands into the sacculus by cleaving the peptide bonds between neighboring strands in mature murein.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["mepA"], "name": "Penicillin-insensitive murein endopeptidase", "drug_actions": []}, "Q59961": {"specific_function": "Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.", "general_function": "Magnesium ion binding", "gene_names": ["parE"], "name": "DNA topoisomerase 4 subunit B", "drug_actions": [{"action": "INHIBITOR", "target": "Q59961", "drug": "DB01044"}]}, "Q15274": {"specific_function": "Involved in the catabolism of quinolinic acid (QA).", "general_function": "Protein homodimerization activity", "gene_names": ["QPRT"], "name": "Nicotinate-nucleotide pyrophosphorylase [carboxylating]", "drug_actions": [{"action": "BINDER", "target": "Q15274", "drug": "DB00627"}]}, "P33247": {"specific_function": "Catalyzes the cyclization of squalene into hopene.", "general_function": "Squalene-hopene cyclase activity", "gene_names": ["shc"], "name": "Squalene--hopene cyclase", "drug_actions": []}, "Q13882": {"specific_function": "Non-receptor tyrosine-protein kinase implicated in the regulation of a variety of signaling pathways that control the differentiation and maintenance of normal epithelia, as well as tumor growth. Function seems to be context dependent and differ depending on cell type, as well as its intracellular localization. A number of potential nuclear and cytoplasmic substrates have been identified. These include the RNA-binding proteins: KHDRBS1/SAM68, KHDRBS2/SLM1, KHDRBS3/SLM2 and SFPQ/PSF; transcription factors: STAT3 and STAT5A/B and a variety of signaling molecules: ARHGAP35/p190RhoGAP, PXN/paxillin, BTK/ATK, STAP2/BKS. Associates also with a variety of proteins that are likely upstream of PTK6 in various signaling pathways, or for which PTK6 may play an adapter-like role. These proteins include ADAM15, EGFR, ERBB2, ERBB3 and IRS4. In normal or non-tumorigenic tissues, PTK6 promotes cellular differentiation and apoptosis. In tumors PTK6 contributes to cancer progression by sensitizing cells to mitogenic signals and enhancing proliferation, anchorage-independent survival and migration/invasion. Association with EGFR, ERBB2, ERBB3 may contribute to mammary tumor development and growth through enhancement of EGF-induced signaling via BTK/AKT and PI3 kinase. Contributes to migration and proliferation by contributing to EGF-mediated phosphorylation of ARHGAP35/p190RhoGAP, which promotes association with RASA1/p120RasGAP, inactivating RhoA while activating RAS. EGF stimulation resulted in phosphorylation of PNX/Paxillin by PTK6 and activation of RAC1 via CRK/CrKII, thereby promoting migration and invasion. PTK6 activates STAT3 and STAT5B to promote proliferation. Nuclear PTK6 may be important for regulating growth in normal epithelia, while cytoplasmic PTK6 might activate oncogenic signaling pathways.Isoform 2 inhibits PTK6 phosphorylation and PTK6 association with other tyrosine-phosphorylated proteins.", "general_function": "Receptor binding", "gene_names": ["PTK6"], "name": "Protein-tyrosine kinase 6", "drug_actions": [{"action": "INHIBITOR", "target": "Q13882", "drug": "DB05294"}]}, "Q13885": {"specific_function": "Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity).", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["TUBB2A"], "name": "Tubulin beta-2A chain", "drug_actions": []}, "O00142": {"specific_function": "Deoxyribonucleoside kinase that phosphorylates thymidine, deoxycytidine, and deoxyuridine. Also phosphorylates anti-viral and anti-cancer nucleoside analogs.", "general_function": "Thymidine kinase activity", "gene_names": ["TK2"], "name": "Thymidine kinase 2, mitochondrial", "drug_actions": []}, "O67135": {"general_function": "Metal ion binding", "gene_names": ["acuC1"], "name": "Acetoin utilization protein", "drug_actions": []}, "O00141": {"specific_function": "Serine/threonine-protein kinase which is involved in the regulation of a wide variety of ion channels, membrane transporters, cellular enzymes, transcription factors, neuronal excitability, cell growth, proliferation, survival, migration and apoptosis. Plays an important role in cellular stress response. Contributes to regulation of renal Na(+) retention, renal K(+) elimination, salt appetite, gastric acid secretion, intestinal Na(+)/H(+) exchange and nutrient transport, insulin-dependent salt sensitivity of blood pressure, salt sensitivity of peripheral glucose uptake, cardiac repolarization and memory consolidation. Up-regulates Na(+) channels: SCNN1A/ENAC, SCN5A and ASIC1/ACCN2, K(+) channels: KCNJ1/ROMK1, KCNA1-5, KCNQ1-5 and KCNE1, epithelial Ca(2+) channels: TRPV5 and TRPV6, chloride channels: BSND, CLCN2 and CFTR, glutamate transporters: SLC1A3/EAAT1, SLC1A2 /EAAT2, SLC1A1/EAAT3, SLC1A6/EAAT4 and SLC1A7/EAAT5, amino acid transporters: SLC1A5/ASCT2, SLC38A1/SN1 and SLC6A19, creatine transporter: SLC6A8, Na(+)/dicarboxylate cotransporter: SLC13A2/NADC1, Na(+)-dependent phosphate cotransporter: SLC34A2/NAPI-2B, glutamate receptor: GRIK2/GLUR6. Up-regulates carriers: SLC9A3/NHE3, SLC12A1/NKCC2, SLC12A3/NCC, SLC5A3/SMIT, SLC2A1/GLUT1, SLC5A1/SGLT1 and SLC15A2/PEPT2. Regulates enzymes: GSK3A/B, PMM2 and Na(+)/K(+) ATPase, and transcription factors: CTNNB1 and nuclear factor NF-kappa-B. Stimulates sodium transport into epithelial cells by enhancing the stability and expression of SCNN1A/ENAC. This is achieved by phosphorylating the NEDD4L ubiquitin E3 ligase, promoting its interaction with 14-3-3 proteins, thereby preventing it from binding to SCNN1A/ENAC and targeting it for degradation. Regulates store-operated Ca(+2) entry (SOCE) by stimulating ORAI1 and STIM1. Regulates KCNJ1/ROMK1 directly via its phosphorylation or indirectly via increased interaction with SLC9A3R2/NHERF2. Phosphorylates MDM2 and activates MDM2-dependent ubiquitination of p53/TP53. Phosphorylates MAPT/TAU and mediates microtubule depolymerization and neurite formation in hippocampal neurons. Phosphorylates SLC2A4/GLUT4 and up-regulates its activity. Phosphorylates APBB1/FE65 and promotes its localization to the nucleus. Phosphorylates MAPK1/ERK2 and activates it by enhancing its interaction with MAP2K1/MEK1 and MAP2K2/MEK2. Phosphorylates FBXW7 and plays an inhibitory role in the NOTCH1 signaling. Phosphorylates FOXO1 resulting in its relocalization from the nucleus to the cytoplasm. Phosphorylates FOXO3, promoting its exit from the nucleus and interference with FOXO3-dependent transcription. Phosphorylates BRAF and MAP3K3/MEKK3 and inhibits their activity. Phosphorylates SLC9A3/NHE3 in response to dexamethasone, resulting in its activation and increased localization at the cell membrane. Phosphorylates CREB1. Necessary for vascular remodeling during angiogenesis. Sustained high levels and activity may contribute to conditions such as hypertension and diabetic nephropathy. Isoform 2 exhibited a greater effect on cell plasma membrane expression of SCNN1A/ENAC and Na(+) transport than isoform 1.", "general_function": "Sodium channel regulator activity", "gene_names": ["SGK1"], "name": "Serine/threonine-protein kinase Sgk1", "drug_actions": []}, "P12499": {"specific_function": "Gag-Pol polyprotein: Mediates, with Gag polyrotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shutt off translation.Matrix protein p17: Targets the polyprotein to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus. Matrix protein is part of the pre-integration complex. Implicated in the release from host cell mediated by Vpu. Binds to RNA.Capsid protein p24: Forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion. Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry (By similarity). Host restriction factors such as TRIM5-alpha or TRIMCyp bind retroviral capsids and cause premature capsid disassembly, leading to blocks in reverse transcription. Capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species. Host PIN1 apparently facilitates the virion uncoating. On the other hand, interactions with PDZD8 or CYPA stabilize the capsid.Nucleocapsid protein p7: Encapsulates and protects viral dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its zinc fingers. Acts as a nucleic acid chaperone which is involved in rearangement of nucleic acid secondary structure during gRNA retrotranscription. Also facilitates template switch leading to recombination. As part of the polyprotein, participates to gRNA dimerization, packaging, tRNA incorporation and virion assembly.Protease: Aspartyl protease that mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane. Cleavages take place as an ordered, step-wise cascade to yield mature proteins. This process is called maturation. Displays maximal activity during the budding process just prior to particle release from the cell. Also cleaves Nef and Vif, probably concomitantly with viral structural proteins on maturation of virus particles. Hydrolyzes host EIF4GI and PABP1 in order to shut off the capped cellular mRNA translation. The resulting inhibition of cellular protein synthesis serves to ensure maximal viral gene expression and to evade host immune response (By similarity).Reverse transcriptase/ribonuclease H: Multifunctional enzyme that converts the viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for two polypurine tracts (PPTs) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPTs that have not been removed by RNase H as primers. PPTs and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends.Integrase: Catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration.", "general_function": "Zinc ion binding", "gene_names": ["gag-pol"], "name": "Gag-Pol polyprotein", "drug_actions": []}, "P77390": {"specific_function": "Acetylation of prosthetic group (2-(5''-phosphoribosyl)-3'-dephosphocoenzyme-A) of the gamma subunit of citrate lyase.", "general_function": "N-acetyltransferase activity", "gene_names": ["citC"], "name": "[Citrate [pro-3S]-lyase] ligase", "drug_actions": [{"action": "INHIBITOR", "target": "P77390", "drug": "DB00336"}]}, "O52806": {"general_function": "Dtdp-4-dehydrorhamnose 3,5-epimerase activity", "gene_names": [], "name": "PCZA361.16", "drug_actions": []}, "P0A574": {"specific_function": "Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP. Catalyzes the first condensation reaction which initiates fatty acid synthesis and may therefore play a role in governing the total rate of fatty acid production. Possesses both acetoacetyl-ACP synthase and acetyl transacylase activities. Has some substrate specificity for long chain acyl-CoA such as myristoyl-CoA. Does not use acyl-CoA as primer. Its substrate specificity determines the biosynthesis of mycolic acid fatty acid chain, which is characteristic of mycobacterial cell wall", "general_function": "Lipid transport and metabolism", "gene_names": ["fabH"], "name": "3-oxoacyl-[acyl-carrier-protein] synthase 3", "drug_actions": []}, "Q8WTV0": {"specific_function": "Receptor for different ligands such as phospholipids, cholesterol ester, lipoproteins, phosphatidylserine and apoptotic cells. Probable receptor for HDL, located in particular region of the plasma membrane, called caveolae. Facilitates the flux of free and esterified cholesterol between the cell surface and extracellular donors and acceptors, such as HDL and to a lesser extent, apoB-containing lipoproteins and modified lipoproteins. Probably involved in the phagocytosis of apoptotic cells, via its phosphatidylserine binding activity. Receptor for hepatitis C virus glycoprotein E2. Binding between SCARB1 and E2 was found to be independent of the genotype of the viral isolate. Plays an important role in the uptake of HDL cholesteryl ester (By similarity).(Microbial infection) Acts as a receptor for hepatitis C virus in hepatocytes.", "general_function": "Virus receptor activity", "gene_names": ["SCARB1"], "name": "Scavenger receptor class B member 1", "drug_actions": []}, "P77398": {"specific_function": "Bifunctional enzyme that catalyzes the oxidative decarboxylation of UDP-glucuronic acid (UDP-GlcUA) to UDP-4-keto-arabinose (UDP-Ara4O) and the addition of a formyl group to UDP-4-amino-4-deoxy-L-arabinose (UDP-L-Ara4N) to form UDP-L-4-formamido-arabinose (UDP-L-Ara4FN). The modified arabinose is attached to lipid A and is required for resistance to polymyxin and cationic antimicrobial peptides.", "general_function": "Udp-glucuronate decarboxylase activity", "gene_names": ["arnA"], "name": "Bifunctional polymyxin resistance protein ArnA", "drug_actions": []}, "Q9P0X4": {"specific_function": "Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. Isoform alpha-1I gives rise to T-type calcium currents. T-type calcium channels belong to the \"low-voltage activated (LVA)\" group and are strongly blocked by nickel and mibefradil. A particularity of this type of channels is an opening at quite negative potentials, and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes. Gates in voltage ranges similar to, but higher than alpha 1G or alpha 1H (By similarity).", "name": "Voltage-dependent T-type calcium channel subunit alpha-1I", "drug_actions": [{"action": "INHIBITOR", "target": "Q9P0X4", "drug": "DB00568"}, {"action": "SUPPRESSOR", "target": "Q9P0X4", "drug": "DB00617"}, {"action": "INHIBITOR", "target": "Q9P0X4", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "Q9P0X4", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q9P0X4", "drug": "DB01388"}, {"action": "INHIBITOR", "target": "Q9P0X4", "drug": "DB04841"}], "general_function": "Voltage-gated calcium channel activity", "in_complexes": ["Voltage-dependent calcium channel"], "gene_names": ["CACNA1I"]}, "P0A6I0": {"specific_function": "ATP, dATP, and GTP are equally effective as phosphate donors. CMP and dCMP are the best phosphate acceptors.", "general_function": "Cytidylate kinase activity", "gene_names": ["cmk"], "name": "Cytidylate kinase", "drug_actions": []}, "P13995": {"general_function": "Phosphate ion binding", "gene_names": ["MTHFD2"], "name": "Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial", "drug_actions": [{"action": "COFACTOR", "target": "P13995", "drug": "DB00116"}]}, "P55011": {"specific_function": "Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.", "general_function": "Sodium:potassium:chloride symporter activity", "gene_names": ["SLC12A2"], "name": "Solute carrier family 12 member 2", "drug_actions": [{"action": "INHIBITOR", "target": "P55011", "drug": "DB00887"}, {"action": "INHIBITOR", "target": "P55011", "drug": "DB01325"}]}, "P0A6I3": {"general_function": "Pantothenate kinase activity", "gene_names": ["coaA"], "name": "Pantothenate kinase", "drug_actions": []}, "P20594": {"specific_function": "Receptor for the C-type natriuretic peptide NPPC/CNP hormone. Has guanylate cyclase activity upon binding of its ligand. May play a role in the regulation of skeletal growth.", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["NPR2"], "name": "Atrial natriuretic peptide receptor 2", "drug_actions": [{"action": "AGONIST", "target": "P20594", "drug": "DB01613"}]}, "P34903": {"specific_function": "GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.", "name": "Gamma-aminobutyric acid receptor subunit alpha-3", "drug_actions": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00228"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00237"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00292"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00306"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00349"}, {"action": "AGONIST", "target": "P34903", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00371"}, {"action": "AGONIST", "target": "P34903", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00404"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00418"}, {"action": "AGONIST", "target": "P34903", "drug": "DB00425"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00475"}, {"action": "BINDER", "target": "P34903", "drug": "DB00543"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00599"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00628"}, {"action": "POSITIVE MODULATOR", "target": "P34903", "drug": "DB00659"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00690"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00753"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00794"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00818"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00849"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01028"}, {"action": "AGONIST", "target": "P34903", "drug": "DB01049"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01189"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01198"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01205"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01236"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01351"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01352"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01353"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01354"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01355"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01437"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01483"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01496"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01544"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P34903", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P34903", "drug": "DB01595"}, {"action": "ANTAGONIST", "target": "P34903", "drug": "DB01708"}], "general_function": "Inhibitory extracellular ligand-gated ion channel activity", "in_complexes": ["GABA-A receptor (anion channel)"], "gene_names": ["GABRA3"]}, "P0A6I8": {"specific_function": "Reversibly transfers an adenylyl group from ATP to 4'-phosphopantetheine, yielding dephospho-CoA (dPCoA) and pyrophosphate.", "general_function": "Pantetheine-phosphate adenylyltransferase activity", "gene_names": ["coaD"], "name": "Phosphopantetheine adenylyltransferase", "drug_actions": []}, "P51553": {"general_function": "Nad binding", "gene_names": ["IDH3G"], "name": "Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial", "drug_actions": []}, "P51003": {"specific_function": "Polymerase that creates the 3'-poly(A) tail of mRNA's. Also required for the endoribonucleolytic cleavage reaction at some polyadenylation sites. May acquire specificity through interaction with a cleavage and polyadenylation specificity factor (CPSF) at its C-terminus.", "general_function": "Rna binding", "gene_names": ["PAPOLA"], "name": "Poly(A) polymerase alpha", "drug_actions": []}, "P52209": {"specific_function": "Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH.", "general_function": "Phosphogluconate dehydrogenase (decarboxylating) activity", "gene_names": ["PGD"], "name": "6-phosphogluconate dehydrogenase, decarboxylating", "drug_actions": [{"action": "INHIBITOR", "target": "P52209", "drug": "DB00789"}, {"action": "INHIBITOR", "target": "P52209", "drug": "DB00851"}, {"action": "INHIBITOR", "target": "P52209", "drug": "DB00920"}]}, "P05177": {"specific_function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.", "general_function": "Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen", "gene_names": ["CYP1A2"], "name": "Cytochrome P450 1A2", "drug_actions": []}, "Q38087": {"specific_function": "Replicates the viral genomic DNA. This polymerase possesses two enzymatic activities: DNA synthesis (polymerase) and an exonucleolytic activity that degrades single-stranded DNA in the 3'- to 5'-direction for proofreading purpose.", "general_function": "Nucleotide binding", "gene_names": ["43"], "name": "DNA polymerase", "drug_actions": []}, "Q60037": {"general_function": "Endo-1,4-beta-xylanase activity", "gene_names": ["xynA"], "name": "Endo-1,4-beta-xylanase A", "drug_actions": []}, "P29813": {"specific_function": "Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host CD55 to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP2: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP3: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP4: Lies on the inner surface of the capsid shell. After binding to the host receptor, the capsid undergoes conformational changes. Capsid protein VP4 is released, Capsid protein VP1 N-terminus is externalized, and together, they shape a pore in the host membrane through which the viral genome is translocated into the host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP0: Component of immature procapsids, which is cleaved into capsid proteins VP4 and VP2 after maturation. Allows the capsid to remain inactive before the maturation step (By similarity).Protein 2A: Cysteine protease that cleaves viral polyprotein and specific host proteins. It is responsible for the cleavage between the P1 and P2 regions, first cleavage occurring in the polyprotein. Cleaves also the host translation initiation factor EIF4G1, in order to shut down the capped cellular mRNA translation. Inhibits the host nucleus-cytoplasm protein and RNA trafficking by cleaving host members of the nuclear pores (By similarity).Protein 2B: Plays an essential role in the virus replication cycle by acting as a viroporin. Creates a pore in the host reticulum endoplasmic and as a consequence releases Ca2+ in the cytoplasm of infected cell. In turn, high levels of cyctoplasmic calcium may trigger membrane trafficking and transport of viral ER-associated proteins to viroplasms, sites of viral genome replication (By similarity).Protein 2C: Induces and associates with structural rearrangements of intracellular membranes. Displays RNA-binding, nucleotide binding and NTPase activities. May play a role in virion morphogenesis and viral RNA encapsidation by interacting with the capsid protein VP3 (By similarity).Protein 3AB: Localizes the viral replication complex to the surface of membranous vesicles. Together with protein 3CD binds the Cis-Active RNA Element (CRE) which is involved in RNA synthesis initiation. Acts as a cofactor to stimulate the activity of 3D polymerase, maybe through a nucleid acid chaperone activity (By similarity).Protein 3A: Localizes the viral replication complex to the surface of membranous vesicles. It inhibits host cell endoplasmic reticulum-to-Golgi apparatus transport and causes the dissassembly of the Golgi complex, possibly through GBF1 interaction. This would result in depletion of MHC, trail receptors and IFN receptors at the host cell surface (By similarity).Viral protein genome-linked: acts as a primer for viral RNA replication and remains covalently bound to viral genomic RNA. VPg is uridylylated prior to priming replication into VPg-pUpU. The oriI viral genomic sequence may act as a template for this. The VPg-pUpU is then used as primer on the genomic RNA poly(A) by the RNA-dependent RNA polymerase to replicate the viral genome. VPg may be removed in the cytoplasm by an unknown enzyme termed \"unlinkase\". VPg is not cleaved off virion genomes because replicated genomic RNA are encapsidated at the site of replication (By similarity).Protein 3CD: Is involved in the viral replication complex and viral polypeptide maturation. It exhibits protease activity with a specificity and catalytic efficiency that is different from protease 3C. Protein 3CD lacks polymerase activity. The 3C domain in the context of protein 3CD may have an RNA binding activity (By similarity).Protease 3C: cleaves host DDX58/RIG-I and thus contributes to the inhibition of type I interferon production. Cleaves also host PABPC1 (By similarity).RNA-directed RNA polymerase: Replicates the viral genomic RNA on the surface of intracellular membranes. May form linear arrays of subunits that propagate along a strong head-to-tail interaction called interface-I. Covalently attaches UMP to a tyrosine of VPg, which is used to prime RNA synthesis. The positive stranded RNA genome is first replicated at virus induced membranous vesicles, creating a dsRNA genomic replication form. This dsRNA is then used as template to synthesize positive stranded RNA genomes. ss(+)RNA genomes are either translated, replicated or encapsidated (By similarity).", "general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P30049": {"specific_function": "Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain. F-type ATPases consist of two structural domains, F(1) - containing the extramembraneous catalytic core, and F(0) - containing the membrane proton channel, linked together by a central stalk and a peripheral stalk. During catalysis, ATP turnover in the catalytic domain of F(1) is coupled via a rotary mechanism of the central stalk subunits to proton translocation. Part of the complex F(1) domain and of the central stalk which is part of the complex rotary element. Rotation of the central stalk against the surrounding alpha(3)beta(3) subunits leads to hydrolysis of ATP in three separate catalytic sites on the beta subunits.", "general_function": "Transporter activity", "gene_names": ["ATP5D"], "name": "ATP synthase subunit delta, mitochondrial", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "P30049", "drug": "DB00228"}, {"action": "UNKNOWN", "target": "P30049", "drug": "DB00753"}, {"action": "UNKNOWN", "target": "P30049", "drug": "DB01028"}, {"action": "OTHER/UNKNOWN", "target": "P30049", "drug": "DB01159"}, {"action": "OTHER/UNKNOWN", "target": "P30049", "drug": "DB01189"}, {"action": "OTHER/UNKNOWN", "target": "P30049", "drug": "DB01236"}]}, "Q9BYF1": {"specific_function": "Carboxypeptidase which converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. Also able to hydrolyze apelin-13 and dynorphin-13 with high efficiency. May be an important regulator of heart function.(Microbial infection) Acts as a receptor for SARS coronavirus/SARS-CoV and human coronavirus NL63/HCoV-NL63.", "general_function": "Zinc ion binding", "gene_names": ["ACE2"], "name": "Angiotensin-converting enzyme 2", "drug_actions": [{"action": "INHIBITOR", "target": "Q9BYF1", "drug": "DB00691"}, {"action": "INHIBITOR", "target": "Q9BYF1", "drug": "DB00722"}]}, "A9JQL9": {"specific_function": "Catalyzes the head-to-head condensation of two molecules of farnesyl diphosphate (FPP) into the colorless C(30) carotenoid dehydrosqualene (4,4'-diapophytoene). This is the initial step in the biosynthesis of staphyloxanthin, an orange carotenoid present in most staphylococci strains.", "general_function": "Transferase activity, transferring alkyl or aryl (other than methyl) groups", "gene_names": ["crtM"], "name": "Dehydrosqualene synthase", "drug_actions": []}, "Q9XBQ3": {"specific_function": "Involved in the degradation of arabinan and is a key enzyme in the complete degradation of the plant cell wall. Catalyzes the cleavage of terminal alpha-(1->5)-arabinofuranosyl bonds in different hemicellulosic homopolysaccharides (branched and debranched arabinans). It acts preferentially on aryl-alpha-L-arabinofuranosides, and is much less effective on aryl-beta-D-xylopyranosides.", "general_function": "Alpha-l-arabinofuranosidase activity", "gene_names": ["abfA"], "name": "Intracellular exo-alpha-(1->5)-L-arabinofuranosidase", "drug_actions": []}, "P06149": {"specific_function": "First component of the membrane-bound D-lactate oxidase, which is believed to play an important role in the energization of the active transport of a variety of sugars and amino acids.", "general_function": "Oxidoreductase activity, acting on the ch-oh group of donors, quinone or similar compound as acceptor", "gene_names": ["dld"], "name": "D-lactate dehydrogenase", "drug_actions": [{"action": "INHIBITOR", "target": "P06149", "drug": "DB00756"}]}, "P30043": {"specific_function": "Broad specificity oxidoreductase that catalyzes the NADPH-dependent reduction of a variety of flavins, such as riboflavin, FAD or FMN, biliverdins, methemoglobin and PQQ (pyrroloquinoline quinone). Contributes to heme catabolism and metabolizes linear tetrapyrroles. Can also reduce the complexed Fe(3+) iron to Fe(2+) in the presence of FMN and NADPH. In the liver, converts biliverdin to bilirubin.", "general_function": "Riboflavin reductase (nadph) activity", "gene_names": ["BLVRB"], "name": "Flavin reductase (NADPH)", "drug_actions": [{"action": "PRODUCT OF", "target": "P30043", "drug": "DB00140"}]}, "P30044": {"specific_function": "Reduces hydrogen peroxide and alkyl hydroperoxides with reducing equivalents provided through the thioredoxin system. Involved in intracellular redox signaling.", "general_function": "Rna polymerase iii regulatory region dna binding", "gene_names": ["PRDX5"], "name": "Peroxiredoxin-5, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "P30044", "drug": "DB00995"}]}, "P35340": {"specific_function": "Serves to protect the cell against DNA damage by alkyl hydroperoxides. It can use either NADH or NADPH as electron donor for direct reduction of redox dyes or of alkyl hydroperoxides when combined with the AhpC protein.", "general_function": "Protein disulfide oxidoreductase activity", "gene_names": ["ahpF"], "name": "Alkyl hydroperoxide reductase subunit F", "drug_actions": []}, "Q9NQS7": {"specific_function": "Component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Probably acts through association with AURKB or AURKC. Seems to bind directly to microtubules. Controls the kinetochore localization of BUB1.", "gene_names": ["INCENP"], "name": "Inner centromere protein", "drug_actions": []}, "Q59GM9": {"specific_function": "Phosphorylase is an important allosteric enzyme in carbohydrate metabolism. Enzymes from different sources differ in their regulatory mechanisms and in their natural substrates. However, all known phosphorylases share catalytic and structural properties.", "general_function": "Pyridoxal phosphate binding", "gene_names": [], "name": "Alpha-1,4 glucan phosphorylase", "drug_actions": [{"action": "COFACTOR", "target": "Q59GM9", "drug": "DB00114"}]}, "Q9Y678": {"specific_function": "The coatomer is a cytosolic protein complex that binds to dilysine motifs and reversibly associates with Golgi non-clathrin-coated vesicles, which further mediate biosynthetic protein transport from the ER, via the Golgi up to the trans Golgi network. Coatomer complex is required for budding from Golgi membranes, and is essential for the retrograde Golgi-to-ER transport of dilysine-tagged proteins. In mammals, the coatomer can only be recruited by membranes associated to ADP-ribosylation factors (ARFs), which are small GTP-binding proteins; the complex also influences the Golgi structural integrity, as well as the processing, activity, and endocytic recycling of LDL receptors. Required for limiting lipid storage in lipid droplets. Involved in lipid homeostasis by regulating the presence of perilipin family members PLIN2 and PLIN3 at the lipid droplet surface and promoting the association of adipocyte triglyceride lipase (PNPLA2) with the lipid droplet surface to mediate lipolysis (By similarity).", "general_function": "Structural molecule activity", "gene_names": ["COPG1"], "name": "Coatomer subunit gamma-1", "drug_actions": []}, "Q8GJ44": {"specific_function": "Endoxylanase that degrades arabinoxylan and glucuronoxylan to xylobiose and xylotriose (in vitro).", "general_function": "Metal ion binding", "gene_names": ["xynA"], "name": "Endo-1,4-beta-xylanase A", "drug_actions": []}, "P55789": {"specific_function": "Isoform 1: FAD-dependent sulfhydryl oxidase that regenerates the redox-active disulfide bonds in CHCHD4/MIA40, a chaperone essential for disulfide bond formation and protein folding in the mitochondrial intermembrane space. The reduced form of CHCHD4/MIA40 forms a transient intermolecular disulfide bridge with GFER/ERV1, resulting in regeneration of the essential disulfide bonds in CHCHD4/MIA40, while GFER/ERV1 becomes re-oxidized by donating electrons to cytochrome c or molecular oxygen.Isoform 2: May act as an autocrine hepatotrophic growth factor promoting liver regeneration.", "general_function": "Thiol oxidase activity", "gene_names": ["GFER"], "name": "FAD-linked sulfhydryl oxidase ALR", "drug_actions": []}, "P0A6W9": {"general_function": "Metal ion binding", "gene_names": ["gshA"], "name": "Glutamate--cysteine ligase", "drug_actions": []}, "P17752": {"general_function": "Tryptophan 5-monooxygenase activity", "gene_names": ["TPH1"], "name": "Tryptophan 5-hydroxylase 1", "drug_actions": [{"action": "COFACTOR", "target": "P17752", "drug": "DB00360"}]}, "P55786": {"specific_function": "Aminopeptidase with broad substrate specificity for several peptides. Involved in proteolytic events essential for cell growth and viability. May act as regulator of neuropeptide activity. Plays a role in the antigen-processing pathway for MHC class I molecules. Involved in the N-terminal trimming of cytotoxic T-cell epitope precursors. Digests the poly-Q peptides found in many cellular proteins. Digests tau from normal brain more efficiently than tau from Alzheimer disease brain.", "general_function": "Zinc ion binding", "gene_names": ["NPEPPS"], "name": "Puromycin-sensitive aminopeptidase", "drug_actions": []}, "P00775": {"general_function": "Serine-type endopeptidase activity", "gene_names": ["sprT"], "name": "Trypsin", "drug_actions": []}, "Q9H6Z9": {"specific_function": "Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific proline found in each of the oxygen-dependent degradation (ODD) domains (N-terminal, NODD, and C-terminal, CODD) of HIF1A. Also hydroxylates HIF2A. Has a preference for the CODD site for both HIF1A and HIF2A. Hydroxylation on the NODD site by EGLN3 appears to require prior hydroxylation on the CODD site. Hydroxylated HIFs are then targeted for proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Under hypoxic conditions, the hydroxylation reaction is attenuated allowing HIFs to escape degradation resulting in their translocation to the nucleus, heterodimerization with HIF1B, and increased expression of hypoxy-inducible genes. EGLN3 is the most important isozyme in limiting physiological activation of HIFs (particularly HIF2A) in hypoxia. Also hydroxylates PKM in hypoxia, limiting glycolysis. Under normoxia, hydroxylates and regulates the stability of ADRB2. Regulator of cardiomyocyte and neuronal apoptosis. In cardiomyocytes, inhibits the anti-apoptotic effect of BCL2 by disrupting the BAX-BCL2 complex. In neurons, has a NGF-induced proapoptotic effect, probably through regulating CASP3 activity. Also essential for hypoxic regulation of neutrophilic inflammation. Plays a crucial role in DNA damage response (DDR) by hydroxylating TELO2, promoting its interaction with ATR which is required for activation of the ATR/CHK1/p53 pathway. Target proteins are preferentially recognized via a LXXLAP motif.", "general_function": "Peptidyl-proline 4-dioxygenase activity", "gene_names": ["EGLN3"], "name": "Egl nine homolog 3", "drug_actions": []}, "O14556": {"specific_function": "May play an important role in regulating the switch between different pathways for energy production during spermiogenesis and in the spermatozoon. Required for sperm motility and male fertility (By similarity).", "general_function": "Nadp binding", "gene_names": ["GAPDHS"], "name": "Glyceraldehyde-3-phosphate dehydrogenase, testis-specific", "drug_actions": []}, "P25101": {"specific_function": "Receptor for endothelin-1. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of binding affinities for ET-A is: ET1 > ET2 >> ET3.", "general_function": "Phosphatidylinositol phospholipase c activity", "gene_names": ["EDNRA"], "name": "Endothelin-1 receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "P25101", "drug": "DB00559"}, {"action": "ANTAGONIST", "target": "P25101", "drug": "DB06268"}, {"action": "ANTAGONIST", "target": "P25101", "drug": "DB06403"}, {"action": "ANTAGONIST", "target": "P25101", "drug": "DB08932"}]}, "Q9KWT6": {"general_function": "Transporter activity", "gene_names": ["algQ1"], "name": "AlgQ1", "drug_actions": []}, "Q9KWT5": {"general_function": "Transporter activity", "gene_names": ["algQ2"], "name": "AlgQ2", "drug_actions": []}, "P40926": {"general_function": "Poly(a) rna binding", "gene_names": ["MDH2"], "name": "Malate dehydrogenase, mitochondrial", "drug_actions": []}, "P13661": {"specific_function": "This is an oxacillin-hydrolyzing beta-lactamase.", "general_function": "Penicillin binding", "gene_names": ["bla"], "name": "Beta-lactamase OXA-1", "drug_actions": []}, "P49862": {"specific_function": "May catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. Specific for amino acid residues with aromatic side chains in the P1 position. Cleaves insulin A chain at '14-Tyr-|-Gln-15' and insulin B chain at '6-Leu-|-Cys-7', '16-Tyr-|-Leu-17', '25-Phe-|-Tyr-26' and '26-Tyr-|-Thr-27'. Could play a role in the activation of precursors to inflammatory cytokines.", "general_function": "Serine-type peptidase activity", "gene_names": ["KLK7"], "name": "Kallikrein-7", "drug_actions": []}, "P13196": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["ALAS1"], "name": "5-aminolevulinate synthase, nonspecific, mitochondrial", "drug_actions": [{"action": "COFACTOR", "target": "P13196", "drug": "DB00114"}]}, "Q54276": {"general_function": "Chitinase activity", "gene_names": ["chiB"], "name": "Chitinase", "drug_actions": []}, "Q9Y697": {"specific_function": "Catalyzes the removal of elemental sulfur from cysteine to produce alanine. It supplies the inorganic sulfur for iron-sulfur (Fe-S) clusters. May be involved in the biosynthesis of molybdenum cofactor.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["NFS1"], "name": "Cysteine desulfurase, mitochondrial", "drug_actions": [{"action": "COFACTOR", "target": "Q9Y697", "drug": "DB00114"}]}, "Q9Y694": {"specific_function": "Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.", "general_function": "Sodium-independent organic anion transmembrane transporter activity", "gene_names": ["SLC22A7"], "name": "Solute carrier family 22 member 7", "drug_actions": []}, "P35961": {"specific_function": "Envelope glycoprotein gp160: Oligomerizes in the host endoplasmic reticulum into predominantly trimers. In a second time, gp160 transits in the host Golgi, where glycosylation is completed. The precursor is then proteolytically cleaved in the trans-Golgi and thereby activated by cellular furin or furin-like proteases to produce gp120 and gp41.Surface protein gp120: Attaches the virus to the host lymphoid cell by binding to the primary receptor CD4. This interaction induces a structural rearrangement creating a high affinity binding site for a chemokine coreceptor like CXCR4 and/or CCR5. Acts as a ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on endothelial cells of liver sinusoids and lymph node sinuses. These interactions allow capture of viral particles at mucosal surfaces by these cells and subsequent transmission to permissive cells. HIV subverts the migration properties of dendritic cells to gain access to CD4+ T-cells in lymph nodes. Virus transmission to permissive T-cells occurs either in trans (without DCs infection, through viral capture and transmission), or in cis (following DCs productive infection, through the usual CD4-gp120 interaction), thereby inducing a robust infection. In trans infection, bound virions remain infectious over days and it is proposed that they are not degraded, but protected in non-lysosomal acidic organelles within the DCs close to the cell membrane thus contributing to the viral infectious potential during DCs' migration from the periphery to the lymphoid tissues. On arrival at lymphoid tissues, intact virions recycle back to DCs' cell surface allowing virus transmission to CD4+ T-cells.Transmembrane protein gp41: Acts as a class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of viral and target intracellular membranes, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Complete fusion occurs in host cell endosomes and is dynamin-dependent, however some lipid transfer might occur at the plasma membrane. The virus undergoes clathrin-dependent internalization long before endosomal fusion, thus minimizing the surface exposure of conserved viral epitopes during fusion and reducing the efficacy of inhibitors targeting these epitopes. Membranes fusion leads to delivery of the nucleocapsid into the cytoplasm.", "general_function": "Structural molecule activity", "gene_names": ["env"], "name": "Envelope glycoprotein gp160", "drug_actions": []}, "P35963": {"specific_function": "Gag-Pol polyprotein: Mediates, with Gag polyrotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shutt off translation.Matrix protein p17: Targets the polyprotein to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus. Matrix protein is part of the pre-integration complex. Implicated in the release from host cell mediated by Vpu. Binds to RNA.Capsid protein p24: Forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion. Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry (By similarity). Host restriction factors such as TRIM5-alpha or TRIMCyp bind retroviral capsids and cause premature capsid disassembly, leading to blocks in reverse transcription. Capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species. Host PIN1 apparently facilitates the virion uncoating. On the other hand, interactions with PDZD8 or CYPA stabilize the capsid.Nucleocapsid protein p7: Encapsulates and protects viral dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its zinc fingers. Acts as a nucleic acid chaperone which is involved in rearangement of nucleic acid secondary structure during gRNA retrotranscription. Also facilitates template switch leading to recombination. As part of the polyprotein, participates to gRNA dimerization, packaging, tRNA incorporation and virion assembly.Protease: Aspartyl protease that mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane. Cleavages take place as an ordered, step-wise cascade to yield mature proteins. This process is called maturation. Displays maximal activity during the budding process just prior to particle release from the cell. Also cleaves Nef and Vif, probably concomitantly with viral structural proteins on maturation of virus particles. Hydrolyzes host EIF4GI and PABP1 in order to shut off the capped cellular mRNA translation. The resulting inhibition of cellular protein synthesis serves to ensure maximal viral gene expression and to evade host immune response (By similarity).Reverse transcriptase/ribonuclease H: Multifunctional enzyme that converts the viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for two polypurine tracts (PPTs) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPTs that have not been removed by RNase H as primers. PPTs and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends.Integrase: Catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration.", "general_function": "Zinc ion binding", "gene_names": ["gag-pol"], "name": "Gag-Pol polyprotein", "drug_actions": []}, "Q9Y691": {"specific_function": "Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Acts as a negative regulator that confers rapid and complete inactivation of KCNMA1 channel complex. May participate in KCNMA1 inactivation in chromaffin cells of the adrenal gland or in hippocampal CA1 neurons.", "name": "Calcium-activated potassium channel subunit beta-2", "drug_actions": [{"action": "BINDER", "target": "Q9Y691", "drug": "DB00721"}, {"action": "INHIBITOR", "target": "Q9Y691", "drug": "DB01110"}], "general_function": "Potassium channel regulator activity", "in_complexes": ["Calcium-activated potassium channel"], "gene_names": ["KCNMB2"]}, "Q59771": {"specific_function": "Catalyzes the reversible, NAD-dependent deamination of L-phenylalanine to phenyl pyruvate, ammonia and NADH.", "general_function": "Phenylalanine dehydrogenase activity", "gene_names": ["pdh"], "name": "Phenylalanine dehydrogenase", "drug_actions": []}, "P0C0Y9": {"specific_function": "The reaction center is a membrane-bound complex that mediates the initial photochemical event in the electron transfer process of photosynthesis.", "general_function": "Metal ion binding", "gene_names": ["pufM"], "name": "Reaction center protein M chain", "drug_actions": []}, "P35968": {"specific_function": "Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.", "general_function": "Vascular endothelial growth factor-activated receptor activity", "gene_names": ["KDR"], "name": "Vascular endothelial growth factor receptor 2", "drug_actions": [{"action": "ANTAGONIST", "target": "P35968", "drug": "DB00398"}, {"action": "MULTITARGET", "target": "P35968", "drug": "DB01268"}, {"action": "ANTAGONIST", "target": "P35968", "drug": "DB05578"}, {"action": "INHIBITOR", "target": "P35968", "drug": "DB06589"}, {"action": "INHIBITOR", "target": "P35968", "drug": "DB06626"}, {"action": "ANTAGONIST", "target": "P35968", "drug": "DB08875"}, {"action": "INHIBITOR", "target": "P35968", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P35968", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P35968", "drug": "DB09078"}, {"action": "INHIBITOR", "target": "P35968", "drug": "DB09079"}]}, "Q9Y698": {"specific_function": "Regulates the trafficking and gating properties of AMPA-selective glutamate receptors (AMPARs). Promotes their targeting to the cell membrane and synapses and modulates their gating properties by slowing their rates of activation, deactivation and desensitization. Does not show subunit-specific AMPA receptor regulation and regulates all AMPAR subunits. Thought to stabilize the calcium channel in an inactivated (closed) state.", "general_function": "Voltage-gated calcium channel activity", "gene_names": ["CACNG2"], "name": "Voltage-dependent calcium channel gamma-2 subunit", "drug_actions": []}, "P0AGJ9": {"specific_function": "Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr).", "general_function": "Tyrosine-trna ligase activity", "gene_names": ["tyrS"], "name": "Tyrosine--tRNA ligase", "drug_actions": []}, "Q83WG3": {"general_function": "Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen", "gene_names": ["staP"], "name": "Cytochrome P450", "drug_actions": []}, "P24183": {"specific_function": "Formate dehydrogenase allows E.coli to use formate as major electron donor during anaerobic respiration, when nitrate is used as electron acceptor. The alpha subunit FdnG contains the formate oxidation site. Electrons are transferred from formate to menaquinone in the gamma subunit (FdnI), through the 4Fe-4S clusters in the beta subunit (FdnH). Formate dehydrogenase-N is part of a system that generates proton motive force, together with the dissimilatory nitrate reductase (Nar).", "general_function": "Selenium binding", "gene_names": ["fdnG"], "name": "Formate dehydrogenase, nitrate-inducible, major subunit", "drug_actions": []}, "P56653": {"specific_function": "Hydrolyzes 4-hydroxybenzoate-CoA, and to a lesser extent benzoyl-CoA and 4-chlorobenzoate-CoA. Not active against aliphatic acyl-CoA thioesters, including palmitoyl-CoA, hexanoyl-CoA and acetyl-CoA.", "general_function": "4-hydroxybenzoyl-coa thioesterase activity", "gene_names": [], "name": "4-hydroxybenzoyl-CoA thioesterase", "drug_actions": []}, "Q9UKG9": {"specific_function": "Beta-oxidation of fatty acids. The highest activity concerns the C6 to C10 chain length substrate. Converts the end product of pristanic acid beta oxidation, 4,8-dimethylnonanoyl-CoA, to its corresponding carnitine ester.", "general_function": "Receptor binding", "gene_names": ["CROT"], "name": "Peroxisomal carnitine O-octanoyltransferase", "drug_actions": []}, "Q07912": {"specific_function": "Non-receptor tyrosine-protein and serine/threonine-protein kinase that is implicated in cell spreading and migration, cell survival, cell growth and proliferation. Transduces extracellular signals to cytosolic and nuclear effectors. Phosphorylates AKT1, AR, MCF2, WASL and WWOX. Implicated in trafficking and clathrin-mediated endocytosis through binding to epidermal growth factor receptor (EGFR) and clathrin. Binds to both poly- and mono-ubiquitin and regulates ligand-induced degradation of EGFR, thereby contributing to the accumulation of EGFR at the limiting membrane of early endosomes. Downstream effector of CDC42 which mediates CDC42-dependent cell migration via phosphorylation of BCAR1. May be involved both in adult synaptic function and plasticity and in brain development. Activates AKT1 by phosphorylating it on 'Tyr-176'. Phosphorylates AR on 'Tyr-267' and 'Tyr-363' thereby promoting its recruitment to androgen-responsive enhancers (AREs). Phosphorylates WWOX on 'Tyr-287'. Phosphorylates MCF2, thereby enhancing its activity as a guanine nucleotide exchange factor (GEF) toward Rho family proteins. Contributes to the control of AXL receptor levels. Confers metastatic properties on cancer cells and promotes tumor growth by negatively regulating tumor suppressor such as WWOX and positively regulating pro-survival factors such as AKT1 and AR.", "general_function": "Ww domain binding", "gene_names": ["TNK2"], "name": "Activated CDC42 kinase 1", "drug_actions": []}, "P28566": {"specific_function": "G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.", "name": "5-hydroxytryptamine receptor 1E", "drug_actions": [{"action": "AGONIST", "target": "P28566", "drug": "DB00216"}, {"action": "ANTAGONIST", "target": "P28566", "drug": "DB00246"}, {"action": "BINDER", "target": "P28566", "drug": "DB00247"}, {"action": "ANTAGONIST", "target": "P28566", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P28566", "drug": "DB00363"}, {"action": "BINDER", "target": "P28566", "drug": "DB00408"}, {"action": "ANTAGONIST", "target": "P28566", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P28566", "drug": "DB01221"}, {"action": "OTHER/UNKNOWN", "target": "P28566", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P28566", "drug": "DB01238"}], "general_function": "Serotonin receptor activity", "in_complexes": ["5-hydroxytryptamine receptor 1", "Serotonin Receptors"], "gene_names": ["HTR1E"]}, "O00764": {"specific_function": "Required for synthesis of pyridoxal-5-phosphate from vitamin B6.", "general_function": "Zinc ion binding", "gene_names": ["PDXK"], "name": "Pyridoxal kinase", "drug_actions": [{"action": "LIGAND", "target": "O00764", "drug": "DB00165"}]}, "O15399": {"specific_function": "NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine.", "name": "Glutamate receptor ionotropic, NMDA 2D", "drug_actions": [{"action": "BLOCKER", "target": "O15399", "drug": "DB00289"}, {"action": "ANTAGONIST", "target": "O15399", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "O15399", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "O15399", "drug": "DB00454"}, {"action": "ANTAGONIST", "target": "O15399", "drug": "DB00659"}, {"action": "ANTAGONIST", "target": "O15399", "drug": "DB01173"}, {"action": "ANTAGONIST", "target": "O15399", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "O15399", "drug": "DB01520"}, {"action": "AGONIST", "target": "O15399", "drug": "DB01708"}, {"action": "INHIBITOR", "target": "O15399", "drug": "DB04896"}, {"action": "ACTIVATOR", "target": "O15399", "drug": "DB06151"}, {"action": "ANTAGONIST", "target": "O15399", "drug": "DB06738"}, {"action": "ANTAGONIST", "target": "O15399", "drug": "DB06741"}], "general_function": "Nmda glutamate receptor activity", "in_complexes": ["Glutamate (NMDA) receptor", "NMDA receptor"], "gene_names": ["GRIN2D"]}, "O00763": {"specific_function": "Catalyzes the ATP-dependent carboxylation of acetyl-CoA to malonyl-CoA. Carries out three functions: biotin carboxyl carrier protein, biotin carboxylase and carboxyltransferase. Involved in inhibition of fatty acid and glucose oxidation and enhancement of fat storage (By similarity). May play a role in regulation of mitochondrial fatty acid oxidation through malonyl-CoA-dependent inhibition of carnitine palmitoyltransferase 1 (By similarity).", "general_function": "Metal ion binding", "gene_names": ["ACACB"], "name": "Acetyl-CoA carboxylase 2", "drug_actions": []}, "P43353": {"specific_function": "Oxidizes medium and long chain saturated and unsaturated aldehydes. Metabolizes also benzaldehyde. Low activity towards acetaldehyde and 3,4-dihydroxyphenylacetaldehyde. May not metabolize short chain aldehydes. May use both NADP(+) and NAD(+) as cofactors. May have a protective role against the cytotoxicity induced by lipid peroxidation.", "general_function": "Aldehyde dehydrogenase [nad(p)+] activity", "gene_names": ["ALDH3B1"], "name": "Aldehyde dehydrogenase family 3 member B1", "drug_actions": []}, "P02458": {"specific_function": "Type II collagen is specific for cartilaginous tissues. It is essential for the normal embryonic development of the skeleton, for linear growth and for the ability of cartilage to resist compressive forces.", "general_function": "Platelet-derived growth factor binding", "gene_names": ["COL2A1"], "name": "Collagen alpha-1(II) chain", "drug_actions": []}, "Q9UM73": {"specific_function": "Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK.", "general_function": "Transmembrane receptor protein tyrosine kinase activity", "gene_names": ["ALK"], "name": "ALK tyrosine kinase receptor", "drug_actions": [{"action": "INHIBITOR", "target": "Q9UM73", "drug": "DB08865"}, {"action": "ANTAGONIST", "target": "Q9UM73", "drug": "DB09063"}, {"action": "INHIBITOR", "target": "Q9UM73", "drug": "DB11363"}]}, "O15392": {"specific_function": "Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis. Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis. Acts as an important regulator of the localization of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. May counteract a default induction of apoptosis in G2/M phase. The acetylated form represses STAT3 transactivation of target gene promoters. May play a role in neoplasia. Inhibitor of CASP3 and CASP7. Isoform 2 and isoform 3 do not appear to play vital roles in mitosis. Isoform 3 shows a marked reduction in its anti-apoptotic effects when compared with the displayed wild-type isoform.", "general_function": "Zinc ion binding", "gene_names": ["BIRC5"], "name": "Baculoviral IAP repeat-containing protein 5", "drug_actions": []}, "P07766": {"specific_function": "The CD3 complex mediates signal transduction, resulting in T cell activation and proliferation. Required for normal immune responses (PubMed:15546002, PubMed:8490660).", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["CD3E"], "name": "T-cell surface glycoprotein CD3 epsilon chain", "drug_actions": [{"action": "BINDER", "target": "P07766", "drug": "DB00075"}]}, "P51170": {"specific_function": "Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical membrane of epithelial cells. Plays an essential role in electrolyte and blood pressure homeostasis, but also in airway surface liquid homeostasis, which is important for proper clearance of mucus. Controls the reabsorption of sodium in kidney, colon, lung and sweat glands. Also plays a role in taste perception.", "general_function": "Ww domain binding", "gene_names": ["SCNN1G"], "name": "Amiloride-sensitive sodium channel subunit gamma", "drug_actions": [{"action": "INHIBITOR", "target": "P51170", "drug": "DB00384"}, {"action": "INHIBITOR", "target": "P51170", "drug": "DB00594"}]}, "P51172": {"specific_function": "Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical membrane of epithelial cells. Controls the reabsorption of sodium in kidney, colon, lung and sweat glands. Also plays a role in taste perception.", "general_function": "Ligand-gated sodium channel activity", "gene_names": ["SCNN1D"], "name": "Amiloride-sensitive sodium channel subunit delta", "drug_actions": [{"action": "INHIBITOR", "target": "P51172", "drug": "DB00384"}, {"action": "INHIBITOR", "target": "P51172", "drug": "DB00594"}]}, "P78330": {"specific_function": "Catalyzes the last step in the biosynthesis of serine from carbohydrates. The reaction mechanism proceeds via the formation of a phosphoryl-enzyme intermediates.", "general_function": "Protein homodimerization activity", "gene_names": ["PSPH"], "name": "Phosphoserine phosphatase", "drug_actions": []}, "P51178": {"specific_function": "The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes. Essential for trophoblast and placental development.", "general_function": "Signal transducer activity", "gene_names": ["PLCD1"], "name": "1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1", "drug_actions": []}, "Q01726": {"specific_function": "Receptor for MSH (alpha, beta and gamma) and ACTH. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["MC1R"], "name": "Melanocyte-stimulating hormone receptor", "drug_actions": []}, "P78334": {"specific_function": "GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.", "name": "Gamma-aminobutyric acid receptor subunit epsilon", "drug_actions": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00228"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00475"}, {"action": "BINDER", "target": "P78334", "drug": "DB00543"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB00546"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00628"}, {"action": "POSITIVE MODULATOR", "target": "P78334", "drug": "DB00659"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB00690"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00794"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00818"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01028"}, {"action": "AGONIST", "target": "P78334", "drug": "DB01049"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01205"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01437"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB01587"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P78334", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P78334", "drug": "DB01595"}, {"action": "ANTAGONIST", "target": "P78334", "drug": "DB01708"}], "general_function": "Inhibitory extracellular ligand-gated ion channel activity", "in_complexes": ["GABA-A receptor (anion channel)"], "gene_names": ["GABRE"]}, "P18085": {"specific_function": "GTP-binding protein that functions as an allosteric activator of the cholera toxin catalytic subunit, an ADP-ribosyltransferase. Involved in protein trafficking; may modulate vesicle budding and uncoating within the Golgi apparatus.", "general_function": "Gtpase activity", "gene_names": ["ARF4"], "name": "ADP-ribosylation factor 4", "drug_actions": []}, "P08254": {"specific_function": "Can degrade fibronectin, laminin, gelatins of type I, III, IV, and V; collagens III, IV, X, and IX, and cartilage proteoglycans. Activates procollagenase.", "general_function": "Zinc ion binding", "gene_names": ["MMP3"], "name": "Stromelysin-1", "drug_actions": [{"action": "ANTAGONIST", "target": "P08254", "drug": "DB00786"}]}, "P08253": {"specific_function": "Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-|-Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro. Involved in the formation of the fibrovascular tissues in association with MMP14.PEX, the C-terminal non-catalytic fragment of MMP2, posseses anti-angiogenic and anti-tumor properties and inhibits cell migration and cell adhesion to FGF2 and vitronectin. Ligand for integrinv/beta3 on the surface of blood vessels.Isoform 2: Mediates the proteolysis of CHUK/IKKA and initiates a primary innate immune response by inducing mitochondrial-nuclear stress signaling with activation of the pro-inflammatory NF-kappaB, NFAT and IRF transcriptional pathways.", "general_function": "Zinc ion binding", "gene_names": ["MMP2"], "name": "72 kDa type IV collagenase", "drug_actions": [{"action": "INHIBITOR", "target": "P08253", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "P08253", "drug": "DB01197"}]}, "P0AER0": {"specific_function": "Transporter of glycerol across the cytoplasmic membrane, with limited permeability to water and small uncharged compounds such as polyols.", "general_function": "Water channel activity", "gene_names": ["glpF"], "name": "Glycerol uptake facilitator protein", "drug_actions": []}, "Q08209": {"specific_function": "Calcium-dependent, calmodulin-stimulated protein phosphatase. Many of the substrates contain a PxIxIT motif. This subunit may have a role in the calmodulin activation of calcineurin. Dephosphorylates DNM1L, HSPB1 and SSH1.", "general_function": "Protein serine/threonine phosphatase activity", "gene_names": ["PPP3CA"], "name": "Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform", "drug_actions": []}, "P52758": {"specific_function": "Endoribonuclease responsible for the inhibition of the translation by cleaving mRNA. Inhibits cell-free protein synthesis. Cleaves phosphodiester bonds only in single-stranded RNA (By similarity).", "general_function": "Xenon atom binding", "gene_names": ["HRSP12"], "name": "Ribonuclease UK114", "drug_actions": []}, "P46439": {"specific_function": "Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.", "general_function": "Glutathione transferase activity", "gene_names": ["GSTM5"], "name": "Glutathione S-transferase Mu 5", "drug_actions": []}, "Q9PPP5": {"general_function": "Zinc ion binding", "gene_names": ["tdk"], "name": "Thymidine kinase", "drug_actions": []}, "P63208": {"specific_function": "Essential component of the SCF (SKP1-CUL1-F-box protein) ubiquitin ligase complex, which mediates the ubiquitination of proteins involved in cell cycle progression, signal transduction and transcription. In the SCF complex, serves as an adapter that links the F-box protein to CUL1. The functional specificity of the SCF complex depends on the F-box protein as substrate recognition component. SCF(BTRC) and SCF(FBXW11) direct ubiquitination of CTNNB1 and participate in Wnt signaling. SCF(FBXW11) directs ubiquitination of phosphorylated NFKBIA. SCF(BTRC) directs ubiquitination of NFKBIB, NFKBIE, ATF4, SMAD3, SMAD4, CDC25A, FBXO5, CEP68 and probably NFKB2 (PubMed:25704143). SCF(SKP2) directs ubiquitination of phosphorylated CDKN1B/p27kip and is involved in regulation of G1/S transition. SCF(SKP2) directs ubiquitination of ORC1, CDT1, RBL2, ELF4, CDKN1A, RAG2, FOXO1A, and probably MYC and TAL1. SCF(FBXW7) directs ubiquitination of cyclin E, NOTCH1 released notch intracellular domain (NICD), and probably PSEN1. SCF(FBXW2) directs ubiquitination of GCM1. SCF(FBXO32) directs ubiquitination of MYOD1. SCF(FBXO7) directs ubiquitination of BIRC2 and DLGAP5. SCF(FBXO33) directs ubiquitination of YBX1. SCF(FBXO11) directs ubiquitination of BCL6 and DTL but does not seem to direct ubiquitination of TP53. SCF(BTRC) mediates the ubiquitination of NFKBIA at 'Lys-21' and 'Lys-22'; the degradation frees the associated NFKB1-RELA dimer to translocate into the nucleus and to activate transcription. SCF(CCNF) directs ubiquitination of CCP110. SCF(FBXL3) and SCF(FBXL21) direct ubiquitination of CRY1 and CRY2. SCF(FBXO9) directs ubiquitination of TTI1 and TELO2. SCF(FBXO10) directs ubiquitination of BCL2.", "general_function": "Ubiquitin-protein transferase activity", "gene_names": ["SKP1"], "name": "S-phase kinase-associated protein 1", "drug_actions": []}, "P18089": {"specific_function": "Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phentolamine > mianserine > spiperone > prazosin > alprenolol > propanolol > pindolol.", "name": "Alpha-2B adrenergic receptor", "drug_actions": [{"action": "AGONIST", "target": "P18089", "drug": "DB00182"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00217"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00248"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00268"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00292"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00363"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00368"}, {"action": "BINDER", "target": "P18089", "drug": "DB00408"}, {"action": "UNKNOWN", "target": "P18089", "drug": "DB00413"}, {"action": "BINDER", "target": "P18089", "drug": "DB00457"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00484"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00543"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00575"}, {"action": "OTHER/UNKNOWN", "target": "P18089", "drug": "DB00589"}, {"action": "BINDER", "target": "P18089", "drug": "DB00629"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00668"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00696"}, {"action": "PARTIAL AGONIST", "target": "P18089", "drug": "DB00696"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00697"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00714"}, {"action": "OTHER/UNKNOWN", "target": "P18089", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00734"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00734"}, {"action": "BINDER", "target": "P18089", "drug": "DB00797"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00800"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00925"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB00934"}, {"action": "BINDER", "target": "P18089", "drug": "DB00935"}, {"action": "AGONIST", "target": "P18089", "drug": "DB00964"}, {"action": "BINDER", "target": "P18089", "drug": "DB01018"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB01136"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB01142"}, {"action": "BINDER", "target": "P18089", "drug": "DB01151"}, {"action": "AGONIST", "target": "P18089", "drug": "DB01186"}, {"action": "AGONIST", "target": "P18089", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB01267"}, {"action": "AGONIST", "target": "P18089", "drug": "DB01363"}, {"action": "AGONIST", "target": "P18089", "drug": "DB01365"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB01392"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB01403"}, {"action": "AGONIST", "target": "P18089", "drug": "DB01577"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB05271"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB06216"}, {"action": "AGONIST", "target": "P18089", "drug": "DB06262"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB06678"}, {"action": "AGONIST", "target": "P18089", "drug": "DB06694"}, {"action": "ANTAGONIST", "target": "P18089", "drug": "DB09202"}], "general_function": "Epinephrine binding", "in_complexes": ["Alpha adrenergic receptor", "Alpha-2 adrenergic receptor"], "gene_names": ["ADRA2B"]}, "Q53901": {"general_function": "Dna binding", "gene_names": ["actII"], "name": "ActII protein", "drug_actions": []}, "Q9F0I5": {"general_function": "Transferase activity", "gene_names": ["cft"], "name": "Cycloinulo-oligosaccharide fructanotransferase", "drug_actions": [{"action": "BINDER", "target": "Q9F0I5", "drug": "DB00638"}]}, "P15555": {"specific_function": "Catalyzes distinct carboxypeptidation and transpeptidation reactions during the last stages of wall peptidoglycan synthesis. Mistaking a beta-lactam antibiotic molecule for a normal substrate (i.e. a D-alanyl-D-alanine-terminated peptide), it becomes immobilized in the form of a long-lived, serine-ester-linked acyl enzyme and thus behave as penicillin-binding protein (PBP).", "general_function": "Serine-type d-ala-d-ala carboxypeptidase activity", "gene_names": [], "name": "D-alanyl-D-alanine carboxypeptidase", "drug_actions": [{"action": "INHIBITOR", "target": "P15555", "drug": "DB00456"}]}, "P51584": {"general_function": "Endo-1,4-beta-xylanase activity", "gene_names": ["xynY"], "name": "Endo-1,4-beta-xylanase Y", "drug_actions": []}, "P35368": {"specific_function": "This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.", "name": "Alpha-1B adrenergic receptor", "drug_actions": [{"action": "AGONIST", "target": "P35368", "drug": "DB00182"}, {"action": "AGONIST", "target": "P35368", "drug": "DB00211"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00246"}, {"action": "BINDER", "target": "P35368", "drug": "DB00248"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00298"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00346"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00363"}, {"action": "AGONIST", "target": "P35368", "drug": "DB00368"}, {"action": "BINDER", "target": "P35368", "drug": "DB00370"}, {"action": "BINDER", "target": "P35368", "drug": "DB00408"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00457"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00477"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00543"}, {"action": "AGONIST", "target": "P35368", "drug": "DB00575"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00590"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00598"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00622"}, {"action": "AGONIST", "target": "P35368", "drug": "DB00668"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00679"}, {"action": "PARTIAL AGONIST", "target": "P35368", "drug": "DB00696"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00706"}, {"action": "AGONIST", "target": "P35368", "drug": "DB00723"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00734"}, {"action": "PARTIAL AGONIST", "target": "P35368", "drug": "DB00745"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00925"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB00934"}, {"action": "AGONIST", "target": "P35368", "drug": "DB00935"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01136"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01142"}, {"action": "OTHER/UNKNOWN", "target": "P35368", "drug": "DB01149"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01151"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01162"}, {"action": "AGONIST", "target": "P35368", "drug": "DB01186"}, {"action": "AGONIST", "target": "P35368", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01255"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01267"}, {"action": "AGONIST", "target": "P35368", "drug": "DB01365"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01576"}, {"action": "AGONIST", "target": "P35368", "drug": "DB01579"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01608"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01614"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB01622"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB04855"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB06207"}, {"action": "AGONIST", "target": "P35368", "drug": "DB06262"}, {"action": "AGONIST", "target": "P35368", "drug": "DB06694"}, {"action": "ANTAGONIST", "target": "P35368", "drug": "DB09128"}, {"action": "PARTIAL AGONIST", "target": "P35368", "drug": "DB09202"}], "general_function": "Protein heterodimerization activity", "in_complexes": ["Alpha adrenergic receptor", "Alpha-1 adrenergic receptor"], "gene_names": ["ADRA1B"]}, "P35367": {"specific_function": "In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.", "general_function": "Histamine receptor activity", "gene_names": ["HRH1"], "name": "Histamine H1 receptor", "drug_actions": [{"action": "BINDER", "target": "P35367", "drug": "DB00215"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00245"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00283"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00341"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00342"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00354"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00366"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00370"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00405"}, {"action": "BINDER", "target": "P35367", "drug": "DB00408"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00427"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00434"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00455"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00477"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00557"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00568"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00637"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00656"}, {"action": "AGONIST", "target": "P35367", "drug": "DB00667"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00719"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00737"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00748"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00751"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00767"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00768"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00792"}, {"action": "AGONIST", "target": "P35367", "drug": "DB00797"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00835"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00902"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00920"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00950"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00967"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00972"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB00985"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01069"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01071"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01075"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01084"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01106"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01114"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01146"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01151"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01173"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01175"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01176"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01237"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01246"}, {"action": "AGONIST", "target": "P35367", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01615"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01619"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01620"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB01624"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB04837"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB04841"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB04890"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB04905"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB04946"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB06016"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB06282"}, {"action": "INHIBITOR", "target": "P35367", "drug": "DB06282"}, {"action": "INVERSE AGONIST", "target": "P35367", "drug": "DB06678"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB06691"}, {"action": "AGONIST", "target": "P35367", "drug": "DB06698"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB06766"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB08799"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB08800"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB08801"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB08802"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB08936"}, {"action": "ANTAGONIST", "target": "P35367", "drug": "DB09016"}]}, "P0C0H6": {"specific_function": "Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth.", "general_function": "Metal ion binding", "gene_names": ["guaB"], "name": "Inosine-5'-monophosphate dehydrogenase", "drug_actions": []}, "Q8WYK2": {"specific_function": "Component of the AP-1 transcription factor that represses transactivation mediated by the Jun family of proteins. Involved in a variety of transcriptional responses associated with AP-1 such as UV-induced apoptosis, cell differentiation, tumorigenesis and antitumogeneris. Can also function as a repressor by recruiting histone deacetylase 3/HDAC3 to the promoter region of JUN. May control transcription via direct regulation of the modification of histones and the assembly of chromatin.", "name": "Jun dimerization protein 2", "drug_actions": [], "general_function": "Transcriptional repressor activity, rna polymerase ii core promoter proximal region sequence-specific binding", "in_complexes": ["activator protein 1"], "gene_names": ["JDP2"]}, "P13009": {"specific_function": "Catalyzes the transfer of a methyl group from methyl-cobalamin to homocysteine, yielding enzyme-bound cob(I)alamin and methionine. Subsequently, remethylates the cofactor using methyltetrahydrofolate.", "general_function": "Zinc ion binding", "gene_names": ["metH"], "name": "Methionine synthase", "drug_actions": []}, "Q9Z4N6": {"general_function": "Metal ion binding", "gene_names": ["fbpA"], "name": "Iron ABC transporter substrate-binding protein", "drug_actions": []}, "Q9Y6L7": {"specific_function": "Protease which specifically processes pro-lysyl oxidase. Required for the embryonic development. Predominant protease, which in the development, influences dorsal-ventral patterning and skeletogenesis.", "general_function": "Zinc ion binding", "gene_names": ["TLL2"], "name": "Tolloid-like protein 2", "drug_actions": []}, "Q9Y6L6": {"specific_function": "Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.", "general_function": "Sodium-independent organic anion transmembrane transporter activity", "gene_names": ["SLCO1B1"], "name": "Solute carrier organic anion transporter family member 1B1", "drug_actions": []}, "P27986": {"specific_function": "Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF, KIT, PDGFRA and PDGFRB. Likewise, plays a role in ITGB2 signaling (PubMed:17626883, PubMed:19805105, PubMed:7518429). Modulates the cellular response to ER stress by promoting nuclear translocation of XBP1 isoform 2 in a ER stress-and/or insulin-dependent manner during metabolic overloading in the liver and hence plays a role in glucose tolerance improvement (PubMed:20348923).", "general_function": "Transmembrane receptor protein tyrosine kinase adaptor activity", "gene_names": ["PIK3R1"], "name": "Phosphatidylinositol 3-kinase regulatory subunit alpha", "drug_actions": [{"action": "AGONIST", "target": "P27986", "drug": "DB01064"}]}, "P62619": {"specific_function": "Involved in the biosynthesis of isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), two major building blocks of isoprenoid compounds. Catalyzes the conversion of 4-diphosphocytidyl-2-C-methyl-D-erythritol 2-phosphate (CDP-ME2P) to 2-C-methyl-D-erythritol 2,4-cyclodiphosphate (ME-CPP) with a corresponding release of cytidine 5-monophosphate (CMP).", "general_function": "Metal ion binding", "gene_names": ["ispF"], "name": "2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase", "drug_actions": []}, "P00935": {"specific_function": "Catalyzes the formation of L-cystathionine from O-succinyl-L-homoserine (OSHS) and L-cysteine, via a gamma-replacement reaction. In the absence of thiol, catalyzes gamma-elimination to form 2-oxobutanoate, succinate and ammonia.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["metB"], "name": "Cystathionine gamma-synthase", "drug_actions": []}, "Q59HE2": {"general_function": "Transaminase activity", "gene_names": [], "name": "Ornithine aminotransferase variant", "drug_actions": [{"action": "COFACTOR", "target": "Q59HE2", "drug": "DB00114"}]}, "Q96CD2": {"specific_function": "Necessary for the biosynthesis of coenzyme A. Catalyzes the decarboxylation of 4-phosphopantothenoylcysteine to form 4'-phosphopantotheine.", "general_function": "Phosphopantothenoylcysteine decarboxylase activity", "gene_names": ["PPCDC"], "name": "Phosphopantothenoylcysteine decarboxylase", "drug_actions": []}, "O60547": {"specific_function": "Catalyzes the conversion of GDP-D-mannose to GDP-4-dehydro-6-deoxy-D-mannose.", "general_function": "Nadp+ binding", "gene_names": ["GMDS"], "name": "GDP-mannose 4,6 dehydratase", "drug_actions": []}, "Q8TDS4": {"specific_function": "Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.", "general_function": "Nicotinic acid receptor activity", "gene_names": ["HCAR2"], "name": "Hydroxycarboxylic acid receptor 2", "drug_actions": [{"action": "AGONIST", "target": "Q8TDS4", "drug": "DB00627"}]}, "Q9X108": {"specific_function": "Hydrolyzes cellobiose 6'-phosphate into glucose 6-phosphate (Glc6P) and glucose.", "general_function": "Oxidoreductase activity, acting on the ch-oh group of donors, nad or nadp as acceptor", "gene_names": ["bglT"], "name": "6-phospho-beta-glucosidase BglT", "drug_actions": []}, "P02689": {"specific_function": "May play a role in lipid transport protein in Schwann cells. May bind cholesterol.", "general_function": "Transporter activity", "gene_names": ["PMP2"], "name": "Myelin P2 protein", "drug_actions": []}, "O43837": {"general_function": "Nad binding", "gene_names": ["IDH3B"], "name": "Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial", "drug_actions": []}, "Q92930": {"specific_function": "The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different sets of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion. That Rab may be involved in polarized vesicular trafficking and neurotransmitter release. May participate in cell junction dynamics in Sertoli cells (By similarity).", "general_function": "Receptor binding", "gene_names": ["RAB8B"], "name": "Ras-related protein Rab-8B", "drug_actions": []}, "P95673": {"specific_function": "Antenna complexes are light-harvesting systems, which transfer the excitation energy to the reaction centers.", "general_function": "Metal ion binding", "gene_names": ["B1"], "name": "Light-harvesting protein B-800/850 beta 1 chain", "drug_actions": []}, "Q92934": {"specific_function": "Promotes cell death. Successfully competes for the binding to Bcl-X(L), Bcl-2 and Bcl-W, thereby affecting the level of heterodimerization of these proteins with BAX. Can reverse the death repressor activity of Bcl-X(L), but not that of Bcl-2 (By similarity). Appears to act as a link between growth factor receptor signaling and the apoptotic pathways.", "general_function": "Protein kinase binding", "gene_names": ["BAD"], "name": "Bcl2-associated agonist of cell death", "drug_actions": []}, "P42085": {"specific_function": "Converts the preformed base xanthine, a product of nucleic acid breakdown, to xanthosine 5'-monophosphate (XMP), so that it can be reused for RNA or DNA synthesis.", "general_function": "Xanthine phosphoribosyltransferase activity", "gene_names": ["xpt"], "name": "Xanthine phosphoribosyltransferase", "drug_actions": []}, "P42081": {"specific_function": "Receptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin-2 production, by binding CD28 or CTLA-4. May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T-cells within 24 hours after activation. Isoform 2 interferes with the formation of CD86 clusters, and thus acts as a negative regulator of T-cell activation.(Microbial infection) Acts as a receptor for adenovirus subgroup B.", "general_function": "Virus receptor activity", "gene_names": ["CD86"], "name": "T-lymphocyte activation antigen CD86", "drug_actions": [{"action": "ANTAGONIST", "target": "P42081", "drug": "DB01281"}]}, "Q92206": {"specific_function": "Catalyzes the first oxygenation step in sterol biosynthesis and is suggested to be one of the rate-limiting enzymes in this pathway.", "general_function": "Squalene monooxygenase activity", "gene_names": ["ERG1"], "name": "Squalene monooxygenase", "drug_actions": [{"action": "INHIBITOR", "target": "Q92206", "drug": "DB00525"}]}, "P0A749": {"specific_function": "Cell wall formation. Adds enolpyruvyl to UDP-N-acetylglucosamine. Target for the antibiotic fosfomycin.", "general_function": "Udp-n-acetylglucosamine 1-carboxyvinyltransferase activity", "gene_names": ["murA"], "name": "UDP-N-acetylglucosamine 1-carboxyvinyltransferase", "drug_actions": [{"action": "INHIBITOR", "target": "P0A749", "drug": "DB00828"}]}, "Q8Y7N7": {"specific_function": "Provides the (R)-glutamate required for cell wall biosynthesis.", "general_function": "Glutamate racemase activity", "gene_names": ["murI"], "name": "Glutamate racemase", "drug_actions": []}, "P0A745": {"specific_function": "Has an important function as a repair enzyme for proteins that have been inactivated by oxidation. Catalyzes the reversible oxidation-reduction of methionine sulfoxide in proteins to methionine (By similarity).", "general_function": "Peptide-methionine (s)-s-oxide reductase activity", "gene_names": ["msrA"], "name": "Peptide methionine sulfoxide reductase MsrA", "drug_actions": []}, "P49286": {"specific_function": "High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that inhibit adenylate cyclase activity.", "general_function": "Melatonin receptor activity", "gene_names": ["MTNR1B"], "name": "Melatonin receptor type 1B", "drug_actions": [{"action": "MULTITARGET", "target": "P49286", "drug": "DB00980"}, {"action": "AGONIST", "target": "P49286", "drug": "DB01065"}, {"action": "AGONIST", "target": "P49286", "drug": "DB06594"}, {"action": "AGONIST", "target": "P49286", "drug": "DB09071"}]}, "P53848": {"specific_function": "Catalyzes three sequential steps of tetrahydrofolate biosynthesis.", "general_function": "Metal ion binding", "gene_names": ["FOL1"], "name": "Folic acid synthesis protein FOL1", "drug_actions": [{"action": "INHIBITOR", "target": "P53848", "drug": "DB00634"}]}, "A7J8L3": {"general_function": "Zinc ion binding", "gene_names": ["orf1ab"], "name": "Orf1a polyprotein", "drug_actions": []}, "P46098": {"specific_function": "This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.", "name": "5-hydroxytryptamine receptor 3A", "drug_actions": [{"action": "ANTAGONIST", "target": "P46098", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00333"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00370"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00377"}, {"action": "BINDER", "target": "P46098", "drug": "DB00408"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00543"}, {"action": "AGONIST", "target": "P46098", "drug": "DB00604"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00721"}, {"action": "BINDER", "target": "P46098", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00728"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00757"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00889"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00904"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB00969"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB01043"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB01161"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB01199"}, {"action": "OTHER/UNKNOWN", "target": "P46098", "drug": "DB01224"}, {"action": "AGONIST", "target": "P46098", "drug": "DB01233"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P46098", "drug": "DB09068"}], "general_function": "Voltage-gated potassium channel activity", "in_complexes": ["Serotonin Receptors"], "gene_names": ["HTR3A"]}, "Q72EF3": {"general_function": "Nitrite reductase (cytochrome, ammonia-forming) activity", "gene_names": [], "name": "Cytochrome c-552", "drug_actions": []}, "P15559": {"specific_function": "The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinons involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis.", "general_function": "Superoxide dismutase activity", "gene_names": ["NQO1"], "name": "NAD(P)H dehydrogenase [quinone] 1", "drug_actions": [{"action": "INHIBITOR", "target": "P15559", "drug": "DB00266"}]}, "P46721": {"specific_function": "Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.", "general_function": "Sodium-independent organic anion transmembrane transporter activity", "gene_names": ["SLCO1A2"], "name": "Solute carrier organic anion transporter family member 1A2", "drug_actions": []}, "P09142": {"general_function": "Alkanal monooxygenase (fmn-linked) activity", "gene_names": ["luxF"], "name": "Non-fluorescent flavoprotein", "drug_actions": []}, "P23181": {"specific_function": "Responsible for gentamicin resistance and has a limited substrate range.", "general_function": "Aminoglycoside 3-n-acetyltransferase activity", "gene_names": ["aacC1"], "name": "Gentamicin 3-N-acetyltransferase", "drug_actions": []}, "Q9X6V3": {"general_function": "Penicillin binding", "gene_names": ["pbpA"], "name": "Penicillin-binding protein 2", "drug_actions": [{"action": "INHIBITOR", "target": "Q9X6V3", "drug": "DB00438"}, {"action": "INHIBITOR", "target": "Q9X6V3", "drug": "DB01413"}]}, "O07529": {"specific_function": "Catalyzes the reductive cleavage of azo bond in aromatic azo compounds to the corresponding amines. Requires NADPH, but not NADH, as an electron donor for its activity.", "general_function": "Oxidoreductase activity", "gene_names": ["azr"], "name": "FMN-dependent NADPH-azoreductase", "drug_actions": []}, "Q87MW5": {"gene_names": [], "name": "Uncharacterized protein", "drug_actions": []}, "P00338": {"general_function": "Nad binding", "gene_names": ["LDHA"], "name": "L-lactate dehydrogenase A chain", "drug_actions": []}, "Q92847": {"specific_function": "Receptor for ghrelin, coupled to G-alpha-11 proteins. Stimulates growth hormone secretion. Binds also other growth hormone releasing peptides (GHRP) (e.g. Met-enkephalin and GHRP-6) as well as non-peptide, low molecular weight secretagogues (e.g. L-692,429, MK-0677, adenosine).", "general_function": "Peptide hormone binding", "gene_names": ["GHSR"], "name": "Growth hormone secretagogue receptor type 1", "drug_actions": []}, "Q92843": {"specific_function": "Promotes cell survival. Blocks dexamethasone-induced apoptosis. Mediates survival of postmitotic Sertoli cells by suppressing death-promoting activity of BAX.", "general_function": "Protein homodimerization activity", "gene_names": ["BCL2L2"], "name": "Bcl-2-like protein 2", "drug_actions": []}, "P06213": {"specific_function": "Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.", "general_function": "Receptor signaling protein tyrosine kinase activity", "gene_names": ["INSR"], "name": "Insulin receptor", "drug_actions": [{"action": "AGONIST", "target": "P06213", "drug": "DB00030"}, {"action": "AGONIST", "target": "P06213", "drug": "DB00046"}, {"action": "AGONIST", "target": "P06213", "drug": "DB00047"}, {"action": "BINDER", "target": "P06213", "drug": "DB00071"}, {"action": "AGONIST", "target": "P06213", "drug": "DB01306"}, {"action": "AGONIST", "target": "P06213", "drug": "DB01307"}, {"action": "AGONIST", "target": "P06213", "drug": "DB01309"}, {"action": "AGONIST", "target": "P06213", "drug": "DB08914"}]}, "P0A988": {"specific_function": "DNA polymerase III is a complex, multichain enzyme responsible for most of the replicative synthesis in bacteria. This DNA polymerase also exhibits 3' to 5' exonuclease activity. The beta chain is required for initiation of replication; once it is clamped onto DNA it slides freely (bidirectional and ATP-independent) along duplex DNA. Coordinates protein traffic at the replication fork, where it interacts with multiple DNA polymerases.", "general_function": "Identical protein binding", "gene_names": ["dnaN"], "name": "DNA polymerase III subunit beta", "drug_actions": []}, "Q9KEI9": {"specific_function": "Endonuclease that specifically degrades the RNA of RNA-DNA hybrids.", "general_function": "Rna-dna hybrid ribonuclease activity", "gene_names": ["rnhA"], "name": "Ribonuclease H", "drug_actions": []}, "Q05397": {"specific_function": "Non-receptor protein-tyrosine kinase that plays an essential role in regulating cell migration, adhesion, spreading, reorganization of the actin cytoskeleton, formation and disassembly of focal adhesions and cell protrusions, cell cycle progression, cell proliferation and apoptosis. Required for early embryonic development and placenta development. Required for embryonic angiogenesis, normal cardiomyocyte migration and proliferation, and normal heart development. Regulates axon growth and neuronal cell migration, axon branching and synapse formation; required for normal development of the nervous system. Plays a role in osteogenesis and differentiation of osteoblasts. Functions in integrin signal transduction, but also in signaling downstream of numerous growth factor receptors, G-protein coupled receptors (GPCR), EPHA2, netrin receptors and LDL receptors. Forms multisubunit signaling complexes with SRC and SRC family members upon activation; this leads to the phosphorylation of additional tyrosine residues, creating binding sites for scaffold proteins, effectors and substrates. Regulates numerous signaling pathways. Promotes activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascade. Promotes activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling cascade. Promotes localized and transient activation of guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs), and thereby modulates the activity of Rho family GTPases. Signaling via CAS family members mediates activation of RAC1. Recruits the ubiquitin ligase MDM2 to P53/TP53 in the nucleus, and thereby regulates P53/TP53 activity, P53/TP53 ubiquitination and proteasomal degradation. Phosphorylates SRC; this increases SRC kinase activity. Phosphorylates ACTN1, ARHGEF7, GRB7, RET and WASL. Promotes phosphorylation of PXN and STAT1; most likely PXN and STAT1 are phosphorylated by a SRC family kinase that is recruited to autophosphorylated PTK2/FAK1, rather than by PTK2/FAK1 itself. Promotes phosphorylation of BCAR1; GIT2 and SHC1; this requires both SRC and PTK2/FAK1. Promotes phosphorylation of BMX and PIK3R1. Isoform 6 (FRNK) does not contain a kinase domain and inhibits PTK2/FAK1 phosphorylation and signaling. Its enhanced expression can attenuate the nuclear accumulation of LPXN and limit its ability to enhance serum response factor (SRF)-dependent gene transcription.", "general_function": "Signal transducer activity", "gene_names": ["PTK2"], "name": "Focal adhesion kinase 1", "drug_actions": []}, "P07814": {"specific_function": "Catalyzes the attachment of the cognate amino acid to the corresponding tRNA in a two-step reaction: the amino acid is first activated by ATP to form a covalent intermediate with AMP and is then transferred to the acceptor end of the cognate tRNA. Component of the GAIT (gamma interferon-activated inhibitor of translation) complex which mediates interferon-gamma-induced transcript-selective translation inhibition in inflammation processes. Upon interferon-gamma activation and subsequent phosphorylation dissociates from the multisynthetase complex and assembles into the GAIT complex which binds to stem loop-containing GAIT elements in the 3'-UTR of diverse inflammatory mRNAs (such as ceruplasmin) and suppresses their translation.", "general_function": "Rna stem-loop binding", "gene_names": ["EPRS"], "name": "Bifunctional glutamate/proline--tRNA ligase", "drug_actions": []}, "P81180": {"specific_function": "Mannose-binding lectin.", "general_function": "Carbohydrate binding", "gene_names": [], "name": "Cyanovirin-N", "drug_actions": []}, "P06818": {"specific_function": "Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells. Likely to plays a role in the budding process through its association with lipid rafts during intracellular transport. May additionally display a raft-association independent effect on budding. Plays a role in the determination of host range restriction on replication and virulence. Sialidase activity in late endosome/lysosome traffic seems to enhance virus replication.", "general_function": "Metal ion binding", "gene_names": ["NA"], "name": "Neuraminidase", "drug_actions": [{"action": "INHIBITOR", "target": "P06818", "drug": "DB00558"}]}, "P0AEB2": {"specific_function": "Removes C-terminal D-alanyl residues from sugar-peptide cell wall precursors.", "general_function": "Serine-type d-ala-d-ala carboxypeptidase activity", "gene_names": ["dacA"], "name": "D-alanyl-D-alanine carboxypeptidase DacA", "drug_actions": [{"action": "INHIBITOR", "target": "P0AEB2", "drug": "DB00274"}, {"action": "INHIBITOR", "target": "P0AEB2", "drug": "DB01329"}, {"action": "INHIBITOR", "target": "P0AEB2", "drug": "DB01331"}]}, "P0AEB3": {"specific_function": "Removes C-terminal D-alanyl residues from sugar-peptide cell wall precursors.", "general_function": "Serine-type d-ala-d-ala carboxypeptidase activity", "gene_names": ["dacA"], "name": "D-alanyl-D-alanine carboxypeptidase DacA", "drug_actions": [{"action": "INHIBITOR", "target": "P0AEB3", "drug": "DB01147"}]}, "P98164": {"specific_function": "Acts together with cubilin to mediate HDL endocytosis (By similarity). May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release.", "general_function": "Calcium ion binding", "gene_names": ["LRP2"], "name": "Low-density lipoprotein receptor-related protein 2", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "P98164", "drug": "DB00798"}]}, "Q5SJH3": {"specific_function": "Binds to the lower part of the body of the 30S subunit, where it stabilizes two of its domains.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsP"], "name": "30S ribosomal protein S16", "drug_actions": []}, "Q8WU03": {"specific_function": "Mitochondrial acyltransferase which transfers the acyl group to the N-terminus of glycine. Conjugates numerous substrates, such as arachidonoyl-CoA and saturated medium and long-chain acyl-CoAs ranging from chain-length C8:0-CoA to C18:0-CoA, to form a variety of N-acylglycines. Shows a preference for monounsaturated fatty acid oleoyl-CoA (C18:1-CoA) as an acyl donor. Does not exhibit any activity toward C22:6-CoA and chenodeoxycholoyl-CoA, nor toward serine or alanine.", "general_function": "Glycine n-acyltransferase activity", "gene_names": ["GLYATL2"], "name": "Glycine N-acyltransferase-like protein 2", "drug_actions": []}, "P96420": {"specific_function": "Catalyzes the condensation of the acetyl group of acetyl-CoA with 3-methyl-2-oxobutanoate (2-oxoisovalerate) to form 3-carboxy-3-hydroxy-4-methylpentanoate (2-isopropylmalate)", "general_function": "Amino acid transport and metabolism", "gene_names": ["leuA"], "name": "2-isopropylmalate synthase", "drug_actions": []}, "P98160": {"specific_function": "Integral component of basement membranes. Component of the glomerular basement membrane (GBM), responsible for the fixed negative electrostatic membrane charge, and which provides a barrier which is both size- and charge-selective. It serves as an attachment substrate for cells. Plays essential roles in vascularization. Critical for normal heart development and for regulating the vascular response to injury. Also required for avascular cartilage development.Endorepellin in an anti-angiogenic and anti-tumor peptide that inhibits endothelial cell migration, collagen-induced endothelial tube morphogenesis and blood vessel growth in the chorioallantoic membrane. Blocks endothelial cell adhesion to fibronectin and type I collagen. Anti-tumor agent in neovascularization. Interaction with its ligand, integrin alpha2/beta1, is required for the anti-angiogenic properties. Evokes a reduction in phosphorylation of receptor tyrosine kinases via alpha2/beta1 integrin-mediated activation of the tyrosine phosphatase, PTPN6.The LG3 peptide has anti-angiogenic properties that require binding of calcium ions for full activity.", "general_function": "Protein c-terminus binding", "gene_names": ["HSPG2"], "name": "Basement membrane-specific heparan sulfate proteoglycan core protein", "drug_actions": []}, "Q6NUS8": {"specific_function": "UDP-glucuronosyltransferases catalyze phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase water solubility and enhance excretion. They are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds (By similarity).", "general_function": "Udp-glycosyltransferase activity", "gene_names": ["UGT3A1"], "name": "UDP-glucuronosyltransferase 3A1", "drug_actions": []}, "P27169": {"specific_function": "Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation.", "general_function": "Protein homodimerization activity", "gene_names": ["PON1"], "name": "Serum paraoxonase/arylesterase 1", "drug_actions": [{"action": "INHIBITOR", "target": "P27169", "drug": "DB01327"}]}, "P22102": {"general_function": "Phosphoribosylglycinamide formyltransferase activity", "gene_names": ["GART"], "name": "Trifunctional purine biosynthetic protein adenosine-3", "drug_actions": [{"action": "INHIBITOR", "target": "P22102", "drug": "DB00642"}]}, "O75311": {"specific_function": "The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).", "general_function": "Transmitter-gated ion channel activity", "gene_names": ["GLRA3"], "name": "Glycine receptor subunit alpha-3", "drug_actions": [{"action": "ANTAGONIST", "target": "O75311", "drug": "DB00431"}, {"action": "ANTAGONIST", "target": "O75311", "drug": "DB00466"}, {"action": "AGONIST", "target": "O75311", "drug": "DB00602"}]}, "P56868": {"specific_function": "Provides the (R)-glutamate required for cell wall biosynthesis. Converts L- or D-glutamate to D- or L-glutamate, respectively, but not other amino acids such as alanine, aspartate, and glutamine.", "general_function": "Glutamate racemase activity", "gene_names": ["murI"], "name": "Glutamate racemase", "drug_actions": []}, "P0A8P1": {"specific_function": "Functions in the N-end rule pathway of protein degradation where it conjugates Leu, Phe and, less efficiently, Met from aminoacyl-tRNAs to the N-termini of proteins containing an N-terminal arginine or lysine.", "general_function": "Transferase activity, transferring amino-acyl groups", "gene_names": ["aat"], "name": "Leucyl/phenylalanyl-tRNA--protein transferase", "drug_actions": []}, "P14649": {"specific_function": "Regulatory light chain of myosin. Does not bind calcium.", "general_function": "Structural constituent of muscle", "gene_names": ["MYL6B"], "name": "Myosin light chain 6B", "drug_actions": []}, "Q4L5E4": {"general_function": "Trna binding", "gene_names": ["pheT"], "name": "Phenylalanine--tRNA ligase beta subunit", "drug_actions": []}, "Q04759": {"specific_function": "Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-co-stimulated T-cells, is required for the activation of NF-kappa-B and JUN, which in turn are essential for IL2 production, and participates to the calcium-dependent NFATC1 and NFATC2 transactivation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11 on several serine residues, inducing CARD11 association with lipid rafts and recruitment of the BCL10-MALT1 complex, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. May also play an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. In the signaling pathway leading to JUN activation, acts by phosphorylating the mediator STK39/SPAK and may not act through MAP kinases signaling. Plays a critical role in TCR/CD28-induced NFATC1 and NFATC2 transactivation by participating in the regulation of reduced inositol 1,4,5-trisphosphate generation and intracellular calcium mobilization. After costimulation of T-cells through CD28 can phosphorylate CBLB and is required for the ubiquitination and subsequent degradation of CBLB, which is a prerequisite for the activation of TCR. During T-cells differentiation, plays an important role in the development of T-helper 2 (Th2) cells following immune and inflammatory responses, and, in the development of inflammatory autoimmune diseases, is necessary for the activation of IL17-producing Th17 cells. May play a minor role in Th1 response. Upon TCR stimulation, mediates T-cell protective survival signal by phosphorylating BAD, thus protecting T-cells from BAD-induced apoptosis, and by up-regulating BCL-X(L)/BCL2L1 levels through NF-kappa-B and JUN pathways. In platelets, regulates signal transduction downstream of the ITGA2B, CD36/GP4, F2R/PAR1 and F2RL3/PAR4 receptors, playing a positive role in 'outside-in' signaling and granule secretion signal transduction. May relay signals from the activated ITGA2B receptor by regulating the uncoupling of WASP and WIPF1, thereby permitting the regulation of actin filament nucleation and branching activity of the Arp2/3 complex. May mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1, which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway. Phosphorylates MSN (moesin) in the presence of phosphatidylglycerol or phosphatidylinositol. Phosphorylates PDPK1 at 'Ser-504' and 'Ser-532' and negatively regulates its ability to phosphorylate PKB/AKT1.", "name": "Protein kinase C theta type", "drug_actions": [], "general_function": "Ubiquitin-protein transferase activity", "in_complexes": ["Protein kinase C"], "gene_names": ["PRKCQ"]}, "Q8IVL5": {"specific_function": "Shows prolyl 3-hydroxylase activity catalyzing the post-translational formation of 3-hydroxyproline in -Xaa-Pro-Gly-sequences in collagens, especially types II, IV and V.", "general_function": "Procollagen-proline 3-dioxygenase activity", "gene_names": ["P3H2"], "name": "Prolyl 3-hydroxylase 2", "drug_actions": []}, "Q8IVL6": {"specific_function": "Has prolyl 3-hydroxylase activity catalyzing the post-translational formation of 3-hydroxyproline in -Xaa-Pro-Gly-sequences in collagens, especially types IV and V.", "general_function": "Procollagen-proline 3-dioxygenase activity", "gene_names": ["P3H3"], "name": "Prolyl 3-hydroxylase 3", "drug_actions": []}, "P04040": {"specific_function": "Occurs in almost all aerobically respiring organisms and serves to protect cells from the toxic effects of hydrogen peroxide. Promotes growth of cells including T-cells, B-cells, myeloid leukemia cells, melanoma cells, mastocytoma cells and normal and transformed fibroblast cells.", "general_function": "Receptor binding", "gene_names": ["CAT"], "name": "Catalase", "drug_actions": [{"action": "INHIBITOR", "target": "P04040", "drug": "DB01213"}]}, "P32322": {"specific_function": "Housekeeping enzyme that catalyzes the last step in proline biosynthesis. Can utilize both NAD and NADP, but has higher affinity for NAD. Involved in the cellular response to oxidative stress.", "general_function": "Pyrroline-5-carboxylate reductase activity", "gene_names": ["PYCR1"], "name": "Pyrroline-5-carboxylate reductase 1, mitochondrial", "drug_actions": []}, "P32320": {"specific_function": "This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis.", "general_function": "Zinc ion binding", "gene_names": ["CDA"], "name": "Cytidine deaminase", "drug_actions": []}, "P0C0Y7": {"specific_function": "The reaction center is a membrane-bound complex that mediates the initial photochemical event in the electron transfer process of photosynthesis.", "general_function": "Electron transporter, transferring electrons within the cyclic electron transport pathway of photosynthesis activity", "gene_names": ["puhA"], "name": "Reaction center protein H chain", "drug_actions": []}, "Q13085": {"specific_function": "Catalyzes the rate-limiting reaction in the biogenesis of long-chain fatty acids. Carries out three functions: biotin carboxyl carrier protein, biotin carboxylase and carboxyltransferase.", "general_function": "Metal ion binding", "gene_names": ["ACACA"], "name": "Acetyl-CoA carboxylase 1", "drug_actions": []}, "P12821": {"specific_function": "Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.", "general_function": "Zinc ion binding", "gene_names": ["ACE"], "name": "Angiotensin-converting enzyme", "drug_actions": [{"action": "INHIBITOR", "target": "P12821", "drug": "DB00178"}, {"action": "INHIBITOR", "target": "P12821", "drug": "DB00492"}, {"action": "INHIBITOR", "target": "P12821", "drug": "DB00519"}, {"action": "INHIBITOR", "target": "P12821", "drug": "DB00542"}, {"action": "INHIBITOR", "target": "P12821", "drug": "DB00584"}, {"action": "INHIBITOR", "target": "P12821", "drug": "DB00616"}, {"action": "INHIBITOR", "target": "P12821", "drug": "DB00691"}, {"action": "INHIBITOR", "target": "P12821", "drug": "DB00722"}, {"action": "INHIBITOR", "target": "P12821", "drug": "DB00790"}, {"action": "INHIBITOR", "target": "P12821", "drug": "DB00881"}, {"action": "INHIBITOR", "target": "P12821", "drug": "DB01180"}, {"action": "INHIBITOR", "target": "P12821", "drug": "DB01197"}, {"action": "INHIBITOR", "target": "P12821", "drug": "DB01340"}, {"action": "INHIBITOR", "target": "P12821", "drug": "DB01348"}, {"action": "INHIBITOR", "target": "P12821", "drug": "DB08836"}]}, "P04049": {"specific_function": "Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF-kB activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["RAF1"], "name": "RAF proto-oncogene serine/threonine-protein kinase", "drug_actions": [{"action": "INHIBITOR", "target": "P04049", "drug": "DB00398"}, {"action": "INHIBITOR", "target": "P04049", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P04049", "drug": "DB08912"}]}, "O43766": {"specific_function": "Catalyzes the radical-mediated insertion of two sulfur atoms into the C-6 and C-8 positions of the octanoyl moiety bound to the lipoyl domains of lipoate-dependent enzymes, thereby converting the octanoylated domains into lipoylated derivatives.", "general_function": "Metal ion binding", "gene_names": ["LIAS"], "name": "Lipoyl synthase, mitochondrial", "drug_actions": []}, "P20248": {"specific_function": "Essential for the control of the cell cycle at the G1/S (start) and the G2/M (mitosis) transitions.", "gene_names": ["CCNA2"], "name": "Cyclin-A2", "drug_actions": []}, "P05546": {"specific_function": "Thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT-III). Also inhibits chymotrypsin, but in a glycosaminoglycan-independent manner.Peptides at the N-terminal of HC-II have chemotactic activity for both monocytes and neutrophils.", "general_function": "Serine-type endopeptidase inhibitor activity", "gene_names": ["SERPIND1"], "name": "Heparin cofactor 2", "drug_actions": [{"action": "AGONIST", "target": "P05546", "drug": "DB00407"}, {"action": "AGONIST", "target": "P05546", "drug": "DB06271"}]}, "P00750": {"specific_function": "Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Plays a direct role in facilitating neuronal migration.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["PLAT"], "name": "Tissue-type plasminogen activator", "drug_actions": [{"action": "ANTAGONIST", "target": "P00750", "drug": "DB00513"}, {"action": "NEGATIVE MODULATOR", "target": "P00750", "drug": "DB01050"}, {"action": "OTHER/UNKNOWN", "target": "P00750", "drug": "DB01088"}]}, "O95237": {"specific_function": "Transfers the acyl group from the sn-1 position of phosphatidylcholine to all-trans retinol, producing all-trans retinyl esters. Retinyl esters are storage forms of vitamin A. LRAT plays a critical role in vision. It provides the all-trans retinyl ester substrates for the isomerohydrolase which processes the esters into 11-cis-retinol in the retinal pigment epithelium; due to a membrane-associated alcohol dehydrogenase, 11 cis-retinol is oxidized and converted into 11-cis-retinaldehyde which is the chromophore for rhodopsin and the cone photopigments.", "general_function": "Transferase activity, transferring acyl groups", "gene_names": ["LRAT"], "name": "Lecithin retinol acyltransferase", "drug_actions": []}, "P35222": {"specific_function": "Key downstream component of the canonical Wnt signaling pathway. In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. Involved in the regulation of cell adhesion. Acts as a negative regulator of centrosome cohesion. Involved in the CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. Blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. Disrupts PML function and PML-NB formation by inhibiting RANBP2-mediated sumoylation of PML (PubMed:17524503, PubMed:18077326, PubMed:18086858, PubMed:18957423, PubMed:21262353, PubMed:22647378, PubMed:22699938, PubMed:22155184). Promotes neurogenesis by maintaining sympathetic neuroblasts within the cell cycle (By similarity).", "general_function": "Transcription regulatory region dna binding", "gene_names": ["CTNNB1"], "name": "Catenin beta-1", "drug_actions": []}, "P45568": {"specific_function": "Catalyzes the NADP-dependent rearrangement and reduction of 1-deoxy-D-xylulose-5-phosphate (DXP) to 2-C-methyl-D-erythritol 4-phosphate (MEP).", "general_function": "Nadph binding", "gene_names": ["dxr"], "name": "1-deoxy-D-xylulose 5-phosphate reductoisomerase", "drug_actions": []}, "P0CG22": {"specific_function": "Putative oxidoreductase.", "general_function": "Oxidoreductase activity", "gene_names": ["DHRS4L1"], "name": "Putative dehydrogenase/reductase SDR family member 4-like 1", "drug_actions": []}, "P68638": {"specific_function": "Serves to protect the virus against complement attack by inhibiting both classical and alternative pathways of complement activation. Binds C3b and C4b.", "gene_names": [], "name": "Complement control protein C3", "drug_actions": []}, "P44160": {"general_function": "Involved in isomerase activity", "gene_names": ["HI_1317"], "name": "Putative glucose-6-phosphate 1-epimerase", "drug_actions": []}, "Q02750": {"specific_function": "Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis.", "general_function": "Receptor signaling protein tyrosine phosphatase activity", "gene_names": ["MAP2K1"], "name": "Dual specificity mitogen-activated protein kinase kinase 1", "drug_actions": [{"action": "INHIBITOR", "target": "Q02750", "drug": "DB05239"}, {"action": "INHIBITOR", "target": "Q02750", "drug": "DB06616"}, {"action": "INHIBITOR", "target": "Q02750", "drug": "DB08911"}]}, "Q4R2T2": {"general_function": "Transferase activity", "gene_names": [], "name": "Prenyltransferase", "drug_actions": []}, "Q13332": {"specific_function": "Interacts with LAR-interacting protein LIP.1.", "general_function": "Transmembrane receptor protein tyrosine phosphatase activity", "gene_names": ["PTPRS"], "name": "Receptor-type tyrosine-protein phosphatase S", "drug_actions": [{"action": "INHIBITOR", "target": "Q13332", "drug": "DB00630"}, {"action": "INHIBITOR", "target": "Q13332", "drug": "DB01077"}]}, "P54750": {"specific_function": "Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a higher affinity for cGMP than for cAMP.", "name": "Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "P54750", "drug": "DB00201"}, {"action": "INHIBITOR", "target": "P54750", "drug": "DB00622"}, {"action": "INHIBITOR", "target": "P54750", "drug": "DB01023"}, {"action": "INHIBITOR", "target": "P54750", "drug": "DB01244"}], "general_function": "Metal ion binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE1A"]}, "P54317": {"specific_function": "Lipase with broad substrate specificity. Can hydrolyze both phospholipids and galactolipids. Acts preferentially on monoglycerides, phospholipids and galactolipids. Contributes to milk fat hydrolysis.", "general_function": "Triglyceride lipase activity", "gene_names": ["PNLIPRP2"], "name": "Pancreatic lipase-related protein 2", "drug_actions": []}, "Q9F663": {"specific_function": "Hydrolyzes carbapenems, penicillins, cephalosporins and monobactams with varying efficiency.", "general_function": "Beta-lactamase activity", "gene_names": ["bla"], "name": "Carbapenem-hydrolyzing beta-lactamase KPC", "drug_actions": [{"action": "INHIBITOR", "target": "Q9F663", "drug": "DB09060"}]}, "Q99584": {"specific_function": "Plays a role in the export of proteins that lack a signal peptide and are secreted by an alternative pathway. Binds two calcium ions per subunit. Binds one copper ion. Binding of one copper ion does not interfere with calcium binding. Required for the copper-dependent stress-induced export of IL1A and FGF1. The calcium-free protein binds to lipid vesicles containing phosphatidylserine, but not to vesicles containing phosphatidylcholine (By similarity).", "general_function": "Zinc ion binding", "gene_names": ["S100A13"], "name": "Protein S100-A13", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "Q99584", "drug": "DB00768"}, {"action": "ANTAGONIST", "target": "Q99584", "drug": "DB01025"}]}, "P04547": {"specific_function": "Catalyzes the transfer of glucose (Glc) from uridine diphosphoglucose (UDP-Glc) to 5-hydroxymethylcytosine (5-HMC) in double-stranded DNA. Is involved in a DNA modification process to protect the phage genome against its own nucleases and the host restriction endonuclease system.", "general_function": "Dna beta-glucosyltransferase activity", "gene_names": ["bgt"], "name": "DNA beta-glucosyltransferase", "drug_actions": []}, "Q9NWZ3": {"specific_function": "Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signaling pathways (PubMed:17878374). Is rapidly recruited by MYD88 to the receptor-signaling complex upon TLR activation to form the Myddosome together with IRAK2. Phosphorylates initially IRAK1, thus stimulating the kinase activity and intensive autophosphorylation of IRAK1. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and activation. Alternatively, phosphorylates TIRAP to promote its ubiquitination and subsequent degradation. Phosphorylates NCF1 and regulates NADPH oxidase activation after LPS stimulation suggesting a similar mechanism during microbial infections.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["IRAK4"], "name": "Interleukin-1 receptor-associated kinase 4", "drug_actions": []}, "Q7SIE2": {"general_function": "Endo-1,4-beta-xylanase activity", "gene_names": [], "name": "Endo-1,4-beta-xylanase", "drug_actions": []}, "P83788": {"specific_function": "Catalyzes the cleavage of L-kynurenine (L-Kyn) and L-3-hydroxykynurenine (L-3OHKyn) into anthranilic acid (AA) and 3-hydroxyanthranilic acid (3-OHAA), respectively.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["kynU"], "name": "Kynureninase", "drug_actions": []}, "Q9UNQ0": {"specific_function": "High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. Implicated in the efflux of numerous drugs and xenobiotics: mitoxantrone, the photosensitizer pheophorbide, camptothecin, methotrexate, azidothymidine (AZT), and the anthracyclines daunorubicin and doxorubicin.", "general_function": "Xenobiotic-transporting atpase activity", "gene_names": ["ABCG2"], "name": "ATP-binding cassette sub-family G member 2", "drug_actions": []}, "P00861": {"specific_function": "Specifically catalyzes the decarboxylation of meso-diaminopimelate (meso-DAP) to L-lysine. Is not active against the DD- or LL-isomers of diaminopimelate.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["lysA"], "name": "Diaminopimelate decarboxylase", "drug_actions": []}, "P09958": {"specific_function": "Furin is likely to represent the ubiquitous endoprotease activity within constitutive secretory pathways and capable of cleavage at the RX(K/R)R consensus motif.", "general_function": "Serine-type endopeptidase inhibitor activity", "gene_names": ["FURIN"], "name": "Furin", "drug_actions": []}, "P22073": {"specific_function": "BglA is intracellular and cleaves cellobiose probably through inorganic phosphate mediated hydrolysis.", "general_function": "Beta-glucosidase activity", "gene_names": ["bglA"], "name": "Beta-glucosidase A", "drug_actions": []}, "P25092": {"specific_function": "Receptor for the E.coli heat-stable enterotoxin (E.coli enterotoxin markedly stimulates the accumulation of cGMP in mammalian cells expressing GC-C). Also activated by the endogenous peptides guanylin and uroguanylin.", "general_function": "Toxic substance binding", "gene_names": ["GUCY2C"], "name": "Heat-stable enterotoxin receptor", "drug_actions": [{"action": "AGONIST", "target": "P25092", "drug": "DB08890"}]}, "P10186": {"specific_function": "Excises uracil residues from the DNA which can arise as a result of misincorporation of dUMP residues by DNA polymerase or deamination of cytosine. Therefore may reduce deleterious uracil incorporation into the viral genome, particularly, in terminally differentiated neurons which lack DNA repair enzymes.", "general_function": "Uracil dna n-glycosylase activity", "gene_names": [], "name": "Uracil-DNA glycosylase", "drug_actions": []}, "P02778": {"specific_function": "Chemotactic for monocytes and T-lymphocytes. Binds to CXCR3.", "general_function": "Receptor binding", "gene_names": ["CXCL10"], "name": "C-X-C motif chemokine 10", "drug_actions": []}, "P27361": {"specific_function": "Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade plays also a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation. However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis and apoptosis. Moreover, the MAPK/ERK cascade is also involved in the regulation of the endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC); as well as in the fragmentation of the Golgi apparatus during mitosis. The substrates include transcription factors (such as ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of translation (such as EIF4EBP1) and a variety of other signaling-related molecules (like ARHGEF2, FRS2 or GRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates which enable the propagation the MAPK/ERK signal to additional cytosolic and nuclear targets, thereby extending the specificity of the cascade.", "general_function": "Phosphatase binding", "gene_names": ["MAPK3"], "name": "Mitogen-activated protein kinase 3", "drug_actions": [{"action": "INHIBITOR", "target": "P27361", "drug": "DB00605"}, {"action": "INDUCER", "target": "P27361", "drug": "DB01169"}, {"action": "INHIBITOR", "target": "P27361", "drug": "DB02733"}]}, "Q7Z2H8": {"specific_function": "Neutral amino acid/proton symporter. Has a pH-dependent electrogenic transport activity for small amino acids such as glycine, alanine and proline. Besides small apolar L-amino acids, it also recognize their D-enantiomers and selected amino acid derivatives such as gamma-aminobutyric acid (By similarity).", "general_function": "L-proline transmembrane transporter activity", "gene_names": ["SLC36A1"], "name": "Proton-coupled amino acid transporter 1", "drug_actions": []}, "Q8VVD2": {"general_function": "Xylan alpha-1,2-glucuronosidase activity", "gene_names": ["aguA"], "name": "Xylan alpha-1,2-glucuronidase", "drug_actions": []}, "O67757": {"specific_function": "Participates in transcription elongation, termination and antitermination.", "gene_names": ["nusG"], "name": "Transcription termination/antitermination protein NusG", "drug_actions": []}, "Q8IWT1": {"specific_function": "Modulates channel gating kinetics. Causes negative shifts in the voltage dependence of activation of certain alpha sodium channels, but does not affect the voltage dependence of inactivation. Modulates the suceptibility of the sodium channel to inhibition by toxic peptides from spider, scorpion, wasp and sea anemone venom.", "name": "Sodium channel subunit beta-4", "drug_actions": [{"action": "INHIBITOR", "target": "Q8IWT1", "drug": "DB00909"}], "general_function": "Voltage-gated sodium channel activity involved in cardiac muscle cell action potential", "in_complexes": ["Sodium channel protein"], "gene_names": ["SCN4B"]}, "O60264": {"specific_function": "Helicase that possesses intrinsic ATP-dependent nucleosome-remodeling activity. Complexes containing SMARCA5 are capable of forming ordered nucleosome arrays on chromatin; this may require intact histone H4 tails. Also required for replication of pericentric heterochromatin in S-phase specifically in conjunction with BAZ1A. Probably plays a role in repression of polI dependent transcription of the rDNA locus, through the recruitment of the SIN3/HDAC1 corepressor complex to the rDNA promoter. Essential component of the WICH complex, a chromatin remodeling complex that mobilizes nucleosomes and reconfigures irregular chromatin to a regular nucleosomal array structure. The WICH complex regulates the transcription of various genes, has a role in RNA polymerase I and RNA polymerase III transcription, mediates the histone H2AX phosphorylation at 'Tyr-142', and is involved in the maintenance of chromatin structures during DNA replication processes. Essential component of the NoRC (nucleolar remodeling complex) complex, a complex that mediates silencing of a fraction of rDNA by recruiting histone-modifying enzymes and DNA methyltransferases, leading to heterochromatin formation and transcriptional silencing.", "general_function": "Helicase activity", "gene_names": ["SMARCA5"], "name": "SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5", "drug_actions": []}, "Q7CL96": {"gene_names": ["sspA"], "name": "Putative stringent starvation protein A", "drug_actions": []}, "P11362": {"specific_function": "Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (GnRH) neuronal system. Phosphorylates PLCG1, FRS2, GAB1 and SHB. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes phosphorylation of SHC1, STAT1 and PTPN11/SHP2. In the nucleus, enhances RPS6KA1 and CREB1 activity and contributes to the regulation of transcription. FGFR1 signaling is down-regulated by IL17RD/SEF, and by FGFR1 ubiquitination, internalization and degradation.", "general_function": "Protein tyrosine kinase activity", "gene_names": ["FGFR1"], "name": "Fibroblast growth factor receptor 1", "drug_actions": [{"action": "INHIBITOR", "target": "P11362", "drug": "DB00398"}, {"action": "INHIBITOR", "target": "P11362", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P11362", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P11362", "drug": "DB09078"}, {"action": "INHIBITOR", "target": "P11362", "drug": "DB09079"}]}, "P11586": {"general_function": "Methylenetetrahydrofolate dehydrogenase [nad(p)+] activity", "gene_names": ["MTHFD1"], "name": "C-1-tetrahydrofolate synthase, cytoplasmic", "drug_actions": [{"action": "COFACTOR", "target": "P11586", "drug": "DB00116"}]}, "P33038": {"specific_function": "Cell wall formation. Adds enolpyruvyl to UDP-N-acetylglucosamine. Target for the antibiotic fosfomycin.", "general_function": "Udp-n-acetylglucosamine 1-carboxyvinyltransferase activity", "gene_names": ["murA"], "name": "UDP-N-acetylglucosamine 1-carboxyvinyltransferase", "drug_actions": []}, "P19878": {"specific_function": "NCF2, NCF1, and a membrane bound cytochrome b558 are required for activation of the latent NADPH oxidase (necessary for superoxide production).", "name": "Neutrophil cytosol factor 2", "drug_actions": [{"action": "INHIBITOR", "target": "P19878", "drug": "DB00514"}], "general_function": "Protein c-terminus binding", "in_complexes": ["NADPH oxidase"], "gene_names": ["NCF2"]}, "P0AF14": {"specific_function": "Catalyzes the irreversible cleavage of the glycosidic bond in both 5'-methylthioadenosine (MTA) and S-adenosylhomocysteine (SAH/AdoHcy) to adenine and the corresponding thioribose, 5'-methylthioribose and S-ribosylhomocysteine, respectively.", "general_function": "Methylthioadenosine nucleosidase activity", "gene_names": ["mtnN"], "name": "5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase", "drug_actions": []}, "Q96PR1": {"specific_function": "Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Contributes to the regulation of the fast action potential repolarization and in sustained high-frequency firing in neurons of the central nervous system. Homotetramer channels mediate delayed-rectifier voltage-dependent potassium currents that activate rapidly at high-threshold voltages and inactivate slowly. Forms tetrameric channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane (PubMed:15709110). Can form functional homotetrameric and heterotetrameric channels that contain variable proportions of KCNC1, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel. Channel properties may be modulated either by the association with ancillary subunits, such as KCNE1, KCNE2 or KCNE3 or indirectly by nitric oxide (NO) through a cGMP- and PKG-mediated signaling cascade, slowing channel activation and deactivation of delayed rectifier potassium channels (By similarity). Contributes to fire sustained trains of very brief action potentials at high frequency in retinal ganglion cells, thalamocortical and suprachiasmatic nucleus (SCN) neurons and in hippocampal and neocortical interneurons (PubMed:15709110). Sustained maximal action potential firing frequency in inhibitory hippocampal interneurons is negatively modulated by histamine H2 receptor activation in a cAMP- and protein kinase (PKA) phosphorylation-dependent manner. Plays a role in maintaining the fidelity of synaptic transmission in neocortical GABAergic interneurons by generating action potential (AP) repolarization at nerve terminals, thus reducing spike-evoked calcium influx and GABA neurotransmitter release. Required for long-range synchronization of gamma oscillations over distance in the neocortex. Contributes to the modulation of the circadian rhythm of spontaneous action potential firing in suprachiasmatic nucleus (SCN) neurons in a light-dependent manner (By similarity).", "general_function": "Voltage-gated potassium channel activity", "gene_names": ["KCNC2"], "name": "Potassium voltage-gated channel subfamily C member 2", "drug_actions": [{"action": "ANTAGONIST", "target": "Q96PR1", "drug": "DB06637"}]}, "Q9Y619": {"specific_function": "Ornithine transport across inner mitochondrial membrane, from the cytoplasm to the matrix.", "general_function": "L-ornithine transmembrane transporter activity", "gene_names": ["SLC25A15"], "name": "Mitochondrial ornithine transporter 1", "drug_actions": []}, "O31168": {"general_function": "Chloride peroxidase activity", "gene_names": ["cpo"], "name": "Non-heme chloroperoxidase", "drug_actions": []}, "P0AF12": {"specific_function": "Catalyzes the irreversible cleavage of the glycosidic bond in both 5'-methylthioadenosine (MTA) and S-adenosylhomocysteine (SAH/AdoHcy) to adenine and the corresponding thioribose, 5'-methylthioribose and S-ribosylhomocysteine, respectively. Can also use 5'-isobutylthioadenosine, 5'-n-butylthioadenosine, S-adenosyl-D-homocysteine, decarboxylated adenosylhomocysteine, deaminated adenosylhomocysteine and S-2-aza-adenosylhomocysteine as substrates.", "general_function": "Methylthioadenosine nucleosidase activity", "gene_names": ["mtnN"], "name": "5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase", "drug_actions": []}, "P21918": {"specific_function": "Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.", "name": "D(1B) dopamine receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "P21918", "drug": "DB00246"}, {"action": "AGONIST", "target": "P21918", "drug": "DB00248"}, {"action": "AGONIST", "target": "P21918", "drug": "DB00248"}, {"action": "AGONIST", "target": "P21918", "drug": "DB00268"}, {"action": "ANTAGONIST", "target": "P21918", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P21918", "drug": "DB00334"}, {"action": "BINDER", "target": "P21918", "drug": "DB00370"}, {"action": "BINDER", "target": "P21918", "drug": "DB00408"}, {"action": "BINDER", "target": "P21918", "drug": "DB00408"}, {"action": "UNKNOWN", "target": "P21918", "drug": "DB00413"}, {"action": "BINDER", "target": "P21918", "drug": "DB00458"}, {"action": "BINDER", "target": "P21918", "drug": "DB00568"}, {"action": "ANTAGONIST", "target": "P21918", "drug": "DB00589"}, {"action": "AGONIST", "target": "P21918", "drug": "DB00696"}, {"action": "AGONIST", "target": "P21918", "drug": "DB00714"}, {"action": "BINDER", "target": "P21918", "drug": "DB00726"}, {"action": "AGONIST", "target": "P21918", "drug": "DB00800"}, {"action": "AGONIST", "target": "P21918", "drug": "DB00988"}, {"action": "AGONIST", "target": "P21918", "drug": "DB00988"}, {"action": "ANTAGONIST", "target": "P21918", "drug": "DB01038"}, {"action": "AGONIST", "target": "P21918", "drug": "DB01186"}, {"action": "AGONIST", "target": "P21918", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P21918", "drug": "DB01224"}, {"action": "AGONIST", "target": "P21918", "drug": "DB01235"}, {"action": "ANTAGONIST", "target": "P21918", "drug": "DB01238"}, {"action": "PARTIAL AGONIST", "target": "P21918", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P21918", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P21918", "drug": "DB01624"}, {"action": "AGONIST", "target": "P21918", "drug": "DB05271"}, {"action": "BINDER", "target": "P21918", "drug": "DB06148"}], "general_function": "G-protein coupled amine receptor activity", "in_complexes": ["D(1) dopamine receptor"], "gene_names": ["DRD5"]}, "Q7B8V4": {"general_function": "Zinc ion binding", "gene_names": ["bont/a"], "name": "BoNT/A", "drug_actions": []}, "Q15648": {"specific_function": "Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors (PubMed:10406464, PubMed:11867769, PubMed:12037571, PubMed:12218053, PubMed:12556447, PubMed:14636573, PubMed:15340084, PubMed:15471764, PubMed:15989967, PubMed:16574658, PubMed:9653119). Acts as a coactivator for GATA1-mediated transcriptional activation during erythroid differentiation of K562 erythroleukemia cells (PubMed:24245781).", "general_function": "Vitamin d receptor binding", "gene_names": ["MED1"], "name": "Mediator of RNA polymerase II transcription subunit 1", "drug_actions": []}, "O15554": {"specific_function": "Forms a voltage-independent potassium channel that is activated by intracellular calcium (PubMed:26148990). Activation is followed by membrane hyperpolarization which promotes calcium influx. Required for maximal calcium influx and proliferation during the reactivation of naive T-cells. The channel is blocked by clotrimazole and charybdotoxin but is insensitive to apamin (PubMed:17157250, PubMed:18796614).", "name": "Intermediate conductance calcium-activated potassium channel protein 4", "drug_actions": [{"action": "INHIBITOR", "target": "O15554", "drug": "DB00228"}, {"action": "INHIBITOR", "target": "O15554", "drug": "DB00257"}, {"action": "INHIBITOR", "target": "O15554", "drug": "DB00468"}, {"action": "BINDER", "target": "O15554", "drug": "DB00721"}, {"action": "INHIBITOR", "target": "O15554", "drug": "DB01110"}, {"action": "INHIBITOR", "target": "O15554", "drug": "DB01159"}], "general_function": "Protein phosphatase binding", "in_complexes": ["Calcium-activated potassium channel"], "gene_names": ["KCNN4"]}, "Q9Y4W6": {"specific_function": "ATP-dependent protease which is essential for axonal development.", "general_function": "Zinc ion binding", "gene_names": ["AFG3L2"], "name": "AFG3-like protein 2", "drug_actions": []}, "P51955": {"specific_function": "Protein kinase which is involved in the control of centrosome separation and bipolar spindle formation in mitotic cells and chromatin condensation in meiotic cells. Regulates centrosome separation (essential for the formation of bipolar spindles and high-fidelity chromosome separation) by phosphorylating centrosomal proteins such as CROCC, CEP250 and NINL, resulting in their displacement from the centrosomes. Regulates kinetochore microtubule attachment stability in mitosis via phosphorylation of NDC80. Involved in regulation of mitotic checkpoint protein complex via phosphorylation of CDC20 and MAD2L1. Plays an active role in chromatin condensation during the first meiotic division through phosphorylation of HMGA2. Phosphorylates: PPP1CC; SGOL1; NECAB3 and NPM1. Essential for localization of MAD2L1 to kinetochore and MAPK1 and NPM1 to the centrosome. Isoform 1 phosphorylates and activates NEK11 in G1/S-arrested cells. Isoform 2, which is not present in the nucleolus, does not.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["NEK2"], "name": "Serine/threonine-protein kinase Nek2", "drug_actions": []}, "P21912": {"specific_function": "Iron-sulfur protein (IP) subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q).", "general_function": "Ubiquinone binding", "gene_names": ["SDHB"], "name": "Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial", "drug_actions": []}, "P03300": {"specific_function": "Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host cell receptor PVR to provide virion attachment to target host epithelial cells. This attachment induces virion internalization predominantly through clathrin- and caveolin-independent endocytosis in Hela cells and through caveolin-mediated endocytosis in brain microvascular endothelial cells. Tyrosine kinases are probably involved in the entry process. Virus binding to PVR induces increased junctional permeability and rearrangement of junctional proteins. Modulation of endothelial tight junctions, as well as cytolytic infection of endothelial cells themselves, may result in loss of endothelial integrity which may help the virus to reach the CNS. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks.Capsid protein VP2: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome.Capsid protein VP3: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome.Capsid protein VP4: Lies on the inner surface of the capsid shell. After binding to the host receptor, the capsid undergoes conformational changes. Capsid protein VP4 is released, Capsid protein VP1 N-terminus is externalized, and together, they shape a pore in the host membrane through which the viral genome is translocated into the host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP0: Component of immature procapsids, which is cleaved into capsid proteins VP4 and VP2 after maturation. Allows the capsid to remain inactive before the maturation step (By similarity).Protein 2A: Cysteine protease that cleaves viral polyprotein and specific host proteins. It is responsible for the cleavage between the P1 and P2 regions, first cleavage occurring in the polyprotein. Cleaves also the host translation initiation factor EIF4G1, in order to shut down the capped cellular mRNA translation. Inhibits the host nucleus-cytoplasm protein and RNA trafficking by cleaving host members of the nuclear pores including NUP98, NUP62 and NUP153.Protein 2B: Plays an essential role in the virus replication cycle by acting as a viroporin. Creates a pore in the host reticulum endoplasmic and as a consequence releases Ca2+ in the cytoplasm of infected cell. In turn, high levels of cyctoplasmic calcium may trigger membrane trafficking and transport of viral ER-associated proteins to viroplasms, sites of viral genome replication.Protein 2C: Induces and associates with structural rearrangements of intracellular membranes. Triggers host autophagy by interacting with host BECN1 and thereby promotes viral replication. Participates in viral replication and interacts with host DHX9. Displays RNA-binding, nucleotide binding and NTPase activities. May play a role in virion morphogenesis and viral RNA encapsidation by interacting with the capsid protein VP3.Protein 3AB: Localizes the viral replication complex to the surface of membranous vesicles. Together with protein 3CD binds the Cis-Active RNA Element (CRE) which is involved in RNA synthesis initiation. Acts as a cofactor to stimulate the activity of 3D polymerase, maybe through a nucleid acid chaperone activity.Protein 3A: Localizes the viral replication complex to the surface of membranous vesicles. It inhibits host cell endoplasmic reticulum-to-Golgi apparatus transport and causes the dissassembly of the Golgi complex, possibly through GBF1 interaction. This would result in depletion of MHC, trail receptors and IFN receptors at the host cell surface.Viral protein genome-linked: acts as a primer for viral RNA replication and remains covalently bound to viral genomic RNA. VPg is uridylylated prior to priming replication into VPg-pUpU. The oriI viral genomic sequence may act as a template for this. The VPg-pUpU is then used as primer on the genomic RNA poly(A) by the RNA-dependent RNA polymerase to replicate the viral genome. VPg may be removed in the cytoplasm by an unknown enzyme termed \"unlinkase\". VPg is not cleaved off virion genomes because replicated genomic RNA are encapsidated at the site of replication.Protein 3CD: Is involved in the viral replication complex and viral polypeptide maturation. It exhibits protease activity with a specificity and catalytic efficiency that is different from protease 3C. Protein 3CD lacks polymerase activity. The 3C domain in the context of protein 3CD may have an RNA binding activity.Protease 3C: May cleave host PABP and contribute to host translation shutoff.RNA-directed RNA polymerase: Replicates the viral genomic RNA on the surface of intracellular membranes. May form linear arrays of subunits that propagate along a strong head-to-tail interaction called interface-I. Covalently attaches UMP to a tyrosine of VPg, which is used to prime RNA synthesis. The positive stranded RNA genome is first replicated at virus induced membranous vesicles, creating a dsRNA genomic replication form. This dsRNA is then used as template to synthesize positive stranded RNA genomes. ss(+)RNA genomes are either translated, replicated or encapsidated.", "general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P48029": {"specific_function": "Required for the uptake of creatine in muscles and brain.", "general_function": "Neurotransmitter:sodium symporter activity", "gene_names": ["SLC6A8"], "name": "Sodium- and chloride-dependent creatine transporter 1", "drug_actions": []}, "P21917": {"specific_function": "Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).", "general_function": "Sh3 domain binding", "gene_names": ["DRD4"], "name": "D(4) dopamine receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "P21917", "drug": "DB00246"}, {"action": "AGONIST", "target": "P21917", "drug": "DB00248"}, {"action": "AGONIST", "target": "P21917", "drug": "DB00268"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB00372"}, {"action": "BINDER", "target": "P21917", "drug": "DB00408"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB00409"}, {"action": "AGONIST", "target": "P21917", "drug": "DB00413"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB00420"}, {"action": "BINDER", "target": "P21917", "drug": "DB00477"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB00543"}, {"action": "AGONIST", "target": "P21917", "drug": "DB00589"}, {"action": "AGONIST", "target": "P21917", "drug": "DB00714"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB00777"}, {"action": "AGONIST", "target": "P21917", "drug": "DB00988"}, {"action": "AGONIST", "target": "P21917", "drug": "DB01186"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB01224"}, {"action": "AGONIST", "target": "P21917", "drug": "DB01235"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB01238"}, {"action": "PARTIAL AGONIST", "target": "P21917", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB04908"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB04946"}, {"action": "AGONIST", "target": "P21917", "drug": "DB05271"}, {"action": "ANTAGONIST", "target": "P21917", "drug": "DB06216"}]}, "P03303": {"specific_function": "Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host ICAM1 to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP2: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP3: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP4: Lies on the inner surface of the capsid shell. After binding to the host receptor, the capsid undergoes conformational changes. Capsid protein VP4 is released, Capsid protein VP1 N-terminus is externalized, and together, they shape a pore in the host membrane through which the viral genome is translocated into the host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP0: Component of immature procapsids, which is cleaved into capsid proteins VP4 and VP2 after maturation. Allows the capsid to remain inactive before the maturation step (By similarity).Protein 2A: Cysteine protease that cleaves viral polyprotein and specific host proteins. It is responsible for the cleavage between the P1 and P2 regions, first cleavage occurring in the polyprotein. Cleaves also the host translation initiation factor EIF4G1, in order to shut down the capped cellular mRNA translation. Inhibits the host nucleus-cytoplasm protein and RNA trafficking by cleaving host members of the nuclear pores (By similarity).Protein 2B: Plays an essential role in the virus replication cycle by acting as a viroporin. Creates a pore in the host reticulum endoplasmic and as a consequence releases Ca2+ in the cytoplasm of infected cell. In turn, high levels of cyctoplasmic calcium may trigger membrane trafficking and transport of viral ER-associated proteins to viroplasms, sites of viral genome replication (By similarity).Protein 2C: Induces and associates with structural rearrangements of intracellular membranes. Displays RNA-binding, nucleotide binding and NTPase activities. May play a role in virion morphogenesis and viral RNA encapsidation by interacting with the capsid protein VP3 (By similarity).Protein 3AB: Localizes the viral replication complex to the surface of membranous vesicles. Together with protein 3CD binds the Cis-Active RNA Element (CRE) which is involved in RNA synthesis initiation. Acts as a cofactor to stimulate the activity of 3D polymerase, maybe through a nucleid acid chaperone activity (By similarity).Protein 3A: Localizes the viral replication complex to the surface of membranous vesicles. It inhibits host cell endoplasmic reticulum-to-Golgi apparatus transport and causes the dissassembly of the Golgi complex, possibly through GBF1 interaction. This would result in depletion of MHC, trail receptors and IFN receptors at the host cell surface (By similarity).Viral protein genome-linked: acts as a primer for viral RNA replication and remains covalently bound to viral genomic RNA. VPg is uridylylated prior to priming replication into VPg-pUpU. The oriI viral genomic sequence may act as a template for this. The VPg-pUpU is then used as primer on the genomic RNA poly(A) by the RNA-dependent RNA polymerase to replicate the viral genome. VPg may be removed in the cytoplasm by an unknown enzyme termed \"unlinkase\". VPg is not cleaved off virion genomes because replicated genomic RNA are encapsidated at the site of replication (By similarity).Protein 3CD: Is involved in the viral replication complex and viral polypeptide maturation. It exhibits protease activity with a specificity and catalytic efficiency that is different from protease 3C. Protein 3CD lacks polymerase activity. The 3C domain in the context of protein 3CD may have an RNA binding activity (By similarity).Protease 3C: cleaves host DDX58/RIG-I and thus contributes to the inhibition of type I interferon production. Cleaves also host PABPC1 (By similarity).RNA-directed RNA polymerase: Replicates the viral genomic RNA on the surface of intracellular membranes. May form linear arrays of subunits that propagate along a strong head-to-tail interaction called interface-I. Covalently attaches UMP to a tyrosine of VPg, which is used to prime RNA synthesis. The positive stranded RNA genome is first replicated at virus induced membranous vesicles, creating a dsRNA genomic replication form. This dsRNA is then used as template to synthesize positive stranded RNA genomes. ss(+)RNA genomes are either translated, replicated or encapsidated (By similarity).", "general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P76216": {"specific_function": "Catalyzes the hydrolysis of N(2)-succinylarginine into N(2)-succinylornithine, ammonia and CO(2).", "general_function": "N-succinylarginine dihydrolase activity", "gene_names": ["astB"], "name": "N-succinylarginine dihydrolase", "drug_actions": []}, "P45954": {"specific_function": "Has greatest activity toward short branched chain acyl-CoA derivative such as (s)-2-methylbutyryl-CoA, isobutyryl-CoA, and 2-methylhexanoyl-CoA as well as toward short straight chain acyl-CoAs such as butyryl-CoA and hexanoyl-CoA. Can use valproyl-CoA as substrate and may play a role in controlling the metabolic flux of valproic acid in the development of toxicity of this agent.", "general_function": "Oxidoreductase activity, acting on the ch-ch group of donors, with a flavin as acceptor", "gene_names": ["ACADSB"], "name": "Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "P45954", "drug": "DB00313"}]}, "P45381": {"specific_function": "Catalyzes the deacetylation of N-acetylaspartic acid (NAA) to produce acetate and L-aspartate. NAA occurs in high concentration in brain and its hydrolysis NAA plays a significant part in the maintenance of intact white matter. In other tissues it act as a scavenger of NAA from body fluids.", "general_function": "Metal ion binding", "gene_names": ["ASPA"], "name": "Aspartoacylase", "drug_actions": []}, "Q13427": {"specific_function": "PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. May be implicated in the folding, transport, and assembly of proteins. May play an important role in the regulation of pre-mRNA splicing.", "general_function": "Poly(a) rna binding", "gene_names": ["PPIG"], "name": "Peptidyl-prolyl cis-trans isomerase G", "drug_actions": []}, "Q13426": {"specific_function": "Involved in DNA non-homologous end joining (NHEJ) required for double-strand break repair and V(D)J recombination. Binds to DNA and to DNA ligase IV (LIG4). The LIG4-XRCC4 complex is responsible for the NHEJ ligation step, and XRCC4 enhances the joining activity of LIG4. Binding of the LIG4-XRCC4 complex to DNA ends is dependent on the assembly of the DNA-dependent protein kinase complex DNA-PK to these DNA ends.", "general_function": "Protein c-terminus binding", "gene_names": ["XRCC4"], "name": "DNA repair protein XRCC4", "drug_actions": []}, "Q7Z2Z2": {"specific_function": "Involved in the biogenesis of the 60S ribosomal subunit and translational activation of ribosomes. Together with SBDS, triggers the GTP-dependent release of EIF6 from 60S pre-ribosomes in the cytoplasm, thereby activating ribosomes for translation competence by allowing 80S ribosome assembly and facilitating EIF6 recycling to the nucleus, where it is required for 60S rRNA processing and nuclear export. Has low intrinsic GTPase activity. GTPase activity is increased by contact with 60S ribosome subunits.", "general_function": "Ribosome binding", "gene_names": ["EFTUD1"], "name": "Elongation factor Tu GTP-binding domain-containing protein 1", "drug_actions": []}, "P15289": {"specific_function": "Hydrolyzes cerebroside sulfate.", "general_function": "Sulfuric ester hydrolase activity", "gene_names": ["ARSA"], "name": "Arylsulfatase A", "drug_actions": []}, "Q13423": {"specific_function": "The transhydrogenation between NADH and NADP is coupled to respiration and ATP hydrolysis and functions as a proton pump across the membrane. May play a role in reactive oxygen species (ROS) detoxification in the adrenal gland.", "general_function": "Nadp binding", "gene_names": ["NNT"], "name": "NAD(P) transhydrogenase, mitochondrial", "drug_actions": []}, "P0A094": {"specific_function": "Catalyzes the production of nitric oxide.", "general_function": "Nitric-oxide synthase activity", "gene_names": ["nos"], "name": "Nitric oxide synthase oxygenase", "drug_actions": []}, "P44490": {"specific_function": "Activates KDO (a required 8-carbon sugar) for incorporation into bacterial lipopolysaccharide in Gram-negative bacteria.", "general_function": "3-deoxy-manno-octulosonate cytidylyltransferase activity", "gene_names": ["kdsB"], "name": "3-deoxy-manno-octulosonate cytidylyltransferase", "drug_actions": []}, "Q9X1F8": {"specific_function": "GTPase that plays an essential role in the late steps of ribosome biogenesis (By similarity). Has GTPase activity but no ATPase activity. GTP, GDP, and dGTP but not GMP, ATP, CTP, and UTP compete for GTP binding.", "general_function": "Gtp binding", "gene_names": ["der"], "name": "GTPase Der", "drug_actions": []}, "Q9WZC2": {"specific_function": "Catalyzes the irreversible transfer of a propylamine group from the amino donor S-adenosylmethioninamine (decarboxy-AdoMet) to putrescine (1,4-diaminobutane) to yield spermidine. It has lower affinity and lower activity towards 1,3-diaminopropane, cadaverine (1,5-diaminopentane), agmatine, norspermidine and spermidine (in vitro).", "general_function": "Thermospermine synthase activity", "gene_names": ["speE"], "name": "Polyamine aminopropyltransferase", "drug_actions": []}, "Q9H1R3": {"specific_function": "Implicated in the level of global muscle contraction and cardiac function. Phosphorylates a specific serine in the N-terminus of a myosin light chain.", "general_function": "Myosin light chain kinase activity", "gene_names": ["MYLK2"], "name": "Myosin light chain kinase 2, skeletal/cardiac muscle", "drug_actions": []}, "Q99542": {"specific_function": "Endopeptidase that degrades various components of the extracellular matrix, such as aggrecan and cartilage oligomeric matrix protein (comp), during development, haemostasis and pathological conditions (arthritic disease). May also play a role in neovascularization or angiogenesis. Hydrolyzes collagen type IV, laminin, nidogen, nascin-C isoform, fibronectin, and type I gelatin.", "general_function": "Zinc ion binding", "gene_names": ["MMP19"], "name": "Matrix metalloproteinase-19", "drug_actions": [{"action": "INHIBITOR", "target": "Q99542", "drug": "DB00786"}]}, "P0A3S0": {"specific_function": "NCS has antibiotic activity (for Gram-positive bacteria) and antitumor activity (for certain mouse tumors). NCS binds non-covalently to a chromophore which is the cytotoxic and mutagenic component of the antibiotic. The chromophore binds to DNA as a weak intercalator and causes single- and double-strand breaks.", "general_function": "Dna binding", "gene_names": ["ncsA"], "name": "Neocarzinostatin", "drug_actions": []}, "Q9HD40": {"specific_function": "Converts O-phosphoseryl-tRNA(Sec) to selenocysteinyl-tRNA(Sec) required for selenoprotein biosynthesis.", "general_function": "Trna binding", "gene_names": ["SEPSECS"], "name": "O-phosphoseryl-tRNA(Sec) selenium transferase", "drug_actions": [{"action": "COFACTOR", "target": "Q9HD40", "drug": "DB00114"}]}, "P01138": {"specific_function": "Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems. Extracellular ligand for the NTRK1 and NGFR receptors, activates cellular signaling cascades through those receptor tyrosine kinase to regulate neuronal proliferation, differentiation and survival. Inhibits metalloproteinase dependent proteolysis of platelet glycoprotein VI (PubMed:20164177).", "general_function": "Receptor signaling protein activity", "gene_names": ["NGF"], "name": "Beta-nerve growth factor", "drug_actions": [{"action": "STIMULATOR", "target": "P01138", "drug": "DB01407"}]}, "Q8ZKF6": {"specific_function": "Catalyzes the conversion of acetate into acetyl-CoA (AcCoA), an essential intermediate at the junction of anabolic and catabolic pathways. Acs undergoes a two-step reaction. In the first half reaction, Acs combines acetate with ATP to form acetyl-adenylate (AcAMP) intermediate. In the second half reaction, it can then transfer the acetyl group from AcAMP to the sulfhydryl group of CoA, forming the product AcCoA.Enables the cell to use acetate during aerobic growth to generate energy via the TCA cycle, and biosynthetic compounds via the glyoxylate shunt. Acetylates CheY, the response regulator involved in flagellar movement and chemotaxis.", "general_function": "Metal ion binding", "gene_names": ["acs"], "name": "Acetyl-coenzyme A synthetase", "drug_actions": []}, "O60911": {"specific_function": "Cysteine protease. May have an important role in corneal physiology.", "general_function": "Peptide binding", "gene_names": ["CTSV"], "name": "Cathepsin L2", "drug_actions": []}, "O67636": {"general_function": "Prephenate dehydrogenase activity", "gene_names": ["tyrA"], "name": "Prephenate dehydrogenase", "drug_actions": []}, "Q8NI22": {"specific_function": "The MCFD2-LMAN1 complex forms a specific cargo receptor for the ER-to-Golgi transport of selected proteins. Plays a role in the secretion of coagulation factors.", "general_function": "Calcium ion binding", "gene_names": ["MCFD2"], "name": "Multiple coagulation factor deficiency protein 2", "drug_actions": [{"action": "MODULATOR", "target": "Q8NI22", "drug": "DB00025"}]}, "P07858": {"specific_function": "Thiol protease which is believed to participate in intracellular degradation and turnover of proteins. Has also been implicated in tumor invasion and metastasis.", "general_function": "Proteoglycan binding", "gene_names": ["CTSB"], "name": "Cathepsin B", "drug_actions": []}, "Q13526": {"specific_function": "Peptidyl-prolyl cis/trans isomerase (PPIase) that binds to and isomerizes specific phosphorylated Ser/Thr-Pro (pSer/Thr-Pro) motifs in a subset of proteins, resulting in conformational changes in the proteins (PubMed:21497122, PubMed:22033920). Displays a preference for an acidic residue N-terminal to the isomerized proline bond. Regulates mitosis presumably by interacting with NIMA and attenuating its mitosis-promoting activity. Down-regulates kinase activity of BTK (PubMed:16644721). Can transactivate multiple oncogenes and induce centrosome amplification, chromosome instability and cell transformation. Required for the efficient dephosphorylation and recycling of RAF1 after mitogen activation (PubMed:15664191). Binds and targets PML and BCL6 for degradation in a phosphorylation-dependent manner (PubMed:17828269). Acts as a regulator of JNK cascade by binding to phosphorylated FBXW7, disrupting FBXW7 dimerization and promoting FBXW7 autoubiquitination and degradation: degradation of FBXW7 leads to subsequent stabilization of JUN (PubMed:22608923).", "general_function": "Phosphothreonine binding", "gene_names": ["PIN1"], "name": "Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1", "drug_actions": []}, "P07024": {"specific_function": "Degradation of external UDP-glucose to uridine monophosphate and glucose-1-phosphate, which can then be used by the cell.", "general_function": "Udp-sugar diphosphatase activity", "gene_names": ["ushA"], "name": "Protein UshA", "drug_actions": []}, "O14732": {"specific_function": "Can use myo-inositol monophosphates, scylloinositol 1,4-diphosphate, glucose-1-phosphate, beta-glycerophosphate, and 2'-AMP as substrates. Has been implicated as the pharmacological target for lithium Li(+) action in brain.", "general_function": "Protein homodimerization activity", "gene_names": ["IMPA2"], "name": "Inositol monophosphatase 2", "drug_actions": [{"action": "INHIBITOR", "target": "O14732", "drug": "DB01356"}]}, "P07026": {"specific_function": "Activates cell division by specifically increasing transcription from one of the two promoters that lie immediately upstream of the ftsQAZ gene cluster. Activates ydiV expression in response to extracellular autoinducer AI-1 (Vibrio fischeri autoinducer oxoC6).", "general_function": "Dna binding", "gene_names": ["sdiA"], "name": "Regulatory protein SdiA", "drug_actions": []}, "Q9NZD2": {"specific_function": "Accelerates the intermembrane transfer of various glycolipids. Catalyzes the transfer of various glycosphingolipids between membranes but does not catalyze the transfer of phospholipids. May be involved in the intracellular translocation of glucosylceramides.", "general_function": "Lipid binding", "gene_names": ["GLTP"], "name": "Glycolipid transfer protein", "drug_actions": []}, "Q9X1H9": {"specific_function": "Binds long-chain fatty acids, such as palmitate, and may play a role in lipid transport or fatty acid metabolism.", "general_function": "Lipid binding", "gene_names": [], "name": "Fatty acid-binding protein TM_1468", "drug_actions": []}, "Q9UBS5": {"specific_function": "Component of a heterodimeric G-protein coupled receptor for GABA, formed by GABBR1 and GABBR2. Within the heterodimeric GABA receptor, only GABBR1 seems to bind agonists, while GABBR2 mediates coupling to G proteins. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase, stimulates phospholipase A2, activates potassium channels, inactivates voltage-dependent calcium-channels and modulates inositol phospholipid hydrolysis. Calcium is required for high affinity binding to GABA. Plays a critical role in the fine-tuning of inhibitory synaptic transmission. Pre-synaptic GABA receptor inhibits neurotransmitter release by down-regulating high-voltage activated calcium channels, whereas postsynaptic GABA receptor decreases neuronal excitability by activating a prominent inwardly rectifying potassium (Kir) conductance that underlies the late inhibitory postsynaptic potentials. Not only implicated in synaptic inhibition but also in hippocampal long-term potentiation, slow wave sleep, muscle relaxation and antinociception. Activated by (-)-baclofen, cgp27492 and blocked by phaclofen.Isoform 1E may regulate the formation of functional GABBR1/GABBR2 heterodimers by competing for GABBR2 binding. This could explain the observation that certain small molecule ligands exhibit differential affinity for central versus peripheral sites.", "general_function": "G-protein coupled gaba receptor activity", "gene_names": ["GABBR1"], "name": "Gamma-aminobutyric acid type B receptor subunit 1", "drug_actions": [{"action": "AGONIST", "target": "Q9UBS5", "drug": "DB00181"}, {"action": "AGONIST", "target": "Q9UBS5", "drug": "DB00837"}, {"action": "AGONIST", "target": "Q9UBS5", "drug": "DB01080"}, {"action": "AGONIST", "target": "Q9UBS5", "drug": "DB08891"}, {"action": "AGONIST", "target": "Q9UBS5", "drug": "DB08892"}]}, "Q9RW27": {"general_function": "Oxidoreductase activity", "gene_names": [], "name": "NimA-related protein", "drug_actions": []}, "P48735": {"specific_function": "Plays a role in intermediary metabolism and energy production. It may tightly associate or interact with the pyruvate dehydrogenase complex.", "general_function": "Nad binding", "gene_names": ["IDH2"], "name": "Isocitrate dehydrogenase [NADP], mitochondrial", "drug_actions": []}, "P48736": {"specific_function": "Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Links G-protein coupled receptor activation to PIP3 production. Involved in immune, inflammatory and allergic responses. Modulates leukocyte chemotaxis to inflammatory sites and in response to chemoattractant agents. May control leukocyte polarization and migration by regulating the spatial accumulation of PIP3 and by regulating the organization of F-actin formation and integrin-based adhesion at the leading edge. Controls motility of dendritic cells. Together with PIK3CD is involved in natural killer (NK) cell development and migration towards the sites of inflammation. Participates in T-lymphocyte migration. Regulates T-lymphocyte proliferation and cytokine production. Together with PIK3CD participates in T-lymphocyte development. Required for B-lymphocyte development and signaling. Together with PIK3CD participates in neutrophil respiratory burst. Together with PIK3CD is involved in neutrophil chemotaxis and extravasation. Together with PIK3CB promotes platelet aggregation and thrombosis. Regulates alpha-IIb/beta-3 integrins (ITGA2B/ ITGB3) adhesive function in platelets downstream of P2Y12 through a lipid kinase activity-independent mechanism. May have also a lipid kinase activity-dependent function in platelet aggregation. Involved in endothelial progenitor cell migration. Negative regulator of cardiac contractility. Modulates cardiac contractility by anchoring protein kinase A (PKA) and PDE3B activation, reducing cAMP levels. Regulates cardiac contractility also by promoting beta-adrenergic receptor internalization by binding to ADRBK1 and by non-muscle tropomyosin phosphorylation. Also has serine/threonine protein kinase activity: both lipid and protein kinase activities are required for beta-adrenergic receptor endocytosis. May also have a scaffolding role in modulating cardiac contractility. Contributes to cardiac hypertrophy under pathological stress. Through simultaneous binding of PDE3B to RAPGEF3 and PIK3R6 is assembled in a signaling complex in which the PI3K gamma complex is activated by RAPGEF3 and which is involved in angiogenesis.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["PIK3CG"], "name": "Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform", "drug_actions": []}, "P16233": {"general_function": "Triglyceride lipase activity", "gene_names": ["PNLIP"], "name": "Pancreatic triacylglycerol lipase", "drug_actions": [{"action": "INHIBITOR", "target": "P16233", "drug": "DB01083"}]}, "P16234": {"specific_function": "Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor.", "general_function": "Vascular endothelial growth factor-activated receptor activity", "gene_names": ["PDGFRA"], "name": "Platelet-derived growth factor receptor alpha", "drug_actions": [{"action": "ANTAGONIST", "target": "P16234", "drug": "DB00619"}, {"action": "ANTAGONIST", "target": "P16234", "drug": "DB01268"}, {"action": "INHIBITOR", "target": "P16234", "drug": "DB06589"}, {"action": "INHIBITOR", "target": "P16234", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P16234", "drug": "DB08901"}]}, "P0A9B2": {"specific_function": "Catalyzes the oxidative phosphorylation of glyceraldehyde 3-phosphate (G3P) to 1,3-bisphosphoglycerate (BPG) using the cofactor NAD. The first reaction step involves the formation of a hemiacetal intermediate between G3P and a cysteine residue, and this hemiacetal intermediate is then oxidized to a thioester, with concomitant reduction of NAD to NADH. The reduced NADH is then exchanged with the second NAD, and the thioester is attacked by a nucleophilic inorganic phosphate to produce BPG.", "general_function": "Nadp binding", "gene_names": ["gapA"], "name": "Glyceraldehyde-3-phosphate dehydrogenase A", "drug_actions": []}, "P09884": {"specific_function": "Plays an essential role in the initiation of DNA replication. During the S phase of the cell cycle, the DNA polymerase alpha complex (composed of a catalytic subunit POLA1/p180, a regulatory subunit POLA2/p70 and two primase subunits PRIM1/p49 and PRIM2/p58) is recruited to DNA at the replicative forks via direct interactions with MCM10 and WDHD1. The primase subunit of the polymerase alpha complex initiates DNA synthesis by oligomerising short RNA primers on both leading and lagging strands. These primers are initially extended by the polymerase alpha catalytic subunit and subsequently transferred to polymerase delta and polymerase epsilon for processive synthesis on the lagging and leading strand, respectively. The reason this transfer occurs is because the polymerase alpha has limited processivity and lacks intrinsic 3' exonuclease activity for proofreading error, and therefore is not well suited for replicating long complexes.", "general_function": "Protein kinase binding", "gene_names": ["POLA1"], "name": "DNA polymerase alpha catalytic subunit", "drug_actions": [{"action": "INHIBITOR", "target": "P09884", "drug": "DB00242"}, {"action": "INHIBITOR", "target": "P09884", "drug": "DB00631"}, {"action": "INHIBITOR", "target": "P09884", "drug": "DB01073"}, {"action": "INHIBITOR", "target": "P09884", "drug": "DB01280"}]}, "Q16772": {"specific_function": "Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Catalyzes isomerization reactions that contribute to the biosynthesis of steroid hormones. Efficiently catalyze obligatory double-bond isomerizations of delta(5)-androstene-3,17-dione and delta(5)-pregnene-3,20-dione, precursors to testosterone and progesterone, respectively.", "general_function": "Glutathione transferase activity", "gene_names": ["GSTA3"], "name": "Glutathione S-transferase A3", "drug_actions": []}, "Q16773": {"specific_function": "Catalyzes the irreversible transamination of the L-tryptophan metabolite L-kynurenine to form kynurenic acid (KA). Metabolizes the cysteine conjugates of certain halogenated alkenes and alkanes to form reactive metabolites. Catalyzes the beta-elimination of S-conjugates and Se-conjugates of L-(seleno)cysteine, resulting in the cleavage of the C-S or C-Se bond.", "general_function": "Transaminase activity", "gene_names": ["CCBL1"], "name": "Kynurenine--oxoglutarate transaminase 1", "drug_actions": [{"action": "COFACTOR", "target": "Q16773", "drug": "DB00114"}]}, "Q16774": {"specific_function": "Essential for recycling GMP and indirectly, cGMP.", "general_function": "Guanylate kinase activity", "gene_names": ["GUK1"], "name": "Guanylate kinase", "drug_actions": []}, "Q16775": {"specific_function": "Thiolesterase that catalyzes the hydrolysis of S-D-lactoyl-glutathione to form glutathione and D-lactic acid.", "general_function": "Metal ion binding", "gene_names": ["HAGH"], "name": "Hydroxyacylglutathione hydrolase, mitochondrial", "drug_actions": []}, "P40394": {"specific_function": "Could function in retinol oxidation for the synthesis of retinoic acid, a hormone important for cellular differentiation. Medium-chain (octanol) and aromatic (m-nitrobenzaldehyde) compounds are the best substrates. Ethanol is not a good substrate but at the high ethanol concentrations reached in the digestive tract, it plays a role in the ethanol oxidation and contributes to the first pass ethanol metabolism.", "general_function": "Zinc ion binding", "gene_names": ["ADH7"], "name": "Alcohol dehydrogenase class 4 mu/sigma chain", "drug_actions": []}, "P01130": {"specific_function": "Binds LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits.(Microbial infection) Acts as a receptor for hepatitis C virus in hepatocytes, but not through a direct interaction with viral proteins (PubMed:10535997, PubMed:12615904). Acts as a receptor for vesicular stomatitis virus (PubMed:23589850). In case of HIV-1 infection, may function as a receptor for extracellular Tat in neurons, mediating its internalization in uninfected cells (PubMed:11100124).", "general_function": "Virus receptor activity", "gene_names": ["LDLR"], "name": "Low-density lipoprotein receptor", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "P01130", "drug": "DB00707"}]}, "P61586": {"specific_function": "Regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibers. Involved in a microtubule-dependent signal that is required for the myosin contractile ring formation during cell cycle cytokinesis. Plays an essential role in cleavage furrow formation. Required for the apical junction formation of keratinocyte cell-cell adhesion. Stimulates PKN2 kinase activity. May be an activator of PLCE1. Activated by ARHGEF2, which promotes the exchange of GDP for GTP. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. The MEMO1-RHOA-DIAPH1 signaling pathway plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It controls the localization of APC and CLASP2 to the cell membrane, via the regulation of GSK3B activity. In turn, membrane-bound APC allows the localization of the MACF1 to the cell membrane, which is required for microtubule capture and stabilization. Regulates a signal transduction pathway linking plasma membrane receptors to the assembly of focal adhesions and actin stress fibers. Involved in a microtubule-dependent signal that is required for the myosin contractile ring formation during cell cycle cytokinesis. Plays an essential role in cleavage furrow formation. Required for the apical junction formation of keratinocyte cell-cell adhesion. May be an activator of PLCE1. Activated by ARHGEF2, which promotes the exchange of GDP for GTP. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. The MEMO1-RHOA-DIAPH1 signaling pathway plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It controls the localization of APC and CLASP2 to the cell membrane, via the regulation of GSK3B activity. In turn, membrane-bound APC allows the localization of the MACF1 to the cell membrane, which is required for microtubule capture and stabilization (By similarity). Regulates KCNA2 potassium channel activity by reducing its location at the cell surface in response to CHRM1 activation; promotes KCNA2 endocytosis (PubMed:9635436, PubMed:19403695).(Microbial infection) Serves as a target for the yopT cysteine peptidase from Yersinia pestis, vector of the plague, and Yersinia pseudotuberculosis, which causes gastrointestinal disorders.", "general_function": "Myosin binding", "gene_names": ["RHOA"], "name": "Transforming protein RhoA", "drug_actions": []}, "Q72LA6": {"gene_names": [], "name": "Hypothetical membrane spanning protein", "drug_actions": []}, "P08637": {"specific_function": "Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.", "gene_names": ["FCGR3A"], "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "drug_actions": [{"action": "ANTAGONIST", "target": "P08637", "drug": "DB00028"}]}, "Q9CBQ2": {"specific_function": "Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides (By similarity).", "general_function": "Ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor", "gene_names": ["nrdF"], "name": "Ribonucleoside-diphosphate reductase subunit beta", "drug_actions": []}, "P0C0X8": {"specific_function": "Cytochrome c2 is found mainly in purple, non-sulfur, photosynthetic bacteria where it functions as the electron donor to the oxidized bacteriochlorophyll in the photophosphorylation pathway. However, it may also have a role in the respiratory chain and is found in some non-photosynthetic bacteria.", "general_function": "Metal ion binding", "gene_names": ["cycA"], "name": "Cytochrome c2", "drug_actions": []}, "O66529": {"specific_function": "Catalyzes the formation of 6,7-dimethyl-8-ribityllumazine by condensation of 5-amino-6-(D-ribitylamino)uracil with 3,4-dihydroxy-2-butanone 4-phosphate. This is the penultimate step in the biosynthesis of riboflavin.", "general_function": "Transferase activity", "gene_names": ["ribH"], "name": "6,7-dimethyl-8-ribityllumazine synthase", "drug_actions": []}, "P53674": {"specific_function": "Crystallins are the dominant structural components of the vertebrate eye lens.", "general_function": "Structural constituent of eye lens", "gene_names": ["CRYBB1"], "name": "Beta-crystallin B1", "drug_actions": []}, "P10768": {"specific_function": "Serine hydrolase involved in the detoxification of formaldehyde.", "general_function": "S-formylglutathione hydrolase activity", "gene_names": ["ESD"], "name": "S-formylglutathione hydrolase", "drug_actions": []}, "P0A5H3": {"specific_function": "Isocitrate = succinate + glyoxylate", "general_function": "Energy production and conversion", "gene_names": ["icl"], "name": "Isocitrate lyase", "drug_actions": []}, "P80357": {"specific_function": "Catalyzes the transfer of succinyl-CoA to arginine to produce N(2)-succinylarginine. Also acts on L-ornithine.", "general_function": "Arginine n-succinyltransferase activity", "gene_names": ["astA"], "name": "Arginine N-succinyltransferase subunit alpha", "drug_actions": []}, "Q13946": {"specific_function": "Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May have a role in muscle signal transduction.", "name": "High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "Q13946", "drug": "DB00201"}, {"action": "INHIBITOR", "target": "Q13946", "drug": "DB00651"}, {"action": "INHIBITOR", "target": "Q13946", "drug": "DB00920"}], "general_function": "Metal ion binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE7A"]}, "P77541": {"specific_function": "Involved in the catabolism of short chain fatty acids (SCFA) via the 2-methylcitrate cycle I (propionate degradation route). Catalyzes the thermodynamically favored C-C bond cleavage of (2R,3S)-2-methylisocitrate to yield pyruvate and succinate via an alpha-carboxy-carbanion intermediate.", "general_function": "Transferase activity, transferring acyl groups, acyl groups converted into alkyl on transfer", "gene_names": ["prpB"], "name": "2-methylisocitrate lyase", "drug_actions": []}, "P84098": {"general_function": "Structural constituent of ribosome", "gene_names": ["RPL19"], "name": "60S ribosomal protein L19", "drug_actions": []}, "Q6IA69": {"general_function": "Nad+ synthase (glutamine-hydrolyzing) activity", "gene_names": ["NADSYN1"], "name": "Glutamine-dependent NAD(+) synthetase", "drug_actions": []}, "P60757": {"specific_function": "Catalyzes the condensation of ATP and 5-phosphoribose 1-diphosphate to form N'-(5'-phosphoribosyl)-ATP (PR-ATP). Has a crucial role in the pathway because the rate of histidine biosynthesis seems to be controlled primarily by regulation of HisG enzymatic activity.", "general_function": "Magnesium ion binding", "gene_names": ["hisG"], "name": "ATP phosphoribosyltransferase", "drug_actions": []}, "P48651": {"specific_function": "Catalyzes a base-exchange reaction in which the polar head group of phosphatidylethanolamine (PE) or phosphatidylcholine (PC) is replaced by L-serine. In membranes, PTDSS1 catalyzes mainly the conversion of phosphatidylcholine. Also converts, in vitro and to a lesser extent, phosphatidylethanolamine.", "general_function": "Transferase activity", "gene_names": ["PTDSS1"], "name": "Phosphatidylserine synthase 1", "drug_actions": []}, "Q9UJM8": {"specific_function": "Has 2-hydroxyacid oxidase activity. Most active on the 2-carbon substrate glycolate, but is also active on 2-hydroxy fatty acids, with high activity towards 2-hydroxy palmitate and 2-hydroxy octanoate.", "general_function": "Very-long-chain-(s)-2-hydroxy-acid oxidase activity", "gene_names": ["HAO1"], "name": "Hydroxyacid oxidase 1", "drug_actions": []}, "P43026": {"specific_function": "Growth factor involved in bone and cartilage formation. During cartilage development regulates differentiation of chondrogenic tissue through two pathways. Firstly, positively regulates differentiation of chondrogenic tissue through its binding of high affinity with BMPR1B and of less affinity with BMPR1A, leading to induction of SMAD1-SMAD5-SMAD8 complex phosphorylation and then SMAD protein signaling transduction (PubMed:24098149, PubMed:21976273, PubMed:15530414, PubMed:25092592). Secondly, negatively regulates chondrogenic differentiation through its interaction with NOG (PubMed:21976273). Required to prevent excessive muscle loss upon denervation. This function requires SMAD4 and is mediated by phosphorylated SMAD1/5/8 (By similarity). Binds bacterial lipopolysaccharide (LPS) and mediates LPS-induced inflammatory response, including TNF secretion by monocytes (PubMed:11276205).", "general_function": "Transforming growth factor beta receptor binding", "gene_names": ["GDF5"], "name": "Growth/differentiation factor 5", "drug_actions": []}, "P53778": {"specific_function": "Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK12 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors such as ELK1 and ATF2. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. Some of the targets are downstream kinases such as MAPKAPK2, which are activated through phosphorylation and further phosphorylate additional targets. Plays a role in myoblast differentiation and also in the down-regulation of cyclin D1 in response to hypoxia in adrenal cells suggesting MAPK12 may inhibit cell proliferation while promoting differentiation. Phosphorylates DLG1. Following osmotic shock, MAPK12 in the cell nucleus increases its association with nuclear DLG1, thereby causing dissociation of DLG1-SFPQ complexes. This function is independent of its catalytic activity and could affect mRNA processing and/or gene transcription to aid cell adaptation to osmolarity changes in the environment. Regulates UV-induced checkpoint signaling and repair of UV-induced DNA damage and G2 arrest after gamma-radiation exposure. MAPK12 is involved in the regulation of SLC2A1 expression and basal glucose uptake in L6 myotubes; and negatively regulates SLC2A4 expression and contraction-mediated glucose uptake in adult skeletal muscle. C-Jun (JUN) phosphorylation is stimulated by MAPK14 and inhibited by MAPK12, leading to a distinct AP-1 regulation. MAPK12 is required for the normal kinetochore localization of PLK1, prevents chromosomal instability and supports mitotic cell viability. MAPK12-signaling is also positively regulating the expansion of transient amplifying myogenic precursor cells during muscle growth and regeneration.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["MAPK12"], "name": "Mitogen-activated protein kinase 12", "drug_actions": []}, "P13299": {"specific_function": "This endonuclease is specific to the thymidylate synthase (td) gene splice junction and is involved in intron homing.", "general_function": "Endonuclease activity", "gene_names": ["ITEVIR"], "name": "Intron-associated endonuclease 1", "drug_actions": []}, "P51788": {"specific_function": "Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport.", "general_function": "Voltage-gated chloride channel activity", "gene_names": ["CLCN2"], "name": "Chloride channel protein 2", "drug_actions": [{"action": "INDUCER", "target": "P51788", "drug": "DB01046"}]}, "Q9ULA0": {"specific_function": "Aminopeptidase with specificity towards an acidic amino acid at the N-terminus. Likely to play an important role in intracellular protein and peptide metabolism.", "general_function": "Zinc ion binding", "gene_names": ["DNPEP"], "name": "Aspartyl aminopeptidase", "drug_actions": []}, "Q06187": {"specific_function": "Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. After BCR engagement and activation at the plasma membrane, phosphorylates PLCG2 at several sites, igniting the downstream signaling pathway through calcium mobilization, followed by activation of the protein kinase C (PKC) family members. PLCG2 phosphorylation is performed in close cooperation with the adapter protein B-cell linker protein BLNK. BTK acts as a platform to bring together a diverse array of signaling proteins and is implicated in cytokine receptor signaling pathways. Plays an important role in the function of immune cells of innate as well as adaptive immunity, as a component of the Toll-like receptors (TLR) pathway. The TLR pathway acts as a primary surveillance system for the detection of pathogens and are crucial to the activation of host defense. Especially, is a critical molecule in regulating TLR9 activation in splenic B-cells. Within the TLR pathway, induces tyrosine phosphorylation of TIRAP which leads to TIRAP degradation. BTK plays also a critical role in transcription regulation. Induces the activity of NF-kappa-B, which is involved in regulating the expression of hundreds of genes. BTK is involved on the signaling pathway linking TLR8 and TLR9 to NF-kappa-B. Transiently phosphorylates transcription factor GTF2I on tyrosine residues in response to BCR. GTF2I then translocates to the nucleus to bind regulatory enhancer elements to modulate gene expression. ARID3A and NFAT are other transcriptional target of BTK. BTK is required for the formation of functional ARID3A DNA-binding complexes. There is however no evidence that BTK itself binds directly to DNA. BTK has a dual role in the regulation of apoptosis.", "general_function": "Protein tyrosine kinase activity", "gene_names": ["BTK"], "name": "Tyrosine-protein kinase BTK", "drug_actions": [{"action": "INHIBITOR", "target": "Q06187", "drug": "DB09053"}]}, "Q9LCX5": {"general_function": "Dna topoisomerase type ii (atp-hydrolyzing) activity", "gene_names": ["gyrB"], "name": "DNA gyrase subunit B", "drug_actions": []}, "Q13639": {"specific_function": "This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.", "name": "5-hydroxytryptamine receptor 4", "drug_actions": [{"action": "AGONIST", "target": "Q13639", "drug": "DB00604"}, {"action": "AGONIST", "target": "Q13639", "drug": "DB00904"}, {"action": "ANTAGONIST", "target": "Q13639", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "Q13639", "drug": "DB01079"}, {"action": "PARTIAL AGONIST", "target": "Q13639", "drug": "DB01079"}, {"action": "AGONIST", "target": "Q13639", "drug": "DB01233"}, {"action": "AGONIST", "target": "Q13639", "drug": "DB06480"}, {"action": "AGONIST", "target": "Q13639", "drug": "DB08810"}], "general_function": "Serotonin receptor activity", "in_complexes": ["Serotonin Receptors"], "gene_names": ["HTR4"]}, "P17297": {"general_function": "Ferrous iron binding", "gene_names": ["bphC"], "name": "Biphenyl-2,3-diol 1,2-dioxygenase", "drug_actions": []}, "Q9LCX9": {"general_function": "Transferase activity, transferring acyl groups, acyl groups converted into alkyl on transfer", "gene_names": ["cit"], "name": "Citrate synthase", "drug_actions": []}, "P51787": {"specific_function": "Potassium channel that plays an important role in a number of tissues, including heart, inner ear, stomach and colon (By similarity) (PubMed:10646604). Associates with KCNE beta subunits that modulates current kinetics (By similarity) (PubMed:9312006, PubMed:9108097, PubMed:8900283, PubMed:10646604, PubMed:11101505, PubMed:19687231). Induces a voltage-dependent by rapidly activating and slowly deactivating potassium-selective outward current (By similarity) (PubMed:9312006, PubMed:9108097, PubMed:8900283, PubMed:10646604, PubMed:11101505). Promotes also a delayed voltage activated potassium current showing outward rectification characteristic (By similarity). During beta-adrenergic receptor stimulation participates in cardiac repolarization by associating with KCNE1 to form the I(Ks) cardiac potassium current that increases the amplitude and slows down the activation kinetics of outward potassium current I(Ks) (By similarity) (PubMed:9312006, PubMed:9108097, PubMed:8900283, PubMed:10646604, PubMed:11101505). Muscarinic agonist oxotremorine-M strongly suppresses KCNQ1/KCNE1 current (PubMed:10713961). When associated with KCNE3, forms the potassium channel that is important for cyclic AMP-stimulated intestinal secretion of chloride ions (PubMed:10646604). This interaction with KCNE3 is reduced by 17beta-estradiol, resulting in the reduction of currents (By similarity). During conditions of increased substrate load, maintains the driving force for proximal tubular and intestinal sodium ions absorption, gastric acid secretion, and cAMP-induced jejunal chloride ions secretion (By similarity). Allows the provision of potassium ions to the luminal membrane of the secretory canaliculus in the resting state as well as during stimulated acid secretion (By similarity). When associated with KCNE2, forms an heterooligomer complex leading to currents with an apparently instantaneous activation, a rapid deactivation process and a linear current-voltage relationship and decreases the amplitude of the outward current (PubMed:11101505). When associated with KCNE4, inhibits voltage-gated potassium channel activity (PubMed:19687231). When associated with KCNE5, this complex only conducts current upon strong and continued depolarization (PubMed:12324418). Also forms an heterotetramer with KCNQ5; has a voltage-gated potassium channel activity (PubMed:24855057). Binds with phosphatidylinositol 4,5-bisphosphate (PubMed:25037568).Isoform 2: Non-functional alone but modulatory when coexpressed with the full-length isoform 1.", "general_function": "Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization", "gene_names": ["KCNQ1"], "name": "Potassium voltage-gated channel subfamily KQT member 1", "drug_actions": [{"action": "INHIBITOR", "target": "P51787", "drug": "DB00808"}, {"action": "INHIBITOR", "target": "P51787", "drug": "DB01244"}]}, "Q13630": {"specific_function": "Catalyzes the two-step NADP-dependent conversion of GDP-4-dehydro-6-deoxy-D-mannose to GDP-fucose, involving an epimerase and a reductase reaction.", "general_function": "Isomerase activity", "gene_names": ["TSTA3"], "name": "GDP-L-fucose synthase", "drug_actions": []}, "P15336": {"specific_function": "Transcriptional activator which regulates the transcription of various genes, including those involved in anti-apoptosis, cell growth, and DNA damage response. Dependent on its binding partner, binds to CRE (cAMP response element) consensus sequences (5'-TGACGTCA-3') or to AP-1 (activator protein 1) consensus sequences (5'-TGACTCA-3'). In the nucleus, contributes to global transcription and the DNA damage response, in addition to specific transcriptional activities that are related to cell development, proliferation and death. In the cytoplasm, interacts with and perturbs HK1- and VDAC1-containing complexes at the mitochondrial outer membrane, thereby impairing mitochondrial membrane potential, inducing mitochondrial leakage and promoting cell death. The phosphorylated form (mediated by ATM) plays a role in the DNA damage response and is involved in the ionizing radiation (IR)-induced S phase checkpoint control and in the recruitment of the MRN complex into the IR-induced foci (IRIF). Exhibits histone acetyltransferase (HAT) activity which specifically acetylates histones H2B and H4 in vitro. In concert with CUL3 and RBX1, promotes the degradation of KAT5 thereby attenuating its ability to acetylate and activate ATM. Can elicit oncogenic or tumor suppressor activities depending on the tissue or cell type.", "name": "Cyclic AMP-dependent transcription factor ATF-2", "drug_actions": [], "general_function": "Transcriptional activator activity, rna polymerase ii transcription regulatory region sequence-specific binding", "in_complexes": ["activator protein 1"], "gene_names": ["ATF2"]}, "P11233": {"specific_function": "Multifunctional GTPase involved in a variety of cellular processes including gene expression, cell migration, cell proliferation, oncogenic transformation and membrane trafficking. Accomplishes its multiple functions by interacting with distinct downstream effectors. Acts as a GTP sensor for GTP-dependent exocytosis of dense core vesicles. Plays a role in the early stages of cytokinesis and is required to tether the exocyst to the cytokinetic furrow. The RALA-exocyst complex regulates integrin-dependent membrane raft exocytosis and growth signaling. Key regulator of LPAR1 signaling and competes with ADRBK1 for binding to LPAR1 thus affecting the signaling properties of the receptor. Required for anchorage-independent proliferation of transformed cells.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["RALA"], "name": "Ras-related protein Ral-A", "drug_actions": []}, "P05327": {"specific_function": "Involved in repair of UV radiation-induced DNA damage. Catalyzes the light-dependent monomerization (300-600 nm) of cyclobutyl pyrimidine dimers (in cis-syn configuration), which are formed between adjacent bases on the same DNA strand upon exposure to ultraviolet radiation.", "general_function": "Nucleotide binding", "gene_names": ["phr"], "name": "Deoxyribodipyrimidine photo-lyase", "drug_actions": []}, "P0A6H7": {"specific_function": "ATPase subunit of a proteasome-like degradation complex; this subunit has chaperone activity. The binding of ATP and its subsequent hydrolysis by HslU are essential for unfolding of protein substrates subsequently hydrolyzed by HslV. HslU recognizes the N-terminal part of its protein substrates and unfolds these before they are guided to HslV for hydrolysis.", "general_function": "Peptidase activity, acting on l-amino acid peptides", "gene_names": ["hslU"], "name": "ATP-dependent protease ATPase subunit HslU", "drug_actions": []}, "Q6A8X5": {"general_function": "Oxidoreductase activity", "gene_names": [], "name": "Putative aminooxidase", "drug_actions": []}, "Q1LCS4": {"specific_function": "Catalyzes the oxidative ring opening of 3-hydroxyanthranilate to 2-amino-3-carboxymuconate semialdehyde, which spontaneously cyclizes to quinolinate.", "general_function": "Iron ion binding", "gene_names": ["nbaC"], "name": "3-hydroxyanthranilate 3,4-dioxygenase", "drug_actions": []}, "Q8P8J2": {"specific_function": "Catalyzes the conversion of N-acetylornithine to N-acetylcitrulline in an alternative arginine biosynthesis pathway. The enzyme has no activity with ornithine.", "general_function": "N-acetylornithine carbamoyltransferase activity", "gene_names": ["argF'"], "name": "N-acetylornithine carbamoyltransferase", "drug_actions": []}, "Q3JWH7": {"specific_function": "Catalyzes the interconversion of 2-phosphoglycerate and 3-phosphoglycerate.", "general_function": "2,3-bisphosphoglycerate-dependent phosphoglycerate mutase activity", "gene_names": ["gpmA"], "name": "2,3-bisphosphoglycerate-dependent phosphoglycerate mutase", "drug_actions": []}, "O00483": {"specific_function": "Cytochrome c oxidase (COX, complex IV) is the terminal component of the mitochondrial respiratory chain that catalyzes the reduction of oxygen to water. Required for complex IV maintenance.", "general_function": "Protein complex binding", "gene_names": ["NDUFA4"], "name": "Cytochrome c oxidase subunit NDUFA4", "drug_actions": []}, "Q9F0J6": {"specific_function": "Catalyzes the four-electron reduction of one oxygen molecule to two water molecules.", "general_function": "Oxidoreductase activity", "gene_names": ["roo"], "name": "Rubredoxin-oxygen oxidoreductase", "drug_actions": []}, "Q9KIE5": {"general_function": "Flavin adenine dinucleotide binding", "gene_names": ["fkbI"], "name": "FkbI", "drug_actions": []}, "P29803": {"specific_function": "The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links the glycolytic pathway to the tricarboxylic cycle.", "general_function": "Pyruvate dehydrogenase (acetyl-transferring) activity", "gene_names": ["PDHA2"], "name": "Pyruvate dehydrogenase E1 component subunit alpha, testis-specific form, mitochondrial", "drug_actions": []}, "P96945": {"general_function": "Transferase activity, transferring glycosyl groups", "gene_names": ["lgtC"], "name": "Glycosyl transferase", "drug_actions": []}, "Q5SIR5": {"specific_function": "Catalyzes the reversible conversion of ribose-5-phosphate to ribulose 5-phosphate.", "general_function": "Ribose-5-phosphate isomerase activity", "gene_names": ["rpiA"], "name": "Ribose-5-phosphate isomerase A", "drug_actions": []}, "P05141": {"specific_function": "Catalyzes the exchange of cytoplasmic ADP with mitochondrial ATP across the mitochondrial inner membrane. As part of the mitotic spindle-associated MMXD complex it may play a role in chromosome segregation.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["SLC25A5"], "name": "ADP/ATP translocase 2", "drug_actions": [{"action": "INHIBITOR", "target": "P05141", "drug": "DB00720"}]}, "P69488": {"specific_function": "Involved in resistance toward heavy metals.", "general_function": "Metal ion binding", "gene_names": ["cutA"], "name": "Divalent-cation tolerance protein CutA", "drug_actions": []}, "P52895": {"specific_function": "Works in concert with the 5-alpha/5-beta-steroid reductases to convert steroid hormones into the 3-alpha/5-alpha and 3-alpha/5-beta-tetrahydrosteroids. Catalyzes the inactivation of the most potent androgen 5-alpha-dihydrotestosterone (5-alpha-DHT) to 5-alpha-androstane-3-alpha,17-beta-diol (3-alpha-diol). Has a high bile-binding ability.", "general_function": "Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity", "gene_names": ["AKR1C2"], "name": "Aldo-keto reductase family 1 member C2", "drug_actions": [{"action": "INDUCER", "target": "P52895", "drug": "DB01586"}]}, "P84141": {"general_function": "Carbon-oxygen lyase activity, acting on polysaccharides", "gene_names": [], "name": "Chondroitinase (Chondroitin lyase)", "drug_actions": []}, "Q8N8R3": {"specific_function": "Transports arginine, lysine, homoarginine, methylarginine and, to a much lesser extent, ornithine and histidine. Does not transport carnitine nor acylcarnitines. Functions by both counter-exchange and uniport mechanisms.", "general_function": "Acyl carnitine transmembrane transporter activity", "gene_names": ["SLC25A29"], "name": "Mitochondrial basic amino acids transporter", "drug_actions": []}, "P95468": {"specific_function": "Shows activities toward both dicarboxylic and aromatic substrates.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["tyrB"], "name": "Aromatic-amino-acid aminotransferase", "drug_actions": []}, "P16640": {"specific_function": "The oxidation of camphor by cytochrome P450-CAM requires the participation of a flavoprotein, putidaredoxin reductase, and an iron-sulfur protein, putidaredoxin, to mediate the transfer of electrons from NADH to P450 for oxygen activation.", "general_function": "Oxidoreductase activity", "gene_names": ["camA"], "name": "Putidaredoxin reductase", "drug_actions": []}, "P47712": {"specific_function": "Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response.", "general_function": "Phospholipase a2 activity", "gene_names": ["PLA2G4A"], "name": "Cytosolic phospholipase A2", "drug_actions": [{"action": "INHIBITOR", "target": "P47712", "drug": "DB00588"}, {"action": "INHIBITOR", "target": "P47712", "drug": "DB01103"}]}, "P08887": {"specific_function": "Part of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal. Signal activation necessitate an association with IL6ST. Activation may lead to the regulation of the immune response, acute-phase reactions and hematopoiesis.Low concentration of a soluble form of IL6 receptor acts as an agonist of IL6 activity.", "general_function": "Protein homodimerization activity", "gene_names": ["IL6R"], "name": "Interleukin-6 receptor subunit alpha", "drug_actions": [{"action": "ANTIBODY", "target": "P08887", "drug": "DB06273"}]}, "P29371": {"specific_function": "This is a receptor for the tachykinin neuropeptide neuromedin-K (neurokinin B). It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: neuromedin-K > substance K > substance P.", "general_function": "Tachykinin receptor activity", "gene_names": ["TACR3"], "name": "Neuromedin-K receptor", "drug_actions": []}, "Q14145": {"specific_function": "Acts as a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1 and targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. Retains NFE2L2/NRF2 and may also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome.", "general_function": "Transcription factor binding", "gene_names": ["KEAP1"], "name": "Kelch-like ECH-associated protein 1", "drug_actions": [{"action": "BINDER", "target": "Q14145", "drug": "DB08908"}]}, "P0AA43": {"specific_function": "Responsible for synthesis of pseudouridine from uracil-516 in 16S ribosomal RNA.", "general_function": "Rna binding", "gene_names": ["rsuA"], "name": "Ribosomal small subunit pseudouridine synthase A", "drug_actions": []}, "P0A6V8": {"specific_function": "Not highly important in E.coli as glucose is transported into the cell by the PTS system already as glucose 6-phosphate.", "general_function": "Glucokinase activity", "gene_names": ["glk"], "name": "Glucokinase", "drug_actions": []}, "P29377": {"general_function": "Vitamin d binding", "gene_names": ["S100G"], "name": "Protein S100-G", "drug_actions": []}, "Q9Y663": {"specific_function": "Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) to catalyze the transfer of a sulfo group to an N-unsubstituted glucosamine linked to a 2-O-sulfo iduronic acid unit on heparan sulfate. Catalyzes the O-sulfation of glucosamine in IdoUA2S-GlcNS and also in IdoUA2S-GlcNH2. The substrate-specific O-sulfation generates an enzyme-modified heparan sulfate which acts as a binding receptor to Herpes simplex virus-1 (HSV-1) and permits its entry. Unlike 3-OST-1, does not convert non-anticoagulant heparan sulfate to anticoagulant heparan sulfate.", "general_function": "Sulfotransferase activity", "gene_names": ["HS3ST3A1"], "name": "Heparan sulfate glucosamine 3-O-sulfotransferase 3A1", "drug_actions": []}, "P0A6V7": {"specific_function": "Catalyzes, although with low efficiency, the sulfur transfer reaction from thiosulfate to cyanide.", "general_function": "Thiosulfate sulfurtransferase activity", "gene_names": ["glpE"], "name": "Thiosulfate sulfurtransferase GlpE", "drug_actions": []}, "P25116": {"specific_function": "High affinity receptor for activated thrombin coupled to G proteins that stimulate phosphoinositide hydrolysis. May play a role in platelets activation and in vascular development.", "general_function": "Thrombin receptor activity", "gene_names": ["F2R"], "name": "Proteinase-activated receptor 1", "drug_actions": [{"action": "CLEAVAGE", "target": "P25116", "drug": "DB00086"}, {"action": "ANTAGONIST", "target": "P25116", "drug": "DB09030"}]}, "Q04830": {"specific_function": "Responsible for initial absorption of the phage to the host bacterium. Degradation of the alpha-2,8-linked polysialic acid K1 capsule.", "general_function": "Endo-alpha-(2,8)-sialidase activity", "gene_names": [], "name": "Endo-N-acetylneuraminidase", "drug_actions": []}, "Q9Y666": {"specific_function": "Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May mediate K(+) uptake into Deiters' cells in the cochlea and contribute to K(+) recycling in the inner ear. Important for the survival of cochlear outer and inner hair cells and the maintenance of the organ of Corti. May be required for basolateral Cl(-) extrusion in the kidney and contribute to renal acidification (By similarity).", "general_function": "Protein kinase binding", "gene_names": ["SLC12A7"], "name": "Solute carrier family 12 member 7", "drug_actions": []}, "Q9KWU1": {"general_function": "Lyase activity", "gene_names": ["aly"], "name": "Alginate lyase", "drug_actions": []}, "P08912": {"specific_function": "The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.", "name": "Muscarinic acetylcholine receptor M5", "drug_actions": [{"action": "ANTAGONIST", "target": "P08912", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00340"}, {"action": "BINDER", "target": "P08912", "drug": "DB00342"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00376"}, {"action": "BINDER", "target": "P08912", "drug": "DB00408"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00420"}, {"action": "BINDER", "target": "P08912", "drug": "DB00454"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00496"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00543"}, {"action": "BINDER", "target": "P08912", "drug": "DB00568"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00572"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00622"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00715"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00725"}, {"action": "BINDER", "target": "P08912", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00747"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00767"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00785"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00835"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB01036"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB01069"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB01151"}, {"action": "BINDER", "target": "P08912", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB01591"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB06702"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB08897"}, {"action": "ANTAGONIST", "target": "P08912", "drug": "DB09076"}], "general_function": "Phosphatidylinositol phospholipase c activity", "in_complexes": ["Muscarinic acetylcholine receptor"], "gene_names": ["CHRM5"]}, "P08913": {"specific_function": "Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.", "name": "Alpha-2A adrenergic receptor", "drug_actions": [{"action": "AGONIST", "target": "P08913", "drug": "DB00182"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00217"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00248"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00268"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00320"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00363"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00368"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00370"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00397"}, {"action": "BINDER", "target": "P08913", "drug": "DB00408"}, {"action": "PARTIAL AGONIST", "target": "P08913", "drug": "DB00413"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00449"}, {"action": "BINDER", "target": "P08913", "drug": "DB00457"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00484"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00543"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00575"}, {"action": "OTHER/UNKNOWN", "target": "P08913", "drug": "DB00589"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00629"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00633"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00656"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00668"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00692"}, {"action": "PARTIAL AGONIST", "target": "P08913", "drug": "DB00696"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00697"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00714"}, {"action": "DESENSITIZE THE TARGET", "target": "P08913", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00734"}, {"action": "UNKNOWN", "target": "P08913", "drug": "DB00751"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00797"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00800"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00852"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00865"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00925"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB00934"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00935"}, {"action": "AGONIST", "target": "P08913", "drug": "DB00964"}, {"action": "AGONIST", "target": "P08913", "drug": "DB01018"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01136"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01149"}, {"action": "BINDER", "target": "P08913", "drug": "DB01151"}, {"action": "AGONIST", "target": "P08913", "drug": "DB01186"}, {"action": "AGONIST", "target": "P08913", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01267"}, {"action": "AGONIST", "target": "P08913", "drug": "DB01363"}, {"action": "AGONIST", "target": "P08913", "drug": "DB01365"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01392"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01403"}, {"action": "AGONIST", "target": "P08913", "drug": "DB01472"}, {"action": "AGONIST", "target": "P08913", "drug": "DB01577"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01608"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB01624"}, {"action": "AGONIST", "target": "P08913", "drug": "DB04948"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB06216"}, {"action": "AGONIST", "target": "P08913", "drug": "DB06262"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB06678"}, {"action": "AGONIST", "target": "P08913", "drug": "DB06694"}, {"action": "AGONIST", "target": "P08913", "drug": "DB06711"}, {"action": "ANTAGONIST", "target": "P08913", "drug": "DB09202"}], "general_function": "Thioesterase binding", "in_complexes": ["Alpha adrenergic receptor", "Alpha-2 adrenergic receptor"], "gene_names": ["ADRA2A"]}, "P31677": {"specific_function": "Catalyzes the transfer of glucose from UDP-glucose to glucose-6-phosphate to form alpha,alpha-1,1 trehalose-6-phosphate. Acts with retention of the anomeric configuration of the UDP-sugar donor. Essential for viability of the cells at low temperatures and at elevated osmotic strength.", "general_function": "Alpha,alpha-trehalose-phosphate synthase (udp-forming) activity", "gene_names": ["otsA"], "name": "Alpha,alpha-trehalose-phosphate synthase [UDP-forming]", "drug_actions": []}, "P0C8P8": {"specific_function": "Has bacteriocidal activity. Inhibits bacterial protein biosynthesis by acting on the elongation factor Tu (EF-Tu) (By similarity).", "gene_names": ["tpdA"], "name": "Thiostrepton", "drug_actions": []}, "P07986": {"specific_function": "Hydrolyzes both cellulose and xylan. Has also weak endoglucanase activity.The biological conversion of cellulose to glucose generally requires three types of hydrolytic enzymes: (1) Endoglucanases which cut internal beta-1,4-glucosidic bonds; (2) Exocellobiohydrolases that cut the dissaccharide cellobiose from the non-reducing end of the cellulose polymer chain; (3) Beta-1,4-glucosidases which hydrolyze the cellobiose and other short cello-oligosaccharides to glucose.", "general_function": "Polysaccharide binding", "gene_names": ["cex"], "name": "Exoglucanase/xylanase", "drug_actions": []}, "P13674": {"specific_function": "Catalyzes the post-translational formation of 4-hydroxyproline in -Xaa-Pro-Gly- sequences in collagens and other proteins.", "general_function": "Procollagen-proline 4-dioxygenase activity", "gene_names": ["P4HA1"], "name": "Prolyl 4-hydroxylase subunit alpha-1", "drug_actions": [{"action": "INHIBITOR", "target": "P13674", "drug": "DB01275"}]}, "Q04230": {"general_function": "Nucleotide binding", "gene_names": ["trwB"], "name": "TrwB", "drug_actions": []}, "P03905": {"specific_function": "Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["MT-ND4"], "name": "NADH-ubiquinone oxidoreductase chain 4", "drug_actions": []}, "Q53908": {"gene_names": ["actVA 6"], "name": "ActVA 6 protein", "drug_actions": []}, "P29972": {"specific_function": "Forms a water-specific channel that provides the plasma membranes of red cells and kidney proximal tubules with high permeability to water, thereby permitting water to move in the direction of an osmotic gradient.", "general_function": "Water transmembrane transporter activity", "gene_names": ["AQP1"], "name": "Aquaporin-1", "drug_actions": [{"action": "INHIBITOR", "target": "P29972", "drug": "DB00819"}]}, "A1A2B5": {"general_function": "Prephenate dehydratase activity", "gene_names": ["pheA"], "name": "Probable chorismate mutase", "drug_actions": []}, "P03901": {"specific_function": "Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["MT-ND4L"], "name": "NADH-ubiquinone oxidoreductase chain 4L", "drug_actions": []}, "Q9Y689": {"specific_function": "Lacks ADP-ribosylation enhancing activity.", "general_function": "Gtp binding", "gene_names": ["ARL5A"], "name": "ADP-ribosylation factor-like protein 5A", "drug_actions": []}, "P02452": {"specific_function": "Type I collagen is a member of group I collagen (fibrillar forming collagen).", "general_function": "Platelet-derived growth factor binding", "gene_names": ["COL1A1"], "name": "Collagen alpha-1(I) chain", "drug_actions": []}, "Q969S8": {"specific_function": "Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes.", "general_function": "Protein deacetylase activity", "gene_names": ["HDAC10"], "name": "Histone deacetylase 10", "drug_actions": [{"action": "INHIBITOR", "target": "Q969S8", "drug": "DB06603"}]}, "P14867": {"specific_function": "Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).", "name": "Gamma-aminobutyric acid receptor subunit alpha-1", "drug_actions": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00228"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00237"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00241"}, {"action": "AGONIST", "target": "P14867", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00273"}, {"action": "AGONIST", "target": "P14867", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00292"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00306"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00349"}, {"action": "AGONIST", "target": "P14867", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00371"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00404"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00418"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00425"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00463"}, {"action": "ANTAGONIST", "target": "P14867", "drug": "DB00466"}, {"action": "ANTAGONIST", "target": "P14867", "drug": "DB00474"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00475"}, {"action": "ANTAGONIST", "target": "P14867", "drug": "DB00543"}, {"action": "BINDER", "target": "P14867", "drug": "DB00543"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00599"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00628"}, {"action": "POSITIVE MODULATOR", "target": "P14867", "drug": "DB00659"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00690"}, {"action": "AGONIST", "target": "P14867", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00753"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00794"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00818"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00829"}, {"action": "AGONIST", "target": "P14867", "drug": "DB00837"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00849"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB00897"}, {"action": "AGONIST", "target": "P14867", "drug": "DB00898"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB00962"}, {"action": "AGONIST", "target": "P14867", "drug": "DB01028"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01028"}, {"action": "AGONIST", "target": "P14867", "drug": "DB01049"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01068"}, {"action": "AGONIST", "target": "P14867", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01107"}, {"action": "AGONIST", "target": "P14867", "drug": "DB01154"}, {"action": "OTHER/UNKNOWN", "target": "P14867", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01159"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01174"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01189"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01198"}, {"action": "ANTAGONIST", "target": "P14867", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01205"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01215"}, {"action": "AGONIST", "target": "P14867", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01236"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01341"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01346"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01351"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01352"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01353"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01354"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01355"}, {"action": "NEGATIVE MODULATOR", "target": "P14867", "drug": "DB01381"}, {"action": "AGONIST", "target": "P14867", "drug": "DB01437"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01437"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01483"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01496"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01587"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14867", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P14867", "drug": "DB01595"}, {"action": "ANTAGONIST", "target": "P14867", "drug": "DB01708"}], "general_function": "Inhibitory extracellular ligand-gated ion channel activity", "in_complexes": ["GABA-A receptor (anion channel)"], "gene_names": ["GABRA1"]}, "P35089": {"specific_function": "Antenna complexes are light-harvesting systems, which transfer the excitation energy to the reaction centers.", "general_function": "Metal ion binding", "gene_names": [], "name": "Light-harvesting protein B-800/820 alpha chain", "drug_actions": []}, "Q15075": {"specific_function": "Binds phospholipid vesicles containing phosphatidylinositol 3-phosphate and participates in endosomal trafficking.", "general_function": "Zinc ion binding", "gene_names": ["EEA1"], "name": "Early endosome antigen 1", "drug_actions": []}, "P0A0Z8": {"general_function": "N-acylneuraminate cytidylyltransferase activity", "gene_names": ["neuA"], "name": "N-acylneuraminate cytidylyltransferase", "drug_actions": []}, "Q15078": {"specific_function": "p35 is a neuron specific activator of CDK5. The complex p35/CDK5 is required for neurite outgrowth and cortical lamination. Involved in dendritic spine morphogenesis by mediating the EFNA1-EPHA4 signaling. Activator of TPKII. The complex p35/CDK5 participates in the regulation of the circadian clock by modulating the function of CLOCK protein: phosphorylates CLOCK at 'Thr-451' and 'Thr-461' and regulates the transcriptional activity of the CLOCK-ARNTL/BMAL1 heterodimer in association with altered stability and subcellular distribution.", "general_function": "Protein serine/threonine kinase activator activity", "gene_names": ["CDK5R1"], "name": "Cyclin-dependent kinase 5 activator 1", "drug_actions": []}, "P31751": {"specific_function": "AKT2 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development.One of the few specific substrates of AKT2 identified recently is PITX2. Phosphorylation of PITX2 impairs its association with the CCND1 mRNA-stabilizing complex thus shortening the half-life of CCND1. AKT2 seems also to be the principal isoform responsible of the regulation of glucose uptake. Phosphorylates C2CD5 on 'Ser-197' during insulin-stimulated adipocytes. AKT2 is also specifically involved in skeletal muscle differentiation, one of its substrates in this process being ANKRD2. Down-regulation by RNA interference reduces the expression of the phosphorylated form of BAD, resulting in the induction of caspase-dependent apoptosis. Phosphorylates CLK2 on 'Thr-343'.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["AKT2"], "name": "RAC-beta serine/threonine-protein kinase", "drug_actions": []}, "P17600": {"specific_function": "Neuronal phosphoprotein that coats synaptic vesicles, binds to the cytoskeleton, and is believed to function in the regulation of neurotransmitter release. The complex formed with NOS1 and CAPON proteins is necessary for specific nitric-oxid functions at a presynaptic level.", "general_function": "Transporter activity", "gene_names": ["SYN1"], "name": "Synapsin-1", "drug_actions": []}, "P14868": {"specific_function": "Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA.", "general_function": "Poly(a) rna binding", "gene_names": ["DARS"], "name": "Aspartate--tRNA ligase, cytoplasmic", "drug_actions": []}, "P24228": {"specific_function": "Not involved in transpeptidation but exclusively catalyzes a DD-carboxypeptidase and DD-endopeptidase reaction.", "general_function": "Serine-type d-ala-d-ala carboxypeptidase activity", "gene_names": ["dacB"], "name": "D-alanyl-D-alanine carboxypeptidase DacB", "drug_actions": [{"action": "INHIBITOR", "target": "P24228", "drug": "DB00303"}, {"action": "INHIBITOR", "target": "P24228", "drug": "DB00760"}, {"action": "INHIBITOR", "target": "P24228", "drug": "DB01328"}, {"action": "INHIBITOR", "target": "P24228", "drug": "DB01329"}, {"action": "INHIBITOR", "target": "P24228", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "P24228", "drug": "DB04570"}]}, "Q9AQS0": {"specific_function": "Plays a role in xanthan depolymerization pathway by cleaving the linkage between the terminal mannosyl and glucuronyl residues of the side chain of xanthan to liberate pyruvylated mannose.", "general_function": "Xanthan lyase activity", "gene_names": ["xly"], "name": "Xanthan lyase", "drug_actions": []}, "Q9L915": {"general_function": "Metal ion binding", "gene_names": ["cytc3"], "name": "Cytochrome c3", "drug_actions": []}, "P0C0Y8": {"specific_function": "The reaction center is a membrane-bound complex that mediates the initial photochemical event in the electron transfer process of photosynthesis.", "general_function": "Metal ion binding", "gene_names": ["pufL"], "name": "Reaction center protein L chain", "drug_actions": []}, "P05093": {"specific_function": "Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty.", "general_function": "Steroid 17-alpha-monooxygenase activity", "gene_names": ["CYP17A1"], "name": "Steroid 17-alpha-hydroxylase/17,20 lyase", "drug_actions": [{"action": "INHIBITOR", "target": "P05093", "drug": "DB00396"}, {"action": "INHIBITOR", "target": "P05093", "drug": "DB05812"}]}, "P05091": {"general_function": "Electron carrier activity", "gene_names": ["ALDH2"], "name": "Aldehyde dehydrogenase, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "P05091", "drug": "DB00822"}]}, "Q5EK40": {"specific_function": "An NAD-dependent ADP-ribosyltransferase (ADPRT), it catalyzes the transfer of the ADP-ribosyl moiety of oxidized NAD onto eukaryotic elongation factor 2 (eEF-2) thus arresting protein synthesis. It probably uses the eukaryotic prolow-density lipoprotein receptor-related protein 1 (LRP1) to enter mouse cells, although there seems to be at least one other receptor as well. Is active against mouse fibroblasts, Chinese hamster ovary eEF-2, brine shrimp (Artemia spp. nauplii) and upon expression in S.cerevisiae.", "general_function": "Nad+-diphthamide adp-ribosyltransferase activity", "gene_names": ["chxA"], "name": "Cholix toxin", "drug_actions": []}, "Q9UM07": {"specific_function": "Catalyzes the citrullination/deimination of arginine residues of proteins such as histones, thereby playing a key role in histone code and regulation of stem cell maintenance. Citrullinates histone H1 at 'Arg-54' (to form H1R54ci), histone H3 at 'Arg-2', 'Arg-8', 'Arg-17' and/or 'Arg-26' (to form H3R2ci, H3R8ci, H3R17ci, H3R26ci, respectively) and histone H4 at 'Arg-3' (to form H4R3ci). Acts as a key regulator of stem cell maintenance by mediating citrullination of histone H1: citrullination of 'Arg-54' of histone H1 (H1R54ci) results in H1 displacement from chromatin and global chromatin decondensation, thereby promoting pluripotency and stem cell maintenance. Promotes profound chromatin decondensation during the innate immune response to infection in neutrophils by mediating formation of H1R54ci. Citrullination of histone H3 prevents their methylation by CARM1 and HRMT1L2/PRMT1 and represses transcription. Citrullinates EP300/P300 at 'Arg-2142', which favors its interaction with NCOA2/GRIP1.", "general_function": "Protein-arginine deiminase activity", "gene_names": ["PADI4"], "name": "Protein-arginine deiminase type-4", "drug_actions": []}, "P09467": {"specific_function": "Catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate in the presence of divalent cations, acting as a rate-limiting enzyme in gluconeogenesis. Plays a role in regulating glucose sensing and insulin secretion of pancreatic beta-cells. Appears to modulate glycerol gluconeogenesis in liver. Important regulator of appetite and adiposity; increased expression of the protein in liver after nutrient excess increases circulating satiety hormones and reduces appetite-stimulating neuropeptides and thus seems to provide a feedback mechanism to limit weight gain.", "general_function": "Monosaccharide binding", "gene_names": ["FBP1"], "name": "Fructose-1,6-bisphosphatase 1", "drug_actions": [{"action": "ANTAGONIST", "target": "P09467", "drug": "DB00131"}, {"action": "INHIBITORY ALLOSTERIC MODULATOR", "target": "P09467", "drug": "DB00131"}]}, "P09466": {"specific_function": "This protein is, quantitatively, the main protein synthesized and secreted in the endometrium from mid-luteal phase of the menstrual cycle and during the first semester of pregnancy.", "general_function": "Small molecule binding", "gene_names": ["PAEP"], "name": "Glycodelin", "drug_actions": []}, "P51161": {"specific_function": "Ileal protein which stimulates gastric acid and pepsinogen secretion. Seems to be able to bind to bile salts and bilirubins. Isoform 2 is essential for the survival of colon cancer cells to bile acid-induced apoptosis.", "general_function": "Transporter activity", "gene_names": ["FABP6"], "name": "Gastrotropin", "drug_actions": []}, "P51160": {"in_complexes": ["Cyclic nucleotide phosphodiesterase"], "general_function": "Metal ion binding", "gene_names": ["PDE6C"], "name": "Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "P51160", "drug": "DB00201"}]}, "P07771": {"specific_function": "Electron transfer component of benzoate 1,2-dioxygenase system.", "general_function": "Metal ion binding", "gene_names": ["benC"], "name": "Benzoate 1,2-dioxygenase electron transfer component", "drug_actions": []}, "P07773": {"general_function": "Ferric iron binding", "gene_names": ["catA"], "name": "Catechol 1,2-dioxygenase", "drug_actions": []}, "P51168": {"specific_function": "Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical membrane of epithelial cells. Plays an essential role in electrolyte and blood pressure homeostasis, but also in airway surface liquid homeostasis, which is important for proper clearance of mucus. Controls the reabsorption of sodium in kidney, colon, lung and sweat glands. Also plays a role in taste perception.", "general_function": "Ww domain binding", "gene_names": ["SCNN1B"], "name": "Amiloride-sensitive sodium channel subunit beta", "drug_actions": [{"action": "INHIBITOR", "target": "P51168", "drug": "DB00384"}, {"action": "INHIBITOR", "target": "P51168", "drug": "DB00594"}]}, "Q08698": {"specific_function": "Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. R1E contains the binding sites for both substrates and allosteric effectors and carries out the actual reduction of the ribonucleotide.", "general_function": "Ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor", "gene_names": ["nrdE"], "name": "Ribonucleoside-diphosphate reductase 2 subunit alpha", "drug_actions": []}, "P83786": {"general_function": "Involved in transaminase activity", "gene_names": [], "name": "Aspartate aminotransferase", "drug_actions": []}, "P83787": {"general_function": "Oxidoreductase activity", "gene_names": [], "name": "Cytochrome c peroxidase", "drug_actions": []}, "P39135": {"specific_function": "Activates the seven peptidyl carrier protein (PCP) domains of surfactin synthase SRF1/2/3 by transferring the 4'-phosphopantetheinyl moiety of coenzyme A (CoA) to a serine residue. Required for cells of B.subtilis to become producers of the lipopeptide antibiotics surfactin and plipastatin B1.", "general_function": "Magnesium ion binding", "gene_names": ["sfp"], "name": "4'-phosphopantetheinyl transferase sfp", "drug_actions": []}, "Q9H1K4": {"specific_function": "Involved in the transport of glutamate across the inner mitochondrial membrane. Glutamate is cotransported with H(+).", "general_function": "Symporter activity", "gene_names": ["SLC25A18"], "name": "Mitochondrial glutamate carrier 2", "drug_actions": []}, "P29600": {"specific_function": "Subtilisin is an extracellular alkaline serine protease, it catalyzes the hydrolysis of proteins and peptide amides.", "general_function": "Serine-type endopeptidase activity", "gene_names": [], "name": "Subtilisin Savinase", "drug_actions": []}, "Q5TDP6": {"specific_function": "May act as a component of the cytoskeleton or as a chaperone for the reorganization of intermediate filament proteins during terminal differentiation in the lens. Does not seem to have enzymatic activity (By similarity).", "general_function": "Glutamate-ammonia ligase activity", "gene_names": ["LGSN"], "name": "Lengsin", "drug_actions": []}, "Q01064": {"specific_function": "Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a preference for cGMP as a substrate.", "name": "Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "Q01064", "drug": "DB00201"}, {"action": "INHIBITOR", "target": "Q01064", "drug": "DB00622"}, {"action": "INHIBITOR", "target": "Q01064", "drug": "DB01023"}, {"action": "INHIBITOR", "target": "Q01064", "drug": "DB01244"}], "general_function": "Metal ion binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE1B"]}, "P28221": {"specific_function": "G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Regulates the release of 5-hydroxytryptamine in the brain, and thereby affects neural activity. May also play a role in regulating the release of other neurotransmitters. May play a role in vasoconstriction.", "name": "5-hydroxytryptamine receptor 1D", "drug_actions": [{"action": "AGONIST", "target": "P28221", "drug": "DB00216"}, {"action": "ANTAGONIST", "target": "P28221", "drug": "DB00246"}, {"action": "AGONIST", "target": "P28221", "drug": "DB00248"}, {"action": "AGONIST", "target": "P28221", "drug": "DB00268"}, {"action": "AGONIST", "target": "P28221", "drug": "DB00315"}, {"action": "AGONIST", "target": "P28221", "drug": "DB00320"}, {"action": "BINDER", "target": "P28221", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P28221", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P28221", "drug": "DB00363"}, {"action": "BINDER", "target": "P28221", "drug": "DB00408"}, {"action": "UNKNOWN", "target": "P28221", "drug": "DB00413"}, {"action": "AGONIST", "target": "P28221", "drug": "DB00589"}, {"action": "AGONIST", "target": "P28221", "drug": "DB00669"}, {"action": "AGONIST", "target": "P28221", "drug": "DB00696"}, {"action": "AGONIST", "target": "P28221", "drug": "DB00714"}, {"action": "BINDER", "target": "P28221", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P28221", "drug": "DB00734"}, {"action": "AGONIST", "target": "P28221", "drug": "DB00918"}, {"action": "AGONIST", "target": "P28221", "drug": "DB00952"}, {"action": "AGONIST", "target": "P28221", "drug": "DB00953"}, {"action": "AGONIST", "target": "P28221", "drug": "DB00998"}, {"action": "ANTAGONIST", "target": "P28221", "drug": "DB01049"}, {"action": "AGONIST", "target": "P28221", "drug": "DB01186"}, {"action": "AGONIST", "target": "P28221", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P28221", "drug": "DB01221"}, {"action": "OTHER/UNKNOWN", "target": "P28221", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P28221", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P28221", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P28221", "drug": "DB01392"}], "general_function": "Serotonin receptor activity", "in_complexes": ["5-hydroxytryptamine receptor 1", "Serotonin Receptors"], "gene_names": ["HTR1D"]}, "P28222": {"specific_function": "G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Regulates the release of 5-hydroxytryptamine, dopamine and acetylcholine in the brain, and thereby affects neural activity, nociceptive processing, pain perception, mood and behavior. Besides, plays a role in vasoconstriction of cerebral arteries.", "name": "5-hydroxytryptamine receptor 1B", "drug_actions": [{"action": "AGONIST", "target": "P28222", "drug": "DB00216"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB00246"}, {"action": "BINDER", "target": "P28222", "drug": "DB00247"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00248"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00268"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00315"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00320"}, {"action": "BINDER", "target": "P28222", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB00363"}, {"action": "BINDER", "target": "P28222", "drug": "DB00408"}, {"action": "UNKNOWN", "target": "P28222", "drug": "DB00413"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB00543"}, {"action": "OTHER/UNKNOWN", "target": "P28222", "drug": "DB00571"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00589"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00669"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00696"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00714"}, {"action": "OTHER/UNKNOWN", "target": "P28222", "drug": "DB00904"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00918"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00952"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00953"}, {"action": "OTHER/UNKNOWN", "target": "P28222", "drug": "DB00960"}, {"action": "AGONIST", "target": "P28222", "drug": "DB00998"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB01049"}, {"action": "AGONIST", "target": "P28222", "drug": "DB01186"}, {"action": "AGONIST", "target": "P28222", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB01221"}, {"action": "OTHER/UNKNOWN", "target": "P28222", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB01359"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB01392"}, {"action": "ANTAGONIST", "target": "P28222", "drug": "DB06216"}, {"action": "PARTIAL AGONIST", "target": "P28222", "drug": "DB09068"}], "general_function": "Serotonin receptor activity", "in_complexes": ["5-hydroxytryptamine receptor 1", "Serotonin Receptors"], "gene_names": ["HTR1B"]}, "P28223": {"specific_function": "G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates phospholipase C and a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and promotes the release of Ca(2+) ions from intracellular stores. Affects neural activity, perception, cognition and mood. Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction.(Microbial infection) Acts as a receptor for human JC polyomavirus/JCPyV.", "name": "5-hydroxytryptamine receptor 2A", "drug_actions": [{"action": "ANTAGONIST", "target": "P28223", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00247"}, {"action": "AGONIST", "target": "P28223", "drug": "DB00248"}, {"action": "AGONIST", "target": "P28223", "drug": "DB00268"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00370"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00408"}, {"action": "OTHER/UNKNOWN", "target": "P28223", "drug": "DB00409"}, {"action": "UNKNOWN", "target": "P28223", "drug": "DB00413"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00434"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00477"}, {"action": "BINDER", "target": "P28223", "drug": "DB00477"}, {"action": "OTHER/UNKNOWN", "target": "P28223", "drug": "DB00502"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00543"}, {"action": "AGONIST", "target": "P28223", "drug": "DB00589"}, {"action": "AGONIST", "target": "P28223", "drug": "DB00604"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00656"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00679"}, {"action": "AGONIST", "target": "P28223", "drug": "DB00696"}, {"action": "AGONIST", "target": "P28223", "drug": "DB00714"}, {"action": "OTHER/UNKNOWN", "target": "P28223", "drug": "DB00715"}, {"action": "AGONIST", "target": "P28223", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00751"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00805"}, {"action": "OTHER/UNKNOWN", "target": "P28223", "drug": "DB00843"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00875"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00924"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB00933"}, {"action": "BINDER", "target": "P28223", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01069"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01079"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01149"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01151"}, {"action": "AGONIST", "target": "P28223", "drug": "DB01186"}, {"action": "AGONIST", "target": "P28223", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01242"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01392"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01403"}, {"action": "AGONIST", "target": "P28223", "drug": "DB01442"}, {"action": "AGONIST", "target": "P28223", "drug": "DB01454"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01614"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01618"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01621"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01622"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01623"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB01624"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB04842"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB04908"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB04946"}, {"action": "INVERSE AGONIST", "target": "P28223", "drug": "DB05316"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB06016"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB06144"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB06288"}, {"action": "INVERSE AGONIST", "target": "P28223", "drug": "DB06678"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB08810"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB08815"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB08927"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB09016"}, {"action": "ANTAGONIST", "target": "P28223", "drug": "DB09128"}], "general_function": "Virus receptor activity", "in_complexes": ["5-hydroxytryptamine 2 receptor", "5-hydroxytryptamine receptor 2", "Serotonin Receptors"], "gene_names": ["HTR2A"]}, "P16115": {"general_function": "L-malate dehydrogenase activity", "gene_names": ["ldh"], "name": "L-lactate dehydrogenase", "drug_actions": []}, "P14262": {"specific_function": "Cleaves glycosylphosphatidylinositol (GPI) and phosphatidylinositol (PI) anchors but not PI phosphates.", "general_function": "Phosphoric diester hydrolase activity", "gene_names": [], "name": "1-phosphatidylinositol phosphodiesterase", "drug_actions": []}, "P29597": {"specific_function": "Probably involved in intracellular signal transduction by being involved in the initiation of type I IFN signaling. Phosphorylates the interferon-alpha/beta receptor alpha chain.", "general_function": "Protein tyrosine kinase activity", "gene_names": ["TYK2"], "name": "Non-receptor tyrosine-protein kinase TYK2", "drug_actions": []}, "P19634": {"specific_function": "Involved in pH regulation to eliminate acids generated by active metabolism or to counter adverse environmental conditions. Major proton extruding system driven by the inward sodium ion chemical gradient. Plays an important role in signal transduction.", "general_function": "Solute:proton antiporter activity", "gene_names": ["SLC9A1"], "name": "Sodium/hydrogen exchanger 1", "drug_actions": [{"action": "INHIBITOR", "target": "P19634", "drug": "DB00594"}]}, "Q07837": {"specific_function": "Involved in the high-affinity, sodium-independent transport of cystine and neutral and dibasic amino acids (system B(0,+)-like activity). May function as an activator of SLC7A9 and be involved in the high-affinity reabsorption of cystine in the kidney tubule.", "general_function": "L-cystine transmembrane transporter activity", "gene_names": ["SLC3A1"], "name": "Neutral and basic amino acid transport protein rBAT", "drug_actions": []}, "P60327": {"specific_function": "The enzyme catalyzes the hydrolysis of N-carbamoyl-D-amino acids to the corresponding which are useful intermediates in the preparation of beta-lactam antibiotics. Industrial production of beta-lactam antibiotics is now being developed using this enzyme.", "general_function": "N-carbamoyl-d-amino acid hydrolase activity", "gene_names": [], "name": "N-carbamoyl-D-amino acid hydrolase", "drug_actions": []}, "O33830": {"specific_function": "Alpha-glycosidase with a very broad specificity. Hydrolyzes maltose and other small maltooligosaccharides but is inactive against the polymeric substrate starch. AglA is not specific with respect to the configuration at the C-4 position of its substrates because glycosidic derivatives of D-galactose are also hydrolyzed. Does not cleave beta-glycosidic bonds.", "general_function": "Oxidoreductase activity, acting on the ch-oh group of donors, nad or nadp as acceptor", "gene_names": ["aglA"], "name": "Alpha-glucosidase", "drug_actions": []}, "P04234": {"specific_function": "The CD3 complex mediates signal transduction.", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["CD3D"], "name": "T-cell surface glycoprotein CD3 delta chain", "drug_actions": [{"action": "ACTIVATOR", "target": "P04234", "drug": "DB09052"}]}, "O33833": {"specific_function": "Hydrolysis of sucrose, raffinose, inulin and levan. Specific for the fructose moiety and the beta-anomeric configuration of the glycosidic linkages of its substrates. The enzyme released fructose from sucrose and raffinose, and the fructose polymer inulin is hydrolyzed quantitatively in an exo-type fashion.", "general_function": "Sucrose alpha-glucosidase activity", "gene_names": ["bfrA"], "name": "Beta-fructosidase", "drug_actions": []}, "P54760": {"specific_function": "Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Together with its cognate ligand/functional ligand EFNB2 plays a central role in heart morphogenesis and angiogenesis through regulation of cell adhesion and cell migration. EPHB4-mediated forward signaling controls cellular repulsion and segregation form EFNB2-expressing cells. Plays also a role in postnatal blood vessel remodeling, morphogenesis and permeability and is thus important in the context of tumor angiogenesis.", "general_function": "Transmembrane receptor protein tyrosine kinase activity", "gene_names": ["EPHB4"], "name": "Ephrin type-B receptor 4", "drug_actions": []}, "P05102": {"specific_function": "This methylase recognizes the double-stranded sequence GCGC, causes specific methylation on C-2 on both strands, and protects the DNA from cleavage by the HhaI endonuclease.", "general_function": "Dna (cytosine-5-)-methyltransferase activity", "gene_names": ["hhaIM"], "name": "Modification methylase HhaI", "drug_actions": []}, "P00439": {"general_function": "Phenylalanine 4-monooxygenase activity", "gene_names": ["PAH"], "name": "Phenylalanine-4-hydroxylase", "drug_actions": [{"action": "COFACTOR", "target": "P00439", "drug": "DB00360"}, {"action": "INHIBITOR", "target": "P00439", "drug": "DB00368"}, {"action": "ANTAGONIST", "target": "P00439", "drug": "DB00668"}, {"action": "INHIBITOR", "target": "P00439", "drug": "DB06262"}]}, "P00438": {"general_function": "Fad binding", "gene_names": ["pobA"], "name": "p-hydroxybenzoate hydroxylase", "drug_actions": []}, "P00929": {"specific_function": "The alpha subunit is responsible for the aldol cleavage of indoleglycerol phosphate to indole and glyceraldehyde 3-phosphate.", "general_function": "Tryptophan synthase activity", "gene_names": ["trpA"], "name": "Tryptophan synthase alpha chain", "drug_actions": []}, "Q09470": {"specific_function": "Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:19903818). Contributes to the regulation of the membrane potential and nerve signaling, and prevents neuronal hyperexcitability (PubMed:17156368). Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane (PubMed:19912772). Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA5, KCNA6, KCNA7, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel (PubMed:12077175, PubMed:17156368). Channel properties are modulated by cytoplasmic beta subunits that regulate the subcellular location of the alpha subunits and promote rapid inactivation of delayed rectifier potassium channels (PubMed:12077175, PubMed:17156368). In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Homotetrameric KCNA1 forms a delayed-rectifier potassium channel that opens in response to membrane depolarization, followed by slow spontaneous channel closure (PubMed:19912772, PubMed:19968958, PubMed:19307729, PubMed:19903818). In contrast, a heterotetrameric channel formed by KCNA1 and KCNA4 shows rapid inactivation (PubMed:17156368). Regulates neuronal excitability in hippocampus, especially in mossy fibers and medial perforant path axons, preventing neuronal hyperexcitability. Response to toxins that are selective for KCNA1, respectively for KCNA2, suggests that heteromeric potassium channels composed of both KCNA1 and KCNA2 play a role in pacemaking and regulate the output of deep cerebellar nuclear neurons (By similarity). May function as down-stream effector for G protein-coupled receptors and inhibit GABAergic inputs to basolateral amygdala neurons (By similarity). May contribute to the regulation of neurotransmitter release, such as gamma-aminobutyric acid (GABA) release (By similarity). Plays a role in regulating the generation of action potentials and preventing hyperexcitability in myelinated axons of the vagus nerve, and thereby contributes to the regulation of heart contraction (By similarity). Required for normal neuromuscular responses (PubMed:11026449, PubMed:17136396). Regulates the frequency of neuronal action potential firing in response to mechanical stimuli, and plays a role in the perception of pain caused by mechanical stimuli, but does not play a role in the perception of pain due to heat stimuli (By similarity). Required for normal responses to auditory stimuli and precise location of sound sources, but not for sound perception (By similarity). The use of toxins that block specific channels suggest that it contributes to the regulation of the axonal release of the neurotransmitter dopamine (By similarity). Required for normal postnatal brain development and normal proliferation of neuronal precursor cells in the brain (By similarity). Plays a role in the reabsorption of Mg(2+) in the distal convoluted tubules in the kidney and in magnesium ion homeostasis, probably via its effect on the membrane potential (PubMed:23903368, PubMed:19307729).", "general_function": "Voltage-gated potassium channel activity", "gene_names": ["KCNA1"], "name": "Potassium voltage-gated channel subfamily A member 1", "drug_actions": [{"action": "INDUCER", "target": "Q09470", "drug": "DB00228"}, {"action": "INHIBITOR", "target": "Q09470", "drug": "DB00321"}, {"action": "INDUCER", "target": "Q09470", "drug": "DB00753"}, {"action": "INDUCER", "target": "Q09470", "drug": "DB01028"}, {"action": "INHIBITOR", "target": "Q09470", "drug": "DB01115"}, {"action": "INDUCER", "target": "Q09470", "drug": "DB01189"}, {"action": "INDUCER", "target": "Q09470", "drug": "DB01236"}, {"action": "ANTAGONIST", "target": "Q09470", "drug": "DB06637"}]}, "P35080": {"specific_function": "Binds to actin and affects the structure of the cytoskeleton. At high concentrations, profilin prevents the polymerization of actin, whereas it enhances it at low concentrations. By binding to PIP2, it inhibits the formation of IP3 and DG.", "general_function": "Phosphatidylinositol-4,5-bisphosphate binding", "gene_names": ["PFN2"], "name": "Profilin-2", "drug_actions": []}, "P00437": {"specific_function": "Plays an essential role in the utilization of numerous aromatic and hydroaromatic compounds via the beta-ketoadipate pathway.", "general_function": "Protocatechuate 3,4-dioxygenase activity", "gene_names": ["pcaH"], "name": "Protocatechuate 3,4-dioxygenase beta chain", "drug_actions": []}, "P00436": {"specific_function": "Plays an essential role in the utilization of numerous aromatic and hydroaromatic compounds via the beta-ketoadipate pathway.", "general_function": "Protocatechuate 3,4-dioxygenase activity", "gene_names": ["pcaG"], "name": "Protocatechuate 3,4-dioxygenase alpha chain", "drug_actions": []}, "P17516": {"specific_function": "Catalyzes the transformation of the potent androgen dihydrotestosterone (DHT) into the less active form, 5-alpha-androstan-3-alpha,17-beta-diol (3-alpha-diol). Also has some 20-alpha-hydroxysteroid dehydrogenase activity. The biotransformation of the pesticide chlordecone (kepone) to its corresponding alcohol leads to increased biliary excretion of the pesticide and concomitant reduction of its neurotoxicity since bile is the major excretory route.", "general_function": "Retinal dehydrogenase activity", "gene_names": ["AKR1C4"], "name": "Aldo-keto reductase family 1 member C4", "drug_actions": []}, "P68133": {"specific_function": "Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["ACTA1"], "name": "Actin, alpha skeletal muscle", "drug_actions": [{"action": "INHIBITOR", "target": "P68133", "drug": "DB02621"}]}, "O95838": {"specific_function": "This is a receptor for glucagon-like peptide 2. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.", "general_function": "Glucagon receptor activity", "gene_names": ["GLP2R"], "name": "Glucagon-like peptide 2 receptor", "drug_actions": [{"action": "AGONIST", "target": "O95838", "drug": "DB08900"}]}, "P21728": {"specific_function": "Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.", "name": "D(1A) dopamine receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "P21728", "drug": "DB00246"}, {"action": "AGONIST", "target": "P21728", "drug": "DB00248"}, {"action": "AGONIST", "target": "P21728", "drug": "DB00248"}, {"action": "AGONIST", "target": "P21728", "drug": "DB00268"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00353"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00363"}, {"action": "BINDER", "target": "P21728", "drug": "DB00370"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00372"}, {"action": "PARTIAL AGONIST", "target": "P21728", "drug": "DB00397"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00408"}, {"action": "BINDER", "target": "P21728", "drug": "DB00408"}, {"action": "UNKNOWN", "target": "P21728", "drug": "DB00413"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00420"}, {"action": "BINDER", "target": "P21728", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00477"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00502"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00508"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00543"}, {"action": "BINDER", "target": "P21728", "drug": "DB00568"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00589"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00623"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00679"}, {"action": "AGONIST", "target": "P21728", "drug": "DB00696"}, {"action": "AGONIST", "target": "P21728", "drug": "DB00714"}, {"action": "BINDER", "target": "P21728", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00777"}, {"action": "AGONIST", "target": "P21728", "drug": "DB00800"}, {"action": "AGONIST", "target": "P21728", "drug": "DB00805"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00850"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB00875"}, {"action": "AGONIST", "target": "P21728", "drug": "DB00988"}, {"action": "AGONIST", "target": "P21728", "drug": "DB00988"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01038"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01049"}, {"action": "AGONIST", "target": "P21728", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01063"}, {"action": "AGONIST", "target": "P21728", "drug": "DB01186"}, {"action": "AGONIST", "target": "P21728", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01224"}, {"action": "AGONIST", "target": "P21728", "drug": "DB01235"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01238"}, {"action": "PARTIAL AGONIST", "target": "P21728", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01608"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01614"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01621"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01622"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01623"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB01624"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB04946"}, {"action": "AGONIST", "target": "P21728", "drug": "DB05271"}, {"action": "BINDER", "target": "P21728", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P21728", "drug": "DB06216"}], "general_function": "G-protein coupled amine receptor activity", "in_complexes": ["D(1) dopamine receptor"], "gene_names": ["DRD1"]}, "Q9I5I9": {"general_function": "Metal ion binding", "gene_names": ["sdsA1"], "name": "SDS hydrolase SdsA1", "drug_actions": []}, "Q9HUR5": {"general_function": "Porin activity", "gene_names": ["opdK"], "name": "Vanillate porin OpdK", "drug_actions": []}, "P10943": {"specific_function": "Antiterminator that binds to cis-acting regulatory sequences on the mRNA in the presence of histidine, thereby suppressing transcription termination and activating the hut operon for histidine utilization.", "general_function": "Mrna binding", "gene_names": ["hutP"], "name": "Hut operon positive regulatory protein", "drug_actions": []}, "P24530": {"specific_function": "Non-specific receptor for endothelin 1, 2, and 3. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.", "general_function": "Peptide hormone binding", "gene_names": ["EDNRB"], "name": "Endothelin B receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "P24530", "drug": "DB00559"}, {"action": "ANTAGONIST", "target": "P24530", "drug": "DB06268"}, {"action": "ANTAGONIST", "target": "P24530", "drug": "DB06403"}, {"action": "ANTAGONIST", "target": "P24530", "drug": "DB08932"}]}, "O95831": {"specific_function": "Functions both as NADH oxidoreductase and as regulator of apoptosis. In response to apoptotic stimuli, it is released from the mitochondrion intermembrane space into the cytosol and to the nucleus, where it functions as a proapoptotic factor in a caspase-independent pathway. In contrast, functions as an antiapoptotic factor in normal mitochondria via its NADH oxidoreductase activity. The soluble form (AIFsol) found in the nucleus induces 'parthanatos' i.e. caspase-independent fragmentation of chromosomal DNA. Interacts with EIF3G,and thereby inhibits the EIF3 machinery and protein synthesis, and activates casapse-7 to amplify apoptosis. Plays a critical role in caspase-independent, pyknotic cell death in hydrogen peroxide-exposed cells. Binds to DNA in a sequence-independent manner.", "general_function": "Oxidoreductase activity, acting on nad(p)h", "gene_names": ["AIFM1"], "name": "Apoptosis-inducing factor 1, mitochondrial", "drug_actions": []}, "Q01668": {"specific_function": "Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin-GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA).", "name": "Voltage-dependent L-type calcium channel subunit alpha-1D", "drug_actions": [{"action": "INHIBITOR", "target": "Q01668", "drug": "DB00270"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB00381"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB00393"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB00401"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB00568"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB00622"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB01023"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB01054"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB01115"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB01388"}, {"action": "INHIBITOR", "target": "Q01668", "drug": "DB06712"}], "general_function": "Voltage-gated calcium channel activity involved sa node cell action potential", "in_complexes": ["Voltage-dependent calcium channel"], "gene_names": ["CACNA1D"]}, "O31410": {"specific_function": "Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions.", "general_function": "Peptide deformylase activity", "gene_names": [], "name": "Peptide deformylase 2", "drug_actions": []}, "O43920": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFS5"], "name": "NADH dehydrogenase [ubiquinone] iron-sulfur protein 5", "drug_actions": []}, "P22262": {"specific_function": "Positively regulates expression of listeriolysin, of 1-phosphadidylinositol phosphodiesterase (PI-PLC) and other virulence factors.", "general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": ["prfA"], "name": "Listeriolysin regulatory protein", "drug_actions": []}, "P54819": {"specific_function": "Catalyzes the reversible transfer of the terminal phosphate group between ATP and AMP. Plays an important role in cellular energy homeostasis and in adenine nucleotide metabolism. Adenylate kinase activity is critical for regulation of the phosphate utilization and the AMP de novo biosynthesis pathways. Plays a key role in hematopoiesis.", "general_function": "Atp binding", "gene_names": ["AK2"], "name": "Adenylate kinase 2, mitochondrial", "drug_actions": []}, "O75251": {"specific_function": "Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).", "general_function": "Quinone binding", "gene_names": ["NDUFS7"], "name": "NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial", "drug_actions": []}, "P0A759": {"specific_function": "Catalyzes the reversible isomerization-deamination of glucosamine 6-phosphate (GlcN6P) to form fructose 6-phosphate (Fru6P) and ammonium ion.", "general_function": "Identical protein binding", "gene_names": ["nagB"], "name": "Glucosamine-6-phosphate deaminase", "drug_actions": []}, "P0C1U9": {"specific_function": "Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.", "general_function": "Dna topoisomerase type ii (atp-hydrolyzing) activity", "gene_names": ["parC"], "name": "DNA topoisomerase 4 subunit A", "drug_actions": []}, "P0A751": {"specific_function": "Cell wall formation. Adds enolpyruvyl to UDP-N-acetylglucosamine.", "general_function": "Udp-n-acetylglucosamine 1-carboxyvinyltransferase activity", "gene_names": ["murA"], "name": "UDP-N-acetylglucosamine 1-carboxyvinyltransferase", "drug_actions": []}, "P0A753": {"specific_function": "Catalyzes the reversible adenylation of nicotinate mononucleotide (NaMN) to nicotinic acid adenine dinucleotide (NaAD).", "general_function": "Nicotinate-nucleotide adenylyltransferase activity", "gene_names": ["nadD"], "name": "Nicotinate-nucleotide adenylyltransferase", "drug_actions": []}, "Q7DC80": {"general_function": "Isochorismatase activity", "gene_names": ["phzD1"], "name": "Phenazine biosynthesis protein PhzD", "drug_actions": []}, "Q14181": {"specific_function": "May play an essential role at the early stage of chromosomal DNA replication by coupling the polymerase alpha/primase complex to the cellular replication machinery.", "general_function": "Protein heterodimerization activity", "gene_names": ["POLA2"], "name": "DNA polymerase alpha subunit B", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "Q14181", "drug": "DB00851"}]}, "P35557": {"specific_function": "Catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. Glucokinase has a high Km for glucose, and so it is effective only when glucose is abundant. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage.", "general_function": "Glucose binding", "gene_names": ["GCK"], "name": "Glucokinase", "drug_actions": []}, "P08684": {"specific_function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).", "general_function": "Vitamin d3 25-hydroxylase activity", "gene_names": ["CYP3A4"], "name": "Cytochrome P450 3A4", "drug_actions": []}, "P00692": {"general_function": "Calcium ion binding", "gene_names": [], "name": "Alpha-amylase", "drug_actions": []}, "P08686": {"specific_function": "Specifically catalyzes the 21-hydroxylation of steroids. Required for the adrenal synthesis of mineralocorticoids and glucocorticoids.", "general_function": "Steroid hydroxylase activity", "gene_names": ["CYP21A2"], "name": "Steroid 21-hydroxylase", "drug_actions": []}, "O75493": {"specific_function": "Does not have a catalytic activity.", "gene_names": ["CA11"], "name": "Carbonic anhydrase-related protein 11", "drug_actions": [{"action": "INHIBITOR", "target": "O75493", "drug": "DB00909"}]}, "P60493": {"specific_function": "Found on the solvent side of the large subunit.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpmA"], "name": "50S ribosomal protein L27", "drug_actions": []}, "P35558": {"specific_function": "Catalyzes the conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP), the rate-limiting step in the metabolic pathway that produces glucose from lactate and other precursors derived from the citric acid cycle.", "general_function": "Phosphoenolpyruvate carboxykinase (gtp) activity", "gene_names": ["PCK1"], "name": "Phosphoenolpyruvate carboxykinase, cytosolic [GTP]", "drug_actions": []}, "P10176": {"specific_function": "This protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport.", "general_function": "Cytochrome-c oxidase activity", "gene_names": ["COX8A"], "name": "Cytochrome c oxidase subunit 8A, mitochondrial", "drug_actions": []}, "P35228": {"specific_function": "Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such COX2. As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-nitrosylation of GAPDH on 'Cys-247' implicated in regulation of the GAIT complex activity and probably multiple targets including ANXA5, EZR, MSN and VIM.", "general_function": "Tetrahydrobiopterin binding", "gene_names": ["NOS2"], "name": "Nitric oxide synthase, inducible", "drug_actions": [{"action": "INHIBITOR", "target": "P35228", "drug": "DB01110"}, {"action": "NEGATIVE MODULATOR", "target": "P35228", "drug": "DB01234"}, {"action": "INHIBITOR", "target": "P35228", "drug": "DB02533"}, {"action": "AGONIST", "target": "P35228", "drug": "DB08814"}]}, "P00326": {"general_function": "Zinc ion binding", "gene_names": ["ADH1C"], "name": "Alcohol dehydrogenase 1C", "drug_actions": [{"action": "INHIBITOR", "target": "P00326", "drug": "DB01213"}]}, "P00325": {"general_function": "Zinc ion binding", "gene_names": ["ADH1B"], "name": "Alcohol dehydrogenase 1B", "drug_actions": [{"action": "INHIBITOR", "target": "P00325", "drug": "DB01213"}]}, "P00323": {"specific_function": "Low-potential electron donor to a number of redox enzymes.", "general_function": "Iron ion binding", "gene_names": [], "name": "Flavodoxin", "drug_actions": []}, "P00322": {"specific_function": "Low-potential electron donor to a number of redox enzymes.", "general_function": "Fmn binding", "gene_names": [], "name": "Flavodoxin", "drug_actions": []}, "O60678": {"specific_function": "Methylates (mono and asymmetric dimethylation) the guanidino nitrogens of arginyl residues in some proteins.", "general_function": "Protein-arginine omega-n asymmetric methyltransferase activity", "gene_names": ["PRMT3"], "name": "Protein arginine N-methyltransferase 3", "drug_actions": []}, "Q15119": {"specific_function": "Kinase that plays a key role in the regulation of glucose and fatty acid metabolism and homeostasis via phosphorylation of the pyruvate dehydrogenase subunits PDHA1 and PDHA2. This inhibits pyruvate dehydrogenase activity, and thereby regulates metabolite flux through the tricarboxylic acid cycle, down-regulates aerobic respiration and inhibits the formation of acetyl-coenzyme A from pyruvate. Inhibition of pyruvate dehydrogenase decreases glucose utilization and increases fat metabolism. Mediates cellular responses to insulin. Plays an important role in maintaining normal blood glucose levels and in metabolic adaptation to nutrient availability. Via its regulation of pyruvate dehydrogenase activity, plays an important role in maintaining normal blood pH and in preventing the accumulation of ketone bodies under starvation. Plays a role in the regulation of cell proliferation and in resistance to apoptosis under oxidative stress. Plays a role in p53/TP53-mediated apoptosis.", "general_function": "Pyruvate dehydrogenase (acetyl-transferring) kinase activity", "gene_names": ["PDK2"], "name": "[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial", "drug_actions": []}, "P02974": {"specific_function": "This protein is the predominant Neisseria surface antigen, which allows adhesion of the bacterium to various host cells.", "gene_names": ["pilE1"], "name": "Fimbrial protein", "drug_actions": []}, "O67854": {"general_function": "Neurotransmitter:sodium symporter activity", "gene_names": ["snf"], "name": "Transporter", "drug_actions": []}, "P83797": {"specific_function": "Component of the cytochrome b6-f complex, which mediates electron transfer between photosystem II (PSII) and photosystem I (PSI), cyclic electron flow around PSI, and state transitions. PetG is required for either the stability or assembly of the cytochrome b6-f complex.", "general_function": "Electron transporter, transferring electrons within cytochrome b6/f complex of photosystem ii activity", "gene_names": ["petG"], "name": "Cytochrome b6-f complex subunit 5", "drug_actions": []}, "Q9BXI2": {"specific_function": "Ornithine transport across inner mitochondrial membrane, from the cytoplasm to the matrix.", "gene_names": ["SLC25A2"], "name": "Mitochondrial ornithine transporter 2", "drug_actions": []}, "P21430": {"specific_function": "Forms a proton-selective ion channel that is necessary for the efficient release of the viral genome during virus entry. After attaching to the cell surface, the virion enters the cell by endocytosis. Acidification of the endosome triggers M2 ion channel activity. The influx of protons into virion interior is believed to disrupt interactions between the viral ribonucleoprotein (RNP), matrix protein 1 (M1), and lipid bilayers, thereby freeing the viral genome from interaction with viral proteins and enabling RNA segments to migrate to the host cell nucleus, where influenza virus RNA transcription and replication occur. Also plays a role in viral proteins secretory pathway. Elevates the intravesicular pH of normally acidic compartments, such as trans-Golgi network, preventing newly formed hemagglutinin from premature switching to the fusion-active conformation (By similarity).", "general_function": "Ion channel activity", "gene_names": ["M"], "name": "Matrix protein 2", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "P21430", "drug": "DB00478"}, {"action": "INHIBITOR", "target": "P21430", "drug": "DB00915"}]}, "Q96QU6": {"specific_function": "Does not catalyze the synthesis of 1-aminocyclopropane-1-carboxylate but is capable of catalyzing the deamination of L-vinylglycine.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["ACCS"], "name": "1-aminocyclopropane-1-carboxylate synthase-like protein 1", "drug_actions": []}, "O15239": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFA1"], "name": "NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1", "drug_actions": []}, "P24158": {"specific_function": "Polymorphonuclear leukocyte serine protease that degrades elastin, fibronectin, laminin, vitronectin, and collagen types I, III, and IV (in vitro) and causes emphysema when administered by tracheal insufflation to hamsters.", "general_function": "Serine-type peptidase activity", "gene_names": ["PRTN3"], "name": "Myeloblastin", "drug_actions": []}, "Q53707": {"general_function": "Penicillin binding", "gene_names": ["mecA"], "name": "MecA PBP2' (penicillin binding protein 2')", "drug_actions": [{"action": "INHIBITOR", "target": "Q53707", "drug": "DB00417"}, {"action": "INHIBITOR", "target": "Q53707", "drug": "DB01332"}, {"action": "INHIBITOR", "target": "Q53707", "drug": "DB01603"}]}, "P0A578": {"specific_function": "DHPS catalyzes the formation of the immediate precursor of folic acid. It is implicated in resistance to sulfonamide", "general_function": "Coenzyme transport and metabolism", "gene_names": ["folP1"], "name": "Dihydropteroate synthase 1", "drug_actions": []}, "P07801": {"specific_function": "Methylation of the membrane-bound methyl-accepting chemotaxis proteins (MCP) to form gamma-glutamyl methyl ester residues in MCP.", "general_function": "Protein-glutamate o-methyltransferase activity", "gene_names": ["cheR"], "name": "Chemotaxis protein methyltransferase", "drug_actions": []}, "P42898": {"specific_function": "Catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine.", "general_function": "Protein complex binding", "gene_names": ["MTHFR"], "name": "Methylenetetrahydrofolate reductase", "drug_actions": [{"action": "COFACTOR", "target": "P42898", "drug": "DB00115"}, {"action": "COFACTOR", "target": "P42898", "drug": "DB00116"}, {"action": "COFACTOR", "target": "P42898", "drug": "DB00116"}]}, "P15121": {"specific_function": "Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies.", "general_function": "Glyceraldehyde oxidoreductase activity", "gene_names": ["AKR1B1"], "name": "Aldose reductase", "drug_actions": [{"action": "INHIBITOR", "target": "P15121", "drug": "DB00605"}, {"action": "INHIBITOR", "target": "P15121", "drug": "DB02021"}, {"action": "INHIBITOR", "target": "P15121", "drug": "DB02383"}, {"action": "INHIBITOR", "target": "P15121", "drug": "DB02712"}]}, "P42892": {"specific_function": "Converts big endothelin-1 to endothelin-1.", "general_function": "Protein homodimerization activity", "gene_names": ["ECE1"], "name": "Endothelin-converting enzyme 1", "drug_actions": []}, "Q14432": {"specific_function": "Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.", "name": "cGMP-inhibited 3',5'-cyclic phosphodiesterase A", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "Q14432", "drug": "DB00201"}, {"action": "INHIBITOR", "target": "Q14432", "drug": "DB00235"}, {"action": "INHIBITOR", "target": "Q14432", "drug": "DB00261"}, {"action": "INHIBITOR", "target": "Q14432", "drug": "DB00277"}, {"action": "INHIBITOR", "target": "Q14432", "drug": "DB00922"}, {"action": "INHIBITOR", "target": "Q14432", "drug": "DB01166"}, {"action": "INHIBITOR", "target": "Q14432", "drug": "DB01223"}, {"action": "INHIBITOR", "target": "Q14432", "drug": "DB01303"}, {"action": "INHIBITOR", "target": "Q14432", "drug": "DB01427"}, {"action": "INHIBITOR", "target": "Q14432", "drug": "DB04880"}, {"action": "INHIBITOR", "target": "Q14432", "drug": "DB05266"}, {"action": "INHIBITOR", "target": "Q14432", "drug": "DB08811"}], "general_function": "Metal ion binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE3A"]}, "Q13003": {"specific_function": "Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists. This receptor binds domoate > kainate >> L-glutamate = quisqualate >> AMPA = NMDA.", "general_function": "Kainate selective glutamate receptor activity", "gene_names": ["GRIK3"], "name": "Glutamate receptor ionotropic, kainate 3", "drug_actions": []}, "P00101": {"specific_function": "Electron donor for cytochrome cd1 in nitrite and nitrate respiration.", "general_function": "Iron ion binding", "gene_names": ["nirM"], "name": "Cytochrome c-551", "drug_actions": []}, "P05556": {"specific_function": "Integrins alpha-1/beta-1, alpha-2/beta-1, alpha-10/beta-1 and alpha-11/beta-1 are receptors for collagen. Integrins alpha-1/beta-1 and alpha-2/beta-2 recognize the proline-hydroxylated sequence G-F-P-G-E-R in collagen. Integrins alpha-2/beta-1, alpha-3/beta-1, alpha-4/beta-1, alpha-5/beta-1, alpha-8/beta-1, alpha-10/beta-1, alpha-11/beta-1 and alpha-V/beta-1 are receptors for fibronectin. Alpha-4/beta-1 recognizes one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. Integrin alpha-5/beta-1 is a receptor for fibrinogen. Integrin alpha-1/beta-1, alpha-2/beta-1, alpha-6/beta-1 and alpha-7/beta-1 are receptors for lamimin. Integrin alpha-4/beta-1 is a receptor for VCAM1. It recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-9/beta-1 is a receptor for VCAM1, cytotactin and osteopontin. It recognizes the sequence A-E-I-D-G-I-E-L in cytotactin. Integrin alpha-3/beta-1 is a receptor for epiligrin, thrombospondin and CSPG4. Alpha-3/beta-1 may mediate with LGALS3 the stimulation by CSPG4 of endothelial cells migration. Integrin alpha-V/beta-1 is a receptor for vitronectin. Beta-1 integrins recognize the sequence R-G-D in a wide array of ligands. Isoform 2 interferes with isoform 1 resulting in a dominant negative effect on cell adhesion and migration (in vitro). When associated with alpha-7/beta-1 integrin, regulates cell adhesion and laminin matrix deposition. Involved in promoting endothelial cell motility and angiogenesis. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process and the formation of mineralized bone nodules. May be involved in up-regulation of the activity of kinases such as PKC via binding to KRT1. Together with KRT1 and GNB2L1/RACK1, serves as a platform for SRC activation or inactivation. Plays a mechanistic adhesive role during telophase, required for the successful completion of cytokinesis. Integrin alpha-3/beta-1 provides a docking site for FAP (seprase) at invadopodia plasma membranes in a collagen-dependent manner and hence may participate in the adhesion, formation of invadopodia and matrix degradation processes, promoting cell invasion.Isoform 5: Isoform 5 displaces isoform 1 in striated muscles.(Microbial infection) Integrin ITGA2:ITGB1 acts as a receptor for human echoviruses 1 and 8 (PubMed:8411387). Acts as a receptor for cytomegalovirus/HHV-5 (PubMed:20660204). Acts as a receptor for Epstein-Barr virus/HHV-4 (PubMed:17945327). Integrin ITGA5:ITGB1 acts as a receptor for human parvovirus B19 (PubMed:12907437). Integrin ITGA2:ITGB1 acts as a receptor for human rotavirus (PubMed:12941907). Acts as a receptor for mammalian reovirus (PubMed:16501085). In case of HIV-1 infection, integrin ITGA5:ITGB1 binding to extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions (PubMed:10397733).", "general_function": "Virus receptor activity", "gene_names": ["ITGB1"], "name": "Integrin beta-1", "drug_actions": []}, "O06644": {"specific_function": "Involved in the catabolism of oxalate and in the adapatation to low pH via the induction of the oxalate-dependent acid tolerance response (ATR). Essential enzyme for the bacterium survival, as it relies on oxalic acid as its sole source of energy. Catalyzes the transfer of the CoA moiety from formyl-CoA to oxalate. It can also use succinate as acceptor.", "general_function": "Formyl-coa transferase activity", "gene_names": ["frc"], "name": "Formyl-CoA:oxalate CoA-transferase", "drug_actions": []}, "Q04760": {"specific_function": "Catalyzes the conversion of hemimercaptal, formed from methylglyoxal and glutathione, to S-lactoylglutathione. Involved in the regulation of TNF-induced transcriptional activity of NF-kappa-B. Required for normal osteoclastogenesis.", "general_function": "Zinc ion binding", "gene_names": ["GLO1"], "name": "Lactoylglutathione lyase", "drug_actions": [{"action": "INHIBITOR", "target": "Q04760", "drug": "DB00328"}]}, "P14679": {"specific_function": "This is a copper-containing oxidase that functions in the formation of pigments such as melanins and other polyphenolic compounds. Catalyzes the rate-limiting conversions of tyrosine to DOPA, DOPA to DOPA-quinone and possibly 5,6-dihydroxyindole to indole-5,6 quinone.", "general_function": "Protein homodimerization activity", "gene_names": ["TYR"], "name": "Tyrosinase", "drug_actions": [{"action": "INHIBITOR", "target": "P14679", "drug": "DB00548"}, {"action": "INHIBITOR", "target": "P14679", "drug": "DB00600"}, {"action": "INHIBITOR", "target": "P14679", "drug": "DB01055"}]}, "P15151": {"specific_function": "Mediates NK cell adhesion and triggers NK cell effector functions. Binds two different NK cell receptors: CD96 and CD226. These interactions accumulates at the cell-cell contact site, leading to the formation of a mature immunological synapse between NK cell and target cell. This may trigger adhesion and secretion of lytic granules and IFN-gamma and activate cytoxicity of activated NK cells. May also promote NK cell-target cell modular exchange, and PVR transfer to the NK cell. This transfer is more important in some tumor cells expressing a lot of PVR, and may trigger fratricide NK cell activation, providing tumors with a mechanism of immunoevasion. Plays a role in mediating tumor cell invasion and migration.(Microbial infection) Acts as a receptor for poliovirus. May play a role in axonal transport of poliovirus, by targeting virion-PVR-containing endocytic vesicles to the microtubular network through interaction with DYNLT1. This interaction would drive the virus-containing vesicle to the axonal retrograde transport (PubMed:2538245). Acts as a receptor for pseudorabies virus (PubMed:9616127). Is prevented to reach cell surface upon infection by human cytomegalovirus /HHV-5, presumably to escape immune recognition of infected cell by NK cells (PubMed:15640804).", "general_function": "Virus receptor activity", "gene_names": ["PVR"], "name": "Poliovirus receptor", "drug_actions": []}, "P22266": {"general_function": "Carboxylic ester hydrolase activity", "gene_names": ["estA"], "name": "Esterase", "drug_actions": []}, "P14677": {"specific_function": "Penicillin-binding proteins (PBPs) function in the late steps of murein biosynthesis. Beta-lactams inactivate the PBPs by acylating an essential serine residue in the active site of these proteins.", "general_function": "Penicillin binding", "gene_names": ["pbpX"], "name": "Penicillin-binding protein 2x", "drug_actions": [{"action": "INHIBITOR", "target": "P14677", "drug": "DB01150"}]}, "P80874": {"general_function": "Oxidoreductase activity", "gene_names": ["yhdN"], "name": "General stress protein 69", "drug_actions": []}, "P41407": {"specific_function": "Catalyzes the reductive cleavage of azo bond in aromatic azo compounds to the corresponding amines. Requires NADH, but not NADPH, as an electron donor for its activity. The enzyme can reduce ethyl red and methyl red, but is not able to convert sulfonated azo dyes.", "general_function": "Oxidoreductase activity, acting on nad(p)h, quinone or similar compound as acceptor", "gene_names": ["azoR"], "name": "FMN-dependent NADH-azoreductase", "drug_actions": []}, "P0A7Z4": {"specific_function": "DNA-dependent RNA polymerase (RNAP) catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. This subunit plays an important role in subunit assembly since its dimerization is the first step in the sequential assembly of subunits to form the holoenzyme.", "general_function": "Zinc ion binding", "gene_names": ["rpoA"], "name": "DNA-directed RNA polymerase subunit alpha", "drug_actions": [{"action": "INHIBITOR", "target": "P0A7Z4", "drug": "DB00615"}]}, "P04054": {"specific_function": "PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides, this releases glycerophospholipids and arachidonic acid that serve as the precursors of signal molecules.", "general_function": "Receptor binding", "gene_names": ["PLA2G1B"], "name": "Phospholipase A2", "drug_actions": [{"action": "ANTAGONIST", "target": "P04054", "drug": "DB00795"}, {"action": "INHIBITOR", "target": "P04054", "drug": "DB04552"}]}, "O07746": {"general_function": "Amino acid transport and metabolism", "gene_names": ["MT1933"], "name": "Secreted chorismate mutase", "drug_actions": []}, "Q01082": {"specific_function": "Fodrin, which seems to be involved in secretion, interacts with calmodulin in a calcium-dependent manner and is thus candidate for the calcium-dependent movement of the cytoskeleton at the membrane.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["SPTBN1"], "name": "Spectrin beta chain, non-erythrocytic 1", "drug_actions": [{"action": "AGONIST", "target": "Q01082", "drug": "DB01373"}]}, "P04053": {"specific_function": "Template-independent DNA polymerase which catalyzes the random addition of deoxynucleoside 5'-triphosphate to the 3'-end of a DNA initiator. One of the in vivo functions of this enzyme is the addition of nucleotides at the junction (N region) of rearranged Ig heavy chain and T-cell receptor gene segments during the maturation of B- and T-cells.", "general_function": "Metal ion binding", "gene_names": ["DNTT"], "name": "DNA nucleotidylexotransferase", "drug_actions": []}, "P0A7Z3": {"specific_function": "Catalyzes the reversible conversion of ribose-5-phosphate to ribulose 5-phosphate.", "general_function": "Ribose-5-phosphate isomerase activity", "gene_names": ["rpiA"], "name": "Ribose-5-phosphate isomerase A", "drug_actions": []}, "Q5SHR6": {"specific_function": "DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates.", "general_function": "Dna-directed rna polymerase activity", "gene_names": ["rpoA"], "name": "DNA-directed RNA polymerase subunit alpha", "drug_actions": []}, "P12851": {"general_function": "Xylose isomerase activity", "gene_names": ["xylA"], "name": "Xylose isomerase", "drug_actions": []}, "P01019": {"specific_function": "Essential component of the renin-angiotensin system (RAS), a potent regulator of blood pressure, body fluid and electrolyte homeostasis.Angiotensin-2: acts directly on vascular smooth muscle as a potent vasoconstrictor, affects cardiac contractility and heart rate through its action on the sympathetic nervous system, and alters renal sodium and water absorption through its ability to stimulate the zona glomerulosa cells of the adrenal cortex to synthesize and secrete aldosterone.Angiotensin-3: stimulates aldosterone release.Angiotensin 1-7: is a ligand for the G-protein coupled receptor MAS1. Has vasodilator and antidiuretic effects. Has an antithrombotic effect that involves MAS1-mediated release of nitric oxide from platelets.", "general_function": "Type 2 angiotensin receptor binding", "gene_names": ["AGT"], "name": "Angiotensinogen", "drug_actions": []}, "B2ZTR6": {"general_function": "Beta-lactamase activity", "gene_names": [], "name": "Beta-lactamase", "drug_actions": []}, "P00747": {"specific_function": "Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.", "general_function": "Serine-type peptidase activity", "gene_names": ["PLG"], "name": "Plasminogen", "drug_actions": [{"action": "ACTIVATOR", "target": "P00747", "drug": "DB00009"}, {"action": "ACTIVATOR", "target": "P00747", "drug": "DB00013"}, {"action": "ACTIVATOR", "target": "P00747", "drug": "DB00015"}, {"action": "ACTIVATOR", "target": "P00747", "drug": "DB00029"}, {"action": "ACTIVATOR", "target": "P00747", "drug": "DB00031"}, {"action": "ACTIVATOR", "target": "P00747", "drug": "DB00086"}, {"action": "INHIBITOR", "target": "P00747", "drug": "DB00302"}, {"action": "INHIBITOR", "target": "P00747", "drug": "DB00513"}]}, "P00746": {"specific_function": "Factor D cleaves factor B when the latter is complexed with factor C3b, activating the C3bbb complex, which then becomes the C3 convertase of the alternate pathway. Its function is homologous to that of C1s in the classical pathway.", "general_function": "Serine-type peptidase activity", "gene_names": ["CFD"], "name": "Complement factor D", "drug_actions": []}, "P00740": {"specific_function": "Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["F9"], "name": "Coagulation factor IX", "drug_actions": [{"action": "COFACTOR", "target": "P00740", "drug": "DB00025"}, {"action": "ACTIVATOR", "target": "P00740", "drug": "DB00170"}]}, "O11885": {"specific_function": "Multifunctional enzyme that converts the viral RNA genome into dsDNA in viral cytoplasmic capsids. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3'- to 5'-endonucleasic mode. Neo-synthesized pregenomic RNA (pgRNA) are encapsidated together with the P protein, and reverse-transcribed inside the nucleocapsid. Initiation of reverse-transcription occurs first by binding the epsilon loop on the pgRNA genome, and is initiated by protein priming, thereby the 5'-end of (-)DNA is covalently linked to P protein. Partial (+)DNA is synthesized from the (-)DNA template and generates the relaxed circular DNA (RC-DNA) genome. After budding and infection, the RC-DNA migrates in the nucleus, and is converted into a plasmid-like covalently closed circular DNA (cccDNA). The activity of P protein does not seem to be necessary for cccDNA generation, and is presumably released from (+)DNA by host nuclear DNA repair machinery (By similarity).", "general_function": "Rna-dna hybrid ribonuclease activity", "gene_names": [], "name": "Protein P", "drug_actions": []}, "P00742": {"specific_function": "Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["F10"], "name": "Coagulation factor X", "drug_actions": [{"action": "ACTIVATOR", "target": "P00742", "drug": "DB00025"}, {"action": "ACTIVATOR", "target": "P00742", "drug": "DB00100"}, {"action": "ACTIVATOR", "target": "P00742", "drug": "DB00170"}, {"action": "INHIBITOR", "target": "P00742", "drug": "DB00569"}, {"action": "INHIBITOR", "target": "P00742", "drug": "DB01109"}, {"action": "INHIBITOR", "target": "P00742", "drug": "DB01225"}, {"action": "ANTAGONIST", "target": "P00742", "drug": "DB06228"}, {"action": "INHIBITOR", "target": "P00742", "drug": "DB06605"}, {"action": "INHIBITOR", "target": "P00742", "drug": "DB09075"}]}, "Q9KB30": {"specific_function": "Hydrolyzes xylooligosaccharides with a degree of polymerization of greater than or equal to 3, releasing xylose from the reducing end. Only hydrolyzes the beta anomers of xylooligosaccharides, with inversion of anomeric configuration. Hydrolyzes the glucose and xylose-based trisaccharides where xylose is located at the -1 subsite, GXX, XXG and GXG. Does not hydrolyze xylan, chitosan, lichenan, curdlan or carboxymethylcellulose.", "general_function": "Oligosaccharide reducing-end xylanase activity", "gene_names": [], "name": "Reducing end xylose-releasing exo-oligoxylanase", "drug_actions": []}, "P00749": {"specific_function": "Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["PLAU"], "name": "Urokinase-type plasminogen activator", "drug_actions": [{"action": "INHIBITOR", "target": "P00749", "drug": "DB00594"}]}, "Q14500": {"specific_function": "Inward rectifying potassium channel that is activated by phosphatidylinositol 4,5-bisphosphate and that probably participates in controlling the resting membrane potential in electrically excitable cells. Probably participates in establishing action potential waveform and excitability of neuronal and muscle tissues. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium.", "name": "ATP-sensitive inward rectifier potassium channel 12", "drug_actions": [{"action": "INHIBITOR", "target": "Q14500", "drug": "DB00204"}], "general_function": "Inward rectifier potassium channel activity", "in_complexes": ["ATP-sensitive potassium channel"], "gene_names": ["KCNJ12"]}, "P26396": {"specific_function": "Involved in the biosynthesis of the tyvelose, a 3,6-dideoxyhexose found in the O-antigen of the surface lipopolysaccharides. It catalyzes the transfer of a CMP moiety from CTP to glucose 1-phosphate (By similarity).", "general_function": "Nucleotide binding", "gene_names": ["rfbF"], "name": "Glucose-1-phosphate cytidylyltransferase", "drug_actions": []}, "P26397": {"general_function": "Cdp-glucose 4,6-dehydratase activity", "gene_names": ["rfbG"], "name": "CDP-glucose 4,6-dehydratase", "drug_actions": []}, "P26394": {"specific_function": "Catalyzes the epimerization of the C3' and C5'positions of dTDP-6-deoxy-D-xylo-4-hexulose, forming dTDP-6-deoxy-L-lyxo-4-hexulose.", "general_function": "Dtdp-4-dehydrorhamnose 3,5-epimerase activity", "gene_names": ["rfbC"], "name": "dTDP-4-dehydrorhamnose 3,5-epimerase", "drug_actions": []}, "Q9GZU7": {"specific_function": "Preferentially catalyzes the dephosphorylation of 'Ser-5' within the tandem 7 residue repeats in the C-terminal domain (CTD) of the largest RNA polymerase II subunit POLR2A. Negatively regulates RNA polymerase II transcription, possibly by controlling the transition from initiation/capping to processive transcript elongation. Recruited by REST to neuronal genes that contain RE-1 elements, leading to neuronal gene silencing in non-neuronal cells.", "general_function": "Metal ion binding", "gene_names": ["CTDSP1"], "name": "Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1", "drug_actions": []}, "Q96RD7": {"specific_function": "Structural component of the gap junctions and the hemichannels. May play a role as a Ca(2+)-leak channel to regulate ER Ca(2+) homeostasis.", "general_function": "Receptor binding", "gene_names": ["PANX1"], "name": "Pannexin-1", "drug_actions": [{"action": "ANTAGONIST", "target": "Q96RD7", "drug": "DB01032"}]}, "P26393": {"specific_function": "Catalyzes the formation of dTDP-glucose, from dTTP and glucose 1-phosphate, as well as its pyrophosphorolysis. Is also able to convert non natural substrates such as a wide array of alpha-D-hexopyranosyl, deoxy-alpha-D-glucopyranosyl, aminodeoxy-alpha-D-hexopyranosyl and acetamidodeoxy-alpha-D-hexopyranosyl phosphates to their corresponding dTDP- and UDP-nucleotide sugars.", "general_function": "Magnesium ion binding", "gene_names": ["rmlA"], "name": "Glucose-1-phosphate thymidylyltransferase", "drug_actions": []}, "P59998": {"specific_function": "Functions as actin-binding component of the Arp2/3 complex which is involved in regulation of actin polymerization and together with an activating nucleation-promoting factor (NPF) mediates the formation of branched actin networks. Seems to contact the mother actin filament.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["ARPC4"], "name": "Actin-related protein 2/3 complex subunit 4", "drug_actions": []}, "P26391": {"specific_function": "Catalyzes the dehydration of dTDP-D-glucose to form dTDP-6-deoxy-D-xylo-4-hexulose via a three-step process involving oxidation, dehydration and reduction.", "general_function": "Nadh binding", "gene_names": ["rfbB"], "name": "dTDP-glucose 4,6-dehydratase", "drug_actions": []}, "Q94M05": {"general_function": "Atp binding", "gene_names": ["4"], "name": "NTPase P4", "drug_actions": []}, "C9EH48": {"general_function": "Transporter activity", "gene_names": ["mdfA"], "name": "Multidrug translocase MdfA", "drug_actions": []}, "Q64823": {"general_function": "Metal ion binding", "gene_names": ["L5"], "name": "Fiber", "drug_actions": []}, "Q64822": {"gene_names": ["L5"], "name": "Fiber", "drug_actions": []}, "P12931": {"specific_function": "Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors. Participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. SRC appears to be one of the primary kinases activated following engagement of receptors and plays a role in the activation of other protein tyrosine kinase (PTK) families. Receptor clustering or dimerization leads to recruitment of SRC to the receptor complexes where it phosphorylates the tyrosine residues within the receptor cytoplasmic domains. Plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1. Phosphorylation of AFAP1 allows the SRC SH2 domain to bind AFAP1 and to localize to actin filaments. Cytoskeletal reorganization is also controlled through the phosphorylation of cortactin (CTTN). When cells adhere via focal adhesions to the extracellular matrix, signals are transmitted by integrins into the cell resulting in tyrosine phosphorylation of a number of focal adhesion proteins, including PTK2/FAK1 and paxillin (PXN). In addition to phosphorylating focal adhesion proteins, SRC is also active at the sites of cell-cell contact adherens junctions and phosphorylates substrates such as beta-catenin (CTNNB1), delta-catenin (CTNND1), and plakoglobin (JUP). Another type of cell-cell junction, the gap junction, is also a target for SRC, which phosphorylates connexin-43 (GJA1). SRC is implicated in regulation of pre-mRNA-processing and phosphorylates RNA-binding proteins such as KHDRBS1. Also plays a role in PDGF-mediated tyrosine phosphorylation of both STAT1 and STAT3, leading to increased DNA binding activity of these transcription factors. Involved in the RAS pathway through phosphorylation of RASA1 and RASGRF1. Plays a role in EGF-mediated calcium-activated chloride channel activation. Required for epidermal growth factor receptor (EGFR) internalization through phosphorylation of clathrin heavy chain (CLTC and CLTCL1) at 'Tyr-1477'. Involved in beta-arrestin (ARRB1 and ARRB2) desensitization through phosphorylation and activation of ADRBK1, leading to beta-arrestin phosphorylation and internalization. Has a critical role in the stimulation of the CDK20/MAPK3 mitogen-activated protein kinase cascade by epidermal growth factor. Might be involved not only in mediating the transduction of mitogenic signals at the level of the plasma membrane but also in controlling progression through the cell cycle via interaction with regulatory proteins in the nucleus. Plays an important role in osteoclastic bone resorption in conjunction with PTK2B/PYK2. Both the formation of a SRC-PTK2B/PYK2 complex and SRC kinase activity are necessary for this function. Recruited to activated integrins by PTK2B/PYK2, thereby phosphorylating CBL, which in turn induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. Promotes energy production in osteoclasts by activating mitochondrial cytochrome C oxidase. Phosphorylates DDR2 on tyrosine residues, thereby promoting its subsequent autophosphorylation. Phosphorylates RUNX3 and COX2 on tyrosine residues, TNK2 on 'Tyr-284' and CBL on 'Tyr-731'. Enhances DDX58/RIG-I-elicited antiviral signaling. Phosphorylates PDPK1 at 'Tyr-9', 'Tyr-373' and 'Tyr-376'. Phosphorylates BCAR1 at 'Tyr-128'. Phosphorylates CBLC at multiple tyrosine residues, phosphorylation at 'Tyr-341' activates CBLC E3 activity. Required for podosome formation (By similarity).", "general_function": "Sh3/sh2 adaptor activity", "gene_names": ["SRC"], "name": "Proto-oncogene tyrosine-protein kinase Src", "drug_actions": [{"action": "MULTITARGET", "target": "P12931", "drug": "DB01254"}, {"action": "INHIBITOR", "target": "P12931", "drug": "DB06616"}, {"action": "INHIBITOR", "target": "P12931", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P12931", "drug": "DB09079"}]}, "P03276": {"specific_function": "Major capsid protein that self-associates to form penton base pentamers, each in the shape of a pentagon, situated at the 12 vertices of the pseudo T=25 capsid. Involved in virus secondary attachment to host cell after initial attachment by the fiber protein. Binds host integrin heterodimer ITGAV-ITGB5 (alphaV-beta5) thereby triggering clathrin-mediated endocytosis of virions. Mediates initial virus attachment to CXADR-negative cells. Binding to integrins ITGAV-ITGB5 also seems to induce macropinocytosis uptake of the virus. As the virus enters the host cell, penton proteins are shed concomitant with virion acidification in the endosome.", "general_function": "Structural molecule activity", "gene_names": [], "name": "Penton protein", "drug_actions": []}, "P03277": {"specific_function": "Major capsid protein that self-associates to form 240 hexon trimers, each in the shape of a hexagon, building most of the pseudo T=25 capsid. Assembled into trimeric units with the help of the chaperone shutoff protein. Transported by pre-protein VI to the nucleus where it associates with other structural proteins to form an empty capsid. Might be involved, through its interaction with host dyneins, in the intracellular microtubule-dependent transport of incoming viral capsid to the nucleus.", "general_function": "Structural molecule activity", "gene_names": [], "name": "Hexon protein", "drug_actions": []}, "Q8IW54": {"general_function": "Metal ion binding", "gene_names": ["PDE2A"], "name": "Phosphodiesterase 2A, cGMP-stimulated", "drug_actions": []}, "P05884": {"specific_function": "Allows rapid transcytosis of the virus through CD4 negative cells such as simple epithelial monolayers of the intestinal, rectal and endocervical epithelial barriers. Both gp120 and gp41 specifically recognize glycosphingolipids galactosyl-ceramide (GalCer) or 3' sulfo-galactosyl-ceramide (GalS) present in the lipid rafts structures of epithelial cells. Binding to these alternative receptors allows the rapid transcytosis of the virus through the epithelial cells. This transcytotic vesicle-mediated transport of virions from the apical side to the basolateral side of the epithelial cells does not involve infection of the cells themselves (By similarity)", "general_function": "Involved in structural molecule activity", "gene_names": ["env"], "name": "Envelope glycoprotein gp160", "drug_actions": []}, "Q02218": {"specific_function": "The 2-oxoglutarate dehydrogenase complex catalyzes the overall conversion of 2-oxoglutarate to succinyl-CoA and CO(2). It contains multiple copies of three enzymatic components: 2-oxoglutarate dehydrogenase (E1), dihydrolipoamide succinyltransferase (E2) and lipoamide dehydrogenase (E3).", "general_function": "Thiamine pyrophosphate binding", "gene_names": ["OGDH"], "name": "2-oxoglutarate dehydrogenase, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "Q02218", "drug": "DB00313"}]}, "Q96FL8": {"specific_function": "Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acyclovir, ganciclovir and also the zwitterionic cephalosporin, cephalexin and cephradin. Seems to also play a role in the uptake of oxaliplatin (a new platinum anticancer agent). Able to transport paraquat (PQ or N,N-dimethyl-4-4'-bipiridinium); a widely used herbicid. Responsible for the secretion of cationic drugs across the brush border membranes.", "general_function": "Monovalent cation:proton antiporter activity", "gene_names": ["SLC47A1"], "name": "Multidrug and toxin extrusion protein 1", "drug_actions": []}, "C1KC03": {"general_function": "Penicillin binding", "gene_names": ["mecA"], "name": "Penicillin binding protein 2a", "drug_actions": [{"action": "INHIBITOR", "target": "C1KC03", "drug": "DB00274"}, {"action": "INHIBITOR", "target": "C1KC03", "drug": "DB00430"}, {"action": "INHIBITOR", "target": "C1KC03", "drug": "DB01000"}, {"action": "INHIBITOR", "target": "C1KC03", "drug": "DB01607"}]}, "P03474": {"specific_function": "Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells (By similarity).", "general_function": "Metal ion binding", "gene_names": ["NA"], "name": "Neuraminidase", "drug_actions": []}, "Q13183": {"specific_function": "Cotransport of sodium ions and dicarboxylates such as succinate and citrate.", "general_function": "Low-affinity sodium:dicarboxylate symporter activity", "gene_names": ["SLC13A2"], "name": "Solute carrier family 13 member 2", "drug_actions": []}, "P03472": {"specific_function": "Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells. Likely to plays a role in the budding process through its association with lipid rafts during intracellular transport. May additionally display a raft-association independent effect on budding. Plays a role in the determination of host range restriction on replication and virulence. Sialidase activity in late endosome/lysosome traffic seems to enhance virus replication.", "general_function": "Metal ion binding", "gene_names": ["NA"], "name": "Neuraminidase", "drug_actions": []}, "Q9UG56": {"general_function": "Phosphatidylserine decarboxylase activity", "gene_names": ["PISD"], "name": "Phosphatidylserine decarboxylase proenzyme", "drug_actions": []}, "P46976": {"specific_function": "Self-glucosylates, via an inter-subunit mechanism, to form an oligosaccharide primer that serves as substrate for glycogen synthase.", "general_function": "Metal ion binding", "gene_names": ["GYG1"], "name": "Glycogenin-1", "drug_actions": []}, "P49257": {"specific_function": "Mannose-specific lectin. May recognize sugar residues of glycoproteins, glycolipids, or glycosylphosphatidyl inositol anchors and may be involved in the sorting or recycling of proteins, lipids, or both. The LMAN1-MCFD2 complex forms a specific cargo receptor for the ER-to-Golgi transport of selected proteins.", "general_function": "Unfolded protein binding", "gene_names": ["LMAN1"], "name": "Protein ERGIC-53", "drug_actions": [{"action": "CHAPERONE", "target": "P49257", "drug": "DB00025"}]}, "P25787": {"specific_function": "The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. PSMA2 may have a potential regulatory effect on another component(s) of the proteasome complex through tyrosine phosphorylation.", "general_function": "Threonine-type endopeptidase activity", "gene_names": ["PSMA2"], "name": "Proteasome subunit alpha type-2", "drug_actions": []}, "A8MPY1": {"specific_function": "GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.", "general_function": "Gaba-a receptor activity", "gene_names": ["GABRR3"], "name": "Gamma-aminobutyric acid receptor subunit rho-3", "drug_actions": [{"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB01215"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "A8MPY1", "drug": "DB01595"}]}, "Q9GPQ4": {"general_function": "Metal ion binding", "gene_names": [], "name": "IAG-nucleoside hydrolase", "drug_actions": []}, "P35225": {"specific_function": "Cytokine. Inhibits inflammatory cytokine production. Synergizes with IL2 in regulating interferon-gamma synthesis. May be critical in regulating inflammatory and immune responses.", "general_function": "Interleukin-13 receptor binding", "gene_names": ["IL13"], "name": "Interleukin-13", "drug_actions": []}, "P60472": {"specific_function": "Generates ditrans,octacis-undecaprenyl pyrophosphate (UPP) from isopentenyl pyrophosphate (IPP) and farnesyl diphosphate (FPP). UPP is the precursor of glycosyl carrier lipid in the biosynthesis of bacterial cell wall polysaccharide components such as peptidoglycan and lipopolysaccharide.", "general_function": "Magnesium ion binding", "gene_names": ["ispU"], "name": "Ditrans,polycis-undecaprenyl-diphosphate synthase ((2E,6E)-farnesyl-diphosphate specific)", "drug_actions": []}, "P11350": {"specific_function": "The nitrate reductase enzyme complex allows E.coli to use nitrate as an electron acceptor during anaerobic growth. The gamma chain is a membrane-embedded heme-iron unit resembling cytochrome b, which transfers electrons from quinones to the beta subunit.", "general_function": "Nitrate reductase activity", "gene_names": ["narI"], "name": "Respiratory nitrate reductase 1 gamma chain", "drug_actions": []}, "P52647": {"specific_function": "Oxidoreductase required for the transfer of electrons from pyruvate to flavodoxin.", "general_function": "Thiamine pyrophosphate binding", "gene_names": ["ydbK"], "name": "Probable pyruvate-flavodoxin oxidoreductase", "drug_actions": [{"action": "POTENTIATOR", "target": "P52647", "drug": "DB00698"}]}, "P60479": {"gene_names": ["uppS"], "name": "Decaprenyl diphosphate synthase", "drug_actions": []}, "P28908": {"specific_function": "Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B.", "general_function": "Tumor necrosis factor-activated receptor activity", "gene_names": ["TNFRSF8"], "name": "Tumor necrosis factor receptor superfamily member 8", "drug_actions": [{"action": "BINDER", "target": "P28908", "drug": "DB08870"}]}, "P61322": {"specific_function": "Plays a critical role in the incorporation of lipoproteins in the outer membrane after they are released by the LolA protein.", "general_function": "Protein transporter activity", "gene_names": ["lolB"], "name": "Outer-membrane lipoprotein LolB", "drug_actions": []}, "P51149": {"specific_function": "Key regulator in endo-lysosomal trafficking. Governs early-to-late endosomal maturation, microtubule minus-end as well as plus-end directed endosomal migration and positioning, and endosome-lysosome transport through different protein-protein interaction cascades. Plays a central role, not only in endosomal traffic, but also in many other cellular and physiological events, such as growth-factor-mediated cell signaling, nutrient-transportor mediated nutrient uptake, neurotrophin transport in the axons of neurons and lipid metabolism. Also involved in regulation of some specialized endosomal membrane trafficking, such as maturation of melanosomes, pathogen-induced phagosomes (or vacuoles) and autophagosomes. Plays a role in the maturation and acidification of phagosomes that engulf pathogens, such as S.aureus and M.tuberculosis. Plays a role in the fusion of phagosomes with lysosomes. Plays important roles in microbial pathogen infection and survival, as well as in participating in the life cycle of viruses. Microbial pathogens possess survival strategies governed by RAB7A, sometimes by employing RAB7A function (e.g. Salmonella) and sometimes by excluding RAB7A function (e.g. Mycobacterium). In concert with RAC1, plays a role in regulating the formation of RBs (ruffled borders) in osteoclasts. Controls the endosomal trafficking and neurite outgrowth signaling of NTRK1/TRKA (PubMed:11179213, PubMed:12944476, PubMed:14617358, PubMed:20028791, PubMed:21255211). Regulates the endocytic trafficking of the EGF-EGFR complex by regulating its lysosomal degradation. Involved in the ADRB2-stimulated lipolysis through lipophagy, a cytosolic lipase-independent autophagic pathway (By similarity).", "general_function": "Gtpase activity", "gene_names": ["RAB7A"], "name": "Ras-related protein Rab-7a", "drug_actions": []}, "P61320": {"specific_function": "Plays a critical role in the incorporation of lipoproteins in the outer membrane after they are released by the LolA protein. Essential for E.coli viability.", "general_function": "Protein transporter activity", "gene_names": ["lolB"], "name": "Outer-membrane lipoprotein LolB", "drug_actions": []}, "O52646": {"gene_names": ["acma"], "name": "Aklanonic acid methyl ester cyclase AcmA", "drug_actions": []}, "O14832": {"specific_function": "Converts phytanoyl-CoA to 2-hydroxyphytanoyl-CoA.", "general_function": "Phytanoyl-coa dioxygenase activity", "gene_names": ["PHYH"], "name": "Phytanoyl-CoA dioxygenase, peroxisomal", "drug_actions": [{"action": "ANTAGONIST", "target": "O14832", "drug": "DB00025"}]}, "Q6PYX1": {"gene_names": [], "name": "Hepatitis B virus receptor binding protein", "drug_actions": []}, "P06993": {"specific_function": "Positively regulates the transcription of the maltose regulon whose gene products are responsible for uptake and catabolism of malto-oligosaccharides. Binds and recognizes a DNA motif (called the malT box): 5'-GGA[TG]GA-3'.", "general_function": "Trisaccharide binding", "gene_names": ["malT"], "name": "HTH-type transcriptional regulator MalT", "drug_actions": []}, "O43447": {"specific_function": "PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. Participates in pre-mRNA splicing. May play a role in the assembly of the U4/U5/U6 tri-snRNP complex, one of the building blocks of the spliceosome. May act as a chaperone.", "general_function": "Ribonucleoprotein complex binding", "gene_names": ["PPIH"], "name": "Peptidyl-prolyl cis-trans isomerase H", "drug_actions": []}, "P48039": {"specific_function": "High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that inhibit adenylate cyclase activity.", "general_function": "Organic cyclic compound binding", "gene_names": ["MTNR1A"], "name": "Melatonin receptor type 1A", "drug_actions": [{"action": "MULTITARGET", "target": "P48039", "drug": "DB00980"}, {"action": "AGONIST", "target": "P48039", "drug": "DB01065"}, {"action": "AGONIST", "target": "P48039", "drug": "DB06594"}, {"action": "AGONIST", "target": "P48039", "drug": "DB09071"}]}, "P03316": {"specific_function": "Capsid protein possesses a protease activity that results in its autocatalytic cleavage from the nascent structural protein. Following its self-cleavage, the capsid protein transiently associates with ribosomes, and within several minutes the protein binds to viral RNA and rapidly assembles into icosaedric core particles. The resulting nucleocapsid eventually associates with the cytoplasmic domain of E2 at the cell membrane, leading to budding and formation of mature virions. New virions attach to target cells, and after clathrin-mediated endocytosis their membrane fuses with the host endosomal membrane. This leads to the release of the nucleocapsid into the cytoplasm, followed by an uncoating event necessary for the genomic RNA to become accessible. The uncoating might be triggered by the interaction of capsid proteins with ribosomes. Binding of ribosomes would release the genomic RNA since the same region is genomic RNA-binding and ribosome-binding (By similarity).E3 protein's function is unknown.E2 is responsible for viral attachment to target host cell, by binding to the cell receptor. Synthesized as a p62 precursor which is processed by furin at the cell membrane just before virion budding, giving rise to E2-E1 heterodimer. The p62-E1 heterodimer is stable, whereas E2-E1 is unstable and dissociate at low pH. p62 is processed at the last step, presumably to avoid E1 fusion activation before its final export to cell surface. E2 C-terminus contains a transitory transmembrane that would be disrupted by palmitoylation, resulting in reorientation of the C-terminal tail from lumenal to cytoplasmic side. This step is critical since E2 C-terminus is involved in budding by interacting with capsid proteins. This release of E2 C-terminus in cytoplasm occurs lately in protein export, and precludes premature assembly of particles at the endoplasmic reticulum membrane (By similarity).6K is a constitutive membrane protein involved in virus glycoprotein processing, cell permeabilization, and the budding of viral particles. Disrupts the calcium homeostasis of the cell, probably at the endoplasmic reticulum level. This leads to cytoplasmic calcium elevation. Because of its lipophilic properties, the 6K protein is postulated to influence the selection of lipids that interact with the transmembrane domains of the glycoproteins, which, in turn, affects the deformability of the bilayer required for the extreme curvature that occurs as budding proceeds. Present in low amount in virions, about 3% compared to viral glycoproteins.E1 is a class II viral fusion protein. Fusion activity is inactive as long as E1 is bound to E2 in mature virion. After virus attachment to target cell and endocytosis, acidification of the endosome would induce dissociation of E1/E2 heterodimer and concomitant trimerization of the E1 subunits. This E1 trimer is fusion active, and promotes release of viral nucleocapsid in cytoplasm after endosome and viral membrane fusion. Efficient fusion requires the presence of cholesterol and sphingolipid in the target membrane (By similarity).", "general_function": "Ubiquitin-like protein ligase binding", "gene_names": [], "name": "Structural polyprotein", "drug_actions": []}, "P0AAI5": {"specific_function": "Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP. Has a preference for short chain acid substrates and may function to supply the octanoic substrates for lipoic acid biosynthesis.", "general_function": "Beta-ketoacyl-acyl-carrier-protein synthase ii activity", "gene_names": ["fabF"], "name": "3-oxoacyl-[acyl-carrier-protein] synthase 2", "drug_actions": [{"action": "INHIBITOR", "target": "P0AAI5", "drug": "DB01034"}]}, "P98194": {"specific_function": "This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the transport of the calcium.", "general_function": "Signal transducer activity", "gene_names": ["ATP2C1"], "name": "Calcium-transporting ATPase type 2C member 1", "drug_actions": [{"action": "INHIBITOR", "target": "P98194", "drug": "DB00228"}, {"action": "INHIBITOR", "target": "P98194", "drug": "DB00753"}, {"action": "INHIBITOR", "target": "P98194", "drug": "DB01028"}, {"action": "OTHER/UNKNOWN", "target": "P98194", "drug": "DB01159"}, {"action": "INHIBITOR", "target": "P98194", "drug": "DB01189"}, {"action": "INHIBITOR", "target": "P98194", "drug": "DB01236"}, {"action": "AGONIST", "target": "P98194", "drug": "DB01373"}]}, "P11137": {"specific_function": "The exact function of MAP2 is unknown but MAPs may stabilize the microtubules against depolymerization. They also seem to have a stiffening effect on microtubules.", "general_function": "Structural molecule activity", "gene_names": ["MAP2"], "name": "Microtubule-associated protein 2", "drug_actions": [{"action": "ANTAGONIST", "target": "P11137", "drug": "DB01196"}]}, "P04936": {"specific_function": "Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host VLDLR to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP2: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP3: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP4: Lies on the inner surface of the capsid shell. After binding to the host receptor, the capsid undergoes conformational changes. Capsid protein VP4 is released, Capsid protein VP1 N-terminus is externalized, and together, they shape a pore in the host membrane through which the viral genome is translocated into the host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP0: Component of immature procapsids, which is cleaved into capsid proteins VP4 and VP2 after maturation. Allows the capsid to remain inactive before the maturation step (By similarity).Protein 2A: Cysteine protease that cleaves viral polyprotein and specific host proteins. It is responsible for the cleavage between the P1 and P2 regions, first cleavage occurring in the polyprotein. Cleaves also the host translation initiation factor EIF4G1, in order to shut down the capped cellular mRNA translation. Inhibits the host nucleus-cytoplasm protein and RNA trafficking by cleaving host members of the nuclear pores (By similarity).Protein 2B: Plays an essential role in the virus replication cycle by acting as a viroporin. Creates a pore in the host reticulum endoplasmic and as a consequence releases Ca2+ in the cytoplasm of infected cell. In turn, high levels of cyctoplasmic calcium may trigger membrane trafficking and transport of viral ER-associated proteins to viroplasms, sites of viral genome replication (By similarity).Protein 2C: Induces and associates with structural rearrangements of intracellular membranes. Displays RNA-binding, nucleotide binding and NTPase activities. May play a role in virion morphogenesis and viral RNA encapsidation by interacting with the capsid protein VP3 (By similarity).Protein 3AB: Localizes the viral replication complex to the surface of membranous vesicles. Together with protein 3CD binds the Cis-Active RNA Element (CRE) which is involved in RNA synthesis initiation. Acts as a cofactor to stimulate the activity of 3D polymerase, maybe through a nucleid acid chaperone activity (By similarity).Protein 3A: Localizes the viral replication complex to the surface of membranous vesicles. It inhibits host cell endoplasmic reticulum-to-Golgi apparatus transport and causes the dissassembly of the Golgi complex, possibly through GBF1 interaction. This would result in depletion of MHC, trail receptors and IFN receptors at the host cell surface (By similarity).Viral protein genome-linked: acts as a primer for viral RNA replication and remains covalently bound to viral genomic RNA. VPg is uridylylated prior to priming replication into VPg-pUpU. The oriI viral genomic sequence may act as a template for this. The VPg-pUpU is then used as primer on the genomic RNA poly(A) by the RNA-dependent RNA polymerase to replicate the viral genome. VPg may be removed in the cytoplasm by an unknown enzyme termed \"unlinkase\". VPg is not cleaved off virion genomes because replicated genomic RNA are encapsidated at the site of replication (By similarity).Protein 3CD: Is involved in the viral replication complex and viral polypeptide maturation. It exhibits protease activity with a specificity and catalytic efficiency that is different from protease 3C. Protein 3CD lacks polymerase activity. The 3C domain in the context of protein 3CD may have an RNA binding activity (By similarity).Protease 3C: cleaves host DDX58/RIG-I and thus contributes to the inhibition of type I interferon production. Cleaves also host PABPC1 (By similarity).RNA-directed RNA polymerase: Replicates the viral genomic RNA on the surface of intracellular membranes. May form linear arrays of subunits that propagate along a strong head-to-tail interaction called interface-I. Covalently attaches UMP to a tyrosine of VPg, which is used to prime RNA synthesis. The positive stranded RNA genome is first replicated at virus induced membranous vesicles, creating a dsRNA genomic replication form. This dsRNA is then used as template to synthesize positive stranded RNA genomes. ss(+)RNA genomes are either translated, replicated or encapsidated (By similarity).", "general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "Q60049": {"specific_function": "Can oxidize either NADH or NADPH with a preference for NADH. Can catalyze electron transfer from NADH to various electron acceptors which include, in addition to molecular oxygen, cytochrome c, 2,6 dichlorphenolindophenol, methylene blue, ferricyanide or P-nitroblue tetrazolium.", "general_function": "Nadh dehydrogenase activity", "gene_names": ["nox"], "name": "NADH dehydrogenase", "drug_actions": []}, "Q9HZZ3": {"gene_names": ["ohr"], "name": "Organic hydroperoxide resistance protein", "drug_actions": []}, "Q16348": {"specific_function": "Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.", "general_function": "Peptide:proton symporter activity", "gene_names": ["SLC15A2"], "name": "Solute carrier family 15 member 2", "drug_actions": []}, "P34024": {"specific_function": "Cleaves glycosylphosphatidylinositol (GPI) and phosphatidylinositol (PI) anchors but not PI phosphates. Important factor in pathogenesis, PI-PLC activity is present only in virulent listeria species. It may participate in the lysis of the phagolysosomal membrane.", "general_function": "Phosphoric diester hydrolase activity", "gene_names": ["plcA"], "name": "1-phosphatidylinositol phosphodiesterase", "drug_actions": []}, "P0AGE0": {"specific_function": "Plays an important role in DNA replication, recombination and repair. Binds to ssDNA and to an array of partner proteins to recruit them to their sites of action during DNA metabolism. Acts as a sliding platform that migrates on DNA via reptation.", "general_function": "Single-stranded dna binding", "gene_names": ["ssb"], "name": "Single-stranded DNA-binding protein", "drug_actions": []}, "P50225": {"specific_function": "Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of catecholamines, phenolic drugs and neurotransmitters. Has also estrogen sulfotransferase activity. responsible for the sulfonation and activation of minoxidil. Is Mediates the metabolic activation of carcinogenic N-hydroxyarylamines to DNA binding products and could so participate as modulating factor of cancer risk.", "general_function": "Sulfotransferase activity", "gene_names": ["SULT1A1"], "name": "Sulfotransferase 1A1", "drug_actions": []}, "P22340": {"specific_function": "Porin for sucrose uptake.", "general_function": "Porin activity", "gene_names": ["scrY"], "name": "Sucrose porin", "drug_actions": []}, "P63096": {"specific_function": "Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems. The G(i) proteins are involved in hormonal regulation of adenylate cyclase: they inhibit the cyclase in response to beta-adrenergic stimuli. The inactive GDP-bound form prevents the association of RGS14 with centrosomes and is required for the translocation of RGS14 from the cytoplasm to the plasma membrane. May play a role in cell division.", "general_function": "Signal transducer activity", "gene_names": ["GNAI1"], "name": "Guanine nucleotide-binding protein G(i) subunit alpha-1", "drug_actions": []}, "P03951": {"specific_function": "Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["F11"], "name": "Coagulation factor XI", "drug_actions": [{"action": "LIGAND", "target": "P03951", "drug": "DB00100"}]}, "P63092": {"specific_function": "Guanine nucleotide-binding proteins (G proteins) function as transducers in numerous signaling pathways controlled by G protein-coupled receptors (GPCRs) (PubMed:17110384). Signaling involves the activation of adenylyl cyclases, resulting in increased levels of the signaling molecule cAMP (PubMed:26206488, PubMed:8702665). GNAS functions downstream of several GPCRs, including beta-adrenergic receptors (PubMed:21488135). Stimulates the Ras signaling pathway via RAPGEF2 (PubMed:12391161).", "general_function": "Signal transducer activity", "gene_names": ["GNAS"], "name": "Guanine nucleotide-binding protein G(s) subunit alpha isoforms short", "drug_actions": []}, "Q9UGJ0": {"specific_function": "AMP/ATP-binding subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin. Gamma non-catalytic subunit mediates binding to AMP, ADP and ATP, leading to activate or inhibit AMPK: AMP-binding results in allosteric activation of alpha catalytic subunit (PRKAA1 or PRKAA2) both by inducing phosphorylation and preventing dephosphorylation of catalytic subunits. ADP also stimulates phosphorylation, without stimulating already phosphorylated catalytic subunit. ATP promotes dephosphorylation of catalytic subunit, rendering the AMPK enzyme inactive.", "name": "5'-AMP-activated protein kinase subunit gamma-2", "drug_actions": [{"action": "ACTIVATOR", "target": "Q9UGJ0", "drug": "DB00945"}], "general_function": "Protein kinase binding", "in_complexes": ["5'-AMP-activated protein kinase"], "gene_names": ["PRKAG2"]}, "Q15116": {"specific_function": "Inhibitory cell surface receptor involved in the regulation of T-cell function during immunity and tolerance. Upon ligand binding, inhibits T-cell effector functions in an antigen-specific manner. Possible cell death inducer, in association with other factors.", "general_function": "Signal transducer activity", "gene_names": ["PDCD1"], "name": "Programmed cell death protein 1", "drug_actions": [{"action": "ANTIBODY", "target": "Q15116", "drug": "DB09035"}, {"action": "ANTAGONIST", "target": "Q15116", "drug": "DB09037"}, {"action": "ANTIBODY", "target": "Q15116", "drug": "DB09037"}]}, "P63098": {"specific_function": "Regulatory subunit of calcineurin, a calcium-dependent, calmodulin stimulated protein phosphatase. Confers calcium sensitivity.", "general_function": "Protein domain specific binding", "gene_names": ["PPP3R1"], "name": "Calcineurin subunit B type 1", "drug_actions": []}, "P05695": {"specific_function": "Anion specific, the binding site has higher affinity for phosphate than chloride ions. Porin O has a higher affinity for polyphosphates (tripolyphosphate and pyrophosphate) while porin P has a higher affinity for orthophosphate.", "general_function": "Porin activity", "gene_names": ["oprP"], "name": "Porin P", "drug_actions": []}, "P33316": {"specific_function": "This enzyme is involved in nucleotide metabolism: it produces dUMP, the immediate precursor of thymidine nucleotides and it decreases the intracellular concentration of dUTP so that uracil cannot be incorporated into DNA.", "general_function": "Poly(a) rna binding", "gene_names": ["DUT"], "name": "Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial", "drug_actions": []}, "P09110": {"general_function": "Palmitoyl-coa oxidase activity", "gene_names": ["ACAA1"], "name": "3-ketoacyl-CoA thiolase, peroxisomal", "drug_actions": [{"action": "INHIBITOR", "target": "P09110", "drug": "DB09069"}]}, "O69007": {"general_function": "Hydrolase activity, hydrolyzing o-glycosyl compounds", "gene_names": [], "name": "Maltogenic amylase", "drug_actions": []}, "P33644": {"general_function": "Copper ion binding", "gene_names": ["yfiH"], "name": "Laccase domain protein YfiH", "drug_actions": []}, "P01133": {"specific_function": "EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in the renal distal convoluted tubule via engagement of EGFR and activation of the magnesium channel TRPM6. Can induce neurite outgrowth in motoneurons of the pond snail Lymnaea stagnalis in vitro (PubMed:10964941).", "general_function": "Transmembrane receptor protein tyrosine kinase activator activity", "gene_names": ["EGF"], "name": "Pro-epidermal growth factor", "drug_actions": [{"action": "INDUCER", "target": "P01133", "drug": "DB00364"}]}, "O24990": {"specific_function": "Catalyzes the reduction of a carbon-carbon double bond in an enoyl moiety that is covalently linked to an acyl carrier protein (ACP). Involved in the elongation cycle of fatty acid which are used in the lipid metabolism (By similarity).", "general_function": "Enoyl-[acyl-carrier-protein] reductase (nadh) activity", "gene_names": ["fabI"], "name": "Enoyl-[acyl-carrier-protein] reductase [NADH] FabI", "drug_actions": []}, "P37321": {"general_function": "Beta-lactamase activity", "gene_names": ["per1"], "name": "Extended-spectrum beta-lactamase PER-1", "drug_actions": [{"action": "INHIBITOR", "target": "P37321", "drug": "DB09060"}]}, "P03007": {"specific_function": "DNA polymerase III is a complex, multichain enzyme responsible for most of the replicative synthesis in bacteria. The epsilon subunit contain the editing function and is a proofreading 3'-5' exonuclease.", "general_function": "Metal ion binding", "gene_names": ["dnaQ"], "name": "DNA polymerase III subunit epsilon", "drug_actions": []}, "Q44532": {"general_function": "Ferredoxin-nadp+ reductase activity", "gene_names": ["fpr"], "name": "Ferredoxin--NADP reductase", "drug_actions": []}, "O14727": {"specific_function": "Oligomeric Apaf-1 mediates the cytochrome c-dependent autocatalytic activation of pro-caspase-9 (Apaf-3), leading to the activation of caspase-3 and apoptosis. This activation requires ATP. Isoform 6 is less effective in inducing apoptosis.", "general_function": "Nucleotide binding", "gene_names": ["APAF1"], "name": "Apoptotic protease-activating factor 1", "drug_actions": []}, "P07014": {"specific_function": "Two distinct, membrane-bound, FAD-containing enzymes are responsible for the catalysis of fumarate and succinate interconversion; the fumarate reductase is used in anaerobic growth, and the succinate dehydrogenase is used in aerobic growth.", "general_function": "Succinate dehydrogenase (ubiquinone) activity", "gene_names": ["sdhB"], "name": "Succinate dehydrogenase iron-sulfur subunit", "drug_actions": []}, "Q9X1K9": {"specific_function": "Catalyzes the condensation of (S)-aspartate-beta-semialdehyde [(S)-ASA] and pyruvate to 4-hydroxy-tetrahydrodipicolinate (HTPA).", "general_function": "4-hydroxy-tetrahydrodipicolinate synthase", "gene_names": ["dapA"], "name": "4-hydroxy-tetrahydrodipicolinate synthase", "drug_actions": []}, "Q82EE4": {"gene_names": [], "name": "Uncharacterized protein", "drug_actions": []}, "Q07973": {"specific_function": "Has a role in maintaining calcium homeostasis. Catalyzes the NADPH-dependent 24-hydroxylation of calcidiol (25-hydroxyvitamin D(3)) and calcitriol (1-alpha,25-dihydroxyvitamin D(3)). The enzyme can perform up to 6 rounds of hydroxylation of calcitriol leading to calcitroic acid. It also shows 23-hydroxylating activity leading to 1-alpha,25-dihydroxyvitamin D(3)-26,23-lactone as end product.", "general_function": "Oxidoreductase activity", "gene_names": ["CYP24A1"], "name": "1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial", "drug_actions": []}, "P13861": {"specific_function": "Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells. Type II regulatory chains mediate membrane association by binding to anchoring proteins, including the MAP2 kinase.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["PRKAR2A"], "name": "cAMP-dependent protein kinase type II-alpha regulatory subunit", "drug_actions": []}, "Q9HGT2": {"general_function": "Leucine-trna ligase activity", "gene_names": ["CDC60"], "name": "Cytosolic leucyl-tRNA synthetase", "drug_actions": [{"action": "INHIBITOR", "target": "Q9HGT2", "drug": "DB09041"}]}, "P19909": {"gene_names": ["spg"], "name": "Immunoglobulin G-binding protein G", "drug_actions": []}, "O52791": {"specific_function": "Required to synthesize hydroxyphenylglycine, a recurring skeletal component of nonproteinogenic macrocyclic peptide antibiotics such as vancomycin. Catalyzes the conversion of p-hydroxyphenylpyruvate to p-hydroxymandelate. The decarboxylation and hydroxylation activities of HmaS show novel and distinct regioselectivity, compared to all other known p-hydroxyphenylpyruvate dioxygenases, by hydroxylating the benzylic position of the substrate instead of the phenyl ring.", "general_function": "Iron ion binding", "gene_names": [], "name": "4-hydroxymandelate synthase", "drug_actions": []}, "Q16566": {"specific_function": "Calcium/calmodulin-dependent protein kinase that operates in the calcium-triggered CaMKK-CaMK4 signaling cascade and regulates, mainly by phosphorylation, the activity of several transcription activators, such as CREB1, MEF2D, JUN and RORA, which play pivotal roles in immune response, inflammation, and memory consolidation. In the thymus, regulates the CD4(+)/CD8(+) double positive thymocytes selection threshold during T-cell ontogeny. In CD4 memory T-cells, is required to link T-cell antigen receptor (TCR) signaling to the production of IL2, IFNG and IL4 (through the regulation of CREB and MEF2). Regulates the differentiation and survival phases of osteoclasts and dendritic cells (DCs). Mediates DCs survival by linking TLR4 and the regulation of temporal expression of BCL2. Phosphorylates the transcription activator CREB1 on 'Ser-133' in hippocampal neuron nuclei and contribute to memory consolidation and long term potentiation (LTP) in the hippocampus. Can activate the MAP kinases MAPK1/ERK2, MAPK8/JNK1 and MAPK14/p38 and stimulate transcription through the phosphorylation of ELK1 and ATF2. Can also phosphorylate in vitro CREBBP, PRM2, MEF2A and STMN1/OP18.", "general_function": "Calmodulin-dependent protein kinase activity", "gene_names": ["CAMK4"], "name": "Calcium/calmodulin-dependent protein kinase type IV", "drug_actions": []}, "P48728": {"specific_function": "The glycine cleavage system catalyzes the degradation of glycine.", "general_function": "Transaminase activity", "gene_names": ["AMT"], "name": "Aminomethyltransferase, mitochondrial", "drug_actions": [{"action": "COFACTOR", "target": "P48728", "drug": "DB00116"}]}, "P16220": {"specific_function": "Phosphorylation-dependent transcription factor that stimulates transcription upon binding to the DNA cAMP response element (CRE), a sequence present in many viral and cellular promoters. Transcription activation is enhanced by the TORC coactivators which act independently of Ser-133 phosphorylation. Involved in different cellular processes including the synchronization of circadian rhythmicity and the differentiation of adipose cells.", "general_function": "Transcriptional activator activity, rna polymerase ii transcription factor binding", "gene_names": ["CREB1"], "name": "Cyclic AMP-responsive element-binding protein 1", "drug_actions": [{"action": "ACTIVATOR", "target": "P16220", "drug": "DB00131"}, {"action": "OTHER/UNKNOWN", "target": "P16220", "drug": "DB01183"}]}, "P22906": {"specific_function": "Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis.", "general_function": "Nadp binding", "gene_names": ["DFR1"], "name": "Dihydrofolate reductase", "drug_actions": []}, "P31937": {"general_function": "Phosphogluconate dehydrogenase (decarboxylating) activity", "gene_names": ["HIBADH"], "name": "3-hydroxyisobutyrate dehydrogenase, mitochondrial", "drug_actions": []}, "P31930": {"specific_function": "This is a component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is part of the mitochondrial respiratory chain. This protein may mediate formation of the complex between cytochromes c and c1.", "general_function": "Zinc ion binding", "gene_names": ["UQCRC1"], "name": "Cytochrome b-c1 complex subunit 1, mitochondrial", "drug_actions": []}, "P08877": {"specific_function": "General (non sugar-specific) component of the phosphoenolpyruvate-dependent sugar phosphotransferase system (sugar PTS). This major carbohydrate active-transport system catalyzes the phosphorylation of incoming sugar substrates concomitantly with their translocation across the cell membrane. The phosphoryl group from phosphoenolpyruvate (PEP) is transferred to the phosphoryl carrier protein HPr by enzyme I. Phospho-HPr then transfers it to the permease (enzymes II/III).P-Ser-HPr interacts with the catabolite control protein A (CcpA), forming a complex that binds to DNA at the catabolite response elements cre, operator sites preceding a large number of catabolite-regulated genes. Thus, P-Ser-HPr is a corepressor in carbon catabolite repression (CCR), a mechanism that allows bacteria to coordinate and optimize the utilization of available carbon sources. P-Ser-HPr also plays a role in inducer exclusion, in which it probably interacts with several non-PTS permeases and inhibits their transport activity.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["ptsH"], "name": "Phosphocarrier protein HPr", "drug_actions": []}, "Q56148": {"specific_function": "Inactivates chloramphenicol by catalyzing the transfer of the gamma-phosphate of ATP to the antibiotic's C-3' hydroxyl group.", "general_function": "Kinase activity", "gene_names": [], "name": "Chloramphenicol 3-O phosphotransferase", "drug_actions": []}, "Q16762": {"specific_function": "Formation of iron-sulfur complexes, cyanide detoxification or modification of sulfur-containing enzymes. Other thiol compounds, besides cyanide, can act as sulfur ion acceptors. Also has weak mercaptopyruvate sulfurtransferase (MST) activity (By similarity). Together with MRPL18, acts as a mitochondrial import factor for the cytosolic 5S rRNA. Only the nascent unfolded cytoplasmic form is able to bind to the 5S rRNA.", "general_function": "Thiosulfate sulfurtransferase activity", "gene_names": ["TST"], "name": "Thiosulfate sulfurtransferase", "drug_actions": []}, "Q16760": {"specific_function": "May function as signaling molecule.Isoform 2 may be involved in cell growth and tumorigenesis. Involved in clathrin-dependent endocytosis.", "general_function": "Protein homodimerization activity", "gene_names": ["DGKD"], "name": "Diacylglycerol kinase delta", "drug_actions": []}, "Q96BH3": {"specific_function": "Binds to spermatozoa upon ejaculation and may play a role in sperm capacitation. Has phosphorylcholine-binding activity (By similarity).", "gene_names": ["ELSPBP1"], "name": "Epididymal sperm-binding protein 1", "drug_actions": []}, "Q9LAG2": {"general_function": "Oxidoreductase activity", "gene_names": ["pheA2"], "name": "Phenol 2-hydroxylase component B", "drug_actions": []}, "Q9UQD0": {"specific_function": "Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. In macrophages and melanoma cells, isoform 5 may participate in the control of podosome and invadopodia formation.", "name": "Sodium channel protein type 8 subunit alpha", "drug_actions": [], "general_function": "Voltage-gated sodium channel activity", "in_complexes": ["Sodium channel protein"], "gene_names": ["SCN8A"]}, "O06796": {"gene_names": [], "name": "Possible exported protein", "drug_actions": []}, "Q9HTQ2": {"specific_function": "Isomerizes L-alanine to D-alanine which is then oxidized to pyruvate by DadA.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["dadX"], "name": "Alanine racemase, catabolic", "drug_actions": []}, "O05935": {"general_function": "Monooxygenase activity", "gene_names": ["oxoO"], "name": "2-oxo-1,2-dihydroquinoline 8-monooxygenase, oxygenase component", "drug_actions": []}, "P33260": {"specific_function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.", "general_function": "Steroid hydroxylase activity", "gene_names": ["CYP2C18"], "name": "Cytochrome P450 2C18", "drug_actions": []}, "P33261": {"specific_function": "Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.", "general_function": "Steroid hydroxylase activity", "gene_names": ["CYP2C19"], "name": "Cytochrome P450 2C19", "drug_actions": []}, "P47895": {"specific_function": "Recognizes as substrates free retinal and cellular retinol-binding protein-bound retinal. Seems to be the key enzyme in the formation of an RA gradient along the dorso-ventral axis during the early eye development and also in the development of the olfactory system (By similarity).", "general_function": "Thyroid hormone binding", "gene_names": ["ALDH1A3"], "name": "Aldehyde dehydrogenase family 1 member A3", "drug_actions": []}, "P47898": {"specific_function": "This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins.", "general_function": "Serotonin receptor activity", "gene_names": ["HTR5A"], "name": "5-hydroxytryptamine receptor 5A", "drug_actions": [{"action": "ANTAGONIST", "target": "P47898", "drug": "DB00334"}, {"action": "BINDER", "target": "P47898", "drug": "DB00408"}, {"action": "ANTAGONIST", "target": "P47898", "drug": "DB06216"}]}, "Q53I07": {"general_function": "Structural molecule activity", "gene_names": ["gp41"], "name": "Envelope glycoprotein", "drug_actions": []}, "P25052": {"specific_function": "Catalyzes an amino-pyrimidine hydrolysis reaction at the C5' of the pyrimidine moiety of thiamine compounds, a reaction that is part of a thiamine salvage pathway. Thus, catalyzes the conversion of 4-amino-5-aminomethyl-2-methylpyrimidine to 4-amino-5-hydroxymethyl-2-methylpyrimidine (HMP). To a lesser extent, is also able to catalyze the hydrolytic cleavage of thiamine; however, this thiaminase activity is unlikely to be physiologically relevant. Therefore, is involved in the regeneration of the thiamine pyrimidine from thiamine degraded products present in the environment, rather than in thiamine degradation.", "general_function": "Thiaminase activity", "gene_names": ["tenA"], "name": "Aminopyrimidine aminohydrolase", "drug_actions": []}, "P81989": {"specific_function": "The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate. Cleaves guanosine, inosine, 2'-deoxyguanosine and 2'-deoxyinosine.", "general_function": "Purine-nucleoside phosphorylase activity", "gene_names": ["punA"], "name": "Purine nucleoside phosphorylase", "drug_actions": []}, "P19835": {"specific_function": "Catalyzes fat and vitamin absorption. Acts in concert with pancreatic lipase and colipase for the complete digestion of dietary triglycerides.", "general_function": "Triglyceride lipase activity", "gene_names": ["CEL"], "name": "Bile salt-activated lipase", "drug_actions": []}, "Q9BYV1": {"specific_function": "Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["AGXT2"], "name": "Alanine--glyoxylate aminotransferase 2, mitochondrial", "drug_actions": [{"action": "COFACTOR", "target": "Q9BYV1", "drug": "DB00114"}]}, "P59768": {"specific_function": "Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction (By similarity).", "general_function": "Signal transducer activity", "gene_names": ["GNG2"], "name": "Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "P59768", "drug": "DB01159"}]}, "Q96KS0": {"specific_function": "Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific proline found in each of the oxygen-dependent degradation (ODD) domains (N-terminal, NODD, and C-terminal, CODD) of HIF1A. Also hydroxylates HIF2A. Has a preference for the CODD site for both HIF1A and HIF2A. Hydroxylated HIFs are then targeted for proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Under hypoxic conditions, the hydroxylation reaction is attenuated allowing HIFs to escape degradation resulting in their translocation to the nucleus, heterodimerization with HIF1B, and increased expression of hypoxy-inducible genes. EGLN2 is involved in regulating hypoxia tolerance and apoptosis in cardiac and skeletal muscle. Also regulates susceptibility to normoxic oxidative neuronal death. Links oxygen sensing to cell cycle and primary cilia formation by hydroxylating the critical centrosome component CEP192 which promotes its ubiquitination and subsequent proteasomal degradation. Hydroxylates IKBKB, mediating NF-kappaB activation in hypoxic conditions. Target proteins are preferentially recognized via a LXXLAP motif.", "general_function": "Peptidyl-proline 4-dioxygenase activity", "gene_names": ["EGLN2"], "name": "Egl nine homolog 2", "drug_actions": []}, "Q79FD7": {"specific_function": "D-ribose 5-phosphate = D-ribulose 5-phosphate", "general_function": "Carbohydrate transport and metabolism", "gene_names": ["rpiB"], "name": "Ribose-5-phosphate isomerase B", "drug_actions": []}, "Q13627": {"specific_function": "May play a role in a signaling pathway regulating nuclear functions of cell proliferation. Modulates alternative splicing by phosphorylating the splice factor SRSF6 (By similarity). Phosphorylates serine, threonine and tyrosine residues in its sequence and in exogenous substrates such as CRY2, FOXO1, SRSF6 and SIRT1. Exhibits a sugstrate preference for proline at position P+1 and arginine at position P-3.", "general_function": "Tau protein binding", "gene_names": ["DYRK1A"], "name": "Dual specificity tyrosine-phosphorylation-regulated kinase 1A", "drug_actions": []}, "P34969": {"specific_function": "This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.", "name": "5-hydroxytryptamine receptor 7", "drug_actions": [{"action": "AGONIST", "target": "P34969", "drug": "DB00216"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00247"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00248"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00363"}, {"action": "BINDING", "target": "P34969", "drug": "DB00370"}, {"action": "BINDER", "target": "P34969", "drug": "DB00408"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00458"}, {"action": "BINDER", "target": "P34969", "drug": "DB00477"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00543"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00751"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB00934"}, {"action": "BINDER", "target": "P34969", "drug": "DB00988"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB04946"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB06288"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB08815"}, {"action": "ANTAGONIST", "target": "P34969", "drug": "DB09068"}], "general_function": "Serotonin receptor activity", "in_complexes": ["Serotonin Receptors"], "gene_names": ["HTR7"]}, "Q13621": {"specific_function": "Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.", "general_function": "Sodium:potassium:chloride symporter activity", "gene_names": ["SLC12A1"], "name": "Solute carrier family 12 member 1", "drug_actions": [{"action": "INHIBITOR", "target": "Q13621", "drug": "DB00214"}, {"action": "INHIBITOR", "target": "Q13621", "drug": "DB00232"}, {"action": "INHIBITOR", "target": "Q13621", "drug": "DB00310"}, {"action": "INDUCER", "target": "Q13621", "drug": "DB00534"}, {"action": "INHIBITOR", "target": "Q13621", "drug": "DB00695"}, {"action": "BINDER", "target": "Q13621", "drug": "DB00761"}, {"action": "INHIBITOR", "target": "Q13621", "drug": "DB00774"}, {"action": "INHIBITOR", "target": "Q13621", "drug": "DB00887"}, {"action": "INHIBITOR", "target": "Q13621", "drug": "DB00903"}, {"action": "INHIBITOR", "target": "Q13621", "drug": "DB01021"}, {"action": "INHIBITOR", "target": "Q13621", "drug": "DB01325"}, {"action": "INHIBITOR", "target": "Q13621", "drug": "DB02925"}]}, "P19838": {"specific_function": "NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.", "name": "Nuclear factor NF-kappa-B p105 subunit", "drug_actions": [{"action": "ANTAGONIST", "target": "P19838", "drug": "DB00945"}, {"action": "ANTAGONIST", "target": "P19838", "drug": "DB01041"}, {"action": "OTHER/UNKNOWN", "target": "P19838", "drug": "DB01411"}, {"action": "ANTAGONIST", "target": "P19838", "drug": "DB08814"}], "general_function": "Transcriptional repressor activity, rna polymerase ii transcription regulatory region sequence-specific binding", "in_complexes": ["Nuclear factor NF-kappa-B"], "gene_names": ["NFKB1"]}, "Q8NG66": {"specific_function": "Protein kinase which plays an important role in the G2/M checkpoint response to DNA damage. Controls degradation of CDC25A by directly phosphorylating it on residues whose phosphorylation is required for BTRC-mediated polyubiquitination and degradation.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["NEK11"], "name": "Serine/threonine-protein kinase Nek11", "drug_actions": [{"action": "INHIBITOR", "target": "Q8NG66", "drug": "DB08912"}]}, "O95907": {"specific_function": "Proton-linked monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate (By similarity).", "general_function": "Symporter activity", "gene_names": ["SLC16A8"], "name": "Monocarboxylate transporter 3", "drug_actions": []}, "P61158": {"specific_function": "Functions as ATP-binding component of the Arp2/3 complex which is involved in regulation of actin polymerization and together with an activating nucleation-promoting factor (NPF) mediates the formation of branched actin networks. Seems to contact the pointed end of the daughter actin filament. Plays a role in ciliogenesis.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["ACTR3"], "name": "Actin-related protein 3", "drug_actions": []}, "P51570": {"specific_function": "Major enzyme for galactose metabolism.", "general_function": "Galactose binding", "gene_names": ["GALK1"], "name": "Galactokinase", "drug_actions": []}, "Q8DR59": {"specific_function": "Cell wall formation.", "general_function": "Penicillin binding", "gene_names": ["pbpA"], "name": "Penicillin-binding protein 1A", "drug_actions": [{"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB00415"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB00438"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB00456"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB00485"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB00493"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB00567"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB00607"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB00713"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB00739"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB01000"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB01140"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB01163"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB01603"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB03313"}, {"action": "INHIBITOR", "target": "Q8DR59", "drug": "DB08795"}]}, "P29768": {"specific_function": "Cleaves the terminal sialic acid (N-acetyl neuraminic acid) from carbohydrate chains in glycoproteins providing free sialic acid which can be used as carbon and energy sources. Sialidases have been suggested to be pathogenic factors in microbial infections.", "general_function": "Exo-alpha-(2->8)-sialidase activity", "gene_names": ["nanH"], "name": "Sialidase", "drug_actions": []}, "P15328": {"specific_function": "Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells. Has high affinity for folate and folic acid analogs at neutral pH. Exposure to slightly acidic pH after receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release. Required for normal embryonic development and normal cell proliferation.", "general_function": "Receptor activity", "gene_names": ["FOLR1"], "name": "Folate receptor alpha", "drug_actions": [{"action": "ANTIBODY", "target": "P15328", "drug": "DB05595"}]}, "Q6GI75": {"specific_function": "Catalyzes the reduction of a carbon-carbon double bond in an enoyl moiety that is covalently linked to an acyl carrier protein (ACP). Involved in the elongation cycle of fatty acid which are used in the lipid metabolism (By similarity).", "general_function": "Nadp binding", "gene_names": ["fabI"], "name": "Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI", "drug_actions": []}, "O34714": {"specific_function": "Converts oxalate to formate and CO(2) in an O(2)-dependent reaction. Can also catalyze minor side reactions: oxalate oxidation to produce H(2)O(2), and oxalate-dependent, H(2)O(2)-independent dye oxidations.", "general_function": "Oxalate decarboxylase activity", "gene_names": ["oxdC"], "name": "Oxalate decarboxylase OxdC", "drug_actions": []}, "P49759": {"specific_function": "Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates. Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex and may be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing. Phosphorylates: SRSF1, SRSF3 and PTPN1. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells and adenovirus E1A pre-mRNA.", "general_function": "Protein serine/threonine/tyrosine kinase activity", "gene_names": ["CLK1"], "name": "Dual specificity protein kinase CLK1", "drug_actions": []}, "Q8GEZ8": {"general_function": "Catalytic activity", "gene_names": ["dhaB1"], "name": "B12-independent glycerol dehydratase", "drug_actions": []}, "O00341": {"specific_function": "Transports L-glutamate; the L-glutamate uptake is sodium- and voltage-dependent and chloride-independent. Its associated chloride conductance may participate in visual processing.", "general_function": "Sodium:dicarboxylate symporter activity", "gene_names": ["SLC1A7"], "name": "Excitatory amino acid transporter 5", "drug_actions": []}, "O60896": {"specific_function": "Plays a role in cardioprotection by reducing cardiac hypertrophy and perivascular fibrosis in a GPER1-dependent manner. Transports the calcitonin gene-related peptide type 1 receptor (CALCRL) and GPER1 to the plasma membrane. Acts as a receptor for adrenomedullin (AM) together with CALCRL.", "general_function": "Receptor activity", "gene_names": ["RAMP3"], "name": "Receptor activity-modifying protein 3", "drug_actions": [{"action": "AGONIST", "target": "O60896", "drug": "DB01278"}]}, "O60894": {"specific_function": "Transports the calcitonin gene-related peptide type 1 receptor (CALCRL) to the plasma membrane. Acts as a receptor for calcitonin-gene-related peptide (CGRP) together with CALCRL.", "general_function": "Receptor activity", "gene_names": ["RAMP1"], "name": "Receptor activity-modifying protein 1", "drug_actions": [{"action": "AGONIST", "target": "O60894", "drug": "DB01278"}]}, "O60895": {"specific_function": "Transports the calcitonin gene-related peptide type 1 receptor (CALCRL) to the plasma membrane. Acts as a receptor for adrenomedullin (AM) together with CALCRL.", "general_function": "Protein transporter activity", "gene_names": ["RAMP2"], "name": "Receptor activity-modifying protein 2", "drug_actions": [{"action": "AGONIST", "target": "O60895", "drug": "DB01278"}]}, "P51970": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Protein complex binding", "gene_names": ["NDUFA8"], "name": "NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8", "drug_actions": []}, "P18405": {"specific_function": "Converts testosterone into 5-alpha-dihydrotestosterone and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.", "name": "3-oxo-5-alpha-steroid 4-dehydrogenase 1", "drug_actions": [{"action": "INHIBITOR", "target": "P18405", "drug": "DB00367"}, {"action": "ANTAGONIST", "target": "P18405", "drug": "DB00421"}, {"action": "INHIBITOR", "target": "P18405", "drug": "DB01126"}, {"action": "INHIBITOR", "target": "P18405", "drug": "DB01216"}], "general_function": "Electron carrier activity", "in_complexes": ["3-oxo-5-alpha-steroid 4-dehydrogenase"], "gene_names": ["SRD5A1"]}, "P05154": {"specific_function": "Heparin-dependent serine protease inhibitor acting in body fluids and secretions. Inactivates serine proteases by binding irreversibly to their serine activation site. Involved in the regulation of intravascular and extravascular proteolytic activities. Plays hemostatic roles in the blood plasma. Acts as a procoagulant and proinflammatory factor by inhibiting the anticoagulant activated protein C factor as well as the generation of activated protein C factor by the thrombin/thrombomodulin complex. Acts as an anticoagulant factor by inhibiting blood coagulation factors like prothrombin, factor XI, factor Xa, plasma kallikrein and fibrinolytic enzymes such as tissue- and urinary-type plasminogen activators. In seminal plasma, inactivates several serine proteases implicated in the reproductive system. Inhibits the serpin acrosin; indirectly protects component of the male genital tract from being degraded by excessive released acrosin. Inhibits tissue-and urinary-type plasminogen activator, prostate-specific antigen and kallikrein activities; has a control on the sperm motility and fertilization. Inhibits the activated protein C-catalyzed degradation of SEMG1 and SEMG2; regulates the degradation of semenogelin during the process of transfer of spermatozoa from the male reproductive tract into the female tract. In urine, inhibits urinary-type plasminogen activator and kallikrein activities. Inactivates membrane-anchored serine proteases activities such as MPRSS7 and TMPRSS11E. Inhibits urinary-type plasminogen activator-dependent tumor cell invasion and metastasis. May also play a non-inhibitory role in seminal plasma and urine as a hydrophobic hormone carrier by its binding to retinoic acid.", "general_function": "Serine-type endopeptidase inhibitor activity", "gene_names": ["SERPINA5"], "name": "Plasma serine protease inhibitor", "drug_actions": []}, "P52961": {"specific_function": "Has ADP-ribosyltransferase activity toward GLP1R.", "general_function": "Nad+ adp-ribosyltransferase activity", "gene_names": ["ART1"], "name": "GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1", "drug_actions": []}, "O95139": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFB6"], "name": "NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6", "drug_actions": []}, "P55210": {"specific_function": "Involved in the activation cascade of caspases responsible for apoptosis execution. Cleaves and activates sterol regulatory element binding proteins (SREBPs). Proteolytically cleaves poly(ADP-ribose) polymerase (PARP) at a '216-Asp-|-Gly-217' bond. Overexpression promotes programmed cell death.", "general_function": "Cysteine-type peptidase activity", "gene_names": ["CASP7"], "name": "Caspase-7", "drug_actions": []}, "P31243": {"specific_function": "Forms channels that allow the passive diffusion of small hydrophilic solutes up to an exclusion limit of about 0.6 kDa.", "general_function": "Porin activity", "gene_names": [], "name": "Porin", "drug_actions": []}, "P0A7G9": {"specific_function": "Can catalyze the hydrolysis of ATP in the presence of single-stranded DNA, the ATP-dependent uptake of single-stranded DNA by duplex DNA, and the ATP-dependent hybridization of homologous single-stranded DNAs. It interacts with LexA causing its activation and leading to its autocatalytic cleavage.", "general_function": "Single-stranded dna binding", "gene_names": ["recA"], "name": "Protein RecA", "drug_actions": []}, "P17174": {"specific_function": "Biosynthesis of L-glutamate from L-aspartate or L-cysteine. Important regulator of levels of glutamate, the major excitatory neurotransmitter of the vertebrate central nervous system. Acts as a scavenger of glutamate in brain neuroprotection. The aspartate aminotransferase activity is involved in hepatic glucose synthesis during development and in adipocyte glyceroneogenesis. Using L-cysteine as substrate, regulates levels of mercaptopyruvate, an important source of hydrogen sulfide. Mercaptopyruvate is converted into H(2)S via the action of 3-mercaptopyruvate sulfurtransferase (3MST). Hydrogen sulfide is an important synaptic modulator and neuroprotectant in the brain.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["GOT1"], "name": "Aspartate aminotransferase, cytoplasmic", "drug_actions": [{"action": "ACTIVATOR", "target": "P17174", "drug": "DB00114"}]}, "Q04828": {"specific_function": "Converts progesterone to its inactive form, 20-alpha-dihydroxyprogesterone (20-alpha-OHP). In the liver and intestine, may have a role in the transport of bile. May have a role in monitoring the intrahepatic bile acid concentration. Has a low bile-binding ability. May play a role in myelin formation.", "general_function": "Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity", "gene_names": ["AKR1C1"], "name": "Aldo-keto reductase family 1 member C1", "drug_actions": [{"action": "INHIBITOR", "target": "Q04828", "drug": "DB00936"}, {"action": "INHIBITOR", "target": "Q04828", "drug": "DB00945"}]}, "P51686": {"specific_function": "Receptor for chemokine SCYA25/TECK. Subsequently transduces a signal by increasing the intracellular calcium ions level. Alternative coreceptor with CD4 for HIV-1 infection.", "general_function": "Chemokine receptor activity", "gene_names": ["CCR9"], "name": "C-C chemokine receptor type 9", "drug_actions": []}, "P51687": {"general_function": "Sulfite oxidase activity", "gene_names": ["SUOX"], "name": "Sulfite oxidase, mitochondrial", "drug_actions": []}, "P66952": {"specific_function": "Has antioxidant activity. Could remove peroxides or H(2)O(2) (By similarity)", "general_function": "Involved in oxidoreductase activity", "gene_names": ["tpx"], "name": "Probable thiol peroxidase", "drug_actions": []}, "Q9BW91": {"specific_function": "Hydrolyzes ADP-ribose (ADPR) to AMP and ribose 5'-phosphate.", "general_function": "Adp-sugar diphosphatase activity", "gene_names": ["NUDT9"], "name": "ADP-ribose pyrophosphatase, mitochondrial", "drug_actions": []}, "Q59976": {"general_function": "Beta-glucosidase activity", "gene_names": ["bgl3"], "name": "Beta-glucosidase", "drug_actions": []}, "Q79ZY6": {"general_function": "Involved in hydroxymethylglutaryl-CoA synthase activity", "gene_names": ["mvaS"], "name": "3-hydroxy-3-methylglutaryl CoA synthase", "drug_actions": []}, "P0A5I4": {"specific_function": "Essential for recycling GMP and indirectly, cGMP (By similarity)", "general_function": "Nucleotide transport and metabolism", "gene_names": ["gmk"], "name": "Guanylate kinase", "drug_actions": []}, "Q9NP99": {"specific_function": "Stimulates neutrophil and monocyte-mediated inflammatory responses. Triggers release of pro-inflammatory chemokines and cytokines, as well as increased surface expression of cell activation markers. Amplifier of inflammatory responses that are triggered by bacterial and fungal infections and is a crucial mediator of septic shock.", "general_function": "Scaffold protein binding", "gene_names": ["TREM1"], "name": "Triggering receptor expressed on myeloid cells 1", "drug_actions": []}, "P08909": {"specific_function": "G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and down-stream signaling cascades and promotes the release of Ca(2+) ions from intracellular stores. Regulates neuronal activity via the activation of short transient receptor potential calcium channels in the brain, and thereby modulates the activation of pro-opiomelacortin neurons and the release of CRH that then regulates the release of corticosterone. Plays a role in the regulation of appetite and feeding behavior, responses to anxiogenic stimuli and stress. Plays a role in insulin sensitivity and glucose homeostasis.", "general_function": "Serotonin receptor activity", "gene_names": ["Htr2c"], "name": "5-hydroxytryptamine receptor 2C", "drug_actions": [{"action": "ANTAGONIST", "target": "P08909", "drug": "DB00540"}, {"action": "BINDER", "target": "P08909", "drug": "DB00726"}]}, "P08908": {"specific_function": "G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism. Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior. Plays a role in the response to anxiogenic stimuli.", "name": "5-hydroxytryptamine receptor 1A", "drug_actions": [{"action": "AGONIST", "target": "P08908", "drug": "DB00216"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00246"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00247"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00248"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00268"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00315"}, {"action": "INHIBITOR", "target": "P08908", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00363"}, {"action": "BINDER", "target": "P08908", "drug": "DB00408"}, {"action": "UNKNOWN", "target": "P08908", "drug": "DB00413"}, {"action": "ACTIVATOR", "target": "P08908", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00477"}, {"action": "PARTIAL AGONIST", "target": "P08908", "drug": "DB00490"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00543"}, {"action": "OTHER/UNKNOWN", "target": "P08908", "drug": "DB00571"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00589"}, {"action": "PARTIAL AGONIST", "target": "P08908", "drug": "DB00656"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00669"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00696"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00714"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00734"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00866"}, {"action": "OTHER/UNKNOWN", "target": "P08908", "drug": "DB00904"}, {"action": "AGONIST", "target": "P08908", "drug": "DB00952"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB00960"}, {"action": "BINDER", "target": "P08908", "drug": "DB00988"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01149"}, {"action": "BINDER", "target": "P08908", "drug": "DB01151"}, {"action": "AGONIST", "target": "P08908", "drug": "DB01186"}, {"action": "AGONIST", "target": "P08908", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01238"}, {"action": "PARTIAL AGONIST", "target": "P08908", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01359"}, {"action": "PARTIAL AGONIST", "target": "P08908", "drug": "DB01392"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01614"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01616"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01618"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01621"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB01622"}, {"action": "AGONIST", "target": "P08908", "drug": "DB04908"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB04946"}, {"action": "AGONIST", "target": "P08908", "drug": "DB05271"}, {"action": "AGONIST", "target": "P08908", "drug": "DB06016"}, {"action": "PARTIAL AGONIST", "target": "P08908", "drug": "DB06016"}, {"action": "BLOCKER", "target": "P08908", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB06216"}, {"action": "AGONIST", "target": "P08908", "drug": "DB06684"}, {"action": "AGONIST", "target": "P08908", "drug": "DB08810"}, {"action": "ANTAGONIST", "target": "P08908", "drug": "DB08815"}, {"action": "AGONIST", "target": "P08908", "drug": "DB09068"}, {"action": "AGONIST", "target": "P08908", "drug": "DB09128"}, {"action": "PARTIAL AGONIST", "target": "P08908", "drug": "DB09128"}], "general_function": "Serotonin receptor activity", "in_complexes": ["5-hydroxytryptamine receptor 1", "Serotonin Receptors"], "gene_names": ["HTR1A"]}, "P31644": {"specific_function": "GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.", "name": "Gamma-aminobutyric acid receptor subunit alpha-5", "drug_actions": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00228"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00237"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00292"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00306"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00349"}, {"action": "AGONIST", "target": "P31644", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00371"}, {"action": "AGONIST", "target": "P31644", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00404"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00418"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00475"}, {"action": "BINDER", "target": "P31644", "drug": "DB00543"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00599"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00628"}, {"action": "POSITIVE MODULATOR", "target": "P31644", "drug": "DB00659"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00690"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00753"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00794"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00818"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00849"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01028"}, {"action": "AGONIST", "target": "P31644", "drug": "DB01049"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01189"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01198"}, {"action": "ANTAGONIST", "target": "P31644", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01205"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01236"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01351"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01352"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01353"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01354"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01355"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01437"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01483"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01496"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01544"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P31644", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P31644", "drug": "DB01595"}, {"action": "ANTAGONIST", "target": "P31644", "drug": "DB01708"}], "general_function": "Transporter activity", "in_complexes": ["GABA-A receptor (anion channel)"], "gene_names": ["GABRA5"]}, "P31645": {"specific_function": "Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin and recycles it in a sodium-dependent manner.", "general_function": "Serotonin:sodium symporter activity", "gene_names": ["SLC6A4"], "name": "Sodium-dependent serotonin transporter", "drug_actions": [{"action": "INHIBITOR", "target": "P31645", "drug": "DB00176"}, {"action": "BINDER", "target": "P31645", "drug": "DB00182"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00191"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00193"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00215"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00285"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00321"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00344"}, {"action": "BINDER", "target": "P31645", "drug": "DB00370"}, {"action": "BINDER", "target": "P31645", "drug": "DB00408"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00422"}, {"action": "BINDING", "target": "P31645", "drug": "DB00454"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00458"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00472"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00476"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00514"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00540"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00543"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00574"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00579"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00656"}, {"action": "OTHER/UNKNOWN", "target": "P31645", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00715"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00726"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00805"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00852"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB00907"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB01104"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB01105"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB01114"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB01142"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB01149"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB01151"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB01175"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB01191"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB01242"}, {"action": "NEGATIVE MODULATOR", "target": "P31645", "drug": "DB01363"}, {"action": "NEGATIVE MODULATOR", "target": "P31645", "drug": "DB01442"}, {"action": "NEGATIVE MODULATOR", "target": "P31645", "drug": "DB01454"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB01472"}, {"action": "NEGATIVE MODULATOR", "target": "P31645", "drug": "DB01577"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB04896"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB06148"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB06204"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB06700"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB06701"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB08918"}, {"action": "ANTAGONIST", "target": "P31645", "drug": "DB09016"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB09016"}, {"action": "INHIBITOR", "target": "P31645", "drug": "DB09068"}]}, "Q59401": {"general_function": "Defense mechanisms", "gene_names": [], "name": "Class C beta-lactamase", "drug_actions": []}, "Q7L0J3": {"specific_function": "Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readily releasable pool of secretory vesicles (By similarity).", "general_function": "Transmembrane transporter activity", "gene_names": ["SV2A"], "name": "Synaptic vesicle glycoprotein 2A", "drug_actions": [{"action": "AGONIST", "target": "Q7L0J3", "drug": "DB01202"}]}, "P03915": {"specific_function": "Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["MT-ND5"], "name": "NADH-ubiquinone oxidoreductase chain 5", "drug_actions": []}, "Q86XF0": {"specific_function": "Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Required to prevent uracil accumulation in mtDNA. Binds its own mRNA and that of DHFR.", "general_function": "Nadp binding", "gene_names": ["DHFRL1"], "name": "Dihydrofolate reductase, mitochondrial", "drug_actions": []}, "P09250": {"specific_function": "In latent infection, may allow the virus to be reactivated and to grow in cells lacking a high concentration of phosphorylated nucleic acid precursors, such as nerve cells that do not replicate their genome.", "general_function": "Thymidine kinase activity", "gene_names": [], "name": "Thymidine kinase", "drug_actions": [{"action": "INDUCER", "target": "P09250", "drug": "DB00194"}]}, "P09252": {"specific_function": "Replicates viral genomic DNA. The replication complex is composed of six viral proteins: the DNA polymerase, processivity factor, primase, primase-associated factor, helicase, and ssDNA-binding protein. Additionally, the polymerase contains an intrinsic ribonuclease H (RNase H) activity that specifically degrades RNA/DNA heteroduplexes or duplex DNA substrates in the 5' to 3' direction. Therefore, it can catalyze the excision of the RNA primers that initiate the synthesis of Okazaki fragments at a replication fork during viral DNA replication (By similarity).", "general_function": "Rna-dna hybrid ribonuclease activity", "gene_names": [], "name": "DNA polymerase catalytic subunit", "drug_actions": [{"action": "INHIBITOR", "target": "P09252", "drug": "DB00426"}, {"action": "INHIBITOR", "target": "P09252", "drug": "DB00787"}]}, "O53831": {"general_function": "Involved in N-acetyltransferase activity", "gene_names": ["mshD"], "name": "Mycothiol acetyltransferase", "drug_actions": []}, "O93182": {"specific_function": "Gag polyprotein: Mediates, with Gag-Pol polyrotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi).Matrix protein p17: Targets the polyprotein to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus (By similarity). Matrix protein is part of the pre-integration complex. Implicated in the release from host cell mediated by Vpu. Binds to RNA (By similarity).Capsid protein p24: Forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion. Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry (By similarity). Host restriction factors such as TRIM5-alpha or TRIMCyp bind retroviral capsids and cause premature capsid disassembly, leading to blocks in reverse transcription. Capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species. Host PIN1 apparently facilitates the virion uncoating (By similarity). On the other hand, interactions with PDZD8 or CYPA stabilize the capsid (By similarity).Nucleocapsid protein p7: Encapsulates and protects viral dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its zinc fingers. Acts as a nucleic acid chaperone which is involved in rearangement of nucleic acid secondary structure during gRNA retrotranscription. Also facilitates template switch leading to recombination. As part of the polyprotein, participates to gRNA dimerization, packaging, tRNA incorporation and virion assembly.p6-gag: Plays a role in budding of the assembled particle by interacting with the host class E VPS proteins TSG101 and PDCD6IP/AIP1.", "general_function": "Zinc ion binding", "gene_names": ["gag"], "name": "Gag polyprotein", "drug_actions": []}, "Q5T6L4": {"general_function": "Toxic substance binding", "gene_names": ["ASS"], "name": "Argininosuccinate synthetase, isoform CRA_a", "drug_actions": []}, "P14854": {"specific_function": "Connects the two COX monomers into the physiological dimeric form.", "general_function": "Cytochrome-c oxidase activity", "gene_names": ["COX6B1"], "name": "Cytochrome c oxidase subunit 6B1", "drug_actions": []}, "Q15067": {"specific_function": "Catalyzes the desaturation of acyl-CoAs to 2-trans-enoyl-CoAs. Isoform 1 shows highest activity against medium-chain fatty acyl-CoAs and activity decreases with increasing chain length. Isoform 2 is active against a much broader range of substrates and shows activity towards very long-chain acyl-CoAs. Isoform 2 is twice as active as isoform 1 against 16-hydroxy-palmitoyl-CoA and is 25% more active against 1,16-hexadecanodioyl-CoA.", "general_function": "Receptor binding", "gene_names": ["ACOX1"], "name": "Peroxisomal acyl-coenzyme A oxidase 1", "drug_actions": []}, "P17612": {"specific_function": "Phosphorylates a large number of substrates in the cytoplasm and the nucleus. Regulates the abundance of compartmentalized pools of its regulatory subunits through phosphorylation of PJA2 which binds and ubiquitinates these subunits, leading to their subsequent proteolysis. Phosphorylates CDC25B, ABL1, NFKB1, CLDN3, PSMC5/RPT6, PJA2, RYR2, RORA and VASP. RORA is activated by phosphorylation. Required for glucose-mediated adipogenic differentiation increase and osteogenic differentiation inhibition from osteoblasts. Involved in the regulation of platelets in response to thrombin and collagen; maintains circulating platelets in a resting state by phosphorylating proteins in numerous platelet inhibitory pathways when in complex with NF-kappa-B (NFKB1 and NFKB2) and I-kappa-B-alpha (NFKBIA), but thrombin and collagen disrupt these complexes and free active PRKACA stimulates platelets and leads to platelet aggregation by phosphorylating VASP. Prevents the antiproliferative and anti-invasive effects of alpha-difluoromethylornithine in breast cancer cells when activated. RYR2 channel activity is potentiated by phosphorylation in presence of luminal Ca(2+), leading to reduced amplitude and increased frequency of store overload-induced Ca(2+) release (SOICR) characterized by an increased rate of Ca(2+) release and propagation velocity of spontaneous Ca(2+) waves, despite reduced wave amplitude and resting cytosolic Ca(2+). PSMC5/RPT6 activation by phosphorylation stimulates proteasome. Negatively regulates tight junctions (TJs) in ovarian cancer cells via CLDN3 phosphorylation. NFKB1 phosphorylation promotes NF-kappa-B p50-p50 DNA binding. Involved in embryonic development by down-regulating the Hedgehog (Hh) signaling pathway that determines embryo pattern formation and morphogenesis. Prevents meiosis resumption in prophase-arrested oocytes via CDC25B inactivation by phosphorylation. May also regulate rapid eye movement (REM) sleep in the pedunculopontine tegmental (PPT). Phosphorylates APOBEC3G and AICDA. Isoform 2 phosphorylates and activates ABL1 in sperm flagellum to promote spermatozoa capacitation.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["PRKACA"], "name": "cAMP-dependent protein kinase catalytic subunit alpha", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "P17612", "drug": "DB08846"}]}, "Q51225": {"general_function": "Flavin adenine dinucleotide binding", "gene_names": ["m-6"], "name": "Dihydrolipoyl dehydrogenase", "drug_actions": []}, "Q97R46": {"specific_function": "Catalyzes the last two sequential reactions in the de novo biosynthetic pathway for UDP-N-acetylglucosamine (UDP-GlcNAc). The C-terminal domain catalyzes the transfer of acetyl group from acetyl coenzyme A to glucosamine-1-phosphate (GlcN-1-P) to produce N-acetylglucosamine-1-phosphate (GlcNAc-1-P), which is converted into UDP-GlcNAc by the transfer of uridine 5-monophosphate (from uridine 5-triphosphate), a reaction catalyzed by the N-terminal domain (By similarity).", "general_function": "Udp-n-acetylglucosamine diphosphorylase activity", "gene_names": ["glmU"], "name": "Bifunctional protein GlmU", "drug_actions": []}, "Q9Y234": {"specific_function": "Catalyzes the transfer of the lipoyl group from lipoyl-AMP to the specific lysine residue of lipoyl domains of lipoate-dependent enzymes.", "general_function": "Transferase activity, transferring acyl groups", "gene_names": ["LIPT1"], "name": "Lipoyltransferase 1, mitochondrial", "drug_actions": []}, "P83796": {"specific_function": "Component of the cytochrome b6-f complex, which mediates electron transfer between photosystem II (PSII) and photosystem I (PSI), cyclic electron flow around PSI, and state transitions.", "general_function": "Electron carrier activity", "gene_names": ["petM"], "name": "Cytochrome b6-f complex subunit 7", "drug_actions": []}, "P83795": {"specific_function": "Component of the cytochrome b6-f complex, which mediates electron transfer between photosystem II (PSII) and photosystem I (PSI), cyclic electron flow around PSI, and state transitions (PubMed:14526088). PetL is important for photoautotrophic growth as well as for electron transfer efficiency and stability of the cytochrome b6-f complex.", "general_function": "Electron transporter, transferring electrons within cytochrome b6/f complex of photosystem ii activity", "gene_names": ["petL"], "name": "Cytochrome b6-f complex subunit 6", "drug_actions": []}, "Q9NYX4": {"specific_function": "Interacts with clathrin light chain A and stimulates clathrin self-assembly and clathrin-mediated endocytosis.", "general_function": "Clathrin light chain binding", "gene_names": ["CALY"], "name": "Neuron-specific vesicular protein calcyon", "drug_actions": [{"action": "UNKNOWN", "target": "Q9NYX4", "drug": "DB00363"}, {"action": "AGONIST", "target": "Q9NYX4", "drug": "DB00714"}, {"action": "ANTAGONIST", "target": "Q9NYX4", "drug": "DB00831"}]}, "P83793": {"specific_function": "Component of the cytochrome b6-f complex, which mediates electron transfer between photosystem II (PSII) and photosystem I (PSI), cyclic electron flow around PSI, and state transitions.", "general_function": "Iron ion binding", "gene_names": ["petA"], "name": "Cytochrome f", "drug_actions": []}, "P16581": {"specific_function": "Cell-surface glycoprotein having a role in immunoadhesion. Mediates in the adhesion of blood neutrophils in cytokine-activated endothelium through interaction with PSGL1/SELPLG. May have a role in capillary morphogenesis.", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["SELE"], "name": "E-selectin", "drug_actions": [{"action": "INHIBITOR", "target": "P16581", "drug": "DB01136"}]}, "P83791": {"specific_function": "Component of the cytochrome b6-f complex, which mediates electron transfer between photosystem II (PSII) and photosystem I (PSI), cyclic electron flow around PSI, and state transitions.", "general_function": "Oxidoreductase activity", "gene_names": ["petB"], "name": "Cytochrome b6", "drug_actions": []}, "Q9Y233": {"specific_function": "Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.", "name": "cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "Q9Y233", "drug": "DB00201"}, {"action": "INHIBITOR", "target": "Q9Y233", "drug": "DB00975"}, {"action": "INHIBITOR", "target": "Q9Y233", "drug": "DB01113"}, {"action": "INHIBITOR", "target": "Q9Y233", "drug": "DB08811"}, {"action": "ANTAGONIST", "target": "Q9Y233", "drug": "DB08814"}], "general_function": "Metal ion binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE10A"]}, "Q93088": {"specific_function": "Involved in the regulation of homocysteine metabolism. Converts betaine and homocysteine to dimethylglycine and methionine, respectively. This reaction is also required for the irreversible oxidation of choline.", "general_function": "Zinc ion binding", "gene_names": ["BHMT"], "name": "Betaine--homocysteine S-methyltransferase 1", "drug_actions": [{"action": "PRODUCT OF", "target": "Q93088", "drug": "DB00134"}]}, "Q9HBH5": {"specific_function": "Exhibits an oxidoreductive catalytic activity towards retinoids. Most efficient as an NADPH-dependent retinal reductase. Displays high activity toward 9-cis and all-trans-retinol. No steroid dehydrogenase activity detected.", "general_function": "Alcohol dehydrogenase (nadp+) activity", "gene_names": ["RDH14"], "name": "Retinol dehydrogenase 14", "drug_actions": []}, "P10515": {"specific_function": "The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links the glycolytic pathway to the tricarboxylic cycle.", "general_function": "Dihydrolipoyllysine-residue acetyltransferase activity", "gene_names": ["DLAT"], "name": "Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial", "drug_actions": []}, "P0C0X2": {"specific_function": "Has very low affinity for the DHPS substrate 6-hydroxymethyl-7,8-dihydropterin-pyrophosphate, but can bind the inhibitor dapsone. Seems to lack dihydropteroate synthase activity, and does probably not function in folate metabolism (By similarity).", "general_function": "Dihydropteroate synthase activity", "gene_names": ["folP2"], "name": "Inactive dihydropteroate synthase 2", "drug_actions": [{"action": "INHIBITOR", "target": "P0C0X2", "drug": "DB00250"}]}, "P0C0X1": {"specific_function": "Catalyzes the condensation of para-aminobenzoate (pABA) with 6-hydroxymethyl-7,8-dihydropterin diphosphate (DHPt-PP) to form 7,8-dihydropteroate, the immediate precursor of folate derivatives.", "general_function": "Metal ion binding", "gene_names": ["folP1"], "name": "Dihydropteroate synthase", "drug_actions": [{"action": "INHIBITOR", "target": "P0C0X1", "drug": "DB00250"}]}, "Q9HBH1": {"specific_function": "Removes the formyl group from the N-terminal Met of newly synthesized proteins.", "general_function": "Peptide deformylase activity", "gene_names": ["PDF"], "name": "Peptide deformylase, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "Q9HBH1", "drug": "DB04368"}]}, "P0A110": {"specific_function": "Component of the naphthalene dioxygenase (NDO) multicomponent enzyme system which catalyzes the incorporation of both atoms of molecular oxygen into naphthalene to form cis-naphthalene dihydrodiol.", "general_function": "Naphthalene 1,2-dioxygenase activity", "gene_names": ["ndoB"], "name": "Naphthalene 1,2-dioxygenase subunit alpha", "drug_actions": []}, "P07741": {"specific_function": "Catalyzes a salvage reaction resulting in the formation of AMP, that is energically less costly than de novo synthesis.", "general_function": "Amp binding", "gene_names": ["APRT"], "name": "Adenine phosphoribosyltransferase", "drug_actions": []}, "P83223": {"specific_function": "Catalyzes fumarate reduction using artificial electron donors such as methyl viologen. The physiological reductant is unknown, but evidence indicates that flavocytochrome c participates in electron transfer from formate to fumarate and possibly also to trimethylamine oxide (TMAO). This enzyme is essentially unidirectional (By similarity).", "general_function": "Succinate dehydrogenase activity", "gene_names": [], "name": "Fumarate reductase flavoprotein subunit", "drug_actions": [{"action": "INHIBITOR", "target": "P83223", "drug": "DB00518"}]}, "P09417": {"specific_function": "The product of this enzyme, tetrahydrobiopterin (BH-4), is an essential cofactor for phenylalanine, tyrosine, and tryptophan hydroxylases.", "general_function": "Nadph binding", "gene_names": ["QDPR"], "name": "Dihydropteridine reductase", "drug_actions": []}, "P39304": {"specific_function": "Catalyzes the decarboxylation of 3-keto-L-gulonate-6-P into L-xylulose-5-P. Is involved in the anaerobic L-ascorbate utilization.", "general_function": "Orotidine-5'-phosphate decarboxylase activity", "gene_names": ["ulaD"], "name": "3-keto-L-gulonate-6-phosphate decarboxylase UlaD", "drug_actions": []}, "Q888A4": {"general_function": "Oxidoreductase activity", "gene_names": [], "name": "Amine oxidase, flavin-containing protein", "drug_actions": []}, "P39300": {"specific_function": "Probably catalyzes the hydrolysis of L-ascorbate-6-P into 3-keto-L-gulonate-6-P. Is essential for L-ascorbate utilization under anaerobic conditions. Also shows phosphodiesterase activity, hydrolyzing phosphodiester bond in the artificial chromogenic substrate bis-p-nitrophenyl phosphate (bis-pNPP).", "general_function": "Manganese ion binding", "gene_names": ["ulaG"], "name": "Probable L-ascorbate-6-phosphate lactonase UlaG", "drug_actions": []}, "Q12866": {"specific_function": "Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to several ligands including LGALS3, TUB, TULP1 or GAS6. Regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells (efferocytosis). Ligand binding at the cell surface induces autophosphorylation of MERTK on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with GRB2 or PLCG2 and induces phosphorylation of MAPK1, MAPK2, FAK/PTK2 or RAC1. MERTK signaling plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. Plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1, which selectively induces production of suppressors of cytokine signaling SOCS1 and SOCS3.", "general_function": "Transmembrane receptor protein tyrosine kinase activity", "gene_names": ["MERTK"], "name": "Tyrosine-protein kinase Mer", "drug_actions": []}, "Q7K9G0": {"general_function": "3-mercaptopyruvate sulfurtransferase activity", "gene_names": ["MST"], "name": "3-mercaptopyruvate sulfurtransferase", "drug_actions": []}, "P39126": {"general_function": "Nad binding", "gene_names": ["icd"], "name": "Isocitrate dehydrogenase [NADP]", "drug_actions": []}, "P08235": {"specific_function": "Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels.", "general_function": "Zinc ion binding", "gene_names": ["NR3C2"], "name": "Mineralocorticoid receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "P08235", "drug": "DB00393"}, {"action": "ANTAGONIST", "target": "P08235", "drug": "DB00396"}, {"action": "ANTAGONIST", "target": "P08235", "drug": "DB00421"}, {"action": "ANTAGONIST", "target": "P08235", "drug": "DB00588"}, {"action": "AGONIST", "target": "P08235", "drug": "DB00687"}, {"action": "ANTAGONIST", "target": "P08235", "drug": "DB00700"}, {"action": "ANTAGONIST", "target": "P08235", "drug": "DB01023"}, {"action": "AGONIST", "target": "P08235", "drug": "DB01134"}, {"action": "ANTAGONIST", "target": "P08235", "drug": "DB01395"}]}, "P15587": {"specific_function": "Involved in D-xylose catabolism.", "general_function": "Xylose isomerase activity", "gene_names": ["xylA"], "name": "Xylose isomerase", "drug_actions": []}, "P48061": {"gene_names": ["CXCL12"], "name": "Stromal cell-derived factor 1", "drug_actions": [{"action": "BINDER", "target": "P48061", "drug": "DB06822"}]}, "P28720": {"specific_function": "Exchanges the guanine residue with 7-aminomethyl-7-deazaguanine in tRNAs with GU(N) anticodons (tRNA-Asp, -Asn, -His and -Tyr). After this exchange, a cyclopentendiol moiety is attached to the 7-aminomethyl group of 7-deazaguanine, resulting in the hypermodified nucleoside queuosine (Q) (7-(((4,5-cis-dihydroxy-2-cyclopenten-1-yl)amino)methyl)-7-deazaguanosine).", "general_function": "Queuine trna-ribosyltransferase activity", "gene_names": ["tgt"], "name": "Queuine tRNA-ribosyltransferase", "drug_actions": []}, "P23297": {"specific_function": "Weakly binds calcium but binds zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer. Physiological concentrations of potassium ion antagonize the binding of both divalent cations, especially affecting high-affinity calcium-binding sites. May mediate calcium-dependent regulation on many physiological processes by interacting with other proteins, such as TPR-containing proteins, and modulating their activity.", "general_function": "S100 protein binding", "gene_names": ["S100A1"], "name": "Protein S100-A1", "drug_actions": [{"action": "ANTAGONIST", "target": "P23297", "drug": "DB00768"}]}, "Q59192": {"specific_function": "Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.", "general_function": "Magnesium ion binding", "gene_names": ["parE"], "name": "DNA topoisomerase 4 subunit B", "drug_actions": []}, "Q07806": {"specific_function": "Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits) (By similarity).", "general_function": "Transferase activity, transferring glycosyl groups", "gene_names": ["mrcA"], "name": "Penicillin-binding protein 1A", "drug_actions": [{"action": "INHIBITOR", "target": "Q07806", "drug": "DB00430"}, {"action": "INHIBITOR", "target": "Q07806", "drug": "DB01329"}]}, "P24093": {"specific_function": "Hemagglutinins of uropathogenic E.coli mediate adherence to the upper urinary tract. These adhesins bind to the Dr blood group antigen and also agglutinate human erythrocytes in the presence of D-mannose (mannose-resistant hemagglutination (MRHA)).", "gene_names": ["draA"], "name": "Dr hemagglutinin structural subunit", "drug_actions": [{"action": "ANTAGONIST", "target": "P24093", "drug": "DB00446"}]}, "P24092": {"specific_function": "HMWC (high-molecular-weight cytochrome c), ORF2, ORF3, ORF4, ORF5 and ORF6 in the HMC operon form a transmembrane protein complex that allows electron flow from the periplasmic hydrogenase to the cytoplasmic enzymes that catalyze reduction of sulfates.", "general_function": "Metal ion binding", "gene_names": ["hmcA"], "name": "High-molecular-weight cytochrome c", "drug_actions": []}, "P56740": {"specific_function": "Catalyzes the conversion of 7,8-dihydroneopterin to 6-hydroxymethyl-7,8-dihydropterin. Can also catalyze the epimerization of carbon 2' of dihydroneopterin to dihydromonapterin.", "general_function": "Isomerase activity", "gene_names": ["folB"], "name": "Dihydroneopterin aldolase", "drug_actions": []}, "P0A4Z6": {"specific_function": "Catalyzes a trans-dehydration via an enolate intermediate", "general_function": "Amino acid transport and metabolism", "gene_names": ["aroQ"], "name": "3-dehydroquinate dehydratase", "drug_actions": []}, "P13981": {"general_function": "Arginine deiminase activity", "gene_names": ["arcA"], "name": "Arginine deiminase", "drug_actions": []}, "P20083": {"specific_function": "Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule. MukB stimulates the relaxation activity of topoisomerase IV and also has a modest effect on decatenation.", "general_function": "Magnesium ion binding", "gene_names": ["parE"], "name": "DNA topoisomerase 4 subunit B", "drug_actions": []}, "P00918": {"specific_function": "Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate exchange activity of SLC26A6.", "general_function": "Zinc ion binding", "gene_names": ["CA2"], "name": "Carbonic anhydrase 2", "drug_actions": [{"action": "INHIBITOR", "target": "P00918", "drug": "DB00232"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00273"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00311"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00436"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00562"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00606"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00703"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00774"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00819"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00869"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00880"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB00999"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB01021"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB01031"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB01119"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB01144"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB01194"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB01325"}, {"action": "INHIBITOR", "target": "P00918", "drug": "DB08846"}]}, "P14218": {"specific_function": "The branched-chain alpha-keto dehydrogenase complex catalyzes the overall conversion of alpha-keto acids to acyl-CoA and CO(2). It contains multiple copies of 3 enzymatic components: branched-chain alpha-keto acid decarboxylase (E1), lipoamide acyltransferase (E2) and lipoamide dehydrogenase (E3).", "general_function": "Flavin adenine dinucleotide binding", "gene_names": ["lpd"], "name": "Dihydrolipoyl dehydrogenase", "drug_actions": []}, "Q96AZ6": {"specific_function": "Interferon-induced antiviral exoribonuclease that acts on single-stranded RNA and also has minor activity towards single-stranded DNA. Exhibits antiviral activity against RNA viruses including hepatitis C virus (HCV), hepatitis A virus (HAV) and yellow fever virus (YFV) in an exonuclease-dependent manner. May also play additional roles in the maturation of snRNAs and rRNAs, and in ribosome biogenesis.", "general_function": "U3 snorna binding", "gene_names": ["ISG20"], "name": "Interferon-stimulated gene 20 kDa protein", "drug_actions": []}, "Q10404": {"gene_names": ["lipB"], "name": "Octanoyltransferase", "drug_actions": []}, "Q15118": {"specific_function": "Kinase that plays a key role in regulation of glucose and fatty acid metabolism and homeostasis via phosphorylation of the pyruvate dehydrogenase subunits PDHA1 and PDHA2. This inhibits pyruvate dehydrogenase activity, and thereby regulates metabolite flux through the tricarboxylic acid cycle, down-regulates aerobic respiration and inhibits the formation of acetyl-coenzyme A from pyruvate. Plays an important role in cellular responses to hypoxia and is important for cell proliferation under hypoxia. Protects cells against apoptosis in response to hypoxia and oxidative stress.", "general_function": "Pyruvate dehydrogenase (acetyl-transferring) kinase activity", "gene_names": ["PDK1"], "name": "[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "Q15118", "drug": "DB08809"}]}, "P20648": {"specific_function": "Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.", "general_function": "Sodium:potassium-exchanging atpase activity", "gene_names": ["ATP4A"], "name": "Potassium-transporting ATPase alpha chain 1", "drug_actions": [{"action": "INHIBITOR", "target": "P20648", "drug": "DB00213"}, {"action": "INHIBITOR", "target": "P20648", "drug": "DB00338"}, {"action": "INHIBITOR", "target": "P20648", "drug": "DB00448"}, {"action": "INHIBITOR", "target": "P20648", "drug": "DB00736"}, {"action": "INHIBITOR", "target": "P20648", "drug": "DB01129"}]}, "Q70KI2": {"general_function": "Penicillin binding", "gene_names": ["pbpA"], "name": "Penicillin-binding protein 2", "drug_actions": [{"action": "INHIBITOR", "target": "Q70KI2", "drug": "DB00923"}, {"action": "INHIBITOR", "target": "Q70KI2", "drug": "DB01326"}]}, "Q27743": {"general_function": "L-lactate dehydrogenase activity", "gene_names": [], "name": "L-lactate dehydrogenase", "drug_actions": []}, "P13631": {"specific_function": "Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, acts mainly as an activator of gene expression due to weak binding to corepressors. Required for limb bud development. In concert with RARA or RARB, required for skeletal growth, matrix homeostasis and growth plate function (By similarity).", "general_function": "Zinc ion binding", "gene_names": ["RARG"], "name": "Retinoic acid receptor gamma", "drug_actions": [{"action": "AGONIST", "target": "P13631", "drug": "DB00210"}, {"action": "AGONIST", "target": "P13631", "drug": "DB00459"}, {"action": "AGONIST", "target": "P13631", "drug": "DB00523"}, {"action": "AGONIST", "target": "P13631", "drug": "DB00755"}, {"action": "AGONIST", "target": "P13631", "drug": "DB00799"}, {"action": "AGONIST", "target": "P13631", "drug": "DB00926"}]}, "Q15111": {"specific_function": "Involved in an inositol phospholipid-based intracellular signaling cascade. Shows no PLC activity to phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol. Component in the phospho-dependent endocytosis process of GABA A receptor (By similarity). Regulates the turnover of receptors and thus contributes to the maintenance of GABA-mediated synaptic inhibition. Its aberrant expression could contribute to the genesis and progression of lung carcinoma. Acts as a inhibitor of PPP1C.", "general_function": "Signal transducer activity", "gene_names": ["PLCL1"], "name": "Inactive phospholipase C-like protein 1", "drug_actions": [{"action": "INHIBITOR", "target": "Q15111", "drug": "DB01103"}]}, "P00915": {"specific_function": "Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.", "general_function": "Zinc ion binding", "gene_names": ["CA1"], "name": "Carbonic anhydrase 1", "drug_actions": [{"action": "INHIBITOR", "target": "P00915", "drug": "DB00232"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00311"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00381"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00423"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00436"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00562"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00606"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00703"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00774"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00819"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00869"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00880"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB00999"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB01021"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB01031"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB01119"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB01144"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB01194"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB01325"}, {"action": "INHIBITOR", "target": "P00915", "drug": "DB08846"}]}, "Q819U0": {"specific_function": "Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions.", "general_function": "Peptide deformylase activity", "gene_names": ["def1"], "name": "Peptide deformylase 1", "drug_actions": []}, "Q701N4": {"specific_function": "In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated protein (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins.", "gene_names": ["KRTAP5-2"], "name": "Keratin-associated protein 5-2", "drug_actions": []}, "Q7ADF8": {"specific_function": "Catalyzes the dephosphorylation of 2-deoxyglucose 6-phosphate (2dGlu6P).", "general_function": "Sugar-phosphatase activity", "gene_names": ["yniC"], "name": "2-deoxyglucose-6-phosphate phosphatase", "drug_actions": []}, "P29120": {"specific_function": "Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues. Substrates include POMC, renin, enkephalin, dynorphin, somatostatin, insulin and AGRP.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["PCSK1"], "name": "Neuroendocrine convertase 1", "drug_actions": []}, "Q9P2J5": {"specific_function": "Catalyzes the specific attachment of an amino acid to its cognate tRNA in a two step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA. Exhibits a post-transfer editing activity to hydrolyze mischarged tRNAs.", "general_function": "Leucine-trna ligase activity", "gene_names": ["LARS"], "name": "Leucine--tRNA ligase, cytoplasmic", "drug_actions": []}, "P21731": {"specific_function": "Receptor for thromboxane A2 (TXA2), a potent stimulator of platelet aggregation. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system. In the kidney, the binding of TXA2 to glomerular TP receptors causes intense vasoconstriction. Activates phospholipase C. Isoform 1 activates adenylyl cyclase. Isoform 2 inhibits adenylyl cyclase.", "general_function": "Thromboxane a2 receptor activity", "gene_names": ["TBXA2R"], "name": "Thromboxane A2 receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "P21731", "drug": "DB01207"}]}, "P10930": {"specific_function": "Structural component of the short tail fiber. Adhesion protein that binds irreversibly to the lipopolysaccharides component (LPS) on the cell surface of Escherichia coli B strains during virus attachment. After at least three long tail fibers have bound, short tail fibers extend and bind irreversibly to the core region of the host cell LPS.", "general_function": "Metal ion binding", "gene_names": ["12"], "name": "Short tail fiber protein gp12", "drug_actions": []}, "Q08462": {"specific_function": "Catalyzes the formation of the signaling molecule cAMP in response to G-protein signaling (PubMed:15385642). Down-stream signaling cascades mediate changes in gene expression patterns and lead to increased IL6 production. Functions in signaling cascades downstream of the muscarinic acetylcholine receptors (By similarity).", "general_function": "Protein heterodimerization activity", "gene_names": ["ADCY2"], "name": "Adenylate cyclase type 2", "drug_actions": []}, "Q08460": {"specific_function": "Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential. Plays a key role in controlling excitability in a number of systems, such as regulation of the contraction of smooth muscle, the tuning of hair cells in the cochlea, regulation of transmitter release, and innate immunity. In smooth muscles, its activation by high level of Ca(2+), caused by ryanodine receptors in the sarcoplasmic reticulum, regulates the membrane potential. In cochlea cells, its number and kinetic properties partly determine the characteristic frequency of each hair cell and thereby helps to establish a tonotopic map. Kinetics of KCNMA1 channels are determined by alternative splicing, phosphorylation status and its combination with modulating beta subunits. Highly sensitive to both iberiotoxin (IbTx) and charybdotoxin (CTX).", "general_function": "Voltage-gated potassium channel activity", "gene_names": ["Kcnma1"], "name": "Calcium-activated potassium channel subunit alpha-1", "drug_actions": [{"action": "INHIBITOR", "target": "Q08460", "drug": "DB08837"}]}, "Q9H4Y5": {"specific_function": "Exhibits glutathione-dependent thiol transferase activity. Has high dehydroascorbate reductase activity and may contribute to the recycling of ascorbic acid. Participates in the biotransformation of inorganic arsenic and reduces monomethylarsonic acid (MMA).", "general_function": "Oxidoreductase activity", "gene_names": ["GSTO2"], "name": "Glutathione S-transferase omega-2", "drug_actions": []}, "Q8TF76": {"specific_function": "Serine/threonine-protein kinase that phosphorylates histone H3 at 'Ser-3' (H3T3ph) during mitosis. This positions and activates AURKB and other components of the chromosomal passenger complex (CPC) at centromeres to ensure proper chromatid cohesion, metaphase alignment and normal progression through the cell cycle.", "general_function": "Protein kinase activity", "gene_names": ["GSG2"], "name": "Serine/threonine-protein kinase haspin", "drug_actions": []}, "O75676": {"specific_function": "Serine/threonine-protein kinase that is required for the mitogen or stress-induced phosphorylation of the transcription factors CREB1 and ATF1 and for the regulation of the transcription factor RELA, and that contributes to gene activation by histone phosphorylation and functions in the regulation of inflammatory genes. Phosphorylates CREB1 and ATF1 in response to mitogenic or stress stimuli such as UV-C irradiation, epidermal growth factor (EGF) and anisomycin. Plays an essential role in the control of RELA transcriptional activity in response to TNF. Phosphorylates 'Ser-10' of histone H3 in response to mitogenics, stress stimuli and EGF, which results in the transcriptional activation of several immediate early genes, including proto-oncogenes c-fos/FOS and c-jun/JUN. May also phosphorylate 'Ser-28' of histone H3. Mediates the mitogen- and stress-induced phosphorylation of high mobility group protein 1 (HMGN1/HMG14). In lipopolysaccharide-stimulated primary macrophages, acts downstream of the Toll-like receptor TLR4 to limit the production of pro-inflammatory cytokines. Functions probably by inducing transcription of the MAP kinase phosphatase DUSP1 and the anti-inflammatory cytokine interleukin 10 (IL10), via CREB1 and ATF1 transcription factors.", "general_function": "Ribosomal protein s6 kinase activity", "gene_names": ["RPS6KA4"], "name": "Ribosomal protein S6 kinase alpha-4", "drug_actions": []}, "O08498": {"specific_function": "Hydrolyzes penicillins, cephalosporins (including cefoxitin), carbapenems and 6-beta-iodopenicillanate.", "general_function": "Zinc ion binding", "gene_names": ["blaB1"], "name": "Carbapenem-hydrolyzing beta-lactamase BlaB-1", "drug_actions": []}, "O14983": {"specific_function": "Key regulator of striated muscle performance by acting as the major Ca(2+) ATPase responsible for the reuptake of cytosolic Ca(2+) into the sarcoplasmic reticulum. Catalyzes the hydrolysis of ATP coupled with the translocation of calcium from the cytosol to the sarcoplasmic reticulum lumen. Contributes to calcium sequestration involved in muscular excitation/contraction.", "general_function": "Protein homodimerization activity", "gene_names": ["ATP2A1"], "name": "Sarcoplasmic/endoplasmic reticulum calcium ATPase 1", "drug_actions": []}, "P0A917": {"gene_names": ["ompX"], "name": "Outer membrane protein X", "drug_actions": []}, "P49069": {"specific_function": "Likely involved in the mobilization of calcium as a result of the TCR/CD3 complex interaction. Binds to cyclophilin B.", "gene_names": ["CAMLG"], "name": "Calcium signal-modulating cyclophilin ligand", "drug_actions": [{"action": "BINDER", "target": "P49069", "drug": "DB00091"}]}, "P32238": {"specific_function": "Receptor for cholecystokinin. Mediates pancreatic growth and enzyme secretion, smooth muscle contraction of the gall bladder and stomach. Has a 1000-fold higher affinity for CCK rather than for gastrin. It modulates feeding and dopamine-induced behavior in the central and peripheral nervous system. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.", "general_function": "Peptide binding", "gene_names": ["CCKAR"], "name": "Cholecystokinin receptor type A", "drug_actions": [{"action": "INDUCER", "target": "P32238", "drug": "DB00403"}]}, "P32239": {"specific_function": "Receptor for gastrin and cholecystokinin. The CKK-B receptors occur throughout the central nervous system where they modulate anxiety, analgesia, arousal, and neuroleptic activity. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.Isoform 2 is constitutively activated and may regulate cancer cell proliferation via a gastrin-independent mechanism.", "general_function": "Type b gastrin/cholecystokinin receptor binding", "gene_names": ["CCKBR"], "name": "Gastrin/cholecystokinin type B receptor", "drug_actions": [{"action": "AGONIST", "target": "P32239", "drug": "DB00183"}]}, "P35237": {"specific_function": "May be involved in the regulation of serine proteinases present in the brain or extravasated from the blood (By similarity). Inhibitor of cathepsin G, kallikrein-8 and thrombin. May play an important role in the inner ear in the protection against leakage of lysosomal content during stress and loss of this protection results in cell death and sensorineural hearing loss.", "general_function": "Serine-type endopeptidase inhibitor activity", "gene_names": ["SERPINB6"], "name": "Serpin B6", "drug_actions": []}, "Q93CA2": {"general_function": "Beta-lactamase activity", "gene_names": ["ampC"], "name": "Beta-lactamase", "drug_actions": [{"action": "INHIBITOR", "target": "Q93CA2", "drug": "DB09060"}]}, "O15511": {"specific_function": "Functions as component of the Arp2/3 complex which is involved in regulation of actin polymerization and together with an activating nucleation-promoting factor (NPF) mediates the formation of branched actin networks.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["ARPC5"], "name": "Actin-related protein 2/3 complex subunit 5", "drug_actions": []}, "P05655": {"general_function": "Levansucrase activity", "gene_names": ["sacB"], "name": "Levansucrase", "drug_actions": []}, "P30874": {"specific_function": "Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and PLC via pertussis toxin insensitive as well as sensitive G proteins. Inhibits calcium entry by suppressing voltage-dependent calcium channels. Acts as the functionally dominant somatostatin receptor in pancreatic alpha- and beta-cells where it mediates the inhibitory effect of somatostatin-14 on hormone secretion. Inhibits cell growth through enhancement of MAPK1 and MAPK2 phosphorylation and subsequent up-regulation of CDKN1B. Stimulates neuronal migration and axon outgrowth and may participate in neuron development and maturation during brain development. Mediates negative regulation of insulin receptor signaling through PTPN6. Inactivates SSTR3 receptor function following heterodimerization.", "general_function": "Somatostatin receptor activity", "gene_names": ["SSTR2"], "name": "Somatostatin receptor type 2", "drug_actions": [{"action": "BINDER", "target": "P30874", "drug": "DB00104"}, {"action": "INDUCER", "target": "P30874", "drug": "DB04894"}, {"action": "AGONIST", "target": "P30874", "drug": "DB06791"}]}, "O75489": {"specific_function": "Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).", "general_function": "Nadh dehydrogenase activity", "gene_names": ["NDUFS3"], "name": "NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial", "drug_actions": []}, "P04118": {"specific_function": "Colipase is a cofactor of pancreatic lipase. It allows the lipase to anchor itself to the lipid-water interface. Without colipase the enzyme is washed off by bile salts, which have an inhibitory effect on the lipase.Enterostatin has a biological activity as a satiety signal.", "general_function": "Enzyme activator activity", "gene_names": ["CLPS"], "name": "Colipase", "drug_actions": []}, "P08692": {"specific_function": "Reduction of arsenate [As(V)] to arsenite [As(III)]. This protein expands the substrate specificity of ArsAB pump which can extrude arsenite and antimonite to allow for arsenate pumping and resistance.", "general_function": "Arsenate reductase (glutaredoxin) activity", "gene_names": ["arsC"], "name": "Arsenate reductase", "drug_actions": []}, "P08123": {"specific_function": "Type I collagen is a member of group I collagen (fibrillar forming collagen).", "general_function": "Protein binding, bridging", "gene_names": ["COL1A2"], "name": "Collagen alpha-2(I) chain", "drug_actions": []}, "P08690": {"specific_function": "Anion-transporting ATPase. Catalyzes the extrusion of the oxyanions arsenite, antimonite and arsenate. Maintenance of a low intracellular concentration of oxyanion produces resistance to the toxic agents.", "general_function": "Atp binding", "gene_names": ["arsA"], "name": "Arsenical pump-driving ATPase", "drug_actions": []}, "P00352": {"specific_function": "Binds free retinal and cellular retinol-binding protein-bound retinal. Can convert/oxidize retinaldehyde to retinoic acid (By similarity).", "general_function": "Retinal dehydrogenase activity", "gene_names": ["ALDH1A1"], "name": "Retinal dehydrogenase 1", "drug_actions": []}, "P14324": {"specific_function": "Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate.", "general_function": "Poly(a) rna binding", "gene_names": ["FDPS"], "name": "Farnesyl pyrophosphate synthase", "drug_actions": [{"action": "INHIBITOR", "target": "P14324", "drug": "DB00282"}, {"action": "INHIBITOR", "target": "P14324", "drug": "DB00399"}, {"action": "INHIBITOR", "target": "P14324", "drug": "DB00630"}, {"action": "INHIBITOR", "target": "P14324", "drug": "DB00710"}, {"action": "INHIBITOR", "target": "P14324", "drug": "DB00884"}]}, "O60669": {"specific_function": "Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. Functions as high-affinity pyruvate transporter.", "general_function": "Symporter activity", "gene_names": ["SLC16A7"], "name": "Monocarboxylate transporter 2", "drug_actions": []}, "P18357": {"specific_function": "BlaR1 is a potential penicillin-binding protein required for induction of beta-lactamase.", "general_function": "Penicillin binding", "gene_names": ["blaR1"], "name": "Regulatory protein BlaR1", "drug_actions": []}, "P53608": {"specific_function": "Controls arginine catabolism.", "general_function": "Metal ion binding", "gene_names": ["rocF"], "name": "Arginase", "drug_actions": []}, "Q9H598": {"specific_function": "Involved in the uptake of GABA and glycine into the synaptic vesicles.", "general_function": "Glycine transmembrane transporter activity", "gene_names": ["SLC32A1"], "name": "Vesicular inhibitory amino acid transporter", "drug_actions": []}, "Q81Y15": {"specific_function": "Catalyzes the transfer of a two-carbon ketol group from a ketose donor to an aldose acceptor, via a covalent intermediate with the cofactor thiamine pyrophosphate.", "general_function": "Transketolase activity", "gene_names": ["tkt2"], "name": "Transketolase", "drug_actions": []}, "Q8TCC7": {"specific_function": "Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).", "general_function": "Sodium-independent organic anion transmembrane transporter activity", "gene_names": ["SLC22A8"], "name": "Solute carrier family 22 member 8", "drug_actions": [{"action": "INHIBITOR", "target": "Q8TCC7", "drug": "DB01032"}]}, "Q13133": {"specific_function": "Nuclear receptor. Interaction with RXR shifts RXR from its role as a silent DNA-binding partner to an active ligand-binding subunit in mediating retinoid responses through target genes defined by LXRES. LXRES are DR4-type response elements characterized by direct repeats of two similar hexanuclotide half-sites spaced by four nucleotides. Plays an important role in the regulation of cholesterol homeostasis, regulating cholesterol uptake through MYLIP-dependent ubiquitination of LDLR, VLDLR and LRP8. Interplays functionally with RORA for the regulation of genes involved in liver metabolism (By similarity). Exhibits a ligand-dependent transcriptional activation activity (PubMed:25661920).", "general_function": "Zinc ion binding", "gene_names": ["NR1H3"], "name": "Oxysterols receptor LXR-alpha", "drug_actions": []}, "P06239": {"specific_function": "Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells. Plays a key role in T-cell antigen receptor (TCR)-linked signal transduction pathways. Constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors. Association of the TCR with a peptide antigen-bound MHC complex facilitates the interaction of CD4 and CD8 with MHC class II and class I molecules, respectively, thereby recruiting the associated LCK protein to the vicinity of the TCR/CD3 complex. LCK then phosphorylates tyrosines residues within the immunoreceptor tyrosine-based activation motifs (ITAM) of the cytoplasmic tails of the TCR-gamma chains and CD3 subunits, initiating the TCR/CD3 signaling pathway. Once stimulated, the TCR recruits the tyrosine kinase ZAP70, that becomes phosphorylated and activated by LCK. Following this, a large number of signaling molecules are recruited, ultimately leading to lymphokine production. LCK also contributes to signaling by other receptor molecules. Associates directly with the cytoplasmic tail of CD2, which leads to hyperphosphorylation and activation of LCK. Also plays a role in the IL2 receptor-linked signaling pathway that controls the T-cell proliferative response. Binding of IL2 to its receptor results in increased activity of LCK. Is expressed at all stages of thymocyte development and is required for the regulation of maturation events that are governed by both pre-TCR and mature alpha beta TCR. Phosphorylates other substrates including RUNX3, PTK2B/PYK2, the microtubule-associated protein MAPT, RHOH or TYROBP.", "general_function": "Sh2 domain binding", "gene_names": ["LCK"], "name": "Tyrosine-protein kinase Lck", "drug_actions": [{"action": "MULTITARGET", "target": "P06239", "drug": "DB01254"}, {"action": "INHIBITOR", "target": "P06239", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P06239", "drug": "DB09079"}]}, "P43522": {"specific_function": "Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions (By similarity).", "general_function": "Peptide deformylase activity", "gene_names": ["def"], "name": "Peptide deformylase", "drug_actions": []}, "P07585": {"specific_function": "May affect the rate of fibrils formation.", "general_function": "Poly(a) rna binding", "gene_names": ["DCN"], "name": "Decorin", "drug_actions": []}, "Q9BXJ7": {"specific_function": "Necessary for efficient absorption of vitamin B12. May direct the production of trunk mesoderm during development by modulating a bone morphogenetic protein (BMP) signaling pathway in the underlying visceral endoderm (By similarity).", "general_function": "Receptor binding", "gene_names": ["AMN"], "name": "Protein amnionless", "drug_actions": [{"action": "OTHER", "target": "Q9BXJ7", "drug": "DB00200"}]}, "Q8KNZ7": {"gene_names": [], "name": "Long-chain N-acyl amino acid synthase", "drug_actions": []}, "Q47764": {"general_function": "N-acetyltransferase activity", "gene_names": ["aac(6')-Ii"], "name": "Aac(6')-Ii protein", "drug_actions": []}, "Q9RA63": {"specific_function": "Part of a stress-induced multi-chaperone system, it is involved in the recovery of the cell from heat-induced damage, in cooperation with DnaK, DnaJ and GrpE. Acts before DnaK, in the processing of protein aggregates. Protein binding stimulates the ATPase activity; ATP hydrolysis unfolds the denatured protein aggregates, which probably helps expose new hydrophobic binding sites on the surface of ClpB-bound aggregates, contributing to the solubilization and refolding of denatured protein aggregates by DnaK.", "general_function": "Identical protein binding", "gene_names": ["clpB"], "name": "Chaperone protein ClpB", "drug_actions": []}, "Q96QT4": {"specific_function": "Essential ion channel and serine/threonine-protein kinase. Divalent cation channel permeable to calcium and magnesium. Has a central role in magnesium ion homeostasis and in the regulation of anoxic neuronal cell death. Involved in TNF-induced necroptosis downstream of MLKL by mediating calcium influx. The kinase activity is essential for the channel function. May be involved in a fundamental process that adjusts plasma membrane divalent cation fluxes according to the metabolic state of the cell. Phosphorylates annexin A1 (ANXA1).", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["TRPM7"], "name": "Transient receptor potential cation channel subfamily M member 7", "drug_actions": []}, "Q9WZS7": {"general_function": "Oxidoreductase activity", "gene_names": [], "name": "NADH-dependent butanol dehydrogenase A", "drug_actions": []}, "P27142": {"specific_function": "Catalyzes the reversible transfer of the terminal phosphate group between ATP and AMP. Plays an important role in cellular energy homeostasis and in adenine nucleotide metabolism.", "general_function": "Metal ion binding", "gene_names": ["adk"], "name": "Adenylate kinase", "drug_actions": []}, "Q86UW8": {"specific_function": "Binds to hyaluronic acid and may be involved in formation of the extracellular matrix.", "general_function": "Hyaluronic acid binding", "gene_names": ["HAPLN4"], "name": "Hyaluronan and proteoglycan link protein 4", "drug_actions": [{"action": "BINDER", "target": "Q86UW8", "drug": "DB08818"}]}, "Q9AFC7": {"specific_function": "Catalyzes the attachment of L-vancosamine to a monoglucosylated heptapeptide intermediate during the final stage of glycopeptide antibiotic vancomycin biosynthesis.", "general_function": "Transferase activity, transferring hexosyl groups", "gene_names": ["gtfD"], "name": "Desvancosaminyl-vancomycin vancosaminetransferase", "drug_actions": []}, "O68874": {"specific_function": "Channel that permits osmotically driven movement of water in both directions. It is involved in the osmoregulation and in the maintenance of cell turgor during volume expansion in rapidly growing cells. It mediates rapid entry or exit of water in response to abrupt changes in osmolarity.", "general_function": "Water channel activity", "gene_names": ["aqpZ"], "name": "Aquaporin Z", "drug_actions": []}, "Q46702": {"gene_names": ["traN"], "name": "TraN protein", "drug_actions": []}, "Q46704": {"gene_names": ["traO"], "name": "TraO protein", "drug_actions": []}, "Q46705": {"gene_names": ["traF"], "name": "TraF protein", "drug_actions": []}, "P67775": {"specific_function": "PP2A is the major phosphatase for microtubule-associated proteins (MAPs). PP2A can modulate the activity of phosphorylase B kinase casein kinase 2, mitogen-stimulated S6 kinase, and MAP-2 kinase. Cooperates with SGOL2 to protect centromeric cohesin from separase-mediated cleavage in oocytes specifically during meiosis I (By similarity). Can dephosphorylate SV40 large T antigen and p53/TP53. Activates RAF1 by dephosphorylating it at 'Ser-259'.", "general_function": "Phosphoprotein phosphatase activity", "gene_names": ["PPP2CA"], "name": "Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform", "drug_actions": []}, "Q04771": {"specific_function": "On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin. May be involved for left-right pattern formation during embryogenesis (By similarity).", "general_function": "Transmembrane receptor protein serine/threonine kinase activity", "gene_names": ["ACVR1"], "name": "Activin receptor type-1", "drug_actions": []}, "Q13093": {"specific_function": "Modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. Has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids.", "general_function": "Phospholipid binding", "gene_names": ["PLA2G7"], "name": "Platelet-activating factor acetylhydrolase", "drug_actions": []}, "P22869": {"specific_function": "Responsible for the initial oxygenation of methane to methanol in methanotrophs. It also catalyzes the monohydroxylation of a variety of unactivated alkenes, alicyclic, aromatic and heterocyclic compounds.", "general_function": "Methane monooxygenase activity", "gene_names": ["mmoX"], "name": "Methane monooxygenase component A alpha chain", "drug_actions": []}, "P76577": {"specific_function": "Cell wall formation. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a transpeptidase C-terminal domain which may not be functional.", "general_function": "Peptidoglycan glycosyltransferase activity", "gene_names": ["pbpC"], "name": "Penicillin-binding protein 1C", "drug_actions": [{"action": "INHIBITOR", "target": "P76577", "drug": "DB01327"}]}, "P02775": {"specific_function": "LA-PF4 stimulates DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by human synovial cells. NAP-2 is a ligand for CXCR1 and CXCR2, and NAP-2, NAP-2(73), NAP-2(74), NAP-2(1-66), and most potent NAP-2(1-63) are chemoattractants and activators for neutrophils. TC-1 and TC-2 are antibacterial proteins, in vitro released from activated platelet alpha-granules. CTAP-III(1-81) is more potent than CTAP-III desensitize chemokine-induced neutrophil activation.", "general_function": "Glucose transmembrane transporter activity", "gene_names": ["PPBP"], "name": "Platelet basic protein", "drug_actions": []}, "P45494": {"specific_function": "Is a relatively unspecific dipeptidase cleaving a variety of dipeptides, notably those with an N-terminal beta-Ala or D-Ala residue, e.g. carnosine (beta-Ala-His). To a lesser extent, also shows aminopeptidase activity, since it is able to catalyze the removal of the N-terminal amino acid from a few distinct tripeptides.", "general_function": "Zinc ion binding", "gene_names": ["pepV"], "name": "Beta-Ala-Xaa dipeptidase", "drug_actions": []}, "P53597": {"specific_function": "Catalyzes the ATP- or GTP-dependent ligation of succinate and CoA to form succinyl-CoA. The nature of the beta subunit determines the nucleotide specificity (By similarity).", "general_function": "Succinate-coa ligase (gdp-forming) activity", "gene_names": ["SUCLG1"], "name": "Succinyl-CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial", "drug_actions": []}, "Q13233": {"specific_function": "Component of a protein kinase signal transduction cascade. Activates the ERK and JNK kinase pathways by phosphorylation of MAP2K1 and MAP2K4. Activates CHUK and IKBKB, the central protein kinases of the NF-kappa-B pathway.", "general_function": "Zinc ion binding", "gene_names": ["MAP3K1"], "name": "Mitogen-activated protein kinase kinase kinase 1", "drug_actions": []}, "P04062": {"general_function": "Receptor binding", "gene_names": ["GBA"], "name": "Glucosylceramidase", "drug_actions": []}, "P0A872": {"specific_function": "Transaldolase is important for the balance of metabolites in the pentose-phosphate pathway.", "general_function": "Sedoheptulose-7-phosphate:d-glyceraldehyde-3-phosphate glyceronetransferase activity", "gene_names": ["talB"], "name": "Transaldolase B", "drug_actions": []}, "Q6PI48": {"general_function": "Trna binding", "gene_names": ["DARS2"], "name": "Aspartate--tRNA ligase, mitochondrial", "drug_actions": []}, "Q14081": {"gene_names": [], "name": "Carcinoembryonic antigen", "drug_actions": []}, "P10109": {"specific_function": "Participates in the synthesis of thyroid hormones. Essential for the synthesis of various steroid hormones, participates in the reduction of mitochondrial cytochrome P450 for steroidogenesis. Transfers electrons from adrenodoxin reductase to CYP11A1, a cytochrome P450 that catalyzes cholesterol side-chain cleavage.", "general_function": "Iron ion binding", "gene_names": ["FDX1"], "name": "Adrenodoxin, mitochondrial", "drug_actions": [{"action": "UNKNOWN", "target": "P10109", "drug": "DB00648"}]}, "P14061": {"specific_function": "Favors the reduction of estrogens and androgens. Also has 20-alpha-HSD activity. Uses preferentially NADH.", "general_function": "Testosterone dehydrogenase (nad+) activity", "gene_names": ["HSD17B1"], "name": "Estradiol 17-beta-dehydrogenase 1", "drug_actions": [{"action": "INDUCER", "target": "P14061", "drug": "DB01536"}]}, "P14060": {"specific_function": "3-beta-HSD is a bifunctional enzyme, that catalyzes the oxidative conversion of Delta(5)-ene-3-beta-hydroxy steroid, and the oxidative conversion of ketosteroids. The 3-beta-HSD enzymatic system plays a crucial role in the biosynthesis of all classes of hormonal steroids. Efficiently catalyzes the transformation of pregnenolone to progesterone, 17-alpha-hydroxypregnenolone to 17-alpha-hydroxyprogesterone, DHEA to 4-androstenedione, dihydrotestosterone to 5-alpha-androstane-3 beta,17 beta-diol, dehydroepiandrosterone to androstenedione and 5-alpha-androstan-3 beta,17 beta-diol to 5-alpha-dihydrotestosterone.", "general_function": "Steroid delta-isomerase activity", "gene_names": ["HSD3B1"], "name": "3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1", "drug_actions": [{"action": "INHIBITOR", "target": "P14060", "drug": "DB01108"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P14060", "drug": "DB01536"}]}, "O53512": {"specific_function": "Catalyzes an aldol-like condensation reaction between phosphoenolpyruvate (PEP) and D-erythrose 4-phosphate (E4P) to generate 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAH7P) and inorganic phosphate.", "general_function": "Manganese ion binding", "gene_names": ["aroG"], "name": "Phospho-2-dehydro-3-deoxyheptonate aldolase AroG", "drug_actions": []}, "Q15842": {"specific_function": "This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by external barium (By similarity).", "name": "ATP-sensitive inward rectifier potassium channel 8", "drug_actions": [{"action": "INHIBITOR", "target": "Q15842", "drug": "DB00914"}, {"action": "INDUCER", "target": "Q15842", "drug": "DB00922"}, {"action": "INHIBITOR", "target": "Q15842", "drug": "DB01154"}, {"action": "INHIBITOR", "target": "Q15842", "drug": "DB01251"}, {"action": "INHIBITOR", "target": "Q15842", "drug": "DB01289"}], "general_function": "Inward rectifier potassium channel activity", "in_complexes": ["ATP-sensitive potassium channel", "Mitochondrial ATP-sensitive potassium channel"], "gene_names": ["KCNJ8"]}, "Q8NFJ5": {"specific_function": "Orphan receptor. Could be involved in modulating differentiation and maintaining homeostasis of epithelial cells. This retinoic acid-inducible GPCR provide evidence for a possible interaction between retinoid and G-protein signaling pathways. Functions as a negative modulator of EGFR signaling (By similarity). May act as a lung tumor suppressor (PubMed:18000218).", "general_function": "G-protein coupled receptor activity", "gene_names": ["GPRC5A"], "name": "Retinoic acid-induced protein 3", "drug_actions": []}, "P54802": {"specific_function": "Involved in the degradation of heparan sulfate.", "general_function": "Alpha-n-acetylglucosaminidase activity", "gene_names": ["NAGLU"], "name": "Alpha-N-acetylglucosaminidase", "drug_actions": [{"action": "ACTIVATOR", "target": "P54802", "drug": "DB00141"}]}, "Q9H936": {"specific_function": "Involved in the transport of glutamate across the inner mitochondrial membrane. Glutamate is cotransported with H(+).", "general_function": "Symporter activity", "gene_names": ["SLC25A22"], "name": "Mitochondrial glutamate carrier 1", "drug_actions": []}, "P20061": {"specific_function": "Binds vitamin B12 with femtomolar affinity and protects it from the acidic environment of the stomach.", "general_function": "Cobalamin binding", "gene_names": ["TCN1"], "name": "Transcobalamin-1", "drug_actions": [{"action": "OTHER", "target": "P20061", "drug": "DB00200"}]}, "P00778": {"general_function": "Serine-type endopeptidase activity", "gene_names": ["alpha-LP"], "name": "Alpha-lytic protease", "drug_actions": []}, "O43708": {"specific_function": "Bifunctional enzyme showing minimal glutathione-conjugating activity with ethacrynic acid and 7-chloro-4-nitrobenz-2-oxa-1,3-diazole and maleylacetoacetate isomerase activity. Has also low glutathione peroxidase activity with T-butyl and cumene hydroperoxides. Is able to catalyze the glutathione dependent oxygenation of dichloroacetic acid to glyoxylic acid.", "general_function": "Protein homodimerization activity", "gene_names": ["GSTZ1"], "name": "Maleylacetoacetate isomerase", "drug_actions": []}, "P51681": {"specific_function": "Receptor for a number of inflammatory CC-chemokines including MIP-1-alpha, MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ion level. May play a role in the control of granulocytic lineage proliferation or differentiation. Acts as a coreceptor (CD4 being the primary receptor) for HIV-1 R5 isolates.(Microbial infection) Acts as a receptor for human immunodeficiency virus-1/HIV-1.", "general_function": "Virus receptor activity", "gene_names": ["CCR5"], "name": "C-C chemokine receptor type 5", "drug_actions": [{"action": "ANTAGONIST", "target": "P51681", "drug": "DB04835"}]}, "P11797": {"general_function": "Chitinase activity", "gene_names": ["chiB"], "name": "Chitinase B", "drug_actions": []}, "Q14534": {"specific_function": "Catalyzes the first oxygenation step in sterol biosynthesis and is suggested to be one of the rate-limiting enzymes in this pathway.", "general_function": "Squalene monooxygenase activity", "gene_names": ["SQLE"], "name": "Squalene monooxygenase", "drug_actions": [{"action": "INHIBITOR", "target": "Q14534", "drug": "DB00735"}, {"action": "INHIBITOR", "target": "Q14534", "drug": "DB00857"}, {"action": "INHIBITOR", "target": "Q14534", "drug": "DB01091"}, {"action": "INHIBITOR", "target": "Q14534", "drug": "DB08846"}]}, "P42261": {"specific_function": "Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate.", "general_function": "Pdz domain binding", "gene_names": ["GRIA1"], "name": "Glutamate receptor 1", "drug_actions": [{"action": "ANTAGONIST", "target": "P42261", "drug": "DB00228"}, {"action": "ANTAGONIST", "target": "P42261", "drug": "DB00753"}, {"action": "ANTAGONIST", "target": "P42261", "drug": "DB01028"}, {"action": "ANTAGONIST", "target": "P42261", "drug": "DB01189"}, {"action": "ANTAGONIST", "target": "P42261", "drug": "DB01236"}, {"action": "ANTAGONIST", "target": "P42261", "drug": "DB08883"}]}, "P42262": {"specific_function": "Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate.", "general_function": "Ionotropic glutamate receptor activity", "gene_names": ["GRIA2"], "name": "Glutamate receptor 2", "drug_actions": [{"action": "ANTAGONIST", "target": "P42262", "drug": "DB00237"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB00241"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB00306"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB00463"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB00599"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB00794"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB00849"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB01346"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB01351"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB01352"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB01353"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB01354"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB01355"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB01483"}, {"action": "ANTAGONIST", "target": "P42262", "drug": "DB01496"}]}, "P42263": {"specific_function": "Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate.", "general_function": "Extracellular-glutamate-gated ion channel activity", "gene_names": ["GRIA3"], "name": "Glutamate receptor 3", "drug_actions": [{"action": "POTENTIATOR", "target": "P42263", "drug": "DB01356"}]}, "Q7SIG1": {"general_function": "Hydrolase activity", "gene_names": [], "name": "Hydrolase", "drug_actions": []}, "Q9GZT4": {"specific_function": "Catalyzes the synthesis of D-serine from L-serine. D-serine is a key coagonist with glutamate at NMDA receptors. Has dehydratase activity towards both L-serine and D-serine.", "general_function": "Threonine racemase activity", "gene_names": ["SRR"], "name": "Serine racemase", "drug_actions": [{"action": "COFACTOR", "target": "Q9GZT4", "drug": "DB00114"}]}, "Q9GZT9": {"specific_function": "Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific proline found in each of the oxygen-dependent degradation (ODD) domains (N-terminal, NODD, and C-terminal, CODD) of HIF1A. Also hydroxylates HIF2A. Has a preference for the CODD site for both HIF1A and HIF1B. Hydroxylated HIFs are then targeted for proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Under hypoxic conditions, the hydroxylation reaction is attenuated allowing HIFs to escape degradation resulting in their translocation to the nucleus, heterodimerization with HIF1B, and increased expression of hypoxy-inducible genes. EGLN1 is the most important isozyme under normoxia and, through regulating the stability of HIF1, involved in various hypoxia-influenced processes such as angiogenesis in retinal and cardiac functionality. Target proteins are preferentially recognized via a LXXLAP motif.", "general_function": "Peptidyl-proline dioxygenase activity", "gene_names": ["EGLN1"], "name": "Egl nine homolog 1", "drug_actions": []}, "Q84424": {"specific_function": "mRNA capping. Transfers a GMP cap onto the end of mRNA that terminates with a 5'-diphosphate tail.", "general_function": "Mrna guanylyltransferase activity", "gene_names": [], "name": "mRNA-capping enzyme", "drug_actions": []}, "Q16134": {"specific_function": "Accepts electrons from ETF and reduces ubiquinone.", "general_function": "Ubiquinone binding", "gene_names": ["ETFDH"], "name": "Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial", "drug_actions": []}, "P19021": {"specific_function": "Bifunctional enzyme that catalyzes 2 sequential steps in C-terminal alpha-amidation of peptides. The monooxygenase part produces an unstable peptidyl(2-hydroxyglycine) intermediate that is dismutated to glyoxylate and the corresponding desglycine peptide amide by the lyase part. C-terminal amidation of peptides such as neuropeptides is essential for full biological activity.", "general_function": "Zinc ion binding", "gene_names": ["PAM"], "name": "Peptidyl-glycine alpha-amidating monooxygenase", "drug_actions": []}, "Q9NPA1": {"specific_function": "Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Alters the functional properties of the current expressed by the KCNMA1 channel. Isoform 2, isoform 3 and isoform 4 partially inactivate the current of KCNBMA. Isoform 4 induces a fast and incomplete inactivation of KCNMA1 channel that is detectable only at large depolarizations. In contrast, isoform 1 does not induce detectable inactivation of KCNMA1. Two or more subunits of KCNMB3 are required to block the KCNMA1 tetramer.", "name": "Calcium-activated potassium channel subunit beta-3", "drug_actions": [{"action": "BINDER", "target": "Q9NPA1", "drug": "DB00721"}, {"action": "INHIBITOR", "target": "Q9NPA1", "drug": "DB01110"}], "general_function": "Potassium channel regulator activity", "in_complexes": ["Calcium-activated potassium channel"], "gene_names": ["KCNMB3"]}, "Q9NPA2": {"specific_function": "May activate progelatinase A.", "general_function": "Zinc ion binding", "gene_names": ["MMP25"], "name": "Matrix metalloproteinase-25", "drug_actions": [{"action": "INHIBITOR", "target": "Q9NPA2", "drug": "DB00786"}]}, "P68871": {"specific_function": "Involved in oxygen transport from the lung to the various peripheral tissues.LVV-hemorphin-7 potentiates the activity of bradykinin, causing a decrease in blood pressure.Spinorphin: functions as an endogenous inhibitor of enkephalin-degrading enzymes such as DPP3, and as a selective antagonist of the P2RX3 receptor which is involved in pain signaling, these properties implicate it as a regulator of pain and inflammation.", "general_function": "Oxygen transporter activity", "gene_names": ["HBB"], "name": "Hemoglobin subunit beta", "drug_actions": [{"action": "ACTIVATOR", "target": "P68871", "drug": "DB00893"}]}, "P07900": {"specific_function": "Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function. Binds bacterial lipopolysaccharide (LPS) et mediates LPS-induced inflammatory response, including TNF secretion by monocytes.", "general_function": "Tpr domain binding", "gene_names": ["HSP90AA1"], "name": "Heat shock protein HSP 90-alpha", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "P07900", "drug": "DB00615"}]}, "O43525": {"specific_function": "Probably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic inputs.", "general_function": "Voltage-gated potassium channel activity", "gene_names": ["KCNQ3"], "name": "Potassium voltage-gated channel subfamily KQT member 3", "drug_actions": [{"action": "OTHER", "target": "O43525", "drug": "DB00586"}, {"action": "OTHER", "target": "O43525", "drug": "DB00939"}]}, "Q9UHC3": {"specific_function": "Cation channel with high affinity for sodium, which is gated by extracellular protons and inhibited by the diuretic amiloride. Generates a biphasic current with a fast inactivating and a slow sustained phase. In sensory neurons is proposed to mediate the pain induced by acidosis that occurs in ischemic, damaged or inflamed tissue. May be involved in hyperalgesia. May play a role in mechanoreception. Heteromeric channel assembly seems to modulate channel properties.", "general_function": "Sodium channel activity", "gene_names": ["ASIC3"], "name": "Acid-sensing ion channel 3", "drug_actions": [{"action": "AGONIST", "target": "Q9UHC3", "drug": "DB08838"}]}, "O43526": {"specific_function": "Probably important in the regulation of neuronal excitability. Associates with KCNQ3 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic inputs. KCNQ2/KCNQ3 current is blocked by linopirdine and XE991, and activated by the anticonvulsant retigabine. Muscarinic agonist oxotremorine-M strongly suppress KCNQ2/KCNQ3 current in cells in which cloned KCNQ2/KCNQ3 channels were coexpressed with M1 muscarinic receptors.", "general_function": "Voltage-gated potassium channel activity", "gene_names": ["KCNQ2"], "name": "Potassium voltage-gated channel subfamily KQT member 2", "drug_actions": [{"action": "INHIBITOR", "target": "O43526", "drug": "DB00321"}, {"action": "OTHER", "target": "O43526", "drug": "DB00586"}, {"action": "OTHER", "target": "O43526", "drug": "DB00939"}]}, "P53667": {"specific_function": "Serine/threonine-protein kinase that plays an essential role in the regulation of actin filament dynamics. Acts downstream of several Rho family GTPase signal transduction pathways. Activated by upstream kinases including ROCK1, PAK1 and PAK4, which phosphorylate LIMK1 on a threonine residue located in its activation loop. LIMK1 subsequently phosphorylates and inactivates the actin binding/depolymerizing factors cofilin-1/CFL1, cofilin-2/CFL2 and destrin/DSTN, thereby preventing the cleavage of filamentous actin (F-actin), and stabilizing the actin cytoskeleton. In this way LIMK1 regulates several actin-dependent biological processes including cell motility, cell cycle progression, and differentiation. Phosphorylates TPPP on serine residues, thereby promoting microtubule disassembly. Stimulates axonal outgrowth and may be involved in brain development. Isoform 3 has a dominant negative effect on actin cytoskeletal changes. Required for atypical chemokine receptor ACKR2-induced phosphorylation of cofilin (CFL1).", "general_function": "Zinc ion binding", "gene_names": ["LIMK1"], "name": "LIM domain kinase 1", "drug_actions": [{"action": "INHIBITOR", "target": "P53667", "drug": "DB08912"}]}, "P36204": {"general_function": "Triose-phosphate isomerase activity", "gene_names": ["pgk/tpi"], "name": "Bifunctional PGK/TIM", "drug_actions": []}, "A5X5Y0": {"specific_function": "This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses. It is a cation-specific, but otherwise relatively nonselective, ion channel.", "name": "5-hydroxytryptamine receptor 3E", "drug_actions": [{"action": "ANTAGONIST", "target": "A5X5Y0", "drug": "DB01049"}], "general_function": "Serotonin-activated cation-selective channel activity", "in_complexes": ["Serotonin Receptors"], "gene_names": ["HTR3E"]}, "P49247": {"general_function": "Ribose-5-phosphate isomerase activity", "gene_names": ["RPIA"], "name": "Ribose-5-phosphate isomerase", "drug_actions": []}, "P32019": {"specific_function": "Hydrolyzes phosphatidylinositol 4,5-bisphosphate (PtIns(4,5)P2) and the signaling molecule phosphatidylinositol 1,4,5-trisphosphate (PtIns(1,4,5)P3), and thereby modulates cellular signaling events.", "general_function": "Phosphatidylinositol-4,5-bisphosphate 5-phosphatase activity", "gene_names": ["INPP5B"], "name": "Type II inositol 1,4,5-trisphosphate 5-phosphatase", "drug_actions": []}, "Q99720": {"specific_function": "Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma membrane. Involved in the regulation of different receptors it plays a role in BDNF signaling and EGF signaling. Also regulates ion channels like the potassium channel and could modulate neurotransmitter release. Plays a role in calcium signaling through modulation together with ANK2 of the ITP3R-dependent calcium efflux at the endoplasmic reticulum. Plays a role in several other cell functions including proliferation, survival and death. Originally identified for its ability to bind various psychoactive drugs it is involved in learning processes, memory and mood alteration (PubMed:16472803, PubMed:9341151). Necessary for proper mitochondrial axonal transport in motor neurons, in particular the retrograde movement of mitochondria (By similarity).", "name": "Sigma non-opioid intracellular receptor 1", "drug_actions": [{"action": "AGONIST", "target": "Q99720", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "Q99720", "drug": "DB00409"}, {"action": "AGONIST", "target": "Q99720", "drug": "DB00514"}, {"action": "BINDER", "target": "Q99720", "drug": "DB00540"}, {"action": "AGONIST", "target": "Q99720", "drug": "DB00652"}, {"action": "AGONIST", "target": "Q99720", "drug": "DB01708"}, {"action": "AGONIST", "target": "Q99720", "drug": "DB09014"}], "general_function": "Opioid receptor activity", "in_complexes": ["Sigma receptor"], "gene_names": ["SIGMAR1"]}, "P04926": {"gene_names": ["EXP-1"], "name": "Malaria protein EXP-1", "drug_actions": [{"action": "INHIBITOR", "target": "P04926", "drug": "DB09274"}]}, "P11349": {"specific_function": "The nitrate reductase enzyme complex allows E.coli to use nitrate as an electron acceptor during anaerobic growth. The beta chain is an electron transfer unit containing four cysteine clusters involved in the formation of iron-sulfur centers. Electrons are transferred from the gamma chain to the molybdenum cofactor of the alpha subunit.", "general_function": "Oxidoreductase activity", "gene_names": ["narH"], "name": "Respiratory nitrate reductase 1 beta chain", "drug_actions": []}, "P0A8V6": {"specific_function": "Multifunctional regulator of fatty acid metabolism. Represses transcription of at least eight genes required for fatty acid transport and beta-oxidation including fadA, fadB, fadD, fadL and fadE. Activates transcription of at least three genes required for unsaturated fatty acid biosynthesis: fabA, fabB and iclR, the gene encoding the transcriptional regulator of the aceBAK operon encoding the glyoxylate shunt enzymes. Binding of FadR is specifically inhibited by long chain fatty acyl-CoA compounds.", "general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": ["fadR"], "name": "Fatty acid metabolism regulator protein", "drug_actions": []}, "P0A544": {"specific_function": "3-phospho-D-glycerate + NAD(+) = 3- phosphonooxypyruvate + NADH", "general_function": "Involved in oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor", "gene_names": ["serA"], "name": "D-3-phosphoglycerate dehydrogenase", "drug_actions": []}, "P19113": {"specific_function": "Catalyzes the biosynthesis of histamine from histidine.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["HDC"], "name": "Histidine decarboxylase", "drug_actions": [{"action": "COFACTOR", "target": "P19113", "drug": "DB00114"}]}, "P0A546": {"specific_function": "5,6,7,8-tetrahydrofolate + NADP(+) = 7,8- dihydrofolate + NADPH", "general_function": "Coenzyme transport and metabolism", "gene_names": ["folA"], "name": "Dihydrofolate reductase", "drug_actions": []}, "P51580": {"specific_function": "Catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine.", "general_function": "Thiopurine s-methyltransferase activity", "gene_names": ["TPMT"], "name": "Thiopurine S-methyltransferase", "drug_actions": [{"action": "INHIBITOR", "target": "P51580", "drug": "DB01250"}]}, "P14193": {"specific_function": "Involved in the biosynthesis of ribose 1,5-bisphosphate. Catalyzes the transfer of pyrophosphoryl group from ATP to ribose-5-phosphate to yield phosphoribosyl diphosphate (PRPP) and AMP.", "general_function": "Ribose phosphate diphosphokinase activity", "gene_names": ["prs"], "name": "Ribose-phosphate pyrophosphokinase", "drug_actions": []}, "P17544": {"specific_function": "Plays important functions in early cell signaling. Binds the cAMP response element (CRE) (consensus: 5'-GTGACGT[AG][AG]-3'), a sequence present in many viral and cellular promoters. Activator of the NF-ELAM1/delta-A site of the E-selectin promoter. Has no intrinsic transcriptional activity, but activates transcription on formation of JUN or FOS heterodimers. Also can bind TRE promoter sequences when heterodimerized with members of the JUN family.Isoform 4/ATF-A0 acts as a dominant repressor of the E-selectin/NF-ELAM1/delta-A promoter.Isoform 5/ATF-4 acts as a negative regulator, inhibiting both ATF2 and ATF7 transcriptional activities. It may exert these effects by sequestrating in the cytoplasm the Thr-53 phosphorylating kinase, preventing activation.", "name": "Cyclic AMP-dependent transcription factor ATF-7", "drug_actions": [], "general_function": "Transcriptional repressor activity, rna polymerase ii core promoter proximal region sequence-specific binding", "in_complexes": ["activator protein 1"], "gene_names": ["ATF7"]}, "Q46604": {"specific_function": "Functions as a redox protein with a potential of -325 mV.", "general_function": "Pyridoxamine-phosphate oxidase activity", "gene_names": [], "name": "FMN-binding protein", "drug_actions": []}, "O14842": {"specific_function": "G-protein coupled receptor for medium and long chain saturated and unsaturated fatty acids that plays an important role in glucose homeostasis. Fatty acid binding increases glucose-stimulated insulin secretion, and may also enhance the secretion of glucagon-like peptide 1 (GLP-1). May also play a role in bone homeostasis; receptor signaling activates pathways that inhibit osteoclast differentiation (By similarity). Ligand binding leads to a conformation change that triggers signaling via G-proteins that activate phospholipase C, leading to an increase of the intracellular calcium concentration. Seems to act through a G(q) and G(i)-mediated pathway.", "general_function": "Lipid binding", "gene_names": ["FFAR1"], "name": "Free fatty acid receptor 1", "drug_actions": [{"action": "AGONIST", "target": "O14842", "drug": "DB00159"}]}, "Q9UHQ9": {"specific_function": "NADH-cytochrome b5 reductases are involved in desaturation and elongation of fatty acids, cholesterol biosynthesis, drug metabolism, and, in erythrocyte, methemoglobin reduction.", "general_function": "Cytochrome-b5 reductase activity, acting on nad(p)h", "gene_names": ["CYB5R1"], "name": "NADH-cytochrome b5 reductase 1", "drug_actions": []}, "P21283": {"specific_function": "Subunit of the peripheral V1 complex of vacuolar ATPase. Subunit C is necessary for the assembly of the catalytic sector of the enzyme and is likely to have a specific function in its catalytic activity. V-ATPase is responsible for acidifying a variety of intracellular compartments in eukaryotic cells.", "general_function": "Transporter activity", "gene_names": ["ATP6V1C1"], "name": "V-type proton ATPase subunit C 1", "drug_actions": []}, "O14841": {"specific_function": "Catalyzes the cleavage of 5-oxo-L-proline to form L-glutamate coupled to the hydrolysis of ATP to ADP and inorganic phosphate.", "general_function": "Atp binding", "gene_names": ["OPLAH"], "name": "5-oxoprolinase", "drug_actions": []}, "Q9NYR8": {"specific_function": "Retinol dehydrogenase with a clear preference for NADP. Converts all-trans-retinal to all-trans-retinol. May play a role in the regeneration of visual pigment at high light intensity (By similarity).", "general_function": "Retinol dehydrogenase activity", "gene_names": ["RDH8"], "name": "Retinol dehydrogenase 8", "drug_actions": []}, "Q15661": {"specific_function": "Tryptase is the major neutral protease present in mast cells and is secreted upon the coupled activation-degranulation response of this cell type. May play a role in innate immunity. Isoform 2 cleaves large substrates, such as fibronectin, more efficiently than isoform 1, but seems less efficient toward small substrates (PubMed:18854315).", "general_function": "Serine-type peptidase activity", "gene_names": ["TPSAB1"], "name": "Tryptase alpha/beta-1", "drug_actions": []}, "Q746I8": {"specific_function": "Involved in the biosynthesis of isoprenoids. Catalyzes the 1,3-allylic rearrangement of the homoallylic substrate isopentenyl (IPP) to its allylic isomer, dimethylallyl diphosphate (DMAPP).", "general_function": "Oxidoreductase activity", "gene_names": ["fni"], "name": "Isopentenyl-diphosphate delta-isomerase", "drug_actions": []}, "P36021": {"specific_function": "Very active and specific thyroid hormone transporter. Stimulates cellular uptake of thyroxine (T4), triiodothyronine (T3), reverse triiodothyronine (rT3) and diidothyronine. Does not transport Leu, Phe, Trp or Tyr.", "general_function": "Transporter activity", "gene_names": ["SLC16A2"], "name": "Monocarboxylate transporter 8", "drug_actions": []}, "P61278": {"specific_function": "Somatostatin inhibits the release of somatotropin.", "general_function": "Hormone activity", "gene_names": ["SST"], "name": "Somatostatin", "drug_actions": [{"action": "BINDER", "target": "P61278", "drug": "DB00847"}]}, "P06986": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["hisC"], "name": "Histidinol-phosphate aminotransferase", "drug_actions": []}, "P39646": {"general_function": "Phosphate acetyltransferase activity", "gene_names": ["pta"], "name": "Phosphate acetyltransferase", "drug_actions": []}, "P06983": {"specific_function": "Tetrapolymerization of the monopyrrole PBG into the hydroxymethylbilane pre-uroporphyrinogen in several discrete steps.", "general_function": "Hydroxymethylbilane synthase activity", "gene_names": ["hemC"], "name": "Porphobilinogen deaminase", "drug_actions": []}, "P05451": {"specific_function": "Might act as an inhibitor of spontaneous calcium carbonate precipitation. May be associated with neuronal sprouting in brain, and with brain and pancreas regeneration.", "general_function": "Growth factor activity", "gene_names": ["REG1A"], "name": "Lithostathine-1-alpha", "drug_actions": []}, "P16109": {"specific_function": "Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. The ligand recognized is sialyl-Lewis X. Mediates rapid rolling of leukocyte rolling over vascular surfaces during the initial steps in inflammation through interaction with PSGL1.", "general_function": "Sialic acid binding", "gene_names": ["SELP"], "name": "P-selectin", "drug_actions": [{"action": "INHIBITOR", "target": "P16109", "drug": "DB01109"}, {"action": "INHIBITOR", "target": "P16109", "drug": "DB06779"}, {"action": "INHIBITOR", "target": "P16109", "drug": "DB08813"}]}, "O43451": {"specific_function": "May serve as an alternate pathway for starch digestion when luminal alpha-amylase activity is reduced because of immaturity or malnutrition. May play a unique role in the digestion of malted dietary oligosaccharides used in food manufacturing.", "general_function": "Maltose alpha-glucosidase activity", "gene_names": ["MGAM"], "name": "Maltase-glucoamylase, intestinal", "drug_actions": [{"action": "INHIBITOR", "target": "O43451", "drug": "DB00284"}, {"action": "ANTAGONIST", "target": "O43451", "drug": "DB00491"}, {"action": "INHIBITOR", "target": "O43451", "drug": "DB00491"}, {"action": "INHIBITOR", "target": "O43451", "drug": "DB04878"}]}, "O07347": {"specific_function": "Involved in targeting and insertion of nascent membrane proteins into the cytoplasmic membrane. Binds to the hydrophobic signal sequence of the ribosome-nascent chain (RNC) as it emerges from the ribosomes. The SRP-RNC complex is then targeted to the cytoplasmic membrane where it interacts with the SRP receptor FtsY.", "general_function": "Gtpase activity", "gene_names": ["ffh"], "name": "Signal recognition particle protein", "drug_actions": []}, "P16100": {"general_function": "Metal ion binding", "gene_names": ["icd"], "name": "Isocitrate dehydrogenase [NADP]", "drug_actions": []}, "P19622": {"general_function": "Sequence-specific dna binding", "gene_names": ["EN2"], "name": "Homeobox protein engrailed-2", "drug_actions": []}, "Q03403": {"specific_function": "Inhibits gastrointestinal motility and gastric acid secretion. Could function as a structural component of gastric mucus, possibly by stabilizing glycoproteins in the mucus gel through interactions with carbohydrate side chains (By similarity).", "gene_names": ["TFF2"], "name": "Trefoil factor 2", "drug_actions": []}, "P19624": {"specific_function": "Catalyzes the NAD(P)-dependent oxidation of 4-(phosphohydroxy)-L-threonine (HTP) into 2-amino-3-oxo-4-(phosphohydroxy)butyric acid which spontaneously decarboxylates to form 3-amino-2-oxopropyl phosphate (AHAP).", "general_function": "Zinc ion binding", "gene_names": ["pdxA"], "name": "4-hydroxythreonine-4-phosphate dehydrogenase", "drug_actions": []}, "P41007": {"specific_function": "Regulates transcriptional attenuation of the pyrimidine nucleotide (pyr) operon by binding in a uridine-dependent manner to specific sites on pyr mRNA. This disrupts an antiterminator hairpin in the RNA and favors formation of a downstream transcription terminator, leading to a reduced expression of downstream genes (Probable).Also displays a weak uracil phosphoribosyltransferase activity which is not physiologically significant.", "general_function": "Uracil phosphoribosyltransferase activity", "gene_names": ["pyrR"], "name": "Bifunctional protein PyrR", "drug_actions": []}, "B7JBP8": {"specific_function": "Catalyzes the oxidation of hydrogen sulfide, with the help of a quinone. Consecutive reaction cycles lead to the accumulation of a polysulfide product on the active site Cys residues; these products are released when they exceed a critical length, typically as cyclooctasulfur.", "general_function": "Quinone binding", "gene_names": [], "name": "Sulfide-quinone reductase", "drug_actions": []}, "Q99436": {"specific_function": "The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This unit is responsible of the trypsin-like activity.", "general_function": "Threonine-type endopeptidase activity", "gene_names": ["PSMB7"], "name": "Proteasome subunit beta type-7", "drug_actions": []}, "Q02338": {"general_function": "3-hydroxybutyrate dehydrogenase activity", "gene_names": ["BDH1"], "name": "D-beta-hydroxybutyrate dehydrogenase, mitochondrial", "drug_actions": []}, "O75116": {"specific_function": "Protein kinase which is a key regulator of actin cytoskeleton and cell polarity. Involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of ADD1, BRCA2, CNN1, EZR, DPYSL2, EP300, MSN, MYL9/MLC2, NPM1, RDX, PPP1R12A and VIM. Phosphorylates SORL1 and IRF4. Acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation. Positively regulates the activation of p42/MAPK1-p44/MAPK3 and of p90RSK/RPS6KA1 during myogenic differentiation. Plays an important role in the timely initiation of centrosome duplication. Inhibits keratinocyte terminal differentiation. May regulate closure of the eyelids and ventral body wall through organization of actomyosin bundles. Plays a critical role in the regulation of spine and synaptic properties in the hippocampus. Plays an important role in generating the circadian rhythm of the aortic myofilament Ca(2+) sensitivity and vascular contractility by modulating the myosin light chain phosphorylation.", "general_function": "Structural molecule activity", "gene_names": ["ROCK2"], "name": "Rho-associated protein kinase 2", "drug_actions": []}, "P60174": {"general_function": "Ubiquitin protein ligase binding", "gene_names": ["TPI1"], "name": "Triosephosphate isomerase", "drug_actions": []}, "P62330": {"specific_function": "GTP-binding protein involved in protein trafficking that regulates endocytic recycling and cytoskeleton remodeling. Required for normal completion of mitotic cytokinesis. Plays a role in the reorganization of the actin cytoskeleton and the formation of stress fibers. May also modulate vesicle budding and uncoating within the Golgi apparatus. Involved in the regulation of dendritic spine development, contributing to the regulation of dendritic branching and filopodia extension. Functions as an allosteric activator of the cholera toxin catalytic subunit, an ADP-ribosyltransferase.", "general_function": "Thioesterase binding", "gene_names": ["ARF6"], "name": "ADP-ribosylation factor 6", "drug_actions": []}, "Q15858": {"specific_function": "Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-sensitive Na(+) channel isoform. Plays a role in pain mechanisms, especially in the development of inflammatory pain (By similarity).", "name": "Sodium channel protein type 9 subunit alpha", "drug_actions": [{"action": "INHIBITOR", "target": "Q15858", "drug": "DB00243"}, {"action": "INHIBITOR", "target": "Q15858", "drug": "DB00281"}, {"action": "INHIBITOR", "target": "Q15858", "drug": "DB00909"}, {"action": "MODULATOR", "target": "Q15858", "drug": "DB06201"}], "general_function": "Voltage-gated sodium channel activity", "in_complexes": ["Sodium channel protein"], "gene_names": ["SCN9A"]}, "Q13443": {"specific_function": "Probable zinc protease. May mediate cell-cell or cell-matrix interactions. Isoform 2 displays alpha-secretase activity for APP.", "general_function": "Zinc ion binding", "gene_names": ["ADAM9"], "name": "Disintegrin and metalloproteinase domain-containing protein 9", "drug_actions": []}, "Q9UPY5": {"specific_function": "Sodium-independent, high-affinity exchange of anionic amino acids with high specificity for anionic form of cystine and glutamate.", "general_function": "Cystine:glutamate antiporter activity", "gene_names": ["SLC7A11"], "name": "Cystine/glutamate transporter", "drug_actions": [{"action": "INDUCER", "target": "Q9UPY5", "drug": "DB00740"}, {"action": "INHIBITOR", "target": "Q9UPY5", "drug": "DB00795"}, {"action": "ACTIVATOR", "target": "Q9UPY5", "drug": "DB06151"}]}, "P00748": {"specific_function": "Factor XII is a serum glycoprotein that participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then trypsin cleaves it to beta-factor XIIa. Alpha-factor XIIa activates factor XI to factor XIa.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["F12"], "name": "Coagulation factor XII", "drug_actions": [{"action": "ACTIVATOR", "target": "P00748", "drug": "DB06689"}]}, "P55882": {"specific_function": "Catalyzes the phosphorylation of hydroxymethylpyrimidine phosphate (HMP-P) to HMP-PP, and of HMP to HMP-P.", "general_function": "Phosphomethylpyrimidine kinase activity", "gene_names": ["thiD"], "name": "Hydroxymethylpyrimidine/phosphomethylpyrimidine kinase", "drug_actions": []}, "Q9WXV1": {"specific_function": "Catalyzes the synthesis of 5,6-dihydrouridine (D), a modified base found in the D-loop of most tRNAs, via the reduction of the C5-C6 double bond in target uridines.", "general_function": "Trna dihydrouridine synthase activity", "gene_names": [], "name": "tRNA-dihydrouridine synthase", "drug_actions": []}, "Q8WUI4": {"specific_function": "Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Involved in muscle maturation by repressing transcription of myocyte enhancer factors such as MEF2A, MEF2B and MEF2C. During muscle differentiation, it shuttles into the cytoplasm, allowing the expression of myocyte enhancer factors (By similarity). May be involved in Epstein-Barr virus (EBV) latency, possibly by repressing the viral BZLF1 gene. Positively regulates the transcriptional repressor activity of FOXP3 (PubMed:17360565).", "general_function": "Transcription corepressor activity", "gene_names": ["HDAC7"], "name": "Histone deacetylase 7", "drug_actions": [{"action": "INHIBITOR", "target": "Q8WUI4", "drug": "DB06603"}]}, "P33121": {"specific_function": "Activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially uses palmitoleate, oleate and linoleate.", "general_function": "Long-chain fatty acid-coa ligase activity", "gene_names": ["ACSL1"], "name": "Long-chain-fatty-acid--CoA ligase 1", "drug_actions": [{"action": "PRODUCT OF", "target": "P33121", "drug": "DB00131"}]}, "P26639": {"general_function": "Threonine-trna ligase activity", "gene_names": ["TARS"], "name": "Threonine--tRNA ligase, cytoplasmic", "drug_actions": []}, "P38484": {"specific_function": "Part of the receptor for interferon gamma. Required for signal transduction. This accessory factor is an integral part of the IFN-gamma signal transduction pathway and is likely to interact with GAF, JAK1, and/or JAK2.", "general_function": "Interferon-gamma receptor activity", "gene_names": ["IFNGR2"], "name": "Interferon gamma receptor 2", "drug_actions": [{"action": "BINDER", "target": "P38484", "drug": "DB00033"}]}, "O67040": {"general_function": "Metal ion binding", "gene_names": ["ppx"], "name": "Exopolyphosphatase", "drug_actions": []}, "Q9K597": {"general_function": "Porin activity", "gene_names": ["ompC"], "name": "Membrane protein", "drug_actions": []}, "Q96GA7": {"specific_function": "Has low serine dehydratase and threonine dehydratase activity.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["SDSL"], "name": "Serine dehydratase-like", "drug_actions": [{"action": "COFACTOR", "target": "Q96GA7", "drug": "DB00114"}]}, "Q15596": {"specific_function": "Transcriptional coactivator for steroid receptors and nuclear receptors. Coactivator of the steroid binding domain (AF-2) but not of the modulating N-terminal domain (AF-1). Required with NCOA1 to control energy balance between white and brown adipose tissues. Critical regulator of glucose metabolism regulation, acts as RORA coactivator to specifically modulate G6PC expression. Involved in the positive regulation of the transcriptional activity of the glucocorticoid receptor NR3C1 by sumoylation enhancer RWDD3. Positively regulates the circadian clock by acting as a transcriptional coactivator for the CLOCK-ARNTL/BMAL1 heterodimer (By similarity).", "general_function": "Transcription coactivator activity", "gene_names": ["NCOA2"], "name": "Nuclear receptor coactivator 2", "drug_actions": []}, "O00555": {"specific_function": "Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1A gives rise to P and/or Q-type calcium currents. P/Q-type calcium channels belong to the 'high-voltage activated' (HVA) group and are blocked by the funnel toxin (Ftx) and by the omega-agatoxin-IVA (omega-Aga-IVA). They are however insensitive to dihydropyridines (DHP), and omega-conotoxin-GVIA (omega-CTx-GVIA).", "name": "Voltage-dependent P/Q-type calcium channel subunit alpha-1A", "drug_actions": [{"action": "INHIBITOR", "target": "O00555", "drug": "DB00230"}, {"action": "INHIBITOR", "target": "O00555", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "O00555", "drug": "DB00836"}, {"action": "INHIBITOR", "target": "O00555", "drug": "DB01244"}], "general_function": "Voltage-gated calcium channel activity", "in_complexes": ["Voltage-dependent calcium channel"], "gene_names": ["CACNA1A"]}, "P17181": {"specific_function": "Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.", "general_function": "Type i interferon receptor activity", "gene_names": ["IFNAR1"], "name": "Interferon alpha/beta receptor 1", "drug_actions": [{"action": "AGONIST", "target": "P17181", "drug": "DB00008"}, {"action": "AGONIST", "target": "P17181", "drug": "DB00011"}, {"action": "AGONIST", "target": "P17181", "drug": "DB00018"}, {"action": "AGONIST", "target": "P17181", "drug": "DB00022"}, {"action": "AGONIST", "target": "P17181", "drug": "DB00060"}, {"action": "AGONIST", "target": "P17181", "drug": "DB00068"}, {"action": "BINDER", "target": "P17181", "drug": "DB00069"}, {"action": "BINDER", "target": "P17181", "drug": "DB00105"}]}, "P08865": {"specific_function": "Required for the assembly and/or stability of the 40S ribosomal subunit. Required for the processing of the 20S rRNA-precursor to mature 18S rRNA in a late step of the maturation of 40S ribosomal subunits. Also functions as a cell surface receptor for laminin. Plays a role in cell adhesion to the basement membrane and in the consequent activation of signaling transduction pathways. May play a role in cell fate determination and tissue morphogenesis. Acts as a PPP1R16B-dependent substrate of PPP1CA.(Microbial infection) Acts as a receptor for the adeno-associated viruses 2,3,8 and 9, dengue virus, Sindbis virus and Venezuelan equine encephalitis virus (PubMed:1385835, PubMed:15507651, PubMed:16973587). Also acts as a receptor for pathogenic prion protein and bacteria (PubMed:9396609, PubMed:11689427, PubMed:15516338).", "general_function": "Virus receptor activity", "gene_names": ["RPSA"], "name": "40S ribosomal protein SA", "drug_actions": []}, "O14949": {"specific_function": "This is a component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is part of the mitochondrial respiratory chain. This subunit, together with cytochrome b, binds to ubiquinone.", "general_function": "Ubiquinol-cytochrome-c reductase activity", "gene_names": ["UQCRQ"], "name": "Cytochrome b-c1 complex subunit 8", "drug_actions": []}, "Q9RBW8": {"gene_names": ["tbuX"], "name": "TbuX", "drug_actions": []}, "Q13509": {"specific_function": "Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. TUBB3 plays a critical role in proper axon guidance and mantainance.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["TUBB3"], "name": "Tubulin beta-3 chain", "drug_actions": [{"action": "INHIBITOR", "target": "Q13509", "drug": "DB04845"}]}, "Q8ZPC0": {"general_function": "N-acetyltransferase activity", "gene_names": ["rimL"], "name": "Acetyl transferase", "drug_actions": []}, "Q56232": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["aspC"], "name": "Aspartate aminotransferase", "drug_actions": []}, "P07003": {"general_function": "Thiamine pyrophosphate binding", "gene_names": ["poxB"], "name": "Pyruvate dehydrogenase [ubiquinone]", "drug_actions": [{"action": "INHIBITOR", "target": "P07003", "drug": "DB00336"}]}, "P61024": {"specific_function": "Binds to the catalytic subunit of the cyclin dependent kinases and is essential for their biological function.", "general_function": "Cyclin-dependent protein serine/threonine kinase regulator activity", "gene_names": ["CKS1B"], "name": "Cyclin-dependent kinases regulatory subunit 1", "drug_actions": []}, "P27623": {"specific_function": "Provides activated glycerol phosphate for teichoic acid synthesis, via incorporation into both the linkage unit and the teichoic acid polymer by TagB and TagF.", "general_function": "Metal ion binding", "gene_names": ["tagD"], "name": "Glycerol-3-phosphate cytidylyltransferase", "drug_actions": []}, "P19938": {"specific_function": "Acts on the D-isomers of alanine, leucine, aspartate, glutamate, aminobutyrate, norvaline and asparagine. The enzyme transfers an amino group from a substrate D-amino acid to the pyridoxal phosphate cofactor to form pyridoxamine and an alpha-keto acid in the first half-reaction. The second-half reaction is the reverse of the first, transferring the amino group from the pyridoxamine to a second alpha-keto acid to form the product D-amino acid via a ping-pong mechanism. This is an important process in the formation of D-alanine and D-glutamate, which are essential bacterial cell wall components.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["dat"], "name": "D-alanine aminotransferase", "drug_actions": []}, "P16219": {"specific_function": "Introduces a double bond at position 2 in saturated acyl-CoA's of short chain length, i.e. less than 6 carbon atoms.", "general_function": "Flavin adenine dinucleotide binding", "gene_names": ["ACADS"], "name": "Short-chain specific acyl-CoA dehydrogenase, mitochondrial", "drug_actions": []}, "P17342": {"specific_function": "Receptor for the natriuretic peptide hormones, binding with similar affinities atrial natriuretic peptide NPPA/ANP, brain natriuretic peptide NPPB/BNP, and C-type natriuretic peptide NPPC/CNP. May function as a clearance receptor for NPPA, NPPB and NPPC, regulating their local concentrations and effects. May regulate diuresis, blood pressure and skeletal development. Does not have guanylate cyclase activity.", "general_function": "Peptide hormone binding", "gene_names": ["NPR3"], "name": "Atrial natriuretic peptide receptor 3", "drug_actions": []}, "Q96A70": {"specific_function": "Antizyme inhibitor protein that positively regulates ornithine decarboxylase (ODC) activity and polyamine uptake by counteracting the negative effect of antizymes OAZ1, OAZ2 and OAZ3 on ODC1 activity (PubMed:17900240). Inhibits antizyme-dependent ODC1 degradation by binding to antizymes. Releases ODC1 from its inactive complex with antizymes, leading to formation of the catalytically active ODC1. Participates in the morphological integrity of the trans-Golgi network (TGN) and functions as a regulator of intracellular secretory vesicle trafficking (PubMed:20188728).", "general_function": "Putrescine transmembrane transporter activity", "gene_names": ["AZIN2"], "name": "Antizyme inhibitor 2", "drug_actions": [{"action": "COFACTOR", "target": "Q96A70", "drug": "DB00114"}]}, "Q72LA4": {"general_function": "Oxidoreductase activity", "gene_names": [], "name": "Thiosulfate reductase", "drug_actions": []}, "Q7ZJM1": {"general_function": "Zinc ion binding", "gene_names": ["pol"], "name": "Integrase", "drug_actions": [{"action": "INHIBITOR", "target": "Q7ZJM1", "drug": "DB06817"}, {"action": "INHIBITOR", "target": "Q7ZJM1", "drug": "DB08930"}, {"action": "INHIBITOR", "target": "Q7ZJM1", "drug": "DB09101"}]}, "Q820S6": {"general_function": "Metal ion binding", "gene_names": [], "name": "Chain A, Red Copper Protein Nitrosocyanin", "drug_actions": []}, "P13501": {"specific_function": "Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of histamine from basophils and activates eosinophils. May activate several chemokine receptors including CCR1, CCR3, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form RANTES(3-68) acts as a natural chemotaxis inhibitor and is a more potent inhibitor of HIV-1-infection. The second processed form RANTES(4-68) exhibits reduced chemotactic and HIV-suppressive activity compared with RANTES(1-68) and RANTES(3-68) and is generated by an unidentified enzyme associated with monocytes and neutrophils (PubMed:16791620, PubMed:1380064, PubMed:8525373, PubMed:9516414, PubMed:15923218). May also be an agonist of the G protein-coupled receptor GPR75, stimulating inositol trisphosphate production and calcium mobilization through its activation. Together with GPR75, may play a role in neuron survival through activation of a downstream signaling pathway involving the PI3, Akt and MAP kinases. By activating GPR75 may also play a role in insulin secretion by islet cells (PubMed:23979485).", "general_function": "Receptor signaling protein tyrosine kinase activator activity", "gene_names": ["CCL5"], "name": "C-C motif chemokine 5", "drug_actions": []}, "P13500": {"gene_names": ["CCL2"], "name": "C-C motif chemokine 2", "drug_actions": [{"action": "INHIBITOR", "target": "P13500", "drug": "DB01055"}, {"action": "INHIBITOR", "target": "P13500", "drug": "DB01406"}]}, "P13507": {"general_function": "Starch binding", "gene_names": ["amyP"], "name": "Glucan 1,4-alpha-maltotetraohydrolase", "drug_actions": []}, "Q12756": {"specific_function": "Motor for anterograde axonal transport of synaptic vesicle precursors.", "general_function": "Motor activity", "gene_names": ["KIF1A"], "name": "Kinesin-like protein KIF1A", "drug_actions": []}, "Q16718": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFA5"], "name": "NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5", "drug_actions": []}, "Q16719": {"specific_function": "Catalyzes the cleavage of L-kynurenine (L-Kyn) and L-3-hydroxykynurenine (L-3OHKyn) into anthranilic acid (AA) and 3-hydroxyanthranilic acid (3-OHAA), respectively. Has a preference for the L-3-hydroxy form. Also has cysteine-conjugate-beta-lyase activity.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["KYNU"], "name": "Kynureninase", "drug_actions": [{"action": "COFACTOR", "target": "Q16719", "drug": "DB00114"}]}, "O06162": {"specific_function": "May play a role in fatty acid biosynthesis (Potential)", "general_function": "Involved in citrate (pro-3S)-lyase activity", "gene_names": ["citE"], "name": "Citrate lyase subunit beta-like protein", "drug_actions": []}, "P04587": {"specific_function": "Gag-Pol polyprotein: Mediates, with Gag polyrotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shutt off translation.Matrix protein p17: Targets the polyprotein to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus. Matrix protein is part of the pre-integration complex. Implicated in the release from host cell mediated by Vpu. Binds to RNA.Capsid protein p24: Forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion. Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry (By similarity). Host restriction factors such as TRIM5-alpha or TRIMCyp bind retroviral capsids and cause premature capsid disassembly, leading to blocks in reverse transcription. Capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species. Host PIN1 apparently facilitates the virion uncoating. On the other hand, interactions with PDZD8 or CYPA stabilize the capsid.Nucleocapsid protein p7: Encapsulates and protects viral dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its zinc fingers. Acts as a nucleic acid chaperone which is involved in rearangement of nucleic acid secondary structure during gRNA retrotranscription. Also facilitates template switch leading to recombination. As part of the polyprotein, participates to gRNA dimerization, packaging, tRNA incorporation and virion assembly.Protease: Aspartyl protease that mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane. Cleavages take place as an ordered, step-wise cascade to yield mature proteins. This process is called maturation. Displays maximal activity during the budding process just prior to particle release from the cell. Also cleaves Nef and Vif, probably concomitantly with viral structural proteins on maturation of virus particles. Hydrolyzes host EIF4GI and PABP1 in order to shut off the capped cellular mRNA translation. The resulting inhibition of cellular protein synthesis serves to ensure maximal viral gene expression and to evade host immune response (By similarity).Reverse transcriptase/ribonuclease H: Multifunctional enzyme that converts the viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for two polypurine tracts (PPTs) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPTs that have not been removed by RNase H as primers. PPTs and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends.Integrase: Catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration.", "general_function": "Zinc ion binding", "gene_names": ["gag-pol"], "name": "Gag-Pol polyprotein", "drug_actions": []}, "P04585": {"specific_function": "Gag-Pol polyprotein: Mediates, with Gag polyrotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shutt off translation.Matrix protein p17: Targets the polyprotein to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus (By similarity). Matrix protein is part of the pre-integration complex. Implicated in the release from host cell mediated by Vpu. Binds to RNA (By similarity).Capsid protein p24: Forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion (PubMed:8648689). Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry (PubMed:12660176). Host restriction factors such as monkey TRIM5-alpha or TRIMCyp bind retroviral capsids and cause premature capsid disassembly, leading to blocks in reverse transcription. Capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species (PubMed:23785198). Host PIN1 apparently facilitates the virion uncoating (By similarity). On the other hand, interactions with PDZD8 or CYPA stabilize the capsid (PubMed:24554657).Nucleocapsid protein p7: Encapsulates and protects viral dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its zinc fingers. Acts as a nucleic acid chaperone which is involved in rearangement of nucleic acid secondary structure during gRNA retrotranscription. Also facilitates template switch leading to recombination. As part of the polyprotein, participates to gRNA dimerization, packaging, tRNA incorporation and virion assembly.Protease: Aspartyl protease that mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane (PubMed:9573231) (PubMed:11932404). Cleavages take place as an ordered, step-wise cascade to yield mature proteins (PubMed:9573231) (PubMed:11932404). This process is called maturation (PubMed:9573231) (PubMed:11932404). Displays maximal activity during the budding process just prior to particle release from the cell (PubMed:9573231) (PubMed:11932404). Also cleaves Nef and Vif, probably concomitantly with viral structural proteins on maturation of virus particles (PubMed:7835426). Hydrolyzes host EIF4GI and PABP1 in order to shut off the capped cellular mRNA translation. The resulting inhibition of cellular protein synthesis serves to ensure maximal viral gene expression and to evade host immune response (PubMed:12660176) (PubMed:19914170).Reverse transcriptase/ribonuclease H: Multifunctional enzyme that converts the viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for two polypurine tracts (PPTs) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPTs that have not been removed by RNase H as primers. PPTs and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends.Integrase: Catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration.", "general_function": "Zinc ion binding", "gene_names": ["gag-pol"], "name": "Gag-Pol polyprotein", "drug_actions": []}, "P04584": {"specific_function": "Gag-Pol polyprotein: Mediates, with Gag polyrotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shutt off translation.Matrix protein p17: Targets the polyprotein to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus. Matrix protein is part of the pre-integration complex. Implicated in the release from host cell mediated by Vpu. Binds to RNA.Capsid protein p24: Forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion. Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry (By similarity). Host restriction factors such as TRIM5-alpha or TRIMCyp bind retroviral capsids and cause premature capsid disassembly, leading to blocks in reverse transcription. Capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species. Host PIN1 apparently facilitates the virion uncoating. On the other hand, interactions with PDZD8 or CYPA stabilize the capsid.Nucleocapsid protein p7: Encapsulates and protects viral dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its zinc fingers. Acts as a nucleic acid chaperone which is involved in rearangement of nucleic acid secondary structure during gRNA retrotranscription. Also facilitates template switch leading to recombination. As part of the polyprotein, participates to gRNA dimerization, packaging, tRNA incorporation and virion assembly.Protease: Aspartyl protease that mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane. Cleavages take place as an ordered, step-wise cascade to yield mature proteins. This process is called maturation. Displays maximal activity during the budding process just prior to particle release from the cell. Also cleaves Nef and Vif, probably concomitantly with viral structural proteins on maturation of virus particles. Hydrolyzes host EIF4GI and PABP1 in order to shut off the capped cellular mRNA translation. The resulting inhibition of cellular protein synthesis serves to ensure maximal viral gene expression and to evade host immune response (By similarity).Reverse transcriptase/ribonuclease H: Multifunctional enzyme that converts the viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for two polypurine tracts (PPTs) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPTs that have not been removed by RNase H as primers. PPTs and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends.Integrase: Catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration.", "general_function": "Zinc ion binding", "gene_names": ["gag-pol"], "name": "Gag-Pol polyprotein", "drug_actions": []}, "P14532": {"specific_function": "Catalyzes the peroxidative oxidation of azurin and cytochrome c551. Likely to provide protection against toxic peroxides.", "general_function": "Metal ion binding", "gene_names": ["ccpA"], "name": "Cytochrome c551 peroxidase", "drug_actions": []}, "Q9NWZ5": {"specific_function": "May contribute to UTP accumulation needed for blast transformation and proliferation.", "general_function": "Uridine kinase activity", "gene_names": ["UCKL1"], "name": "Uridine-cytidine kinase-like 1", "drug_actions": []}, "P37551": {"specific_function": "Controls the transcription of the pur operon for purine biosynthetic genes, binds to the control region of the operon. DNA binding is inhibited by 5-phosphoribosyl 1-pyrophosphate.", "general_function": "Dna binding", "gene_names": ["purR"], "name": "Pur operon repressor", "drug_actions": []}, "Q06528": {"gene_names": ["dnrK"], "name": "Carminomycin 4-O-methyltransferase DnrK", "drug_actions": []}, "P51512": {"specific_function": "Endopeptidase that degrades various components of the extracellular matrix, such as collagen type III and fibronectin. Activates progelatinase A. Involved in the matrix remodeling of blood vessels. Isoform short cleaves fibronectin and also collagen type III, but at lower rate. It has no effect on type I, II, IV and V collagen. However, upon interaction with CSPG4, it may be involved in degradation and invasion of type I collagen by melanoma cells.", "general_function": "Zinc ion binding", "gene_names": ["MMP16"], "name": "Matrix metalloproteinase-16", "drug_actions": [{"action": "INHIBITOR", "target": "P51512", "drug": "DB00786"}]}, "Q3JP94": {"general_function": "Flavin adenine dinucleotide binding", "gene_names": [], "name": "Glutaryl-CoA dehydrogenase", "drug_actions": []}, "P37957": {"specific_function": "Active toward p-nitrophenyl esters and triacylglycerides with a marked preference for esters with C8 acyl groups.", "general_function": "Triglyceride lipase activity", "gene_names": ["estA"], "name": "Lipase EstA", "drug_actions": []}, "Q15102": {"specific_function": "Inactivates paf by removing the acetyl group at the sn-2 position. This is a catalytic subunit. Plays an important role during the development of brain.", "general_function": "Platelet-activating factor acetyltransferase activity", "gene_names": ["PAFAH1B3"], "name": "Platelet-activating factor acetylhydrolase IB subunit gamma", "drug_actions": []}, "Q06520": {"specific_function": "Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfonation of steroids and bile acids in the liver and adrenal glands.", "general_function": "Sulfotransferase activity", "gene_names": ["SULT2A1"], "name": "Bile salt sulfotransferase", "drug_actions": []}, "P10745": {"specific_function": "IRBP shuttles 11-cis and all trans retinoids between the retinol isomerase in the pigment epithelium and the visual pigments in the photoreceptor cells of the retina.", "general_function": "Serine-type peptidase activity", "gene_names": ["RBP3"], "name": "Retinol-binding protein 3", "drug_actions": []}, "P12271": {"specific_function": "Soluble retinoid carrier essential the proper function of both rod and cone photoreceptors. Participates in the regeneration of active 11-cis-retinol and 11-cis-retinaldehyde, from the inactive 11-trans products of the rhodopsin photocycle and in the de novo synthesis of these retinoids from 11-trans metabolic precursors. The cycling of retinoids between photoreceptor and adjacent pigment epithelium cells is known as the 'visual cycle'.", "general_function": "Transporter activity", "gene_names": ["RLBP1"], "name": "Retinaldehyde-binding protein 1", "drug_actions": []}, "P12277": {"specific_function": "Reversibly catalyzes the transfer of phosphate between ATP and various phosphogens (e.g. creatine phosphate). Creatine kinase isoenzymes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, brain and spermatozoa.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["CKB"], "name": "Creatine kinase B-type", "drug_actions": [{"action": "LIGAND", "target": "P12277", "drug": "DB00148"}]}, "C0H419": {"gene_names": ["yngHB"], "name": "Biotin/lipoyl attachment protein", "drug_actions": []}, "P27914": {"specific_function": "Envelope protein E binding to host cell surface receptor is followed by virus internalization through clathrin-mediated endocytosis. Envelope protein E is subsequently involved in membrane fusion between virion and host late endosomes. Synthesized as a homodimer with prM which acts as a chaperone for envelope protein E. After cleavage of prM, envelope protein E dissociate from small envelope protein M and homodimerizes (By similarity).Non-structural protein 1 is involved in virus replication and regulation of the innate immune response. Soluble and membrane-associated NS1 may activate human complement and induce host vascular leakage. This effect might explain the clinical manifestations of dengue hemorrhagic fever and dengue shock syndrome (By similarity).Non-structural protein 2A may be involved viral RNA replication and capsid assembly.Non-structural protein 2B is a required cofactor for the serine protease function of NS3.Serine protease NS3 displays three enzymatic activities: serine protease, NTPase and RNA helicase. NS3 serine protease, in association with NS2B, performs its autocleavage and cleaves the polyprotein at dibasic sites in the cytoplasm: C-prM, NS2A-NS2B, NS2B-NS3, NS3-NS4A, NS4A-2K and NS4B-NS5. NS3 RNA helicase binds RNA and unwinds dsRNA in the 3' to 5' direction (By similarity).", "general_function": "Serine-type peptidase activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "Q9NWT6": {"specific_function": "Hydroxylates HIF-1 alpha at 'Asp-803' in the C-terminal transactivation domain (CAD). Functions as an oxygen sensor and, under normoxic conditions, the hydroxylation prevents interaction of HIF-1 with transcriptional coactivators including Cbp/p300-interacting transactivator. Involved in transcriptional repression through interaction with HIF1A, VHL and histone deacetylases. Hydroxylates specific Asn residues within ankyrin repeat domains (ARD) of NFKB1, NFKBIA, NOTCH1, ASB4, PPP1R12A and several other ARD-containing proteins. Also hydroxylates Asp and His residues within ARDs of ANK1 and TNKS2, respectively. Negatively regulates NOTCH1 activity, accelerating myogenic differentiation. Positively regulates ASB4 activity, promoting vascular differentiation.", "general_function": "Zinc ion binding", "gene_names": ["HIF1AN"], "name": "Hypoxia-inducible factor 1-alpha inhibitor", "drug_actions": []}, "P07173": {"specific_function": "The reaction center of purple bacteria contains a tightly bound cytochrome molecule which re-reduces the photo oxidized primary electron donor.", "general_function": "Iron ion binding", "gene_names": ["pufC"], "name": "Photosynthetic reaction center cytochrome c subunit", "drug_actions": []}, "P48637": {"general_function": "Protein homodimerization activity", "gene_names": ["GSS"], "name": "Glutathione synthetase", "drug_actions": [{"action": "STIMULATOR", "target": "P48637", "drug": "DB06151"}]}, "P71278": {"general_function": "Oxidoreductase activity", "gene_names": ["onr"], "name": "Pentaerythritol tetranitrate reductase", "drug_actions": []}, "P29827": {"specific_function": "Can act as inhibitor of the enzyme phospholipase A2, and of the angiotensin-converting enzyme. Shows inhibitory activities against herpes simplex virus and immunopotentiating activities. Its antimicrobial activities are not very pronounced.", "gene_names": ["cinA"], "name": "Lantibiotic cinnamycin", "drug_actions": []}, "O66496": {"general_function": "3-deoxy-8-phosphooctulonate synthase activity", "gene_names": ["kdsA"], "name": "2-dehydro-3-deoxyphosphooctonate aldolase", "drug_actions": []}, "P69681": {"specific_function": "Involved in the uptake of ammonia.", "general_function": "Uniporter activity", "gene_names": ["amtB"], "name": "Ammonia channel", "drug_actions": []}, "P19801": {"specific_function": "Catalyzes the degradation of compounds such as putrescine, histamine, spermine, and spermidine, substances involved in allergic and immune responses, cell proliferation, tissue differentiation, tumor formation, and possibly apoptosis. Placental DAO is thought to play a role in the regulation of the female reproductive function.", "general_function": "Zinc ion binding", "gene_names": ["AOC1"], "name": "Amiloride-sensitive amine oxidase [copper-containing]", "drug_actions": [{"action": "INHIBITOR", "target": "P19801", "drug": "DB00594"}]}, "P34972": {"specific_function": "Heterotrimeric G protein-coupled receptor for endocannabinoid 2-arachidonoylglycerol mediating inhibition of adenylate cyclase. May function in inflammatory response, nociceptive transmission and bone homeostasis.", "general_function": "Cannabinoid receptor activity", "gene_names": ["CNR2"], "name": "Cannabinoid receptor 2", "drug_actions": [{"action": "AGONIST", "target": "P34972", "drug": "DB00470"}, {"action": "PARTIAL AGONIST", "target": "P34972", "drug": "DB00486"}]}, "Q9LCV9": {"specific_function": "Involved in the biosynthesis of the beta-lactamase inhibitor, clavulanic acid. Catalyzes the thiamine diphosphate (ThDP) dependent condensation of D-glyceraldehyde-3-phosphate (D-G3P) with L-arginine to yield the beta-amino acid, N2-(2-carboxyethyl)arginine (CEA) via a beta-elimination resulting in the formation of an enol which undergoes a second elimination to generate the alpha,beta-unsaturated acryloyl-ThDP.", "general_function": "Thiamine pyrophosphate binding", "gene_names": ["ceaS"], "name": "N(2)-(2-carboxyethyl)arginine synthase", "drug_actions": []}, "Q9WYA5": {"general_function": "Methionine synthase activity", "gene_names": [], "name": "5-methyltetrahydrofolate S-homocysteine methyltransferase", "drug_actions": []}, "P49720": {"specific_function": "The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity.", "general_function": "Threonine-type endopeptidase activity", "gene_names": ["PSMB3"], "name": "Proteasome subunit beta type-3", "drug_actions": []}, "P49721": {"specific_function": "The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit has a trypsin-like activity.", "general_function": "Threonine-type endopeptidase activity", "gene_names": ["PSMB2"], "name": "Proteasome subunit beta type-2", "drug_actions": [{"action": "ANTAGONIST", "target": "P49721", "drug": "DB00188"}, {"action": "INHIBITOR", "target": "P49721", "drug": "DB08889"}]}, "Q9P2W7": {"specific_function": "Involved in the biosynthesis of L2/HNK-1 carbohydrate epitope on glycoproteins. Can also play a role in glycosaminoglycan biosynthesis. Substrates include asialo-orosomucoid (ASOR), asialo-fetuin, and asialo-neural cell adhesion molecule. Requires sphingomyelin for activity: stearoyl-sphingomyelin was the most effective, followed by palmitoyl-sphingomyelin and lignoceroyl-sphingomyelin. Activity was demonstrated only for sphingomyelin with a saturated fatty acid and not for that with an unsaturated fatty acid, regardless of the length of the acyl group (By similarity).", "general_function": "Udp-galactose:beta-n-acetylglucosamine beta-1,3-galactosyltransferase activity", "gene_names": ["B3GAT1"], "name": "Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1", "drug_actions": []}, "P84147": {"general_function": "Phospholipase d activity", "gene_names": [], "name": "Phospholipase D", "drug_actions": []}, "Q16620": {"specific_function": "Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity. Receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2. Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation. Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades. Through SHC1, FRS2, SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for instance neuronal differentiation including neurite outgrowth. Through the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade that mainly regulates growth and survival. Through PLCG1 and the downstream protein kinase C-regulated pathways controls synaptic plasticity. Thereby, plays a role in learning and memory by regulating both short term synaptic function and long-term potentiation. PLCG1 also leads to NF-Kappa-B activation and the transcription of genes involved in cell survival. Hence, it is able to suppress anoikis, the apoptosis resulting from loss of cell-matrix interactions. May also play a role in neutrophin-dependent calcium signaling in glial cells and mediate communication between neurons and glia.", "general_function": "Protein homodimerization activity", "gene_names": ["NTRK2"], "name": "BDNF/NT-3 growth factors receptor", "drug_actions": [{"action": "AGONIST", "target": "Q16620", "drug": "DB00321"}]}, "P0A6F3": {"specific_function": "Key enzyme in the regulation of glycerol uptake and metabolism. Catalyzes the phosphorylation of glycerol to yield sn-glycerol 3-phosphate. It also catalyzes the phosphorylation of dihydroxyacetone, L-glyceraldehyde and D-glyceraldehyde. It uses only ATP.", "general_function": "Zinc ion binding", "gene_names": ["glpK"], "name": "Glycerol kinase", "drug_actions": []}, "Q5SKH6": {"general_function": "Precorrin-2 dehydrogenase activity", "gene_names": [], "name": "Uncharacterized protein", "drug_actions": []}, "P64143": {"general_function": "Coenzyme transport and metabolism", "gene_names": ["folK"], "name": "2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase", "drug_actions": [{"action": "UNKNOWN", "target": "P64143", "drug": "DB00233"}]}, "O14672": {"specific_function": "Cleaves the membrane-bound precursor of TNF-alpha at '76-Ala-|-Val-77' to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including heparin-binding epidermal growth-like factor, ephrin-A2 and for constitutive and regulated alpha-secretase cleavage of amyloid precursor protein (APP). Contributes to the normal cleavage of the cellular prion protein. Involved in the cleavage of the adhesion molecule L1 at the cell surface and in released membrane vesicles, suggesting a vesicle-based protease activity. Controls also the proteolytic processing of Notch and mediates lateral inhibition during neurogenesis. Responsible for the FasL ectodomain shedding and for the generation of the remnant ADAM10-processed FasL (FasL APL) transmembrane form. Also cleaves the ectodomain of the integral membrane proteins CORIN and ITM2B. May regulate the EFNA5-EPHA3 signaling.", "general_function": "Zinc ion binding", "gene_names": ["ADAM10"], "name": "Disintegrin and metalloproteinase domain-containing protein 10", "drug_actions": []}, "P50613": {"specific_function": "Serine/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription. Cyclin-dependent kinases (CDKs) are activated by the binding to a cyclin and mediate the progression through the cell cycle. Each different complex controls a specific transition between 2 subsequent phases in the cell cycle. Required for both activation and complex formation of CDK1/cyclin-B during G2-M transition, and for activation of CDK2/cyclins during G1-S transition (but not complex formation). CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation, thus regulating cell cycle progression. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminal domain (CTD) of its large subunit (POLR2A), allowing its escape from the promoter and elongation of the transcripts. Phosphorylation of POLR2A in complex with DNA promotes transcription initiation by triggering dissociation from DNA. Its expression and activity are constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 activation by phosphorylation, but is inactivated in turn by p53/TP53; this feedback loop may lead to an arrest of the cell cycle and of the transcription, helping in cell recovery, or to apoptosis. Required for DNA-bound peptides-mediated transcription and cellular growth inhibition.", "general_function": "Transcription coactivator activity", "gene_names": ["CDK7"], "name": "Cyclin-dependent kinase 7", "drug_actions": []}, "Q8NBQ5": {"specific_function": "Can convert androstan-3-alpha,17-beta-diol (3-alpha-diol) to androsterone in vitro, suggesting that it may participate in androgen metabolism during steroidogenesis. May act by metabolizing compounds that stimulate steroid synthesis and/or by generating metabolites that inhibit it. Has no activity toward DHEA (dehydroepiandrosterone), or A-dione (4-androste-3,17-dione), and only a slight activity toward testosterone to A-dione. Tumor-associated antigen in cutaneous T-cell lymphoma.", "general_function": "Steroid dehydrogenase activity", "gene_names": ["HSD17B11"], "name": "Estradiol 17-beta-dehydrogenase 11", "drug_actions": []}, "Q57VC7": {"general_function": "Nucleoside deoxyribosyltransferase activity", "gene_names": [], "name": "Uncharacterized protein", "drug_actions": []}, "P13254": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["mdeA"], "name": "Methionine gamma-lyase", "drug_actions": []}, "Q00441": {"specific_function": "Catalyzes the NADPH-dependent conversion of 6-deoxyerythronolide B (6-DEB) to erythronolide B (EB) by the insertion of an oxygen at the 6S position of 6-DEB. Requires the participation of a ferredoxin and a ferredoxin reductase for the transfer of electrons from NADPH to the monooxygenase.", "general_function": "Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen", "gene_names": ["eryF"], "name": "6-deoxyerythronolide B hydroxylase", "drug_actions": [{"action": "INDUCER", "target": "Q00441", "drug": "DB01536"}]}, "Q96I59": {"general_function": "Nucleic acid binding", "gene_names": ["NARS2"], "name": "Probable asparagine--tRNA ligase, mitochondrial", "drug_actions": []}, "P50618": {"specific_function": "Probably involved in ribonucleotide reductase function.", "gene_names": ["nrdI"], "name": "Protein NrdI", "drug_actions": []}, "O60882": {"specific_function": "Degrades amelogenin, the major protein component of the enamel matrix and two of the macromolecules characterizing the cartilage extracellular matrix: aggrecan and the cartilage oligomeric matrix protein (COMP). May play a central role in tooth enamel formation.", "general_function": "Zinc ion binding", "gene_names": ["MMP20"], "name": "Matrix metalloproteinase-20", "drug_actions": [{"action": "INHIBITOR", "target": "O60882", "drug": "DB00786"}]}, "O14521": {"specific_function": "Membrane-anchoring subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q).", "general_function": "Ubiquinone binding", "gene_names": ["SDHD"], "name": "Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "O14521", "drug": "DB00756"}]}, "P19440": {"specific_function": "Cleaves the gamma-glutamyl bond of extracellular glutathione (gamma-Glu-Cys-Gly), glutathione conjugates, and other gamma-glutamyl compounds. The metabolism of glutathione releases free glutamate and the dipeptide, cysteinyl-glycine, which is hydrolyzed to cysteine and glycine by dipeptidases. In the presence of high concentrations of dipeptides and some amino acids, can also catalyze a transpeptidation reaction, transferring the gamma-glutamyl moiety to an acceptor amino acid to form a new gamma-glutamyl compound. Initiates extracellular glutathione (GSH) breakdown, provides cells with a local cysteine supply and contributes to maintain intracellular GSH level. It is part of the cell antioxidant defense mechanism. Isoform 3 seems to be inactive.", "general_function": "Glutathione hydrolase activity", "gene_names": ["GGT1"], "name": "Gamma-glutamyltranspeptidase 1", "drug_actions": []}, "Q51782": {"specific_function": "Specifically hydrolyzes phosphonoacetate. Does not have activity on other organophosphonates or acetates.", "general_function": "Phosphonoacetate hydrolase activity", "gene_names": ["phnA"], "name": "Phosphonoacetate hydrolase", "drug_actions": []}, "Q9BYC2": {"specific_function": "Key enzyme for ketone body catabolism. Transfers the CoA moiety from succinate to acetoacetate. Formation of the enzyme-CoA intermediate proceeds via an unstable anhydride species formed between the carboxylate groups of the enzyme and substrate (By similarity).", "general_function": "3-oxoacid coa-transferase activity", "gene_names": ["OXCT2"], "name": "Succinyl-CoA:3-ketoacid coenzyme A transferase 2, mitochondrial", "drug_actions": []}, "P30305": {"specific_function": "Tyrosine protein phosphatase which functions as a dosage-dependent inducer of mitotic progression. Required for G2/M phases of the cell cycle progression and abscission during cytokinesis in a ECT2-dependent manner. Directly dephosphorylates CDK1 and stimulates its kinase activity. The three isoforms seem to have a different level of activity.", "general_function": "Protein tyrosine phosphatase activity", "gene_names": ["CDC25B"], "name": "M-phase inducer phosphatase 2", "drug_actions": []}, "P31785": {"specific_function": "Common subunit for the receptors for a variety of interleukins.", "general_function": "Interleukin-2 binding", "gene_names": ["IL2RG"], "name": "Cytokine receptor common subunit gamma", "drug_actions": [{"action": "AGONIST", "target": "P31785", "drug": "DB00041"}]}, "Q9NVH6": {"specific_function": "Converts trimethyllysine (TML) into hydroxytrimethyllysine (HTML).", "general_function": "Trimethyllysine dioxygenase activity", "gene_names": ["TMLHE"], "name": "Trimethyllysine dioxygenase, mitochondrial", "drug_actions": []}, "Q9X180": {"general_function": "Phosphorelay sensor kinase activity", "gene_names": [], "name": "Sensor histidine kinase", "drug_actions": []}, "P51691": {"general_function": "Phosphoric diester hydrolase activity", "gene_names": ["atsA"], "name": "Arylsulfatase", "drug_actions": []}, "P00524": {"specific_function": "This phosphoprotein, required for both the initiation and the maintenance of neoplastic transformation, is a protein kinase that catalyzes the phosphorylation of tyrosine residues in vitro.", "general_function": "Non-membrane spanning protein tyrosine kinase activity", "gene_names": ["V-SRC"], "name": "Tyrosine-protein kinase transforming protein Src", "drug_actions": []}, "P51692": {"specific_function": "Carries out a dual function: signal transduction and activation of transcription. Mediates cellular responses to the cytokine KITLG/SCF and other growth factors. Binds to the GAS element and activates PRL-induced transcription.", "general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": ["STAT5B"], "name": "Signal transducer and activator of transcription 5B", "drug_actions": [{"action": "INHIBITOR", "target": "P51692", "drug": "DB01254"}]}, "P51698": {"specific_function": "Catalyzes hydrolytic cleavage of carbon-halogen bonds in halogenated aliphatic compounds, leading to the formation of the corresponding primary alcohols, halide ions and protons. Has a broad substrate specificity since not only monochloroalkanes (C3 to C10) but also dichloroalkanes (> C3), bromoalkanes, and chlorinated aliphatic alcohols were good substrates. Shows almost no activity with 1,2-dichloroethane, but very high activity with the brominated analog. Is involved in the degradation of the important environmental pollutant gamma-hexachlorocyclohexane (lindane) as it also catalyzes conversion of 1,3,4,6-tetrachloro-1,4-cyclohexadiene (1,4-TCDN) to 2,5-dichloro-2,5-cyclohexadiene-1,4-diol (2,5-DDOL) via the intermediate 2,4,5-trichloro-2,5-cyclohexadiene-1-ol (2,4,5-DNOL).", "general_function": "Haloalkane dehalogenase activity", "gene_names": ["linB"], "name": "Haloalkane dehalogenase", "drug_actions": []}, "P10696": {"general_function": "Metal ion binding", "gene_names": ["ALPPL2"], "name": "Alkaline phosphatase, placental-like", "drug_actions": [{"action": "INHIBITOR", "target": "P10696", "drug": "DB00848"}, {"action": "INDUCER", "target": "P10696", "drug": "DB01143"}]}, "P06756": {"specific_function": "The alpha-V (ITGAV) integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands.(Microbial infection) Integrin ITGAV:ITGB5 acts as a receptor for adenovirus type C (PubMed:20615244). Integrin ITGAV:ITGB5 and ITGAV:ITGB3 act as receptors for coxsackievirus A9 and B1 (PubMed:9426447, PubMed:15194773, PubMed:7519807). Integrin ITGAV:ITGB3 acts as a receptor for herpes virus 8/HHV-8 (PubMed:18045938). Integrin ITGAV:ITGB6 acts as a receptor for herpes simplex 1/HHV-1 (PubMed:24367260). Integrin ITGAV:ITGB3 acts as a receptor for Human parechovirus 1 (PubMed:11160695). Integrin ITGAV:ITGB3 acts as a receptor for West nile virus (PubMed:23658209). In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions (PubMed:10397733).", "general_function": "Voltage-gated calcium channel activity", "gene_names": ["ITGAV"], "name": "Integrin alpha-V", "drug_actions": []}, "P06870": {"specific_function": "Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["KLK1"], "name": "Kallikrein-1", "drug_actions": []}, "O07015": {"specific_function": "Positive regulator required for energy stress activation of the sigma-B transcription factor. Could be required for RsbP phosphatase activity.", "gene_names": ["rsbQ"], "name": "Sigma factor SigB regulation protein RsbQ", "drug_actions": []}, "P0A5N0": {"specific_function": "Catalyzes the coenzyme A-dependent acetylation of the 2' hydroxyl or amino group of a broad spectrum of aminoglycosides. It confers resistance to aminoglycosides", "general_function": "Involved in N-acetyltransferase activity", "gene_names": ["aac"], "name": "Aminoglycoside 2'-N-acetyltransferase", "drug_actions": []}, "P80377": {"specific_function": "Located at the top of the head of the 30S subunit, it contacts several helices of the 16S rRNA. In the 70S ribosome structure it contacts the 23S rRNA (bridge B1a) and protein L5 of the 50S subunit (bridge B1b), connecting the top of the two subunits; these bridges are in contact with the A site and P site tRNAs respectively and are implicated in movement during ribosome translocation. Separately contacts the tRNAs in the A and P sites.", "general_function": "Trna binding", "gene_names": ["rpsM"], "name": "30S ribosomal protein S13", "drug_actions": []}, "Q9NSD5": {"specific_function": "Sodium-dependent GABA and taurine transporter. In presynaptic terminals, regulates GABA signaling termination through GABA uptake. May also be involved in beta-alanine transport.", "general_function": "Neurotransmitter:sodium symporter activity", "gene_names": ["SLC6A13"], "name": "Sodium- and chloride-dependent GABA transporter 2", "drug_actions": [{"action": "INHIBITOR", "target": "Q9NSD5", "drug": "DB08848"}]}, "Q5HFX3": {"general_function": "Cell wall/membrane/envelope biogenesis", "gene_names": ["pbp2"], "name": "Penicillin-binding protein 2", "drug_actions": []}, "P80372": {"specific_function": "Binds the lower part of the 30S subunit head. Binds mRNA in the 70S ribosome, positioning it for translation.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsC"], "name": "30S ribosomal protein S3", "drug_actions": []}, "P58758": {"specific_function": "Transfers dimethylallyl groups to AMP as part of the biosynthesis of cytokinin phytohormones.", "general_function": "Dimethylallyltranstransferase activity", "gene_names": ["tzs"], "name": "Adenylate dimethylallyltransferase", "drug_actions": []}, "Q9NSD9": {"general_function": "Rna binding", "gene_names": ["FARSB"], "name": "Phenylalanine--tRNA ligase beta subunit", "drug_actions": []}, "P37268": {"general_function": "Squalene synthase activity", "gene_names": ["FDFT1"], "name": "Squalene synthase", "drug_actions": []}, "P83812": {"general_function": "Lipid binding", "gene_names": [], "name": "Lipid binding protein", "drug_actions": []}, "P25705": {"specific_function": "Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain. F-type ATPases consist of two structural domains, F(1) - containing the extramembraneous catalytic core, and F(0) - containing the membrane proton channel, linked together by a central stalk and a peripheral stalk. During catalysis, ATP synthesis in the catalytic domain of F(1) is coupled via a rotary mechanism of the central stalk subunits to proton translocation. Subunits alpha and beta form the catalytic core in F(1). Rotation of the central stalk against the surrounding alpha(3)beta(3) subunits leads to hydrolysis of ATP in three separate catalytic sites on the beta subunits. Subunit alpha does not bear the catalytic high-affinity ATP-binding sites (By similarity).", "general_function": "Transmembrane transporter activity", "gene_names": ["ATP5A1"], "name": "ATP synthase subunit alpha, mitochondrial", "drug_actions": []}, "P03923": {"specific_function": "Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["MT-ND6"], "name": "NADH-ubiquinone oxidoreductase chain 6", "drug_actions": []}, "P18507": {"specific_function": "Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.", "name": "Gamma-aminobutyric acid receptor subunit gamma-2", "drug_actions": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00228"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00475"}, {"action": "BINDER", "target": "P18507", "drug": "DB00543"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB00546"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00628"}, {"action": "POSITIVE MODULATOR", "target": "P18507", "drug": "DB00659"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB00690"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00794"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00818"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01028"}, {"action": "AGONIST", "target": "P18507", "drug": "DB01049"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01189"}, {"action": "ANTAGONIST", "target": "P18507", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01205"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01236"}, {"action": "NEGATIVE MODULATOR", "target": "P18507", "drug": "DB01381"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01437"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18507", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P18507", "drug": "DB01595"}, {"action": "ANTAGONIST", "target": "P18507", "drug": "DB01708"}], "general_function": "Inhibitory extracellular ligand-gated ion channel activity", "in_complexes": ["GABA-A receptor (anion channel)"], "gene_names": ["GABRG2"]}, "P09063": {"specific_function": "The branched-chain alpha-keto dehydrogenase complex catalyzes the overall conversion of alpha-keto acids to acyl-CoA and CO(2). It contains multiple copies of 3 enzymatic components: branched-chain alpha-keto acid decarboxylase (E1), lipoamide acyltransferase (E2) and lipoamide dehydrogenase (E3).", "general_function": "Flavin adenine dinucleotide binding", "gene_names": ["lpdV"], "name": "Dihydrolipoyl dehydrogenase", "drug_actions": []}, "P18505": {"specific_function": "Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).", "name": "Gamma-aminobutyric acid receptor subunit beta-1", "drug_actions": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00228"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00404"}, {"action": "ANTAGONIST", "target": "P18505", "drug": "DB00431"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00475"}, {"action": "BINDER", "target": "P18505", "drug": "DB00543"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB00546"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00628"}, {"action": "POSITIVE MODULATOR", "target": "P18505", "drug": "DB00659"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB00690"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00794"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00818"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01028"}, {"action": "AGONIST", "target": "P18505", "drug": "DB01049"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01205"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01437"}, {"action": "AGONIST", "target": "P18505", "drug": "DB01440"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB01587"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P18505", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P18505", "drug": "DB01595"}, {"action": "ANTAGONIST", "target": "P18505", "drug": "DB01708"}], "general_function": "Ligand-gated ion channel activity", "in_complexes": ["GABA-A receptor (anion channel)"], "gene_names": ["GABRB1"]}, "Q70GK9": {"specific_function": "Involved in the biosynthesis of fluorometabolites. Catalyzes the formation of a C-F bond by combining S-adenosyl-L-methionine (SAM) and fluoride to generate 5'-fluoro-5'-deoxyadenosine (5'-FDA) and L-methionine. It can also use 2'-deoxyadenosine in place of adenosine as substrate.", "general_function": "Adenosyl-fluoride synthase activity", "gene_names": ["flA"], "name": "5'-fluoro-5'-deoxy-adenosine synthase", "drug_actions": []}, "P18509": {"specific_function": "Binding to its receptor activates G proteins and stimulates adenylate cyclase in pituitary cells. Promotes neuron projection development through the RAPGEF2/Rap1/B-Raf/ERK pathway.", "general_function": "Receptor signaling protein activity", "gene_names": ["ADCYAP1"], "name": "Pituitary adenylate cyclase-activating polypeptide", "drug_actions": []}, "Q9H8P0": {"specific_function": "Plays a key role in early steps of protein N-linked glycosylation by being required for the conversion of polyprenol into dolichol. Dolichols are required for the synthesis of dolichol-linked monosaccharides and the oligosaccharide precursor used for N-glycosylation. Acts as a polyprenol reductase that promotes the reduction of the alpha-isoprene unit of polyprenols into dolichols in a NADP-dependent mechanism. Also able to convert testosterone (T) into 5-alpha-dihydrotestosterone (DHT).", "name": "Polyprenol reductase", "drug_actions": [{"action": "ANTAGONIST", "target": "Q9H8P0", "drug": "DB00421"}], "general_function": "Oxidoreductase activity, acting on the ch-ch group of donors, nad or nadp as acceptor", "in_complexes": ["3-oxo-5-alpha-steroid 4-dehydrogenase"], "gene_names": ["SRD5A3"]}, "O75521": {"specific_function": "Able to isomerize both 3-cis and 3-trans double bonds into the 2-trans form in a range of enoyl-CoA species. Has a preference for 3-trans substrates (By similarity).", "general_function": "Receptor binding", "gene_names": ["ECI2"], "name": "Enoyl-CoA delta isomerase 2, mitochondrial", "drug_actions": []}, "P16753": {"specific_function": "Capsid scaffolding protein: Acts as a scaffold protein by binding major capsid protein VP5 in the cytoplasm, inducing the nuclear localization of both proteins. Multimerizes in the nucleus such as VP5 forms the icosahedral T=16 capsid. Autocatalytic cleavage releases the assembly protein, and subsequently abolishes interaction with major capsid protein VP5. Cleavages products are evicted from the capsid before or during DNA packaging.Assemblin: Protease that plays an essential role in virion assembly within the nucleus. Catalyzes the cleavage of the assembly protein after formation of the spherical procapsid. By that cleavage, the capsid matures and gains its icosahedral shape. The cleavage sites seem to include -Ala-|-Ser-, -Ala-|-Ala-, as well as Ala-Thr bonds. Assemblin and cleavages products are evicted from the capsid before or during DNA packaging.Assembly protein: Plays a major role in capsid assembly. Acts as a scaffold protein by binding major capsid protein VP5. Multimerizes in the nucleus such as VP5 forms the icosahedral T=16 capsid. Cleaved by assemblin after capsid completion. The cleavages products are evicted from the capsid before or during DNA packaging.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["UL80"], "name": "Capsid scaffolding protein", "drug_actions": []}, "Q3J1A6": {"specific_function": "The reaction center is a membrane-bound complex that mediates the initial photochemical event in the electron transfer process of photosynthesis.", "general_function": "Metal ion binding", "gene_names": ["pufM"], "name": "Reaction center protein M chain", "drug_actions": []}, "Q3J1A5": {"specific_function": "The reaction center is a membrane-bound complex that mediates the initial photochemical event in the electron transfer process of photosynthesis.", "general_function": "Metal ion binding", "gene_names": ["pufL"], "name": "Reaction center protein L chain", "drug_actions": []}, "Q91RS4": {"general_function": "Serine-type peptidase activity", "gene_names": [], "name": "NS3 protease", "drug_actions": [{"action": "INHIBITOR", "target": "Q91RS4", "drug": "DB06290"}]}, "P11836": {"specific_function": "This protein may be involved in the regulation of B-cell activation and proliferation.", "general_function": "Mhc class ii protein complex binding", "gene_names": ["MS4A1"], "name": "B-lymphocyte antigen CD20", "drug_actions": [{"action": "ANTIBODY", "target": "P11836", "drug": "DB00073"}, {"action": "ANTIBODY", "target": "P11836", "drug": "DB00078"}, {"action": "ANTIBODY", "target": "P11836", "drug": "DB00081"}, {"action": "ANTIBODY", "target": "P11836", "drug": "DB08935"}]}, "O00591": {"specific_function": "GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to modulatory agents such as pregnanolone.", "name": "Gamma-aminobutyric acid receptor subunit pi", "drug_actions": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00228"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00475"}, {"action": "BINDER", "target": "O00591", "drug": "DB00543"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB00546"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00628"}, {"action": "POSITIVE MODULATOR", "target": "O00591", "drug": "DB00659"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB00690"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00794"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00818"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01028"}, {"action": "AGONIST", "target": "O00591", "drug": "DB01049"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01205"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01437"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "O00591", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "O00591", "drug": "DB01595"}, {"action": "ANTAGONIST", "target": "O00591", "drug": "DB01708"}], "general_function": "Gaba-a receptor activity", "in_complexes": ["GABA-A receptor (anion channel)"], "gene_names": ["GABRP"]}, "Q99661": {"specific_function": "In complex with KIF18B, constitutes the major microtubule plus-end depolymerizing activity in mitotic cells. Regulates the turnover of microtubules at the kinetochore and functions in chromosome segregation during mitosis.", "general_function": "Microtubule plus-end binding", "gene_names": ["KIF2C"], "name": "Kinesin-like protein KIF2C", "drug_actions": []}, "Q9UNP4": {"specific_function": "Catalyzes the formation of ganglioside GM3 (alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-1, 4-beta-D-glucosylceramide).", "general_function": "Sialyltransferase activity", "gene_names": ["ST3GAL5"], "name": "Lactosylceramide alpha-2,3-sialyltransferase", "drug_actions": []}, "P27816": {"specific_function": "Non-neuronal microtubule-associated protein. Promotes microtubule assembly.", "general_function": "Structural molecule activity", "gene_names": ["MAP4"], "name": "Microtubule-associated protein 4", "drug_actions": []}, "P27815": {"specific_function": "Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.", "name": "cAMP-specific 3',5'-cyclic phosphodiesterase 4A", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "P27815", "drug": "DB00201"}, {"action": "INHIBITOR", "target": "P27815", "drug": "DB00277"}, {"action": "INHIBITOR", "target": "P27815", "drug": "DB00651"}, {"action": "INHIBITOR", "target": "P27815", "drug": "DB00806"}, {"action": "INHIBITOR", "target": "P27815", "drug": "DB00824"}, {"action": "INHIBITOR", "target": "P27815", "drug": "DB00920"}, {"action": "INHIBITOR", "target": "P27815", "drug": "DB00975"}, {"action": "INDUCER", "target": "P27815", "drug": "DB01088"}, {"action": "INHIBITOR", "target": "P27815", "drug": "DB01303"}, {"action": "INHIBITOR", "target": "P27815", "drug": "DB01656"}, {"action": "INHIBITOR", "target": "P27815", "drug": "DB05266"}, {"action": "ANTAGONIST", "target": "P27815", "drug": "DB05676"}, {"action": "INHIBITOR", "target": "P27815", "drug": "DB06751"}, {"action": "INHIBITOR", "target": "P27815", "drug": "DB08811"}], "general_function": "Metal ion binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE4A"]}, "Q9UL54": {"specific_function": "Serine/threonine-protein kinase involved in different processes such as membrane blebbing and apoptotic bodies formation DNA damage response and MAPK14/p38 MAPK stress-activated MAPK cascade. Phosphorylates itself, MBP, activated MAPK8, MAP2K3, MAP2K6 and tubulins. Activates the MAPK14/p38 MAPK signaling pathway through the specific activation and phosphorylation of the upstream MAP2K3 and MAP2K6 kinases. In response to DNA damage, involved in the G2/M transition DNA damage checkpoint by activating the p38/MAPK14 stress-activated MAPK cascade, probably by mediating phosphorylation of upstream MAP2K3 and MAP2K6 kinases. Isoform 1, but not isoform 2, plays a role in apoptotic morphological changes, including cell contraction, membrane blebbing and apoptotic bodies formation. This function, which requires the activation of MAPK8/JNK and nuclear localization of C-terminally truncated isoform 1, may be linked to the mitochondrial CASP9-associated death pathway. Isoform 1 binds to microtubules and affects their organization and stability independently of its kinase activity. Prevents MAP3K7-mediated activation of CHUK, and thus NF-kappa-B activation, but not that of MAPK8/JNK. May play a role in the osmotic stress-MAPK8 pathway. Isoform 2, but not isoform 1, is required for PCDH8 endocytosis. Following homophilic interactions between PCDH8 extracellular domains, isoform 2 phosphorylates and activates MAPK14/p38 MAPK which in turn phosphorylates isoform 2. This process leads to PCDH8 endocytosis and CDH2 cointernalization. Both isoforms are involved in MAPK14 phosphorylation.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["TAOK2"], "name": "Serine/threonine-protein kinase TAO2", "drug_actions": []}, "P21631": {"specific_function": "Catalyzes the methylation of both C-2 and C-7 of uroporphyrinogen III leading to precorrin-1 and precorrin-2; their oxidative esterification gives respectively factor I octamethyl ester and sirohydrochlorin.", "general_function": "Uroporphyrin-iii c-methyltransferase activity", "gene_names": ["cobA"], "name": "Uroporphyrinogen-III C-methyltransferase", "drug_actions": []}, "P11216": {"specific_function": "Phosphorylase is an important allosteric enzyme in carbohydrate metabolism. Enzymes from different sources differ in their regulatory mechanisms and in their natural substrates. However, all known phosphorylases share catalytic and structural properties.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["PYGB"], "name": "Glycogen phosphorylase, brain form", "drug_actions": [{"action": "COFACTOR", "target": "P11216", "drug": "DB00114"}]}, "P76045": {"specific_function": "Forms channels functionally larger than those of classical porins.May act as a regulator of the RCS-phosphorelay signal transduction pathway.", "general_function": "Porin activity", "gene_names": ["ompG"], "name": "Outer membrane protein G", "drug_actions": []}, "Q12879": {"specific_function": "NMDA receptor subtype of glutamate-gated ion channels possesses high calcium permeability and voltage-dependent sensitivity to magnesium. Activation requires binding of agonist to both types of subunits.", "name": "Glutamate receptor ionotropic, NMDA 2A", "drug_actions": [{"action": "ANTAGONIST", "target": "Q12879", "drug": "DB00145"}, {"action": "BLOCKER", "target": "Q12879", "drug": "DB00289"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB00454"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB00659"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB00949"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB01043"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB01159"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB01520"}, {"action": "AGONIST", "target": "Q12879", "drug": "DB01708"}, {"action": "INHIBITOR", "target": "Q12879", "drug": "DB04896"}, {"action": "ACTIVATOR", "target": "Q12879", "drug": "DB06151"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB06738"}, {"action": "ANTAGONIST", "target": "Q12879", "drug": "DB06741"}], "general_function": "Zinc ion binding", "in_complexes": ["Glutamate (NMDA) receptor", "NMDA receptor"], "gene_names": ["GRIN2A"]}, "P05089": {"general_function": "Manganese ion binding", "gene_names": ["ARG1"], "name": "Arginase-1", "drug_actions": []}, "P49902": {"specific_function": "May have a critical role in the maintenance of a constant composition of intracellular purine/pyrimidine nucleotides in cooperation with other nucleotidases. Preferentially hydrolyzes inosine 5'-monophosphate (IMP) and other purine nucleotides.", "general_function": "Nucleotide binding", "gene_names": ["NT5C2"], "name": "Cytosolic purine 5'-nucleotidase", "drug_actions": [{"action": "INDUCER", "target": "P49902", "drug": "DB00811"}]}, "P00782": {"specific_function": "Subtilisin is an extracellular alkaline serine protease, it catalyzes the hydrolysis of proteins and peptide amides. Has a high substrate specificity to fibrin.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["apr"], "name": "Subtilisin BPN'", "drug_actions": []}, "P55055": {"specific_function": "Nuclear receptor. Binds preferentially to double-stranded oligonucleotide direct repeats having the consensus half-site sequence 5'-AGGTCA-3' and 4-nt spacing (DR-4). Regulates cholesterol uptake through MYLIP-dependent ubiquitination of LDLR, VLDLR and LRP8; DLDLR and LRP8. Interplays functionally with RORA for the regulation of genes involved in liver metabolism (By similarity). Exhibits a ligand-dependent transcriptional activation activity (PubMed:25661920).", "general_function": "Zinc ion binding", "gene_names": ["NR1H2"], "name": "Oxysterols receptor LXR-beta", "drug_actions": []}, "Q16515": {"specific_function": "Cation channel with high affinity for sodium, which is gated by extracellular protons and inhibited by the diuretic amiloride. Also permeable for Li(+) and K(+). Generates a biphasic current with a fast inactivating and a slow sustained phase. Heteromeric channel assembly seems to modulate.", "general_function": "Ligand-gated sodium channel activity", "gene_names": ["ASIC2"], "name": "Acid-sensing ion channel 2", "drug_actions": [{"action": "INHIBITOR", "target": "Q16515", "drug": "DB00594"}]}, "Q9BTZ2": {"specific_function": "Reduces all-trans-retinal and 9-cis retinal. Can also catalyze the oxidation of all-trans-retinol with NADP as co-factor, but with much lower efficiency. Reduces alkyl phenyl ketones and alpha-dicarbonyl compounds with aromatic rings, such as pyrimidine-4-aldehyde, 3-benzoylpyridine, 4-benzoylpyridine, menadione and 4-hexanoylpyridine. Has no activity towards aliphatic aldehydes and ketones (By similarity).", "general_function": "Receptor binding", "gene_names": ["DHRS4"], "name": "Dehydrogenase/reductase SDR family member 4", "drug_actions": []}, "P22001": {"specific_function": "Mediates the voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient.", "general_function": "Voltage-gated ion channel activity", "gene_names": ["KCNA3"], "name": "Potassium voltage-gated channel subfamily A member 3", "drug_actions": [{"action": "ANTAGONIST", "target": "P22001", "drug": "DB06637"}]}, "P52664": {"specific_function": "Hydrolyzes broad-spectrum beta-lactam antibiotics. Active against cephalosporins such as cefuroxime and cefotaxime.", "general_function": "Beta-lactamase activity", "gene_names": ["blaB"], "name": "Beta-lactamase", "drug_actions": []}, "P08758": {"specific_function": "This protein is an anticoagulant protein that acts as an indirect inhibitor of the thromboplastin-specific complex, which is involved in the blood coagulation cascade.", "general_function": "Phospholipid binding", "gene_names": ["ANXA5"], "name": "Annexin A5", "drug_actions": []}, "P23280": {"specific_function": "Reversible hydration of carbon dioxide. Its role in saliva is unknown.", "general_function": "Zinc ion binding", "gene_names": ["CA6"], "name": "Carbonic anhydrase 6", "drug_actions": [{"action": "INHIBITOR", "target": "P23280", "drug": "DB00909"}, {"action": "ANTAGONIST", "target": "P23280", "drug": "DB06795"}, {"action": "INHIBITOR", "target": "P23280", "drug": "DB08846"}]}, "P08200": {"general_function": "Nad binding", "gene_names": ["icd"], "name": "Isocitrate dehydrogenase [NADP]", "drug_actions": []}, "P23284": {"specific_function": "PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides.", "general_function": "Unfolded protein binding", "gene_names": ["PPIB"], "name": "Peptidyl-prolyl cis-trans isomerase B", "drug_actions": [{"action": "BINDER", "target": "P23284", "drug": "DB00172"}]}, "Q07817": {"specific_function": "Potent inhibitor of cell death. Inhibits activation of caspases. Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.Isoform Bcl-X(L) also regulates presynaptic plasticity, including neurotransmitter release and recovery, number of axonal mitochondria as well as size and number of synaptic vesicle clusters. During synaptic stimulation, increases ATP availability from mitochondria through regulation of mitochondrial membrane ATP synthase F(1)F(0) activity and regulates endocytic vesicle retrieval in hippocampal neurons through association with DMN1L and stimulation of its GTPase activity in synaptic vesicles. May attenuate inflammation impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785).Isoform Bcl-X(S) promotes apoptosis.", "general_function": "Protein kinase binding", "gene_names": ["BCL2L1"], "name": "Bcl-2-like protein 1", "drug_actions": []}, "P31327": {"specific_function": "Involved in the urea cycle of ureotelic animals where the enzyme plays an important role in removing excess ammonia from the cell.", "general_function": "Phospholipid binding", "gene_names": ["CPS1"], "name": "Carbamoyl-phosphate synthase [ammonia], mitochondrial", "drug_actions": [{"action": "ALLOSTERIC MODULATOR", "target": "P31327", "drug": "DB06775"}]}, "P62937": {"specific_function": "PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides.", "general_function": "Virion binding", "gene_names": ["PPIA"], "name": "Peptidyl-prolyl cis-trans isomerase A", "drug_actions": [{"action": "BINDER", "target": "P62937", "drug": "DB00172"}]}, "P09622": {"specific_function": "Lipoamide dehydrogenase is a component of the glycine cleavage system as well as of the alpha-ketoacid dehydrogenase complexes. Involved in the hyperactivation of spermatazoa during capacitation and in the spermatazoal acrosome reaction.", "general_function": "Nad binding", "gene_names": ["DLD"], "name": "Dihydrolipoyl dehydrogenase, mitochondrial", "drug_actions": []}, "P31323": {"specific_function": "Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells. Type II regulatory chains mediate membrane association by binding to anchoring proteins, including the MAP2 kinase.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["PRKAR2B"], "name": "cAMP-dependent protein kinase type II-beta regulatory subunit", "drug_actions": []}, "P00909": {"specific_function": "Bifunctional enzyme that catalyzes two sequential steps of tryptophan biosynthetic pathway. The first reaction is catalyzed by the isomerase, coded by the TrpF domain; the second reaction is catalyzed by the synthase, coded by the TrpC domain.", "general_function": "Phosphoribosylanthranilate isomerase activity", "gene_names": ["trpC"], "name": "Tryptophan biosynthesis protein TrpCF", "drug_actions": []}, "Q59325": {"general_function": "Metal ion binding", "gene_names": ["cbhA"], "name": "Glucanase", "drug_actions": []}, "Q9H853": {"general_function": "Structural constituent of cytoskeleton", "gene_names": ["TUBA4B"], "name": "Putative tubulin-like protein alpha-4B", "drug_actions": []}, "P24557": {"general_function": "Thromboxane-a synthase activity", "gene_names": ["TBXAS1"], "name": "Thromboxane-A synthase", "drug_actions": [{"action": "ANTAGONIST", "target": "P24557", "drug": "DB00795"}, {"action": "INHIBITOR", "target": "P24557", "drug": "DB01207"}, {"action": "INHIBITOR", "target": "P24557", "drug": "DB03052"}]}, "P05187": {"general_function": "Zinc ion binding", "gene_names": ["ALPP"], "name": "Alkaline phosphatase, placental type", "drug_actions": []}, "Q15120": {"specific_function": "Inhibits pyruvate dehydrogenase activity by phosphorylation of the E1 subunit PDHA1, and thereby regulates glucose metabolism and aerobic respiration. Can also phosphorylate PDHA2. Decreases glucose utilization and increases fat metabolism in response to prolonged fasting, and as adaptation to a high-fat diet. Plays a role in glucose homeostasis and in maintaining normal blood glucose levels in function of nutrient levels and under starvation. Plays a role in the generation of reactive oxygen species.", "general_function": "Pyruvate dehydrogenase (acetyl-transferring) kinase activity", "gene_names": ["PDK3"], "name": "[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial", "drug_actions": []}, "Q01693": {"general_function": "Metal ion binding", "gene_names": [], "name": "Bacterial leucyl aminopeptidase", "drug_actions": []}, "Q15125": {"specific_function": "Catalyzes the conversion of Delta(8)-sterols to their corresponding Delta(7)-isomers.", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["EBP"], "name": "3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase", "drug_actions": []}, "P14207": {"specific_function": "Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells. Has high affinity for folate and folic acid analogs at neutral pH. Exposure to slightly acidic pH after receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release.", "general_function": "Methotrexate binding", "gene_names": ["FOLR2"], "name": "Folate receptor beta", "drug_actions": [{"action": "BINDER", "target": "P14207", "drug": "DB00158"}]}, "P0AFM2": {"specific_function": "Member of a multicomponent binding-protein-dependent transport system (the ProU transporter) which serves as the glycine betaine/L-proline transporter.", "general_function": "Transporter activity", "gene_names": ["proX"], "name": "Glycine betaine-binding periplasmic protein", "drug_actions": []}, "Q74EF5": {"gene_names": [], "name": "Sensor cyclic diguanylate phosphodiesterase, GAF and GAF domain-containing", "drug_actions": []}, "P0A0K8": {"specific_function": "DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.", "general_function": "Magnesium ion binding", "gene_names": ["gyrB"], "name": "DNA gyrase subunit B", "drug_actions": [{"action": "INHIBITOR", "target": "P0A0K8", "drug": "DB01051"}]}, "Q14003": {"specific_function": "This protein mediates the voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient.", "general_function": "Voltage-gated potassium channel activity", "gene_names": ["KCNC3"], "name": "Potassium voltage-gated channel subfamily C member 3", "drug_actions": [{"action": "ANTAGONIST", "target": "Q14003", "drug": "DB06637"}]}, "Q2M3G0": {"specific_function": "Drug efflux transporter present in a number of stem cells that acts as a regulator of cellular differentiation. Able to mediate efflux from cells of the rhodamine dye and of the therapeutic drug doxorubicin. Specifically present in limbal stem cells, where it plays a key role in corneal development and repair.", "general_function": "Efflux transmembrane transporter activity", "gene_names": ["ABCB5"], "name": "ATP-binding cassette sub-family B member 5", "drug_actions": []}, "Q9Y6M4": {"specific_function": "Serine/threonine-protein kinase. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. It can phosphorylate a large number of proteins. Participates in Wnt signaling. Regulates fast synaptic transmission mediated by glutamate (By similarity).", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["CSNK1G3"], "name": "Casein kinase I isoform gamma-3", "drug_actions": []}, "Q89ZI2": {"specific_function": "Can hydrolyze the glycosidic link of O-GlcNAcylated proteins. Can use p-nitrophenyl-beta-GlcNAc and 4-methylumbelliferone-GlcNAc as substrates (in vitro).", "general_function": "Beta-n-acetylglucosaminidase activity", "gene_names": [], "name": "O-GlcNAcase BT_4395", "drug_actions": [{"action": "ANTAGONIST", "target": "Q89ZI2", "drug": "DB00428"}]}, "P01744": {"general_function": "Involved in antigen binding", "gene_names": [], "name": "Ig heavy chain V-I region ND", "drug_actions": []}, "P01583": {"specific_function": "Produced by activated macrophages, IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity. IL-1 proteins are involved in the inflammatory response, being identified as endogenous pyrogens, and are reported to stimulate the release of prostaglandin and collagenase from synovial cells.", "general_function": "Cytokine activity", "gene_names": ["IL1A"], "name": "Interleukin-1 alpha", "drug_actions": [{"action": "BINDER", "target": "P01583", "drug": "DB06372"}]}, "P43700": {"specific_function": "DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.", "general_function": "Dna topoisomerase type ii (atp-hydrolyzing) activity", "gene_names": ["gyrA"], "name": "DNA gyrase subunit A", "drug_actions": [{"action": "INHIBITOR", "target": "P43700", "drug": "DB00218"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB00365"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB00467"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB00487"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB00537"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB00685"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB00827"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB00978"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB01059"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB01137"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB01155"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB01165"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB01208"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB01405"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB04576"}, {"action": "ANTAGONIST", "target": "P43700", "drug": "DB06771"}, {"action": "INHIBITOR", "target": "P43700", "drug": "DB09047"}]}, "Q86WA6": {"specific_function": "Serine hydrolase that catalyzes the hydrolytic activation of amino acid ester prodrugs of nucleoside analogs such as valacyclovir and valganciclovir. Activates valacyclovir to acyclovir. May play a role in detoxification processes. It is a specific alpha-amino acid ester hydrolase that prefers small, hydrophobic, and aromatic side chains and does not have a stringent requirement for the leaving group other than preferring a primary alcohol.", "general_function": "Hydrolase activity", "gene_names": ["BPHL"], "name": "Valacyclovir hydrolase", "drug_actions": []}, "P43702": {"specific_function": "Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.", "general_function": "Dna topoisomerase type ii (atp-hydrolyzing) activity", "gene_names": ["parC"], "name": "DNA topoisomerase 4 subunit A", "drug_actions": [{"action": "INHIBITOR", "target": "P43702", "drug": "DB00218"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB00365"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB00467"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB00487"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB00537"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB00685"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB00978"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB01059"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB01137"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB01155"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB01165"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB01208"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB01405"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB04576"}, {"action": "ANTAGONIST", "target": "P43702", "drug": "DB06771"}, {"action": "INHIBITOR", "target": "P43702", "drug": "DB09047"}]}, "P26514": {"specific_function": "Contributes to hydrolyze hemicellulose, the major component of plant cell-walls. XLNA and XLNB seem to act sequentially on the substrate to yield xylobiose and xylose as carbon sources.", "general_function": "Endo-1,4-beta-xylanase activity", "gene_names": ["xlnA"], "name": "Endo-1,4-beta-xylanase A", "drug_actions": []}, "B4YQT9": {"general_function": "Dna topoisomerase type ii (atp-hydrolyzing) activity", "gene_names": [], "name": "Gyrase A", "drug_actions": []}, "O75908": {"specific_function": "Plays a role in lipoprotein assembly and dietary cholesterol absorption. In addition to its acyltransferase activity, it may act as a ligase. May provide cholesteryl esters for lipoprotein secretion from hepatocytes and intestinal mucosa.", "general_function": "Transferase activity, transferring acyl groups", "gene_names": ["SOAT2"], "name": "Sterol O-acyltransferase 2", "drug_actions": [{"action": "INHIBITOR", "target": "O75908", "drug": "DB01094"}]}, "P64170": {"specific_function": "This protein is essential to the cell-division process. It seems to assemble into a dynamic ring on the inner surface of the cytoplasmic membrane at the place where division will occur, and the formation of the ring is the signal for septation to begin. Binds to and hydrolyzes GTP", "general_function": "Cell cycle control, cell division, chromosome partitioning", "gene_names": ["ftsZ"], "name": "Cell division protein FtsZ", "drug_actions": []}, "P49019": {"specific_function": "Receptor for 3-OH-octanoid acid mediates a negative feedback regulation of adipocyte lipolysis to counteract prolipolytic influences under conditions of physiological or pathological increases in beta-oxidation rates. Acts as a low affinity receptor for nicotinic acid. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet.", "general_function": "G-protein coupled receptor activity", "gene_names": ["HCAR3"], "name": "Hydroxycarboxylic acid receptor 3", "drug_actions": [{"action": "AGONIST", "target": "P49019", "drug": "DB00627"}]}, "O75900": {"specific_function": "Protease. May regulate the surface expression of some potassium channels by retaining them in the endoplasmic reticulum (By similarity).", "general_function": "Zinc ion binding", "gene_names": ["MMP23A"], "name": "Matrix metalloproteinase-23", "drug_actions": [{"action": "INHIBITOR", "target": "O75900", "drug": "DB00786"}]}, "Q05940": {"specific_function": "Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles. Requisite for vesicular amine storage prior to secretion via exocytosis.", "general_function": "Monoamine transmembrane transporter activity", "gene_names": ["SLC18A2"], "name": "Synaptic vesicular amine transporter", "drug_actions": [{"action": "INHIBITOR", "target": "Q05940", "drug": "DB00182"}, {"action": "INHIBITOR", "target": "Q05940", "drug": "DB00206"}, {"action": "BINDER", "target": "Q05940", "drug": "DB00368"}, {"action": "INHIBITOR", "target": "Q05940", "drug": "DB00386"}, {"action": "INDUCER", "target": "Q05940", "drug": "DB00865"}, {"action": "INHIBITOR", "target": "Q05940", "drug": "DB01089"}, {"action": "INHIBITOR", "target": "Q05940", "drug": "DB01363"}, {"action": "INHIBITOR", "target": "Q05940", "drug": "DB01364"}, {"action": "INHIBITOR", "target": "Q05940", "drug": "DB01442"}, {"action": "INHIBITOR", "target": "Q05940", "drug": "DB01454"}, {"action": "INHIBITOR", "target": "Q05940", "drug": "DB01472"}, {"action": "INDUCER", "target": "Q05940", "drug": "DB01576"}, {"action": "INHIBITOR", "target": "Q05940", "drug": "DB01577"}, {"action": "INHIBITOR", "target": "Q05940", "drug": "DB04844"}, {"action": "INHIBITOR", "target": "Q05940", "drug": "DB06706"}]}, "P71143": {"general_function": "Carbohydrate binding", "gene_names": ["sdbA"], "name": "Scaffolding dockerin binding protein A", "drug_actions": []}, "Q2RJ67": {"general_function": "Methionine synthase activity", "gene_names": [], "name": "5-methyltetrahydrofolate--homocysteine S-methyltransferase", "drug_actions": []}, "Q8RJN5": {"general_function": "Carbon-nitrogen ligase activity, with glutamine as amido-n-donor", "gene_names": ["pam"], "name": "Peptide amidase", "drug_actions": []}, "Q53ZE5": {"specific_function": "Catalyzes the conversion of dihydroorotate to orotate with fumarate as the electron acceptor.", "general_function": "Dihydroorotate dehydrogenase (fumarate) activity", "gene_names": ["pyrDA"], "name": "Dihydroorotate dehydrogenase A (fumarate)", "drug_actions": []}, "P01584": {"specific_function": "Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells.", "general_function": "Protein domain specific binding", "gene_names": ["IL1B"], "name": "Interleukin-1 beta", "drug_actions": [{"action": "MODULATOR", "target": "P01584", "drug": "DB01017"}, {"action": "ANTAGONIST", "target": "P01584", "drug": "DB05260"}, {"action": "BINDER", "target": "P01584", "drug": "DB06168"}, {"action": "BINDER", "target": "P01584", "drug": "DB06372"}]}, "Q6GII7": {"specific_function": "Involved in the third step of the chorismate pathway, which leads to the biosynthesis of aromatic amino acids. Catalyzes the cis-dehydration of 3-dehydroquinate (DHQ) and introduces the first double bond of the aromatic ring to yield 3-dehydroshikimate.", "general_function": "3-dehydroquinate dehydratase activity", "gene_names": ["aroD"], "name": "3-dehydroquinate dehydratase", "drug_actions": []}, "O90777": {"general_function": "Aspartic-type endopeptidase activity", "gene_names": ["HIV-1 protease"], "name": "HIV-1 protease", "drug_actions": [{"action": "INHIBITOR", "target": "O90777", "drug": "DB00220"}]}, "P26951": {"specific_function": "This is a receptor for interleukin-3.", "general_function": "Interleukin-3 receptor activity", "gene_names": ["IL3RA"], "name": "Interleukin-3 receptor subunit alpha", "drug_actions": [{"action": "AGONIST", "target": "P26951", "drug": "DB00020"}]}, "P15954": {"specific_function": "This protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport.", "general_function": "Cytochrome-c oxidase activity", "gene_names": ["COX7C"], "name": "Cytochrome c oxidase subunit 7C, mitochondrial", "drug_actions": []}, "P01556": {"specific_function": "The B subunit pentameric ring directs the A subunit to its target by binding to the GM1 gangliosides present on the surface of the intestinal epithelial cells. It can bind five GM1 gangliosides. It has no toxic activity by itself.", "general_function": "Host cell surface binding", "gene_names": ["ctxB"], "name": "Cholera enterotoxin subunit B", "drug_actions": []}, "O60658": {"specific_function": "Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in maintaining basal levels of the cyclic nucleotide and/or in the cAMP regulation of germ cell development.", "name": "High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "O60658", "drug": "DB00201"}, {"action": "INHIBITOR", "target": "O60658", "drug": "DB00920"}], "general_function": "Metal ion binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE8A"]}, "P48066": {"specific_function": "Terminates the action of GABA by its high affinity sodium-dependent reuptake into presynaptic terminals.", "general_function": "Neurotransmitter:sodium symporter activity", "gene_names": ["SLC6A11"], "name": "Sodium- and chloride-dependent GABA transporter 3", "drug_actions": [{"action": "INHIBITOR", "target": "P48066", "drug": "DB08848"}]}, "P63462": {"specific_function": "Catalyzes the reductive cleavage of azo bond in aromatic azo compounds to the corresponding amines. Requires NADH, but not NADPH, as an electron donor for its activity.", "general_function": "Oxidoreductase activity, acting on other nitrogenous compounds as donors", "gene_names": ["azoR"], "name": "FMN-dependent NADH-azoreductase", "drug_actions": []}, "P33517": {"specific_function": "Cytochrome c oxidase is the component of the respiratory chain that catalyzes the reduction of oxygen to water. Subunits 1-3 form the functional core of the enzyme complex. Co I is the catalytic subunit of the enzyme. Electrons originating in cytochrome c are transferred via the copper A center of subunit 2 and heme a of subunit 1 to the bimetallic center formed by heme a3 and copper B. This cytochrome c oxidase shows proton pump activity across the membrane in addition to the electron transfer.", "general_function": "Iron ion binding", "gene_names": ["ctaD"], "name": "Cytochrome c oxidase subunit 1", "drug_actions": []}, "P05452": {"specific_function": "Tetranectin binds to plasminogen and to isolated kringle 4. May be involved in the packaging of molecules destined for exocytosis.", "general_function": "Kringle domain binding", "gene_names": ["CLEC3B"], "name": "Tetranectin", "drug_actions": []}, "P17405": {"specific_function": "Converts sphingomyelin to ceramide. Also has phospholipase C activities toward 1,2-diacylglycerolphosphocholine and 1,2-diacylglycerolphosphoglycerol. Isoform 2 and isoform 3 have lost catalytic activity.", "general_function": "Sphingomyelin phosphodiesterase activity", "gene_names": ["SMPD1"], "name": "Sphingomyelin phosphodiesterase", "drug_actions": [{"action": "INHIBITOR", "target": "P17405", "drug": "DB01151"}]}, "P44868": {"specific_function": "Methylates the ribose at the nucleotide 34 wobble position in the two leucyl isoacceptors tRNA(Leu)(CmAA) and tRNA(Leu)(cmnm5UmAA). Catalyzes the methyl transfer from S-adenosyl-L-methionine to the 2'-OH of the wobble nucleotide.", "general_function": "Trna methyltransferase activity", "gene_names": ["trmL"], "name": "tRNA (cytidine(34)-2'-O)-methyltransferase", "drug_actions": []}, "O60656": {"specific_function": "UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.", "general_function": "Retinoic acid binding", "gene_names": ["UGT1A9"], "name": "UDP-glucuronosyltransferase 1-9", "drug_actions": []}, "P00582": {"specific_function": "In addition to polymerase activity, this DNA polymerase exhibits 3' to 5' and 5' to 3' exonuclease activity. It is able to utilize nicked circular duplex DNA as a template and can unwind the parental DNA strand from its template.", "general_function": "Dna-directed dna polymerase activity", "gene_names": ["polA"], "name": "DNA polymerase I", "drug_actions": [{"action": "INHIBITOR", "target": "P00582", "drug": "DB00548"}]}, "P0A7J6": {"specific_function": "Protein L10 is also a translational repressor protein. It controls the translation of the rplJL-rpoBC operon by binding to its mRNA (By similarity).Forms part of the ribosomal stalk, playing a central role in the interaction of the ribosome with GTP-bound translation factors.", "general_function": "Structural constituent of ribosome", "gene_names": ["rplJ"], "name": "50S ribosomal protein L10", "drug_actions": [{"action": "INHIBITOR", "target": "P0A7J6", "drug": "DB00778"}, {"action": "INHIBITOR", "target": "P0A7J6", "drug": "DB01190"}, {"action": "INHIBITOR", "target": "P0A7J6", "drug": "DB01211"}, {"action": "INHIBITOR", "target": "P0A7J6", "drug": "DB01369"}, {"action": "INHIBITOR", "target": "P0A7J6", "drug": "DB01627"}]}, "Q08257": {"specific_function": "Does not have alcohol dehydrogenase activity. Binds NADP and acts through a one-electron transfer process. Orthoquinones, such as 1,2-naphthoquinone or 9,10-phenanthrenequinone, are the best substrates (in vitro). May act in the detoxification of xenobiotics. Interacts with (AU)-rich elements (ARE) in the 3'-UTR of target mRNA species. Enhances the stability of mRNA coding for BCL2. NADPH binding interferes with mRNA binding.", "general_function": "Zinc ion binding", "gene_names": ["CRYZ"], "name": "Quinone oxidoreductase", "drug_actions": [{"action": "INHIBITOR", "target": "Q08257", "drug": "DB00266"}]}, "P00587": {"specific_function": "Diphtheria toxin, produced by a phage infecting Corynebacterium diphtheriae, is a proenzyme that, after activation, catalyzes the covalent attachment of the ADP ribose moiety of NAD to elongation factor 2. Fragment A is responsible for enzymatic ADP-ribosylation of elongation factor 2, while fragment B is responsible for binding of toxin to cell receptors and entry of fragment A.", "general_function": "Nad+-diphthamide adp-ribosyltransferase activity", "gene_names": [], "name": "Diphtheria toxin", "drug_actions": []}, "O75874": {"general_function": "Receptor binding", "gene_names": ["IDH1"], "name": "Isocitrate dehydrogenase [NADP] cytoplasmic", "drug_actions": []}, "Q92876": {"specific_function": "Serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position. Shows activity against amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen. Degrades alpha-synuclein and prevents its polymerization, indicating that it may be involved in the pathogenesis of Parkinson disease and other synucleinopathies. May be involved in regulation of axon outgrowth following spinal cord injury. Tumor cells treated with a neutralizing KLK6 antibody migrate less than control cells, suggesting a role in invasion and metastasis.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["KLK6"], "name": "Kallikrein-6", "drug_actions": []}, "P28248": {"general_function": "Dctp deaminase activity", "gene_names": ["dcd"], "name": "Deoxycytidine triphosphate deaminase", "drug_actions": []}, "O75879": {"specific_function": "Allows the formation of correctly charged Gln-tRNA(Gln) through the transamidation of misacylated Glu-tRNA(Gln) in the mitochondria. The reaction takes place in the presence of glutamine and ATP through an activated gamma-phospho-Glu-tRNA(Gln).", "general_function": "Translation factor activity, rna binding", "gene_names": ["GATB"], "name": "Glutamyl-tRNA(Gln) amidotransferase subunit B, mitochondrial", "drug_actions": []}, "Q969G6": {"specific_function": "Catalyzes the phosphorylation of riboflavin (vitamin B2) to form flavin-mononucleotide (FMN), hence rate-limiting enzyme in the synthesis of FAD. Essential for TNF-induced reactive oxygen species (ROS) production. Through its interaction with both TNFRSF1A and CYBA, physically and functionally couples TNFRSF1A to NADPH oxidase. TNF-activation of RFK may enhance the incorporation of FAD in NADPH oxidase, a critical step for the assembly and activation of NADPH oxidase.", "general_function": "Riboflavin kinase activity", "gene_names": ["RFK"], "name": "Riboflavin kinase", "drug_actions": [{"action": "LIGAND", "target": "Q969G6", "drug": "DB00140"}]}, "Q92696": {"specific_function": "Catalyzes the transfer of a geranylgeranyl moiety from geranylgeranyl diphosphate to both cysteines of Rab proteins with the C-terminal sequence -XXCC, -XCXC and -CCXX, such as RAB1A, RAB3A, RAB5A and RAB7A.", "general_function": "Zinc ion binding", "gene_names": ["RABGGTA"], "name": "Geranylgeranyl transferase type-2 subunit alpha", "drug_actions": []}, "P11439": {"specific_function": "An NAD-dependent ADP-ribosyltransferase (ADPRT). Catalyzes the transfer of the ADP ribosyl moiety of oxidized NAD (NAD(+)) onto eukaryotic elongation factor 2 (eEF-2) thus arresting protein synthesis. Has an LD(50) of 65 ng/ml against the human lung epithelial cell line C38.", "general_function": "Nad+-diphthamide adp-ribosyltransferase activity", "gene_names": ["eta"], "name": "Exotoxin A", "drug_actions": []}, "P0A3D9": {"specific_function": "Low-potential electron donor to a number of redox enzymes.", "general_function": "Fmn binding", "gene_names": ["isiB"], "name": "Flavodoxin", "drug_actions": []}, "P54278": {"specific_function": "Component of the post-replicative DNA mismatch repair system (MMR). Heterodimerizes with MLH1 to form MutL alpha. DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH6) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages.", "general_function": "Single base insertion or deletion binding", "gene_names": ["PMS2"], "name": "Mismatch repair endonuclease PMS2", "drug_actions": []}, "P53582": {"specific_function": "Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). Required for normal progression through the cell cycle.", "general_function": "Metalloexopeptidase activity", "gene_names": ["METAP1"], "name": "Methionine aminopeptidase 1", "drug_actions": []}, "P08373": {"specific_function": "Cell wall formation.", "general_function": "Udp-n-acetylmuramate dehydrogenase activity", "gene_names": ["murB"], "name": "UDP-N-acetylenolpyruvoylglucosamine reductase", "drug_actions": []}, "P46597": {"specific_function": "Isoform 1 catalyzes the transfer of a methyl group onto N-acetylserotonin, producing melatonin (N-acetyl-5-methoxytryptamine). Isoform 2 and isoform 3 lack enzyme activity.", "general_function": "Protein homodimerization activity", "gene_names": ["ASMT"], "name": "Acetylserotonin O-methyltransferase", "drug_actions": []}, "Q02834": {"specific_function": "To release sialic acids for use as carbon and energy sources for this non-pathogenic bacterium while in pathogenic microorganisms, sialidases have been suggested to be pathogenic factors.", "general_function": "Exo-alpha-(2->8)-sialidase activity", "gene_names": ["nedA"], "name": "Sialidase", "drug_actions": []}, "P96113": {"specific_function": "Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions (By similarity).", "general_function": "Peptide deformylase activity", "gene_names": ["def"], "name": "Peptide deformylase", "drug_actions": []}, "P21926": {"specific_function": "Involved in platelet activation and aggregation. Regulates paranodal junction formation. Involved in cell adhesion, cell motility and tumor metastasis. Required for sperm-egg fusion.", "gene_names": ["CD9"], "name": "CD9 antigen", "drug_actions": []}, "P00167": {"specific_function": "Cytochrome b5 is a membrane bound hemoprotein which function as an electron carrier for several membrane bound oxygenases.", "general_function": "Metal ion binding", "gene_names": ["CYB5A"], "name": "Cytochrome b5", "drug_actions": []}, "O06620": {"specific_function": "ATP + 7,8-diaminononanoate + CO(2) = ADP + phosphate + dethiobiotin", "general_function": "Coenzyme transport and metabolism", "gene_names": ["bioD"], "name": "ATP-dependent dethiobiotin synthetase BioD", "drug_actions": []}, "P08574": {"specific_function": "This is the heme-containing component of the cytochrome b-c1 complex, which accepts electrons from Rieske protein and transfers electrons to cytochrome c in the mitochondrial respiratory chain.", "general_function": "Metal ion binding", "gene_names": ["CYC1"], "name": "Cytochrome c1, heme protein, mitochondrial", "drug_actions": []}, "P23467": {"specific_function": "Plays an important role in blood vessel remodeling and angiogenesis. Not necessary for the initial formation of blood vessels, but is essential for their maintenance and remodeling. Can induce dephosphorylation of TEK/TIE2, CDH5/VE-cadherin and KDR/VEGFR-2. Regulates angiopoietin-TIE2 signaling in endothelial cells. Acts as a negative regulator of TIE2, and controls TIE2 driven endothelial cell proliferation, which in turn affects blood vessel remodeling during embryonic development and determines blood vessel size during perinatal growth. Essential for the maintenance of endothelial cell contact integrity and for the adhesive function of VE-cadherin in endothelial cells and this requires the presence of plakoglobin (By similarity).", "general_function": "Transmembrane receptor protein tyrosine phosphatase activity", "gene_names": ["PTPRB"], "name": "Receptor-type tyrosine-protein phosphatase beta", "drug_actions": []}, "P04531": {"specific_function": "Phosphorylates dGMP, dTMP and 5-hydroxymethyl-dCMP while excluding dCMP and dAMP. The phosphorylation of 5-hydroxymethyl-dCMP represents the first step in the replacement of cytosine by hydroxymethylcytosine in new viral DNA genomes.", "general_function": "Atp binding", "gene_names": ["1"], "name": "Deoxynucleotide monophosphate kinase", "drug_actions": []}, "Q8N0U8": {"specific_function": "Involved in vitamin K metabolism. Can reduce inactive vitamin K 2,3-epoxide to active vitamin K (in vitro), and may contribute to vitamin K-mediated protection against oxidative stress. Plays a role in vitamin K-dependent gamma-carboxylation of Glu residues in target proteins.", "general_function": "Vitamin-k-epoxide reductase (warfarin-sensitive) activity", "gene_names": ["VKORC1L1"], "name": "Vitamin K epoxide reductase complex subunit 1-like protein 1", "drug_actions": [{"action": "COFACTOR", "target": "Q8N0U8", "drug": "DB00170"}]}, "P23469": {"specific_function": "Isoform 1 plays a critical role in signaling transduction pathways and phosphoprotein network topology in red blood cells. May play a role in osteoclast formation and function (By similarity).Isoform 2 acts as a negative regulator of insulin receptor (IR) signaling in skeletal muscle. Regulates insulin-induced tyrosine phosphorylation of insulin receptor (IR) and insulin receptor substrate 1 (IRS-1), phosphorylation of protein kinase B and glycogen synthase kinase-3 and insulin induced stimulation of glucose uptake (By similarity).Isoform 1 and isoform 2 act as a negative regulator of FceRI-mediated signal transduction leading to cytokine production and degranulation, most likely by acting at the level of SYK to affect downstream events such as phosphorylation of SLP76 and LAT and mobilization of Ca(2+).", "general_function": "Transmembrane receptor protein tyrosine phosphatase activity", "gene_names": ["PTPRE"], "name": "Receptor-type tyrosine-protein phosphatase epsilon", "drug_actions": [{"action": "INHIBITOR", "target": "P23469", "drug": "DB00630"}]}, "P0A8D6": {"specific_function": "Deacetylates O-acetyl-ADP ribose. Down-regulates ribonuclease 3 (RNase III) activity. Acts by interacting directly with the region of the ribonuclease that is required for dimerization/activation.", "general_function": "Ribonuclease inhibitor activity", "gene_names": ["ymdB"], "name": "O-acetyl-ADP-ribose deacetylase", "drug_actions": []}, "Q04782": {"specific_function": "Catalyzes the cyclization of (S)-2,3 oxidosqualene to lanosterol, a reaction that forms the sterol nucleus.", "general_function": "Lanosterol synthase activity", "gene_names": ["ERG7"], "name": "Lanosterol synthase", "drug_actions": [{"action": "INHIBITOR", "target": "Q04782", "drug": "DB00239"}]}, "P10724": {"specific_function": "Catalyzes the interconversion of L-alanine and D-alanine. Also weakly active on serine.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["alr"], "name": "Alanine racemase", "drug_actions": []}, "P0A1X2": {"specific_function": "Involved in the secretion of the Ipa antigens.", "gene_names": ["mxiM"], "name": "Lipoprotein MxiM", "drug_actions": []}, "P0A1X3": {"specific_function": "Involved in the secretion of the Ipa antigens.", "gene_names": ["mxiM"], "name": "Lipoprotein MxiM", "drug_actions": []}, "P20273": {"specific_function": "Mediates B-cell B-cell interactions. May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B-cell antigen receptor signaling. Plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.", "general_function": "Carbohydrate binding", "gene_names": ["CD22"], "name": "B-cell receptor CD22", "drug_actions": []}, "P00558": {"specific_function": "In addition to its role as a glycolytic enzyme, it seems that PGK-1 acts as a polymerase alpha cofactor protein (primer recognition protein).", "general_function": "Phosphoglycerate kinase activity", "gene_names": ["PGK1"], "name": "Phosphoglycerate kinase 1", "drug_actions": []}, "Q14524": {"specific_function": "This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is responsible for the initial upstroke of the action potential. Channel inactivation is regulated by intracellular calcium levels.", "name": "Sodium channel protein type 5 subunit alpha", "drug_actions": [{"action": "INHIBITOR", "target": "Q14524", "drug": "DB00192"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00243"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00252"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00280"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00281"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00379"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00473"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00527"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00532"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00564"}, {"action": "OTHER", "target": "Q14524", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00680"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00740"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00750"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00754"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00776"}, {"action": "ANTAGONIST", "target": "Q14524", "drug": "DB00868"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00907"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00908"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB01035"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB01056"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB01182"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB01195"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB01228"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB01320"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB01346"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB01426"}, {"action": "INHIBITOR", "target": "Q14524", "drug": "DB01429"}], "general_function": "Voltage-gated sodium channel activity involved in sa node cell action potential", "in_complexes": ["Sodium channel protein"], "gene_names": ["SCN5A"]}, "O31156": {"specific_function": "Involved in phosphonate degradation.", "general_function": "Phosphonoacetaldehyde hydrolase activity", "gene_names": ["phnX"], "name": "Phosphonoacetaldehyde hydrolase", "drug_actions": []}, "P20276": {"specific_function": "One of the primary rRNA binding proteins. Required for association of the 30S and 50S subunits to form the 70S ribosome, for tRNA binding and peptide bond formation. It has been suggested to have peptidyltransferase activity; this is somewhat controversial. Makes several contacts with the 16S rRNA in the 70S ribosome (By similarity).", "general_function": "Structural constituent of ribosome", "gene_names": ["rpl2"], "name": "50S ribosomal protein L2", "drug_actions": [{"action": "ANTAGONIST", "target": "P20276", "drug": "DB04865"}]}, "P62750": {"specific_function": "This protein binds to a specific region on the 26S rRNA.", "general_function": "Structural constituent of ribosome", "gene_names": ["RPL23A"], "name": "60S ribosomal protein L23a", "drug_actions": []}, "P18031": {"specific_function": "Tyrosine-protein phosphatase which acts as a regulator of endoplasmic reticulum unfolded protein response. Mediates dephosphorylation of EIF2AK3/PERK; inactivating the protein kinase activity of EIF2AK3/PERK. May play an important role in CKII- and p60c-src-induced signal transduction cascades. May regulate the EFNA5-EPHA3 signaling pathway which modulates cell reorganization and cell-cell repulsion. May also regulate the hepatocyte growth factor receptor signaling pathway through dephosphorylation of MET.", "general_function": "Zinc ion binding", "gene_names": ["PTPN1"], "name": "Tyrosine-protein phosphatase non-receptor type 1", "drug_actions": [{"action": "INHIBITOR", "target": "P18031", "drug": "DB01133"}]}, "P22392": {"specific_function": "Major role in the synthesis of nucleoside triphosphates other than ATP. Negatively regulates Rho activity by interacting with AKAP13/LBC. Acts as a transcriptional activator of the MYC gene; binds DNA non-specifically (PubMed:8392752). Exhibits histidine protein kinase activity.", "general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": ["NME2"], "name": "Nucleoside diphosphate kinase B", "drug_actions": []}, "P04075": {"specific_function": "Plays a key role in glycolysis and gluconeogenesis. In addition, may also function as scaffolding protein (By similarity).", "general_function": "Tubulin binding", "gene_names": ["ALDOA"], "name": "Fructose-bisphosphate aldolase A", "drug_actions": []}, "P02671": {"specific_function": "Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the immune response via both innate and T-cell mediated pathways.", "general_function": "Structural molecule activity", "gene_names": ["FGA"], "name": "Fibrinogen alpha chain", "drug_actions": [{"action": "ANTAGONIST", "target": "P02671", "drug": "DB00364"}]}, "P04070": {"specific_function": "Protein C is a vitamin K-dependent serine protease that regulates blood coagulation by inactivating factors Va and VIIIa in the presence of calcium ions and phospholipids (PubMed:25618265). Exerts a protective effect on the endothelial cell barrier function (PubMed:25651845).", "general_function": "Serine-type endopeptidase activity", "gene_names": ["PROC"], "name": "Vitamin K-dependent protein C", "drug_actions": [{"action": "ACTIVATOR", "target": "P04070", "drug": "DB00170"}, {"action": "INHIBITOR", "target": "P04070", "drug": "DB00464"}]}, "P77967": {"specific_function": "May have a photoreceptor function. Binds DNA; represses transcription of at least 8 genes, including slr0364 and slr1866. Does not encode a DNA photolyase function. Its disruption does not affect circadian rhythm.", "general_function": "Dna photolyase activity", "gene_names": ["cry"], "name": "Cryptochrome DASH", "drug_actions": []}, "Q9RC23": {"specific_function": "Catalyzes the oxidative decarboxylation of the C-terminal cysteine residue of mersacidin to an aminoenethiol residue.", "general_function": "Oxidoreductase activity", "gene_names": ["mrsD"], "name": "Mersacidin decarboxylase", "drug_actions": []}, "O43739": {"specific_function": "Promotes guanine-nucleotide exchange on ARF1 and ARF6. Promotes the activation of ARF factors through replacement of GDP with GTP.", "general_function": "Phosphatidylinositol-3,4,5-trisphosphate binding", "gene_names": ["CYTH3"], "name": "Cytohesin-3", "drug_actions": []}, "O00206": {"specific_function": "Cooperates with LY96 and CD14 to mediate the innate immune response to bacterial lipopolysaccharide (LPS). Acts via MYD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:9237759, PubMed:10835634). Also involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni(2+). Responses triggered by Ni(2+) require non-conserved histidines and are, therefore, species-specific (PubMed:20711192). In complex with TLR6, promotes sterile inflammation in monocytes/macrophages in response to oxidized low-density lipoprotein (oxLDL) or amyloid-beta 42. In this context, the initial signal is provided by oxLDL- or amyloid-beta 42-binding to CD36. This event induces the formation of a heterodimer of TLR4 and TLR6, which is rapidly internalized and triggers inflammatory response, leading to the NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway, as well as IL1B secretion. Binds electronegative LDL (LDL(-)) and mediates the cytokine release induced by LDL(-) (PubMed:23880187).", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["TLR4"], "name": "Toll-like receptor 4", "drug_actions": [{"action": "INHIBITOR", "target": "O00206", "drug": "DB01183"}]}, "Q9LAK3": {"general_function": "Transferase activity, transferring glycosyl groups", "gene_names": ["cst-II"], "name": "Alpha-2,3-/2,8-sialyltransferase", "drug_actions": []}, "P0A9S1": {"general_function": "Lactaldehyde reductase activity", "gene_names": ["fucO"], "name": "Lactaldehyde reductase", "drug_actions": []}, "Q5SHF5": {"specific_function": "Catalyzes the condensation of pantoate with beta-alanine in an ATP-dependent reaction via a pantoyl-adenylate intermediate.", "general_function": "Pantoate-beta-alanine ligase activity", "gene_names": ["panC"], "name": "Pantothenate synthetase", "drug_actions": []}, "Q9UN88": {"specific_function": "GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.", "name": "Gamma-aminobutyric acid receptor subunit theta", "drug_actions": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00228"}, {"action": "POTENTIATOR", "target": "Q9UN88", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00475"}, {"action": "BINDER", "target": "Q9UN88", "drug": "DB00543"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00628"}, {"action": "POSITIVE MODULATOR", "target": "Q9UN88", "drug": "DB00659"}, {"action": "POTENTIATOR", "target": "Q9UN88", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "Q9UN88", "drug": "DB00690"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00818"}, {"action": "POTENTIATOR", "target": "Q9UN88", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "Q9UN88", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "Q9UN88", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01028"}, {"action": "AGONIST", "target": "Q9UN88", "drug": "DB01049"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01437"}, {"action": "POTENTIATOR", "target": "Q9UN88", "drug": "DB01558"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q9UN88", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "Q9UN88", "drug": "DB01595"}, {"action": "ANTAGONIST", "target": "Q9UN88", "drug": "DB01708"}], "general_function": "Transmembrane signaling receptor activity", "in_complexes": ["GABA-A receptor (anion channel)"], "gene_names": ["GABRQ"]}, "Q70Z44": {"specific_function": "This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses. It is a cation-specific, but otherwise relatively nonselective, ion channel.", "name": "5-hydroxytryptamine receptor 3D", "drug_actions": [{"action": "ANTAGONIST", "target": "Q70Z44", "drug": "DB01049"}], "general_function": "Serotonin-activated cation-selective channel activity", "in_complexes": ["Serotonin Receptors"], "gene_names": ["HTR3D"]}, "Q06AK7": {"specific_function": "Releases the supercoiling and torsional tension of DNA, which is introduced during the DNA replication and transcription, by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(5'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 3'-OH DNA strand. The free DNA strand then undergoes passage around the unbroken strand, thus removing DNA supercoils. Finally, in the religation step, the DNA 3'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone.", "general_function": "Magnesium ion binding", "gene_names": ["topA"], "name": "DNA topoisomerase 1", "drug_actions": []}, "O43519": {"gene_names": ["RET"], "name": "RET proto-oncogene", "drug_actions": [{"action": "INHIBITOR", "target": "O43519", "drug": "DB00619"}]}, "Q46393": {"specific_function": "Intermediary in the transfer of excitation energy from the chlorophyll to the reaction centers.", "general_function": "Metal ion binding", "gene_names": ["fmoA"], "name": "Bacteriochlorophyll a protein", "drug_actions": []}, "Q9NPB1": {"specific_function": "Dephosphorylates specifically the 5' and 2'(3')-phosphates of uracil and thymine deoxyribonucleotides, and so protects mitochondrial DNA replication from excess dTTP. Has only marginal activity towards dIMP and dGMP.", "general_function": "Nucleotide binding", "gene_names": ["NT5M"], "name": "5'(3')-deoxyribonucleotidase, mitochondrial", "drug_actions": []}, "P54619": {"specific_function": "AMP/ATP-binding subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin. Gamma non-catalytic subunit mediates binding to AMP, ADP and ATP, leading to activate or inhibit AMPK: AMP-binding results in allosteric activation of alpha catalytic subunit (PRKAA1 or PRKAA2) both by inducing phosphorylation and preventing dephosphorylation of catalytic subunits. ADP also stimulates phosphorylation, without stimulating already phosphorylated catalytic subunit. ATP promotes dephosphorylation of catalytic subunit, rendering the AMPK enzyme inactive.", "name": "5'-AMP-activated protein kinase subunit gamma-1", "drug_actions": [{"action": "ACTIVATOR", "target": "P54619", "drug": "DB00945"}], "general_function": "Protein kinase binding", "in_complexes": ["5'-AMP-activated protein kinase"], "gene_names": ["PRKAG1"]}, "Q9Y5Y9": {"specific_function": "Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.", "name": "Sodium channel protein type 10 subunit alpha", "drug_actions": [{"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00281"}, {"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00296"}, {"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00297"}, {"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00473"}, {"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00527"}, {"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00645"}, {"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00721"}, {"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00807"}, {"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00892"}, {"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00907"}, {"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB00961"}, {"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB01002"}, {"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB01086"}, {"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB01161"}, {"action": "INHIBITOR", "target": "Q9Y5Y9", "drug": "DB01173"}], "general_function": "Voltage-gated sodium channel activity", "in_complexes": ["Sodium channel protein"], "gene_names": ["SCN10A"]}, "P28793": {"specific_function": "Involved in the aerobic and anaerobic degradation of long-chain fatty acids via beta-oxidation cycle. Catalyzes the formation of 3-oxoacyl-CoA from enoyl-CoA via L-3-hydroxyacyl-CoA. It can also use D-3-hydroxyacyl-CoA and cis-3-enoyl-CoA as substrate.", "general_function": "Enoyl-coa hydratase activity", "gene_names": ["fadB"], "name": "Fatty acid oxidation complex subunit alpha", "drug_actions": []}, "P41250": {"specific_function": "Catalyzes the attachment of glycine to tRNA(Gly). Is also able produce diadenosine tetraphosphate (Ap4A), a universal pleiotropic signaling molecule needed for cell regulation pathways, by direct condensation of 2 ATPs.", "general_function": "Protein dimerization activity", "gene_names": ["GARS"], "name": "Glycine--tRNA ligase", "drug_actions": []}, "Q9Y5Y4": {"specific_function": "Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-protein. Receptor activation may result in pertussis toxin-sensitive decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is also implicated in mediating PTGDR2 effects. PGD2 induced receptor internalization. CRTH2 internalization can be regulated by diverse kinases such as, PKC, PKA, ADRBK1/GRK2, GPRK5/GRK5 and GRK6. Receptor activation is responsible, at least in part, in immune regulation and allergic/inflammation responses.", "general_function": "Prostaglandin j receptor activity", "gene_names": ["PTGDR2"], "name": "Prostaglandin D2 receptor 2", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "Q9Y5Y4", "drug": "DB00328"}, {"action": "ANTAGONIST", "target": "Q9Y5Y4", "drug": "DB00605"}]}, "P41252": {"general_function": "Isoleucine-trna ligase activity", "gene_names": ["IARS"], "name": "Isoleucine--tRNA ligase, cytoplasmic", "drug_actions": []}, "Q9Y5Y6": {"specific_function": "Degrades extracellular matrix. Proposed to play a role in breast cancer invasion and metastasis. Exhibits trypsin-like activity as defined by cleavage of synthetic substrates with Arg or Lys as the P1 site. Involved in the terminal differentiation of keratinocytes through prostasin (PRSS8) activation and filaggrin (FLG) processing.", "general_function": "Serine-type peptidase activity", "gene_names": ["ST14"], "name": "Suppressor of tumorigenicity 14 protein", "drug_actions": []}, "P15636": {"general_function": "Serine-type endopeptidase activity", "gene_names": [], "name": "Protease 1", "drug_actions": []}, "P12915": {"specific_function": "Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host cell receptor to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP2: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP3: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP4: Lies on the inner surface of the capsid shell. After binding to the host receptor, the capsid undergoes conformational changes. Capsid protein VP4 is released, Capsid protein VP1 N-terminus is externalized, and together, they shape a pore in the host membrane through which the viral genome is translocated into the host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP0: Component of immature procapsids, which is cleaved into capsid proteins VP4 and VP2 after maturation. Allows the capsid to remain inactive before the maturation step (By similarity).Protein 2A: Cysteine protease that cleaves viral polyprotein and specific host proteins. It is responsible for the cleavage between the P1 and P2 regions, first cleavage occurring in the polyprotein. Cleaves also the host translation initiation factor EIF4G1, in order to shut down the capped cellular mRNA translation. Inhibits the host nucleus-cytoplasm protein and RNA trafficking by cleaving host members of the nuclear pores (By similarity).Protein 2B: Plays an essential role in the virus replication cycle by acting as a viroporin. Creates a pore in the host reticulum endoplasmic and as a consequence releases Ca2+ in the cytoplasm of infected cell. In turn, high levels of cyctoplasmic calcium may trigger membrane trafficking and transport of viral ER-associated proteins to viroplasms, sites of viral genome replication (By similarity).Protein 2C: Induces and associates with structural rearrangements of intracellular membranes. Displays RNA-binding, nucleotide binding and NTPase activities. May play a role in virion morphogenesis and viral RNA encapsidation by interacting with the capsid protein VP3 (By similarity).Protein 3AB: Localizes the viral replication complex to the surface of membranous vesicles. Together with protein 3CD binds the Cis-Active RNA Element (CRE) which is involved in RNA synthesis initiation. Acts as a cofactor to stimulate the activity of 3D polymerase, maybe through a nucleid acid chaperone activity (By similarity).Protein 3A: Localizes the viral replication complex to the surface of membranous vesicles. It inhibits host cell endoplasmic reticulum-to-Golgi apparatus transport and causes the dissassembly of the Golgi complex, possibly through GBF1 interaction. This would result in depletion of MHC, trail receptors and IFN receptors at the host cell surface (By similarity).Viral protein genome-linked: acts as a primer for viral RNA replication and remains covalently bound to viral genomic RNA. VPg is uridylylated prior to priming replication into VPg-pUpU. The oriI viral genomic sequence may act as a template for this. The VPg-pUpU is then used as primer on the genomic RNA poly(A) by the RNA-dependent RNA polymerase to replicate the viral genome. VPg may be removed in the cytoplasm by an unknown enzyme termed \"unlinkase\". VPg is not cleaved off virion genomes because replicated genomic RNA are encapsidated at the site of replication (By similarity).Protein 3CD: Is involved in the viral replication complex and viral polypeptide maturation. It exhibits protease activity with a specificity and catalytic efficiency that is different from protease 3C. Protein 3CD lacks polymerase activity. The 3C domain in the context of protein 3CD may have an RNA binding activity (By similarity).Protease 3C: cleaves host DDX58/RIG-I and thus contributes to the inhibition of type I interferon production. Cleaves also host PABPC1 (By similarity).RNA-directed RNA polymerase: Replicates the viral genomic RNA on the surface of intracellular membranes. May form linear arrays of subunits that propagate along a strong head-to-tail interaction called interface-I. Covalently attaches UMP to a tyrosine of VPg, which is used to prime RNA synthesis. The positive stranded RNA genome is first replicated at virus induced membranous vesicles, creating a dsRNA genomic replication form. This dsRNA is then used as template to synthesize positive stranded RNA genomes. ss(+)RNA genomes are either translated, replicated or encapsidated (By similarity).", "general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "Q8IZS8": {"specific_function": "The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) but not T-type (CACNA1G) (By similarity).", "name": "Voltage-dependent calcium channel subunit alpha-2/delta-3", "drug_actions": [{"action": "INHIBITOR", "target": "Q8IZS8", "drug": "DB00381"}, {"action": "INHIBITOR", "target": "Q8IZS8", "drug": "DB06712"}], "general_function": "Voltage-gated ion channel activity", "in_complexes": ["Voltage-dependent calcium channel"], "gene_names": ["CACNA2D3"]}, "P00091": {"specific_function": "Cytochrome c2 is found mainly in purple, non-sulfur, photosynthetic bacteria where it functions as the electron donor to the oxidized bacteriochlorophyll in the photophosphorylation pathway. However, it may also have a role in the respiratory chain and is found in some non-photosynthetic bacteria.", "general_function": "Metal ion binding", "gene_names": ["cycA"], "name": "Cytochrome c2", "drug_actions": []}, "P28861": {"specific_function": "Transports electrons between flavodoxin or ferredoxin and NADPH. Involved in the reductive activation of cobalamin-independent methionine synthase, pyruvate formate lyase and anaerobic ribonucleotide reductase. Also protects against superoxide radicals due to methyl viologen in the presence of oxygen.", "general_function": "Oxidoreductase activity", "gene_names": ["fpr"], "name": "Ferredoxin--NADP reductase", "drug_actions": []}, "Q8Z2X8": {"specific_function": "Part of the ABC transporter complex LsrABCD involved in autoinducer 2 (AI-2) import. Binds AI-2 and delivers it to the LsrC and LsrD permeases (By similarity).", "gene_names": ["lsrB"], "name": "Autoinducer 2-binding protein LsrB", "drug_actions": []}, "P54583": {"specific_function": "Has a very high specific activity on carboxymethylcellulose.", "general_function": "Polysaccharide binding", "gene_names": [], "name": "Endoglucanase E1", "drug_actions": []}, "Q99735": {"specific_function": "Can catalyze the production of LTC4 from LTA4 and reduced glutathione. Can catalyze the conjugation of 1-chloro-2,4-dinitrobenzene with reduced glutathione.", "general_function": "Leukotriene-c4 synthase activity", "gene_names": ["MGST2"], "name": "Microsomal glutathione S-transferase 2", "drug_actions": []}, "P14169": {"specific_function": "Catalyzes the isomeration of CDP-paratose to CDP-tyvelose.", "general_function": "Cdp-abequose epimerase activity", "gene_names": ["rfbE"], "name": "CDP-paratose 2-epimerase", "drug_actions": []}, "P0A805": {"specific_function": "Responsible for the release of ribosomes from messenger RNA at the termination of protein biosynthesis. May increase the efficiency of translation by recycling ribosomes from one round of translation to another.", "general_function": "Ribosomal large subunit binding", "gene_names": ["frr"], "name": "Ribosome-recycling factor", "drug_actions": []}, "P0A552": {"specific_function": "This enzyme is involved in nucleotide metabolism:it produces dUMP, the immediate precursor of thymidine nucleotides and it decreases the intracellular concentration of dUTP so that uracil cannot be incorporated into DNA", "general_function": "Nucleotide transport and metabolism", "gene_names": ["dut"], "name": "Deoxyuridine 5'-triphosphate nucleotidohydrolase", "drug_actions": []}, "P19105": {"specific_function": "Myosin regulatory subunit that plays an important role in regulation of both smooth muscle and nonmuscle cell contractile activity via its phosphorylation. Implicated in cytokinesis, receptor capping, and cell locomotion (By similarity).", "general_function": "Calcium ion binding", "gene_names": ["MYL12A"], "name": "Myosin regulatory light chain 12A", "drug_actions": []}, "Q14416": {"specific_function": "G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization.", "general_function": "Group ii metabotropic glutamate receptor activity", "gene_names": ["GRM2"], "name": "Metabotropic glutamate receptor 2", "drug_actions": []}, "P29208": {"gene_names": ["menC"], "name": "o-succinylbenzoate synthase", "drug_actions": []}, "Q6ZMR3": {"specific_function": "Displays an lactate dehydrogenase activity. Significantly increases the transcriptional activity of JUN, when overexpressed.", "general_function": "L-lactate dehydrogenase activity", "gene_names": ["LDHAL6A"], "name": "L-lactate dehydrogenase A-like 6A", "drug_actions": []}, "Q26966": {"general_function": "Exo-alpha-sialidase activity", "gene_names": [], "name": "Trans-sialidase", "drug_actions": []}, "P0A808": {"specific_function": "Responsible for the release of ribosomes from messenger RNA at the termination of protein biosynthesis. May increase the efficiency of translation by recycling ribosomes from one round of translation to another.", "gene_names": ["frr"], "name": "Ribosome-recycling factor", "drug_actions": []}, "Q16498": {"gene_names": ["CSF2RA"], "name": "GM-CSF receptor alpha subunit", "drug_actions": []}, "P10827": {"specific_function": "Isoform Alpha-1: Nuclear hormone receptor that can act as a repressor or activator of transcription. High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine.Isoform Alpha-2: Does not bind thyroid hormone and functions as a weak dominant negative inhibitor of thyroid hormone action.", "general_function": "Zinc ion binding", "gene_names": ["THRA"], "name": "Thyroid hormone receptor alpha", "drug_actions": [{"action": "AGONIST", "target": "P10827", "drug": "DB00279"}, {"action": "AGONIST", "target": "P10827", "drug": "DB00451"}, {"action": "AGONIST", "target": "P10827", "drug": "DB00509"}, {"action": "AGONIST", "target": "P10827", "drug": "DB01583"}]}, "P10826": {"specific_function": "Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to corepressors. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function.", "general_function": "Zinc ion binding", "gene_names": ["RARB"], "name": "Retinoic acid receptor beta", "drug_actions": [{"action": "AGONIST", "target": "P10826", "drug": "DB00210"}, {"action": "AGONIST", "target": "P10826", "drug": "DB00459"}, {"action": "AGONIST", "target": "P10826", "drug": "DB00523"}, {"action": "AGONIST", "target": "P10826", "drug": "DB00799"}, {"action": "AGONIST", "target": "P10826", "drug": "DB00926"}, {"action": "AGONIST", "target": "P10826", "drug": "DB04942"}]}, "P16113": {"specific_function": "Photoactive blue light protein. Probably functions as a photoreceptor for a negative phototaxis response.", "general_function": "Photoreceptor activity", "gene_names": ["pyp"], "name": "Photoactive yellow protein", "drug_actions": []}, "P16112": {"specific_function": "This proteoglycan is a major component of extracellular matrix of cartilagenous tissues. A major function of this protein is to resist compression in cartilage. It binds avidly to hyaluronic acid via an N-terminal globular region.", "general_function": "Metal ion binding", "gene_names": ["ACAN"], "name": "Aggrecan core protein", "drug_actions": []}, "P0A8V2": {"specific_function": "DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates.", "general_function": "Ribonucleoside binding", "gene_names": ["rpoB"], "name": "DNA-directed RNA polymerase subunit beta", "drug_actions": [{"action": "INHIBITOR", "target": "P0A8V2", "drug": "DB00615"}, {"action": "INHIBITOR", "target": "P0A8V2", "drug": "DB01045"}, {"action": "INHIBITOR", "target": "P0A8V2", "drug": "DB01220"}]}, "Q9NYQ3": {"specific_function": "Catalyzes the oxidation of L-alpha-hydroxy acids as well as, more slowly, that of L-alpha-amino acids.", "general_function": "Very-long-chain-(s)-2-hydroxy-acid oxidase activity", "gene_names": ["HAO2"], "name": "Hydroxyacid oxidase 2", "drug_actions": []}, "P10828": {"specific_function": "Nuclear hormone receptor that can act as a repressor or activator of transcription. High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine.", "general_function": "Zinc ion binding", "gene_names": ["THRB"], "name": "Thyroid hormone receptor beta", "drug_actions": [{"action": "AGONIST", "target": "P10828", "drug": "DB00279"}, {"action": "AGONIST", "target": "P10828", "drug": "DB00451"}, {"action": "AGONIST", "target": "P10828", "drug": "DB00509"}, {"action": "AGONIST", "target": "P10828", "drug": "DB01583"}]}, "P16118": {"specific_function": "Synthesis and degradation of fructose 2,6-bisphosphate.", "general_function": "Identical protein binding", "gene_names": ["PFKFB1"], "name": "6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1", "drug_actions": []}, "Q9H4B7": {"specific_function": "Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity).", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["TUBB1"], "name": "Tubulin beta-1 chain", "drug_actions": [{"action": "INHIBITOR", "target": "Q9H4B7", "drug": "DB00309"}, {"action": "INHIBITOR", "target": "Q9H4B7", "drug": "DB01229"}, {"action": "INHIBITOR", "target": "Q9H4B7", "drug": "DB01394"}, {"action": "BINDER", "target": "Q9H4B7", "drug": "DB06772"}]}, "Q9KM65": {"specific_function": "Required for the synthesis of the quorum-sensing autoinducer CAI-1 ((S)-3-hydroxytridecan-4-one) which probably functions as an intragenus signal.", "general_function": "Transferase activity, transferring acyl groups", "gene_names": ["cqsA"], "name": "CAI-1 autoinducer synthase", "drug_actions": []}, "P23677": {"general_function": "Inositol-1,4,5-trisphosphate 3-kinase activity", "gene_names": ["ITPKA"], "name": "Inositol-trisphosphate 3-kinase A", "drug_actions": []}, "P07355": {"specific_function": "Calcium-regulated membrane-binding protein whose affinity for calcium is greatly enhanced by anionic phospholipids. It binds two calcium ions with high affinity. May be involved in heat-stress response. Inhibits PCSK9-enhanced LDLR degradation, probably reduces PCSK9 protein levels via a translational mechanism but also competes with LDLR for binding with PCSK9 (PubMed:18799458, PubMed:24808179, PubMed:22848640).", "general_function": "S100 protein binding", "gene_names": ["ANXA2"], "name": "Annexin A2", "drug_actions": []}, "P19320": {"specific_function": "Important in cell-cell recognition. Appears to function in leukocyte-endothelial cell adhesion. Interacts with integrin alpha-4/beta-1 (ITGA4/ITGB1) on leukocytes, and mediates both adhesion and signal transduction. The VCAM1/ITGA4/ITGB1 interaction may play a pathophysiologic role both in immune responses and in leukocyte emigration to sites of inflammation.", "general_function": "Primary amine oxidase activity", "gene_names": ["VCAM1"], "name": "Vascular cell adhesion protein 1", "drug_actions": [{"action": "INHIBITOR", "target": "P19320", "drug": "DB01136"}]}, "P07359": {"specific_function": "GP-Ib, a surface membrane protein of platelets, participates in the formation of platelet plugs by binding to the A1 domain of vWF, which is already bound to the subendothelium.", "general_function": "Thrombin receptor activity", "gene_names": ["GP1BA"], "name": "Platelet glycoprotein Ib alpha chain", "drug_actions": []}, "Q99AU2": {"general_function": "Zinc ion binding", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "Q9JZW6": {"specific_function": "Catalyzes the reversible reaction in which hydroxymethyl group from 5,10-methylenetetrahydrofolate is tranferred onto alpha-ketoisovalerate to form ketopantoate.", "general_function": "Metal ion binding", "gene_names": ["panB"], "name": "3-methyl-2-oxobutanoate hydroxymethyltransferase", "drug_actions": []}, "Q96JQ3": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["pcap"], "name": "P-selectin cytoplasmic tail-associated protein (PCAP)", "drug_actions": [{"action": "COFACTOR", "target": "Q96JQ3", "drug": "DB00114"}]}, "O43193": {"specific_function": "Receptor for motilin.", "general_function": "Growth hormone-releasing hormone receptor activity", "gene_names": ["MLNR"], "name": "Motilin receptor", "drug_actions": []}, "P11488": {"specific_function": "Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems. Transducin is an amplifier and one of the transducers of a visual impulse that performs the coupling between rhodopsin and cGMP-phosphodiesterase.", "general_function": "Signal transducer activity", "gene_names": ["GNAT1"], "name": "Guanine nucleotide-binding protein G(t) subunit alpha-1", "drug_actions": []}, "Q8GBW6": {"specific_function": "The 12S subunit specifically catalyzes the transfer of the carboxyl group of methylmalonyl CoA to the biotin of the 1.3S subunit forming propanoyl-CoA and carboxylated 1.3S-biotin.", "general_function": "Methylmalonyl-coa carboxytransferase activity", "gene_names": [], "name": "Methylmalonyl-CoA carboxyltransferase 12S subunit", "drug_actions": []}, "P11485": {"specific_function": "Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells. Likely to plays a role in the budding process through its association with lipid rafts during intracellular transport. May additionally display a raft-association independent effect on budding. Plays a role in the determination of host range restriction on replication and virulence. Sialidase activity in late endosome/lysosome traffic seems to enhance virus replication.", "general_function": "Metal ion binding", "gene_names": ["NA"], "name": "Neuraminidase", "drug_actions": [{"action": "INHIBITOR", "target": "P11485", "drug": "DB00198"}]}, "Q9HAN9": {"specific_function": "Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP. Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency. Can use triazofurin monophosphate (TrMP) as substrate. Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD(+). For the pyrophosphorolytic activity, prefers NAD(+) and NaAD as substrates and degrades NADH, nicotinic acid adenine dinucleotide phosphate (NHD) and nicotinamide guanine dinucleotide (NGD) less effectively. Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and NaADP(+). Protects against axonal degeneration following mechanical or toxic insults.", "general_function": "Nicotinate-nucleotide adenylyltransferase activity", "gene_names": ["NMNAT1"], "name": "Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1", "drug_actions": []}, "Q672W7": {"specific_function": "Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions.", "general_function": "Peptide deformylase activity", "gene_names": ["def"], "name": "Peptide deformylase", "drug_actions": []}, "P46828": {"specific_function": "Global transcriptional regulator of carbon catabolite repression (CCR) and carbon catabolite activation (CCA), which ensures optimal energy usage under diverse conditions.", "general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": ["ccpA"], "name": "Catabolite control protein A", "drug_actions": []}, "Q9UJ68": {"specific_function": "Has an important function as a repair enzyme for proteins that have been inactivated by oxidation. Catalyzes the reversible oxidation-reduction of methionine sulfoxide in proteins to methionine.", "general_function": "Peptide-methionine (s)-s-oxide reductase activity", "gene_names": ["MSRA"], "name": "Mitochondrial peptide methionine sulfoxide reductase", "drug_actions": []}, "Q6UWN8": {"specific_function": "Serine protease inhibitor selective for kallikreins. Efficiently inhibits KLK4, KLK5, KLK6, KLK7, KLK12, KLK13 and KLK14. Doesn't inhibit KLK8.", "general_function": "Serine-type endopeptidase inhibitor activity", "gene_names": ["SPINK6"], "name": "Serine protease inhibitor Kazal-type 6", "drug_actions": []}, "P26602": {"specific_function": "Removes the pyruvyl group from chorismate, with concomitant aromatization of the ring, to provide 4-hydroxybenzoate (4HB) for the ubiquinone pathway.", "general_function": "Chorismate lyase activity", "gene_names": ["ubiC"], "name": "Chorismate pyruvate-lyase", "drug_actions": []}, "Q16568": {"specific_function": "Satiety factor closely associated with the actions of leptin and neuropeptide y; this anorectic peptide inhibits both normal and starvation-induced feeding and completely blocks the feeding response induced by neuropeptide Y and regulated by leptin in the hypothalamus. It promotes neuronal development and survival in vitro.", "gene_names": ["CARTPT"], "name": "Cocaine- and amphetamine-regulated transcript protein", "drug_actions": [{"action": "AGONIST", "target": "Q16568", "drug": "DB00182"}]}, "Q5JAM2": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["ALAS1"], "name": "5-aminolevulinate synthase", "drug_actions": [{"action": "COFACTOR", "target": "Q5JAM2", "drug": "DB00114"}]}, "P05231": {"specific_function": "Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. Acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. Required for the generation of T(H)17 cells. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation.", "general_function": "Interleukin-6 receptor binding", "gene_names": ["IL6"], "name": "Interleukin-6", "drug_actions": [{"action": "ANTAGONIST", "target": "P05231", "drug": "DB01404"}, {"action": "ANTAGONIST", "target": "P05231", "drug": "DB09036"}, {"action": "ANTIBODY", "target": "P05231", "drug": "DB09036"}]}, "P0A1V8": {"specific_function": "This is an oxacillin-hydrolyzing beta-lactamase.", "general_function": "Penicillin binding", "gene_names": ["bla"], "name": "Beta-lactamase OXA-2", "drug_actions": []}, "P0A5Y6": {"specific_function": "Involved in the resistance against the antituberculosis drugs isoniazid and ethionamide", "general_function": "Lipid transport and metabolism", "gene_names": ["inhA"], "name": "Enoyl-[acyl-carrier-protein] reductase [NADH]", "drug_actions": [{"action": "ADDUCT", "target": "P0A5Y6", "drug": "DB00609"}, {"action": "ADDUCT", "target": "P0A5Y6", "drug": "DB00951"}]}, "Q9UQF2": {"specific_function": "The JNK-interacting protein (JIP) group of scaffold proteins selectively mediates JNK signaling by aggregating specific components of the MAPK cascade to form a functional JNK signaling module. Required for JNK activation in response to excitotoxic stress. Cytoplasmic MAPK8IP1 causes inhibition of JNK-regulated activity by retaining JNK in the cytoplasm and inhibiting JNK phosphorylation of c-Jun. May also participate in ApoER2-specific reelin signaling. Directly, or indirectly, regulates GLUT2 gene expression and beta-cell function. Appears to have a role in cell signaling in mature and developing nerve terminals. May function as a regulator of vesicle transport, through interactions with the JNK-signaling components and motor proteins (By similarity). Functions as an anti-apoptotic protein and whose level seems to influence the beta-cell death or survival response.", "general_function": "Protein kinase inhibitor activity", "gene_names": ["MAPK8IP1"], "name": "C-Jun-amino-terminal kinase-interacting protein 1", "drug_actions": []}, "Q8DP79": {"specific_function": "Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions.", "general_function": "Peptide deformylase activity", "gene_names": ["def"], "name": "Peptide deformylase", "drug_actions": []}, "P48065": {"specific_function": "Transports betaine and GABA. May have a role in regulation of GABAergic transmission in the brain through the reuptake of GABA into presynaptic terminals, as well as in osmotic regulation.", "general_function": "Neurotransmitter:sodium symporter activity", "gene_names": ["SLC6A12"], "name": "Sodium- and chloride-dependent betaine transporter", "drug_actions": [{"action": "INHIBITOR", "target": "P48065", "drug": "DB08848"}]}, "Q9NZ42": {"specific_function": "Essential subunit of the gamma-secretase complex, an endoprotease complex that catalyzes the intramembrane cleavage of integral membrane proteins such as Notch receptors and APP (beta-amyloid precursor protein). Probably represents the last step of maturation of gamma-secretase, facilitating endoproteolysis of presenilin and conferring gamma-secretase activity.", "gene_names": ["PSENEN"], "name": "Gamma-secretase subunit PEN-2", "drug_actions": []}, "Q9UDX3": {"specific_function": "Probable hydrophobic ligand-binding protein; may play a role in the transport of hydrophobic ligands like tocopherol, squalene and phospholipids.", "general_function": "Transporter activity", "gene_names": ["SEC14L4"], "name": "SEC14-like protein 4", "drug_actions": []}, "P19926": {"specific_function": "Absolutely required for the growth of E.coli in a high-phosphate medium containing G-1-P as the sole carbon source.", "general_function": "Glucose-1-phosphatase activity", "gene_names": ["agp"], "name": "Glucose-1-phosphatase", "drug_actions": []}, "Q9UDX4": {"specific_function": "Probable hydrophobic ligand-binding protein; may play a role in the transport of hydrophobic ligands like tocopherol, squalene and phospholipids.", "general_function": "Transporter activity", "gene_names": ["SEC14L3"], "name": "SEC14-like protein 3", "drug_actions": []}, "P36946": {"specific_function": "Catalyzes the interconversion of beta-pyran and beta-furan forms of D-ribose.", "general_function": "Monosaccharide binding", "gene_names": ["rbsD"], "name": "D-ribose pyranase", "drug_actions": []}, "P44469": {"specific_function": "Cell wall formation; PBP-2 is responsible for the determination of the rod shape of the cell. Its synthesize cross-linked peptidoglycan from the lipid intermediates (By similarity).", "general_function": "Penicillin binding", "gene_names": ["mrdA"], "name": "Penicillin-binding protein 2", "drug_actions": [{"action": "INHIBITOR", "target": "P44469", "drug": "DB00303"}, {"action": "INHIBITOR", "target": "P44469", "drug": "DB00671"}]}, "P0CI79": {"specific_function": "Provides the sole de novo source of dTMP for DNA biosynthesis.", "general_function": "Thymidylate synthase activity", "gene_names": ["thyA1"], "name": "Thymidylate synthase 1", "drug_actions": []}, "Q93RD8": {"general_function": "Electron transporter, transferring electrons within the cyclic electron transport pathway of photosynthesis activity", "gene_names": ["puhA"], "name": "H subunit of photosynthetic reaction center complex", "drug_actions": []}, "Q06203": {"general_function": "Metal ion binding", "gene_names": ["PPAT"], "name": "Amidophosphoribosyltransferase", "drug_actions": [{"action": "PRODUCT OF", "target": "Q06203", "drug": "DB00130"}]}, "Q9AGP8": {"specific_function": "Catalyzes the oxidative demethylation of N,N-dimethylglycine to yield sarcosine, formaldehyde and hydrogen peroxide. The oxidation of dimethylglycine is coupled to the synthesis of 5,10-methylenetetrahydrofolate through an unusual substrate channeling mechanism. This channeling occurs by nonbiased diffusion of the iminium intermediate through a large solvent cavity connecting active site 1 (N-terminus) and active site 2 (C-terminus). The synthesis of 5,10-methylenetetrahydrofolate (at active site 2) prevents the accumulation of formaldehyde, formed by hydrolysis of the iminium intermediate product (at active site 1). Does not oxidize sarcosine.", "general_function": "Nucleotide binding", "gene_names": ["dmg"], "name": "Dimethylglycine oxidase", "drug_actions": []}, "P25553": {"specific_function": "Acts on lactaldehyde as well as other aldehydes.", "general_function": "Succinate-semialdehyde dehydrogenase [nad(p)+] activity", "gene_names": ["aldA"], "name": "Lactaldehyde dehydrogenase", "drug_actions": []}, "P62219": {"gene_names": ["recA"], "name": "Protein RecA", "drug_actions": []}, "Q494W8": {"general_function": "Extracellular ligand-gated ion channel activity", "gene_names": ["CHRFAM7A"], "name": "CHRNA7-FAM7A fusion protein", "drug_actions": []}, "P48745": {"specific_function": "Immediate-early protein playing a role in various cellular processes including proliferation, adhesion, migration, differentiation and survival (PubMed:15181016, PubMed:15611078, PubMed:12695522, PubMed:21344378, PubMed:12050162). Acts by binding to integrins or membrane receptors such as NOTCH1 (PubMed:12695522, PubMed:21344378, PubMed:15611078). Essential regulator of hematopoietic stem and progenitor cell function (PubMed:17463287). Inhibits myogenic differentiation through the activation of Notch-signaling pathway (PubMed:12050162). Inhibits vascular smooth muscle cells proliferation by increasing expression of cell-cycle regulators such as CDKN2B or CDKN1A independently of TGFB1 signaling (PubMed:20139355). Ligand of integrins ITGAV:ITGB3 and ITGA5:ITGB1, acts directly upon endothelial cells to stimulate pro-angiogenic activities and induces angiogenesis. In endothelial cells, supports cell adhesion, induces directed cell migration (chemotaxis) and promotes cell survival (PubMed:12695522). Plays also a role in cutaneous wound healing acting as integrin receptor ligand. Supports skin fibroblast adhesion through ITGA5:ITGB1 and ITGA6:ITGB1 and induces fibroblast chemotaxis through ITGAV:ITGB5. Seems to enhance bFGF-induced DNA synthesis in fibroblasts (PubMed:15611078). Involved in bone regeneration as a negative regulator (By similarity). Enhances the articular chondrocytic phenotype, whereas it repressed the one representing endochondral ossification (PubMed:21871891). Impairs pancreatic beta-cell function, inhibits beta-cell proliferation and insulin secretion (By similarity). Plays a role as negative regulator of endothelial pro-inflammatory activation reducing monocyte adhesion, its anti-inflammatory effects occur secondary to the inhibition of NF-kappaB signaling pathway (PubMed:21063504). Contributes to the control and coordination of inflammatory processes in atherosclerosis (By similarity). Attenuates inflammatory pain through regulation of IL1B- and TNF-induced MMP9, MMP2 and CCL2 expression. Inhibits MMP9 expression through ITGB1 engagement (PubMed:21871891).", "general_function": "Notch binding", "gene_names": ["NOV"], "name": "Protein NOV homolog", "drug_actions": []}, "P10153": {"specific_function": "This is a non-secretory ribonuclease. It is a pyrimidine specific nuclease with a slight preference for U. Cytotoxin and helminthotoxin. Selectively chemotactic for dendritic cells. Possesses a wide variety of biological activities.", "general_function": "Ribonuclease activity", "gene_names": ["RNASE2"], "name": "Non-secretory ribonuclease", "drug_actions": []}, "P36542": {"specific_function": "Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain. F-type ATPases consist of two structural domains, F(1) - containing the extramembraneous catalytic core, and F(0) - containing the membrane proton channel, linked together by a central stalk and a peripheral stalk. During catalysis, ATP synthesis in the catalytic domain of F(1) is coupled via a rotary mechanism of the central stalk subunits to proton translocation. Part of the complex F(1) domain and the central stalk which is part of the complex rotary element. The gamma subunit protrudes into the catalytic domain formed of alpha(3)beta(3). Rotation of the central stalk against the surrounding alpha(3)beta(3) subunits leads to hydrolysis of ATP in three separate catalytic sites on the beta subunits.", "general_function": "Transmembrane transporter activity", "gene_names": ["ATP5C1"], "name": "ATP synthase subunit gamma, mitochondrial", "drug_actions": []}, "Q56313": {"specific_function": "The RuvA-RuvB complex in the presence of ATP renatures cruciform structure in supercoiled DNA with palindromic sequence, indicating that it may promote strand exchange reactions in homologous recombination. RuvAB is a helicase that mediates the Holliday junction migration by localized denaturation and reannealing.", "general_function": "Four-way junction helicase activity", "gene_names": ["ruvB"], "name": "Holliday junction ATP-dependent DNA helicase RuvB", "drug_actions": []}, "Q56310": {"specific_function": "Involved in the transmission of sensory signals from the chemoreceptors to the flagellar motors. CheA is autophosphorylated; it can transfer its phosphate group to either CheB or CheY (By similarity).", "general_function": "Phosphorelay sensor kinase activity", "gene_names": ["cheA"], "name": "Chemotaxis protein CheA", "drug_actions": []}, "Q9Y5K3": {"specific_function": "Controls phosphatidylcholine synthesis.", "general_function": "Choline-phosphate cytidylyltransferase activity", "gene_names": ["PCYT1B"], "name": "Choline-phosphate cytidylyltransferase B", "drug_actions": [{"action": "PRODUCT OF", "target": "Q9Y5K3", "drug": "DB00122"}]}, "P36544": {"specific_function": "After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.", "general_function": "Toxic substance binding", "gene_names": ["CHRNA7"], "name": "Neuronal acetylcholine receptor subunit alpha-7", "drug_actions": [{"action": "AGONIST", "target": "P36544", "drug": "DB00184"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00237"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00241"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00306"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00463"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00514"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00599"}, {"action": "ALLOSTERIC MODULATOR", "target": "P36544", "drug": "DB00674"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00794"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB00849"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB01174"}, {"action": "AGONIST", "target": "P36544", "drug": "DB01273"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB01351"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB01352"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB01353"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB01354"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB01355"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB01483"}, {"action": "ANTAGONIST", "target": "P36544", "drug": "DB01496"}, {"action": "AGONIST", "target": "P36544", "drug": "DB09028"}]}, "P15104": {"specific_function": "This enzyme has 2 functions: it catalyzes the production of glutamine and 4-aminobutanoate (gamma-aminobutyric acid, GABA), the latter in a pyridoxal phosphate-independent manner (By similarity). Essential for proliferation of fetal skin fibroblasts.", "general_function": "Manganese ion binding", "gene_names": ["GLUL"], "name": "Glutamine synthetase", "drug_actions": [{"action": "PRODUCT OF", "target": "P15104", "drug": "DB00130"}]}, "P14543": {"specific_function": "Sulfated glycoprotein widely distributed in basement membranes and tightly associated with laminin. Also binds to collagen IV and perlecan. It probably has a role in cell-extracellular matrix interactions.", "general_function": "Proteoglycan binding", "gene_names": ["NID1"], "name": "Nidogen-1", "drug_actions": []}, "Q96KC2": {"specific_function": "Binds and exchanges GTP and GDP.", "general_function": "Gtp binding", "gene_names": ["ARL5B"], "name": "ADP-ribosylation factor-like protein 5B", "drug_actions": []}, "P61497": {"specific_function": "Involved in repair of UV radiation-induced DNA damage. Catalyzes the light-dependent monomerization (300-600 nm) of cyclobutyl pyrimidine dimers (in cis-syn configuration), which are formed between adjacent bases on the same DNA strand upon exposure to ultraviolet radiation (By similarity).", "general_function": "Nucleotide binding", "gene_names": ["phr"], "name": "Deoxyribodipyrimidine photo-lyase", "drug_actions": []}, "P31949": {"specific_function": "Facilitates the differentiation and the cornification of keratinocytes.", "general_function": "S100 protein binding", "gene_names": ["S100A11"], "name": "Protein S100-A11", "drug_actions": []}, "Q16706": {"specific_function": "Catalyzes the first committed step in the biosynthesis of complex N-glycans. It controls conversion of high mannose to complex N-glycans; the final hydrolytic step in the N-glycan maturation pathway.", "general_function": "Zinc ion binding", "gene_names": ["MAN2A1"], "name": "Alpha-mannosidase 2", "drug_actions": []}, "P12268": {"specific_function": "Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in the development of malignancy and the growth progression of some tumors.", "name": "Inosine-5'-monophosphate dehydrogenase 2", "drug_actions": [{"action": "INHIBITOR", "target": "P12268", "drug": "DB00688"}, {"action": "INHIBITOR", "target": "P12268", "drug": "DB01024"}, {"action": "INHIBITOR", "target": "P12268", "drug": "DB01033"}], "general_function": "Rna binding", "in_complexes": ["Inosine-5'-monophosphate dehydrogenase"], "gene_names": ["IMPDH2"]}, "Q9WYV8": {"specific_function": "Methylates the class 1 translation termination release factors RF1/PrfA and RF2/PrfB on the glutamine residue of the universally conserved GGQ motif.", "general_function": "Protein-glutamine n-methyltransferase activity", "gene_names": ["prmC"], "name": "Release factor glutamine methyltransferase", "drug_actions": []}, "P80561": {"specific_function": "An exopeptidase specific for larger hydrophobic amino acids (especially leucine), no cleavage occurs if the next residue is proline (PubMed:8444149).", "general_function": "Serine-type endopeptidase activity", "gene_names": [], "name": "Aminopeptidase S", "drug_actions": []}, "Q9NR33": {"specific_function": "May play a role in allowing polymerase epsilon to carry out its replication and/or repair function.", "general_function": "Dna-directed dna polymerase activity", "gene_names": ["POLE4"], "name": "DNA polymerase epsilon subunit 4", "drug_actions": [{"action": "INHIBITOR", "target": "Q9NR33", "drug": "DB00242"}]}, "P34896": {"specific_function": "Interconversion of serine and glycine.", "general_function": "Serine binding", "gene_names": ["SHMT1"], "name": "Serine hydroxymethyltransferase, cytosolic", "drug_actions": [{"action": "COFACTOR", "target": "P34896", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P34896", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P34896", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P34896", "drug": "DB00116"}, {"action": "COFACTOR", "target": "P34896", "drug": "DB00116"}, {"action": "COFACTOR", "target": "P34896", "drug": "DB00116"}, {"action": "INHIBITOR", "target": "P34896", "drug": "DB01055"}]}, "P34897": {"specific_function": "Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Required to prevent uracil accumulation in mtDNA. Interconversion of serine and glycine. Associates with mitochondrial DNA.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["SHMT2"], "name": "Serine hydroxymethyltransferase, mitochondrial", "drug_actions": [{"action": "COFACTOR", "target": "P34897", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P34897", "drug": "DB00114"}, {"action": "COFACTOR", "target": "P34897", "drug": "DB00116"}, {"action": "COFACTOR", "target": "P34897", "drug": "DB00116"}]}, "A3FMN7": {"general_function": "Endonuclease activity", "gene_names": ["bpuJIR"], "name": "Restriction endonuclease R.BpuJI", "drug_actions": []}, "Q9RYA6": {"gene_names": ["menC"], "name": "o-succinylbenzoate synthase", "drug_actions": []}, "P07101": {"specific_function": "Plays an important role in the physiology of adrenergic neurons.", "general_function": "Tyrosine 3-monooxygenase activity", "gene_names": ["TH"], "name": "Tyrosine 3-monooxygenase", "drug_actions": [{"action": "BINDER", "target": "P07101", "drug": "DB00120"}, {"action": "BINDER", "target": "P07101", "drug": "DB00135"}, {"action": "COFACTOR", "target": "P07101", "drug": "DB00360"}, {"action": "BINDER", "target": "P07101", "drug": "DB00765"}]}, "P40616": {"specific_function": "GTP-binding protein that has very low efficiency as allosteric activator of the cholera toxin catalytic subunit, an ADP-ribosyltransferase. Can activate phospholipase D with very low efficiency. Important for normal function of the Golgi apparatus.", "general_function": "Protein domain specific binding", "gene_names": ["ARL1"], "name": "ADP-ribosylation factor-like protein 1", "drug_actions": []}, "O34453": {"specific_function": "Catalyzes the production of nitric oxide.", "general_function": "Nitric-oxide synthase activity", "gene_names": ["nos"], "name": "Nitric oxide synthase oxygenase", "drug_actions": []}, "P07108": {"specific_function": "Binds medium- and long-chain acyl-CoA esters with very high affinity and may function as an intracellular carrier of acyl-CoA esters. It is also able to displace diazepam from the benzodiazepine (BZD) recognition site located on the GABA type A receptor. It is therefore possible that this protein also acts as a neuropeptide to modulate the action of the GABA receptor.", "general_function": "Protein dimerization activity", "gene_names": ["DBI"], "name": "Acyl-CoA-binding protein", "drug_actions": []}, "O34450": {"specific_function": "Involved in the first committed step in the biosynthesis of amino-sugar-nucleotides. Catalyzes the hydrolysis of the N-acetyl group of N-acetylglucosamine-6-phosphate (GlcNAc-6-P) to yield glucosamine 6-phosphate and acetate.", "general_function": "Protein homodimerization activity", "gene_names": ["nagA"], "name": "N-acetylglucosamine-6-phosphate deacetylase", "drug_actions": []}, "P69054": {"specific_function": "Membrane-anchoring subunit of succinate dehydrogenase (SDH).", "general_function": "Ubiquinone binding", "gene_names": ["sdhC"], "name": "Succinate dehydrogenase cytochrome b556 subunit", "drug_actions": []}, "P06400": {"specific_function": "Key regulator of entry into cell division that acts as a tumor suppressor. Promotes G0-G1 transition when phosphorylated by CDK3/cyclin-C. Acts as a transcription repressor of E2F1 target genes. The underphosphorylated, active form of RB1 interacts with E2F1 and represses its transcription activity, leading to cell cycle arrest. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases SUV39H1, SUV420H1 and SUV420H2, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Inhibits the intrinsic kinase activity of TAF1. Mediates transcriptional repression by SMARCA4/BRG1 by recruiting a histone deacetylase (HDAC) complex to the c-FOS promoter. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex (By similarity). In case of viral infections, interactions with SV40 large T antigen, HPV E7 protein or adenovirus E1A protein induce the disassembly of RB1-E2F1 complex thereby disrupting RB1's activity.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["RB1"], "name": "Retinoblastoma-associated protein", "drug_actions": []}, "P06401": {"specific_function": "The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor isoform B (PRB) is involved activation of c-SRC/MAPK signaling on hormone stimulation.Isoform A: inactive in stimulating c-Src/MAPK signaling on hormone stimulation.Isoform 4: Increases mitochondrial membrane potential and cellular respiration upon stimulation by progesterone.", "general_function": "Zinc ion binding", "gene_names": ["PGR"], "name": "Progesterone receptor", "drug_actions": [{"action": "AGONIST", "target": "P06401", "drug": "DB00294"}, {"action": "AGONIST", "target": "P06401", "drug": "DB00304"}, {"action": "AGONIST", "target": "P06401", "drug": "DB00351"}, {"action": "BINDER", "target": "P06401", "drug": "DB00367"}, {"action": "AGONIST", "target": "P06401", "drug": "DB00378"}, {"action": "AGONIST", "target": "P06401", "drug": "DB00396"}, {"action": "AGONIST", "target": "P06401", "drug": "DB00421"}, {"action": "AGONIST", "target": "P06401", "drug": "DB00588"}, {"action": "AGONIST", "target": "P06401", "drug": "DB00603"}, {"action": "AGONIST", "target": "P06401", "drug": "DB00717"}, {"action": "AGONIST", "target": "P06401", "drug": "DB00823"}, {"action": "ANTAGONIST", "target": "P06401", "drug": "DB00834"}, {"action": "AGONIST", "target": "P06401", "drug": "DB00957"}, {"action": "AGONIST", "target": "P06401", "drug": "DB01395"}, {"action": "AGONIST", "target": "P06401", "drug": "DB01406"}, {"action": "AGONIST", "target": "P06401", "drug": "DB01431"}, {"action": "AGONIST", "target": "P06401", "drug": "DB04787"}, {"action": "AGONIST", "target": "P06401", "drug": "DB06713"}, {"action": "MODULATOR", "target": "P06401", "drug": "DB08867"}]}, "P51511": {"specific_function": "Endopeptidase that degrades various components of the extracellular matrix. May activate progelatinase A.", "general_function": "Zinc ion binding", "gene_names": ["MMP15"], "name": "Matrix metalloproteinase-15", "drug_actions": [{"action": "INHIBITOR", "target": "P51511", "drug": "DB00786"}]}, "P41743": {"specific_function": "Calcium- and diacylglycerol-independent serine/ threonine-protein kinase that plays a general protective role against apoptotic stimuli, is involved in NF-kappa-B activation, cell survival, differentiation and polarity, and contributes to the regulation of microtubule dynamics in the early secretory pathway. Is necessary for BCR-ABL oncogene-mediated resistance to apoptotic drug in leukemia cells, protecting leukemia cells against drug-induced apoptosis. In cultured neurons, prevents amyloid beta protein-induced apoptosis by interrupting cell death process at a very early step. In glioblastoma cells, may function downstream of phosphatidylinositol 3-kinase (PI(3)K) and PDPK1 in the promotion of cell survival by phosphorylating and inhibiting the pro-apoptotic factor BAD. Can form a protein complex in non-small cell lung cancer (NSCLC) cells with PARD6A and ECT2 and regulate ECT2 oncogenic activity by phosphorylation, which in turn promotes transformed growth and invasion. In response to nerve growth factor (NGF), acts downstream of SRC to phosphorylate and activate IRAK1, allowing the subsequent activation of NF-kappa-B and neuronal cell survival. Functions in the organization of the apical domain in epithelial cells by phosphorylating EZR. This step is crucial for activation and normal distribution of EZR at the early stages of intestinal epithelial cell differentiation. Forms a protein complex with LLGL1 and PARD6B independently of PARD3 to regulate epithelial cell polarity. Plays a role in microtubule dynamics in the early secretory pathway through interaction with RAB2A and GAPDH and recruitment to vesicular tubular clusters (VTCs). In human coronary artery endothelial cells (HCAEC), is activated by saturated fatty acids and mediates lipid-induced apoptosis.", "name": "Protein kinase C iota type", "drug_actions": [], "general_function": "Protein serine/threonine kinase activity", "in_complexes": ["Protein kinase C"], "gene_names": ["PRKCI"]}, "Q96C86": {"specific_function": "Decapping scavenger enzyme that catalyzes the cleavage of a residual cap structure following the degradation of mRNAs by the 3'->5' exosome-mediated mRNA decay pathway. Hydrolyzes cap analog structures like 7-methylguanosine nucleoside triphosphate (m7GpppG) with up to 10 nucleotide substrates (small capped oligoribonucleotides) and specifically releases 5'-phosphorylated RNA fragments and 7-methylguanosine monophosphate (m7GMP). Cleaves cap analog structures like tri-methyl guanosine nucleoside triphosphate (m3(2,2,7)GpppG) with very poor efficiency. Does not hydrolyze unmethylated cap analog (GpppG) and shows no decapping activity on intact m7GpppG-capped mRNA molecules longer than 25 nucleotides. Does not hydrolyze 7-methylguanosine diphosphate (m7GDP) to m7GMP (PubMed:22985415). May also play a role in the 5'->3 mRNA decay pathway; m7GDP, the downstream product released by the 5'->3' mRNA mediated decapping activity, may be also converted by DCPS to m7GMP (PubMed:14523240). Binds to m7GpppG and strongly to m7GDP. Plays a role in first intron splicing of pre-mRNAs. Inhibits activation-induced cell death.", "general_function": "Rna 7-methylguanosine cap binding", "gene_names": ["DCPS"], "name": "m7GpppX diphosphatase", "drug_actions": []}, "Q5G940": {"specific_function": "Involved in unsaturated fatty acids biosynthesis. Catalyzes the dehydration of short chain beta-hydroxyacyl-ACPs and long chain saturated and unsaturated beta-hydroxyacyl-ACPs.Involved in unsaturated fatty acids biosynthesis. Catalyzes the dehydration of short chain beta-hydroxyacyl-ACPs and long chain saturated and unsaturated beta-hydroxyacyl-ACPs (By similarity).", "general_function": "3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase activity", "gene_names": ["fabZ"], "name": "3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ", "drug_actions": []}, "P50579": {"specific_function": "Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). The catalytic activity of human METAP2 toward Met-Val peptides is consistently two orders of magnitude higher than that of METAP1, suggesting that it is responsible for processing proteins containing N-terminal Met-Val and Met-Thr sequences in vivo.Protects eukaryotic initiation factor EIF2S1 from translation-inhibiting phosphorylation by inhibitory kinases such as EIF2AK2/PKR and EIF2AK1/HCR. Plays a critical role in the regulation of protein synthesis.", "general_function": "Poly(a) rna binding", "gene_names": ["METAP2"], "name": "Methionine aminopeptidase 2", "drug_actions": [{"action": "PRODUCT OF", "target": "P50579", "drug": "DB00134"}, {"action": "INHIBITOR", "target": "P50579", "drug": "DB01422"}, {"action": "LIGAND", "target": "P50579", "drug": "DB02640"}]}, "P09960": {"specific_function": "Epoxide hydrolase that catalyzes the final step in the biosynthesis of the proinflammatory mediator leukotriene B4. Has also aminopeptidase activity.", "general_function": "Zinc ion binding", "gene_names": ["LTA4H"], "name": "Leukotriene A-4 hydrolase", "drug_actions": []}, "Q9UNN8": {"specific_function": "Binds activated protein C. Enhances protein C activation by the thrombin-thrombomodulin complex; plays a role in the protein C pathway controlling blood coagulation.", "general_function": "Receptor activity", "gene_names": ["PROCR"], "name": "Endothelial protein C receptor", "drug_actions": []}, "P43876": {"specific_function": "Involved in the biosynthesis of the chorismate, which leads to the biosynthesis of aromatic amino acids. Catalyzes the reversible NADPH linked reduction of 3-dehydroshikimate (DHSA) to yield shikimate (SA).", "general_function": "Shikimate 3-dehydrogenase (nadp+) activity", "gene_names": ["aroE"], "name": "Shikimate dehydrogenase (NADP(+))", "drug_actions": []}, "Q8DW21": {"general_function": "Oxidoreductase activity", "gene_names": [], "name": "Uncharacterized protein", "drug_actions": []}, "P84139": {"specific_function": "Catalyzes the reversible transfer of the terminal phosphate group between ATP and AMP. Plays an important role in cellular energy homeostasis and in adenine nucleotide metabolism.", "general_function": "Metal ion binding", "gene_names": ["adk"], "name": "Adenylate kinase", "drug_actions": []}, "P0A6E4": {"general_function": "Atp binding", "gene_names": ["argG"], "name": "Argininosuccinate synthase", "drug_actions": []}, "P12461": {"general_function": "Thymidylate synthase activity", "gene_names": ["TMP1"], "name": "Thymidylate synthase", "drug_actions": [{"action": "INHIBITOR", "target": "P12461", "drug": "DB01099"}]}, "Q9NQ25": {"specific_function": "Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform 1 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway (PubMed:11698418). Positively regulates NK cell functions by a mechanism dependent on phosphorylated SH2D1B. Downstream signaling implicates PLCG1, PLCG2 and PI3K (PubMed:16339536). In addition to heterotypic NK cells-target cells interactions also homotypic interactions between NK cells may contribute to activation. However, in the absence of SH2D1B, inhibits NK cell function. Acts also inhibitory in T-cells (By similarity). May play a role in lymphocyte adhesion (PubMed:11802771). In LPS-activated monocytes negatively regulates production of proinflammatory cytokines (PubMed:23695528).Isoform 3 does not mediate any NK cell activation.", "gene_names": ["SLAMF7"], "name": "SLAM family member 7", "drug_actions": []}, "P12314": {"specific_function": "High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.", "general_function": "Receptor signaling protein activity", "gene_names": ["FCGR1A"], "name": "High affinity immunoglobulin gamma Fc receptor I", "drug_actions": [{"action": "ANTAGONIST", "target": "P12314", "drug": "DB00028"}, {"action": "ANTAGONIST", "target": "P12314", "drug": "DB00707"}, {"action": "ANTIBODY", "target": "P12314", "drug": "DB00992"}]}, "P50607": {"specific_function": "Functions in signal transduction from heterotrimeric G protein-coupled receptors. Binds to membranes containing phosphatidylinositol 4,5-bisphosphate. Can bind DNA (in vitro). May contribute to the regulation of transcription in the nucleus. Could be involved in the hypothalamic regulation of body weight (By similarity). Contribute to stimulation of phagocytosis of apoptotic retinal pigment epithelium (RPE) cells and macrophages.", "general_function": "Protein complex binding", "gene_names": ["TUB"], "name": "Tubby protein homolog", "drug_actions": []}, "Q6NVY1": {"specific_function": "Hydrolyzes 3-hydroxyisobutyryl-CoA (HIBYL-CoA), a saline catabolite. Has high activity toward isobutyryl-CoA. Could be an isobutyryl-CoA dehydrogenase that functions in valine catabolism. Also hydrolyzes 3-hydroxypropanoyl-CoA.", "general_function": "Hydro-lyase activity", "gene_names": ["HIBCH"], "name": "3-hydroxyisobutyryl-CoA hydrolase, mitochondrial", "drug_actions": []}, "P31224": {"specific_function": "AcrA-AcrB-AcrZ-TolC is a drug efflux protein complex with broad substrate specificity that uses the proton motive force to export substrates.Involved in contact-dependent growth inhibition (CDI), acts downstream of BamA, the receptor for CDI. Its role in CDI is independent of the AcrA-AcrB-TolC efflux pump complex.", "general_function": "Identical protein binding", "gene_names": ["acrB"], "name": "Multidrug efflux pump subunit AcrB", "drug_actions": []}, "P30085": {"specific_function": "Catalyzes the phosphorylation of pyrimidine nucleoside monophosphates at the expense of ATP. Plays an important role in de novo pyrimidine nucleotide biosynthesis. Has preference for UMP and CMP as phosphate acceptors. Also displays broad nucleoside diphosphate kinase activity.", "general_function": "Uridylate kinase activity", "gene_names": ["CMPK1"], "name": "UMP-CMP kinase", "drug_actions": [{"action": "INHIBITOR", "target": "P30085", "drug": "DB00441"}]}, "P30084": {"specific_function": "Straight-chain enoyl-CoA thioesters from C4 up to at least C16 are processed, although with decreasing catalytic rate.", "general_function": "Enoyl-coa hydratase activity", "gene_names": ["ECHS1"], "name": "Enoyl-CoA hydratase, mitochondrial", "drug_actions": []}, "P12319": {"specific_function": "Binds to the Fc region of immunoglobulins epsilon. High affinity receptor. Responsible for initiating the allergic response. Binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators (such as histamine) responsible for the manifestations of allergy. The same receptor also induces the secretion of important lymphokines.", "general_function": "Ige receptor activity", "gene_names": ["FCER1A"], "name": "High affinity immunoglobulin epsilon receptor subunit alpha", "drug_actions": [{"action": "AGONIST", "target": "P12319", "drug": "DB00895"}]}, "P12318": {"specific_function": "Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.", "gene_names": ["FCGR2A"], "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "drug_actions": [{"action": "ANTAGONIST", "target": "P12318", "drug": "DB00028"}]}, "P94182": {"general_function": "Nucleotide binding", "gene_names": ["cyaB2"], "name": "Adenylate cyclase", "drug_actions": []}, "P06746": {"specific_function": "Repair polymerase that plays a key role in base-excision repair. Has 5'-deoxyribose-5-phosphate lyase (dRP lyase) activity that removes the 5' sugar phosphate and also acts as a DNA polymerase that adds one nucleotide to the 3' end of the arising single-nucleotide gap. Conducts 'gap-filling' DNA synthesis in a stepwise distributive fashion rather than in a processive fashion as for other DNA polymerases.", "general_function": "Microtubule binding", "gene_names": ["POLB"], "name": "DNA polymerase beta", "drug_actions": [{"action": "INHIBITOR", "target": "P06746", "drug": "DB00987"}]}, "P50597": {"specific_function": "Phosphorolytic exoribonuclease that removes nucleotide residues following the -CCA terminus of tRNA and adds nucleotides to the ends of RNA molecules by using nucleoside diphosphates as substrates.", "general_function": "Trna-specific ribonuclease activity", "gene_names": ["rph"], "name": "Ribonuclease PH", "drug_actions": []}, "P06744": {"specific_function": "Besides it's role as a glycolytic enzyme, mammalian GPI can function as a tumor-secreted cytokine and an angiogenic factor (AMF) that stimulates endothelial cell motility. GPI is also a neurotrophic factor (Neuroleukin) for spinal and sensory neurons.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["GPI"], "name": "Glucose-6-phosphate isomerase", "drug_actions": []}, "P0CG48": {"specific_function": "Ubiquitin: Exists either covalently attached to another protein, or free (unanchored). When covalently bound, it is conjugated to target proteins via an isopeptide bond either as a monomer (monoubiquitin), a polymer linked via different Lys residues of the ubiquitin (polyubiquitin chains) or a linear polymer linked via the initiator Met of the ubiquitin (linear polyubiquitin chains). Polyubiquitin chains, when attached to a target protein, have different functions depending on the Lys residue of the ubiquitin that is linked: Lys-6-linked may be involved in DNA repair; Lys-11-linked is involved in ERAD (endoplasmic reticulum-associated degradation) and in cell-cycle regulation; Lys-29-linked is involved in lysosomal degradation; Lys-33-linked is involved in kinase modification; Lys-48-linked is involved in protein degradation via the proteasome; Lys-63-linked is involved in endocytosis, DNA-damage responses as well as in signaling processes leading to activation of the transcription factor NF-kappa-B. Linear polymer chains formed via attachment by the initiator Met lead to cell signaling. Ubiquitin is usually conjugated to Lys residues of target proteins, however, in rare cases, conjugation to Cys or Ser residues has been observed. When polyubiquitin is free (unanchored-polyubiquitin), it also has distinct roles, such as in activation of protein kinases, and in signaling.", "general_function": "Protease binding", "gene_names": ["UBC"], "name": "Polyubiquitin-C", "drug_actions": []}, "Q51793": {"specific_function": "Involved in the biosynthesis of the antibiotic phenazine, a nitrogen-containing heterocyclic molecule having important roles in virulence, competition and biological control. Probably catalyzes the final step in the conversion of trans-2,3-dihydro-3-hydroxyanthranilic acid (DHHA) to phenazine-1-carboxylic acid (PCA).", "general_function": "Pyridoxamine-phosphate oxidase activity", "gene_names": ["phzG"], "name": "Phenazine biosynthesis protein PhzG", "drug_actions": []}, "Q51792": {"specific_function": "Isomerase that catalyzes the condensation of two molecules of trans-2,3-dihydro-3-hydroxyanthranilic acid (DHHA) into the phenazine ring system. The final product is not yet known.", "general_function": "Isomerase activity", "gene_names": ["phzF"], "name": "Trans-2,3-dihydro-3-hydroxyanthranilate isomerase", "drug_actions": []}, "P06968": {"specific_function": "This enzyme is involved in nucleotide metabolism: it produces dUMP, the immediate precursor of thymidine nucleotides and it decreases the intracellular concentration of dUTP so that uracil cannot be incorporated into DNA.", "general_function": "Magnesium ion binding", "gene_names": ["dut"], "name": "Deoxyuridine 5'-triphosphate nucleotidohydrolase", "drug_actions": []}, "P47989": {"specific_function": "Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Has also low oxidase activity towards aldehydes (in vitro).", "general_function": "Xanthine oxidase activity", "gene_names": ["XDH"], "name": "Xanthine dehydrogenase/oxidase", "drug_actions": [{"action": "INHIBITOR", "target": "P47989", "drug": "DB00437"}, {"action": "INHIBITOR", "target": "P47989", "drug": "DB03516"}, {"action": "ANTAGONIST", "target": "P47989", "drug": "DB04854"}]}, "Q9WWU5": {"specific_function": "Catalyzes the oxigenolytic cleavage of 2-ethylhexyl sulfate (2-EHS) in the presence of alpha-ketoglutarate to yield 2-ethyl-hexanal and succinate, the decarboxylated form of alpha-ketoglutarate. It can accept a wide range of alpha-keto acids including 2-oxo-valerate, 2-oxo-adipate, 2-oxo-octanoate, 3-methyl-2-oxo-butyrate, oxaloacetate-alpha-ketoadipate, and alpha-ketooctanoate. It can catalyze the cleavage of medium-chain alkyl sulfate esters such as butylsulfate, pentylsulfate, hexylsulfate, heptylsulfate, octylsulfate, nonylsulfate, decylsulfate and sodium dodecyl sulfate (SDS).", "general_function": "Metal ion binding", "gene_names": ["atsK"], "name": "Alpha-ketoglutarate-dependent sulfate ester dioxygenase", "drug_actions": []}, "P38435": {"specific_function": "Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium-binding gamma-carboxyglutamate (Gla) residues with the concomitant conversion of the reduced hydroquinone form of vitamin K to vitamin K epoxide.", "general_function": "Gamma-glutamyl carboxylase activity", "gene_names": ["GGCX"], "name": "Vitamin K-dependent gamma-carboxylase", "drug_actions": [{"action": "COFACTOR", "target": "P38435", "drug": "DB00170"}, {"action": "INDUCER", "target": "P38435", "drug": "DB01022"}, {"action": "INHIBITOR", "target": "P38435", "drug": "DB01125"}]}, "P49821": {"specific_function": "Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFV1"], "name": "NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial", "drug_actions": []}, "P08617": {"specific_function": "Capsid proteins VP1, VP2, and VP3 form a closed capsid enclosing the viral positive strand RNA genome. All these proteins contain a beta-sheet structure called beta-barrel jelly roll. Together they form an icosahedral capsid (T=3) composed of 60 copies of each VP1, VP2, and VP3, with a diameter of approximately 300 Angstroms. VP1 is situated at the 12 fivefold axes, whereas VP2 and VP3 are located at the quasi-sixfold axes. The capsid interacts with HAVCR1 to provide virion attachment to target cell (By similarity).Protein VP0: VP0 precursor is a component of immature procapsids. The N-terminal domain of VP0, protein VP4, is needed for the assembly of 12 pentamers into the icosahedral structure. Unlike other picornaviruses, HAV VP4 does not seem to be myristoylated and has not been detected in mature virions, supposedly owing to its small size.VP1-2A precursor is a component of immature procapsids and corresponds to an extended form of the structural protein VP1. The C-terminal domain of VP1-2A, protein 2A, acts as an assembly signal that allows pentamerization of P1-2A, which is the precursor of the structural proteins. 2A is proteolytically removed from particulate VP1-2A by a host protease and does not seem to be found in mature particles.Protein 2B and 2BC precursor affect membrane integrity and cause an increase in membrane permeability.Protein 2C: Associates with and induces structural rearrangements of intracellular membranes. It displays RNA-binding, nucleotide binding and NTPase activities (By similarity).Protein 3A, via its hydrophobic domain, serves as membrane anchor to the 3AB and 3ABC precursors.The 3AB precursor interacts with the 3CD precursor and with RNA structures found at both the 5'- and 3'-termini of the viral genome. Since the 3AB precursor contains the hydrophobic domain 3A, it probably anchors the whole viral replicase complex to intracellular membranes on which viral RNA synthesis occurs.The 3ABC precursor is targeted to the mitochondrial membrane where protease 3C activity cleaves and inhibits the host antiviral protein MAVS, thereby disrupting activation of IRF3 through the IFIH1/MDA5 pathway. In vivo, the protease activity of 3ABC precursor is more efficient in cleaving the 2BC precursor than that of protein 3C. The 3ABC precursor may therefore play a role in the proteolytic processing of the polyprotein.Protein 3B is covalently linked to the 5'-end of both the positive-strand and negative-strand genomic RNAs. It acts as a genome-linked replication primer.Protease 3C: cysteine protease that generates mature viral proteins from the precursor polyprotein. In addition to its proteolytic activity, it binds to viral RNA, and thus influences viral genome replication. RNA and substrate bind cooperatively to the protease. Also cleaves host proteins such as PCBP2.RNA-directed RNA polymerase 3D-POL replicates genomic and antigenomic RNA by recognizing replications specific signals.", "general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P33681": {"specific_function": "Involved in the costimulatory signal essential for T-lymphocyte activation. T-cell proliferation and cytokine production is induced by the binding of CD28, binding to CTLA-4 has opposite effects and inhibits T-cell activation.(Microbial infection) Acts as a receptor for adenovirus subgroup B.", "general_function": "Virus receptor activity", "gene_names": ["CD80"], "name": "T-lymphocyte activation antigen CD80", "drug_actions": [{"action": "ANTAGONIST", "target": "P33681", "drug": "DB01281"}]}, "P07617": {"specific_function": "Displays methyltransferase, positive regulation of the poly(A) polymerase and transcription elongation activities. Involved in the modification of both mRNA ends and in intermediate and late gene positive transcription elongation. At the mRNAs 5' end, methylates the ribose 2' OH group of the first transcribed nucleotide, thereby producing a 2'-O-methylpurine cap. At the 3' end, functions as a processivity factor which stimulates the activity of the viral poly(A) polymerase VP55 that creates mRNA's poly(A) tail. In the presence of VP39, VP55 does not dissociate from the RNA allowing tail elongation to around 250 adenylates.", "general_function": "Translation elongation factor activity", "gene_names": ["PAPS"], "name": "Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase", "drug_actions": []}, "P20472": {"specific_function": "In muscle, parvalbumin is thought to be involved in relaxation after contraction. It binds two calcium ions.", "general_function": "Calcium ion binding", "gene_names": ["PVALB"], "name": "Parvalbumin alpha", "drug_actions": []}, "Q96EB6": {"specific_function": "NAD-dependent protein deacetylase that links transcriptional regulation directly to intracellular energetics and participates in the coordination of several separated cellular functions such as cell cycle, response to DNA damage, metobolism, apoptosis and autophagy. Can modulate chromatin function through deacetylation of histones and can promote alterations in the methylation of histones and DNA, leading to transcriptional repression. Deacetylates a broad range of transcription factors and coregulators, thereby regulating target gene expression positively and negatively. Serves as a sensor of the cytosolic ratio of NAD(+)/NADH which is altered by glucose deprivation and metabolic changes associated with caloric restriction. Is essential in skeletal muscle cell differentiation and in response to low nutrients mediates the inhibitory effect on skeletal myoblast differentiation which also involves 5'-AMP-activated protein kinase (AMPK) and nicotinamide phosphoribosyltransferase (NAMPT). Component of the eNoSC (energy-dependent nucleolar silencing) complex, a complex that mediates silencing of rDNA in response to intracellular energy status and acts by recruiting histone-modifying enzymes. The eNoSC complex is able to sense the energy status of cell: upon glucose starvation, elevation of NAD(+)/NADP(+) ratio activates SIRT1, leading to histone H3 deacetylation followed by dimethylation of H3 at 'Lys-9' (H3K9me2) by SUV39H1 and the formation of silent chromatin in the rDNA locus. Deacetylates 'Lys-266' of SUV39H1, leading to its activation. Inhibits skeletal muscle differentiation by deacetylating PCAF and MYOD1. Deacetylates H2A and 'Lys-26' of HIST1H1E. Deacetylates 'Lys-16' of histone H4 (in vitro). Involved in NR0B2/SHP corepression function through chromatin remodeling: Recruited to LRH1 target gene promoters by NR0B2/SHP thereby stimulating histone H3 and H4 deacetylation leading to transcriptional repression. Proposed to contribute to genomic integrity via positive regulation of telomere length; however, reports on localization to pericentromeric heterochromatin are conflicting. Proposed to play a role in constitutive heterochromatin (CH) formation and/or maintenance through regulation of the available pool of nuclear SUV39H1. Upon oxidative/metabolic stress decreases SUV39H1 degradation by inhibiting SUV39H1 polyubiquitination by MDM2. This increase in SUV39H1 levels enhances SUV39H1 turnover in CH, which in turn seems to accelerate renewal of the heterochromatin which correlates with greater genomic integrity during stress response. Deacetylates 'Lys-382' of p53/TP53 and impairs its ability to induce transcription-dependent proapoptotic program and modulate cell senescence. Deacetylates TAF1B and thereby represses rDNA transcription by the RNA polymerase I. Deacetylates MYC, promotes the association of MYC with MAX and decreases MYC stability leading to compromised transformational capability. Deacetylates FOXO3 in response to oxidative stress thereby increasing its ability to induce cell cycle arrest and resistance to oxidative stress but inhibiting FOXO3-mediated induction of apoptosis transcriptional activity; also leading to FOXO3 ubiquitination and protesomal degradation. Appears to have a similar effect on MLLT7/FOXO4 in regulation of transcriptional activity and apoptosis. Deacetylates DNMT1; thereby impairs DNMT1 methyltransferase-independent transcription repressor activity, modulates DNMT1 cell cycle regulatory function and DNMT1-mediated gene silencing. Deacetylates RELA/NF-kappa-B p65 thereby inhibiting its transactivating potential and augments apoptosis in response to TNF-alpha. Deacetylates HIF1A, KAT5/TIP60, RB1 and HIC1. Deacetylates FOXO1 resulting in its nuclear retention and enhancement of its transcriptional activity leading to increased gluconeogenesis in liver. Inhibits E2F1 transcriptional activity and apoptotic function, possibly by deacetylation. Involved in HES1- and HEY2-mediated transcriptional repression. In cooperation with MYCN seems to be involved in transcriptional repression of DUSP6/MAPK3 leading to MYCN stabilization by phosphorylation at 'Ser-62'. Deacetylates MEF2D. Required for antagonist-mediated transcription suppression of AR-dependent genes which may be linked to local deacetylation of histone H3. Represses HNF1A-mediated transcription. Required for the repression of ESRRG by CREBZF. Modulates AP-1 transcription factor activity. Deacetylates NR1H3 AND NR1H2 and deacetylation of NR1H3 at 'Lys-434' positively regulates transcription of NR1H3:RXR target genes, promotes NR1H3 proteosomal degradation and results in cholesterol efflux; a promoter clearing mechanism after reach round of transcription is proposed. Involved in lipid metabolism. Implicated in regulation of adipogenesis and fat mobilization in white adipocytes by repression of PPARG which probably involves association with NCOR1 and SMRT/NCOR2. Deacetylates ACSS2 leading to its activation, and HMGCS1. Involved in liver and muscle metabolism. Through deacteylation and activation of PPARGC1A is required to activate fatty acid oxidation in skeletel muscle under low-glucose conditions and is involved in glucose homeostasis. Involved in regulation of PPARA and fatty acid beta-oxidation in liver. Involved in positive regulation of insulin secretion in pancreatic beta cells in response to glucose; the function seems to imply transcriptional repression of UCP2. Proposed to deacetylate IRS2 thereby facilitating its insulin-induced tyrosine phosphorylation. Deacetylates SREBF1 isoform SREBP-1C thereby decreasing its stability and transactivation in lipogenic gene expression. Involved in DNA damage response by repressing genes which are involved in DNA repair, such as XPC and TP73, deacetylating XRCC6/Ku70, and faciliting recruitment of additional factors to sites of damaged DNA, such as SIRT1-deacetylated NBN can recruit ATM to initiate DNA repair and SIRT1-deacetylated XPA interacts with RPA2. Also involved in DNA repair of DNA double-strand breaks by homologous recombination and specifically single-strand annealing independently of XRCC6/Ku70 and NBN. Transcriptional suppression of XPC probably involves an E2F4:RBL2 suppressor complex and protein kinase B (AKT) signaling. Transcriptional suppression of TP73 probably involves E2F4 and PCAF. Deacetylates WRN thereby regulating its helicase and exonuclease activities and regulates WRN nuclear translocation in response to DNA damage. Deacetylates APEX1 at 'Lys-6' and 'Lys-7' and stimulates cellular AP endonuclease activity by promoting the association of APEX1 to XRCC1. Increases p53/TP53-mediated transcription-independent apoptosis by blocking nuclear translocation of cytoplasmic p53/TP53 and probably redirecting it to mitochondria. Deacetylates XRCC6/Ku70 at 'Lys-539' and 'Lys-542' causing it to sequester BAX away from mitochondria thereby inhibiting stress-induced apoptosis. Is involved in autophagy, presumably by deacetylating ATG5, ATG7 and MAP1LC3B/ATG8. Deacetylates AKT1 which leads to enhanced binding of AKT1 and PDK1 to PIP3 and promotes their activation. Proposed to play role in regulation of STK11/LBK1-dependent AMPK signaling pathways implicated in cellular senescence which seems to involve the regulation of the acetylation status of STK11/LBK1. Can deacetylate STK11/LBK1 and thereby increase its activity, cytoplasmic localization and association with STRAD; however, the relevance of such activity in normal cells is unclear. In endothelial cells is shown to inhibit STK11/LBK1 activity and to promote its degradation. Deacetylates SMAD7 at 'Lys-64' and 'Lys-70' thereby promoting its degradation. Deacetylates CIITA and augments its MHC class II transactivation and contributes to its stability. Deacteylates MECOM/EVI1. Isoform 2 is shown to deacetylate 'Lys-382' of p53/TP53, however with lower activity than isoform 1. In combination, the two isoforms exert an additive effect. Isoform 2 regulates p53/TP53 expression and cellular stress response and is in turn repressed by p53/TP53 presenting a SIRT1 isoform-dependent auto-regulatory loop. In case of HIV-1 infection, interacts with and deacetylates the viral Tat protein. The viral Tat protein inhibits SIRT1 deacetylation activity toward RELA/NF-kappa-B p65, thereby potentiates its transcriptional activity and SIRT1 is proposed to contribute to T-cell hyperactivation during infection. Deacetylates PML at 'Lys-487' and this deacetylation promotes PML control of PER2 nuclear localization. During the neurogenic transition, repress selective NOTCH1-target genes through histone deacetylation in a BCL6-dependent manner and leading to neuronal differentiation. Regulates the circadian expression of several core clock genes, including ARNTL/BMAL1, RORC, PER2 and CRY1 and plays a critical role in maintaining a controlled rhythmicity in histone acetylation, thereby contributing to circadian chromatin remodeling. Deacetylates ARNTL/BMAL1 and histones at the circadian gene promoters in order to facilitate repression by inhibitory components of the circadian oscillator. Deacetylates PER2, facilitating its ubiquitination and degradation by the proteosome. Protects cardiomyocytes against palmitate-induced apoptosis (PubMed:11672523, PubMed:12006491, PubMed:14976264, PubMed:14980222, PubMed:15126506, PubMed:15152190, PubMed:15205477, PubMed:15469825, PubMed:15692560, PubMed:16079181, PubMed:16166628, PubMed:16892051, PubMed:16998810, PubMed:17283066, PubMed:17334224, PubMed:17505061, PubMed:17612497, PubMed:17620057, PubMed:17936707, PubMed:18203716, PubMed:18296641, PubMed:18662546, PubMed:18687677, PubMed:19188449, PubMed:19220062, PubMed:19364925, PubMed:19690166, PubMed:19934257, PubMed:20097625, PubMed:20100829, PubMed:20203304, PubMed:20375098, PubMed:20620956, PubMed:20670893, PubMed:20817729, PubMed:20975832, PubMed:21149730, PubMed:21245319, PubMed:21471201, PubMed:21504832, PubMed:21555002, PubMed:21698133, PubMed:21701047, PubMed:21775285, PubMed:21807113, PubMed:21841822, PubMed:21890893, PubMed:21909281, PubMed:21947282, PubMed:22274616). Deacetylates XBP1 isoform 2; deacetylation decreases protein stability of XBP1 isoform 2 and inhibits its transcriptional activity (PubMed:20955178). Involved in the CCAR2-mediated regulation of PCK1 and NR1D1 (PubMed:24415752). Deacetylates CTNB1 at 'Lys-49' (PubMed:24824780).SirtT1 75 kDa fragment: catalytically inactive 75SirT1 may be involved in regulation of apoptosis. May be involved in protecting chondrocytes from apoptotic death by associating with cytochrome C and interfering with apoptosome assembly.", "general_function": "Transcription factor binding", "gene_names": ["SIRT1"], "name": "NAD-dependent protein deacetylase sirtuin-1", "drug_actions": []}, "P30793": {"specific_function": "Positively regulates nitric oxide synthesis in umbilical vein endothelial cells (HUVECs). May be involved in dopamine synthesis. May modify pain sensitivity and persistence. Isoform GCH-1 is the functional enzyme, the potential function of the enzymatically inactive isoforms remains unknown.", "general_function": "Zinc ion binding", "gene_names": ["GCH1"], "name": "GTP cyclohydrolase 1", "drug_actions": [{"action": "INHIBITOR", "target": "P30793", "drug": "DB02377"}]}, "Q03013": {"specific_function": "Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Active on 1-chloro-2,4-dinitrobenzene.", "general_function": "Protein homodimerization activity", "gene_names": ["GSTM4"], "name": "Glutathione S-transferase Mu 4", "drug_actions": []}, "P14751": {"specific_function": "This methylase recognizes the double-stranded sequence GAATTC, causes specific methylation on A-? on both strands, and protects the DNA from cleavage by the RsrI endonuclease.", "general_function": "Site-specific dna-methyltransferase (adenine-specific) activity", "gene_names": ["rsrIM"], "name": "Modification methylase RsrI", "drug_actions": []}, "P80365": {"specific_function": "Catalyzes the conversion of cortisol to the inactive metabolite cortisone. Modulates intracellular glucocorticoid levels, thus protecting the nonselective mineralocorticoid receptor from occupation by glucocorticoids.", "general_function": "Steroid binding", "gene_names": ["HSD11B2"], "name": "Corticosteroid 11-beta-dehydrogenase isozyme 2", "drug_actions": []}, "P23921": {"specific_function": "Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides.", "general_function": "Ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor", "gene_names": ["RRM1"], "name": "Ribonucleoside-diphosphate reductase large subunit", "drug_actions": [{"action": "INHIBITOR", "target": "P23921", "drug": "DB00242"}, {"action": "INHIBITOR", "target": "P23921", "drug": "DB00441"}, {"action": "INHIBITOR", "target": "P23921", "drug": "DB00631"}, {"action": "INHIBITOR", "target": "P23921", "drug": "DB01005"}, {"action": "INHIBITOR", "target": "P23921", "drug": "DB01073"}]}, "Q8YWS4": {"gene_names": [], "name": "Alr1529 protein", "drug_actions": []}, "Q96GR2": {"specific_function": "Mediates activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. Able to activate long-chain fatty acids. Also able to activate very long-chain fatty acids; however, the relevance of such activity is unclear in vivo. Can activate diverse saturated, monosaturated and polyunsaturated fatty acids.", "general_function": "Very long-chain fatty acid-coa ligase activity", "gene_names": ["ACSBG1"], "name": "Long-chain-fatty-acid--CoA ligase ACSBG1", "drug_actions": []}, "Q07001": {"specific_function": "After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.", "general_function": "Acetylcholine-activated cation-selective channel activity", "gene_names": ["CHRND"], "name": "Acetylcholine receptor subunit delta", "drug_actions": [{"action": "ALLOSTERIC MODULATOR", "target": "Q07001", "drug": "DB00674"}]}, "P18510": {"specific_function": "Inhibits the activity of interleukin-1 by binding to receptor IL1R1 and preventing its association with the coreceptor IL1RAP for signaling. Has no interleukin-1 like activity. Binds functional interleukin-1 receptor IL1R1 with greater affinity than decoy receptor IL1R2; however, the physiological relevance of the latter association is unsure.", "general_function": "Interleukin-1, type ii receptor binding", "gene_names": ["IL1RN"], "name": "Interleukin-1 receptor antagonist protein", "drug_actions": [{"action": "BINDER", "target": "P18510", "drug": "DB06372"}]}, "Q07954": {"specific_function": "Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission.Functions as a receptor for Pseudomonas aeruginosa exotoxin A.", "general_function": "Receptor activity", "gene_names": ["LRP1"], "name": "Prolow-density lipoprotein receptor-related protein 1", "drug_actions": [{"action": "MODULATOR", "target": "Q07954", "drug": "DB00025"}]}, "P52333": {"specific_function": "Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A AND STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion.", "general_function": "Protein tyrosine kinase activity", "gene_names": ["JAK3"], "name": "Tyrosine-protein kinase JAK3", "drug_actions": [{"action": "INHIBITOR", "target": "P52333", "drug": "DB08895"}]}, "Q969P6": {"specific_function": "Releases the supercoiling and torsional tension of DNA introduced during duplication of mitochondrial DNA by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then undergoes passage around the unbroken strand thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone (By similarity).", "general_function": "Dna topoisomerase type ii (atp-hydrolyzing) activity", "gene_names": ["TOP1MT"], "name": "DNA topoisomerase I, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "Q969P6", "drug": "DB00762"}, {"action": "INHIBITOR", "target": "Q969P6", "drug": "DB01030"}]}, "P51648": {"specific_function": "Catalyzes the oxidation of long-chain aliphatic aldehydes to fatty acids. Active on a variety of saturated and unsaturated aliphatic aldehydes between 6 and 24 carbons in length. Responsible for conversion of the sphingosine 1-phosphate (S1P) degradation product hexadecenal to hexadecenoic acid.", "general_function": "Medium-chain-aldehyde dehydrogenase activity", "gene_names": ["ALDH3A2"], "name": "Fatty aldehyde dehydrogenase", "drug_actions": []}, "P51649": {"specific_function": "Catalyzes one step in the degradation of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA).", "general_function": "Succinate-semialdehyde dehydrogenase [nad(p)+] activity", "gene_names": ["ALDH5A1"], "name": "Succinate-semialdehyde dehydrogenase, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "P51649", "drug": "DB00139"}, {"action": "INHIBITOR", "target": "P51649", "drug": "DB00313"}, {"action": "INHIBITOR", "target": "P51649", "drug": "DB00534"}]}, "P05100": {"specific_function": "Hydrolysis of the deoxyribose N-glycosidic bond to excise 3-methyladenine from the damaged DNA polymer formed by alkylation lesions.", "general_function": "Metal ion binding", "gene_names": ["tag"], "name": "DNA-3-methyladenine glycosylase 1", "drug_actions": []}, "P56181": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Poly(a) rna binding", "gene_names": ["NDUFV3"], "name": "NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial", "drug_actions": []}, "P11802": {"specific_function": "Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex.", "general_function": "Cyclin-dependent protein serine/threonine kinase regulator activity", "gene_names": ["CDK4"], "name": "Cyclin-dependent kinase 4", "drug_actions": [{"action": "INHIBITOR", "target": "P11802", "drug": "DB09073"}]}, "Q96S86": {"specific_function": "May function in hyaluronic acid binding.", "general_function": "Hyaluronic acid binding", "gene_names": ["HAPLN3"], "name": "Hyaluronan and proteoglycan link protein 3", "drug_actions": [{"action": "BINDER", "target": "Q96S86", "drug": "DB08818"}]}, "Q75Y35": {"general_function": "Serine-type d-ala-d-ala carboxypeptidase activity", "gene_names": ["pbp3"], "name": "Penicillin-binding protein 3", "drug_actions": [{"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00319"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00415"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00438"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00447"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00456"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00485"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00567"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00607"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00713"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00739"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00833"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB00948"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB01000"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB01140"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB01163"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB01330"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB01603"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB03313"}, {"action": "INHIBITOR", "target": "Q75Y35", "drug": "DB08795"}]}, "P20711": {"specific_function": "Catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to dopamine, L-5-hydroxytryptophan to serotonin and L-tryptophan to tryptamine.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["DDC"], "name": "Aromatic-L-amino-acid decarboxylase", "drug_actions": [{"action": "COFACTOR", "target": "P20711", "drug": "DB00114"}, {"action": "INHIBITOR", "target": "P20711", "drug": "DB00190"}]}, "O85361": {"general_function": "Beta-n-acetylhexosaminidase activity", "gene_names": ["hex"], "name": "B-N-acetylhexosaminidase", "drug_actions": []}, "O15111": {"specific_function": "Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. Negatively regulates the pathway by phosphorylating the scaffold protein TAXBP1 and thus promoting the assembly of the A20/TNFAIP3 ubiquitin-editing complex (composed of A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH and RNF11). Therefore, CHUK plays a key role in the negative feedback of NF-kappa-B canonical signaling to limit inflammatory gene activation. As part of the non-canonical pathway of NF-kappa-B activation, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. In turn, these complexes regulate genes encoding molecules involved in B-cell survival and lymphoid organogenesis. Participates also in the negative feedback of the non-canonical NF-kappa-B signaling pathway by phosphorylating and destabilizing MAP3K14/NIK. Within the nucleus, phosphorylates CREBBP and consequently increases both its transcriptional and histone acetyltransferase activities. Modulates chromatin accessibility at NF-kappa-B-responsive promoters by phosphorylating histones H3 at 'Ser-10' that are subsequently acetylated at 'Lys-14' by CREBBP. Additionally, phosphorylates the CREBBP-interacting protein NCOA3. Also phosphorylates FOXO3 and may regulate this pro-apoptotic transcription factor (PubMed:15084260).", "general_function": "Scaffold protein binding", "gene_names": ["CHUK"], "name": "Inhibitor of nuclear factor kappa-B kinase subunit alpha", "drug_actions": [{"action": "INHIBITOR", "target": "O15111", "drug": "DB00233"}, {"action": "INHIBITOR", "target": "O15111", "drug": "DB00244"}, {"action": "INHIBITOR", "target": "O15111", "drug": "DB00795"}, {"action": "INHIBITOR", "target": "O15111", "drug": "DB06151"}]}, "P01625": {"general_function": "Antigen binding", "gene_names": [], "name": "Ig kappa chain V-IV region Len", "drug_actions": []}, "Q7KZA3": {"specific_function": "Catalyzes the ferrous insertion into protoporphyrin IX.", "general_function": "Ferrochelatase activity", "gene_names": ["DKFZp686P18130"], "name": "Ferrochelatase", "drug_actions": []}, "Q5JVS0": {"specific_function": "May be involved in nuclear functions such as the remodeling of chromatin and the regulation of transcription.", "gene_names": ["HABP4"], "name": "Intracellular hyaluronan-binding protein 4", "drug_actions": [{"action": "BINDER", "target": "Q5JVS0", "drug": "DB08818"}]}, "Q12809": {"specific_function": "Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are retained intracellularly and undergo ubiquitin-dependent degradation.", "general_function": "Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization", "gene_names": ["KCNH2"], "name": "Potassium voltage-gated channel subfamily H member 2", "drug_actions": [{"action": "INHIBITOR", "target": "Q12809", "drug": "DB00204"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00276"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00308"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00342"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00457"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00458"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00489"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00590"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00604"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00637"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00679"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB00908"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB01100"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB01110"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB01118"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB01136"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB01162"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB01182"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB01218"}, {"action": "INHIBITOR", "target": "Q12809", "drug": "DB06144"}]}, "P94692": {"specific_function": "Catalyzes the ferredoxin-dependent oxidative decarboxylation of pyruvate. Required for the transfer of electrons from pyruvate to ferredoxin (PubMed:9294422, PubMed:7612653). Ferredoxin I and ferredoxin II, which are single 4Fe-4S cluster ferredoxins are the most effective electron carriers of POR (PubMed:7612653).", "general_function": "Thiamine pyrophosphate binding", "gene_names": ["por"], "name": "Pyruvate synthase", "drug_actions": [{"action": "INHIBITOR", "target": "P94692", "drug": "DB00507"}]}, "P94690": {"specific_function": "Exchanges electrons specifically with the basic cytochrome c3.", "general_function": "Metal ion binding", "gene_names": [], "name": "Acidic cytochrome c3", "drug_actions": []}, "Q15046": {"specific_function": "Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA. When secreted, acts as a signaling molecule that induces immune response through the activation of monocyte/macrophages. Catalyzes the synthesis of diadenosine oligophosphate (Ap4A), a signaling molecule involved in the activation of MITF transcriptional activity. Interacts with HIV-1 virus GAG protein, facilitating the selective packaging of tRNA(3)(Lys), the primer for reverse transcription initiation.", "general_function": "Trna binding", "gene_names": ["KARS"], "name": "Lysine--tRNA ligase", "drug_actions": []}, "P29723": {"specific_function": "This antigen is a pathogen-specific membrane immunogen. Most abundant of the membrane lipoproteins, only found so far in pathogenic treponemes, suggesting that it is an important structural moiety in the cell envelope of virulent treponemal subspecies.", "gene_names": [], "name": "47 kDa membrane antigen", "drug_actions": []}, "P06875": {"general_function": "Penicillin amidase activity", "gene_names": ["pac"], "name": "Penicillin G acylase", "drug_actions": []}, "P34096": {"specific_function": "This RNase has marked specificity towards the 3' side of uridine nucleotides.", "general_function": "Ribonuclease activity", "gene_names": ["RNASE4"], "name": "Ribonuclease 4", "drug_actions": []}, "Q93LD7": {"general_function": "Zinc ion binding", "gene_names": ["opdA"], "name": "Phosphotriesterase", "drug_actions": []}, "Q55813": {"general_function": "O-methyltransferase activity", "gene_names": [], "name": "O-methyltransferase", "drug_actions": []}, "P25098": {"specific_function": "Specifically phosphorylates the agonist-occupied form of the beta-adrenergic and closely related receptors, probably inducing a desensitization of them. Key regulator of LPAR1 signaling. Competes with RALA for binding to LPAR1 thus affecting the signaling properties of the receptor. Desensitizes LPAR1 and LPAR2 in a phosphorylation-independent manner.", "general_function": "Protein kinase activity", "gene_names": ["ADRBK1"], "name": "Beta-adrenergic receptor kinase 1", "drug_actions": []}, "P49916": {"specific_function": "Isoform 3 functions as heterodimer with DNA-repair protein XRCC1 in the nucleus and can correct defective DNA strand-break repair and sister chromatid exchange following treatment with ionizing radiation and alkylating agents. Isoform 1 is targeted to mitochondria, where it functions as DNA ligase in mitochondrial base-excision DNA repair (PubMed:10207110, PubMed:24674627).", "general_function": "Zinc ion binding", "gene_names": ["LIG3"], "name": "DNA ligase 3", "drug_actions": [{"action": "INHIBITOR", "target": "P49916", "drug": "DB00290"}]}, "P49915": {"specific_function": "Involved in the de novo synthesis of guanine nucleotides which are not only essential for DNA and RNA synthesis, but also provide GTP, which is involved in a number of cellular processes important for cell division.", "general_function": "Pyrophosphatase activity", "gene_names": ["GMPS"], "name": "GMP synthase [glutamine-hydrolyzing]", "drug_actions": []}, "P05107": {"specific_function": "Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrins alpha-M/beta-2 and alpha-X/beta-2 are receptors for the iC3b fragment of the third complement component and for fibrinogen. Integrin alpha-X/beta-2 recognizes the sequence G-P-R in fibrinogen alpha-chain. Integrin alpha-M/beta-2 recognizes P1 and P2 peptides of fibrinogen gamma chain. Integrin alpha-M/beta-2 is also a receptor for factor X. Integrin alpha-D/beta-2 is a receptor for ICAM3 and VCAM1. Triggers neutrophil transmigration during lung injury through PTK2B/PYK2-mediated activation.", "general_function": "Protein kinase binding", "gene_names": ["ITGB2"], "name": "Integrin beta-2", "drug_actions": [{"action": "OTHER", "target": "P05107", "drug": "DB00641"}]}, "P49913": {"specific_function": "Binds to bacterial lipopolysaccharides (LPS), has antibacterial activity.", "gene_names": ["CAMP"], "name": "Cathelicidin antimicrobial peptide", "drug_actions": []}, "P0A2K1": {"specific_function": "The beta subunit is responsible for the synthesis of L-tryptophan from indole and L-serine.", "general_function": "Tryptophan synthase activity", "gene_names": ["trpB"], "name": "Tryptophan synthase beta chain", "drug_actions": []}, "O32248": {"specific_function": "Probable N-acetyltransferase.", "general_function": "N-acetyltransferase activity", "gene_names": ["yvbK"], "name": "Uncharacterized N-acetyltransferase YvbK", "drug_actions": []}, "Q46856": {"specific_function": "NADP-dependent ADH activity.", "general_function": "Zinc ion binding", "gene_names": ["yqhD"], "name": "Alcohol dehydrogenase YqhD", "drug_actions": []}, "P0C0L5": {"specific_function": "Non-enzymatic component of the C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. Covalently binds to immunoglobulins and immune complexes and enhances the solubilization of immune aggregates and the clearance of IC through CR1 on erythrocytes. C4A isotype is responsible for effective binding to form amide bonds with immune aggregates or protein antigens, while C4B isotype catalyzes the transacylation of the thioester carbonyl group to form ester bonds with carbohydrate antigens.Derived from proteolytic degradation of complement C4, C4a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.", "general_function": "Endopeptidase inhibitor activity", "gene_names": ["C4B"], "name": "Complement C4-B", "drug_actions": [{"action": "BINDER", "target": "P0C0L5", "drug": "DB00028"}]}, "P0C0L4": {"specific_function": "Non-enzymatic component of C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. Covalently binds to immunoglobulins and immune complexes and enhances the solubilization of immune aggregates and the clearance of IC through CR1 on erythrocytes. C4A isotype is responsible for effective binding to form amide bonds with immune aggregates or protein antigens, while C4B isotype catalyzes the transacylation of the thioester carbonyl group to form ester bonds with carbohydrate antigens.Derived from proteolytic degradation of complement C4, C4a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.", "general_function": "Endopeptidase inhibitor activity", "gene_names": ["C4A"], "name": "Complement C4-A", "drug_actions": [{"action": "BINDER", "target": "P0C0L4", "drug": "DB00028"}]}, "Q9ZGI2": {"general_function": "Transferase activity", "gene_names": ["pikAIV"], "name": "Type I polyketide synthase PikAIV", "drug_actions": []}, "P08217": {"specific_function": "Acts upon elastin.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["CELA2A"], "name": "Chymotrypsin-like elastase family member 2A", "drug_actions": []}, "P09619": {"specific_function": "Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth muscle cells to endothelial cells. Plays a role in the migration of vascular smooth muscle cells and the formation of neointima at vascular injury sites. Required for normal development of the cardiovascular system. Required for normal recruitment of pericytes (mesangial cells) in the kidney glomerulus, and for normal formation of a branched network of capillaries in kidney glomeruli. Promotes rearrangement of the actin cytoskeleton and the formation of membrane ruffles. Binding of its cognate ligands - homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to the activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or of the C-terminus of PTPN11, creates a binding site for GRB2, resulting in the activation of HRAS, RAF1 and down-stream MAP kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and STAM. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor.", "general_function": "Vascular endothelial growth factor binding", "gene_names": ["PDGFRB"], "name": "Platelet-derived growth factor receptor beta", "drug_actions": [{"action": "ANTAGONIST", "target": "P09619", "drug": "DB00398"}, {"action": "ANTAGONIST", "target": "P09619", "drug": "DB00619"}, {"action": "ANTAGONIST", "target": "P09619", "drug": "DB01254"}, {"action": "ANTAGONIST", "target": "P09619", "drug": "DB01268"}, {"action": "INHIBITOR", "target": "P09619", "drug": "DB06589"}, {"action": "INHIBITOR", "target": "P09619", "drug": "DB08896"}]}, "Q5SL87": {"specific_function": "The RuvA-RuvB complex in the presence of ATP renatures cruciform structure in supercoiled DNA with palindromic sequence, indicating that it may promote strand exchange reactions in homologous recombination. RuvAB is a helicase that mediates the Holliday junction migration by localized denaturation and reannealing. RuvB is a Mg(2+)-dependent, DNA-dependent ATPase with an equal preference for supercoiled and linear duplex DNA. It can promote Holliday junction migration alone.", "general_function": "Four-way junction helicase activity", "gene_names": ["ruvB"], "name": "Holliday junction ATP-dependent DNA helicase RuvB", "drug_actions": []}, "P31012": {"general_function": "Tyrosine phenol-lyase activity", "gene_names": ["tpl"], "name": "Tyrosine phenol-lyase", "drug_actions": []}, "P00973": {"specific_function": "Interferon-induced, dsRNA-activated antiviral enzyme which plays a critical role in cellular innate antiviral response. In addition, it may also play a role in other cellular processes such as apoptosis, cell growth, differentiation and gene regulation. Synthesizes higher oligomers of 2'-5'-oligoadenylates (2-5A) from ATP which then bind to the inactive monomeric form of ribonuclease L (RNase L) leading to its dimerization and subsequent activation. Activation of RNase L leads to degradation of cellular as well as viral RNA, resulting in the inhibition of protein synthesis, thus terminating viral replication. Can mediate the antiviral effect via the classical RNase L-dependent pathway or an alternative antiviral pathway independent of RNase L. The secreted form displays antiviral effect against vesicular stomatitis virus (VSV), herpes simplex virus type 2 (HSV-2), and encephalomyocarditis virus (EMCV) and stimulates the alternative antiviral pathway independent of RNase L.", "general_function": "Zinc ion binding", "gene_names": ["OAS1"], "name": "2'-5'-oligoadenylate synthase 1", "drug_actions": []}, "P31358": {"specific_function": "May play a role in carrying and orienting carbohydrate, as well as having a more specific role.", "gene_names": ["CD52"], "name": "CAMPATH-1 antigen", "drug_actions": [{"action": "ANTIBODY", "target": "P31358", "drug": "DB00087"}]}, "Q00653": {"specific_function": "NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer.", "name": "Nuclear factor NF-kappa-B p100 subunit", "drug_actions": [{"action": "ANTAGONIST", "target": "Q00653", "drug": "DB00945"}, {"action": "ANTAGONIST", "target": "Q00653", "drug": "DB01296"}], "general_function": "Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding", "in_complexes": ["Nuclear factor NF-kappa-B"], "gene_names": ["NFKB2"]}, "P0C2P0": {"specific_function": "Catalyzes the deamination of the cytosine moiety of the antibiotics blasticidin S, cytomycin and acetylblasticidin S.", "general_function": "Zinc ion binding", "gene_names": ["bsd"], "name": "Blasticidin-S deaminase", "drug_actions": []}, "P14941": {"specific_function": "Alcohol dehydrogenase with a preference for medium chain secondary alcohols, such as 2-butanol and isopropanol. Has very low activity with primary alcohols, such as ethanol. Under physiological conditions, the enzyme reduces aldehydes and 2-ketones to produce secondary alcohols. Is also active with acetaldehyde and propionaldehyde.", "general_function": "Zinc ion binding", "gene_names": ["adh"], "name": "NADP-dependent isopropanol dehydrogenase", "drug_actions": []}, "P71447": {"specific_function": "Catalyzes the interconversion of D-glucose 1-phosphate (G1P) and D-glucose 6-phosphate (G6P), forming beta-D-glucose 1,6-(bis)phosphate (beta-G16P) as an intermediate. The beta-phosphoglucomutase (Beta-PGM) acts on the beta-C(1) anomer of G1P. Glucose or lactose are used in preference to maltose, which is only utilized after glucose or lactose has been exhausted. It plays a key role in the regulation of the flow of carbohydrate intermediates in glycolysis and the formation of the sugar nucleotide UDP-glucose.", "general_function": "Magnesium ion binding", "gene_names": ["pgmB"], "name": "Beta-phosphoglucomutase", "drug_actions": []}, "P17568": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFB7"], "name": "NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7", "drug_actions": []}, "P31350": {"specific_function": "Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. Inhibits Wnt signaling.", "general_function": "Ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor", "gene_names": ["RRM2"], "name": "Ribonucleoside-diphosphate reductase subunit M2", "drug_actions": [{"action": "INHIBITOR", "target": "P31350", "drug": "DB00242"}, {"action": "INHIBITOR", "target": "P31350", "drug": "DB05260"}]}, "Q01782": {"specific_function": "Exhibits a NADPH-dependent biopterin reductase activity. Has good activity with folate and significant activity with dihydrofolate and dihydrobiopterin, but not with quinonoid dihydrobiopterin. Confers resistance to methotrexate (MTX).", "general_function": "Thymidylate synthase activity", "gene_names": ["PTR1"], "name": "Pteridine reductase 1", "drug_actions": []}, "Q81R22": {"specific_function": "Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis.", "general_function": "Nadp binding", "gene_names": ["dfrA"], "name": "Dihydrofolate reductase", "drug_actions": []}, "Q59334": {"specific_function": "Catalyzes an early step in the biosynthesis of tetrapyrroles. Binds two molecules of 5-aminolevulinate per subunit, each at a distinct site, and catalyzes their condensation to form porphobilinogen.", "general_function": "Porphobilinogen synthase activity", "gene_names": ["hemB"], "name": "Delta-aminolevulinic acid dehydratase", "drug_actions": []}, "Q4ZHU6": {"general_function": "Metal ion binding", "gene_names": ["PDE4"], "name": "CAMP phosphodiesterase", "drug_actions": [{"action": "ACTIVATOR", "target": "Q4ZHU6", "drug": "DB01064"}]}, "Q9BVA1": {"specific_function": "Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity). TUBB2B is implicated in neuronal migration.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["TUBB2B"], "name": "Tubulin beta-2B chain", "drug_actions": []}, "P43088": {"specific_function": "Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis in the corpus luteum (By similarity). Isoforms 2 to 7 do not bind PGF2-alpha but are proposed to modulate signaling by participating in variant receptor complexes; heterodimers between isoform 1 and isoform 5 are proposed to be a receptor for prostamides including the synthetic analog bimatoprost.", "general_function": "Prostaglandin f receptor activity", "gene_names": ["PTGFR"], "name": "Prostaglandin F2-alpha receptor", "drug_actions": [{"action": "AGONIST", "target": "P43088", "drug": "DB00287"}, {"action": "AGONIST", "target": "P43088", "drug": "DB00654"}, {"action": "AGONIST", "target": "P43088", "drug": "DB00905"}, {"action": "AGONIST", "target": "P43088", "drug": "DB01160"}, {"action": "AGONIST", "target": "P43088", "drug": "DB08819"}]}, "Q09428": {"specific_function": "Subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release.", "general_function": "Sulfonylurea receptor activity", "gene_names": ["ABCC8"], "name": "ATP-binding cassette sub-family C member 8", "drug_actions": [{"action": "INDUCER", "target": "Q09428", "drug": "DB00222"}, {"action": "INHIBITOR", "target": "Q09428", "drug": "DB00672"}, {"action": "INHIBITOR", "target": "Q09428", "drug": "DB00731"}, {"action": "INHIBITOR", "target": "Q09428", "drug": "DB00912"}, {"action": "MODULATOR", "target": "Q09428", "drug": "DB01016"}, {"action": "INHIBITOR", "target": "Q09428", "drug": "DB01067"}, {"action": "BINDER", "target": "Q09428", "drug": "DB01120"}, {"action": "INHIBITOR", "target": "Q09428", "drug": "DB01124"}, {"action": "INHIBITOR", "target": "Q09428", "drug": "DB01251"}, {"action": "INHIBITOR", "target": "Q09428", "drug": "DB01252"}, {"action": "INDUCER", "target": "Q09428", "drug": "DB01382"}]}, "P07445": {"general_function": "Steroid delta-isomerase activity", "gene_names": ["ksi"], "name": "Steroid Delta-isomerase", "drug_actions": []}, "Q9H2X9": {"specific_function": "Mediates electroneutral potassium-chloride cotransport in mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in neurons.", "general_function": "Protein kinase binding", "gene_names": ["SLC12A5"], "name": "Solute carrier family 12 member 5", "drug_actions": [{"action": "INHIBITOR", "target": "Q9H2X9", "drug": "DB00887"}]}, "P43080": {"specific_function": "Stimulates guanylyl cyclase 1 (GC1) when free calcium ions concentration is low and inhibits GC1 when free calcium ions concentration is elevated. This Ca(2+)-sensitive regulation of GC is a key event in recovery of the dark state of rod photoreceptors following light exposure.", "general_function": "Calcium sensitive guanylate cyclase activator activity", "gene_names": ["GUCA1A"], "name": "Guanylyl cyclase-activating protein 1", "drug_actions": []}, "P05193": {"specific_function": "This protein is a serine beta-lactamase with a substrate specificity for cephalosporins.", "general_function": "Beta-lactamase activity", "gene_names": ["ampC"], "name": "Beta-lactamase", "drug_actions": [{"action": "POTENTIATOR", "target": "P05193", "drug": "DB00355"}]}, "Q52369": {"specific_function": "Diheme, high potential cytochrome c believed to be an intermediate electron donor to terminal oxidation systems.", "general_function": "Iron ion binding", "gene_names": ["cc4"], "name": "Cytochrome c4", "drug_actions": []}, "P0A2Y7": {"specific_function": "Catalyzes the anti-1,4-elimination of the C-3 phosphate and the C-6 proR hydrogen from 5-enolpyruvylshikimate-3-phosphate (EPSP) to yield chorismate, which is the branch point compound that serves as the starting substrate for the three terminal pathways of aromatic amino acid biosynthesis. This reaction introduces a second double bond into the aromatic ring system.", "general_function": "Chorismate synthase activity", "gene_names": ["aroC"], "name": "Chorismate synthase", "drug_actions": []}, "P07437": {"specific_function": "Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["TUBB"], "name": "Tubulin beta chain", "drug_actions": [{"action": "INHIBITOR", "target": "P07437", "drug": "DB00361"}, {"action": "INHIBITOR", "target": "P07437", "drug": "DB00541"}, {"action": "ADDUCT", "target": "P07437", "drug": "DB00570"}, {"action": "INHIBITOR", "target": "P07437", "drug": "DB01179"}, {"action": "INHIBITOR", "target": "P07437", "drug": "DB01394"}]}, "Q96SW2": {"specific_function": "Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2. Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. May play a role in memory and learning by regulating the assembly and neuronal surface expression of large-conductance calcium-activated potassium channels in brain regions involved in memory and learning via its interaction with KCNT1. Binding of pomalidomide and other thalidomide-related drugs changes the substrate specificity of the human protein, leading to decreased degradation of MEIS2 and other target proteins and increased degradation of MYC, IRF4, IKZF1 and IKZF3.", "general_function": "Metal ion binding", "gene_names": ["CRBN"], "name": "Protein cereblon", "drug_actions": [{"action": "INHIBITOR", "target": "Q96SW2", "drug": "DB00480"}, {"action": "INHIBITOR", "target": "Q96SW2", "drug": "DB01041"}, {"action": "INHIBITOR", "target": "Q96SW2", "drug": "DB08910"}]}, "Q9PM68": {"specific_function": "Bifunctional enzyme that catalyzes the formation of 4-diphosphocytidyl-2-C-methyl-D-erythritol from CTP and 2-C-methyl-D-erythritol 4-phosphate (MEP) (IspD), and catalyzes the conversion of 4-diphosphocytidyl-2-C-methyl-D-erythritol 2-phosphate (CDP-ME2P) to 2-C-methyl-D-erythritol 2,4-cyclodiphosphate (ME-CPP) with a corresponding release of cytidine 5-monophosphate (CMP) (IspF).", "general_function": "Metal ion binding", "gene_names": ["ispDF"], "name": "Bifunctional enzyme IspD/IspF", "drug_actions": []}, "Q9UGI6": {"specific_function": "Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to the slow component of synaptic afterhyperpolarization. The channel is blocked by apamin.", "name": "Small conductance calcium-activated potassium channel protein 3", "drug_actions": [{"action": "BINDER", "target": "Q9UGI6", "drug": "DB00721"}, {"action": "INHIBITOR", "target": "Q9UGI6", "drug": "DB01110"}], "general_function": "Small conductance calcium-activated potassium channel activity", "in_complexes": ["Calcium-activated potassium channel"], "gene_names": ["KCNN3"]}, "Q9UGI5": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["GAD65"], "name": "Glutamic acid decarboxylase", "drug_actions": [{"action": "COFACTOR", "target": "Q9UGI5", "drug": "DB00114"}, {"action": "INHIBITOR", "target": "Q9UGI5", "drug": "DB00780"}]}, "P23381": {"specific_function": "Isoform 1, isoform 2 and T1-TrpRS have aminoacylation activity while T2-TrpRS lacks it. Isoform 2, T1-TrpRS and T2-TrpRS possess angiostatic activity whereas isoform 1 lacks it. T2-TrpRS inhibits fluid shear stress-activated responses of endothelial cells. Regulates ERK, Akt, and eNOS activation pathways that are associated with angiogenesis, cytoskeletal reorganization and shear stress-responsive gene expression.", "general_function": "Tryptophan-trna ligase activity", "gene_names": ["WARS"], "name": "Tryptophan--tRNA ligase, cytoplasmic", "drug_actions": [{"action": "INHIBITOR", "target": "P23381", "drug": "DB00150"}]}, "P08100": {"specific_function": "Photoreceptor required for image-forming vision at low light intensity. Required for photoreceptor cell viability after birth. Light-induced isomerization of 11-cis to all-trans retinal triggers a conformational change leading to G-protein activation and release of all-trans retinal.", "general_function": "Photoreceptor activity", "gene_names": ["RHO"], "name": "Rhodopsin", "drug_actions": [{"action": "OTHER", "target": "P08100", "drug": "DB01159"}]}, "Q05932": {"specific_function": "Catalyzes conversion of folates to polyglutamate derivatives allowing concentration of folate compounds in the cell and the intracellular retention of these cofactors, which are important substrates for most of the folate-dependent enzymes that are involved in one-carbon transfer reactions involved in purine, pyrimidine and amino acid synthesis. Unsubstituted reduced folates are the preferred substrates. Metabolizes methotrexate (MTX) to polyglutamates.", "general_function": "Tetrahydrofolylpolyglutamate synthase activity", "gene_names": ["FPGS"], "name": "Folylpolyglutamate synthase, mitochondrial", "drug_actions": [{"action": "ANTAGONIST", "target": "Q05932", "drug": "DB00293"}]}, "P42593": {"specific_function": "Catalyzes the NADP-dependent reduction of 2,4-dienoyl-CoA to yield trans-2- enoyl-CoA.", "general_function": "Nadph dehydrogenase activity", "gene_names": ["fadH"], "name": "2,4-dienoyl-CoA reductase [NADPH]", "drug_actions": []}, "P00480": {"general_function": "Phospholipid binding", "gene_names": ["OTC"], "name": "Ornithine carbamoyltransferase, mitochondrial", "drug_actions": []}, "Q9UHY7": {"specific_function": "Bifunctional enzyme that catalyzes the enolization of 2,3-diketo-5-methylthiopentyl-1-phosphate (DK-MTP-1-P) into the intermediate 2-hydroxy-3-keto-5-methylthiopentenyl-1-phosphate (HK-MTPenyl-1-P), which is then dephosphorylated to form the acireductone 1,2-dihydroxy-3-keto-5-methylthiopentene (DHK-MTPene).", "general_function": "Magnesium ion binding", "gene_names": ["ENOPH1"], "name": "Enolase-phosphatase E1", "drug_actions": []}, "O75911": {"specific_function": "Catalyzes the reduction of all-trans-retinal to all-trans-retinol in the presence of NADPH.", "general_function": "Retinol dehydrogenase activity", "gene_names": ["DHRS3"], "name": "Short-chain dehydrogenase/reductase 3", "drug_actions": []}, "Q95460": {"specific_function": "Antigen-presenting molecule specialized in presenting microbial vitamin B metabolites. Involved in the development and expansion of a small population of T-cells expressing an invariant T-cell receptor alpha chain called mucosal-associated invariant T-cells (MAIT). MAIT lymphocytes are preferentially located in the gut lamina propria and therefore may be involved in monitoring commensal flora or serve as a distress signal. Expression and MAIT cell recognition seem to be ligand-dependent.", "general_function": "Peptide antigen binding", "gene_names": ["MR1"], "name": "Major histocompatibility complex class I-related gene protein", "drug_actions": [{"action": "ANTAGONIST", "target": "Q95460", "drug": "DB00098"}]}, "Q9UGI9": {"specific_function": "AMP/ATP-binding subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin. Gamma non-catalytic subunit mediates binding to AMP, ADP and ATP, leading to activate or inhibit AMPK: AMP-binding results in allosteric activation of alpha catalytic subunit (PRKAA1 or PRKAA2) both by inducing phosphorylation and preventing dephosphorylation of catalytic subunits. ADP also stimulates phosphorylation, without stimulating already phosphorylated catalytic subunit. ATP promotes dephosphorylation of catalytic subunit, rendering the AMPK enzyme inactive.", "name": "5'-AMP-activated protein kinase subunit gamma-3", "drug_actions": [{"action": "ACTIVATOR", "target": "Q9UGI9", "drug": "DB00945"}], "general_function": "Protein kinase binding", "in_complexes": ["5'-AMP-activated protein kinase"], "gene_names": ["PRKAG3"]}, "P0AC47": {"specific_function": "Two distinct, membrane-bound, FAD-containing enzymes are responsible for the catalysis of fumarate and succinate interconversion; the fumarate reductase is used in anaerobic growth, and the succinate dehydrogenase is used in aerobic growth.", "general_function": "Succinate dehydrogenase activity", "gene_names": ["frdB"], "name": "Fumarate reductase iron-sulfur subunit", "drug_actions": []}, "P52045": {"specific_function": "Catalyzes the decarboxylation of methylmalonyl-CoA to propionyl-CoA. Could be part of a pathway that converts succinate to propionate.", "general_function": "Methylmalonyl-coa decarboxylase activity", "gene_names": ["scpB"], "name": "Methylmalonyl-CoA decarboxylase", "drug_actions": []}, "Q9UK23": {"specific_function": "Catalyzes the second step in the formation of the mannose 6-phosphate targeting signal on lysosomal enzyme oligosaccharides by removing GlcNAc residues from GlcNAc-alpha-P-mannose moieties, which are formed in the first step. Also hydrolyzes UDP-GlcNAc, a sugar donor for Golgi N-acetylglucosaminyltransferases.", "general_function": "N-acetylglucosamine-1-phosphodiester alpha-n-acetylglucosaminidase activity", "gene_names": ["NAGPA"], "name": "N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase", "drug_actions": []}, "O75469": {"specific_function": "Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and isoflavones. Response to specific ligands is species-specific. Activated by naturally occurring steroids, such as pregnenolone and progesterone. Binds to a response element in the promoters of the CYP3A4 and ABCB1/MDR1 genes.", "general_function": "Zinc ion binding", "gene_names": ["NR1I2"], "name": "Nuclear receptor subfamily 1 group I member 2", "drug_actions": [{"action": "AGONIST", "target": "O75469", "drug": "DB00530"}, {"action": "AGONIST", "target": "O75469", "drug": "DB00977"}, {"action": "AGONIST", "target": "O75469", "drug": "DB01045"}, {"action": "AGONIST", "target": "O75469", "drug": "DB01220"}, {"action": "INDUCER", "target": "O75469", "drug": "DB01229"}, {"action": "BINDER", "target": "O75469", "drug": "DB01248"}, {"action": "ACTIVATOR", "target": "O75469", "drug": "DB01708"}, {"action": "AGONIST", "target": "O75469", "drug": "DB08864"}]}, "P43886": {"general_function": "Serine o-acetyltransferase activity", "gene_names": ["cysE"], "name": "Serine acetyltransferase", "drug_actions": []}, "P35219": {"specific_function": "Does not have a carbonic anhydrase catalytic activity.", "general_function": "Zinc ion binding", "gene_names": ["CA8"], "name": "Carbonic anhydrase-related protein", "drug_actions": [{"action": "INHIBITOR", "target": "P35219", "drug": "DB00909"}]}, "P35218": {"specific_function": "Reversible hydration of carbon dioxide. Low activity.", "general_function": "Zinc ion binding", "gene_names": ["CA5A"], "name": "Carbonic anhydrase 5A, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "P35218", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P35218", "drug": "DB01194"}, {"action": "INHIBITOR", "target": "P35218", "drug": "DB08846"}]}, "P17413": {"specific_function": "The fumarate reductase enzyme complex is required for fumarate respiration using formate or sulfide as electron donor.", "general_function": "Oxidoreductase activity, acting on the ch-ch group of donors", "gene_names": ["frdC"], "name": "Fumarate reductase cytochrome b subunit", "drug_actions": []}, "P07360": {"specific_function": "C8 is a constituent of the membrane attack complex. C8 binds to the C5B-7 complex, forming the C5B-8 complex. C5-B8 binds C9 and acts as a catalyst in the polymerization of C9. The gamma subunit seems to be able to bind retinol.", "general_function": "Retinol binding", "gene_names": ["C8G"], "name": "Complement component C8 gamma chain", "drug_actions": []}, "O75460": {"specific_function": "Senses unfolded proteins in the lumen of the endoplasmic reticulum via its N-terminal domain which leads to enzyme auto-activation. The active endoribonuclease domain splices XBP1 mRNA to generate a new C-terminus, converting it into a potent unfolded-protein response transcriptional activator and triggering growth arrest and apoptosis.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["ERN1"], "name": "Serine/threonine-protein kinase/endoribonuclease IRE1", "drug_actions": []}, "Q9RA47": {"general_function": "Nucleotide binding", "gene_names": ["metF"], "name": "Methylenetetrahydrofolate reductase", "drug_actions": []}, "P08179": {"specific_function": "Catalyzes the transfer of a formyl group from 10-formyltetrahydrofolate to 5-phospho-ribosyl-glycinamide (GAR), producing 5-phospho-ribosyl-N-formylglycinamide (FGAR) and tetrahydrofolate.", "general_function": "Phosphoribosylglycinamide formyltransferase activity", "gene_names": ["purN"], "name": "Phosphoribosylglycinamide formyltransferase", "drug_actions": []}, "P27707": {"specific_function": "Required for the phosphorylation of the deoxyribonucleosides deoxycytidine (dC), deoxyguanosine (dG) and deoxyadenosine (dA). Has broad substrate specificity, and does not display selectivity based on the chirality of the substrate. It is also an essential enzyme for the phosphorylation of numerous nucleoside analogs widely employed as antiviral and chemotherapeutic agents.", "general_function": "Protein homodimerization activity", "gene_names": ["DCK"], "name": "Deoxycytidine kinase", "drug_actions": [{"action": "AGONIST", "target": "P27707", "drug": "DB01073"}]}, "P00808": {"general_function": "Beta-lactamase activity", "gene_names": ["penP"], "name": "Beta-lactamase", "drug_actions": []}, "P00374": {"specific_function": "Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFRL1.", "general_function": "Nadph binding", "gene_names": ["DHFR"], "name": "Dihydrofolate reductase", "drug_actions": [{"action": "INHIBITOR", "target": "P00374", "drug": "DB00205"}, {"action": "INHIBITOR", "target": "P00374", "drug": "DB00440"}, {"action": "INHIBITOR", "target": "P00374", "drug": "DB00563"}, {"action": "INHIBITOR", "target": "P00374", "drug": "DB00642"}, {"action": "INHIBITOR", "target": "P00374", "drug": "DB01131"}, {"action": "INHIBITOR", "target": "P00374", "drug": "DB01157"}, {"action": "INHIBITOR", "target": "P00374", "drug": "DB06813"}]}, "P00807": {"general_function": "Beta-lactamase activity", "gene_names": ["blaZ"], "name": "Beta-lactamase", "drug_actions": [{"action": "INHIBITOR", "target": "P00807", "drug": "DB00766"}, {"action": "OTHER/UNKNOWN", "target": "P00807", "drug": "DB01598"}]}, "P27708": {"specific_function": "This protein is a \"fusion\" protein encoding four enzymatic activities of the pyrimidine pathway (GATase, CPSase, ATCase and DHOase).", "general_function": "Zinc ion binding", "gene_names": ["CAD"], "name": "CAD protein", "drug_actions": []}, "P00805": {"general_function": "Identical protein binding", "gene_names": ["ansB"], "name": "L-asparaginase 2", "drug_actions": []}, "P00803": {"general_function": "Toxic substance binding", "gene_names": ["lepB"], "name": "Signal peptidase I", "drug_actions": []}, "P00800": {"specific_function": "Extracellular zinc metalloprotease.", "general_function": "Metalloendopeptidase activity", "gene_names": ["npr"], "name": "Thermolysin", "drug_actions": []}, "P42443": {"specific_function": "Can catalyze the hydrolysis of ATP in the presence of single-stranded DNA, the ATP-dependent uptake of single-stranded DNA by duplex DNA, and the ATP-dependent hybridization of homologous single-stranded DNAs. It interacts with LexA causing its activation and leading to its autocatalytic cleavage.", "general_function": "Single-stranded dna binding", "gene_names": ["recA"], "name": "Protein RecA", "drug_actions": []}, "P01579": {"specific_function": "Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons.", "general_function": "Interferon-gamma receptor binding", "gene_names": ["IFNG"], "name": "Interferon gamma", "drug_actions": []}, "P28702": {"specific_function": "Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5 (By similarity). Specifically binds 9-cis retinoic acid (9C-RA).", "general_function": "Zinc ion binding", "gene_names": ["RXRB"], "name": "Retinoic acid receptor RXR-beta", "drug_actions": [{"action": "AGONIST", "target": "P28702", "drug": "DB00210"}, {"action": "AGONIST", "target": "P28702", "drug": "DB00307"}, {"action": "AGONIST", "target": "P28702", "drug": "DB00459"}, {"action": "AGONIST", "target": "P28702", "drug": "DB00523"}, {"action": "AGONIST", "target": "P28702", "drug": "DB00755"}, {"action": "AGONIST", "target": "P28702", "drug": "DB00799"}, {"action": "AGONIST", "target": "P28702", "drug": "DB00926"}]}, "P43405": {"specific_function": "Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR). Regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. Assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. Direct downstream effectors phosphorylated by SYK include VAV1, PLCG1, PI-3-kinase, LCP2 and BLNK. Initially identified as essential in B-cell receptor (BCR) signaling, it is necessary for the maturation of B-cells most probably at the pro-B to pre-B transition. Activated upon BCR engagement, it phosphorylates and activates BLNK an adapter linking the activated BCR to downstream signaling adapters and effectors. It also phosphorylates and activates PLCG1 and the PKC signaling pathway. It also phosphorylates BTK and regulates its activity in B-cell antigen receptor (BCR)-coupled signaling. In addition to its function downstream of BCR plays also a role in T-cell receptor signaling. Plays also a crucial role in the innate immune response to fungal, bacterial and viral pathogens. It is for instance activated by the membrane lectin CLEC7A. Upon stimulation by fungal proteins, CLEC7A together with SYK activates immune cells inducing the production of ROS. Also activates the inflammasome and NF-kappa-B-mediated transcription of chemokines and cytokines in presence of pathogens. Regulates neutrophil degranulation and phagocytosis through activation of the MAPK signaling cascade. Also mediates the activation of dendritic cells by cell necrosis stimuli. Also involved in mast cells activation. Also functions downstream of receptors mediating cell adhesion. Relays for instance, integrin-mediated neutrophils and macrophages activation and P-selectin receptor/SELPG-mediated recruitment of leukocytes to inflammatory loci. Plays also a role in non-immune processes. It is for instance involved in vascular development where it may regulate blood and lymphatic vascular separation. It is also required for osteoclast development and function. Functions in the activation of platelets by collagen, mediating PLCG2 phosphorylation and activation. May be coupled to the collagen receptor by the ITAM domain-containing FCER1G. Also activated by the membrane lectin CLEC1B that is required for activation of platelets by PDPN/podoplanin. Involved in platelet adhesion being activated by ITGB3 engaged by fibrinogen.", "general_function": "Receptor signaling protein tyrosine kinase activity", "gene_names": ["SYK"], "name": "Tyrosine-protein kinase SYK", "drug_actions": [{"action": "INHIBITOR", "target": "P43405", "drug": "DB08846"}]}, "P08588": {"specific_function": "Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.", "name": "Beta-1 adrenergic receptor", "drug_actions": [{"action": "AGONIST", "target": "P08588", "drug": "DB00182"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB00187"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB00195"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB00217"}, {"action": "AGONIST", "target": "P08588", "drug": "DB00221"}, {"action": "BINDER", "target": "P08588", "drug": "DB00248"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB00264"}, {"action": "BINDER", "target": "P08588", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB00335"}, {"action": "AGONIST", "target": "P08588", "drug": "DB00368"}, {"action": "BINDER", "target": "P08588", "drug": "DB00370"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB00373"}, {"action": "AGONIST", "target": "P08588", "drug": "DB00397"}, {"action": "BINDER", "target": "P08588", "drug": "DB00408"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB00489"}, {"action": "PARTIAL AGONIST", "target": "P08588", "drug": "DB00521"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB00571"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB00598"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB00612"}, {"action": "AGONIST", "target": "P08588", "drug": "DB00668"}, {"action": "BINDER", "target": "P08588", "drug": "DB00726"}, {"action": "AGONIST", "target": "P08588", "drug": "DB00841"}, {"action": "AGONIST", "target": "P08588", "drug": "DB00852"}, {"action": "PARTIAL AGONIST", "target": "P08588", "drug": "DB00852"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB00866"}, {"action": "PARTIAL AGONIST", "target": "P08588", "drug": "DB00960"}, {"action": "AGONIST", "target": "P08588", "drug": "DB01001"}, {"action": "AGONIST", "target": "P08588", "drug": "DB01064"}, {"action": "AGONIST", "target": "P08588", "drug": "DB01102"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB01118"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB01136"}, {"action": "OTHER", "target": "P08588", "drug": "DB01151"}, {"action": "PARTIAL AGONIST", "target": "P08588", "drug": "DB01193"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB01203"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB01210"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB01214"}, {"action": "AGONIST", "target": "P08588", "drug": "DB01288"}, {"action": "AGONIST", "target": "P08588", "drug": "DB01291"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB01295"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB01297"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB01359"}, {"action": "PARTIAL AGONIST", "target": "P08588", "drug": "DB01359"}, {"action": "AGONIST", "target": "P08588", "drug": "DB01363"}, {"action": "AGONIST", "target": "P08588", "drug": "DB01365"}, {"action": "AGONIST", "target": "P08588", "drug": "DB01407"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB01580"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB04846"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB04861"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB06216"}, {"action": "AGONIST", "target": "P08588", "drug": "DB06262"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB06726"}, {"action": "PARTIAL AGONIST", "target": "P08588", "drug": "DB08807"}, {"action": "ANTAGONIST", "target": "P08588", "drug": "DB08808"}, {"action": "LIGAND", "target": "P08588", "drug": "DB09068"}], "general_function": "Receptor signaling protein activity", "in_complexes": ["Beta adrenergic receptor"], "gene_names": ["ADRB1"]}, "P43403": {"specific_function": "Tyrosine kinase that plays an essential role in regulation of the adaptive immune response. Regulates motility, adhesion and cytokine expression of mature T-cells, as well as thymocyte development. Contributes also to the development and activation of primary B-lymphocytes. When antigen presenting cells (APC) activate T-cell receptor (TCR), a serie of phosphorylations lead to the recruitment of ZAP70 to the doubly phosphorylated TCR component CD247/CD3Z through ITAM motif at the plasma membrane. This recruitment serves to localization to the stimulated TCR and to relieve its autoinhibited conformation. Release of ZAP70 active conformation is further stabilized by phosphorylation mediated by LCK. Subsequently, ZAP70 phosphorylates at least 2 essential adapter proteins: LAT and LCP2. In turn, a large number of signaling molecules are recruited and ultimately lead to lymphokine production, T-cell proliferation and differentiation. Furthermore, ZAP70 controls cytoskeleton modifications, adhesion and mobility of T-lymphocytes, thus ensuring correct delivery of effectors to the APC. ZAP70 is also required for TCR-CD247/CD3Z internalization and degradation through interaction with the E3 ubiquitin-protein ligase CBL and adapter proteins SLA and SLA2. Thus, ZAP70 regulates both T-cell activation switch on and switch off by modulating TCR expression at the T-cell surface. During thymocyte development, ZAP70 promotes survival and cell-cycle progression of developing thymocytes before positive selection (when cells are still CD4/CD8 double negative). Additionally, ZAP70-dependent signaling pathway may also contribute to primary B-cells formation and activation through B-cell receptor (BCR).", "general_function": "Receptor binding", "gene_names": ["ZAP70"], "name": "Tyrosine-protein kinase ZAP-70", "drug_actions": []}, "P25963": {"specific_function": "Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL dimers in the cytoplasm through masking of their nuclear localization signals. On cellular stimulation by immune and proinflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["NFKBIA"], "name": "NF-kappa-B inhibitor alpha", "drug_actions": []}, "Q9WXS0": {"general_function": "Dna binding", "gene_names": [], "name": "Transcriptional regulator, IclR family", "drug_actions": []}, "Q96EY8": {"general_function": "Cob(i)yrinic acid a,c-diamide adenosyltransferase activity", "gene_names": ["MMAB"], "name": "Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial", "drug_actions": [{"action": "OTHER", "target": "Q96EY8", "drug": "DB00200"}]}, "P08581": {"specific_function": "Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells.Acts as a receptor for Listeria internalin inlB, mediating entry of the pathogen into cells.", "general_function": "Protein tyrosine kinase activity", "gene_names": ["MET"], "name": "Hepatocyte growth factor receptor", "drug_actions": [{"action": "INHIBITOR", "target": "P08581", "drug": "DB08865"}, {"action": "ANTAGONIST", "target": "P08581", "drug": "DB08875"}]}, "P21404": {"specific_function": "Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host integrin ITGAV/ITGB6 to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP2: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP3: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP4: Lies on the inner surface of the capsid shell. After binding to the host receptor, the capsid undergoes conformational changes. Capsid protein VP4 is released, Capsid protein VP1 N-terminus is externalized, and together, they shape a pore in the host membrane through which the viral genome is translocated into the host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP0: Component of immature procapsids, which is cleaved into capsid proteins VP4 and VP2 after maturation. Allows the capsid to remain inactive before the maturation step (By similarity).Protein 2A: Cysteine protease that cleaves viral polyprotein and specific host proteins. It is responsible for the cleavage between the P1 and P2 regions, first cleavage occurring in the polyprotein. Cleaves also the host translation initiation factor EIF4G1, in order to shut down the capped cellular mRNA translation. Inhibits the host nucleus-cytoplasm protein and RNA trafficking by cleaving host members of the nuclear pores (By similarity).Protein 2B: Plays an essential role in the virus replication cycle by acting as a viroporin. Creates a pore in the host reticulum endoplasmic and as a consequence releases Ca2+ in the cytoplasm of infected cell. In turn, high levels of cyctoplasmic calcium may trigger membrane trafficking and transport of viral ER-associated proteins to viroplasms, sites of viral genome replication (By similarity).Protein 2C: Induces and associates with structural rearrangements of intracellular membranes. Displays RNA-binding, nucleotide binding and NTPase activities. May play a role in virion morphogenesis and viral RNA encapsidation by interacting with the capsid protein VP3 (By similarity).Protein 3AB: Localizes the viral replication complex to the surface of membranous vesicles. Together with protein 3CD binds the Cis-Active RNA Element (CRE) which is involved in RNA synthesis initiation. Acts as a cofactor to stimulate the activity of 3D polymerase, maybe through a nucleid acid chaperone activity (By similarity).Protein 3A: Localizes the viral replication complex to the surface of membranous vesicles. It inhibits host cell endoplasmic reticulum-to-Golgi apparatus transport and causes the dissassembly of the Golgi complex, possibly through GBF1 interaction. This would result in depletion of MHC, trail receptors and IFN receptors at the host cell surface (By similarity).Viral protein genome-linked: acts as a primer for viral RNA replication and remains covalently bound to viral genomic RNA. VPg is uridylylated prior to priming replication into VPg-pUpU. The oriI viral genomic sequence may act as a template for this. The VPg-pUpU is then used as primer on the genomic RNA poly(A) by the RNA-dependent RNA polymerase to replicate the viral genome. VPg may be removed in the cytoplasm by an unknown enzyme termed \"unlinkase\". VPg is not cleaved off virion genomes because replicated genomic RNA are encapsidated at the site of replication (By similarity).Protein 3CD: Is involved in the viral replication complex and viral polypeptide maturation. It exhibits protease activity with a specificity and catalytic efficiency that is different from protease 3C. Protein 3CD lacks polymerase activity. The 3C domain in the context of protein 3CD may have an RNA binding activity (By similarity).Protease 3C: cleaves host DDX58/RIG-I and thus contributes to the inhibition of type I interferon production. Cleaves also host PABPC1 (By similarity).RNA-directed RNA polymerase: Replicates the viral genomic RNA on the surface of intracellular membranes. May form linear arrays of subunits that propagate along a strong head-to-tail interaction called interface-I. Covalently attaches UMP to a tyrosine of VPg, which is used to prime RNA synthesis. The positive stranded RNA genome is first replicated at virus induced membranous vesicles, creating a dsRNA genomic replication form. This dsRNA is then used as template to synthesize positive stranded RNA genomes. ss(+)RNA genomes are either translated, replicated or encapsidated (By similarity).", "general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "Q92806": {"specific_function": "This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium (By similarity).", "general_function": "G-protein activated inward rectifier potassium channel activity", "gene_names": ["KCNJ9"], "name": "G protein-activated inward rectifier potassium channel 3", "drug_actions": []}, "P01574": {"specific_function": "Has antiviral, antibacterial and anticancer activities.", "general_function": "Type i interferon receptor binding", "gene_names": ["IFNB1"], "name": "Interferon beta", "drug_actions": []}, "P00395": {"specific_function": "Cytochrome c oxidase is the component of the respiratory chain that catalyzes the reduction of oxygen to water. Subunits 1-3 form the functional core of the enzyme complex. CO I is the catalytic subunit of the enzyme. Electrons originating in cytochrome c are transferred via the copper A center of subunit 2 and heme A of subunit 1 to the bimetallic center formed by heme A3 and copper B.", "general_function": "Iron ion binding", "gene_names": ["MT-CO1"], "name": "Cytochrome c oxidase subunit 1", "drug_actions": []}, "P00390": {"specific_function": "Maintains high levels of reduced glutathione in the cytosol.", "general_function": "Nadp binding", "gene_names": ["GSR"], "name": "Glutathione reductase, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "P00390", "drug": "DB00262"}]}, "P0A108": {"specific_function": "Involved in the naphthalene catabolic pathway. Catalyzes the meta-cleavage of 1,2-dihydroxynaphthalene (1,2-DHN) to yield 2-hydroxychromene-2-carboxylic acid (By similarity).", "general_function": "Oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen", "gene_names": ["doxG"], "name": "1,2-dihydroxynaphthalene dioxygenase", "drug_actions": []}, "Q13285": {"specific_function": "Transcriptional activator. Seems to be essential for sexual differentiation and formation of the primary steroidogenic tissues. Binds to the Ad4 site found in the promoter region of steroidogenic P450 genes such as CYP11A, CYP11B and CYP21B. Also regulates the AMH/Muellerian inhibiting substance gene as well as the AHCH and STAR genes. 5'-YCAAGGYC-3' and 5'-RRAGGTCA-3' are the consensus sequences for the recognition by NR5A1. The SFPQ-NONO-NR5A1 complex binds to the CYP17 promoter and regulates basal and cAMP-dependent transcriptional avtivity. Binds phosphatidylcholine (By similarity). Binds phospholipids with a phosphatidylinositol (PI) headgroup, in particular PI(3,4)P2 and PI(3,4,5)P3. Activated by the phosphorylation of NR5A1 by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation.", "general_function": "Zinc ion binding", "gene_names": ["NR5A1"], "name": "Steroidogenic factor 1", "drug_actions": []}, "P02751": {"specific_function": "Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell shape. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralization. Participates in the regulation of type I collagen deposition by osteoblasts.Anastellin binds fibronectin and induces fibril formation. This fibronectin polymer, named superfibronectin, exhibits enhanced adhesive properties. Both anastellin and superfibronectin inhibit tumor growth, angiogenesis and metastasis. Anastellin activates p38 MAPK and inhibits lysophospholipid signaling.", "general_function": "Protease binding", "gene_names": ["FN1"], "name": "Fibronectin", "drug_actions": [{"action": "CLEAVAGE", "target": "P02751", "drug": "DB08888"}]}, "Q9Z4J7": {"specific_function": "Catalyzes the oxidation of primary alcohols except for methanol that is a very poor substrate.", "general_function": "Ethanol:cytochrome c oxidoreductase activity", "gene_names": ["exaA"], "name": "Quinoprotein ethanol dehydrogenase", "drug_actions": []}, "Q82ZJ0": {"specific_function": "Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions.", "general_function": "Peptide deformylase activity", "gene_names": ["def"], "name": "Peptide deformylase", "drug_actions": []}, "O75600": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["GCAT"], "name": "2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial", "drug_actions": [{"action": "COFACTOR", "target": "O75600", "drug": "DB00114"}]}, "P49137": {"specific_function": "Stress-activated serine/threonine-protein kinase involved in cytokines production, endocytosis, reorganization of the cytoskeleton, cell migration, cell cycle control, chromatin remodeling, DNA damage response and transcriptional regulation. Following stress, it is phosphorylated and activated by MAP kinase p38-alpha/MAPK14, leading to phosphorylation of substrates. Phosphorylates serine in the peptide sequence, Hyd-X-R-X(2)-S, where Hyd is a large hydrophobic residue. Phosphorylates ALOX5, CDC25B, CDC25C, ELAVL1, HNRNPA0, HSF1, HSP27/HSPB1, KRT18, KRT20, LIMK1, LSP1, PABPC1, PARN, PDE4A, RCSD1, RPS6KA3, TAB3 and TTP/ZFP36. Mediates phosphorylation of HSP27/HSPB1 in response to stress, leading to dissociate HSP27/HSPB1 from large small heat-shock protein (sHsps) oligomers and impair their chaperone activities and ability to protect against oxidative stress effectively. Involved in inflammatory response by regulating tumor necrosis factor (TNF) and IL6 production post-transcriptionally: acts by phosphorylating AU-rich elements (AREs)-binding proteins ELAVL1, HNRNPA0, PABPC1 and TTP/ZFP36, leading to regulate the stability and translation of TNF and IL6 mRNAs. Phosphorylation of TTP/ZFP36, a major post-transcriptional regulator of TNF, promotes its binding to 14-3-3 proteins and reduces its ARE mRNA affinity leading to inhibition of dependent degradation of ARE-containing transcript. Also involved in late G2/M checkpoint following DNA damage through a process of post-transcriptional mRNA stabilization: following DNA damage, relocalizes from nucleus to cytoplasm and phosphorylates HNRNPA0 and PARN, leading to stabilize GADD45A mRNA. Involved in toll-like receptor signaling pathway (TLR) in dendritic cells: required for acute TLR-induced macropinocytosis by phosphorylating and activating RPS6KA3.", "general_function": "Signal transducer activity", "gene_names": ["MAPKAPK2"], "name": "MAP kinase-activated protein kinase 2", "drug_actions": []}, "P53355": {"specific_function": "Calcium/calmodulin-dependent serine/threonine kinase involved in multiple cellular signaling pathways that trigger cell survival, apoptosis, and autophagy. Regulates both type I apoptotic and type II autophagic cell deaths signal, depending on the cellular setting. The former is caspase-dependent, while the latter is caspase-independent and is characterized by the accumulation of autophagic vesicles. Phosphorylates PIN1 resulting in inhibition of its catalytic activity, nuclear localization, and cellular function. Phosphorylates TPM1, enhancing stress fiber formation in endothelial cells. Phosphorylates STX1A and significantly decreases its binding to STXBP1. Phosphorylates PRKD1 and regulates JNK signaling by binding and activating PRKD1 under oxidative stress. Phosphorylates BECN1, reducing its interaction with BCL2 and BCL2L1 and promoting the induction of autophagy. Phosphorylates TSC2, disrupting the TSC1-TSC2 complex and stimulating mTORC1 activity in a growth factor-dependent pathway. Phosphorylates RPS6, MYL9 and DAPK3. Acts as a signaling amplifier of NMDA receptors at extrasynaptic sites for mediating brain damage in stroke. Cerebral ischemia recruits DAPK1 into the NMDA receptor complex and it phosphorylates GRINB at Ser-1303 inducing injurious Ca(2+) influx through NMDA receptor channels, resulting in an irreversible neuronal death. Required together with DAPK3 for phosphorylation of RPL13A upon interferon-gamma activation which is causing RPL13A involvement in transcript-selective translation inhibition.Isoform 2 cannot induce apoptosis but can induce membrane blebbing.", "general_function": "Syntaxin-1 binding", "gene_names": ["DAPK1"], "name": "Death-associated protein kinase 1", "drug_actions": []}, "P0A8T7": {"specific_function": "DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates.", "general_function": "Dna-directed rna polymerase activity", "gene_names": ["rpoC"], "name": "DNA-directed RNA polymerase subunit beta'", "drug_actions": [{"action": "INHIBITOR", "target": "P0A8T7", "drug": "DB00615"}, {"action": "INHIBITOR", "target": "P0A8T7", "drug": "DB01045"}]}, "P62745": {"specific_function": "Mediates apoptosis in neoplastically transformed cells after DNA damage. Not essential for development but affects cell adhesion and growth factor signaling in transformed cells. Plays a negative role in tumorigenesis as deletion causes tumor formation. Involved in intracellular protein trafficking of a number of proteins. Targets PKN1 to endosomes and is involved in trafficking of the EGF receptor from late endosomes to lysosomes. Also required for stability and nuclear trafficking of AKT1/AKT which promotes endothelial cell survival during vascular development. Serves as a microtubule-dependent signal that is required for the myosin contractile ring formation during cell cycle cytokinesis. Required for genotoxic stress-induced cell death in breast cancer cells.", "general_function": "Gtpase activity", "gene_names": ["RHOB"], "name": "Rho-related GTP-binding protein RhoB", "drug_actions": []}, "P04079": {"specific_function": "Catalyzes the synthesis of GMP from XMP.", "general_function": "Pyrophosphatase activity", "gene_names": ["guaA"], "name": "GMP synthase [glutamine-hydrolyzing]", "drug_actions": []}, "P32055": {"specific_function": "Catalyzes the two-step NADP-dependent conversion of GDP-4-dehydro-6-deoxy-D-mannose to GDP-fucose, involving an epimerase and a reductase reaction.", "general_function": "Nadp+ binding", "gene_names": ["fcl"], "name": "GDP-L-fucose synthase", "drug_actions": []}, "P23258": {"specific_function": "Tubulin is the major constituent of microtubules. The gamma chain is found at microtubule organizing centers (MTOC) such as the spindle poles or the centrosome. Pericentriolar matrix component that regulates alpha/beta chain minus-end nucleation, centrosome duplication and spindle formation.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["TUBG1"], "name": "Tubulin gamma-1 chain", "drug_actions": [{"action": "ADDUCT", "target": "P23258", "drug": "DB00570"}]}, "P13639": {"specific_function": "Catalyzes the GTP-dependent ribosomal translocation step during translation elongation. During this step, the ribosome changes from the pre-translocational (PRE) to the post-translocational (POST) state as the newly formed A-site-bound peptidyl-tRNA and P-site-bound deacylated tRNA move to the P and E sites, respectively. Catalyzes the coordinated movement of the two tRNA molecules, the mRNA and conformational changes in the ribosome.", "general_function": "Translation elongation factor activity", "gene_names": ["EEF2"], "name": "Elongation factor 2", "drug_actions": []}, "P03369": {"specific_function": "Gag-Pol polyprotein: Mediates, with Gag polyrotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shutt off translation.Matrix protein p17: Targets the polyprotein to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus. Matrix protein is part of the pre-integration complex. Implicated in the release from host cell mediated by Vpu. Binds to RNA.Capsid protein p24: Forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion. Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry (By similarity). Host restriction factors such as TRIM5-alpha or TRIMCyp bind retroviral capsids and cause premature capsid disassembly, leading to blocks in reverse transcription. Capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species. Host PIN1 apparently facilitates the virion uncoating. On the other hand, interactions with PDZD8 or CYPA stabilize the capsid.Nucleocapsid protein p7: Encapsulates and protects viral dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its zinc fingers. Acts as a nucleic acid chaperone which is involved in rearangement of nucleic acid secondary structure during gRNA retrotranscription. Also facilitates template switch leading to recombination. As part of the polyprotein, participates to gRNA dimerization, packaging, tRNA incorporation and virion assembly.Protease: Aspartyl protease that mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane. Cleavages take place as an ordered, step-wise cascade to yield mature proteins. This process is called maturation. Displays maximal activity during the budding process just prior to particle release from the cell. Also cleaves Nef and Vif, probably concomitantly with viral structural proteins on maturation of virus particles. Hydrolyzes host EIF4GI and PABP1 in order to shut off the capped cellular mRNA translation. The resulting inhibition of cellular protein synthesis serves to ensure maximal viral gene expression and to evade host immune response (By similarity).Reverse transcriptase/ribonuclease H: Multifunctional enzyme that converts the viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for two polypurine tracts (PPTs) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPTs that have not been removed by RNase H as primers. PPTs and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends.Integrase: Catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration.", "general_function": "Zinc ion binding", "gene_names": ["gag-pol"], "name": "Gag-Pol polyprotein", "drug_actions": []}, "O96017": {"specific_function": "Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks. May also negatively regulate cell cycle progression during unperturbed cell cycles. Following activation, phosphorylates numerous effectors preferentially at the consensus sequence [L-X-R-X-X-S/T]. Regulates cell cycle checkpoint arrest through phosphorylation of CDC25A, CDC25B and CDC25C, inhibiting their activity. Inhibition of CDC25 phosphatase activity leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression. May also phosphorylate NEK6 which is involved in G2/M cell cycle arrest. Regulates DNA repair through phosphorylation of BRCA2, enhancing the association of RAD51 with chromatin which promotes DNA repair by homologous recombination. Also stimulates the transcription of genes involved in DNA repair (including BRCA2) through the phosphorylation and activation of the transcription factor FOXM1. Regulates apoptosis through the phosphorylation of p53/TP53, MDM4 and PML. Phosphorylation of p53/TP53 at 'Ser-20' by CHEK2 may alleviate inhibition by MDM2, leading to accumulation of active p53/TP53. Phosphorylation of MDM4 may also reduce degradation of p53/TP53. Also controls the transcription of pro-apoptotic genes through phosphorylation of the transcription factor E2F1. Tumor suppressor, it may also have a DNA damage-independent function in mitotic spindle assembly by phosphorylating BRCA1. Its absence may be a cause of the chromosomal instability observed in some cancer cells. Promotes the CCAR2-SIRT1 association and is required for CCAR2-mediated SIRT1 inhibition (PubMed:25361978).", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["CHEK2"], "name": "Serine/threonine-protein kinase Chk2", "drug_actions": []}, "A1AFW1": {"general_function": "Involved in transferase activity", "gene_names": ["assT"], "name": "Arylsulfate sulfotransferase", "drug_actions": []}, "P04004": {"specific_function": "Vitronectin is a cell adhesion and spreading factor found in serum and tissues. Vitronectin interact with glycosaminoglycans and proteoglycans. Is recognized by certain members of the integrin family and serves as a cell-to-substrate adhesion molecule. Inhibitor of the membrane-damaging effect of the terminal cytolytic complement pathway.Somatomedin-B is a growth hormone-dependent serum factor with protease-inhibiting activity.", "general_function": "Scavenger receptor activity", "gene_names": ["VTN"], "name": "Vitronectin", "drug_actions": []}, "Q72K87": {"specific_function": "Reversibly transfers an adenylyl group from ATP to 4'-phosphopantetheine, yielding dephospho-CoA (dPCoA) and pyrophosphate.", "general_function": "Pantetheine-phosphate adenylyltransferase activity", "gene_names": ["coaD"], "name": "Phosphopantetheine adenylyltransferase", "drug_actions": []}, "Q0P8G4": {"general_function": "Metal ion binding", "gene_names": ["dut"], "name": "DUTPase", "drug_actions": []}, "B0Q840": {"general_function": "Lipid transport and metabolism", "gene_names": ["fabI"], "name": "Enoyl-[acyl-carrier-protein] reductase [NADH]", "drug_actions": []}, "P01375": {"specific_function": "Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Upregulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:23396208). Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line (PubMed:22517918).The TNF intracellular domain (ICD) form induces IL12 production in dendritic cells.", "general_function": "Tumor necrosis factor receptor binding", "gene_names": ["TNF"], "name": "Tumor necrosis factor", "drug_actions": [{"action": "ANTIBODY", "target": "P01375", "drug": "DB00005"}, {"action": "ANTIBODY", "target": "P01375", "drug": "DB00051"}, {"action": "INHIBITOR", "target": "P01375", "drug": "DB00065"}, {"action": "ANTAGONIST", "target": "P01375", "drug": "DB00668"}, {"action": "INHIBITOR", "target": "P01375", "drug": "DB01041"}, {"action": "OTHER/UNKNOWN", "target": "P01375", "drug": "DB01407"}, {"action": "OTHER/UNKNOWN", "target": "P01375", "drug": "DB01411"}, {"action": "INHIBITOR", "target": "P01375", "drug": "DB01427"}, {"action": "ANTIBODY", "target": "P01375", "drug": "DB06674"}, {"action": "NEUTRALIZER", "target": "P01375", "drug": "DB08904"}, {"action": "INHIBITOR", "target": "P01375", "drug": "DB08910"}]}, "P01374": {"specific_function": "Cytokine that in its homotrimeric form binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR and TNFRSF14/HVEM. In its heterotrimeric form with LTB binds to TNFRSF3/LTBR. Lymphotoxin is produced by lymphocytes and cytotoxic for a wide range of tumor cells in vitro and in vivo.", "general_function": "Receptor binding", "gene_names": ["LTA"], "name": "Lymphotoxin-alpha", "drug_actions": []}, "P27017": {"specific_function": "Negatively regulates the expression of the aliphatic amidase operon. AmiC functions by inhibiting the action of AmiR at the protein level. It exhibits protein kinase activity.", "general_function": "Kinase activity", "gene_names": ["amiC"], "name": "Aliphatic amidase expression-regulating protein", "drug_actions": []}, "Q8V397": {"general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "Q7SIA3": {"general_function": "Nitrous-oxide reductase activity", "gene_names": [], "name": "Oxidoreductase", "drug_actions": []}, "Q02224": {"specific_function": "Essential for the maintenance of chromosomal stability through efficient stabilization of microtubule capture at kinetochores. Plays a key role in the movement of chromosomes toward the metaphase plate during mitosis. Is a slow plus end-directed motor whose activity is essential for metaphase chromosome alignment. Couples chromosome position to microtubule depolymerizing activity. The highly processive microtubule-dependent motor activity of CENPE serves to power chromosome congression and provides a flexible, motile tether linking kinetochores to dynamic spindle microtubules. Necessary for the mitotic checkpoint signal at individual kinetochores to prevent aneuploidy due to single chromosome loss. Required for the efficient recruitment of BUBR1, MAD1 and MAD2 to attached and newly unattached kinetochores. Stimulates mammalian BUBR1 kinase activity. Accumulates just before mitosis at the G2 phase of the cell cycle.", "general_function": "Microtubule motor activity", "gene_names": ["CENPE"], "name": "Centromere-associated protein E", "drug_actions": []}, "Q7SIA5": {"gene_names": [], "name": "Carboxylesterase", "drug_actions": []}, "Q9UJX1": {"general_function": "Transaminase activity", "gene_names": ["TLH6"], "name": "Alanine-glyoxylate aminotransferase homolog", "drug_actions": [{"action": "COFACTOR", "target": "Q9UJX1", "drug": "DB00114"}]}, "Q02221": {"specific_function": "This protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport.", "general_function": "Cytochrome-c oxidase activity", "gene_names": ["COX6A2"], "name": "Cytochrome c oxidase subunit 6A2, mitochondrial", "drug_actions": []}, "P41240": {"specific_function": "Non-receptor tyrosine-protein kinase that plays an important role in the regulation of cell growth, differentiation, migration and immune response. Phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs) including LCK, SRC, HCK, FYN, LYN or YES1. Upon tail phosphorylation, Src-family members engage in intramolecular interactions between the phosphotyrosine tail and the SH2 domain that result in an inactive conformation. To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. Suppresses signaling by various surface receptors, including T-cell receptor (TCR) and B-cell receptor (BCR) by phosphorylating and maintaining inactive several positive effectors such as FYN or LCK.", "general_function": "Receptor binding", "gene_names": ["CSK"], "name": "Tyrosine-protein kinase CSK", "drug_actions": []}, "P0A9P4": {"general_function": "Thioredoxin-disulfide reductase activity", "gene_names": ["trxB"], "name": "Thioredoxin reductase", "drug_actions": []}, "P47985": {"specific_function": "Component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is a respiratory chain that generates an electrochemical potential coupled to ATP synthesis.The transit peptide of the Rieske protein seems to form part of the bc1 complex and is considered to be the subunit 11/IX of that complex.", "general_function": "Ubiquinol-cytochrome-c reductase activity", "gene_names": ["UQCRFS1"], "name": "Cytochrome b-c1 complex subunit Rieske, mitochondrial", "drug_actions": []}, "Q9GZZ6": {"specific_function": "Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane. In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma.", "general_function": "Receptor binding", "gene_names": ["CHRNA10"], "name": "Neuronal acetylcholine receptor subunit alpha-10", "drug_actions": [{"action": "AGONIST", "target": "Q9GZZ6", "drug": "DB00184"}, {"action": "AGONIST", "target": "Q9GZZ6", "drug": "DB00202"}, {"action": "ANTAGONIST", "target": "Q9GZZ6", "drug": "DB00333"}, {"action": "ALLOSTERIC MODULATOR", "target": "Q9GZZ6", "drug": "DB00674"}, {"action": "ANTAGONIST", "target": "Q9GZZ6", "drug": "DB01090"}, {"action": "ANTAGONIST", "target": "Q9GZZ6", "drug": "DB01116"}, {"action": "ANTAGONIST", "target": "Q9GZZ6", "drug": "DB01161"}]}, "P0A434": {"specific_function": "Has an unusual substrate specificity for synthetic organophosphate triesters and phosphorofluoridates. All of the phosphate triesters found to be substrates are synthetic compounds. The identity of any naturally occurring substrate for the enzyme is unknown. Has no detectable activity with phosphate monoesters or diesters and no activity as an esterase or protease. It catalyzes the hydrolysis of the insecticide paraoxon at a rate approaching the diffusion limit and thus appears to be optimally evolved for utilizing this synthetic substrate.", "general_function": "Zinc ion binding", "gene_names": ["opd"], "name": "Parathion hydrolase", "drug_actions": []}, "P22513": {"general_function": "Nadp binding", "gene_names": [], "name": "Glyceraldehyde-3-phosphate dehydrogenase, glycosomal", "drug_actions": []}, "P22033": {"specific_function": "Involved in the degradation of several amino acids, odd-chain fatty acids and cholesterol via propionyl-CoA to the tricarboxylic acid cycle. MCM has different functions in other species.", "general_function": "Modified amino acid binding", "gene_names": ["MUT"], "name": "Methylmalonyl-CoA mutase, mitochondrial", "drug_actions": [{"action": "COFACTOR", "target": "P22033", "drug": "DB00115"}, {"action": "COFACTOR", "target": "P22033", "drug": "DB00200"}]}, "Q9KPI8": {"specific_function": "Catalyzes the irreversible cleavage of the glycosidic bond in both 5'-methylthioadenosine (MTA) and S-adenosylhomocysteine (SAH/AdoHcy) to adenine and the corresponding thioribose, 5'-methylthioribose and S-ribosylhomocysteine, respectively.", "general_function": "Methylthioadenosine nucleosidase activity", "gene_names": ["mtnN"], "name": "5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase", "drug_actions": []}, "Q99707": {"specific_function": "Catalyzes the transfer of a methyl group from methyl-cobalamin to homocysteine, yielding enzyme-bound cob(I)alamin and methionine. Subsequently, remethylates the cofactor using methyltetrahydrofolate (By similarity).", "general_function": "Zinc ion binding", "gene_names": ["MTR"], "name": "Methionine synthase", "drug_actions": [{"action": "COFACTOR", "target": "Q99707", "drug": "DB00115"}, {"action": "COFACTOR", "target": "Q99707", "drug": "DB00116"}, {"action": "PRODUCT OF", "target": "Q99707", "drug": "DB00134"}, {"action": "COFACTOR", "target": "Q99707", "drug": "DB00200"}]}, "Q99250": {"specific_function": "Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient.", "name": "Sodium channel protein type 2 subunit alpha", "drug_actions": [{"action": "INHIBITOR", "target": "Q99250", "drug": "DB00555"}, {"action": "INHIBITOR", "target": "Q99250", "drug": "DB00818"}, {"action": "INHIBITOR", "target": "Q99250", "drug": "DB00909"}], "general_function": "Voltage-gated sodium channel activity", "in_complexes": ["Sodium channel protein"], "gene_names": ["SCN2A"]}, "P46881": {"general_function": "Tryptamine:oxygen oxidoreductase (deaminating) activity", "gene_names": [], "name": "Phenylethylamine oxidase", "drug_actions": []}, "O96000": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFB10"], "name": "NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10", "drug_actions": []}, "P48357": {"specific_function": "Receptor for obesity factor (leptin). On ligand binding, mediates signaling through JAK2/STAT3. Involved in the regulation of fat metabolism and, in a hematopoietic pathway, required for normal lymphopoiesis. May play a role in reproduction. Can also mediate the ERK/FOS signaling pathway (By similarity).", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["LEPR"], "name": "Leptin receptor", "drug_actions": [{"action": "AGONIST", "target": "P48357", "drug": "DB09046"}]}, "Q9UHA3": {"specific_function": "Involved in the biogenesis of the 60S ribosomal subunit. Ensures the docking of GTPBP4/NOG1 to pre-60S particles (By similarity).", "general_function": "Structural constituent of ribosome", "gene_names": ["RSL24D1"], "name": "Probable ribosome biogenesis protein RLP24", "drug_actions": []}, "Q9NPC2": {"specific_function": "pH-dependent, voltage-insensitive, background potassium channel protein.", "general_function": "Voltage-gated potassium channel activity", "gene_names": ["KCNK9"], "name": "Potassium channel subfamily K member 9", "drug_actions": [{"action": "INHIBITOR", "target": "Q9NPC2", "drug": "DB00561"}, {"action": "BINDER", "target": "Q9NPC2", "drug": "DB01159"}]}, "Q99259": {"specific_function": "Catalyzes the production of GABA.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["GAD1"], "name": "Glutamate decarboxylase 1", "drug_actions": [{"action": "COFACTOR", "target": "Q99259", "drug": "DB00114"}]}, "P05618": {"general_function": "Starch binding", "gene_names": ["cgt"], "name": "Cyclomaltodextrin glucanotransferase", "drug_actions": []}, "P49228": {"specific_function": "Forms a cluster with L17 and L22, and with L22, a pair of \"tweezers\" that hold together all the domains of the 23S rRNA. Interacts with the antibiotic troleandomycin which blocks the peptide exit tunnel.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpmF"], "name": "50S ribosomal protein L32", "drug_actions": [{"action": "INHIBITOR", "target": "P49228", "drug": "DB01361"}]}, "P07822": {"specific_function": "Part of the ABC transporter complex FhuCDB involved in iron(3+)-hydroxamate import. Binds the iron(3+)-hydroxamate complex and transfers it to the membrane-bound permease. Required for the transport of all iron(3+)-hydroxamate siderophores such as ferrichrome, gallichrome, desferrioxamine, coprogen, aerobactin, shizokinen, rhodotorulic acid and the antibiotic albomycin.", "gene_names": ["fhuD"], "name": "Iron(3+)-hydroxamate-binding protein FhuD", "drug_actions": [{"action": "ANTAGONIST", "target": "P07822", "drug": "DB03436"}]}, "P72181": {"general_function": "Nitrite reductase (no-forming) activity", "gene_names": ["nirS"], "name": "Nitrite reductase", "drug_actions": []}, "O43617": {"specific_function": "May play a role in vesicular transport from endoplasmic reticulum to Golgi.", "gene_names": ["TRAPPC3"], "name": "Trafficking protein particle complex subunit 3", "drug_actions": []}, "P00156": {"specific_function": "Component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is a respiratory chain that generates an electrochemical potential coupled to ATP synthesis.", "general_function": "Ubiquinol-cytochrome-c reductase activity", "gene_names": ["MT-CYB"], "name": "Cytochrome b", "drug_actions": []}, "O43614": {"specific_function": "Nonselective, high-affinity receptor for both orexin-A and orexin-B neuropeptides.", "general_function": "Peptide hormone binding", "gene_names": ["HCRTR2"], "name": "Orexin receptor type 2", "drug_actions": [{"action": "ANTAGONIST", "target": "O43614", "drug": "DB09034"}]}, "O43613": {"specific_function": "Moderately selective excitatory receptor for orexin-A and, with a lower affinity, for orexin-B neuropeptide. Seems to be exclusively coupled to the G(q) subclass of heteromeric G proteins, which activates the phospholipase C mediated signaling cascade (By similarity).", "general_function": "Peptide hormone binding", "gene_names": ["HCRTR1"], "name": "Orexin receptor type 1", "drug_actions": [{"action": "ANTAGONIST", "target": "O43613", "drug": "DB09034"}]}, "O43612": {"specific_function": "Neuropeptides that play a significant role in the regulation of food intake and sleep-wakefulness, possibly by coordinating the complex behavioral and physiologic responses of these complementary homeostatic functions. A broader role in the homeostatic regulation of energy metabolism, autonomic function, hormonal balance and the regulation of body fluids, is also suggested. Orexin-A binds to both OX1R and OX2R with a high affinity, whereas orexin-B binds only to OX2R with a similar high affinity.", "gene_names": ["HCRT"], "name": "Orexin", "drug_actions": []}, "P53350": {"specific_function": "Serine/threonine-protein kinase that performs several important functions throughout M phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal of cohesins from chromosome arms, the inactivation of anaphase-promoting complex/cyclosome (APC/C) inhibitors, and the regulation of mitotic exit and cytokinesis. Polo-like kinase proteins acts by binding and phosphorylating proteins are that already phosphorylated on a specific motif recognized by the POLO box domains. Phosphorylates BORA, BUB1B/BUBR1, CCNB1, CDC25C, CEP55, ECT2, ERCC6L, FBXO5/EMI1, FOXM1, KIF20A/MKLP2, CENPU, NEDD1, NINL, NPM1, NUDC, PKMYT1/MYT1, KIZ, PPP1R12A/MYPT1, PRC1, RACGAP1/CYK4, SGOL1, STAG2/SA2, TEX14, TOPORS, p73/TP73, TPT1 and WEE1. Plays a key role in centrosome functions and the assembly of bipolar spindles by phosphorylating KIZ, NEDD1 and NINL. NEDD1 phosphorylation promotes subsequent targeting of the gamma-tubulin ring complex (gTuRC) to the centrosome, an important step for spindle formation. Phosphorylation of NINL component of the centrosome leads to NINL dissociation from other centrosomal proteins. Involved in mitosis exit and cytokinesis by phosphorylating CEP55, ECT2, KIF20A/MKLP2, CENPU, PRC1 and RACGAP1. Recruited at the central spindle by phosphorylating and docking PRC1 and KIF20A/MKLP2; creates its own docking sites on PRC1 and KIF20A/MKLP2 by mediating phosphorylation of sites subsequently recognized by the POLO box domains. Phosphorylates RACGAP1, thereby creating a docking site for the Rho GTP exchange factor ECT2 that is essential for the cleavage furrow formation. Promotes the central spindle recruitment of ECT2. Plays a central role in G2/M transition of mitotic cell cycle by phosphorylating CCNB1, CDC25C, FOXM1, CENPU, PKMYT1/MYT1, PPP1R12A/MYPT1 and WEE1. Part of a regulatory circuit that promotes the activation of CDK1 by phosphorylating the positive regulator CDC25C and inhibiting the negative regulators WEE1 and PKMYT1/MYT1. Also acts by mediating phosphorylation of cyclin-B1 (CCNB1) on centrosomes in prophase. Phosphorylates FOXM1, a key mitotic transcription regulator, leading to enhance FOXM1 transcriptional activity. Involved in kinetochore functions and sister chromatid cohesion by phosphorylating BUB1B/BUBR1, FBXO5/EMI1 and STAG2/SA2. PLK1 is high on non-attached kinetochores suggesting a role of PLK1 in kinetochore attachment or in spindle assembly checkpoint (SAC) regulation. Required for kinetochore localization of BUB1B. Regulates the dissociation of cohesin from chromosomes by phosphorylating cohesin subunits such as STAG2/SA2. Phosphorylates SGOL1: required for spindle pole localization of isoform 3 of SGOL1 and plays a role in regulating its centriole cohesion function. Mediates phosphorylation of FBXO5/EMI1, a negative regulator of the APC/C complex during prophase, leading to FBXO5/EMI1 ubiquitination and degradation by the proteasome. Acts as a negative regulator of p53 family members: phosphorylates TOPORS, leading to inhibit the sumoylation of p53/TP53 and simultaneously enhance the ubiquitination and subsequent degradation of p53/TP53. Phosphorylates the transactivation domain of the transcription factor p73/TP73, leading to inhibit p73/TP73-mediated transcriptional activation and pro-apoptotic functions. Phosphorylates BORA, and thereby promotes the degradation of BORA. Contributes to the regulation of AURKA function. Also required for recovery after DNA damage checkpoint and entry into mitosis. Phosphorylates MISP, leading to stabilization of cortical and astral microtubule attachments required for proper spindle positioning (PubMed:8991084, PubMed:11202906, PubMed:12207013, PubMed:12447691, PubMed:12524548, PubMed:12738781, PubMed:12852856, PubMed:12939256, PubMed:14532005, PubMed:14734534, PubMed:15070733, PubMed:15148369, PubMed:15469984, PubMed:16198290, PubMed:16247472, PubMed:16980960, PubMed:17081991, PubMed:17351640, PubMed:17376779, PubMed:17617734, PubMed:18174154, PubMed:18331714, PubMed:18418051, PubMed:18477460, PubMed:18521620, PubMed:18615013, PubMed:19160488, PubMed:19351716, PubMed:19468300, PubMed:19468302, PubMed:19473992, PubMed:19509060, PubMed:19597481, PubMed:23455478, PubMed:23509069). Together with MEIKIN, acts as a regulator of kinetochore function during meiosis I: required both for mono-orientation of kinetochores on sister chromosomes and protection of centromeric cohesin from separase-mediated cleavage (By similarity). Phosphorylates CEP68 and is required for its degradation (PubMed:25503564).", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["PLK1"], "name": "Serine/threonine-protein kinase PLK1", "drug_actions": []}, "Q93UV9": {"general_function": "Serine-type endopeptidase activity", "gene_names": ["PROF"], "name": "Protease", "drug_actions": []}, "Q9H4M7": {"specific_function": "Binds specifically to phosphatidylinositol 3-phosphate (PtdIns3P), but not to other phosphoinositides.", "general_function": "1-phosphatidylinositol binding", "gene_names": ["PLEKHA4"], "name": "Pleckstrin homology domain-containing family A member 4", "drug_actions": []}, "P44725": {"specific_function": "Catalyzes the reversible conversion of ribose-5-phosphate to ribulose 5-phosphate.", "general_function": "Ribose-5-phosphate isomerase activity", "gene_names": ["rpiA"], "name": "Ribose-5-phosphate isomerase A", "drug_actions": []}, "P41022": {"general_function": "Urease activity", "gene_names": ["ureA"], "name": "Urease subunit gamma", "drug_actions": []}, "P41021": {"general_function": "Urease activity", "gene_names": ["ureB"], "name": "Urease subunit beta", "drug_actions": []}, "P41020": {"general_function": "Urease activity", "gene_names": ["ureC"], "name": "Urease subunit alpha", "drug_actions": []}, "Q16769": {"specific_function": "Responsible for the biosynthesis of pyroglutamyl peptides. Has a bias against acidic and tryptophan residues adjacent to the N-terminal glutaminyl residue and a lack of importance of chain length after the second residue. Also catalyzes N-terminal pyroglutamate formation. In vitro, catalyzes pyroglutamate formation of N-terminally truncated form of APP amyloid-beta peptides [Glu-3]-beta-amyloid. May be involved in the N-terminal pyroglutamate formation of several amyloid-related plaque-forming peptides.", "general_function": "Zinc ion binding", "gene_names": ["QPCT"], "name": "Glutaminyl-peptide cyclotransferase", "drug_actions": []}, "Q9F6D4": {"specific_function": "Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP. Catalyzes the first condensation reaction which initiates fatty acid synthesis and may therefore play a role in governing the total rate of fatty acid production. Possesses both acetoacetyl-ACP synthase and acetyl transacylase activities. Has some substrate preference for butyryl-CoA and can tolerate branched substrates. Can also prime acyl-CoA. Its substrate specificity determines the biosynthesis of branched-chain and/or straight-chain of fatty acids. Involved in the biosynthesis of R1128 polyketide.", "general_function": "Beta-ketoacyl-acyl-carrier-protein synthase iii activity", "gene_names": ["fabH"], "name": "3-oxoacyl-[acyl-carrier-protein] synthase 3", "drug_actions": []}, "Q8IUR0": {"specific_function": "May play a role in vesicular transport from endoplasmic reticulum to Golgi.", "gene_names": ["TRAPPC5"], "name": "Trafficking protein particle complex subunit 5", "drug_actions": []}, "Q8XB74": {"specific_function": "The exact function is not known. Can catalyze the reduction of a variety of substrates like dimethyl sulfoxide, trimethylamine N-oxide, phenylmethyl sulfoxide and L-methionine sulfoxide. Cannot reduce cyclic N-oxides. Shows no activity as sulfite oxidase.", "general_function": "Oxidoreductase activity, acting on a sulfur group of donors", "gene_names": ["yedY"], "name": "Sulfoxide reductase catalytic subunit YedY", "drug_actions": []}, "Q5SHP7": {"specific_function": "One of the primary rRNA binding proteins, it binds directly to 16S rRNA where it helps nucleate assembly of the platform and body of the 30S subunit by bringing together and stabilizing interactions between several different RNA helices. The combined cluster of proteins S8, S12 and S17 appears to hold together the shoulder and platform of the 30S subunit.Deletion of the protein leads to an increased generation time and a temperature-sensitive phenotype.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsQ"], "name": "30S ribosomal protein S17", "drug_actions": []}, "Q9AIU0": {"specific_function": "Represses expression from the ttgABC operon promoter and its own expression. Binds to a promoter region between the divergently transcribed ttgR and ttgABC genes/operons; in the presence of chloramphenicol or tetracycline this binding no longer occurs and ttgR and ttgABC are derepressed. This suggests that TtgR binds these antibiotics.", "general_function": "Dna binding", "gene_names": ["ttgR"], "name": "HTH-type transcriptional regulator TtgR", "drug_actions": []}, "P15153": {"specific_function": "Plasma membrane-associated small GTPase which cycles between an active GTP-bound and inactive GDP-bound state. In active state binds to a variety of effector proteins to regulate cellular responses, such as secretory processes, phagocytose of apoptotic cells and epithelial cell polarization. Augments the production of reactive oxygen species (ROS) by NADPH oxidase.", "name": "Ras-related C3 botulinum toxin substrate 2", "drug_actions": [{"action": "INHIBITOR", "target": "P15153", "drug": "DB00514"}], "general_function": "Protein kinase regulator activity", "in_complexes": ["NADPH oxidase"], "gene_names": ["RAC2"]}, "P45059": {"specific_function": "Essential cell division protein that is required for the synthesis of peptidoglycan at the division septum. Catalyzes the synthesis of cross-linked peptidoglycan from the lipid-linked precursors.", "general_function": "Peptidoglycan glycosyltransferase activity", "gene_names": ["ftsI"], "name": "Peptidoglycan synthase FtsI", "drug_actions": [{"action": "INHIBITOR", "target": "P45059", "drug": "DB00303"}]}, "Q02641": {"specific_function": "The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.", "name": "Voltage-dependent L-type calcium channel subunit beta-1", "drug_actions": [{"action": "ACTIVATOR", "target": "Q02641", "drug": "DB00308"}, {"action": "INHIBITOR", "target": "Q02641", "drug": "DB00393"}, {"action": "INHIBITOR", "target": "Q02641", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "Q02641", "drug": "DB01388"}], "general_function": "Voltage-gated calcium channel activity", "in_complexes": ["Voltage-dependent calcium channel"], "gene_names": ["CACNB1"]}, "Q02643": {"specific_function": "Receptor for GRF, coupled to G proteins which activate adenylyl cyclase. Stimulates somatotroph cell growth, growth hormone gene transcription and growth hormone secretion.", "general_function": "Peptide hormone binding", "gene_names": ["GHRHR"], "name": "Growth hormone-releasing hormone receptor", "drug_actions": [{"action": "AGONIST", "target": "Q02643", "drug": "DB00010"}, {"action": "BINDER", "target": "Q02643", "drug": "DB08869"}]}, "Q13464": {"specific_function": "Protein kinase which is a key regulator of actin cytoskeleton and cell polarity. Involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of DAPK3, GFAP, LIMK1, LIMK2, MYL9/MLC2, PFN1 and PPP1R12A. Phosphorylates FHOD1 and acts synergistically with it to promote SRC-dependent non-apoptotic plasma membrane blebbing. Phosphorylates JIP3 and regulates the recruitment of JNK to JIP3 upon UVB-induced stress. Acts as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. Acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation. Required for centrosome positioning and centrosome-dependent exit from mitosis. Plays a role in terminal erythroid differentiation. May regulate closure of the eyelids and ventral body wall by inducing the assembly of actomyosin bundles. Promotes keratinocyte terminal differentiation. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralization.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["ROCK1"], "name": "Rho-associated protein kinase 1", "drug_actions": [{"action": "INHIBITOR", "target": "Q13464", "drug": "DB04707"}]}, "P24941": {"specific_function": "Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2. Interacts with cyclins A, B1, B3, D, or E. Triggers duplication of centrosomes and DNA. Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synthesis, and modulates G2 progression; controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus. Crucial role in orchestrating a fine balance between cellular proliferation, cell death, and DNA repair in human embryonic stem cells (hESCs). Activity of CDK2 is maximal during S phase and G2; activated by interaction with cyclin E during the early stages of DNA synthesis to permit G1-S transition, and subsequently activated by cyclin A2 (cyclin A1 in germ cells) during the late stages of DNA replication to drive the transition from S phase to mitosis, the G2 phase. EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing. Phosphorylates CABLES1 (By similarity). Cyclin E/CDK2 prevents oxidative stress-mediated Ras-induced senescence by phosphorylating MYC. Involved in G1-S phase DNA damage checkpoint that prevents cells with damaged DNA from initiating mitosis; regulates homologous recombination-dependent repair by phosphorylating BRCA2, this phosphorylation is low in S phase when recombination is active, but increases as cells progress towards mitosis. In response to DNA damage, double-strand break repair by homologous recombination a reduction of CDK2-mediated BRCA2 phosphorylation. Phosphorylation of RB1 disturbs its interaction with E2F1. NPM1 phosphorylation by cyclin E/CDK2 promotes its dissociates from unduplicated centrosomes, thus initiating centrosome duplication. Cyclin E/CDK2-mediated phosphorylation of NPAT at G1-S transition and until prophase stimulates the NPAT-mediated activation of histone gene transcription during S phase. Required for vitamin D-mediated growth inhibition by being itself inactivated. Involved in the nitric oxide- (NO) mediated signaling in a nitrosylation/activation-dependent manner. USP37 is activated by phosphorylation and thus triggers G1-S transition. CTNNB1 phosphorylation regulates insulin internalization. Phosphorylates FOXP3 and negatively regulates its transcriptional activity and protein stability (By similarity).", "general_function": "Metal ion binding", "gene_names": ["CDK2"], "name": "Cyclin-dependent kinase 2", "drug_actions": [{"action": "INHIBITOR", "target": "P24941", "drug": "DB02052"}, {"action": "INHIBITOR", "target": "P24941", "drug": "DB02116"}, {"action": "INHIBITOR", "target": "P24941", "drug": "DB02950"}, {"action": "INHIBITOR", "target": "P24941", "drug": "DB03428"}, {"action": "INHIBITOR", "target": "P24941", "drug": "DB03496"}, {"action": "INHIBITOR", "target": "P24941", "drug": "DB06616"}]}, "P29508": {"specific_function": "May act as a papain-like cysteine protease inhibitor to modulate the host immune response against tumor cells. Also functions as an inhibitor of UV-induced apoptosis via suppression of the activity of c-Jun NH(2)-terminal kinase (JNK1).", "general_function": "Virus receptor activity", "gene_names": ["SERPINB3"], "name": "Serpin B3", "drug_actions": []}, "P62594": {"specific_function": "TEM-type are the most prevalent beta-lactamases in enterobacteria; they hydrolyze the beta-lactam bond in susceptible beta-lactam antibiotics, thus conferring resistance to penicillins and cephalosporins.", "general_function": "Beta-lactamase activity", "gene_names": ["bla"], "name": "Beta-lactamase TEM", "drug_actions": [{"action": "INHIBITOR", "target": "P62594", "drug": "DB01606"}]}, "P54284": {"specific_function": "The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.", "name": "Voltage-dependent L-type calcium channel subunit beta-3", "drug_actions": [{"action": "INHIBITOR", "target": "P54284", "drug": "DB00393"}, {"action": "INHIBITOR", "target": "P54284", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "P54284", "drug": "DB01388"}], "general_function": "Voltage-gated calcium channel activity", "in_complexes": ["Voltage-dependent calcium channel"], "gene_names": ["CACNB3"]}, "P11498": {"specific_function": "Pyruvate carboxylase catalyzes a 2-step reaction, involving the ATP-dependent carboxylation of the covalently attached biotin in the first step and the transfer of the carboxyl group to pyruvate in the second. Catalyzes in a tissue specific manner, the initial reactions of glucose (liver, kidney) and lipid (adipose tissue, liver, brain) synthesis from pyruvate.", "general_function": "Pyruvate carboxylase activity", "gene_names": ["PC"], "name": "Pyruvate carboxylase, mitochondrial", "drug_actions": []}, "Q8NX78": {"specific_function": "Removes the formyl group from the N-terminal Met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal L-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions.", "general_function": "Peptide deformylase activity", "gene_names": ["def"], "name": "Peptide deformylase", "drug_actions": []}, "P62593": {"specific_function": "TEM-type are the most prevalent beta-lactamases in enterobacteria; they hydrolyze the beta-lactam bond in susceptible beta-lactam antibiotics, thus conferring resistance to penicillins and cephalosporins. TEM-3 and TEM-4 are capable of hydrolyzing cefotaxime and ceftazidime. TEM-5 is capable of hydrolyzing ceftazidime. TEM-6 is capable of hydrolyzing ceftazidime and aztreonam. TEM-8/CAZ-2, TEM-16/CAZ-7 and TEM-24/CAZ-6 are markedly active against ceftazidime. IRT-4 shows resistance to beta-lactamase inhibitors.", "general_function": "Beta-lactamase activity", "gene_names": ["bla"], "name": "Beta-lactamase TEM", "drug_actions": [{"action": "INHIBITOR", "target": "P62593", "drug": "DB09060"}]}, "Q99418": {"specific_function": "Acts as a guanine-nucleotide exchange factor (GEF). Promotes guanine-nucleotide exchange on ARF1, ARF3 and ARF6. Promotes the activation of ARF factors through replacement of GDP with GTP. The cell membrane form, in association with ARL4 proteins, recruits ARF6 to the plasma membrane. Involved in neurite growth (By similarity).", "general_function": "Lipid binding", "gene_names": ["CYTH2"], "name": "Cytohesin-2", "drug_actions": []}, "Q86SZ2": {"specific_function": "May play a role in vesicular transport from endoplasmic reticulum to Golgi.", "gene_names": ["TRAPPC6B"], "name": "Trafficking protein particle complex subunit 6B", "drug_actions": []}, "Q5SHP2": {"specific_function": "Located at the top of the head of the 30S subunit, extending towards the 50S subunit, which it may contact in the 70S complex. Contacts several RNA helices of the 16S rRNA.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsS"], "name": "30S ribosomal protein S19", "drug_actions": []}, "P54289": {"specific_function": "The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).", "name": "Voltage-dependent calcium channel subunit alpha-2/delta-1", "drug_actions": [{"action": "INHIBITOR", "target": "P54289", "drug": "DB00270"}, {"action": "ACTIVATOR", "target": "P54289", "drug": "DB00308"}, {"action": "INHIBITOR", "target": "P54289", "drug": "DB00381"}, {"action": "INHIBITOR", "target": "P54289", "drug": "DB00401"}, {"action": "INHIBITOR", "target": "P54289", "drug": "DB00622"}, {"action": "INHIBITOR", "target": "P54289", "drug": "DB00996"}, {"action": "INHIBITOR", "target": "P54289", "drug": "DB01023"}, {"action": "INHIBITOR", "target": "P54289", "drug": "DB01054"}, {"action": "INHIBITOR", "target": "P54289", "drug": "DB01115"}, {"action": "INHIBITOR", "target": "P54289", "drug": "DB04838"}, {"action": "INHIBITOR", "target": "P54289", "drug": "DB06712"}], "general_function": "Voltage-gated calcium channel activity", "in_complexes": ["Voltage-dependent calcium channel"], "gene_names": ["CACNA2D1"]}, "Q7L5Y9": {"specific_function": "Plays a role in erythroblast enucleation and in the development of the mature macrophages. Mediates the attachment of erythroid cell to mature macrophages, in correlation with the presence of MAEA at cell surface of mature macrophages; This MAEA-mediated contact inhibits erythroid cells apoptosis. Participates to erythroblastic island formation, which is the functional unit of definitive erythropoiesis. Associates with F-actin to regulate actin distribution in erythroblasts and macrophages. May contribute to nuclear architecture and cells division events.", "general_function": "Actin binding", "gene_names": ["MAEA"], "name": "Macrophage erythroblast attacher", "drug_actions": []}, "O43181": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFS4"], "name": "NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial", "drug_actions": []}, "P15034": {"general_function": "Metallopeptidase activity", "gene_names": ["pepP"], "name": "Xaa-Pro aminopeptidase", "drug_actions": []}, "Q16558": {"specific_function": "Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Increases the apparent Ca(2+)/voltage sensitivity of the KCNMA1 channel. It also modifies KCNMA1 channel kinetics and alters its pharmacological properties. It slows down the activation and the deactivation kinetics of the channel. Acts as a negative regulator of smooth muscle contraction by enhancing the calcium sensitivity to KCNMA1. Its presence is also a requirement for internal binding of the KCNMA1 channel opener dehydrosoyasaponin I (DHS-1) triterpene glycoside and for external binding of the agonist hormone 17-beta-estradiol (E2). Increases the binding activity of charybdotoxin (CTX) toxin to KCNMA1 peptide blocker by increasing the CTX association rate and decreasing the dissociation rate.", "name": "Calcium-activated potassium channel subunit beta-1", "drug_actions": [{"action": "BINDER", "target": "Q16558", "drug": "DB00721"}, {"action": "INHIBITOR", "target": "Q16558", "drug": "DB01110"}], "general_function": "Potassium channel regulator activity", "in_complexes": ["Calcium-activated potassium channel"], "gene_names": ["KCNMB1"]}, "Q83M58": {"general_function": "Geranyltranstransferase activity", "gene_names": ["ispA"], "name": "Geranyltranstransferase (Farnesyldiphosphate synthase)", "drug_actions": []}, "O87696": {"specific_function": "Catalyzes the methylation of C-11 in cobalt-precorrin-4 to form cobalt-precorrin-5A.", "general_function": "Precorrin-4 c11-methyltransferase activity", "gene_names": ["cbiF"], "name": "Cobalt-precorrin-4 C(11)-methyltransferase", "drug_actions": []}, "Q16552": {"specific_function": "Induces stromal cells to produce proinflammatory and hematopoietic cytokines. Enhances the surface expression of ICAM1/intracellular adhesion molecule 1 in fibroblasts.", "general_function": "Cytokine receptor binding", "gene_names": ["IL17A"], "name": "Interleukin-17A", "drug_actions": [{"action": "ANTAGONIST", "target": "Q16552", "drug": "DB09029"}]}, "P31939": {"specific_function": "Bifunctional enzyme that catalyzes 2 steps in purine biosynthesis.Promotes insulin receptor/INSR autophosphorylation and is involved in INSR internalization (PubMed:25687571).", "general_function": "Protein homodimerization activity", "gene_names": ["ATIC"], "name": "Bifunctional purine biosynthesis protein PURH", "drug_actions": [{"action": "COFACTOR", "target": "P31939", "drug": "DB00116"}, {"action": "INHIBITOR", "target": "P31939", "drug": "DB00642"}]}, "Q8Q3H0": {"general_function": "Aspartic-type endopeptidase activity", "gene_names": ["pol"], "name": "Pol protein", "drug_actions": []}, "P21397": {"specific_function": "Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.", "name": "Amine oxidase [flavin-containing] A", "drug_actions": [{"action": "ANTAGONIST", "target": "P21397", "drug": "DB00191"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB00752"}, {"action": "ANTAGONIST", "target": "P21397", "drug": "DB00780"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB00805"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB01037"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB01171"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB01247"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB01363"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB01442"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB01472"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB01577"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB01626"}, {"action": "INHIBITOR", "target": "P21397", "drug": "DB04832"}], "general_function": "Serotonin binding", "in_complexes": ["Monoamine oxidase"], "gene_names": ["MAOA"]}, "P11474": {"specific_function": "Binds to an ERR-alpha response element (ERRE) containing a single consensus half-site, 5'-TNAAGGTCA-3'. Can bind to the medium-chain acyl coenzyme A dehydrogenase (MCAD) response element NRRE-1 and may act as an important regulator of MCAD promoter. Binds to the C1 region of the lactoferrin gene promoter. Requires dimerization and the coactivator, PGC-1A, for full activity. The ERRalpha/PGC1alpha complex is a regulator of energy metabolism. Induces the expression of PERM1 in the skeletal muscle.", "general_function": "Zinc ion binding", "gene_names": ["ESRRA"], "name": "Steroid hormone receptor ERR1", "drug_actions": [{"action": "INVERSE AGONIST", "target": "P11474", "drug": "DB00197"}]}, "P03422": {"specific_function": "Essential component of the RNA polymerase and the nascent chain assembly complex. Also required during RNA synthesis.", "general_function": "Rna-directed rna polymerase activity", "gene_names": ["P/V"], "name": "Phosphoprotein", "drug_actions": []}, "Q9K578": {"general_function": "Metal ion binding", "gene_names": ["blaFEZ-1"], "name": "FEZ-1 protein", "drug_actions": []}, "P11473": {"specific_function": "Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Recruited to promoters via its interaction with BAZ1B/WSTF which mediates the interaction with acetylated histones, an essential step for VDR-promoter association. Plays a central role in calcium homeostasis.", "general_function": "Zinc ion binding", "gene_names": ["VDR"], "name": "Vitamin D3 receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "P11473", "drug": "DB00136"}, {"action": "AGONIST", "target": "P11473", "drug": "DB00146"}, {"action": "AGONIST", "target": "P11473", "drug": "DB00153"}, {"action": "AGONIST", "target": "P11473", "drug": "DB00169"}, {"action": "AGONIST", "target": "P11473", "drug": "DB00910"}, {"action": "AGONIST", "target": "P11473", "drug": "DB01070"}, {"action": "AGONIST", "target": "P11473", "drug": "DB01436"}, {"action": "ANTAGONIST", "target": "P11473", "drug": "DB02300"}]}, "P33673": {"specific_function": "Aids in the defense against invading fungal pathogens by degrading their cell wall chitosan.", "general_function": "Chitosanase activity", "gene_names": ["csn"], "name": "Chitosanase", "drug_actions": []}, "P50747": {"specific_function": "Post-translational modification of specific protein by attachment of biotin. Acts on various carboxylases such as acetyl-CoA-carboxylase, pyruvate carboxylase, propionyl CoA carboxylase, and 3-methylcrotonyl CoA carboxylase.", "general_function": "Enzyme binding", "gene_names": ["HLCS"], "name": "Biotin--protein ligase", "drug_actions": []}, "Q9REC4": {"general_function": "Oxidoreductase activity", "gene_names": ["MOD"], "name": "Aldehyde oxidoreductase", "drug_actions": []}, "Q9WZ57": {"general_function": "Nucleotide binding", "gene_names": [], "name": "Rod shape-determining protein MreB", "drug_actions": []}, "P36959": {"specific_function": "Catalyzes the irreversible NADPH-dependent deamination of GMP to IMP. It functions in the conversion of nucleobase, nucleoside and nucleotide derivatives of G to A nucleotides, and in maintaining the intracellular balance of A and G nucleotides.", "general_function": "Metal ion binding", "gene_names": ["GMPR"], "name": "GMP reductase 1", "drug_actions": []}, "Q15738": {"specific_function": "Involved in the sequential removal of two C-4 methyl groups in post-squalene cholesterol biosynthesis.", "general_function": "Sterol-4-alpha-carboxylate 3-dehydrogenase (decarboxylating) activity", "gene_names": ["NSDHL"], "name": "Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating", "drug_actions": []}, "Q53H96": {"general_function": "Pyrroline-5-carboxylate reductase activity", "gene_names": ["PYCRL"], "name": "Pyrroline-5-carboxylate reductase 3", "drug_actions": []}, "P22629": {"specific_function": "The biological function of streptavidin is not known. Forms a strong non-covalent specific complex with biotin (one molecule of biotin per subunit of streptavidin).", "gene_names": [], "name": "Streptavidin", "drug_actions": []}, "Q08881": {"specific_function": "Tyrosine kinase that plays an essential role in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. When antigen presenting cells (APC) activate T-cell receptor (TCR), a series of phosphorylation lead to the recruitment of ITK to the cell membrane, in the vicinity of the stimulated TCR receptor, where it is phosphorylated by LCK. Phosphorylation leads to ITK autophosphorylation and full activation. Once activated, phosphorylates PLCG1, leading to the activation of this lipase and subsequent cleavage of its substrates. In turn, the endoplasmic reticulum releases calcium in the cytoplasm and the nuclear activator of activated T-cells (NFAT) translocates into the nucleus to perform its transcriptional duty. Phosphorylates 2 essential adapter proteins: the linker for activation of T-cells/LAT protein and LCP2. Then, a large number of signaling molecules such as VAV1 are recruited and ultimately lead to lymphokine production, T-cell proliferation and differentiation.", "general_function": "Non-membrane spanning protein tyrosine kinase activity", "gene_names": ["ITK"], "name": "Tyrosine-protein kinase ITK/TSK", "drug_actions": [{"action": "INHIBITOR", "target": "Q08881", "drug": "DB06589"}]}, "Q9UDW1": {"specific_function": "This is a component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is part of the mitochondrial respiratory chain. This subunit interacts with cytochrome c1 (By similarity).", "general_function": "Ubiquinol-cytochrome-c reductase activity", "gene_names": ["UQCR10"], "name": "Cytochrome b-c1 complex subunit 9", "drug_actions": []}, "P19793": {"specific_function": "Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXRs is 9-cis retinoic acid. RXRA serves as a common heterodimeric partner for a number of nuclear receptors. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. The RXRA/PPARA heterodimer is required for PPARA transcriptional activity on fatty acid oxidation genes such as ACOX1 and the P450 system genes.", "general_function": "Zinc ion binding", "gene_names": ["RXRA"], "name": "Retinoic acid receptor RXR-alpha", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "P19793", "drug": "DB00210"}, {"action": "AGONIST", "target": "P19793", "drug": "DB00307"}, {"action": "AGONIST", "target": "P19793", "drug": "DB00459"}, {"action": "AGONIST", "target": "P19793", "drug": "DB00523"}, {"action": "OTHER", "target": "P19793", "drug": "DB00749"}, {"action": "AGONIST", "target": "P19793", "drug": "DB00926"}]}, "P72524": {"specific_function": "DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.", "general_function": "Dna topoisomerase type ii (atp-hydrolyzing) activity", "gene_names": ["gyrA"], "name": "DNA gyrase subunit A", "drug_actions": [{"action": "INHIBITOR", "target": "P72524", "drug": "DB01044"}, {"action": "ANTAGONIST", "target": "P72524", "drug": "DB06771"}]}, "P72525": {"specific_function": "Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.", "general_function": "Dna topoisomerase type ii (atp-hydrolyzing) activity", "gene_names": ["parC"], "name": "DNA topoisomerase 4 subunit A", "drug_actions": [{"action": "INHIBITOR", "target": "P72525", "drug": "DB01044"}, {"action": "ANTAGONIST", "target": "P72525", "drug": "DB06771"}]}, "P12070": {"general_function": "Xylose isomerase activity", "gene_names": ["xylA"], "name": "Xylose isomerase", "drug_actions": []}, "Q16739": {"specific_function": "Catalyzes the first glycosylation step in glycosphingolipid biosynthesis, the transfer of glucose to ceramide. May also serve as a \"flippase\".", "general_function": "Ceramide glucosyltransferase activity", "gene_names": ["UGCG"], "name": "Ceramide glucosyltransferase", "drug_actions": [{"action": "INHIBITOR", "target": "Q16739", "drug": "DB00419"}, {"action": "ANTAGONIST", "target": "Q16739", "drug": "DB09039"}]}, "Q06278": {"specific_function": "Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N-methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal, and vanillin. Plays a key role in the metabolism of xenobiotics and drugs containing aromatic azaheterocyclic substituents. Participates in the bioactivation of prodrugs such as famciclovir, catalyzing the oxidation step from 6-deoxypenciclovir to penciclovir, which is a potent antiviral agent. Is probably involved in the regulation of reactive oxygen species homeostasis. May be a prominent source of superoxide generation via the one-electron reduction of molecular oxygen. Also may catalyze nitric oxide (NO) production via the reduction of nitrite to NO with NADH or aldehyde as electron donor. May play a role in adipogenesis.", "general_function": "Xanthine dehydrogenase activity", "gene_names": ["AOX1"], "name": "Aldehyde oxidase", "drug_actions": []}, "P12676": {"specific_function": "Bifunctional enzyme that catalyzes the oxidation of the 3-beta-hydroxy group of cholesterol and the isomerization of the double bond of the resulting product.", "general_function": "Steroid delta-isomerase activity", "gene_names": ["choA"], "name": "Cholesterol oxidase", "drug_actions": []}, "Q56308": {"specific_function": "Catalyzes the methyl esterification of L-isoaspartyl residues in peptides and proteins that result from spontaneous decomposition of normal L-aspartyl and L-asparaginyl residues. It plays a role in the repair and/or degradation of damaged proteins.", "general_function": "Protein-l-isoaspartate (d-aspartate) o-methyltransferase activity", "gene_names": ["pcm"], "name": "Protein-L-isoaspartate O-methyltransferase", "drug_actions": []}, "P37330": {"specific_function": "Involved in the glycolate utilization. Catalyzes the condensation and subsequent hydrolysis of acetyl-coenzyme A (acetyl-CoA) and glyoxylate to form malate and CoA.", "general_function": "Metal ion binding", "gene_names": ["glcB"], "name": "Malate synthase G", "drug_actions": []}, "Q9UHW9": {"specific_function": "Mediates electroneutral potassium-chloride cotransport. May be activated by cell swelling. May contribute to cell volume homeostasis in single cells.", "general_function": "Rubidium ion transmembrane transporter activity", "gene_names": ["SLC12A6"], "name": "Solute carrier family 12 member 6", "drug_actions": []}, "P14555": {"specific_function": "Thought to participate in the regulation of the phospholipid metabolism in biomembranes including eicosanoid biosynthesis. Catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides.", "general_function": "Phospholipid binding", "gene_names": ["PLA2G2A"], "name": "Phospholipase A2, membrane associated", "drug_actions": [{"action": "INHIBITOR", "target": "P14555", "drug": "DB00328"}, {"action": "INHIBITOR", "target": "P14555", "drug": "DB00586"}, {"action": "INHIBITOR", "target": "P14555", "drug": "DB01381"}, {"action": "INHIBITOR", "target": "P14555", "drug": "DB04786"}]}, "P20333": {"specific_function": "Receptor with high affinity for TNFSF2/TNF-alpha and approximately 5-fold lower affinity for homotrimeric TNFSF1/lymphotoxin-alpha. The TRAF1/TRAF2 complex recruits the apoptotic suppressors BIRC2 and BIRC3 to TNFRSF1B/TNFR2. This receptor mediates most of the metabolic effects of TNF-alpha. Isoform 2 blocks TNF-alpha-induced apoptosis, which suggests that it regulates TNF-alpha function by antagonizing its biological activity.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["TNFRSF1B"], "name": "Tumor necrosis factor receptor superfamily member 1B", "drug_actions": []}, "Q5SJI0": {"general_function": "Thiosulfate sulfurtransferase activity", "gene_names": [], "name": "Sulfurtransferase", "drug_actions": []}, "P20783": {"specific_function": "Seems to promote the survival of visceral and proprioceptive sensory neurons.", "general_function": "Receptor binding", "gene_names": ["NTF3"], "name": "Neurotrophin-3", "drug_actions": []}, "Q9BY66": {"specific_function": "Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'. Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-4'. May play a role in spermatogenesis.", "general_function": "Zinc ion binding", "gene_names": ["KDM5D"], "name": "Lysine-specific demethylase 5D", "drug_actions": []}, "P0CK31": {"specific_function": "RNA-directed RNA polymerase that is involved in transcription and genome replication. Following infection, it catalyzes the synthesis of fully conservative plus strands. After core assembly, which consists in recruitment of one capped plus-strand for each genomic segments and polymerase complexes, the polymerase switches mode and catalyzes the synthesis of complementary minus-strands.", "general_function": "Rna-directed rna polymerase activity", "gene_names": ["L1"], "name": "RNA-directed RNA polymerase lambda-3", "drug_actions": []}, "A9CJ63": {"gene_names": [], "name": "Uncharacterized protein", "drug_actions": []}, "O31440": {"specific_function": "Catalyzes the alpha- and beta-hydroxylation of myristic acid in the presence of hydrogen peroxide.", "general_function": "Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen", "gene_names": ["cypC"], "name": "Fatty-acid peroxygenase", "drug_actions": []}, "O25927": {"specific_function": "Involved in the biosynthesis of lipid A, a phosphorylated glycolipid that anchors the lipopolysaccharide to the outer membrane of the cell.", "general_function": "Acyl-[acyl-carrier-protein]-udp-n-acetylglucosamine o-acyltransferase activity", "gene_names": ["lpxA"], "name": "Acyl-[acyl-carrier-protein]--UDP-N-acetylglucosamine O-acyltransferase", "drug_actions": []}, "P30520": {"specific_function": "Plays an important role in the de novo pathway and in the salvage pathway of purine nucleotide biosynthesis. Catalyzes the first committed step in the biosynthesis of AMP from IMP.", "general_function": "Phosphate ion binding", "gene_names": ["ADSS"], "name": "Adenylosuccinate synthetase isozyme 2", "drug_actions": []}, "Q9FDN7": {"specific_function": "Has nitric oxide reductase activity in combination with Hrb; probably involved in nitrosative stress protection.", "general_function": "Oxidoreductase activity", "gene_names": ["fprA"], "name": "Nitric oxide reductase", "drug_actions": []}, "P07110": {"specific_function": "Involved in the export and assembly of pili subunits across the outer membrane. Forms a hexameric ring-shaped pore in the outer bacterial membrane. The 2 nanometer-diameter pore allows the passage of the thin tip fibrillum. As for the rod, it probably unwinds into linear fibers which would therefore be narrow enough to pass through the pore.", "general_function": "Transporter activity", "gene_names": ["papC"], "name": "Outer membrane usher protein PapC", "drug_actions": []}, "O14646": {"specific_function": "ATP-dependent chromatin-remodeling factor which functions as substrate recognition component of the transcription regulatory histone acetylation (HAT) complex SAGA. Regulates polymerase II transcription. Also required for efficient transcription by RNA polymerase I, and more specifically the polymerase I transcription termination step. Regulates negatively DNA replication. Not only involved in transcription-related chromatin-remodeling, but also required to maintain a specific chromatin configuration across the genome. Is also associated with histone deacetylase (HDAC) activity (By similarity). Required for the bridging of SNF2, the FACT complex, the PAF complex as well as the U2 snRNP complex to H3K4me3. Functions to modulate the efficiency of pre-mRNA splicing in part through physical bridging of spliceosomal components to H3K4me3. Required for maintaining open chromatin and pluripotency in embryonic stem cells.", "general_function": "Methylated histone binding", "gene_names": ["CHD1"], "name": "Chromodomain-helicase-DNA-binding protein 1", "drug_actions": [{"action": "ANTAGONIST", "target": "O14646", "drug": "DB00445"}]}, "O15143": {"specific_function": "Functions as component of the Arp2/3 complex which is involved in regulation of actin polymerization and together with an activating nucleation-promoting factor (NPF) mediates the formation of branched actin networks.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["ARPC1B"], "name": "Actin-related protein 2/3 complex subunit 1B", "drug_actions": []}, "P49747": {"specific_function": "May play a role in the structural integrity of cartilage via its interaction with other extracellular matrix proteins such as the collagens and fibronectin. Can mediate the interaction of chondrocytes with the cartilage extracellular matrix through interaction with cell surface integrin receptors. Could play a role in the pathogenesis of osteoarthritis. Potent suppressor of apoptosis in both primary chondrocytes and transformed cells. Suppresses apoptosis by blocking the activation of caspase-3 and by inducing the IAP family of survival proteins (BIRC3, BIRC2, BIRC5 and XIAP). Essential for maintaining a vascular smooth muscle cells (VSMCs) contractile/differentiated phenotype under physiological and pathological stimuli. Maintains this phenotype of VSMCs by interacting with ITGA7 (By similarity).", "general_function": "Protease binding", "gene_names": ["COMP"], "name": "Cartilage oligomeric matrix protein", "drug_actions": []}, "Q14957": {"specific_function": "NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine.", "name": "Glutamate receptor ionotropic, NMDA 2C", "drug_actions": [{"action": "BLOCKER", "target": "Q14957", "drug": "DB00289"}, {"action": "ANTAGONIST", "target": "Q14957", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "Q14957", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "Q14957", "drug": "DB00454"}, {"action": "ANTAGONIST", "target": "Q14957", "drug": "DB00659"}, {"action": "ANTAGONIST", "target": "Q14957", "drug": "DB01174"}, {"action": "ANTAGONIST", "target": "Q14957", "drug": "DB01520"}, {"action": "AGONIST", "target": "Q14957", "drug": "DB01708"}, {"action": "INHIBITOR", "target": "Q14957", "drug": "DB04896"}, {"action": "ANTAGONIST", "target": "Q14957", "drug": "DB06738"}, {"action": "ANTAGONIST", "target": "Q14957", "drug": "DB06741"}], "general_function": "Nmda glutamate receptor activity", "in_complexes": ["Glutamate (NMDA) receptor", "NMDA receptor"], "gene_names": ["GRIN2C"]}, "O95069": {"specific_function": "Ion channel that contributes to passive transmembrane potassium transport (PubMed:23169818). Reversibly converts between a voltage-insensitive potassium leak channel and a voltage-dependent outward rectifying potassium channel in a phosphorylation-dependent manner (PubMed:11319556). In astrocytes, forms mostly heterodimeric potassium channels with KCNK1, with only a minor proportion of functional channels containing homodimeric KCNK2. In astrocytes, the heterodimer formed by KCNK1 and KCNK2 is required for rapid glutamate release in response to activation of G-protein coupled receptors, such as F2R and CNR1 (By similarity).Isoform 4: Does not display channel activity but reduces the channel activity of isoform 1 and isoform 2 and reduces cell surface expression of isoform 2.", "general_function": "Potassium ion leak channel activity", "gene_names": ["KCNK2"], "name": "Potassium channel subfamily K member 2", "drug_actions": [{"action": "INHIBITOR", "target": "O95069", "drug": "DB00204"}, {"action": "INHIBITOR", "target": "O95069", "drug": "DB04855"}]}, "O14649": {"specific_function": "pH-dependent, voltage-insensitive, background potassium channel protein. Rectification direction results from potassium ion concentration on either side of the membrane. Acts as an outward rectifier when external potassium concentration is low. When external potassium concentration is high, current is inward.", "general_function": "S100 protein binding", "gene_names": ["KCNK3"], "name": "Potassium channel subfamily K member 3", "drug_actions": [{"action": "INHIBITOR", "target": "O14649", "drug": "DB00561"}, {"action": "BINDER", "target": "O14649", "drug": "DB01159"}]}, "O95665": {"specific_function": "Receptor for the tridecapeptide neurotensin. It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system.", "general_function": "G-protein coupled receptor activity", "gene_names": ["NTSR2"], "name": "Neurotensin receptor type 2", "drug_actions": [{"action": "PARTIAL ANTAGONIST", "target": "O95665", "drug": "DB01106"}]}, "P49585": {"specific_function": "Controls phosphatidylcholine synthesis.", "general_function": "Lipid binding", "gene_names": ["PCYT1A"], "name": "Choline-phosphate cytidylyltransferase A", "drug_actions": [{"action": "PRODUCT OF", "target": "P49585", "drug": "DB00122"}]}, "Q5T601": {"specific_function": "Orphan receptor.", "general_function": "G-protein coupled receptor activity", "gene_names": ["ADGRF1"], "name": "Adhesion G-protein coupled receptor F1", "drug_actions": []}, "P0A6D3": {"specific_function": "Catalyzes the transfer of the enolpyruvyl moiety of phosphoenolpyruvate (PEP) to the 5-hydroxyl of shikimate-3-phosphate (S3P) to produce enolpyruvyl shikimate-3-phosphate and inorganic phosphate.", "general_function": "3-phosphoshikimate 1-carboxyvinyltransferase activity", "gene_names": ["aroA"], "name": "3-phosphoshikimate 1-carboxyvinyltransferase", "drug_actions": []}, "O14880": {"specific_function": "Also functions as a glutathione peroxidase.", "general_function": "Peroxidase activity", "gene_names": ["MGST3"], "name": "Microsomal glutathione S-transferase 3", "drug_actions": []}, "P49588": {"specific_function": "Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala). Also edits incorrectly charged tRNA(Ala) via its editing domain.", "general_function": "Trna binding", "gene_names": ["AARS"], "name": "Alanine--tRNA ligase, cytoplasmic", "drug_actions": []}, "P49589": {"general_function": "Trna binding", "gene_names": ["CARS"], "name": "Cysteine--tRNA ligase, cytoplasmic", "drug_actions": []}, "P16304": {"specific_function": "Catalyzes the reversible transfer of the terminal phosphate group between ATP and AMP. Plays an important role in cellular energy homeostasis and in adenine nucleotide metabolism.", "general_function": "Metal ion binding", "gene_names": ["adk"], "name": "Adenylate kinase", "drug_actions": []}, "P50897": {"specific_function": "Removes thioester-linked fatty acyl groups such as palmitate from modified cysteine residues in proteins or peptides during lysosomal degradation. Prefers acyl chain lengths of 14 to 18 carbons.", "general_function": "Palmitoyl-coa hydrolase activity", "gene_names": ["PPT1"], "name": "Palmitoyl-protein thioesterase 1", "drug_actions": []}, "Q9RX51": {"general_function": "Cation binding", "gene_names": ["treZ"], "name": "Malto-oligosyltrehalose trehalohydrolase", "drug_actions": []}, "P84124": {"general_function": "Posttranslational modification, protein turnover, chaperones", "gene_names": ["tthHB8IM"], "name": "Osmotically inducible protein C", "drug_actions": []}, "Q9HCC0": {"specific_function": "Carboxyltransferase subunit of the 3-methylcrotonyl-CoA carboxylase, an enzyme that catalyzes the conversion of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA, a critical step for leucine and isovaleric acid catabolism.", "general_function": "Methylcrotonoyl-coa carboxylase activity", "gene_names": ["MCCC2"], "name": "Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial", "drug_actions": []}, "Q8IWL2": {"specific_function": "In presence of calcium ions, it binds to surfactant phospholipids and contributes to lower the surface tension at the air-liquid interface in the alveoli of the mammalian lung and is essential for normal respiration.", "general_function": "Lipid transporter activity", "gene_names": ["SFTPA1"], "name": "Pulmonary surfactant-associated protein A1", "drug_actions": []}, "P60844": {"specific_function": "Channel that permits osmotically driven movement of water in both directions. It is involved in the osmoregulation and in the maintenance of cell turgor during volume expansion in rapidly growing cells. It mediates rapid entry or exit of water in response to abrupt changes in osmolarity.", "general_function": "Water channel activity", "gene_names": ["aqpZ"], "name": "Aquaporin Z", "drug_actions": []}, "P30418": {"specific_function": "Adds a myristoyl group to the N-terminal glycine residue of certain cellular proteins. Substrate specificity requires an N-terminal glycine in the nascent polypeptide substrates. Ser is present at position 5 in almost all known N-myristoyl proteins and Lys is commonly encountered at postion 6. Basic residues are preferred at positions 7 and 8.", "general_function": "Glycylpeptide n-tetradecanoyltransferase activity", "gene_names": ["NMT1"], "name": "Glycylpeptide N-tetradecanoyltransferase", "drug_actions": []}, "P11678": {"specific_function": "Mediates tyrosine nitration of secondary granule proteins in mature resting eosinophils. Shows significant inhibitory activity towards Mycobacterium tuberculosis H37Rv by inducing bacterial fragmentation and lysis.", "general_function": "Peroxidase activity", "gene_names": ["EPX"], "name": "Eosinophil peroxidase", "drug_actions": [{"action": "INHIBITOR", "target": "P11678", "drug": "DB01065"}]}, "Q8N8N7": {"specific_function": "Functions as 15-oxo-prostaglandin 13-reductase and acts on 15-keto-PGE1, 15-keto-PGE2, 15-keto-PGE1-alpha and 15-keto-PGE2-alpha with highest activity towards 15-keto-PGE2. Overexpression represses transcriptional activity of PPARG and inhibits adipocyte differentiation (By similarity).", "general_function": "15-oxoprostaglandin 13-oxidase activity", "gene_names": ["PTGR2"], "name": "Prostaglandin reductase 2", "drug_actions": [{"action": "INHIBITOR", "target": "Q8N8N7", "drug": "DB00328"}]}, "P01112": {"specific_function": "Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.", "general_function": "Protein c-terminus binding", "gene_names": ["HRAS"], "name": "GTPase HRas", "drug_actions": []}, "Q82IZ1": {"gene_names": ["ptlH"], "name": "1-deoxypentalenic acid 11-beta-hydroxylase", "drug_actions": []}, "Q7Z406": {"specific_function": "Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping.", "general_function": "Microfilament motor activity", "gene_names": ["MYH14"], "name": "Myosin-14", "drug_actions": []}, "P11922": {"specific_function": "Invasin is a protein that allows enteric bacteria to penetrate cultured mammalian cells. The entry of invasin in the cell is mediated by binding several beta-1 chain integrins.", "gene_names": [], "name": "Invasin", "drug_actions": []}, "P11926": {"specific_function": "Key enzyme of polyamine biosynthesis that converts ornithine into putrescine, which is the precursor for the polyamines, spermidine and spermine.", "general_function": "Protein homodimerization activity", "gene_names": ["ODC1"], "name": "Ornithine decarboxylase", "drug_actions": [{"action": "COFACTOR", "target": "P11926", "drug": "DB00114"}, {"action": "PRODUCT OF", "target": "P11926", "drug": "DB00127"}, {"action": "ANTAGONIST", "target": "P11926", "drug": "DB06243"}, {"action": "BLOCKER", "target": "P11926", "drug": "DB06243"}]}, "P05364": {"specific_function": "This protein is a serine beta-lactamase with a substrate specificity for cephalosporins.", "general_function": "Beta-lactamase activity", "gene_names": ["ampC"], "name": "Beta-lactamase", "drug_actions": []}, "P06732": {"specific_function": "Reversibly catalyzes the transfer of phosphate between ATP and various phosphogens (e.g. creatine phosphate). Creatine kinase isoenzymes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, brain and spermatozoa.", "general_function": "Creatine kinase activity", "gene_names": ["CKM"], "name": "Creatine kinase M-type", "drug_actions": [{"action": "LIGAND", "target": "P06732", "drug": "DB00148"}]}, "P48506": {"general_function": "Magnesium ion binding", "gene_names": ["GCLC"], "name": "Glutamate--cysteine ligase catalytic subunit", "drug_actions": []}, "P06730": {"specific_function": "Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation of protein synthesis and facilitates ribosome binding by inducing the unwinding of the mRNAs secondary structures. Component of the CYFIP1-EIF4E-FMR1 complex which binds to the mRNA cap and mediates translational repression. In the CYFIP1-EIF4E-FMR1 complex this subunit mediates the binding to the mRNA cap.", "general_function": "Translation initiation factor activity", "gene_names": ["EIF4E"], "name": "Eukaryotic translation initiation factor 4E", "drug_actions": []}, "P06731": {"specific_function": "Cell surface glycoprotein that plays a role in cell adhesion and in intracellular signaling. Receptor for E.coli Dr adhesins.", "general_function": "Protein homodimerization activity", "gene_names": ["CEACAM5"], "name": "Carcinoembryonic antigen-related cell adhesion molecule 5", "drug_actions": []}, "P06737": {"specific_function": "Phosphorylase is an important allosteric enzyme in carbohydrate metabolism. Enzymes from different sources differ in their regulatory mechanisms and in their natural substrates. However, all known phosphorylases share catalytic and structural properties.", "general_function": "Vitamin binding", "gene_names": ["PYGL"], "name": "Glycogen phosphorylase, liver form", "drug_actions": [{"action": "COFACTOR", "target": "P06737", "drug": "DB00114"}, {"action": "ACTIVATOR", "target": "P06737", "drug": "DB00131"}]}, "P17787": {"specific_function": "After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodiun ions.", "general_function": "Ligand-gated ion channel activity", "gene_names": ["CHRNB2"], "name": "Neuronal acetylcholine receptor subunit beta-2", "drug_actions": [{"action": "AGONIST", "target": "P17787", "drug": "DB00184"}, {"action": "ANTAGONIST", "target": "P17787", "drug": "DB00514"}, {"action": "ALLOSTERIC MODULATOR", "target": "P17787", "drug": "DB00674"}]}, "Q9Y6Y9": {"specific_function": "Binds bacterial lipopolysaccharide (LPS) (PubMed:17803912, PubMed:17569869). Cooperates with TLR4 in the innate immune response to bacterial lipopolysaccharide (LPS), and with TLR2 in the response to cell wall components from Gram-positive and Gram-negative bacteria (PubMed:11160242, PubMed:11593030). Enhances TLR4-dependent activation of NF-kappa-B (PubMed:10359581). Cells expressing both LY96 and TLR4, but not TLR4 alone, respond to LPS (PubMed:10359581).", "general_function": "Lipopolysaccharide receptor activity", "gene_names": ["LY96"], "name": "Lymphocyte antigen 96", "drug_actions": []}, "O05891": {"specific_function": "Catalyzes the reversible phosphorylation of deoxythymidine monophosphate (dTMP) to deoxythymidine diphosphate (dTDP), using ATP as its preferred phosphoryl donor. Situated at the junction of both de novo and salvage pathways of deoxythymidine triphosphate (dTTP) synthesis, is essential for DNA synthesis and cellular growth. Has a broad specificity for nucleoside triphosphates, being highly active with ATP or dATP as phosphate donors, and less active with ITP, GTP, CTP and UTP", "general_function": "Nucleotide transport and metabolism", "gene_names": ["tmk"], "name": "Thymidylate kinase", "drug_actions": []}, "Q56691": {"specific_function": "Involved in bioluminescence. It is a good supplier of reduced flavin mononucleotide (FMNH2) to the bioluminescence reaction.", "general_function": "Oxidoreductase activity", "gene_names": ["frp"], "name": "NADPH-flavin oxidoreductase", "drug_actions": []}, "P69795": {"specific_function": "The phosphoenolpyruvate-dependent sugar phosphotransferase system (sugar PTS), a major carbohydrate active -transport system, catalyzes the phosphorylation of incoming sugar substrates concomitantly with their translocation across the cell membrane. This system is involved in N,N'-diacetylchitobiose transport.", "general_function": "Protein-phosphocysteine-n,n'-diacetylchitobiose phosphotransferase system transporter activity", "gene_names": ["chbB"], "name": "N,N'-diacetylchitobiose-specific phosphotransferase enzyme IIB component", "drug_actions": []}, "Q70AC7": {"specific_function": "The 5S subunit specifically catalyzes the transfer of the carboxyl group from biotin of the 1.3S subunit to pyruvate to form oxaloacetate and 1.3S biotin.", "general_function": "Methylmalonyl-coa carboxytransferase activity", "gene_names": [], "name": "Methylmalonyl-CoA carboxyltransferase 5S subunit", "drug_actions": []}, "P16410": {"specific_function": "Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.", "gene_names": ["CTLA4"], "name": "Cytotoxic T-lymphocyte protein 4", "drug_actions": []}, "P38424": {"specific_function": "Necessary for normal cell division and for the maintenance of normal septation.Binds GTP and GDP.", "general_function": "Magnesium ion binding", "gene_names": ["engB"], "name": "Probable GTP-binding protein EngB", "drug_actions": []}, "Q7Z4W1": {"specific_function": "Catalyzes the NADPH-dependent reduction of several pentoses, tetroses, trioses, alpha-dicarbonyl compounds and L-xylulose. Participates in the uronate cycle of glucose metabolism. May play a role in the water absorption and cellular osmoregulation in the proximal renal tubules by producing xylitol, an osmolyte, thereby preventing osmolytic stress from occurring in the renal tubules.", "general_function": "Oxidoreductase activity, acting on nad(p)h, quinone or similar compound as acceptor", "gene_names": ["DCXR"], "name": "L-xylulose reductase", "drug_actions": []}, "Q14627": {"specific_function": "Binds as a monomer with high affinity to interleukin-13 (IL13), but not to interleukin-4 (IL4).", "general_function": "Signal transducer activity", "gene_names": ["IL13RA2"], "name": "Interleukin-13 receptor subunit alpha-2", "drug_actions": []}, "Q07785": {"specific_function": "Plays a key role in the control of the eukaryotic cell cycle. It is required in higher cells for entry into S-phase and mitosis. Component of the kinase complex that phosphorylates the repetitive C-terminus of RNA polymerase II (By similarity).", "general_function": "Rna polymerase ii carboxy-terminal domain kinase activity", "gene_names": ["CRK2"], "name": "Cell division control protein 2 homolog", "drug_actions": []}, "P07602": {"specific_function": "Saposin-A and saposin-C stimulate the hydrolysis of glucosylceramide by beta-glucosylceramidase (EC 3.2.1.45) and galactosylceramide by beta-galactosylceramidase (EC 3.2.1.46). Saposin-C apparently acts by combining with the enzyme and acidic lipid to form an activated complex, rather than by solubilizing the substrate.Saposin-B stimulates the hydrolysis of galacto-cerebroside sulfate by arylsulfatase A (EC 3.1.6.8), GM1 gangliosides by beta-galactosidase (EC 3.2.1.23) and globotriaosylceramide by alpha-galactosidase A (EC 3.2.1.22). Saposin-B forms a solubilizing complex with the substrates of the sphingolipid hydrolases.Saposin-D is a specific sphingomyelin phosphodiesterase activator (EC 3.1.4.12).Prosaposin: Behaves as a myelinotrophic and neurotrophic factor, these effects are mediated by its G-protein-coupled receptors, GPR37 and GPR37L1, undergoing ligand-mediated internalization followed by ERK phosphorylation signaling.Saposins are specific low-molecular mass non-enzymic proteins, they participate in the lysosomal degradation of sphingolipids, which takes place by the sequential action of specific hydrolases.", "general_function": "Lipid binding", "gene_names": ["PSAP"], "name": "Prosaposin", "drug_actions": []}, "P12256": {"specific_function": "The enzyme catalyzes the conversion of penicillin to 6-aminopenicillanate The precursor, furthermore, acts as a self-processing peptidase that cleaves off the propeptide. All peptidase activity is lost on conversion to the mature peptidase.", "general_function": "Penicillin amidase activity", "gene_names": [], "name": "Penicillin acylase", "drug_actions": []}, "P0A5L8": {"gene_names": ["nat"], "name": "Arylamine N-acetyltransferase", "drug_actions": []}, "O67987": {"general_function": "Ferric iron binding", "gene_names": ["clcA"], "name": "Chlorocatechol 1,2-dioxygenase", "drug_actions": []}, "P25053": {"specific_function": "Catalyzes the irreversible aromatization of 2-((2R,5Z)-2-carboxy-4-methylthiazol-5(2H)-ylidene)ethyl phosphate (cThz*-P) to 2-(2-carboxy-4-methylthiazol-5-yl)ethyl phosphate (cThz-P), a step in the biosynthesis of the thiazole phosphate moiety of thiamine. Cannot use cThz* as substrate, indicating that the phosphate group is essential. Has no thiamine phosphate synthase activity, despite a high sequence similarity with ThiE.", "general_function": "Thiamine-phosphate diphosphorylase activity", "gene_names": ["tenI"], "name": "Thiazole tautomerase", "drug_actions": []}, "P12259": {"specific_function": "Central regulator of hemostasis. It serves as a critical cofactor for the prothrombinase activity of factor Xa that results in the activation of prothrombin to thrombin.", "general_function": "Copper ion binding", "gene_names": ["F5"], "name": "Coagulation factor V", "drug_actions": [{"action": "MULTITARGET", "target": "P12259", "drug": "DB00055"}]}, "P12528": {"specific_function": "Structural component of the short non-contractile tail. The tail comprises six fibers that mediate primary attachment to the host cell lipopolysaccharides (LPS) and display endorhamnosidase enzymatic activity, hydrolyzing the alpha-1,3-O-glycosidic linkage between rhamnose and galactose of the O-antigen polysaccharide. Digestion of the LPS brings the capsid near the cell outer membrane.", "general_function": "Hydrolase activity, acting on glycosyl bonds", "gene_names": ["9"], "name": "Tail fiber protein", "drug_actions": []}, "P0A5P0": {"specific_function": "Transfers a methylene group from S-adenosyl-L-methionine to the cis double bond of an unsaturated fatty acid chain resulting in the replacement of the double bond with a methylene bridge. Mycolic acids, which represent the major constituent of mycobacterial cell wall complex, act as substrates", "general_function": "Cell wall/membrane/envelope biogenesis", "gene_names": ["cmaA2"], "name": "Cyclopropane mycolic acid synthase 2", "drug_actions": []}, "P56601": {"specific_function": "Catalyzes the 6-electron oxidation of protoporphyrinogen-IX to form protoporphyrin-IX.", "general_function": "Oxygen-dependent protoporphyrinogen oxidase activity", "gene_names": ["hemY"], "name": "Protoporphyrinogen oxidase", "drug_actions": []}, "P06988": {"specific_function": "Catalyzes the sequential NAD-dependent oxidations of L-histidinol to L-histidinaldehyde and then to L-histidine.", "general_function": "Zinc ion binding", "gene_names": ["hisD"], "name": "Histidinol dehydrogenase", "drug_actions": []}, "P24385": {"specific_function": "Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D1/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Exhibits transcriptional corepressor activity with INSM1 on the NEUROD1 and INS promoters in a cell cycle-independent manner.", "general_function": "Transcription factor binding", "gene_names": ["CCND1"], "name": "G1/S-specific cyclin-D1", "drug_actions": [{"action": "ANTAGONIST", "target": "P24385", "drug": "DB01169"}]}, "Q00266": {"specific_function": "Catalyzes the formation of S-adenosylmethionine from methionine and ATP.", "general_function": "Methionine adenosyltransferase activity", "gene_names": ["MAT1A"], "name": "S-adenosylmethionine synthase isoform type-1", "drug_actions": [{"action": "COFACTOR", "target": "Q00266", "drug": "DB00118"}]}, "Q55793": {"specific_function": "Catalyzes the removal of elemental sulfur and selenium atoms from L-cysteine, L-cystine, L-selenocysteine, and L-selenocystine to produce L-alanine.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["csd"], "name": "Probable cysteine desulfurase", "drug_actions": []}, "P29395": {"specific_function": "Forms part of the ribosomal stalk which helps the ribosome interact with GTP-bound translation factors.", "general_function": "Structural constituent of ribosome", "gene_names": ["rplK"], "name": "50S ribosomal protein L11", "drug_actions": []}, "Q9UQQ2": {"specific_function": "Links T-cell receptor activation signal to phospholipase C-gamma-1, GRB2 and phosphatidylinositol 3-kinase.", "general_function": "Signaling adaptor activity", "gene_names": ["SH2B3"], "name": "SH2B adapter protein 3", "drug_actions": [{"action": "INHIBITOR", "target": "Q9UQQ2", "drug": "DB06589"}]}, "P51659": {"specific_function": "Bifunctional enzyme acting on the peroxisomal beta-oxidation pathway for fatty acids. Catalyzes the formation of 3-ketoacyl-CoA intermediates from both straight-chain and 2-methyl-branched-chain fatty acids.", "general_function": "Receptor binding", "gene_names": ["HSD17B4"], "name": "Peroxisomal multifunctional enzyme type 2", "drug_actions": []}, "P50740": {"specific_function": "Involved in the biosynthesis of isoprenoids. Catalyzes the 1,3-allylic rearrangement of the homoallylic substrate isopentenyl (IPP) to its allylic isomer, dimethylallyl diphosphate (DMAPP).", "general_function": "Oxidoreductase activity", "gene_names": ["fni"], "name": "Isopentenyl-diphosphate delta-isomerase", "drug_actions": []}, "P29422": {"specific_function": "Decomposes hydrogen peroxide into water and oxygen; serves to protect cells from the toxic effects of hydrogen peroxide.", "general_function": "Metal ion binding", "gene_names": ["katA"], "name": "Catalase", "drug_actions": []}, "P05155": {"specific_function": "Activation of the C1 complex is under control of the C1-inhibitor. It forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases. May play a potentially crucial role in regulating important physiological pathways including complement activation, blood coagulation, fibrinolysis and the generation of kinins. Very efficient inhibitor of FXIIa. Inhibits chymotrypsin and kallikrein.", "general_function": "Serine-type endopeptidase inhibitor activity", "gene_names": ["SERPING1"], "name": "Plasma protease C1 inhibitor", "drug_actions": []}, "O60427": {"specific_function": "Isoform 2 does not exhibit any catalytic activity toward 20:3n-6, but it may enhance FADS2 activity (By similarity). Isoform 1 is a component of a lipid metabolic pathway that catalyzes biosynthesis of highly unsaturated fatty acids (HUFA) from precursor essential polyunsaturated fatty acids (PUFA) linoleic acid (LA) (18:2n-6) and alpha-linolenic acid (ALA) (18:3n-3). Catalyzes the desaturation of dihomo-gamma-linoleic acid (DHGLA) (20:3n-6) and eicosatetraenoic acid (20:4n-3) to generate arachidonic acid (AA) (20:4n-6) and eicosapentaenoic acid (EPA)(20:5n-3), respectively.", "general_function": "Oxidoreductase activity", "gene_names": ["FADS1"], "name": "Fatty acid desaturase 1", "drug_actions": [{"action": "LIGAND", "target": "O60427", "drug": "DB00132"}, {"action": "AGONIST", "target": "O60427", "drug": "DB00159"}]}, "P56194": {"general_function": "Histidine-trna ligase activity", "gene_names": ["hisS"], "name": "Histidine--tRNA ligase", "drug_actions": []}, "Q9UBK8": {"specific_function": "Involved in the reductive regeneration of cob(I)alamin (vitamin B12) cofactor required for the maintenance of methionine synthase in a functional state. Necessary for utilization of methylgroups from the folate cycle, thereby affecting transgenerational epigenetic inheritance. Folate pathway donates methyl groups necessary for cellular methylation and affects different pathways such as DNA methylation, possibly explaining the transgenerational epigenetic inheritance effects.", "general_function": "Oxidoreductase activity, oxidizing metal ions, nad or nadp as acceptor", "gene_names": ["MTRR"], "name": "Methionine synthase reductase", "drug_actions": [{"action": "COFACTOR", "target": "Q9UBK8", "drug": "DB00115"}, {"action": "PRODUCT OF", "target": "Q9UBK8", "drug": "DB00134"}, {"action": "OTHER", "target": "Q9UBK8", "drug": "DB00200"}]}, "P20701": {"specific_function": "Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. It is involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes.", "general_function": "Metal ion binding", "gene_names": ["ITGAL"], "name": "Integrin alpha-L", "drug_actions": [{"action": "ANTIBODY", "target": "P20701", "drug": "DB00095"}, {"action": "OTHER/UNKNOWN", "target": "P20701", "drug": "DB00227"}]}, "P10875": {"specific_function": "Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.", "general_function": "Structural constituent of cytoskeleton", "gene_names": ["TUB2"], "name": "Tubulin beta chain", "drug_actions": [{"action": "INHIBITOR", "target": "P10875", "drug": "DB00400"}]}, "P0C0E6": {"specific_function": "In latent infection, may allow the virus to be reactivated and to grow in cells lacking a high concentration of phosphorylated nucleic acid precursors, such as nerve cells that do not replicate their genome.", "general_function": "Thymidine kinase activity", "gene_names": [], "name": "Thymidine kinase", "drug_actions": []}, "P30749": {"specific_function": "Converts molybdopterin precursor Z to molybdopterin. This requires the incorporation of two sulfur atoms into precursor Z to generate a dithiolene group. The sulfur is provided by MoaD.", "general_function": "Molybdopterin synthase activity", "gene_names": ["moaE"], "name": "Molybdopterin synthase catalytic subunit", "drug_actions": []}, "P40406": {"specific_function": "Plays a role in peptidoglycan recycling by cleaving the terminal beta-1,4-linked N-acetylglucosamine (GlcNAc) from peptide-linked peptidoglycan fragments, giving rise to free GlcNAc, anhydro-N-acetylmuramic acid and anhydro-N-acetylmuramic acid-linked peptides. Cleaves muropeptides, but not peptidoglycan.", "general_function": "Beta-n-acetylhexosaminidase activity", "gene_names": ["nagZ"], "name": "Beta-hexosaminidase", "drug_actions": []}, "P43889": {"specific_function": "Catalyzes the last two sequential reactions in the de novo biosynthetic pathway for UDP-N-acetylglucosamine (UDP-GlcNAc). The C-terminal domain catalyzes the transfer of acetyl group from acetyl coenzyme A to glucosamine-1-phosphate (GlcN-1-P) to produce N-acetylglucosamine-1-phosphate (GlcNAc-1-P), which is converted into UDP-GlcNAc by the transfer of uridine 5-monophosphate (from uridine 5-triphosphate), a reaction catalyzed by the N-terminal domain.", "general_function": "Udp-n-acetylglucosamine diphosphorylase activity", "gene_names": ["glmU"], "name": "Bifunctional protein GlmU", "drug_actions": []}, "P54997": {"specific_function": "Part of a pathway to remove covalently bound sulfur from dibenzothiophene (DBT) without breaking carbon-carbon bonds. This enzyme metabolizes DBT-sulfone (DBTO2 or DBT 5,5-dioxide) to 2-hydroxybiphenyl (2-HBP).", "general_function": "Monooxygenase activity", "gene_names": ["soxB"], "name": "2'-hydroxybiphenyl-2-sulfinate desulfinase", "drug_actions": []}, "P11310": {"specific_function": "Acyl-CoA dehydrogenase specific for acyl chain lengths of 4 to 16 that catalyzes the initial step of fatty acid beta-oxidation. Utilizes the electron transfer flavoprotein (ETF) as an electron acceptor to transfer electrons to the main mitochondrial respiratory chain via ETF-ubiquinone oxidoreductase (ETF dehydrogenase).", "general_function": "Oxidoreductase activity, acting on the ch-ch group of donors, with a flavin as acceptor", "gene_names": ["ACADM"], "name": "Medium-chain specific acyl-CoA dehydrogenase, mitochondrial", "drug_actions": []}, "Q7SIE9": {"general_function": "Metal ion binding", "gene_names": [], "name": "Hydrolase", "drug_actions": []}, "P01617": {"general_function": "Involved in regulation of immune response", "gene_names": [], "name": "Ig kappa chain V-II region TEW", "drug_actions": []}, "P39594": {"specific_function": "Condenses 4-methyl-5-(beta-hydroxyethyl)thiazole monophosphate (THZ-P) and 2-methyl-4-amino-5-hydroxymethyl pyrimidine pyrophosphate (HMP-PP) to form thiamine monophosphate (TMP). Is also able to use the 2-methoxy analog MeO-HMP-PP, as substrate in vitro, but not the 2-trifluoromethyl analog CF(3)-HMP-PP.", "general_function": "Thiamine-phosphate diphosphorylase activity", "gene_names": ["thiE"], "name": "Thiamine-phosphate synthase", "drug_actions": []}, "Q9H2G2": {"specific_function": "Mediates apoptosis and actin stress fiber dissolution.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["SLK"], "name": "STE20-like serine/threonine-protein kinase", "drug_actions": []}, "P09429": {"specific_function": "Multifunctional redox sensitive protein with various roles in different cellular compartments. In the nucleus is one of the major chromatin-associated non-histone proteins and acts as a DNA chaperone involved in replication, transcription, chromatin remodeling, V(D)J recombination, DNA repair and genome stability. Proposed to be an universal biosensor for nucleic acids. Promotes host inflammatory response to sterile and infectious signals and is involved in the coordination and integration of innate and adaptive immune responses. In the cytoplasm functions as sensor and/or chaperone for immunogenic nucleic acids implicating the activation of TLR9-mediated immune responses, and mediates autophagy. Acts as danger associated molecular pattern (DAMP) molecule that amplifies immune responses during tissue injury. Released to the extracellular environment can bind DNA, nucleosomes, IL-1 beta, CXCL12, AGER isoform 2/sRAGE, lipopolysaccharide (LPS) and lipoteichoic acid (LTA), and activates cells through engagement of multiple surface receptors. In the extracellular compartment fully reduced HMGB1 (released by necrosis) acts as a chemokine, disulfide HMGB1 (actively secreted) as a cytokine, and sulfonyl HMGB1 (released from apoptotic cells) promotes immunological tolerance (PubMed:23519706, PubMed:23446148, PubMed:23994764, PubMed:25048472). Has proangiogdenic activity (By similarity). May be involved in platelet activation (By similarity). Binds to phosphatidylserine and phosphatidylethanolamide (By similarity). Bound to RAGE mediates signaling for neuronal outgrowth (By similarity). May play a role in accumulation of expanded polyglutamine (polyQ) proteins such as huntingtin (HTT) or TBP (PubMed:23303669, PubMed:25549101).Nuclear functions are attributed to fully reduced HGMB1. Associates with chromatin and binds DNA with a preference to non-canonical DNA structures such as single-stranded DNA, DNA-containing cruciforms or bent structures, supercoiled DNA and ZDNA. Can bent DNA and enhance DNA flexibility by looping thus providing a mechanism to promote activities on various gene promoters by enhancing transcription factor binding and/or bringing distant regulatory sequences into close proximity (PubMed:20123072). May have an enhancing role in nucleotide excision repair (NER) (By similarity). However, effects in NER using in vitro systems have been reported conflictingly (PubMed:19446504, PubMed:19360789). May be involved in mismatch repair (MMR) and base excision repair (BER) pathways (PubMed:15014079, PubMed:16143102, PubMed:17803946). May be involved in double strand break repair such as non-homologous end joining (NHEJ) (By similarity). Involved in V(D)J recombination by acting as a cofactor of the RAG complex: acts by stimulating cleavage and RAG protein binding at the 23 bp spacer of conserved recombination signal sequences (RSS) (By similarity). In vitro can displace histone H1 from highly bent DNA (By similarity). Can restructure the canonical nucleosome leading to relaxation of structural constraints for transcription factor-binding (By similarity). Enhances binding of sterol regulatory element-binding proteins (SREBPs) such as SREBF1 to their cognate DNA sequences and increases their transcriptional activities (By similarity). Facilitates binding of TP53 to DNA (PubMed:23063560). Proposed to be involved in mitochondrial quality control and autophagy in a transcription-dependent fashion implicating HSPB1; however, this function has been questioned (By similarity). Can modulate the activity of the telomerase complex and may be involved in telomere maintenance (By similarity).In the cytoplasm proposed to dissociate the BECN1:BCL2 complex via competitive interaction with BECN1 leading to autophagy activation (PubMed:20819940). Involved in oxidative stress-mediated autophagy (PubMed:21395369). Can protect BECN1 and ATG5 from calpain-mediated cleavage and thus proposed to control their proautophagic and proapoptotic functions and to regulate the extent and severity of inflammation-associated cellular injury (By similarity). In myeloid cells has a protective role against endotoxemia and bacterial infection by promoting autophagy (By similarity). Involved in endosomal translocation and activation of TLR9 in response to CpG-DNA in macrophages (By similarity).In the extracellular compartment (following either active secretion or passive release) involved in regulation of the inflammatory response. Fully reduced HGMB1 (which subsequently gets oxidized after release) in association with CXCL12 mediates the recruitment of inflammatory cells during the initial phase of tissue injury; the CXCL12:HMGB1 complex triggers CXCR4 homodimerization (PubMed:22370717). Induces the migration of monocyte-derived immature dendritic cells and seems to regulate adhesive and migratory functions of neutrophils implicating AGER/RAGE and ITGAM (By similarity). Can bind to various types of DNA and RNA including microbial unmethylated CpG-DNA to enhance the innate immune response to nucleic acids. Proposed to act in promiscuous DNA/RNA sensing which cooperates with subsequent discriminative sensing by specific pattern recognition receptors (By similarity). Promotes extracellular DNA-induced AIM2 inflammasome activation implicating AGER/RAGE (PubMed:24971542). Disulfide HMGB1 binds to transmembrane receptors, such as AGER/RAGE, TLR2, TLR4 and probably TREM1, thus activating their signal transduction pathways. Mediates the release of cytokines/chemokines such as TNF, IL-1, IL-6, IL-8, CCL2, CCL3, CCL4 and CXCL10 (PubMed:12765338, PubMed:18354232, PubMed:19264983, PubMed:20547845, PubMed:24474694). Promotes secretion of interferon-gamma by macrophage-stimulated natural killer (NK) cells in concert with other cytokines like IL-2 or IL-12 (PubMed:15607795). TLR4 is proposed to be the primary receptor promoting macrophage activation and signaling through TLR4 seems to implicate LY96/MD-2 (PubMed:20547845). In bacterial LPS- or LTA-mediated inflammatory responses binds to the endotoxins and transfers them to CD14 for signaling to the respective TLR4:LY96 and TLR2 complexes (PubMed:18354232, PubMed:21660935, PubMed:25660311). Contributes to tumor proliferation by association with ACER/RAGE (By similarity). Can bind to IL1-beta and signals through the IL1R1:IL1RAP receptor complex (PubMed:18250463). Binding to class A CpG activates cytokine production in plasmacytoid dendritic cells implicating TLR9, MYD88 and AGER/RAGE and can activate autoreactive B cells. Via HMGB1-containing chromatin immune complexes may also promote B cell responses to endogenous TLR9 ligands through a B-cell receptor (BCR)-dependent and ACER/RAGE-independent mechanism (By similarity). Inhibits phagocytosis of apoptotic cells by macrophages; the function is dependent on poly-ADP-ribosylation and involves binding to phosphatidylserine on the cell surface of apoptotic cells (By similarity). In adaptive immunity may be involved in enhancing immunity through activation of effector T cells and suppression of regulatory T (TReg) cells (PubMed:15944249, PubMed:22473704). In contrast, without implicating effector or regulatory T cells, required for tumor infiltration and activation of T cells expressing the lymphotoxin LTA:LTB heterotrimer thus promoting tumor malignant progression (By similarity). Also reported to limit proliferation of T cells (By similarity). Released HMGB1:nucleosome complexes formed during apoptosis can signal through TLR2 to induce cytokine production (PubMed:19064698). Involved in induction of immunological tolerance by apoptotic cells; its pro-inflammatory activities when released by apoptotic cells are neutralized by reactive oxygen species (ROS)-dependent oxidation specifically on Cys-106 (PubMed:18631454). During macrophage activation by activated lymphocyte-derived self apoptotic DNA (ALD-DNA) promotes recruitment of ALD-DNA to endosomes (By similarity).", "general_function": "Transcription factor binding", "gene_names": ["HMGB1"], "name": "High mobility group protein B1", "drug_actions": []}, "P39593": {"specific_function": "Catalyzes the phosphorylation of the hydroxyl group of 4-methyl-5-beta-hydroxyethylthiazole (THZ).", "general_function": "Magnesium ion binding", "gene_names": ["thiM"], "name": "Hydroxyethylthiazole kinase", "drug_actions": []}, "P38516": {"specific_function": "One of the primary rRNA binding proteins, this protein initially binds near the 5'-end of the 23S rRNA. It is important during the early stages of 50S assembly. It makes multiple contacts with different domains of the 23S rRNA in the assembled 50S subunit and ribosome (By similarity).This protein only weakly controls expression of the E.coli S10 operon. It is incorporated into E.coli ribosomes, however it is not as firmly associated as the endogenous protein.Forms part of the polypeptide exit tunnel.", "general_function": "Structural constituent of ribosome", "gene_names": ["rplD"], "name": "50S ribosomal protein L4", "drug_actions": []}, "O15169": {"specific_function": "Component of the beta-catenin destruction complex required for regulating CTNNB1 levels through phosphorylation and ubiquitination, and modulating Wnt-signaling. Controls dorsoventral patterning via two opposing effects; down-regulates CTNNB1 to inhibit the Wnt signaling pathway and ventralize embryos, but also dorsalizes embryos by activating a Wnt-independent JNK signaling pathway. In Wnt signaling, probably facilitates the phosphorylation of CTNNB1 and APC by GSK3B. Likely to function as a tumor suppressor. Facilitates the phosphorylation of TP53 by HIPK2 upon ultraviolet irradiation. Enhances TGF-beta signaling by recruiting the RNF111 E3 ubiquitin ligase and promoting the degradation of inhibitory SMAD7. Also component of the AXIN1-HIPK2-TP53 complex which controls cell growth, apoptosis and development.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["AXIN1"], "name": "Axin-1", "drug_actions": []}, "P0AFL3": {"specific_function": "PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides.", "general_function": "Peptidyl-prolyl cis-trans isomerase activity", "gene_names": ["ppiA"], "name": "Peptidyl-prolyl cis-trans isomerase A", "drug_actions": []}, "P07737": {"specific_function": "Binds to actin and affects the structure of the cytoskeleton. At high concentrations, profilin prevents the polymerization of actin, whereas it enhances it at low concentrations. By binding to PIP2, it inhibits the formation of IP3 and DG. Inhibits androgen receptor (AR) and HTT aggregation and binding of G-actin is essential for its inhibition of AR.", "general_function": "Proline-rich region binding", "gene_names": ["PFN1"], "name": "Profilin-1", "drug_actions": []}, "P04271": {"specific_function": "Weakly binds calcium but binds zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer. Physiological concentrations of potassium ion antagonize the binding of both divalent cations, especially affecting high-affinity calcium-binding sites. Binds to and initiates the activation of STK38 by releasing autoinhibitory intramolecular interactions within the kinase. Interaction with AGER after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling. Could assist ATAD3A cytoplasmic processing, preventing aggregation and favoring mitochondrial localization. May mediate calcium-dependent regulation on many physiological processes by interacting with other proteins, such as TPR-containing proteins, and modulating their activity.", "general_function": "Zinc ion binding", "gene_names": ["S100B"], "name": "Protein S100-B", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "P04271", "drug": "DB00768"}]}, "O53240": {"general_function": "Pyridoxamine-phosphate oxidase activity", "gene_names": [], "name": "Conserved protein", "drug_actions": []}, "P09601": {"specific_function": "Heme oxygenase cleaves the heme ring at the alpha methene bridge to form biliverdin. Biliverdin is subsequently converted to bilirubin by biliverdin reductase. Under physiological conditions, the activity of heme oxygenase is highest in the spleen, where senescent erythrocytes are sequestrated and destroyed. Exhibits cytoprotective effects since excess of free heme sensitizes cells to undergo apoptosis.", "general_function": "Signal transducer activity", "gene_names": ["HMOX1"], "name": "Heme oxygenase 1", "drug_actions": []}, "P24289": {"specific_function": "Hydrolyzes only single-stranded DNA and RNA without apparent specificity for bases.", "general_function": "Nucleic acid binding", "gene_names": [], "name": "Nuclease P1", "drug_actions": []}, "P04275": {"specific_function": "Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.", "general_function": "Protein n-terminus binding", "gene_names": ["VWF"], "name": "von Willebrand factor", "drug_actions": [{"action": "BINDER", "target": "P04275", "drug": "DB00025"}]}, "P02708": {"specific_function": "After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.", "general_function": "Ion channel activity", "gene_names": ["CHRNA1"], "name": "Acetylcholine receptor subunit alpha", "drug_actions": [{"action": "ALLOSTERIC MODULATOR", "target": "P02708", "drug": "DB00674"}, {"action": "ANTAGONIST", "target": "P02708", "drug": "DB08838"}]}, "P28066": {"specific_function": "The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity.", "general_function": "Threonine-type endopeptidase activity", "gene_names": ["PSMA5"], "name": "Proteasome subunit alpha type-5", "drug_actions": []}, "P04278": {"specific_function": "Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone, and 17-beta-estradiol. Regulates the plasma metabolic clearance rate of steroid hormones by controlling their plasma concentration.", "general_function": "Androgen binding", "gene_names": ["SHBG"], "name": "Sex hormone-binding globulin", "drug_actions": [{"action": "BINDER", "target": "P04278", "drug": "DB00421"}]}, "Q9ZF99": {"specific_function": "Catalyzes the reversible oxidation of malate to oxaloacetate.", "general_function": "L-malate dehydrogenase activity", "gene_names": ["mdh"], "name": "Malate dehydrogenase", "drug_actions": []}, "P08773": {"general_function": "Thymidylate synthase activity", "gene_names": ["42"], "name": "Deoxycytidylate 5-hydroxymethyltransferase", "drug_actions": []}, "P28062": {"specific_function": "The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Acts as a major component of interferon gamma-induced sensitivity. Plays a key role in apoptosis via the degradation of the apoptotic inhibitor MCL1. May be involved in the inflammatory response pathway. In cancer cells, substitution of isoform 1 (E2) by isoform 2 (E1) results in immunoproteasome deficiency. Required for the differentiation of preadipocytes into adipocytes.", "general_function": "Threonine-type endopeptidase activity", "gene_names": ["PSMB8"], "name": "Proteasome subunit beta type-8", "drug_actions": [{"action": "INHIBITOR", "target": "P28062", "drug": "DB08889"}]}, "P00488": {"specific_function": "Factor XIII is activated by thrombin and calcium ion to a transglutaminase that catalyzes the formation of gamma-glutamyl-epsilon-lysine cross-links between fibrin chains, thus stabilizing the fibrin clot. Also cross-link alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin.", "general_function": "Protein-glutamine gamma-glutamyltransferase activity", "gene_names": ["F13A1"], "name": "Coagulation factor XIII A chain", "drug_actions": []}, "Q01959": {"specific_function": "Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.", "general_function": "Monoamine transmembrane transporter activity", "gene_names": ["SLC6A3"], "name": "Sodium-dependent dopamine transporter", "drug_actions": [{"action": "NEGATIVE MODULATOR", "target": "Q01959", "drug": "DB00182"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00191"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00245"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00285"}, {"action": "BINDER", "target": "Q01959", "drug": "DB00289"}, {"action": "BINDER", "target": "Q01959", "drug": "DB00370"}, {"action": "BINDER", "target": "Q01959", "drug": "DB00408"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00422"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00476"}, {"action": "BINDER", "target": "Q01959", "drug": "DB00543"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00579"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00721"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00726"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00745"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00830"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00852"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00865"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00907"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB00937"}, {"action": "INDUCER", "target": "Q01959", "drug": "DB00988"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB01104"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB01105"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB01114"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB01146"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB01149"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB01156"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB01161"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB01175"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB01255"}, {"action": "NEGATIVE MODULATOR", "target": "Q01959", "drug": "DB01363"}, {"action": "NEGATIVE MODULATOR", "target": "Q01959", "drug": "DB01442"}, {"action": "NEGATIVE MODULATOR", "target": "Q01959", "drug": "DB01454"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB01463"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB01472"}, {"action": "NEGATIVE MODULATOR", "target": "Q01959", "drug": "DB01576"}, {"action": "NEGATIVE MODULATOR", "target": "Q01959", "drug": "DB01577"}, {"action": "BINDER", "target": "Q01959", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "Q01959", "drug": "DB06413"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB06413"}, {"action": "INHIBITOR", "target": "Q01959", "drug": "DB06701"}]}, "P0C2S2": {"specific_function": "This enzyme catalyzes the endohydrolysis of 1,4-beta-glucosidic linkages in cellulose, lichenin and cereal beta-D-glucans.", "general_function": "Cellulase activity", "gene_names": ["celA"], "name": "Endoglucanase A", "drug_actions": []}, "Q8DNB6": {"general_function": "Transferase activity, transferring acyl groups", "gene_names": ["pbp2a"], "name": "Penicillin-binding protein 2a", "drug_actions": [{"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB00319"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB00415"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB00456"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB00485"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB00493"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB00567"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB00607"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB00713"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB00739"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB01147"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB01163"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB01331"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB01603"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB03313"}, {"action": "INHIBITOR", "target": "Q8DNB6", "drug": "DB08795"}]}, "P0C2S5": {"specific_function": "This enzyme catalyzes the exohydrolysis of 1,4-beta-glucosidic linkages in cellulose with a preference for amorphous or crystalline cellulose over carboxymethyl cellulose.", "general_function": "Metal ion binding", "gene_names": ["celS"], "name": "Cellulose 1,4-beta-cellobiosidase (reducing end) CelS", "drug_actions": []}, "P00966": {"specific_function": "Is indirectly involved in the control of blood pressure.", "general_function": "Toxic substance binding", "gene_names": ["ASS1"], "name": "Argininosuccinate synthase", "drug_actions": []}, "Q27796": {"general_function": "Hypoxanthine phosphoribosyltransferase activity", "gene_names": ["HGPRTase"], "name": "Hypoxanthine-guanine phosphoribosyltransferase", "drug_actions": []}, "P43099": {"general_function": "Ornithine decarboxylase activity", "gene_names": ["odcI"], "name": "Ornithine decarboxylase, inducible", "drug_actions": []}, "P62913": {"specific_function": "Binds to 5S ribosomal RNA (By similarity). Required for rRNA maturation and formation of the 60S ribosomal subunits. Promotes nucleolar location of PML (By similarity).", "general_function": "Structural constituent of ribosome", "gene_names": ["RPL11"], "name": "60S ribosomal protein L11", "drug_actions": []}, "Q9ZEU2": {"specific_function": "Catalyzes the synthesis of alpha-glucan from sucrose. Catalyzes, in addition, sucrose hydrolysis, maltose and maltotriose synthesis by successive transfers of the glucosyl moiety of sucrose onto the released glucose, and finally turanose and trehalulose synthesis, these two sucrose isomers being obtained by glucosyl transfer onto fructose.", "general_function": "Cation binding", "gene_names": ["ams"], "name": "Amylosucrase", "drug_actions": []}, "P62917": {"general_function": "Structural constituent of ribosome", "gene_names": ["RPL8"], "name": "60S ribosomal protein L8", "drug_actions": []}, "Q9ZB17": {"specific_function": "Converts alpha-aldose to the beta-anomer.", "general_function": "Carbohydrate binding", "gene_names": ["galM"], "name": "Aldose 1-epimerase", "drug_actions": []}, "Q6IB77": {"specific_function": "Mitochondrial acyltransferase which transfers an acyl group to the N-terminus of glycine and glutamine, although much less efficiently. Can conjugate numerous substrates to form a variety of N-acylglycines, with a preference for benzoyl-CoA over phenylacetyl-CoA as acyl donors. Thereby detoxify xenobiotics, such as benzoic acid or salicylic acid, and endogenous organic acids, such as isovaleric acid.", "general_function": "Transferase activity, transferring acyl groups", "gene_names": ["GLYAT"], "name": "Glycine N-acyltransferase", "drug_actions": []}, "Q15382": {"specific_function": "Activates the protein kinase activity of mTORC1, and thereby plays a role in the regulation of apoptosis. Stimulates the phosphorylation of S6K1 and EIF4EBP1 through activation of mTORC1 signaling. Has low intrinsic GTPase activity.", "general_function": "Metal ion binding", "gene_names": ["RHEB"], "name": "GTP-binding protein Rheb", "drug_actions": []}, "P10253": {"specific_function": "Essential for the degradation of glygogen to glucose in lysosomes.", "general_function": "Maltose alpha-glucosidase activity", "gene_names": ["GAA"], "name": "Lysosomal alpha-glucosidase", "drug_actions": [{"action": "INHIBITOR", "target": "P10253", "drug": "DB00284"}, {"action": "ANTAGONIST", "target": "P10253", "drug": "DB00491"}]}, "Q6GGU4": {"general_function": "3-dehydroquinate synthase activity", "gene_names": ["aroB"], "name": "3-dehydroquinate synthase", "drug_actions": []}, "O60513": {"specific_function": "Responsible for the synthesis of complex-type N-linked oligosaccharides in many glycoproteins as well as the carbohydrate moieties of glycolipids.", "general_function": "N-acetyllactosamine synthase activity", "gene_names": ["B4GALT4"], "name": "Beta-1,4-galactosyltransferase 4", "drug_actions": []}, "P56282": {"specific_function": "Participates in DNA repair and in chromosomal DNA replication.", "general_function": "Dna-directed dna polymerase activity", "gene_names": ["POLE2"], "name": "DNA polymerase epsilon subunit 2", "drug_actions": [{"action": "INHIBITOR", "target": "P56282", "drug": "DB00242"}]}, "P06396": {"specific_function": "Calcium-regulated, actin-modulating protein that binds to the plus (or barbed) ends of actin monomers or filaments, preventing monomer exchange (end-blocking or capping). It can promote the assembly of monomers into filaments (nucleation) as well as sever filaments already formed. Plays a role in ciliogenesis.", "general_function": "Protein domain specific binding", "gene_names": ["GSN"], "name": "Gelsolin", "drug_actions": []}, "P35914": {"specific_function": "Key enzyme in ketogenesis (ketone body formation). Terminal step in leucine catabolism. Ketone bodies (beta-hydroxybutyrate, acetoacetate and acetone) are essential as an alternative source of energy to glucose, as lipid precursors and as regulators of metabolism.", "general_function": "Receptor binding", "gene_names": ["HMGCL"], "name": "Hydroxymethylglutaryl-CoA lyase, mitochondrial", "drug_actions": []}, "P02144": {"specific_function": "Serves as a reserve supply of oxygen and facilitates the movement of oxygen within muscles.", "general_function": "Oxygen transporter activity", "gene_names": ["MB"], "name": "Myoglobin", "drug_actions": []}, "P35916": {"specific_function": "Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-185', and of AKT1 at 'Ser-473'.", "general_function": "Vascular endothelial growth factor-activated receptor activity", "gene_names": ["FLT4"], "name": "Vascular endothelial growth factor receptor 3", "drug_actions": [{"action": "ANTAGONIST", "target": "P35916", "drug": "DB00398"}, {"action": "ANTAGONIST", "target": "P35916", "drug": "DB01268"}, {"action": "INHIBITOR", "target": "P35916", "drug": "DB06626"}, {"action": "INHIBITOR", "target": "P35916", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P35916", "drug": "DB09078"}, {"action": "INHIBITOR", "target": "P35916", "drug": "DB09079"}]}, "P55072": {"gene_names": ["VCP"], "name": "Transitional endoplasmic reticulum ATPase", "drug_actions": []}, "P35913": {"specific_function": "This protein participates in processes of transmission and amplification of the visual signal. Necessary for the formation of a functional phosphodiesterase holoenzyme.", "name": "Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "P35913", "drug": "DB00201"}], "general_function": "Metal ion binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE6B"]}, "O15270": {"specific_function": "Serine palmitoyltransferase (SPT). The heterodimer formed with LCB1/SPTLC1 constitutes the catalytic core. The composition of the serine palmitoyltransferase (SPT) complex determines the substrate preference. The SPTLC1-SPTLC2-SPTSSA complex shows a strong preference for C16-CoA substrate, while the SPTLC1-SPTLC2-SPTSSB complex displays a preference for C18-CoA substrate.", "general_function": "Serine c-palmitoyltransferase activity", "gene_names": ["SPTLC2"], "name": "Serine palmitoyltransferase 2", "drug_actions": [{"action": "COFACTOR", "target": "O15270", "drug": "DB00114"}]}, "Q49AK1": {"general_function": "Amino acid transport and metabolism", "gene_names": ["GAD1"], "name": "GAD1 protein", "drug_actions": [{"action": "COFACTOR", "target": "Q49AK1", "drug": "DB00114"}]}, "P01764": {"general_function": "Immunoglobulin receptor binding", "gene_names": ["IGHV3-23"], "name": "Ig heavy chain V-III region 23", "drug_actions": []}, "P08172": {"specific_function": "The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol.", "name": "Muscarinic acetylcholine receptor M2", "drug_actions": [{"action": "AGONIST", "target": "P08172", "drug": "DB00202"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00280"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00332"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00340"}, {"action": "BINDER", "target": "P08172", "drug": "DB00342"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00376"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00383"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00387"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00392"}, {"action": "BINDER", "target": "P08172", "drug": "DB00408"}, {"action": "AGONIST", "target": "P08172", "drug": "DB00411"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00424"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00434"}, {"action": "BINDER", "target": "P08172", "drug": "DB00454"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00462"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00483"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00496"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00505"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00508"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00517"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00543"}, {"action": "BINDER", "target": "P08172", "drug": "DB00568"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00572"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00622"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00715"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00725"}, {"action": "BINDER", "target": "P08172", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00728"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00747"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00767"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00785"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00804"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00809"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00835"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00907"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB00934"}, {"action": "BINDER", "target": "P08172", "drug": "DB00986"}, {"action": "AGONIST", "target": "P08172", "drug": "DB01019"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01036"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01062"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01069"}, {"action": "AGONIST", "target": "P08172", "drug": "DB01085"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01135"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01148"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01151"}, {"action": "BINDER", "target": "P08172", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01226"}, {"action": "PARTIAL AGONIST", "target": "P08172", "drug": "DB01226"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01231"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01336"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01337"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01338"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01409"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB01591"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB06702"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB08801"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB08897"}, {"action": "ANTAGONIST", "target": "P08172", "drug": "DB09076"}], "general_function": "G-protein coupled acetylcholine receptor activity", "in_complexes": ["Muscarinic acetylcholine receptor"], "gene_names": ["CHRM2"]}, "P08173": {"specific_function": "The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.", "name": "Muscarinic acetylcholine receptor M4", "drug_actions": [{"action": "ANTAGONIST", "target": "P08173", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00340"}, {"action": "BINDER", "target": "P08173", "drug": "DB00342"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00376"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00387"}, {"action": "BINDER", "target": "P08173", "drug": "DB00408"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00420"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00424"}, {"action": "BINDER", "target": "P08173", "drug": "DB00454"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00458"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00496"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00543"}, {"action": "BINDER", "target": "P08173", "drug": "DB00568"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00572"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00622"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00715"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00725"}, {"action": "BINDER", "target": "P08173", "drug": "DB00726"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00747"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00767"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00777"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00785"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00809"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00835"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB00934"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01036"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01069"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01142"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01151"}, {"action": "BINDER", "target": "P08173", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01591"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB01625"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB06702"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB08897"}, {"action": "ANTAGONIST", "target": "P08173", "drug": "DB09076"}], "general_function": "Guanyl-nucleotide exchange factor activity", "in_complexes": ["Muscarinic acetylcholine receptor"], "gene_names": ["CHRM4"]}, "P08174": {"specific_function": "This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade.(Microbial infection) Acts as a receptor for coxsackievirus A21, coxsackieviruses B1, B3 and B5 (PubMed:9151867). Acts as a receptor for human enterovirus 70 and D68 (Probable) (PubMed:8764022). Acts as a receptor for human echoviruses 6, 7, 11, 12, 20 and 21 (PubMed:7525274).", "general_function": "Virus receptor activity", "gene_names": ["CD55"], "name": "Complement decay-accelerating factor", "drug_actions": [{"action": "OTHER", "target": "P08174", "drug": "DB00446"}]}, "Q8VP84": {"specific_function": "Catalyzes the transfer of the phosphoribosyl group of 5-phosphorylribose-1-pyrophosphate (PRPP) to anthranilate to yield N-(5'-phosphoribosyl)-anthranilate (PRA).", "general_function": "Magnesium ion binding", "gene_names": ["trpD"], "name": "Anthranilate phosphoribosyltransferase", "drug_actions": []}, "P00491": {"specific_function": "The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate.", "general_function": "Purine-nucleoside phosphorylase activity", "gene_names": ["PNP"], "name": "Purine nucleoside phosphorylase", "drug_actions": [{"action": "INDUCER", "target": "P00491", "drug": "DB00242"}]}, "P00490": {"specific_function": "Phosphorylase is an important allosteric enzyme in carbohydrate metabolism. Enzymes from different sources differ in their regulatory mechanisms and in their natural substrates. However, all known phosphorylases share catalytic and structural properties.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["malP"], "name": "Maltodextrin phosphorylase", "drug_actions": []}, "P00492": {"specific_function": "Converts guanine to guanosine monophosphate, and hypoxanthine to inosine monophosphate. Transfers the 5-phosphoribosyl group from 5-phosphoribosylpyrophosphate onto the purine. Plays a central role in the generation of purine nucleotides through the purine salvage pathway.", "general_function": "Protein homodimerization activity", "gene_names": ["HPRT1"], "name": "Hypoxanthine-guanine phosphoribosyltransferase", "drug_actions": [{"action": "INHIBITOR", "target": "P00492", "drug": "DB00993"}, {"action": "INHIBITOR", "target": "P00492", "drug": "DB01033"}]}, "P00497": {"specific_function": "Catalyzes the formation of phosphoribosylamine from phosphoribosylpyrophosphate (PRPP) and glutamine.", "general_function": "Magnesium ion binding", "gene_names": ["purF"], "name": "Amidophosphoribosyltransferase", "drug_actions": []}, "Q08345": {"specific_function": "Tyrosine kinase that functions as cell surface receptor for fibrillar collagen and regulates cell attachment to the extracellular matrix, remodeling of the extracellular matrix, cell migration, differentiation, survival and cell proliferation. Collagen binding triggers a signaling pathway that involves SRC and leads to the activation of MAP kinases. Regulates remodeling of the extracellular matrix by up-regulation of the matrix metalloproteinases MMP2, MMP7 and MMP9, and thereby facilitates cell migration and wound healing. Required for normal blastocyst implantation during pregnancy, for normal mammary gland differentiation and normal lactation. Required for normal ear morphology and normal hearing (By similarity). Promotes smooth muscle cell migration, and thereby contributes to arterial wound healing. Also plays a role in tumor cell invasion. Phosphorylates PTPN11.", "general_function": "Transmembrane receptor protein tyrosine kinase activity", "gene_names": ["DDR1"], "name": "Epithelial discoidin domain-containing receptor 1", "drug_actions": [{"action": "ANTAGONIST", "target": "Q08345", "drug": "DB00619"}]}, "P19971": {"specific_function": "May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro.Catalyzes the reversible phosphorolysis of thymidine. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis.", "general_function": "Transferase activity, transferring pentosyl groups", "gene_names": ["TYMP"], "name": "Thymidine phosphorylase", "drug_actions": []}, "P27797": {"specific_function": "Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER. Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export. Involved in maternal gene expression regulation. May participate in oocyte maturation via the regulation of calcium homeostasis (By similarity).", "general_function": "Zinc ion binding", "gene_names": ["CALR"], "name": "Calreticulin", "drug_actions": [{"action": "CHAPERONE", "target": "P27797", "drug": "DB00025"}]}, "P27487": {"specific_function": "Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Its interaction with ADA also regulates lymphocyte-epithelial cell adhesion. In association with FAP is involved in the pericellular proteolysis of the extracellular matrix (ECM), the migration and invasion of endothelial cells into the ECM. May be involved in the promotion of lymphatic endothelial cells adhesion, migration and tube formation. When overexpressed, enhanced cell proliferation, a process inhibited by GPC3. Acts also as a serine exopeptidase with a dipeptidyl peptidase activity that regulates various physiological processes by cleaving peptides in the circulation, including many chemokines, mitogenic growth factors, neuropeptides and peptide hormones. Removes N-terminal dipeptides sequentially from polypeptides having unsubstituted N-termini provided that the penultimate residue is proline.", "general_function": "Virus receptor activity", "gene_names": ["DPP4"], "name": "Dipeptidyl peptidase 4", "drug_actions": [{"action": "INHIBITOR", "target": "P27487", "drug": "DB01076"}, {"action": "INHIBITOR", "target": "P27487", "drug": "DB01261"}, {"action": "INHIBITOR", "target": "P27487", "drug": "DB04876"}, {"action": "INHIBITOR", "target": "P27487", "drug": "DB06203"}, {"action": "INHIBITOR", "target": "P27487", "drug": "DB06335"}, {"action": "INHIBITOR", "target": "P27487", "drug": "DB08882"}]}, "P0A6G7": {"specific_function": "Cleaves peptides in various proteins in a process that requires ATP hydrolysis. Has a chymotrypsin-like activity. Plays a major role in the degradation of misfolded proteins. May play the role of a master protease which is attracted to different substrates by different specificity factors such as ClpA or ClpX. Participates in the final steps of RseA-sigma-E degradation, liberating sigma-E to induce the extracytoplasmic-stress response. Degrades antitoxin MazE (PubMed:24375411).", "general_function": "Serine-type peptidase activity", "gene_names": ["clpP"], "name": "ATP-dependent Clp protease proteolytic subunit", "drug_actions": []}, "Q04416": {"general_function": "4-hydroxybenzoyl-coa thioesterase activity", "gene_names": ["fcbC"], "name": "4-hydroxybenzoyl-CoA thioesterase", "drug_actions": []}, "Q45515": {"specific_function": "Catalyzes the stereospecific hydrolysis of the cyclic amide bond of D-hydantoin. Has no activity on dihydropyrimidines.", "general_function": "Metal ion binding", "gene_names": [], "name": "D-hydantoinase", "drug_actions": []}, "Q5SKW1": {"specific_function": "Sigma factors are initiation factors that promote the attachment of RNA polymerase to specific initiation sites and are then released.Sigma factors are initiation factors that promote the attachment of RNA polymerase to specific initiation sites and are then released. This sigma factor is the primary sigma factor during exponential growth.", "general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": ["sigA"], "name": "RNA polymerase sigma factor SigA", "drug_actions": []}, "Q96Q40": {"specific_function": "Serine/threonine-protein kinase that acts like an antiapoptotic protein that counters TRAIL/TNFSF10-induced apoptosis by inducing phosphorylation of BIRC5 at 'Thr-34'.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["CDK15"], "name": "Cyclin-dependent kinase 15", "drug_actions": []}, "P21340": {"specific_function": "Involved in the protection against polyamine toxicity by regulating their concentration. Also could be involved in the negative control of sporulation as well as production of degradative enzymes such as alpha-amylase, levansucrase and alkaline phosphatase. Catalyzes the transfer of an acetyl group from acetyl coenzyme A (AcCoA) to an acceptor substrate and releases both CoA and the acetylated product. It possesses N1-acetyltransferase activity toward polyamine substrates including spermidine, spermine, aminopropylcadaverine, norspermidine, homospermidine, N(8)-acetylspermidine, diaminopropane and agmatine.", "general_function": "Diamine n-acetyltransferase activity", "gene_names": ["paiA"], "name": "Spermidine/spermine N(1)-acetyltransferase", "drug_actions": []}, "Q59EB3": {"general_function": "Protein tyrosine kinase activity", "gene_names": [], "name": "Met proto-oncogene variant", "drug_actions": []}, "P0A955": {"specific_function": "Involved in the degradation of glucose via the Entner-Doudoroff pathway. Catalyzes the reversible, stereospecific retro-aldol cleavage of 2-Keto-3-deoxy-6-phosphogluconate (KDPG) to pyruvate and D-glyceraldehyde-3-phosphate. In the synthetic direction, it catalyzes the addition of pyruvate to electrophilic aldehydes with si-facial selectivity. It accepts some nucleophiles other than pyruvate, including 2-oxobutanoate, phenylpyruvate, and fluorobutanoate. It has a preference for the S-configuration at C2 of the electrophile.", "general_function": "Identical protein binding", "gene_names": ["eda"], "name": "KHG/KDPG aldolase", "drug_actions": []}, "P0A953": {"specific_function": "Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP. Specific for elongation from C-10 to unsaturated C-16 and C-18 fatty acids.", "general_function": "3-oxoacyl-[acyl-carrier-protein] synthase activity", "gene_names": ["fabB"], "name": "3-oxoacyl-[acyl-carrier-protein] synthase 1", "drug_actions": [{"action": "INHIBITOR", "target": "P0A953", "drug": "DB01034"}]}, "Q8IYQ7": {"general_function": "Threonine synthase activity", "gene_names": ["THNSL1"], "name": "Threonine synthase-like 1", "drug_actions": [{"action": "COFACTOR", "target": "Q8IYQ7", "drug": "DB00114"}]}, "P00363": {"specific_function": "Two distinct, membrane-bound, FAD-containing enzymes are responsible for the catalysis of fumarate and succinate interconversion; the fumarate reductase is used in anaerobic growth, and the succinate dehydrogenase is used in aerobic growth.", "general_function": "Succinate dehydrogenase activity", "gene_names": ["frdA"], "name": "Fumarate reductase flavoprotein subunit", "drug_actions": [{"action": "INHIBITOR", "target": "P00363", "drug": "DB00730"}]}, "P00362": {"specific_function": "Catalyzes the oxidative phosphorylation of glyceraldehyde 3-phosphate (G3P) to 1,3-bisphosphoglycerate (BPG) using the cofactor NAD. The first reaction step involves the formation of a hemiacetal intermediate between G3P and a cysteine residue, and this hemiacetal intermediate is then oxidized to a thioester, with concomitant reduction of NAD to NADH. The reduced NADH is then exchanged with the second NAD, and the thioester is attacked by a nucleophilic inorganic phosphate to produce BPG.", "general_function": "Nadp binding", "gene_names": ["gap"], "name": "Glyceraldehyde-3-phosphate dehydrogenase", "drug_actions": []}, "P00811": {"specific_function": "This protein is a serine beta-lactamase with a substrate specificity for cephalosporins.", "general_function": "Beta-lactamase activity", "gene_names": ["ampC"], "name": "Beta-lactamase", "drug_actions": [{"action": "POTENTIATOR", "target": "P00811", "drug": "DB00456"}, {"action": "INDUCER", "target": "P00811", "drug": "DB01147"}]}, "P00813": {"specific_function": "Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion.", "general_function": "Zinc ion binding", "gene_names": ["ADA"], "name": "Adenosine deaminase", "drug_actions": [{"action": "INHIBITOR", "target": "P00813", "drug": "DB00552"}, {"action": "INHIBITOR", "target": "P00813", "drug": "DB00975"}]}, "P25971": {"specific_function": "Catalyzes the decarboxylation of orotidine 5'-monophosphate (OMP) to uridine 5'-monophosphate (UMP).", "general_function": "Orotidine-5'-phosphate decarboxylase activity", "gene_names": ["pyrF"], "name": "Orotidine 5'-phosphate decarboxylase", "drug_actions": []}, "Q9X519": {"specific_function": "Essential for rapid growth and for sporulation. Catalyzes the interconversion of 2-phosphoglycerate (2-PGA) and 3-phosphoglycerate (3-PGA).", "general_function": "Manganese ion binding", "gene_names": ["gpmI"], "name": "2,3-bisphosphoglycerate-independent phosphoglycerate mutase", "drug_actions": []}, "Q7BJM5": {"general_function": "Metal ion binding", "gene_names": ["VIM-2"], "name": "Class B carbapenemase VIM-2", "drug_actions": []}, "P00568": {"specific_function": "Catalyzes the reversible transfer of the terminal phosphate group between ATP and AMP. Also displays broad nucleoside diphosphate kinase activity. Plays an important role in cellular energy homeostasis and in adenine nucleotide metabolism.", "general_function": "Nucleoside diphosphate kinase activity", "gene_names": ["AK1"], "name": "Adenylate kinase isoenzyme 1", "drug_actions": []}, "Q8KI25": {"general_function": "Monooxygenase activity", "gene_names": ["rbmD"], "name": "Putative FAD-monooxygenase", "drug_actions": []}, "Q04095": {"specific_function": "Capsid protein p27 forms the spherical core of the virus that encapsulates the genomic RNA-nucleocapsid complex.The aspartyl protease mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane. Cleavages take place as an ordered, step-wise cascade to yield mature proteins. This process is called maturation. Displays maximal activity during the budding process just prior to particle release from the cell.", "general_function": "Zinc ion binding", "gene_names": ["gag-pro-pol"], "name": "Gag-Pro-Pol polyprotein", "drug_actions": []}, "P0A7D4": {"specific_function": "Plays an important role in the de novo pathway of purine nucleotide biosynthesis. Catalyzes the first committed step in the biosynthesis of AMP from IMP.", "general_function": "Magnesium ion binding", "gene_names": ["purA"], "name": "Adenylosuccinate synthetase", "drug_actions": []}, "Q8IVS2": {"specific_function": "Catalyzes the transfer of a malonyl moiety from malonyl-CoA to the free thiol group of the phosphopantetheine arm of the mitochondrial ACP protein (NDUFAB1). This suggests the existence of the biosynthesis of fatty acids in mitochondrias.", "general_function": "Transferase activity", "gene_names": ["MCAT"], "name": "Malonyl-CoA-acyl carrier protein transacylase, mitochondrial", "drug_actions": []}, "P0A1F6": {"specific_function": "Catalyzes the reversible phosphorylytic cleavage of uridine and deoxyuridine to uracil and ribose- or deoxyribose-1-phosphate. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis (By similarity).", "general_function": "Uridine phosphorylase activity", "gene_names": ["udp"], "name": "Uridine phosphorylase", "drug_actions": []}, "P00387": {"specific_function": "Desaturation and elongation of fatty acids, cholesterol biosynthesis, drug metabolism, and, in erythrocyte, methemoglobin reduction.", "general_function": "Nad binding", "gene_names": ["CYB5R3"], "name": "NADH-cytochrome b5 reductase 3", "drug_actions": []}, "Q99624": {"specific_function": "Sodium-dependent amino acid/proton antiporter. Mediates electrogenic cotransport of glutamine and sodium ions in exchange for protons. Also recognizes histidine, asparagine and alanine. May mediate amino acid transport in either direction under physiological conditions. May play a role in nitrogen metabolism and synaptic transmission.", "general_function": "Symporter activity", "gene_names": ["SLC38A3"], "name": "Sodium-coupled neutral amino acid transporter 3", "drug_actions": []}, "P00381": {"specific_function": "Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis.", "general_function": "Nadp binding", "gene_names": ["folA"], "name": "Dihydrofolate reductase", "drug_actions": []}, "Q96RJ0": {"specific_function": "Receptor for trace amines, including beta-phenylethylamine (b-PEA), p-tyramine (p-TYR), octopamine and tryptamine, with highest affinity for b-PEA and p-TYR. Unresponsive to classical biogenic amines, such as epinephrine and histamine and only partially activated by dopamine and serotonine. Trace amines are biogenic amines present in very low levels in mammalian tissues. Although some trace amines have clearly defined roles as neurotransmitters in invertebrates, the extent to which they function as true neurotransmitters in vertebrates has remained speculative. Trace amines are likely to be involved in a variety of physiological functions that have yet to be fully understood. The signal transduced by this receptor is mediated by the G(s)-class of G-proteins which activate adenylate cyclase.", "general_function": "Trace-amine receptor activity", "gene_names": ["TAAR1"], "name": "Trace amine-associated receptor 1", "drug_actions": [{"action": "AGONIST", "target": "Q96RJ0", "drug": "DB00182"}, {"action": "AGONIST", "target": "Q96RJ0", "drug": "DB01576"}, {"action": "AGONIST", "target": "Q96RJ0", "drug": "DB01577"}, {"action": "AGONIST", "target": "Q96RJ0", "drug": "DB06714"}]}, "Q9H015": {"specific_function": "Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Relative uptake activity ratio of carnitine to TEA is 1.78. A key substrate of this transporter seems to be ergothioneine (ET).", "general_function": "Symporter activity", "gene_names": ["SLC22A4"], "name": "Solute carrier family 22 member 4", "drug_actions": []}, "Q734I1": {"general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": [], "name": "Transcriptional regulator, GntR family", "drug_actions": []}, "Q05329": {"specific_function": "Catalyzes the production of GABA.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["GAD2"], "name": "Glutamate decarboxylase 2", "drug_actions": []}, "P0A006": {"specific_function": "Reduces arsenate [As(V)] to arsenite [As(III)] and dephosphorylates tyrosine phosphorylated proteins, low-MW aryl phosphates and natural and synthetic acyl phosphates. Could switch between different functions in different circumstances.", "general_function": "Protein tyrosine phosphatase activity", "gene_names": ["arsC"], "name": "Protein ArsC", "drug_actions": []}, "P0AEG4": {"specific_function": "Required for disulfide bond formation in some periplasmic proteins such as PhoA or OmpA. Acts by transferring its disulfide bond to other proteins and is reduced in the process. DsbA is reoxidized by DsbB. Required for pilus biogenesis. PhoP-regulated transcription is redox-sensitive, being activated when the periplasm becomes more reducing (deletion of dsbA/dsbB, treatment with dithiothreitol). MgrB acts between DsbA/DsbB and PhoP/PhoQ in this pathway.", "general_function": "Protein disulfide oxidoreductase activity", "gene_names": ["dsbA"], "name": "Thiol:disulfide interchange protein DsbA", "drug_actions": []}, "Q02817": {"specific_function": "Coats the epithelia of the intestines, airways, and other mucus membrane-containing organs. Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. Major constituent of both the inner and outer mucus layers of the colon and may play a role in excluding bacteria from the inner mucus layer.", "gene_names": ["MUC2"], "name": "Mucin-2", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "Q02817", "drug": "DB01411"}]}, "P26841": {"specific_function": "This enzyme is an effector of chloramphenicol (Cm) resistance in bacteria. Acetylates Cm but not 1-acetoxy-Cm.", "general_function": "Chloramphenicol o-acetyltransferase activity", "gene_names": ["cat"], "name": "Chloramphenicol acetyltransferase", "drug_actions": []}, "P35462": {"specific_function": "Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.", "general_function": "G-protein coupled amine receptor activity", "gene_names": ["DRD3"], "name": "D(3) dopamine receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "P35462", "drug": "DB00246"}, {"action": "AGONIST", "target": "P35462", "drug": "DB00248"}, {"action": "AGONIST", "target": "P35462", "drug": "DB00268"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB00363"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB00391"}, {"action": "BINDER", "target": "P35462", "drug": "DB00408"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB00409"}, {"action": "AGONIST", "target": "P35462", "drug": "DB00413"}, {"action": "INVERSE AGONIST", "target": "P35462", "drug": "DB00502"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB00543"}, {"action": "AGONIST", "target": "P35462", "drug": "DB00589"}, {"action": "AGONIST", "target": "P35462", "drug": "DB00714"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB00734"}, {"action": "AGONIST", "target": "P35462", "drug": "DB00988"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB01100"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB01184"}, {"action": "AGONIST", "target": "P35462", "drug": "DB01186"}, {"action": "AGONIST", "target": "P35462", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB01224"}, {"action": "AGONIST", "target": "P35462", "drug": "DB01235"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB01238"}, {"action": "PARTIAL AGONIST", "target": "P35462", "drug": "DB01238"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB01267"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB01392"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB01403"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB04946"}, {"action": "AGONIST", "target": "P35462", "drug": "DB05271"}, {"action": "AGONIST", "target": "P35462", "drug": "DB06016"}, {"action": "PARTIAL AGONIST", "target": "P35462", "drug": "DB06016"}, {"action": "BINDER", "target": "P35462", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB06216"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB06288"}, {"action": "AGONIST", "target": "P35462", "drug": "DB09014"}, {"action": "ANTAGONIST", "target": "P35462", "drug": "DB09207"}]}, "P08559": {"specific_function": "The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links the glycolytic pathway to the tricarboxylic cycle.", "general_function": "Pyruvate dehydrogenase activity", "gene_names": ["PDHA1"], "name": "Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial", "drug_actions": []}, "P0AEZ1": {"specific_function": "Methylenetetrahydrofolate reductase required to generate the methyl groups necessary for methionine synthetase to convert homocysteine to methionine.", "general_function": "Methylenetetrahydrofolate reductase (nad(p)h) activity", "gene_names": ["metF"], "name": "5,10-methylenetetrahydrofolate reductase", "drug_actions": []}, "P46336": {"general_function": "Oxidoreductase activity", "gene_names": ["iolS"], "name": "Protein IolS", "drug_actions": []}, "P54455": {"specific_function": "Catalyzes the reversible adenylation of nicotinate mononucleotide (NaMN) to nicotinic acid adenine dinucleotide (NaAD).", "general_function": "Nicotinate-nucleotide adenylyltransferase activity", "gene_names": ["nadD"], "name": "Nicotinate-nucleotide adenylyltransferase", "drug_actions": []}, "Q8IVA8": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["GAD1"], "name": "Glutamate decarboxylase 1 (Brain, 67kDa)", "drug_actions": [{"action": "COFACTOR", "target": "Q8IVA8", "drug": "DB00114"}]}, "P0A7V8": {"specific_function": "One of two assembly initiator proteins for the 30S subunit, it binds directly to 16S rRNA where it nucleates assembly of the body of the 30S subunit.With S5 and S12 plays an important role in translational accuracy; many suppressors of streptomycin-dependent mutants of protein S12 are found in this protein, some but not all of which decrease translational accuracy (ram, ribosomal ambiguity mutations).Plays a role in mRNA unwinding by the ribosome, possibly by forming part of a processivity clamp.Protein S4 is also a translational repressor protein, it controls the translation of the alpha-operon (which codes for S13, S11, S4, RNA polymerase alpha subunit, and L17) by binding to its mRNA.Also functions as a rho-dependent antiterminator of rRNA transcription, increasing the synthesis of rRNA under conditions of excess protein, allowing a more rapid return to homeostasis. Binds directly to RNA polymerase.", "general_function": "Translation repressor activity, nucleic acid binding", "gene_names": ["rpsD"], "name": "30S ribosomal protein S4", "drug_actions": [{"action": "INHIBITOR", "target": "P0A7V8", "drug": "DB00254"}, {"action": "INHIBITOR", "target": "P0A7V8", "drug": "DB00256"}, {"action": "INHIBITOR", "target": "P0A7V8", "drug": "DB00453"}, {"action": "INHIBITOR", "target": "P0A7V8", "drug": "DB00595"}, {"action": "INHIBITOR", "target": "P0A7V8", "drug": "DB00618"}, {"action": "INHIBITOR", "target": "P0A7V8", "drug": "DB01017"}]}, "Q14542": {"specific_function": "Mediates equilibrative transport of purine, pyrimidine nucleosides and the purine base hypoxanthine. Very less sensitive than SLC29A1 to inhibition by nitrobenzylthioinosine (NBMPR), dipyridamole, dilazep and draflazine.", "general_function": "Nucleoside transmembrane transporter activity", "gene_names": ["SLC29A2"], "name": "Equilibrative nucleoside transporter 2", "drug_actions": []}, "P0A7V3": {"specific_function": "Binds the lower part of the 30S subunit head. Binds mRNA in the 70S ribosome, positioning it for translation (By similarity).Plays a role in mRNA unwinding by the ribosome, possibly by forming part of a processivity clamp.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsC"], "name": "30S ribosomal protein S3", "drug_actions": [{"action": "INHIBITOR", "target": "P0A7V3", "drug": "DB00759"}]}, "P04015": {"specific_function": "Plays a role in the initiation of viral DNA replication. A dimer of E2 interacts with a dimer of E1 in order to improve specificity of E1 DNA binding activity. Once the complex recognizes and binds DNA at specific sites, the E2 dimer is removed from DNA. E2 also regulates viral transcription through binding to the E2RE response element (5'-ACCNNNNNNGGT-3') present in multiple copies in the regulatory regions of the viral genome. Activates or represses transcription depending on E2RE's position with regards to proximal promoter elements including the TATA-box. Repression occurs by sterically hindering the assembly of the transcription initiation complex.", "general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": ["E2"], "name": "Regulatory protein E2", "drug_actions": []}, "P78527": {"specific_function": "Serine/threonine-protein kinase that acts as a molecular sensor for DNA damage. Involved in DNA non-homologous end joining (NHEJ) required for double-strand break (DSB) repair and V(D)J recombination. Must be bound to DNA to express its catalytic properties. Promotes processing of hairpin DNA structures in V(D)J recombination by activation of the hairpin endonuclease artemis (DCLRE1C). The assembly of the DNA-PK complex at DNA ends is also required for the NHEJ ligation step. Required to protect and align broken ends of DNA. May also act as a scaffold protein to aid the localization of DNA repair proteins to the site of damage. Found at the ends of chromosomes, suggesting a further role in the maintenance of telomeric stability and the prevention of chromosomal end fusion. Also involved in modulation of transcription. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX, thereby regulating DNA damage response mechanism. Phosphorylates DCLRE1C, c-Abl/ABL1, histone H1, HSPCA, c-jun/JUN, p53/TP53, PARP1, POU2F1, DHX9, SRF, XRCC1, XRCC1, XRCC4, XRCC5, XRCC6, WRN, MYC and RFA2. Can phosphorylate C1D not only in the presence of linear DNA but also in the presence of supercoiled DNA. Ability to phosphorylate p53/TP53 in the presence of supercoiled DNA is dependent on C1D. Contributes to the determination of the circadian period length by antagonizing phosphorylation of CRY1 'Ser-588' and increasing CRY1 protein stability, most likely through an indirect machanism. Interacts with CRY1 and CRY2; negatively regulates CRY1 phosphorylation.", "general_function": "Transcription factor binding", "gene_names": ["PRKDC"], "name": "DNA-dependent protein kinase catalytic subunit", "drug_actions": []}, "P00709": {"specific_function": "Regulatory subunit of lactose synthase, changes the substrate specificity of galactosyltransferase in the mammary gland making glucose a good acceptor substrate for this enzyme. This enables LS to synthesize lactose, the major carbohydrate component of milk. In other tissues, galactosyltransferase transfers galactose onto the N-acetylglucosamine of the oligosaccharide chains in glycoproteins.", "general_function": "Lactose synthase activity", "gene_names": ["LALBA"], "name": "Alpha-lactalbumin", "drug_actions": []}, "P24024": {"specific_function": "Multifunctional enzyme that converts the viral RNA genome into dsDNA in viral cytoplasmic capsids. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3'- to 5'-endonucleasic mode. Neo-synthesized pregenomic RNA (pgRNA) are encapsidated together with the P protein, and reverse-transcribed inside the nucleocapsid. Initiation of reverse-transcription occurs first by binding the epsilon loop on the pgRNA genome, and is initiated by protein priming, thereby the 5'-end of (-)DNA is covalently linked to P protein. Partial (+)DNA is synthesized from the (-)DNA template and generates the relaxed circular DNA (RC-DNA) genome. After budding and infection, the RC-DNA migrates in the nucleus, and is converted into a plasmid-like covalently closed circular DNA (cccDNA). The activity of P protein does not seem to be necessary for cccDNA generation, and is presumably released from (+)DNA by host nuclear DNA repair machinery (By similarity).", "general_function": "Rna-dna hybrid ribonuclease activity", "gene_names": ["P"], "name": "Protein P", "drug_actions": [{"action": "OTHER", "target": "P24024", "drug": "DB00718"}]}, "P24752": {"specific_function": "Plays a major role in ketone body metabolism.", "general_function": "Metal ion binding", "gene_names": ["ACAT1"], "name": "Acetyl-CoA acetyltransferase, mitochondrial", "drug_actions": [{"action": "INHIBITOR", "target": "P24752", "drug": "DB00795"}]}, "Q86VU5": {"specific_function": "Putative O-methyltransferase.", "general_function": "O-methyltransferase activity", "gene_names": ["COMTD1"], "name": "Catechol O-methyltransferase domain-containing protein 1", "drug_actions": []}, "A7B6P0": {"general_function": "Lipid binding", "gene_names": [], "name": "EDD domain protein, DegV family", "drug_actions": []}, "Q47644": {"gene_names": ["stx2eB"], "name": "Orf protein", "drug_actions": []}, "Q02252": {"specific_function": "Plays a role in valine and pyrimidine metabolism. Binds fatty acyl-CoA.", "general_function": "Thiolester hydrolase activity", "gene_names": ["ALDH6A1"], "name": "Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial", "drug_actions": []}, "P41231": {"specific_function": "Receptor for ATP and UTP coupled to G-proteins that activate a phosphatidylinositol-calcium second messenger system. The affinity range is UTP = ATP > ATP-gamma-S >> 2-methylthio-ATP = ADP.", "general_function": "Utp-activated nucleotide receptor activity", "gene_names": ["P2RY2"], "name": "P2Y purinoceptor 2", "drug_actions": [{"action": "ANTAGONIST", "target": "P41231", "drug": "DB04786"}]}, "P41235": {"specific_function": "Transcriptionally controlled transcription factor. Binds to DNA sites required for the transcription of alpha 1-antitrypsin, apolipoprotein CIII, transthyretin genes and HNF1-alpha. May be essential for development of the liver, kidney and intestine.", "general_function": "Zinc ion binding", "gene_names": ["HNF4A"], "name": "Hepatocyte nuclear factor 4-alpha", "drug_actions": []}, "Q5L2G3": {"general_function": "Oxidoreductase activity", "gene_names": [], "name": "Uncharacterized oxidoreductase CzcO-like", "drug_actions": [{"action": "INHIBITOR", "target": "Q5L2G3", "drug": "DB00845"}]}, "P42126": {"specific_function": "Able to isomerize both 3-cis and 3-trans double bonds into the 2-trans form in a range of enoyl-CoA species.", "general_function": "Intramolecular oxidoreductase activity", "gene_names": ["ECI1"], "name": "Enoyl-CoA delta isomerase 1, mitochondrial", "drug_actions": []}, "P48181": {"specific_function": "Acetylcholine receptor.", "general_function": "Acetylcholine-activated cation-selective channel activity", "gene_names": ["unc-29"], "name": "Acetylcholine receptor subunit beta-type unc-29", "drug_actions": [{"action": "ACTIVATOR", "target": "P48181", "drug": "DB00848"}]}, "A9UF02": {"general_function": "Protein serine/threonine kinase activity", "gene_names": ["BCR/ABL fusion"], "name": "BCR/ABL fusion protein isoform X9", "drug_actions": [{"action": "INHIBITOR", "target": "A9UF02", "drug": "DB00619"}]}, "P24046": {"specific_function": "GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.", "general_function": "Gaba-a receptor activity", "gene_names": ["GABRR1"], "name": "Gamma-aminobutyric acid receptor subunit rho-1", "drug_actions": [{"action": "POTENTIATOR", "target": "P24046", "drug": "DB00231"}, {"action": "ANTAGONIST", "target": "P24046", "drug": "DB00466"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB01215"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P24046", "drug": "DB01595"}]}, "Q99712": {"specific_function": "Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium.", "name": "ATP-sensitive inward rectifier potassium channel 15", "drug_actions": [], "general_function": "Inward rectifier potassium channel activity", "in_complexes": ["ATP-sensitive potassium channel"], "gene_names": ["KCNJ15"]}, "Q96RI1": {"specific_function": "Ligand-activated transcription factor. Receptor for bile acids such as chenodeoxycholic acid, lithocholic acid and deoxycholic acid. Represses the transcription of the cholesterol 7-alpha-hydroxylase gene (CYP7A1) through the induction of NR0B2 or FGF19 expression, via two distinct mechanisms. Activates the intestinal bile acid-binding protein (IBABP). Activates the transcription of bile salt export pump ABCB11 by directly recruiting histone methyltransferase CARM1 to this locus.", "general_function": "Zinc ion binding", "gene_names": ["NR1H4"], "name": "Bile acid receptor", "drug_actions": [{"action": "OTHER", "target": "Q96RI1", "drug": "DB06777"}]}, "Q8NFA2": {"specific_function": "Constitutively potentiates the superoxide-generating activity of NOX1 and NOX3 and is required for the biogenesis of otoconia/otolith, which are crystalline structures of the inner ear involved in the perception of gravity. Isoform 3 is more potent than isoform 1 in activating NOX3. Together with NOXA1, may also substitute to NCF1/p47phox and NCF2/p67phox in supporting the phagocyte NOX2/gp91phox superoxide-generating activity.", "general_function": "Superoxide-generating nadph oxidase activator activity", "gene_names": ["NOXO1"], "name": "NADPH oxidase organizer 1", "drug_actions": [{"action": "ANTAGONIST", "target": "Q8NFA2", "drug": "DB05265"}]}, "Q9RME2": {"specific_function": "Catalyzes the reversible conversion of 3-phosphohydroxypyruvate to phosphoserine and of 3-hydroxy-2-oxo-4-phosphonooxybutanoate to phosphohydroxythreonine.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["serC"], "name": "Phosphoserine aminotransferase", "drug_actions": []}, "Q99714": {"specific_function": "Functions in mitochondrial tRNA maturation. Part of mitochondrial ribonuclease P, an enzyme composed of MRPP1/TRMT10C, MRPP2/HSD17B10 and MRPP3/KIAA0391, which cleaves tRNA molecules in their 5'-ends. Catalyzes the beta-oxidation at position 17 of androgens and estrogens and has 3-alpha-hydroxysteroid dehydrogenase activity with androsterone. Catalyzes the third step in the beta-oxidation of fatty acids. Carries out oxidative conversions of 7-alpha-OH and 7-beta-OH bile acids. Also exhibits 20-beta-OH and 21-OH dehydrogenase activities with C21 steroids. By interacting with intracellular amyloid-beta, it may contribute to the neuronal dysfunction associated with Alzheimer disease (AD).", "general_function": "Testosterone dehydrogenase [nad(p)] activity", "gene_names": ["HSD17B10"], "name": "3-hydroxyacyl-CoA dehydrogenase type-2", "drug_actions": []}, "P14784": {"specific_function": "Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.", "general_function": "Interleukin-2 receptor activity", "gene_names": ["IL2RB"], "name": "Interleukin-2 receptor subunit beta", "drug_actions": [{"action": "AGONIST", "target": "P14784", "drug": "DB00004"}, {"action": "AGONIST", "target": "P14784", "drug": "DB00041"}, {"action": "MODULATOR", "target": "P14784", "drug": "DB00041"}, {"action": "ANTIBODY", "target": "P14784", "drug": "DB00074"}, {"action": "ANTIBODY", "target": "P14784", "drug": "DB00111"}]}, "Q9H306": {"specific_function": "Matrix metalloproteinases degrade protein components of the extracellular matrix such as fibronectin, laminin, gelatins and/or collagens.", "general_function": "Zinc ion binding", "gene_names": ["MMP27"], "name": "Matrix metalloproteinase-27", "drug_actions": [{"action": "INHIBITOR", "target": "Q9H306", "drug": "DB00786"}]}, "P14780": {"specific_function": "May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide.", "general_function": "Zinc ion binding", "gene_names": ["MMP9"], "name": "Matrix metalloproteinase-9", "drug_actions": [{"action": "INHIBITOR", "target": "P14780", "drug": "DB00786"}, {"action": "INHIBITOR", "target": "P14780", "drug": "DB01017"}, {"action": "INHIBITOR", "target": "P14780", "drug": "DB01197"}, {"action": "ANTAGONIST", "target": "P14780", "drug": "DB01296"}]}, "P97084": {"specific_function": "Decarboxylates L-threonine-O-3-phosphate to yield (R)-1-amino-2-propanol O-2-phosphate, the precursor for the linkage between the nucleotide loop and the corrin ring in cobalamin.", "general_function": "Threonine-phosphate decarboxylase activity", "gene_names": ["cobD"], "name": "Threonine-phosphate decarboxylase", "drug_actions": []}, "Q9NPD5": {"specific_function": "Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.", "general_function": "Sodium-independent organic anion transmembrane transporter activity", "gene_names": ["SLCO1B3"], "name": "Solute carrier organic anion transporter family member 1B3", "drug_actions": []}, "P28845": {"specific_function": "Catalyzes reversibly the conversion of cortisol to the inactive metabolite cortisone. Catalyzes reversibly the conversion of 7-ketocholesterol to 7-beta-hydroxycholesterol. In intact cells, the reaction runs only in one direction, from 7-ketocholesterol to 7-beta-hydroxycholesterol (By similarity).", "general_function": "11-beta-hydroxysteroid dehydrogenase [nad(p)] activity", "gene_names": ["HSD11B1"], "name": "Corticosteroid 11-beta-dehydrogenase isozyme 1", "drug_actions": [{"action": "LIGAND", "target": "P28845", "drug": "DB00635"}, {"action": "INHIBITOR", "target": "P28845", "drug": "DB02329"}]}, "P52700": {"specific_function": "Has a high activity against imipenem.", "general_function": "Zinc ion binding", "gene_names": [], "name": "Metallo-beta-lactamase L1", "drug_actions": []}, "P14147": {"specific_function": "Member of the two-component regulatory system phoQ/phoP which regulates the expression of genes involved in virulence, adaptation to low Mg(2+) environments and resistance to host defense antimicrobial peptides. In presence of low periplasmic Mg(2+) concentrations, phoQ functions as a membrane-associated protein kinase that undergoes autophosphorylation and subsequently transfers the phosphate to phoP, which results in the expression of phoP-activated genes (PAG) and repression of phoP-repressed genes (PRG). In presence of high periplasmic Mg(2+) concentrations, acts as a protein phosphatase that dephosphorylates phospho-phoP, which results in the repression of phoP-activated genes and may lead to expression of some phoP- repressed genes. Promotes intramacrophage survival of S.typhimurium. Is essential for transcription of spiC inside macrophages by controlling the expression of the two-component regulatory system ssrB/spiR at transcriptional and post- transcriptional levels respectively. Promotes expression of the two-component regulatory system pmrA/pmrB via activation of pmrD gene. Is required to attenuate bacterial growth within fibroblast cells and to enhance bacterial resistance to bile in intestinal cells. Also, negatively regulates prgH, which is required for invasion of epithelial cells", "general_function": "Signal transduction mechanisms", "gene_names": ["phoQ"], "name": "Virulence sensor histidine kinase PhoQ", "drug_actions": []}, "O60294": {"specific_function": "Probable S-adenosyl-L-methionine-dependent methyltransferase that acts as a component of the wybutosine biosynthesis pathway. Wybutosine is a hyper modified guanosine with a tricyclic base found at the 3'-position adjacent to the anticodon of eukaryotic phenylalanine tRNA (By similarity). May methylate the carboxyl group of leucine residues to form alpha-leucine ester residues.", "general_function": "Trna methyltransferase activity", "gene_names": ["LCMT2"], "name": "tRNA wybutosine-synthesizing protein 4", "drug_actions": []}, "P26281": {"general_function": "Magnesium ion binding", "gene_names": ["folK"], "name": "2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase", "drug_actions": []}, "P00634": {"general_function": "Zinc ion binding", "gene_names": ["phoA"], "name": "Alkaline phosphatase", "drug_actions": []}, "P00147": {"specific_function": "Cytochrome c' is the most widely occurring bacterial c-type cytochrome. Cytochromes c' are high-spin proteins and the heme has no sixth ligand. Their exact function is not known.", "general_function": "Iron ion binding", "gene_names": [], "name": "Cytochrome c'", "drug_actions": []}, "P61925": {"specific_function": "Extremely potent competitive inhibitor of cAMP-dependent protein kinase activity, this protein interacts with the catalytic subunit of the enzyme after the cAMP-induced dissociation of its regulatory chains.", "general_function": "Protein kinase a catalytic subunit binding", "gene_names": ["PKIA"], "name": "cAMP-dependent protein kinase inhibitor alpha", "drug_actions": []}, "P61927": {"specific_function": "Binds to the 23S rRNA.", "general_function": "Structural constituent of ribosome", "gene_names": ["RPL37"], "name": "60S ribosomal protein L37", "drug_actions": []}, "P0A827": {"specific_function": "Catalyzes the reversible interconversion of serine and glycine with tetrahydrofolate (THF) serving as the one-carbon carrier. This reaction serves as the major source of one-carbon groups required for the biosynthesis of purines, thymidylate, methionine, and other important biomolecules. Also exhibits THF-independent aldolase activity toward beta-hydroxyamino acids, producing glycine and aldehydes, via a retro-aldol mechanism.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["glyA"], "name": "Serine hydroxymethyltransferase", "drug_actions": []}, "P26447": {"general_function": "Rage receptor binding", "gene_names": ["S100A4"], "name": "Protein S100-A4", "drug_actions": [{"action": "INHIBITOR", "target": "P26447", "drug": "DB00831"}]}, "O69755": {"specific_function": "Catalyzes the oxidation of either pyridoxine 5'-phosphate (PNP) or pyridoxamine 5'-phosphate (PMP) into pyridoxal 5'-phosphate (PLP).", "general_function": "Pyridoxamine-phosphate oxidase activity", "gene_names": ["phzG"], "name": "Phenazine biosynthesis protein", "drug_actions": []}, "P26440": {"general_function": "Oxidoreductase activity, acting on the ch-ch group of donors, with a flavin as acceptor", "gene_names": ["IVD"], "name": "Isovaleryl-CoA dehydrogenase, mitochondrial", "drug_actions": []}, "P0A820": {"specific_function": "Catalyzes the formation of S-adenosylmethionine from methionine and ATP. The overall synthetic reaction is composed of two sequential steps, AdoMet formation and the subsequent tripolyphosphate hydrolysis which occurs prior to release of AdoMet from the enzyme (By similarity).", "general_function": "Methionine adenosyltransferase activity", "gene_names": ["metK"], "name": "S-adenosylmethionine synthase", "drug_actions": []}, "Q9WYT0": {"specific_function": "Catalyzes the formation of dTMP and tetrahydrofolate from dUMP and methylenetetrahydrofolate.", "general_function": "Thymidylate synthase (fad) activity", "gene_names": ["thyX"], "name": "Thymidylate synthase ThyX", "drug_actions": []}, "B7JA91": {"gene_names": [], "name": "Uncharacterized protein", "drug_actions": []}, "P19652": {"in_complexes": ["alpha1-acid glycoprotein"], "specific_function": "Functions as transport protein in the blood stream. Binds various hydrophobic ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability. Appears to function in modulating the activity of the immune system during the acute-phase reaction.", "gene_names": ["ORM2"], "name": "Alpha-1-acid glycoprotein 2", "drug_actions": [{"action": "BINDER", "target": "P19652", "drug": "DB00477"}, {"action": "BINDER", "target": "P19652", "drug": "DB00497"}, {"action": "BINDER", "target": "P19652", "drug": "DB01041"}]}, "P25524": {"specific_function": "Catalyzes the hydrolytic deamination of cytosine to uracil. Is involved in the pyrimidine salvage pathway, which allows the cell to utilize cytosine for pyrimidine nucleotide synthesis. Is also able to catalyze deamination of isoguanine, a mutagenic oxidation product of adenine in DNA, and of isocytosine. To a lesser extent, also catalyzes the conversion of 5-fluorocytosine (5FC) to 5-fluorouracil (5FU); this activity allows the formation of a cytotoxic chemotherapeutic agent from a non-cytotoxic precursor.", "general_function": "Zinc ion binding", "gene_names": ["codA"], "name": "Cytosine deaminase", "drug_actions": []}, "Q81ZY9": {"general_function": "Protein serine/threonine kinase activity", "gene_names": ["pkn3"], "name": "Putative serine/threonine protein kinase", "drug_actions": []}, "P10802": {"specific_function": "The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2). It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and lipoamide dehydrogenase (E3).", "general_function": "Dihydrolipoyllysine-residue acetyltransferase activity", "gene_names": [], "name": "Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex", "drug_actions": []}, "O14874": {"specific_function": "Catalyzes the phosphorylation and inactivation of the branched-chain alpha-ketoacid dehydrogenase complex, the key regulatory enzyme of the valine, leucine and isoleucine catabolic pathways. Key enzyme that regulate the activity state of the BCKD complex.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["BCKDK"], "name": "[3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial", "drug_actions": []}, "O95479": {"specific_function": "Oxidizes glucose-6-phosphate and glucose, as well as other hexose-6-phosphates.", "general_function": "Nadp binding", "gene_names": ["H6PD"], "name": "GDH/6PGL endoplasmic bifunctional protein", "drug_actions": []}, "P15144": {"specific_function": "Broad specificity aminopeptidase. Plays a role in the final digestion of peptides generated from hydrolysis of proteins by gastric and pancreatic proteases. May play a critical role in the pathogenesis of cholesterol gallstone disease. May be involved in the metabolism of regulatory peptides of diverse cell types, responsible for the processing of peptide hormones, such as angiotensin III and IV, neuropeptides, and chemokines. Found to cleave antigen peptides bound to major histocompatibility complex class II molecules of presenting cells and to degrade neurotransmitters at synaptic junctions. Is also implicated as a regulator of IL-8 bioavailability in the endometrium, and therefore may contribute to the regulation of angiogenesis. Is used as a marker for acute myeloid leukemia and plays a role in tumor invasion. In case of human coronavirus 229E (HCoV-229E) infection, serves as receptor for HCoV-229E spike glycoprotein. Mediates as well human cytomegalovirus (HCMV) infection.(Microbial infection) Acts as a receptor for human coronavirus 229E/HCoV-229E.", "general_function": "Zinc ion binding", "gene_names": ["ANPEP"], "name": "Aminopeptidase N", "drug_actions": [{"action": "OTHER", "target": "P15144", "drug": "DB00973"}, {"action": "INHIBITOR", "target": "P15144", "drug": "DB06196"}]}, "Q16831": {"specific_function": "Catalyzes the reversible phosphorylytic cleavage of uridine and deoxyuridine to uracil and ribose- or deoxyribose-1-phosphate (PubMed:7488099). The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis.", "general_function": "Uridine phosphorylase activity", "gene_names": ["UPP1"], "name": "Uridine phosphorylase 1", "drug_actions": []}, "O95470": {"specific_function": "Cleaves phosphorylated sphingoid bases (PSBs), such as sphingosine-1-phosphate, into fatty aldehydes and phosphoethanolamine. Elevates stress-induced ceramide production and apoptosis.", "general_function": "Sphinganine-1-phosphate aldolase activity", "gene_names": ["SGPL1"], "name": "Sphingosine-1-phosphate lyase 1", "drug_actions": [{"action": "COFACTOR", "target": "O95470", "drug": "DB00114"}]}, "Q7L3T8": {"general_function": "Proline-trna ligase activity", "gene_names": ["PARS2"], "name": "Probable proline--tRNA ligase, mitochondrial", "drug_actions": []}, "P17412": {"specific_function": "The fumarate reductase enzyme complex is required for fumarate respiration using formate or sulfide as electron donor.", "general_function": "Oxidoreductase activity, acting on the ch-ch group of donors", "gene_names": ["frdA"], "name": "Fumarate reductase flavoprotein subunit", "drug_actions": []}, "P32173": {"specific_function": "Transfers a GMP moiety from GTP to Mo-molybdopterin (Mo-MPT) cofactor (Moco or molybdenum cofactor) to form Mo-molybdopterin guanine dinucleotide (Mo-MGD) cofactor. Is also involved in the biosynthesis of the bis-MGD form of the Moco cofactor (Mo-bisMGD) in which the metal is symmetrically ligated by the dithiolene groups of two MGD molecules. Is necessary and sufficient for the in vitro activation of the DMSOR molybdoenzyme that uses the Mo-bisMGD form of molybdenum cofactor, which implies formation and efficient insertion of the cofactor into the enzyme without the need of a chaperone. Is specific for GTP since other nucleotides such as ATP and GMP can not be utilized.", "general_function": "Molybdenum cofactor guanylyltransferase activity", "gene_names": ["mobA"], "name": "Molybdenum cofactor guanylyltransferase", "drug_actions": []}, "O95477": {"specific_function": "cAMP-dependent and sulfonylurea-sensitive anion transporter. Key gatekeeper influencing intracellular cholesterol transport.", "general_function": "Syntaxin binding", "gene_names": ["ABCA1"], "name": "ATP-binding cassette sub-family A member 1", "drug_actions": [{"action": "INHIBITOR", "target": "O95477", "drug": "DB01016"}, {"action": "INHIBITOR", "target": "O95477", "drug": "DB01599"}]}, "P52197": {"general_function": "Thiosulfate sulfurtransferase activity", "gene_names": ["rhdA"], "name": "Thiosulfate sulfurtransferase", "drug_actions": []}, "P62580": {"specific_function": "This enzyme is an effector of chloramphenicol resistance in bacteria.", "general_function": "Chloramphenicol o-acetyltransferase activity", "gene_names": ["cat"], "name": "Chloramphenicol acetyltransferase", "drug_actions": [{"action": "INHIBITOR", "target": "P62580", "drug": "DB02703"}]}, "Q13255": {"specific_function": "G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol-calcium second messenger system. May participate in the central action of glutamate in the CNS, such as long-term potentiation in the hippocampus and long-term depression in the cerebellum.", "general_function": "Glutamate receptor activity", "gene_names": ["GRM1"], "name": "Metabotropic glutamate receptor 1", "drug_actions": []}, "P49366": {"specific_function": "Catalyzes the NAD-dependent oxidative cleavage of spermidine and the subsequent transfer of the butylamine moiety of spermidine to the epsilon-amino group of a specific lysine residue of the eIF-5A precursor protein to form the intermediate deoxyhypusine residue.", "general_function": "Deoxyhypusine synthase activity", "gene_names": ["DHPS"], "name": "Deoxyhypusine synthase", "drug_actions": [{"action": "INHIBITOR", "target": "P49366", "drug": "DB03639"}]}, "P76187": {"specific_function": "May function as oxidoreductase.", "general_function": "Oxidoreductase activity", "gene_names": ["ydhF"], "name": "Oxidoreductase YdhF", "drug_actions": []}, "Q13258": {"specific_function": "Receptor for prostaglandin D2 (PGD2). The activity of this receptor is mainly mediated by G(s) proteins that stimulate adenylate cyclase, resulting in an elevation of intracellular cAMP. A mobilization of calcium is also observed, but without formation of inositol 1,4,5-trisphosphate (By similarity).", "general_function": "Prostaglandin j receptor activity", "gene_names": ["PTGDR"], "name": "Prostaglandin D2 receptor", "drug_actions": [{"action": "UNKNOWN", "target": "Q13258", "drug": "DB00716"}]}, "P32119": {"specific_function": "Involved in redox regulation of the cell. Reduces peroxides with reducing equivalents provided through the thioredoxin system. It is not able to receive electrons from glutaredoxin. May play an important role in eliminating peroxides generated during metabolism. Might participate in the signaling cascades of growth factors and tumor necrosis factor-alpha by regulating the intracellular concentrations of H(2)O(2).", "general_function": "Thioredoxin peroxidase activity", "gene_names": ["PRDX2"], "name": "Peroxiredoxin-2", "drug_actions": []}, "Q9Y6B6": {"specific_function": "Involved in transport from the endoplasmic reticulum to the Golgi apparatus. Activated by the guanine nucleotide exchange factor PREB. Involved in the selection of the protein cargo and the assembly of the COPII coat complex.", "general_function": "Metal ion binding", "gene_names": ["SAR1B"], "name": "GTP-binding protein SAR1b", "drug_actions": []}, "Q8NX63": {"gene_names": ["srtB"], "name": "NPQTN specific sortase B", "drug_actions": []}, "P60725": {"specific_function": "One of the primary rRNA binding proteins, this protein initially binds near the 5'-end of the 23S rRNA. It is important during the early stages of 50S assembly. It makes multiple contacts with different domains of the 23S rRNA in the assembled 50S subunit and ribosome.Protein L4 is a both a transcriptional repressor and a translational repressor protein. It regulates transcription of the S10 operon (to which L4 belongs) by causing premature termination of transcription within the S10 leader. L4 controls the translation of the S10 operon by binding to its mRNA (By similarity).Forms part of the polypeptide exit tunnel.", "general_function": "Structural constituent of ribosome", "gene_names": ["rplD"], "name": "50S ribosomal protein L4", "drug_actions": [{"action": "INHIBITOR", "target": "P60725", "drug": "DB00199"}, {"action": "INHIBITOR", "target": "P60725", "drug": "DB00207"}]}, "Q9H3S4": {"specific_function": "Catalyzes the phosphorylation of thiamine to thiamine pyrophosphate. Can also catalyze the phosphorylation of pyrithiamine to pyrithiamine pyrophosphate.", "general_function": "Thiamine diphosphokinase activity", "gene_names": ["TPK1"], "name": "Thiamin pyrophosphokinase 1", "drug_actions": [{"action": "LIGAND", "target": "Q9H3S4", "drug": "DB00152"}]}, "P60723": {"specific_function": "One of the primary rRNA binding proteins, this protein initially binds near the 5'-end of the 23S rRNA. It is important during the early stages of 50S assembly. It makes multiple contacts with different domains of the 23S rRNA in the assembled 50S subunit and ribosome.Protein L4 is a both a transcriptional repressor and a translational repressor protein; these two functions are independent of each other. It regulates transcription of the S10 operon (to which L4 belongs) by causing premature termination of transcription within the S10 leader; termination absolutely requires the NusA protein. L4 controls the translation of the S10 operon by binding to its mRNA. The regions of L4 that control regulation (residues 131-210) are different from those required for ribosome assembly (residues 89-103).Forms part of the polypeptide exit tunnel.Can regulate expression from Citrobacter freundii, Haemophilus influenzae, Morganella morganii, Salmonella typhimurium, Serratia marcescens, Vibrio cholerae and Yersinia enterocolitica (but not Pseudomonas aeruginosa) S10 leaders in vitro.", "general_function": "Translation repressor activity", "gene_names": ["rplD"], "name": "50S ribosomal protein L4", "drug_actions": [{"action": "INHIBITOR", "target": "P60723", "drug": "DB01361"}]}, "P26662": {"specific_function": "Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).E1 and E2 glycoproteins form a heterodimer that is involved in virus attachment to the host cell, virion internalization through clathrin-dependent endocytosis and fusion with host membrane. E1/E2 heterodimer binds to human LDLR, CD81 and SCARB1/SR-BI receptors, but this binding is not sufficient for infection, some additional liver specific cofactors may be needed. The fusion function may possibly be carried by E1. E2 inhibits human EIF2AK2/PKR activation, preventing the establishment of an antiviral state. E2 is a viral ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on liver sinusoidal endothelial cells and macrophage-like cells of lymph node sinuses. These interactions allow capture of circulating HCV particles by these cells and subsequent transmission to permissive cells. DCs act as sentinels in various tissues where they entrap pathogens and convey them to local lymphoid tissue or lymph node for establishment of immunity. Capture of circulating HCV particles by these SIGN+ cells may facilitate virus infection of proximal hepatocytes and lymphocyte subpopulations and may be essential for the establishment of persistent infection (By similarity).P7 seems to be a heptameric ion channel protein (viroporin) and is inhibited by the antiviral drug amantadine. Also inhibited by long-alkyl-chain iminosugar derivatives. Essential for infectivity (By similarity).Protease NS2-3 is a cysteine protease responsible for the autocatalytic cleavage of NS2-NS3. Seems to undergo self-inactivation following maturation (By similarity).NS3 displays three enzymatic activities: serine protease, NTPase and RNA helicase. NS3 serine protease, in association with NS4A, is responsible for the cleavages of NS3-NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also prevents phosphorylation of human IRF3, thus preventing the establishment of dsRNA induced antiviral state. NS3 RNA helicase binds to RNA and unwinds dsRNA in the 3' to 5' direction and likely RNA stable secondary structure in the template strand. Cleaves and inhibits the host antiviral protein MAVS (By similarity).NS4B induces a specific membrane alteration that serves as a scaffold for the virus replication complex. This membrane alteration gives rise to the so-called ER-derived membranous web that contains the replication complex.NS5A is a component of the replication complex involved in RNA-binding. Its interaction with Human VAPB may target the viral replication complex to vesicles. Down-regulates viral IRES translation initiation. Mediates interferon resistance, presumably by interacting with and inhibiting human EIF2AK2/PKR. Seems to inhibit apoptosis by interacting with BIN1 and FKBP8. The hyperphosphorylated form of NS5A is an inhibitor of viral replication.NS5B is an RNA-dependent RNA polymerase that plays an essential role in the virus replication.", "general_function": "Zinc ion binding", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P26663": {"specific_function": "Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).E1 and E2 glycoproteins form a heterodimer that is involved in virus attachment to the host cell, virion internalization through clathrin-dependent endocytosis and fusion with host membrane. E1/E2 heterodimer binds to human LDLR, CD81 and SCARB1/SR-BI receptors, but this binding is not sufficient for infection, some additional liver specific cofactors may be needed. The fusion function may possibly be carried by E1. E2 inhibits human EIF2AK2/PKR activation, preventing the establishment of an antiviral state. E2 is a viral ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on liver sinusoidal endothelial cells and macrophage-like cells of lymph node sinuses. These interactions allow capture of circulating HCV particles by these cells and subsequent transmission to permissive cells. DCs act as sentinels in various tissues where they entrap pathogens and convey them to local lymphoid tissue or lymph node for establishment of immunity. Capture of circulating HCV particles by these SIGN+ cells may facilitate virus infection of proximal hepatocytes and lymphocyte subpopulations and may be essential for the establishment of persistent infection (By similarity).P7 seems to be a heptameric ion channel protein (viroporin) and is inhibited by the antiviral drug amantadine. Also inhibited by long-alkyl-chain iminosugar derivatives. Essential for infectivity (By similarity).Protease NS2-3 is a cysteine protease responsible for the autocatalytic cleavage of NS2-NS3. Seems to undergo self-inactivation following maturation (By similarity).NS3 displays three enzymatic activities: serine protease, NTPase and RNA helicase. NS3 serine protease, in association with NS4A, is responsible for the cleavages of NS3-NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also prevents phosphorylation of human IRF3, thus preventing the establishment of dsRNA induced antiviral state. NS3 RNA helicase binds to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA stable secondary structure in the template strand. Cleaves and inhibits the host antiviral protein MAVS (By similarity).NS4B induces a specific membrane alteration that serves as a scaffold for the virus replication complex. This membrane alteration gives rise to the so-called ER-derived membranous web that contains the replication complex (By similarity).NS5A is a component of the replication complex involved in RNA-binding. Its interaction with Human VAPB may target the viral replication complex to vesicles. Down-regulates viral IRES translation initiation. Mediates interferon resistance, presumably by interacting with and inhibiting human EIF2AK2/PKR. Seems to inhibit apoptosis by interacting with BIN1 and FKBP8. The hyperphosphorylated form of NS5A is an inhibitor of viral replication (By similarity).NS5B is an RNA-dependent RNA polymerase that plays an essential role in the virus replication.", "general_function": "Zinc ion binding", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P26660": {"specific_function": "Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).E1 and E2 glycoproteins form a heterodimer that is involved in virus attachment to the host cell, virion internalization through clathrin-dependent endocytosis and fusion with host membrane. E1/E2 heterodimer binds to human LDLR, CD81 and SCARB1/SR-BI receptors, but this binding is not sufficient for infection, some additional liver specific cofactors may be needed. The fusion function may possibly be carried by E1. E2 inhibits human EIF2AK2/PKR activation, preventing the establishment of an antiviral state. E2 is a viral ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on liver sinusoidal endothelial cells and macrophage-like cells of lymph node sinuses. These interactions allow capture of circulating HCV particles by these cells and subsequent transmission to permissive cells. DCs act as sentinels in various tissues where they entrap pathogens and convey them to local lymphoid tissue or lymph node for establishment of immunity. Capture of circulating HCV particles by these SIGN+ cells may facilitate virus infection of proximal hepatocytes and lymphocyte subpopulations and may be essential for the establishment of persistent infection (By similarity).P7 seems to be a heptameric ion channel protein (viroporin) and is inhibited by the antiviral drug amantadine. Also inhibited by long-alkyl-chain iminosugar derivatives. Essential for infectivity (By similarity).Protease NS2-3 is a cysteine protease responsible for the autocatalytic cleavage of NS2-NS3. Seems to undergo self-inactivation following maturation (By similarity).NS3 displays three enzymatic activities: serine protease, NTPase and RNA helicase. NS3 serine protease, in association with NS4A, is responsible for the cleavages of NS3-NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3 RNA helicase binds to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA stable secondary structure in the template strand. Cleaves the host antiviral protein MAVS (By similarity). NS3/NS4A complex also prevents phosphorylation of human IRF3, thus preventing the establishment of dsRNA induced antiviral state.NS4B induces a specific membrane alteration that serves as a scaffold for the virus replication complex. This membrane alteration gives rise to the so-called ER-derived membranous web that contains the replication complex (By similarity).NS5A is a component of the replication complex involved in RNA-binding. Its interaction with Human VAPB may target the viral replication complex to vesicles. Down-regulates viral IRES translation initiation. Mediates interferon resistance, presumably by interacting with and inhibiting human EIF2AK2/PKR. Seems to inhibit apoptosis by interacting with BIN1 and FKBP8. The hyperphosphorylated form of NS5A is an inhibitor of viral replication (By similarity).NS5B is an RNA-dependent RNA polymerase that plays an essential role in the virus replication.", "general_function": "Zinc ion binding", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P26661": {"specific_function": "Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) (By similarity).E1 and E2 glycoproteins form a heterodimer that is involved in virus attachment to the host cell, virion internalization through clathrin-dependent endocytosis and fusion with host membrane. E1/E2 heterodimer binds to human LDLR, CD81 and SCARB1/SR-BI receptors, but this binding is not sufficient for infection, some additional liver specific cofactors may be needed. The fusion function may possibly be carried by E1. E2 inhibits human EIF2AK2/PKR activation, preventing the establishment of an antiviral state. E2 is a viral ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on liver sinusoidal endothelial cells and macrophage-like cells of lymph node sinuses. These interactions allow capture of circulating HCV particles by these cells and subsequent transmission to permissive cells. DCs act as sentinels in various tissues where they entrap pathogens and convey them to local lymphoid tissue or lymph node for establishment of immunity. Capture of circulating HCV particles by these SIGN+ cells may facilitate virus infection of proximal hepatocytes and lymphocyte subpopulations and may be essential for the establishment of persistent infection (By similarity).P7 seems to be a heptameric ion channel protein (viroporin) and is inhibited by the antiviral drug amantadine. Also inhibited by long-alkyl-chain iminosugar derivatives. Essential for infectivity (By similarity).Protease NS2-3 is a cysteine protease responsible for the autocatalytic cleavage of NS2-NS3. Seems to undergo self-inactivation following maturation (By similarity).NS3 displays three enzymatic activities: serine protease, NTPase and RNA helicase. NS3 serine protease, in association with NS4A, is responsible for the cleavages of NS3-NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also prevents phosphorylation of human IRF3, thus preventing the establishment of dsRNA induced antiviral state. NS3 RNA helicase binds to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA stable secondary structure in the template strand. Cleaves and inhibits the host antiviral protein MAVS (By similarity).NS4B induces a specific membrane alteration that serves as a scaffold for the virus replication complex. This membrane alteration gives rise to the so-called ER-derived membranous web that contains the replication complex (By similarity).NS5A is a component of the replication complex involved in RNA-binding. Its interaction with Human VAPB may target the viral replication complex to vesicles. Down-regulates viral IRES translation initiation. Mediates interferon resistance, presumably by interacting with and inhibiting human EIF2AK2/PKR. Seems to inhibit apoptosis by interacting with BIN1 and FKBP8. The hyperphosphorylated form of NS5A is an inhibitor of viral replication (By similarity).NS5B is an RNA-dependent RNA polymerase that plays an essential role in the virus replication.", "general_function": "Zinc ion binding", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P21890": {"general_function": "Nadp binding", "gene_names": ["petH"], "name": "Ferredoxin--NADP reductase", "drug_actions": []}, "P26196": {"specific_function": "In the process of mRNA degradation, may play a role in mRNA decapping.", "general_function": "Rna helicase activity", "gene_names": ["DDX6"], "name": "Probable ATP-dependent RNA helicase DDX6", "drug_actions": []}, "P61073": {"specific_function": "Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation. Acts as a receptor for extracellular ubiquitin; leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. Involved in hematopoiesis and in cardiac ventricular septum formation. Also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells. Involved in cerebellar development. In the CNS, could mediate hippocampal-neuron survival.(Microbial infection) Acts as a coreceptor (CD4 being the primary receptor) for human immunodeficiency virus-1/HIV-1 X4 isolates and as a primary receptor for some HIV-2 isolates. Promotes Env-mediated fusion of the virus (PubMed:9427609, PubMed:10074122, PubMed:10756055). Binds bacterial lipopolysaccharide (LPS) et mediates LPS-induced inflammatory response, including TNF secretion by monocytes (PubMed:11276205).", "general_function": "Virus receptor activity", "gene_names": ["CXCR4"], "name": "C-X-C chemokine receptor type 4", "drug_actions": [{"action": "ANTAGONIST", "target": "P61073", "drug": "DB00452"}, {"action": "ANTAGONIST", "target": "P61073", "drug": "DB06809"}]}, "P11444": {"general_function": "Metal ion binding", "gene_names": ["mdlA"], "name": "Mandelate racemase", "drug_actions": []}, "P17315": {"specific_function": "Not yet known. Postulated to participate in iron transport. Outer membrane receptor for colicins IA and IB.", "general_function": "Siderophore transmembrane transporter activity", "gene_names": ["cirA"], "name": "Colicin I receptor", "drug_actions": []}, "P50281": {"specific_function": "Seems to specifically activate progelatinase A. May thus trigger invasion by tumor cells by activating progelatinase A on the tumor cell surface. May be involved in actin cytoskeleton reorganization by cleaving PTK7. Acts as a positive regulator of cell growth and migration via activation of MMP15. Involved in the formation of the fibrovascular tissues in association with pro-MMP2.", "general_function": "Zinc ion binding", "gene_names": ["MMP14"], "name": "Matrix metalloproteinase-14", "drug_actions": [{"action": "INHIBITOR", "target": "P50281", "drug": "DB00786"}]}, "Q82122": {"specific_function": "Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host cell receptor to provide virion attachment to target host cells. This attachment induces virion internalization. Tyrosine kinases are probably involved in the entry process. After binding to its receptor, the capsid undergoes conformational changes. Capsid protein VP1 N-terminus (that contains an amphipathic alpha-helix) and capsid protein VP4 are externalized. Together, they shape a pore in the host membrane through which viral genome is translocated to host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP2: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP3: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome (By similarity).Capsid protein VP4: Lies on the inner surface of the capsid shell. After binding to the host receptor, the capsid undergoes conformational changes. Capsid protein VP4 is released, Capsid protein VP1 N-terminus is externalized, and together, they shape a pore in the host membrane through which the viral genome is translocated into the host cell cytoplasm. After genome has been released, the channel shrinks (By similarity).Capsid protein VP0: Component of immature procapsids, which is cleaved into capsid proteins VP4 and VP2 after maturation. Allows the capsid to remain inactive before the maturation step (By similarity).Protein 2A: Cysteine protease that cleaves viral polyprotein and specific host proteins. It is responsible for the cleavage between the P1 and P2 regions, first cleavage occurring in the polyprotein. Cleaves also the host translation initiation factor EIF4G1, in order to shut down the capped cellular mRNA translation. Inhibits the host nucleus-cytoplasm protein and RNA trafficking by cleaving host members of the nuclear pores (By similarity).Protein 2B: Plays an essential role in the virus replication cycle by acting as a viroporin. Creates a pore in the host reticulum endoplasmic and as a consequence releases Ca2+ in the cytoplasm of infected cell. In turn, high levels of cyctoplasmic calcium may trigger membrane trafficking and transport of viral ER-associated proteins to viroplasms, sites of viral genome replication (By similarity).Protein 2C: Induces and associates with structural rearrangements of intracellular membranes. Displays RNA-binding, nucleotide binding and NTPase activities. May play a role in virion morphogenesis and viral RNA encapsidation by interacting with the capsid protein VP3 (By similarity).Protein 3AB: Localizes the viral replication complex to the surface of membranous vesicles. Together with protein 3CD binds the Cis-Active RNA Element (CRE) which is involved in RNA synthesis initiation. Acts as a cofactor to stimulate the activity of 3D polymerase, maybe through a nucleid acid chaperone activity (By similarity).Protein 3A: Localizes the viral replication complex to the surface of membranous vesicles. It inhibits host cell endoplasmic reticulum-to-Golgi apparatus transport and causes the dissassembly of the Golgi complex, possibly through GBF1 interaction. This would result in depletion of MHC, trail receptors and IFN receptors at the host cell surface (By similarity).Viral protein genome-linked: acts as a primer for viral RNA replication and remains covalently bound to viral genomic RNA. VPg is uridylylated prior to priming replication into VPg-pUpU. The oriI viral genomic sequence may act as a template for this. The VPg-pUpU is then used as primer on the genomic RNA poly(A) by the RNA-dependent RNA polymerase to replicate the viral genome. VPg may be removed in the cytoplasm by an unknown enzyme termed \"unlinkase\". VPg is not cleaved off virion genomes because replicated genomic RNA are encapsidated at the site of replication (By similarity).Protein 3CD: Is involved in the viral replication complex and viral polypeptide maturation. It exhibits protease activity with a specificity and catalytic efficiency that is different from protease 3C. Protein 3CD lacks polymerase activity. The 3C domain in the context of protein 3CD may have an RNA binding activity (By similarity).Protease 3C: cleaves host DDX58/RIG-I and thus contributes to the inhibition of type I interferon production. Cleaves also host PABPC1 (By similarity).RNA-directed RNA polymerase: Replicates the viral genomic RNA on the surface of intracellular membranes. May form linear arrays of subunits that propagate along a strong head-to-tail interaction called interface-I. Covalently attaches UMP to a tyrosine of VPg, which is used to prime RNA synthesis. The positive stranded RNA genome is first replicated at virus induced membranous vesicles, creating a dsRNA genomic replication form. This dsRNA is then used as template to synthesize positive stranded RNA genomes. ss(+)RNA genomes are either translated, replicated or encapsidated (By similarity).", "general_function": "Structural molecule activity", "gene_names": [], "name": "Genome polyprotein", "drug_actions": []}, "P21408": {"specific_function": "Part of the ABC transporter complex FbpABC (TC 3.A.1.10.1) involved in Fe(3+) ions import. This protein specifically binds Fe(3+) and is involved in its transmembrane transport (By similarity).", "general_function": "Transporter activity", "gene_names": ["fbpA"], "name": "Fe(3+)-binding periplasmic protein", "drug_actions": []}, "Q7D8I1": {"general_function": "Secondary metabolites biosynthesis, transport and catabolism", "gene_names": ["MT1417"], "name": "Alpha-pyrone synthesis polyketide synthase-like Pks18", "drug_actions": []}, "P36969": {"specific_function": "Protects cells against membrane lipid peroxidation and cell death. Required for normal sperm development and male fertility. Could play a major role in protecting mammals from the toxicity of ingested lipid hydroperoxides. Essential for embryonic development. Protects from radiation and oxidative damage.", "general_function": "Phospholipid-hydroperoxide glutathione peroxidase activity", "gene_names": ["GPX4"], "name": "Phospholipid hydroperoxide glutathione peroxidase, mitochondrial", "drug_actions": [{"action": "COFACTOR", "target": "P36969", "drug": "DB00143"}]}, "Q9WZ40": {"specific_function": "Involved in targeting and insertion of nascent membrane proteins into the cytoplasmic membrane. Acts as a receptor for the complex formed by the signal recognition particle (SRP) and the ribosome-nascent chain (RNC).", "general_function": "Gtpase activity", "gene_names": ["ftsY"], "name": "Signal recognition particle receptor FtsY", "drug_actions": []}, "P22637": {"specific_function": "Catalyzes the oxidation and isomerization of cholesterol to cholestenone (4-cholesten-3-one), which is an initial step in the cholesterol degradation process.", "general_function": "Steroid delta-isomerase activity", "gene_names": ["choB"], "name": "Cholesterol oxidase", "drug_actions": []}, "Q9UKQ2": {"specific_function": "May play a role in the adhesive and proteolytic events that occur during lymphocyte emigration or may function in ectodomain shedding of lymphocyte surface target proteins, such as FASL and CD40L. May be involved in sperm maturation.", "general_function": "Zinc ion binding", "gene_names": ["ADAM28"], "name": "Disintegrin and metalloproteinase domain-containing protein 28", "drug_actions": []}, "Q16832": {"specific_function": "Tyrosine kinase that functions as cell surface receptor for fibrillar collagen and regulates cell differentiation, remodeling of the extracellular matrix, cell migration and cell proliferation. Required for normal bone development. Regulates osteoblast differentiation and chondrocyte maturation via a signaling pathway that involves MAP kinases and leads to the activation of the transcription factor RUNX2. Regulates remodeling of the extracellular matrix by up-regulation of the collagenases MMP1, MMP2 and MMP13, and thereby facilitates cell migration and tumor cell invasion. Promotes fibroblast migration and proliferation, and thereby contributes to cutaneous wound healing.", "general_function": "Transmembrane receptor protein tyrosine kinase activity", "gene_names": ["DDR2"], "name": "Discoidin domain-containing receptor 2", "drug_actions": [{"action": "INHIBITOR", "target": "Q16832", "drug": "DB08896"}]}, "P33447": {"specific_function": "Transaminase involved in tyrosine breakdown. Converts tyrosine to p-hydroxyphenylpyruvate (By similarity).", "general_function": "Pyridoxal phosphate binding", "gene_names": [], "name": "Tyrosine aminotransferase", "drug_actions": []}, "Q9NPJ3": {"specific_function": "Acyl-CoA thioesterases are a group of enzymes that catalyze the hydrolysis of acyl-CoAs to the free fatty acid and coenzyme A (CoASH), providing the potential to regulate intracellular levels of acyl-CoAs, free fatty acids and CoASH. Has acyl-CoA thioesterase activity towards medium (C12) and long-chain (C18) fatty acyl-CoA substrates. Can also hydrolyze 3-hydroxyphenylacetyl-CoA and 3,4-dihydroxyphenylacetyl-CoA (in vitro). May play a role in controlling adaptive thermogenesis (By similarity).", "general_function": "Acyl-coa hydrolase activity", "gene_names": ["ACOT13"], "name": "Acyl-coenzyme A thioesterase 13", "drug_actions": []}, "P48167": {"specific_function": "The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).", "name": "Glycine receptor subunit beta", "drug_actions": [{"action": "AGONIST", "target": "P48167", "drug": "DB00228"}, {"action": "ANTAGONIST", "target": "P48167", "drug": "DB00431"}], "general_function": "Glycine binding", "in_complexes": ["Glycine receptor (alpha-1/beta)"], "gene_names": ["GLRB"]}, "Q9NTG7": {"specific_function": "NAD-dependent protein deacetylase. Activates or deactivates mitochondrial target proteins by deacetylating key lysine residues. Known targets include ACSS1, IDH, GDH, SOD2, PDHA1, LCAD, SDHA and the ATP synthase subunit ATP5O. Contributes to the regulation of the cellular energy metabolism. Important for regulating tissue-specific ATP levels.", "general_function": "Zinc ion binding", "gene_names": ["SIRT3"], "name": "NAD-dependent protein deacetylase sirtuin-3, mitochondrial", "drug_actions": []}, "P48163": {"general_function": "Oxaloacetate decarboxylase activity", "gene_names": ["ME1"], "name": "NADP-dependent malic enzyme", "drug_actions": []}, "Q7Z3Y4": {"gene_names": [], "name": "Uncharacterized protein", "drug_actions": []}, "P19784": {"specific_function": "Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection. May act as a regulatory node which integrates and coordinates numerous signals leading to an appropriate cellular response. During mitosis, functions as a component of the p53/TP53-dependent spindle assembly checkpoint (SAC) that maintains cyclin-B-CDK1 activity and G2 arrest in response to spindle damage. Also required for p53/TP53-mediated apoptosis, phosphorylating 'Ser-392' of p53/TP53 following UV irradiation. Can also negatively regulate apoptosis. Phosphorylates the caspases CASP9 and CASP2 and the apoptotic regulator NOL3. Phosphorylation protects CASP9 from cleavage and activation by CASP8, and inhibits the dimerization of CASP2 and activation of CASP8. Regulates transcription by direct phosphorylation of RNA polymerases I, II, III and IV. Also phosphorylates and regulates numerous transcription factors including NF-kappa-B, STAT1, CREB1, IRF1, IRF2, ATF1, SRF, MAX, JUN, FOS, MYC and MYB. Phosphorylates Hsp90 and its co-chaperones FKBP4 and CDC37, which is essential for chaperone function. Regulates Wnt signaling by phosphorylating CTNNB1 and the transcription factor LEF1. Acts as an ectokinase that phosphorylates several extracellular proteins. During viral infection, phosphorylates various proteins involved in the viral life cycles of EBV, HSV, HBV, HCV, HIV, CMV and HPV.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["CSNK2A2"], "name": "Casein kinase II subunit alpha'", "drug_actions": []}, "P48169": {"specific_function": "GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.", "name": "Gamma-aminobutyric acid receptor subunit alpha-4", "drug_actions": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00228"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00237"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00292"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00306"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00349"}, {"action": "AGONIST", "target": "P48169", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00404"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00418"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00475"}, {"action": "BINDER", "target": "P48169", "drug": "DB00543"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00599"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00628"}, {"action": "POSITIVE MODULATOR", "target": "P48169", "drug": "DB00659"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00690"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00753"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00849"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01028"}, {"action": "AGONIST", "target": "P48169", "drug": "DB01049"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01236"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB01351"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB01352"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB01353"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB01354"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB01355"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01437"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB01483"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB01496"}, {"action": "AGONIST", "target": "P48169", "drug": "DB01544"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB01558"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P48169", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P48169", "drug": "DB01595"}, {"action": "ANTAGONIST", "target": "P48169", "drug": "DB01708"}], "general_function": "Inhibitory extracellular ligand-gated ion channel activity", "in_complexes": ["GABA-A receptor (anion channel)"], "gene_names": ["GABRA4"]}, "P01303": {"specific_function": "NPY is implicated in the control of feeding and in secretion of gonadotrophin-release hormone.", "general_function": "Receptor binding", "gene_names": ["NPY"], "name": "Pro-neuropeptide Y", "drug_actions": []}, "Q746L7": {"general_function": "Ribokinase activity", "gene_names": [], "name": "2-keto-3-deoxy-gluconate kinase", "drug_actions": []}, "Q51911": {"specific_function": "Binds serum albumin.", "gene_names": ["pab"], "name": "Peptostreptococcal albumin-binding protein", "drug_actions": []}, "Q9X0F9": {"gene_names": [], "name": "Putative L-rhamnose mutarotase", "drug_actions": []}, "Q99UY8": {"general_function": "Involved in ATP binding", "gene_names": ["pycA"], "name": "Pyruvate carboxylase", "drug_actions": []}, "Q8RQP5": {"specific_function": "Involved in the biosynthesis of isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), two major building blocks of isoprenoid compounds. Catalyzes the conversion of 4-diphosphocytidyl-2-C-methyl-D-erythritol 2-phosphate (CDP-ME2P) to 2-C-methyl-D-erythritol 2,4-cyclodiphosphate (ME-CPP) with a corresponding release of cytidine 5-monophosphate (CMP).", "general_function": "Metal ion binding", "gene_names": ["ispF"], "name": "2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase", "drug_actions": []}, "P12081": {"general_function": "Histidine-trna ligase activity", "gene_names": ["HARS"], "name": "Histidine--tRNA ligase, cytoplasmic", "drug_actions": []}, "P33221": {"specific_function": "Catalyzes two reactions: the first one is the production of beta-formyl glycinamide ribonucleotide (GAR) from formate, ATP and beta GAR; the second, a side reaction, is the production of acetyl phosphate and ADP from acetate and ATP.", "general_function": "Phosphoribosylglycinamide formyltransferase activity", "gene_names": ["purT"], "name": "Phosphoribosylglycinamide formyltransferase 2", "drug_actions": []}, "P37747": {"specific_function": "Catalyzes the interconversion through a 2-keto intermediate of uridine diphosphogalactopyranose (UDP-GalP) into uridine diphosphogalactofuranose (UDP-GalF).", "general_function": "Udp-galactopyranose mutase activity", "gene_names": ["glf"], "name": "UDP-galactopyranose mutase", "drug_actions": []}, "P30536": {"specific_function": "Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism (PubMed:24814875), but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis. Was initially identified as peripheral-type benzodiazepine receptor; can also bind isoquinoline carboxamides (PubMed:1847678).", "general_function": "Cholesterol binding", "gene_names": ["TSPO"], "name": "Translocator protein", "drug_actions": [{"action": "OTHER", "target": "P30536", "drug": "DB00186"}, {"action": "OTHER", "target": "P30536", "drug": "DB00231"}, {"action": "AGONIST", "target": "P30536", "drug": "DB00402"}, {"action": "AGONIST", "target": "P30536", "drug": "DB00628"}, {"action": "POTENTIATOR", "target": "P30536", "drug": "DB00829"}, {"action": "OTHER", "target": "P30536", "drug": "DB00897"}, {"action": "OTHER", "target": "P30536", "drug": "DB00962"}, {"action": "OTHER/UNKNOWN", "target": "P30536", "drug": "DB01068"}, {"action": "AGONIST", "target": "P30536", "drug": "DB01178"}, {"action": "AGONIST", "target": "P30536", "drug": "DB01198"}, {"action": "AGONIST", "target": "P30536", "drug": "DB01544"}, {"action": "AGONIST", "target": "P30536", "drug": "DB01587"}]}, "P30531": {"specific_function": "Terminates the action of GABA by its high affinity sodium-dependent reuptake into presynaptic terminals.", "general_function": "Neurotransmitter:sodium symporter activity", "gene_names": ["SLC6A1"], "name": "Sodium- and chloride-dependent GABA transporter 1", "drug_actions": [{"action": "INHIBITOR", "target": "P30531", "drug": "DB00906"}, {"action": "INHIBITOR", "target": "P30531", "drug": "DB08848"}]}, "P30532": {"specific_function": "After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.", "general_function": "Ligand-gated ion channel activity", "gene_names": ["CHRNA5"], "name": "Neuronal acetylcholine receptor subunit alpha-5", "drug_actions": [{"action": "AGONIST", "target": "P30532", "drug": "DB00184"}, {"action": "ALLOSTERIC MODULATOR", "target": "P30532", "drug": "DB00674"}]}, "Q81VW8": {"specific_function": "Catalyzes the condensation of para-aminobenzoate (pABA) with 6-hydroxymethyl-7,8-dihydropterin diphosphate (DHPt-PP) to form 7,8-dihydropteroate (H2Pte), the immediate precursor of folate derivatives.", "general_function": "Metal ion binding", "gene_names": ["folP"], "name": "Dihydropteroate synthase", "drug_actions": []}, "P0ADY7": {"specific_function": "This protein binds directly to 23S ribosomal RNA and is located at the A site of the peptidyltransferase center. It contacts the A and P site tRNAs. It has an essential role in subunit assembly, which is not well understood.", "general_function": "Trna binding", "gene_names": ["rplP"], "name": "50S ribosomal protein L16", "drug_actions": [{"action": "INHIBITOR", "target": "P0ADY7", "drug": "DB00446"}]}, "P12488": {"specific_function": "Envelope glycoprotein gp160: Oligomerizes in the host endoplasmic reticulum into predominantly trimers. In a second time, gp160 transits in the host Golgi, where glycosylation is completed. The precursor is then proteolytically cleaved in the trans-Golgi and thereby activated by cellular furin or furin-like proteases to produce gp120 and gp41.Surface protein gp120: Attaches the virus to the host lymphoid cell by binding to the primary receptor CD4. This interaction induces a structural rearrangement creating a high affinity binding site for a chemokine coreceptor like CXCR4 and/or CCR5. Acts as a ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on endothelial cells of liver sinusoids and lymph node sinuses. These interactions allow capture of viral particles at mucosal surfaces by these cells and subsequent transmission to permissive cells. HIV subverts the migration properties of dendritic cells to gain access to CD4+ T-cells in lymph nodes. Virus transmission to permissive T-cells occurs either in trans (without DCs infection, through viral capture and transmission), or in cis (following DCs productive infection, through the usual CD4-gp120 interaction), thereby inducing a robust infection. In trans infection, bound virions remain infectious over days and it is proposed that they are not degraded, but protected in non-lysosomal acidic organelles within the DCs close to the cell membrane thus contributing to the viral infectious potential during DCs' migration from the periphery to the lymphoid tissues. On arrival at lymphoid tissues, intact virions recycle back to DCs' cell surface allowing virus transmission to CD4+ T-cells.Transmembrane protein gp41: Acts as a class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of viral and target intracellular membranes, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Complete fusion occurs in host cell endosomes and is dynamin-dependent, however some lipid transfer might occur at the plasma membrane. The virus undergoes clathrin-dependent internalization long before endosomal fusion, thus minimizing the surface exposure of conserved viral epitopes during fusion and reducing the efficacy of inhibitors targeting these epitopes. Membranes fusion leads to delivery of the nucleocapsid into the cytoplasm.", "general_function": "Structural molecule activity", "gene_names": ["env"], "name": "Envelope glycoprotein gp160", "drug_actions": []}, "P60981": {"specific_function": "Actin-depolymerizing protein. Severs actin filaments (F-actin) and binds to actin monomers (G-actin). Acts in a pH-independent manner.", "gene_names": ["DSTN"], "name": "Destrin", "drug_actions": []}, "Q9A1B7": {"gene_names": ["murI"], "name": "Glutamate racemase", "drug_actions": []}, "P0A9M5": {"specific_function": "Acts on guanine, xanthine and to a lesser extent hypoxanthine.", "general_function": "Xanthine phosphoribosyltransferase activity", "gene_names": ["gpt"], "name": "Xanthine phosphoribosyltransferase", "drug_actions": []}, "Q9RRU8": {"specific_function": "Involved in the synthesis of autoinducer 2 (AI-2) which is secreted by bacteria and is used to communicate both the cell density and the metabolic potential of the environment. The regulation of gene expression in response to changes in cell density is called quorum sensing. Catalyzes the transformation of S-ribosylhomocysteine (RHC) to homocysteine (HC) and 4,5-dihydroxy-2,3-pentadione (DPD).", "general_function": "S-ribosylhomocysteine lyase activity", "gene_names": ["luxS"], "name": "S-ribosylhomocysteine lyase", "drug_actions": []}, "Q15418": {"specific_function": "Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1. In fibroblast, is required for EGF-stimulated phosphorylation of CREB1, which results in the subsequent transcriptional activation of several immediate-early genes. In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP. Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity. Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the pre-initiation complex. In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation. Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway. Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function. Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4). Mediates induction of hepatocyte prolifration by TGFA through phosphorylation of CEBPB (By similarity). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression.", "general_function": "Ribosomal protein s6 kinase activity", "gene_names": ["RPS6KA1"], "name": "Ribosomal protein S6 kinase alpha-1", "drug_actions": []}, "P0A9M2": {"specific_function": "Acts preferentially on hypoxanthine; has very low activity towards guanine. Inactive towards xanthine.", "general_function": "Nucleotide binding", "gene_names": ["hpt"], "name": "Hypoxanthine phosphoribosyltransferase", "drug_actions": []}, "Q96DP5": {"specific_function": "Formylates methionyl-tRNA in mitochondria. A single tRNA(Met) gene gives rise to both an initiator and an elongator species via an unknown mechanism (By similarity).", "general_function": "Methionyl-trna formyltransferase activity", "gene_names": ["MTFMT"], "name": "Methionyl-tRNA formyltransferase, mitochondrial", "drug_actions": [{"action": "COFACTOR", "target": "Q96DP5", "drug": "DB00116"}]}, "P0A9J8": {"specific_function": "Catalyzes the Claisen rearrangement of chorismate to prephenate and the decarboxylation/dehydration of prephenate to phenylpyruvate.", "general_function": "Prephenate dehydratase activity", "gene_names": ["pheA"], "name": "P-protein", "drug_actions": []}, "O94788": {"specific_function": "Recognizes as substrates free retinal and cellular retinol-binding protein-bound retinal. Does metabolize octanal and decanal but does not metabolize citral, benzaldehyde, acetaldehyde and propanal efficiently (By similarity).", "general_function": "Retinal dehydrogenase activity", "gene_names": ["ALDH1A2"], "name": "Retinal dehydrogenase 2", "drug_actions": []}, "P49591": {"specific_function": "Catalyzes the attachment of serine to tRNA(Ser). Is also probably able to aminoacylate tRNA(Sec) with serine, to form the misacylated tRNA L-seryl-tRNA(Sec), which will be further converted into selenocysteinyl-tRNA(Sec).", "general_function": "Serine-trna ligase activity", "gene_names": ["SARS"], "name": "Serine--tRNA ligase, cytoplasmic", "drug_actions": []}, "P23837": {"specific_function": "Member of the two-component regulatory system PhoP/PhoQ involved in adaptation to low Mg(2+) environments and the control of acid resistance genes. In low periplasmic Mg(2+), PhoQ functions as a membrane-associated protein kinase that undergoes autophosphorylation and subsequently transfers the phosphate to PhoP, resulting in the expression of PhoP-activated genes (PAG) and repression of PhoP-repressed genes (PRG). In high periplasmic Mg(2+), acts as a protein phosphatase that dephosphorylates phospho-PhoP, resulting in the repression of PAG and may lead to expression of some PRG (By similarity). PhoP-regulated transcription is redox-sensitive, being activated when the periplasm becomes more reducing (deletion of dsbA/dsbB, or treatment with dithiothreitol). MgrB acts between DsbA/DsbB and PhoP/PhoQ in this pathway; the 2 periplasmic Cys residues of MgrB are required for its action on PhoQ, which then acts on PhoP. Mediates magnesium influx to the cytosol by activation of mgtA. Promotes expression of the two-component regulatory system rstA/rstB and transcription of the hemL, mgrB, nagA, slyB, vboR and yrbL genes.", "general_function": "Phosphorelay sensor kinase activity", "gene_names": ["phoQ"], "name": "Sensor protein PhoQ", "drug_actions": []}, "P45124": {"specific_function": "Responsible for synthesis of pseudouridine from uracil-516 in 16S ribosomal RNA.", "general_function": "Rna binding", "gene_names": ["rsuA"], "name": "Ribosomal small subunit pseudouridine synthase A", "drug_actions": []}, "P37698": {"specific_function": "Probable endoglucanase involved in the degradation of cellulose or related beta-glucans.", "general_function": "Cellulase activity", "gene_names": ["celCCF"], "name": "Endoglucanase F", "drug_actions": []}, "P0A6C8": {"general_function": "Atp binding", "gene_names": ["argB"], "name": "Acetylglutamate kinase", "drug_actions": []}, "P22830": {"specific_function": "Catalyzes the ferrous insertion into protoporphyrin IX.", "general_function": "Iron-responsive element binding", "gene_names": ["FECH"], "name": "Ferrochelatase, mitochondrial", "drug_actions": []}, "Q9S400": {"specific_function": "Catalyzes the transfer of the enolpyruvyl moiety of phosphoenolpyruvate (PEP) to the 5-hydroxyl of shikimate-3-phosphate (S3P) to produce enolpyruvyl shikimate-3-phosphate and inorganic phosphate.", "general_function": "3-phosphoshikimate 1-carboxyvinyltransferase activity", "gene_names": ["aroA"], "name": "3-phosphoshikimate 1-carboxyvinyltransferase", "drug_actions": [{"action": "INHIBITOR", "target": "Q9S400", "drug": "DB04539"}]}, "Q06319": {"specific_function": "Has an optimum specificity for 4-carbon length fatty acyl-CoAs.", "general_function": "Flavin adenine dinucleotide binding", "gene_names": [], "name": "Acyl-CoA dehydrogenase, short-chain specific", "drug_actions": []}, "P13423": {"specific_function": "One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.", "general_function": "Metal ion binding", "gene_names": ["pagA"], "name": "Protective antigen", "drug_actions": [{"action": "ANTIBODY", "target": "P13423", "drug": "DB08902"}]}, "O25608": {"specific_function": "Reduction of a variety of nitroaromatic compounds using NADPH as source of reducing equivalents; two electrons are transferred (By similarity). Capable of reducing metronidazole; inactive RdxA renders the bacterium resistant to this compound. The reduction of metronidazole generates hydroxylamine, a potent mutagen and bactericide.", "general_function": "Oxidoreductase activity", "gene_names": ["rdxA"], "name": "Oxygen-insensitive NADPH nitroreductase", "drug_actions": [{"action": "POTENTIATOR", "target": "O25608", "drug": "DB00916"}]}, "Q07021": {"specific_function": "Is believed to be a multifunctional and multicompartmental protein involved in inflammation and infection processes, ribosome biogenesis, regulation of apoptosis, transcriptional regulation and pre-mRNA splicing. At the cell surface is thought to act as an endothelial receptor for plasma proteins of the complement and kallikrein-kinin cascades. Putative receptor for C1q; specifically binds to the globular \"heads\" of C1q thus inhibiting C1; may perform the receptor function through a complex with C1qR/CD93. In complex with cytokeratin-1/KRT1 is a high affinity receptor for kininogen-1/HMWK. Can also bind other plasma proteins, such as coagulation factor XII leading to its autoactivation. May function to bind initially fluid kininogen-1 to the cell membrane. The secreted form may enhance both extrinsic and intrinsic coagulation pathways. It is postulated that the cell surface form requires docking with transmembrane proteins for downstream signaling which might be specific for a cell-type or response. By acting as C1q receptor is involved in chemotaxis of immature dendritic cells and neutrophils and is proposed to signal through CD209/DC-SIGN on immature dendritic cells, through integrin alpha-4/beta-1 during trophoblast invasion of the decidua, and through integrin beta-1 during endothelial cell adhesion and spreading. Signaling involved in inhibition of innate immune response is implicating the PI3K-AKT/PKB pathway. In mitochondrial translation may be involved in formation of functional 55S mitoribosomes; the function seems to involve its RNA-binding activity. May be involved in the nucleolar ribosome maturation process; the function may involve the exchange of FBL for RRP1 in the association with pre-ribosome particles. Involved in regulation of RNA splicing by inhibiting the RNA-binding capacity of SRSF1 and its phosphorylation. Is required for the nuclear translocation of splicing factor U2AF1L4. Involved in regulation of CDKN2A- and HRK-mediated apoptosis. Stabilizes mitochondrial CDKN2A isoform smARF. May be involved in regulation of FOXC1 transcriptional activity and NFY/CCAAT-binding factor complex-mediated transcription. In infection processes acts as an attachment site for microbial proteins, including Listeria monocytogenes internalin B and Staphylococcus aureus protein A. May play a role in antibacterial defense as it can bind to cell surface hyaluronan and inhibit Streptococcus pneumoniae hyaluronate lyase. Involved in replication of Rubella virus. May be involved in modulation of the immune response; ligation by HCV core protein is resulting in suppresion of interleukin-12 production in monocyte-derived dendritic cells. Involved in regulation of antiviral response by inhibiting DDX58- and IFIH1-mediated signaling pathways probably involving its association with MAVS after viral infection. Involved in HIV-1 replication, presumably by contributing to splicing of viral RNA.", "general_function": "Transcription factor binding", "gene_names": ["C1QBP"], "name": "Complement component 1 Q subcomponent-binding protein, mitochondrial", "drug_actions": [{"action": "BINDER", "target": "Q07021", "drug": "DB08818"}]}, "P30405": {"specific_function": "PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. Involved in regulation of the mitochondrial permeability transition pore (mPTP). It is proposed that its association with the mPTP is masking a binding site for inhibiting inorganic phosphate (Pi) and promotes the open probability of the mPTP leading to apoptosis or necrosis; the requirement of the PPIase activity for this function is debated. In cooperation with mitochondrial TP53 is involved in activating oxidative stress-induced necrosis. Involved in modulation of mitochondrial membrane F(1)F(0) ATP synthase activity and regulation of mitochondrial matrix adenine nucleotide levels. Has anti-apoptotic activity independently of mPTP and in cooperation with BCL2 inhibits cytochrome c-dependent apoptosis.", "general_function": "Peptidyl-prolyl cis-trans isomerase activity", "gene_names": ["PPIF"], "name": "Peptidyl-prolyl cis-trans isomerase F, mitochondrial", "drug_actions": [{"action": "BINDER", "target": "P30405", "drug": "DB00091"}]}, "P61587": {"specific_function": "Binds GTP but lacks intrinsic GTPase activity and is resistant to Rho-specific GTPase-activating proteins.", "general_function": "Gtpase activity", "gene_names": ["RND3"], "name": "Rho-related GTP-binding protein RhoE", "drug_actions": []}, "P50750": {"specific_function": "Protein kinase involved in the regulation of transcription. Member of the cyclin-dependent kinase pair (CDK9/cyclin-T) complex, also called positive transcription elongation factor b (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAP II) POLR2A, SUPT5H and RDBP. This complex is inactive when in the 7SK snRNP complex form. Phosphorylates EP300, MYOD1, RPB1/POLR2A and AR, and the negative elongation factors DSIF and NELF. Regulates cytokine inducible transcription networks by facilitating promoter recognition of target transcription factors (e.g. TNF-inducible RELA/p65 activation and IL-6-inducible STAT3 signaling). Promotes RNA synthesis in genetic programs for cell growth, differentiation and viral pathogenesis. P-TEFb is also involved in cotranscriptional histone modification, mRNA processing and mRNA export. Modulates a complex network of chromatin modifications including histone H2B monoubiquitination (H2Bub1), H3 lysine 4 trimethylation (H3K4me3) and H3K36me3; integrates phosphorylation during transcription with chromatin modifications to control co-transcriptional histone mRNA processing. The CDK9/cyclin-K complex has also a kinase activity towards CTD of RNAP II and can substitute for CDK9/cyclin-T P-TEFb in vitro. Replication stress response protein; the CDK9/cyclin-K complex is required for genome integrity maintenance, by promoting cell cycle recovery from replication arrest and limiting single-stranded DNA amount in response to replication stress, thus reducing the breakdown of stalled replication forks and avoiding DNA damage. In addition, probable function in DNA repair of isoform 2 via interaction with KU70/XRCC6. Promotes cardiac myocyte enlargement. RPB1/POLR2A phosphorylation on 'Ser-2' in CTD activates transcription. AR phosphorylation modulates AR transcription factor promoter selectivity and cell growth. DSIF and NELF phosphorylation promotes transcription by inhibiting their negative effect. The phosphorylation of MYOD1 enhances its transcriptional activity and thus promotes muscle differentiation.", "general_function": "Transcription regulatory region dna binding", "gene_names": ["CDK9"], "name": "Cyclin-dependent kinase 9", "drug_actions": []}, "P11684": {"specific_function": "Binds phosphatidylcholine, phosphatidylinositol, polychlorinated biphenyls (PCB) and weakly progesterone, potent inhibitor of phospholipase A2.", "general_function": "Polychlorinated biphenyl binding", "gene_names": ["SCGB1A1"], "name": "Uteroglobin", "drug_actions": []}, "P21905": {"specific_function": "F(1)F(0) ATP synthase produces ATP from ADP in the presence of a proton or sodium gradient. F-type ATPases consist of two structural domains, F(1) containing the extramembraneous catalytic core and F(0) containing the membrane sodium channel, linked together by a central stalk and a peripheral stalk. During catalysis, ATP synthesis in the catalytic domain of F(1) is coupled via a rotary mechanism of the central stalk subunits to sodium translocation.Key component of the F(0) channel; it plays a direct role in translocation across the membrane. A homomeric c-ring of between 10-14 subunits forms the central stalk rotor element with the F(1) delta and epsilon subunits (Probable).", "general_function": "Lipid binding", "gene_names": ["atpE"], "name": "ATP synthase subunit c, sodium ion specific", "drug_actions": []}, "Q16613": {"specific_function": "Controls the night/day rhythm of melatonin production in the pineal gland. Catalyzes the N-acetylation of serotonin into N-acetylserotonin, the penultimate step in the synthesis of melatonin.", "general_function": "Arylamine n-acetyltransferase activity", "gene_names": ["AANAT"], "name": "Serotonin N-acetyltransferase", "drug_actions": []}, "P42216": {"specific_function": "Activates KDO (a required 8-carbon sugar) for incorporation into bacterial lipopolysaccharide in Gram-negative bacteria.", "general_function": "3-deoxy-manno-octulosonate cytidylyltransferase activity", "gene_names": ["kpsU"], "name": "3-deoxy-manno-octulosonate cytidylyltransferase", "drug_actions": []}, "Q9NSE4": {"general_function": "Isoleucine-trna ligase activity", "gene_names": ["IARS2"], "name": "Isoleucine--tRNA ligase, mitochondrial", "drug_actions": []}, "Q06174": {"specific_function": "Involved in the detoxification of xenobiotics. Shows maximal activity with C6 substrates, with gradually decreasing activity from C8 to C12 substrates. No activity for higher chain length substrates acids rather than long-chain ones.", "general_function": "Carboxylic ester hydrolase activity", "gene_names": ["est"], "name": "Carboxylesterase", "drug_actions": []}, "Q55013": {"specific_function": "Low-potential cytochrome c that plays a role in the oxygen-evolving complex of photosystem II (PSII). Required for normal function or stabilization of PSII. Extrinsic protein associated with PSII that enhances oxygen evolution.", "general_function": "Iron ion binding", "gene_names": ["psbV"], "name": "Cytochrome c-550", "drug_actions": []}, "Q07343": {"specific_function": "Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents.", "name": "cAMP-specific 3',5'-cyclic phosphodiesterase 4B", "drug_actions": [{"action": "PRODUCT OF", "target": "Q07343", "drug": "DB00131"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB00201"}, {"action": "INHIBITOR, COMPETITIVE", "target": "Q07343", "drug": "DB00201"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB00277"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB00651"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB00806"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB00824"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB00920"}, {"action": "INDUCER", "target": "Q07343", "drug": "DB01088"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB01113"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB01412"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB01427"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB01656"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB03606"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB04149"}, {"action": "INHIBITOR", "target": "Q07343", "drug": "DB05266"}, {"action": "ANTAGONIST", "target": "Q07343", "drug": "DB05676"}], "general_function": "Metal ion binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE4B"]}, "Q840M4": {"general_function": "Involved in beta-lactamase activity", "gene_names": ["blaCTX-M-27"], "name": "Beta-lactamase CTX-M-27", "drug_actions": []}, "P20906": {"general_function": "Thiamine pyrophosphate binding", "gene_names": ["mdlC"], "name": "Benzoylformate decarboxylase", "drug_actions": []}, "P39900": {"specific_function": "May be involved in tissue injury and remodeling. Has significant elastolytic activity. Can accept large and small amino acids at the P1' site, but has a preference for leucine. Aromatic or hydrophobic residues are preferred at the P1 site, with small hydrophobic residues (preferably alanine) occupying P3.", "general_function": "Zinc ion binding", "gene_names": ["MMP12"], "name": "Macrophage metalloelastase", "drug_actions": [{"action": "INHIBITOR", "target": "P39900", "drug": "DB00551"}, {"action": "INHIBITOR", "target": "P39900", "drug": "DB00786"}]}, "P06729": {"specific_function": "CD2 interacts with lymphocyte function-associated antigen (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. CD2 is implicated in the triggering of T-cells, the cytoplasmic domain is implicated in the signaling function.", "general_function": "Receptor binding", "gene_names": ["CD2"], "name": "T-cell surface antigen CD2", "drug_actions": [{"action": "INHIBITOR", "target": "P06729", "drug": "DB00092"}]}, "P0A6Q5": {"specific_function": "Necessary for the introduction of cis unsaturation into fatty acids. Catalyzes the dehydration of (3R)-3-hydroxydecanoyl-ACP to E-(2)-decenoyl-ACP and then its isomerization to Z-(3)-decenoyl-ACP. Can catalyze the dehydratase reaction for beta-hydroxyacyl-ACPs with saturated chain lengths up to 16:0, being most active on intermediate chain length (By similarity).", "general_function": "Trans-2-decenoyl-acyl-carrier-protein isomerase activity", "gene_names": ["fabA"], "name": "3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase", "drug_actions": []}, "P0C6X7": {"specific_function": "Replicase polyprotein 1ab: Multifunctional protein involved in the transcription and replication of viral RNAs. Contains the proteinases responsible for the cleavages of the polyprotein.Host translation inhibitor nsp1: Inhibits host translation by interacting with the 40S ribosomal subunit. The nsp1-40S ribosome complex further induces an endonucleolytic cleavage near the 5'UTR of host mRNAs, targeting them for degradation. Viral mRNAs are not susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the presence of a 5'-end leader sequence and are therefore protected from degradation. By suppressing host gene expression, nsp1 facilitates efficient viral gene expression in infected cells and evasion from host immune response.Non-structural protein 2: May play a role in the modulation of host cell survival signaling pathway by interacting with host PHB and PHB2. Indeed, these two proteins play a role in maintaining the functional integrity of the mitochondria and protecting cells from various stresses.Papain-like proteinase: Responsible for the cleavages located at the N-terminus of the replicase polyprotein. In addition, PL-PRO possesses a deubiquitinating/deISGylating activity and processes both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular substrates. Participates together with nsp4 in the assembly of virally-induced cytoplasmic double-membrane vesicles necessary for viral replication. Antagonizes innate immune induction of type I interferon by blocking the phosphorylation, dimerization and subsequent nuclear translocation of host IRF3. Prevents also host NF-kappa-B signaling.Non-structural protein 4: Participates in the assembly of virally-induced cytoplasmic double-membrane vesicles necessary for viral replication.Proteinase 3CL-PRO: Ccleaves the C-terminus of replicase polyprotein at 11 sites. Recognizes substrates containing the core sequence [ILMVF]-Q-|-[SGACN]. Also able to bind an ADP-ribose-1''-phosphate (ADRP).Non-structural protein 6: Plays a role in the initial induction of autophagosomes from host reticulum endoplasmic. Later, limits the expansion of these phagosomes that are no longer able to deliver viral components to lysosomes.Non-structural protein 7: Forms an hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers.Non-structural protein 8: Forms an hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers.Non-structural protein 9: May participate in viral replication by acting as a ssRNA-binding protein.Non-structural protein 10: Plays a pivotal role in viral transcription by stimulating both nsp14 3'-5' exoribonuclease and nsp16 2'-O-methyltransferase activities. Therefore plays an essential role in viral mRNAs cap methylation.RNA-directed RNA polymerase: Responsible for replication and transcription of the viral RNA genome.Helicase: Multi-functional protein with a zinc-binding domain in N-terminus displaying RNA and DNA duplex-unwinding activities with 5' to 3' polarity. Activity of helicase is dependent on magnesium.Guanine-N7 methyltransferase: Enzyme possessing two different activities: an exoribonuclease activity acting on both ssRNA and dsRNA in a 3' to 5' direction and a N7-guanine methyltransferase activity.Uridylate-specific endoribonuclease: Mn(2+)-dependent, uridylate-specific enzyme, which leaves 2'-3'-cyclic phosphates 5' to the cleaved bond.2'-O-methyltransferase: Methyltransferase that mediates mRNA cap 2'-O-ribose methylation to the 5'-cap structure of viral mRNAs. N7-methyl guanosine cap is a prerequisite for binding of nsp16. Therefore plays an essential role in viral mRNAs cap methylation which is essential to evade immune system.", "general_function": "Zinc ion binding", "gene_names": ["rep"], "name": "Replicase polyprotein 1ab", "drug_actions": []}, "P0A6Q3": {"specific_function": "Necessary for the introduction of cis unsaturation into fatty acids. Catalyzes the dehydration of (3R)-3-hydroxydecanoyl-ACP to E-(2)-decenoyl-ACP and then its isomerization to Z-(3)-decenoyl-ACP. Can catalyze the dehydratase reaction for beta-hydroxyacyl-ACPs with saturated chain lengths up to 16:0, being most active on intermediate chain length. Is inactive in the dehydration of long chain unsaturated beta-hydroxyacyl-ACP.", "general_function": "Trans-2-decenoyl-acyl-carrier-protein isomerase activity", "gene_names": ["fabA"], "name": "3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase", "drug_actions": []}, "P13688": {"general_function": "Protein homodimerization activity", "gene_names": ["CEACAM1"], "name": "Carcinoembryonic antigen-related cell adhesion molecule 1", "drug_actions": [{"action": "OTHER/UNKNOWN", "target": "P13688", "drug": "DB00113"}]}, "O07653": {"general_function": "Metal ion binding", "gene_names": ["celB"], "name": "Cellulase B", "drug_actions": []}, "Q9UBX1": {"specific_function": "Thiol protease which is believed to participate in intracellular degradation and turnover of proteins. Has also been implicated in tumor invasion and metastasis.", "general_function": "Cysteine-type endopeptidase activity", "gene_names": ["CTSF"], "name": "Cathepsin F", "drug_actions": []}, "Q9UBX3": {"specific_function": "Involved in translocation of malonate, malate and succinate in exchange for phosphate, sulfate, sulfite or thiosulfate across mitochondrial inner membrane.", "general_function": "Dicarboxylic acid transmembrane transporter activity", "gene_names": ["SLC25A10"], "name": "Mitochondrial dicarboxylate carrier", "drug_actions": []}, "P98170": {"specific_function": "Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation, as well as cell invasion and metastasis. Acts as a direct caspase inhibitor. Directly bind to the active site pocket of CASP3 and CASP7 and obstructs substrate entry. Inactivates CASP9 by keeping it in a monomeric, inactive state. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and the target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, CASP3, CASP7, CASP8, CASP9, MAP3K2/MEKK2, DIABLO/SMAC, AIFM1, CCS and BIRC5/survivin. Ubiquitinion of CCS leads to enhancement of its chaperone activity toward its physiologic target, SOD1, rather than proteasomal degradation. Ubiquitinion of MAP3K2/MEKK2 and AIFM1 does not lead to proteasomal degradation. Plays a role in copper homeostasis by ubiquitinationg COMMD1 and promoting its proteasomal degradation. Can also function as E3 ubiquitin-protein ligase of the NEDD8 conjugation pathway, targeting effector caspases for neddylation and inactivation. Regulates the BMP signaling pathway and the SMAD and MAP3K7/TAK1 dependent pathways leading to NF-kappa-B and JNK activation. Acts as an important regulator of innate immune signaling via regulation of Nodlike receptors (NLRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Acts as a positive regulator of Wnt signaling and ubiquitinates TLE1, TLE2, TLE3, TLE4 and AES. Ubiquitination of TLE3 results in inhibition of its interaction with TCF7L2/TCF4 thereby allowing efficient recruitment and binding of the transcriptional coactivator beta-catenin to TCF7L2/TCF4 that is required to initiate a Wnt-specific transcriptional program.", "general_function": "Zinc ion binding", "gene_names": ["XIAP"], "name": "E3 ubiquitin-protein ligase XIAP", "drug_actions": []}, "P13686": {"specific_function": "Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias.", "general_function": "Ferrous iron binding", "gene_names": ["ACP5"], "name": "Tartrate-resistant acid phosphatase type 5", "drug_actions": []}, "P23904": {"general_function": "Licheninase activity", "gene_names": [], "name": "Beta-glucanase", "drug_actions": []}, "P23905": {"specific_function": "This protein is involved in the active transport of galactose and glucose. It plays a role in the chemotaxis towards the two sugars by interacting with the trg chemoreceptor.", "general_function": "Metal ion binding", "gene_names": ["mglB"], "name": "D-galactose-binding periplasmic protein", "drug_actions": []}, "P50135": {"specific_function": "Inactivates histamine by N-methylation. Plays an important role in degrading histamine and in regulating the airway response to histamine.", "general_function": "Histamine n-methyltransferase activity", "gene_names": ["HNMT"], "name": "Histamine N-methyltransferase", "drug_actions": [{"action": "INHIBITOR", "target": "P50135", "drug": "DB00613"}]}, "P12532": {"specific_function": "Reversibly catalyzes the transfer of phosphate between ATP and various phosphogens (e.g. creatine phosphate). Creatine kinase isoenzymes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, brain and spermatozoa.", "general_function": "Creatine kinase activity", "gene_names": ["CKMT1A"], "name": "Creatine kinase U-type, mitochondrial", "drug_actions": [{"action": "LIGAND", "target": "P12532", "drug": "DB00148"}]}, "Q9NR19": {"specific_function": "Activates acetate so that it can be used for lipid synthesis or for energy generation.", "general_function": "Atp binding", "gene_names": ["ACSS2"], "name": "Acetyl-coenzyme A synthetase, cytoplasmic", "drug_actions": [{"action": "PRODUCT OF", "target": "Q9NR19", "drug": "DB00131"}]}, "P16422": {"specific_function": "May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E.", "general_function": "Protein complex binding", "gene_names": ["EPCAM"], "name": "Epithelial cell adhesion molecule", "drug_actions": []}, "P80380": {"specific_function": "One of the primary rRNA binding proteins, it binds directly to 16S rRNA where it nucleates assembly of the bottom of the body of the 30S subunit, by binding to several RNA helices of the 16S rRNA.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsT"], "name": "30S ribosomal protein S20", "drug_actions": []}, "P78368": {"specific_function": "Serine/threonine-protein kinase. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. It can phosphorylate a large number of proteins. Participates in Wnt signaling. Phosphorylates COL4A3BP/CERT, MTA1 and SMAD3. Involved in brain development and vesicular trafficking and neurotransmitter releasing from small synaptic vesicles. Regulates fast synaptic transmission mediated by glutamate. SMAD3 phosphorylation promotes its ligand-dependent ubiquitination and subsequent proteasome degradation, thus inhibiting SMAD3-mediated TGF-beta responses. Hyperphosphorylation of the serine-repeat motif of COL4A3BP/CERT leads to its inactivation by dissociation from the Golgi complex, thus down-regulating ER-to-Golgi transport of ceramide and sphingomyelin synthesis. Triggers PER1 proteasomal degradation probably through phosphorylation.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["CSNK1G2"], "name": "Casein kinase I isoform gamma-2", "drug_actions": []}, "P18825": {"specific_function": "Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.", "name": "Alpha-2C adrenergic receptor", "drug_actions": [{"action": "AGONIST", "target": "P18825", "drug": "DB00182"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00217"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB00246"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB00248"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00268"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB00363"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00368"}, {"action": "BINDER", "target": "P18825", "drug": "DB00370"}, {"action": "BINDER", "target": "P18825", "drug": "DB00408"}, {"action": "UNKNOWN", "target": "P18825", "drug": "DB00413"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00484"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB00540"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB00543"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00575"}, {"action": "OTHER/UNKNOWN", "target": "P18825", "drug": "DB00589"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00668"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00697"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00714"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00734"}, {"action": "BINDER", "target": "P18825", "drug": "DB00797"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB00800"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB00925"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB00934"}, {"action": "AGONIST", "target": "P18825", "drug": "DB00935"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB01136"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB01142"}, {"action": "BINDER", "target": "P18825", "drug": "DB01151"}, {"action": "AGONIST", "target": "P18825", "drug": "DB01186"}, {"action": "AGONIST", "target": "P18825", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB01224"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB01238"}, {"action": "OTHER/UNKNOWN", "target": "P18825", "drug": "DB01238"}, {"action": "AGONIST", "target": "P18825", "drug": "DB01267"}, {"action": "AGONIST", "target": "P18825", "drug": "DB01363"}, {"action": "AGONIST", "target": "P18825", "drug": "DB01365"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB01392"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB01403"}, {"action": "AGONIST", "target": "P18825", "drug": "DB01577"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB04946"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB06216"}, {"action": "AGONIST", "target": "P18825", "drug": "DB06262"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB06678"}, {"action": "AGONIST", "target": "P18825", "drug": "DB06694"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB08815"}, {"action": "AGONIST", "target": "P18825", "drug": "DB08838"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB09128"}, {"action": "ANTAGONIST", "target": "P18825", "drug": "DB09202"}], "general_function": "Protein homodimerization activity", "in_complexes": ["Alpha adrenergic receptor", "Alpha-2 adrenergic receptor"], "gene_names": ["ADRA2C"]}, "P03950": {"specific_function": "Binds to actin on the surface of endothelial cells; once bound, angiogenin is endocytosed and translocated to the nucleus. Stimulates ribosomal RNA synthesis including that containing the initiation site sequences of 45S rRNA. Cleaves tRNA within anticodon loops to produce tRNA-derived stress-induced fragments (tiRNAs) which inhibit protein synthesis and triggers the assembly of stress granules (SGs). Angiogenin induces vascularization of normal and malignant tissues. Angiogenic activity is regulated by interaction with RNH1 in vivo.", "general_function": "Rrna binding", "gene_names": ["ANG"], "name": "Angiogenin", "drug_actions": []}, "P03952": {"specific_function": "The enzyme cleaves Lys-Arg and Arg-Ser bonds. It activates, in a reciprocal reaction, factor XII after its binding to a negatively charged surface. It also releases bradykinin from HMW kininogen and may also play a role in the renin-angiotensin system by converting prorenin into renin.", "general_function": "Serine-type endopeptidase activity", "gene_names": ["KLKB1"], "name": "Plasma kallikrein", "drug_actions": [{"action": "INHIBITOR", "target": "P03952", "drug": "DB05311"}]}, "Q7Z4J2": {"general_function": "Transferase activity, transferring hexosyl groups", "gene_names": ["GLT6D1"], "name": "Glycosyltransferase 6 domain-containing protein 1", "drug_actions": []}, "P28305": {"specific_function": "Involved in the biosynthesis of p-aminobenzoate (PABA), a precursor of tetrahydrofolate. Converts 4-amino-4-deoxychorismate into 4-aminobenzoate (PABA) and pyruvate.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["pabC"], "name": "Aminodeoxychorismate lyase", "drug_actions": []}, "P03956": {"specific_function": "Cleaves collagens of types I, II, and III at one site in the helical domain. Also cleaves collagens of types VII and X. In case of HIV infection, interacts and cleaves the secreted viral Tat protein, leading to a decrease in neuronal Tat's mediated neurotoxicity.", "general_function": "Zinc ion binding", "gene_names": ["MMP1"], "name": "Interstitial collagenase", "drug_actions": [{"action": "INHIBITOR", "target": "P03956", "drug": "DB00786"}]}, "O95263": {"specific_function": "Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in specific signaling in the thyroid gland.", "name": "High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B", "drug_actions": [{"action": "INHIBITOR, COMPETITIVE", "target": "O95263", "drug": "DB00201"}, {"action": "INHIBITOR", "target": "O95263", "drug": "DB00920"}], "general_function": "Metal ion binding", "in_complexes": ["Cyclic nucleotide phosphodiesterase"], "gene_names": ["PDE8B"]}, "O95264": {"specific_function": "This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses. It is a cation-specific, but otherwise relatively nonselective, ion channel.", "name": "5-hydroxytryptamine receptor 3B", "drug_actions": [{"action": "ANTAGONIST", "target": "O95264", "drug": "DB01049"}], "general_function": "Serotonin-activated cation-selective channel activity", "in_complexes": ["Serotonin Receptors"], "gene_names": ["HTR3B"]}, "Q9HBL8": {"specific_function": "Redox sensor protein. Undergoes restructuring and subcellular redistribution in response to changes in intracellular NADPH/NADP(+) levels. At low NADPH concentrations the protein is found mainly as a monomer, and binds argininosuccinate synthase (ASS1), the enzyme involved in nitric oxide synthesis. Association with ASS1 impairs its activity and reduces the production of nitric oxide, which subsecuently prevents apoptosis. Under normal NADPH concentrations, the protein is found as a dimer and hides the binding site for ASS1. The homodimer binds one molecule of NADPH. Has higher affinity for NADPH than for NADP(+). Binding to NADPH is necessary to form a stable dimer.", "gene_names": ["NMRAL1"], "name": "NmrA-like family domain-containing protein 1", "drug_actions": []}, "O08398": {"specific_function": "Essential cell division protein that forms a contractile ring structure (Z ring) at the future cell division site. The regulation of the ring assembly controls the timing and the location of cell division. One of the functions of the FtsZ ring is to recruit other cell division proteins to the septum to produce a new cell wall between the dividing cells. Binds GTP and shows GTPase activity.", "general_function": "Gtpase activity", "gene_names": ["ftsZ"], "name": "Cell division protein FtsZ", "drug_actions": []}, "P05041": {"specific_function": "Part of a heterodimeric complex that catalyzes the two-step biosynthesis of 4-amino-4-deoxychorismate (ADC), a precursor of p-aminobenzoate (PABA) and tetrahydrofolate. In the first step, a glutamine amidotransferase (PabA) generates ammonia as a substrate that, along with chorismate, is used in the second step, catalyzed by aminodeoxychorismate synthase (PabB) to produce ADC. PabB, in the absence of PabA, can catalyze the formation of ADC in the presence of exogenous ammonia.", "general_function": "Oxo-acid-lyase activity", "gene_names": ["pabB"], "name": "Aminodeoxychorismate synthase component 1", "drug_actions": []}, "A5HEI4": {"general_function": "Hydrogen ion transmembrane transporter activity", "gene_names": ["atpH"], "name": "AtpH", "drug_actions": []}, "Q8WWT9": {"specific_function": "High-affinity sodium-dicarboxylate cotransporter that accepts a range of substrates with 4-5 carbon atoms. The stoichiometry is probably 3 Na(+) for 1 divalent succinate.", "general_function": "Succinate transmembrane transporter activity", "gene_names": ["SLC13A3"], "name": "Solute carrier family 13 member 3", "drug_actions": []}, "P05042": {"specific_function": "Catalyzes the reversible addition of water to fumarate to give L-malate.", "general_function": "Fumarate hydratase activity", "gene_names": ["fumC"], "name": "Fumarate hydratase class II", "drug_actions": []}, "Q9BW92": {"general_function": "Threonine-trna ligase activity", "gene_names": ["TARS2"], "name": "Threonine--tRNA ligase, mitochondrial", "drug_actions": []}, "P27828": {"specific_function": "Catalyzes the reversible epimerization at C-2 of UDP-N-acetylglucosamine (UDP-GlcNAc) and thereby provides bacteria with UDP-N-acetylmannosamine (UDP-ManNAc), the activated donor of ManNAc residues. Also involved in bacteriophage N4 adsorption.", "general_function": "Udp-n-acetylglucosamine 2-epimerase activity", "gene_names": ["wecB"], "name": "UDP-N-acetylglucosamine 2-epimerase", "drug_actions": []}, "P27824": {"specific_function": "Calcium-binding protein that interacts with newly synthesized glycoproteins in the endoplasmic reticulum. It may act in assisting protein assembly and/or in the retention within the ER of unassembled protein subunits. It seems to play a major role in the quality control apparatus of the ER by the retention of incorrectly folded proteins. Associated with partial T-cell antigen receptor complexes that escape the ER of immature thymocytes, it may function as a signaling complex regulating thymocyte maturation. Additionally it may play a role in receptor-mediated endocytosis at the synapse.", "general_function": "Poly(a) rna binding", "gene_names": ["CANX"], "name": "Calnexin", "drug_actions": [{"action": "CHAPERONE", "target": "P27824", "drug": "DB00025"}]}, "P16544": {"general_function": "Oxidoreductase activity", "gene_names": ["actIII"], "name": "Putative ketoacyl reductase", "drug_actions": []}, "P06653": {"specific_function": "Autolysins are involved in some important biological processes such as cell separation, cell-wall turnover, competence for genetic transformation, formation of the flagella and sporulation. Autolysin strictly depends on the presence of choline-containing cell walls for activity.", "general_function": "N-acetylmuramoyl-l-alanine amidase activity", "gene_names": ["lytA"], "name": "Autolysin", "drug_actions": []}, "O32723": {"specific_function": "In the phosphorylated form it could act as an anti-anti-sigma factor that counteracts SpoIIAB and thus releases sigma f from inhibition.", "gene_names": ["spoIIAA"], "name": "Anti-sigma F factor antagonist", "drug_actions": []}, "O30527": {"gene_names": ["pcrV"], "name": "Low calcium response locus protein V", "drug_actions": []}, "P0AFK9": {"specific_function": "Required for the activity of the bacterial periplasmic transport system of putrescine and spermidine. Polyamine binding protein.", "general_function": "Polyamine-transporting atpase activity", "gene_names": ["potD"], "name": "Spermidine/putrescine-binding periplasmic protein", "drug_actions": []}, "P52848": {"specific_function": "Essential bifunctional enzyme that catalyzes both the N-deacetylation and the N-sulfation of glucosamine (GlcNAc) of the glycosaminoglycan in heparan sulfate. Modifies the GlcNAc-GlcA disaccharide repeating sugar backbone to make N-sulfated heparosan, a prerequisite substrate for later modifications in heparin biosynthesis. Plays a role in determining the extent and pattern of sulfation of heparan sulfate. Compared to other NDST enzymes, its presence is absolutely required. Participates in biosynthesis of heparan sulfate that can ultimately serve as L-selectin ligands, thereby playing a role in inflammatory response.", "general_function": "Deacetylase activity", "gene_names": ["NDST1"], "name": "Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1", "drug_actions": []}, "P61457": {"specific_function": "Involved in tetrahydrobiopterin biosynthesis. Seems to both prevent the formation of 7-pterins and accelerate the formation of quinonoid-BH2. Coactivator for HNF1A-dependent transcription. Regulates the dimerization of homeodomain protein HNF1A and enhances its transcriptional activity.", "general_function": "Transcription coactivator activity", "gene_names": ["PCBD1"], "name": "Pterin-4-alpha-carbinolamine dehydratase", "drug_actions": []}, "Q86VB7": {"specific_function": "Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron, via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization, inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.After shedding, the soluble form (sCD163) may play an anti-inflammatory role, and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.", "general_function": "Scavenger receptor activity", "gene_names": ["CD163"], "name": "Scavenger receptor cysteine-rich type 1 protein M130", "drug_actions": []}, "P24298": {"specific_function": "Catalyzes the reversible transamination between alanine and 2-oxoglutarate to form pyruvate and glutamate. Participates in cellular nitrogen metabolism and also in liver gluconeogenesis starting with precursors transported from skeletal muscles (By similarity).", "general_function": "Pyridoxal phosphate binding", "gene_names": ["GPT"], "name": "Alanine aminotransferase 1", "drug_actions": [{"action": "COFACTOR", "target": "P24298", "drug": "DB00114"}, {"action": "INHIBITOR", "target": "P24298", "drug": "DB00780"}]}, "P29074": {"specific_function": "May act at junctions between the membrane and the cytoskeleton.", "general_function": "Non-membrane spanning protein tyrosine phosphatase activity", "gene_names": ["PTPN4"], "name": "Tyrosine-protein phosphatase non-receptor type 4", "drug_actions": [{"action": "INHIBITOR", "target": "P29074", "drug": "DB00630"}]}, "Q01234": {"specific_function": "Reduction of a variety of nitroaromatic compounds using NADH (and to lesser extent NADPH) as source of reducing equivalents; two electrons are transferred.", "general_function": "Oxidoreductase activity", "gene_names": ["nfsB"], "name": "Oxygen-insensitive NAD(P)H nitroreductase", "drug_actions": []}, "Q59643": {"specific_function": "Catalyzes an early step in the biosynthesis of tetrapyrroles. Binds two molecules of 5-aminolevulinate per subunit, each at a distinct site, and catalyzes their condensation to form porphobilinogen (By similarity).", "general_function": "Zinc ion binding", "gene_names": ["hemB"], "name": "Delta-aminolevulinic acid dehydratase", "drug_actions": []}, "P28074": {"specific_function": "The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This unit is responsible of the chymotrypsin-like activity of the proteasome and is one of the principal target of the proteasome inhibitor bortezomib. May catalyze basal processing of intracellular antigens. Plays a role in the protection against oxidative damage through the Nrf2-ARE pathway (By similarity).", "general_function": "Threonine-type endopeptidase activity", "gene_names": ["PSMB5"], "name": "Proteasome subunit beta type-5", "drug_actions": [{"action": "ANTAGONIST", "target": "P28074", "drug": "DB00188"}, {"action": "INHIBITOR", "target": "P28074", "drug": "DB08889"}]}, "Q9ZLT0": {"specific_function": "Provides the (R)-glutamate required for cell wall biosynthesis.", "general_function": "Glutamate racemase activity", "gene_names": ["murI"], "name": "Glutamate racemase", "drug_actions": []}, "P02776": {"specific_function": "Released during platelet aggregation. Neutralizes the anticoagulant effect of heparin because it binds more strongly to heparin than to the chondroitin-4-sulfate chains of the carrier molecule. Chemotactic for neutrophils and monocytes. Inhibits endothelial cell proliferation, the short form is a more potent inhibitor than the longer form.", "general_function": "Heparin binding", "gene_names": ["PF4"], "name": "Platelet factor 4", "drug_actions": []}, "P28070": {"specific_function": "The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. Mediates the lipopolysaccharide-induced signal macrophage proteasome (By similarity). SMAD1/OAZ1/PSMB4 complex mediates the degradation of the CREBBP/EP300 repressor SNIP1.", "general_function": "Threonine-type endopeptidase activity", "gene_names": ["PSMB4"], "name": "Proteasome subunit beta type-4", "drug_actions": []}, "P0C188": {"specific_function": "The transhydrogenation between NADH and NADP is coupled to respiration and ATP hydrolysis and functions as a proton pump across the membrane.", "general_function": "Nadp binding", "gene_names": ["pntB"], "name": "NAD(P) transhydrogenase subunit beta", "drug_actions": []}, "P28072": {"specific_function": "The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This unit is responsible of the peptidyl glutamyl-like activity. May catalyze basal processing of intracellular antigens.", "general_function": "Threonine-type endopeptidase activity", "gene_names": ["PSMB6"], "name": "Proteasome subunit beta type-6", "drug_actions": []}, "P29894": {"specific_function": "Methylamine dehydrogenase carries out the oxidation of methylamine. Electrons are passed from methylamine dehydrogenase to amicyanin.", "general_function": "Methylamine dehydrogenase (amicyanin) activity", "gene_names": ["mauB"], "name": "Methylamine dehydrogenase heavy chain", "drug_actions": []}, "P31572": {"specific_function": "Catalyzes the reversible transfer of the CoA moiety from gamma-butyrobetainyl-CoA to L-carnitine to generate L-carnitinyl-CoA and gamma-butyrobetaine. Is also able to catalyze the reversible transfer of the CoA moiety from gamma-butyrobetainyl-CoA or L-carnitinyl-CoA to crotonobetaine to generate crotonobetainyl-CoA.", "general_function": "Coa-transferase activity", "gene_names": ["caiB"], "name": "L-carnitine CoA-transferase", "drug_actions": []}, "P00959": {"specific_function": "Is required not only for elongation of protein synthesis but also for the initiation of all mRNA translation through initiator tRNA(fMet) aminoacylation.", "general_function": "Zinc ion binding", "gene_names": ["metG"], "name": "Methionine--tRNA ligase", "drug_actions": []}, "P96965": {"general_function": "Hydrolase activity", "gene_names": ["cumD"], "name": "2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase", "drug_actions": []}, "P00914": {"specific_function": "Involved in repair of UV radiation-induced DNA damage. Catalyzes the light-dependent monomerization (300-600 nm) of cyclobutyl pyrimidine dimers (in cis-syn configuration), which are formed between adjacent bases on the same DNA strand upon exposure to ultraviolet radiation.", "general_function": "Nucleotide binding", "gene_names": ["phrB"], "name": "Deoxyribodipyrimidine photo-lyase", "drug_actions": []}, "P17540": {"specific_function": "Reversibly catalyzes the transfer of phosphate between ATP and various phosphogens (e.g. creatine phosphate). Creatine kinase isoenzymes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, brain and spermatozoa.", "general_function": "Creatine kinase activity", "gene_names": ["CKMT2"], "name": "Creatine kinase S-type, mitochondrial", "drug_actions": [{"action": "LIGAND", "target": "P17540", "drug": "DB00148"}]}, "P01178": {"specific_function": "Neurophysin 1 specifically binds oxytocin.Oxytocin causes contraction of the smooth muscle of the uterus and of the mammary gland.", "gene_names": ["OXT"], "name": "Oxytocin-neurophysin 1", "drug_actions": [{"action": "BINDER", "target": "P01178", "drug": "DB00107"}]}, "P29899": {"specific_function": "Electron acceptor for MDH. Acts in methanol oxidation.", "general_function": "Iron ion binding", "gene_names": ["moxG"], "name": "Cytochrome c-L", "drug_actions": []}, "P00953": {"general_function": "Tryptophan-trna ligase activity", "gene_names": ["trpS"], "name": "Tryptophan--tRNA ligase", "drug_actions": [{"action": "INHIBITOR", "target": "P00953", "drug": "DB00150"}]}, "Q9Y345": {"specific_function": "Terminates the action of glycine by its high affinity sodium-dependent reuptake into presynaptic terminals. May be responsible for the termination of neurotransmission at strychnine-sensitive glycinergic synapses.", "general_function": "Neurotransmitter:sodium symporter activity", "gene_names": ["SLC6A5"], "name": "Sodium- and chloride-dependent glycine transporter 2", "drug_actions": []}, "O60568": {"specific_function": "Forms hydroxylysine residues in -Xaa-Lys-Gly- sequences in collagens. These hydroxylysines serve as sites of attachment for carbohydrate units and are essential for the stability of the intermolecular collagen cross-links.", "general_function": "Procollagen-lysine 5-dioxygenase activity", "gene_names": ["PLOD3"], "name": "Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3", "drug_actions": []}, "P28472": {"specific_function": "Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.", "name": "Gamma-aminobutyric acid receptor subunit beta-3", "drug_actions": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00228"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00237"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00292"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00349"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00404"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00475"}, {"action": "BINDER", "target": "P28472", "drug": "DB00543"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB00546"}, {"action": "AGONIST", "target": "P28472", "drug": "DB00592"}, {"action": "AGONIST", "target": "P28472", "drug": "DB00602"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00628"}, {"action": "POSITIVE MODULATOR", "target": "P28472", "drug": "DB00659"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB00690"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00753"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00794"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00818"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB00829"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01028"}, {"action": "AGONIST", "target": "P28472", "drug": "DB01049"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01205"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01236"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01437"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB01589"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "P28472", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB01595"}, {"action": "ANTAGONIST", "target": "P28472", "drug": "DB01708"}, {"action": "POTENTIATOR", "target": "P28472", "drug": "DB06716"}], "general_function": "Gaba-gated chloride ion channel activity", "in_complexes": ["GABA-A receptor (anion channel)"], "gene_names": ["GABRB3"]}, "Q08426": {"general_function": "Receptor binding", "gene_names": ["EHHADH"], "name": "Peroxisomal bifunctional enzyme", "drug_actions": []}, "P28476": {"specific_function": "GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.", "general_function": "Gaba-a receptor activity", "gene_names": ["GABRR2"], "name": "Gamma-aminobutyric acid receptor subunit rho-2", "drug_actions": [{"action": "POTENTIATOR", "target": "P28476", "drug": "DB00231"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB00546"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB00690"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB00801"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB00897"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB01215"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB01558"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB01559"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB01567"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB01588"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB01594"}, {"action": "POTENTIATOR", "target": "P28476", "drug": "DB01595"}]}, "Q84HQ2": {"general_function": "Sucrose phosphorylase activity", "gene_names": ["sucP"], "name": "Sucrose phosphorylase", "drug_actions": []}, "P63151": {"specific_function": "The B regulatory subunit might modulate substrate selectivity and catalytic activity, and also might direct the localization of the catalytic enzyme to a particular subcellular compartment.", "general_function": "Protein serine/threonine phosphatase activity", "gene_names": ["PPP2R2A"], "name": "Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform", "drug_actions": []}, "P20292": {"specific_function": "Required for leukotriene biosynthesis by ALOX5 (5-lipoxygenase). Anchors ALOX5 to the membrane. Binds arachidonic acid, and could play an essential role in the transfer of arachidonic acid to ALOX5. Binds to MK-886, a compound that blocks the biosynthesis of leukotrienes.", "general_function": "Protein n-terminus binding", "gene_names": ["ALOX5AP"], "name": "Arachidonate 5-lipoxygenase-activating protein", "drug_actions": []}, "O95865": {"specific_function": "Hydrolyzes N(G),N(G)-dimethyl-L-arginine (ADMA) and N(G)-monomethyl-L-arginine (MMA) which act as inhibitors of NOS. Has therefore a role in the regulation of nitric oxide generation.", "general_function": "Dimethylargininase activity", "gene_names": ["DDAH2"], "name": "N(G),N(G)-dimethylarginine dimethylaminohydrolase 2", "drug_actions": []}, "O95864": {"specific_function": "Component of a lipid metabolic pathway that catalyzes biosynthesis of highly unsaturated fatty acids (HUFA) from precursor essential polyunsaturated fatty acids (PUFA) linoleic acid (LA) (18:2n-6) and alpha-linolenic acid (ALA) (18:3n-3). Catalyzes the first and rate limiting step in this pathway which is the desaturation of LA (18:2n-6) and ALA (18:3n-3) into gamma-linoleic acid (GLA) (18:3n-6) and stearidonic acid (18:4n-3) respectively and other desaturation steps. Highly unsaturated fatty acids (HUFA) play pivotal roles in many biological functions. It catalizes as well the introduction of a cis double bond in palmitate to produce the mono-unsaturated fatty acid sapienate, the most abundant fatty acid in sebum.", "general_function": "Stearoyl-coa 9-desaturase activity", "gene_names": ["FADS2"], "name": "Fatty acid desaturase 2", "drug_actions": [{"action": "LIGAND", "target": "O95864", "drug": "DB00132"}]}, "O15269": {"specific_function": "Serine palmitoyltransferase (SPT). The heterodimer formed with SPTLC2 or SPTLC3 constitutes the catalytic core. The composition of the serine palmitoyltransferase (SPT) complex determines the substrate preference. The SPTLC1-SPTLC2-SPTSSA complex shows a strong preference for C16-CoA substrate, while the SPTLC1-SPTLC3-SPTSSA isozyme uses both C14-CoA and C16-CoA as substrates, with a slight preference for C14-CoA. The SPTLC1-SPTLC2-SPTSSB complex shows a strong preference for C18-CoA substrate, while the SPTLC1-SPTLC3-SPTSSB isozyme displays an ability to use a broader range of acyl-CoAs, without apparent preference.", "general_function": "Serine c-palmitoyltransferase activity", "gene_names": ["SPTLC1"], "name": "Serine palmitoyltransferase 1", "drug_actions": [{"action": "COFACTOR", "target": "O15269", "drug": "DB00114"}]}, "P62662": {"specific_function": "Spans the head-body hinge region of the 30S subunit. Is loosely associated with the 30S subunit (By similarity).", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsB"], "name": "30S ribosomal protein S2", "drug_actions": []}, "Q13936": {"specific_function": "Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin-GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing the alpha-1C subunit play an important role in excitation-contraction coupling in the heart. The various isoforms display marked differences in the sensitivity to DHP compounds. Binding of calmodulin or CABP1 at the same regulatory sites results in an opposit effects on the channel function.", "name": "Voltage-dependent L-type calcium channel subunit alpha-1C", "drug_actions": [{"action": "INHIBITOR", "target": "Q13936", "drug": "DB00270"}, {"action": "ACTIVATOR", "target": "Q13936", "drug": "DB00308"}, {"action": "INHIBITOR", "target": "Q13936", "drug": "DB00381"}, {"action": "INHIBITOR", "target": "Q13936", "drug": "DB00393"}, {"action": "INHIBITOR", "target": "Q13936", "drug": "DB00401"}, {"action": "INHIBITOR", "target": "Q13936", "drug": "DB00568"}, {"action": "INHIBITOR", "target": "Q13936", "drug": "DB00622"}, {"action": "INHIBITOR", "target": "Q13936", "drug": "DB00661"}, {"action": "INHIBITOR", "target": "Q13936", "drug": "DB01023"}, {"action": "INHIBITOR", "target": "Q13936", "drug": "DB01054"}, {"action": "INHIBITOR", "target": "Q13936", "drug": "DB01115"}, {"action": "LIGAND", "target": "Q13936", "drug": "DB01373"}, {"action": "INHIBITOR", "target": "Q13936", "drug": "DB01388"}, {"action": "INHIBITOR", "target": "Q13936", "drug": "DB06712"}, {"action": "INHIBITOR", "target": "Q13936", "drug": "DB06751"}], "general_function": "Voltage-gated calcium channel activity", "in_complexes": ["Voltage-dependent calcium channel"], "gene_names": ["CACNA1C"]}, "P62663": {"specific_function": "Binds the lower part of the 30S subunit head. Binds mRNA in the 70S ribosome, positioning it for translation (By similarity).", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsC"], "name": "30S ribosomal protein S3", "drug_actions": []}, "P39767": {"specific_function": "Forms channels that allow the passive diffusion of small hydrophilic solutes up to an exclusion limit of about 0.6 kDa.", "general_function": "Porin activity", "gene_names": ["opmA"], "name": "Porin", "drug_actions": []}, "O15264": {"specific_function": "Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK13 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors such as ELK1 and ATF2. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. MAPK13 is one of the less studied p38 MAPK isoforms. Some of the targets are downstream kinases such as MAPKAPK2, which are activated through phosphorylation and further phosphorylate additional targets. Plays a role in the regulation of protein translation by phosphorylating and inactivating EEF2K. Involved in cytoskeletal remodeling through phosphorylation of MAPT and STMN1. Mediates UV irradiation induced up-regulation of the gene expression of CXCL14. Plays an important role in the regulation of epidermal keratinocyte differentiation, apoptosis and skin tumor development. Phosphorylates the transcriptional activator MYB in response to stress which leads to rapid MYB degradation via a proteasome-dependent pathway. MAPK13 also phosphorylates and down-regulates PRKD1 during regulation of insulin secretion in pancreatic beta cells.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["MAPK13"], "name": "Mitogen-activated protein kinase 13", "drug_actions": []}, "O34928": {"specific_function": "Catalyzes the deacetylation of N-acetylmuramic acid (MurNAc) residues in glycan strands of peptidoglycan, leading to the formation of muramic delta-lactam residues in spore cortex, after transpeptidation of deacetylated muramic acid residues. PdaA probably carries out both deacetylation and lactam ring formation and requires the product of CwlD activity on peptidoglycan as a substrate. Is required for germination. Cannot use chitin oligomer (hexa-N-acetylchitohexaose) as a substrate.", "general_function": "Metal ion binding", "gene_names": ["pdaA"], "name": "Peptidoglycan-N-acetylmuramic acid deacetylase PdaA", "drug_actions": []}, "Q7RTV2": {"general_function": "Glutathione transferase activity", "gene_names": ["GSTA5"], "name": "Glutathione S-transferase A5", "drug_actions": []}, "P33981": {"specific_function": "Phosphorylates proteins on serine, threonine, and tyrosine. Probably associated with cell proliferation. Essential for chromosome alignment by enhancing AURKB activity (via direct CDCA8 phosphorylation) at the centromere, and for the mitotic checkpoint.", "general_function": "Protein tyrosine kinase activity", "gene_names": ["TTK"], "name": "Dual specificity protein kinase TTK", "drug_actions": []}, "Q72JD8": {"general_function": "Metal ion binding", "gene_names": [], "name": "Hypothetical conserved protein", "drug_actions": []}, "Q5KWF3": {"gene_names": [], "name": "Hypothetical conserved protein", "drug_actions": []}, "O95881": {"specific_function": "Possesses significant protein thiol-disulfide oxidase activity.", "general_function": "Protein-disulfide reductase (glutathione) activity", "gene_names": ["TXNDC12"], "name": "Thioredoxin domain-containing protein 12", "drug_actions": []}, "P08164": {"specific_function": "Catalyzes a key step in NAD biosynthesis, transforming deamido-NAD into NAD by a two-step reaction.", "general_function": "Nad+ synthase activity", "gene_names": ["nadE"], "name": "NH(3)-dependent NAD(+) synthetase", "drug_actions": []}, "P53004": {"specific_function": "Reduces the gamma-methene bridge of the open tetrapyrrole, biliverdin IX alpha, to bilirubin with the concomitant oxidation of a NADH or NADPH cofactor.", "general_function": "Zinc ion binding", "gene_names": ["BLVRA"], "name": "Biliverdin reductase A", "drug_actions": []}, "Q48255": {"specific_function": "Catalyzes a trans-dehydration via an enolate intermediate.", "general_function": "3-dehydroquinate dehydratase activity", "gene_names": ["aroQ"], "name": "3-dehydroquinate dehydratase", "drug_actions": []}, "P81006": {"specific_function": "Rather more predominant for the cleavage of aryl- than for alkyl-hydantoin derivatives. The stereoselectivity of this enzyme depends on the substrate used for bioconversion: strictly L-selective for the cleavage of D,L-5-indolylmethylhydantoin, but D-selective for the hydrolysis of D,L-methylthioethylhydantoin.", "general_function": "Zinc ion binding", "gene_names": ["lhyD"], "name": "L-hydantoinase", "drug_actions": []}, "P0A7U3": {"specific_function": "In the E.coli 70S ribosome in the initiation state (PubMed:12809609) it has been modeled to contact the 23S rRNA of the 50S subunit forming part of bridge B1a; this bridge is broken in the model with bound EF-G. The 23S rRNA contact site in bridge B1a is modeled to differ in different ribosomal states (PubMed:12859903), contacting alternately S13 or S19. In the 3.5 angstroms resolved ribosome structures (PubMed:16272117) the contacts between L5, S13 and S19 bridge B1b are different, confirming the dynamic nature of this interaction. Bridge B1a is not visible in the crystallized ribosomes due to 23S rRNA disorder.Protein S19 forms a complex with S13 that binds strongly to the 16S ribosomal RNA. Contacts the A site tRNA.", "general_function": "Trna binding", "gene_names": ["rpsS"], "name": "30S ribosomal protein S19", "drug_actions": [{"action": "ADDUCT", "target": "P0A7U3", "drug": "DB00560"}, {"action": "INHIBITOR", "target": "P0A7U3", "drug": "DB00759"}]}, "Q00740": {"specific_function": "Catalyzes a cyclopropane ring-opening reaction, the irreversible conversion of 1-aminocyclopropane-1-carboxylate (ACC) to ammonia and alpha-ketobutyrate. Allows growth on ACC as a nitrogen source.", "general_function": "Pyridoxal phosphate binding", "gene_names": ["acdS"], "name": "1-aminocyclopropane-1-carboxylate deaminase", "drug_actions": []}, "P18314": {"general_function": "Urease activity", "gene_names": ["ureC"], "name": "Urease subunit alpha", "drug_actions": [{"action": "INHIBITOR", "target": "P18314", "drug": "DB00551"}, {"action": "INHIBITOR", "target": "P18314", "drug": "DB05265"}]}, "Q8NBN7": {"specific_function": "Does not exhibit retinol dehydrogenase (RDH) activity in vitro.", "general_function": "Oxidoreductase activity", "gene_names": ["RDH13"], "name": "Retinol dehydrogenase 13", "drug_actions": []}, "P35270": {"specific_function": "Catalyzes the final one or two reductions in tetra-hydrobiopterin biosynthesis to form 5,6,7,8-tetrahydrobiopterin.", "general_function": "Sepiapterin reductase activity", "gene_names": ["SPR"], "name": "Sepiapterin reductase", "drug_actions": []}, "Q14494": {"specific_function": "Activates erythroid-specific, globin gene expression.", "general_function": "Transcriptional activator activity, rna polymerase ii transcription factor binding", "gene_names": ["NFE2L1"], "name": "Nuclear factor erythroid 2-related factor 1", "drug_actions": []}, "Q9NVS9": {"specific_function": "Catalyzes the oxidation of either pyridoxine 5'-phosphate (PNP) or pyridoxamine 5'-phosphate (PMP) into pyridoxal 5'-phosphate (PLP).", "general_function": "Pyridoxamine-phosphate oxidase activity", "gene_names": ["PNPO"], "name": "Pyridoxine-5'-phosphate oxidase", "drug_actions": [{"action": "COFACTOR", "target": "Q9NVS9", "drug": "DB00114"}]}, "P01552": {"specific_function": "Staphylococcal enterotoxins cause the intoxication staphylococcal food poisoning syndrome. The illness characterized by high fever, hypotension, diarrhea, shock, and in some cases death.", "gene_names": ["entB"], "name": "Enterotoxin type B", "drug_actions": []}, "P0A921": {"specific_function": "Has broad substrate specificity including hydrolysis of phosphatidylcholine with phospholipase A2 (EC 3.1.1.4) and phospholipase A1 (EC 3.1.1.32) activities. Strong expression leads to outer membrane breakdown and cell death; is dormant in normal growing cells. Required for efficient secretion of bacteriocins.", "general_function": "Protein homodimerization activity", "gene_names": ["pldA"], "name": "Phospholipase A1", "drug_actions": []}, "P06276": {"specific_function": "Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.", "general_function": "Identical protein binding", "gene_names": ["BCHE"], "name": "Cholinesterase", "drug_actions": [{"action": "PRODUCT OF", "target": "P06276", "drug": "DB00122"}, {"action": "INHIBITOR", "target": "P06276", "drug": "DB00382"}, {"action": "POTENTIATOR", "target": "P06276", "drug": "DB00449"}, {"action": "ANTAGONIST", "target": "P06276", "drug": "DB00545"}, {"action": "INHIBITOR", "target": "P06276", "drug": "DB00674"}, {"action": "INHIBITOR", "target": "P06276", "drug": "DB00677"}, {"action": "ACTIVATOR", "target": "P06276", "drug": "DB00733"}, {"action": "INHIBITOR", "target": "P06276", "drug": "DB00772"}, {"action": "INHIBITOR", "target": "P06276", "drug": "DB00941"}, {"action": "INHIBITOR", "target": "P06276", "drug": "DB00944"}, {"action": "INHIBITOR", "target": "P06276", "drug": "DB00989"}, {"action": "INHIBITOR", "target": "P06276", "drug": "DB01010"}, {"action": "INHIBITOR", "target": "P06276", "drug": "DB01057"}, {"action": "INHIBITOR", "target": "P06276", "drug": "DB04892"}]}, "P04392": {"specific_function": "Methyltransferase that methylates adenine residues in the dsDNA sequence GATC. May prevents degradation of viral DNA by the host restriction-modification antiviral defense system.", "general_function": "Site-specific dna-methyltransferase (adenine-specific) activity", "gene_names": ["DAM"], "name": "DNA adenine methylase", "drug_actions": []}, "Q9H3N8": {"specific_function": "The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist).", "general_function": "Histamine receptor activity", "gene_names": ["HRH4"], "name": "Histamine H4 receptor", "drug_actions": [{"action": "BINDER", "target": "Q9H3N8", "drug": "DB00321"}, {"action": "ANTAGONIST", "target": "Q9H3N8", "drug": "DB00334"}, {"action": "ANTAGONIST", "target": "Q9H3N8", "drug": "DB00363"}, {"action": "BINDER", "target": "Q9H3N8", "drug": "DB00408"}, {"action": "BINDER", "target": "Q9H3N8", "drug": "DB00477"}, {"action": "BINDER", "target": "Q9H3N8", "drug": "DB00543"}, {"action": "AGONIST", "target": "Q9H3N8", "drug": "DB00667"}, {"action": "BINDER", "target": "Q9H3N8", "drug": "DB01142"}, {"action": "BINDER", "target": "Q9H3N8", "drug": "DB06148"}]}, "P04390": {"specific_function": "Recognizes the double-stranded sequence GATATC and cleaves after T-3.", "general_function": "Type ii site-specific deoxyribonuclease activity", "gene_names": ["ecoRVR"], "name": "Type-2 restriction enzyme EcoRV", "drug_actions": []}, "P04391": {"specific_function": "Reversibly catalyzes the transfer of the carbamoyl group from carbamoyl phosphate (CP) to the N(epsilon) atom of ornithine (ORN) to produce L-citrulline, which is a substrate for argininosuccinate synthetase, the enzyme involved in the final step in arginine biosynthesis.", "general_function": "Ornithine carbamoyltransferase activity", "gene_names": ["argI"], "name": "Ornithine carbamoyltransferase chain I", "drug_actions": []}, "O60674": {"specific_function": "Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain. Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation. Plays a role in cell cycle by phosphorylating CDKN1B. Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin.", "general_function": "Sh2 domain binding", "gene_names": ["JAK2"], "name": "Tyrosine-protein kinase JAK2", "drug_actions": [{"action": "INHIBITOR", "target": "O60674", "drug": "DB08877"}, {"action": "INHIBITOR", "target": "O60674", "drug": "DB08895"}]}, "P17948": {"specific_function": "Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts (in vitro). Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Likewise, isoforms lacking a transmembrane domain, such as isoform 2, isoform 3 and isoform 4, may function as decoy receptors for VEGFA. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates SRC and YES1, and may also phosphorylate CBL. Isoform 1 phosphorylates PLCG. Promotes phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of PTK2/FAK1. Isoform 7 has a truncated kinase domain; it increases phosphorylation of SRC at 'Tyr-418' by unknown means and promotes tumor cell invasion.", "general_function": "Vegf-b-activated receptor activity", "gene_names": ["FLT1"], "name": "Vascular endothelial growth factor receptor 1", "drug_actions": [{"action": "INHIBITOR", "target": "P17948", "drug": "DB00398"}, {"action": "ANTAGONIST", "target": "P17948", "drug": "DB01268"}, {"action": "INHIBITOR", "target": "P17948", "drug": "DB06589"}, {"action": "INHIBITOR", "target": "P17948", "drug": "DB06626"}, {"action": "INHIBITOR", "target": "P17948", "drug": "DB08896"}, {"action": "INHIBITOR", "target": "P17948", "drug": "DB09078"}, {"action": "INHIBITOR", "target": "P17948", "drug": "DB09079"}]}, "P0ABA0": {"specific_function": "F(1)F(0) ATP synthase produces ATP from ADP in the presence of a proton or sodium gradient. F-type ATPases consist of two structural domains, F(1) containing the extramembraneous catalytic core and F(0) containing the membrane proton channel, linked together by a central stalk and a peripheral stalk. During catalysis, ATP synthesis in the catalytic domain of F(1) is coupled via a rotary mechanism of the central stalk subunits to proton translocation.Component of the F(0) channel, it forms part of the peripheral stalk, linking F(1) to F(0).", "general_function": "Proton-transporting atpase activity, rotational mechanism", "gene_names": ["atpF"], "name": "ATP synthase subunit b", "drug_actions": []}, "Q56320": {"general_function": "Phosphoribosylanthranilate isomerase activity", "gene_names": ["trpF"], "name": "N-(5'-phosphoribosyl)anthranilate isomerase", "drug_actions": []}, "P03437": {"specific_function": "Binds to sialic acid-containing receptors on the cell surface, bringing about the attachment of the virus particle to the cell. This attachment induces virion internalization of about two third of the virus particles through clathrin-dependent endocytosis and about one third through a clathrin- and caveolin-independent pathway. Plays a major role in the determination of host range restriction and virulence. Class I viral fusion protein. Responsible for penetration of the virus into the cell cytoplasm by mediating the fusion of the membrane of the endocytosed virus particle with the endosomal membrane. Low pH in endosomes induces an irreversible conformational change in HA2, releasing the fusion hydrophobic peptide. Several trimers are required to form a competent fusion pore.", "gene_names": ["HA"], "name": "Hemagglutinin", "drug_actions": []}, "Q9ZHG9": {"general_function": "Lyase activity", "gene_names": ["c-des"], "name": "L-cysteine/cystine lyase C-DES", "drug_actions": []}, "P21462": {"specific_function": "High affinity receptor for N-formyl-methionyl peptides (fMLP), which are powerful neutrophil chemotactic factors (PubMed:2161213, PubMed:2176894, PubMed:10514456, PubMed:15153520). Binding of fMLP to the receptor stimulates intracellular calcium mobilization and superoxide anion release (PubMed:2161213, PubMed:1712023, PubMed:15153520). This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system (PubMed:1712023, PubMed:10514456).", "general_function": "Receptor activity", "gene_names": ["FPR1"], "name": "fMet-Leu-Phe receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "P21462", "drug": "DB00716"}]}, "P0A7E1": {"specific_function": "Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor.", "general_function": "Fmn binding", "gene_names": ["pyrD"], "name": "Dihydroorotate dehydrogenase (quinone)", "drug_actions": []}, "Q15080": {"specific_function": "Component of the NADPH-oxidase, a multicomponent enzyme system responsible for the oxidative burst in which electrons are transported from NADPH to molecular oxygen, generating reactive oxidant intermediates. It may be important for the assembly and/or activation of the NADPH-oxidase complex.", "name": "Neutrophil cytosol factor 4", "drug_actions": [{"action": "INHIBITOR", "target": "Q15080", "drug": "DB00514"}], "general_function": "Superoxide-generating nadph oxidase activator activity", "in_complexes": ["NADPH oxidase"], "gene_names": ["NCF4"]}, "Q8RLY5": {"general_function": "Nucleoside deoxyribosyltransferase activity", "gene_names": ["ptd"], "name": "Nucleoside 2-deoxyribosyltransferase", "drug_actions": []}, "Q8KN66": {"general_function": "Racemase and epimerase activity, acting on carbohydrates and derivatives", "gene_names": [], "name": "WbpP", "drug_actions": []}, "Q14289": {"specific_function": "Non-receptor protein-tyrosine kinase that regulates reorganization of the actin cytoskeleton, cell polarization, cell migration, adhesion, spreading and bone remodeling. Plays a role in the regulation of the humoral immune response, and is required for normal levels of marginal B-cells in the spleen and normal migration of splenic B-cells. Required for normal macrophage polarization and migration towards sites of inflammation. Regulates cytoskeleton rearrangement and cell spreading in T-cells, and contributes to the regulation of T-cell responses. Promotes osteoclastic bone resorption; this requires both PTK2B/PYK2 and SRC. May inhibit differentiation and activity of osteoprogenitor cells. Functions in signaling downstream of integrin and collagen receptors, immune receptors, G-protein coupled receptors (GPCR), cytokine, chemokine and growth factor receptors, and mediates responses to cellular stress. Forms multisubunit signaling complexes with SRC and SRC family members upon activation; this leads to the phosphorylation of additional tyrosine residues, creating binding sites for scaffold proteins, effectors and substrates. Regulates numerous signaling pathways. Promotes activation of phosphatidylinositol 3-kinase and of the AKT1 signaling cascade. Promotes activation of NOS3. Regulates production of the cellular messenger cGMP. Promotes activation of the MAP kinase signaling cascade, including activation of MAPK1/ERK2, MAPK3/ERK1 and MAPK8/JNK1. Promotes activation of Rho family GTPases, such as RHOA and RAC1. Recruits the ubiquitin ligase MDM2 to P53/TP53 in the nucleus, and thereby regulates P53/TP53 activity, P53/TP53 ubiquitination and proteasomal degradation. Acts as a scaffold, binding to both PDPK1 and SRC, thereby allowing SRC to phosphorylate PDPK1 at 'Tyr-9, 'Tyr-373', and 'Tyr-376'. Promotes phosphorylation of NMDA receptors by SRC family members, and thereby contributes to the regulation of NMDA receptor ion channel activity and intracellular Ca(2+) levels. May also regulate potassium ion transport by phosphorylation of potassium channel subunits. Phosphorylates SRC; this increases SRC kinase activity. Phosphorylates ASAP1, NPHP1, KCNA2 and SHC1. Promotes phosphorylation of ASAP2, RHOU and PXN; this requires both SRC and PTK2/PYK2.", "general_function": "Signal transducer activity", "gene_names": ["PTK2B"], "name": "Protein-tyrosine kinase 2-beta", "drug_actions": [{"action": "ANTAGONIST", "target": "Q14289", "drug": "DB01097"}]}, "Q99873": {"specific_function": "Arginine methyltransferase that methylates (mono and asymmetric dimethylation) the guanidino nitrogens of arginyl residues present in proteins such as ESR1, histone H2, H3 and H4, PIAS1, HNRNPA1, HNRNPD, NFATC2IP, SUPT5H, TAF15 and EWS. Constitutes the main enzyme that mediates monomethylation and asymmetric dimethylation of histone H4 'Arg-4' (H4R3me1 and H4R3me2a, respectively), a specific tag for epigenetic transcriptional activation. Together with dimethylated PIAS1, represses STAT1 transcriptional activity, in the late phase of interferon gamma (IFN-gamma) signaling. May be involved in the regulation of TAF15 transcriptional activity, act as an activator of estrogen receptor (ER)-mediated transactivation, play a key role in neurite outgrowth and act as a negative regulator of megakaryocytic differentiation, by modulating p38 MAPK pathway. Methylates FOXO1 and retains it in the nucleus increasing its transcriptional activity.", "general_function": "Protein-arginine omega-n asymmetric methyltransferase activity", "gene_names": ["PRMT1"], "name": "Protein arginine N-methyltransferase 1", "drug_actions": []}, "P42338": {"specific_function": "Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4-phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Involved in the activation of AKT1 upon stimulation by G-protein coupled receptors (GPCRs) ligands such as CXCL12, sphingosine 1-phosphate, and lysophosphatidic acid. May also act downstream receptor tyrosine kinases. Required in different signaling pathways for stable platelet adhesion and aggregation. Plays a role in platelet activation signaling triggered by GPCRs, alpha-IIb/beta-3 integrins (ITGA2B/ ITGB3) and ITAM (immunoreceptor tyrosine-based activation motif)-bearing receptors such as GP6. Regulates the strength of adhesion of ITGA2B/ ITGB3 activated receptors necessary for the cellular transmission of contractile forces. Required for platelet aggregation induced by F2 (thrombin) and thromboxane A2 (TXA2). Has a role in cell survival. May have a role in cell migration. Involved in the early stage of autophagosome formation. Modulates the intracellular level of PtdIns3P (Phosphatidylinositol 3-phosphate) and activates PIK3C3 kinase activity. May act as a scaffold, independently of its lipid kinase activity to positively regulate autophagy. May have a role in insulin signaling as scaffolding protein in which the lipid kinase activity is not required. May have a kinase-independent function in regulating cell proliferation and in clathrin-mediated endocytosis. Mediator of oncogenic signal in cell lines lacking PTEN. The lipid kinase activity is necessary for its role in oncogenic transformation. Required for the growth of ERBB2 and RAS driven tumors.", "general_function": "Phosphatidylinositol-4,5-bisphosphate 3-kinase activity", "gene_names": ["PIK3CB"], "name": "Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform", "drug_actions": []}, "P42336": {"specific_function": "Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4-phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Participates in cellular signaling in response to various growth factors. Involved in the activation of AKT1 upon stimulation by receptor tyrosine kinases ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in signaling via insulin-receptor substrate (IRS) proteins. Essential in endothelial cell migration during vascular development through VEGFA signaling, possibly by regulating RhoA activity. Required for lymphatic vasculature development, possibly by binding to RAS and by activation by EGF and FGF2, but not by PDGF. Regulates invadopodia formation in breast cancer cells through the PDPK1-AKT1 pathway. Participates in cardiomyogenesis in embryonic stem cells through a AKT1 pathway. Participates in vasculogenesis in embryonic stem cells through PDK1 and protein kinase C pathway. Has also serine-protein kinase activity: phosphorylates PIK3R1 (p85alpha regulatory subunit), EIF4EBP1 and HRAS.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["PIK3CA"], "name": "Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform", "drug_actions": []}, "P0A8V9": {"specific_function": "Multifunctional regulator of fatty acid metabolism.", "general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": ["fadR"], "name": "Fatty acid metabolism regulator protein", "drug_actions": []}, "Q9WZW1": {"general_function": "Riboflavin kinase activity", "gene_names": [], "name": "Riboflavin biosynthesis protein", "drug_actions": []}, "P45452": {"specific_function": "Plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN. Cleaves triple helical collagens, including type I, type II and type III collagen, but has the highest activity with soluble type II collagen. Can also degrade collagen type IV, type XIV and type X. May also function by activating or degrading key regulatory proteins, such as TGFB1 and CTGF. Plays a role in wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification. Required for normal embryonic bone development and ossification. Plays a role in the healing of bone fractures via endochondral ossification. Plays a role in wound healing, probably by a mechanism that involves proteolytic activation of TGFB1 and degradation of CTGF. Plays a role in keratinocyte migration during wound healing. May play a role in cell migration and in tumor cell invasion.", "general_function": "Zinc ion binding", "gene_names": ["MMP13"], "name": "Collagenase 3", "drug_actions": [{"action": "INHIBITOR", "target": "P45452", "drug": "DB00786"}]}, "P42330": {"specific_function": "Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone.", "general_function": "Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity", "gene_names": ["AKR1C3"], "name": "Aldo-keto reductase family 1 member C3", "drug_actions": [{"action": "INDUCER", "target": "P42330", "drug": "DB01536"}]}, "P24630": {"general_function": "Transaminase activity", "gene_names": ["hemL"], "name": "Glutamate-1-semialdehyde 2,1-aminomutase", "drug_actions": []}, "P0A7W7": {"specific_function": "One of the primary rRNA binding proteins, it binds directly to 16S rRNA central domain where it helps coordinate assembly of the platform of the 30S subunit.Protein S8 is a translational repressor protein, it controls the translation of the spc operon by binding to its mRNA.", "general_function": "Structural constituent of ribosome", "gene_names": ["rpsH"], "name": "30S ribosomal protein S8", "drug_actions": [{"action": "INHIBITOR", "target": "P0A7W7", "drug": "DB00759"}]}, "P72059": {"specific_function": "Arabinosyl transferase responsible for the polymerization of arabinose into the arabinan of arabinogalactan", "general_function": "Involved in transferase activity, transferring pentosyl groups", "gene_names": ["embC"], "name": "Probable arabinosyltransferase C", "drug_actions": [{"action": "INHIBITOR", "target": "P72059", "drug": "DB00330"}]}, "P83794": {"specific_function": "Component of the cytochrome b6-f complex, which mediates electron transfer between photosystem II (PSII) and photosystem I (PSI), cyclic electron flow around PSI, and state transitions.", "general_function": "Ubiquinol-cytochrome-c reductase activity", "gene_names": ["petC"], "name": "Cytochrome b6-f complex iron-sulfur subunit", "drug_actions": []}, "P30988": {"specific_function": "This is a receptor for calcitonin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The calcitonin receptor is thought to couple to the heterotrimeric guanosine triphosphate-binding protein that is sensitive to cholera toxin.", "general_function": "Receptor activity", "gene_names": ["CALCR"], "name": "Calcitonin receptor", "drug_actions": [{"action": "AGONIST", "target": "P30988", "drug": "DB00017"}, {"action": "AGONIST", "target": "P30988", "drug": "DB01278"}]}, "Q9BY41": {"specific_function": "Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Also involved in the deacetylation of cohesin complex protein SMC3 regulating release of cohesin complexes from chromatin. May play a role in smooth muscle cell contractility.", "general_function": "Transcription factor binding", "gene_names": ["HDAC8"], "name": "Histone deacetylase 8", "drug_actions": [{"action": "INHIBITOR", "target": "Q9BY41", "drug": "DB06603"}]}, "O07732": {"general_function": "Protein homodimerization activity", "gene_names": ["lipJ"], "name": "Cyclase", "drug_actions": []}, "P08546": {"specific_function": "Replicates viral genomic DNA in the late phase of lytic infection, producing long concatemeric DNA. The replication complex is composed of six viral proteins: the DNA polymerase, processivity factor, primase, primase-associated factor, helicase, and ssDNA-binding protein (By similarity).", "general_function": "Nucleotide binding", "gene_names": ["UL54"], "name": "DNA polymerase catalytic subunit", "drug_actions": [{"action": "INHIBITOR", "target": "P08546", "drug": "DB00369"}, {"action": "INHIBITOR", "target": "P08546", "drug": "DB00529"}]}, "P12883": {"specific_function": "Muscle contraction.", "general_function": "Microfilament motor activity", "gene_names": ["MYH7"], "name": "Myosin-7", "drug_actions": []}, "P83792": {"specific_function": "Component of the cytochrome b6-f complex, which mediates electron transfer between photosystem II (PSII) and photosystem I (PSI), cyclic electron flow around PSI, and state transitions.", "general_function": "Oxidoreductase activity", "gene_names": ["petD"], "name": "Cytochrome b6-f complex subunit 4", "drug_actions": []}, "P00734": {"specific_function": "Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.", "general_function": "Thrombospondin receptor activity", "gene_names": ["F2"], "name": "Prothrombin", "drug_actions": [{"action": "INHIBITOR", "target": "P00734", "drug": "DB00001"}, {"action": "INHIBITOR", "target": "P00734", "drug": "DB00006"}, {"action": "ACTIVATOR", "target": "P00734", "drug": "DB00170"}, {"action": "INHIBITOR", "target": "P00734", "drug": "DB00278"}, {"action": "OTHER/UNKNOWN", "target": "P00734", "drug": "DB01123"}, {"action": "INHIBITOR", "target": "P00734", "drug": "DB02351"}, {"action": "INHIBITOR", "target": "P00734", "drug": "DB04786"}, {"action": "INHIBITOR", "target": "P00734", "drug": "DB04898"}, {"action": "INHIBITOR", "target": "P00734", "drug": "DB06695"}]}, "P00736": {"specific_function": "C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system.", "general_function": "Serine-type peptidase activity", "gene_names": ["C1R"], "name": "Complement C1r subcomponent", "drug_actions": []}, "P09382": {"specific_function": "Lectin that binds beta-galactoside and a wide array of complex carbohydrates. Plays a role in regulating apoptosis, cell proliferation and cell differentiation. Inhibits CD45 protein phosphatase activity and therefore the dephosphorylation of Lyn kinase. Strong inducer of T-cell apoptosis.", "general_function": "Signal transducer activity", "gene_names": ["LGALS1"], "name": "Galectin-1", "drug_actions": []}, "P60176": {"specific_function": "S-adenosyl-L-homocysteine + H(2)O = L- homocysteine + adenosine", "general_function": "Coenzyme transport and metabolism", "gene_names": ["ahcY"], "name": "Adenosylhomocysteinase", "drug_actions": []}, "Q9X0V0": {"general_function": "Metal ion binding", "gene_names": [], "name": "Mannoside ABC transport system, sugar-binding protein", "drug_actions": []}, "P0CG47": {"specific_function": "Ubiquitin: Exists either covalently attached to another protein, or free (unanchored). When covalently bound, it is conjugated to target proteins via an isopeptide bond either as a monomer (monoubiquitin), a polymer linked via different Lys residues of the ubiquitin (polyubiquitin chains) or a linear polymer linked via the initiator Met of the ubiquitin (linear polyubiquitin chains). Polyubiquitin chains, when attached to a target protein, have different functions depending on the Lys residue of the ubiquitin that is linked: Lys-6-linked may be involved in DNA repair; Lys-11-linked is involved in ERAD (endoplasmic reticulum-associated degradation) and in cell-cycle regulation; Lys-29-linked is involved in lysosomal degradation; Lys-33-linked is involved in kinase modification; Lys-48-linked is involved in protein degradation via the proteasome; Lys-63-linked is involved in endocytosis, DNA-damage responses as well as in signaling processes leading to activation of the transcription factor NF-kappa-B. Linear polymer chains formed via attachment by the initiator Met lead to cell signaling. Ubiquitin is usually conjugated to Lys residues of target proteins, however, in rare cases, conjugation to Cys or Ser residues has been observed. When polyubiquitin is free (unanchored-polyubiquitin), it also has distinct roles, such as in activation of protein kinases, and in signaling.", "gene_names": ["UBB"], "name": "Polyubiquitin-B", "drug_actions": []}, "Q14571": {"specific_function": "Receptor for inositol 1,4,5-trisphosphate, a second messenger that mediates the release of intracellular calcium. This release is regulated by cAMP both dependently and independently of PKA (By similarity).", "name": "Inositol 1,4,5-trisphosphate receptor type 2", "drug_actions": [], "general_function": "Phosphatidylinositol binding", "in_complexes": ["Inositol 1,4,5-trisphosphate receptor"], "gene_names": ["ITPR2"]}, "P23234": {"general_function": "Thiamine pyrophosphate binding", "gene_names": ["ipdC"], "name": "Indole-3-pyruvate decarboxylase", "drug_actions": []}, "Q14573": {"specific_function": "Receptor for inositol 1,4,5-trisphosphate, a second messenger that mediates the release of intracellular calcium.", "name": "Inositol 1,4,5-trisphosphate receptor type 3", "drug_actions": [], "general_function": "Phosphatidylinositol binding", "in_complexes": ["Inositol 1,4,5-trisphosphate receptor"], "gene_names": ["ITPR3"]}, "O75936": {"specific_function": "Catalyzes the formation of L-carnitine from gamma-butyrobetaine.", "general_function": "Zinc ion binding", "gene_names": ["BBOX1"], "name": "Gamma-butyrobetaine dioxygenase", "drug_actions": []}, "Q9Z9H6": {"specific_function": "DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates.", "general_function": "Dna-directed rna polymerase activity", "gene_names": ["rpoA"], "name": "DNA-directed RNA polymerase subunit alpha", "drug_actions": []}, "Q46891": {"specific_function": "Catalyzes the reversible isomerization between hydroxypyruvate and 2-hydroxy-3-oxopropanoate (also termed tartronate semialdehyde).", "general_function": "Hydroxypyruvate isomerase activity", "gene_names": ["ygbM"], "name": "Putative hydroxypyruvate isomerase YgbM", "drug_actions": []}, "Q14376": {"specific_function": "Catalyzes two distinct but analogous reactions: the reversible epimerization of UDP-glucose to UDP-galactose and the reversible epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The reaction with UDP-Gal plays a critical role in the Leloir pathway of galactose catabolism in which galactose is converted to the glycolytic intermediate glucose 6-phosphate. It contributes to the catabolism of dietary galactose and enables the endogenous biosynthesis of both UDP-Gal and UDP-GalNAc when exogenous sources are limited. Both UDP-sugar interconversions are important in the synthesis of glycoproteins and glycolipids.", "general_function": "Udp-n-acetylglucosamine 4-epimerase activity", "gene_names": ["GALE"], "name": "UDP-glucose 4-epimerase", "drug_actions": []}, "P22455": {"specific_function": "Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling.", "general_function": "Protein tyrosine kinase activity", "gene_names": ["FGFR4"], "name": "Fibroblast growth factor receptor 4", "drug_actions": [{"action": "INHIBITOR", "target": "P22455", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P22455", "drug": "DB09078"}]}, "Q9Y5R8": {"specific_function": "May play a role in vesicular transport from endoplasmic reticulum to Golgi.", "general_function": "Rab guanyl-nucleotide exchange factor activity", "gene_names": ["TRAPPC1"], "name": "Trafficking protein particle complex subunit 1", "drug_actions": []}, "P43681": {"specific_function": "After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.", "general_function": "Ligand-gated ion channel activity", "gene_names": ["CHRNA4"], "name": "Neuronal acetylcholine receptor subunit alpha-4", "drug_actions": [{"action": "AGONIST", "target": "P43681", "drug": "DB00184"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00237"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00241"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00306"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00312"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00418"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00463"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00514"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00599"}, {"action": "ALLOSTERIC MODULATOR", "target": "P43681", "drug": "DB00674"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00794"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB00849"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB01174"}, {"action": "PARTIAL AGONIST", "target": "P43681", "drug": "DB01273"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB01351"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB01352"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB01353"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB01354"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB01355"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB01483"}, {"action": "ANTAGONIST", "target": "P43681", "drug": "DB01496"}, {"action": "AGONIST", "target": "P43681", "drug": "DB09028"}]}, "P0A721": {"specific_function": "Catalyzes the reversible phosphorylation of deoxythymidine monophosphate (dTMP) to deoxythymidine diphosphate (dTDP), using ATP as its preferred phosphoryl donor. Situated at the junction of both de novo and salvage pathways of deoxythymidine triphosphate (dTTP) synthesis, is essential for DNA synthesis and cellular growth (By similarity).", "general_function": "Thymidylate kinase activity", "gene_names": ["tmk"], "name": "Thymidylate kinase", "drug_actions": []}, "P43683": {"specific_function": "Kills a number of Gram-positive bacteria. Acts at the level of cell wall biosynthesis by interfering with bacterial peptidoglycan biosynthesis. Specifically inhibits the conversion of the lipid II intermediate into polymeric nascent glycan strands by transglycosylation. May interact with the peptidoglycan precursor rather than with the enzyme.", "gene_names": ["mrsA"], "name": "Lantibiotic mersacidin", "drug_actions": []}, "Q83LD8": {"specific_function": "Catalyzes the phosphorylation of the position 2 hydroxy group of 4-diphosphocytidyl-2C-methyl-D-erythritol.", "general_function": "Atp binding", "gene_names": ["ispE"], "name": "4-diphosphocytidyl-2-C-methyl-D-erythritol kinase", "drug_actions": []}, "Q13393": {"specific_function": "Implicated as a critical step in numerous cellular pathways, including signal transduction, membrane trafficking, and the regulation of mitosis. May be involved in the regulation of perinuclear intravesicular membrane traffic (By similarity).", "general_function": "Phospholipase d activity", "gene_names": ["PLD1"], "name": "Phospholipase D1", "drug_actions": [{"action": "PRODUCT OF", "target": "Q13393", "drug": "DB00122"}]}, "Q46893": {"specific_function": "Catalyzes the formation of 4-diphosphocytidyl-2-C-methyl-D-erythritol from CTP and 2-C-methyl-D-erythritol 4-phosphate (MEP).", "general_function": "Magnesium ion binding", "gene_names": ["ispD"], "name": "2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase", "drug_actions": []}, "Q7WT42": {"general_function": "Kinase activity", "gene_names": ["ppgmk"], "name": "Inorganic polyphosphate/ATP-glucomannokinase", "drug_actions": []}, "P0AF93": {"specific_function": "Accelerates the release of ammonia from reactive enamine/imine intermediates of the PLP-dependent threonine dehydratase (IlvA) in the low water environment of the cell. It catalyzes the deamination of enamine/imine intermediates to yield 2-ketobutyrate and ammonia. It is required for the detoxification of reactive intermediates of IlvA due to their highly nucleophilic abilities. Involved in the isoleucine biosynthesis (By similarity).", "general_function": "Unfolded protein binding", "gene_names": ["ridA"], "name": "2-iminobutanoate/2-iminopropanoate deaminase", "drug_actions": []}, "Q6ZQY3": {"specific_function": "May catalyze the decarboxylation of aspartate, cysteine sulfinic acid, and cysteic acid to beta-alanine, hypotaurine and taurine, respectively. Does not exhibit any decarboxylation activity toward glutamate.", "general_function": "Sulfinoalanine decarboxylase activity", "gene_names": ["GADL1"], "name": "Acidic amino acid decarboxylase GADL1", "drug_actions": [{"action": "COFACTOR", "target": "Q6ZQY3", "drug": "DB00114"}]}, "P95276": {"general_function": "Protein homodimerization activity", "gene_names": [], "name": "Epoxide hydrolase", "drug_actions": []}, "Q9X0D0": {"general_function": "Pyridoxal phosphate binding", "gene_names": ["hisC"], "name": "Histidinol-phosphate aminotransferase", "drug_actions": []}, "Q05599": {"specific_function": "Catalyzes ATP-dependent phosphorylation of adenosylcobinamide and addition of GMP to adenosylcobinamide phosphate.", "general_function": "Gtp binding", "gene_names": ["cobU"], "name": "Bifunctional adenosylcobalamin biosynthesis protein CobU", "drug_actions": []}, "P32056": {"specific_function": "Hydrolyzes both GDP-mannose and GDP-glucose. Could participate in the regulation of cell wall biosynthesis by influencing the concentration of GDP-mannose or GDP-glucose in the cell. Might also be involved in the biosynthesis of the slime polysaccharide colanic acid.", "general_function": "Manganese ion binding", "gene_names": ["gmm"], "name": "GDP-mannose mannosyl hydrolase", "drug_actions": []}, "P32722": {"specific_function": "Porin with a specificity for basic amino acids. Also possesses serine protease activity.", "general_function": "Serine-type peptidase activity", "gene_names": ["oprD"], "name": "Porin D", "drug_actions": []}, "P46926": {"specific_function": "Seems to trigger calcium oscillations in mammalian eggs. These oscillations serve as the essential trigger for egg activation and early development of the embryo (By similarity).", "general_function": "Hydrolase activity", "gene_names": ["GNPDA1"], "name": "Glucosamine-6-phosphate isomerase 1", "drug_actions": []}, "P46925": {"general_function": "Aspartic-type endopeptidase activity", "gene_names": [], "name": "Plasmepsin-2", "drug_actions": [{"action": "INHIBITOR", "target": "P46925", "drug": "DB01218"}]}, "P49765": {"specific_function": "Growth factor for endothelial cells. VEGF-B167 binds heparin and neuropilin-1 whereas the binding to neuropilin-1 of VEGF-B186 is regulated by proteolysis.", "general_function": "Vascular endothelial growth factor receptor 1 binding", "gene_names": ["VEGFB"], "name": "Vascular endothelial growth factor B", "drug_actions": [{"action": "BINDER", "target": "P49765", "drug": "DB08885"}]}, "O75715": {"specific_function": "Protects cells and enzymes from oxidative damage, by catalyzing the reduction of hydrogen peroxide, lipid peroxides and organic hydroperoxide, by glutathione. May constitute a glutathione peroxidase-like protective system against peroxide damage in sperm membrane lipids.", "general_function": "Glutathione peroxidase activity", "gene_names": ["GPX5"], "name": "Epididymal secretory glutathione peroxidase", "drug_actions": [{"action": "COFACTOR", "target": "O75715", "drug": "DB00143"}]}, "P83798": {"specific_function": "Component of the cytochrome b6-f complex, which mediates electron transfer between photosystem II (PSII) and photosystem I (PSI), cyclic electron flow around PSI, and state transitions.", "general_function": "Electron transporter, transferring electrons within cytochrome b6/f complex of photosystem ii activity", "gene_names": ["petN"], "name": "Cytochrome b6-f complex subunit 8", "drug_actions": []}, "O43272": {"specific_function": "Converts proline to delta-1-pyrroline-5-carboxylate.", "general_function": "Proline dehydrogenase activity", "gene_names": ["PRODH"], "name": "Proline dehydrogenase 1, mitochondrial", "drug_actions": []}, "P32297": {"specific_function": "After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.", "general_function": "Ligand-gated ion channel activity", "gene_names": ["CHRNA3"], "name": "Neuronal acetylcholine receptor subunit alpha-3", "drug_actions": [{"action": "AGONIST", "target": "P32297", "drug": "DB00184"}, {"action": "ANTAGONIST", "target": "P32297", "drug": "DB00514"}, {"action": "ALLOSTERIC MODULATOR", "target": "P32297", "drug": "DB00674"}, {"action": "AGONIST", "target": "P32297", "drug": "DB00848"}, {"action": "ANTAGONIST", "target": "P32297", "drug": "DB01090"}, {"action": "ANTAGONIST", "target": "P32297", "drug": "DB01156"}, {"action": "ANTAGONIST", "target": "P32297", "drug": "DB01227"}, {"action": "PARTIAL AGONIST", "target": "P32297", "drug": "DB01273"}, {"action": "AGONIST", "target": "P32297", "drug": "DB09028"}]}, "P11309": {"specific_function": "Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post-translational levels. Phosphorylation of CDKN1B,induces 14-3-3-proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis.", "general_function": "Transcription factor binding", "gene_names": ["PIM1"], "name": "Serine/threonine-protein kinase pim-1", "drug_actions": [{"action": "PRODUCT OF", "target": "P11309", "drug": "DB00131"}]}, "Q8I372": {"specific_function": "Removes the formyl group from the N-terminal Met of newly synthesized proteins.", "general_function": "Peptide deformylase activity", "gene_names": [], "name": "Peptide deformylase", "drug_actions": []}, "P23340": {"specific_function": "This enzyme catalyzes the endohydrolysis of 1,4-beta-glucosidic linkages in cellulose, lichenin and cereal beta-D-glucans.", "general_function": "Cellulase activity", "gene_names": ["celC307"], "name": "Endoglucanase C307", "drug_actions": []}, "P0A4V4": {"specific_function": "Proteins of the antigen 85 complex are responsible for the high affinity of mycobacteria to fibronectin. Possesses a mycolyltransferase activity required for the biogenesis of trehalose dimycolate (cord factor), a dominant structure necessary for maintaining cell wall integrity", "gene_names": ["fbpC"], "name": "Diacylglycerol acyltransferase/mycolyltransferase Ag85C", "drug_actions": []}, "Q9Q2G8": {"general_function": "Aspartic-type endopeptidase activity", "gene_names": ["ORF"], "name": "V-1 protease", "drug_actions": []}, "O43674": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFB5"], "name": "NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial", "drug_actions": []}, "O43677": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFC1"], "name": "NADH dehydrogenase [ubiquinone] 1 subunit C1, mitochondrial", "drug_actions": []}, "O43676": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFB3"], "name": "NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3", "drug_actions": []}, "O43678": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.", "general_function": "Nadh dehydrogenase (ubiquinone) activity", "gene_names": ["NDUFA2"], "name": "NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2", "drug_actions": []}, "Q02809": {"specific_function": "Forms hydroxylysine residues in -Xaa-Lys-Gly- sequences in collagens. These hydroxylysines serve as sites of attachment for carbohydrate units and are essential for the stability of the intermolecular collagen cross-links.", "general_function": "Protein homodimerization activity", "gene_names": ["PLOD1"], "name": "Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1", "drug_actions": [{"action": "ACTIVATOR", "target": "Q02809", "drug": "DB00126"}]}, "P20339": {"specific_function": "The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different sets of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion. RAB5A is required for the fusion of plasma membranes and early endosomes. Contributes to the regulation of filopodia extension.", "general_function": "Gtpase activity", "gene_names": ["RAB5A"], "name": "Ras-related protein Rab-5A", "drug_actions": []}, "Q8ZKR2": {"general_function": "Ribokinase activity", "gene_names": [], "name": "Putative sugar kinase", "drug_actions": []}, "P26276": {"specific_function": "Highly reversible phosphoryltransferase. The phosphomannomutase activity produces a precursor for alginate polymerization, the alginate layer causes a mucoid phenotype and provides a protective barrier against host immune defenses and antibiotics. Also involved in core lipopolysaccaride (LPS) biosynthesis due to its phosphoglucomutase activity. Essential for rhamnolipid production, an exoproduct correlated with pathogenicity (PubMed:10481091). Required for biofilm production. The reaction proceeds via 2 processive phosphoryl transferase reactions; first from enzyme-phospho-Ser-108 to the substrate (generating a bisphosphorylated substrate intermediate and a dephosphorylated enzyme), a 180 degree rotation of the intermediate (probably aided by movement of domain 4), and subsequent transfer of phosphate back to the enzyme (PubMed:11716469, PubMed:16880541, PubMed:16595672, PubMed:22242625).", "general_function": "Phosphomannomutase activity", "gene_names": ["algC"], "name": "Phosphomannomutase/phosphoglucomutase", "drug_actions": []}, "Q09013": {"specific_function": "Non-receptor serine/threonine protein kinase which is necessary for the maintenance of skeletal muscle structure and function. May play a role in myocyte differentiation and survival by regulating the integrity of the nuclear envelope and the expression of muscle-specific genes. May also phosphorylate PPP1R12A and inhibit the myosin phosphatase activity to regulate myosin phosphorylation. Also critical to the modulation of cardiac contractility and to the maintenance of proper cardiac conduction activity probably through the regulation of cellular calcium homeostasis. Phosphorylates PLN, a regulator of calcium pumps and may regulate sarcoplasmic reticulum calcium uptake in myocytes. May also phosphorylate FXYD1/PLM which is able to induce chloride currents. May also play a role in synaptic plasticity.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["DMPK"], "name": "Myotonin-protein kinase", "drug_actions": []}, "Q14626": {"specific_function": "Receptor for interleukin-11. The receptor systems for IL6, LIF, OSM, CNTF, IL11 and CT1 can utilize IL6ST for initiating signal transmission. The IL11/IL11RA/IL6ST complex may be involved in the control of proliferation and/or differentiation of skeletogenic progenitor or other mesenchymal cells. Essential for the normal development of craniofacial bones and teeth. Restricts suture fusion and tooth number.", "general_function": "Transmembrane signaling receptor activity", "gene_names": ["IL11RA"], "name": "Interleukin-11 receptor subunit alpha", "drug_actions": [{"action": "AGONIST", "target": "Q14626", "drug": "DB00038"}]}, "Q2FGH1": {"general_function": "Involved in penicillin binding", "gene_names": ["pbp3"], "name": "Penicillin-binding protein 3", "drug_actions": [{"action": "INHIBITOR", "target": "Q2FGH1", "drug": "DB01053"}]}, "P16144": {"specific_function": "Integrin alpha-6/beta-4 is a receptor for laminin. Plays a critical structural role in the hemidesmosome of epithelial cells. Is required for the regulation of keratinocyte polarity and motility.", "general_function": "Receptor activity", "gene_names": ["ITGB4"], "name": "Integrin beta-4", "drug_actions": []}, "Q86Y39": {"specific_function": "Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).", "gene_names": ["NDUFA11"], "name": "NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11", "drug_actions": []}, "P03989": {"specific_function": "Involved in the presentation of foreign antigens to the immune system.", "general_function": "Peptide antigen binding", "gene_names": ["HLA-B"], "name": "HLA class I histocompatibility antigen, B-27 alpha chain", "drug_actions": []}, "P41597": {"specific_function": "Receptor for the CCL2, CCL7 and CCL13 chemokines. Transduces a signal by increasing intracellular calcium ion levels. Alternative coreceptor with CD4 for HIV-1 infection.", "general_function": "Protein homodimerization activity", "gene_names": ["CCR2"], "name": "C-C chemokine receptor type 2", "drug_actions": []}, "P41595": {"specific_function": "G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and down-stream signaling cascades and promotes the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of dopamine and 5-hydroxytryptamine release, 5-hydroxytryptamine uptake and in the regulation of extracellular dopamine and 5-hydroxytryptamine levels, and thereby affects neural activity. May play a role in the perception of pain. Plays a role in the regulation of behavior, including impulsive behavior. Required for normal proliferation of embryonic cardiac myocytes and normal heart development. Protects cardiomyocytes against apoptosis. Plays a role in the adaptation of pulmonary arteries to chronic hypoxia. Plays a role in vasoconstriction. Required for normal osteoblast function and proliferation, and for maintaining normal bone density. Required for normal proliferation of the interstitial cells of Cajal in the intestine.", "name": "5-hydroxytryptamine receptor 2B", "drug_actions": [{"action": "AGONIST", "target": "P41595", "drug": "DB00216"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB00247"}, {"action": "AGONIST", "target": "P41595", "drug": "DB00248"}, {"action": "AGONIST", "target": "P41595", "drug": "DB00268"}, {"action": "AGONIST", "target": "P41595", "drug": "DB00320"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB00334"}, {"action": "BINDER", "target": "P41595", "drug": "DB00370"}, {"action": "UNKNOWN", "target": "P41595", "drug": "DB00413"}, {"action": "BINDER", "target": "P41595", "drug": "DB00477"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB00508"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB00543"}, {"action": "AGONIST", "target": "P41595", "drug": "DB00574"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB00589"}, {"action": "AGONIST", "target": "P41595", "drug": "DB00714"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB00805"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB01049"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB01079"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB01142"}, {"action": "AGONIST", "target": "P41595", "drug": "DB01186"}, {"action": "AGONIST", "target": "P41595", "drug": "DB01200"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB01221"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB01239"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB01242"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB01392"}, {"action": "AGONIST", "target": "P41595", "drug": "DB01454"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB06016"}, {"action": "BINDER", "target": "P41595", "drug": "DB06148"}, {"action": "ANTAGONIST", "target": "P41595", "drug": "DB06216"}, {"action": "INVERSE AGONIST", "target": "P41595", "drug": "DB06678"}], "general_function": "Serotonin receptor activity", "in_complexes": ["5-hydroxytryptamine 2 receptor", "5-hydroxytryptamine receptor 2", "Serotonin Receptors"], "gene_names": ["HTR2B"]}, "P41594": {"specific_function": "G-protein coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol-calcium second messenger system and generates a calcium-activated chloride current. Plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity.", "general_function": "Glutamate receptor activity", "gene_names": ["GRM5"], "name": "Metabotropic glutamate receptor 5", "drug_actions": [{"action": "ANTAGONIST", "target": "P41594", "drug": "DB00659"}, {"action": "INHIBITOR", "target": "P41594", "drug": "DB06201"}]}, "P54716": {"specific_function": "Hydrolyzes maltose-6'-phosphate and trehalose-6'-phosphate. Is involved in the catabolism of alpha-glycosides accumulated via a phosphoenolpyruvate-dependent maltose phosphotransferase system (PEP-PTS). Is also able to significantly catalyze the hydrolysis of both 6-phospho-alpha- and 6-phospho-beta-glucosides containing activated leaving groups such as p-nitrophenol and does so with retention and inversion, respectively, of the substrate anomeric configuration.", "general_function": "Oxidoreductase activity, acting on the ch-oh group of donors, nad or nadp as acceptor", "gene_names": ["glvA"], "name": "Maltose-6'-phosphate glucosidase", "drug_actions": []}, "P63185": {"specific_function": "This phosphoprotein, required for both the initiation and the maintenance of neoplastic transformation, is a protein kinase that catalyzes the phosphorylation of tyrosine residues in vitro.", "general_function": "Non-membrane spanning protein tyrosine kinase activity", "gene_names": ["V-SRC"], "name": "Tyrosine-protein kinase transforming protein Src", "drug_actions": []}, "P07384": {"specific_function": "Calcium-regulated non-lysosomal thiol-protease which catalyze limited proteolysis of substrates involved in cytoskeletal remodeling and signal transduction.", "general_function": "Calcium-dependent cysteine-type endopeptidase activity", "gene_names": ["CAPN1"], "name": "Calpain-1 catalytic subunit", "drug_actions": []}, "P14489": {"specific_function": "Hydrolyzes both carbenicillin and oxacillin.", "general_function": "Penicillin binding", "gene_names": ["bla"], "name": "Beta-lactamase OXA-10", "drug_actions": []}, "P54710": {"specific_function": "May be involved in forming the receptor site for cardiac glycoside binding or may modulate the transport function of the sodium ATPase.", "general_function": "Transporter activity", "gene_names": ["FXYD2"], "name": "Sodium/potassium-transporting ATPase subunit gamma", "drug_actions": [{"action": "INHIBITOR", "target": "P54710", "drug": "DB00606"}]}, "P22749": {"specific_function": "Antimicrobial protein that kills intracellular pathogens. Active against a broad range of microbes, including Gram-positive and Gram-negative bacteria, fungi, and parasites. Kills Mycobacterium tuberculosis.", "gene_names": ["GNLY"], "name": "Granulysin", "drug_actions": []}, "P22748": {"specific_function": "Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.", "general_function": "Zinc ion binding", "gene_names": ["CA4"], "name": "Carbonic anhydrase 4", "drug_actions": [{"action": "INHIBITOR", "target": "P22748", "drug": "DB00232"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00273"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00311"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00436"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00562"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00606"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00703"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00774"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00819"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00869"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00880"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00909"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB00999"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB01021"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB01144"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB01194"}, {"action": "INHIBITOR", "target": "P22748", "drug": "DB08846"}]}, "P11274": {"specific_function": "GTPase-activating protein for RAC1 and CDC42. Promotes the exchange of RAC or CDC42-bound GDP by GTP, thereby activating them. Displays serine/threonine kinase activity.", "general_function": "Rho guanyl-nucleotide exchange factor activity", "gene_names": ["BCR"], "name": "Breakpoint cluster region protein", "drug_actions": [{"action": "INHIBITOR", "target": "P11274", "drug": "DB06616"}, {"action": "INHIBITOR", "target": "P11274", "drug": "DB08901"}]}, "P06576": {"specific_function": "Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain. F-type ATPases consist of two structural domains, F(1) - containing the extramembraneous catalytic core, and F(0) - containing the membrane proton channel, linked together by a central stalk and a peripheral stalk. During catalysis, ATP synthesis in the catalytic domain of F(1) is coupled via a rotary mechanism of the central stalk subunits to proton translocation. Subunits alpha and beta form the catalytic core in F(1). Rotation of the central stalk against the surrounding alpha(3)beta(3) subunits leads to hydrolysis of ATP in three separate catalytic sites on the beta subunits.", "general_function": "Transporter activity", "gene_names": ["ATP5B"], "name": "ATP synthase subunit beta, mitochondrial", "drug_actions": []}, "P0A3Y5": {"specific_function": "Resistance to kanamycin and structurally-related aminoglycosides, including amikacin.", "general_function": "Kanamycin kinase activity", "gene_names": ["aphA"], "name": "Aminoglycoside 3'-phosphotransferase", "drug_actions": []}, "Q99470": {"general_function": "Dolichyl-phosphate-mannose-protein mannosyltransferase activity", "gene_names": ["SDF2"], "name": "Stromal cell-derived factor 2", "drug_actions": []}, "Q16539": {"specific_function": "Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK14 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. Some of the targets are downstream kinases which are activated through phosphorylation and further phosphorylate additional targets. RPS6KA5/MSK1 and RPS6KA4/MSK2 can directly phosphorylate and activate transcription factors such as CREB1, ATF1, the NF-kappa-B isoform RELA/NFKB3, STAT1 and STAT3, but can also phosphorylate histone H3 and the nucleosomal protein HMGN1. RPS6KA5/MSK1 and RPS6KA4/MSK2 play important roles in the rapid induction of immediate-early genes in response to stress or mitogenic stimuli, either by inducing chromatin remodeling or by recruiting the transcription machinery. On the other hand, two other kinase targets, MAPKAPK2/MK2 and MAPKAPK3/MK3, participate in the control of gene expression mostly at the post-transcriptional level, by phosphorylating ZFP36 (tristetraprolin) and ELAVL1, and by regulating EEF2K, which is important for the elongation of mRNA during translation. MKNK1/MNK1 and MKNK2/MNK2, two other kinases activated by p38 MAPKs, regulate protein synthesis by phosphorylating the initiation factor EIF4E2. MAPK14 interacts also with casein kinase II, leading to its activation through autophosphorylation and further phosphorylation of TP53/p53. In the cytoplasm, the p38 MAPK pathway is an important regulator of protein turnover. For example, CFLAR is an inhibitor of TNF-induced apoptosis whose proteasome-mediated degradation is regulated by p38 MAPK phosphorylation. In a similar way, MAPK14 phosphorylates the ubiquitin ligase SIAH2, regulating its activity towards EGLN3. MAPK14 may also inhibit the lysosomal degradation pathway of autophagy by interfering with the intracellular trafficking of the transmembrane protein ATG9. Another function of MAPK14 is to regulate the endocytosis of membrane receptors by different mechanisms that impinge on the small GTPase RAB5A. In addition, clathrin-mediated EGFR internalization induced by inflammatory cytokines and UV irradiation depends on MAPK14-mediated phosphorylation of EGFR itself as well as of RAB5A effectors. Ectodomain shedding of transmembrane proteins is regulated by p38 MAPKs as well. In response to inflammatory stimuli, p38 MAPKs phosphorylate the membrane-associated metalloprotease ADAM17. Such phosphorylation is required for ADAM17-mediated ectodomain shedding of TGF-alpha family ligands, which results in the activation of EGFR signaling and cell proliferation. Another p38 MAPK substrate is FGFR1. FGFR1 can be translocated from the extracellular space into the cytosol and nucleus of target cells, and regulates processes such as rRNA synthesis and cell growth. FGFR1 translocation requires p38 MAPK activation. In the nucleus, many transcription factors are phosphorylated and activated by p38 MAPKs in response to different stimuli. Classical examples include ATF1, ATF2, ATF6, ELK1, PTPRH, DDIT3, TP53/p53 and MEF2C and MEF2A. The p38 MAPKs are emerging as important modulators of gene expression by regulating chromatin modifiers and remodelers. The promoters of several genes involved in the inflammatory response, such as IL6, IL8 and IL12B, display a p38 MAPK-dependent enrichment of histone H3 phosphorylation on 'Ser-10' (H3S10ph) in LPS-stimulated myeloid cells. This phosphorylation enhances the accessibility of the cryptic NF-kappa-B-binding sites marking promoters for increased NF-kappa-B recruitment. Phosphorylates CDC25B and CDC25C which is required for binding to 14-3-3 proteins and leads to initiation of a G2 delay after ultraviolet radiation. Phosphorylates TIAR following DNA damage, releasing TIAR from GADD45A mRNA and preventing mRNA degradation. The p38 MAPKs may also have kinase-independent roles, which are thought to be due to the binding to targets in the absence of phosphorylation. Protein O-Glc-N-acylation catalyzed by the OGT is regulated by MAPK14, and, although OGT does not seem to be phosphorylated by MAPK14, their interaction increases upon MAPK14 activation induced by glucose deprivation. This interaction may regulate OGT activity by recruiting it to specific targets such as neurofilament H, stimulating its O-Glc-N-acylation. Required in mid-fetal development for the growth of embryo-derived blood vessels in the labyrinth layer of the placenta. Also plays an essential role in developmental and stress-induced erythropoiesis, through regulation of EPO gene expression. Isoform MXI2 activation is stimulated by mitogens and oxidative stress and only poorly phosphorylates ELK1 and ATF2. Isoform EXIP may play a role in the early onset of apoptosis. Phosphorylates S100A9 at 'Thr-113'.", "general_function": "Protein serine/threonine kinase activity", "gene_names": ["MAPK14"], "name": "Mitogen-activated protein kinase 14", "drug_actions": []}, "O60218": {"specific_function": "Acts as all-trans-retinaldehyde reductase. Can efficiently reduce aliphatic and aromatic aldehydes, and is less active on hexoses (in vitro). May be responsible for detoxification of reactive aldehydes in the digested food before the nutrients are passed on to other organs.", "general_function": "Retinal dehydrogenase activity", "gene_names": ["AKR1B10"], "name": "Aldo-keto reductase family 1 member B10", "drug_actions": []}, "P15770": {"specific_function": "Involved in the biosynthesis of the chorismate, which leads to the biosynthesis of aromatic amino acids. Catalyzes the reversible NADPH linked reduction of 3-dehydroshikimate (DHSA) to yield shikimate (SA). It displays no activity in the presence of NAD.", "general_function": "Shikimate 3-dehydrogenase (nadp+) activity", "gene_names": ["aroE"], "name": "Shikimate dehydrogenase (NADP(+))", "drug_actions": []}, "P07464": {"specific_function": "May assist cellular detoxification by acetylating non-metabolizable pyranosides, thereby preventing their reentry into the cell.", "general_function": "Galactoside o-acetyltransferase activity", "gene_names": ["lacA"], "name": "Galactoside O-acetyltransferase", "drug_actions": []}, "P30967": {"general_function": "Phenylalanine 4-monooxygenase activity", "gene_names": ["phhA"], "name": "Phenylalanine-4-hydroxylase", "drug_actions": []}, "Q8WY07": {"specific_function": "Mediates the uptake of the cationic amino acids arginine, lysine and ornithine in a sodium-independent manner.", "general_function": "L-ornithine transmembrane transporter activity", "gene_names": ["SLC7A3"], "name": "Cationic amino acid transporter 3", "drug_actions": []}, "P55038": {"general_function": "Metal ion binding", "gene_names": ["gltS"], "name": "Ferredoxin-dependent glutamate synthase 2", "drug_actions": []}, "Q9L6V3": {"general_function": "Oxidoreductase activity", "gene_names": ["fpr"], "name": "NADPH:ferredoxin reductase", "drug_actions": []}, "O39930": {"general_function": "Rna-directed rna polymerase activity", "gene_names": ["NS5b"], "name": "RNA-dependent RNA-polymerase", "drug_actions": []}, "P43490": {"specific_function": "Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD. It is the rate limiting component in the mammalian NAD biosynthesis pathway. The secreted form behaves both as a cytokine with immunomodulating properties and an adipokine with anti-diabetic properties, it has no enzymatic activity, partly because of lack of activation by ATP, which has a low level in extracellular space and plasma. Plays a role in the modulation of circadian clock function. NAMPT-dependent oscillatory production of NAD regulates oscillation of clock target gene expression by releasing the core clock component: CLOCK-ARNTL/BMAL1 heterodimer from NAD-dependent SIRT1-mediated suppression (By similarity).", "general_function": "Nicotinate-nucleotide diphosphorylase (carboxylating) activity", "gene_names": ["NAMPT"], "name": "Nicotinamide phosphoribosyltransferase", "drug_actions": []}, "P30968": {"specific_function": "Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act as an inhibitor of GnRH-R signaling.", "general_function": "Peptide binding", "gene_names": ["GNRHR"], "name": "Gonadotropin-releasing hormone receptor", "drug_actions": [{"action": "AGONIST", "target": "P30968", "drug": "DB00007"}, {"action": "AGONIST", "target": "P30968", "drug": "DB00014"}, {"action": "ANTAGONIST", "target": "P30968", "drug": "DB00050"}, {"action": "ANTAGONIST", "target": "P30968", "drug": "DB00106"}, {"action": "AGONIST", "target": "P30968", "drug": "DB00644"}, {"action": "AGONIST", "target": "P30968", "drug": "DB00666"}, {"action": "NEGATIVE MODULATOR", "target": "P30968", "drug": "DB01406"}, {"action": "ANTAGONIST", "target": "P30968", "drug": "DB06699"}, {"action": "ANTAGONIST", "target": "P30968", "drug": "DB06785"}, {"action": "AGONIST", "target": "P30968", "drug": "DB06825"}]}, "P26676": {"specific_function": "Displays RNA-directed RNA polymerase, mRNA guanylyl transferase, mRNA (guanine-N(7)-)-methyltransferase and poly(A) synthetase activities. The viral mRNA guanylyl transferase displays a different biochemical reaction than the cellular enzyme. The template is composed of the viral RNA tightly encapsidated by the nucleoprotein (N). Functions either as transcriptase or as replicase. The transcriptase synthesizes subsequently the subgenomic RNAs, assuring their capping and polyadenylation by a stuttering mechanism. The transcriptase stutters on a specific sequence, resulting on a cotranscriptional editing of the phosphoprotein (P) mRNA. The replicase mode is dependent on intracellular N protein concentration. In this mode, the polymerase replicates the whole viral genome without recognizing the transcriptional signals (By similarity).", "general_function": "Rna-directed rna polymerase activity", "gene_names": ["L"], "name": "RNA-directed RNA polymerase L", "drug_actions": [{"action": "ANTAGONIST", "target": "P26676", "drug": "DB00811"}]}, "O14792": {"specific_function": "Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) to catalyze the transfer of a sulfo group to position 3 of glucosamine residues in heparan. Catalyzes the rate limiting step in the biosynthesis of heparan sulfate (HSact). This modification is a crucial step in the biosynthesis of anticoagulant heparan sulfate as it completes the structure of the antithrombin pentasaccharide binding site.", "general_function": "Sulfotransferase activity", "gene_names": ["HS3ST1"], "name": "Heparan sulfate glucosamine 3-O-sulfotransferase 1", "drug_actions": []}, "O14793": {"specific_function": "Acts specifically as a negative regulator of skeletal muscle growth.", "general_function": "Transforming growth factor beta receptor binding", "gene_names": ["MSTN"], "name": "Growth/differentiation factor 8", "drug_actions": []}, "P17302": {"specific_function": "Gap junction protein that acts as a regulator of bladder capacity. A gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. May play a critical role in the physiology of hearing by participating in the recycling of potassium to the cochlear endolymph. Negative regulator of bladder functional capacity: acts by enhancing intercellular electrical and chemical transmission, thus sensitizing bladder muscles to cholinergic neural stimuli and causing them to contract (By similarity). May play a role in cell growth inhibition through the regulation of NOV expression and localization. Plays an essential role in gap junction communication in the ventricles (By similarity).", "general_function": "Signal transducer activity", "gene_names": ["GJA1"], "name": "Gap junction alpha-1 protein", "drug_actions": [{"action": "OTHER", "target": "P17302", "drug": "DB01136"}]}, "P10902": {"specific_function": "Catalyzes the oxidation of L-aspartate to iminoaspartate.", "general_function": "L-aspartate:fumarate oxidoreductase activity", "gene_names": ["nadB"], "name": "L-aspartate oxidase", "drug_actions": []}, "P15291": {"specific_function": "The Golgi complex form catalyzes the production of lactose in the lactating mammary gland and could also be responsible for the synthesis of complex-type N-linked oligosaccharides in many glycoproteins as well as the carbohydrate moieties of glycolipids.The cell surface form functions as a recognition molecule during a variety of cell to cell and cell to matrix interactions, as those occurring during development and egg fertilization, by binding to specific oligosaccharide ligands on opposing cells or in the extracellular matrix.", "general_function": "Udp-galactosyltransferase activity", "gene_names": ["B4GALT1"], "name": "Beta-1,4-galactosyltransferase 1", "drug_actions": []}, "P54219": {"specific_function": "Involved in the transport of biogenic monoamines, such as serotonin, from the cytoplasm into the secretory vesicles of neuroendocrine and endocrine cells.", "general_function": "Serotonin transmembrane transporter activity", "gene_names": ["SLC18A1"], "name": "Chromaffin granule amine transporter", "drug_actions": [{"action": "BINDER", "target": "P54219", "drug": "DB00368"}, {"action": "INHIBITOR", "target": "P54219", "drug": "DB01363"}, {"action": "INHIBITOR", "target": "P54219", "drug": "DB01442"}, {"action": "INHIBITOR", "target": "P54219", "drug": "DB01577"}]}, "Q9BWD1": {"general_function": "Acetyl-coa c-acetyltransferase activity", "gene_names": ["ACAT2"], "name": "Acetyl-CoA acetyltransferase, cytosolic", "drug_actions": []}, "P19961": {"general_function": "Metal ion binding", "gene_names": ["AMY2B"], "name": "Alpha-amylase 2B", "drug_actions": []}, "Q8GMG0": {"specific_function": "Involved in the biosynthesis of the enediyne antitumor antibiotic C-1027. Catalyzes the MIO-dependent deamination of L-tyrosine generating the corresponding alpha,beta-unsaturated acid, (S)-beta-tyrosine.", "general_function": "Tyrosine ammonia-lyase activity", "gene_names": [], "name": "MIO-dependent tyrosine 2,3-aminomutase", "drug_actions": []}, "Q9NUV7": {"specific_function": "Serine palmitoyltransferase (SPT). The heterodimer formed with LCB1/SPTLC1 constitutes the catalytic core. The composition of the serine palmitoyltransferase (SPT) complex determines the substrate preference. The SPTLC1-SPTLC3-SPTSSA isozyme uses both C14-CoA and C16-CoA as substrates, while the SPTLC1-SPTLC3-SPTSSB has the ability to use a broader range of acyl-CoAs without apparent preference.", "general_function": "Serine c-palmitoyltransferase activity", "gene_names": ["SPTLC3"], "name": "Serine palmitoyltransferase 3", "drug_actions": [{"action": "COFACTOR", "target": "Q9NUV7", "drug": "DB00114"}]}, "P22607": {"specific_function": "Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferation. Required for normal development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Plays a role in the regulation of vitamin D metabolism. Mutations that lead to constitutive kinase activation or impair normal FGFR3 maturation, internalization and degradation lead to aberrant signaling. Over-expressed or constitutively activated FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 retains its capacity to bind FGF1 and FGF2 and hence may interfere with FGF signaling.", "general_function": "Protein tyrosine kinase activity", "gene_names": ["FGFR3"], "name": "Fibroblast growth factor receptor 3", "drug_actions": [{"action": "INHIBITOR", "target": "P22607", "drug": "DB06589"}, {"action": "INHIBITOR", "target": "P22607", "drug": "DB08901"}, {"action": "INHIBITOR", "target": "P22607", "drug": "DB09078"}, {"action": "INHIBITOR", "target": "P22607", "drug": "DB09079"}]}, "Q9GV41": {"specific_function": "Catalyzes the NADP-dependent formation of prostaglandin F2-alpha from prostaglandin H2. Has also aldo/ketoreductase activity towards the synthetic substrates 9,10-phenanthrenequinone and p-nitrobenzaldehyde.", "general_function": "Prostaglandin-f synthase activity", "gene_names": [], "name": "Prostaglandin F synthase", "drug_actions": []}, "P07254": {"general_function": "Chitinase activity", "gene_names": ["chiA"], "name": "Chitinase A", "drug_actions": []}, "P16099": {"general_function": "Trimethylamine dehydrogenase activity", "gene_names": ["tmd"], "name": "Trimethylamine dehydrogenase", "drug_actions": []}, "Q93D82": {"general_function": "Oxidoreductase activity", "gene_names": ["hheC"], "name": "Halohydrin dehalogenase", "drug_actions": []}, "P04818": {"specific_function": "Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.", "general_function": "Thymidylate synthase activity", "gene_names": ["TYMS"], "name": "Thymidylate synthase", "drug_actions": [{"action": "INHIBITOR", "target": "P04818", "drug": "DB00293"}, {"action": "INHIBITOR", "target": "P04818", "drug": "DB00432"}, {"action": "INHIBITOR", "target": "P04818", "drug": "DB00440"}, {"action": "INHIBITOR", "target": "P04818", "drug": "DB00441"}, {"action": "OTHER/UNKNOWN", "target": "P04818", "drug": "DB00544"}, {"action": "INHIBITOR", "target": "P04818", "drug": "DB00642"}, {"action": "INHIBITOR", "target": "P04818", "drug": "DB00650"}, {"action": "INHIBITOR", "target": "P04818", "drug": "DB01101"}, {"action": "INHIBITOR", "target": "P04818", "drug": "DB06813"}]}, "Q59721": {"general_function": "Glutathione transferase activity", "gene_names": ["bphK"], "name": "Glutathione S-transferase", "drug_actions": []}, "O15460": {"specific_function": "Catalyzes the post-translational formation of 4-hydroxyproline in -Xaa-Pro-Gly- sequences in collagens and other proteins.", "general_function": "Procollagen-proline 4-dioxygenase activity", "gene_names": ["P4HA2"], "name": "Prolyl 4-hydroxylase subunit alpha-2", "drug_actions": []}, "P14770": {"specific_function": "The GPIb-V-IX complex functions as the vWF receptor and mediates vWF-dependent platelet adhesion to blood vessels. The adhesion of platelets to injured vascular surfaces in the arterial circulation is a critical initiating event in hemostasis. GP-IX may provide for membrane insertion and orientation of GP-Ib.", "gene_names": ["GP9"], "name": "Platelet glycoprotein IX", "drug_actions": [{"action": "OTHER", "target": "P14770", "drug": "DB00468"}]}, "P08238": {"specific_function": "Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function.", "general_function": "Utp binding", "gene_names": ["HSP90AB1"], "name": "Heat shock protein HSP 90-beta", "drug_actions": []}, "Q16445": {"specific_function": "GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.", "name": "Gamma-aminobutyric acid receptor subunit alpha-6", "drug_actions": [{"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00186"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00228"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00231"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00237"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00241"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00273"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00292"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00306"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00306"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00312"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00349"}, {"action": "AGONIST", "target": "Q16445", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00371"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00402"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00404"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00418"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00463"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00475"}, {"action": "BINDER", "target": "Q16445", "drug": "DB00543"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00599"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00628"}, {"action": "POSITIVE MODULATOR", "target": "Q16445", "drug": "DB00659"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00683"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00690"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00753"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00794"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00801"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00818"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00829"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00842"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00842"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00849"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB00897"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01028"}, {"action": "AGONIST", "target": "Q16445", "drug": "DB01049"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01068"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01107"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01159"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01189"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01205"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01215"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01236"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01351"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01352"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01353"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01354"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01355"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01437"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01483"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01496"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01544"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01558"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01588"}, {"action": "POSITIVE ALLOSTERIC MODULATOR", "target": "Q16445", "drug": "DB01589"}, {"action": "POTENTIATOR", "target": "Q16445", "drug": "DB01595"}, {"action": "ANTAGONIST", "target": "Q16445", "drug": "DB01708"}], "general_function": "Inhibitory extracellular ligand-gated ion channel activity", "in_complexes": ["GABA-A receptor (anion channel)"], "gene_names": ["GABRA6"]}, "P14779": {"specific_function": "Functions as a fatty acid monooxygenase. Catalyzes hydroxylation of medium and long-chain fatty acids at omega-1, omega-2 and omega-3 positions, with optimum chain lengths of 12-16 carbons (lauric, myristic, and palmitic acids). The reductase domain is required for electron transfer from NADP to cytochrome P450.", "general_function": "Nadph-hemoprotein reductase activity", "gene_names": ["cyp102A1"], "name": "Bifunctional cytochrome P450/NADPH--P450 reductase", "drug_actions": []}, "Q9Y5N1": {"specific_function": "The H3 subclass of histamine receptors could mediate the histamine signals in CNS and peripheral nervous system. Signals through the inhibition of adenylate cyclase and displays high constitutive activity (spontaneous activity in the absence of agonist). Agonist stimulation of isoform 3 neither modified adenylate cyclase activity nor induced intracellular calcium mobilization.", "general_function": "Histamine receptor activity", "gene_names": ["HRH3"], "name": "Histamine H3 receptor", "drug_actions": [{"action": "ANTAGONIST", "target": "Q9Y5N1", "drug": "DB00370"}, {"action": "AGONIST", "target": "Q9Y5N1", "drug": "DB00667"}, {"action": "ANTAGONIST", "target": "Q9Y5N1", "drug": "DB06698"}]}, "P21638": {"specific_function": "Catalyzes the conversion of precorrin-8X to hydrogenobyrinate.", "general_function": "Precorrin-8x methylmutase activity", "gene_names": ["cobH"], "name": "Precorrin-8X methylmutase", "drug_actions": []}, "Q9UJS0": {"specific_function": "Catalyzes the calcium-dependent exchange of cytoplasmic glutamate with mitochondrial aspartate across the mitochondrial inner membrane. May have a function in the urea cycle.", "general_function": "Transporter activity", "gene_names": ["SLC25A13"], "name": "Calcium-binding mitochondrial carrier protein Aralar2", "drug_actions": []}, "Q9Y2I1": {"specific_function": "Acts either as the functional imidazoline-1 receptor (I1R) candidate or as a membrane-associated mediator of the I1R signaling. Binds numerous imidazoline ligands that induces initiation of cell-signaling cascades triggering to cell survival, growth and migration. Its activation by the agonist rilmenidine induces an increase in phosphorylation of mitogen-activated protein kinases MAPK1 and MAPK3 in rostral ventrolateral medulla (RVLM) neurons that exhibited rilmenidine-evoked hypotension (By similarity). Blocking its activation with efaroxan abolished rilmenidine-induced mitogen-activated protein kinase phosphorylation in RVLM neurons (By similarity). Acts as a modulator of Rac-regulated signal transduction pathways (By similarity). Suppresses Rac1-stimulated cell migration by interacting with PAK1 and inhibiting its kinase activity (By similarity). Also blocks Pak-independent Rac signaling by interacting with RAC1 and inhibiting Rac1-stimulated NF-kB response element and cyclin D1 promoter activation (By similarity). Inhibits also LIMK1 kinase activity by reducing LIMK1 'Tyr-508' phosphorylation (By similarity). Inhibits Rac-induced cell migration and invasion in breast and colon epithelial cells (By similarity). Inhibits lamellipodia formation, when overexpressed (By similarity). Plays a role in protection against apoptosis. Involved in association with IRS4 in the enhancement of insulin activation of MAPK1 and MAPK3. When overexpressed, induces a redistribution of cell surface ITGA5 integrin to intracellular endosomal structures.", "general_function": "Phosphatidylinositol binding", "gene_names": ["NISCH"], "name": "Nischarin", "drug_actions": [{"action": "AGONIST", "target": "Q9Y2I1", "drug": "DB00697"}, {"action": "AGONIST", "target": "Q9Y2I1", "drug": "DB08838"}, {"action": "AGONIST", "target": "Q9Y2I1", "drug": "DB09242"}]}, "Q9HVZ0": {"specific_function": "Catalyzes the isomerization of sedoheptulose 7-phosphate in D-glycero-D-manno-heptose 7-phosphate.", "general_function": "Zinc ion binding", "gene_names": ["gmhA"], "name": "Phosphoheptose isomerase", "drug_actions": []}, "Q9BY49": {"gene_names": ["PECR"], "name": "Peroxisomal trans-2-enoyl-CoA reductase", "drug_actions": []}, "P55157": {"specific_function": "Catalyzes the transport of triglyceride, cholesteryl ester, and phospholipid between phospholipid surfaces (PubMed:23475612, PubMed:8939939, PubMed:26224785, PubMed:25108285, PubMed:22236406). Required for the secretion of plasma lipoproteins that contain apolipoprotein B (PubMed:23475612, PubMed:8939939, PubMed:26224785).", "general_function": "Protein heterodimerization activity", "gene_names": ["MTTP"], "name": "Microsomal triglyceride transfer protein large subunit", "drug_actions": [{"action": "ANTAGONIST", "target": "P55157", "drug": "DB01094"}, {"action": "ANTAGONIST", "target": "P55157", "drug": "DB08827"}]}, "Q6GJI1": {"specific_function": "Is required not only for elongation of protein synthesis but also for the initiation of all mRNA translation through initiator tRNA(fMet) aminoacylation.", "general_function": "Trna binding", "gene_names": ["metG"], "name": "Methionine--tRNA ligase", "drug_actions": []}, "P62258": {"specific_function": "Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["YWHAE"], "name": "14-3-3 protein epsilon", "drug_actions": []}, "P50921": {"specific_function": "Involved in the gluconeogenesis. Catalyzes stereospecifically the conversion of dihydroxyacetone phosphate (DHAP) to D-glyceraldehyde-3-phosphate (G3P).", "general_function": "Triose-phosphate isomerase activity", "gene_names": ["tpiA"], "name": "Triosephosphate isomerase", "drug_actions": []}, "Q8XJ01": {"specific_function": "Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits) (By similarity).", "general_function": "Transferase activity, transferring glycosyl groups", "gene_names": ["pbpA"], "name": "Penicillin-binding protein 1A", "drug_actions": [{"action": "INDUCER", "target": "Q8XJ01", "drug": "DB00229"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB00267"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB00301"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB00447"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB00456"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB00713"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB00833"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB00948"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01000"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01060"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01061"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01066"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01112"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01139"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01147"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01602"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01604"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB01605"}, {"action": "INHIBITOR", "target": "Q8XJ01", "drug": "DB04133"}]}, "Q9ULK0": {"specific_function": "Receptor for glutamate. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists.", "general_function": "Ionotropic glutamate receptor activity", "gene_names": ["GRID1"], "name": "Glutamate receptor ionotropic, delta-1", "drug_actions": []}, "Q18BX5": {"specific_function": "Sigma factors are initiation factors that promote the attachment of RNA polymerase to specific initiation sites and are then released.Sigma factors are initiation factors that promote the attachment of RNA polymerase to specific initiation sites and are then released. This sigma factor is the primary sigma factor during exponential growth.", "general_function": "Transcription factor activity, sequence-specific dna binding", "gene_names": ["sigA1"], "name": "RNA polymerase sigma factor SigA", "drug_actions": [{"action": "INHIBITOR", "target": "Q18BX5", "drug": "DB08874"}]}, "Q9ZAG3": {"specific_function": "Catalyzes the conversion of limonene-1,2-epoxide to limonene-1,2-diol. Can use both the (-) and (+) isomers of limonene-1,2-epoxide as substrates and also has some activity with 1-methylcyclohexene oxide, cyclohexene oxide and indene oxide as substrates.", "general_function": "Limonene-1,2-epoxide hydrolase activity", "gene_names": ["limA"], "name": "Limonene-1,2-epoxide hydrolase", "drug_actions": []}, "P47205": {"specific_function": "Involved in the biosynthesis of lipid A, a phosphorylated glycolipid that anchors the lipopolysaccharide to the outer membrane of the cell.", "general_function": "Udp-3-o-[3-hydroxymyristoyl] n-acetylglucosamine deacetylase activity", "gene_names": ["lpxC"], "name": "UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase", "drug_actions": []}, "Q56694": {"specific_function": "Catalyzes the oxidation of long-chain aliphatic aldehydes to acids. May be implicated in controlling luminescence as it catalyzes the oxidation of the fatty aldehyde substrate for the light-emitting reaction.", "general_function": "Aldehyde dehydrogenase (nadp+) activity", "gene_names": ["aldH"], "name": "NADP-dependent fatty aldehyde dehydrogenase", "drug_actions": []}, "P00484": {"specific_function": "This enzyme is an effector of chloramphenicol resistance in bacteria.", "general_function": "Chloramphenicol o-acetyltransferase activity", "gene_names": ["cat3"], "name": "Chloramphenicol acetyltransferase 3", "drug_actions": [{"action": "INHIBITOR", "target": "P00484", "drug": "DB02703"}]}, "P39045": {"specific_function": "Removes C-terminal D-alanyl residues from sugar-peptide cell wall precursors.", "general_function": "Serine-type d-ala-d-ala carboxypeptidase activity", "gene_names": ["dac"], "name": "D-alanyl-D-alanine carboxypeptidase", "drug_actions": []}, "P0A9J6": {"general_function": "Ribokinase activity", "gene_names": ["rbsK"], "name": "Ribokinase", "drug_actions": []}, "P49761": {"specific_function": "Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates. Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex. May be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing and can cause redistribution of SR proteins from speckles to a diffuse nucleoplasmic distribution. Phosphorylates SRSF1 and SRSF3. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells.", "general_function": "Protein tyrosine kinase activity", "gene_names": ["CLK3"], "name": "Dual specificity protein kinase CLK3", "drug_actions": []}, "P49763": {"specific_function": "Growth factor active in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. Isoform PlGF-2 binds NRP1/neuropilin-1 and NRP2/neuropilin-2 in a heparin-dependent manner. Also promotes cell tumor growth.", "general_function": "Heparin binding", "gene_names": ["PGF"], "name": "Placenta growth factor", "drug_actions": [{"action": "BINDER", "target": "P49763", "drug": "DB08885"}]}, "Q9UNK4": {"specific_function": "PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. L-alpha-1-palmitoyl-2-linoleoyl phosphatidylethanolamine is more efficiently hydrolyzed than the other phospholipids examined.", "general_function": "Phospholipase a2 activity", "gene_names": ["PLA2G2D"], "name": "Group IID secretory phospholipase A2", "drug_actions": []}, "P06478": {"specific_function": "In latent infection, may allow the virus to be reactivated and to grow in cells lacking a high concentration of phosphorylated nucleic acid precursors, such as nerve cells that do not replicate their genome.", "general_function": "Thymidine kinase activity", "gene_names": ["TK"], "name": "Thymidine kinase", "drug_actions": [{"action": "INDUCER", "target": "P06478", "drug": "DB00299"}]}, "P13929": {"specific_function": "Appears to have a function in striated muscle development and regeneration.", "general_function": "Phosphopyruvate hydratase activity", "gene_names": ["ENO3"], "name": "Beta-enolase", "drug_actions": []}, "P21266": {"specific_function": "Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. May govern uptake and detoxification of both endogenous compounds and xenobiotics at the testis and brain blood barriers.", "general_function": "Protein homodimerization activity", "gene_names": ["GSTM3"], "name": "Glutathione S-transferase Mu 3", "drug_actions": []}, "O95644": {"specific_function": "Plays a role in the inducible expression of cytokine genes in T-cells, especially in the induction of the IL-2 or IL-4 gene transcription. Also controls gene expression in embryonic cardiac cells. Could regulate not only the activation and proliferation but also the differentiation and programmed death of T-lymphocytes as well as lymphoid and non-lymphoid cells.", "general_function": "Transcriptional activator activity, rna polymerase ii distal enhancer sequence-specific binding", "gene_names": ["NFATC1"], "name": "Nuclear factor of activated T-cells, cytoplasmic 1", "drug_actions": []}, "P62158": {"specific_function": "Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.", "general_function": "Titin binding", "gene_names": ["CALM1"], "name": "Calmodulin", "drug_actions": [{"action": "INHIBITOR", "target": "P62158", "drug": "DB00527"}, {"action": "OTHER/UNKNOWN", "target": "P62158", "drug": "DB00622"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB00623"}, {"action": "OTHER/UNKNOWN", "target": "P62158", "drug": "DB00753"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB00831"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB00836"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB00850"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB00925"}, {"action": "OTHER", "target": "P62158", "drug": "DB01023"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB01069"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB01100"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB01115"}, {"action": "BINDER", "target": "P62158", "drug": "DB01244"}, {"action": "INHIBITOR", "target": "P62158", "drug": "DB01429"}]}, "P13922": {"specific_function": "Bifunctional enzyme. Involved in de novo dTMP biosynthesis. Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, DNA precursor synthesis, and for the conversion of dUMP to dTMP.", "general_function": "Thymidylate synthase activity", "gene_names": [], "name": "Bifunctional dihydrofolate reductase-thymidylate synthase", "drug_actions": [{"action": "INHIBITOR", "target": "P13922", "drug": "DB00205"}, {"action": "INHIBITOR", "target": "P13922", "drug": "DB01131"}, {"action": "INHIBITOR", "target": "P13922", "drug": "DB01299"}]}, "Q8WXA8": {"specific_function": "This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses. It is a cation-specific, but otherwise relatively nonselective, ion channel.", "name": "5-hydroxytryptamine receptor 3C", "drug_actions": [{"action": "ANTAGONIST", "target": "Q8WXA8", "drug": "DB01049"}], "general_function": "Serotonin-activated cation-selective channel activity", "in_complexes": ["Serotonin Receptors"], "gene_names": ["HTR3C"]}, "P49189": {"specific_function": "Converts gamma-trimethylaminobutyraldehyde into gamma-butyrobetaine. Catalyzes the irreversible oxidation of a broad range of aldehydes to the corresponding acids in an NAD-dependent reaction.", "general_function": "Aminobutyraldehyde dehydrogenase activity", "gene_names": ["ALDH9A1"], "name": "4-trimethylaminobutyraldehyde dehydrogenase", "drug_actions": []}, "Q460N3": {"specific_function": "Transcriptional repressor. Has ADP-ribosyltransferase activity.", "general_function": "Nad+ adp-ribosyltransferase activity", "gene_names": ["PARP15"], "name": "Poly [ADP-ribose] polymerase 15", "drug_actions": []}, "O06330": {"specific_function": "dTDP-4-dehydro-6-deoxy-D-glucose = dTDP-4- dehydro-6-deoxy-L-mannose", "general_function": "Involved in dTDP-4-dehydrorhamnose 3,5-epimerase activity", "gene_names": ["rmlC"], "name": "dTDP-4-dehydrorhamnose 3,5-epimerase", "drug_actions": []}, "Q16665": {"specific_function": "Functions as a master transcriptional regulator of the adaptive response to hypoxia. Under hypoxic conditions, activates the transcription of over 40 genes, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. Plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. Binds to core DNA sequence 5'-[AG]CGTG-3' within the hypoxia response element (HRE) of target gene promoters. Activation requires recruitment of transcriptional coactivators such as CREBPB and EP300. Activity is enhanced by interaction with both, NCOA1 or NCOA2. Interaction with redox regulatory protein APEX seems to activate CTAD and potentiates activation by NCOA1 and CREBBP. Involved in the axonal distribution and transport of mitochondria in neurons during hypoxia.", "general_function": "Ubiquitin protein ligase binding", "gene_names": ["HIF1A"], "name": "Hypoxia-inducible factor 1-alpha", "drug_actions": [{"action": "MODULATOR", "target": "Q16665", "drug": "DB01136"}]}}}